RELATION_ID,CONCEPT1_ID,CONCEPT2_ID,RELATION_TYPE,C1_NAME,C2_NAME,WEIGHT,SENTENCE,C1_SEMTYPES,C2_SEMTYPES,C1_MESHTREENUM,C2_MESHTREENUM
244bc1f6-b6a9-4a85-9536-facb4f51b774,C1422064,C3266262,using large-scale omics ,ACE2 gene,Multiple Chronic Conditions,1,X,[gngm],[dsyn],,C23.550.291.500.500
1c897f0e-0c05-47ae-a210-c2b88511b64e,C1422064,omics,using large-scale omics ,ACE2 gene,omics,1,X,[gngm],????,,????
59fb1824-2089-47c3-9d87-92dcbf9bcebd,C1422064,C0178784,using omics data from 30,ACE2 gene,Organ,1,X,[gngm],[bpoc],,
0934d98c-ad62-43dc-a31b-fcaad27cf308,C1422064,C0040300,using omics data from 30,ACE2 gene,Body tissue,1,X,[gngm],[tisu],,A10
0934d98c-ad62-43dc-a31b-fcaad27cf308,C1422064,C0040300,were widely disturbed among ,ACE2 gene,Body tissue,5,X,[gngm],[tisu],,A10
a7014030-8afe-4a7b-9dbf-981e3a783e3a,C1422064,C1175743,receptor for,ACE2 gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
a7014030-8afe-4a7b-9dbf-981e3a783e3a,C1422064,C1175743,point for ,ACE2 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
dfbd7ff6-1ded-4ef5-93fc-f7e58efe6cf5,C1422064,C0279671,was up-regulated in ,ACE2 gene,Cervical Squamous Cell Carcinoma,1,X,[gngm],[neop],,
b55a0682-e00d-4184-96fb-94ff0272f448,C0012634,C0178784,could lead to multi ,Disease,Organ,1,X,[dsyn],[bpoc],C23.550.288,
ec4b162e-c4d6-4624-8907-373506f27400,C0012634,C1175175,rapidly progresses to ,Disease,Severe Acute Respiratory Syndrome,19,X,[dsyn],[dsyn],C23.550.288,C02.782.600.550.200.750;C08.730.730
691ceaa7-03ad-400a-a63d-1b40f3559179,C0012634,C0012655,could lead to their higher ,Disease,Disease susceptibility,1,X,[dsyn],[clna],C23.550.288,C23.550.291.687;G07.100.250
691ceaa7-03ad-400a-a63d-1b40f3559179,C0012634,C0012655,potentially influence ,Disease,Disease susceptibility,2,X,[dsyn],[clna],C23.550.288,C23.550.291.687;G07.100.250
d2322b8b-6a97-45da-8308-93de8bc26525,C0206750,C1825598,reducing ,Coronavirus Infections,IMPACT gene,34,X,[dsyn],[gngm],C02.782.600.550.200,
fe25c977-65b8-4928-8cff-0d15c6c42db7,non-at,C0021053,is with ,non-at,Immune System Diseases,2,X,????,[dsyn],????,C20
9a5cbfd2-bcc2-4eed-b64c-b279382e10f9,non-at,C0037274,is with ,non-at,Dermatologic disorders,1,X,????,[dsyn],????,C17.800
e964a0b2-344d-4b8e-aa91-f7d2d3fd0b5e,C1609165,C0206750,is under Given its approval investigation in ,tocilizumab,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
e964a0b2-344d-4b8e-aa91-f7d2d3fd0b5e,C1609165,C0206750,may may beneficial for severe ,tocilizumab,Coronavirus Infections,2,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
e964a0b2-344d-4b8e-aa91-f7d2d3fd0b5e,C1609165,C0206750,has has proposed to ,tocilizumab,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
fb1b4b45-2b17-4da6-813e-4212a939fe07,C1609165,C1412268,with events is ,tocilizumab,AES gene,1,X,[aapp/imft/phsu],[gngm],x.x.x.x,
bce44ba0-efe9-4e6c-887a-1574f3ec7613,C1707391,C1412268,with events is ,Choose (action),AES gene,1,X,[acty],[gngm],,
6cf66dfa-5d64-4d56-9d8b-4e22bf778c57,C1412268,C0369718,as Drug-Induced Liver Disease is,AES gene,N not otherwise specified Antibody,1,X,[gngm],[aapp/imft],,
ce50b5b8-4fa6-4450-b0f4-dbc992e2ca30,C0301872,C0009450,probably plays role in pathophysiology of ,Immune response,Communicable Diseases,2,X,[ortf],[dsyn],,C01.539.221
4a8b9439-700e-4ae9-82d2-7ea779c4e5eb,C0589104,C1947933,is in ,Process training,care activity,2,X,[topp],[acty],,
423c1db7-bfdf-4a4a-9edb-aa867958a340,C0278996,C0020517,are clinically time ,Malignant Head and Neck Neoplasm,Hypersensitivity,2,X,[neop],[patf],,C20.543
c9be49c6-f96c-4a12-a1c9-c525bf0e3e3a,C0543467,C0038952,alter individuals chance of ,Operative Surgical Procedures,Continuance of life,2,X,[topp],[acty],E04,I03.784
cb417dd0-252d-44e7-967b-6b3f153fe365,C0018799,C0206750,is in context of ,Heart Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.280,C02.782.600.550.200
d9605b60-1698-485b-bdd0-f27d9797b7db,C0018799,C0012634,is in context of ,Heart Diseases,Disease,1,X,[dsyn],[dsyn],C14.280,C23.550.288
4babbd54-aff8-497d-8924-c13da31d061a,C0013964,C0007189,Society of ,emergency medicine (field),Cardiology discipline,1,X,[bmod],[bmod],H02.403.250,H02.403.429.163
6a0d1c74-581f-4f71-81f3-b32d29e2e525,C0013964,C0013227,Association of Intensive Care ,emergency medicine (field),Pharmaceutical Preparations,1,X,[bmod],[phsu],H02.403.250,D26
c38ea195-140f-4c74-83ad-bcb6ff079d0b,C1947933,C0035273,should otherwise follow namely 2015 International Liaison Committee on ,care activity,Resuscitation procedure,1,X,[acty],[topp],,E02.365.647
e70061b7-e1fd-4a22-8fab-63a547ec167c,C1947933,C0007189,should follow 2019 Update to Society of ,care activity,Cardiology discipline,1,X,[acty],[bmod],,H02.403.429.163
1b100489-68ab-46c0-a978-d517da69c7d6,C1947933,C0007203,should follow 2019 Update to Society of ,care activity,Cardiopulmonary Resuscitation,1,X,[acty],[topp],,E02.365.647.110
7c853f0e-5049-4f15-bf2f-a006d96c4603,C0042769,C0960756,is ,Virus Diseases,factor A,4,X,[dsyn],[orch],C02,x.x.x.x
1e2fe167-601a-4979-9c44-6f720bd41000,C0042769,C0032930,is ,Virus Diseases,Precipitating Factors,2,X,[dsyn],[clna],C02,N05.715.350.200.650;N06.850.490.625.500
6b77400f-db6a-4089-ae26-cc085477b50f,C0042769,C0004096,is ,Virus Diseases,Asthma,3,X,[dsyn],[dsyn],C02,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
cb6446db-944e-4260-bc0f-fcb07102b980,HWC,C1706374,was launched on ,HWC,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
055f2a60-55df-4bf4-8e81-89f7c42a3bde,HWC,C1856053,was launched on ,HWC,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
b3570a6a-8ac6-4dd6-a892-766c6f52a812,C1175743,C0034019,serious threat to global ,SARS coronavirus,public health medicine (field),30,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.720;N01.400.550;N06.850
5fda6f1f-dad8-44b0-8667-167714347b72,C1175743,C2745965,was declared pandemic health ,SARS coronavirus,Emergencies [Disease/Finding],16,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.291.781;N06.230.100.083;N06.850.376
675fbc29-2b7b-400a-9535-00bbcc938ee2,C1175743,C0206750,with patients is ,SARS coronavirus,Coronavirus Infections,265,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
68c1224d-b584-4146-8395-50425fcf6354,C1175743,C0012634,with patients is ,SARS coronavirus,Disease,74,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.288
db372019-cace-401b-8fb5-44b9313ffe4e,C0319157,C0042765,is hypothesized increased ,AS virus,Virulence,6,X,[virs],[biof],,G06.930
ca056b5b-7db3-41dd-ba71-763261c82aed,C0035736,C1521806,unexpectedly been detected in multiple bodily ,RNA Viral,Body Fluids and Substances,2,X,[nnon],[tisu],D13.444.735.828,
9750a5ba-1ae6-46bd-b618-07dbf32e65ca,C0035736,C0370003,was detected in of ,RNA Viral,Specimen,16,X,[nnon],[sbst],D13.444.735.828,
e8e99f61-96a0-4da1-a34e-2ee189ed452d,C0319157,C0007634,gains ,AS virus,Cells,2,X,[virs],[cell],,A11
e8e99f61-96a0-4da1-a34e-2ee189ed452d,C0319157,C0007634,entered ,AS virus,Cells,1,X,[virs],[cell],,A11
5ff7e011-4924-4764-a11e-d69939919970,C0319157,C1422064,gains ,AS virus,ACE2 gene,1,X,[virs],[gngm],,
74ee17b2-c72c-4300-9d4d-cd37b58569a4,C0597357,C0009450,thereby potentiating its ,receptor,Communicable Diseases,3,X,[aapp/rcpt],[dsyn],,C01.539.221
74ee17b2-c72c-4300-9d4d-cd37b58569a4,C0597357,C0009450,Additionally potentiating its ,receptor,Communicable Diseases,1,X,[aapp/rcpt],[dsyn],,C01.539.221
435b881f-d774-4ff7-8fde-f2c1132c5886,C0021853,C0009368,is in ,Intestines,Colon structure (body structure),4,X,[bpoc],[bpoc],A03.556.124,A03.556.124.526.356;A03.556.249.249.356
df224a90-8b14-470b-a868-32c5f8ebf89a,C0598312,C0021853,is in ,DNA Replication,Intestines,4,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124
8a70ee27-43e8-4c1a-9ff1-c3be98eb9857,C0206750,C0149978,is with ,Coronavirus Infections,Adenocarcinoma of rectum,2,X,[dsyn],[neop],C02.782.600.550.200,
902f8fcb-7530-4662-a8d5-36061813715f,RT-PCR,C1292533,was performed on rectal ,RT-PCR,Tissue specimen,4,X,????,[tisu],????,
c52a9239-39c3-4d49-9a99-c1d58d5f66d4,RT-PCR,C0015252,was performed on rectal ,RT-PCR,removal technique,4,X,????,[topp],????,
8f430efb-c5ca-40b8-b5c8-4f47bea69464,C1522472,C1175743,were observed for ,section sample,SARS coronavirus,8,X,[sbst],[virs],,B04.820.504.540.150.113.937
aff0ef2d-1a74-4830-88a4-f902f654188f,C0677043,C0018964,using ,Histopathology,Hematoxylin,8,X,[bmod],[irda/orch],,D03.383.663.283.600;D03.633.100.150.600
db64f91c-34ba-4bba-96dd-313b4307ea7d,C0677043,C0014448,using ,Histopathology,Eosine Yellowish,4,X,[bmod],[chvf/orch],,D02.455.426.779.347.325;D03.633.300.953.275.325;D04.711.347.325
37baf08d-d4cc-470f-b995-bcf9804caeb2,C0010200,C0206750,was diagnosed with ,Coughing,Coronavirus Infections,6,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
37baf08d-d4cc-470f-b995-bcf9804caeb2,C0010200,C0206750,were most common symptoms of ,Coughing,Coronavirus Infections,4,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
37baf08d-d4cc-470f-b995-bcf9804caeb2,C0010200,C0206750,including Coronavirus Infections is,Coughing,Coronavirus Infections,2,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200
4671ce30-ebf2-45e3-899f-92eba63b1c2a,C0028606,C0206750,positive for typical ,Nucleic Acids,Coronavirus Infections,6,X,[bacs/nnon],[dsyn],D13.444,C02.782.600.550.200
943db510-4f05-4108-bc76-96d5079e43c3,C0028606,C0042760,positive for typical ,Nucleic Acids,Virion,3,X,[bacs/nnon],[celc],D13.444,A21.249;B04.950
8f0b0062-327a-4c6d-b2a0-4b530405923d,C0028606,C0040300,positive for typical ,Nucleic Acids,Body tissue,3,X,[bacs/nnon],[tisu],D13.444,A10
30eeaea5-c36e-47f1-969a-f69026d412df,C0206750,C0040300,is in rectal ,Coronavirus Infections,Body tissue,3,X,[dsyn],[tisu],C02.782.600.550.200,A10
30eeaea5-c36e-47f1-969a-f69026d412df,C0206750,C0040300,is associated with particularly facultative progenitors of ,Coronavirus Infections,Body tissue,1,X,[dsyn],[tisu],C02.782.600.550.200,A10
e5a2e17f-67f2-47df-8c7d-2552bb485865,C0042760,C0040300,is in rectal ,Virion,Body tissue,3,X,[celc],[tisu],A21.249;B04.950,A10
e5a2e17f-67f2-47df-8c7d-2552bb485865,C0042760,C0040300,progenitors of ,Virion,Body tissue,1,X,[celc],[tisu],A21.249;B04.950,A10
853dce4c-67ef-4dc9-9047-a437af093abe,C0028606,C1175743,positive for ,Nucleic Acids,SARS coronavirus,3,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150.113.937
853dce4c-67ef-4dc9-9047-a437af093abe,C0028606,C1175743,antibodies-based test for ,Nucleic Acids,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150.113.937
0aca934d-3e33-410c-9082-16979bb04b0f,C1175743,C0040300,is in combination with morphological findings from postmortem ,SARS coronavirus,Body tissue,7,X,[virs],[tisu],B04.820.504.540.150.113.937,A10
78a873fa-4eae-4755-95bf-95be16adf08f,C0598312,C0034896,is in patients ,DNA Replication,Rectum,4,X,[genf],[bpoc],G02.111.225;G05.226,A03.556.124.526.767;A03.556.249.249.767
d46a91ee-6dbf-4609-86f1-1f6308caf973,C1175743,C0007634,uses membrane- form as,SARS coronavirus,Cells,9,X,[virs],[cell],B04.820.504.540.150.113.937,A11
2d827121-7807-4e13-a40b-64fc2d49b3d6,C0086418,C1422064,exhibits greater ,Homo sapiens,ACE2 gene,1,X,[humn],[gngm],B01.050.150.900.649.313.988.400.112.400.400,
dd7cdd07-3766-4106-99de-8da2191a93e2,C0018787,C1422064,exhibits greater ,Heart,ACE2 gene,1,X,[bpoc],[gngm],A07.541,
dd7cdd07-3766-4106-99de-8da2191a93e2,C0018787,C1422064,also express ,Heart,ACE2 gene,1,X,[bpoc],[gngm],A07.541,
3825c520-ed5b-471c-89c8-1a28a726e438,C0086418,C0024109,exhibits ACE2 gene expression Compared with,Homo sapiens,Lung,1,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
3825c520-ed5b-471c-89c8-1a28a726e438,C0086418,C0024109,exhibits Peptidyl-Dipeptidase A expression Compared with,Homo sapiens,Lung,1,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
3825c520-ed5b-471c-89c8-1a28a726e438,C0086418,C0024109,sustained high loads in ,Homo sapiens,Lung,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.411
b41692a7-a5c5-4e85-a941-9a7c8b95f1ec,C0018787,C0024109,exhibits ACE2 gene expression Compared with,Heart,Lung,1,X,[bpoc],[bpoc],A07.541,A04.411
b41692a7-a5c5-4e85-a941-9a7c8b95f1ec,C0018787,C0024109,exhibits Peptidyl-Dipeptidase A expression Compared with,Heart,Lung,1,X,[bpoc],[bpoc],A07.541,A04.411
7e41d43a-a9f4-4de6-91af-13714fd98816,C0018787,C0206750,is in ,Heart,Coronavirus Infections,3,X,[bpoc],[dsyn],A07.541,C02.782.600.550.200
ba968d5a-3c5d-4b2b-8d39-a9a83ba2e5f4,C0029896,C0206750,is in ,Otorhinolaryngologic Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C09,C02.782.600.550.200
1cf7d0d0-9389-48c4-ac6c-b917c96c91a6,C4082587,C1829939,is in ,HLA Class II Histocompatibility Antigen Gamma Chain human,{Non-patient},2,X,[aapp/imft],[clna],,
eb5f73aa-0720-473f-83d6-51acc2ceccd1,sup2,C1829939,is in ,sup2,{Non-patient},2,X,????,[clna],????,
108e545f-990b-4b17-91e7-4563d076df65,C1422064,C0024109,is higher than that in ,ACE2 gene,Lung,2,X,[gngm],[bpoc],,A04.411
108e545f-990b-4b17-91e7-4563d076df65,C1422064,C0024109,were widely disturbed among ,ACE2 gene,Lung,4,X,[gngm],[bpoc],,A04.411
108e545f-990b-4b17-91e7-4563d076df65,C1422064,C0024109,is expressed in ,ACE2 gene,Lung,1,X,[gngm],[bpoc],,A04.411
f03d1073-8c2e-4974-b154-ddd06527360b,C1422064,C0018787,is in adult human ,ACE2 gene,Heart,1,X,[gngm],[bpoc],,A07.541
f03d1073-8c2e-4974-b154-ddd06527360b,C1422064,C0018787,is relatively highly expressed in ,ACE2 gene,Heart,1,X,[gngm],[bpoc],,A07.541
f03d1073-8c2e-4974-b154-ddd06527360b,C1422064,C0018787,were widely disturbed among ,ACE2 gene,Heart,4,X,[gngm],[bpoc],,A07.541
2bb2fbe3-8565-4c3c-b1f7-5da71f45b049,C4281807,C0018787,is in ,Vitronectin human,Heart,3,X,[aapp/bacs],[bpoc],,A07.541
646ba9a0-51da-49a9-aafc-0f842c3ee208,C0024109,C1175743,may restrict entry of ,Lung,SARS coronavirus,2,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
646ba9a0-51da-49a9-aafc-0f842c3ee208,C0024109,C1175743,are damaged due to presence of ,Lung,SARS coronavirus,1,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
646ba9a0-51da-49a9-aafc-0f842c3ee208,C0024109,C1175743,is in patient with presumed ,Lung,SARS coronavirus,2,X,[bpoc],[virs],A04.411,B04.820.504.540.150.113.937
1a2bf834-40f4-4271-94a4-2afafbd02911,C1422064,C0086418,is relatively highly expressed in ,ACE2 gene,Homo sapiens,1,X,[gngm],[humn],,B01.050.150.900.649.313.988.400.112.400.400
aa8e43cd-f301-48ff-98bb-8a394a0bd556,C0287990,C1175175,mediate ,paired basic amino acid cleaving enzyme,Severe Acute Respiratory Syndrome,2,X,[aapp/enzy],[dsyn],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,C02.782.600.550.200.750;C08.730.730
5854b48b-3a9d-407d-bd85-81bd5a99964f,C0287990,C4281807,may Vitronectin human for S,paired basic amino acid cleaving enzyme,Vitronectin human,2,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
8c538839-2385-4baa-9d26-5f55465f7384,C0054871,C4281807,may Vitronectin human for S,Cathepsin L,Vitronectin human,2,X,[aapp/enzy],[aapp/bacs],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,
bfab5118-4745-4be7-af99-7a187dfca368,C0034052,C0206750,are associated with injury in patients with ,Pulmonary artery structure,Coronavirus Infections,2,X,[bpoc],[dsyn],A07.015.114.715,C02.782.600.550.200
bfab5118-4745-4be7-af99-7a187dfca368,C0034052,C0206750,is independent risk factor for injury in patients with ,Pulmonary artery structure,Coronavirus Infections,2,X,[bpoc],[dsyn],A07.015.114.715,C02.782.600.550.200
839352c9-cdb1-475e-bf58-adc1b68de61b,C0741923,C0206750,is with ,cardiac event,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
14551818-81d0-446a-aef2-89813f86630e,C0005775,C0741923,is pivotal pathological cardiac event with,Blood Circulation,cardiac event,4,X,[phsf],[dsyn],G09.330.100,
8d7fd9e1-0624-4daf-a3b4-068722acfa33,C0005775,C0206750,is pivotal pathological cardiac event with,Blood Circulation,Coronavirus Infections,2,X,[phsf],[dsyn],G09.330.100,C02.782.600.550.200
c36df813-65cb-4826-8a96-9ff505780aca,C0009450,C0221423,is associated with neurological ,Communicable Diseases,Illness (finding),2,X,[dsyn],[sosy],C01.539.221,
c36df813-65cb-4826-8a96-9ff505780aca,C0009450,C0221423,causes mild ,Communicable Diseases,Illness (finding),1,X,[dsyn],[sosy],C01.539.221,
c36df813-65cb-4826-8a96-9ff505780aca,C0009450,C0221423,causing respiratory ,Communicable Diseases,Illness (finding),1,X,[dsyn],[sosy],C01.539.221,
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was established at National Hospital in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was established in early ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,with patients is 2020 ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,reached In ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,published in mid ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was noted third most common stressor in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,be third most common stressor in early ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,opened in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was declared pandemic on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,13,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,became on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was recorded in ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,was reported on ,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
d7a6d0a4-edca-4788-b73e-54ea79638dd4,C0206750,C1856053,has had IMPACT gene decreed in Spain on,Coronavirus Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
db32e886-500b-4493-b933-d8e8664b8008,C0012634,C1856053,was recognized by World Health Organization as pandemic on ,Disease,Hydranencephaly with Renal Aplasia-Dysplasia,25,X,[dsyn],[dsyn],C23.550.288,x.x.x.x
a5f512e2-3eee-490f-9d4b-7d91c2798b7e,C0206750,C1705178,was established at National Hospital in ,Coronavirus Infections,Order (action),6,X,[dsyn],[acty],C02.782.600.550.200,
6af9942b-640e-465d-8586-68e40fdc74a0,C0012634,C1705178,was established in early ,Disease,Order (action),5,X,[dsyn],[acty],C23.550.288,
8dfd7120-59d1-45b0-9dce-06678af25a3e,C1856053,C1705178,is in ,Hydranencephaly with Renal Aplasia-Dysplasia,Order (action),1,X,[dsyn],[acty],x.x.x.x,
5cbb367e-b483-4b3d-9ece-30fb4c13b613,C0014038,C0019080,is with ,Encephalitis,Hemorrhage,2,X,[dsyn],[patf],C10.228.140.430,C23.550.414
68d9e9bb-6e10-43f1-853e-d20a70c33610,C0019080,C0014059,with Encephalitis is,Hemorrhage,Encephalomyelitis Acute Disseminated,2,X,[patf],[dsyn],C23.550.414,C10.114.375.225;C10.228.140.695.562.225;C10.314.350.225;C20.111.258.250.350
675c068b-a137-4ced-9864-ea47ef288450,C0019080,C0369718,with Encephalitis is,Hemorrhage,N not otherwise specified Antibody,2,X,[patf],[aapp/imft],C23.550.414,
5c033697-9431-4597-9252-3af644cec8b0,C0085584,C0011206,is with ,Encephalopathies,Delirium,2,X,[dsyn],[mobd],C10.228.140,C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350
caaccf95-4655-427b-aaa0-16c77b7c84a5,C0085584,C0033975,is with ,Encephalopathies,Psychotic Disorders,2,X,[dsyn],[mobd],C10.228.140,F03.700.675
cdaeb620-c612-47b9-8e7a-b8a39ef3bd15,C0948008,C0087086,associated with pro ,Ischemic stroke,Thrombus,2,X,[dsyn],[patf],,C14.907.355.830
c62e9809-0a0f-49ef-b287-b7d7e179193b,C1175175,C0039082,is associated with wide spectrum of neurological ,Severe Acute Respiratory Syndrome,Syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288.500
c62e9809-0a0f-49ef-b287-b7d7e179193b,C1175175,C0039082,can lead to acute respiratory ,Severe Acute Respiratory Syndrome,Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288.500
7e364e64-36b4-4c4e-a33d-120d827f25f5,C0030054,C0206750,play role in severity of hypoxemia in ,Oxygen,Coronavirus Infections,2,X,[bacs/elii/phsu],[dsyn],D01.268.185.550;D01.362.670;x.x.x.x,C02.782.600.550.200
7e364e64-36b4-4c4e-a33d-120d827f25f5,C0030054,C0206750,Red blood cell disorder from,Oxygen,Coronavirus Infections,2,X,[bacs/elii/phsu],[dsyn],D01.268.185.550;D01.362.670;x.x.x.x,C02.782.600.550.200
b1ab6cc6-5a1b-4cfe-9173-dd5f4ca19941,C0598783,C0522534,was observed especially short ,Lipid Metabolism,Saturated,3,X,[moft],[npop],G03.458,
f6c1cb9a-773f-43ad-99de-a570480096a7,C0598783,C0522094,was observed especially short ,Lipid Metabolism,Medium chain fatty acid,3,X,[moft],[bacs/orch],G03.458,
506ae833-7bb8-4cf9-8a38-156c90926cef,C0598783,C0368608,was observed especially short ,Lipid Metabolism,acylcarnitine,3,X,[moft],[orch],G03.458,x.x.x.x
f483aa0e-ea86-4310-88a0-402f6cefbd57,C0598783,C0037900,was observed especially short ,Lipid Metabolism,Sphingolipids,3,X,[moft],[orch],G03.458,D10.570.877
59d13e31-a1db-4969-b634-6b64f6c7cfc7,C0369718,C0428174,responding in ,N not otherwise specified Antibody,Hemoglobin saturation with oxygen,3,X,[aapp/imft],[ortf],,
a639fe75-0922-46e1-8b4a-11a0e93dd18e,C0369718,C0206750,Red blood cell disorder from,N not otherwise specified Antibody,Coronavirus Infections,2,X,[aapp/imft],[dsyn],,C02.782.600.550.200
2c638654-29d5-43f4-a36b-6ef65e6c0941,C0040802,C0030054,deliver ,travel,Oxygen,2,X,[dora],[bacs/elii/phsu],I03.883,D01.268.185.550;D01.362.670;x.x.x.x
af0efef0-eb31-4eac-aa2f-ff655160af10,C1175175,C0086418,is third zoonotic ,Severe Acute Respiratory Syndrome,Homo sapiens,6,X,[dsyn],[humn],C02.782.600.550.200.750;C08.730.730,B01.050.150.900.649.313.988.400.112.400.400
4586924f-49ae-46f0-99e7-dbecc98429e7,C1175175,C1185740,using respiratory ,Severe Acute Respiratory Syndrome,Tract,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,
01e0ce90-ea3f-4b82-8aa0-2d2bea44b265,C1175175,C0370003,using respiratory ,Severe Acute Respiratory Syndrome,Specimen,1,X,[dsyn],[sbst],C02.782.600.550.200.750;C08.730.730,
332165cc-c1ec-44ac-96d0-dedd92ec8f73,C0206750,C1175743,was diagnosed by ,Coronavirus Infections,SARS coronavirus,321,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113.937
cb957760-008d-4a79-a3d2-ba94e308faf4,C0012634,C1175743,was run on ,Disease,SARS coronavirus,251,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.113.937
ffee9d7f-74f9-47b7-99ab-be4db78893f1,C0035736,C0302908,unexpectedly been detected in multiple ,RNA Viral,Liquid substance,1,X,[nnon],[sbst],D13.444.735.828,
8bd38d76-f8af-49ac-8230-a765f2026147,C0319157,C0022709,gains ,AS virus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
8bd38d76-f8af-49ac-8230-a765f2026147,C0319157,C0022709,interact with ,AS virus,Peptidyl-Dipeptidase A,2,X,[virs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
8bd38d76-f8af-49ac-8230-a765f2026147,C0319157,C0022709,also promotes ,AS virus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
1fad7878-e59f-4b95-8589-c12e9802764f,C0030054,C0428174,responding in ,Oxygen,Hemoglobin saturation with oxygen,2,X,[bacs/elii/phsu],[ortf],D01.268.185.550;D01.362.670;x.x.x.x,
b336b35a-2cc4-4cf1-985c-30593ab79dad,C0221016,C0030054,deliver ,Red blood cell disorder,Oxygen,1,X,[dsyn],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
392e6580-cfb3-431a-94b3-ceb2b0550712,C0007222,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,PCR,4,X,[dsyn],????,C14,????
9e4c941a-50f8-4103-a4db-bf44e811c1f9,C0020538,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,PCR,4,X,[dsyn],????,C14.907.489,????
f3319bb5-f91c-423f-a93d-a9b85fddd0f3,C0022658,PCR,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,PCR,4,X,[dsyn],????,C12.777.419;C13.351.968.419,????
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C14,C02.782.600.550.200
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,are at with comorbidities risk of ,Cardiovascular Diseases,Coronavirus Infections,7,X,[dsyn],[dsyn],C14,C02.782.600.550.200
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,were most prevalent comorbidities in ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,are Additionally risk factors for ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,was associated with critical ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
922bc8d2-bac9-4a2c-834a-7b1ff202a58d,C0007222,C0206750,initial considerations of ,Cardiovascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200
3bbcb2b6-12c6-407a-aa52-198c04d9cddd,C0020538,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,Coronavirus Infections,17,X,[dsyn],[dsyn],C14.907.489,C02.782.600.550.200
9ed331a1-38c6-4425-b917-8ced9da65457,C0022658,C0206750,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,Coronavirus Infections,3,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C02.782.600.550.200
9ed331a1-38c6-4425-b917-8ced9da65457,C0022658,C0206750,were predominant premorbid risk factors for ,Kidney Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C02.782.600.550.200
62047fb5-3a5f-49ef-9ba8-3180cfec03e9,C0002871,C0206750,were predominant premorbid risk factors for ,Anemia,Coronavirus Infections,3,X,[dsyn],[dsyn],C15.378.071,C02.782.600.550.200
68a18716-318d-4f9d-b292-a1afa800767d,C0022658,C0022661, includes ,Kidney Diseases,Kidney Failure Chronic,3,X,[dsyn],[dsyn],C12.777.419;C13.351.968.419,C12.777.419.780.750.500;C13.351.968.419.780.750.500
4af27b68-0573-4270-a781-978a755a4612,C0022661,C0206750,were predominant premorbid risk factors for ,Kidney Failure Chronic,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419.780.750.500;C13.351.968.419.780.750.500,C02.782.600.550.200
76821c6a-b9b6-4170-a8c3-febfd471d5ab,C1706374,C1708476,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Implementation,4,X,[aapp/bacs],[acty],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
57885866-44a0-4ae8-b19c-2bb858dd9384,C1706374,C1856053,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,x.x.x.x
57885866-44a0-4ae8-b19c-2bb858dd9384,C1706374,C1856053,with,Tumor Necrosis Factor Ligand Superfamily Member 13,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,x.x.x.x
9090c899-2c4e-49de-af09-6244f20447e7,C1706374,C1705178,was associated with ,Tumor Necrosis Factor Ligand Superfamily Member 13,Order (action),3,X,[aapp/bacs],[acty],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
a05de0f4-7b10-484b-8ac6-e1bd4d6c224e,C1175175,C0035222,is with ,Severe Acute Respiratory Syndrome,Respiratory Distress Syndrome Adult,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.840;C08.618.840
cb439d3e-b9e0-468b-af22-51877929bfdc,C0035222,C0206750,phenotype of ,Respiratory Distress Syndrome Adult,Coronavirus Infections,11,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C02.782.600.550.200
1a9c19e1-159a-4d04-b7ec-a0a8399bc96b,C0206750,C0225698,is associated with ,Coronavirus Infections,Alveolar Epithelial Cells,2,X,[dsyn],[cell],C02.782.600.550.200,A04.411.715.100;A11.436.081
ca97f223-6315-4beb-a463-64e26e1d1b7c,C0206750,C0042760,is associated with ,Coronavirus Infections,Virion,1,X,[dsyn],[celc],C02.782.600.550.200,A21.249;B04.950
301a1c45-671f-45ed-9eff-93d242dc0673,C1537068,C0086418,is in ,Virus Internalization,Homo sapiens,1,X,[biof],[humn],G06.920.881,B01.050.150.900.649.313.988.400.112.400.400
dc08946c-dbcd-472a-b0c5-7b6fa2ba4ea4,C1537068,C1440080,is in ,Virus Internalization,Alveolar,1,X,[biof],[bpoc],G06.920.881,
c199f9d9-96b8-457c-beae-0fc36a2e24f0,C0206750,C1521827,took us ill ,Coronavirus Infections,Preparation,1,X,[dsyn],[acty],C02.782.600.550.200,
c199f9d9-96b8-457c-beae-0fc36a2e24f0,C0206750,C1521827,severe cases of be ,Coronavirus Infections,Preparation,1,X,[dsyn],[acty],C02.782.600.550.200,
277d4354-fdbc-4bd8-8a66-ef440294a011,C0086418,C0042210,develop ,Homo sapiens,Vaccines,2,X,[humn],[aapp/imft/phsu],B01.050.150.900.649.313.988.400.112.400.400,D20.215.894
63a28e6e-2c94-4de7-af00-a34d939e19f9,C1659605,C0042210,develop ,interaction with host,Vaccines,2,X,[celf],[aapp/imft/phsu],,D20.215.894
8c4fe145-3475-4f2b-8164-52926dd798ce,C0086418,C0013227,develop ,Homo sapiens,Pharmaceutical Preparations,1,X,[humn],[phsu],B01.050.150.900.649.313.988.400.112.400.400,D26
8c4fe145-3475-4f2b-8164-52926dd798ce,C0086418,C0013227,was admitted to Hubei Provincial 1day 1week,Homo sapiens,Pharmaceutical Preparations,3,X,[humn],[phsu],B01.050.150.900.649.313.988.400.112.400.400,D26
3083e32d-74ce-43d3-a7df-e4caaadb547c,C1659605,C0013227,develop ,interaction with host,Pharmaceutical Preparations,1,X,[celf],[phsu],,D26
b53165a1-f8be-426e-a3aa-680cba1c3efa,C0086418,C0475463,develop ,Homo sapiens,Antibodies Neutralizing,2,X,[humn],[aapp/imft],B01.050.150.900.649.313.988.400.112.400.400,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
67a07d0b-46a6-4a95-b2eb-8c7cbb80c1fe,C1659605,C0475463,develop ,interaction with host,Antibodies Neutralizing,2,X,[celf],[aapp/imft],,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
3436cf77-ae92-44b2-accd-21b4dca61f1a,3D,C1539905,is in ,3D,SYNC gene,3,X,????,[gngm],????,
038857a2-3f0d-4a5b-95da-147a473cf700,C0206750,C0034019,was declared ,Coronavirus Infections,public health medicine (field),63,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.720;N01.400.550;N06.850
4b05792b-abed-4765-bcc5-c497246129a0,C1610422,C0597357,was identified as entry ,ACE2 protein human,receptor,1,X,[aapp/enzy],[aapp/rcpt],,
59bdfba8-4de9-4c4a-9fab-ecc4db8ad0e5,C1610422,C1175743,was identified as entry ,ACE2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],,B04.820.504.540.150.113.937
5c1c5547-7df3-41ce-a20e-4030b9437336,C0006100,C2258685,characterize ,Bradykinin,angiotensin converting enzyme activity,1,X,[aapp/horm],[moft],D12.644.276.812.169;D12.644.400.090;D12.644.456.193;D12.776.467.812.169;D12.776.631.650.090;D23.469.050.375.110;D23.529.812.169;x.x.x.x,
b59a0128-a600-4042-a7ec-a81f27d84cf2,C0243071,C2258685,characterize ,Analog,angiotensin converting enzyme activity,1,X,[chvs],[moft],,
0017145f-ece5-48c0-bb5a-de584069e980,C0030956,C2258685,characterize ,Peptides,angiotensin converting enzyme activity,1,X,[aapp/phsu],[moft],D12.644,
0cc4d0af-c387-4079-9c88-28c75d6694ad,C1175743,C2258685,increased ,SARS coronavirus,angiotensin converting enzyme activity,4,X,[virs],[moft],B04.820.504.540.150.113.937,
8b28a7a9-16b5-4ad0-898e-d7d212429fe9,C0700271,C2258685,increased ,M Protein multiple myeloma,angiotensin converting enzyme activity,4,X,[aapp/imft],[moft],x.x.x.x,
17e7547e-5f4d-4dfd-b987-986e876d8365,C0033684,C2258685,increased ,Proteins,angiotensin converting enzyme activity,4,X,[aapp/bacs],[moft],D12.776,
56a775f4-fc62-449e-a7a5-a5755a9f7502,C1175743,C1947941,increased ,SARS coronavirus,Proteolytic Enzyme,2,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,
e77ed560-8d42-4cb2-90b5-b54241ab147b,C0700271,C1947941,increased ,M Protein multiple myeloma,Proteolytic Enzyme,2,X,[aapp/imft],[aapp/enzy],x.x.x.x,
67f65735-b214-467f-8cfa-815a8c3b36a0,C0033684,C1947941,increased ,Proteins,Proteolytic Enzyme,2,X,[aapp/bacs],[aapp/enzy],D12.776,
a7f78dcc-5a21-4d2b-a999-18bbf4bd78c4,C2349975,C0960880,was mediated by ,Enhance (action),angiotensin converting enzyme 2,4,X,[acty],[aapp/enzy],,x.x.x.x
1402840e-6cb0-4ca8-9893-21e381907f4d,C2349975,C1167622,was mediated by ,Enhance (action),Binding (Molecular Function),2,X,[acty],[moft],,
f70dda2f-34d1-4134-93aa-cacf86e600b0,C2349975,C1522002,was mediated by ,Enhance (action),RNA Recognition Motif,2,X,[acty],[aapp/bacs],,G02.111.570.820.709.275.500.869.500
4f6847c9-cbf2-4b2e-b3b7-ac540f96467b,C2349975,C1175743,was mediated by ,Enhance (action),SARS coronavirus,2,X,[acty],[virs],,B04.820.504.540.150.113.937
40089504-592f-424b-bd7a-a7de668c1f7f,C0039902,C0010813,inhibits 2 viral polyprotein ,Thioguanine,Cytokinesis,1,X,[orch/phsu],[celf],D03.633.100.759.854,G04.144.220.250
de230e54-48f3-40c4-8245-24b9d00c6287,C0039902,C0598312,inhibits ,Thioguanine,DNA Replication,1,X,[orch/phsu],[genf],D03.633.100.759.854,G02.111.225;G05.226
c1a8be7f-324f-4f4e-be82-86e421889c23,C0039902,C1175743,inhibits ,Thioguanine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.759.854,B04.820.504.540.150.113.937
0f83080f-ec14-4064-8acb-1e1febb85d64,C0039902,C0013227,represents Therapeutic procedure As well-characterized FDA-approved delivered,Thioguanine,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D03.633.100.759.854,D26
d8764e86-eb42-430c-8fdf-880d03774a4c,C0039902,C0087111,represents promising ,Thioguanine,Therapeutic procedure,2,X,[orch/phsu],[topp],D03.633.100.759.854,E02
647861e2-50f9-43ff-ada6-c408b55c5acb,C0039902,C0206750,represents promising ,Thioguanine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.759.854,C02.782.600.550.200
764cb2cc-7078-4045-8520-67a3d516bc00,C0013227,C2267219,targets essential ,Pharmaceutical Preparations,Enzymatic Activity,2,X,[phsu],[moft],D26,
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,targets essential ,Pharmaceutical Preparations,SARS coronavirus,4,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,entry of ,Pharmaceutical Preparations,SARS coronavirus,8,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,have have tested as ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,may also have risks beyond anti ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,might might potent to ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,Therapeutic procedure,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
c962ca88-469c-4e64-8cac-e6b7b37da692,C0013227,C1175743,exhibited anti ,Pharmaceutical Preparations,SARS coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150.113.937
4d1e52f1-74fe-49ab-bf6b-4861c4089a26,C1175743,C0439056,was detected via ,SARS coronavirus,Throat swab sample,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
a671ddf0-f7c2-4c13-9070-1b09a85addfb,C0439056,C0206750,is in ,Throat swab sample,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
7a7a92dd-0c8c-4cb3-b55b-3f4023378a6b,C0009450,C0242781,produced For early ,Communicable Diseases,disease transmission,3,X,[dsyn],[patf],C01.539.221,N06.850.310
55e82a18-f5f4-4a3b-848c-1e4598a0a904,C0199176,C0206750,control ,Prophylactic treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
55e82a18-f5f4-4a3b-848c-1e4598a0a904,C0199176,C0206750,became ,Prophylactic treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
55e82a18-f5f4-4a3b-848c-1e4598a0a904,C0199176,C0206750,mitigate ,Prophylactic treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
55e82a18-f5f4-4a3b-848c-1e4598a0a904,C0199176,C0206750,is in severe hospitalized ,Prophylactic treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d18434da-b459-4f24-82c9-5fa6ce90083e,C0199176,C0012634,control pandemic ,Prophylactic treatment,Disease,2,X,[topp],[dsyn],,C23.550.288
0378e711-3cee-483e-906c-f00277938943,C1175743,C0877629,of awareness is mode for ,SARS coronavirus,infection prophylaxis,1,X,[virs],[topp],B04.820.504.540.150.113.937,
909a8396-4465-4988-8a3a-dab643bdf7c0,C1457887,C0015967,were ,Symptoms,Fever,89,X,[sosy],[sosy],,C23.888.119.344
c3f53c78-a9a6-42e6-b4e2-04fdd8d2ab8d,C1175743,C1856053,were enrolled From ,SARS coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,29,X,[virs],[dsyn],B04.820.504.540.150.113.937,x.x.x.x
3f7f0342-3b90-4b0c-8e49-280cefc652c3,CoV2,C1856053,rapidly spread all over world becoming in ,CoV2,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,????,[dsyn],????,x.x.x.x
1b25991f-ad04-49cb-9b37-0befa7020dfb,C0319157,C0017968,uses its spike ,AS virus,Glycoproteins,2,X,[virs],[aapp/bacs],,D09.400.430;D12.776.395
43952abd-0b3a-4ab8-a5e3-60871bfa9db1,C0319157,C0597357,uses its spike ,AS virus,receptor,2,X,[virs],[aapp/rcpt],,
f53a6d26-9feb-414c-92f6-6633ce1267b8,C0319157,C4689723,uses its spike ,AS virus,glycoprotein binding,2,X,[virs],[moft],,
16e22464-9c95-49b2-ab87-12ae67013e86,C0319157,C1819995,interact with ,AS virus,Host Cell,2,X,[virs],[celc],,
04222964-35a1-4381-a386-c445cc5285e8,C0199176,C0013216,repurposing existing ,Prophylactic treatment,Pharmacotherapy,5,X,[topp],[topp],,E02.319
04222964-35a1-4381-a386-c445cc5285e8,C0199176,C0013216,repurposing Pharmacotherapy as potential,Prophylactic treatment,Pharmacotherapy,3,X,[topp],[topp],,E02.319
63435c0e-5086-4173-85f7-5282645d0f0d,C0042210,C0013216,repurposing existing ,Vaccines,Pharmacotherapy,5,X,[aapp/imft/phsu],[topp],D20.215.894,E02.319
63435c0e-5086-4173-85f7-5282645d0f0d,C0042210,C0013216,repurposing Pharmacotherapy as potential,Vaccines,Pharmacotherapy,3,X,[aapp/imft/phsu],[topp],D20.215.894,E02.319
0506d0d4-26f8-4e3a-9a20-fa7ed91b4a6d,C0206750,C0012634,with patients is ,Coronavirus Infections,Disease,42,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.288
41c92ddb-1f77-4e09-905d-7c8b3f7a1ea7,C0206419,C1457887,diagnosis of been has challenge in many countries due to ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
41c92ddb-1f77-4e09-905d-7c8b3f7a1ea7,C0206419,C1457887,relating ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
41c92ddb-1f77-4e09-905d-7c8b3f7a1ea7,C0206419,C1457887,could lead to serious of ,Genus: Coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150,
19ef9fe1-ec51-4bd8-9005-d74c0f14bc4f,C0012634,C1457887,diagnosis of been has challenge in many countries due to ,Disease,Symptoms,1,X,[dsyn],[sosy],C23.550.288,
19ef9fe1-ec51-4bd8-9005-d74c0f14bc4f,C0012634,C1457887,relating ,Disease,Symptoms,1,X,[dsyn],[sosy],C23.550.288,
f7ddba05-e999-4503-be3c-3e3a19859ff5,C0030664,C0009368,is in ,Pathology,Colon structure (body structure),2,X,[bmod],[bpoc],H02.403.650,A03.556.124.526.356;A03.556.249.249.356
3120d3f4-aa97-4130-a1de-6d8d6096ced4,C1175743,C0021853,is in ,SARS coronavirus,Intestines,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A03.556.124
e13c0b7b-d608-4294-8524-5ff4e58240fe,C1175743,C0030664,is in ,SARS coronavirus,Pathology,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.650
635ee5c1-f3ad-4733-9e3a-66667df2f932,C0598312,C0030664,is in ,DNA Replication,Pathology,2,X,[genf],[bmod],G02.111.225;G05.226,H02.403.650
b0b88183-b711-4c9b-97e0-eb5d2435cc5e,C0206419,C0149978,is with ,Genus: Coronavirus,Adenocarcinoma of rectum,1,X,[virs],[neop],B04.820.504.540.150,
76247fb0-f3fc-4b42-b3d9-70b38e12c05a,RT-PCR,C0237820,Rectal mucous membrane after,RT-PCR,Recovery - action,2,X,????,[acty],????,
232aadf3-74ff-4f0d-b193-46e1e955ee1e,C0010200,C0206419,was diagnosed with ,Coughing,Genus: Coronavirus,2,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150
232aadf3-74ff-4f0d-b193-46e1e955ee1e,C0010200,C0206419,were most common Symptoms of,Coughing,Genus: Coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150
232aadf3-74ff-4f0d-b193-46e1e955ee1e,C0010200,C0206419,were correlated with hospitalizations for ,Coughing,Genus: Coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150
8774a6c7-3aff-4f6a-bf86-38f3b56e448c,C0206419,C1856053,was launched in France in ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
8774a6c7-3aff-4f6a-bf86-38f3b56e448c,C0206419,C1856053,with patients is 2020 ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
8774a6c7-3aff-4f6a-bf86-38f3b56e448c,C0206419,C1856053,was declared pandemic on ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,14,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
8774a6c7-3aff-4f6a-bf86-38f3b56e448c,C0206419,C1856053,was noted third common stressor among respondents in ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
8774a6c7-3aff-4f6a-bf86-38f3b56e448c,C0206419,C1856053,outbreak of was On ,Genus: Coronavirus,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
01cfcd4f-d49a-4b3a-b247-8091779a935e,C0206419,C1705178,was established in early ,Genus: Coronavirus,Order (action),3,X,[virs],[acty],B04.820.504.540.150,
27344c49-2b22-4b4d-815b-3c6d93a36fa6,C0007222,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
27344c49-2b22-4b4d-815b-3c6d93a36fa6,C0007222,C0206419,are at higher risk of ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
27344c49-2b22-4b4d-815b-3c6d93a36fa6,C0007222,C0206419,is risk factor for novel ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
27344c49-2b22-4b4d-815b-3c6d93a36fa6,C0007222,C0206419,is associated with more severe manifestations of ,Cardiovascular Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,were predictors protective for mortality in ,Hypertensive disease,Genus: Coronavirus,4,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,followed by ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,are risk factors for morbidity from ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,is most common comorbidity associated with mortality in current ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
ba72477d-7bd0-4772-bb1b-243076ada649,C0020538,C0206419,independent predictors of lethal outcome in ,Hypertensive disease,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.489,B04.820.504.540.150
291e18ca-1c49-40d8-8dfc-c79f6766b9d9,C0022658,C0206419,were premorbid risk factors present before SARS-CoV-2 PCR ,Kidney Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419;C13.351.968.419,B04.820.504.540.150
291e18ca-1c49-40d8-8dfc-c79f6766b9d9,C0022658,C0206419,were predominant premorbid risk factors for ,Kidney Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419;C13.351.968.419,B04.820.504.540.150
9c9f86b6-55b6-432a-ab2e-973031a6ffa5,C0022661,C0206419,were predominant premorbid risk factors for ,Kidney Failure Chronic,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419.780.750.500;C13.351.968.419.780.750.500,B04.820.504.540.150
1e3a423f-39d8-44a3-90be-f37dba727acc,C0002871,C0206419,were predominant premorbid risk factors for ,Anemia,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.071,B04.820.504.540.150
46ba7a83-f8a1-41e8-bc39-21434ffaf7dc,C1175175,C0225828,is in ,Severe Acute Respiratory Syndrome,Myocytes Cardiac,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A07.541.704.570;A10.690.552.750.570;A11.620.500
ac146371-5649-41e4-a9c6-0c4c2526b0b3,C0079679,C0017337,selected ,Genus: Lentivirus group,Genes,1,X,[virs],[gngm],B04.820.650.589,G05.360.340.024.340
b72b9f91-0c83-4f19-bffc-44d9a4da7ade,C1514559,C0017337,selected ,Protein Overexpression,Genes,1,X,[genf],[gngm],,G05.360.340.024.340
82e19d18-9716-42ec-a0f8-949f231e514f,C0079679,C1175743,selected ,Genus: Lentivirus group,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589,B04.820.504.540.150.113.937
82e19d18-9716-42ec-a0f8-949f231e514f,C0079679,C1175743,Genes of,Genus: Lentivirus group,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589,B04.820.504.540.150.113.937
c90f6389-810f-4d25-ab24-1a34c233fa97,C1514559,C1175743,selected ,Protein Overexpression,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
c90f6389-810f-4d25-ab24-1a34c233fa97,C1514559,C1175743,Genes of,Protein Overexpression,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
51035382-edea-4e77-87b8-bca567d66942,C3888108,C0041904,led to ,Import into cell,Up-Regulation (Physiology),1,X,[celf],[moft],,G02.111.905;G05.308.850;G07.690.773.998
3a871301-d9ca-4ac6-80a4-5f453943eb34,C3888108,C0225828,led to ,Import into cell,Myocytes Cardiac,1,X,[celf],[cell],,A07.541.704.570;A10.690.552.750.570;A11.620.500
7eae8c97-b67d-4610-884e-b197636fb025,C0041904,C0225828,is in ,Up-Regulation (Physiology),Myocytes Cardiac,1,X,[moft],[cell],G02.111.905;G05.308.850;G07.690.773.998,A07.541.704.570;A10.690.552.750.570;A11.620.500
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,stop ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,is in older patients with ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,specific to ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,are main class of therapeutic agents evaluated against ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,may prove effective respiratory ,Antiviral Agents,Genus: Coronavirus,3,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
6717efdc-d5f9-474c-91b3-6e1ceec54ce4,C0003451,C0206419,are are given empirically to patients with ,Antiviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150
1d9e54a9-e86d-4526-bfda-51541649d58b,C0030946,C0282568,is attractive ,Endopeptidases,Drugs Essential,3,X,[aapp/enzy/phsu],[phsu],D08.811.277.656.300,D26.355
ea411c71-821a-4058-8c15-e6a1cdc0827d,C1516048,C3826426,using newly developed GPU-accelerated implicit-solvent constant pH ,Assessed,Dynamics,1,X,[acty],[npop],,
ea411c71-821a-4058-8c15-e6a1cdc0827d,C1516048,C3826426,using newly developed implicit-solvent continuous pH ,Assessed,Dynamics,1,X,[acty],[npop],,
2d17814c-18a4-409d-9cc4-c3bbc384f86a,C1516048,C4019011,using newly developed GPU-accelerated implicit-solvent constant pH ,Assessed,Exchange (clinical),1,X,[acty],[clna],,
2d17814c-18a4-409d-9cc4-c3bbc384f86a,C1516048,C4019011,using newly developed implicit-solvent continuous pH ,Assessed,Exchange (clinical),1,X,[acty],[clna],,
eb754396-eab9-4f92-b0d5-30ea1967caf3,C3826426,C4019011,is with asynchronous replica ,Dynamics,Exchange (clinical),3,X,[npop],[clna],,
7e6fe390-9421-417a-986f-ae60173635d1,C1441506,C0007382,support ,Calculation,Catalysis,3,X,[acty],[npop],,G02.130
1877e15b-a092-48ec-ba89-82b87939e4b4,C0034348,C0007382,support ,Pyruvate Kinase,Catalysis,3,X,[aapp/enzy],[npop],D08.811.913.696.620.695,G02.130
85fb2a5f-08ed-46bf-bb43-23f1d58628e2,C1441506,C0010654,support ,Calculation,Cysteine,3,X,[acty],[aapp/bacs],,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
6039f0da-6ef9-437a-83cd-783c35ce8958,C0034348,C0010654,support ,Pyruvate Kinase,Cysteine,3,X,[aapp/enzy],[aapp/bacs],D08.811.913.696.620.695,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
cb8b09ef-9064-4ba1-80eb-f35dd4bff929,C1441506,C0076994,support ,Calculation,Triad Acrylic Resin,3,X,[acty],[bodm/orch],,x.x.x.x
0f2aac12-6f42-4dd3-a390-135ea7d8e2fd,C0034348,C0076994,support ,Pyruvate Kinase,Triad Acrylic Resin,3,X,[aapp/enzy],[bodm/orch],D08.811.913.696.620.695,x.x.x.x
a364116e-1270-4156-a0b4-29f5f1587c20,BL2,C0444626,is coupled to titration of C271/270 in agreement with ,BL2,Crystal Structure,6,X,????,[chvs],????,
0f1be93c-79de-4226-89ba-68391116f14f,C3826426,C0444626,is coupled to titration of C271/270 in agreement with ,Dynamics,Crystal Structure,6,X,[npop],[chvs],,
c84428c0-c01b-4084-a89f-49f018192655,BL2,C1175743,is coupled to titration of C271/270 in agreement with ,BL2,SARS coronavirus,6,X,????,[virs],????,B04.820.504.540.150.113.937
094a6991-8953-44c4-a8c1-3931f9eabab8,C3826426,C1175743,is coupled to titration of C271/270 in agreement with ,Dynamics,SARS coronavirus,6,X,[npop],[virs],,B04.820.504.540.150.113.937
d6c9b23b-550c-4324-95db-5371fcdd6d85,BL2,C3698360,is in ,BL2,Middle East Respiratory Syndrome Coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.750
e46edc7c-defd-4d1c-ba22-78c8545fa818,C0010813,C1175743,is in cells of ,Cytokinesis,SARS coronavirus,1,X,[celf],[virs],G04.144.220.250,B04.820.504.540.150.113.937
6bc0dce0-6a8c-4828-864c-c6d250f76f13,C0039902,C0206419,represents promising ,Thioguanine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.759.854,B04.820.504.540.150
04ded713-528c-43d1-a898-ab302015406e,C1175743,C0206419,recently emerged as responsible for ,SARS coronavirus,Genus: Coronavirus,90,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150
fc9a59ab-50fa-4fe3-92bb-23c8379cdcea,C0010340,C0024109,clinical outcomes of are most likely impaired exchange in ,Critical Illness,Lung,1,X,[dsyn],[bpoc],C23.550.291.625,A04.411
87f1c6aa-2796-435e-b304-d5bae9ac888f,C0032105,C0206419,were applied to severe ,Plasma,Genus: Coronavirus,5,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,B04.820.504.540.150
64781ef2-1a26-4f0a-b792-ac1d7d0d9598,C0206419,C0034019,was controlled with coordinated ,Genus: Coronavirus,public health medicine (field),28,X,[virs],[bmod],B04.820.504.540.150,H02.403.720;N01.400.550;N06.850
764eccbd-2915-4248-ac09-66b5abf34dde,C0012634,27th,has resulted As of May 27th,Disease,27th,2,X,[dsyn],????,C23.550.288,????
a0115f95-5560-4b10-a877-b9ca79a062e1,C0013216,C0199176,suitable for ,Pharmacotherapy,Prophylactic treatment,3,X,[topp],[topp],E02.319,
16181153-b16f-4efe-b39c-cfc7402b359b,C0013216,C0206419,suitable for ,Pharmacotherapy,Genus: Coronavirus,1,X,[topp],[virs],E02.319,B04.820.504.540.150
6e00576c-0c5b-4cad-90a8-5c2456da8d15,C0003968,C0042890,is crucial ,Ascorbic Acid,Vitamins,3,X,[orch/phsu/vita],[orch/phsu/vita],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,D27.505.696.377.683.500.600;G07.203.300.681.500.600;J02.500.681.500.600
48639b53-3977-4136-911e-778584804ad4,C0034392,C0596577,is well-known ,Quercetin,Flavonoids,3,X,[orch/phsu/vita],[orch],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D03.383.663.283.266.450;D03.633.100.150.266.450
17df82df-fab2-467d-bfdc-7d997258740d,C0003968,C0003451,exerts synergistic ,Ascorbic Acid,Antiviral Agents,2,X,[orch/phsu/vita],[phsu],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,D27.505.954.122.388
13e91e77-cd28-4bea-9fca-b037db44cd55,C0003968,C3266814,exerts synergistic ,Ascorbic Acid,Action,1,X,[orch/phsu/vita],[acty],D02.241.081.844.107;D02.241.511.902.107;D09.811.100,
ec0d6b61-7af6-49aa-b542-fbc72bfbc3ad,C0206419,C1175743,successively named ,Genus: Coronavirus,SARS coronavirus,114,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113.937
bd654974-9363-4855-b045-41bcb070fed3,C0206419,C0012634,with patients is ,Genus: Coronavirus,Disease,27,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288
860eade2-b5d7-4922-9acf-a2477db6fd92,C0206419,C0027051,management of ,Genus: Coronavirus,Myocardial Infarction,4,X,[virs],[dsyn],B04.820.504.540.150,C14.280.647.500;C14.907.585.500
7f3cc171-6270-4dcf-b7fb-ac88dd3e040d,C1457887,C3714514,is necessary For patients with suspected ,Symptoms,Infection,4,X,[sosy],[patf],,C01.539
7f3cc171-6270-4dcf-b7fb-ac88dd3e040d,C1457887,C3714514,people with suspected ,Symptoms,Infection,1,X,[sosy],[patf],,C01.539
02c899d2-b71d-4735-9255-7c2126a80902,C0013879,C0042210,is In absence of ,Elements,Vaccines,3,X,[elii],[aapp/imft/phsu],D01.268,D20.215.894
37fef159-786b-4efe-a6d5-aea759fdd40d,C0024109,C1440080,are damaged due to presence on epithelial ,Lung,Alveolar,3,X,[bpoc],[bpoc],A04.411,
c6aa2415-7849-4ea6-b898-0e7935c7218f,C0024109,C0014597,are damaged due to presence on epithelial ,Lung,Epithelial Cells,5,X,[bpoc],[cell],A04.411,A11.436
2bb6e828-6f92-47a5-82d4-75305a0875a1,C0242656,C0018801, includes ,Disease Progression,Heart failure,3,X,[patf],[dsyn],C23.550.291.656,C14.280.434
f479942a-4a56-4349-b190-97eb73681312,C0030660,C0242656,strongly associated to atherosclerotic ,Pathologic Processes,Disease Progression,3,X,[patf],[patf],C23.550,C23.550.291.656
b3f445f5-397b-4872-a9a5-bf64beb06f6c,C0030660,C0018801,strongly associated to atherosclerotic ,Pathologic Processes,Heart failure,3,X,[patf],[dsyn],C23.550,C14.280.434
c6de7190-d539-4a7a-9108-67ee7b8e1fe5,C0030660,C1175175,could serve as predictive factors for severity during ,Pathologic Processes,Severe Acute Respiratory Syndrome,1,X,[patf],[dsyn],C23.550,C02.782.600.550.200.750;C08.730.730
efaeaf8e-6fb4-484f-aa94-bb746598945f,C0242656,C0021764,is characterized by immune system dysregulation leading to pro-inflammatory ,Disease Progression,Interleukins,6,X,[patf],[aapp/imft],C23.550.291.656,D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465
1846efb9-1f07-4ce8-9437-1cc12e6ed71d,C0242656,C1817997,is characterized as ,Disease Progression,chronic inflammatory response,9,X,[patf],[patf],C23.550.291.656,
a4fbbb3e-5e89-403e-8174-4119ff8c4767,C0004153,C3891814,may may ideal pathogenetic ,Atherosclerosis,Substrate,3,X,[dsyn],[sbst],C14.907.137.126.307,
8e448996-185a-4f74-b674-4e046b9a8615,C0004153,C0598312,may may ideal pathogenetic ,Atherosclerosis,DNA Replication,3,X,[dsyn],[genf],C14.907.137.126.307,G02.111.225;G05.226
ff43a52e-3672-4f67-9b3d-c1fb705fb894,C0282580,C3711684,potential B-Lymphocytes of,Epitopes T-Lymphocyte,S protein severe acute respiratory syndrome coronavirus,9,X,[imft],[aapp/bacs],D23.050.550.402,x.x.x.x
d9d96a7e-d37f-4df5-b847-1794f2a6ef83,C0282580,C0030956,potential B-Lymphocytes of,Epitopes T-Lymphocyte,Peptides,2,X,[imft],[aapp/phsu],D23.050.550.402,D12.644
3afa6618-9f5a-408a-9324-7608c7c3cc25,C3711684,C0003320,has S protein severe acute respiratory syndrome coronavirus different,S protein severe acute respiratory syndrome coronavirus,Antigens,10,X,[aapp/bacs],[imft],x.x.x.x,D23.050
83ce37fb-096c-4b01-ac2a-7de382c81981,C0185027,C0030956,is with fusion ,Imbrication (procedure),Peptides,5,X,[topp],[aapp/phsu],,D12.644
e6534761-6938-4f21-91d6-0dc388b9b01b,C0003316,C3711684,is in,Epitopes,S protein severe acute respiratory syndrome coronavirus,10,X,[imft],[aapp/bacs],D23.050.550,x.x.x.x
60e97993-aa36-465f-b845-7d24543fdcd2,C3711684,C0021083,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Immunotherapy,1,X,[aapp/bacs],[topp],x.x.x.x,E02.095.465.425
ebfb66a2-ed2c-488c-aa0f-c3fc0fd22f0a,C3711684,C0206419,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Genus: Coronavirus,4,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
f147996b-0ddb-4b08-8395-c30d7e718cb8,C0319157,C0086418,started from single ,AS virus,Homo sapiens,17,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
cc371810-9223-4f35-9b5e-dc2f107b34be,COVID-19,C0149978,is with ,COVID-19,Adenocarcinoma of rectum,1,X,[virs],[neop],C000657245,
0a4e6788-4312-4ded-ac63-4cb6e62829b4,C0010200,COVID-19,was diagnosed with ,Coughing,COVID-19,2,X,[sosy],[virs],C08.618.248;C23.888.852.293,C000657245
4349ebfc-4a2f-466b-a73a-31e4acdb3ebb,C1175743,COVID-19,is responsible for ,SARS coronavirus,COVID-19,20,X,[virs],[virs],B04.820.504.540.150.113.937,C000657245
e8e5fb52-b067-45f1-92e6-ee3f4f5ec560,C0369718,COVID-19,RBCs from ,N not otherwise specified Antibody,COVID-19,1,X,[aapp/imft],[virs],,C000657245
48e24212-7392-4911-bd33-67928e05b0ec,C0030054,COVID-19,RBCs from ,Oxygen,COVID-19,1,X,[bacs/elii/phsu],[virs],D01.268.185.550;D01.362.670;x.x.x.x,C000657245
86999d7e-9a07-4aac-a7c8-85b2883e63ba,C0009450,C1457887,may progress without ,Communicable Diseases,Symptoms,2,X,[dsyn],[sosy],C01.539.221,
15187aca-82a5-48f7-a755-6ffecef53899,C0543467,C0023693,is mandatory in ,Operative Surgical Procedures,Light,6,X,[topp],[npop],E04,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
6f202aa3-8ce5-44e9-ad63-7aaf69b55fb9,C0206750,C1880355,was ,Coronavirus Infections,Discover,1,X,[dsyn],[acty],C02.782.600.550.200,
5abb7454-e231-428c-9112-37b83ebbbdaa,C0012634,C1880355,was ,Disease,Discover,1,X,[dsyn],[acty],C23.550.288,
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,discuss ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,was to COVID19 ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,evaluate ,Aim,COVID-19,3,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,explore ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,provide ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,identify ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,better quantify ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,show ,Aim,COVID-19,2,X,[inch/phsu],[virs],,C000657245
bc8bc29d-555d-4149-adf2-3df5288fd669,C2948600,COVID-19,preserve healthcare resources during ,Aim,COVID-19,1,X,[inch/phsu],[virs],,C000657245
d83517e4-058f-4f09-b4ed-a608b8274e5b,C2948600,C1521863,discuss ,Aim,estrogen receptor alpha human,1,X,[inch/phsu],[aapp/rcpt],,x.x.x.x
603adb75-2fb0-4c37-9d54-e942ebbaba22,C0035668,C0036087,is in ,RNA,saliva,5,X,[nnon],[bdsu],D13.444.735,A12.200.666
f7e8a889-c4ca-43db-bff9-6003bc25a842,C0003342,C0003320,was detected by rapid ,Antigens Viral,Antigens,4,X,[imft],[imft],D23.050.327,D23.050
f7e8a889-c4ca-43db-bff9-6003bc25a842,C0003342,C0003320,was Detection by rapid,Antigens Viral,Antigens,1,X,[imft],[imft],D23.050.327,D23.050
f79f2fff-28d2-4c42-9330-c83f81e79137,C0036087,COVID-19,diagnosing ,saliva,COVID-19,1,X,[bdsu],[virs],A12.200.666,C000657245
8c80f1c6-d0b4-4854-b5b5-2e964108313d,C0014507,C3714514,is necessary For patients with ,Epidemiology,Infection,3,X,[bmod],[patf],H02.403.720.500,C01.539
f464a857-0ffc-4ba0-97de-4d57fca99dd2,C0319157,C1856053,was declared pandemic on ,AS virus,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],,x.x.x.x
ed3eb2e2-87f0-4ca1-8571-0c10e3bd522e,C0030946,C0007428, includes ,Endopeptidases,Cathepsins,3,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,D08.811.277.656.224
9eb3e215-ca41-43c1-bf44-6c1fb5914c8a,C0030946,C1742865, includes ,Endopeptidases,TMPRSS2 protein human,3,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,x.x.x.x
9eb3e215-ca41-43c1-bf44-6c1fb5914c8a,C0030946,C1742865,as Serine Endopeptidases is,Endopeptidases,TMPRSS2 protein human,1,X,[aapp/enzy/phsu],[aapp/enzy],D08.811.277.656.300,x.x.x.x
43c34a5b-f251-4444-ab3e-c8ef42151620,C0030946,C0700271,splits up ,Endopeptidases,M Protein multiple myeloma,1,X,[aapp/enzy/phsu],[aapp/imft],D08.811.277.656.300,x.x.x.x
9a117c3f-abdf-420e-8445-21d2d8092dac,C0007428,C0700271,splits up ,Cathepsins,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],D08.811.277.656.224,x.x.x.x
b5825220-f093-4773-89fe-1ce80d88530c,C1742865,C0700271,splits up ,TMPRSS2 protein human,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,x.x.x.x
b5825220-f093-4773-89fe-1ce80d88530c,C1742865,C0700271,used for ,TMPRSS2 protein human,M Protein multiple myeloma,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,x.x.x.x
8e8ca1a1-f045-4f31-9f8a-a71c81bd2e14,C3698360,C1447020,uses ,Middle East Respiratory Syndrome Coronavirus,DPP4 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.750,x.x.x.x
942ab815-b837-4c3c-9788-538b8c681349,C0079189,COVID-19,was analyzed in ,cytokine,COVID-19,6,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,C000657245
67a36540-f4e6-4600-838d-a85b4ea4b31e,C1861452,COVID-19,was analyzed in ,Storm Syndrome,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
67a36540-f4e6-4600-838d-a85b4ea4b31e,C1861452,COVID-19,may complicate ,Storm Syndrome,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
da699b64-8aff-406c-b484-7ae5a44c429e,COVID-19,C0206750,of propagation is ,COVID-19,Coronavirus Infections,11,X,[virs],[dsyn],C000657245,C02.782.600.550.200
c816d1e0-772a-4dd1-9d91-a9fcd18c05eb,COVID-19,C1175743,was diagnosed by ,COVID-19,SARS coronavirus,41,X,[virs],[virs],C000657245,B04.820.504.540.150.113.937
b98bec1d-425e-4fd4-9d2e-b311ef3fb22d,C0012634,C0087111,pose major ,Disease,Therapeutic procedure,3,X,[dsyn],[topp],C23.550.288,E02
b98bec1d-425e-4fd4-9d2e-b311ef3fb22d,C0012634,C0087111,modifying ,Disease,Therapeutic procedure,1,X,[dsyn],[topp],C23.550.288,E02
b98bec1d-425e-4fd4-9d2e-b311ef3fb22d,C0012634,C0087111,develop ,Disease,Therapeutic procedure,2,X,[dsyn],[topp],C23.550.288,E02
092f8bfc-fac3-43fe-8f3b-a37cc1b7a056,C0021764,C0021368,play role in ,Interleukins,Inflammation,3,X,[aapp/imft],[patf],D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465,C23.550.470
76742397-c051-4ee6-8dc7-a6938a847057,C0021764,C3819028,play role in ,Interleukins,Interleukin 6 Receptor Antagonists,1,X,[aapp/imft],[celf],D12.644.276.374.465;D12.776.467.374.465;D23.529.374.465,
67cf3a48-83dd-412b-83f2-a7551ff149c4,C0021368,C1609165,Interleukin 6 Receptor Antagonists such as,Inflammation,tocilizumab,1,X,[patf],[aapp/imft/phsu],C23.550.470,x.x.x.x
200e1c2a-7f7d-4ec2-ad7c-706403d45f6b,C0948245,COVID-19,is in ,Cytokine Release Syndrome,COVID-19,8,X,[dsyn],[virs],,C000657245
ac33f94f-2658-46a2-9967-2131e60d2b14,C0030664,C0040145, includes ,Pathology,Thyroidectomy,1,X,[bmod],[topp],H02.403.650,E04.270.856
2659e7d5-c80d-4b50-8c19-4fa451269aed,C0185115,COVID-19,radiological Materials of,Extraction,COVID-19,1,X,[topp],[virs],,C000657245
68f3961c-1a51-4fbe-b895-d2dd9be98844,C1880355,C0013203,will will paramount for efficient delivery of possible ,Discover,Drug resistance,3,X,[acty],[biof],,G07.690.773.984
b5f3e205-0c48-4271-8ba3-373205b1fb97,C0849867,C0034386,has necessitated self ,Widespread Disease,Quarantine,2,X,[dsyn],[topp],,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,has necessitated self ,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,can can exploited for early ,Coronavirus Infections,Quarantine,2,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,using strategies of ,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
bc73b905-566c-4331-847d-c5514968c465,C0206750,C0034386,One of were,Coronavirus Infections,Quarantine,1,X,[dsyn],[topp],C02.782.600.550.200,N06.850.780.200.450.700
faeb470a-cf3b-4939-890e-0995ea24fa99,C0849867,C0012634,so prevent spread of ,Widespread Disease,Disease,3,X,[dsyn],[dsyn],,C23.550.288
faeb470a-cf3b-4939-890e-0995ea24fa99,C0849867,C0012634,may drive interest in ,Widespread Disease,Disease,1,X,[dsyn],[dsyn],,C23.550.288
350924a3-b88b-4192-a428-ca8cd7fecacc,C0150593,C0038443,cope with ,game,Stress Psychological,4,X,[dora],[mobd],,F01.145.126.990;F02.830.900
02513166-5c1b-49cd-a4fe-42ba9649d888,C0278627,COVID-19,is in ,oncology field,COVID-19,1,X,[bmod],[virs],,C000657245
6140b81c-3bac-474c-ba4d-2a6a3a1da767,C0086418,C0022709,exhibits greater ,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
6140b81c-3bac-474c-ba4d-2a6a3a1da767,C0086418,C0022709,in Peptidyl-Dipeptidase A is,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
6140b81c-3bac-474c-ba4d-2a6a3a1da767,C0086418,C0022709,Failed have higher percentage of ,Homo sapiens,Peptidyl-Dipeptidase A,1,X,[humn],[aapp/enzy/imft],B01.050.150.900.649.313.988.400.112.400.400,D08.811.277.656.350.350.687
09e1ebd7-1ca6-4fed-92e8-b87e7f313321,C0018787,C0022709,exhibits greater ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
09e1ebd7-1ca6-4fed-92e8-b87e7f313321,C0018787,C0022709,also express ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
09e1ebd7-1ca6-4fed-92e8-b87e7f313321,C0018787,C0022709,Failed have higher percentage of ,Heart,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.541,D08.811.277.656.350.350.687
0604791f-8c29-4bfb-bfe8-663e1aebd250,C0022709,C0024109,were widely disturbed among ,Peptidyl-Dipeptidase A,Lung,16,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A04.411
3c890e7e-d790-4721-a3ab-9ef62ccde73c,C0022709,C0018787,is in adult human ,Peptidyl-Dipeptidase A,Heart,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.541
3c890e7e-d790-4721-a3ab-9ef62ccde73c,C0022709,C0018787,is more highly expressed in ,Peptidyl-Dipeptidase A,Heart,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.541
3c890e7e-d790-4721-a3ab-9ef62ccde73c,C0022709,C0018787,were widely disturbed among ,Peptidyl-Dipeptidase A,Heart,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.541
443aed7e-2767-43de-91bf-fdde1e808a83,C0018787,C1742865,in TMPRSS2 protein human is,Heart,TMPRSS2 protein human,2,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
074be556-f4fd-4022-bfb4-c41cab73e14d,C0010813,C0018787,is in ,Cytokinesis,Heart,1,X,[celf],[bpoc],G04.144.220.250,A07.541
a0020bbf-269d-485c-9b10-f3905d92dcea,C0030946,C0018787,is in ,Endopeptidases,Heart,1,X,[aapp/enzy/phsu],[bpoc],D08.811.277.656.300,A07.541
8f4d34ac-c889-4afe-8257-55bec849ab5b,C1742865,C0018787,is in ,TMPRSS2 protein human,Heart,1,X,[aapp/enzy],[bpoc],x.x.x.x,A07.541
70bfe140-7680-468c-a211-587795bde26b,C0022709,C0086418,is widely expressed in ,Peptidyl-Dipeptidase A,Homo sapiens,15,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,B01.050.150.900.649.313.988.400.112.400.400
71f61495-eb3c-4dca-a0d1-39a9d06be419,C3714514,C1457887,may even progress without ,Infection,Symptoms,1,X,[patf],[sosy],C01.539,
71f61495-eb3c-4dca-a0d1-39a9d06be419,C3714514,C1457887,generally have few ,Infection,Symptoms,1,X,[patf],[sosy],C01.539,
e6f1d92a-717f-460a-b664-be58f3bf0d96,C3714514,C0242781,produced For early ,Infection,disease transmission,1,X,[patf],[patf],C01.539,N06.850.310
d68785ed-f587-44e2-ab10-fbf31ce1fdc9,C0013216,C0206750,suitable for ,Pharmacotherapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.319,C02.782.600.550.200
4bd00a37-7928-43a5-8293-029ebb5e319f,C0036087,C0206750,diagnosing ,saliva,Coronavirus Infections,3,X,[bdsu],[dsyn],A12.200.666,C02.782.600.550.200
c52807e7-4e66-4748-ad59-d2efca532150,C0206750,C1547282,has ,Coronavirus Infections,Show,1,X,[dsyn],[anim],C02.782.600.550.200,
2115240c-3c2a-49cb-8bc9-69dc7e39622e,C0022709,C1819995,is recognized ,Peptidyl-Dipeptidase A,Host Cell,4,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
2115240c-3c2a-49cb-8bc9-69dc7e39622e,C0022709,C1819995,prevent SARS coronavirus attaching to,Peptidyl-Dipeptidase A,Host Cell,5,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
a389f2f3-8cd9-4c26-aade-6114b78a6e38,C0022709,C0597357,was identified as ,Peptidyl-Dipeptidase A,receptor,26,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,
fdbb196c-ca6d-48e6-929d-7b8e77ed336a,C1819995,C1175743,mediating SARS coronavirus by,Host Cell,SARS coronavirus,8,X,[celc],[virs],,B04.820.504.540.150.113.937
e93c5c7e-78d2-4a4c-ba03-a1fb2d47b433,C0597357,C1175743,mediating SARS coronavirus by,receptor,SARS coronavirus,8,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
e93c5c7e-78d2-4a4c-ba03-a1fb2d47b433,C0597357,C1175743,be functional target for spike ,receptor,SARS coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
e93c5c7e-78d2-4a4c-ba03-a1fb2d47b433,C0597357,C1175743,prevent ,receptor,SARS coronavirus,6,X,[aapp/rcpt],[virs],,B04.820.504.540.150.113.937
7fe25e37-0ae2-4d92-a248-0ad9f7f0bf73,C2258685,C1879547,mitigates deleterious effects associated with ,angiotensin converting enzyme activity,Activation action,4,X,[moft],[acty],,
9a7d9851-f7aa-4724-ae4f-13274a708b64,C2258685,C0178784,mitigates deleterious effects associated with ,angiotensin converting enzyme activity,Organ,4,X,[moft],[bpoc],,
b1bf4a00-cc7c-40fe-8cb4-670dae3f3f20,C0233929,C0034019,affecting ,Emission - Male genitalia finding,public health medicine (field),4,X,[bdsu],[bmod],,H02.403.720;N01.400.550;N06.850
4c77fbd8-5753-41ea-8634-dfb0d382fa10,C0206750,C0087111,could could applied as ,Coronavirus Infections,Therapeutic procedure,1,X,[dsyn],[topp],C02.782.600.550.200,E02
4c77fbd8-5753-41ea-8634-dfb0d382fa10,C0206750,C0087111,toxic effect increased of,Coronavirus Infections,Therapeutic procedure,2,X,[dsyn],[topp],C02.782.600.550.200,E02
4c77fbd8-5753-41ea-8634-dfb0d382fa10,C0206750,C0087111,has IMPACT gene toxic,Coronavirus Infections,Therapeutic procedure,2,X,[dsyn],[topp],C02.782.600.550.200,E02
4c77fbd8-5753-41ea-8634-dfb0d382fa10,C0206750,C0087111,mobilized institutions worldwide in race towards ,Coronavirus Infections,Therapeutic procedure,3,X,[dsyn],[topp],C02.782.600.550.200,E02
2bc43840-38ee-4de2-bf28-054b9caadceb,C0008269,C3541371,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,Quinoline derivatives antiseptics and disinfectants,2,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,
3b6d23b6-c5b7-48fa-9926-b6914c326ae7,C0008269,C0019398,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,Heterocyclic Compounds,2,X,[orch/phsu],[orch],D03.633.100.810.050.180,D03
bfe7a41a-830d-4e0d-b256-644acc75b508,C0008269,C0772162,are Quinoline derivatives antiseptics and disinfectants of,Chloroquine,AROMATICS,1,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,
914478ee-fcb2-4ca7-bb6f-e655bd7128d9,C0020336,C0019398,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,Heterocyclic Compounds,4,X,[orch/phsu],[orch],D03.633.100.810.050.180.350,D03
df5cf0c5-d3df-4e21-a457-abd276c13bcc,C0020336,C0772162,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,AROMATICS,2,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,
9d59d2dd-cec3-4fbb-8c8a-68ff246c4ee5,C0020336,C3541371,are Quinoline derivatives antiseptics and disinfectants of,Hydroxychloroquine,Quinoline derivatives antiseptics and disinfectants,3,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,
cacc7ac7-892e-4256-985e-109f0b0be2b7,C0004364,C0024141, includes ,Autoimmune Diseases,Lupus Erythematosus Systemic,2,X,[dsyn],[dsyn],C20.111,C17.300.480;C20.111.590
aabbfa19-1af9-449c-8d98-932978bbe21f,C0008269,U.S.,were Recently approved for U.S. ,Chloroquine,U.S.,1,X,[orch/phsu],????,D03.633.100.810.050.180,????
69252146-0fcd-4b4b-af06-ce58570fcd98,C0008269,C1175743,were Recently approved for U.S. ,Chloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150.113.937
69252146-0fcd-4b4b-af06-ce58570fcd98,C0008269,C1175743,exhibited anti ,Chloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150.113.937
2ed91fc9-93d7-45a4-bcc3-a287f78bc9e1,C0206750,C1175175,rapidly progresses to ,Coronavirus Infections,Severe Acute Respiratory Syndrome,19,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200.750;C08.730.730
7a77529c-e899-4829-8620-80daab410708,C0206750,C0022709,is cause with ,Coronavirus Infections,Peptidyl-Dipeptidase A,4,X,[dsyn],[aapp/enzy/imft],C02.782.600.550.200,D08.811.277.656.350.350.687
7a77529c-e899-4829-8620-80daab410708,C0206750,C0022709,acts through ,Coronavirus Infections,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C02.782.600.550.200,D08.811.277.656.350.350.687
dada0c85-84b8-468d-bd0d-9937bbf8145b,C0206750,C0086418,took 0.39 million ,Coronavirus Infections,Homo sapiens,23,X,[dsyn],[humn],C02.782.600.550.200,B01.050.150.900.649.313.988.400.112.400.400
78d61cf9-c732-437c-b081-6f7b50a4b057,C0206750,C1167622,is cause with ,Coronavirus Infections,Binding (Molecular Function),2,X,[dsyn],[moft],C02.782.600.550.200,
31ac50c2-f609-4936-b017-645fa455a208,C0206750,C0014597,is cause with ,Coronavirus Infections,Epithelial Cells,4,X,[dsyn],[cell],C02.782.600.550.200,A11.436
94a25f02-b978-4347-8f69-af953ec8942d,C0206750,C0024109,is cause with ,Coronavirus Infections,Lung,3,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
94a25f02-b978-4347-8f69-af953ec8942d,C0206750,C0024109,predominantly involves ,Coronavirus Infections,Lung,3,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
94a25f02-b978-4347-8f69-af953ec8942d,C0206750,C0024109,leading to ,Coronavirus Infections,Lung,1,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
94a25f02-b978-4347-8f69-af953ec8942d,C0206750,C0024109, includes ,Coronavirus Infections,Lung,1,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
94a25f02-b978-4347-8f69-af953ec8942d,C0206750,C0024109,directly targets ,Coronavirus Infections,Lung,2,X,[dsyn],[bpoc],C02.782.600.550.200,A04.411
8e5ed53c-7da3-44e4-b2c5-80ed678007ac,C0815017,C2258685,may interfere with ,Angiotensin Receptor Antagonists,angiotensin converting enzyme activity,8,X,[phsu],[moft],D27.505.519.162,
593bd782-efc6-4b41-a4b6-19c31c5b81a5,C0022709,C2258685,may interfere with ,Peptidyl-Dipeptidase A,angiotensin converting enzyme activity,8,X,[aapp/enzy/imft],[moft],D08.811.277.656.350.350.687,
38e49790-b77f-4035-b364-e473e29b972a,C0243077,C2258685,may interfere with ,inhibitors,angiotensin converting enzyme activity,8,X,[chvf],[moft],,
75b34789-881c-4ac3-aaa7-6575140b46e8,nt,C0206750,did affect prognosis in ,nt,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
5a7cb5d7-dbde-4ade-9a51-a6e3ecb40aee,C0206750,C1628999,is caused by single-stranded ,Coronavirus Infections,SARS coronavirus RNA,4,X,[dsyn],[nnon],C02.782.600.550.200,
fea2a842-2733-43cc-8960-02dfec9200df,C0243077,C0003015, includes ,inhibitors,Angiotensin-Converting Enzyme Inhibitors,3,X,[chvf],[phsu],,D27.505.519.389.745.085
aac3cfd8-879f-4a52-8094-ea70507e7486,RAS,C0020538,are widely used in treatment of ,RAS,Hypertensive disease,5,X,????,[dsyn],????,C14.907.489
3cfe4c1b-8957-453a-9b75-4f3383cc1096,C0243077,C0020538,are widely used in treatment of ,inhibitors,Hypertensive disease,5,X,[chvf],[dsyn],,C14.907.489
ce9f069a-bca9-4ae3-9160-b07bab5c728c,C1175743,C0960880,is with ,SARS coronavirus,angiotensin converting enzyme 2,5,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,x.x.x.x
39d86c83-53e3-4c54-94d4-0e7dc5a6cade,C0042731,C0960880,attach ,Viral Matrix Proteins,angiotensin converting enzyme 2,4,X,[aapp/bacs],[aapp/enzy],D12.776.964.970.880.940,x.x.x.x
02bdb94c-d8a9-42d6-b845-e1db273fcfcd,C1175743,C0007603,attach angiotensin converting enzyme 2 on,SARS coronavirus,Plasma membrane,4,X,[virs],[celc],B04.820.504.540.150.113.937,A11.284.149
1db305b3-8b7e-4349-a63d-26d7c98b9a29,C0042731,C0007603,attach angiotensin converting enzyme 2 on,Viral Matrix Proteins,Plasma membrane,4,X,[aapp/bacs],[celc],D12.776.964.970.880.940,A11.284.149
ebf73407-0e1c-4e8d-818b-e6c536efbfab,RAS,C0206750,be maintained during current ,RAS,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
04f75073-e09b-4833-b767-2ab701fa0d60,C3540676,C0206750,be maintained during current ,Blockade,Coronavirus Infections,2,X,[elii/phsu],[dsyn],,C02.782.600.550.200
04f75073-e09b-4833-b767-2ab701fa0d60,C3540676,C0206750,be maintained in patients with ,Blockade,Coronavirus Infections,1,X,[elii/phsu],[dsyn],,C02.782.600.550.200
e64852f0-6b19-4bb6-8830-b38dfd21ffc9,C0013227,C0206750,point for ,Pharmaceutical Preparations,Coronavirus Infections,6,X,[phsu],[dsyn],D26,C02.782.600.550.200
18272cf8-2b9f-46b2-a92b-5a66b5afee9f,C2347218,C0206750,be alternative in ,Bronchial Artery Infusion Procedure,Coronavirus Infections,4,X,[topp],[dsyn],,C02.782.600.550.200
a05b6ad4-a005-4d46-a684-e7f47d994ced,C2347218,C0304229,be alternative in ,Bronchial Artery Infusion Procedure,Experimental drug,8,X,[topp],[phsu],,
74636723-6b43-494a-9bf9-50c8b02c16b5,C2347218,C0392877,be alternative for systemic ,Bronchial Artery Infusion Procedure,infusion of drug,9,X,[topp],[topp],,
59184b13-214a-46d6-b60f-49a09f240e28,C0206750,C0304229,is with superadded benefits of high ,Coronavirus Infections,Experimental drug,1,X,[dsyn],[phsu],C02.782.600.550.200,
f8a44d7b-9237-4e6d-9193-01a0c0285832,C0003451,C0206750,stop ,Antiviral Agents,Coronavirus Infections,7,X,[phsu],[dsyn],D27.505.954.122.388,C02.782.600.550.200
fb6ad8f0-bef5-4f7e-9c50-5fd9dddfb0b2,C0003451,C0309872,stop ,Antiviral Agents,PREVENT (product),1,X,[phsu],[phsu],D27.505.954.122.388,
49f2cb49-a26c-4f90-8058-778c6b750bfb,C0012634,C0206750,was named ,Disease,Coronavirus Infections,41,X,[dsyn],[dsyn],C23.550.288,C02.782.600.550.200
f295777b-dec7-4e31-9064-6bfd4f5a5e17,C4042834,C0206750,gained importance during ,Compassion Fatigue,Coronavirus Infections,2,X,[mobd],[dsyn],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C02.782.600.550.200
f295777b-dec7-4e31-9064-6bfd4f5a5e17,C4042834,C0206750,directly working with ,Compassion Fatigue,Coronavirus Infections,1,X,[mobd],[dsyn],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C02.782.600.550.200
7f80099f-40dc-4436-9804-e44b32a8703a,C4042834,C0012634,gained importance during ,Compassion Fatigue,Disease,2,X,[mobd],[dsyn],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C23.550.288
306db04c-92ea-4943-9f51-ec440f257c0c,C0042776,C0004391,exploit ,Virus,Autophagy,4,X,[virs],[celf],B04,G04.146.399;G04.417.350.091
52b7e33c-d3e0-4a2a-924b-e7c99b506fd5,C0947647,C0042776,allows ,Manipulation procedure,Virus,4,X,[topp],[virs],,B04
5a46f340-0eac-4ec0-9e2f-668633e60be7,C1704259,C0206750,might play role in ,Biochemical Pathway,Coronavirus Infections,3,X,[moft],[dsyn],,C02.782.600.550.200
5a46f340-0eac-4ec0-9e2f-668633e60be7,C1704259,C0206750,Dysregulation of were proposed mechanisms of ,Biochemical Pathway,Coronavirus Infections,2,X,[moft],[dsyn],,C02.782.600.550.200
b79899ac-15aa-4330-b016-4f915333090e,C1704259,C0598312,might play role in ,Biochemical Pathway,DNA Replication,4,X,[moft],[genf],,G02.111.225;G05.226
0b4ab216-1b5c-4956-87bc-a8cc3fa48877,C3711684,C0005525,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Biological Response Modifiers,4,X,[aapp/bacs],[imft/phsu],x.x.x.x,D27.505.696.477
61bf3109-8208-4330-a5e3-f5812f8184e7,C3711684,C0206750,may improve vaccine design diagnosis and ,S protein severe acute respiratory syndrome coronavirus,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
30fef593-d343-4280-9071-73f438392fa9,COVID,C1175743,are similar to those of ,COVID,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
30fef593-d343-4280-9071-73f438392fa9,COVID,C1175743,is much more than ,COVID,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
3dd4cdd7-00d8-46b4-9340-5c868f88f5dd,C1552133,C1175743,are similar to those of ,19s,SARS coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150.113.937
1356cc7c-457e-4902-8230-e401937894f8,C1882932,C0556656,should have Inclusion Bodies in strategic,Representation (action),Meetings,2,X,[acty],[acty],,
7eec227f-7b32-4518-b298-8e8949d077fe,C1882932,C0007637,should have equal ,Representation (action),Inclusion Bodies,2,X,[acty],[celc],,A11.284.420
bb2ccacf-25d9-4736-ad37-64c58c808a6c,C0011311,COVID-19,have ,Dengue Fever,COVID-19,2,X,[dsyn],[virs],C02.081.270;C02.782.350.250.214;C02.782.417.214,C000657245
b4bdb0fd-d0d8-466b-97be-a68fdd8f5aee,C0275524,C0011311,trigger alert especially for health care professionals in ,Coinfection,Dengue Fever,3,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,C02.081.270;C02.782.350.250.214;C02.782.417.214
f85200ad-0ba2-46b7-8b99-bc9735028877,C0042769,C0035243,is ,Virus Diseases,Respiratory Tract Infections,1,X,[dsyn],[dsyn],C02,C01.539.739;C08.730
fd189692-f998-4331-96b0-b87d3929d802,C3714514,C0023884,lead to ,Infection,Liver,1,X,[patf],[bpoc],C01.539,A03.620
430465df-9a6b-4980-a665-08462f67d067,C1175743,C0015733,was detected in ,SARS coronavirus,Feces,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
430465df-9a6b-4980-a665-08462f67d067,C1175743,C0015733,was isolated from ,SARS coronavirus,Feces,1,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
430465df-9a6b-4980-a665-08462f67d067,C1175743,C0015733,is shed via ,SARS coronavirus,Feces,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.459
8e1a34a0-4c50-4310-ab81-f70f1a0b7adc,CoV2,C0015733,was detected in ,CoV2,Feces,1,X,????,[bdsu],????,A12.459
f9111e66-71a2-449d-8409-c3e07610084f,C0022709,C2699153,enables ,Peptidyl-Dipeptidase A,Cell Invasion,1,X,[aapp/enzy/imft],[patf],D08.811.277.656.350.350.687,
4c5403f8-6185-4b73-93a5-276dd11a2893,C0022709,C0836205,enables ,Peptidyl-Dipeptidase A,Gut Epithelium,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
052f7309-c6c8-4727-ad9d-21f727693bcf,C0022709,vivo,enables Cell Invasion demonstrated and in vivo,Peptidyl-Dipeptidase A,vivo,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
125b6a41-cf6d-4b0a-b6ce-0cf954b643ff,C4529962,C0016059,is with ,Fatty Liver Disease,Fibrosis,1,X,[dsyn],[patf],,C23.550.355
4e13a1c0-8bfd-4c62-9b03-2a04bf6e086d,C0023890,C0206750,are at high risk for severe ,Liver Cirrhosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.552.630,C02.782.600.550.200
33ea23a0-b822-4290-8cb8-9bb263aad5b8,C1175175,C0032285,causes severe form of ,Severe Acute Respiratory Syndrome,Pneumonia,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.677;C08.730.610
33ea23a0-b822-4290-8cb8-9bb263aad5b8,C1175175,C0032285,COVID-19 as clinical ,Severe Acute Respiratory Syndrome,Pneumonia,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.677;C08.730.610
fe4e51b8-819f-494b-be3f-579147a1cbfd,C0086418,C3687832,develop ,Homo sapiens,Drugs - dental services,1,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,
d82c2691-0471-4ffb-a6eb-d5d1726d0e1b,C1659605,C3687832,develop ,interaction with host,Drugs - dental services,1,X,[celf],[topp],,
8b737a79-2bbd-4932-b17b-a2fea308935c,C0023870,C1979799,is commonly prescribed ,Lithium,Psychiatric drugs,1,X,[elii/phsu],[phsu],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,
951f4da2-1853-4cbd-b0a5-ac24c0666ada,C0042776,C0017968,uses its spike ,Virus,Glycoproteins,2,X,[virs],[aapp/bacs],B04,D09.400.430;D12.776.395
861b0ca1-dc45-4e9c-9cf1-d5eaaaa2c6c3,C0042776,C0597357,uses its spike ,Virus,receptor,2,X,[virs],[aapp/rcpt],B04,
861b0ca1-dc45-4e9c-9cf1-d5eaaaa2c6c3,C0042776,C0597357,recognizes other ,Virus,receptor,1,X,[virs],[aapp/rcpt],B04,
ef3625a0-39e8-4ad6-a521-0025d48e8145,C0042776,C4689723,uses its spike ,Virus,glycoprotein binding,2,X,[virs],[moft],B04,
9f06f2ff-4611-4606-8136-7673f730cb98,C0042776,C1819995,interact with ,Virus,Host Cell,2,X,[virs],[celc],B04,
9f06f2ff-4611-4606-8136-7673f730cb98,C0042776,C1819995,mediates altered ,Virus,Host Cell,2,X,[virs],[celc],B04,
9f06f2ff-4611-4606-8136-7673f730cb98,C0042776,C1819995,use ,Virus,Host Cell,2,X,[virs],[celc],B04,
9f06f2ff-4611-4606-8136-7673f730cb98,C0042776,C1819995,enter ,Virus,Host Cell,1,X,[virs],[celc],B04,
16bf58f1-1c45-4596-83e3-282a5929c5c4,C0042776,C0022709,interact with ,Virus,Peptidyl-Dipeptidase A,2,X,[virs],[aapp/enzy/imft],B04,D08.811.277.656.350.350.687
16bf58f1-1c45-4596-83e3-282a5929c5c4,C0042776,C0022709,exploit ,Virus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04,D08.811.277.656.350.350.687
9bc0476a-aaf7-4ed8-aae8-42d00f3fb7f3,C0948245,C0960756,be ,Cytokine Release Syndrome,factor A,2,X,[dsyn],[orch],,x.x.x.x
1cfac161-4233-446c-a739-2d84a8203c9e,C0948245,C1880177,be ,Cytokine Release Syndrome,Contribution,1,X,[dsyn],[acty],,
697d72a3-6ef1-4d52-b94e-056eabee4668,C3819028,C1609165, includes ,Interleukin 6 Receptor Antagonists,tocilizumab,6,X,[celf],[aapp/imft/phsu],,x.x.x.x
c34e6b58-a956-40e3-926d-82b73ad94e5e,C3819028,C0206419,may Therapeutic procedure,Interleukin 6 Receptor Antagonists,Genus: Coronavirus,1,X,[celf],[virs],,B04.820.504.540.150
d9f47c8a-289a-4166-84a6-ce55771895f8,C1609165,C0206419,may Therapeutic procedure,tocilizumab,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150
d9f47c8a-289a-4166-84a6-ce55771895f8,C1609165,C0206419,may may effective for treatment of severe ,tocilizumab,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150
f573e178-d396-4b74-aa66-a26916db02b0,C3819028,C0079189,attenuating ,Interleukin 6 Receptor Antagonists,cytokine,2,X,[celf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
39964f8f-d0a1-4634-80eb-a936686b955d,C1609165,C0079189,attenuating ,tocilizumab,cytokine,2,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.644.276.374;D12.776.467.374;D23.529.374
914d4c8b-d24a-4568-99a2-7259f83a3be3,C0948245,C0206419,is in ,Cytokine Release Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
dba23986-fa4f-4fe5-b89e-29ff3c388291,C2948600,C1947933,define guidelines for safe clinical ,Aim,care activity,1,X,[inch/phsu],[acty],,
dba23986-fa4f-4fe5-b89e-29ff3c388291,C2948600,C1947933,was to COVID19 ,Aim,care activity,1,X,[inch/phsu],[acty],,
dba23986-fa4f-4fe5-b89e-29ff3c388291,C2948600,C1947933,utilize ,Aim,care activity,1,X,[inch/phsu],[acty],,
384727c5-d0b9-4367-882b-4a03ec9d4fa3,C0032105,C0009450,Therapeutic procedure many types of,Plasma,Communicable Diseases,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C01.539.221
5026787e-9375-418a-85c7-a55196fcbb16,C0032105,C0012634,Therapeutic procedure many types of,Plasma,Disease,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
5026787e-9375-418a-85c7-a55196fcbb16,C0032105,C0012634,is explicit option for ,Plasma,Disease,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
5026787e-9375-418a-85c7-a55196fcbb16,C0032105,C0012634,is potential ,Plasma,Disease,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C23.550.288
a567c399-4273-4839-9e68-e0e7f3f9f85f,C0278627,C0206419,is in ,oncology field,Genus: Coronavirus,3,X,[bmod],[virs],,B04.820.504.540.150
8e8f2663-be97-4379-b0a2-93dffa1a142f,C0206419,C0015967,usually presents with ,Genus: Coronavirus,Fever,2,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
8e8f2663-be97-4379-b0a2-93dffa1a142f,C0206419,C0015967,causes severe ,Genus: Coronavirus,Fever,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
8e8f2663-be97-4379-b0a2-93dffa1a142f,C0206419,C0015967,is in patients with ,Genus: Coronavirus,Fever,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.119.344
43971920-cf70-4800-bb71-d5280c6216d2,PINI,C0184661,is low-risk ,PINI,Interventional procedure,1,X,????,[topp],????,
fc4a848c-90a1-48e5-b3a3-e5a03d4e7453,C0184661,C0021925,may prevent ,Interventional procedure,Intubation,1,X,[topp],[topp],,E02.585;E05.497
de2d4161-c672-445a-bafa-524442fd6df0,C0184661,C0035222,may prevent Intubation in certain patients with,Interventional procedure,Respiratory Distress Syndrome Adult,1,X,[topp],[dsyn],,C08.381.840;C08.618.840
6e033ced-da97-4e24-a69a-e64b88f62e19,C0206419,C0010200,be transmitted through ,Genus: Coronavirus,Coughing,1,X,[virs],[sosy],B04.820.504.540.150,C08.618.248;C23.888.852.293
6e033ced-da97-4e24-a69a-e64b88f62e19,C0206419,C0010200,share similar fever ,Genus: Coronavirus,Coughing,2,X,[virs],[sosy],B04.820.504.540.150,C08.618.248;C23.888.852.293
45f159ae-c22c-495d-9760-fd9476eabc9b,C1537432,C0020517,performed equally in terms of ,KALRN gene,Hypersensitivity,3,X,[gngm],[patf],,C20.543
a76d79b3-3c80-4eba-a607-1308894cfc65,C1175743,C0020517,performed equally in terms of ,SARS coronavirus,Hypersensitivity,3,X,[virs],[patf],B04.820.504.540.150.113.937,C20.543
a76d79b3-3c80-4eba-a607-1308894cfc65,C1175743,C0020517,generally exhibited ,SARS coronavirus,Hypersensitivity,1,X,[virs],[patf],B04.820.504.540.150.113.937,C20.543
b462d888-590d-42a7-ade3-84261db7ac88,C0042210,C0206419,is currently available for treatment of ,Vaccines,Genus: Coronavirus,5,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
b462d888-590d-42a7-ade3-84261db7ac88,C0042210,C0206419,show promise in ,Vaccines,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
b462d888-590d-42a7-ade3-84261db7ac88,C0042210,C0206419,prevent person from ,Vaccines,Genus: Coronavirus,1,X,[aapp/imft/phsu],[virs],D20.215.894,B04.820.504.540.150
0097b96c-d2b5-4760-bbdb-fa1f77d42908,C0022709,C0021699,is ,Peptidyl-Dipeptidase A,Integral Membrane Proteins,4,X,[aapp/enzy/imft],[aapp],D08.811.277.656.350.350.687,D12.776.543
be4613ab-3547-4eb2-b4f3-333f14fd366e,C0022709,C0225698,is ,Peptidyl-Dipeptidase A,Alveolar Epithelial Cells,6,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A04.411.715.100;A11.436.081
ec57b034-77df-4dc9-a2aa-8d0385549507,C0022709,C0682610,is ,Peptidyl-Dipeptidase A,Enterocytes,4,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
6036ffa2-362e-4a6b-a7ee-09d3955d5309,C0022709,C1257792,is ,Peptidyl-Dipeptidase A,Vascular Endothelial Cells,4,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436.275
f57f7136-6122-405b-a6fe-830f0c986b94,C0022709,C1175743,serves as major entry point into cells for ,Peptidyl-Dipeptidase A,SARS coronavirus,51,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,B04.820.504.540.150.113.937
b5ca148a-5296-4adb-91bb-6747a0c2c0b0,C0021699,C0024109,expressed by ,Integral Membrane Proteins,Lung,4,X,[aapp],[bpoc],D12.776.543,A04.411
ceaeb7a1-f09a-4c07-a3a1-2d8486cdaa2a,C0021699,C0225698,expressed by ,Integral Membrane Proteins,Alveolar Epithelial Cells,4,X,[aapp],[cell],D12.776.543,A04.411.715.100;A11.436.081
b7a0ad77-2910-407a-bbbc-3c5db58778a4,C0021699,C0682610,expressed by ,Integral Membrane Proteins,Enterocytes,4,X,[aapp],[cell],D12.776.543,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
adecfcc1-d6e1-47a8-81a2-d4edb9108ff4,C0021699,C1257792,expressed by ,Integral Membrane Proteins,Vascular Endothelial Cells,4,X,[aapp],[cell],D12.776.543,A11.436.275
ee365357-db06-4a07-8211-9d08476f1b03,C0042373,C1175743,is in patients with ,Vascular Diseases,SARS coronavirus,4,X,[dsyn],[virs],C14.907,B04.820.504.540.150.113.937
92a74c42-c1d8-448d-99ae-76a71a4cc5ae,C0039082,C1175743,is in patients with ,Syndrome,SARS coronavirus,4,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150.113.937
92a74c42-c1d8-448d-99ae-76a71a4cc5ae,C0039082,C1175743,following CoV2 ,Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150.113.937
6de692d9-c443-4477-989e-73e631e98a4f,C1175175,C0225336,is with focus on ,Severe Acute Respiratory Syndrome,Endothelial Cells,4,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.436.275
6de692d9-c443-4477-989e-73e631e98a4f,C1175175,C0225336,Severe Acute Respiratory Syndrome of,Severe Acute Respiratory Syndrome,Endothelial Cells,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.436.275
62c6b9d2-db3c-4daf-bb67-a736ad525ec3,C0206419,C0009450,triggers mechanisms main ,Genus: Coronavirus,Communicable Diseases,25,X,[virs],[dsyn],B04.820.504.540.150,C01.539.221
9fc8905d-f162-46a4-bc69-a110f55c5fb6,C0032285,C0009450,is very serious ,Pneumonia,Communicable Diseases,4,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C01.539.221
d46d79f4-a206-4767-b42a-1107303602ff,C0206419,C0008679,is associated with much ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
d46d79f4-a206-4767-b42a-1107303602ff,C0206419,C0008679,had more WBC CRP ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
d46d79f4-a206-4767-b42a-1107303602ff,C0206419,C0008679,persons with ,Genus: Coronavirus,Chronic disease,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.500
08dd3989-a3a7-4011-998f-1ec4674adeb3,C0206419,C0011849,is associated with especially ,Genus: Coronavirus,Diabetes Mellitus,1,X,[virs],[dsyn],B04.820.504.540.150,C18.452.394.750;C19.246
a8c9a986-cc9c-4ddf-b2e1-ecffb30d5197,C0008269,C1819995,blocks entry to ,Chloroquine,Host Cell,3,X,[orch/phsu],[celc],D03.633.100.810.050.180,
a8c9a986-cc9c-4ddf-b2e1-ecffb30d5197,C0008269,C1819995,blocks Virus Attachment to,Chloroquine,Host Cell,3,X,[orch/phsu],[celc],D03.633.100.810.050.180,
b28a83c5-9e6b-4a9c-9ce8-14262bf19714,C0008269,C1721019,blocks ,Chloroquine,Virus Attachment,3,X,[orch/phsu],[biof],D03.633.100.810.050.180,G06.920.868
c79e3ddf-d0ae-4eb1-a07e-686c27969d56,C0042776,C1175743, includes ,Virus,SARS coronavirus,7,X,[virs],[virs],B04,B04.820.504.540.150.113.937
c79e3ddf-d0ae-4eb1-a07e-686c27969d56,C0042776,C1175743,extrapolating effectiveness on ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
c79e3ddf-d0ae-4eb1-a07e-686c27969d56,C0042776,C1175743,causes ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
c79e3ddf-d0ae-4eb1-a07e-686c27969d56,C0042776,C1175743,have However since ,Virus,SARS coronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113.937
a80429b7-1a3c-4e8a-a879-f240e4ed84bf,C0042776,C0206419,agent of ,Virus,Genus: Coronavirus,2,X,[virs],[virs],B04,B04.820.504.540.150
a80429b7-1a3c-4e8a-a879-f240e4ed84bf,C0042776,C0206419, includes ,Virus,Genus: Coronavirus,10,X,[virs],[virs],B04,B04.820.504.540.150
a80429b7-1a3c-4e8a-a879-f240e4ed84bf,C0042776,C0206419,causes ,Virus,Genus: Coronavirus,7,X,[virs],[virs],B04,B04.820.504.540.150
8bdb086e-04da-44b9-a1d3-257e385f57d0,C0206419,C0035691,are large positive enveloped ,Genus: Coronavirus,RNA Viruses,2,X,[virs],[virs],B04.820.504.540.150,B04.820
8bdb086e-04da-44b9-a1d3-257e385f57d0,C0206419,C0035691,are group of ,Genus: Coronavirus,RNA Viruses,7,X,[virs],[virs],B04.820.504.540.150,B04.820
8bdb086e-04da-44b9-a1d3-257e385f57d0,C0206419,C0035691,is caused by ,Genus: Coronavirus,RNA Viruses,1,X,[virs],[virs],B04.820.504.540.150,B04.820
70691d3b-855d-4880-8c77-36ea9fd205fd,C0042776,C1704259,enter system from different ,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
70691d3b-855d-4880-8c77-36ea9fd205fd,C0042776,C1704259,entered CEL gene through different,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
70691d3b-855d-4880-8c77-36ea9fd205fd,C0042776,C1704259,entered Cells through different,Virus,Biochemical Pathway,1,X,[virs],[moft],B04,
f070fe23-3f44-4e1b-9b85-e9d0b2442705,C0206419,C1704259,enter system from different ,Genus: Coronavirus,Biochemical Pathway,1,X,[virs],[moft],B04.820.504.540.150,
75602159-bfd9-405f-aa0e-d83bd3cd6035,C0042776,C0004457,could In ,Virus,Axis vertebra,2,X,[virs],[bpoc],B04,A02.835.232.834.151.383
7cb2213a-51b9-4483-9c5b-adc43abff710,C0021368,C0004457,could In ,Inflammation,Axis vertebra,2,X,[patf],[bpoc],C23.550.470,A02.835.232.834.151.383
bf36d9c1-554b-46c6-9ced-7b294184d946,C0042776,C0235031,could In ,Virus,Neurologic Symptoms,2,X,[virs],[sosy],B04,C10.597;C23.888.592
d5d00536-f1f7-4abe-b06c-a5bd9d4da7b7,C0021368,C0235031,could In ,Inflammation,Neurologic Symptoms,2,X,[patf],[sosy],C23.550.470,C10.597;C23.888.592
40fd3ef4-90df-4c58-81cf-4581fddd9417,C0242606,C0004457,could In ,Oxidative Stress,Axis vertebra,2,X,[comd],[bpoc],G03.673;G07.775.750,A02.835.232.834.151.383
c2ee784b-8618-42fb-885c-5089843b2193,C0242606,C0235031,could In ,Oxidative Stress,Neurologic Symptoms,2,X,[comd],[sosy],G03.673;G07.775.750,C10.597;C23.888.592
8cb0b394-21ff-484d-bad5-02e382e1d964,C1150225,C1879547,mitigates deleterious effects associated with ,angiotensin I-converting enzyme activity,Activation action,8,X,[moft],[acty],,
5bd4b505-03cc-4118-b4ed-323e5f34f1d3,C1167622,C0022709,locate at ,Binding (Molecular Function),Peptidyl-Dipeptidase A,7,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
d5c54da9-97aa-4e5e-897e-85db74fe2c54,C1167622,C0010813,favors toform ACE2,Binding (Molecular Function),Cytokinesis,1,X,[moft],[celf],,G04.144.220.250
3b1bdf9f-d98d-4a66-98c0-299e885157f3,C1167622,toform,favors toform ACE2,Binding (Molecular Function),toform,1,X,[moft],????,,????
14d9f239-b183-467a-aa53-3014e92d6397,C1167622,ACE2,favors toform ACE2,Binding (Molecular Function),ACE2,1,X,[moft],????,,????
916f7cae-033c-4966-b69e-3b27a99c56ab,C0185003,COVID-19,were ,Reparative closure,COVID-19,1,X,[topp],[virs],,C000657245
ac0dcf61-1e5c-436e-9c58-d836b3391bb6,C1140694,C1880355,could provide alternative routes to CoV2 ,Bio-Informatics,Discover,1,X,[bmod],[acty],H01.158.273.180;L01.313.124,
949f00eb-6522-4b7b-be24-7ae9cca01d57,C1140694,C0678792,could provide alternative routes to CoV2 ,Bio-Informatics,drug potency,2,X,[bmod],[biof],H01.158.273.180;L01.313.124,
0797f10e-e215-4ef9-90ce-d7787c36a337,C1140694,C1175743,could provide alternative routes to CoV2 ,Bio-Informatics,SARS coronavirus,1,X,[bmod],[virs],H01.158.273.180;L01.313.124,B04.820.504.540.150.113.937
0797f10e-e215-4ef9-90ce-d7787c36a337,C1140694,C1175743,investigate origin of pandemic ,Bio-Informatics,SARS coronavirus,1,X,[bmod],[virs],H01.158.273.180;L01.313.124,B04.820.504.540.150.113.937
f3eec945-906a-4959-a218-fba95d5b6e07,C1140694,CoV2,could provide alternative routes to CoV2 ,Bio-Informatics,CoV2,1,X,[bmod],????,H01.158.273.180;L01.313.124,????
39955483-ba78-4d85-8536-d5622458dac4,C1547282,C0013227,have failed as ,Show,Pharmaceutical Preparations,1,X,[anim],[phsu],,D26
0891ce78-3846-4497-88cf-6dfb2df2edba,C0278627,C0206750,is in ,oncology field,Coronavirus Infections,1,X,[bmod],[dsyn],,C02.782.600.550.200
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,usually presents with ,Coronavirus Infections,Fever,4,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,Interestingly is characterized by ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,could cause wide range of ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,must must considered in evaluation of ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,was After emergence of novel ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
77c4b27c-3c32-465b-a135-04af3018f249,C0206750,C0015967,was initially characterized by ,Coronavirus Infections,Fever,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.119.344
5913d923-acb6-456f-b54f-de3ff2095e23,C0010813,PRRA,is with inserted sequence of PRRA,Cytokinesis,PRRA,2,X,[celf],????,G04.144.220.250,????
5ccbae5a-b1ca-4587-9562-a4b83089a3c9,C1175743,C0010813,has polybasic PRRA,SARS coronavirus,Cytokinesis,2,X,[virs],[celf],B04.820.504.540.150.113.937,G04.144.220.250
1eaa26cf-3ff7-4702-82a4-b015b359e9ea,C1175743,PRRA,has polybasic PRRA,SARS coronavirus,PRRA,2,X,[virs],????,B04.820.504.540.150.113.937,????
1fcc8e5c-3e0e-4ec8-ad61-2b2b30f7dc63,C0036720,C0999626,is in ,Serine,Manidae,2,X,[aapp/bacs/phsu],[mamm],D12.125.154.800,
d8e1b0ae-6469-4ed1-bd2c-ea4bb3170abc,C0036720,RaTG13,were seen in RaTG13,Serine,RaTG13,2,X,[aapp/bacs/phsu],????,D12.125.154.800,????
a43899a1-27f9-473d-902e-a3c465c3122c,C1175743,C0042776,was only ,SARS coronavirus,Virus,6,X,[virs],[virs],B04.820.504.540.150.113.937,B04
5aab6ae0-a4ba-4d79-84eb-4862e62b6c78,C0206750,C0042776,slow spread of ,Coronavirus Infections,Virus,10,X,[dsyn],[virs],C02.782.600.550.200,B04
5a31dfb2-5054-4d8d-914d-c9529168abf0,C1708476,C0242781,prevent further ,Implementation,disease transmission,2,X,[acty],[patf],,N06.850.310
1c36c3f5-f969-483f-bc21-dbcd2e4671fb,C0012634,C0683325,is currently diagnosed by ,Disease,clinical aspects,1,X,[dsyn],[clna],C23.550.288,
81a07952-2913-4b29-86b5-384976382d60,C0013227,C1547282,have ,Pharmaceutical Preparations,Show,1,X,[phsu],[anim],D26,
f01b476f-0a3b-4951-a0fb-0e56b5dcbf2c,C0012634,C3277428,increases ,Disease,Severe viral infections,6,X,[dsyn],[dsyn],C23.550.288,
903e7b99-f667-4c90-8efe-6c585335d265,C0206750,C0544633,can Lead to alterations of,Coronavirus Infections,Modulation cellular,6,X,[dsyn],[ortf],C02.782.600.550.200,
a092d55e-c63f-4433-be63-1f74639eaebe,C0206750,C1157241,can Lead through,Coronavirus Infections,NAD biosynthetic process,3,X,[dsyn],[moft],C02.782.600.550.200,
18d10234-6269-48bd-9095-c5c9f580aefe,C0208355,C0007613,is in ,multicatalytic endopeptidase complex,Cell physiology,3,X,[aapp/enzy],[celf],D05.500.562.500;D08.811.277.656.918;D08.811.600.730,G04
f098d734-d0ec-42c6-9e84-8a9aa064df8f,C0073591,IL-6,can increase IL-6 ,rosoxacin,IL-6,3,X,[antb/orch],????,x.x.x.x,????
accfc3bc-bcc3-49d1-bdd8-17013222350d,C0073591,C0599732,can increase IL-6 ,rosoxacin,cell injury,3,X,[antb/orch],[comd],x.x.x.x,
9e3c1186-285c-43b3-8058-305627b1b6ff,C0003402,C3538756, includes ,Antioxidants,NLRP1 wt Allele,3,X,[phsu],[gngm],D27.505.519.217;D27.505.696.706.125;D27.720.799.047,
a21bfe66-dd0b-47a8-ae0e-5de0d0f96371,C1516048,C0009450,is in ,Assessed,Communicable Diseases,3,X,[acty],[dsyn],,C01.539.221
da3b1dd6-44df-4b6c-9b37-91b538ef70fb,14-day,C0009450,prevent spreading in ,14-day,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
da3b1dd6-44df-4b6c-9b37-91b538ef70fb,14-day,C0009450,be sufficient to ,14-day,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
0c44f095-cf8c-484c-9e79-81b59f83b7d3,C0034386,C0009450,prevent spreading in ,Quarantine,Communicable Diseases,1,X,[topp],[dsyn],N06.850.780.200.450.700,C01.539.221
0c44f095-cf8c-484c-9e79-81b59f83b7d3,C0034386,C0009450,be sufficient to ,Quarantine,Communicable Diseases,1,X,[topp],[dsyn],N06.850.780.200.450.700,C01.539.221
c89c1837-44d9-460c-8d1c-196228490b22,C2728259,C0009450,prevent spreading in ,Program,Communicable Diseases,1,X,[orch/phsu],[dsyn],V02.355.750,C01.539.221
c89c1837-44d9-460c-8d1c-196228490b22,C2728259,C0009450,be sufficient to ,Program,Communicable Diseases,1,X,[orch/phsu],[dsyn],V02.355.750,C01.539.221
3f417032-e8d1-4fff-a356-4d3cd130fb8a,14-day,C0206750,prevent spreading in ,14-day,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
ab1a1b32-86a9-4f7d-91ba-b0f032e6312a,C0034386,C0206750,prevent spreading in ,Quarantine,Coronavirus Infections,1,X,[topp],[dsyn],N06.850.780.200.450.700,C02.782.600.550.200
ab1a1b32-86a9-4f7d-91ba-b0f032e6312a,C0034386,C0206750,confront spread of ,Quarantine,Coronavirus Infections,1,X,[topp],[dsyn],N06.850.780.200.450.700,C02.782.600.550.200
a0d4e494-4e2a-484e-995c-051bd7091132,C2728259,C0206750,prevent spreading in ,Program,Coronavirus Infections,1,X,[orch/phsu],[dsyn],V02.355.750,C02.782.600.550.200
a0d4e494-4e2a-484e-995c-051bd7091132,C2728259,C0206750,assess its efficacy regarding ,Program,Coronavirus Infections,2,X,[orch/phsu],[dsyn],V02.355.750,C02.782.600.550.200
b6f771be-97a0-4863-9ec3-4184a3635b36,C0012656,C1511790,is where determined by community ,Disease Vectors,Detection,4,X,[anim],[topp],N06.850.310.350,
02f7c1ee-6aa0-4915-9a72-c9f3c9a4213b,CPAP,C0087111,is valid ,CPAP,Therapeutic procedure,4,X,????,[topp],????,E02
9a0dd522-6a0b-46e6-93f1-a4d0600bc274,CPAP,C0035222,is valid ,CPAP,Respiratory Distress Syndrome Adult,4,X,????,[dsyn],????,C08.381.840;C08.618.840
21d4fccc-458c-445e-a72b-194dc37eb423,CPAP,C1175743,is valid ,CPAP,SARS coronavirus,4,X,????,[virs],????,B04.820.504.540.150.113.937
17cc1aa4-4aaf-4835-946d-95e5b227d6dd,C0087111,C0035222,is in mild ,Therapeutic procedure,Respiratory Distress Syndrome Adult,4,X,[topp],[dsyn],E02,C08.381.840;C08.618.840
17cc1aa4-4aaf-4835-946d-95e5b227d6dd,C0087111,C0035222,have shown first promise in treatment of ,Therapeutic procedure,Respiratory Distress Syndrome Adult,2,X,[topp],[dsyn],E02,C08.381.840;C08.618.840
70df9e6e-45b0-4883-8e85-80d0120cfc75,C0087111,C1175743,targeting ,Therapeutic procedure,SARS coronavirus,11,X,[topp],[virs],E02,B04.820.504.540.150.113.937
705e46c0-98b1-4712-a8a7-359024afcbb9,C2949735,C0024109,detected by ,Recruitment,Lung,1,X,[acty],[bpoc],,A04.411
2a3828da-670d-4658-bc25-b6c5745aabdb,C0024109,C0041621,detected by ,Lung,Ultrasonic Shockwave,1,X,[bpoc],[npop],A04.411,G01.750.770.776.891.500
3d72863e-1f63-4215-8c3a-3b0cff6ae371,C2949735,C0041621,detected by ,Recruitment,Ultrasonic Shockwave,1,X,[acty],[npop],,G01.750.770.776.891.500
7b93ab5c-6934-468b-9a96-b9903c5db9dd,C0041621,NI-CPAP,underlies therapeutic efficacy of NI-CPAP,Ultrasonic Shockwave,NI-CPAP,4,X,[npop],????,G01.750.770.776.891.500,????
f28d1f75-31c9-4de6-aea0-f626a2245a7c,C0002059,C0006560,were correlated ,Alkaline Phosphatase,C-reactive protein,5,X,[aapp/enzy],[aapp/imft],D08.811.277.352.650.035,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
0cdbf3ac-5f7d-4e1b-8d96-42803a754d1b,C0002059,C0035222,were correlated ,Alkaline Phosphatase,Respiratory Distress Syndrome Adult,6,X,[aapp/enzy],[dsyn],D08.811.277.352.650.035,C08.381.840;C08.618.840
f96010e7-29fc-41f3-bf13-1adf88692352,C0024115,C0206750,is with ,Lung diseases,Coronavirus Infections,8,X,[dsyn],[dsyn],C08.381,C02.782.600.550.200
64b3fe23-cf11-419a-b528-195d301c842e,C0630906,C0206750,was in ,vinyltriethoxysilane,Coronavirus Infections,5,X,[orch],[dsyn],x.x.x.x,C02.782.600.550.200
c0975387-20e5-404f-b81d-2a698cd4ef80,C0024115,C0630906,were categorized as high risk for ,Lung diseases,vinyltriethoxysilane,1,X,[dsyn],[orch],C08.381,x.x.x.x
e6de057b-78df-482c-a593-20f823549417,C0206750,C0630906,were categorized as high risk for ,Coronavirus Infections,vinyltriethoxysilane,1,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
f389f9d5-6504-4819-9f05-675380a40d28,C0206750,C0398623,was associated with ,Coronavirus Infections,Thrombophilia,2,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.925
61666846-dc43-4c04-a438-d5ecc865da0f,C0700271,C0042776,is ,M Protein multiple myeloma,Virus,2,X,[aapp/imft],[virs],x.x.x.x,B04
8bf83762-dc04-4667-948c-7c11f9031433,C0282686,C0206419,different types of ,Respiratory System Agents,Genus: Coronavirus,3,X,[phsu],[virs],D27.505.954.796,B04.820.504.540.150
98ea9a46-973d-4103-bd5c-6047c035d3fd,C1457887,C0206750,prognostic of ,Symptoms,Coronavirus Infections,28,X,[sosy],[dsyn],,C02.782.600.550.200
6ecca73b-20a3-4dcb-b3fe-848e73fdf2d2,C0206750,R0,based on different R0 ,Coronavirus Infections,R0,1,X,[dsyn],????,C02.782.600.550.200,????
dc2ab18f-acf8-4d04-9a64-875bfe60167e,C0242781,R0,based on different R0 ,disease transmission,R0,1,X,[patf],????,N06.850.310,????
72190482-6c80-4823-8b8c-2806cdb94d8e,C0035685,C0243052,is in ,RNA-Directed RNA Polymerase,Virus Physiological Phenomena,4,X,[aapp/enzy],[npop],D08.811.913.696.445.735.780,G06.920
05ae8cf5-a7d6-4979-b1e7-7dc9cad15bce,C0035685,C0040649,is in ,RNA-Directed RNA Polymerase,Transcription Genetic,4,X,[aapp/enzy],[genf],D08.811.913.696.445.735.780,G02.111.873;G05.297.700
ebeb9fa9-8068-4fba-8f87-679151275cfd,C1152412,C0003451,is good broad-spectrum ,RNA-directed RNA polymerase activity,Antiviral Agents,4,X,[genf],[phsu],,D27.505.954.122.388
348edd33-6282-47f9-8539-c1545f589327,C1706701,C0014544,About one-third of patients with ,Acquisition (action),Epilepsy,1,X,[acty],[dsyn],,C10.228.140.490
7ec772a8-6d20-4ff7-9471-4113bf82f0bb,C0206750,C0036974,could could considered as major ,Coronavirus Infections,Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
7ec772a8-6d20-4ff7-9471-4113bf82f0bb,C0206750,C0036974,challenge to health care systems across world causing at places ,Coronavirus Infections,Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
7ec772a8-6d20-4ff7-9471-4113bf82f0bb,C0206750,C0036974,has produced world-wide ,Coronavirus Infections,Shock,1,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835
e05d1779-2dfb-4e82-a2ca-4788b1a26d0e,C0206750,C1321919,take its ,Coronavirus Infections,TLR4 protein human,2,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
e05d1779-2dfb-4e82-a2ca-4788b1a26d0e,C0206750,C1321919,became with potential staggering death ,Coronavirus Infections,TLR4 protein human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
e05d1779-2dfb-4e82-a2ca-4788b1a26d0e,C0206750,C1321919,is progressing with alarming death ,Coronavirus Infections,TLR4 protein human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
0b24b680-630c-4330-95e6-d198ed7b7cf9,C0206750,C0683278,is taking colossal ,Coronavirus Infections,Mental Suffering,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.990;F02.830.900
9df0d6de-15f4-4d04-836c-ac11320e85af,C1321919,C0086418,is in ,TLR4 protein human,Homo sapiens,4,X,[aapp/rcpt],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
47444359-44ef-4356-8013-f3846b82b8ab,C1321919,C0683278,is in ,TLR4 protein human,Mental Suffering,4,X,[aapp/rcpt],[mobd],x.x.x.x,F01.145.126.990;F02.830.900
91b842e8-a1e8-454a-bc6b-9c8dfb54546f,LDH,C0206750,is in ,LDH,Coronavirus Infections,3,X,????,[dsyn],????,C02.782.600.550.200
78384cb9-6a70-433a-b24e-155d64df3d2e,LDH,C0032285,is in ,LDH,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
6049a9eb-f415-4398-a9f4-c5ba770b64fc,C0011438,C1175743,becoming source of ,Dentistry,SARS coronavirus,2,X,[bmod],[virs],E06;H02.163,B04.820.504.540.150.113.937
b3f4dbb6-c4dc-44b8-ba1d-7424c93521c6,C0206750,C0011331,has revealed numerous shortcomings in ,Coronavirus Infections,Dental Procedures,2,X,[dsyn],[topp],C02.782.600.550.200,E06.170;N02.421.240.190
d2bee628-3a7a-4ddc-bb38-807c7f66797c,C0394664,C0206750,may play role in patients in ,Acupuncture procedure,Coronavirus Infections,2,X,[topp],[dsyn],E02.190.044,C02.782.600.550.200
d2bee628-3a7a-4ddc-bb38-807c7f66797c,C0394664,C0206750,is effective and safe Interventional procedure for,Acupuncture procedure,Coronavirus Infections,1,X,[topp],[dsyn],E02.190.044,C02.782.600.550.200
17d1a5df-d87a-4d2b-9b70-f06634d0685a,C0013404,C0206750,should alert clinicians to possibility of ,Dyspnea,Coronavirus Infections,12,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.782.600.550.200
013e7fc4-a8d4-4fbf-a8a6-dc01234146d0,C0020336,C0013227,has effects Like ,Hydroxychloroquine,Pharmaceutical Preparations,7,X,[orch/phsu],[phsu],D03.633.100.810.050.180.350,D26
9b95216f-5814-4173-9f76-6710b4ecba30,C0020336,C0024530,are old ,Hydroxychloroquine,Malaria,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C03.752.530
b73f1629-95e6-4183-b85e-0140f6345b49,C0008269,C0013227,are old ,Chloroquine,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D26
26fa7184-c970-4b5e-8c81-23229e79a2f5,C0008269,C0024530,are old ,Chloroquine,Malaria,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C03.752.530
26fa7184-c970-4b5e-8c81-23229e79a2f5,C0008269,C0024530,impairs digestion In treatment of ,Chloroquine,Malaria,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C03.752.530
8a4934aa-27b2-4778-970d-5ecafeb0671c,C0013227,C0024530,used in treatment ,Pharmaceutical Preparations,Malaria,2,X,[phsu],[dsyn],D26,C03.752.530
f1b9e6e6-2be6-4893-a4d1-9d808c0c000e,C1706202,C1175743,is very important In current race against time triggered by ,Search - action,SARS coronavirus,2,X,[acty],[virs],,B04.820.504.540.150.113.937
f1b9e6e6-2be6-4893-a4d1-9d808c0c000e,C1706202,C1175743,using keywords ,Search - action,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
946df18d-3b42-4f08-ba55-2223d3d238e6,C0520996,C0019134,facilitates activity of low MW ,Anticoagulant effect,heparin,2,X,[ortf],[bacs/orch/phsu],,D09.698.373.400
56c7f1d7-96ea-444f-b07a-60110b50495e,C0520996,C0309872,facilitates activity of low MW ,Anticoagulant effect,PREVENT (product),2,X,[ortf],[phsu],,
fb11b447-8f4d-40a6-b838-87350c88f7b6,pre,C0005516,is in proinflammatory ,pre,Biological Markers,4,X,????,[clna],????,D23.101
d2c59584-532e-49f6-a066-35c3283f81e0,C1609165,C0005516,is in proinflammatory ,tocilizumab,Biological Markers,4,X,[aapp/imft/phsu],[clna],x.x.x.x,D23.101
5776adda-6ea9-4ec9-9e15-f01fbf93000f,C0282636,C0005516,is in proinflammatory ,Cell Respiration,Biological Markers,4,X,[celf],[clna],G03.197;G04.270,D23.101
f69d308e-2de8-408a-927d-5d9672707633,C0030858,C0282636,had improvement in their ,Pentaerythritol Tetranitrate,Cell Respiration,4,X,[orch/phsu],[celf],D02.033.455.706.690,G03.197;G04.270
0677bb09-0586-4c2b-9f6f-99fc7af7dcec,C0206750,C1257792,also invade ,Coronavirus Infections,Vascular Endothelial Cells,1,X,[dsyn],[cell],C02.782.600.550.200,A11.436.275
6ad0f6ef-0fcd-4a9d-9025-3b37da850700,C0042373,C0206750,is in ,Vascular Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907,C02.782.600.550.200
ec2df488-9674-497a-8ca1-370c27bb9c83,C0206750,C0543829,is with definitive ,Coronavirus Infections,pneumonia clinical,9,X,[dsyn],[dsyn],C02.782.600.550.200,
94ce509d-9f34-45aa-8755-f6d550dd8df9,C0023516,C1707455,diagnostic performance of were ,Leukocytes,Comparison,2,X,[cell],[acty],A11.118.637;A15.145.229.637;A15.382.490,
db683c1a-dd80-4981-9850-e600499cd0f5,C0229671,C0206750,indicated poor outcome in patients with ,Serum,Coronavirus Infections,9,X,[bdsu],[dsyn],A12.207.152.846;A15.145.846,C02.782.600.550.200
51d0fcc4-1eba-43ff-b87b-5ed043e449ae,C0079189,C0206750,were elevated in patients with ,cytokine,Coronavirus Infections,27,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02.782.600.550.200
63e25e15-8c82-4231-b8ec-c045daac0637,C0039194,C1514474,was independent ,T-Lymphocyte,Prognostic Factors,4,X,[cell],[clna],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,E01.789
0a63701c-ac85-4a1a-806c-bd5c6c43d74e,C0023516,C0206750,predict clinical outcome of patients with ,Leukocytes,Coronavirus Infections,10,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C02.782.600.550.200
e3ada2c1-7fe5-491f-8ca3-6df1233f9734,C0023516,C0032285,predict clinical outcome of patients with ,Leukocytes,Pneumonia,11,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C08.381.677;C08.730.610
4248033b-831e-4bf6-a503-8286893b1991,C1155266,C1160389,is involved in ,inflammatory response,lung development,12,X,[patf],[ortf],,
439c3b70-e3a5-49e4-867f-236b32649f33,C1150225,C0178784,mitigates deleterious effects associated on ,angiotensin I-converting enzyme activity,Organ,2,X,[moft],[bpoc],,
04c9b9b0-25a3-4f2f-9504-59d6d90f4175,C0277562,C0206750,is with ,Adult disease,Coronavirus Infections,6,X,[dsyn],[dsyn],,C02.782.600.550.200
fc573f7c-bc40-4a7e-85cb-a47730f5601a,C0242656,C0206750,is with ,Disease Progression,Coronavirus Infections,7,X,[patf],[dsyn],C23.550.291.656,C02.782.600.550.200
c65464ac-8197-48c1-9cbb-a6da9a645977,C1175743,C1254351,was causative ,SARS coronavirus,Pharmacologic Substance,9,X,[virs],[phsu],B04.820.504.540.150.113.937,
c8d02bb6-d841-4b96-8109-1b4121d8b0f3,C0030231,C0024501,includes ,Palliative Care,Maintenance,1,X,[topp],[acty],E02.760.666;N02.421.585.666,N02.628
b8c09339-6347-4a0d-8293-7b3e474952b0,C0030231,C4520800,includes ,Palliative Care,Hydration,1,X,[topp],[phsf],E02.760.666;N02.421.585.666,
b8c09339-6347-4a0d-8293-7b3e474952b0,C0030231,C4520800,maintaining ,Palliative Care,Hydration,1,X,[topp],[phsf],E02.760.666;N02.421.585.666,
1c5df673-c564-4f4a-a84b-5da7e48f3b22,C0030231,C0015967,controlling ,Palliative Care,Fever,3,X,[topp],[sosy],E02.760.666;N02.421.585.666,C23.888.119.344
431229ee-2a14-46cc-b72d-06704a61b543,C0030231,C0010200,controlling ,Palliative Care,Coughing,3,X,[topp],[sosy],E02.760.666;N02.421.585.666,C08.618.248;C23.888.852.293
29d9b41a-b75a-4a06-a38f-c5ec31e110b1,C0087111,C0086418,is in ,Therapeutic procedure,Homo sapiens,3,X,[topp],[humn],E02,B01.050.150.900.649.313.988.400.112.400.400
be2fd2c4-16b9-42aa-a092-389c43cb1712,C1276413,C1254351,involve ,Therapeutic regimen,Pharmacologic Substance,3,X,[topp],[phsu],,
208d2d90-034e-4c09-8dfc-37057fc0e19f,C0003873,C1872427,taking ,Rheumatoid Arthritis,iguratimod,4,X,[dsyn],[orch/phsu],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,x.x.x.x
17e0f2ac-72d2-42b5-841a-34fa2e9f8d0e,C1511790,C1457887,was observed after resolution of ,Detection,Symptoms,4,X,[topp],[sosy],,
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,explore effect on outcomes of patients with ,Aim,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,analyze existing research works in relation to prevalence of stress in general population during ,Aim,Coronavirus Infections,3,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,quantify effect of ,Aim,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,present epidemiological analysis of first two months of ,Aim,Coronavirus Infections,11,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,confirmed ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,analyze ENUMX2 during ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,investigate whether ,Aim,Coronavirus Infections,5,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,report radiological ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,evaluate results of protocol established in advanced ,Aim,Coronavirus Infections,7,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,determine maximum number of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,estimate basic reproduction number of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,summarize data on treatment of ,Aim,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,analyze known comorbidities of ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,review typical CT findings in ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,discuss emergent repair in patients affected by ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
b0c7b8bf-e6dc-4213-b599-79c84a0d2091,C2948600,C0206750,is with following patients during ,Aim,Coronavirus Infections,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200
c25a339d-068b-4ae1-b9ef-3c6b684116a8,C0596448,C0020538,increased mortality with ,dimer,Hypertensive disease,6,X,[chvs],[dsyn],,C14.907.489
2495d697-a69a-4308-9a80-b4ea7ed77a37,C0596448,C0206750,is in patients with ,dimer,Coronavirus Infections,3,X,[chvs],[dsyn],,C02.782.600.550.200
2495d697-a69a-4308-9a80-b4ea7ed77a37,C0596448,C0206750,very similar to that of ,dimer,Coronavirus Infections,1,X,[chvs],[dsyn],,C02.782.600.550.200
25256918-5e2d-4b3f-93c4-ec66131ba8aa,C2948600,C1516048,was to ,Aim,Assessed,2,X,[inch/phsu],[acty],,
41ca1433-1678-4788-9856-b7bfcb9f78b2,C0206750,C0041912,key disease characteristic of is,Coronavirus Infections,Upper Respiratory Infections,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.739;C08.730
526a1223-2a5c-4c8f-9ce1-c1e17d71ca2b,C0599878,C0041912,key disease characteristic of is,disease characteristic,Upper Respiratory Infections,1,X,[patf],[dsyn],,C01.539.739;C08.730
19f6c7c8-494c-4e3f-a9b8-79bfd8988df6,C0041912,C1142578,may may complicated by ,Upper Respiratory Infections,Bilateral pneumonia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,
42fcf7e8-1c91-442f-a5b0-d4963387673a,C0022709,C0960756,has has identified as ,Peptidyl-Dipeptidase A,factor A,2,X,[aapp/enzy/imft],[orch],D08.811.277.656.350.350.687,x.x.x.x
b242dd5c-c256-40e9-948d-d133cbbff703,C0022709,C1167395,is ,Peptidyl-Dipeptidase A,Host (organism),5,X,[aapp/enzy/imft],[orgm],D08.811.277.656.350.350.687,
b29d6502-994d-49e8-8af5-accfbb64626f,C0022709,C1537068,is ,Peptidyl-Dipeptidase A,Virus Internalization,5,X,[aapp/enzy/imft],[biof],D08.811.277.656.350.350.687,G06.920.881
e3f32724-801c-4d63-a928-e672c2b31c04,C0022709,C0282686,is expressed in ,Peptidyl-Dipeptidase A,Respiratory System Agents,1,X,[aapp/enzy/imft],[phsu],D08.811.277.656.350.350.687,D27.505.954.796
4edc9c26-93fb-4a8c-9299-a602a40634e5,C0001625,C0206750,is in patients with severe CD3,Adrenal Glands,Coronavirus Infections,1,X,[bpoc],[dsyn],A06.300.071,C02.782.600.550.200
c8e41292-571b-4eb2-8709-ecc0fb8248cf,C0001625,C1692321,is in patients with severe CD3,Adrenal Glands,Cellular infiltrate,1,X,[bpoc],[patf],A06.300.071,
bff94581-560e-4520-97b1-8427844abb95,C0001625,CD3,is in patients with severe CD3,Adrenal Glands,CD3,1,X,[bpoc],????,A06.300.071,????
9c4d1ea8-a7dc-4d78-b558-91a4e2031e31,C1175743,C0001621,might impair ,SARS coronavirus,Adrenal Gland Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C19.053
e41f03ff-b74e-4c91-b0cf-619de0bd1963,C1175743,C0031843,might impair ,SARS coronavirus,physiological aspects,1,X,[virs],[phsf],B04.820.504.540.150.113.937,x.x.x.x
a889b4dc-ec3e-483b-84f7-87e8f0445035,C0001621,C1175743,SARS coronavirus with,Adrenal Gland Diseases,SARS coronavirus,2,X,[dsyn],[virs],C19.053,B04.820.504.540.150.113.937
19e0ff31-e6ec-4c6c-940c-bf3f65a71f07,C0031843,C1175743,SARS coronavirus with,physiological aspects,SARS coronavirus,2,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150.113.937
19e0ff31-e6ec-4c6c-940c-bf3f65a71f07,C0031843,C1175743,is in patients with CoV2 ,physiological aspects,SARS coronavirus,2,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150.113.937
f9e4bd1e-3e21-43ba-bf93-20ec9db76b6e,C0907850,C0032285,is in non-severe ,ciclesonide,Pneumonia,1,X,[bacs/orch/phsu],[dsyn],x.x.x.x,C08.381.677;C08.730.610
96bcc6f9-269d-48f5-be6c-15739286954f,C0277548,C1825598,might have certain ,Epidemic disease,IMPACT gene,2,X,[dsyn],[gngm],,
1c390922-6968-4685-baf1-0d5863d5b41f,C0277548,C0021390,might have certain ,Epidemic disease,Inflammatory Bowel Diseases,2,X,[dsyn],[dsyn],,C06.405.205.731;C06.405.469.432
734e7316-02a0-43f9-b94f-f2e11ef01f41,C0009450,C0206750,is with ,Communicable Diseases,Coronavirus Infections,26,X,[dsyn],[dsyn],C01.539.221,C02.782.600.550.200
1123366a-da5d-4658-aef7-5a1ba5aba0d5,C0016059,C0012634,characterized late-phase ,Fibrosis,Disease,5,X,[patf],[dsyn],C23.550.355,C23.550.288
b2a1d274-ff2a-451b-b1ac-05e5f6170888,C1516048,C0005516,providing visualization compared with non-specific inflammatory ,Assessed,Biological Markers,2,X,[acty],[clna],,D23.101
5dc9c6c7-80e1-4a80-ac08-15433d1fe39c,C0206750,C1514593,know little about ,Coronavirus Infections,Psychological Impact,2,X,[dsyn],[clna],C02.782.600.550.200,
eb11065b-291d-412a-af96-3518b487cef5,C0206750,C0233514,develop general ,Coronavirus Infections,Abnormal behavior,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.972;F01.145.179.750
042cdf53-cfe1-43d5-8a91-3f2e8f01057b,C1457887,C0233514,develop general ,Symptoms,Abnormal behavior,2,X,[sosy],[mobd],,F01.145.126.972;F01.145.179.750
ba6e56bd-f00e-4814-b499-d7596452f9ec,C1514593,C0233514, includes general ,Psychological Impact,Abnormal behavior,4,X,[clna],[mobd],,F01.145.126.972;F01.145.179.750
66d9ca4b-bfb0-4cae-87e6-f4f234a30ae2,C0013216,COVID-19,suitable for ,Pharmacotherapy,COVID-19,1,X,[topp],[virs],E02.319,C000657245
5f71e445-44b6-43e8-8f8c-b58bad5b78fa,C0012634,C0206419,was named ,Disease,Genus: Coronavirus,25,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150
70aa5d82-38e0-418f-a450-ed9b9bd7ab12,C4042834,C0206419,gained importance during ,Compassion Fatigue,Genus: Coronavirus,1,X,[mobd],[virs],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,B04.820.504.540.150
d2027b78-0669-4eba-8a51-b26dc5af7748,C4042834,COVID-19,directly working with ,Compassion Fatigue,COVID-19,1,X,[mobd],[virs],C23.888.369.500.500;F01.145.126.937.500;F01.145.126.990.734.500;F02.830.900.666.750,C000657245
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,caused by novel acute ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,is first pandemic caused by ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,identify therapeutics with evidence of efficacy for treatment of three ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,is acronym of ,COVID-19,Genus: Coronavirus,2,X,[virs],[virs],C000657245,B04.820.504.540.150
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,of propagation is ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
b592af2c-477f-4907-9229-60d07b7bee5b,COVID-19,C0206419,is in patients undergoing during ,COVID-19,Genus: Coronavirus,1,X,[virs],[virs],C000657245,B04.820.504.540.150
05c0824c-2773-41cb-9b75-a3880bc8808d,C3819028,COVID-19,may potentially Therapeutic procedure,Interleukin 6 Receptor Antagonists,COVID-19,1,X,[celf],[virs],,C000657245
c1111e48-3959-40fe-b932-ed394f8d5d0b,C1609165,COVID-19,may potentially Therapeutic procedure,tocilizumab,COVID-19,3,X,[aapp/imft/phsu],[virs],x.x.x.x,C000657245
c1111e48-3959-40fe-b932-ed394f8d5d0b,C1609165,COVID-19,were reported in ,tocilizumab,COVID-19,1,X,[aapp/imft/phsu],[virs],x.x.x.x,C000657245
57a9dc6e-6631-456a-bf37-7c3032f8d669,C2745965,C0206419,were associated with ,Emergencies [Disease/Finding],Genus: Coronavirus,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04.820.504.540.150
57a9dc6e-6631-456a-bf37-7c3032f8d669,C2745965,C0206419,caused by acute viral ,Emergencies [Disease/Finding],Genus: Coronavirus,2,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04.820.504.540.150
dc1d8cd8-38a9-4d42-bef9-dcddbfcef6b3,C0042210,C1160716,contain ,Vaccines,viral transmission,2,X,[aapp/imft/phsu],[celf],D20.215.894,
ba9de690-9d97-4429-9288-5ae49c0d5745,COVID-19,C1321919,is taking colossal ,COVID-19,TLR4 protein human,2,X,[virs],[aapp/rcpt],C000657245,x.x.x.x
2c92ccf4-a7be-4df8-b029-06a1d213eba8,COVID-19,C0086418,is taking colossal ,COVID-19,Homo sapiens,2,X,[virs],[humn],C000657245,B01.050.150.900.649.313.988.400.112.400.400
2c92ccf4-a7be-4df8-b029-06a1d213eba8,COVID-19,C0086418,further disease transmission of was,COVID-19,Homo sapiens,1,X,[virs],[humn],C000657245,B01.050.150.900.649.313.988.400.112.400.400
65277184-05a4-45b4-8124-fe4826e5b96e,COVID-19,C0683278,is taking colossal ,COVID-19,Mental Suffering,2,X,[virs],[mobd],C000657245,F01.145.126.990;F02.830.900
95c6e3cd-6699-43ca-8ca0-00eeae408abe,C0025124,C0304229,is in ,Traditional Chinese Medicine,Experimental drug,3,X,[bmod],[phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,
c09dd7d9-f9ad-4c35-bd08-5df9e1af09c9,C0184661,C0025124,is with ,Interventional procedure,Traditional Chinese Medicine,4,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
4da23b0e-76f8-4265-acf8-97acb4f79210,C0206419,C1412002,causes novel ,Genus: Coronavirus,Atypical pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150,
4da23b0e-76f8-4265-acf8-97acb4f79210,C0206419,C1412002,was reported responsible for cluster of ,Genus: Coronavirus,Atypical pneumonia,2,X,[virs],[dsyn],B04.820.504.540.150,
67cbdb57-71df-4b40-9a92-fbc059cd7925,C0012634,C1412002,causes novel ,Disease,Atypical pneumonia,1,X,[dsyn],[dsyn],C23.550.288,
0f834d3d-39e3-4c9e-bcc8-55f7e3995e35,C1412002,C0015392,has brought public health medicine (field) challenges across,Atypical pneumonia,Eye,1,X,[dsyn],[bpoc],,A01.456.505.420;A09.371
80177e2a-d566-4f90-8f1a-7c96c9b6f27a,C1412002,C0034019,has brought huge ,Atypical pneumonia,public health medicine (field),1,X,[dsyn],[bmod],,H02.403.720;N01.400.550;N06.850
253e711a-4527-44f6-845a-49d46a9bda1d,C0086418,C0015967,was admitted to hospital for ,Homo sapiens,Fever,2,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.119.344
253e711a-4527-44f6-845a-49d46a9bda1d,C0086418,C0015967,presented with ,Homo sapiens,Fever,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.119.344
7e3b97b1-e8bc-44e9-a82c-f326622b63da,C0022661,C0019004,taking regular ,Kidney Failure Chronic,Hemodialysis,1,X,[dsyn],[topp],C12.777.419.780.750.500;C13.351.968.419.780.750.500,E02.870.300;E02.912.800
ea67d116-438f-4e20-ad33-f0871a023b2a,C0019004,COVID-19,is with ,Hemodialysis,COVID-19,4,X,[topp],[virs],E02.870.300;E02.912.800,C000657245
f177d8ab-b5d4-4ff0-bfd3-1c5b99311434,C0005768,COVID-19,supporting ,In Blood,COVID-19,3,X,[bdsu],[virs],x.x.x.x.x,C000657245
d4b41a12-d34c-4d12-aa0b-be48053afe58,C0005768,C0019004,be important option for ,In Blood,Hemodialysis,1,X,[bdsu],[topp],x.x.x.x.x,E02.870.300;E02.912.800
b34cf391-87dc-472c-ac16-fc3121c46166,C1706005,C0035222,was correlated with higher incidences of ,CD40LG wt Allele,Respiratory Distress Syndrome Adult,7,X,[gngm],[dsyn],,C08.381.840;C08.618.840
6f65355c-2e97-493c-9f89-526840288770,titer,C0035222,was correlated with higher incidences of ,titer,Respiratory Distress Syndrome Adult,7,X,????,[dsyn],????,C08.381.840;C08.618.840
80f9c9ab-4629-476e-a588-66e45bf250b3,C0700271,C0319157,is ,M Protein multiple myeloma,AS virus,1,X,[aapp/imft],[virs],x.x.x.x,
91dbe575-e118-4c1c-a579-b956718f4544,C1167622,C0700271,Analyzing of ,Binding (Molecular Function),M Protein multiple myeloma,1,X,[moft],[aapp/imft],,x.x.x.x
2db68afc-63e1-4613-b8ec-7ee6f9ca126f,C1167622,C1167395,Analyzing to ,Binding (Molecular Function),Host (organism),1,X,[moft],[orgm],,
ae9c7866-b762-4488-aa3c-625e97b77650,C1167622,C0034787,Analyzing to ,Binding (Molecular Function),Angiotensin Receptor,1,X,[moft],[aapp/rcpt],,D12.776.543.750.695.047;D12.776.543.750.750.130
ec319ca3-7745-4fe2-9b46-aad6e98e1100,C0206419,C1257792,also invade ,Genus: Coronavirus,Vascular Endothelial Cells,2,X,[virs],[cell],B04.820.504.540.150,A11.436.275
c524c7bc-f76e-442d-a272-1192d8412725,COVID-19,C0018787,target ,COVID-19,Heart,1,X,[virs],[bpoc],C000657245,A07.541
ffc8f4ad-4524-449a-98d6-42f302e21341,C1707455,C0018787,target ,Comparison,Heart,1,X,[acty],[bpoc],,A07.541
56ec2b14-99eb-465b-b080-84eae5bbe232,IFSO,COVID-19,navigating ,IFSO,COVID-19,2,X,????,[virs],????,C000657245
240336b7-e0b5-47c1-b8d7-643deb91585c,C0020852,C1175743,cross-reacted with CoV1 ,Immunoglobulin G,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
240336b7-e0b5-47c1-b8d7-643deb91585c,C0020852,C1175743,was developed for serological detection of anti ,Immunoglobulin G,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
240336b7-e0b5-47c1-b8d7-643deb91585c,C0020852,C1175743,for assay is ,Immunoglobulin G,SARS coronavirus,3,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,B04.820.504.540.150.113.937
c7830e53-0990-48a8-968e-a3037549c56d,C0020852,CoV1,cross-reacted with CoV1 ,Immunoglobulin G,CoV1,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,????
d2ea60af-b9b2-4c56-bc7b-6424f703b97d,C0206419,C0035243,could lead persons with medical conditions to severe ,Genus: Coronavirus,Respiratory Tract Infections,2,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
d2ea60af-b9b2-4c56-bc7b-6424f703b97d,C0206419,C0035243,cause ,Genus: Coronavirus,Respiratory Tract Infections,2,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
d2ea60af-b9b2-4c56-bc7b-6424f703b97d,C0206419,C0035243,are responsible for ,Genus: Coronavirus,Respiratory Tract Infections,5,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
d2ea60af-b9b2-4c56-bc7b-6424f703b97d,C0206419,C0035243,is novel pandemic ,Genus: Coronavirus,Respiratory Tract Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
d2ea60af-b9b2-4c56-bc7b-6424f703b97d,C0206419,C0035243,is novel contagious ,Genus: Coronavirus,Respiratory Tract Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
5ff59d1a-e993-4f73-b4b2-ea269a16df85,C0012634,C0035243,could lead persons with medical conditions to severe ,Disease,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
5ff59d1a-e993-4f73-b4b2-ea269a16df85,C0012634,C0035243,could lead persons with pre-existing conditions to severe ,Disease,Respiratory Tract Infections,1,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
5ff59d1a-e993-4f73-b4b2-ea269a16df85,C0012634,C0035243,is novel pandemic ,Disease,Respiratory Tract Infections,3,X,[dsyn],[dsyn],C23.550.288,C01.539.739;C08.730
7ca3c06f-5046-47bc-9315-6817e9c91d17,PWT1D,C0015259,reported decrease in ,PWT1D,Exercise,6,X,????,[dora],????,G11.427.410.698.277;I03.350
5321e08c-06d4-45a8-8500-0cb55decbc5d,C4476767,C0012634,is severe ,Diffuse alveolar hemorrhage,Disease,4,X,[dsyn],[dsyn],,C23.550.288
ddd70274-759b-4484-8049-77dd091a95ed,C0019079,C4476767,being key symptome of ,Hemoptysis,Diffuse alveolar hemorrhage,11,X,[sosy],[dsyn],C08.381.348;C23.550.414.896;C23.888.852.430,
4892bfbd-1076-45d9-85c9-db0b7ac84aac,C0026691,C0015967,is acute ,Mucocutaneous Lymph Node Syndrome,Fever,2,X,[dsyn],[sosy],C14.907.940.560;C15.604.560;C17.800.862.560,C23.888.119.344
436b5b1e-d539-4a99-bdea-abd4af384f05,C1707455,COVID-19,is with COVID19 ,Comparison,COVID-19,3,X,[acty],[virs],,C000657245
7259f4dd-a662-44fb-b57a-03988525087c,C1706374,C0026691,identified rapid increase of ,Tumor Necrosis Factor Ligand Superfamily Member 13,Mucocutaneous Lymph Node Syndrome,2,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C14.907.940.560;C15.604.560;C17.800.862.560
f9f7b422-2318-4a6d-8bef-4052b968293b,C0026691,C1175743,was related to ,Mucocutaneous Lymph Node Syndrome,SARS coronavirus,2,X,[dsyn],[virs],C14.907.940.560;C15.604.560;C17.800.862.560,B04.820.504.540.150.113.937
a5c8ca2c-0177-44a7-959f-8d3e18dfb068,C1175743,C1706374,was found since ,SARS coronavirus,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
45f9004a-fc5f-473a-8361-6b54d2a7ed63,C1175743,C0030858,was found in eight of ,SARS coronavirus,Pentaerythritol Tetranitrate,4,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,D02.033.455.706.690
937280df-bfa8-47fd-bb42-667f748c5bac,C1175743,C0026691,was found in eight ,SARS coronavirus,Mucocutaneous Lymph Node Syndrome,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.907.940.560;C15.604.560;C17.800.862.560
b27a374f-0fba-4d92-8eec-d6bced4be2b2,C0030858,C0026691,is with ,Pentaerythritol Tetranitrate,Mucocutaneous Lymph Node Syndrome,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,C14.907.940.560;C15.604.560;C17.800.862.560
77536e6a-514c-496e-8ede-95a922364eff,C0877203,C4283882, includes ,Viral Respiratory Tract Infection,NR1I2 wt Allele,6,X,[dsyn],[gngm],,
8b459543-fc24-4c1f-9b22-e6af68771429,C0877203,C0032930,be ,Viral Respiratory Tract Infection,Precipitating Factors,2,X,[dsyn],[clna],,N05.715.350.200.650;N06.850.490.625.500
d3361b32-a005-444e-aba6-60cc0af2a8ce,C4283882,C0032930,be ,NR1I2 wt Allele,Precipitating Factors,2,X,[gngm],[clna],,N05.715.350.200.650;N06.850.490.625.500
6a36a6b5-1dc3-4e11-be96-a970788e5eb7,C0877203,C0026691,be Precipitating Factors for,Viral Respiratory Tract Infection,Mucocutaneous Lymph Node Syndrome,2,X,[dsyn],[dsyn],,C14.907.940.560;C15.604.560;C17.800.862.560
1d21b3e4-7748-4d5b-b257-79425dcc4b44,C4283882,C0026691,be Precipitating Factors for,NR1I2 wt Allele,Mucocutaneous Lymph Node Syndrome,2,X,[gngm],[dsyn],,C14.907.940.560;C15.604.560;C17.800.862.560
69525dbb-bf1f-4e99-bc32-aab3cea5224a,C0877203,COVID-19,indicates ,Viral Respiratory Tract Infection,COVID-19,1,X,[dsyn],[virs],,C000657245
5be5ec14-de6b-4dcd-ba4a-f17d569dc46f,C4283882,COVID-19,indicates ,NR1I2 wt Allele,COVID-19,1,X,[gngm],[virs],,C000657245
ee0d210c-4a29-4d04-be8f-bbc1474c9f7f,C0036087,C0206419,diagnosing ,saliva,Genus: Coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150
ee0d210c-4a29-4d04-be8f-bbc1474c9f7f,C0036087,C0206419,droplets for ,saliva,Genus: Coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150
f38e0ccb-b0fe-4be4-a44a-8a0fb5cbf749,C1704259,C0206419,might play role in ,Biochemical Pathway,Genus: Coronavirus,3,X,[moft],[virs],,B04.820.504.540.150
33dd5a53-bccb-4889-b0e8-4df1550c5b1b,C0206419,C0036974,could could considered as ,Genus: Coronavirus,Shock,3,X,[virs],[patf],B04.820.504.540.150,C23.550.835
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,has had substantial ,Genus: Coronavirus,IMPACT gene,7,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,is having dramatic ,Genus: Coronavirus,IMPACT gene,2,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,had limited ,Genus: Coronavirus,IMPACT gene,2,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,is now epidemic of proportion with major adverse ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,is causing insurmountable ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,has had profound ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,has daunted world with its ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
a9780e5c-ceb5-4aca-8db8-fa8e7621056c,C0206419,C1825598,be negatively ,Genus: Coronavirus,IMPACT gene,1,X,[virs],[gngm],B04.820.504.540.150,
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,study ,Aim,Genus: Coronavirus,3,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,review growing ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,provide information about ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,Assessed efficacy of Chinese medicine for,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,show changes in tertiary referral ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,introduce our experience based remote patient LTSC,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,summarize prevalence of ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
aab45949-4ad7-472e-ae84-e557dde306b2,C2948600,C0206419,describe clinical characteristics of children with ,Aim,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
59bec2ee-6b9c-42ec-95cf-967a635cb0db,C0042776,C0010076,is in ,Virus,Coronaviridae,10,X,[virs],[virs],B04,B04.820.504.540
1c5ce030-4d85-4426-b48e-fa0801e6fdb9,C0003062,C0206419,are involved in ,Animals,Genus: Coronavirus,3,X,[anim],[virs],B01.050,B04.820.504.540.150
aae9118e-38cf-4045-b6db-f99938b81f11,C0242781,C0325089,has has reported in ,disease transmission,Family Felidae,6,X,[patf],[mamm],N06.850.310,B01.050.150.900.649.313.750.377.750
d3f4c836-b15c-4d4d-a0c9-532ac307fcf2,C0021017,C0013227,works in antirheumatoid ,Immunoglobulin Isotypes,Pharmaceutical Preparations,3,X,[aapp/imft],[phsu],D12.776.124.486.485.114.619;D12.776.124.790.651.114.619;D12.776.377.715.548.114.619,D26
59fbfbd7-8ba9-4858-8459-978f179f5904,C3888108,C1721019,involves ,Import into cell,Virus Attachment,2,X,[celf],[biof],,G06.920.868
b4ccd02d-af2e-41c6-a03c-ae9cca53187b,C3888108,C0007634,involves ,Import into cell,Cells,2,X,[celf],[cell],,A11
ac6baa9f-824a-4eff-90dc-5e33300c46d7,C0597357,C0960880,has has identified as ,receptor,angiotensin converting enzyme 2,2,X,[aapp/rcpt],[aapp/enzy],,x.x.x.x
2a1a079d-2c90-4f67-935b-bc855782a8c9,C0007603,C0206419,be involved in internalization of clinically important ,Plasma membrane,Genus: Coronavirus,2,X,[celc],[virs],A11.284.149,B04.820.504.540.150
eee613eb-41e4-4fb8-abeb-3475c7251f66,C0021701,C0206419,be involved in internalization of clinically important ,Integrins,Genus: Coronavirus,2,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.408,B04.820.504.540.150
d531c988-9d99-4e89-89c1-9799e123aa8d,C0021701,C0007634,is involved in ,Integrins,Cells,4,X,[aapp/imft/rcpt],[cell],D12.776.543.750.705.408,A11
6f20ceb4-8d34-45de-91a3-0693a6a39e61,C0507236,C0007634,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Cells,4,X,[bpoc],[cell],,A11
5d183c09-3b78-4be3-8f2f-1401b341a47d,C0021701,C3888108,is involved in ,Integrins,Import into cell,4,X,[aapp/imft/rcpt],[celf],D12.776.543.750.705.408,
62795d31-6efa-4294-8ce3-576f4b658600,C0507236,C3888108,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Import into cell,4,X,[bpoc],[celf],,
da0361d3-623e-41fa-ab3b-b6303b88e0fe,C0021701,C0039005,is involved in ,Integrins,Family suidae,2,X,[aapp/imft/rcpt],[mamm],D12.776.543.750.705.408,B01.050.150.900.649.313.500.880
771b450c-51d8-40d6-8524-c989c46e1456,C0507236,C0039005,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Family suidae,2,X,[bpoc],[mamm],,B01.050.150.900.649.313.500.880
30af6c87-ddd5-45dd-a30f-e9647345c4f9,C0021701,C3310928,is involved in ,Integrins,Enteric coronavirus,4,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.408,
a0875431-d770-4f18-aa46-2bad55d40f04,C0507236,C3310928,is involved in ,Anterior bronchopulmonary segment of superior pulmonary vein,Enteric coronavirus,4,X,[bpoc],[virs],,
43abc098-8c42-4ff0-bf52-1dc26dac3330,C3310928,C0086418,causes ,Enteric coronavirus,Homo sapiens,2,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
d6c416d6-9da1-4da4-a495-2753dc5e733b,C0960880,C1516359,modulates ,angiotensin converting enzyme 2,Intracellular Signaling Process,2,X,[aapp/enzy],[moft],x.x.x.x,
8817fedc-4c8a-4e1e-8ad9-720e8e76822c,C0960880,C3146294,modulates ,angiotensin converting enzyme 2,Generation (action),2,X,[aapp/enzy],[acty],x.x.x.x,
8bc206f7-a2a6-45cb-9d9b-1e32dcdc081c,C0960880,C0021701,modulates Intracellular Signaling Process Generation (action) by,angiotensin converting enzyme 2,Integrins,2,X,[aapp/enzy],[aapp/imft/rcpt],x.x.x.x,D12.776.543.750.705.408
3e617afe-eafd-47ca-ada0-729710096f53,C1167395,C3888108,Leptocyte,Host (organism),Import into cell,2,X,[orgm],[celf],,
b867b68e-d4bf-48f8-b53a-906276db8014,T4,C3888108,Leptocyte,T4,Import into cell,2,X,????,[celf],????,
b867b68e-d4bf-48f8-b53a-906276db8014,T4,C3888108,does influence ,T4,Import into cell,2,X,????,[celf],????,
b867b68e-d4bf-48f8-b53a-906276db8014,T4,C3888108,possibly restrict ,T4,Import into cell,1,X,????,[celf],????,
8c4e54a3-eddd-4fe3-ac86-2c519714061c,C1167395,C0206419,Leptocyte,Host (organism),Genus: Coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150
8c4e54a3-eddd-4fe3-ac86-2c519714061c,C1167395,C0206419,is in alpha-than beta ,Host (organism),Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
8c4e54a3-eddd-4fe3-ac86-2c519714061c,C1167395,C0206419,more highly constrained for beta ,Host (organism),Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
f401503d-8e4b-4fd5-9133-5b5a94a9ad5b,T4,C0206419,Leptocyte,T4,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
f401503d-8e4b-4fd5-9133-5b5a94a9ad5b,T4,C0206419,does influence ,T4,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
d73a5707-ee72-483b-b777-65eea2b4dc44,C0007634,C3888108,applies to ,Cells,Import into cell,2,X,[cell],[celf],A11,
509c9250-c233-473f-9aa2-2c09209da195,C0007634,C0021701,applies to ,Cells,Integrins,2,X,[cell],[aapp/imft/rcpt],A11,D12.776.543.750.705.408
793318aa-60bc-47c1-bcc7-4fea792e734e,C0034843,C0021701,is In same locale on ,Thyroid Hormone Receptor,Integrins,2,X,[aapp/rcpt],[aapp/imft/rcpt],D12.776.624.664.700.830;D12.776.826.850,D12.776.543.750.705.408
732c70ee-4ad6-4784-9ec4-d11356c0250c,C0034843,C0507236,is In same locale on ,Thyroid Hormone Receptor,Anterior bronchopulmonary segment of superior pulmonary vein,2,X,[aapp/rcpt],[bpoc],D12.776.624.664.700.830;D12.776.826.850,
6a157ebc-7114-4eff-b898-4e760e5639fe,T4,C1510827,modulate ,T4,Affinity,2,X,????,[npop],????,
d1be1e29-2bd1-4a9f-8222-3d29e1c1581d,T4,C0021701,modulate ,T4,Integrins,2,X,????,[aapp/imft/rcpt],????,D12.776.543.750.705.408
61425eee-d62c-49b1-b3fe-ca08dbd57681,T4,C0033684,modulate Affinity for other,T4,Proteins,2,X,????,[aapp/bacs],????,D12.776
981365fc-afc2-4c17-8dd5-6eae1b092af9,T4,C1149503,has By ,T4,Integrin Binding,2,X,????,[moft],????,
02f16046-af3d-44c4-bf5e-8b636958d6a2,T4,C0221284,does influence Genus: Coronavirus Import into cell by,T4,Leptocyte,1,X,????,[cell],????,
891c58a5-b45d-4a0a-927e-2210c60418d9,T4,triiodo,deaminated 3 5 3 triiodo ,T4,triiodo,2,X,????,????,????,????
8cd22fce-1ec2-4569-a812-b0bc6f33607f,T4,C0282364,deaminated 3 5 3 triiodo ,T4,Thyronine,2,X,????,[aapp/bacs],????,D06.472.931.740;D12.125.072.050.767.741
1debcc12-a055-4801-bc25-370e54476576,T4,C0042776,possibly restrict ,T4,Virus,1,X,????,[virs],????,B04
4a1bcc78-c6de-41a4-8573-4776067b3f74,C0630906,C0354604,continuation of home ,vinyltriethoxysilane,oral anticoagulants,1,X,[orch],[orch/phsu],x.x.x.x,
219fa072-3f20-45e0-ba23-3b5f0bbd2f6d,C0449867,C0087111,stratified 3-tiered approach of low-intensity ,Use of anticoagulation,Therapeutic procedure,2,X,[topp],[topp],,E02
08d175fd-61a3-42c5-a34d-0bb6b820df07,C2717961,C0012634,is represented by group of different ,Thrombotic Microangiopathies,Disease,1,X,[dsyn],[dsyn],C15.378.140.855.925,C23.550.288
d5d3ece3-2f4e-4d65-82e6-7fb305c5d363,C0206419,C0684309,proposed possible ,Genus: Coronavirus,Disease model,1,X,[virs],[emod],B04.820.504.540.150,
804d3f84-a2c4-47c3-b9db-b73b3dceacb8,C0206419,C0206750,proposed possible ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
804d3f84-a2c4-47c3-b9db-b73b3dceacb8,C0206419,C0206750,etiological Pharmacologic Substance of,Genus: Coronavirus,Coronavirus Infections,3,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
804d3f84-a2c4-47c3-b9db-b73b3dceacb8,C0206419,C0206750,etiological Agent of,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
804d3f84-a2c4-47c3-b9db-b73b3dceacb8,C0206419,C0206750, includes ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
804d3f84-a2c4-47c3-b9db-b73b3dceacb8,C0206419,C0206750,causes ,Genus: Coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
a028f80f-56d7-4315-b735-dee203dedc9d,C0684309,C0206750,is in patients with severe new ,Disease model,Coronavirus Infections,1,X,[emod],[dsyn],,C02.782.600.550.200
a028f80f-56d7-4315-b735-dee203dedc9d,C0684309,C0206750,was constructed in ,Disease model,Coronavirus Infections,2,X,[emod],[dsyn],,C02.782.600.550.200
d6d02c9d-1961-47ad-949d-b341c7810a4e,C0206419,C0960880,utilize ,Genus: Coronavirus,angiotensin converting enzyme 2,4,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
0753e968-95dd-4970-b148-efc3bcbd18a0,C0206419,C0597357,utilize angiotensin converting enzyme 2 as,Genus: Coronavirus,receptor,3,X,[virs],[aapp/rcpt],B04.820.504.540.150,
985d7812-d265-4b59-b477-31510304b39f,C0206419,C1819995,utilize angiotensin converting enzyme 2 as,Genus: Coronavirus,Host Cell,3,X,[virs],[celc],B04.820.504.540.150,
985d7812-d265-4b59-b477-31510304b39f,C0206419,C1819995,determine Protein Biosynthesis Rating (action) to,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
985d7812-d265-4b59-b477-31510304b39f,C0206419,C1819995,were analyzed determine to ,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
985d7812-d265-4b59-b477-31510304b39f,C0206419,C1819995,are easily adapted to ,Genus: Coronavirus,Host Cell,2,X,[virs],[celc],B04.820.504.540.150,
985d7812-d265-4b59-b477-31510304b39f,C0206419,C1819995,determine adaptation to ,Genus: Coronavirus,Host Cell,1,X,[virs],[celc],B04.820.504.540.150,
60b020e0-3cde-4f7c-ba3a-48f06cd80f60,C0206419,C1175175,may cause serious ,Genus: Coronavirus,Severe Acute Respiratory Syndrome,20,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200.750;C08.730.730
9b9c8f24-b3ab-4804-be10-72ef51856fc8,C0022709,C0003009,helps in formation of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
9b9c8f24-b3ab-4804-be10-72ef51856fc8,C0022709,C0003009,counter pro-inflammatory effects mediated by ,Peptidyl-Dipeptidase A,angiotensin II,1,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
9b9c8f24-b3ab-4804-be10-72ef51856fc8,C0022709,C0003009,converts proinflammatory effects of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
9b9c8f24-b3ab-4804-be10-72ef51856fc8,C0022709,C0003009,proinflammatory and prothrombotic effects of ,Peptidyl-Dipeptidase A,angiotensin II,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
9b9c8f24-b3ab-4804-be10-72ef51856fc8,C0022709,C0003009,promotes concomitant increase in levels of ,Peptidyl-Dipeptidase A,angiotensin II,1,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
65a13b12-504f-4c5a-8907-0e38b1897cff,C0022709,C0003006,helps in formation of ,Peptidyl-Dipeptidase A,Angiotensin I,2,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D06.472.699.094.075;D12.644.400.070.075;D12.644.456.073.021;D12.644.548.058.075;D12.776.631.650.070.075;D23.469.050.050.025;x.x.x.x
97b2b789-f54e-4455-9dab-234435e207f2,C0058362,C0042397,has ,dipeptidyl peptidase II,Vasoconstrictor Agents,4,X,[aapp/enzy],[phsu],x.x.x.x,D27.505.954.411.793
c216e855-a967-49f9-9b77-853c49c7cae9,C0058362,C1439284,has properties via ,dipeptidyl peptidase II,AGTR1 gene,4,X,[aapp/enzy],[gngm],x.x.x.x,
3d92970d-7a92-498c-9231-226e502de94a,C0034787,C0819757,has effects in ,Angiotensin Receptor,Structure of parenchyma of lung,3,X,[aapp/rcpt],[tisu],D12.776.543.750.695.047;D12.776.543.750.750.130,
1fe2c81f-6748-49fd-aef2-3cd803942344,C0024115,C0206419,is in ,Lung diseases,Genus: Coronavirus,4,X,[dsyn],[virs],C08.381,B04.820.504.540.150
0f108221-2a94-461f-8edc-cc5d0dd6a7d3,C0024115,C1175743,is in ,Lung diseases,SARS coronavirus,3,X,[dsyn],[virs],C08.381,B04.820.504.540.150.113.937
1b22b06a-1365-4be6-bab0-b60e6a7addac,C0037356,C0206419,threatened lives similar to situation caused by ,Smallpox Viruses,Genus: Coronavirus,1,X,[virs],[virs],B04.280.650.160.650.930,B04.820.504.540.150
a2db8bf8-a8f0-4e83-81d8-a350bfd74b77,C0016504,C0037356,was during ,Foot,Smallpox Viruses,1,X,[bpoc],[virs],A01.378.610.250,B04.280.650.160.650.930
b64c6000-2674-4126-9772-4aa53df571c8,C0206419,C1456573,is major ,Genus: Coronavirus,Global Health,11,X,[virs],[bmod],B04.820.504.540.150,H02.403.371;N01.400.337
2da32406-5202-42eb-993d-0ff8acfcadf1,16cases,C0019004,is in ,16cases,Hemodialysis,5,X,????,[topp],????,E02.870.300;E02.912.800
9dba2a12-0b5f-42a7-b3a4-634802ef3f92,C0206419,C0019004,is in ,Genus: Coronavirus,Hemodialysis,2,X,[virs],[topp],B04.820.504.540.150,E02.870.300;E02.912.800
17d183e3-673b-4e58-9215-ddfa7e6f4e98,C1175743,C3694279,by SARS coronavirus is,SARS coronavirus,Middle East Respiratory Syndrome,12,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
17d183e3-673b-4e58-9215-ddfa7e6f4e98,C1175743,C3694279,was causative Pharmacologic Substance to that of,SARS coronavirus,Middle East Respiratory Syndrome,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200
3685157c-bb56-4931-a7e4-2dd24402d556,C3698360,C3694279,by SARS coronavirus is,Middle East Respiratory Syndrome Coronavirus,Middle East Respiratory Syndrome,4,X,[virs],[dsyn],B04.820.504.540.150.113.750,C02.782.600.550.200
62a41d95-a55d-41c4-be92-493cdf5d5b87,C0206419,C0683212,affect ,Genus: Coronavirus,central nervous system function,6,X,[virs],[ortf],B04.820.504.540.150,
3b68551d-4509-4540-83bd-c0abd6e5bcd0,C0003504,C0012634,tracking ,Aortic Valve Insufficiency,Disease,7,X,[dsyn],[dsyn],C14.280.484.095,C23.550.288
4cc71f4c-8bd4-4522-94f3-c3ea23261bc6,C1707391,C0567416,generate shape-based 3D ,Choose (action),Molecule,3,X,[acty],[sbst],,
e3ee7e5d-3318-48af-87d6-6dc03aed9500,C1707391,C0036563,generate shape-based 3D ,Choose (action),Plant seeds,3,X,[acty],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
11389477-73ae-43bb-89f2-c586bc128e61,C0567416,3D,starting from 3D ,Molecule,3D,7,X,[sbst],????,,????
dedcaeb6-13ea-4078-b568-6ad053c21202,C0567416,C0036563,starting to pharmacophoric features of its ,Molecule,Plant seeds,7,X,[sbst],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
d38c2bbe-9a81-4f04-a8a0-861418afbdf9,6LU7,C0206419,is in ,6LU7,Genus: Coronavirus,3,X,????,[virs],????,B04.820.504.540.150
ab73faf9-f7c7-4899-8a45-91beb27cf0b6,C0014964,6LU7,can can qualified as 6LU7 ,Ethambutol,6LU7,7,X,[orch/phsu],????,D02.092.782.258.368.265,????
9a50be4c-a2ce-4237-9a21-7b35414dac7a,C0014964,C0206419,can can qualified as 6LU7 ,Ethambutol,Genus: Coronavirus,3,X,[orch/phsu],[virs],D02.092.782.258.368.265,B04.820.504.540.150
adc21019-834c-422a-8f19-1cd44bf6d1ea,C1947904,C0206419,Binding (Molecular Function) of,Attachment (action),Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
763dde75-bdd3-475f-b9ba-98743fa4ef96,C1947904,C0033684,Binding (Molecular Function) of,Attachment (action),Proteins,7,X,[acty],[aapp/bacs],,D12.776
37a70c7e-a6c4-406a-901d-3eef927c08cc,C1514562,C1707391,using ,Protein Domain,Choose (action),3,X,[amas],[acty],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
37a70c7e-a6c4-406a-901d-3eef927c08cc,C1514562,C1707391,consisting of ,Protein Domain,Choose (action),3,X,[amas],[acty],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
bf212a7d-fe15-4690-9332-611f6824aea0,C1514562,C0206419,was associated with ,Protein Domain,Genus: Coronavirus,2,X,[amas],[virs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,B04.820.504.540.150
71f9b197-d868-46da-961f-d8ac6cbfc0af,C1514562,C0032285,was significantly associated with ,Protein Domain,Pneumonia,3,X,[amas],[dsyn],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,C08.381.677;C08.730.610
5a721f17-15ca-495b-9529-dd3f87375435,C0024109,C0960880,are damaged due to presence of ,Lung,angiotensin converting enzyme 2,2,X,[bpoc],[aapp/enzy],A04.411,x.x.x.x
b09ea1cd-08f8-4a4c-9a89-91e8a03fe36c,C0024109,C0597358,are damaged due to presence of ,Lung,receptor binding,1,X,[bpoc],[moft],A04.411,
48a8f8ae-ad0d-4aff-9ee5-92db9df2dab7,C1999230,C0008138,related to ,Providing (action),Chiropractic (field),1,X,[acty],[bmod],,H02.110
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,related during ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,manage ,Providing (action),Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,may affect ,Providing (action),Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,lead clinical use of ,Providing (action),Coronavirus Infections,5,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,is with advantageous protection against ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,is in hospital due to ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,Facing shortage during ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
70c8ea38-6d7e-4c11-997c-6aae3bb420e5,C1999230,C0206750,insight into treatment of ,Providing (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
d5fc1b10-159d-415b-ba30-6eb7ad09ca5e,C1999230,C0009450,regarding protecting against ,Providing (action),Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
d5fc1b10-159d-415b-ba30-6eb7ad09ca5e,C1999230,C0009450,lead clinical use of ,Providing (action),Communicable Diseases,6,X,[acty],[dsyn],,C01.539.221
bf23a55c-6c80-4a93-86fc-2933e4a8b886,C0042210,C0206750,is currently available for treatment of ,Vaccines,Coronavirus Infections,2,X,[aapp/imft/phsu],[dsyn],D20.215.894,C02.782.600.550.200
bf23a55c-6c80-4a93-86fc-2933e4a8b886,C0042210,C0206750,are are considered for treatment of ,Vaccines,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C02.782.600.550.200
f1004611-a501-4b1e-b7ca-ba9905ae1eae,C0012634,C0042776,is caused by very small ,Disease,Virus,9,X,[dsyn],[virs],C23.550.288,B04
7c1c2c45-4706-4ff3-a487-6f7513960ecf,C3272452,C2717802,is with spike-like ,Single-Stranded RNA,Viral Structures,3,X,[nnon],[anst],,A21
7d9087cd-a722-41ed-80af-7e4f5cfd3370,C3272452,C1622204,is with spike-like ,Single-Stranded RNA,envelope,3,X,[nnon],[celc],,
65411232-5d14-4561-a1b8-3426582d1a56,C2717802,C1622204,is with spike-like ,Viral Structures,envelope,3,X,[anst],[celc],A21,
65a5193e-c48f-488e-9a84-d83723efb968,C1175743,C3272452,is positive-sense ,SARS coronavirus,Single-Stranded RNA,6,X,[virs],[nnon],B04.820.504.540.150.113.937,
b8174e5b-7ad5-4047-b8ba-572fa73dfe16,C1175743,C2717802,is enveloped ,SARS coronavirus,Viral Structures,6,X,[virs],[anst],B04.820.504.540.150.113.937,A21
6514288b-0516-4ac5-a892-43a35fd22236,C1175743,C1622204,is enveloped ,SARS coronavirus,envelope,3,X,[virs],[celc],B04.820.504.540.150.113.937,
dd45fd72-8255-4923-8b80-1c45a759f278,C1622204,C0010813,can interact after ,envelope,Cytokinesis,3,X,[celc],[celf],,G04.144.220.250
533452b7-4bdc-43eb-94ae-fc47680fb047,C1622204,C0022709,can interact with ,envelope,Peptidyl-Dipeptidase A,3,X,[celc],[aapp/enzy/imft],,D08.811.277.656.350.350.687
75866a75-972f-4d06-ba96-5be3378f10ab,C1622204,C0597357,can interact with ,envelope,receptor,3,X,[celc],[aapp/rcpt],,
40e8c322-dbd9-48f3-a43f-4062aed010ad,C0597357,C0086418,are present in ,receptor,Homo sapiens,3,X,[aapp/rcpt],[humn],,B01.050.150.900.649.313.988.400.112.400.400
82d0e46b-bac7-4bbf-acdb-ea133fbdfb17,C0597357,C0024109,were widely disturbed among ,receptor,Lung,11,X,[aapp/rcpt],[bpoc],,A04.411
921caf66-6c95-4da1-8008-0a56a8bb06a2,C0042776,C1175175,causes ,Virus,Severe Acute Respiratory Syndrome,5,X,[virs],[dsyn],B04,C02.782.600.550.200.750;C08.730.730
690a834c-5947-4a60-8ee0-fcc808ca2e7a,C0086418,C0012634,was confirmed for ,Homo sapiens,Disease,10,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C23.550.288
53446ba9-7ebe-4bce-9f51-4937d7de692b,C0814435,C0920467,may expedite proper management of ,early identification,disorder control (procedure),2,X,[topp],[topp],,
314f98ed-0688-481b-8cf8-fd9e409e823d,C0007531,C0076611,was performed after weeks of ,Cecum,thymoquinone,2,X,[bpoc],[orch],A03.556.124.526.209;A03.556.249.249.209,x.x.x.x
70f55f02-d48c-450d-beb5-d661b57237fb,C0007531,C0041281,was performed after weeks of ,Cecum,Tube feeding of patient,2,X,[bpoc],[topp],A03.556.124.526.209;A03.556.249.249.209,
b576c96e-69bf-4ab1-b78a-765c6a80922a,48h,C0040300,measured histopathological alterations in kidney ,48h,Body tissue,2,X,????,[tisu],????,A10
c077276e-4f39-42e2-b10a-3a359285b6c3,C0076611,C0007531,inhibited CRE,thymoquinone,Cecum,2,X,[orch],[bpoc],x.x.x.x,A03.556.124.526.209;A03.556.249.249.209
8ad2b752-1f07-408e-a125-f2c9faf5cf2a,C0076611,CRE,inhibited CRE,thymoquinone,CRE,2,X,[orch],????,x.x.x.x,????
87773e30-abf8-424c-a862-9b6f1bd0bf80,C0076611,C0600137,inhibited ,thymoquinone,Blood Urea Nitrogen,2,X,[orch],[bacs/inch],x.x.x.x,E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115
c9226c10-799f-436e-8936-300457d9713a,NF-B,C0076611,was Furthermore decreased in ,NF-B,thymoquinone,4,X,????,[orch],????,x.x.x.x
40bda769-97e2-43c2-9b31-ccf595b4e7f6,NF-B,C0007531,was decreased than than ,NF-B,Cecum,4,X,????,[bpoc],????,A03.556.124.526.209;A03.556.249.249.209
1d287e7e-f16b-4e12-a93c-c7eee2a5f25d,C0076611,C0243026,be potential agent for AKI,thymoquinone,Sepsis,2,X,[orch],[dsyn],x.x.x.x,C01.539.757;C23.550.470.790.500
239ba8f5-8935-4297-b3c1-b49a5cdf5270,C0076611,AKI,be potential agent for AKI,thymoquinone,AKI,2,X,[orch],????,x.x.x.x,????
de38d472-5940-4646-8bb5-4f3fe7682a83,C0920687,C1705178,is in ,cancer care,Order (action),2,X,[topp],[acty],,
70786f94-8bf4-4ea8-8f43-21fc4be8abc2,C0206750,C1456573,presents unprecedented threat to ,Coronavirus Infections,Global Health,27,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.371;N01.400.337
a592bc8e-a880-48be-86b8-f29ff6ec95f6,genomic,C0042776,enable understanding of characteristics of ,genomic,Virus,3,X,????,[virs],????,B04
db2bf7b7-355f-45f7-a3d7-64c62ac12fe2,C0014507,C1175743,investigate origin of ,Epidemiology,SARS coronavirus,1,X,[bmod],[virs],H02.403.720.500,B04.820.504.540.150.113.937
058f4457-7cb9-4b25-9a66-203b69c69694,C1175743,C0015219,exhibited ,SARS coronavirus,Biological Evolution,2,X,[virs],[genf],B04.820.504.540.150.113.937,G05.045;G16.075
5b61d690-ac38-4b82-a5d8-beb60012af64,C0206750,C0021403,is unlike ,Coronavirus Infections,Influenza virus vaccine,3,X,[dsyn],[imft/phsu],C02.782.600.550.200,D20.215.894.899.302
a30d7d62-a393-4727-8059-112d3ad533f7,C0012634,C0021403,having ,Disease,Influenza virus vaccine,2,X,[dsyn],[imft/phsu],C23.550.288,D20.215.894.899.302
05952aa5-fe67-444a-8297-07c3a0e74cae,C0275524,C0021403,is with ,Coinfection,Influenza virus vaccine,2,X,[dsyn],[imft/phsu],C01.539.218;C02.219;C03.202,D20.215.894.899.302
94a755be-feab-4228-b6b2-c6b95751c2e2,C0275524,C1880177,is with ,Coinfection,Contribution,2,X,[dsyn],[acty],C01.539.218;C02.219;C03.202,
8f5fb045-b519-45eb-ae4a-4c453aefeb02,C2926735,C0021403,was longer than than those without ,Duration,Influenza virus vaccine,7,X,[orch/phsu],[imft/phsu],,D20.215.894.899.302
903b124a-1ab4-4f64-8409-7d7444b949e4,C2926735,C0275524,was longer than than those without ,Duration,Coinfection,14,X,[orch/phsu],[dsyn],,C01.539.218;C02.219;C03.202
dc5fde92-d14a-4d05-af16-b68b18a3d67e,C0032285,C0206750,is in ,Pneumonia,Coronavirus Infections,7,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C02.782.600.550.200
85dbefd1-a8ae-4af5-a026-eb07553bea18,C0939237,C0748159,eliminated difference of ,lopinavir / Ritonavir,pulmonary involvement,2,X,[phsu],[dsyn],,
0f999ba6-feda-466c-a129-ac2f02a58135,C0939237,C0021403,eliminated difference between ,lopinavir / Ritonavir,Influenza virus vaccine,2,X,[phsu],[imft/phsu],,D20.215.894.899.302
e43f1692-8596-47e5-b82e-357fcce6a672,C0939237,C0032285,is associated with ,lopinavir / Ritonavir,Pneumonia,2,X,[phsu],[dsyn],,C08.381.677;C08.730.610
54555ead-8de0-4feb-95b9-a5df6264e781,C0939237,C0206750,treating non-severe ,lopinavir / Ritonavir,Coronavirus Infections,6,X,[phsu],[dsyn],,C02.782.600.550.200
cc610b71-f4a4-4cbd-b38f-69d15b57ed32,C0007222,C1824356,are at with comorbidities risk of ,Cardiovascular Diseases,KIAA1551 gene,3,X,[dsyn],[gngm],C14,
094a8ad4-f57c-4944-904a-4c256ade7b86,C0017178,C0021079,requiring ,Gastrointestinal Diseases,Therapeutic immunosuppression,9,X,[dsyn],[topp],C06.405,E02.095.465.425.450;E05.478.610
a0dec0a2-e5cc-49a7-8a05-b240add43397,C1516048,C3711684,has ,Assessed,S protein severe acute respiratory syndrome coronavirus,3,X,[acty],[aapp/bacs],,x.x.x.x
10062a9d-08d1-4881-af01-7c2576633337,C1516048,C0003320,has ,Assessed,Antigens,1,X,[acty],[imft],,D23.050
99760531-53c5-4724-99fd-c56ae9c7ae61,C0003316,C0027498,is in ,Epitopes,Nausea and vomiting,1,X,[imft],[sosy],D23.050.550,
1d063501-0e96-43a5-a661-885314c9680d,C0003451,C2948600,is with ,Antiviral Agents,Aim,2,X,[phsu],[inch/phsu],D27.505.954.122.388,
ef54fd2c-b5a1-4dd4-a822-618546e517ad,C0003451,C1999230,is with ,Antiviral Agents,Providing (action),2,X,[phsu],[acty],D27.505.954.122.388,
12e3c133-78e5-4c80-9602-f1df11feec0e,C0206419,C1628999,is caused by single-stranded ,Genus: Coronavirus,SARS coronavirus RNA,1,X,[virs],[nnon],B04.820.504.540.150,
e8a21d1f-0d63-4160-8ac5-f54fd054a286,RAS,C0206419,be maintained during current ,RAS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
38550bbb-d2fc-4f2c-ab4c-dc0415dbcc50,C0206419,C1321919,is taking colossal ,Genus: Coronavirus,TLR4 protein human,1,X,[virs],[aapp/rcpt],B04.820.504.540.150,x.x.x.x
1bfd88f8-644b-4070-924b-40aff1558c7c,C0206419,C0086418,took 0.39 million ,Genus: Coronavirus,Homo sapiens,40,X,[virs],[humn],B04.820.504.540.150,B01.050.150.900.649.313.988.400.112.400.400
5fabe3c3-dcb0-456a-a335-5a2b0f19da8a,C0206419,C0683278,is taking colossal ,Genus: Coronavirus,Mental Suffering,1,X,[virs],[mobd],B04.820.504.540.150,F01.145.126.990;F02.830.900
4da88250-8716-4e5a-9947-9ee0f270f8e5,C0630906,C1516048,Risks of were ,vinyltriethoxysilane,Assessed,1,X,[orch],[acty],x.x.x.x,
24ed2e5f-d14a-47f4-b13a-d0a01d31251d,C1516048,C4050231,using Padua prediction ,Assessed,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[acty],[clna],,
24ed2e5f-d14a-47f4-b13a-d0a01d31251d,C1516048,C4050231,using Household ,Assessed,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[acty],[clna],,
06ce56b4-53e7-41b4-833e-84f4693e69b2,C0630906,C0010076,overall rate of was ,vinyltriethoxysilane,Coronaviridae,6,X,[orch],[virs],x.x.x.x,B04.820.504.540
06ce56b4-53e7-41b4-833e-84f4693e69b2,C0630906,C0010076,incidence of was In patients ,vinyltriethoxysilane,Coronaviridae,6,X,[orch],[virs],x.x.x.x,B04.820.504.540
121d263b-e7b0-4a2b-9654-de7cea61994e,C0630906,C0012634,was in ,vinyltriethoxysilane,Disease,3,X,[orch],[dsyn],x.x.x.x,C23.550.288
01aa2b58-c8c7-4511-b2e6-806353878a74,C0206419,C0398623,was associated with ,Genus: Coronavirus,Thrombophilia,3,X,[virs],[dsyn],B04.820.504.540.150,C15.378.925
ec280f31-c2eb-413f-be42-a14cc18b7d5b,C0206419,C1533724,includes fear coming into contact with ,Genus: Coronavirus,Fomes,1,X,[virs],[fngs],B04.820.504.540.150,B01.300.179.120.174
7c1a3383-b141-45bb-8cc9-f74eb7308f1c,C0039082,C0033927,was correlated with preexisting ,Syndrome,Psychopathology,6,X,[dsyn],[bmod],C23.550.288.500,F04.096.670
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,was correlated with preexisting ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,was correlated with excessive ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,were repeatedly reported after ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,Symptoms of,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,is life-threatening manifestation of ,Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
6df3a1aa-82f2-43f5-879a-11422aa67e20,C0039082,C0206419,seems most common manifestation of ,Syndrome,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.288.500,B04.820.504.540.150
56b417e3-5e07-47d7-a908-07a9215db865,C0039082,C0870238,was correlated with preexisting ,Syndrome,buying,6,X,[dsyn],[acty],C23.550.288.500,
02712d9f-28cf-4dc4-9e4d-8e733bb81ec8,C2607914,C0679381,is common ,Allergic rhinitis (disorder),Pediatric Disorder,1,X,[dsyn],[dsyn],C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443,
5dcc8838-884a-4f73-98d1-03a921ab927b,C0042776,C1290074,are involved in ,Virus,Chronic mucositis,2,X,[virs],[dsyn],B04,
dbfd419e-866d-4e34-81af-a338a1804f5a,C0042776,C0028429,are involved in ,Virus,Nose,1,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
dbfd419e-866d-4e34-81af-a338a1804f5a,C0042776,C0028429,Inflammatory disease of mucous membrane of,Virus,Nose,2,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
dbfd419e-866d-4e34-81af-a338a1804f5a,C0042776,C0028429,produce ,Virus,Nose,2,X,[virs],[bpoc],B04,A01.456.505.733;A04.531;A09.531
0a2a0782-26dd-4bad-a8bf-521e39f1f601,C0206419,C0022709,utilize ,Genus: Coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150,D08.811.277.656.350.350.687
930184aa-072d-44ce-81c0-54e31e7e775a,C1452534,C0003009,helps in formation of ,ACE protein human,angiotensin II,1,X,[aapp/bacs],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
c6b76006-ed88-4465-b631-77aacfcc42e8,C1452534,C0003006,helps in formation of ,ACE protein human,Angiotensin I,1,X,[aapp/bacs],[aapp/bacs],x.x.x.x,D06.472.699.094.075;D12.644.400.070.075;D12.644.456.073.021;D12.644.548.058.075;D12.776.631.650.070.075;D23.469.050.050.025;x.x.x.x
0cc85ad1-e996-4018-a215-f94fa033c24d,C1452534,C0042397,has ,ACE protein human,Vasoconstrictor Agents,1,X,[aapp/bacs],[phsu],x.x.x.x,D27.505.954.411.793
6fd47a0a-393a-4cb7-aa3a-0a91f50d26ab,C0003009,C0042397,has ,angiotensin II,Vasoconstrictor Agents,1,X,[aapp/bacs/phsu],[phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D27.505.954.411.793
d2f140e7-f6e1-4212-bfd7-e9c5db9069f6,C1452534,C1439284,has properties via ,ACE protein human,AGTR1 gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
bd6bdfd9-81bd-4b8d-b10c-ea3407b2e23d,C0003009,C1439284,has properties via ,angiotensin II,AGTR1 gene,1,X,[aapp/bacs/phsu],[gngm],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
16613d49-841a-47c3-af1b-f717093b0a3e,C0597357,C0003009,counter pro-inflammatory effects mediated by ,receptor,angiotensin II,2,X,[aapp/rcpt],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
95b58473-a311-4722-b5dc-e8d801a05d4a,C0022709,C0042402,counter pro-inflammatory effects mediated by ,Peptidyl-Dipeptidase A,Vasodilator Agents,1,X,[aapp/enzy/imft],[phsu],D08.811.277.656.350.350.687,D27.505.954.411.918
3f028139-7e62-4ad1-9c97-e56b211936b7,C0597357,C0042402,counter pro-inflammatory effects mediated by ,receptor,Vasodilator Agents,2,X,[aapp/rcpt],[phsu],,D27.505.954.411.918
de5e6b7d-3487-462e-b93d-97f2b82cbd33,C0184661,C0883301,performed procedures on patients arterial ,Interventional procedure,catheter placement,3,X,[topp],[topp],,
8e1cbaf0-47b0-46e7-b668-84f74bbf48e9,C0740651,C0030193,were ,Abdominal symptom,Pain,1,X,[sosy],[sosy],,C23.888.592.612;F02.830.816.444;G11.561.790.444
ad0f660f-a444-47c6-acba-bf4195369320,C0052796,C0206419,is in hospitalized patients positive for ,Azithromycin,Genus: Coronavirus,2,X,[antb/orch],[virs],D02.540.576.500.992.050,B04.820.504.540.150
b8be2445-adef-4217-885a-b30d5dc815e0,C0020336,C0052796,of Receipt is hydroxychloroquine in combination with ,Hydroxychloroquine,Azithromycin,2,X,[orch/phsu],[antb/orch],D03.633.100.810.050.180.350,D02.540.576.500.992.050
1bb2e2ee-da39-495e-b251-5eba70959df4,C1175175,C0184661,is in patient recovering after Hartmanns ,Severe Acute Respiratory Syndrome,Interventional procedure,2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,
25c6d6bc-8f27-42d2-82c3-4a356e794e64,C1175175,C0518989,is in patient recovering after Hartmanns ,Severe Acute Respiratory Syndrome,acute diverticulitis,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,
8230ebf6-081d-4337-a571-a417db1cd9aa,C1142578,C1175743,confirmed presence of ,Bilateral pneumonia,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
e32ec3e5-5105-49f7-aeda-c4f3c5321289,C0206419,C0543467,is in ,Genus: Coronavirus,Operative Surgical Procedures,2,X,[virs],[topp],B04.820.504.540.150,E04
24919c5e-ffa1-4095-876a-08ff21fdb071,C0598197,C0543467,is in ,contagion,Operative Surgical Procedures,2,X,[npop],[topp],,E04
5491ae8b-b6be-497a-bf45-08b88e5fb72b,C1511790,C1175175,is required for ,Detection,Severe Acute Respiratory Syndrome,4,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
5491ae8b-b6be-497a-bf45-08b88e5fb72b,C1511790,C1175175,was used for confirmation of ,Detection,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
4330faf7-9551-48c9-9991-75627e188a40,C0028606,C0206419,is in ,Nucleic Acids,Genus: Coronavirus,3,X,[bacs/nnon],[virs],D13.444,B04.820.504.540.150
0b4fd3bb-b446-41a7-b83c-e741a8e4e3fe,C1999230,C0028606,effective Complement System Proteins to false-negative results from,Providing (action),Nucleic Acids,3,X,[acty],[bacs/nnon],,D13.444
8d989fb5-649f-4edd-a422-0a389276a5b7,C1999230,C1175175,rapidly evaluate ,Providing (action),Severe Acute Respiratory Syndrome,6,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
e6a8a6e9-519d-4cc8-b3a8-c94275c5d4f7,C0185003,C1160716,prevent ,Reparative closure,viral transmission,5,X,[topp],[celf],,
fb4f74f4-fb4d-440e-b3b3-47e10b11c5ef,C0185003,C1705178,is implemented in ,Reparative closure,Order (action),5,X,[topp],[acty],,
85838849-b63c-4c65-8262-8320b7861080,C0185003,C1825598,prevent its ,Reparative closure,IMPACT gene,5,X,[topp],[gngm],,
41ffe7d3-cb5e-4d81-ba8a-f8c500133890,C0185003,C0242781,prevent significantly ,Reparative closure,disease transmission,5,X,[topp],[patf],,N06.850.310
e143ca79-67cb-4da9-961e-4cfd1a4b789d,COVID-19,C0015967,usually presents with ,COVID-19,Fever,1,X,[virs],[sosy],C000657245,C23.888.119.344
e143ca79-67cb-4da9-961e-4cfd1a4b789d,COVID-19,C0015967,is in patients with ,COVID-19,Fever,1,X,[virs],[sosy],C000657245,C23.888.119.344
8f71348d-3f96-4187-b71a-8de7e942516c,C0086903,C0032105,had titer at time of ,GTP-Binding Protein alpha Subunits Gs,Plasma,1,X,[aapp/enzy],[bdsu],D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400,A12.207.152.693;A12.207.270.695;A15.145.693
11c352ad-cfb1-4d4d-b8a1-fb763ff57f4f,C1522002,C0032105,had titer at time of ,RNA Recognition Motif,Plasma,5,X,[aapp/bacs],[bdsu],G02.111.570.820.709.275.500.869.500,A12.207.152.693;A12.207.270.695;A15.145.693
68f6c0c5-3252-4dab-bb09-38ee65e9a7c4,titer,C0032105,had titer at time of ,titer,Plasma,6,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
ab104565-91f4-4a78-a009-c19f0303f2fb,C0086903,titer,had titer ,GTP-Binding Protein alpha Subunits Gs,titer,1,X,[aapp/enzy],????,D08.811.277.040.330.300.200.100.400;D12.644.360.360.100.400;D12.776.157.325.332.100.400;D12.776.476.375.100.400;D12.776.543.325.100.400,????
13fd30e9-2872-4f11-aab3-133fccf1b289,C1522002,titer,had titer ,RNA Recognition Motif,titer,5,X,[aapp/bacs],????,G02.111.570.820.709.275.500.869.500,????
81a6f12a-ba03-4282-8fa9-95fb13c0af27,C1457887,COVID-19,shift from ,Symptoms,COVID-19,16,X,[sosy],[virs],,C000657245
c1efa191-2044-40b5-95e5-36ec6905addf,C0443640,COVID-19,reaches levels after 4weeks ,Specific antibody,COVID-19,4,X,[aapp/imft],[virs],,C000657245
558da0b5-0971-4e48-bbc4-d9cda5b216df,C0020852,COVID-19,reaches levels after 4weeks ,Immunoglobulin G,COVID-19,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C000657245
f6645ead-4e75-4836-b30a-cb2c1ae5f5c1,C1457887,4weeks,reaches levels after 4weeks ,Symptoms,4weeks,1,X,[sosy],????,,????
d78f5b2d-6435-404b-8d0c-3c6f01aa657f,C0443640,4weeks,reaches levels after 4weeks ,Specific antibody,4weeks,4,X,[aapp/imft],????,,????
c0e1b971-3d15-4649-a6f1-1395686260c1,C0020852,4weeks,reaches levels after 4weeks ,Immunoglobulin G,4weeks,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,????
1a59470d-8a61-4053-8b61-7cd19a0b5022,COVID-19,C1707455,is with smoking history ,COVID-19,Comparison,1,X,[virs],[acty],C000657245,
1a59470d-8a61-4053-8b61-7cd19a0b5022,COVID-19,C1707455,occur among patients on ,COVID-19,Comparison,1,X,[virs],[acty],C000657245,
0e2aa1a8-df82-4afb-bf91-8e13f8b1d76e,C0024530,C1456573,remains major ,Malaria,Global Health,3,X,[dsyn],[bmod],C03.752.530,H02.403.371;N01.400.337
f88bf731-4320-4d6b-b40a-d2e554b3366c,C0024115,C0024530,is with many clinical parallels to ,Lung diseases,Malaria,2,X,[dsyn],[dsyn],C08.381,C03.752.530
dc2c3bc5-875b-4818-ba8d-42fec1e81fdf,C1457887,C0024530,shift from ,Symptoms,Malaria,1,X,[sosy],[dsyn],,C03.752.530
09867dec-9642-4803-ac7b-cba428bd87eb,C1457887,C0003374,repurposing of ,Symptoms,Antimalarials,1,X,[sosy],[phsu],,D27.505.954.122.250.100.085
f1fb2d46-1855-4819-afd5-de466c7d85df,C0012634,C1456573,recently appeared as ,Disease,Global Health,13,X,[dsyn],[bmod],C23.550.288,H02.403.371;N01.400.337
de64cb71-b9c0-4552-96ba-33186e0e3467,MPV,C1707455,was significantly higher as ,MPV,Comparison,4,X,????,[acty],????,
20c554fd-c17c-4e19-b91f-431d59e0723c,MPV,C0011849,was significantly higher as ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
20c554fd-c17c-4e19-b91f-431d59e0723c,MPV,C0011849,was higher to results from last routine visits of same individuals with ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
20c554fd-c17c-4e19-b91f-431d59e0723c,MPV,C0011849,predict Covid ,MPV,Diabetes Mellitus,2,X,????,[dsyn],????,C18.452.394.750;C19.246
bc74cf95-1579-4bc4-a249-4267742de323,C0009450,C0011849,is in subjects with ,Communicable Diseases,Diabetes Mellitus,2,X,[dsyn],[dsyn],C01.539.221,C18.452.394.750;C19.246
bc74cf95-1579-4bc4-a249-4267742de323,C0009450,C0011849,is in individuals with ,Communicable Diseases,Diabetes Mellitus,1,X,[dsyn],[dsyn],C01.539.221,C18.452.394.750;C19.246
e2d610d6-ea7b-403f-b60a-581350912db7,MPV,C0009450,predict Covid ,MPV,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
c8956db3-a757-45ff-a095-9462d7db857a,C0040649,C0086418,is in samples of ,Transcription Genetic,Homo sapiens,1,X,[genf],[humn],G02.111.873;G05.297.700,B01.050.150.900.649.313.988.400.112.400.400
7552606c-52dd-473a-95b2-155206fef2f3,C0040649,C1956101,is in samples of ,Transcription Genetic,Cumulus Cells,1,X,[genf],[cell],G02.111.873;G05.297.700,A05.360.319.114.630.535.200.500;A06.300.312.497.535.300.500;A11.382.812.500;A11.436.329.500
1319a430-ac41-46de-a164-d5c755e660b6,C0022709,C0039597,is in ,Peptidyl-Dipeptidase A,Testis,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.360.444.849;A05.360.576.782;A06.300.312.782
39fb4578-8f1b-47ff-a0d5-d34af00971ed,invitro,C1160716,are associated with very little risk ,invitro,viral transmission,1,X,????,[celf],????,
9d4becbb-e619-4a0b-b863-2936465657c5,invitro,C2718310,are associated with very little risk ,invitro,Gametes,1,X,????,[cell],????,A05.360.490;A11.497
64cd9b19-f9e7-45f7-a617-d2dee059b202,C0301872,murine,is in murine ,Immune response,murine,1,X,[ortf],????,,????
6f76a126-5571-41cf-90fb-e958888965a0,C0301872,C0017260,is in murine ,Immune response,Gene Deletion,1,X,[ortf],[genf],,G05.365.590.762.320;G05.558.800.320
6a2bae5d-b142-4f08-89a3-c2c9d032b23d,C0021083,C0011627,used in ,Immunotherapy,Dermatology field,1,X,[topp],[bmod],E02.095.465.425,H02.403.225
ed3a97f5-fc07-4574-9767-87d5b69c7ad8,C0021083,COVID-19,are most likely safe for ,Immunotherapy,COVID-19,1,X,[topp],[virs],E02.095.465.425,C000657245
c9aa501f-a992-4096-8806-1297b0309746,C0028756,C0206419,were predictors protective for mortality in hospitalized ,Obesity Morbid,Genus: Coronavirus,4,X,[dsyn],[virs],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,B04.820.504.540.150
c9aa501f-a992-4096-8806-1297b0309746,C0028756,C0206419,are associated with greater risk for death with ,Obesity Morbid,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,B04.820.504.540.150
75fefb5f-57d0-4f67-8f2f-1131fdea8201,C4048329,C0206419,were predictors protective for mortality in ,Immunosuppression,Genus: Coronavirus,4,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
75fefb5f-57d0-4f67-8f2f-1131fdea8201,C4048329,C0206419,may may protective in those affected with ,Immunosuppression,Genus: Coronavirus,1,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
75fefb5f-57d0-4f67-8f2f-1131fdea8201,C4048329,C0206419,is largely safe in current ,Immunosuppression,Genus: Coronavirus,1,X,[dsyn],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150
2bb6ec66-8816-4f59-aa17-d516d6d32e82,C1175743,C0015392,spread rapidly around ,SARS coronavirus,Eye,36,X,[virs],[bpoc],B04.820.504.540.150.113.937,A01.456.505.420;A09.371
2bab6d69-c236-4886-9666-2dcf61878304,C0042776,C0013227,could could further explored as potential ,Virus,Pharmaceutical Preparations,5,X,[virs],[phsu],B04,D26
db18b112-fdab-4de5-beee-cddfcee60a91,C0748355,C0221423,are result Like Like ,Acute respiratory distress,Illness (finding),12,X,[dsyn],[sosy],,
3e4552ca-44ed-48f6-b68d-c76dca76531f,C0748355,pro-,are result of disruption in balance of pro- ,Acute respiratory distress,pro-,7,X,[dsyn],????,,????
230c1506-b6e7-466c-840b-4edaf380f074,C0748355,C0079189,are result of disruption in balance of pro- ,Acute respiratory distress,cytokine,12,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
1024c7f9-fd9d-4a51-8d8d-02d0251c1a0c,COVID-19,C0033860,is with ,COVID-19,Psoriasis,2,X,[virs],[dsyn],C000657245,C17.800.859.675
7c3c7ddb-ac14-4c31-b842-dc7dd98d5e2c,C1150225,C0035100,mitigates deleterious effects associated with ,angiotensin I-converting enzyme activity,Chymosin,2,X,[moft],[aapp/enzy],,D08.811.277.656.074.500.200;D08.811.277.656.300.048.200
45081acd-aa3a-4f09-b154-04f8bfb3a5c1,C1149313,C0032105,had titer at time of ,IgG binding,Plasma,1,X,[moft],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
21f0bec4-f86e-4917-8654-f64c109fdac3,C1149313,titer,had titer ,IgG binding,titer,1,X,[moft],????,,????
f4756075-bc11-4d72-b81c-903adc872c26,C2754943,4weeks,reaches levels after 4weeks ,IgG antibody,4weeks,5,X,[celc],????,,????
4ee29b27-93e2-4a8f-a171-8018d9e5203b,C2754943,C0206419,reaches levels after 4weeks ,IgG antibody,Genus: Coronavirus,2,X,[celc],[virs],,B04.820.504.540.150
6f4f3760-9974-4774-9a18-046e62f087b4,C2754943,C1457887,reaches levels after 4weeks ,IgG antibody,Symptoms,5,X,[celc],[sosy],,
159a4353-c381-4332-a998-635d82e808c4,C0206419,3rd,is spreading rapidly as of 3rd ,Genus: Coronavirus,3rd,1,X,[virs],????,B04.820.504.540.150,????
178dbb65-f863-46b3-b3fd-0b964f9e4d8d,C0747919,COVID-19,is with ,pregnancy related,COVID-19,4,X,[dsyn],[virs],,C000657245
a63b3932-81c8-43fb-ac0f-2fdf2e03bf41,C0206419,C1511790,was first ,Genus: Coronavirus,Detection,2,X,[virs],[topp],B04.820.504.540.150,
5744dfb5-e9b4-49c2-8576-266fa46eee7e,C0042776,C0039082,is responsible for acute respiratory ,Virus,Syndrome,3,X,[virs],[dsyn],B04,C23.550.288.500
09313190-da77-4b12-b4a4-1689afc0ed98,C0042776,C0206061,is responsible for acute respiratory ,Virus,Pneumonia Interstitial,6,X,[virs],[dsyn],B04,C08.381.483
ad0dc6d1-379c-4c71-8050-82143b492db6,C0206419,C0042776,is new ,Genus: Coronavirus,Virus,10,X,[virs],[virs],B04.820.504.540.150,B04
4bf85cad-7b1c-4c59-841e-72c0213cda60,C0042776,C0003047,can cause Animal Diseases in,Virus,Animal Diseases,4,X,[virs],[dsyn],B04,C22
23bd97c1-024c-4e73-b252-640147422d65,C0035204,C1175743,caused by highly ,Respiration Disorders,SARS coronavirus,17,X,[dsyn],[virs],C08.618,B04.820.504.540.150.113.937
23bd97c1-024c-4e73-b252-640147422d65,C0035204,C1175743,using much lower dose of ,Respiration Disorders,SARS coronavirus,1,X,[dsyn],[virs],C08.618,B04.820.504.540.150.113.937
c2dcc809-af57-4ba7-9624-77e84f6586b6,C0206419,C3713294,39-year-old woman with ,Genus: Coronavirus,MTR protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
ac89c54b-e94e-4441-aa2f-ea5c2025954c,C0086418,C0036745,exhibited negative ,Homo sapiens,Study of serum,1,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.781
9392dcf7-d3f2-45ac-90d4-e82b6c592005,C0027183,C0003261,blunt 2 ,NN-Dimethyltryptamine,Antibody Formation,1,X,[bacs/orch],[biof],D02.092.211.215.801.451;D03.633.100.473.914.237,G12.070
74c5c5d9-9b55-4d57-b531-bd749638405e,C0030805,C0004364,is most common ,Bullous pemphigoid,Autoimmune Diseases,1,X,[dsyn],[dsyn],C17.800.865.690;C20.111.730,C20.111
9a9c83f5-9b76-4cff-bda7-30c8a1c9a28c,C1825598,C0441516,includes ,IMPACT gene,Demand (clinical),6,X,[gngm],[topp],,
aeabbc79-3985-4cf6-8f8b-e542be3734c0,C1825598,C1420621,shift towards ,IMPACT gene,TCAP gene,10,X,[gngm],[gngm],,
7f188045-6849-4e06-983c-5152880163f6,C0423866,C1825598,could could anticipated as ,Lanugo,IMPACT gene,7,X,[bpoc],[gngm],A17.360,
cc83d4ff-7004-4714-8f14-a54cb5cf82ae,C0032285,C0206419,is in ,Pneumonia,Genus: Coronavirus,6,X,[dsyn],[virs],C08.381.677;C08.730.610,B04.820.504.540.150
29b87b46-739e-4587-82fc-50931f01b83b,C0026766,C0206419,are spectrum of ,Multiple Organ Failure,Genus: Coronavirus,4,X,[patf],[virs],C23.550.835.525,B04.820.504.540.150
50a4743c-fefd-4981-9e6d-b7d001405e5c,C0013227,C0032285,impairing exacerbation of ,Pharmaceutical Preparations,Pneumonia,3,X,[phsu],[dsyn],D26,C08.381.677;C08.730.610
c229bb99-3f54-4c90-8b2e-7600bf0efd5e,C0003374,C0021368,reducing ,Antimalarials,Inflammation,2,X,[phsu],[patf],D27.505.954.122.250.100.085,C23.550.470
dcb7f10e-8f0f-4500-9aa3-390c9dba755c,C0020336,C0021368,reducing ,Hydroxychloroquine,Inflammation,5,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,C23.550.470
bd08b3a3-7f1d-43ad-9758-bef8b72b31d5,C0003374,C0009450,reducing Inflammation to,Antimalarials,Communicable Diseases,2,X,[phsu],[dsyn],D27.505.954.122.250.100.085,C01.539.221
01495059-5cfb-4aa1-9bb7-31403939027d,C0020336,C0009450,reducing Inflammation to,Hydroxychloroquine,Communicable Diseases,5,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
01495059-5cfb-4aa1-9bb7-31403939027d,C0020336,C0009450,was promoted in ,Hydroxychloroquine,Communicable Diseases,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
be5d0c2a-96da-445b-8521-1685e159dfeb,C0013227,C0003374,includes ,Pharmaceutical Preparations,Antimalarials,4,X,[phsu],[phsu],D26,D27.505.954.122.250.100.085
6e473bfa-b18a-4323-8d3a-26e21af75287,C0013227,C0020336,includes antimalarial ,Pharmaceutical Preparations,Hydroxychloroquine,5,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180.350
6e473bfa-b18a-4323-8d3a-26e21af75287,C0013227,C0020336,are are tried for treatment of ,Pharmaceutical Preparations,Hydroxychloroquine,1,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180.350
64a725ba-e2e4-4ccb-a953-0b12cd288ed7,C0020336,C0206419,recently reported duration of ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
64a725ba-e2e4-4ccb-a953-0b12cd288ed7,C0020336,C0206419,may occur in ,Hydroxychloroquine,Genus: Coronavirus,2,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
64a725ba-e2e4-4ccb-a953-0b12cd288ed7,C0020336,C0206419,recently reported as possible therapy for ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
64a725ba-e2e4-4ccb-a953-0b12cd288ed7,C0020336,C0206419,are are repurposed for treatment of ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
64a725ba-e2e4-4ccb-a953-0b12cd288ed7,C0020336,C0206419,have shown in activity on ,Hydroxychloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150
04c58d64-4992-4ee1-bb39-ff0d33fea805,C0020336,C0441636,recently reported duration as possible therapy for ,Hydroxychloroquine,Surgical shortening - action,5,X,[orch/phsu],[topp],D03.633.100.810.050.180.350,
8128cde3-32fe-417d-b7e5-daededfe0928,C0850149,C0206419,had later ,Dry cough,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
09646a40-ef56-45ce-8959-e70c18f70d39,C0850149,2days,had later 2days,Dry cough,2days,5,X,[sosy],????,,????
2fcb98a0-f4c1-4bef-8f56-ca4c4c123f6f,C0850149,C0033771,presented with ,Dry cough,Prurigo,10,X,[sosy],[dsyn],,C17.800.674
62d50e41-3350-4924-84e8-6ea83ccc1661,C0000936,DRF,By damage is DRF ,Visual Accommodation,DRF,2,X,[ortf],????,G14.010,????
c4c9bb7b-93ad-472d-9a1c-1ec126e7a5ba,C0000936,C1999230,By damage is DRF ,Visual Accommodation,Providing (action),2,X,[ortf],[acty],G14.010,
bf84fb4f-cee4-4bad-bbd5-389776704dab,COVID-19,C0012634,refers to ,COVID-19,Disease,10,X,[virs],[dsyn],C000657245,C23.550.288
89c032a3-f68f-4bd9-b787-7c553503a0d3,COVID-19,C0042776,refers ,COVID-19,Virus,1,X,[virs],[virs],C000657245,B04
bd080475-7d15-4b4a-8cdc-266de233781f,C0184661,C0206074,based on PCR,Interventional procedure,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
bab20ed5-32c2-431e-9f67-18f18c8bf856,C0184661,PCR,based on PCR,Interventional procedure,PCR,1,X,[topp],????,,????
1f8fb273-080d-480f-9a17-470a1845c3ad,C0206750,C0030012,can Lead to alterations of,Coronavirus Infections,Oxidation-Reduction,1,X,[dsyn],[moft],C02.782.600.550.200,G02.700;G03.295.531
9a0d6689-4c6c-497f-a873-f55723fefb93,C0020538,COVID-19,also increased risk in ,Hypertensive disease,COVID-19,1,X,[dsyn],[virs],C14.907.489,C000657245
ee7e7cef-b4bc-4eec-b380-c6202eb8fbec,C0596448,COVID-19,increased mortality in ,dimer,COVID-19,1,X,[chvs],[virs],,C000657245
1d4b7c20-42da-4bcc-a360-ff769988b302,C0521991,COVID-19,associated with ,Symptoms of stress,COVID-19,2,X,[sosy],[virs],,C000657245
beb32eba-1ce0-421a-bece-d76fa313ab41,C0028084,COVID-19,related to ,Nightmares,COVID-19,1,X,[sosy],[virs],F02.463.188.634.309;F02.830.855.268,C000657245
4e9f5f4a-db26-4dee-a44b-183f38d3a67c,C0558066,COVID-19,related to ,Intrusive thoughts,COVID-19,1,X,[mobd],[virs],,C000657245
7e7004d3-3c26-4cef-8b46-be8d1da26d53,COVID-19,C1533724,includes fear coming into contact with ,COVID-19,Fomes,1,X,[virs],[fngs],C000657245,B01.300.179.120.174
74f6a1d8-a168-425c-a7e2-9c32eb17b9e9,C0039082,COVID-19,was correlated with ,Syndrome,COVID-19,2,X,[dsyn],[virs],C23.550.288.500,C000657245
84352fcb-2dc6-4dbd-8131-5000926b4b3d,C0747919,C0206419,is with ,pregnancy related,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
ff811ff1-0e8a-40ed-bf05-0cd9269631f0,C0151864,C0206419,is with ,Disorder of pregnancy,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
9a09d431-66e6-4d48-959f-5abf06e38de3,COVID-19,C1856053,was declared on ,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[virs],[dsyn],C000657245,x.x.x.x
9a09d431-66e6-4d48-959f-5abf06e38de3,COVID-19,C1856053,underwent Operative Surgical Procedures during,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],C000657245,x.x.x.x
9a09d431-66e6-4d48-959f-5abf06e38de3,COVID-19,C1856053,is pandemic surface with case fatality rate of estimated by WHO up to ,COVID-19,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[virs],[dsyn],C000657245,x.x.x.x
5f4584e6-2720-4b28-8b31-f733b41fb4a3,COVID-19,C1514593,know little about broader ,COVID-19,Psychological Impact,1,X,[virs],[clna],C000657245,
e2a2f698-9c78-46b0-8bae-58977be8b63d,COVID-19,C0233514,develop general ,COVID-19,Abnormal behavior,1,X,[virs],[mobd],C000657245,F01.145.126.972;F01.145.179.750
049529d0-f61d-4774-83de-f510c1d62360,C1457887,C0018681,included ,Symptoms,Headache,10,X,[sosy],[sosy],,C23.888.592.612.441
049529d0-f61d-4774-83de-f510c1d62360,C1457887,C0018681,can can complicated with ,Symptoms,Headache,3,X,[sosy],[sosy],,C23.888.592.612.441
049529d0-f61d-4774-83de-f510c1d62360,C1457887,C0018681,followed by ,Symptoms,Headache,1,X,[sosy],[sosy],,C23.888.592.612.441
20fcab8e-1fa1-48d7-ae59-82d999ce9a59,C1457887,C0027497, includes ,Symptoms,Nausea,5,X,[sosy],[sosy],,C23.888.821.712
20505c2c-8e83-4bf9-a178-965693c8c116,C1457887,C0152027, includes ,Symptoms,Sensory Disorders,5,X,[sosy],[dsyn],,C10.597.751;C23.888.592.763
7a05b018-9b4f-412d-b5ce-324fcfb0a51b,COVID,C1457887,may show ,COVID,Symptoms,5,X,????,[sosy],????,
055f3768-febb-4a6b-9eb3-f186fb5d5eed,COVID,C0018681,may show ,COVID,Headache,5,X,????,[sosy],????,C23.888.592.612.441
6a97e167-70f9-48bf-aaca-ac90ed477c0a,COVID,C0027497,may show ,COVID,Nausea,5,X,????,[sosy],????,C23.888.821.712
6b4d04d6-4fd7-4b01-a2f4-9bf064ed9586,COVID,C0152027,may show ,COVID,Sensory Disorders,5,X,????,[dsyn],????,C10.597.751;C23.888.592.763
4f4f554b-69dd-40ca-8de6-353fbb0b617a,C0206419,C3873497,is ,Genus: Coronavirus,Severe acute respiratory infection,1,X,[virs],[dsyn],B04.820.504.540.150,
dd14a4a8-fbe0-407b-b592-c016909ed98d,C0012634,C3873497,is ,Disease,Severe acute respiratory infection,1,X,[dsyn],[dsyn],C23.550.288,
9ca9411d-0786-46c4-8c04-68c2f825e7fe,C1947933,C0023186,include people with ,care activity,Learning Disorders,3,X,[acty],[mobd],,C10.597.606.150.550;C23.888.592.604.150.550;F03.625.562
1792d8f6-8628-4211-84c9-94a451f01e78,COVID-19,C1335737,is affecting life-saving option for patients with ,COVID-19,Recurrent Hematologic Malignancy,2,X,[virs],[neop],C000657245,
66afb22a-84be-41b0-8bf7-012275664f32,COVID-19,C1335724,is affecting life-saving option for patients with ,COVID-19,Refractory Hematologic Malignancy,1,X,[virs],[neop],C000657245,
ca0bfa0a-d8fa-4593-8d29-a934ec24e0e4,C2349975,C0034019,is in ,Enhance (action),public health medicine (field),4,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
e71ed1bd-34fc-4c3e-b1d9-d823a1f690e5,COVID-19,C0034019,is global ,COVID-19,public health medicine (field),3,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
e71ed1bd-34fc-4c3e-b1d9-d823a1f690e5,COVID-19,C0034019,unique challenges for ,COVID-19,public health medicine (field),2,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
e71ed1bd-34fc-4c3e-b1d9-d823a1f690e5,COVID-19,C0034019,admitted to Shanghai ,COVID-19,public health medicine (field),1,X,[virs],[bmod],C000657245,H02.403.720;N01.400.550;N06.850
2bc49194-3aa4-478c-b4da-a9dde7793076,C0242781,C0012655,combining age-stratified contact frequencies with age-dependent ,disease transmission,Disease susceptibility,2,X,[patf],[clna],N06.850.310,C23.550.291.687;G07.100.250
96956594-d4ab-46dc-b867-1cd6c8876ec9,C1457887,C0206419,may may attributed to ,Symptoms,Genus: Coronavirus,6,X,[sosy],[virs],,B04.820.504.540.150
1d1467ec-f542-42b7-bc50-3160c8ef39c2,C1865266,C1457887,is common ,RNF217-AS1 gene,Symptoms,3,X,[gngm],[sosy],,
dccfb807-442c-461d-8ce6-9c9482e7393f,C1865266,C0206419,is common Symptoms in,RNF217-AS1 gene,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
8b0b3beb-892e-4748-8ffd-0ce62d1a33e9,C1865266,C0012634,only Symptoms of,RNF217-AS1 gene,Disease,3,X,[gngm],[dsyn],,C23.550.288
2a77686d-d4a8-4e31-ab02-cd668d807a87,C0206419,C0543829,is with definitive ,Genus: Coronavirus,pneumonia clinical,3,X,[virs],[dsyn],B04.820.504.540.150,
af9a2713-588a-4f6e-b6f4-0329750efbf8,C0229671,C0206419,indicated poor outcome in patients with ,Serum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150
af9a2713-588a-4f6e-b6f4-0329750efbf8,C0229671,C0206419,were associated with poor outcome in ,Serum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150
0ee80f32-2e10-4f8a-b4fc-5cac25a8eafa,C0079189,C0206419,indicated poor outcome in patients with ,cytokine,Genus: Coronavirus,2,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
0ee80f32-2e10-4f8a-b4fc-5cac25a8eafa,C0079189,C0206419,patients with severe ,cytokine,Genus: Coronavirus,2,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
0ee80f32-2e10-4f8a-b4fc-5cac25a8eafa,C0079189,C0206419,is emerging as mechanism leading to ,cytokine,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150
b55c9702-c787-456b-b60c-1aa317a5ed4c,C0023516,C0206419,predict clinical outcome of patients with ,Leukocytes,Genus: Coronavirus,3,X,[cell],[virs],A11.118.637;A15.145.229.637;A15.382.490,B04.820.504.540.150
80bba1ed-d8ba-4acf-9db3-610e8549dc3d,C0206419,C0037285,has associated ,Genus: Coronavirus,Skin Manifestations,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.885
eb8a8855-b766-48d1-811d-dbc524beb73a,C0206419,C0349725,is in immediate post ,Genus: Coronavirus,Graft infection,1,X,[virs],[patf],B04.820.504.540.150,
f8a9e643-7733-4e2b-840e-5bb85b2e3c25,C0012634,C0034019,triggering harsh ,Disease,public health medicine (field),31,X,[dsyn],[bmod],C23.550.288,H02.403.720;N01.400.550;N06.850
cd836233-64f6-4d47-bcbe-2280d52ed56f,C0206419,C0221423,may cause serious ,Genus: Coronavirus,Illness (finding),23,X,[virs],[sosy],B04.820.504.540.150,
44f5554a-e230-4da1-9573-c538f611f5d7,C0206419,C0037090,main manifestations of are ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
44f5554a-e230-4da1-9573-c538f611f5d7,C0206419,C0037090,present with ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
44f5554a-e230-4da1-9573-c538f611f5d7,C0206419,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Genus: Coronavirus,Signs and Symptoms Respiratory,4,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
44f5554a-e230-4da1-9573-c538f611f5d7,C0206419,C0037090,clinical manifestations of are ,Genus: Coronavirus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.852
5c221643-6234-464e-8b72-4e5464a275d0,C0035222,C1861172,occurred in acute injury in ,Respiratory Distress Syndrome Adult,Venous Thromboembolism,5,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C14.907.355.590.700
33a3fdde-9ca0-4ed8-8c8f-405d0a2651fc,C0035222,C0005779,occurred in acute injury in ,Respiratory Distress Syndrome Adult,Blood Coagulation Disorders,5,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C15.378.100
c6d15253-748b-4c85-a590-e99609fe43bb,C0003015,C0206419,is in patients with ,Angiotensin-Converting Enzyme Inhibitors,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150
c6d15253-748b-4c85-a590-e99609fe43bb,C0003015,C0206419,was associated with higher ,Angiotensin-Converting Enzyme Inhibitors,Genus: Coronavirus,2,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150
3356377b-5403-45c0-8395-dad7ff852ec4,C0597357,C0206419,is in patients with ,receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150
3356377b-5403-45c0-8395-dad7ff852ec4,C0597357,C0206419,is with previous pandemic ,receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],,B04.820.504.540.150
3356377b-5403-45c0-8395-dad7ff852ec4,C0597357,C0206419,target in ,receptor,Genus: Coronavirus,2,X,[aapp/rcpt],[virs],,B04.820.504.540.150
a478cc25-d160-4dca-af04-e00b1597560d,C0242781,C0026926,was modeled for ,disease transmission,Mycobacterium tuberculosis,7,X,[patf],[bact],N06.850.310,B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702
a478cc25-d160-4dca-af04-e00b1597560d,C0242781,C0026926,were estimated for ,disease transmission,Mycobacterium tuberculosis,6,X,[patf],[bact],N06.850.310,B03.510.024.049.525.500.702;B03.510.460.400.410.552.552.702
deef289a-faf1-4de4-a639-e0323abdb533,C0242781,C0023238,was modeled for ,disease transmission,Legionella pneumophila,7,X,[patf],[bact],N06.850.310,B03.440.400.425.450.450.500;B03.660.250.460.460.580
1cde36cb-22c0-41a8-ade0-705acb79cc23,C0242781,C0025011,was modeled for ,disease transmission,Measles virus,7,X,[patf],[virs],N06.850.310,B04.820.455.600.650.500.500
1cde36cb-22c0-41a8-ade0-705acb79cc23,C0242781,C0025011,were estimated for ,disease transmission,Measles virus,6,X,[patf],[virs],N06.850.310,B04.820.455.600.650.500.500
4abdd9f1-9e33-4f8a-9746-7494d8468261,C0242781,C0029341,was modeled for ,disease transmission,Orthomyxoviridae,7,X,[patf],[virs],N06.850.310,B04.820.545
4abdd9f1-9e33-4f8a-9746-7494d8468261,C0242781,C0029341,were estimated for ,disease transmission,Orthomyxoviridae,6,X,[patf],[virs],N06.850.310,B04.820.545
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,was modeled for ,disease transmission,Genus: Coronavirus,7,X,[patf],[virs],N06.850.310,B04.820.504.540.150
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,were estimated for ,disease transmission,Genus: Coronavirus,6,X,[patf],[virs],N06.850.310,B04.820.504.540.150
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,involving droplets for ,disease transmission,Genus: Coronavirus,2,X,[patf],[virs],N06.850.310,B04.820.504.540.150
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,be main route ,disease transmission,Genus: Coronavirus,6,X,[patf],[virs],N06.850.310,B04.820.504.540.150
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,was reconstructed from 9 120 ,disease transmission,Genus: Coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150
0d737bce-0990-4aee-b8e7-a97f1976d4dd,C0242781,C0206419,was respectively fitted to reported data for ,disease transmission,Genus: Coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150
4e272f32-6fa6-40b4-a79d-2ca24b575c24,C0242781,C0020517,is strongly driven From ,disease transmission,Hypersensitivity,14,X,[patf],[patf],N06.850.310,C20.543
ae6a4b43-a31d-488a-abee-19033b605236,C0035203,C0242781,decrease probability of ,Respiration,disease transmission,4,X,[phsf],[patf],G09.772.705,N06.850.310
f0f5d213-f2b9-4976-a90f-cd46a6bed708,C0035203,C0007012,reduces ,Respiration,Carbon Dioxide,2,X,[phsf],[bacs/inch],G09.772.705,D01.200.200;D01.362.150;D01.650.550.200
c8e4a201-07c4-4272-a5b3-9617b601c243,C0011849,C0206419,know about ,Diabetes Mellitus,Genus: Coronavirus,5,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
c8e4a201-07c4-4272-a5b3-9617b601c243,C0011849,C0206419,is associated with increased ,Diabetes Mellitus,Genus: Coronavirus,1,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
c8e4a201-07c4-4272-a5b3-9617b601c243,C0011849,C0206419,showed significant association with ,Diabetes Mellitus,Genus: Coronavirus,2,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
c8e4a201-07c4-4272-a5b3-9617b601c243,C0011849,C0206419,of history is ,Diabetes Mellitus,Genus: Coronavirus,1,X,[dsyn],[virs],C18.452.394.750;C19.246,B04.820.504.540.150
ec522bcd-e818-4edb-9ce7-3684f0829dbc,C0948092,C0206419,is in patients with ,diabetes mellitus management,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
6fa9caad-7fee-408f-9a49-37331fd1b346,C1706202,C0206419,yielded potential ,Search - action,Genus: Coronavirus,8,X,[acty],[virs],,B04.820.504.540.150
ecf05ea2-ddcc-42d4-8ba0-2804bc7adbfd,C0020538,C0011849,of Presence is ,Hypertensive disease,Diabetes Mellitus,1,X,[dsyn],[dsyn],C14.907.489,C18.452.394.750;C19.246
ecf05ea2-ddcc-42d4-8ba0-2804bc7adbfd,C0020538,C0011849,was followed by ,Hypertensive disease,Diabetes Mellitus,4,X,[dsyn],[dsyn],C14.907.489,C18.452.394.750;C19.246
91f3fe7f-c74b-40a8-bf72-b8c236a993b9,C0622037,C0024117,is with OR ,3'-O-methyl-nordihydroguaiaretic acid,Chronic Obstructive Airway Disease,1,X,[orch/phsu],[dsyn],,C08.381.495.389
5876c471-a56a-4a74-9a62-61aab6fde6e6,COVID,p-value,is with p-value ,COVID,p-value,1,X,????,????,????,????
f72f8b23-0acb-42b9-b847-6b57a9e76753,C0087111,C0206419,is with ,Therapeutic procedure,Genus: Coronavirus,7,X,[topp],[virs],E02,B04.820.504.540.150
a4c91d93-40a4-4c5e-a319-e175e36aad70,C0394664,C0206419,may play role in patients in ,Acupuncture procedure,Genus: Coronavirus,1,X,[topp],[virs],E02.190.044,B04.820.504.540.150
ab317387-dde5-47bf-a626-22611d0c45ad,C0013404,C0206419,is in ,Dyspnea,Genus: Coronavirus,3,X,[sosy],[virs],C08.618.326;C23.888.852.371,B04.820.504.540.150
a646d148-7bee-45c3-bc04-1c0fa91ac34b,C0034019,C1999230,were ,public health medicine (field),Providing (action),2,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
ea6e8559-446f-414c-995a-402ea8f1de8d,C2745965,C1999230,is with view to ,Emergencies [Disease/Finding],Providing (action),1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
038d64fb-0a05-475c-9801-9740f99cb7bb,C0034019,C0026636,is with view to ,public health medicine (field),Mouth Diseases,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C07.465
a26f13cb-51f6-4c07-9656-5f2524b7148c,C2745965,C0026636,is with view to ,Emergencies [Disease/Finding],Mouth Diseases,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C07.465
e3d7ac6e-82a3-4b4b-9db9-fdd1341d8fe8,C2745965,C0034019,is with view to ,Emergencies [Disease/Finding],public health medicine (field),1,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,H02.403.720;N01.400.550;N06.850
2f1c2b46-26f4-4fb9-9399-cd653890e252,C0034019,C2745965,is with view to ,public health medicine (field),Emergencies [Disease/Finding],2,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,C23.550.291.781;N06.230.100.083;N06.850.376
9d337e9f-daf8-4112-88ab-99534bdd6702,C0042776,C0242781,track ,Virus,disease transmission,20,X,[virs],[patf],B04,N06.850.310
d4b8f169-45a3-4d9d-a0b1-02506f6d9128,C1175743,C1167395,utilize same ,SARS coronavirus,Host (organism),10,X,[virs],[orgm],B04.820.504.540.150.113.937,
d4b8f169-45a3-4d9d-a0b1-02506f6d9128,C1175743,C1167395,mediates Cells Virus Internalization through,SARS coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150.113.937,
d4b8f169-45a3-4d9d-a0b1-02506f6d9128,C1175743,C1167395,producing excessive reaction in ,SARS coronavirus,Host (organism),5,X,[virs],[orgm],B04.820.504.540.150.113.937,
d4b8f169-45a3-4d9d-a0b1-02506f6d9128,C1175743,C1167395,caused ,SARS coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150.113.937,
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,uses attach to,SARS coronavirus,Peptidyl-Dipeptidase A,22,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,penetrates cells through direct ,SARS coronavirus,Peptidyl-Dipeptidase A,4,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,mediates Cells Virus Internalization through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,capacity through ,SARS coronavirus,Peptidyl-Dipeptidase A,8,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,being internalized with ,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,cause Disease through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,occurs to ,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,enters Cells by,SARS coronavirus,Peptidyl-Dipeptidase A,2,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
118d5e43-8cf0-4b77-bc28-414e0f9e4cef,C1175743,C0022709,enters Lung through,SARS coronavirus,Peptidyl-Dipeptidase A,1,X,[virs],[aapp/enzy/imft],B04.820.504.540.150.113.937,D08.811.277.656.350.350.687
b538ca36-7cf4-4401-b406-7f9beea30ffc,C1175743,C0597357,utilize same ,SARS coronavirus,receptor,14,X,[virs],[aapp/rcpt],B04.820.504.540.150.113.937,
7068e5b5-6b8d-4eac-9a1a-c5982a6ad3b4,C1175743,C0024109,uses attach in,SARS coronavirus,Lung,14,X,[virs],[bpoc],B04.820.504.540.150.113.937,A04.411
11902e6f-628e-4ec8-be56-4e49c55362b2,C1175743,C1514535,uses S1,SARS coronavirus,Protein Binding Motif,2,X,[virs],[amas],B04.820.504.540.150.113.937,
9b941135-0a26-433e-9180-79fc87ee51c8,C1175743,C0597358,uses S1,SARS coronavirus,receptor binding,2,X,[virs],[moft],B04.820.504.540.150.113.937,
9b941135-0a26-433e-9180-79fc87ee51c8,C1175743,C0597358,has regions in ,SARS coronavirus,receptor binding,2,X,[virs],[moft],B04.820.504.540.150.113.937,
9b941135-0a26-433e-9180-79fc87ee51c8,C1175743,C0597358,affects specific ,SARS coronavirus,receptor binding,2,X,[virs],[moft],B04.820.504.540.150.113.937,
9b941135-0a26-433e-9180-79fc87ee51c8,C1175743,C0597358,belongs in terms of ,SARS coronavirus,receptor binding,1,X,[virs],[moft],B04.820.504.540.150.113.937,
20cc94bc-2f2a-4d9e-bb7e-09afd3c835a7,C1175743,S1,uses S1,SARS coronavirus,S1,2,X,[virs],????,B04.820.504.540.150.113.937,????
d5ea2741-bf47-456e-b8b0-7d4468096c26,C1707455,C0206419,is with that of other previous ,Comparison,Genus: Coronavirus,4,X,[acty],[virs],,B04.820.504.540.150
8e513c24-7709-438a-8538-15e3d97ac5c5,C0476236,C2607914,is in ,Developmental symptoms,Allergic rhinitis (disorder),2,X,[sosy],[dsyn],,C08.460.799.315;C08.674.453;C09.603.799.315;C20.543.480.680.443
cb3e807c-f36e-4417-86b8-0aa0f769fa6a,C0476236,C0206419,serve as clues for new-onset ,Developmental symptoms,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
2472c1b9-000b-4461-a9d1-54bb292cbc90,C1550600,C0042776,inactivate ,Ingredient,Virus,2,X,[chvf],[virs],,B04
7bba3d8a-7c2c-4b50-b659-061a7cf8a6bc,NLR,C0242656,were good predictors of ,NLR,Disease Progression,5,X,????,[patf],????,C23.550.291.656
9ed0034a-4489-43ce-b4d2-36b88a04212a,NLR,C0012634,were good predictors of ,NLR,Disease,2,X,????,[dsyn],????,C23.550.288
9ed0034a-4489-43ce-b4d2-36b88a04212a,NLR,C0012634,were predictors to critical ,NLR,Disease,2,X,????,[dsyn],????,C23.550.288
a54ffead-94a9-4777-9af2-2fd305915c49,C0006560,C0242656,were good predictors of ,C-reactive protein,Disease Progression,2,X,[aapp/imft],[patf],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.291.656
360a31e8-c37e-4175-8fbf-7d886b4f840e,C0006560,C0012634,were good predictors of ,C-reactive protein,Disease,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.288
360a31e8-c37e-4175-8fbf-7d886b4f840e,C0006560,C0012634,were predictors to critical ,C-reactive protein,Disease,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C23.550.288
7a1473de-61b0-41ee-82bf-04e4fea41ea6,C0206419,C3526598,pose urgent tasks for our ,Genus: Coronavirus,Psychiatric service,1,X,[virs],[topp],B04.820.504.540.150,
6991c572-e0df-4ee3-bf9b-5b84a45877e4,C0221423,C1457887,is with ,Illness (finding),Symptoms,1,X,[sosy],[sosy],,
654b68e1-3b76-4201-8a25-66aecc3baf88,C0849867,C0042210,may drive interest in ,Widespread Disease,Vaccines,1,X,[dsyn],[aapp/imft/phsu],,D20.215.894
84161ce6-2afe-48fb-a593-62e44cac4caa,C0231239,GHG,have GHG ,Fluctuation,GHG,2,X,[sosy],????,,????
bc6556ad-fe12-4558-8f63-0635c27a205a,C0231239,C0233929,have GHG ,Fluctuation,Emission - Male genitalia finding,2,X,[sosy],[bdsu],,
034cb1ba-5f03-417a-bf40-61f48433a071,C0206419,C0016452,had on ,Genus: Coronavirus,Food,1,X,[virs],[food],B04.820.504.540.150,G07.203.300;J02.500
c59b4ecc-2bf8-45ee-9b56-8d27b2e23e65,GHG,C1825598,complete multivariable ,GHG,IMPACT gene,4,X,????,[gngm],????,
656c0d36-61a6-40f2-97a4-2f88ded4de24,C0233929,C1825598,complete multivariable ,Emission - Male genitalia finding,IMPACT gene,4,X,[bdsu],[gngm],,
cf40ca16-cc16-42c2-917f-f314cfa8b381,C0037114,C0040300,applied as ,Silicones,Body tissue,2,X,[bodm/orch],[tisu],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,A10
556041a8-8ffc-425b-966b-e4b0cec7d151,C0278286,C0040300,considerably relieved ,Dressing of skin or wound,Body tissue,2,X,[topp],[tisu],,A10
3a379bc3-83f7-4db6-b5f5-4fdeda1b994a,C0278286,C1708715,considerably relieved Body tissue exposures to,Dressing of skin or wound,Loading Technique,2,X,[topp],[acty],,
29a0a790-3010-4f68-911c-039e25b6606c,C0005516,C0229671, includes ,Biological Markers,Serum,2,X,[clna],[bdsu],D23.101,A12.207.152.846;A15.145.846
c7869bca-7696-4668-87bc-4dd7c314762e,C0718133,C0020517,has ,a & d,Hypersensitivity,2,X,[orch/phsu/vita],[patf],,C20.543
88d1d448-aa4f-4cd1-a688-2d13bcfff5fd,C0596448,C0020517,has ,dimer,Hypersensitivity,2,X,[chvs],[patf],,C20.543
e8289391-e244-4485-84de-d0a19cb8c8b8,CRP,C0206419,were associated with poor outcome in ,CRP,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
9f0fa372-5501-4daf-8488-6e10fcdd63fe,C0072027,C0206419,were associated with poor outcome in ,procalcitonin,Genus: Coronavirus,2,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,B04.820.504.540.150
f7f87e15-ba56-4f98-b88e-5198ba9dc6d7,C0060323,C0206419,were related in ,Fibrin fragment D,Genus: Coronavirus,3,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
f7f87e15-ba56-4f98-b88e-5198ba9dc6d7,C0060323,C0206419,have have observed in patients with ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
f7f87e15-ba56-4f98-b88e-5198ba9dc6d7,C0060323,C0206419,were increased in ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
f7f87e15-ba56-4f98-b88e-5198ba9dc6d7,C0060323,C0206419,were on admission in ,Fibrin fragment D,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
f7f87e15-ba56-4f98-b88e-5198ba9dc6d7,C0060323,C0206419,were higher in ,Fibrin fragment D,Genus: Coronavirus,2,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
fdb6978f-2a4d-475a-8e02-20ce600298a4,C0015879,C0206419,were associated with poor outcome in ,Ferritin,Genus: Coronavirus,2,X,[aapp/bacs/phsu],[virs],D12.776.157.427.249;D12.776.556.579.249;x.x.x.x,B04.820.504.540.150
5ef6320e-d089-4bcd-b1e0-afe98822535c,C0042776,C0012634,causes ,Virus,Disease,9,X,[virs],[dsyn],B04,C23.550.288
1e2dd9a1-4781-43cd-ba44-0ef73eae1902,C3890179,C0007286,is in patients with ,Pulmonary Trunk,Carpal Tunnel Syndrome,3,X,[bpoc],[dsyn],,C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206
1e2dd9a1-4781-43cd-ba44-0ef73eae1902,C3890179,C0007286,was higher than cases with ,Pulmonary Trunk,Carpal Tunnel Syndrome,3,X,[bpoc],[dsyn],,C10.668.829.500.500.200;C10.668.829.550.200;C26.844.150.206
3581418a-6b6a-48dd-a92f-7b802e435573,C0003062,C0206750,are involved in ,Animals,Coronavirus Infections,1,X,[anim],[dsyn],B01.050,C02.782.600.550.200
7464b8f4-e910-44dd-bfb6-1547178f68e3,C0243077,C0960880,may increase expression of ,inhibitors,angiotensin converting enzyme 2,3,X,[chvf],[aapp/enzy],,x.x.x.x
61cabe89-4b5a-4975-a6d6-cc0677c41bf0,C0960880,C0597357,is receptor for SARSCoV-2 Spike,angiotensin converting enzyme 2,receptor,7,X,[aapp/enzy],[aapp/rcpt],x.x.x.x,
7ed24808-2c19-4327-ba7a-c577bf2ace0f,C0815017,C0020538,was compatible Among those with ,Angiotensin Receptor Antagonists,Hypertensive disease,4,X,[phsu],[dsyn],D27.505.519.162,C14.907.489
1d5578cc-380b-462c-b258-95f3dcd7c180,C0702249,C0087111,C-reactive protein for specific empirical,Infiltration (procedure),Therapeutic procedure,2,X,[topp],[topp],,E02
0adc88eb-d3bc-4ee1-b775-3631c6a5f3c6,C1522002,4weeks,reaches levels after 4weeks ,RNA Recognition Motif,4weeks,4,X,[aapp/bacs],????,G02.111.570.820.709.275.500.869.500,????
29d0bab5-d5bb-4c37-8136-48676a4fb016,C1522002,C0206750,reaches levels after 4weeks ,RNA Recognition Motif,Coronavirus Infections,3,X,[aapp/bacs],[dsyn],G02.111.570.820.709.275.500.869.500,C02.782.600.550.200
653e90db-4177-4284-aae0-f85e5484735a,C2754943,C0206750,reaches levels after 4weeks ,IgG antibody,Coronavirus Infections,3,X,[celc],[dsyn],,C02.782.600.550.200
3b8e3f65-e8ff-4c3d-87f9-d519883d2a27,C1522002,C1457887,reaches levels after 4weeks ,RNA Recognition Motif,Symptoms,4,X,[aapp/bacs],[sosy],G02.111.570.820.709.275.500.869.500,
d0b9ead6-f046-45c0-ab3f-7c71c275c8fb,C1602245,C0009450,lower intra-hospital spread of ,Prompt,Communicable Diseases,2,X,[phsu],[dsyn],,C01.539.221
a7f54f56-1adb-4bf7-a19d-ca24cc100474,C1511790,C0009450,lower intra-hospital spread of ,Detection,Communicable Diseases,2,X,[topp],[dsyn],,C01.539.221
445d8fbd-6a1f-417e-82b9-fa49796d950d,C4050231,C4048285,was significantly correlated with ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,C-Reactive Protein human,3,X,[clna],[aapp/imft],,
bba4087d-f41e-4738-83c4-58b91a53558d,C1999230,C0005516,visualization compared with non-specific inflammatory ,Providing (action),Biological Markers,7,X,[acty],[clna],,D23.101
f42a1016-e850-4561-9530-e241fcd0aff8,C0085584,C0206750,has has reported for patients including of patients with ,Encephalopathies,Coronavirus Infections,3,X,[dsyn],[dsyn],C10.228.140,C02.782.600.550.200
f42a1016-e850-4561-9530-e241fcd0aff8,C0085584,C0206750,be initial Disease Presentation of,Encephalopathies,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140,C02.782.600.550.200
d0a732ca-761e-4bbd-bde8-ad66e815be79,C0014038,C2348077,has has described in eight patients to ,Encephalitis,Date Fruit,4,X,[dsyn],[food],C10.228.140.430,B01.650.940.800.575.912.250.093.615
af2ffec6-cbd4-4c2d-b132-a41ff0b3e8e6,C1175743,C3540512,has in has ,SARS coronavirus,Circumferential Supracrestal Fiberotomy,4,X,[virs],[topp],B04.820.504.540.150.113.937,
1c8d2012-3b28-45a9-87a4-2959bc9c04ce,C0810006,C0206750,is emerging of patients hospitalised with ,Acute cerebrovascular disease,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
1c8d2012-3b28-45a9-87a4-2959bc9c04ce,C0810006,C0206750,has has observed in patients with ,Acute cerebrovascular disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
89d0cb22-460f-4ac4-a1a2-3b93909f3710,C0810006,C0009566,is emerging as important ,Acute cerebrovascular disease,Complication,4,X,[dsyn],[patf],,
047f1f9a-03f1-4ced-a895-70766757e1da,C0038454,C0398623,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Thrombophilia,4,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C15.378.925
5e4d8586-c43f-4acd-a7b3-a104eb3a3a2b,C0038454,C0060323,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Fibrin fragment D,4,X,[dsyn],[aapp/bacs],C10.228.140.300.775;C14.907.253.855,x.x.x.x
ff093945-fc2b-4b68-a77f-0adfdf509432,C0038454,C0015879,frequently had events in context of pro-inflammatory ,Cerebrovascular accident,Ferritin,4,X,[dsyn],[aapp/bacs/phsu],C10.228.140.300.775;C14.907.253.855,D12.776.157.427.249;D12.776.556.579.249;x.x.x.x
7769c332-4ca9-4c76-921a-bd6ae088400f,C0398623,C0060323,is with elevated C-reactive protein ,Thrombophilia,Fibrin fragment D,4,X,[dsyn],[aapp/bacs],C15.378.925,x.x.x.x
38ed32d4-6837-4e8a-9335-02cf9ecb3842,C0398623,C0015879,is with elevated C-reactive protein ,Thrombophilia,Ferritin,4,X,[dsyn],[aapp/bacs/phsu],C15.378.925,D12.776.157.427.249;D12.776.556.579.249;x.x.x.x
cd3dcaaf-c40c-4c37-a6fb-4f944ecedc31,C0042776,C0009450, includes ,Virus,Communicable Diseases,1,X,[virs],[dsyn],B04,C01.539.221
cd3dcaaf-c40c-4c37-a6fb-4f944ecedc31,C0042776,C0009450,is highly ,Virus,Communicable Diseases,2,X,[virs],[dsyn],B04,C01.539.221
cd3dcaaf-c40c-4c37-a6fb-4f944ecedc31,C0042776,C0009450,encounter Host (organism) compartment in critical step of,Virus,Communicable Diseases,1,X,[virs],[dsyn],B04,C01.539.221
33d1fd3a-e0a5-4155-8498-7c83dbe4ff57,C0398623,C0038454,leading to ,Thrombophilia,Cerebrovascular accident,4,X,[dsyn],[dsyn],C15.378.925,C10.228.140.300.775;C14.907.253.855
1dea3672-8992-4e65-865c-9ef30a75b726,C1511790,C0206750,is in current pandemic of ,Detection,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
1dea3672-8992-4e65-865c-9ef30a75b726,C1511790,C0206750,may play role in development of approaches for ,Detection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
1dea3672-8992-4e65-865c-9ef30a75b726,C1511790,C0206750,is required for diagnosis of ,Detection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
1dea3672-8992-4e65-865c-9ef30a75b726,C1511790,C0206750,low rates of are indicative ,Detection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
1dea3672-8992-4e65-865c-9ef30a75b726,C1511790,C0206750,understanding overall prevalence of ,Detection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
7b0a6d12-18be-4226-b666-cc4e428b47f1,C1511790,C0012634,is in current pandemic of ,Detection,Disease,3,X,[topp],[dsyn],,C23.550.288
7b0a6d12-18be-4226-b666-cc4e428b47f1,C1511790,C0012634,is required for diagnosis of ,Detection,Disease,3,X,[topp],[dsyn],,C23.550.288
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,were tested for ,Specimen,SARS coronavirus,4,X,[sbst],[virs],,B04.820.504.540.150.113.937
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,remained positive for ,Specimen,SARS coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.937
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,spiking ENUMX6 with portion of ,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,spiking ENUMX4 with portion of ,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,spiking ENUMX2 with portion of ,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
2246fa48-6202-4657-a629-735bba6fb3c3,C0370003,C1175743,were analysed for ,Specimen,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
de26ce33-469d-4b48-bdf4-972159da8af3,C1511790,C0036087,was equivalent in ,Detection,saliva,4,X,[topp],[bdsu],,A12.200.666
7ce6055f-f0d1-41b0-a83b-769ee81264c8,C3873497,C1175743,caused by ,Severe acute respiratory infection,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
9e95ceca-222d-4a8d-963b-24b18bf0d86b,C0206750,C0349725,is in immediate post ,Coronavirus Infections,Graft infection,1,X,[dsyn],[patf],C02.782.600.550.200,
6c506244-f219-4ecb-a6fc-5a5bc65d0ccc,C0231239,C0016452,have major consequences on potential ,Fluctuation,Food,1,X,[sosy],[food],,G07.203.300;J02.500
9099cd08-630d-4210-be2d-c1ed8914619b,GHG,C0016452,major consequences on potential ,GHG,Food,1,X,????,[food],????,G07.203.300;J02.500
b1412ee2-4841-4602-80f8-d21a0f0bed82,C0233929,C0016452,major consequences on potential ,Emission - Male genitalia finding,Food,1,X,[bdsu],[food],,G07.203.300;J02.500
1475684d-5656-4f84-95ba-89ab10d0a6cf,C0206750,C0016452,had on ,Coronavirus Infections,Food,1,X,[dsyn],[food],C02.782.600.550.200,G07.203.300;J02.500
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,is characterized by excessive proinflammatory ,Coronavirus Infections,cytokine,4,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,leads to ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,can manifest with ,Coronavirus Infections,cytokine,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,experience high levels of ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,may experience ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
b80742e8-ed32-4fb0-9c0a-4d41d2797c33,C0206750,C0079189,have higher ,Coronavirus Infections,cytokine,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374;D12.776.467.374;D23.529.374
6bfe505d-90d3-46db-b658-2f7f3cd6f58a,C0206750,C0948245,is with ,Coronavirus Infections,Cytokine Release Syndrome,4,X,[dsyn],[dsyn],C02.782.600.550.200,
750cc9ce-605a-4986-94c1-c29c33a7ac46,C0010340,C0206750,is with ,Critical Illness,Coronavirus Infections,5,X,[dsyn],[dsyn],C23.550.291.625,C02.782.600.550.200
8e83b646-80b4-4b08-b5b5-9baa4104692a,C0030858,C0162578,underwent ,Pentaerythritol Tetranitrate,Thrombectomy,2,X,[orch/phsu],[topp],D02.033.455.706.690,E04.100.814.842
e4385295-5def-48d7-9a1d-5f69e3ddb0ea,C0030858,C1856053,underwent ,Pentaerythritol Tetranitrate,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,x.x.x.x
a12ee311-27ab-4765-8a9e-91bb6f4a86e6,NAAT,C0035736,compare diagnostic values of ,NAAT,RNA Viral,1,X,????,[nnon],????,D13.444.735.828
365be2af-6bff-4b79-a6bb-dc5a909910cd,NAAT,C1511790,were used Because of ,NAAT,Detection,1,X,????,[topp],????,
07855057-674a-4f18-8424-4dab1aa40356,C0036537,C1175743,yielded positive results for ,Bodily secretions,SARS coronavirus,7,X,[bdsu],[virs],A12.200,B04.820.504.540.150.113.937
31c36619-5eca-4c27-b2fb-91fc1c621152,C0393706,C1175743,improves accuracy of ,Early infantile epileptic encephalopathy with suppression bursts,SARS coronavirus,4,X,[dsyn],[virs],,B04.820.504.540.150.113.937
df1910ad-e8a6-44a0-8846-87edaf506851,C0162633,C0015733,is in ,Viral Shedding,Feces,8,X,[patf],[bdsu],G07.925,A12.459
4bd5f47c-d334-4092-ad5b-215ad6526a8c,C0015733,C0242781,highlights potentially increased risk of faeco-oral ,Feces,disease transmission,7,X,[bdsu],[patf],A12.459,N06.850.310
f86906fa-3e90-4311-a68f-c22529db0e38,C0042776,C3697872,belongs to ,Virus,Genus Betacoronavirus,4,X,[virs],[virs],B04,
74f0e203-8cd1-483f-ae86-2804878caecb,C0221423,C0206750,with Disease is,Illness (finding),Coronavirus Infections,7,X,[sosy],[dsyn],,C02.782.600.550.200
5bdc2ffa-618e-4d0a-9a44-0681b9e44ca1,C0206750,C0221423,is with variable degree of ,Coronavirus Infections,Illness (finding),21,X,[dsyn],[sosy],C02.782.600.550.200,
2efe507d-bdbd-43a9-a842-9d14e8547173,C0012634,C0221423,is with mild-to-severe respiratory ,Disease,Illness (finding),15,X,[dsyn],[sosy],C23.550.288,
1f235962-748a-4c74-a213-bd48b6cbd009,C0051979,C1550100,is in ,anti-IgG,Specimen Type - Serum,14,X,[aapp/imft],[bdsu],x.x.x.x,
f1d290a3-99e2-4cef-ad83-8e81cbbce9dc,C0051979,C0086418,is in ,anti-IgG,Homo sapiens,4,X,[aapp/imft],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
df872381-b7ee-4b09-96bb-8f6dd641e78f,C1513397,C1175743,is with ,Molecular Medicine,SARS coronavirus,1,X,[bmod],[virs],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,B04.820.504.540.150.113.937
84d6795f-2dc4-4d3f-bb14-bbbb2cb46279,C0597357,C1422064,as dipeptidyl peptidase II is,receptor,ACE2 gene,1,X,[aapp/rcpt],[gngm],,
8c9c4585-a377-4202-bcab-703f9c760c51,C1273412,C0025124,were retrieved from ,Chinese herbal medicine,Traditional Chinese Medicine,1,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
71cbaa07-389b-4ebd-b29a-f6cd705a2392,C0596973,C0025124,were retrieved from ,monomer,Traditional Chinese Medicine,1,X,[chvs],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
b845ef62-0191-436f-8840-6308e34c45c2,C1328819,C0242210,have optimal ,Small Molecule,Binding Proteins,2,X,[orch],[aapp/bacs],,D12.776.157
2aa2cea7-3e92-4de5-81cf-5bf02c94cf31,C0024115,C1704259,is in ,Lung diseases,Biochemical Pathway,1,X,[dsyn],[moft],C08.381,
efd5d2d6-2112-4fa0-9556-e14ccf2016bf,C0206750,C1704259,is in ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
efd5d2d6-2112-4fa0-9556-e14ccf2016bf,C0206750,C1704259,leads with increasing evidence for ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
efd5d2d6-2112-4fa0-9556-e14ccf2016bf,C0206750,C1704259,caused with increasing evidence inflammatory ,Coronavirus Infections,Biochemical Pathway,1,X,[dsyn],[moft],C02.782.600.550.200,
af62df43-a6f6-402f-868f-fc7b7d43239e,C0206750,C0009450,utilizes Angiotensin-converting Enzyme 2 Pathway Angiotensin-converting Enzyme 2 Pathway as means of,Coronavirus Infections,Communicable Diseases,89,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.221
e3fd66d3-60f8-4e2c-ba15-dbe86b603f99,C0206750,C0008679,is associated with much ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3fd66d3-60f8-4e2c-ba15-dbe86b603f99,C0206750,C0008679,had more WBC CRP ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3fd66d3-60f8-4e2c-ba15-dbe86b603f99,C0206750,C0008679,has caused disruption to patients with ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
e3fd66d3-60f8-4e2c-ba15-dbe86b603f99,C0206750,C0008679,persons with ,Coronavirus Infections,Chronic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.500
60551b06-5880-47e5-8755-fa6a6b246c09,C0206750,C0011849,takes course in individuals with ,Coronavirus Infections,Diabetes Mellitus,16,X,[dsyn],[dsyn],C02.782.600.550.200,C18.452.394.750;C19.246
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,was from establishment of database to ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,identify documents published till ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,were performed until ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,10,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,focused on 10 ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,using terms in first week ,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f58ac934-aca5-493d-90de-78190a725161,C1706202,C1706374,were conducted in PubMed 4th,Search - action,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
ca63ca54-a01a-42b3-8399-eb9c8464102d,C0206750,C1511790,was first ,Coronavirus Infections,Detection,8,X,[dsyn],[topp],C02.782.600.550.200,
f8a0eb32-cf9e-4485-9b97-fe0447557d2a,C1516635,C0206750,win battle against ,Clinical Treatment,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
d318cf8b-d6cd-4f22-95b2-0c3ef0e60d93,C0814435,C0206750,mitigating spread of ,early identification,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
9859274f-a106-4fdd-a042-ca971b98a2ab,C0028756,C0206750,are associated with greater risk for death with ,Obesity Morbid,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C02.782.600.550.200
9859274f-a106-4fdd-a042-ca971b98a2ab,C0028756,C0206750,were independent predictors protective for mortality in ,Obesity Morbid,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C02.782.600.550.200
35377e92-d3f9-4f69-a5fc-8cde13487c00,C0028756,C0012634,are associated with greater risk for death with ,Obesity Morbid,Disease,8,X,[dsyn],[dsyn],C18.654.726.500.700;C23.888.144.699.500.500;E01.370.600.115.100.160.120.699.500.500;G07.100.100.160.120.699.500.500,C23.550.288
09739c36-93fd-4c72-b725-222e208b0cf5,C1167622,C0034800,is with ,Binding (Molecular Function),Receptors Cell Surface,4,X,[moft],[aapp/rcpt],,D12.776.543.750
dec11bba-dcd9-417d-a995-314cb9885a8e,C1175743,C1167622,penetrates cells through direct ,SARS coronavirus,Binding (Molecular Function),4,X,[virs],[moft],B04.820.504.540.150.113.937,
dec11bba-dcd9-417d-a995-314cb9885a8e,C1175743,C1167622,uses membrane ,SARS coronavirus,Binding (Molecular Function),1,X,[virs],[moft],B04.820.504.540.150.113.937,
dec11bba-dcd9-417d-a995-314cb9885a8e,C1175743,C1167622,enters Host Cell by,SARS coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150.113.937,
dec11bba-dcd9-417d-a995-314cb9885a8e,C1175743,C1167622,occurs through ,SARS coronavirus,Binding (Molecular Function),1,X,[virs],[moft],B04.820.504.540.150.113.937,
dec11bba-dcd9-417d-a995-314cb9885a8e,C1175743,C1167622,enters Cells by,SARS coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150.113.937,
dc8e5e01-c158-44de-abf6-52a58e2f9097,C1175743,C0034800,penetrates cells through direct ,SARS coronavirus,Receptors Cell Surface,8,X,[virs],[aapp/rcpt],B04.820.504.540.150.113.937,D12.776.543.750
bec1bde0-8e06-45ed-a0cf-730957e6eba7,C0022709,C0001527,is in ,Peptidyl-Dipeptidase A,Adipose tissue,4,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10.165.114
166876f4-6d13-47cc-a0be-932660b3fcef,C0022709,C0819757,was found In ,Peptidyl-Dipeptidase A,Structure of parenchyma of lung,6,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
02419622-cf58-4ffd-9f7b-bb05373ef303,C0001527,C0012655,be ,Adipose tissue,Disease susceptibility,4,X,[tisu],[clna],A10.165.114,C23.550.291.687;G07.100.250
54601407-50d3-4cd6-901a-49964ffb6eb9,C0001527,C0206750,be ,Adipose tissue,Coronavirus Infections,3,X,[tisu],[dsyn],A10.165.114,C02.782.600.550.200
30e3e089-a6fa-4b28-90ec-e641dbe2befe,C0001527,C0009450,be ,Adipose tissue,Communicable Diseases,4,X,[tisu],[dsyn],A10.165.114,C01.539.221
d1bffd32-f6c5-4662-a48e-46993f3fd1df,C0009450,C1145670, includes ,Communicable Diseases,Respiratory Failure,8,X,[dsyn],[dsyn],C01.539.221,C08.618.846
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,also have worse outcomes with ,Obesity,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,is risk factor for severe ,Obesity,Coronavirus Infections,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,BACKGROUND/During 2019 ,Obesity,Coronavirus Infections,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,develop ,Obesity,Coronavirus Infections,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,highlighting role of nutrition in prognosis of ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,represents higher risk of ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
27dd2525-b6f4-4458-b003-04fa2950b33c,C0028754,C0206750,had increased odds progressing to ,Obesity,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02.782.600.550.200
1205129b-0dd9-432a-8700-92fa6c7efde6,C0028754,C0009450,represents higher risk of ,Obesity,Communicable Diseases,7,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C01.539.221
3795eddc-f573-4010-8dbc-ab34de94e8fc,C0028754,C1145670,also have worse outcomes with ,Obesity,Respiratory Failure,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.618.846
f873db90-5ba3-4f94-b579-b99709872480,C0028754,C0199470,need for ,Obesity,Mechanical ventilation,4,X,[dsyn],[topp],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
2a8da407-5054-431d-810e-49095247014b,6LU7,C0206750,is in ,6LU7,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
28b33aaf-6eca-4d34-b018-51957958216c,C0014964,C0206750,can can qualified as 6LU7 ,Ethambutol,Coronavirus Infections,4,X,[orch/phsu],[dsyn],D02.092.782.258.368.265,C02.782.600.550.200
6dbd7c8b-dee3-4c64-ac35-2ce37edbab2e,C1947904,C0206750,Binding (Molecular Function) of,Attachment (action),Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
c6f60230-7596-4051-94bf-4fc09a4f6597,C0007203,C2926735,limit ,Cardiopulmonary Resuscitation,Duration,2,X,[topp],[orch/phsu],E02.365.647.110,
b13b4d3c-02d8-4cb3-abaa-ee8caf863488,C0206750,C1335737,Currently is affecting life-saving option for patients with ,Coronavirus Infections,Recurrent Hematologic Malignancy,2,X,[dsyn],[neop],C02.782.600.550.200,
f75e7f51-0f86-4869-b914-3493d0d0cbf6,C0206750,C1335724,Currently is affecting life-saving option for patients with ,Coronavirus Infections,Refractory Hematologic Malignancy,1,X,[dsyn],[neop],C02.782.600.550.200,
d2cf34aa-de0e-4eb3-965a-bf89cbf59d84,C4039583,C0206750,However has become during ,Chimeric antigen receptor,Coronavirus Infections,1,X,[aapp/imft/rcpt],[dsyn],D12.776.543.750.655.500;D12.776.543.750.705.816.824.150;D12.776.826.387.500,C02.782.600.550.200
a68540b8-57a2-43d6-b8bb-11c1bc5552d8,C0206750,C0007820,is with new onset of ,Coronavirus Infections,Cerebrovascular Disorders,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300;C14.907.253
17726cb5-af07-4cdc-a23b-dc3719294473,C0011849,CVD,Xyzinclude3 of CVD,Diabetes Mellitus,CVD,1,X,[dsyn],????,C18.452.394.750;C19.246,????
d27c7fa4-859d-43e3-a70a-811857ba79df,C0850624,C0020538, includes ,cardiovascular risk factor,Hypertensive disease,4,X,[dsyn],[dsyn],,C14.907.489
81248f05-1d57-48fb-82c2-faf2847f5ccc,C0206750,C0850624,have CVD,Coronavirus Infections,cardiovascular risk factor,1,X,[dsyn],[dsyn],C02.782.600.550.200,
81248f05-1d57-48fb-82c2-faf2847f5ccc,C0206750,C0850624,is in patients with ,Coronavirus Infections,cardiovascular risk factor,1,X,[dsyn],[dsyn],C02.782.600.550.200,
81248f05-1d57-48fb-82c2-faf2847f5ccc,C0206750,C0850624,is emergent ,Coronavirus Infections,cardiovascular risk factor,3,X,[dsyn],[dsyn],C02.782.600.550.200,
520f81e3-eddb-4872-88a8-f3cb8db096a2,C0206750,CVD,have CVD,Coronavirus Infections,CVD,2,X,[dsyn],????,C02.782.600.550.200,????
e31feb6f-19cc-4eef-9851-9964bbfce790,C0206750,C0020538,takes course in individuals with ,Coronavirus Infections,Hypertensive disease,4,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.489
d6373c5d-5d8e-4107-9cb0-c7e6eb344e41,C0007820,C1514474,development of is important negative ,Cerebrovascular Disorders,Prognostic Factors,2,X,[dsyn],[clna],C10.228.140.300;C14.907.253,E01.789
91c95a53-4fa6-4d1f-8214-59034e36ed21,C1706202,MEDLINE,using MEDLINE,Search - action,MEDLINE,3,X,[acty],????,,????
91c95a53-4fa6-4d1f-8214-59034e36ed21,C1706202,MEDLINE,were performed in MEDLINE ,Search - action,MEDLINE,12,X,[acty],????,,????
1be2f568-62a0-4fd0-9af6-66a1b5b36da2,C0184661,C0206750,reduce mortality in severe ,Interventional procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
8d366cbb-560c-41ff-a2dd-93b3e9b6db44,C0087111,C0206750,might higher might mandatory for subset of patients with ,Therapeutic procedure,Coronavirus Infections,9,X,[topp],[dsyn],E02,C02.782.600.550.200
615c6e1b-304a-4bb7-8a8a-8935960ef234,C0087111,C1457887,alleviate ,Therapeutic procedure,Symptoms,4,X,[topp],[sosy],E02,
615c6e1b-304a-4bb7-8a8a-8935960ef234,C0087111,C1457887,lessen ,Therapeutic procedure,Symptoms,2,X,[topp],[sosy],E02,
89580f5a-7e54-404a-ab5d-99ad862aaea7,C0087111,C0003451,were ,Therapeutic procedure,Antiviral Agents,12,X,[topp],[phsu],E02,D27.505.954.122.388
61745009-3a03-4079-9440-85d88371bc6d,C0596577,C0359916,have attracted attention as ,Flavonoids,Phenolic product,4,X,[orch],[orch/phsu],D03.383.663.283.266.450;D03.633.100.150.266.450,
d941486f-4337-40ad-9a84-28cf401132b8,C0068450,C0206750,exert Therapeutic Effect through,naringenin,Coronavirus Infections,9,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
d941486f-4337-40ad-9a84-28cf401132b8,C0068450,C0206750,might exert ,naringenin,Coronavirus Infections,3,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
5a2a8e76-628b-4892-8273-c95076fb665b,C0068450,C3463820,exert Therapeutic Effect through,naringenin,Inhibition,4,X,[orch/phsu],[acty],x.x.x.x,F01.145.544;F02.463.425.475;F02.739.794.405
6d1796b1-8bf8-43e8-b25c-0147df51048a,C0068450,C0030946,exert Therapeutic Effect through,naringenin,Endopeptidases,4,X,[orch/phsu],[aapp/enzy/phsu],x.x.x.x,D08.811.277.656.300
7196b782-9f8c-4507-bb20-d07fe27a329d,C0068450,C0055673,exert Therapeutic Effect through,naringenin,Chymase,4,X,[orch/phsu],[aapp/enzy],x.x.x.x,D08.811.277.656.300.760.103;D08.811.277.656.959.350.103
bba76f49-b20a-4686-ba6a-58dd966e76d9,C0068450,C2258685,exert Therapeutic Effect through,naringenin,angiotensin converting enzyme activity,8,X,[orch/phsu],[moft],x.x.x.x,
adf6cf17-9f8a-4466-9886-d4baed462724,C0068450,C0597357,exert Therapeutic Effect through,naringenin,receptor,4,X,[orch/phsu],[aapp/rcpt],x.x.x.x,
2927f99c-6db5-44ba-9941-84846b8c2e58,C0068450,C1527144,might exert ,naringenin,Therapeutic Effect,8,X,[orch/phsu],[clna],x.x.x.x,
51280e6b-c5e8-42fe-905e-8e8bebc14280,C0040732,C0206750,is with ,Transplantation,Coronavirus Infections,5,X,[topp],[dsyn],E04.936,C02.782.600.550.200
4e12e988-85c6-449f-ad6f-9fd3852f38df,C1865266,COVID-19,is common Symptoms in,RNF217-AS1 gene,COVID-19,2,X,[gngm],[virs],,C000657245
d9b00a32-f97e-456d-b3f3-04faedcf7d58,C0815017,C0003015,was compatible ,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,2,X,[phsu],[phsu],D27.505.519.162,D27.505.519.389.745.085
310a20fb-0f62-4093-8354-855ecc1f1316,C0003015,C0006560,was associated with lower ,Angiotensin-Converting Enzyme Inhibitors,C-reactive protein,2,X,[phsu],[aapp/imft],D27.505.519.389.745.085,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
348afba5-22f8-4c74-a591-c88617def773,C0003015,C0087111,was associated with lower ,Angiotensin-Converting Enzyme Inhibitors,Therapeutic procedure,2,X,[phsu],[topp],D27.505.519.389.745.085,E02
6191ae9c-bcaa-42e9-95fb-b1217429b69d,C0003015,C0702249,was associated with milder ,Angiotensin-Converting Enzyme Inhibitors,Infiltration (procedure),1,X,[phsu],[topp],D27.505.519.389.745.085,
5f1d0bbc-cb67-4930-a202-58aa41d26de4,C0319157,C0242781,is supposed spread to ,AS virus,disease transmission,7,X,[virs],[patf],,N06.850.310
f8cb18c8-ec8c-44cd-9a30-3d4f1f774bd8,C0007634,C1175743,is receptor of,Cells,SARS coronavirus,3,X,[cell],[virs],A11,B04.820.504.540.150.113.937
f8cb18c8-ec8c-44cd-9a30-3d4f1f774bd8,C0007634,C1175743,infected with ,Cells,SARS coronavirus,2,X,[cell],[virs],A11,B04.820.504.540.150.113.937
70a03e0e-d0ed-4b00-a435-ad36508ed8d4,C0007634,C0597357,is ,Cells,receptor,3,X,[cell],[aapp/rcpt],A11,
8136b282-a951-4fc3-95c3-ef2fd2f78d91,C0012984,C0015219,be Neoplasm Metastasis Host (organism) during,Canis familiaris,Biological Evolution,4,X,[mamm],[genf],B01.050.150.900.649.313.750.250.216.200,G05.045;G16.075
6208bc80-b0e2-4a9b-b78b-848f22b7d99d,C0012984,C1175743,be Neoplasm Metastasis Host (organism) during,Canis familiaris,SARS coronavirus,4,X,[mamm],[virs],B01.050.150.900.649.313.750.250.216.200,B04.820.504.540.150.113.937
54d207b1-cba9-4fa1-992b-319febbfd160,C0012984,C0027627,be ,Canis familiaris,Neoplasm Metastasis,4,X,[mamm],[neop],B01.050.150.900.649.313.750.250.216.200,C04.697.650;C23.550.727.650
dbec73e2-5a53-41f0-ad52-f1c3561073a1,C0012984,C1167395,be ,Canis familiaris,Host (organism),4,X,[mamm],[orgm],B01.050.150.900.649.313.750.250.216.200,
54a45707-38cd-440c-91a0-e7edae65354f,C0325089,C1175743,are highly susceptible to ,Family Felidae,SARS coronavirus,4,X,[mamm],[virs],B01.050.150.900.649.313.750.377.750,B04.820.504.540.150.113.937
61817573-a822-4982-8f0f-924ef383e65e,C0015859,C1175743,are susceptible to ,Ferrets,SARS coronavirus,8,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,B04.820.504.540.150.113.937
84503422-fdf2-4e39-9a78-bcc29e7a70a6,C0031268,C1175743,are responsible for ,Pet Animal,SARS coronavirus,4,X,[anim],[virs],B01.050.050.116.600,B04.820.504.540.150.113.937
1983f864-5f76-40e1-a8fb-283673298357,C0086418,C0275521,showing ,Homo sapiens,Clinical infection,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
1d00ceb6-f770-4efe-9632-6b33469c66fc,C0086418,C0037090,showing ,Homo sapiens,Signs and Symptoms Respiratory,8,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.852
1758855e-ade9-4144-bcb5-1abf1bc5d2de,C1175743,C0003062,is in ,SARS coronavirus,Animals,8,X,[virs],[anim],B04.820.504.540.150.113.937,B01.050
a3dc5c7d-ada7-4fac-8896-70d6ebe50e95,C0206074,C0019004,included 30 821 ,Renal Replacement Therapy,Hemodialysis,2,X,[topp],[topp],E02.870,E02.870.300;E02.912.800
b4bd0ed0-53fc-40e7-a65c-de8269d8ec7d,C0033414,C0262762,is in ,Promotion (action),crisis management,3,X,[acty],[topp],,
7e68f424-6572-455c-94e2-b8942f747f89,C4048329,C0206750,were predictors protective for mortality in ,Immunosuppression,Coronavirus Infections,1,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200
7e68f424-6572-455c-94e2-b8942f747f89,C4048329,C0206750,worsen ,Immunosuppression,Coronavirus Infections,2,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200
b312dc7c-407d-478a-8c82-091b5a3d1154,C0012634,C1521863,caused morbidity on unprecedented level in ,Disease,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C23.550.288,x.x.x.x
b312dc7c-407d-478a-8c82-091b5a3d1154,C0012634,C1521863,caused mortality on unprecedented level in ,Disease,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C23.550.288,x.x.x.x
1c67db30-2714-4d18-a199-74d0ee859861,COVID-19,C0009450,is with ,COVID-19,Communicable Diseases,9,X,[virs],[dsyn],C000657245,C01.539.221
4881ff4f-5063-45f4-b59f-04eafa3e9dd2,C0810006,COVID-19,has ,Acute cerebrovascular disease,COVID-19,2,X,[dsyn],[virs],,C000657245
bf69ec5a-fd62-4b6e-a0a8-8863a40506a1,COVID-19,C0007820,is with new onset of ,COVID-19,Cerebrovascular Disorders,1,X,[virs],[dsyn],C000657245,C10.228.140.300;C14.907.253
57aeaa6f-d9bc-47de-8e2d-db24f26b0313,COVID-19,C0850624,have CVD,COVID-19,cardiovascular risk factor,1,X,[virs],[dsyn],C000657245,
369a37b0-e789-49b2-8025-0b248184513b,COVID-19,CVD,have CVD,COVID-19,CVD,2,X,[virs],????,C000657245,????
5cdabdb6-f2f2-4960-8f7e-73ed227a625d,COVID-19,C0020538,have CVD,COVID-19,Hypertensive disease,1,X,[virs],[dsyn],C000657245,C14.907.489
9fe89888-fe2a-4bb0-832c-dc0b48147732,C0007806,C0151857,were notable for mononuclear ,Cerebrospinal Fluid,Pleocytosis,2,X,[bdsu],[dsyn],A12.207.270.210,C15.378.553.475;C23.550.526
e48085a3-325e-4d64-b43b-785da23a1d02,C0006104,C0848027,showed bilateral ,Brain,internal lesion,4,X,[bpoc],[dsyn],A08.186.211,
06e31bd3-e742-48fa-839b-086c6d620d6c,C0006104,C0228427,showed bilateral ,Brain,Basis pontis,2,X,[bpoc],[bpoc],A08.186.211,
1fdf704e-81c8-4d14-87e9-ea65e125e495,C0013227,C1829939,deferring follow-ups in case of ,Pharmaceutical Preparations,{Non-patient},4,X,[phsu],[clna],D26,
ec04dccb-8dd0-437d-82d3-520e3a2678cf,C1947933,C1829939,deferring follow-ups in case of ,care activity,{Non-patient},6,X,[acty],[clna],,
78ee9335-443b-47d0-a1bc-7da89092bd58,C0013227,COVID-19,is in ,Pharmaceutical Preparations,COVID-19,4,X,[phsu],[virs],D26,C000657245
61dc2718-4c3d-4ce8-9a2b-12bff9763e29,C1947933,COVID-19,is in ,care activity,COVID-19,5,X,[acty],[virs],,C000657245
34af9636-809c-4214-ae5a-4814f14d3050,C0008679,C0029166,is with ,Chronic disease,Oral Manifestations,6,X,[dsyn],[sosy],C23.550.291.500,C07.465.634;C23.888.619
457f2f0a-8033-4260-bd54-71f037c26204,C0004364,C0029166,is with ,Autoimmune Diseases,Oral Manifestations,3,X,[dsyn],[sosy],C20.111,C07.465.634;C23.888.619
d06e39e0-2422-4bd7-aac5-222ac1150ae0,C0008679,C0029167,can can exacerbated as result of ,Chronic disease,Oral Medicine,6,X,[dsyn],[bmod],C23.550.291.500,E06.640;H02.163.670
b805966a-0e2f-4ad7-8a6c-61e98e63cf63,C0004364,C0029167,can can exacerbated as result of ,Autoimmune Diseases,Oral Medicine,3,X,[dsyn],[bmod],C20.111,E06.640;H02.163.670
e1b285ab-6be8-4ca4-9fb5-5b1007957ed5,C0035525,C0232910,have ,Ribavirin,Teratogenesis,4,X,[nnon/phsu],[patf],D13.570.800.790,C23.550.863
a969d7b5-d93d-4602-9de4-79304e0f4221,C1138226,C0232910,have ,favipiravir,Teratogenesis,4,X,[orch/phsu],[patf],x.x.x.x,C23.550.863
50f88743-03c7-4c17-a569-705f4830947f,C1706202,C1856053,was conducted On ,Search - action,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[acty],[dsyn],,x.x.x.x
1a1df3a3-367e-4c13-b64d-64f5cf91f440,C0030054,C1947933,individualized ,Oxygen,care activity,1,X,[bacs/elii/phsu],[acty],D01.268.185.550;D01.362.670;x.x.x.x,
d6b1c20d-fb11-4922-9c00-1ff25d0f79d7,C0599779,C1457887,can reflect clinical ,Animal Model,Symptoms,1,X,[anim],[sosy],E05.598,
e1692824-510b-4360-8c87-4c6bfd236d0c,C0599779,COVID-19,underlying ,Animal Model,COVID-19,1,X,[anim],[virs],E05.598,C000657245
f5f3d022-a71c-4838-867e-6f476350893c,C1999230,C0599779,paramount insight into available ,Providing (action),Animal Model,1,X,[acty],[anim],,E05.598
0e5282d5-6191-4983-886b-77fd555e1d2b,C1999230,C1175743,paramount insight into available ,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
0e5282d5-6191-4983-886b-77fd555e1d2b,C1999230,C1175743,is with guidance on entry of patients tested for ,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
0e5282d5-6191-4983-886b-77fd555e1d2b,C1999230,C1175743,example for control of CoV2,Providing (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
24ce75e7-0a9b-4bf0-8579-b6e293240e15,C3694279,C0206419,were In ,Middle East Respiratory Syndrome,Genus: Coronavirus,2,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150
6eba410e-7b1a-4a01-963a-d00e1c973fc3,14-day,C0309872,be sufficient to ,14-day,PREVENT (product),1,X,????,[phsu],????,
0874d1b1-882c-40d9-bf73-546e5aac53b7,C0034386,C0309872,be sufficient to ,Quarantine,PREVENT (product),1,X,[topp],[phsu],N06.850.780.200.450.700,
36f126ef-695b-43a7-abd1-aef968d907d4,C2728259,C0309872,be sufficient to ,Program,PREVENT (product),1,X,[orch/phsu],[phsu],V02.355.750,
1923e2a9-d21e-4f13-be14-e97e27850eeb,14-day,C0206419,be sufficient to ,14-day,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
1c8830ae-2db0-4ff7-8151-e7588e9585f8,C0034386,C0206419,be sufficient to ,Quarantine,Genus: Coronavirus,1,X,[topp],[virs],N06.850.780.200.450.700,B04.820.504.540.150
a16eb12f-a4fa-4c81-9fce-0c92ada57164,C2728259,C0206419,be sufficient to ,Program,Genus: Coronavirus,1,X,[orch/phsu],[virs],V02.355.750,B04.820.504.540.150
89befbbf-cd93-4020-b333-98ca6b143c33,C0309872,C0009450,is in ,PREVENT (product),Communicable Diseases,1,X,[phsu],[dsyn],,C01.539.221
e5440bb1-9620-4125-aa68-9c94d1c7e051,C0309872,C0206419,is in ,PREVENT (product),Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
d9e1e5bf-979e-4269-8638-caeed1747f67,C1334043,C1175743,is with ,Homologous Gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
a9b3305a-2182-49c8-8504-6b7af14fa5e0,C0087111,COVID-19,might ,Therapeutic procedure,COVID-19,8,X,[topp],[virs],E02,C000657245
4ba384fb-1541-42e9-8e52-a1bda61aefdd,C0087111,C1425076,might ,Therapeutic procedure,LIN7B gene,1,X,[topp],[gngm],E02,
edcd628e-718d-4390-aceb-cfa5ee3f98ae,C0206419,C3698360,cause ,Genus: Coronavirus,Middle East Respiratory Syndrome Coronavirus,1,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113.750
ab2931ca-6b1c-4fce-840c-7f1d32dd7a0c,C0087111,C0309872,likely by ,Therapeutic procedure,PREVENT (product),1,X,[topp],[phsu],E02,
ab2931ca-6b1c-4fce-840c-7f1d32dd7a0c,C0087111,C0309872,are aimed at ,Therapeutic procedure,PREVENT (product),4,X,[topp],[phsu],E02,
dc942007-e804-4039-b7e0-fdcf436ec266,C0087111,C1537068,likely by ,Therapeutic procedure,Virus Internalization,1,X,[topp],[biof],E02,G06.920.881
dc942007-e804-4039-b7e0-fdcf436ec266,C0087111,C1537068,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,Virus Internalization,1,X,[topp],[biof],E02,G06.920.881
54523763-696e-431f-93c2-c170e689f544,C0087111,C0014597,likely by ,Therapeutic procedure,Epithelial Cells,1,X,[topp],[cell],E02,A11.436
7a91b4ed-969e-4846-9ad8-8f0a96dfa219,C0108225,C0087111,has shown ,camostate-mesilate,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
aeec0dde-4a5d-4255-86ba-82fadea5af94,C0108225,C0309872,has shown ,camostate-mesilate,PREVENT (product),1,X,[orch/phsu],[phsu],,
c446444e-e2a9-406c-bacd-29444e93a42b,C0108225,C1537068,has shown ,camostate-mesilate,Virus Internalization,1,X,[orch/phsu],[biof],,G06.920.881
257718ae-af27-4605-8fe4-d7deae7e0175,C0108225,C0014597,has shown ,camostate-mesilate,Epithelial Cells,1,X,[orch/phsu],[cell],,A11.436
9cdc441a-2ad0-4bca-aa7a-c8423e699aa6,C4044947,C0309872,improve mortality by ,baricitinib,PREVENT (product),1,X,[orch/phsu],[phsu],x.x.x.x,
9dc9dd4f-f142-4db6-b115-51baf1dd04c5,C0206419,C0002808,has had on teaching of ,Genus: Coronavirus,Science of Anatomy,1,X,[virs],[bmod],B04.820.504.540.150,H01.158.100
a9180256-e644-40ac-9174-8dc270856cbc,C0206419,C1422064,utilize ,Genus: Coronavirus,ACE2 gene,1,X,[virs],[gngm],B04.820.504.540.150,
6d49bb22-0f9f-44d5-86bb-2dcb49bae957,C0022709,C0220781,helps in ,Peptidyl-Dipeptidase A,Anabolism,1,X,[aapp/enzy/imft],[biof],D08.811.277.656.350.350.687,G03
6f00221c-1bf3-484b-bc18-d4dbec9bd050,C1422064,C0003009,counter pro-inflammatory effects mediated by ,ACE2 gene,angiotensin II,1,X,[gngm],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
3bbfd7be-df3b-4839-a1c5-5316c930b4f7,C1422064,C0042402,counter pro-inflammatory effects mediated by ,ACE2 gene,Vasodilator Agents,1,X,[gngm],[phsu],,D27.505.954.411.918
07696962-c459-49df-a9bf-18a5fafcf9ef,C0232741,C0206419,have have reported in ,Liver function,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
78f86935-1f96-4d6a-8d0b-83650705056b,C0232741,C0012634,have have reported in ,Liver function,Disease,2,X,[ortf],[dsyn],,C23.550.288
da6e9b86-b67a-4549-b878-313ddaa1b9d4,SMD,C1707455,is in severe as ,SMD,Comparison,1,X,????,[acty],????,
d8323e47-ea42-47f6-9c14-247782a23063,C0239981,C0017040,followed by derangements ,Hypoalbuminemia,Gamma-glutamyl transferase,1,X,[dsyn],[aapp/enzy],C15.378.147.607.500,D08.811.913.050.200.500
8f7eb06e-5eea-492c-86a9-55ac29627293,C0206419,C0073187,are depicted in ,Genus: Coronavirus,Blood group antigen D,1,X,[virs],[aapp/imft],B04.820.504.540.150,x.x.x.x
5f3a75da-c0ee-4744-a8fc-8a99a7c5c0c6,C2936405,C0013227,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Pharmaceutical Preparations,2,X,[topp],[phsu],E05.290.875,D26
5f3a75da-c0ee-4744-a8fc-8a99a7c5c0c6,C2936405,C0013227,is widely used for rapid identification of potential ,Drug Repositioning,Pharmaceutical Preparations,3,X,[topp],[phsu],E05.290.875,D26
5f3a75da-c0ee-4744-a8fc-8a99a7c5c0c6,C2936405,C0013227,is In scenario widely used for identification of potential ,Drug Repositioning,Pharmaceutical Preparations,2,X,[topp],[phsu],E05.290.875,D26
96930dfc-6d99-41d0-9601-c413debe4382,C2936405,C0087111,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Therapeutic procedure,2,X,[topp],[topp],E05.290.875,E02
96930dfc-6d99-41d0-9601-c413debe4382,C2936405,C0087111,novel Agent as,Drug Repositioning,Therapeutic procedure,1,X,[topp],[topp],E05.290.875,E02
a1a61dbb-ceae-4dc9-bbac-d251509a5ca7,C2936405,C0221423,can facilitate Drug Repositioning Discover process by,Drug Repositioning,Illness (finding),2,X,[topp],[sosy],E05.290.875,
2f2c36d9-e22f-447a-93d8-6f2851e15509,C2936405,C1880355,may facilitate rapid drug ,Drug Repositioning,Discover,4,X,[topp],[acty],E05.290.875,
1e0d64a2-fe37-46e0-b299-2694653aa7d7,C0034019,C0029216,has drastically changed practices in solid ,public health medicine (field),Organ Transplantation,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.936.450
ec876d5f-c4f4-4b87-a7e4-c64b491945d7,C2745965,C0029216,has drastically changed practices in solid ,Emergencies [Disease/Finding],Organ Transplantation,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.936.450
9d58290e-c180-41c2-b6d7-a211a245ccce,C0034019,C0040732,has drastically changed practices in solid ,public health medicine (field),Transplantation,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.936
00da0a56-cf93-40a3-b1b8-c47173669b7a,C2745965,C0040732,has drastically changed practices in solid ,Emergencies [Disease/Finding],Transplantation,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.936
3facd676-3c19-4362-b535-d0cd2b2782a9,C0034019,C0206419,caused by acute viral ,public health medicine (field),Genus: Coronavirus,2,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
3facd676-3c19-4362-b535-d0cd2b2782a9,C0034019,C0206419,should report country-specific ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
3facd676-3c19-4362-b535-d0cd2b2782a9,C0034019,C0206419,curtail ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
3facd676-3c19-4362-b535-d0cd2b2782a9,C0034019,C0206419,would reduce risk of ,public health medicine (field),Genus: Coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150
3a737ac1-9d42-4479-82b3-160b2d0c3c02,C0034019,C1443953,caused by acute viral ,public health medicine (field),Acute viral disease,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,
3f4039dd-3a13-4dae-8c97-534927f8cda3,C2745965,C1443953,caused by acute viral ,Emergencies [Disease/Finding],Acute viral disease,2,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,
33092ee2-8f86-4327-baf6-4d62ecdd4710,C0034019,C0024128,has changed markedly so for ,public health medicine (field),Lung Transplantation,4,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,E04.928.600.495;E04.936.450.495
55ddf4d8-9194-4791-b4bb-ebd7eecafbb8,C2745965,C0024128,has changed markedly so for ,Emergencies [Disease/Finding],Lung Transplantation,4,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E04.928.600.495;E04.936.450.495
0820c2fd-d00a-4457-9dac-6414e3cf1651,C0034019,C0319157,has changed major target of ,public health medicine (field),AS virus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,
838e6275-d16f-4ce1-a7c2-bb9c1905d3fd,C2745965,C0319157,has changed major target of ,Emergencies [Disease/Finding],AS virus,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,
838e6275-d16f-4ce1-a7c2-bb9c1905d3fd,C2745965,C0319157,AS virus as for possible future returns of,Emergencies [Disease/Finding],AS virus,8,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,
673f92bf-5b67-4a5d-b17d-e2c23e311276,C0024128,C0319157,target of ,Lung Transplantation,AS virus,2,X,[topp],[virs],E04.928.600.495;E04.936.450.495,
9d89549a-cabf-4372-b92c-280b946c96de,C1254351,C0206419,cause ,Pharmacologic Substance,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
1d208e60-4925-46e5-a7b7-731d06fbe4c1,C1254351,C0012634,cause ,Pharmacologic Substance,Disease,2,X,[phsu],[dsyn],,C23.550.288
1d208e60-4925-46e5-a7b7-731d06fbe4c1,C1254351,C0012634,may have role in treatment of ,Pharmacologic Substance,Disease,1,X,[phsu],[dsyn],,C23.550.288
4e7d7bb3-add1-49cc-aa2f-2cb9afd73676,C1175743,C0087086,potentially increasing ,SARS coronavirus,Thrombus,1,X,[virs],[patf],B04.820.504.540.150.113.937,C14.907.355.830
185f0221-ad70-4b9f-8cd8-931a99df045b,C0010340,C0206419,is with ,Critical Illness,Genus: Coronavirus,6,X,[dsyn],[virs],C23.550.291.625,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,deferring follow-ups because of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,have Show promise for treatment of,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,are under currently investigation for treatment of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,have performed well in ,Pharmaceutical Preparations,Genus: Coronavirus,2,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,has has experimentally used for ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,are are tried for treatment of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,be re-purposed for prevention of ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
f2a4dbf6-82c3-4bc4-98af-c866e0637612,C0013227,C0206419,be Therefore may developed for future ,Pharmaceutical Preparations,Genus: Coronavirus,1,X,[phsu],[virs],D26,B04.820.504.540.150
dcf85ae1-875b-4b4c-8f02-8c5bfaf386a8,C1947933,C0206419,deferring follow-ups because of ,care activity,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
dcf85ae1-875b-4b4c-8f02-8c5bfaf386a8,C1947933,C0206419,were undertaken as result of ,care activity,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
d09f33a9-6953-4fa4-bf1e-b0e81b383856,C0206419,CBRN,can in respects can viewed as CBRN ,Genus: Coronavirus,CBRN,1,X,[virs],????,B04.820.504.540.150,????
ebe4657a-c945-4c63-bff0-ed251ce95198,C0010356,PPE,minimizing Demand (clinical) for PPE,Cross Infection,PPE,3,X,[patf],????,C01.539.248;C23.550.291.875.500,????
1ef7b6f7-22b5-4201-ac9a-d5460539f775,C0010356,C0441516,minimizing ,Cross Infection,Demand (clinical),3,X,[patf],[topp],C01.539.248;C23.550.291.875.500,
e0ad9d54-f51d-406f-8423-3d486f6a9b90,C0010051,C0021308,is potential cause of ,Coronary Aneurysm,Infarction,2,X,[dsyn],[patf],C14.280.647.250.250;C14.907.055.395;C14.907.585.250.250,C23.550.513.355;C23.550.717.489
e20fa673-5c4c-431c-b233-63e6666251ad,C0009450,C0035554,of Institute is de ,Communicable Diseases,Ribostamycin,2,X,[dsyn],[antb/orch],C01.539.221,D09.408.051.623.800
e20fa673-5c4c-431c-b233-63e6666251ad,C0009450,C0035554,reproducing data of confirmed cases in de ,Communicable Diseases,Ribostamycin,1,X,[dsyn],[antb/orch],C01.539.221,D09.408.051.623.800
0dd1995f-4bad-4e24-9d79-ef0361929150,C0697125,C0035554,of Institute is de ,Inonotus obliquus preparation,Ribostamycin,2,X,[phsu],[antb/orch],,D09.408.051.623.800
1a868fce-45ca-4e62-8997-7b08c92bc7a1,C0009450,de,of Institute is de ,Communicable Diseases,de,2,X,[dsyn],????,C01.539.221,????
1a868fce-45ca-4e62-8997-7b08c92bc7a1,C0009450,de,reproducing data of confirmed cases in de ,Communicable Diseases,de,1,X,[dsyn],????,C01.539.221,????
13841b4b-a728-4ccd-80c8-11933dc137e2,C0697125,de,of Institute is de ,Inonotus obliquus preparation,de,2,X,[phsu],????,,????
e851baf9-3f7f-418d-b504-7b9ba1893a82,C0034602,C0206419,is in ,Interventional radiology,Genus: Coronavirus,1,X,[bmod],[virs],H02.403.740.675,B04.820.504.540.150
0438c311-c803-48f5-9ebd-5a7f2c4fd2e4,C0441655,C0206419,is in ,Activities,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
52c746d7-c260-4394-8528-0657af7782db,C0034602,C1521863,is in ,Interventional radiology,estrogen receptor alpha human,3,X,[bmod],[aapp/rcpt],H02.403.740.675,x.x.x.x
d201f00b-8066-4b6e-a097-1033cb9ec74a,C0441655,C1521863,is in ,Activities,estrogen receptor alpha human,2,X,[acty],[aapp/rcpt],,x.x.x.x
5f6baebd-c468-47b0-8290-2911538d44d1,C0206419,C0034602,changed ,Genus: Coronavirus,Interventional radiology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.740.675
5f6baebd-c468-47b0-8290-2911538d44d1,C0206419,C0034602,reduction of ,Genus: Coronavirus,Interventional radiology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.740.675
16aab4d0-314c-41b8-a926-15d78df443e2,C0012634,C0034602,reduction of ,Disease,Interventional radiology,3,X,[dsyn],[bmod],C23.550.288,H02.403.740.675
dbe86305-9c0f-4136-9820-e2acf0c1185c,C0034602,C0747973,were prioritized opposed to ,Interventional radiology,Elective procedure,6,X,[bmod],[topp],H02.403.740.675,
4842cf2e-d91a-4888-8d25-6c7546c583f5,C0012634,C0032285,may progress to ,Disease,Pneumonia,2,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
4842cf2e-d91a-4888-8d25-6c7546c583f5,C0012634,C0032285,associated with severe ,Disease,Pneumonia,1,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
4842cf2e-d91a-4888-8d25-6c7546c583f5,C0012634,C0032285,can lead to serious problems like ,Disease,Pneumonia,1,X,[dsyn],[dsyn],C23.550.288,C08.381.677;C08.730.610
7d15d30f-09cc-4468-bf4a-e602f9f090ac,C0002085,C1422064,Affinity of,Alleles,ACE2 gene,1,X,[gngm],[gngm],G05.360.340.024.340.030,
dae861ba-0df1-4b19-993c-21391a5d4dcc,C0002085,C0319157,Affinity to S,Alleles,AS virus,1,X,[gngm],[virs],G05.360.340.024.340.030,
dae861ba-0df1-4b19-993c-21391a5d4dcc,C0002085,C0319157,may contribute to ,Alleles,AS virus,1,X,[gngm],[virs],G05.360.340.024.340.030,
3796799f-1c45-4bc4-a1e7-d7394c52286b,C1155099,C0960756,was suggested as ,cytokine biosynthesis,factor A,4,X,[moft],[orch],,x.x.x.x
ac7da07b-33a8-4145-ad5a-3171683ff18d,C1155099,C0024109,exacerbating ,cytokine biosynthesis,Lung,2,X,[moft],[bpoc],,A04.411
79e33ee7-43be-4e4d-a46a-220e202cdf42,C1155099,C0206419,is in ,cytokine biosynthesis,Genus: Coronavirus,1,X,[moft],[virs],,B04.820.504.540.150
5dc8756e-9ad4-4510-bf30-ae99c5368c1f,C1155099,C0012634,is in ,cytokine biosynthesis,Disease,2,X,[moft],[dsyn],,C23.550.288
fb897358-483c-499d-96bc-102a8eb2cf32,C0678951,C0079189,is in ,gene polymorphism,cytokine,2,X,[genf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
66992422-2c58-4ede-9707-842da3e0f53d,C0042776,C0086418,is supposed spread to ,Virus,Homo sapiens,16,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
66992422-2c58-4ede-9707-842da3e0f53d,C0042776,C0086418,has appeared as new ,Virus,Homo sapiens,3,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
66992422-2c58-4ede-9707-842da3e0f53d,C0042776,C0086418,Owing to high rate of ,Virus,Homo sapiens,2,X,[virs],[humn],B04,B01.050.150.900.649.313.988.400.112.400.400
7ddee39b-2635-48c0-9b78-7a7144e9f0e0,C0015859,C0042776,can transmit or indirectly ,Ferrets,Virus,2,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,B04
5addbc17-55fb-4d3c-85b6-266d3ec8f9c0,C1707455,C0206750,related to ,Comparison,Coronavirus Infections,13,X,[acty],[dsyn],,C02.782.600.550.200
65c850d8-e748-4bc2-9d0b-0c0b375b67a6,C1707455,C0009450,is with data from ,Comparison,Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
23db3a89-9ce1-48ed-b1c1-597a02bc6dc8,C1707455,C0027712,is with data from ,Comparison,Nephrology Speciality,1,X,[acty],[bmod],,H02.403.429.580
c642f599-2f9c-4223-8442-7399282e339e,C0206750,C0019004,were less common in patients on ,Coronavirus Infections,Hemodialysis,9,X,[dsyn],[topp],C02.782.600.550.200,E02.870.300;E02.912.800
9817806a-425c-4592-81ea-2844835cbdd8,C0032105,COVID-19,was applied to ,Plasma,COVID-19,5,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,C000657245
9817806a-425c-4592-81ea-2844835cbdd8,C0032105,COVID-19,is explicit option for ,Plasma,COVID-19,1,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,C000657245
608758d8-39da-4e6b-aaaa-3ce5988de2f5,C0032105,C1999230,has potential to ,Plasma,Providing (action),3,X,[bdsu],[acty],A12.207.152.693;A12.207.270.695;A15.145.693,
4a2c35ae-c65f-4846-8996-0d22d6dee16a,C1276305,COVID-19,is In ,Curative - procedure intent,COVID-19,4,X,[topp],[virs],,C000657245
7b00cc77-29f8-4bab-978a-abecf30d42ff,C0032105,C1276305,may may ,Plasma,Curative - procedure intent,5,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,
5c69ab94-1863-45e5-b48b-ce729ccb8b4f,remdesivir,C1175743,is broad spectrum antiviral with in ,remdesivir,SARS coronavirus,3,X,[clnd],[virs],,B04.820.504.540.150.113.937
5c69ab94-1863-45e5-b48b-ce729ccb8b4f,remdesivir,C1175743,potentially act as ,remdesivir,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
5c69ab94-1863-45e5-b48b-ce729ccb8b4f,remdesivir,C1175743,exhibited anti ,remdesivir,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
649a1cbf-8ed0-4312-9a51-45300b7315b1,C0230425,C0032105,is in ,Structure of right thigh,Plasma,4,X,[bpoc],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
f66dd019-e6a3-47e5-8e46-b9c0bd189555,C0444263,C1175743,were positive for ,Plasma specimen,SARS coronavirus,4,X,[bdsu],[virs],,B04.820.504.540.150.113.937
a29ea54a-a38a-463d-99b8-d4d3ce621ff7,remdesivir,C1266129,was interrupted for side effects among four patients including ,remdesivir,Atypical Lipoma,4,X,[clnd],[neop],,C04.557.450.550.400
be3064b5-df6f-4de6-ae77-b0b5283dbb81,C0036658,C0015385,is in distal ,Esthesia,Limb structure,4,X,[ortf],[bpoc],F02.830.816;G11.561.790,A01.378
c4523a41-6bb3-4f32-a896-846d0cbf68f7,C0007806,C0086168,revealed albuminocytologic ,Cerebrospinal Fluid,Dissociation,4,X,[bdsu],[mobd],A12.207.270.210,F03.300
887362f2-d4a2-4ade-a56b-55180d331a62,C0235031,C0012634,were reported in early phase of 3days,Neurologic Symptoms,Disease,7,X,[sosy],[dsyn],C10.597;C23.888.592,C23.550.288
38baa24d-0207-4431-ae9b-474329adf2a9,C0235031,3days,were reported in early phase of 3days,Neurologic Symptoms,3days,1,X,[sosy],????,C10.597;C23.888.592,????
38baa24d-0207-4431-ae9b-474329adf2a9,C0235031,3days,were reported with median onset ranging from to 3days,Neurologic Symptoms,3days,1,X,[sosy],????,C10.597;C23.888.592,????
6baca08d-ff63-4b80-a266-f6160cc5ef6e,C0018681,C0233494,showed ,Headache,Tension,1,X,[sosy],[mobd],C23.888.592.612.441,
95726c0d-386f-4c89-957d-44d02af549cc,C0231528,C0003862,was more frequently associated with ,Myalgia,Arthralgia,1,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350
e2aa5bd4-81cd-4d1f-9288-13f5edba1184,C0553757,C1457887,were In our cohort early ,Olfaction Disorders,Symptoms,1,X,[dsyn],[sosy],C10.597.751.600;C23.888.592.763.550,
c19903fc-093d-4da2-850b-40ac69be0e1c,C0553757,C0206750,were early Symptoms of,Olfaction Disorders,Coronavirus Infections,4,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C02.782.600.550.200
a5cf6002-7cc5-4555-9d80-b51ba7b4eab5,C0553757,C0012634,were In our cohort early ,Olfaction Disorders,Disease,1,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C23.550.288
a5cf6002-7cc5-4555-9d80-b51ba7b4eab5,C0553757,C0012634,more frequently reported by patients with forms of ,Olfaction Disorders,Disease,1,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C23.550.288
e1d24a78-3ae7-4641-b884-28841cf35723,C0018681,C1457887,reflect common ,Headache,Symptoms,1,X,[sosy],[sosy],C23.888.592.612.441,
e1d24a78-3ae7-4641-b884-28841cf35723,C0018681,C1457887,were most prevalent ,Headache,Symptoms,2,X,[sosy],[sosy],C23.888.592.612.441,
e1d24a78-3ae7-4641-b884-28841cf35723,C0018681,C1457887,are main ,Headache,Symptoms,1,X,[sosy],[sosy],C23.888.592.612.441,
e1d24a78-3ae7-4641-b884-28841cf35723,C0018681,C1457887,seems leader on ,Headache,Symptoms,2,X,[sosy],[sosy],C23.888.592.612.441,
221b91e9-a7bc-40a7-93f1-859a6eda49a2,C0018681,C0039082,reflect common ,Headache,Syndrome,1,X,[sosy],[dsyn],C23.888.592.612.441,C23.550.288.500
33b5a1c8-4a25-45cd-a325-46558fd4a01e,C0018681,C0003862,is in association with ,Headache,Arthralgia,1,X,[sosy],[sosy],C23.888.592.612.441,C05.550.091;C23.888.592.612.094;F02.830.816.444.350;G11.561.790.444.350
5409591d-9468-44f7-974e-62da3eae7cd1,C0017428,C0206750,was detected in South African patient with ,Genome,Coronavirus Infections,1,X,[gngm],[dsyn],G05.360.340,C02.782.600.550.200
83a4f433-2166-4d97-8f3a-674665b95fa0,C0017428,C0012634,was detected in South African patient with ,Genome,Disease,1,X,[gngm],[dsyn],G05.360.340,C23.550.288
83a4f433-2166-4d97-8f3a-674665b95fa0,C0017428,C0012634,diagnose possible ,Genome,Disease,1,X,[gngm],[dsyn],G05.360.340,C23.550.288
2154f335-66bc-4f93-83aa-f48143cfae83,C1511790,C0302908,has made biological ,Detection,Liquid substance,1,X,[topp],[sbst],,
b4870521-d379-4b53-a90b-b1be7389f7af,C1511790,C0242781,has made biological ,Detection,disease transmission,2,X,[topp],[patf],,N06.850.310
b4870521-d379-4b53-a90b-b1be7389f7af,C1511790,C0242781,low rates of are indicative ,Detection,disease transmission,3,X,[topp],[patf],,N06.850.310
85983b22-6bf6-43dc-9b05-ee15fd1a8b1c,C0302908,C0242781,relevant in terms of diagnosis of ,Liquid substance,disease transmission,1,X,[sbst],[patf],,N06.850.310
beb48ef6-b8dc-4baa-a969-2401419baf85,C1175743,C0036087,is near ubiquitously present in ,SARS coronavirus,saliva,4,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.200.666
b503cf98-7336-4fc7-b9c5-5d093f99e029,C0206750,C0242781,is emerging disease transmission with widespread,Coronavirus Infections,disease transmission,10,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
b503cf98-7336-4fc7-b9c5-5d093f99e029,C0206750,C0242781,is mainly ,Coronavirus Infections,disease transmission,2,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
b503cf98-7336-4fc7-b9c5-5d093f99e029,C0206750,C0242781,has attracted attention due to its ,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
b503cf98-7336-4fc7-b9c5-5d093f99e029,C0206750,C0242781,was declared public health medicine (field) Emergencies [Disease/Finding] after Singapores first imported case before,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
b503cf98-7336-4fc7-b9c5-5d093f99e029,C0206750,C0242781,was On January 30 declared after Singapores case before ,Coronavirus Infections,disease transmission,1,X,[dsyn],[patf],C02.782.600.550.200,N06.850.310
837e623b-d7f4-466f-a505-690b820c00d8,C0037090,C0850149, includes ,Signs and Symptoms Respiratory,Dry cough,5,X,[sosy],[sosy],C23.888.852,
c5d25c57-bf19-4dfc-98a8-caa0133c8fb5,C0206750,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Coronavirus Infections,Signs and Symptoms Respiratory,5,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
c5d25c57-bf19-4dfc-98a8-caa0133c8fb5,C0206750,C0037090,main manifestations of are ,Coronavirus Infections,Signs and Symptoms Respiratory,3,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
c5d25c57-bf19-4dfc-98a8-caa0133c8fb5,C0206750,C0037090,is principally defined by its ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
c5d25c57-bf19-4dfc-98a8-caa0133c8fb5,C0206750,C0037090,is predominantly defined by ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
c5d25c57-bf19-4dfc-98a8-caa0133c8fb5,C0206750,C0037090,is with only mild ,Coronavirus Infections,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.852
04ef4f52-067d-4681-8d4b-05fffdb34da9,C0206750,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Coronavirus Infections,Dry cough,2,X,[dsyn],[sosy],C02.782.600.550.200,
e7a6caed-979f-4786-87cb-e7bda99ae838,C0221423,C0037090,is with ,Illness (finding),Signs and Symptoms Respiratory,2,X,[sosy],[sosy],,C23.888.852
5ea29000-b555-41e4-ad4a-7ad15017f39d,C0221423,C0850149,is with ,Illness (finding),Dry cough,1,X,[sosy],[sosy],,
7d8b3c90-cef3-40bc-942e-4f07a1b54e57,C0073020,C0012634,have allowed better ,recombinase,Disease,3,X,[aapp/enzy],[dsyn],D08.811.739,C23.550.288
c2f53082-02f5-4de2-a029-f11e6e2396d4,C1335439,C0012634,have allowed better ,Polymerase,Disease,4,X,[aapp/enzy],[dsyn],,C23.550.288
e5510724-0bd1-4573-8df5-3d0edefcd968,C0041199,C0858277,was mildly elevated without ,Troponin,angina symptom,7,X,[aapp/bacs],[sosy],D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825,
27615ff4-f7a3-493a-a7d1-8104970c5a93,C0031039,C0036974,piercing Structure of apex of right ventricle Structure of apex of right ventricle alongside early diastolic,Pericardial effusion,Shock,6,X,[dsyn],[patf],C14.280.695,C23.550.835
ab5dbeba-b589-4aa5-9e32-d38cafe471e6,C0031039,C0445242,piercing Structure of apex of right ventricle Structure of apex of right ventricle alongside early diastolic,Pericardial effusion,Structure of apex of right ventricle,20,X,[dsyn],[bpoc],C14.280.695,
649adcd1-f2ba-4e62-a25d-1fbeb6a94324,C0023175,C1707455,were confirmed on ,Lead,Comparison,7,X,[elii/hops],[acty],D01.268.556.435;D01.552.544.435;x.x.x.x,
5c0c9b1f-3760-4b1b-80cf-482f9cd36d00,C0191234,C0185115,was performed with ,Pericardiocentesis,Extraction,2,X,[topp],[topp],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
338bee2e-b62b-4503-8088-803fcf4c3bf6,C0191234,C0008318,was performed with ,Pericardiocentesis,Cholecalciferol,7,X,[topp],[orch/phsu/vita],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,D04.210.500.247.222.159;D04.210.500.247.808.146;D04.210.500.812.768.196;D10.570.938.146
a1e39937-9788-44de-98e5-7cee00467a7c,C0191234,C0015388,was performed with ,Pericardiocentesis,Exudate,7,X,[topp],[bdsu],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,A12.383
30df103f-d9ae-403c-acd0-d51251879ec8,C0008679,C0920467,requiring Adrenal Cortex Hormones for,Chronic disease,disorder control (procedure),6,X,[dsyn],[topp],C23.550.291.500,
30df103f-d9ae-403c-acd0-d51251879ec8,C0008679,C0920467,requiring Therapeutic immunosuppression for,Chronic disease,disorder control (procedure),6,X,[dsyn],[topp],C23.550.291.500,
85d87526-7ccb-43f2-86c5-26586c19b229,C0017178,C0920467,requiring Adrenal Cortex Hormones for,Gastrointestinal Diseases,disorder control (procedure),4,X,[dsyn],[topp],C06.405,
85d87526-7ccb-43f2-86c5-26586c19b229,C0017178,C0920467,requiring Therapeutic immunosuppression for,Gastrointestinal Diseases,disorder control (procedure),4,X,[dsyn],[topp],C06.405,
0876674c-031c-4345-abd7-674ad5e97fe3,C1262481,C0008679,are ,Eosinophilic gastroenteritis,Chronic disease,8,X,[dsyn],[dsyn],,C23.550.291.500
a09f5ca2-b260-452a-8dbb-86c0638991d2,C1262481,C0017178,are ,Eosinophilic gastroenteritis,Gastrointestinal Diseases,4,X,[dsyn],[dsyn],,C06.405
3e8516c3-a7fc-4fd2-a51a-a677e301b6b8,C0008679,C0021079,requiring ,Chronic disease,Therapeutic immunosuppression,6,X,[dsyn],[topp],C23.550.291.500,E02.095.465.425.450;E05.478.610
9f838247-5dc0-4c47-bd57-128d528ec096,C0008679,C0001617,requiring ,Chronic disease,Adrenal Cortex Hormones,6,X,[dsyn],[horm/orch/phsu],C23.550.291.500,D06.472.040
2e7770e5-2698-4f2d-ad04-8200580ff305,C0017178,C0001617,requiring ,Gastrointestinal Diseases,Adrenal Cortex Hormones,4,X,[dsyn],[horm/orch/phsu],C06.405,D06.472.040
c62b2c0b-5e80-4d11-911d-eef10342ca3c,C0012634,EGID,is in EGID ,Disease,EGID,2,X,[dsyn],????,C23.550.288,????
1f9ecc0c-73dc-4db0-9b92-6e788afe6111,IFSO,C0028754,navigating bariatric procedures in patients with ,IFSO,Obesity,2,X,????,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
87585f7e-31d3-4d9e-8391-f06ec1cf4d0a,C0012634,C0009450,is ominous ,Disease,Communicable Diseases,34,X,[dsyn],[dsyn],C23.550.288,C01.539.221
080905f5-6792-47b5-90e4-a05d8dce0c8c,genomic,C0282688,enable understanding of ,genomic,Evolution Molecular,1,X,????,[biof],????,G05.045.250;G16.075.250
e41eefea-3f4d-425a-a1b5-42e1ce0373a3,genomic,C0319157,enable understanding of ,genomic,AS virus,1,X,????,[virs],????,
203448ac-74c5-4237-a043-ae92cf162d80,C0254211,C1707455,is PCR ,arbidol,Comparison,2,X,[orch/phsu],[acty],x.x.x.x,
40b9189c-c2f3-4771-b7f4-2f23df015ac9,C0254211,PCR,is associated with higher negative rate of PCR,arbidol,PCR,4,X,[orch/phsu],????,x.x.x.x,????
fb2657b9-c956-46ce-ab2c-d7d2ab8162f5,C0319157,C0012222,has ,AS virus,Diffusion,2,X,[virs],[npop],,G01.202;G02.196
64cca7ae-5967-48e5-9fdd-b508531264c5,C0319157,C0040802,closely followed ,AS virus,travel,1,X,[virs],[dora],,I03.883
1d6c51fb-df2f-4ba4-93e5-73b6da673718,C0263237,C1880022,are In particular ,Vesicular eruption,Characterization,1,X,[dsyn],[acty],,
d3116d37-4cdf-4254-9fc5-c0ef2dc94f8d,C0263237,C1457887,occasionally preceding other ,Vesicular eruption,Symptoms,1,X,[dsyn],[sosy],,
c70d69d0-80ec-4dc9-9e97-c50019cda370,C2348077,C1175743,have had four patients with ,Date Fruit,SARS coronavirus,1,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150.113.937
c70d69d0-80ec-4dc9-9e97-c50019cda370,C2348077,C1175743,have have postulated for ,Date Fruit,SARS coronavirus,1,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150.113.937
898ebd54-1e59-4338-a27d-bddcfa20c021,C3272275,C0242781,block ,Urgent Procedure,disease transmission,1,X,[topp],[patf],,N06.850.310
97a2545f-421e-49a7-877a-0a281b4c1b48,C1254351,C1510827,is in currently use for predicted ,Pharmacologic Substance,Affinity,6,X,[phsu],[npop],,
1116cd0f-a8d7-4c38-870e-e3649e31a55f,C0242210,C0033684,is in ,Binding Proteins,Proteins,6,X,[aapp/bacs],[aapp/bacs],D12.776.157,D12.776
54bcbb92-54d7-4c72-bdb8-faec95b9915b,C0597358,C0022709,must move interact with ,receptor binding,Peptidyl-Dipeptidase A,8,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
5946b8bf-ae1c-4f47-b1b6-39bbb0dc37c4,C0013227,C1254351,is in already use as ,Pharmaceutical Preparations,Pharmacologic Substance,3,X,[phsu],[phsu],D26,
5946b8bf-ae1c-4f47-b1b6-39bbb0dc37c4,C0013227,C1254351,may act as ,Pharmaceutical Preparations,Pharmacologic Substance,3,X,[phsu],[phsu],D26,
386ac27d-9585-4758-a3fa-2dac57f82190,C1254351,C0033684,may act interfere with movements of domains within ,Pharmacologic Substance,Proteins,6,X,[phsu],[aapp/bacs],,D12.776
18061545-54fc-4eb7-826e-206a6ca97c88,C1254351,C0745283,may act interfere with movements of domains within ,Pharmacologic Substance,INFECTIOUS PROCESS,6,X,[phsu],[patf],,
f84fe8b2-dfc3-411d-993b-e367ae5b48ea,C1254351,C0086418,already approved for use ,Pharmacologic Substance,Homo sapiens,3,X,[phsu],[humn],,B01.050.150.900.649.313.988.400.112.400.400
4cdd339b-dac2-412e-a4c2-a120e8fab445,C0020336,COVID-19,was promoted in ,Hydroxychloroquine,COVID-19,4,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,C000657245
43af0353-7061-4ca6-bc9e-d0b2a35266aa,C0008269,remdesivir, includes ,Chloroquine,remdesivir,14,X,[orch/phsu],[clnd],D03.633.100.810.050.180,
948be4dc-fa24-483c-b2ab-71d6e1b9e8e0,C3652465,remdesivir, includes ,Interferon,remdesivir,14,X,[aapp/imft/phsu],[clnd],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
c53c58f8-abba-49aa-a90d-3fb7b831df41,C0003451,remdesivir, includes ,Antiviral Agents,remdesivir,14,X,[phsu],[clnd],D27.505.954.122.388,
43764a35-b372-46e5-ae99-584a9092c988,C0008269,C0674432, includes ,Chloroquine,lopinavir,14,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,D03.383.742.698.553
e555a8ed-8123-4b7c-b65a-4148583852df,C3652465,C0674432, includes ,Interferon,lopinavir,14,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D03.383.742.698.553
b0950f49-6167-4845-8be8-5275d2257bd8,C0003451,C0674432, includes ,Antiviral Agents,lopinavir,14,X,[phsu],[orch/phsu],D27.505.954.122.388,D03.383.742.698.553
93d3dacc-1209-461d-b4a5-5d12decc16ef,C0008269,C0292818, includes ,Chloroquine,Ritonavir,14,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180,D02.886.675.653;D03.383.129.708.653
ee1b4775-ae75-4c76-b8f6-b4acf8458baa,C3652465,C0292818, includes ,Interferon,Ritonavir,14,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D02.886.675.653;D03.383.129.708.653
710ce63d-cde7-44ef-b1af-cab3e30a70de,C0003451,C0292818, includes ,Antiviral Agents,Ritonavir,14,X,[phsu],[orch/phsu],D27.505.954.122.388,D02.886.675.653;D03.383.129.708.653
a294a189-9fcc-42f1-83f8-9b1c3c2bb9dd,C0008269,C1875319,are INVESTIGATIONAL AGENTS under,Chloroquine,INVESTIGATIONAL AGENTS,14,X,[orch/phsu],[phsu],D03.633.100.810.050.180,
3e978eff-657b-4874-b555-71a277c708ab,C3652465,C1875319,are INVESTIGATIONAL AGENTS under,Interferon,INVESTIGATIONAL AGENTS,14,X,[aapp/imft/phsu],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
71890af0-dc0d-4a6d-aad1-93049657d287,C0003451,C1875319,are INVESTIGATIONAL AGENTS under,Antiviral Agents,INVESTIGATIONAL AGENTS,14,X,[phsu],[phsu],D27.505.954.122.388,
7edc8f4a-a3cd-4a2f-a761-e1bcdd234a66,remdesivir,C1875319,are INVESTIGATIONAL AGENTS under,remdesivir,INVESTIGATIONAL AGENTS,14,X,[clnd],[phsu],,
25fd0bae-7d76-41cb-9a02-681c557b101b,C0674432,C1875319,are INVESTIGATIONAL AGENTS under,lopinavir,INVESTIGATIONAL AGENTS,14,X,[orch/phsu],[phsu],D03.383.742.698.553,
1622d3e2-e28a-4c43-917a-c1c030c416f4,C0292818,C1875319,are INVESTIGATIONAL AGENTS under,Ritonavir,INVESTIGATIONAL AGENTS,14,X,[orch/phsu],[phsu],D02.886.675.653;D03.383.129.708.653,
43c6cced-787e-4211-8b23-17f0d2d0a229,C0005525,C0021081,using due ,Biological Response Modifiers,Immunosuppressive Agents,3,X,[imft/phsu],[imft/phsu],D27.505.696.477,D27.505.696.477.656
aea82c07-21b7-4b81-b7ca-662bb17dfe0b,C1175743,C0319157,with patients is ,SARS coronavirus,AS virus,10,X,[virs],[virs],B04.820.504.540.150.113.937,
8d0fe911-81ca-497c-b47d-9266142088f8,C0022709,C0174990,coronavirus receptor for,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
8d0fe911-81ca-497c-b47d-9266142088f8,C0022709,C0174990,is In addition ,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
8d0fe911-81ca-497c-b47d-9266142088f8,C0022709,C0174990,may may ,Peptidyl-Dipeptidase A,coronavirus receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
ac26183a-0032-462d-8e01-4e26de130c44,C1175743,C0225336,is with focus on ,SARS coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150.113.937,A11.436.275
ac26183a-0032-462d-8e01-4e26de130c44,C1175743,C0225336,infect ,SARS coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150.113.937,A11.436.275
67eb9f8d-88e0-4b87-a86f-7820d4d2dede,C0206419,C0021403,having ,Genus: Coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150,D20.215.894.899.302
00187655-6351-4168-ba83-fb77c33dbc18,C0939237,C0206419,is associated with ,lopinavir / Ritonavir,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
00187655-6351-4168-ba83-fb77c33dbc18,C0939237,C0206419,are are repurposed for treatment of ,lopinavir / Ritonavir,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
55f46b39-9323-4c2a-9379-3a1513128d8a,C0037088,C0042769,right Virus Diseases for,Signs and Symptoms,Virus Diseases,1,X,[sosy],[dsyn],C23.888,C02
479d9f91-5cf0-4c3b-b684-4834e8f0d46c,C0319157,C0013227,could could explored as potential ,AS virus,Pharmaceutical Preparations,1,X,[virs],[phsu],,D26
c6f918d1-0303-40c3-b029-bae3e67265aa,C2349975,C0024501,was recommended to ,Enhance (action),Maintenance,1,X,[acty],[acty],,N02.628
f1e982a3-4544-454f-8014-f77f5a3135a6,C0024109,C0006145,are ,Lung,Breast Diseases,3,X,[bpoc],[dsyn],A04.411,C17.800.090
cb2a8ca6-8aba-4cba-8bdc-00a5bf165684,C0024109,C0206419,involved in ,Lung,Genus: Coronavirus,3,X,[bpoc],[virs],A04.411,B04.820.504.540.150
04b6e20f-2f8a-4094-a9af-7c8e730a6ee5,C0024109,GGO,distributed GGO,Lung,GGO,1,X,[bpoc],????,A04.411,????
5441fb9c-a978-4785-8538-3d9843377cb8,C0282515,C0020336,is with daily dosing of ,Chemoprevention,Hydroxychloroquine,3,X,[topp],[orch/phsu],E02.319.162,D03.633.100.810.050.180.350
48ad779b-d5c3-4306-bb82-eaf48cd0c9f9,C0282515,C0206419,time to contracting ,Chemoprevention,Genus: Coronavirus,5,X,[topp],[virs],E02.319.162,B04.820.504.540.150
53107521-a124-4217-a725-5bb844332a7e,C0282515,C0012634,is with increases time to contracting ,Chemoprevention,Disease,2,X,[topp],[dsyn],E02.319.162,C23.550.288
3717dfd3-c1aa-4362-915f-53be4325cc13,C0020336,C0032042,dosed weekly with daily ,Hydroxychloroquine,Placebos,2,X,[orch/phsu],[topp],D03.633.100.810.050.180.350,D26.660;E02.785
78ede066-50f0-4ba5-a959-5e625e75b62e,C0319157,C0206419,causes ,AS virus,Genus: Coronavirus,6,X,[virs],[virs],,B04.820.504.540.150
78ede066-50f0-4ba5-a959-5e625e75b62e,C0319157,C0206419,responsible for novel ,AS virus,Genus: Coronavirus,2,X,[virs],[virs],,B04.820.504.540.150
78ede066-50f0-4ba5-a959-5e625e75b62e,C0319157,C0206419,is with specific roles in ,AS virus,Genus: Coronavirus,2,X,[virs],[virs],,B04.820.504.540.150
b221e4ba-3132-4288-9505-73dbb7c42f34,C0319157,C0012634,causing 2019 ,AS virus,Disease,10,X,[virs],[dsyn],,C23.550.288
b221e4ba-3132-4288-9505-73dbb7c42f34,C0319157,C0012634,responsible for novel ,AS virus,Disease,1,X,[virs],[dsyn],,C23.550.288
b221e4ba-3132-4288-9505-73dbb7c42f34,C0319157,C0012634,prevent ,AS virus,Disease,1,X,[virs],[dsyn],,C23.550.288
e19de377-6686-471d-aae8-7993767f9c91,C0009450,C0309872,been effective in ,Communicable Diseases,PREVENT (product),4,X,[dsyn],[phsu],C01.539.221,
c675e3cb-b9f8-47dd-9592-41f64568f522,C1602245,C0412786,Ensure (product),Prompt,Protection of patient,8,X,[phsu],[topp],,
5bca1e1b-7cd3-4119-82b7-8341288642f0,C0206419,C3694279,shows ,Genus: Coronavirus,Middle East Respiratory Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
5bca1e1b-7cd3-4119-82b7-8341288642f0,C0206419,C3694279,may cause ,Genus: Coronavirus,Middle East Respiratory Syndrome,9,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200
546fed05-d953-451b-8b09-2eed508aa594,C0814033,C0319157,are potentially affected by ,neural circuits,AS virus,1,X,[bpoc],[virs],,
3272acb4-f627-4879-a987-df8927e3aeb6,C0206419,C4284302,is with ,Genus: Coronavirus,EHD1 wt Allele,3,X,[virs],[gngm],B04.820.504.540.150,
efad85f3-31e4-4a69-8f11-1f6428388a6c,C0012634,C4284302,affecting ~ 9 million people in ,Disease,EHD1 wt Allele,1,X,[dsyn],[gngm],C23.550.288,
54dc4cd2-24da-487e-a8f4-8dda835d751e,C0019638,C0225695,thickened ,Histology,Alveolar wall,2,X,[bmod],[bpoc],H01.158.100.656,
f9c87a72-717f-471f-8d3a-042b7be60c92,C0019638,C0015982,showed changes with ,Histology,Fibrin,2,X,[bmod],[aapp/bacs/phsu],H01.158.100.656,D12.776.124.270
c326b2ec-0adf-4ddb-86cf-037dedc718c5,C0019638,C0596898,showed changes with ,Histology,membrane biogenesis,2,X,[bmod],[celf],H01.158.100.656,
f1e22006-34a0-44bd-ba9d-b0fd34228798,C0019638,C2328510,thickened ,Histology,Interstitium,2,X,[bmod],[bpoc],H01.158.100.656,
fb8a14d6-23ad-4ad9-9d6e-6d640aacb423,C0019638,C0333386,thickened Alveolar wall with,Histology,Chronic lymphocytic inflammation,2,X,[bmod],[patf],H01.158.100.656,
fb8a14d6-23ad-4ad9-9d6e-6d640aacb423,C0019638,C0333386,thickened Interstitium with,Histology,Chronic lymphocytic inflammation,2,X,[bmod],[patf],H01.158.100.656,
c1cf3637-647b-4802-83b2-61e0e1cf3167,C0699748,C1175175,is in aftermath of 2002 2003 ,Pathogenesis,Severe Acute Respiratory Syndrome,5,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
636ed7ad-91da-4dfe-9559-ee04c419ac62,C2806453,C0013227,of features is potential ,Betacoronavirus,Pharmaceutical Preparations,5,X,[virs],[phsu],B04.820.504.540.150.113,D26
3cdd2a69-1805-474e-a2c3-2a87731b3ef8,C0206419,C0013404,share Xyzinclude5 in ,Genus: Coronavirus,Dyspnea,1,X,[virs],[sosy],B04.820.504.540.150,C08.618.326;C23.888.852.371
3cdd2a69-1805-474e-a2c3-2a87731b3ef8,C0206419,C0013404,share similar fever ,Genus: Coronavirus,Dyspnea,2,X,[virs],[sosy],B04.820.504.540.150,C08.618.326;C23.888.852.371
3cdd2a69-1805-474e-a2c3-2a87731b3ef8,C0206419,C0013404,share Xyzinclude2 in ,Genus: Coronavirus,Dyspnea,1,X,[virs],[sosy],B04.820.504.540.150,C08.618.326;C23.888.852.371
e500a411-4a81-40c9-affe-dd6caeab1bba,C1175743,C0277548,were However ,SARS coronavirus,Epidemic disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
e500a411-4a81-40c9-affe-dd6caeab1bba,C1175743,C0277548,is responsible for ,SARS coronavirus,Epidemic disease,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,
074d5eb0-3e7f-41fa-92b0-9d7469469822,C3714514,C0277548,were However ,Infection,Epidemic disease,1,X,[patf],[dsyn],C01.539,
c85e9a05-013b-4e60-a8ae-971a23f8315d,C1175743,11th,had spread on 11th,SARS coronavirus,11th,6,X,[virs],????,B04.820.504.540.150.113.937,????
cbe54dd8-af1a-49bf-8579-1b9090c3a3be,C0007682,C0497327, includes Alzheimers-like ,CNS disorder,Dementia,6,X,[dsyn],[mobd],C10.228,C10.228.140.380;F03.615.400
8dc67b64-68f1-4fa5-8d73-ebcc1d5bf08f,COVID-19,C0008679,is associated with much ,COVID-19,Chronic disease,1,X,[virs],[dsyn],C000657245,C23.550.291.500
05a449e3-3556-43c7-9893-61996fc4f203,COVID-19,C0011849,is with ,COVID-19,Diabetes Mellitus,3,X,[virs],[dsyn],C000657245,C18.452.394.750;C19.246
fa594648-112e-43b9-9726-c52320192e71,C1707455,C1516048,was ,Comparison,Assessed,1,X,[acty],[acty],,
32f008ef-eefc-448d-be72-f07a6ed6e7c6,C0034386,C1516048,was ,Quarantine,Assessed,1,X,[topp],[acty],N06.850.780.200.450.700,
d3ccc435-f012-4eaf-9ddc-198745caae75,C0206419,C0024109,are consequence of multiorgan dysregulation caused by ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
d3ccc435-f012-4eaf-9ddc-198745caae75,C0206419,C0024109,can affect ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
d3ccc435-f012-4eaf-9ddc-198745caae75,C0206419,C0024109,can can suggested on ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
d3ccc435-f012-4eaf-9ddc-198745caae75,C0206419,C0024109, includes ,Genus: Coronavirus,Lung,4,X,[virs],[bpoc],B04.820.504.540.150,A04.411
d3ccc435-f012-4eaf-9ddc-198745caae75,C0206419,C0024109,colocalized in ,Genus: Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150,A04.411
127c4720-fd0e-4816-8cf4-edbe0ed57663,C0012634,C0024109,are consequence of multiorgan dysregulation caused by ,Disease,Lung,1,X,[dsyn],[bpoc],C23.550.288,A04.411
127c4720-fd0e-4816-8cf4-edbe0ed57663,C0012634,C0024109,is in patients with pattern of ,Disease,Lung,2,X,[dsyn],[bpoc],C23.550.288,A04.411
127c4720-fd0e-4816-8cf4-edbe0ed57663,C0012634,C0024109,is In symptomatic individuals mild immune-mediated ,Disease,Lung,2,X,[dsyn],[bpoc],C23.550.288,A04.411
90a629ef-bac2-4a33-8d82-820d33127754,C0007222,COVID-19,are at ,Cardiovascular Diseases,COVID-19,1,X,[dsyn],[virs],C14,C000657245
56e6cc0a-6124-405a-98b0-2c053a2d9cd9,C0028606,COVID-19,is in ,Nucleic Acids,COVID-19,1,X,[bacs/nnon],[virs],D13.444,C000657245
a1f09927-9cd4-44c2-8088-2d4d38e8c645,C0206419,11th,was characterized as global pandemic by the WHO on 11th,Genus: Coronavirus,11th,2,X,[virs],????,B04.820.504.540.150,????
a1f09927-9cd4-44c2-8088-2d4d38e8c645,C0206419,11th,has has announced by World Health Organization Director General on 11th,Genus: Coronavirus,11th,1,X,[virs],????,B04.820.504.540.150,????
6d94ae8b-0973-4e96-b714-002564971418,C0012634,11th,was characterized as global pandemic by the WHO on 11th,Disease,11th,2,X,[dsyn],????,C23.550.288,????
17a02699-9ac4-44bf-9361-b1bf8dca331b,C0206419,C1155266,is associated with severe ,Genus: Coronavirus,inflammatory response,1,X,[virs],[patf],B04.820.504.540.150,
17a02699-9ac4-44bf-9361-b1bf8dca331b,C0206419,C1155266,triggering ,Genus: Coronavirus,inflammatory response,2,X,[virs],[patf],B04.820.504.540.150,
17a02699-9ac4-44bf-9361-b1bf8dca331b,C0206419,C1155266,direct systemic ,Genus: Coronavirus,inflammatory response,1,X,[virs],[patf],B04.820.504.540.150,
ed696a2b-b128-42bd-99ce-92247882e84d,C0012634,C1155266,is associated with severe ,Disease,inflammatory response,2,X,[dsyn],[patf],C23.550.288,
ec42f13d-1b2c-4ac4-910a-59cb0638b26e,C0021368,C2936350,affects ,Inflammation,Plaque Atherosclerotic,2,X,[patf],[bdsu],C23.550.470,C23.300.823
ec42f13d-1b2c-4ac4-910a-59cb0638b26e,C0021368,C2936350,may result in rupture of vulnerable ,Inflammation,Plaque Atherosclerotic,3,X,[patf],[bdsu],C23.550.470,C23.300.823
adde5171-de21-48ee-93d0-d037938f2b55,COVID-19,C1511790,was diagnosed by ,COVID-19,Detection,1,X,[virs],[topp],C000657245,
9e5b8515-ccba-4590-93b5-81521e4ac22a,C0021368,COVID-19,related to ,Inflammation,COVID-19,7,X,[patf],[virs],C23.550.470,C000657245
307a71cb-f7dd-4b13-a0bc-eb07a78cc685,C0021368,C0302148,resulting in ,Inflammation,Blood Clot,3,X,[patf],[patf],C23.550.470,C14.907.355.830
b81f3926-79dc-4e16-bf50-807deb211f3b,C0026140,RT-PCR,was tested by real-time RT-PCR,Milk Human,RT-PCR,1,X,[bdsu],????,A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,????
da66c475-c491-4b09-87cc-efdecb021589,C0026140,C1175743,was positive for ,Milk Human,SARS coronavirus,1,X,[bdsu],[virs],A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,B04.820.504.540.150.113.937
da66c475-c491-4b09-87cc-efdecb021589,C0026140,C1175743,tested for ,Milk Human,SARS coronavirus,1,X,[bdsu],[virs],A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500,B04.820.504.540.150.113.937
e5b7c346-b338-44cc-9645-eec983032321,C1175743,C0026140,is in ,SARS coronavirus,Milk Human,1,X,[virs],[bdsu],B04.820.504.540.150.113.937,A12.200.467;G07.203.100.700.500;G07.203.300.350.525.500;J02.200.700.500;J02.500.350.525.500
dc2d5b94-13ee-45f9-b9aa-c454521eb5aa,C1457887,C0010200,were ,Symptoms,Coughing,40,X,[sosy],[sosy],,C08.618.248;C23.888.852.293
da65a662-0c67-4bb8-8c41-5fac9bd55090,C1457887,C0231218,include ,Symptoms,Malaise,2,X,[sosy],[sosy],,
0b45bafc-5359-440d-9aa7-a346ca45750f,C0030946,C0872147,using ,Endopeptidases,DNA Library,5,X,[aapp/enzy/phsu],[gngm/nnon],D08.811.277.656.300,G05.360.325
021a69f3-085b-4370-b64b-fce6319cbe39,C0030946,C1566558,using ,Endopeptidases,Natural Products,5,X,[aapp/enzy/phsu],[bacs],D08.811.277.656.300,D20.215
dced0aaf-ba05-4a6f-8523-60ff9ff37442,MDS,C0023688,were performed on ,MDS,Ligands,5,X,????,[chem],????,D27.720.470.480
d04bc33b-0d82-43e3-986d-3fcf7621f32a,MDS,C1180347,were performed on ,MDS,Protein complex,5,X,????,[aapp/bacs],????,
0965fdbd-cd0d-4f67-b0a7-b67c53d67931,MDS,C1167622,verify their ,MDS,Binding (Molecular Function),10,X,????,[moft],????,
f29c50a9-b41e-42ef-b297-e0e92143d025,C0034386,COVID-19,recommended due to ,Quarantine,COVID-19,1,X,[topp],[virs],N06.850.780.200.450.700,C000657245
f29c50a9-b41e-42ef-b297-e0e92143d025,C0034386,COVID-19,significantly reduced ,Quarantine,COVID-19,1,X,[topp],[virs],N06.850.780.200.450.700,C000657245
7c0668b2-c03a-441c-84c9-f7595afc5772,C0004610,C0035243,were attributed to non ,Bacteremia,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C01.252.100;C01.539.757.100;C23.550.470.790.500.100,C01.539.739;C08.730
a90243b7-57e5-4db7-bcdc-bfa7e0288952,C0023237,C1511790,was ,Legionella,Detection,1,X,[bact],[topp],B03.440.400.425.450.450;B03.660.250.460.460,
6306a9e8-71e0-41cf-904f-5f9f5357e802,C4267729,C0033808,isolated with ,Respiratory pathogens,Pseudomonas,1,X,[orgm],[bact],,B03.440.400.425.625.625;B03.660.250.580.590
02145a92-961f-4ba8-bd13-a6b37ba92ae9,C4267729,C0009450,isolated with ,Respiratory pathogens,Communicable Diseases,1,X,[orgm],[dsyn],,C01.539.221
e30de1d9-5d8b-4b1e-ae36-a0b64bbc2f14,C4267729,C0275524,isolated in community-acquired ,Respiratory pathogens,Coinfection,1,X,[orgm],[dsyn],,C01.539.218;C02.219;C03.202
a188a3e9-c958-40a2-b20b-781a80b515fa,C1262313,C3714514,were attributed to line related ,Invasive Fungal Infections,Infection,2,X,[dsyn],[patf],C01.703.492,C01.539
94d02139-4070-4846-8ba6-317e0774e679,C0015967,COVID-19,varied spectra of ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
94d02139-4070-4846-8ba6-317e0774e679,C0015967,COVID-19,ENUMX2 than ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
94d02139-4070-4846-8ba6-317e0774e679,C0015967,COVID-19,was found in ,Fever,COVID-19,1,X,[sosy],[virs],C23.888.119.344,C000657245
aeb4fe50-b06c-4fea-81c1-13b7aba845f0,C4086266,C0230425,reduction in ,Escalation,Structure of right thigh,5,X,[acty],[bpoc],,
12e4b1f8-0d2c-4527-ae8f-1c1498f841dd,C0042776,C0206750,agent of ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
12e4b1f8-0d2c-4527-ae8f-1c1498f841dd,C0042776,C0206750,causing current ,Virus,Coronavirus Infections,53,X,[virs],[dsyn],B04,C02.782.600.550.200
12e4b1f8-0d2c-4527-ae8f-1c1498f841dd,C0042776,C0206750,triggered ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
12e4b1f8-0d2c-4527-ae8f-1c1498f841dd,C0042776,C0206750,is potentially more lethal than ,Virus,Coronavirus Infections,2,X,[virs],[dsyn],B04,C02.782.600.550.200
4ca5a806-baf5-4ab0-bfed-1217d23af79d,C0039082,C2717865,are known Besides ,Syndrome,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[dsyn],[dsyn],C23.550.288.500,C14.907.940.897.249;C20.111.193
c2c96f68-32f2-435e-acbf-52994a638d71,C0024109,C2717865,are known Besides ,Lung,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[bpoc],[dsyn],A04.411,C14.907.940.897.249;C20.111.193
135283fe-681d-4ae2-8e4d-782df6a9c2ba,C0003204,C2717865,are known Besides ,Anti-Infective Agents,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,2,X,[phsu],[dsyn],D27.505.954.122,C14.907.940.897.249;C20.111.193
a21076d0-de3e-487e-9958-414335ac0d6f,C0004364,C0103647, includes ,Autoimmune Diseases,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C20.111,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
51cc8706-effc-4c49-8ccf-2a6971a38cde,C2717865,C0004364,are known Besides ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Autoimmune Diseases,2,X,[dsyn],[dsyn],C14.907.940.897.249;C20.111.193,C20.111
5bacd7be-7e82-4789-a10f-085abbf0bf8d,C0039082,C0004364,are known Besides ,Syndrome,Autoimmune Diseases,2,X,[dsyn],[dsyn],C23.550.288.500,C20.111
8c5d43d5-f08e-40be-bf14-2aab6c1c3d71,C0024109,C0004364,are known Besides ,Lung,Autoimmune Diseases,2,X,[bpoc],[dsyn],A04.411,C20.111
bece2793-73e8-46d1-b7de-2c440616ed9b,C0003204,C0004364,are known Besides ,Anti-Infective Agents,Autoimmune Diseases,2,X,[phsu],[dsyn],D27.505.954.122,C20.111
ecaea664-6f9a-4a02-b387-cf4f4713050f,C2717865,C0103647,are known Besides ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C14.907.940.897.249;C20.111.193,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
ecbc609d-0d55-47da-a7da-86ca4eab29af,C0039082,C0103647,are known Besides ,Syndrome,Antineutrophil Cytoplasmic Antibodies,2,X,[dsyn],[imft],C23.550.288.500,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
dcb76e3e-5b04-493a-855b-74eee5971068,C0024109,C0103647,are known Besides ,Lung,Antineutrophil Cytoplasmic Antibodies,2,X,[bpoc],[imft],A04.411,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
77e02f00-cfaf-4a95-b211-f5cd90032108,C0003204,C0103647,are known Besides ,Anti-Infective Agents,Antineutrophil Cytoplasmic Antibodies,2,X,[phsu],[imft],D27.505.954.122,D12.776.124.486.485.114.323.190;D12.776.124.790.651.114.323.190;D12.776.377.715.548.114.323.190;D23.101.050
d48469f4-638b-43de-8a10-b7598bb36b1c,C2717865,C4476767,be culprits of ,Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis,Diffuse alveolar hemorrhage,4,X,[dsyn],[dsyn],C14.907.940.897.249;C20.111.193,
526bd0dc-4798-435a-826d-a71d6ce84a6c,C0039082,C4476767,be culprits of ,Syndrome,Diffuse alveolar hemorrhage,4,X,[dsyn],[dsyn],C23.550.288.500,
cb561383-b7e9-4a03-a043-d492bf8edaba,C0024109,C4476767,be culprits of ,Lung,Diffuse alveolar hemorrhage,4,X,[bpoc],[dsyn],A04.411,
4f66a853-3ca8-4844-8771-e61186567e29,C0003204,C4476767,be culprits of ,Anti-Infective Agents,Diffuse alveolar hemorrhage,4,X,[phsu],[dsyn],D27.505.954.122,
272058cd-5086-4fb6-88d6-9d3c0df67717,C0206750,C0033860,is with ,Coronavirus Infections,Psoriasis,5,X,[dsyn],[dsyn],C02.782.600.550.200,C17.800.859.675
0a89d213-a657-442b-8803-0b4d9f6dda33,C1678805,C0011627,could could safer alternative for ,apremilast,Dermatology field,4,X,[orch/phsu],[bmod],x.x.x.x,H02.403.225
dba762f4-d2c9-4955-8711-c8ade9fa11f2,C0026766,C0206750,are spectrum of ,Multiple Organ Failure,Coronavirus Infections,4,X,[patf],[dsyn],C23.550.835.525,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,recently reported duration of ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,may occur in ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,was empirically recommended as prophylaxis by National ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,is under evaluation as possible ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,have recently become because of ongoing ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,reduce death risk of ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,should Therefore should prescribed as part of treatment for ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,offered efficacy in treatment of ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,has has proposed as possible treatment for ,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,decreases inflammatory response storm In patients with,Hydroxychloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
7923de87-2afe-4c58-ac3b-21aeff6e3981,C0020336,C0206750,clinical symptoms of ,Hydroxychloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C02.782.600.550.200
c1e5dafd-8cb5-4aad-b73e-c0fb3ae9efde,C0850149,C0206750,had ,Dry cough,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
6f06e856-bd40-4e0d-abcb-f9af4ca9dcd7,C0086418,C0042762,Institute of ,Homo sapiens,Science of Virology,2,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H01.158.273.540.859
d0cce124-15a0-4a52-af2e-101ac30cec73,C0021400,C0042762,Institute of ,Influenza,Science of Virology,2,X,[dsyn],[bmod],C02.782.620.365;C08.730.310,H01.158.273.540.859
9ae7e188-0fb2-425c-b871-511c2297ae0d,CN,C1705178,is in alphabetical ,CN,Order (action),4,X,????,[acty],????,
5125124c-3487-4d0e-a721-b4abb4c7f3cc,ICMR,C1705178,is In alphabetical ,ICMR,Order (action),1,X,????,[acty],????,
f8383cc6-6387-4e56-96e5-bd2d5a4e85f7,COVID,C1705178,is in alphabetical ,COVID,Order (action),4,X,????,[acty],????,
d68de22c-91a8-407b-b61b-e1365dc8f63c,C0014507,C1705178,is in alphabetical ,Epidemiology,Order (action),3,X,[bmod],[acty],H02.403.720.500,
0af228b5-8886-4db5-9865-7e03f063c6ef,C0376576,C1705178,is in alphabetical ,gb virus,Order (action),2,X,[virs],[acty],,
027fdeef-beef-473e-b042-36726796f19f,C0018939,C0002871, includes ,Hematological Disease,Anemia,6,X,[dsyn],[dsyn],C15.378,C15.378.071
31ee1e17-ffa4-4769-a4d7-8631f269b0be,C0018939,C0005779, includes ,Hematological Disease,Blood Coagulation Disorders,6,X,[dsyn],[dsyn],C15.378,C15.378.100
433baffa-7c79-43a5-a9f7-93905fdb7339,C0018939,C0040034, includes ,Hematological Disease,Thrombocytopenia,6,X,[dsyn],[dsyn],C15.378,C15.378.140.855
433baffa-7c79-43a5-a9f7-93905fdb7339,C0018939,C0040034,exhibits ,Hematological Disease,Thrombocytopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.140.855
e9a0263d-6e09-4251-86a8-75da132a92ca,C0206750,C0013404,was initially characterized by ,Coronavirus Infections,Dyspnea,13,X,[dsyn],[sosy],C02.782.600.550.200,C08.618.326;C23.888.852.371
362be0ab-578a-4739-b23c-ae991ae08c06,C0206750,C0010200,was initially characterized by ,Coronavirus Infections,Coughing,11,X,[dsyn],[sosy],C02.782.600.550.200,C08.618.248;C23.888.852.293
bc580b3c-9b7d-4d1b-b04c-10c8bb91d4b1,C0012634,C0370003,is in ,Disease,Specimen,1,X,[dsyn],[sbst],C23.550.288,
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,varied spectra of ,Fever,Coronavirus Infections,4,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,were most common symptoms of ,Fever,Coronavirus Infections,4,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,shows respectively correlation with total ,Fever,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,was predominant Symptom:Find:Pt:^Patient:Nom in,Fever,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,was predominant Symptoms in,Fever,Coronavirus Infections,6,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
dba5771f-69a1-4b5d-a9cf-bac8baf9f64c,C0015967,C0206750,was found in higher number of post ,Fever,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200
f24fb111-5908-4abe-a8eb-debc87412a29,C3274800,C0012634,was observed higher in patients with co morbid ,Disease Presentation,Disease,8,X,[clna],[dsyn],,C23.550.288
f24fb111-5908-4abe-a8eb-debc87412a29,C3274800,C0012634,characteristics of ,Disease Presentation,Disease,1,X,[clna],[dsyn],,C23.550.288
5c4eb6aa-0856-48f0-ae0d-971944c77e0f,HRCT,C0206750,is in ,HRCT,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
8cda17d1-1b91-4ec2-9120-6c9527a839e6,C0549646,C0206750,is in ,chest disorders,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
80c75cb3-c8fe-4d88-beae-7f0757b726b8,C0024312,C0596448,raised D ,Lymphopenia,dimer,3,X,[dsyn],[chvs],C15.378.553.546.605;C20.673.627,
609ce5e6-634a-464d-b44a-3a13f48baa5a,C2347218,C0206419,be alternative in ,Bronchial Artery Infusion Procedure,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
334559cd-cf65-4432-ae98-770b0ad52671,C0206419,C0304229,is with superadded benefits of high ,Genus: Coronavirus,Experimental drug,1,X,[virs],[phsu],B04.820.504.540.150,
53e57d99-5c4e-4136-b565-2a8839008855,C0206419,C1514593,know little about ,Genus: Coronavirus,Psychological Impact,1,X,[virs],[clna],B04.820.504.540.150,
b4ce070a-814c-45d6-bc9e-a34cd899bce3,C0877203,C0206419,indicates potential timing of increase in incidence of disease in ,Viral Respiratory Tract Infection,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
146b519c-8174-4873-8a34-8d5605590400,C4283882,C0206419,indicates potential timing of increase in incidence of disease in ,NR1I2 wt Allele,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
2b42f14c-f1c5-4bef-8422-c4aeb79e22ce,C4553629,C0242781,estimate age-stratified ,MATRix Regimen,disease transmission,1,X,[topp],[patf],,N06.850.310
2ef17208-4150-4316-b940-673424f8a78a,C0037386,C1705178,was followed in ,snow - weather,Order (action),4,X,[npop],[acty],G16.500.175.867;G16.500.275.063.725.480;G16.500.750.775.480;N06.230.300.100.725.480,
f1c8c423-4a6a-4dda-a6ee-75ecd949ecb9,C1706202,C1705178,was followed in ,Search - action,Order (action),4,X,[acty],[acty],,
01b06778-995b-4196-8d8d-0c7f2b63d9b7,C0039195,C1175175,is in ,Cytotoxic T-Lymphocytes,Severe Acute Respiratory Syndrome,4,X,[cell],[dsyn],A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200,C02.782.600.550.200.750;C08.730.730
ba2399b1-79f1-49c6-9a70-ce5739154fb5,C1175175,C2699153,can can partially explained by direct ,Severe Acute Respiratory Syndrome,Cell Invasion,4,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,
57b6b247-a701-45c7-bde8-742f279ee4d8,C1175175,C0039194,can can partially explained by direct ,Severe Acute Respiratory Syndrome,T-Lymphocyte,3,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
498e88a0-3000-4b8f-a1d1-de395bdf48fa,C1175175,C1175743,can can partially explained by direct ,Severe Acute Respiratory Syndrome,SARS coronavirus,4,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
498e88a0-3000-4b8f-a1d1-de395bdf48fa,C1175175,C1175743,diagnostic performance of ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
498e88a0-3000-4b8f-a1d1-de395bdf48fa,C1175175,C1175743,is third zoonotic ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
498e88a0-3000-4b8f-a1d1-de395bdf48fa,C1175175,C1175743,caused by ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
498e88a0-3000-4b8f-a1d1-de395bdf48fa,C1175175,C1175743,in injury is specific presentations of cardiovascular involvement by ,Severe Acute Respiratory Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150.113.937
bda2aee4-47bd-412f-86e8-024459c87a93,C0005778,C0206419,is in ,Blood coagulation,Genus: Coronavirus,1,X,[ortf],[virs],G09.188.390.150,B04.820.504.540.150
1fb85e8f-af4d-409d-a5c8-b73272faba7a,C0042071,C0005778,Dysregulation of were proposed mechanisms of ,Urokinase,Blood coagulation,4,X,[aapp/enzy/phsu],[ortf],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,G09.188.390.150
b2d87217-8afa-434e-b726-4e83e5f8889e,C1704259,C0005778,Dysregulation of were proposed mechanisms of ,Biochemical Pathway,Blood coagulation,4,X,[moft],[ortf],,G09.188.390.150
4103a954-8b49-4056-a81f-91e431ad7c9c,C0042071,C0206419,Dysregulation of were proposed mechanisms of ,Urokinase,Genus: Coronavirus,1,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,B04.820.504.540.150
383a98c1-c053-46d2-80d6-f34e652db15a,C0013404,C1457887,were most common clinical ,Dyspnea,Symptoms,26,X,[sosy],[sosy],C08.618.326;C23.888.852.371,
33f1ccbb-77e5-496d-b727-8255d30458ed,C0015967,C1457887,were major ,Fever,Symptoms,2,X,[sosy],[sosy],C23.888.119.344,
33f1ccbb-77e5-496d-b727-8255d30458ed,C0015967,C1457887,were most common clinical ,Fever,Symptoms,15,X,[sosy],[sosy],C23.888.119.344,
33f1ccbb-77e5-496d-b727-8255d30458ed,C0015967,C1457887,were most prevalent ,Fever,Symptoms,6,X,[sosy],[sosy],C23.888.119.344,
33f1ccbb-77e5-496d-b727-8255d30458ed,C0015967,C1457887,Regarding ,Fever,Symptoms,1,X,[sosy],[sosy],C23.888.119.344,
33f1ccbb-77e5-496d-b727-8255d30458ed,C0015967,C1457887,was most frequent ,Fever,Symptoms,1,X,[sosy],[sosy],C23.888.119.344,
44a3966b-05c9-4c68-ab38-883fdac3ced9,C0010200,C1457887,were major ,Coughing,Symptoms,2,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
44a3966b-05c9-4c68-ab38-883fdac3ced9,C0010200,C1457887,were most common clinical ,Coughing,Symptoms,13,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
44a3966b-05c9-4c68-ab38-883fdac3ced9,C0010200,C1457887,were most prevalent ,Coughing,Symptoms,3,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
42fc21fb-a121-4157-833f-88fd9e63fd7b,C0031350,C1457887,were major ,Pharyngitis,Symptoms,2,X,[dsyn],[sosy],C07.550.781;C08.730.561;C09.775.649,
475d3431-e5cc-471a-89b3-55825253d1b7,C0233401,C0206419,rates of were During ,Psychiatric symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
475d3431-e5cc-471a-89b3-55825253d1b7,C0233401,C0206419,been common during ,Psychiatric symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
0dc9b598-d290-4bf8-8bbf-b7ce1f187017,C0233401,C0011570,rates of were During ,Psychiatric symptom,Mental Depression,6,X,[sosy],[mobd],,F01.145.126.350
11f0ac31-db02-4015-b967-ea483ee0484c,C0233401,C0917801,rates of were During ,Psychiatric symptom,Sleeplessness,6,X,[sosy],[sosy],,C10.886.425.800.800;F03.870.400.800.800
e9106301-7f01-4adb-b188-7fdbb1136597,C0233401,C0009450,people with suspected ,Psychiatric symptom,Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
0853208a-a0b5-4878-9c4e-56976dc631bb,C1457887,C0009450,people with suspected ,Symptoms,Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
0853208a-a0b5-4878-9c4e-56976dc631bb,C1457887,C0009450,prognostic of ,Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],,C01.539.221
0853208a-a0b5-4878-9c4e-56976dc631bb,C1457887,C0009450,were present mostly in early stages of ,Symptoms,Communicable Diseases,3,X,[sosy],[dsyn],,C01.539.221
0853208a-a0b5-4878-9c4e-56976dc631bb,C1457887,C0009450,arise during course of ,Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],,C01.539.221
09a956fd-6a6c-4f1c-b2b8-6052838f5635,on-site,C1319405,is with Department of ,on-site,Clinical microbiology,2,X,????,[bmod],????,
a13e1906-e74a-4aa7-9fd1-2acb9016b396,C0003451,C0042774,inhibit ,Antiviral Agents,Virus Replication,1,X,[phsu],[celf],D27.505.954.122.388,G06.920.925
a13e1906-e74a-4aa7-9fd1-2acb9016b396,C0003451,C0042774,could could related to ,Antiviral Agents,Virus Replication,2,X,[phsu],[celf],D27.505.954.122.388,G06.920.925
09182bf9-03f1-4d2c-870c-df2c44d52b7e,C0013227,C0003451,were ,Pharmaceutical Preparations,Antiviral Agents,8,X,[phsu],[phsu],D26,D27.505.954.122.388
fa77e024-cc7d-4e46-888c-6763aba29b08,C0567416,C0079189,mitigated inflammatory ,Molecule,cytokine,1,X,[sbst],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
2c3858bc-f045-44c3-80eb-2107a6c3a235,C0567416,C0118522,mitigated inflammatory ,Molecule,GA-Binding Protein Transcription Factor,1,X,[sbst],[aapp/bacs],,D12.776.260.615.249;D12.776.930.618.249
5d97529b-8ab4-42ad-b3e4-1e26a799bb7d,C0118522,C0032310,are useful in management of ,GA-Binding Protein Transcription Factor,Pneumonia Viral,1,X,[aapp/bacs],[dsyn],D12.776.260.615.249;D12.776.930.618.249,C02.705;C08.381.677.807;C08.730.610.763
41d460ee-52d2-436b-a8b5-6067b51675bb,C0242781,HK,importation in HK,disease transmission,HK,3,X,[patf],????,N06.850.310,????
e9dfca1f-ebb2-438b-9115-a5458f541c60,C0206419,HK,importation in HK,Genus: Coronavirus,HK,1,X,[virs],????,B04.820.504.540.150,????
ee75bb84-986d-42c6-b691-d624d741f2ad,C0009450,C0042776,caused by new ,Communicable Diseases,Virus,2,X,[dsyn],[virs],C01.539.221,B04
93e60bcb-6df1-4e73-8e57-c9bf050b025c,C0042776,C0035204,causes ,Virus,Respiration Disorders,2,X,[virs],[dsyn],B04,C08.618
bfb6e44f-5394-4932-9ef3-4eff9c0286fa,C0042776,C0010200,causes Respiration Disorders with,Virus,Coughing,5,X,[virs],[sosy],B04,C08.618.248;C23.888.852.293
bfb6e44f-5394-4932-9ef3-4eff9c0286fa,C0042776,C0010200,is spreading through ,Virus,Coughing,1,X,[virs],[sosy],B04,C08.618.248;C23.888.852.293
057610d7-762e-43e0-90ec-5e159da96cb9,C0010076,COVID-19,reaches levels after 4weeks ,Coronaviridae,COVID-19,1,X,[virs],[virs],B04.820.504.540,C000657245
057610d7-762e-43e0-90ec-5e159da96cb9,C0010076,COVID-19,was named ,Coronaviridae,COVID-19,2,X,[virs],[virs],B04.820.504.540,C000657245
6291eb45-14c5-4a21-90e9-557d2a836730,C0010076,4weeks,reaches levels after 4weeks ,Coronaviridae,4weeks,1,X,[virs],????,B04.820.504.540,????
9cb7b0ee-e10e-46bc-a7a9-a34a4a84b178,COVID-19,C0037090,main manifestations of are ,COVID-19,Signs and Symptoms Respiratory,1,X,[virs],[sosy],C000657245,C23.888.852
9cb7b0ee-e10e-46bc-a7a9-a34a4a84b178,COVID-19,C0037090,is defined by its ,COVID-19,Signs and Symptoms Respiratory,1,X,[virs],[sosy],C000657245,C23.888.852
7586ff4b-4de9-4b09-898a-cf066f717a60,C0206750,C0948008,is with ,Coronavirus Infections,Ischemic stroke,11,X,[dsyn],[dsyn],C02.782.600.550.200,
2e751592-06ee-4a16-8d68-0a05bc3dae2b,C0012634,C0948008,is associated with higher risk of ,Disease,Ischemic stroke,2,X,[dsyn],[dsyn],C23.550.288,
3000db3f-f16c-4d5d-911e-fdb497b078bb,C0206750,C0729531,is associated would expected from ,Coronavirus Infections,Viral respiratory infection,8,X,[dsyn],[dsyn],C02.782.600.550.200,
f687ed66-28e7-4dbf-a558-2e115d5e564c,C0012634,C0729531,is associated would expected from ,Disease,Viral respiratory infection,4,X,[dsyn],[dsyn],C23.550.288,
057850a9-049a-4d69-9ef4-b9980b883301,C1707455,C2062441,included adults with emergency department visits with ,Comparison,Influenza A,5,X,[acty],[dsyn],,
f60bf268-5960-451e-a292-d3791ba07920,C1175743,C0027442,is in ,SARS coronavirus,Nasopharynx,6,X,[virs],[bpoc],B04.820.504.540.150.113.937,A04.623.557;A14.724.557
37e02705-dc8d-4699-887e-c5cd92ef7e89,C0948008,C0021403,higher rate with cohort of patients with ,Ischemic stroke,Influenza virus vaccine,4,X,[dsyn],[imft/phsu],,D20.215.894.899.302
e0c2c24a-82c6-4ed1-b97c-907c3ea13aa4,C0948008,C0038454,higher rate of ,Ischemic stroke,Cerebrovascular accident,5,X,[dsyn],[dsyn],,C10.228.140.300.775;C14.907.253.855
e82701d6-0b42-4134-a503-e95412f713db,C0948008,C1707455,higher rate of ,Ischemic stroke,Comparison,5,X,[dsyn],[acty],,
4b76f72b-f4d8-4248-90df-b00d4a81ec39,C0011121,C0026051,is with ,Decontamination,microwave electromagnetic radiation,2,X,[topp],[npop],N06.850.780.325,G01.358.500.505.810.500;G01.750.250.810.500;G01.750.770.721.500
c50ff4d6-5e05-4c33-a84f-3a6757411150,C0011121,C0018837,is with ,Decontamination,Heat (physical force),2,X,[topp],[npop],N06.850.780.325,
352fbd10-883c-460e-a76b-fdc1eb430f24,C3811133,C0011121,be options for successful ,Ethylene Oxide Sterilization,Decontamination,3,X,[acty],[topp],,N06.850.780.325
b0ac996a-5d05-4c0c-be3d-7aa30c4a9b0e,C0038225,C0011121,appear viable options for successful ,Steam,Decontamination,2,X,[inch],[topp],D01.045.250.875.800;D01.248.497.158.459.650.800;D01.650.550.925.800;G16.500.887;N06.230.650,N06.850.780.325
6b4f7e9a-1e04-437f-91c2-ce686e7e68fc,C0041625,C0011121,appear viable options for ,Ultraviolet Rays,Decontamination,2,X,[npop],[topp],G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600,N06.850.780.325
eedb7fce-693f-45fa-98d6-acb9ebb224c6,C0018837,C0011121,appear viable options for successful ,Heat (physical force),Decontamination,2,X,[npop],[topp],,N06.850.780.325
b19dd576-4e31-4fe3-a5d4-5e7fdc735933,COVID-19,C1160716,owing to nature ,COVID-19,viral transmission,1,X,[virs],[celf],C000657245,
931a1102-00c7-41ef-8b51-9e2c138f5162,COVID-19,C0458578,owing to nature possible airborne transmission ,COVID-19,Upper respiratory tract,2,X,[virs],[bpoc],C000657245,
81e2455c-f7b2-481b-889b-ef9f4c90ed8a,C1160716,C0458578,is in ,viral transmission,Upper respiratory tract,2,X,[celf],[bpoc],,
76ad1b2c-fe00-43ed-8da0-9c368ad4c23f,C0032105,C0017082,resembled that of monosialodihexosyl ,Plasma,Gangliosides,1,X,[bdsu],[orch/phsu],A12.207.152.693;A12.207.270.695;A15.145.693,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
c06e8cab-6225-49bc-9997-a54703113ca7,C0032105,C0037906,resembled that of monosialodihexosyl ,Plasma,Sphingomyelins,1,X,[bdsu],[bacs/orch],A12.207.152.693;A12.207.270.695;A15.145.693,D09.400.410.420.525.870;D10.390.470.675.870;D10.570.755.893;D10.570.877.360.612.870
5ea96628-3f80-4060-ad30-e1df349c8306,C0017082,C0037906,is with enhanced levels of ,Gangliosides,Sphingomyelins,1,X,[orch/phsu],[bacs/orch],D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475,D09.400.410.420.525.870;D10.390.470.675.870;D10.570.755.893;D10.570.877.360.612.870
4e73acfd-0d8e-41fd-a568-6f97e7711a52,C2350332,COVID-19,should ,Exosomes,COVID-19,4,X,[celc],[virs],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,C000657245
b1cdcf36-467b-44f6-8013-8b41ae1d0623,C2350332,C0030660,may partake in ,Exosomes,Pathologic Processes,1,X,[celc],[patf],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,C23.550
d07e6720-4048-4954-8bcf-87721bf02027,C2350332,C0699748,may partake in ,Exosomes,Pathogenesis,1,X,[celc],[patf],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
cd2d6854-2536-45bd-9976-016cf9499ef7,C2350332,C0032105,presents ,Exosomes,Plasma,1,X,[celc],[bdsu],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A12.207.152.693;A12.207.270.695;A15.145.693
c116b3b2-9ffd-42db-bdfa-bada2331cc45,C1175743,C1550100,is in matched ,SARS coronavirus,Specimen Type - Serum,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
d673cba5-987b-4dec-b9ee-cb3ca5a9adbb,C1175743,C0521839,is in matched ,SARS coronavirus,Influenza-like illness,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
b98329be-f079-46b9-8691-2c9a86f09f39,C1175743,C0033727,is with interval of at least ,SARS coronavirus,Protons,2,X,[virs],[elii],B04.820.504.540.150.113.937,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
73c92ab6-e1c3-45c3-afd8-a1eb4f32ee21,C0319924,C1265415,is ,Aspergillus versicolor,Endophytes,1,X,[fngs],[fngs],,B05.237
a1687451-bb1b-455e-994d-521c1dd60961,CMS,C0013227,suspend utilization review requirements related to ,CMS,Pharmaceutical Preparations,4,X,????,[phsu],????,D26
e631fa63-f59a-477c-880c-6f3cb34757d9,CMS,C1999230,suspend utilization review requirements related to ,CMS,Providing (action),4,X,????,[acty],????,
41732699-ad8b-479b-a5dd-c53270c70f28,C2948600,C0080078,quantify effect of ,Aim,Range of Motion Articular,3,X,[inch/phsu],[clna],,E01.370.600.700;G11.427.760
01edec70-0e65-4c5a-b067-40bf13113ff5,C0079189,C0021753, includes ,cytokine,Interleukin-1 beta,7,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600
45c5bb74-d490-40ad-bf0b-2ec0ba0dfeb7,C1721019,C0021753,can determine release of pro ,Virus Attachment,Interleukin-1 beta,2,X,[biof],[aapp/imft],G06.920.868,D12.644.276.374.465.010.600;D12.644.276.374.500.400.600;D12.776.467.374.465.010.600;D12.776.467.374.500.400.600;D23.529.374.465.131.600;D23.529.374.500.400.600
ea1fd8c3-3f65-471a-a970-4a2030d892b1,C1721019,C1879547,can determine release with successive ,Virus Attachment,Activation action,5,X,[biof],[acty],G06.920.868,
f4a88393-4b1f-42d4-82ae-096a20896957,C1721019,C0032285,can determine release with successive ,Virus Attachment,Pneumonia,5,X,[biof],[dsyn],G06.920.868,C08.381.677;C08.730.610
23b36228-0520-4311-8518-3240c4ca5104,C1175175,C0206750,was common during ,Severe Acute Respiratory Syndrome,Coronavirus Infections,13,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C02.782.600.550.200
01c774b4-605b-475f-89f6-c3f43d0efb15,CoV-2,C0206750,due to illness is ,CoV-2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
b5fc4e16-fcf1-4e73-a751-88eb7940947a,C0003451,C0178784,limiting viral-induced ,Antiviral Agents,Organ,1,X,[phsu],[bpoc],D27.505.954.122.388,
bbf2fe72-9db0-4fd4-b9ce-7b6e9de5da79,C0206750,C0235031,exhibit ,Coronavirus Infections,Neurologic Symptoms,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597;C23.888.592
bbf2fe72-9db0-4fd4-b9ce-7b6e9de5da79,C0206750,C0235031,patients with ,Coronavirus Infections,Neurologic Symptoms,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597;C23.888.592
98f681ec-92e7-432c-9442-4950b2ae28e2,C0037090,C0206750,is in critical ,Signs and Symptoms Respiratory,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200
98f681ec-92e7-432c-9442-4950b2ae28e2,C0037090,C0206750,are typically found during ,Signs and Symptoms Respiratory,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200
97007d4a-ca4b-480c-b136-973734fbe4fd,C0206750,C1145670,is with ,Coronavirus Infections,Respiratory Failure,4,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618.846
d657c425-cb52-404a-aaf4-bb3ad3c6a80a,C1706202,C1273412,evaluate efficacy of ,Search - action,Chinese herbal medicine,2,X,[acty],[topp],,
baa83bdb-2e8d-46b0-b655-be92f9de82cb,C1706202,C0206750,yielded potential ,Search - action,Coronavirus Infections,12,X,[acty],[dsyn],,C02.782.600.550.200
6c5e2082-1ed6-4af3-8e79-40ad200844db,C1273412,C0206750,could could used as potential candidates for ,Chinese herbal medicine,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
33d6b211-5ec8-4bba-b2eb-e5227ace3e47,C0206750,C3873497,is ,Coronavirus Infections,Severe acute respiratory infection,1,X,[dsyn],[dsyn],C02.782.600.550.200,
a3ad602d-b704-4bb3-b9ce-13963261b8dd,C0204027,C0032285,minimise ,Short wave diathermy,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
157e9e3a-c814-4c20-96ca-dd93026002ce,C0204027,C0012634,shorten Duration to positive-to-negative conversion of,Short wave diathermy,Disease,2,X,[topp],[dsyn],,C23.550.288
71678de5-d653-4062-a6da-36209fc36607,C0204027,C0028606,shorten Duration to positive-to-negative conversion of,Short wave diathermy,Nucleic Acids,2,X,[topp],[bacs/nnon],,D13.444
d0a87ba3-3325-4887-9119-1064faeffba6,C0204027,C2926735,shorten ,Short wave diathermy,Duration,2,X,[topp],[orch/phsu],,
01467979-6336-41dc-ba07-1cc0b9ce8439,C0450254,C0041296, includes ,Pathogenic organism,Tuberculosis,2,X,[orgm],[dsyn],,C01.252.410.040.552.846
80d53325-64da-46fe-adac-00eadab4422e,C0036974,C0005779,have ,Shock,Blood Coagulation Disorders,2,X,[patf],[dsyn],C23.550.835,C15.378.100
89ea61bb-db9b-44f5-a78b-53e24ae7264d,C0028606,C1457887,Recovery - action from,Nucleic Acids,Symptoms,1,X,[bacs/nnon],[sosy],D13.444,
6ca6ae74-4b58-4d56-a191-4a4f8c548d83,C0871208,C1457887,Recovery - action from,Rating (action),Symptoms,1,X,[acty],[sosy],,
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,continues As of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,were registered As of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,has spread worldwide over 80 000 deaths reported by end of ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,has caused IMPACT gene after especially declaration of state of,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,will will enrolled in trial from 6th 31st ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
7dd64203-2877-4a97-b7aa-6e9871f4931f,C0206750,C1706374,occurred as of 30 ,Coronavirus Infections,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
aa0c4dbb-0608-46c1-b32a-f13e56bddd31,C3714514,C1416797,is With longer ,Infection,STMN1 gene,1,X,[patf],[gngm],C01.539,
33f4ceb8-8aec-44eb-9a94-079683c31d60,C1706701,C1035167,Search - action After registration on,Acquisition (action),Prospero,2,X,[acty],[plnt],,
0c1e2de8-52ea-4de3-bf62-246403df70ef,C0004933,C0042024,is in ,Behavior Therapy,Urinary Incontinence,2,X,[topp],[patf],F04.754.137,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
adca83a6-dab2-4546-ab2b-531baf5c6eae,C0932441,C0042024,is in ,Muscle of pelvic diaphragm,Urinary Incontinence,2,X,[bpoc],[patf],,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
86c58c1b-b7ef-4a2b-8ecc-e61023bc668c,C1707391,C0042024,is with PCa ,Choose (action),Urinary Incontinence,2,X,[acty],[patf],,C12.777.934.852;C13.351.968.934.814;C23.888.942.343.800
a5f0ebbd-fcd9-45bb-a9a5-6e71fb1e558e,C1707391,C0877015,is with PCa ,Choose (action),Pelvic Organ Prolapse,2,X,[acty],[dsyn],,C23.300.842.624
cd98195d-d4e1-4f47-9620-02f19eac8d6d,C1707391,C0042018,is with PCa ,Choose (action),Urinary Calculi,2,X,[acty],[bdsu],,C12.777.967.500;C13.351.968.967.500;C23.300.175.850
240faebd-ea7d-4045-805a-59f605936f7a,C1707391,C0042029,is with PCa ,Choose (action),Urinary tract infection,2,X,[acty],[dsyn],,C01.539.895;C12.777.892;C13.351.968.892
77d2e58d-ef75-4602-8033-1f6b88d85bee,C0042075,C0376358, includes ,Urologic Diseases,Malignant neoplasm of prostate,4,X,[dsyn],[neop],C12.777;C13.351.968,
7cf8ea5a-7c8d-45fa-8c71-5a03fad82467,C1707391,C0042075,is with several common clinical ,Choose (action),Urologic Diseases,2,X,[acty],[dsyn],,C12.777;C13.351.968
fc0ca1fb-f81d-4408-a3a8-cbf43c071ce6,C1707391,C0376358,is with several common clinical ,Choose (action),Malignant neoplasm of prostate,2,X,[acty],[neop],,
1d7010ca-94ab-45c5-9972-1571dd7c72d6,C0605411,C0010200,is with ,austin,Coughing,2,X,[orch],[sosy],x.x.x.x,C08.618.248;C23.888.852.293
a369d15c-c4c8-4a2d-9aba-c95993bbb8bd,UTHA,C1856053,conducted contact during ,UTHA,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
59058e2a-504b-4604-91b2-3ba73f5de319,C1175743,U.S.,is in outpatient settings at U.S. ,SARS coronavirus,U.S.,2,X,[virs],????,B04.820.504.540.150.113.937,????
d2a8499d-795b-4dc6-8924-dd80cb26512a,C0008679,C2348077,experienced on ,Chronic disease,Date Fruit,2,X,[dsyn],[food],C23.550.291.500,B01.650.940.800.575.912.250.093.615
35575e2f-cf36-4cb6-b219-22e89ddc11b7,C0163275,C0018939,were In ,Fibrin split products,Hematological Disease,2,X,[aapp/bacs],[dsyn],D12.776.124.270.300;D12.776.811.300.290,C15.378
1c9dcf0c-1a60-4a94-a6f8-5bfbeebe17a1,C1175175,C0040132,can affect ,Severe Acute Respiratory Syndrome,Thyroid Gland,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A06.300.900
187d3426-0545-4609-ba97-0a6aec95cc47,C1175175,C0030518,can affect ,Severe Acute Respiratory Syndrome,Parathyroid gland,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A06.300.560
ca7e3eaf-00b3-4fe4-9134-db036daa3196,C1175175,C0016017,can affect ,Severe Acute Respiratory Syndrome,Fibrinolysis,1,X,[dsyn],[phsf],C02.782.600.550.200.750;C08.730.730,G09.188.390.150.390
d0af1bf0-3f33-4be4-b6b9-93b9103537c9,C1175175,C0596204,can affect ,Severe Acute Respiratory Syndrome,bone metabolism,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,
6c2590d5-6921-4a12-b536-0bf6414e2d6e,C1175175,C0023884,can affect ,Severe Acute Respiratory Syndrome,Liver,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A03.620
c91e7506-de8d-41ac-afaf-9276cd436b75,C1175175,C0017420,can affect ,Severe Acute Respiratory Syndrome,Genitalia,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A05.360
f6862940-8e38-4a86-9b34-51d47bfe9cd4,C1175175,C0019116,can affect ,Severe Acute Respiratory Syndrome,Hemostatic function,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390
f6862940-8e38-4a86-9b34-51d47bfe9cd4,C1175175,C0019116,triggers ,Severe Acute Respiratory Syndrome,Hemostatic function,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390
c6285945-a13d-46b1-94a1-e85fa51789e6,C1175175,C0005778,can affect ,Severe Acute Respiratory Syndrome,Blood coagulation,1,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,G09.188.390.150
f240589d-6e80-4de2-9f74-c5d5bba0e773,C0032285,C0035222,may rapidly progress to ,Pneumonia,Respiratory Distress Syndrome Adult,7,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C08.381.840;C08.618.840
fae3f8fe-8a1f-49e9-b416-c13d93e512ac,C0071216,C0040861,could serve as quick ,Urokinase Plasminogen Activator Receptor,Triage,6,X,[aapp/imft/rcpt],[topp],D12.776.395.550.448.813;D12.776.543.484.500.813;D12.776.543.550.418.813;D12.776.543.750.815,N02.421.297.900
e08bfa21-856f-4ad8-96d8-ec3052e873c1,C0206750,ICMR,maintained by ICMR,Coronavirus Infections,ICMR,2,X,[dsyn],????,C02.782.600.550.200,????
8c37620f-178b-4c76-951e-fb6bbd6ae14e,C0023895,ICMR,maintained by ICMR,Liver diseases,ICMR,2,X,[dsyn],????,C06.552,????
e00dbf6c-00a8-40fd-9187-d761d6b658a2,C0678790,C4554533,existed between frequency of exposure for ,dose-response relationship,Trend:Type:Point in time:^Patient:Nominal,2,X,[biof],[clna],,
3c6e8ae4-80d8-4a93-9c54-f30b7ba17680,C0021966,C0871208,predict range of contact ,Iodides,Rating (action),1,X,[inch],[acty],D01.248.497.158.490;D01.475.410,
311e6d04-e699-4659-b1eb-1b23d67b2899,C0021966,C0012634,predict number of ,Iodides,Disease,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C23.550.288
849c7cd8-6212-49cc-a969-ff766e079545,C2986522,C0376358,is ,Laparoscopic Prostatectomy,Malignant neoplasm of prostate,9,X,[topp],[neop],,
5d9161e6-66ae-4d5a-a3c7-b4ee5e8b7fa6,C1175743,C1145670,may cause severe ,SARS coronavirus,Respiratory Failure,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.618.846
439e6ba7-d6fe-4f07-93a4-7de6bae8e440,C1175743,C0999626,is related to ,SARS coronavirus,Manidae,1,X,[virs],[mamm],B04.820.504.540.150.113.937,
7594c969-7cfb-4d39-896d-44797bceba36,C1622204,C1512488,is with ,envelope,Homologous Protein,1,X,[celc],[aapp],,
087cdcfd-6883-47f2-8ca1-bc115bce46f1,C1142652,C1512488,is with ,NR4A2 protein human,Homologous Protein,1,X,[aapp/bacs],[aapp],x.x.x.x,
29ff9202-531b-4b57-9b14-8c9d00503f04,C1707455,C1175743,timing in relation to timing of ,Comparison,SARS coronavirus,7,X,[acty],[virs],,B04.820.504.540.150.113.937
49224561-36d3-432f-80f0-a90101cae575,C0630906,COVID-19,was in ,vinyltriethoxysilane,COVID-19,4,X,[orch],[virs],x.x.x.x,C000657245
feb0f9cf-4fc9-4582-b368-27cce8d8e783,C0630906,C0032285,overall rate of was ,vinyltriethoxysilane,Pneumonia,1,X,[orch],[dsyn],x.x.x.x,C08.381.677;C08.730.610
feb0f9cf-4fc9-4582-b368-27cce8d8e783,C0630906,C0032285,incidence of was ,vinyltriethoxysilane,Pneumonia,1,X,[orch],[dsyn],x.x.x.x,C08.381.677;C08.730.610
2221b94a-d713-4849-a32e-a1cacb3b21d6,COVID-19,C0398623,was associated with ,COVID-19,Thrombophilia,1,X,[virs],[dsyn],C000657245,C15.378.925
71e81315-e072-4ac1-a12d-924a75c67838,C0032285,C0398623,was associated with ,Pneumonia,Thrombophilia,1,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C15.378.925
002169b0-1ee7-4ec6-8fba-93d546280b8a,remdesivir,C0441655,is broad spectrum antiviral with in ,remdesivir,Activities,2,X,[clnd],[acty],,
002169b0-1ee7-4ec6-8fba-93d546280b8a,remdesivir,C0441655,demonstrated potent ,remdesivir,Activities,1,X,[clnd],[acty],,
c9bdb7e5-c5df-42d8-bfa5-6bf98df8398c,C0026766,COVID-19,are spectrum of ,Multiple Organ Failure,COVID-19,2,X,[patf],[virs],C23.550.835.525,C000657245
52ca043d-3480-4cdf-8130-298a6cd5c838,C0032285,COVID-19,is in ,Pneumonia,COVID-19,4,X,[dsyn],[virs],C08.381.677;C08.730.610,C000657245
f6e62789-00ea-4177-bef8-db2ec6dfb4a9,C0850149,COVID-19,had ,Dry cough,COVID-19,1,X,[sosy],[virs],,C000657245
b579d01f-1f50-4145-af2f-292498c091cd,C1254373,C1175743,is ,etiologic agent,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
bdd3c8e7-f817-44a7-b4d1-f356fca8e998,C0301872,C0242656,are implicated in ,Immune response,Disease Progression,4,X,[ortf],[patf],,C23.550.291.656
bdd3c8e7-f817-44a7-b4d1-f356fca8e998,C0301872,C0242656,prevent its ,Immune response,Disease Progression,1,X,[ortf],[patf],,C23.550.291.656
bdd3c8e7-f817-44a7-b4d1-f356fca8e998,C0301872,C0242656,contribute to ,Immune response,Disease Progression,2,X,[ortf],[patf],,C23.550.291.656
489025ef-4416-4bf2-b0ba-e66a9179d70c,C1301856,C1155266,center on loss of regulation between protective ,All critical points,inflammatory response,4,X,[clna],[patf],,
ac8ed473-1c51-4171-86d9-33021da4b021,C0960880,C0024109,is in ,angiotensin converting enzyme 2,Lung,1,X,[aapp/enzy],[bpoc],x.x.x.x,A04.411
2450a885-80bf-4bda-a592-4b3a4f44bd4b,C1413931,C1422064,may stimulate ,ACE gene,ACE2 gene,1,X,[gngm],[gngm],,
0d8c9c04-f768-4967-9c89-0f8486181f73,C0815017,C1422064,may stimulate ,Angiotensin Receptor Antagonists,ACE2 gene,1,X,[phsu],[gngm],D27.505.519.162,
19129ab2-39b7-4b5c-81d9-63912a9ae901,C0021440,C1422064,increase numbers of ,Intravenous infusion procedures,ACE2 gene,1,X,[topp],[gngm],E02.319.267.082.500;E02.319.267.510.590,
2625bad0-b32f-4ff0-9eba-a0266f7d66d6,C0021440,C0597357,increase numbers of ,Intravenous infusion procedures,receptor,1,X,[topp],[aapp/rcpt],E02.319.267.082.500;E02.319.267.510.590,
e9619e7a-f64e-4fad-9fd4-d669dec3ea51,C0021440,C0003064,is in ,Intravenous infusion procedures,Animals Laboratory,1,X,[topp],[anim],E02.319.267.082.500;E02.319.267.510.590,B01.050.050.199
80bc14b5-9f9b-41cd-898f-767c28ab097d,COVID-19,C0242656,is with spectrum ,COVID-19,Disease Progression,1,X,[virs],[patf],C000657245,C23.550.291.656
b47994b7-a022-4f7d-a239-a4b5dac43532,COVID-19,C0748168,is with spectrum ,COVID-19,Pulmonary Pathology,1,X,[virs],[dsyn],C000657245,
01ebd82c-5677-45c8-89bb-f249e5d457b6,C0035736,C0042760,is encountered with ,RNA Viral,Virion,2,X,[nnon],[celc],D13.444.735.828,A21.249;B04.950
0f149e6e-93c0-4e65-b746-5e1bf9647101,C0035736,C0225336,is encountered with ,RNA Viral,Endothelial Cells,2,X,[nnon],[cell],D13.444.735.828,A11.436.275
68ce9c54-0a5a-4d5b-9b96-d2a4424f972f,C0035736,C0024109,was ,RNA Viral,Lung,3,X,[nnon],[bpoc],D13.444.735.828,A04.411
70d7d4a2-869c-45db-be2a-a788675cc2ac,C0042760,C0225336,is in ,Virion,Endothelial Cells,1,X,[celc],[cell],A21.249;B04.950,A11.436.275
bf8e736b-0a83-475c-93b0-128232d69dc7,C0026766,C0151763,is with severe ,Multiple Organ Failure,Liver damage,1,X,[patf],[patf],C23.550.835.525,
d59bebf4-dd30-4ded-970c-782f58a1ba7c,C0026766,C0079189,is in finally possibly as consequence of early-onset pro-inflammatory ,Multiple Organ Failure,cytokine,1,X,[patf],[aapp/imft],C23.550.835.525,D12.644.276.374;D12.776.467.374;D23.529.374
d59bebf4-dd30-4ded-970c-782f58a1ba7c,C0026766,C0079189,also known as ,Multiple Organ Failure,cytokine,1,X,[patf],[aapp/imft],C23.550.835.525,D12.644.276.374;D12.776.467.374;D23.529.374
c00ca62c-22c5-4f4e-9c3b-ca41cf5e139b,C1175743,C0023693,can speculate its stability in ,SARS coronavirus,Light,2,X,[virs],[npop],B04.820.504.540.150.113.937,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
f3f36766-0f08-42cf-9118-1b9c367dd75a,C0599705,COVID-19,observed as ,perfusion (blood),COVID-19,1,X,[ortf],[virs],,C000657245
09a481f3-a374-42e5-9fe0-f3dcb3b344ef,C0027746,COVID-19,observed as ,Nerve Degeneration,COVID-19,1,X,[comd],[virs],C23.550.737,C000657245
be9eef28-3f20-4cbc-805a-8857a0e3b0fa,C0021368,C0544688,observed as long-term ,Inflammation,complication of disease,5,X,[patf],[patf],C23.550.470,
570c0bb5-1bae-42ee-bf8a-414bd7b45df4,C0599705,C0544688,observed as long-term ,perfusion (blood),complication of disease,5,X,[ortf],[patf],,
61a496e2-0124-45ff-8626-685cdef9bfbd,C0027746,C0544688,observed as long-term ,Nerve Degeneration,complication of disease,5,X,[comd],[patf],C23.550.737,
73d12f55-031d-4175-a77c-1f4ddb835000,C1171208,C1999230,for Older adult care is current article,Older adult care,Providing (action),4,X,[topp],[acty],,
75a7ce22-92de-436e-a265-1c91d085a086,C0020452,COVID-19,were reported in ,Hyperemia,COVID-19,1,X,[dsyn],[virs],C14.907.474,C000657245
1d348570-cc31-4fd0-ae0f-98e69862dacb,C0264545,COVID-19,were reported in ,Thickening of pleura,COVID-19,1,X,[dsyn],[virs],,C000657245
1d348570-cc31-4fd0-ae0f-98e69862dacb,C0264545,COVID-19,were common in ,Thickening of pleura,COVID-19,1,X,[dsyn],[virs],,C000657245
d59424fa-006b-4c26-9b0c-e23b5516966d,C0025062,C0021403,were In contrast reported only in studies on ,Mediastinal Emphysema,Influenza virus vaccine,5,X,[dsyn],[imft/phsu],C08.846.187.290;C23.550.325.250,D20.215.894.899.302
6cd04806-df3c-4f31-b514-4013097684bb,C0022709,Cov2,are associated with greater risk of Cov2 ,Peptidyl-Dipeptidase A,Cov2,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
268a9f30-8496-4c64-be57-152822dddc85,C0004153,C0086418,Society of ,Atherosclerosis,Homo sapiens,6,X,[dsyn],[humn],C14.907.137.126.307,B01.050.150.900.649.313.988.400.112.400.400
65b4a31b-5500-423c-8dc9-a3536232ce2d,C0009450,COVID-19,is case for ,Communicable Diseases,COVID-19,2,X,[dsyn],[virs],C01.539.221,C000657245
65b4a31b-5500-423c-8dc9-a3536232ce2d,C0009450,COVID-19,are obtaining ,Communicable Diseases,COVID-19,1,X,[dsyn],[virs],C01.539.221,C000657245
65b4a31b-5500-423c-8dc9-a3536232ce2d,C0009450,COVID-19,overall prevalence of ,Communicable Diseases,COVID-19,1,X,[dsyn],[virs],C01.539.221,C000657245
241955ea-cb73-46de-8dd4-e06927aeb7e3,C0206750,C0035243,is novel ,Coronavirus Infections,Respiratory Tract Infections,5,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.739;C08.730
b6286e28-2aba-42a3-8e63-28c430f93be5,C0042776,C0450254,has appeared as new ,Virus,Pathogenic organism,3,X,[virs],[orgm],B04,
68761458-264f-431f-8f59-274d7e74917d,C0020974,C0042776,hold back mysterious ,passive immunization procedure,Virus,3,X,[topp],[virs],E02.095.465.425.400.330;E05.478.550.520,B04
18b63a3b-9129-415f-95c0-857caca2ab12,C0020974,20th,has in has use since early 20th ,passive immunization procedure,20th,3,X,[topp],????,E02.095.465.425.400.330;E05.478.550.520,????
68394c28-35d9-424a-a1f3-9fa72adaf3c1,C0027651,C0029355,be how ,Neoplasms,Orthopedics,2,X,[neop],[bmod],C04,H02.403.810.494
427a8ed3-70ac-4700-8a22-f8b4114e4aff,C0042762,C1512717,Division of ,Science of Virology,Infectious Disease Epidemiology,1,X,[bmod],[bmod],H01.158.273.540.859,
0e4d4c8e-d855-4341-b349-c820eb963d9b,C0206750,C0035691,is caused by highly contagious ,Coronavirus Infections,RNA Viruses,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820
0e4d4c8e-d855-4341-b349-c820eb963d9b,C0206750,C0035691,is enveloped ,Coronavirus Infections,RNA Viruses,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820
9c59504d-9a31-4c39-9201-749953a884f8,C0012634,C0035691,is caused by highly contagious ,Disease,RNA Viruses,2,X,[dsyn],[virs],C23.550.288,B04.820
b1bb2305-dd4f-4363-ad4a-cec9e01eb519,C1272248,C0206750,is unnecessary for ,Retinal screening,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
7546befc-f02a-453b-aedc-e73cf262f53b,C1175743,C0370003,causes COVID-19 in ,SARS coronavirus,Specimen,1,X,[virs],[sbst],B04.820.504.540.150.113.937,
7546befc-f02a-453b-aedc-e73cf262f53b,C1175743,C0370003,is in simulated patient ,SARS coronavirus,Specimen,3,X,[virs],[sbst],B04.820.504.540.150.113.937,
11a79405-8353-432b-b6b2-1dca868e8b8b,C0032285,C1175743,positive for CoV2,Pneumonia,SARS coronavirus,4,X,[dsyn],[virs],C08.381.677;C08.730.610,B04.820.504.540.150.113.937
4aaa71ff-edcf-4472-85ce-5a800159a91d,C1706374,C0006145,were hospitalized in ,Tumor Necrosis Factor Ligand Superfamily Member 13,Breast Diseases,2,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C17.800.090
07c5bf6d-17e0-4369-af30-79123ea42a0a,C1539372,C0013404,defined Asthma deterioration as onset of,EXOSC10 gene,Dyspnea,1,X,[gngm],[sosy],,C08.618.326;C23.888.852.371
2f0aaba1-a963-404d-b857-1a0d695c7669,C1539372,C0004096,defined severe ,EXOSC10 gene,Asthma,1,X,[gngm],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
7034485b-862f-45df-8fee-eaebe66e4dec,C4053960,C2987634,inhaled beta 2 ,Systemic Corticosteroid Therapy,Agonist,1,X,[topp],[phsu],,
45b9091e-7423-4450-8d0b-c0b65ef0c474,C0040034,C0022917,raised ,Thrombocytopenia,Lactate Dehydrogenase,4,X,[dsyn],[aapp/enzy],C15.378.140.855,D08.811.682.047.551.400;D08.811.682.047.820.493
fbdaf860-fac3-4352-94ca-dba918f7d204,C0028630,C1707455,is in ,Nucleotides,Comparison,3,X,[nnon],[acty],D09.408.620;D13.695,
99dcf19c-214f-4d24-a013-a2d7cb66bcd5,C3494870,C0026882,harbor common ,Viral isolate,Mutation,6,X,[bacs],[genf],,G05.365.590
34042c98-cd83-4cb0-b182-d0295c408bad,C14408,C0028630,be most common ,C14408,Nucleotides,1,X,????,[nnon],????,D09.408.620;D13.695
25eb502e-2a61-4b87-9219-fb8b8dba24f0,C14408,C3494870,be most common ,C14408,Viral isolate,1,X,????,[bacs],????,
ca8e036a-91de-420b-a351-485a3f3448aa,COVID,C1882932,have ,COVID,Representation (action),1,X,????,[acty],????,
f663bdcb-3d50-4363-82af-741e3a2389e2,C0222045,C1882932,have ,Integumentary scale,Representation (action),1,X,[bpoc],[acty],,
9a0e6823-44dd-42d4-9d75-b977162df926,C0206750,C1533724,includes fear coming into contact with ,Coronavirus Infections,Fomes,1,X,[dsyn],[fngs],C02.782.600.550.200,B01.300.179.120.174
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,was correlated with preexisting ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,was correlated with excessive ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,have have described in patients with ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,seems most common manifestation of ,Syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,were repeatedly reported after ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
8f1aab91-d7a6-4db7-80fb-603320e924e2,C0039082,C0206750,epicenter of ,Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.288.500,C02.782.600.550.200
08de1160-cdd4-4cb9-955d-b59943bc1088,C2948600,C1705178,review typical CT findings in ,Aim,Order (action),3,X,[inch/phsu],[acty],,
865f871b-7391-4c53-b5ff-5d5e466fb909,C2948600,C1999230,was to COVID19 ,Aim,Providing (action),4,X,[inch/phsu],[acty],,
3f625d7d-5d4d-4718-94dc-915e7b741b3f,C0206750,C0037285,has associated ,Coronavirus Infections,Skin Manifestations,2,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.885
5340fe10-2557-4c62-b071-d37b5f408101,C0444192,C0370003,are widely accepted as ,Nasopharyngeal swab (specimen),Specimen,2,X,[bdsu],[sbst],,
25563f0c-ea00-41b7-b4a9-571663ba0e16,C0444192,C1511790,are widely accepted as ,Nasopharyngeal swab (specimen),Detection,2,X,[bdsu],[topp],,
4a480696-c391-478b-bc1c-ed94f5319060,C0444192,C1175743,are widely accepted as ,Nasopharyngeal swab (specimen),SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
a4dfe43d-1086-43d0-be4f-ad1e494b4142,C0444192,C0206750,are widely accepted as ,Nasopharyngeal swab (specimen),Coronavirus Infections,2,X,[bdsu],[dsyn],,C02.782.600.550.200
b6b1d249-7d53-46c7-ae54-0d0452081af1,C0444192,C0012634,are widely accepted as ,Nasopharyngeal swab (specimen),Disease,2,X,[bdsu],[dsyn],,C23.550.288
190b7e8f-63f4-4619-873e-b9def0682e58,C0751142,C0015385,is in distal ,Facial Palsy Lower Motor Neuron,Limb structure,3,X,[sosy],[bpoc],C07.465.327;C10.597.622.214;C23.888.592.636.214,A01.378
1f6427df-3be5-4907-866c-907420618249,C0234170,C0015385,is in distal ,General areflexia,Limb structure,3,X,[dsyn],[bpoc],,A01.378
8bf8e87f-0e61-43b4-8c62-e2094c4910f9,C0030946,C0243052,attractive pharmacological target due to its involvement in ,Endopeptidases,Virus Physiological Phenomena,1,X,[aapp/enzy/phsu],[npop],D08.811.277.656.300,G06.920
48adc6b0-cf48-4d32-831c-403e8a57bec7,C1882932,C0243052,attractive pharmacological target due to its involvement in ,Representation (action),Virus Physiological Phenomena,1,X,[acty],[npop],,G06.920
ab7783fc-c144-4a9e-907d-eb1a9ec7a84c,C0444626,C1433062,shows large structural resemblance with ,Crystal Structure,3C-like protease SARS coronavirus,2,X,[chvs],[aapp/enzy],,x.x.x.x
3d265d85-2b4f-4fc1-a0b8-51fbe8802b13,C0020517,C0010654,is located around exactly catalytic site ,Hypersensitivity,Cysteine,1,X,[patf],[aapp/bacs],C20.543,D02.886.030.230;D02.886.489.155;D12.125.154.299;D12.125.166.230
00dd4ae2-6420-4457-86d4-f91ab86af5bf,C0020517,C1167622,coincides with ,Hypersensitivity,Binding (Molecular Function),1,X,[patf],[moft],C20.543,
5823040f-3c7a-419c-966a-3deb55559960,C0020517,C0243077,coincides with ,Hypersensitivity,inhibitors,1,X,[patf],[chvf],C20.543,
12c161cc-41b3-4afe-9c8b-1841bbd00878,C0012634,C1707455,is in India ,Disease,Comparison,4,X,[dsyn],[acty],C23.550.288,
fae32055-4c18-4e12-833d-36cf468e5aed,C4551660,intra,heavily rely on intra ,Virus Host Interactions,intra,1,X,[npop],????,G06.373;G16.527,????
4eeb303d-3090-43e1-97ac-a48961fabd60,C4551660,C1167395,heavily rely on intra ,Virus Host Interactions,Host (organism),1,X,[npop],[orgm],G06.373;G16.527,
e8781bf6-f104-4a82-ad00-ca35ed3fa6e7,C4551660,C3826426,heavily rely on intra ,Virus Host Interactions,Dynamics,1,X,[npop],[npop],G06.373;G16.527,
5c50d1cf-7336-43d0-b75b-916410a334e8,C0444241,C1175743,is in clinical ,Genetic sample,SARS coronavirus,2,X,[celc],[virs],,B04.820.504.540.150.113.937
ed4075e4-f9a0-420d-a02d-36959a3fb85a,C0038317,C0206750,worsen outcomes in ,Steroids,Coronavirus Infections,5,X,[orch/phsu],[dsyn],D04.210.500,C02.782.600.550.200
f2534a8d-1d1d-4b9f-9d4f-0d3c4e4d659a,C0206750,HK,importation in HK,Coronavirus Infections,HK,2,X,[dsyn],????,C02.782.600.550.200,????
c9a9c777-a2a4-4559-ab8f-ec15451308e1,C1441506,C0206750,can predict critical outcomes in patients with ,Calculation,Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
84395448-f6e6-497e-99c5-fb3ce1a2910c,C2948600,C1167622,investigate together ,Aim,Binding (Molecular Function),3,X,[inch/phsu],[moft],,
bb1a9f5f-998e-4278-b187-fdec675a2bf4,C2948600,C0682997,investigate together ,Aim,Monoterpenes,3,X,[inch/phsu],[orch],,D02.455.849.575
ee62d8f1-3bff-418d-9047-2ff912de7f5c,C2948600,C0030946,investigate Binding (Molecular Function) together with,Aim,Endopeptidases,2,X,[inch/phsu],[aapp/enzy/phsu],,D08.811.277.656.300
ee62d8f1-3bff-418d-9047-2ff912de7f5c,C2948600,C0030946,investigate Binding (Molecular Function) with cellular,Aim,Endopeptidases,1,X,[inch/phsu],[aapp/enzy/phsu],,D08.811.277.656.300
01ba464d-e4a7-472f-a532-2001a1de2ee2,C0054837,C0567416,was found most effective ,carvone,Molecule,4,X,[orch],[sbst],x.x.x.x,
b25d2bf4-fdae-41c3-9fc4-668322620aa3,LD50,C0034721,is in ,LD50,Rattus,4,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.700
f0baf6d1-9774-4b47-b2b6-1c54a2c6cd85,C0054837,mol/kg,dose of was In addition 1.707 mol/kg,carvone,mol/kg,4,X,[orch],????,x.x.x.x,????
759a35f2-efa6-45c4-9b66-162b5172932f,LD50,mol/kg,was In addition 1.707 mol/kg,LD50,mol/kg,4,X,????,????,????,????
dd27f6d8-0055-4a1c-8d6f-017d53476c93,C1254351,C0872152,is in ,Pharmacologic Substance,Drug Development,4,X,[phsu],[bmod],,E05.290;H01.158.703.007.338;H01.181.466.338
d72d2a5d-60a3-4ac8-914d-57d0050e483c,C0054837,C1254351,be considered as alternative ,carvone,Pharmacologic Substance,4,X,[orch],[phsu],x.x.x.x,
f2cab611-01c7-4db4-8338-fae59e057d19,C0054837,C0872152,be considered as alternative ,carvone,Drug Development,4,X,[orch],[bmod],x.x.x.x,E05.290;H01.158.703.007.338;H01.181.466.338
3fe423cb-84a3-40b9-8485-02319ded6126,C0032310,GGO,Most frequent findings of were predominantly mixed pattern of GGO GGO,Pneumonia Viral,GGO,8,X,[dsyn],????,C02.705;C08.381.677.807;C08.730.610.763,????
c7a71ef4-724e-4c53-8c21-b6b20d0144f5,C0206750,C0032310,involvement with non-COVID ,Coronavirus Infections,Pneumonia Viral,3,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
c7a71ef4-724e-4c53-8c21-b6b20d0144f5,C0206750,C0032310,typically presents as ,Coronavirus Infections,Pneumonia Viral,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
c7a71ef4-724e-4c53-8c21-b6b20d0144f5,C0206750,C0032310,emerged as ,Coronavirus Infections,Pneumonia Viral,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.705;C08.381.677.807;C08.730.610.763
2b201e55-a61d-4e24-a4b4-3e0bee09d0e9,C0206750,C1707455,represents variant by ,Coronavirus Infections,Comparison,8,X,[dsyn],[acty],C02.782.600.550.200,
0096f0ab-a465-4e29-b7a0-92a782f50fb3,C0031090,C0012634,comprises group of ,Periodontal Diseases,Disease,2,X,[dsyn],[dsyn],C07.465.714,C23.550.288
760dbc5b-be17-4f23-94b8-b135375ac4a5,C0221423,C1175743,caused by ,Illness (finding),SARS coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150.113.937
92cafd21-5599-4a90-8a0f-79ed88ddd01b,C0031090,C0206750,is associated with severe ,Periodontal Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C07.465.714,C02.782.600.550.200
5d4dc7f4-870f-4c3c-a9f8-46b1330b6372,C0162633,C0206750,clinical course of consecutive symptomatic ,Viral Shedding,Coronavirus Infections,4,X,[patf],[dsyn],G07.925,C02.782.600.550.200
5d4dc7f4-870f-4c3c-a9f8-46b1330b6372,C0162633,C0206750,may pose threat to ,Viral Shedding,Coronavirus Infections,1,X,[patf],[dsyn],G07.925,C02.782.600.550.200
950ebd69-ca80-4bcf-aadd-b7e34384b31b,C0035668,C0206750,clinical course of consecutive symptomatic ,RNA,Coronavirus Infections,1,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
950ebd69-ca80-4bcf-aadd-b7e34384b31b,C0035668,C0206750,play roles in multiple aspects of ,RNA,Coronavirus Infections,4,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
950ebd69-ca80-4bcf-aadd-b7e34384b31b,C0035668,C0206750,are pervasive throughout ,RNA,Coronavirus Infections,4,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
950ebd69-ca80-4bcf-aadd-b7e34384b31b,C0035668,C0206750,isolated from nasopharyngeal swabs collected from ,RNA,Coronavirus Infections,2,X,[nnon],[dsyn],D13.444.735,C02.782.600.550.200
a41e7f7c-6ed9-40e5-bd6a-6447b0b6b773,C0001617,C0162633,is associated with prolonged ,Adrenal Cortex Hormones,Viral Shedding,6,X,[horm/orch/phsu],[patf],D06.472.040,G07.925
661a50e0-c06c-4d56-b373-7dec05514f1e,C0001617,C0035668,is associated with prolonged ,Adrenal Cortex Hormones,RNA,3,X,[horm/orch/phsu],[nnon],D06.472.040,D13.444.735
d12289a8-b9a6-49c5-b22c-f24e332a433f,C0939237,C0162633,may may associated with prolonged ,lopinavir / Ritonavir,Viral Shedding,6,X,[phsu],[patf],,G07.925
388b67cb-5e26-400c-9330-42db4029f390,C0939237,C0035668,may may associated with prolonged ,lopinavir / Ritonavir,RNA,3,X,[phsu],[nnon],,D13.444.735
cd501d4c-8dd0-4e40-9225-028caddac4dc,C0939237,C1829939,may may associated with prolonged ,lopinavir / Ritonavir,{Non-patient},5,X,[phsu],[clna],,
f7b936b0-4ccf-4011-974b-01cb4ddfe7a2,C0162633,C1829939,is in ,Viral Shedding,{Non-patient},12,X,[patf],[clna],G07.925,
b14d274c-5f06-4873-a2d8-7ed6a255fbac,C0035668,C1829939,is in ,RNA,{Non-patient},6,X,[nnon],[clna],D13.444.735,
97cb24bb-3f82-487f-9d7f-e97902a0baef,C1175743,C0206061,was characterized by ,SARS coronavirus,Pneumonia Interstitial,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.483
9b300e71-033c-4e68-9473-ab5a3c856a06,C0206061,C0597404,is in mainly ,Pneumonia Interstitial,Respiratory viruses,2,X,[dsyn],[virs],C08.381.483,
a2e0d60a-5b5a-4bab-a9a4-429d974e0470,C0024400,C0237820,reinfected during early ,Macaca mulatta,Recovery - action,1,X,[mamm],[acty],B01.050.150.900.649.313.988.400.112.199.120.510.550,
6800cc75-b02b-4c0a-b9ba-aa64044dcf4b,C0024400,C1175743,reinfected during early ,Macaca mulatta,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.510.550,B04.820.504.540.150.113.937
6800cc75-b02b-4c0a-b9ba-aa64044dcf4b,C0024400,C1175743,reinfected with identical ,Macaca mulatta,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.510.550,B04.820.504.540.150.113.937
4b2d1105-bd2d-4b3b-8f77-1250b70f5ba4,C0301872,humoral,Comparing humoral ,Immune response,humoral,1,X,[ortf],????,,????
36d84d34-2f9f-44bc-98d3-b28ab541e02e,C0301872,C0948192,Comparing humoral ,Immune response,primary infection nos,1,X,[ortf],[dsyn],,
81b906b5-bcb2-402a-b14b-ae0158c3456d,C1175743,C0024400,protects in ,SARS coronavirus,Macaca mulatta,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.988.400.112.199.120.510.550
b50688a6-8f4c-470a-bb06-7c3917c561a0,C1175743,C0008679,represents unprecedented ,SARS coronavirus,Chronic disease,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.291.500
29ef4fd9-98b6-4755-9e36-e988e2932bb4,C1175743,C0221423,causes ,SARS coronavirus,Illness (finding),4,X,[virs],[sosy],B04.820.504.540.150.113.937,
29ef4fd9-98b6-4755-9e36-e988e2932bb4,C1175743,C0221423,is novel ,SARS coronavirus,Illness (finding),2,X,[virs],[sosy],B04.820.504.540.150.113.937,
29ef4fd9-98b6-4755-9e36-e988e2932bb4,C1175743,C0221423,is etiological Agent of highly contagious,SARS coronavirus,Illness (finding),1,X,[virs],[sosy],B04.820.504.540.150.113.937,
6179cab4-3c4e-44ba-b9fd-74b5a39e7c3c,C0042776,C0042542,is in ,Virus,Vero Cells,1,X,[virs],[cell],B04,A11.251.210.955;A11.436.955
97c1df3c-4cbb-4da6-99cc-bd1f8765c2d3,C0042776,C0007537,is in ,Virus,Cefaclor,1,X,[virs],[antb/orch],B04,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
ad78850c-628c-4d82-a887-3c376ca424b6,C0003320,C0042776,propagating ,Antigens,Virus,1,X,[imft],[virs],D23.050,B04
9b0c34fd-c011-4fdd-b5e1-45be27c5e41c,C0003320,C0042542,propagating ,Antigens,Vero Cells,2,X,[imft],[cell],D23.050,A11.251.210.955;A11.436.955
321d5ed6-5005-4c36-8d1c-7c52da6ce5e8,C0003320,C0007537,propagating ,Antigens,Cefaclor,2,X,[imft],[antb/orch],D23.050,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
861b08d5-546d-4843-95da-3f73e79b2cf4,C0020852,C1550100,was developed for serological detection of anti ,Immunoglobulin G,Specimen Type - Serum,1,X,[aapp/imft/phsu],[bdsu],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,
9e5a4d95-5e96-4211-b774-50a34ea73c7a,C0020852,C0020517,was found ,Immunoglobulin G,Hypersensitivity,2,X,[aapp/imft/phsu],[patf],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C20.543
2086e4b4-5223-4371-8681-bf3bb9962f91,C1175743,C0086418,uses ,SARS coronavirus,Homo sapiens,21,X,[virs],[humn],B04.820.504.540.150.113.937,B01.050.150.900.649.313.988.400.112.400.400
7f6c2b5d-4149-4ead-a590-cc0dca798ad0,C0034019,C0597404,spread of common ,public health medicine (field),Respiratory viruses,2,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,
11285a05-df89-4020-bb41-83d6d71d7c2b,C0009450,C1856053,was declared pandemic on ,Communicable Diseases,Hydranencephaly with Renal Aplasia-Dysplasia,13,X,[dsyn],[dsyn],C01.539.221,x.x.x.x
11285a05-df89-4020-bb41-83d6d71d7c2b,C0009450,C1856053,was reported in ,Communicable Diseases,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[dsyn],[dsyn],C01.539.221,x.x.x.x
4fd6abf4-373a-49b8-93ba-02fd1fcd8b52,C0037088,C1457887,has has reported cases despite lack of ,Signs and Symptoms,Symptoms,1,X,[sosy],[sosy],C23.888,
4fd6abf4-373a-49b8-93ba-02fd1fcd8b52,C0037088,C1457887,has has cases of infectivity despite lack of ,Signs and Symptoms,Symptoms,1,X,[sosy],[sosy],C23.888,
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,is cause of ,SARS coronavirus,Global Health,3,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,has rapidly become ,SARS coronavirus,Global Health,9,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,is emerging ,SARS coronavirus,Global Health,3,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,is new ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,has led to ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,recently appeared as ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
9e0582a8-4a3e-4ac6-b1b1-8d7c9e9fc1d3,C1175743,C1456573,is evolving rapidly at present with unprecedented ,SARS coronavirus,Global Health,1,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403.371;N01.400.337
39f0cfb9-31ad-46c8-9566-09be3946c84f,C0605290,C1819995,interact enter into ,SAS,Host Cell,2,X,[orch],[celc],x.x.x.x,
d209436a-af33-4e43-998f-22979b889aea,C0605290,C1721019,interact for initial ,SAS,Virus Attachment,2,X,[orch],[biof],x.x.x.x,G06.920.868
b51a7d74-bdf3-41b8-9569-fe27ed5034bf,C0605290,C0023206,interact with ,SAS,Lectin,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.503
5619691e-30c2-4109-889c-608b41eda99c,C0605290,C1415188,interact with ,SAS,GP2 gene,2,X,[orch],[gngm],x.x.x.x,
ebddb6f9-6ea4-492f-a086-ddb5f029b7ec,C0605290,C1175743,interact with ,SAS,SARS coronavirus,1,X,[orch],[virs],x.x.x.x,B04.820.504.540.150.113.937
1e099a7f-8292-4c13-9932-e466180c5b30,C1175743,C1148583,acts as classical ,SARS coronavirus,polysaccharide binding,1,X,[virs],[moft],B04.820.504.540.150.113.937,
ede18bfe-54e1-4145-825b-75b3de041485,C0062154,C1148583,acts as classical ,hemagglutinin esterase,polysaccharide binding,1,X,[aapp],[moft],x.x.x.x,
f3a15fe7-5f28-430b-9571-66f7f1e037e1,C1175743,C0023206,acts as classical ,SARS coronavirus,Lectin,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.503
ebf03acc-386c-4275-9c23-eeb6e220aaa1,C0062154,C0023206,acts as classical ,hemagglutinin esterase,Lectin,1,X,[aapp],[aapp/bacs],x.x.x.x,D12.776.503
878de3ff-aa4a-4a3d-8613-1c2745fdf38d,C0062154,C0214192,is specific for ,hemagglutinin esterase,9-aminocamptothecin,2,X,[aapp],[orch/phsu],x.x.x.x,x.x.x.x
878de3ff-aa4a-4a3d-8613-1c2745fdf38d,C0062154,C0214192,prefers 7 di ,hemagglutinin esterase,9-aminocamptothecin,2,X,[aapp],[orch/phsu],x.x.x.x,x.x.x.x
de465c01-1680-4721-a84f-1308fcae85b2,C0062154,C0605290,is specific for ,hemagglutinin esterase,SAS,1,X,[aapp],[orch],x.x.x.x,x.x.x.x
de465c01-1680-4721-a84f-1308fcae85b2,C0062154,C0605290,prefers 7 di ,hemagglutinin esterase,SAS,1,X,[aapp],[orch],x.x.x.x,x.x.x.x
a1dca2c7-c98b-4b4d-8a54-edb93314b231,C1333471,C0242781,was C/D,Esterase Gene,disease transmission,1,X,[gngm],[patf],,N06.850.310
4784b9fc-edb7-4222-82dd-1354fc7347bd,C0017337,C0242781,was C/D,Genes,disease transmission,1,X,[gngm],[patf],G05.360.340.024.340,N06.850.310
b0398dcf-b6c8-4d7a-823a-4633beab3973,C1333471,C0887912,was C/D,Esterase Gene,Gene Transfer Horizontal,1,X,[gngm],[genf],,G05.728.390
4ebf2c5f-b1ec-44f9-8128-6ed399aec05f,C0017337,C0887912,was C/D,Genes,Gene Transfer Horizontal,1,X,[gngm],[genf],G05.360.340.024.340,G05.728.390
f4a9fa8c-bd89-4686-bee7-a49400420392,C1333471,C0029341,was C/D,Esterase Gene,Orthomyxoviridae,1,X,[gngm],[virs],,B04.820.545
8863be2f-a327-48ef-91e0-4808f2bb9df9,C0017337,C0029341,was C/D,Genes,Orthomyxoviridae,1,X,[gngm],[virs],G05.360.340.024.340,B04.820.545
c93b5650-61fe-4be8-918c-17d53885d5fb,C1333471,C/D,was C/D,Esterase Gene,C/D,1,X,[gngm],????,,????
00adce6b-8bb7-45d5-83b5-85562ccbb79c,C0017337,C/D,was C/D,Genes,C/D,1,X,[gngm],????,G05.360.340.024.340,????
f36febc4-8e1b-4b4e-8ab4-f14f886e6cd9,C0062154,C0242781,takes place by cross-species ,hemagglutinin esterase,disease transmission,1,X,[aapp],[patf],x.x.x.x,N06.850.310
acb198de-c391-4c80-b9ad-d3a89e891d49,C1706701,C0242781,takes place by cross-species ,Acquisition (action),disease transmission,1,X,[acty],[patf],,N06.850.310
bbb20c7f-a527-46aa-9179-439c8feb6c29,C1706701,C0062154,takes place over ,Acquisition (action),hemagglutinin esterase,1,X,[acty],[aapp],,x.x.x.x
e9db41c5-749c-4c33-b5f7-a2254151549b,C0062154,C0015219,takes place over ,hemagglutinin esterase,Biological Evolution,1,X,[aapp],[genf],x.x.x.x,G05.045;G16.075
e9db41c5-749c-4c33-b5f7-a2254151549b,C0062154,C0015219,precedes ,hemagglutinin esterase,Biological Evolution,2,X,[aapp],[genf],x.x.x.x,G05.045;G16.075
8cea1661-4f1a-4620-a200-2b70442d1843,C1706701,C0015219,takes place over ,Acquisition (action),Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
08446198-e3f4-44ee-aab9-cd85783dc478,C0062154,C0042776,precedes ,hemagglutinin esterase,Virus,2,X,[aapp],[virs],x.x.x.x,B04
ea456f10-2b68-4d87-b3ab-9f24a4d0f131,C0597357,C0042776,precedes ,receptor,Virus,2,X,[aapp/rcpt],[virs],,B04
ea456f10-2b68-4d87-b3ab-9f24a4d0f131,C0597357,C0042776,considered ,receptor,Virus,3,X,[aapp/rcpt],[virs],,B04
afae6f34-f136-4cd3-a807-ed3bda044018,C0597357,C0015219,precedes ,receptor,Biological Evolution,2,X,[aapp/rcpt],[genf],,G05.045;G16.075
917987b1-5404-4657-9380-9ac21957c0ac,C0062154,C0067762,precedes ,hemagglutinin esterase,N-Acetylneuraminic Acid,2,X,[aapp],[bacs/orch],x.x.x.x,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
6b0e2625-4420-42a1-9953-eb7f4e2636f0,C0597357,C0067762,precedes ,receptor,N-Acetylneuraminic Acid,2,X,[aapp/rcpt],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
7fbcdb78-bc24-4517-9246-700252baa4ea,C0062154,C0032594,precedes ,hemagglutinin esterase,Polysaccharides,2,X,[aapp],[orch/phsu],x.x.x.x,D09.698
52f21cc8-ca07-4edd-ba47-f81b129ff642,C0597357,C0032594,precedes ,receptor,Polysaccharides,2,X,[aapp/rcpt],[orch/phsu],,D09.698
8e74d4e7-6773-447f-a5c7-8bb61cdbcbf8,C0062154,C1167395,precedes ,hemagglutinin esterase,Host (organism),2,X,[aapp],[orgm],x.x.x.x,
7061848b-28f5-4838-aeef-6fb8029a5b17,C0597357,C1167395,precedes ,receptor,Host (organism),2,X,[aapp/rcpt],[orgm],,
eb88ff8b-d147-4b04-b11c-a1276ff1adf1,C3536948,C0023206,potentiates switch by simple conformational shift of,Stereochemistry (Molecular Function),Lectin,1,X,[moft],[aapp/bacs],,D12.776.503
9c656676-aaa7-433d-8749-c79ae35c1d8c,C1514527,C0023206,potentiates switch by simple conformational shift of,Protein-Carbohydrate Interaction,Lectin,1,X,[moft],[aapp/bacs],,D12.776.503
5dd50017-8a2b-41ff-b54c-1844902009b3,C0023206,C0067762,potentiates ,Lectin,N-Acetylneuraminic Acid,1,X,[aapp/bacs],[bacs/orch],D12.776.503,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
7f72d907-845b-485e-80ec-8b5788b69b08,C3536948,C0067762,potentiates ,Stereochemistry (Molecular Function),N-Acetylneuraminic Acid,1,X,[moft],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
7d7058b1-aaca-4c4e-be92-8097b66511e0,C0023206,C0023688,potentiates ,Lectin,Ligands,1,X,[aapp/bacs],[chem],D12.776.503,D27.720.470.480
0746472d-9c8a-4005-8f50-df263f731229,C3536948,C0023688,potentiates ,Stereochemistry (Molecular Function),Ligands,1,X,[moft],[chem],,D27.720.470.480
739d0cad-b749-4b0a-a4ae-b34df314e576,C1514527,C0067762,potentiates ,Protein-Carbohydrate Interaction,N-Acetylneuraminic Acid,1,X,[moft],[bacs/orch],,D02.241.081.844.562.668.050;D02.241.511.902.562.668.050;D09.067.687.668.030;D09.811.589.668.030
789e757a-118a-46c2-8640-0eab99e06285,C1514527,C0023688,potentiates ,Protein-Carbohydrate Interaction,Ligands,1,X,[moft],[chem],,D27.720.470.480
c4f7024b-788c-4a8d-a45b-212c7c64453e,C4321457,C0042776,Therefore can lead to better understanding of ,Examination,Virus,1,X,[acty],[virs],,B04
e81d3008-ad66-4881-91ac-e974ce0dc920,C4321457,C0015219,Therefore can lead to better understanding of ,Examination,Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
f1d09880-c408-4d21-9656-ae9af0c853c7,C4321457,C4277517,Therefore can lead to better understanding of ,Examination,Host Tropism,1,X,[acty],[phsf],,G06.099.925;G06.920.863
6c6ab649-0ab6-4baf-9a8f-771119b6ec61,C1257646,C0062154,is found in BCoV ,PON1 protein human,hemagglutinin esterase,1,X,[aapp/enzy],[aapp],x.x.x.x,x.x.x.x
9aa140fe-e4dd-4d7f-99b4-4ebed3201f9d,C0062154,di,prefers 7 di ,hemagglutinin esterase,di,1,X,[aapp],????,x.x.x.x,????
2265d640-2655-47cf-8e39-38cef8d23ceb,C2247147,C0214192,is with two different subtypes of typical ,sialic acid binding,9-aminocamptothecin,2,X,[moft],[orch/phsu],,x.x.x.x
f648f29f-0c62-4537-a72f-4c9e1f948dad,C0033684,C4277517,Virus Biological Evolution toward,Proteins,Host Tropism,1,X,[aapp/bacs],[phsf],D12.776,G06.099.925;G06.920.863
5d9a6a10-e5b3-4844-9a32-26351d65853b,C0567416,C4277517,Virus Biological Evolution toward,Molecule,Host Tropism,1,X,[sbst],[phsf],,G06.099.925;G06.920.863
f2c39e8f-d3a2-4b38-be87-dffb4a7ab546,C0033684,C0015219,Virus,Proteins,Biological Evolution,1,X,[aapp/bacs],[genf],D12.776,G05.045;G16.075
d50fd1da-c999-4f92-9491-5bda83d2189b,C0567416,C0015219,Virus,Molecule,Biological Evolution,1,X,[sbst],[genf],,G05.045;G16.075
eebff733-6949-42d1-8ed3-b8e8951c0fb1,C0255558,C0087111,are are currently targeted for ,nonstructural protein coronavirus,Therapeutic procedure,1,X,[aapp],[topp],x.x.x.x,E02
efb31052-8244-46f5-ab95-1047d7756a7a,C0206750,C0028606,cases of ,Coronavirus Infections,Nucleic Acids,6,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D13.444
efb31052-8244-46f5-ab95-1047d7756a7a,C0206750,C0028606,is with negative ,Coronavirus Infections,Nucleic Acids,1,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D13.444
eee65daa-16d8-461f-8d31-ceb9cdec0d56,C0206750,C1316572,false negative cases of are worth ,Coronavirus Infections,Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider},2,X,[dsyn],[clna],C02.782.600.550.200,
730e12e6-b77d-4f03-a9cf-842c8cce553f,C0815172,C0206750,is with confirmed ,patient characteristics,Coronavirus Infections,17,X,[clna],[dsyn],,C02.782.600.550.200
7cd60813-58c6-469f-8949-2458f4b1348b,C0815172,C0012634,is with confirmed ,patient characteristics,Disease,15,X,[clna],[dsyn],,C23.550.288
de4f938b-137b-4023-a210-62854aa97de1,C0162595,C0005779,contribute to ,Antiphospholipid Antibodies,Blood Coagulation Disorders,1,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,C15.378.100
68dac66e-10b2-4091-a81e-0d6d522e2931,C0017968,C2825347,was most common aPL present in critically ill patients followed by ,Glycoproteins,Immunoglobulin A Human,1,X,[aapp/bacs],[imft/phsu],D09.400.430;D12.776.395,
68dac66e-10b2-4091-a81e-0d6d522e2931,C0017968,C2825347,was For multiple aPLs type followed by ,Glycoproteins,Immunoglobulin A Human,1,X,[aapp/bacs],[imft/phsu],D09.400.430;D12.776.395,
510949a2-749e-48db-bf0e-c73006ad6d3f,C2825347,C0017968,was For multiple aPLs type followed by ,Immunoglobulin A Human,Glycoproteins,1,X,[imft/phsu],[aapp/bacs],,D09.400.430;D12.776.395
16ed74e8-359c-484d-9d8f-cf15b57e6b27,C0206750,C0008073,may trigger ,Coronavirus Infections,Developmental Disabilities,1,X,[dsyn],[mobd],C02.782.600.550.200,F03.625.421
873a7442-ffef-4f4a-bf9f-3f19e57a8142,C0206750,C0001468,may trigger ,Coronavirus Infections,Adenosine Phosphosulfate,1,X,[dsyn],[bacs/nnon],C02.782.600.550.200,D03.633.100.759.646.138.180.080;D13.695.667.138.180.080;D13.695.827.068.180.080
46b0e5f1-890a-4e54-bb57-1ffb7b682196,C0206750,C0039082,may trigger ,Coronavirus Infections,Syndrome,7,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.288.500
1528c84a-79d1-41f6-b9ec-b04665f12905,C0206750,C0042077,is in also ,Coronavirus Infections,Urology,4,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.860
1528c84a-79d1-41f6-b9ec-b04665f12905,C0206750,C0042077,published by American Confederation ,Coronavirus Infections,Urology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.860
7822db51-4d1e-4d0e-9145-b4ff0b3ec72e,C1175743,C1819995,enters ,SARS coronavirus,Host Cell,5,X,[virs],[celc],B04.820.504.540.150.113.937,
7822db51-4d1e-4d0e-9145-b4ff0b3ec72e,C1175743,C1819995,infects ,SARS coronavirus,Host Cell,3,X,[virs],[celc],B04.820.504.540.150.113.937,
7822db51-4d1e-4d0e-9145-b4ff0b3ec72e,C1175743,C1819995,Viral Components of,SARS coronavirus,Host Cell,2,X,[virs],[celc],B04.820.504.540.150.113.937,
7024ae82-2f97-4e9d-b191-fadf6026297f,C0003015,C0870392,role of is ,Angiotensin-Converting Enzyme Inhibitors,debate,1,X,[phsu],[acty],D27.505.519.389.745.085,
76dec0e4-e5d0-4872-93d3-3d08a918be45,RAAS,C0206750,be maintained in patients with ,RAAS,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
20eb7830-7d89-4209-a4b1-5b3cf06978bd,C0027950,C1514474,was independent ,neutrophil,Prognostic Factors,2,X,[cell],[clna],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,E01.789
20eb7830-7d89-4209-a4b1-5b3cf06978bd,C0027950,C1514474,were selected as final ,neutrophil,Prognostic Factors,1,X,[cell],[clna],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,E01.789
09e67dcb-451e-4af5-99c1-adfdab541751,C0006938,COVID-19,was applied to ,Captopril,COVID-19,1,X,[aapp/phsu],[virs],D12.125.072.401.623.270,C000657245
abb70796-9d2f-42c3-9e99-fa0ad43b3581,C0006938,C1999230,has potential to ,Captopril,Providing (action),1,X,[aapp/phsu],[acty],D12.125.072.401.623.270,
ebc04223-ca21-4315-997e-cd21b62d85e7,C1825598,C1184743,includes development ,IMPACT gene,bony process,1,X,[gngm],[bpoc],,
8cca80e7-bed4-4695-abb1-3955e3847a2c,C0441516,C0206419,Short-term IMPACT gene of,Demand (clinical),Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
cf966234-dfe8-4b33-a6e9-1bb1ef0e79e5,C0441516,C1420621,shift towards ,Demand (clinical),TCAP gene,1,X,[topp],[gngm],,
ae0f8381-c171-454e-a838-b6083e52a6da,C1879547,C1397014,induces prothrombotic state resulting from ,Activation action,Imbalance,2,X,[acty],[sosy],,
ac16af0c-88fe-4d16-8694-187940c523ce,C1879547,C0005778,induces prothrombotic state resulting from ,Activation action,Blood coagulation,1,X,[acty],[ortf],,G09.188.390.150
ac16af0c-88fe-4d16-8694-187940c523ce,C1879547,C0005778,participate in dysfunctional ,Activation action,Blood coagulation,2,X,[acty],[ortf],,G09.188.390.150
7b2a6a4e-103b-4992-96c8-50ebc0555a70,C0003009,C0567416,is central effector ,angiotensin II,Molecule,2,X,[aapp/bacs/phsu],[sbst],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
0c02ff17-e9cc-4809-bc30-dc27c98f9ab9,C0003009,C1879547,is central effector ,angiotensin II,Activation action,2,X,[aapp/bacs/phsu],[acty],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
b08b517b-de87-4c06-afc3-01e1c2bee995,C0003009,C0022709,is degraded by ,angiotensin II,Peptidyl-Dipeptidase A,2,X,[aapp/bacs/phsu],[aapp/enzy/imft],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D08.811.277.656.350.350.687
7da9e659-c053-4ad3-b8b9-9a104673f1d3,C0003009,C0103306,is degraded by ,angiotensin II,angiotensin I (1-7),2,X,[aapp/bacs/phsu],[aapp/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,x.x.x.x
97f7279f-b8ea-4e8f-b895-366a103014e9,C0206750,C0206419,is in same ,Coronavirus Infections,Genus: Coronavirus,3,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150
e4252f66-0789-4c56-8976-8264ea9012b9,C0206750,C1155266,is characterized by exaggerated ,Coronavirus Infections,inflammatory response,2,X,[dsyn],[patf],C02.782.600.550.200,
e4252f66-0789-4c56-8976-8264ea9012b9,C0206750,C1155266,triggers uncontrolled aberrant ,Coronavirus Infections,inflammatory response,3,X,[dsyn],[patf],C02.782.600.550.200,
e4252f66-0789-4c56-8976-8264ea9012b9,C0206750,C1155266,is associated with severe ,Coronavirus Infections,inflammatory response,1,X,[dsyn],[patf],C02.782.600.550.200,
e4252f66-0789-4c56-8976-8264ea9012b9,C0206750,C1155266,is associated with systemic ,Coronavirus Infections,inflammatory response,1,X,[dsyn],[patf],C02.782.600.550.200,
e4252f66-0789-4c56-8976-8264ea9012b9,C0206750,C1155266,features preeminent ,Coronavirus Infections,inflammatory response,2,X,[dsyn],[patf],C02.782.600.550.200,
5353a22a-c313-40d7-b93e-cf12e228ca9a,C1155266,C0035222,can lead patients to severe ,inflammatory response,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
5353a22a-c313-40d7-b93e-cf12e228ca9a,C1155266,C0035222,due to Respiratory Distress Syndrome Adult is,inflammatory response,Respiratory Distress Syndrome Adult,1,X,[patf],[dsyn],,C08.381.840;C08.618.840
52831b7e-9fe4-46b4-a17d-769943878734,C1155266,C0243026,is in ,inflammatory response,Sepsis,3,X,[patf],[dsyn],,C01.539.757;C23.550.470.790.500
87339b6c-8445-41da-a353-5c63e8fb2740,C0022709,C1879547,resulting in ,Peptidyl-Dipeptidase A,Activation action,2,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
0249f444-459f-4598-917b-866203006ac3,C0597357,C1879547,resulting in ,receptor,Activation action,2,X,[aapp/rcpt],[acty],,
c7084e34-ad23-47f7-92fc-7e6855e8a357,C0042397,C0960880,downregulating ,Vasoconstrictor Agents,angiotensin converting enzyme 2,2,X,[phsu],[aapp/enzy],D27.505.954.411.793,x.x.x.x
5e8923be-9722-427f-95e4-01de97c3e9f3,C0003009,C0960880,downregulating ,angiotensin II,angiotensin converting enzyme 2,2,X,[aapp/bacs/phsu],[aapp/enzy],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,x.x.x.x
484da9d3-7c95-4050-891e-2ae9e6fb9e24,C0003009,C0040018,increases ,angiotensin II,Thrombin,2,X,[aapp/bacs/phsu],[aapp/enzy/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
a4bbdb62-368e-4fb3-b370-33d2625fde85,C0003009,C0220781,increases ,angiotensin II,Anabolism,1,X,[aapp/bacs/phsu],[biof],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,G03
7e80100a-f54a-47fd-af2b-0aa4b7181489,C0003009,C0016017,impairs ,angiotensin II,Fibrinolysis,2,X,[aapp/bacs/phsu],[phsf],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,G09.188.390.150.390
073c9dfc-6c88-4759-befd-621d261b4c72,C0034019,C0042776,prevent spread of ,public health medicine (field),Virus,3,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04
073c9dfc-6c88-4759-befd-621d261b4c72,C0034019,C0042776,has changed target of ,public health medicine (field),Virus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04
35f53ca1-10bc-47dd-9b6a-284acfd069a9,C0034019,C1705178,have have introduced in ,public health medicine (field),Order (action),3,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
72d7e48a-aec8-4cf4-9b4a-a120b47652d0,C0015967,C0031350,was most common ,Fever,Pharyngitis,2,X,[sosy],[dsyn],C23.888.119.344,C07.550.781;C08.730.561;C09.775.649
c9b49d1b-8452-4d31-b25a-60353e10f9c2,C0015620,silico,was recently identified in in silico ,Famotidine,silico,2,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
3aef3172-634f-4881-97e4-8d724ac3962e,C0682972,C0017168,used for treatment ,G-Protein-Coupled Receptors,Gastroesophageal reflux disease,2,X,[aapp/rcpt],[dsyn],D12.776.543.750.695,C06.405.117.119.500.484
2726e420-5da3-4ebd-b9bf-8d5dab8a48df,C0231491,C0017168,used for treatment ,Antagonist muscle action,Gastroesophageal reflux disease,2,X,[ortf],[dsyn],,C06.405.117.119.500.484
ef0acfd4-d8aa-44c6-a81e-a9f3c924a5b4,C0015620,1990s,was described In 1990s,Famotidine,1990s,4,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
43e90680-8d43-4ad6-93a0-58d967975df2,C0015620,C0003451,was In 1990s ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
43e90680-8d43-4ad6-93a0-58d967975df2,C0015620,C0003451,was described as ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
43e90680-8d43-4ad6-93a0-58d967975df2,C0015620,C0003451,likely be achieved in only combination with ,Famotidine,Antiviral Agents,2,X,[orch/phsu],[phsu],D02.886.675.215;D03.383.129.708.215,D27.505.954.122.388
86e0621d-f3d7-4fdc-9491-b88220924062,C0015620,C0019682,was In 1990s ,Famotidine,HIV,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.650.589.650.350
86e0621d-f3d7-4fdc-9491-b88220924062,C0015620,C0019682,was described as ,Famotidine,HIV,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.650.589.650.350
7c165802-d5d7-4835-9ea7-c23a66117b0e,C2756991,C1175743,being Interestingly are presently used against CoV2,HIV Protease Inhibitors [MoA],SARS coronavirus,2,X,[moft],[virs],,B04.820.504.540.150.113.937
4a277230-5352-4a8f-af6c-4a0a2922d7b1,C2756991,CoV2,being Interestingly are presently used against CoV2,HIV Protease Inhibitors [MoA],CoV2,2,X,[moft],????,,????
d1bd503f-c626-49ee-8b69-c4be762f0058,C0003451,C3463820,could could related to ,Antiviral Agents,Inhibition,2,X,[phsu],[acty],D27.505.954.122.388,F01.145.544;F02.463.425.475;F02.739.794.405
046081b6-daa8-4a50-9439-0897a2e8e246,C0003451,C0030946,could could related to ,Antiviral Agents,Endopeptidases,2,X,[phsu],[aapp/enzy/phsu],D27.505.954.122.388,D08.811.277.656.300
92539f34-aaed-4d32-851f-aebf5cb6a595,C0015620,C0007382,interact within CoV2 ,Famotidine,Catalysis,2,X,[orch/phsu],[npop],D02.886.675.215;D03.383.129.708.215,G02.130
a5dcc47e-75ef-4b92-87f0-1ce246bc382d,C0015620,C0030946,interact within CoV2 ,Famotidine,Endopeptidases,2,X,[orch/phsu],[aapp/enzy/phsu],D02.886.675.215;D03.383.129.708.215,D08.811.277.656.300
f8845c1d-2a22-42c0-9433-8d72915d0205,C0015620,C1175743,interact within CoV2 ,Famotidine,SARS coronavirus,2,X,[orch/phsu],[virs],D02.886.675.215;D03.383.129.708.215,B04.820.504.540.150.113.937
7ccb77c3-7c5f-4309-b789-aee487d3dfee,C0015620,CoV2,interact within CoV2 ,Famotidine,CoV2,2,X,[orch/phsu],????,D02.886.675.215;D03.383.129.708.215,????
2b3bc20c-d80b-483b-b7cb-08b9a21024ee,C0015620,C0598312,interact within CoV2 ,Famotidine,DNA Replication,2,X,[orch/phsu],[genf],D02.886.675.215;D03.383.129.708.215,G02.111.225;G05.226
03798d2f-7999-4bf0-b517-8ddc525f13f1,C0599878,C0206419,key Epidemiology of,disease characteristic,Genus: Coronavirus,6,X,[patf],[virs],,B04.820.504.540.150
afac2f05-53e0-4024-83ba-1439c4922382,C0008058,C0041834,is with ,Chilblains,Erythema,7,X,[dsyn],[dsyn],C26.212.500.217;C26.417.217,C17.800.229;C23.888.885.328
58bef3b8-3e70-4877-bf97-3fd88ba4660f,C0032105,C0002055,has On ,Plasma,Alkalies,4,X,[bdsu],[inch],A12.207.152.693;A12.207.270.695;A15.145.693,D01.045
a2d69c62-a5e8-4f24-92af-7cd661193a29,C0032105,C0087111,is potential ,Plasma,Therapeutic procedure,4,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,E02
bdb7b51b-dfcf-429b-9272-8d4256696273,C0032105,C0029345,had had used previously for treatment of ,Plasma,Orthomyxovirus Type A Porcine,4,X,[bdsu],[virs],A12.207.152.693;A12.207.270.695;A15.145.693,B04.820.545.405.400
0f3be29d-be41-4817-bf70-75fc744a0d04,C1999230,C0206419,lead clinical use for treatment of patients with severe ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
0f3be29d-be41-4817-bf70-75fc744a0d04,C1999230,C0206419,realistic scheme for healthcare systems in ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
0f3be29d-be41-4817-bf70-75fc744a0d04,C1999230,C0206419,assist communities caring for people affected by ,Providing (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
82fe2df6-1566-45d3-ad44-e673e5b5c947,C1184743,C1706214,is thought crucial for ,bony process,Creation,3,X,[bpoc],[acty],,
d29683bd-aba2-49a3-ac94-17249aca1e84,C0022709,C0009450,serving as portal ,Peptidyl-Dipeptidase A,Communicable Diseases,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
d29683bd-aba2-49a3-ac94-17249aca1e84,C0022709,C0009450,is downregulated after CoV2 ,Peptidyl-Dipeptidase A,Communicable Diseases,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
d29683bd-aba2-49a3-ac94-17249aca1e84,C0022709,C0009450,enable CoV2,Peptidyl-Dipeptidase A,Communicable Diseases,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C01.539.221
d63bf5c3-1d1f-4877-af38-323f1e6202df,C0040044,C1536220,reasonable option for relatively stable ,Thrombolytic Therapy,ST segment elevation myocardial infarction,1,X,[topp],[dsyn],E02.319.913,C14.280.647.500.875;C14.907.585.500.875
9fc06cf5-8254-4957-84b8-f453e4ead8c1,C0949266,C0087111,have been in absence of ,Therapies Investigational,Therapeutic procedure,1,X,[topp],[topp],E02.931,E02
bd49d4d8-45ac-4bd9-80af-bd41d9f11a1f,C1175743,C1709595,retrospectively tested ,SARS coronavirus,Pooled Sample,2,X,[virs],[sbst],B04.820.504.540.150.113.937,
40c2c758-a5a6-4b3f-87c5-bf8222ad9b4b,C1175743,C0037090,retrospectively tested ,SARS coronavirus,Signs and Symptoms Respiratory,2,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.852
40c2c758-a5a6-4b3f-87c5-bf8222ad9b4b,C1175743,C0037090,rapidly spread worldwide with vast majority of confirmed cases presenting with ,SARS coronavirus,Signs and Symptoms Respiratory,2,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.852
47872a76-f382-4cbf-93b4-963e1e67b219,C0009450,C0010200,is with common presenting symptoms of fever ,Communicable Diseases,Coughing,4,X,[dsyn],[sosy],C01.539.221,C08.618.248;C23.888.852.293
47872a76-f382-4cbf-93b4-963e1e67b219,C0009450,C0010200,mainly presents as ,Communicable Diseases,Coughing,2,X,[dsyn],[sosy],C01.539.221,C08.618.248;C23.888.852.293
617f8cf6-caae-4717-939d-133ad4b67edf,C0009450,C0015672,is with common presenting symptoms of fever ,Communicable Diseases,Fatigue,4,X,[dsyn],[sosy],C01.539.221,C23.888.369
51f10f66-edd0-44ea-af81-a4dbec37f1c5,C0206750,C0015672,is highly Communicable Diseases respiratory Communicable Diseases with common symptoms of fever ,Coronavirus Infections,Fatigue,6,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.369
a4f5a4e4-b1f6-4362-9649-4e261d6b9d7c,C1511790,C0005889,has made biological ,Detection,Body Fluids,1,X,[topp],[bdsu],,A12.207
2df4a736-530a-4036-a02f-b9a238c40b11,C0005889,C0242781,relevant in terms of diagnosis of ,Body Fluids,disease transmission,1,X,[bdsu],[patf],A12.207,N06.850.310
006a15a4-a1ae-4f7d-a2a3-5b739f8fcf6c,C0042776,C0242943,can generate ,Virus,Molecular Mimicry,2,X,[virs],[moft],B04,G02.111.560;G05.545;G16.012.750.500
34f49006-1340-4fd8-bdd8-cd63517de0fd,C0042776,C1167395,can generate Molecular Mimicry phenomena within their,Virus,Host (organism),2,X,[virs],[orgm],B04,
34f49006-1340-4fd8-bdd8-cd63517de0fd,C0042776,C1167395,encounter endosomal/lysosomal ,Virus,Host (organism),1,X,[virs],[orgm],B04,
9ad48a8c-b2b7-4fc2-9496-424ebd8b97c2,C0042776,C0040300,thus eliciting autoimmune phenomena withdevasting consequences in ,Virus,Body tissue,2,X,[virs],[tisu],B04,A10
c8c8a5ad-1773-47a2-aa11-a22b3143e452,C2188405,C0206750,suspected for ,urgent Operation,Coronavirus Infections,6,X,[topp],[dsyn],,C02.782.600.550.200
dfdec539-e99c-47eb-9f07-73347ce58532,C0002085,C0042776,Affinity to S,Alleles,Virus,1,X,[gngm],[virs],G05.360.340.024.340.030,B04
73555df7-8e17-4021-b1b4-c771a2becdd7,C0002085,C0022709,Affinity of,Alleles,Peptidyl-Dipeptidase A,1,X,[gngm],[aapp/enzy/imft],G05.360.340.024.340.030,D08.811.277.656.350.350.687
dc0bb527-fa7c-43dd-89f9-94a432a2cd32,C1155099,C0206750,is in ,cytokine biosynthesis,Coronavirus Infections,1,X,[moft],[dsyn],,C02.782.600.550.200
ea52f744-b3db-4a17-a150-a3a45b3634b0,C0021760,ng/ml,were 55.98 ng/ml ,Interleukin-6,ng/ml,2,X,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,????
5ed58f27-d868-4e93-89bb-ffd19493118f,C0623362,ng/ml,were 55.98 ng/ml ,Matrix Metalloproteinases,ng/ml,2,X,[aapp/enzy],????,D08.811.277.656.300.480.525;D08.811.277.656.675.374.525,????
5cdf4f91-522c-4c4f-b01a-4f7361c07c1f,C2948600,C1825598,identify ,Aim,IMPACT gene,2,X,[inch/phsu],[gngm],,
5cdf4f91-522c-4c4f-b01a-4f7361c07c1f,C2948600,C1825598,investigate ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
5cdf4f91-522c-4c4f-b01a-4f7361c07c1f,C2948600,C1825598,evaluate ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
5cdf4f91-522c-4c4f-b01a-4f7361c07c1f,C2948600,C1825598,model ,Aim,IMPACT gene,1,X,[inch/phsu],[gngm],,
9365c75c-d95a-402b-ae91-6cdbd9c2cf3e,C1825598,C2700061,particularly affecting ,IMPACT gene,Transition (action),2,X,[gngm],[acty],,
4ba24079-f08a-4e81-946c-7471d6ccff8b,C0206750,C0027651,has resulted in unprecedented challenges for ,Coronavirus Infections,Neoplasms,2,X,[dsyn],[neop],C02.782.600.550.200,C04
4ba24079-f08a-4e81-946c-7471d6ccff8b,C0206750,C0027651,is in oral ,Coronavirus Infections,Neoplasms,1,X,[dsyn],[neop],C02.782.600.550.200,C04
115d6e3a-68ea-4994-82e8-a0eb43f75569,C0000936,C1140680,Women with current diagnosis ,Visual Accommodation,Malignant neoplasm of ovary,3,X,[ortf],[neop],G14.010,
4fd09e2f-2842-4590-99de-1be44fc19b8f,C0030858,C0920425,experienced participants scheuled for ,Pentaerythritol Tetranitrate,cancer therapy,3,X,[orch/phsu],[topp],D02.033.455.706.690,
79d4b2f6-e7ae-4076-9e48-a51ec6dba3cc,C0040811,C1175743,is with globally obtained 15 277 ,Trees (plant),SARS coronavirus,4,X,[plnt],[virs],B01.650.915,B04.820.504.540.150.113.937
79d4b2f6-e7ae-4076-9e48-a51ec6dba3cc,C0040811,C1175743,analyze phylogeny of ,Trees (plant),SARS coronavirus,1,X,[plnt],[virs],B01.650.915,B04.820.504.540.150.113.937
20a5d822-c807-403a-8720-98a3773e109d,C1293116,C0009450,is earlier than first reported case of ,Introduction procedure,Communicable Diseases,3,X,[topp],[dsyn],,C01.539.221
d4257e65-12c8-4e95-ae60-6e13d90bbeb1,C0042720,C0040811,are dispersed among most types in phylogenetic ,Viral Genome,Trees (plant),3,X,[gngm],[plnt],G05.360.340.358.840,B01.650.915
40c5f000-8b21-41a9-8d29-2c413f7766ad,C0476236,C0206750,serve as clues for new-onset ,Developmental symptoms,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
8a9a60fb-6ce5-4d20-b924-b2b8629bc1c1,C0733529,cut-off,is with cut-off mg/l,CI-825,cut-off,1,X,[nnon/phsu],????,D03.383.742.680.350.200.700;D13.570.230.677;D13.570.685.350.200.700,????
5decf637-1105-4efc-adce-936184c12bc0,C0733529,mg/l,is with cut-off mg/l,CI-825,mg/l,1,X,[nnon/phsu],????,D03.383.742.680.350.200.700;D13.570.230.677;D13.570.685.350.200.700,????
f03b4b7f-0c07-41b7-aee6-63ad488aa8b4,C4048285,C0242656,were predictors of ,C-Reactive Protein human,Disease Progression,2,X,[aapp/imft],[patf],,C23.550.291.656
4bdacf06-9b39-4e0f-8933-2ca1b1909801,C4048285,C0012634,were predictors to critical ,C-Reactive Protein human,Disease,1,X,[aapp/imft],[dsyn],,C23.550.288
4bdacf06-9b39-4e0f-8933-2ca1b1909801,C4048285,C0012634,were good predictors of ,C-Reactive Protein human,Disease,1,X,[aapp/imft],[dsyn],,C23.550.288
8088eb92-6d6a-4b9d-8509-b6745c8d4092,C1292459,C0206750,is with ,Specimen from patient,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
8f202f26-d8e8-48b0-9a15-c5e4be07e05c,C1292459,C0012634,is with ,Specimen from patient,Disease,3,X,[bdsu],[dsyn],,C23.550.288
02895b11-13d9-4347-8806-81348de53388,C0026691,C0442893,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Systemic disease,10,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,
3aa7c531-7d71-47ba-8806-ce2b79133ec6,C0026691,C1290884,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Inflammatory disorder,8,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,
02471c42-59a1-4f59-8ab2-c58e70884b9b,C0086418,C0035222,ventilated due to ,Homo sapiens,Respiratory Distress Syndrome Adult,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C08.381.840;C08.618.840
86666c62-dcb7-4fa3-802e-15622665830f,C0086418,C0206750,was confirmed for ,Homo sapiens,Coronavirus Infections,18,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C02.782.600.550.200
63364567-189e-4d3a-a047-e094454e17e5,C0035239,hoc,were started in ad hoc ,Respiratory Therapy,hoc,2,X,[topp],????,E02.880,????
d22e9b98-b5ec-4b8c-8660-61c65cb825e8,C0013459,hoc,were started in ad hoc ,Early Mobilization,hoc,2,X,[topp],????,E02.760.169.063.500.335;E02.831.335,????
73d8c256-c476-4a87-9f88-5d7de10119cb,C2985393,hoc,were started in ad hoc ,Neuromuscular Electrical Stimulation,hoc,2,X,[topp],????,,????
ed860e35-3454-4567-ac83-9d234fd1d474,C0231484,C3714552,was consistent with intensive care unit-acquired ,Muscle function,Weakness,4,X,[ortf],[sosy],,
a981ded1-7fe6-4bd8-83e5-d5ed2bc8b101,C0035668,C0596402,is with minimal ,RNA,cytotoxicity,1,X,[nnon],[comd],D13.444.735,
18ac09a7-d2fa-4a3b-9114-dcdc532aa34c,C0035668,C1550101,is in cell culture ,RNA,Supernatant,1,X,[nnon],[bdsu],D13.444.735,
498ef1af-a1dd-426d-a817-0b3c7142a0de,C3271951,C1550101,similarly decreased RNA Viral in,macropinocytosis,Supernatant,1,X,[celf],[bdsu],,
5ea1bc6e-1b8a-40d6-9702-12f1a5413541,C0059831,C1550101,similarly decreased RNA Viral in,ethylisopropylamiloride,Supernatant,1,X,[orch/phsu],[bdsu],x.x.x.x,
6437c392-1b82-40bf-9041-ac76d09ae888,C3271951,C0035736,Surprisingly similarly decreased ,macropinocytosis,RNA Viral,2,X,[celf],[nnon],,D13.444.735.828
e62479c1-cf33-43ba-8c91-dc3cb5398848,C0059831,C0035736,Surprisingly similarly decreased ,ethylisopropylamiloride,RNA Viral,2,X,[orch/phsu],[nnon],x.x.x.x,D13.444.735.828
7f9fb00a-5a21-41eb-a462-87ff0030e2bc,C0754188,C0019704,inhibited SARS coronavirus much higher than that required for,Amprenavir,HIV-1,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.650.589.650.350.400
fcae37dd-c098-4079-be41-58c80471e594,IC,C0019704,were higher than that required for ,IC,HIV-1,1,X,????,[virs],????,B04.820.650.589.650.350.400
08199c3a-b288-447e-97cd-e9499dfbe7e2,C4045453,C0019704,inhibited SARS coronavirus much higher than that required for,ALLINI-2,HIV-1,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.650.589.650.350.400
948faf42-daea-4c16-8381-e7af1c0e3add,C0019704,C1175743,inhibited ,HIV-1,SARS coronavirus,1,X,[virs],[virs],B04.820.650.589.650.350.400,B04.820.504.540.150.113.937
5eb60da4-5a4a-4fbe-89aa-e96b110882fa,C0243077,C1175743,shown in case of ,inhibitors,SARS coronavirus,5,X,[chvf],[virs],,B04.820.504.540.150.113.937
d847d008-4c98-430b-9c71-ac3e1aabf288,C0132326,C1175743,inhibited ,Nevirapine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.383.725.506,B04.820.504.540.150.113.937
57056326-35d3-4152-a0bc-098bed117e0f,C4045453,C1175743,inhibited ,ALLINI-2,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
bedc45ef-3809-4a70-a762-3d54f147a1fd,C0754188,C1175743,inhibited ,Amprenavir,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
f8b52275-b7fc-42c9-987a-471996ed17c1,C0243077,C0019704,inhibited SARS coronavirus much higher than that required for,inhibitors,HIV-1,1,X,[chvf],[virs],,B04.820.650.589.650.350.400
5fe01a2e-ee1b-45e6-90b3-8cc9a1bcb13e,C0132326,C0019704,inhibited SARS coronavirus much higher than that required for,Nevirapine,HIV-1,1,X,[orch/phsu],[virs],D03.383.725.506,B04.820.650.589.650.350.400
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,impairing course of routine ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,screened compounds for their ,Coronavirus Infections,Activities,2,X,[dsyn],[acty],C02.782.600.550.200,
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,halting worldwide principal income ,Coronavirus Infections,Activities,2,X,[dsyn],[acty],C02.782.600.550.200,
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,implementing preemptive ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,include population confinement with consequent isolation of their ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
12f999ab-6a75-4776-a8a7-5cee2dcbd0dd,C0206750,C0441655,resume ,Coronavirus Infections,Activities,1,X,[dsyn],[acty],C02.782.600.550.200,
9399ce7f-44ac-4cb5-ac2d-03f3a29f5104,C1443867,C1175743,of SARS coronavirus is,Standard precautions,SARS coronavirus,3,X,[topp],[virs],,B04.820.504.540.150.113.937
9dba6fd5-93d9-4c88-9f15-7590389e883e,C1157562,C0751973,determining composition of ,translational elongation,Proteome,3,X,[genf],[aapp/bacs],,D12.776.817
bafb430a-0d76-4e3b-a97a-983dcd99776a,C0206750,C1819995,determine adaptation of ,Coronavirus Infections,Host Cell,1,X,[dsyn],[celc],C02.782.600.550.200,
bafb430a-0d76-4e3b-a97a-983dcd99776a,C0206750,C1819995,are adapted to ,Coronavirus Infections,Host Cell,1,X,[dsyn],[celc],C02.782.600.550.200,
bafb430a-0d76-4e3b-a97a-983dcd99776a,C0206750,C1819995,also induces severe attack on ,Coronavirus Infections,Host Cell,2,X,[dsyn],[celc],C02.782.600.550.200,
e248906c-9cc0-454a-bcc9-a72a3ff4b432,C0206750,C0597295,determine ,Coronavirus Infections,Protein Biosynthesis,1,X,[dsyn],[moft],C02.782.600.550.200,G02.111.660.871;G03.734.871;G05.297.670
3b7ed8fc-8cf8-45cf-baea-47647bd59fa2,C1175743,C0597295,have faster ,SARS coronavirus,Protein Biosynthesis,3,X,[virs],[moft],B04.820.504.540.150.113.937,G02.111.660.871;G03.734.871;G05.297.670
2800d234-cad8-4ada-a003-738d5c0004bc,C0206750,RSCU,have high RSCU ,Coronavirus Infections,RSCU,1,X,[dsyn],????,C02.782.600.550.200,????
a036e7fa-23de-449b-b6f3-37e184d5d563,C0206750,C0206422,have high RSCU ,Coronavirus Infections,Human coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200,
53f8edfa-6e85-404f-ab75-da8360d5828d,C4698072,C0042333,shows evidence for ,NL63,Variation (Genetics),3,X,[virs],[npop],,G05.365
6f09dfef-7265-40cb-8bcd-8080ee7ea8a5,C1167395,C0682447,portrays relation between ,Host (organism),virus by host,3,X,[orgm],[virs],,
b258b789-8cc2-4255-b472-37f387d0ab48,C0206750,C0278996,potentially disproportionate IMPACT gene on,Coronavirus Infections,Malignant Head and Neck Neoplasm,10,X,[dsyn],[neop],C02.782.600.550.200,
a727dfe4-cf2d-45ea-9762-2cad01fc7cbc,C0206750,C0595938,has IMPACT gene toxic,Coronavirus Infections,effect increased,4,X,[dsyn],[patf],C02.782.600.550.200,
fc3b1243-609b-4711-856d-f76b734168e2,C1825598,C0087111,toxic effect increased of,IMPACT gene,Therapeutic procedure,2,X,[gngm],[topp],,E02
f9f9dc6a-c2d3-4fef-8b60-028158aa8596,C0021055,C0206750,is in patients with ,Immunologic Memory,Coronavirus Infections,1,X,[ortf],[dsyn],G12.450.050.500,C02.782.600.550.200
d249a13d-0c12-4e5f-a362-7ce4eb8963d5,C0021760,C0018681,was found significantly higher in patients with ,Interleukin-6,Headache,2,X,[aapp/imft],[sosy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.888.592.612.441
1f4f7898-bfe8-4f00-8069-e25136a2bcd8,C0235031,C0206750,are seen in patients with ,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
1f4f7898-bfe8-4f00-8069-e25136a2bcd8,C0235031,C0206750,have Recently have noticed in patients with ,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
1f4f7898-bfe8-4f00-8069-e25136a2bcd8,C0235031,C0206750,be initial Disease Presentation of,Neurologic Symptoms,Coronavirus Infections,2,X,[sosy],[dsyn],C10.597;C23.888.592,C02.782.600.550.200
ecbda6b0-058b-4746-abf9-1b1648414dfe,C1457887,C0012634,is in ,Symptoms,Disease,2,X,[sosy],[dsyn],,C23.550.288
024cf989-917f-4402-a795-32fac4ed4a3c,C0235031,C0042776,prohibit ,Neurologic Symptoms,Virus,1,X,[sosy],[virs],C10.597;C23.888.592,B04
6c63e744-69c8-4b17-a46b-ed2f173f6180,C0025118,C0206750,deferring follow-ups because of ,Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403,C02.782.600.550.200
8e680e39-c16d-4cbb-bbd8-45c7633e55b8,C1947933,C0206750,deferring follow-ups because of ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
8e680e39-c16d-4cbb-bbd8-45c7633e55b8,C1947933,C0206750,were undertaken as result of ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
8e680e39-c16d-4cbb-bbd8-45c7633e55b8,C1947933,C0206750,are of Up of patients admitted to ICU with confirmed ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
8e680e39-c16d-4cbb-bbd8-45c7633e55b8,C1947933,C0206750,are reorganizing resources to ,care activity,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
65066d19-ff7a-4aca-b1bb-4a852ea4948f,C0025118,C1829939,deferring follow-ups in case of ,Medicine,{Non-patient},2,X,[bmod],[clna],H02.403,
2d815990-0578-4622-b845-063f2181be5c,C0015967,C1175743,led to testing for ,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
2d815990-0578-4622-b845-063f2181be5c,C0015967,C1175743,stands for ,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
2d815990-0578-4622-b845-063f2181be5c,C0015967,C1175743,are most prevalent Symptoms of adults infected by,Fever,SARS coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
2d815990-0578-4622-b845-063f2181be5c,C0015967,C1175743,can facilitate ,Fever,SARS coronavirus,1,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150.113.937
c201e814-ef96-44f2-9f4d-0e2a60e6bb26,C0029235,C0206750,was identified in January 2020 as novel ,Organism,Coronavirus Infections,9,X,[orgm],[dsyn],,C02.782.600.550.200
c7e4a685-1bea-4dbb-b676-c4817dd84f40,C0019682,C0024312,demonstrated severe ,HIV,Lymphopenia,1,X,[virs],[dsyn],B04.820.650.589.650.350,C15.378.553.546.605;C20.673.627
aa2c001e-455d-4191-a7a3-75c864608394,C0019682,COVID-19,remain at ,HIV,COVID-19,2,X,[virs],[virs],B04.820.650.589.650.350,C000657245
ed425a52-f6cc-4428-9eba-b210f5a03bdf,C0019682,CD4,decreased CD4 ,HIV,CD4,1,X,[virs],????,B04.820.650.589.650.350,????
abf88cfa-fea0-4f87-b316-1b05691e1e14,C0086418,1week,was admitted due to right limb weakness for 1day 1week,Homo sapiens,1week,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
abf88cfa-fea0-4f87-b316-1b05691e1e14,C0086418,1week,was admitted to Hubei Provincial 1day 1week,Homo sapiens,1week,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
3369b5db-4f58-4629-86b9-db475f51272f,C0086418,C0025118,was admitted to Hubei Provincial Hospital of TraditionalChinese ,Homo sapiens,Medicine,1,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.403
467035b2-673a-4f1f-93cf-8126b360b291,C0070166,C0087111,were administered to ,clopidogrel,Therapeutic procedure,3,X,[orch/phsu],[topp],D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500,E02
22bbfc5c-6135-420c-b575-7f3c3bd364dd,C0070166,C0751956,were administered to ,clopidogrel,Acute Cerebrovascular Accidents,6,X,[orch/phsu],[dsyn],D02.886.778.823.500.500;D03.383.725.849.500.500;D03.383.903.830.500.500;D03.633.100.928.500.500,C10.228.140.300.775;C14.907.253.855
8ab129cd-78ea-4185-8d43-bf920a61262f,C1175175,C1327414,caused hypoxemia of ,Severe Acute Respiratory Syndrome,cytokine secretion,4,X,[dsyn],[celf],C02.782.600.550.200.750;C08.730.730,
66eb1b33-f1d8-46e4-bae0-9ad6e7a6720e,C1327414,C0948008,contribute to occurrence of ,cytokine secretion,Ischemic stroke,3,X,[celf],[dsyn],,
211502d6-b178-4f71-ae41-9fdcebfe2164,C0206750,C0751956,show ,Coronavirus Infections,Acute Cerebrovascular Accidents,8,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
211502d6-b178-4f71-ae41-9fdcebfe2164,C0206750,C0751956,be may complicated with ,Coronavirus Infections,Acute Cerebrovascular Accidents,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
211502d6-b178-4f71-ae41-9fdcebfe2164,C0206750,C0751956,simultaneously diagnosed with ,Coronavirus Infections,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
602d5211-6bf8-4fe8-9a99-b12063977743,C0206750,C0000768,induce ,Coronavirus Infections,Congenital Abnormality,2,X,[dsyn],[cgab],C02.782.600.550.200,C16.131
27878620-fb5e-489d-886f-a3f48793f063,C0206750,C1705764,induces ,Coronavirus Infections,Doubling,1,X,[dsyn],[acty],C02.782.600.550.200,
ff7b5ed8-a6ed-45d4-83b6-2f9799371fd7,C1882509,C2741673,is With ,put - instruction imperative,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[acty],[clna],,
cfb591ac-8e7c-4a41-84b9-1a9455c581aa,C1704330,C0221423,Coronavirus Infections,Dental Diseases,Illness (finding),2,X,[dsyn],[sosy],C07,
ae10956a-5312-4934-834e-1ee49bbfcf7e,C0004002,C0001899,was present ,Aspartate Transaminase,Alanine Transaminase,7,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.225,D08.811.913.477.700.100
f5972703-9634-447a-a624-b3b9f395118a,C0596402,C0022917, includes ,cytotoxicity,Lactate Dehydrogenase,12,X,[comd],[aapp/enzy],,D08.811.682.047.551.400;D08.811.682.047.820.493
36faef21-ed4d-4683-9ed8-ae0704ded44e,C0596402,C0266258,is in ,cytotoxicity,Congenital absence of liver,10,X,[comd],[cgab],,
b2f17d63-96d1-43fc-b640-b572e1c61465,remdesivir,C0206750,received emergency use authorization for use in patients hospitalized with ,remdesivir,Coronavirus Infections,2,X,[clnd],[dsyn],,C02.782.600.550.200
b2f17d63-96d1-43fc-b640-b572e1c61465,remdesivir,C0206750,demonstrated powerful ,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
b2f17d63-96d1-43fc-b640-b572e1c61465,remdesivir,C0206750,showed faster time to clinical improvement in severe ,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
b2f17d63-96d1-43fc-b640-b572e1c61465,remdesivir,C0206750,Therapeutic procedure,remdesivir,Coronavirus Infections,1,X,[clnd],[dsyn],,C02.782.600.550.200
5f057ac0-9f8b-412a-b33e-a468d8f4b865,C0304229,C0036658,therefore have created ,Experimental drug,Esthesia,2,X,[phsu],[ortf],,F02.830.816;G11.561.790
ca1843b5-93de-432e-8e44-0fa844b74f32,C0025118,C0544688,is in ,Medicine,complication of disease,1,X,[bmod],[patf],H02.403,
461646a4-72cf-4e01-b1c5-238d6ed9f78d,C1175743,C1511790,was first ,SARS coronavirus,Detection,5,X,[virs],[topp],B04.820.504.540.150.113.937,
25ed1967-5b2f-464b-b1cb-2a8399b0bd12,C0012634,C0003451,are away from still target ,Disease,Antiviral Agents,4,X,[dsyn],[phsu],C23.550.288,D27.505.954.122.388
25ed1967-5b2f-464b-b1cb-2a8399b0bd12,C0012634,C0003451,associated with specific ,Disease,Antiviral Agents,2,X,[dsyn],[phsu],C23.550.288,D27.505.954.122.388
bf82abce-34dc-4a82-8f54-343f9d9b36a8,C0206750,C2348077,have spread to ,Coronavirus Infections,Date Fruit,5,X,[dsyn],[food],C02.782.600.550.200,B01.650.940.800.575.912.250.093.615
ac05699b-3b79-45c4-a8ac-92b4e2b8942d,C0206074,C1185740,performed on respiratory ,Renal Replacement Therapy,Tract,4,X,[topp],[bpoc],E02.870,
ef061fd9-730e-4004-907b-d993c581fb0a,C0032521,C1185740,performed on respiratory ,Polymers,Tract,1,X,[bodm/chvs],[bpoc],D05.750;D25.720;J01.637.051.720,
276739f0-8250-46f2-9347-a930409696d9,C0206074,C0370003,performed on respiratory ,Renal Replacement Therapy,Specimen,2,X,[topp],[sbst],E02.870,
0ad55042-def7-40e3-b852-4364fce5f5bd,C0032521,C0370003,performed on respiratory ,Polymers,Specimen,1,X,[bodm/chvs],[sbst],D05.750;D25.720;J01.637.051.720,
7906af16-9df3-485f-9487-364e310af7f8,C3858690,C1609165,included ,adjunctive treatment,tocilizumab,4,X,[topp],[aapp/imft/phsu],,x.x.x.x
df773e80-6884-41a6-8cc2-da4ba021241f,C3858690,C0087111,included ,adjunctive treatment,Therapeutic procedure,4,X,[topp],[topp],,E02
dfcd0684-c137-46b3-bb14-010c47884e10,C3858690,C0001617,included ,adjunctive treatment,Adrenal Cortex Hormones,4,X,[topp],[horm/orch/phsu],,D06.472.040
1b3340dc-3659-491c-937c-f7c100f0141c,C1160716,intra,heavily rely on intra ,viral transmission,intra,1,X,[celf],????,,????
630f53ec-6c5a-40d7-b08b-783a3de36411,C1160716,C1167395,heavily rely on intra ,viral transmission,Host (organism),1,X,[celf],[orgm],,
88bf8331-c842-45e1-acae-9f6e1aeaff26,C1160716,C3826426,heavily rely on intra ,viral transmission,Dynamics,1,X,[celf],[npop],,
b2e59c5f-d8da-45de-a262-c15c1ddc0bc9,C0035253,C0206750,have have particularly hit during crisis due ,Rest,Coronavirus Infections,1,X,[dora],[dsyn],I03.450.769.647,C02.782.600.550.200
8307c001-ff51-48b9-820c-4332088a3b41,C0242781,C0042776,is easy in context of highly contagious ,disease transmission,Virus,1,X,[patf],[virs],N06.850.310,B04
7478d46a-48fe-4bb9-a454-a4452df347a6,C0032521,C1175743,is in first days for detection of ,Polymers,SARS coronavirus,2,X,[bodm/chvs],[virs],D05.750;D25.720;J01.637.051.720,B04.820.504.540.150.113.937
0004670f-aac2-4bf1-bbde-bf1fb0d2748e,C0032285,C0034019,outbreak of was major ,Pneumonia,public health medicine (field),2,X,[dsyn],[bmod],C08.381.677;C08.730.610,H02.403.720;N01.400.550;N06.850
222dda2e-c928-4fda-affd-c123c5484b00,C0032285,C2745965,outbreak of was major ,Pneumonia,Emergencies [Disease/Finding],2,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.291.781;N06.230.100.083;N06.850.376
bd36be2b-cf97-4605-acf6-f0944c6ed723,C0032285,C0086418,outbreak of was major ,Pneumonia,Homo sapiens,2,X,[dsyn],[humn],C08.381.677;C08.730.610,B01.050.150.900.649.313.988.400.112.400.400
a5dd35b1-ccc7-45a8-bfc8-ce1ccc44409e,C0034019,C0086418,is with substantive ,public health medicine (field),Homo sapiens,5,X,[bmod],[humn],H02.403.720;N01.400.550;N06.850,B01.050.150.900.649.313.988.400.112.400.400
6ce11312-ca24-4116-b304-7afc071c27fb,C2745965,C0086418,is in ,Emergencies [Disease/Finding],Homo sapiens,2,X,[patf],[humn],C23.550.291.781;N06.230.100.083;N06.850.376,B01.050.150.900.649.313.988.400.112.400.400
a29f1edd-6a2b-4723-adeb-18e3ff2b84e7,C0282682,C1175743,primarily target S protein among structural elements of ,Antibodies Blocking,SARS coronavirus,1,X,[aapp/imft/irda],[virs],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,B04.820.504.540.150.113.937
a3efb24d-09e3-4225-91da-d8dd1540937a,C1175743,C1537068,mediates ,SARS coronavirus,Virus Internalization,2,X,[virs],[biof],B04.820.504.540.150.113.937,G06.920.881
a3efb24d-09e3-4225-91da-d8dd1540937a,C1175743,C1537068,occurs through ,SARS coronavirus,Virus Internalization,1,X,[virs],[biof],B04.820.504.540.150.113.937,G06.920.881
740d3abe-4e94-49b9-89a3-936a223b9904,C1175743,C1514760,mediates Cells Virus Internalization through,SARS coronavirus,Receptor Cell,2,X,[virs],[cell],B04.820.504.540.150.113.937,
740d3abe-4e94-49b9-89a3-936a223b9904,C1175743,C1514760,uses membrane form as,SARS coronavirus,Receptor Cell,3,X,[virs],[cell],B04.820.504.540.150.113.937,
740d3abe-4e94-49b9-89a3-936a223b9904,C1175743,C1514760,caused ,SARS coronavirus,Receptor Cell,2,X,[virs],[cell],B04.820.504.540.150.113.937,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,transmissible to medical professionals involved in their ,Coronavirus Infections,care activity,3,X,[dsyn],[acty],C02.782.600.550.200,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,prioritize ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,provides opportunity for health care planners of organizations across India for reformation of disabilities ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,Indeed provides opportunity for reformation of disabilities ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,profound global IMPACT gene on urological,Coronavirus Infections,care activity,2,X,[dsyn],[acty],C02.782.600.550.200,
c13ade38-041e-4c89-9723-2aaa14c9cf51,C0206750,C1947933,has created unprecedented challenges for ,Coronavirus Infections,care activity,1,X,[dsyn],[acty],C02.782.600.550.200,
828db637-46b4-479c-9f9b-2409adf6a565,C0009450,C1947933,transmissible to medical professionals involved in their ,Communicable Diseases,care activity,3,X,[dsyn],[acty],C01.539.221,
ba4f2107-deee-4190-a26e-89bad71dd3b1,C0751956,C0206750,may have undiagnosed ,Acute Cerebrovascular Accidents,Coronavirus Infections,9,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C02.782.600.550.200
bea16f31-c10d-47f0-bfeb-f5859a7d7a54,C0751956,C0009450,may have undiagnosed ,Acute Cerebrovascular Accidents,Communicable Diseases,5,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
95c2baac-4572-4867-9c89-ca2f84bc5555,C0751956,C1947933,may have undiagnosed ,Acute Cerebrovascular Accidents,care activity,5,X,[dsyn],[acty],C10.228.140.300.775;C14.907.253.855,
60b7340c-8eb1-403c-85bd-71a6e010d858,C1167622,C0086418,is with ,Binding (Molecular Function),Homo sapiens,9,X,[moft],[humn],,B01.050.150.900.649.313.988.400.112.400.400
b17d820b-f806-4801-bed9-7555bfc4cbc9,C1510827,C0507236,control internalization of ,Affinity,Anterior bronchopulmonary segment of superior pulmonary vein,1,X,[npop],[bpoc],,
53204844-26f6-4456-8640-6abf50d2db65,C0319157,C3888108,possibly restrict ,AS virus,Import into cell,1,X,[virs],[celf],,
fa6dd97c-a56d-4ba4-9c85-f37bc1685d09,C0009450,C1323511,into Pneumonia is,Communicable Diseases,N-carbamoylputrescine amidase activity,1,X,[dsyn],[moft],C01.539.221,
e820538d-adfd-408d-b2ee-c1df07c57cf2,C0029167,C1705178,is in ,Oral Medicine,Order (action),1,X,[bmod],[acty],E06.640;H02.163.670,
ee12a06b-8209-43fb-bc74-3a6836ca5841,C0029167,C1999230,is in ,Oral Medicine,Providing (action),1,X,[bmod],[acty],E06.640;H02.163.670,
789fc771-42bf-4099-84e1-e955adbb3b56,C0029167,C1290071,is in ,Oral Medicine,Disorder of oral mucous membrane,1,X,[bmod],[dsyn],E06.640;H02.163.670,
53633d8f-1698-47ab-b77a-ace1d49d1f04,C1516048,C0206419,effect on ,Assessed,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
53633d8f-1698-47ab-b77a-ace1d49d1f04,C1516048,C0206419,changes during ,Assessed,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
e3be4988-dd88-4d41-896b-99b880eb8d8b,C0080078,C0206419,are correlated with decreased ,Range of Motion Articular,Genus: Coronavirus,1,X,[clna],[virs],E01.370.600.700;G11.427.760,B04.820.504.540.150
e3be4988-dd88-4d41-896b-99b880eb8d8b,C0080078,C0206419,are strongly correlated with ,Range of Motion Articular,Genus: Coronavirus,1,X,[clna],[virs],E01.370.600.700;G11.427.760,B04.820.504.540.150
3a8bc3b2-76f1-4d8b-9213-7f07395a869a,C0030858,C0206419,infected with ,Pentaerythritol Tetranitrate,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.033.455.706.690,B04.820.504.540.150
a313b35b-9919-4f00-bf8c-ce0d9cd2cc31,C1547282,C0024109,is in ,Show,Lung,2,X,[anim],[bpoc],,A04.411
519369ae-d31c-4d6c-8837-2fda706836f9,GGO,C0024109,is in ,GGO,Lung,2,X,????,[bpoc],????,A04.411
63ccaf28-9c72-4ec7-9924-e52d96a6ead9,C1547282,C1265876,is with reduction in density of lesions of linear ,Show,Abnormally opaque structure (morphologic abnormality),1,X,[anim],[patf],,
e2e4bff0-59c2-4591-9b04-f7186500db4b,C0242656,C1265876,is with reduction in density of lesions of linear ,Disease Progression,Abnormally opaque structure (morphologic abnormality),1,X,[patf],[patf],C23.550.291.656,
a485a88d-0d52-4ebc-a1c0-fea2450a06f3,C1880355,C0032285,is in patients with serious ,Discover,Pneumonia,1,X,[acty],[dsyn],,C08.381.677;C08.730.610
81086215-6eff-4a61-8741-9e7715394de9,C1160638,C1537068,targets during ,Viral life cycle,Virus Internalization,1,X,[biof],[biof],,G06.920.881
965a08a6-6680-4c36-9570-15bb85773926,C1160638,C0598312,targets during ,Viral life cycle,DNA Replication,1,X,[biof],[genf],,G02.111.225;G05.226
46c5b82d-b5c3-4b60-ba4c-7640a86d845b,C1160638,C1706853,targets during ,Viral life cycle,Assembly (construction),1,X,[biof],[acty],,
5d57da37-4edb-415b-a94d-81c8a94fe935,C0019240,C0319157,are awaiting assessment for therapeutic use against ,Herb,AS virus,2,X,[plnt],[virs],,
a2f6165a-9206-4fca-914c-89970666cde9,C0019240,C0206419,are awaiting assessment for therapeutic use against ,Herb,Genus: Coronavirus,1,X,[plnt],[virs],,B04.820.504.540.150
5209cf3a-7742-4a75-a5b2-662834b5b57b,C0577749,C0319157,are awaiting assessment for therapeutic use against ,Phytochemicals,AS virus,2,X,[bacs/orch],[virs],D23.704,
886d0086-8555-467a-8274-d9523ad95885,C0577749,C0206419,are awaiting assessment for therapeutic use against ,Phytochemicals,Genus: Coronavirus,1,X,[bacs/orch],[virs],D23.704,B04.820.504.540.150
a1ac1461-1ab9-43e2-9270-889284024699,C0577749,C1547282,are awaiting assessment As review ,Phytochemicals,Show,1,X,[bacs/orch],[anim],D23.704,
1b8936be-3cd7-4f65-914d-5b773c388932,C0019240,C1547282,are awaiting assessment As review ,Herb,Show,1,X,[plnt],[anim],,
20e2ec85-da4a-49dd-88e2-d8e323fd9fdf,C0021400,C1449759,was shadowed under consequences of ,Influenza,World War I,1,X,[dsyn],[acty],C02.782.620.365;C08.730.310,I01.880.735.950.250.968;K01.400.504.968.900
57588f5b-58a3-4b24-88c6-559b2a2ec902,C0021400,C1825598,had similar ,Influenza,IMPACT gene,1,X,[dsyn],[gngm],C02.782.620.365;C08.730.310,
c55ecec3-0699-45dc-9541-ca4c1050d2b6,C1511790,C2598152,is in ,Detection,Pulmonary Function Tests:-:Point in time:^Patient:-,1,X,[topp],[clna],,
c1955afb-116c-4a02-99d3-9a6c39683fea,C1511790,C0206419,is in more half of ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
c1955afb-116c-4a02-99d3-9a6c39683fea,C1511790,C0206419,may play role in development of therapeutic approaches for ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
c1955afb-116c-4a02-99d3-9a6c39683fea,C1511790,C0206419,is required for diagnosis of ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
c1955afb-116c-4a02-99d3-9a6c39683fea,C1511790,C0206419,low rates of are indicative ,Detection,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
f73b6b63-e0e5-41dc-8819-a38c77ec8d54,C0158644,C0206419,were Detection in half of,Congenital anomaly of lung,Genus: Coronavirus,2,X,[cgab],[virs],,B04.820.504.540.150
ca06fd65-0ea8-4aa3-a989-9c3bf6949e10,C0035231,C1511790,were ,Respiratory Muscles,Detection,1,X,[bpoc],[topp],A02.633.567.900,
01ce06e3-6965-4190-9651-ca304f200ed1,C0517349,C1511790,were ,Muscle Strength,Detection,1,X,[ortf],[topp],E01.370.600.425;G11.427.560,
60be9884-7cc9-4bc9-8156-b743604f63dd,C0035231,C0206419,were Detection in half of,Respiratory Muscles,Genus: Coronavirus,2,X,[bpoc],[virs],A02.633.567.900,B04.820.504.540.150
2967bdae-ca80-4c06-810d-7893328fb76f,C0517349,C0206419,were Detection in half of,Muscle Strength,Genus: Coronavirus,2,X,[ortf],[virs],E01.370.600.425;G11.427.560,B04.820.504.540.150
6d00eafc-be04-4371-a8a6-51d042954c47,C4050231,C0230425,effectively predicts SARS-CoV-2 PCR ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Structure of right thigh,1,X,[clna],[bpoc],,
5f4808b0-3b4f-4aed-accb-6a4b9fb6d25b,C4050231,PCR,effectively predicts SARS-CoV-2 PCR ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,PCR,1,X,[clna],????,,????
a8b7b5d1-6056-4043-83d4-c153947300db,C2948600,COVID19,was to COVID19 ,Aim,COVID19,2,X,[inch/phsu],????,,????
ecb2691d-c454-4204-bf96-adb398a80dff,C1825598,C0011331,viral transmission on,IMPACT gene,Dental Procedures,2,X,[gngm],[topp],,E06.170;N02.421.240.190
db44dbce-f209-4f23-9a7c-ae7076dddae5,C1175743,C0026766,can evolve into ,SARS coronavirus,Multiple Organ Failure,2,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.835.525
aa29195c-35e6-46d6-a295-6124f8f4b227,C0005516,C0599878,reflecting main pathophysiological ,Biological Markers,disease characteristic,4,X,[clna],[patf],D23.101,
6e446567-24e2-4261-94ab-c9f4dbfd1499,C0024312,C0012634,represents hallmark of ,Lymphopenia,Disease,2,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C23.550.288
6e446567-24e2-4261-94ab-c9f4dbfd1499,C0024312,C0012634,suggested ,Lymphopenia,Disease,2,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C23.550.288
e6c20ed1-7540-465e-ade5-25a75746385a,C0009450,C0020964,produce ,Communicable Diseases,Immunity,2,X,[dsyn],[phsf],C01.539.221,G12.450
adb31d03-12ff-4d31-9f95-4bc4adf3d040,C1963758,C0678812,is often considered for,Immunomodulation,systemic administration,3,X,[topp],[topp],E02.095.465;G12.535,
b7c55af8-a858-4a58-b16f-d7f7ff7f0e8d,C1963758,C0007634,is often considered for ,Immunomodulation,Cells,1,X,[topp],[cell],E02.095.465;G12.535,A11
6a0d66d8-7267-4de0-8ce1-09b3fae48951,C0001617,C0042164,is in patients with ,Adrenal Cortex Hormones,Uveitis,3,X,[horm/orch/phsu],[dsyn],D06.472.040,C11.941.879
78e772c3-dd1c-4a2d-80eb-aadbe9e1c104,C0027950,C0039194,percentage to ,neutrophil,T-Lymphocyte,1,X,[cell],[cell],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
49f31368-4a8c-4791-85bb-dd2cba9dbb72,C1947904,C0048243,Binding (Molecular Function) of 6LU7,Attachment (action),4-dichlorobenzene,2,X,[acty],[hops/orch],,x.x.x.x
840273df-5661-493a-9bcf-7068f5487bad,C1947904,C0009450,Binding (Molecular Function) of 6LU7,Attachment (action),Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
2bb292a3-aa69-4dbf-beea-6fee9626034b,C1947904,6LU7,Binding (Molecular Function) of 6LU7,Attachment (action),6LU7,2,X,[acty],????,,????
87f712c8-95f5-4a69-9ddb-41090ad4ea61,C0206750,C1443869,should take ,Coronavirus Infections,Airborne precautions,3,X,[dsyn],[topp],C02.782.600.550.200,
2984124c-8987-4bae-92a9-88b7300d2c70,C0191234,C0728940,was performed with ,Pericardiocentesis,Excision,4,X,[topp],[topp],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
cb87b4ed-db86-4777-813c-ff4bd500e260,C0206750,C0319157,occur through exposure to ,Coronavirus Infections,AS virus,3,X,[dsyn],[virs],C02.782.600.550.200,
a75d14ed-a754-4a11-a580-7512a19360e0,C0012634,C0319157,is in ,Disease,AS virus,4,X,[dsyn],[virs],C23.550.288,
114a6d30-e3b5-46ac-9859-7a4fcce58e92,C0009450,C0319157,caused by new ,Communicable Diseases,AS virus,1,X,[dsyn],[virs],C01.539.221,
ff5548ea-af37-4ecb-91eb-4a1dc6041765,C0319157,C0010200,causes Respiration Disorders with,AS virus,Coughing,2,X,[virs],[sosy],,C08.618.248;C23.888.852.293
ff5548ea-af37-4ecb-91eb-4a1dc6041765,C0319157,C0010200,is spreading through ,AS virus,Coughing,3,X,[virs],[sosy],,C08.618.248;C23.888.852.293
ff5548ea-af37-4ecb-91eb-4a1dc6041765,C0319157,C0010200,survive in droplets of ,AS virus,Coughing,1,X,[virs],[sosy],,C08.618.248;C23.888.852.293
1456f02e-ca59-4cc3-8f1c-bd18b32b6ad4,C0319157,C0035204,causes ,AS virus,Respiration Disorders,1,X,[virs],[dsyn],,C08.618
516e3d0d-b379-4458-b60d-c31418462297,C0319157,C1707455,is in ,AS virus,Comparison,3,X,[virs],[acty],,
3b0c4460-c257-4d5e-8ddf-c837e79297ab,C0319157,C0017428,is in full ,AS virus,Genome,3,X,[virs],[gngm],,G05.360.340
bf16b78a-64d8-4bb6-8974-c48a900481f8,C0310367,C0206750,is rapid outbreak of ,Today,Coronavirus Infections,11,X,[antb/orch],[dsyn],,C02.782.600.550.200
a3d2b517-7a4a-48cb-a6aa-4db9535d85c1,C0599732,C1155357,serve through purinergic ,cell injury,cell surface receptor signaling pathway,7,X,[comd],[moft],,
670faf41-9dbe-40ef-a264-2e4152e6ff8e,C0599732,C0243042,serve as ,cell injury,Inflammation Mediators,7,X,[comd],[phsu],,D23.469
8ac364a1-e176-46ec-bd15-13073b33b763,C0001443,C0087111,is seen as major obstacle to efficacy of immune ,Adenosine,Therapeutic procedure,7,X,[bacs/nnon/phsu],[topp],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,E02
7d36eeee-ef24-4ca8-a841-2c092cf1eff5,C1325584,C0087111,are critical ,lateral element,Therapeutic procedure,7,X,[celc],[topp],,E02
c6c6af59-08ad-40c9-a252-ae56df43dc59,C1704259,C0445623,is in ,Biochemical Pathway,Microorganism,1,X,[moft],[orgm],,
d8a5943b-262d-4cac-96d9-19139b101119,C0243077,C1704259,specific to adenosinergic ,inhibitors,Biochemical Pathway,7,X,[chvf],[moft],,
d8a5943b-262d-4cac-96d9-19139b101119,C0243077,C1704259,is in endosomal ,inhibitors,Biochemical Pathway,1,X,[chvf],[moft],,
188d6fb5-c539-4ec0-8954-0fe92c3d1834,C0243077,C0445623,specific to adenosinergic ,inhibitors,Microorganism,1,X,[chvf],[orgm],,
88bca12b-3efb-477c-98a7-363cc3b7f231,C2745965,C0445623,were ,Emergencies [Disease/Finding],Microorganism,5,X,[patf],[orgm],C23.550.291.781;N06.230.100.083;N06.850.376,
7b4bb5a3-c2dd-43bb-b269-2e963033c8ec,C2745965,C0022568,were ,Emergencies [Disease/Finding],Keratitis,5,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C11.204.564
1db10559-297b-4b09-993f-ddc9261bff28,C1764827,C1175175,is with ,Isolate - microorganism,Severe Acute Respiratory Syndrome,1,X,[bacs],[dsyn],,C02.782.600.550.200.750;C08.730.730
e492ddc9-23e7-4f5c-b27e-1db746882a39,C0034019,C1764827,recommend ,public health medicine (field),Isolate - microorganism,1,X,[bmod],[bacs],H02.403.720;N01.400.550;N06.850,
613bf97d-fbd5-4f7a-b52e-6b0f965a6403,C0034019,C1175175,recommend ,public health medicine (field),Severe Acute Respiratory Syndrome,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200.750;C08.730.730
613bf97d-fbd5-4f7a-b52e-6b0f965a6403,C0034019,C1175175,isolating patients with ,public health medicine (field),Severe Acute Respiratory Syndrome,5,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200.750;C08.730.730
35d17cb0-974a-4832-80bf-0625bf965235,C1880177,C3810578,is in terms of ,Contribution,Gigaxonin human,1,X,[acty],[aapp],,
b376b4c3-c0a3-4ffb-9af6-951b78d4af15,C0042870,C0206750,play role in ,Vitamin D Deficiency,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,C02.782.600.550.200
daf3500f-3784-4000-ba7b-f589a4fd9cf6,C0042870,C0012634,play role in ,Vitamin D Deficiency,Disease,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,C23.550.288
44922547-b9e7-43a8-8f63-c4303c43cd56,ITU,C0220853,had 25 ,ITU,Hydroxide Ion,1,X,????,[elii],????,x.x.x.x
84eb34d7-12e2-4691-9827-500255bdc98d,C1513397,C0087111,is with ,Molecular Medicine,Therapeutic procedure,1,X,[bmod],[topp],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,E02
dd6c5dc3-181e-4ca6-9392-333fbcc14f86,C0687133,C0087111,is with emerging ,Drug Interactions,Therapeutic procedure,4,X,[patf],[topp],G07.690.773.968,E02
e2330c1d-a98e-488a-a5ba-e8a58251547f,C1513397,C0206750,is with ,Molecular Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530,C02.782.600.550.200
04672260-2c94-4ba6-bcbc-0f0133be61a2,C0687133,C0206750,is with emerging ,Drug Interactions,Coronavirus Infections,4,X,[patf],[dsyn],G07.690.773.968,C02.782.600.550.200
31cefdf2-7c54-4a07-9e0b-7815ae5a5007,2-item,C0344315,measure ,2-item,Depressed mood,2,X,????,[mobd],????,
7b96229c-703a-489d-a4d1-7278cde1a5c9,2-item,pre,measure Depressed mood level respectively for pre,2-item,pre,4,X,????,????,????,????
7b5adb46-64a5-44b4-9e8b-b1b496ddf28d,2-item,C0206750,measure Depressed mood level respectively for pre,2-item,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
6b80dce5-8894-4c75-a1a4-f154174db927,C2364111,PHQ-2,also exhibited similar associations with PHQ-2 ,Ageusia,PHQ-2,2,X,[sosy],????,C10.597.751.861.184;C23.888.592.763.861.184,????
bcf36cfb-43f8-426d-ac6f-a3137c6cad97,C0301630,C1824356,is in odds of ,Reduction (chemical),KIAA1551 gene,1,X,[npop],[gngm],,
5419dc18-4a92-4463-a92f-2d2d623aca60,C0301630,C1175743,is in odds of ,Reduction (chemical),SARS coronavirus,1,X,[npop],[virs],,B04.820.504.540.150.113.937
5419dc18-4a92-4463-a92f-2d2d623aca60,C0301630,C1175743,have have implemented in countries with outbreaks of CoV2,Reduction (chemical),SARS coronavirus,4,X,[npop],[virs],,B04.820.504.540.150.113.937
36a94ae5-9629-4b8d-9e62-cc27e11ac6b8,C0029250,C1175743,engage in first comprehensive analysis of ,Organoids,SARS coronavirus,2,X,[tisu],[virs],A10.802,B04.820.504.540.150.113.937
2f53bb89-18e2-47e4-9628-776735689547,C0086418,C1175175,is with severe ,Homo sapiens,Severe Acute Respiratory Syndrome,8,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C02.782.600.550.200.750;C08.730.730
1f341484-398e-4d3d-894e-cd6da0e699c1,C0042769,C0021745,elicits extremely robust intrinsic ,Virus Diseases,Interferon Type II,2,X,[dsyn],[aapp/imft/phsu],C02,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
8555d615-9842-41b2-83f0-3693cd20945e,C0021745,de,controlling de ,Interferon Type II,de,1,X,[aapp/imft/phsu],????,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,????
9d35577b-364e-4d36-8d0f-ae3e128cd298,C0021745,C0319157,controlling de ,Interferon Type II,AS virus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,
9448ef9d-c951-4f9b-8c99-696e9a809a86,C0021745,C1175743,controlling ,Interferon Type II,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,B04.820.504.540.150.113.937
6d53a1d1-7bcb-491b-b8b7-387ed3c3bb58,C0021745,C0598312,controlling ,Interferon Type II,DNA Replication,1,X,[aapp/imft/phsu],[genf],D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350,G02.111.225;G05.226
3b2885e2-709c-4f5f-a80e-e02b22b7d19b,C0086418,C1175743,are productive site of ,Homo sapiens,SARS coronavirus,2,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
3b2885e2-709c-4f5f-a80e-e02b22b7d19b,C0086418,C1175743,be functional target for spike ,Homo sapiens,SARS coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
3b2885e2-709c-4f5f-a80e-e02b22b7d19b,C0086418,C1175743,were productively infected with ,Homo sapiens,SARS coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
3b2885e2-709c-4f5f-a80e-e02b22b7d19b,C0086418,C1175743,has has identified as functional ,Homo sapiens,SARS coronavirus,3,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150.113.937
aafba332-21b6-4c27-81d8-3525d2aed6a5,C0087111,C1825598,limiting ,Therapeutic procedure,IMPACT gene,2,X,[topp],[gngm],E02,
482b9d14-5905-43d4-83b3-85e0f04ddb8a,C0087111,C0042774,are aimed at ,Therapeutic procedure,Virus Replication,2,X,[topp],[celf],E02,G06.920.925
482b9d14-5905-43d4-83b3-85e0f04ddb8a,C0087111,C0042774,reducing effects rather than ,Therapeutic procedure,Virus Replication,1,X,[topp],[celf],E02,G06.920.925
e6a6d515-2d25-4f8c-bbc7-587b98f3c888,C3273807,C0022646,protect ,Sodium-Glucose Transporter 2 Inhibitors,Kidney,6,X,[orch/phsu],[bpoc],D27.505.519.936;D27.505.696.422.750,A05.810.453
3adbd1d8-3221-49af-a038-7b34c2d54864,C3273807,C0018787,protect ,Sodium-Glucose Transporter 2 Inhibitors,Heart,6,X,[orch/phsu],[bpoc],D27.505.519.936;D27.505.696.422.750,A07.541
aa66b476-2e0e-4f37-8316-0c8d393a6001,remdesivir,C0003451,demonstrated powerful ,remdesivir,Antiviral Agents,2,X,[clnd],[phsu],,D27.505.954.122.388
b6978722-5dee-4867-897c-a3594d29baa8,C0475647,C0206750,produce in patients infected with ,Home exercise program,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
e501d57d-49f1-4d52-a5f6-d382fc72092f,C0042769,C0206750,is in ,Virus Diseases,Coronavirus Infections,5,X,[dsyn],[dsyn],C02,C02.782.600.550.200
b7878e67-59f6-4e6f-9cad-479d31bf7a5d,C1175743,C1452534,being internalized with ,SARS coronavirus,ACE protein human,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,x.x.x.x
b7878e67-59f6-4e6f-9cad-479d31bf7a5d,C1175743,C1452534,binding ,SARS coronavirus,ACE protein human,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,x.x.x.x
8c700316-0d80-40ea-82cc-428a9c1cd726,C1175743,C0024264,being internalized with ,SARS coronavirus,Lymphocyte,2,X,[virs],[cell],B04.820.504.540.150.113.937,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
2920b098-0019-4a00-87dd-41e2e7652e31,C1413931,C0242298,modulate protein protein interaction by,ACE gene,Fostering,1,X,[gngm],[dora],,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
2936a361-fba5-4c39-800c-800dfa971ef6,C0032529,C0242298,modulate protein protein interaction by,Genetic Polymorphism,Fostering,1,X,[genf],[dora],G05.365.795,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
2936a361-fba5-4c39-800c-800dfa971ef6,C0032529,C0242298,contribute by ,Genetic Polymorphism,Fostering,1,X,[genf],[dora],G05.365.795,E02.760.352;I01.880.787.416;N02.421.143.452;N02.421.585.352
20254d02-c174-451f-a8dd-b7f0e23fd216,C1413931,C0042396,modulate protein protein interaction by,ACE gene,Vascular constriction (function),1,X,[gngm],[ortf],,G09.330.380.925
5a13e963-ec73-40c3-bc80-dcf7620db1b3,C0032529,C0042396,modulate protein protein interaction by,Genetic Polymorphism,Vascular constriction (function),1,X,[genf],[ortf],G05.365.795,G09.330.380.925
5a13e963-ec73-40c3-bc80-dcf7620db1b3,C0032529,C0042396,contribute by ,Genetic Polymorphism,Vascular constriction (function),1,X,[genf],[ortf],G05.365.795,G09.330.380.925
5b26fb56-e626-42f1-b88f-a0270bd8a6c1,C0032529,C1413931,is in ,Genetic Polymorphism,ACE gene,4,X,[genf],[gngm],G05.365.795,
1710a649-cb1e-4c4c-8f27-2a13650810cf,C1413931,C0872079,modulate intermolecular ,ACE gene,protein protein interaction,1,X,[gngm],[moft],,
1710a649-cb1e-4c4c-8f27-2a13650810cf,C1413931,C0872079,modulate protein protein interaction with spike,ACE gene,protein protein interaction,1,X,[gngm],[moft],,
5a7bb4d6-1247-411f-990a-aadfd9512107,C0032529,C0872079,modulate intermolecular ,Genetic Polymorphism,protein protein interaction,1,X,[genf],[moft],G05.365.795,
5a7bb4d6-1247-411f-990a-aadfd9512107,C0032529,C0872079,modulate protein protein interaction with spike,Genetic Polymorphism,protein protein interaction,1,X,[genf],[moft],G05.365.795,
edd81b4c-7a7e-4019-9253-fc0eafafa535,C1413931,C1175743,modulate protein protein interaction with spike,ACE gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
3a4e4a52-0011-41b8-82e0-b845e0cafdea,C0032529,C1175743,modulate protein protein interaction with spike,Genetic Polymorphism,SARS coronavirus,1,X,[genf],[virs],G05.365.795,B04.820.504.540.150.113.937
b7e78a12-bebc-4ed9-9dcb-217d6340c724,PPE,C2699153,prevent ,PPE,Cell Invasion,2,X,????,[patf],????,
05026e5c-a535-4061-bc47-f469b8748acf,PPE,C0042760,prevent ,PPE,Virion,2,X,????,[celc],????,A21.249;B04.950
71f0e37a-7d23-4ba2-bc59-1461d52a1a5d,C0003015,C0206750,could influence ,Angiotensin-Converting Enzyme Inhibitors,Coronavirus Infections,6,X,[phsu],[dsyn],D27.505.519.389.745.085,C02.782.600.550.200
71f0e37a-7d23-4ba2-bc59-1461d52a1a5d,C0003015,C0206750,make patients susceptible to ,Angiotensin-Converting Enzyme Inhibitors,Coronavirus Infections,2,X,[phsu],[dsyn],D27.505.519.389.745.085,C02.782.600.550.200
7ca12ae7-c5ac-43b0-81c9-417065d89107,C0003015,C0012634,could influence ,Angiotensin-Converting Enzyme Inhibitors,Disease,2,X,[phsu],[dsyn],D27.505.519.389.745.085,C23.550.288
7ca12ae7-c5ac-43b0-81c9-417065d89107,C0003015,C0012634,make patients susceptible to ,Angiotensin-Converting Enzyme Inhibitors,Disease,1,X,[phsu],[dsyn],D27.505.519.389.745.085,C23.550.288
1f662190-4a14-46e6-b627-97cb81a51c24,C0815017,C0206750,could influence ,Angiotensin Receptor Antagonists,Coronavirus Infections,6,X,[phsu],[dsyn],D27.505.519.162,C02.782.600.550.200
1f662190-4a14-46e6-b627-97cb81a51c24,C0815017,C0206750,are Essential Hypertension in,Angiotensin Receptor Antagonists,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.519.162,C02.782.600.550.200
89a04922-acab-4d2e-b84f-2a113e6b4157,C0815017,C0012634,could influence ,Angiotensin Receptor Antagonists,Disease,2,X,[phsu],[dsyn],D27.505.519.162,C23.550.288
20291333-f6ee-442c-8231-bd64c5955424,C0003451,C0022709,Top results for ,Antiviral Agents,Peptidyl-Dipeptidase A,2,X,[phsu],[aapp/enzy/imft],D27.505.954.122.388,D08.811.277.656.350.350.687
9882917b-51fe-42ed-9c14-0f8f8ddf6d81,C0003451,C1167622,Top results for ,Antiviral Agents,Binding (Molecular Function),2,X,[phsu],[moft],D27.505.954.122.388,
4f96b7e5-ad43-41a9-91df-242db7973f92,C0012634,C0012644,was run on ,Disease,Animal Disease Models,2,X,[dsyn],[emod],C23.550.288,C22.232;E05.598.500;E05.599.395.080
452aa2dc-da21-4be3-a1de-b2a8305afadd,C0206074,C0031139,included ,Renal Replacement Therapy,Peritoneal Dialysis,1,X,[topp],[topp],E02.870,E02.870.300.650;E02.912.800.650
037c5e95-742c-4dda-8682-40efd7e3fe04,C0032105,C0206750,is potential ,Plasma,Coronavirus Infections,8,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C02.782.600.550.200
db1ca451-b6be-4221-96e3-4d342698fdd4,C0042776,C1707455,is in ,Virus,Comparison,1,X,[virs],[acty],B04,
01f9017c-cfc3-4e66-ae19-c7cfcb9e7143,C0042776,C0017428,is with positive-polarity ,Virus,Genome,2,X,[virs],[gngm],B04,G05.360.340
bbedea9b-5430-4873-9cf1-5ea30e4c9af4,C0917801,C0206750,experiencing high degree of threat from ,Sleeplessness,Coronavirus Infections,1,X,[sosy],[dsyn],C10.886.425.800.800;F03.870.400.800.800,C02.782.600.550.200
ccca79df-2b37-44e9-b115-3bae39f31874,C0206750,C1880022,performed RNA sequencing from clinically well ,Coronavirus Infections,Characterization,1,X,[dsyn],[acty],C02.782.600.550.200,
df30c003-b52f-4551-a109-9ade474a2471,C0014597,C1175743,showed average three-fold increase in expression of ,Epithelial Cells,SARS coronavirus,2,X,[cell],[virs],A11.436,B04.820.504.540.150.113.937
c3e029f9-7011-42a3-ad68-9ad51ad4fd28,C0014597,C0206750,showed increase In patients with ,Epithelial Cells,Coronavirus Infections,2,X,[cell],[dsyn],A11.436,C02.782.600.550.200
d7104085-d57e-4cd7-96c2-c5eb196deb9e,C0022709,C3652465,correlated with ,Peptidyl-Dipeptidase A,Interferon,2,X,[aapp/enzy/imft],[aapp/imft/phsu],D08.811.277.656.350.350.687,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
39a8cead-e498-40ae-b2fd-f01ec98d2a1e,C0022709,C0037083,correlated with ,Peptidyl-Dipeptidase A,Signal Transduction,4,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G02.111.820;G04.835
8111ed17-2fd7-4c11-840f-b416085ee856,C4330475,C0024432, includes inflammatory ,Immune Cell,macrophage,2,X,[cell],[cell],,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
e79d5743-ad21-4678-aeb5-13bd4d70d6ff,C3463820,C0021053,might suppress ,Inhibition,Immune System Diseases,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C20
e5e9fe1d-10ec-4e89-99c4-58b6de357932,C3463820,C0206750,might suppress Immune System Diseases hyperactivation in critical,Inhibition,Coronavirus Infections,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200
e5e9fe1d-10ec-4e89-99c4-58b6de357932,C3463820,C0206750,is likely part of mechanisms leading to lung injury in ,Inhibition,Coronavirus Infections,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200
602461fd-039c-4837-962e-d5566a144481,C0042109,C0085077,Erythema Nodosum like,Urticaria,Sweet Syndrome,3,X,[dsyn],[dsyn],C17.800.862.945;C20.543.480.904,C17.800.229.800
78b122e4-caf1-42dd-b0a1-8a1cb4280f07,C0012634,C0751956,had significant independent association with ,Disease,Acute Cerebrovascular Accidents,6,X,[dsyn],[dsyn],C23.550.288,C10.228.140.300.775;C14.907.253.855
78b122e4-caf1-42dd-b0a1-8a1cb4280f07,C0012634,C0751956,is significantly associated with imaging confirmation of ,Disease,Acute Cerebrovascular Accidents,6,X,[dsyn],[dsyn],C23.550.288,C10.228.140.300.775;C14.907.253.855
2ff76ace-e45f-48df-b285-c8fb07f787c9,C0003451,C1175743,were independent factors associated with ,Antiviral Agents,SARS coronavirus,21,X,[phsu],[virs],D27.505.954.122.388,B04.820.504.540.150.113.937
0d3b6757-389a-4119-8b8e-e074333d2ce0,C0003241,C1175743,can block entry of ,Antibodies,SARS coronavirus,5,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
0d3b6757-389a-4119-8b8e-e074333d2ce0,C0003241,C1175743,could trigger immunopathogenic events in ,Antibodies,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
0d3b6757-389a-4119-8b8e-e074333d2ce0,C0003241,C1175743,showed performance in detection of ,Antibodies,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
0d3b6757-389a-4119-8b8e-e074333d2ce0,C0003241,C1175743,inhibit ,Antibodies,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,B04.820.504.540.150.113.937
b2b7e971-b0d8-47a7-8c3b-b73722ea957b,C0035736,C2676137,was detected in additional ,RNA Viral,Diamond-Blackfan Anemia 1,4,X,[nnon],[dsyn],D13.444.735.828,x.x.x.x
e952e330-2e08-4ce4-af29-bd1eadc39761,C0035736,C3887642,yielding ,RNA Viral,Hippocampus Proper,4,X,[nnon],[bpoc],D13.444.735.828,A08.186.211.180.405;A08.186.211.200.885.287.500.345
12de5387-788a-46fb-ace9-af17c06ed2a7,C0035736,C0042776,yielding Hippocampus Proper with evidence of,RNA Viral,Virus,2,X,[nnon],[virs],D13.444.735.828,B04
03dda5a1-f76f-4f33-b9cd-bb49bd446586,C0042769,C1175743,is caused by novel ,Virus Diseases,SARS coronavirus,15,X,[dsyn],[virs],C02,B04.820.504.540.150.113.937
029b3f4b-7e15-4c9c-81a3-be40eef5352e,C0545747,C0024109,are at also risk of severe ,pulmonary artery and pulmonary artery,Lung,3,X,[bpoc],[bpoc],,A04.411
f34a2e25-4600-42ef-9017-fb9cfb7e370e,C0086707,C0042776,is possible mode of transmission for ,Nicotiana,Virus,3,X,[plnt],[virs],B01.650.940.800.575.912.250.908.500.900,B04
b0fc33ac-e054-430d-9392-c35da0b4903a,C0035222,C0027950,fueled by exaggerated ,Respiratory Distress Syndrome Adult,neutrophil,7,X,[dsyn],[cell],C08.381.840;C08.618.840,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
7c8a199b-36d4-4691-aa9c-35aaec6dcfdc,C0035222,C0024109,fueled by exaggerated ,Respiratory Distress Syndrome Adult,Lung,7,X,[dsyn],[bpoc],C08.381.840;C08.618.840,A04.411
37a6dc53-7eaf-4bac-8e06-eedac5e69034,C0004561,C0003241,represent unique subpopulation of B lymphocytes critical for natural ,B-Lymphocytes,Antibodies,13,X,[cell],[aapp/imft/phsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
785f50d4-0e34-4717-bc4f-d8036bcf9e04,1a,C0003241,represent unique subpopulation of B lymphocytes critical for natural ,1a,Antibodies,8,X,????,[aapp/imft/phsu],????,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
296c082f-0dba-4a55-b87a-e004cf0c305f,C1706005,C0042776,neutralizes ,CD40LG wt Allele,Virus,8,X,[gngm],[virs],,B04
966562d9-4639-40c7-9f38-158c60baf63f,C0314597,C1292101,induces IgM B lymphocyte production by,Colony-stimulating factor granulocyte-monocyte,IgM B lymphocyte,12,X,[aapp/bacs],[cell],,
8fb75827-2a33-4256-ae07-c0daf7f9a2c0,C1706005,C0004611,opsonizes ,CD40LG wt Allele,Bacteria,7,X,[gngm],[bact],,B03
9214d13c-eccc-4147-99d6-c47ad056812d,C0085295,C0079189,attenuates ,Interleukin-10,cytokine,7,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D12.644.276.374;D12.776.467.374;D23.529.374
33353ab0-c17a-4b0a-8de2-fbf2ed86566b,C0004561,C0029341,ameliorate ,B-Lymphocytes,Orthomyxoviridae,16,X,[cell],[virs],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,B04.820.545
3336e77c-1955-48c2-86e9-a8eda3d65699,1a,C0029341,ameliorate ,1a,Orthomyxoviridae,8,X,????,[virs],????,B04.820.545
b6f3887b-09c0-49b2-b0ed-fd4b549bb521,C0004561,C0243026,ameliorate ,B-Lymphocytes,Sepsis,16,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C01.539.757;C23.550.470.790.500
f116d0be-ac11-4a3a-9896-8962b721c416,1a,C0243026,ameliorate ,1a,Sepsis,8,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
5f3c8082-690e-4d35-ae11-f9e1e5dfcc28,C0004561,C0032285,ameliorate ,B-Lymphocytes,Pneumonia,16,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C08.381.677;C08.730.610
c2a67dd6-32df-467d-b906-a8e35cba7c06,1a,C0032285,ameliorate ,1a,Pneumonia,8,X,????,[dsyn],????,C08.381.677;C08.730.610
334542f9-7e50-49ed-a103-bd2f682a49be,C1880355,C0039082,further reinforces their role against ,Discover,Syndrome,2,X,[acty],[dsyn],,C23.550.288.500
79d9d4fa-eabc-4d1f-bcab-433030927aa9,C1880355,C0086418,is in ,Discover,Homo sapiens,8,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
5447b528-9504-47e1-b4e5-1aa2ae609c88,C0004561,C0003261,protect via ,B-Lymphocytes,Antibody Formation,15,X,[cell],[biof],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,G12.070
733d43f5-30af-4a86-bc0e-aadf7abb1332,1a,C0035222,protect against ,1a,Respiratory Distress Syndrome Adult,8,X,????,[dsyn],????,C08.381.840;C08.618.840
ca105a9e-80f6-4692-bffa-577a06f1c25f,C0004561,C0035222,protect against ,B-Lymphocytes,Respiratory Distress Syndrome Adult,15,X,[cell],[dsyn],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,C08.381.840;C08.618.840
35154c6d-209d-420b-801f-3bf39abe57cb,C0004561,C0032105,anti-effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
35154c6d-209d-420b-801f-3bf39abe57cb,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
35154c6d-209d-420b-801f-3bf39abe57cb,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
35154c6d-209d-420b-801f-3bf39abe57cb,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
35154c6d-209d-420b-801f-3bf39abe57cb,C0004561,C0032105,anti- effects of convalescent,B-Lymphocytes,Plasma,1,X,[cell],[bdsu],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,A12.207.152.693;A12.207.270.695;A15.145.693
7f9f9b25-091a-4332-ac48-618d26712e7f,1a,C0003261,protect via ,1a,Antibody Formation,8,X,????,[biof],????,G12.070
ed0c802f-043e-43b1-a8fc-79c877991e4f,C0036770,C0039082,suggests potential vulnerability of male reproductive system to ,Structure of sertoli cell,Syndrome,1,X,[cell],[dsyn],A05.360.444.849.789;A11.382.952;A11.436.837,C23.550.288.500
321bd2ab-9c3c-42ef-951f-6a2c93e17b6f,C0035668,C2756969,is in ,RNA,Semen,2,X,[nnon],[bdsu],D13.444.735,A12.200.732
64b0d0da-5632-452d-a80b-4e3e573af8d9,C0035668,C0444176,is in ,RNA,Seminal fluid specimen,3,X,[nnon],[bdsu],D13.444.735,
374cc207-f12c-4e21-93d1-27ae22d7dc38,C0444176,C0036563,indicates unlikely possibility of transmission through ,Seminal fluid specimen,Plant seeds,2,X,[bdsu],[plnt],,A18.024.500.750;G07.203.300.775;J02.500.775
0b508385-0180-451c-a0d2-7691791be0b7,C1265876,C0032310,suspicious for ,Abnormally opaque structure (morphologic abnormality),Pneumonia Viral,3,X,[patf],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
65e737c2-9f40-4626-abd2-fea098bc6a5c,C0264490,C0206750,secondary to ,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
65e737c2-9f40-4626-abd2-fea098bc6a5c,C0264490,C0206750,efficient Injury care for,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
65e737c2-9f40-4626-abd2-fea098bc6a5c,C0264490,C0206750,associated with ,Acute respiratory failure,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
b3661994-4dca-433f-9ac4-50a34d675ef2,C0013227,C0042776,approved for prevention of ,Pharmaceutical Preparations,Virus,2,X,[phsu],[virs],D26,B04
b3661994-4dca-433f-9ac4-50a34d675ef2,C0013227,C0042776,are active against ,Pharmaceutical Preparations,Virus,1,X,[phsu],[virs],D26,B04
b3661994-4dca-433f-9ac4-50a34d675ef2,C0013227,C0042776,eradicate ,Pharmaceutical Preparations,Virus,1,X,[phsu],[virs],D26,B04
15b8895e-6baf-4477-9000-fcb0990e17d8,C0012634,C0003062,is in ,Disease,Animals,7,X,[dsyn],[anim],C23.550.288,B01.050
795e60c1-4882-4afb-880e-9d154e5aa010,C0012634,C0005595,is in ,Disease,Aves,7,X,[dsyn],[bird],C23.550.288,B01.050.150.900.248
f39b423c-e404-4ba3-a906-e1d772868451,C0012634,C0086418,threatens health of ,Disease,Homo sapiens,31,X,[dsyn],[humn],C23.550.288,B01.050.150.900.649.313.988.400.112.400.400
294c9206-bbb9-4199-82c2-dfb95e5781e6,C0035691,C0012634,are associated with different ,RNA Viruses,Disease,7,X,[virs],[dsyn],B04.820,C23.550.288
195df539-558f-4e06-a982-93fd4c5a20a2,C0035691,C0003062,are associated with different ,RNA Viruses,Animals,7,X,[virs],[anim],B04.820,B01.050
195df539-558f-4e06-a982-93fd4c5a20a2,C0035691,C0003062,can infect ,RNA Viruses,Animals,1,X,[virs],[anim],B04.820,B01.050
a5581c5b-5f26-48dd-84bb-39989cbccecf,C0035691,C0005595,are associated with different ,RNA Viruses,Aves,7,X,[virs],[bird],B04.820,B01.050.150.900.248
70a4eff1-9188-4eee-9122-dd9edda7d812,C0035691,C0086418,are associated with different ,RNA Viruses,Homo sapiens,7,X,[virs],[humn],B04.820,B01.050.150.900.649.313.988.400.112.400.400
70a4eff1-9188-4eee-9122-dd9edda7d812,C0035691,C0086418,can infect ,RNA Viruses,Homo sapiens,1,X,[virs],[humn],B04.820,B01.050.150.900.649.313.988.400.112.400.400
df1ce00f-13c3-4fda-b486-7e98748ad317,C0206422,C0221423,be causative agents of mild respiratory ,Human coronavirus,Illness (finding),7,X,[virs],[sosy],,
b8230837-2ab0-4ce1-b4ab-bd5157d79f1e,C0003451,C0039082,described for ,Antiviral Agents,Syndrome,7,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
b8230837-2ab0-4ce1-b4ab-bd5157d79f1e,C0003451,C0039082,may prove effective respiratory ,Antiviral Agents,Syndrome,2,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
b8230837-2ab0-4ce1-b4ab-bd5157d79f1e,C0003451,C0039082,may prove effective againstsevere acute ,Antiviral Agents,Syndrome,2,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288.500
72f86be9-735e-44d5-9b2e-ec81772c1cee,C0008058,C0206750,are associated with ,Chilblains,Coronavirus Infections,2,X,[dsyn],[dsyn],C26.212.500.217;C26.417.217,C02.782.600.550.200
f6651d45-7e3f-4123-ba77-70fbeea96083,C1706005,C0039082,were negative for ,CD40LG wt Allele,Syndrome,1,X,[gngm],[dsyn],,C23.550.288.500
9c675a86-fcf1-4be9-87ba-6e6bc67e5242,titers,C0039082,were negative for ,titers,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
6ad51522-a8ea-49ba-83fc-60a098847ce0,C0012634,C0007222,is In ,Disease,Cardiovascular Diseases,13,X,[dsyn],[dsyn],C23.550.288,C14
e055aa27-6022-4f64-b45c-a68c125f256c,C0012634,C0017178, includes ,Disease,Gastrointestinal Diseases,7,X,[dsyn],[dsyn],C23.550.288,C06.405
b3926462-30fb-46e6-9bae-18f2bf7d2b59,C1457887,C0242104,were ,Symptoms,Sputum production,7,X,[sosy],[ortf],,
da64a36f-cb47-40a9-9e80-3950a7a3f348,C0036087,C0039082,detecting ,saliva,Syndrome,1,X,[bdsu],[dsyn],A12.200.666,C23.550.288.500
cd8c05c5-d730-428a-ac44-aa4b0b1d1eae,C0232741,C0206750,have have reported in ,Liver function,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
cd8c05c5-d730-428a-ac44-aa4b0b1d1eae,C0232741,C0206750,is imperative in ,Liver function,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
9325cd0a-3179-4459-be7b-ce203f118e72,C0206750,C0073187,are depicted in ,Coronavirus Infections,Blood group antigen D,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,x.x.x.x
78317b12-be84-4dd9-9959-b3fcba9a0654,C0206750,C0013227, includes promising approved ,Coronavirus Infections,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C02.782.600.550.200,D26
78317b12-be84-4dd9-9959-b3fcba9a0654,C0206750,C0013227,screened approximately 250 ,Coronavirus Infections,Pharmaceutical Preparations,2,X,[dsyn],[phsu],C02.782.600.550.200,D26
78317b12-be84-4dd9-9959-b3fcba9a0654,C0206750,C0013227,sparks fear of ,Coronavirus Infections,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C02.782.600.550.200,D26
f0e0bbf7-6fc6-49b9-beae-071d098f80c7,C0021368,C0206750,related to ,Inflammation,Coronavirus Infections,12,X,[patf],[dsyn],C23.550.470,C02.782.600.550.200
dec1795f-b0a2-407b-a559-2efbf66c3e7d,C0042071,C0206750,Dysregulation of were proposed mechanisms of ,Urokinase,Coronavirus Infections,2,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,C02.782.600.550.200
e6c4ec62-6cd9-4440-a4c9-a75f3bfe4b59,C0005778,C0206750,is in patients with ,Blood coagulation,Coronavirus Infections,5,X,[ortf],[dsyn],G09.188.390.150,C02.782.600.550.200
5fcc4032-a1b7-43cc-bcdf-12fd4ee71dfe,C0030755,C0206750,is with ,Pediatrics,Coronavirus Infections,5,X,[bmod],[dsyn],H02.403.670,C02.782.600.550.200
ae060a1e-9d43-457e-a333-d266c1e1f362,C0034602,C0206750,is in ,Interventional radiology,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.740.675,C02.782.600.550.200
601c1c17-a69f-4013-a922-abeb96db8f5f,C0206750,C0034602,changed ,Coronavirus Infections,Interventional radiology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.740.675
601c1c17-a69f-4013-a922-abeb96db8f5f,C0206750,C0034602,reduction of ,Coronavirus Infections,Interventional radiology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.740.675
6c2187dd-1f39-442d-9864-028879661221,C0008139,C1167395,serve as reservoir ,Chiroptera,Host (organism),5,X,[mamm],[orgm],B01.050.150.900.649.313.937,
6c2187dd-1f39-442d-9864-028879661221,C0008139,C1167395,are considered as reservoir ,Chiroptera,Host (organism),2,X,[mamm],[orgm],B01.050.150.900.649.313.937,
b20d27d6-f1de-490e-992a-54e0e0f124d8,C0014507,C0028606,absence of be Thus may potential risk factors for false ,Epidemiology,Nucleic Acids,2,X,[bmod],[bacs/nnon],H02.403.720.500,D13.444
f67d7e90-ca0b-4270-a52d-dfe2bee4a1bc,ECDC,C1426785,was present in 25 526 of ,ECDC,FCF1 gene,1,X,????,[gngm],????,
fdc0bf57-0070-4bd1-b8ee-4528ee81b772,C0035448,C1426785,was present in 25 526 of ,Rheumatoid Factor,FCF1 gene,1,X,[aapp/imft],[gngm],D12.776.124.486.485.114.323.732;D12.776.124.790.651.114.323.732;D12.776.377.715.548.114.323.732,
6594eb73-235f-44a3-b5a2-9a257a21bf2f,C1426785,C1829939,were significantly more likely than ,FCF1 gene,{Non-patient},2,X,[gngm],[clna],,
7142a6e6-b404-484f-94ff-7f1e3a47e434,C1426785,ECDC,present with at least one ECDC ,FCF1 gene,ECDC,1,X,[gngm],????,,????
4ffd2511-64e3-4e04-932d-7c915f8f07ac,C1426785,C0035448,present with at least one ECDC ,FCF1 gene,Rheumatoid Factor,1,X,[gngm],[aapp/imft],,D12.776.124.486.485.114.323.732;D12.776.124.790.651.114.323.732;D12.776.377.715.548.114.323.732
64cfc8c0-ed3a-4330-8231-56ecc33c9a43,C0282682,C3711684,primarily target ,Antibodies Blocking,S protein severe acute respiratory syndrome coronavirus,2,X,[aapp/imft/irda],[aapp/bacs],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,x.x.x.x
f3dec3f0-c10b-428e-8d89-d3af0db5abe2,C3711684,C0022709,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
bedfc105-7ffc-4f5b-b28d-17dd09b47389,C3711684,C1514760,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Receptor Cell,2,X,[aapp/bacs],[cell],x.x.x.x,
7ad5d64a-4ad7-49aa-b914-f054926d8da2,C3711684,C1167395,mediates CEL gene Virus Internalization through,S protein severe acute respiratory syndrome coronavirus,Host (organism),1,X,[aapp/bacs],[orgm],x.x.x.x,
f9cd0b76-663e-4a1e-9e38-b67cf1a040c6,C3711684,C1413336,mediates ,S protein severe acute respiratory syndrome coronavirus,CEL gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
db39e82b-827f-4a2f-bd74-23669beac568,C3711684,C1537068,mediates ,S protein severe acute respiratory syndrome coronavirus,Virus Internalization,2,X,[aapp/bacs],[biof],x.x.x.x,G06.920.881
2b99c33a-cc6e-4a69-929e-bf61107248f6,C0206750,C1413336,performed single ,Coronavirus Infections,CEL gene,1,X,[dsyn],[gngm],C02.782.600.550.200,
3a16b981-d1f1-48e2-8920-76318d8ea324,C0021390,C0206750,is risk factor for novel ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
3a16b981-d1f1-48e2-8920-76318d8ea324,C0021390,C0206750,should continue during ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
3a16b981-d1f1-48e2-8920-76318d8ea324,C0021390,C0206750,focused ,Inflammatory Bowel Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
3a16b981-d1f1-48e2-8920-76318d8ea324,C0021390,C0206750,is with confirmed ,Inflammatory Bowel Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C06.405.205.731;C06.405.469.432,C02.782.600.550.200
f5754de3-4d8e-4b96-8f5b-2f8561b70f4b,C0021390,C0013227,should continue their usual ,Inflammatory Bowel Diseases,Pharmaceutical Preparations,1,X,[dsyn],[phsu],C06.405.205.731;C06.405.469.432,D26
287c89fa-2fa7-41d5-a29f-b38ce9025efb,C1305957,C0038952,were associated with poor ,Cardiac troponin I,Continuance of life,3,X,[aapp/bacs],[acty],,I03.784
89385131-761b-44fe-9e93-d953f747d81f,U.S.,C1511790,was ,U.S.,Detection,2,X,????,[topp],????,
8a66a56f-9386-4493-b98d-e01afab7b37e,C0012634,C0011849,is In ,Disease,Diabetes Mellitus,7,X,[dsyn],[dsyn],C23.550.288,C18.452.394.750;C19.246
059dc332-0266-41bb-b92d-5a534a89a89c,C0012634,C0020538, includes ,Disease,Hypertensive disease,6,X,[dsyn],[dsyn],C23.550.288,C14.907.489
059dc332-0266-41bb-b92d-5a534a89a89c,C0012634,C0020538,was observed in of patients with ,Disease,Hypertensive disease,4,X,[dsyn],[dsyn],C23.550.288,C14.907.489
84e13af2-cff9-4f5e-81aa-69bcc977bc3b,C0012634,C0028754, includes ,Disease,Obesity,2,X,[dsyn],[dsyn],C23.550.288,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
84e13af2-cff9-4f5e-81aa-69bcc977bc3b,C0012634,C0028754,involve severe inflammation in people with ,Disease,Obesity,1,X,[dsyn],[dsyn],C23.550.288,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
e9d8fac5-ac83-4a54-a9dc-59137023cbb0,C0012634,C1561643, includes ,Disease,Chronic Kidney Diseases,2,X,[dsyn],[dsyn],C23.550.288,C12.777.419.780.750;C13.351.968.419.780.750
42dfe259-6456-46e0-bc27-9f870ffc3688,C0012634,C0264220, includes ,Disease,Chronic disease of respiratory system,2,X,[dsyn],[dsyn],C23.550.288,
5115a6bb-3d91-4ffc-89a1-e0703e5e28df,C0011849,C0028754,lack of insurance male sex smoking and ,Diabetes Mellitus,Obesity,2,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
45f3da7c-eae7-4a33-bbef-83e9f413473f,C3714514,C0042776,is with closely related ,Infection,Virus,4,X,[patf],[virs],C01.539,B04
a5b2b8a2-6acc-4deb-91a2-6e485743450b,C0003241,C0009450,even enhance ,Antibodies,Communicable Diseases,5,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C01.539.221
7a540900-92e0-4476-b30c-fafdefb08065,C1175743,C0242656,is in ,SARS coronavirus,Disease Progression,3,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.291.656
0bdb1c17-6b5d-4a92-b17e-7ee59ca1184b,C0206750,sera,is with convalescent sera,Coronavirus Infections,sera,3,X,[dsyn],????,C02.782.600.550.200,????
904a6e40-6be8-4d82-bfb8-8b2425702e6e,C0206750,C0340515,more severely involve Lung with multiple organ-system,Coronavirus Infections,Myocardial dysfunction,2,X,[dsyn],[patf],C02.782.600.550.200,
904a6e40-6be8-4d82-bfb8-8b2425702e6e,C0206750,C0340515,involve Myocardial dysfunction with multiple organ-system,Coronavirus Infections,Myocardial dysfunction,1,X,[dsyn],[patf],C02.782.600.550.200,
cd96edba-8ebf-47b2-b14a-54362eb7baaf,C3714514,C0340515,more severely involve Lung with multiple organ-system,Infection,Myocardial dysfunction,2,X,[patf],[patf],C01.539,
cd96edba-8ebf-47b2-b14a-54362eb7baaf,C3714514,C0340515,involve Myocardial dysfunction with multiple organ-system,Infection,Myocardial dysfunction,1,X,[patf],[patf],C01.539,
800bed95-c93e-4385-9683-4ed27fb86980,C3714514,C0024109,more severely involve ,Infection,Lung,1,X,[patf],[bpoc],C01.539,A04.411
800bed95-c93e-4385-9683-4ed27fb86980,C3714514,C0024109,mainly involve ,Infection,Lung,2,X,[patf],[bpoc],C01.539,A04.411
f0b36cbe-93ac-4d20-ab46-776da18c67f7,C0026691,C0036974,was defined by presence of ,Mucocutaneous Lymph Node Syndrome,Shock,2,X,[dsyn],[patf],C14.907.940.560;C15.604.560;C17.800.862.560,C23.550.835
aa069472-d7a5-4098-8e47-8702f257952d,C1706374,C0521982,fits description course and ,Tumor Necrosis Factor Ligand Superfamily Member 13,Response to treatment,1,X,[aapp/bacs],[clna],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,
6504d90a-ecbe-4cd4-9935-f47fdaf08151,C0206419,C0034386,Mortality of is major concern for ,Genus: Coronavirus,Quarantine,1,X,[virs],[topp],B04.820.504.540.150,N06.850.780.200.450.700
d841b061-615b-4024-a8d0-33771c2fab29,C1825598,C0042077,is in ,IMPACT gene,Urology,3,X,[gngm],[bmod],,H02.403.810.860
e09d7a45-8932-42b5-b65f-3a3f87c58dd3,C0012634,C1641588,is in medical ,Disease,Urological oncology,1,X,[dsyn],[bmod],C23.550.288,
83cba231-f54b-476c-85f9-f75db518f8a1,C0012634,C0027651,is in medical ,Disease,Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
e032ce0b-3d09-48d6-9d71-c88b5f68d209,C1515090,C0871208,had low cancellation ,Surgical Oncology specialty,Rating (action),1,X,[bmod],[acty],H02.403.429.515.750;H02.403.810.796,
ae612b34-805a-432f-a403-fb02ede40e51,C0206419,C0871208,had higher total cancellation ,Genus: Coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150,
ae612b34-805a-432f-a403-fb02ede40e51,C0206419,C0871208,determine ,Genus: Coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150,
849c30bb-b5a0-4ee0-aa05-5d28b09dcaac,C0206419,C0199939,had higher total cancellation ,Genus: Coronavirus,Oncologic procedure NOS,1,X,[virs],[topp],B04.820.504.540.150,
73ca4ed7-df13-457c-b227-ccc47f059e48,C0871208,C0030231,is in adjuvant ,Rating (action),Palliative Care,1,X,[acty],[topp],,E02.760.666;N02.421.585.666
c1deeb1a-78b6-4553-ad85-b9a4fedd5b16,C0086418,C0033684,be functional target for spike ,Homo sapiens,Proteins,1,X,[humn],[aapp/bacs],B01.050.150.900.649.313.988.400.112.400.400,D12.776
6e87d4c1-cd15-41b5-85da-7320ab86e823,C0022709,C0033684,be functional target for spike ,Peptidyl-Dipeptidase A,Proteins,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D12.776
7e2fc39c-be36-48f1-bf3a-9025718b7597,C0014442,C0033684,be functional target for spike ,Enzymes,Proteins,1,X,[aapp/enzy],[aapp/bacs],D08.811,D12.776
396107cd-e51f-4cc9-b677-52c0ba9b2ab4,C0597357,C0033684,be functional target for spike ,receptor,Proteins,1,X,[aapp/rcpt],[aapp/bacs],,D12.776
b3e24fcd-f410-490f-b74a-07a4de555ef8,C0014442,C1175743,be functional target for spike ,Enzymes,SARS coronavirus,1,X,[aapp/enzy],[virs],D08.811,B04.820.504.540.150.113.937
00ac4bbf-442c-42f4-9776-2032fa0c7c0c,C0003015,C0011860,are currently used for treatment of patients with ,Angiotensin-Converting Enzyme Inhibitors,Diabetes Mellitus Non-Insulin-Dependent,1,X,[phsu],[dsyn],D27.505.519.389.745.085,C18.452.394.750.149;C19.246.300
654b9139-9e5e-4151-92f4-5d8769222d49,C0087111,C1175175,favorably alter clinical course of ,Therapeutic procedure,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02,C02.782.600.550.200.750;C08.730.730
654b9139-9e5e-4151-92f4-5d8769222d49,C0087111,C1175175,Symptoms of,Therapeutic procedure,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02,C02.782.600.550.200.750;C08.730.730
87197e53-e9dc-42b1-8eb2-add96725f9b6,IBT,C0011860,is in patients with ,IBT,Diabetes Mellitus Non-Insulin-Dependent,1,X,????,[dsyn],????,C18.452.394.750.149;C19.246.300
09f387da-832c-4bb0-9778-c3244fdf3be6,IBT,C0206419,is in patients with ,IBT,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
c2a95585-a678-4de9-b8bf-b3d7a4aaccac,C0024264,CD3, includes total CD3,Lymphocyte,CD3,6,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
bd76fe04-0aca-46a9-a180-76445e595422,C0206419,C0027926,is with ,Genus: Coronavirus,Science of neurosurgery,2,X,[virs],[bmod],B04.820.504.540.150,H02.403.810.425
454c78dc-3fee-426d-8dd5-888b96178e89,pre,C0242781,is proposed based on risk of ,pre,disease transmission,2,X,????,[patf],????,N06.850.310
1907c893-233b-4c31-ae98-b528fa85f337,C0543467,C0242781,is proposed based on risk of ,Operative Surgical Procedures,disease transmission,2,X,[topp],[patf],E04,N06.850.310
5902f46f-f574-4bcd-a8ac-1348749414f8,C4050231,C0242781,is proposed based on risk of ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,disease transmission,2,X,[clna],[patf],,N06.850.310
65ba8f72-75b5-4c00-a138-93bd5cbb1c42,C0206419,C0450254,is caused by highly ,Genus: Coronavirus,Pathogenic organism,1,X,[virs],[orgm],B04.820.504.540.150,
65ba8f72-75b5-4c00-a138-93bd5cbb1c42,C0206419,C0450254,are severe ,Genus: Coronavirus,Pathogenic organism,3,X,[virs],[orgm],B04.820.504.540.150,
8d5362fc-c5fc-45c3-942e-e843368a4eec,C0265267,C0206419,is with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Genus: Coronavirus,3,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
1de903d4-97ce-43b6-ba9d-46905eb61bf9,C0265267,C0559758,is with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,MULTISYSTEM DISORDER,1,X,[dsyn],[dsyn],x.x.x.x,
32d7fd78-5714-44ed-8e6b-15ae9d7f65f5,C1457887,C0742038,included ,Symptoms,Cerebellar signs,1,X,[sosy],[sosy],,
e8f005a1-f06f-4f50-bef5-a94af3f2675d,C1457887,C0151786,included ,Symptoms,Muscle Weakness,1,X,[sosy],[sosy],,C05.651.515;C10.597.613.593;C23.550.695;C23.888.592.608.593
4b6d6b7f-2022-461d-9bce-f0d84e24d61b,C1457887,C0085584,included ,Symptoms,Encephalopathies,1,X,[sosy],[dsyn],,C10.228.140
28b9aad6-df3a-45b2-a9b7-06e401240c7f,C1457887,C0006121,included ,Symptoms,Brain Stem,1,X,[sosy],[bpoc],,A08.186.211.132
ffe3de95-5136-4816-9f02-b6339464a7a6,C0206419,C3272452,are group with ,Genus: Coronavirus,Single-Stranded RNA,8,X,[virs],[nnon],B04.820.504.540.150,
b0d3d513-af10-4e14-99bb-5b197d6b2bda,C0206419,C0036658,are group with ,Genus: Coronavirus,Esthesia,2,X,[virs],[ortf],B04.820.504.540.150,F02.830.816;G11.561.790
29a87fd6-35b5-4daa-b6b3-ba56ecaf10e4,C0206419,C0017428,are group with ,Genus: Coronavirus,Genome,4,X,[virs],[gngm],B04.820.504.540.150,G05.360.340
3f94801a-fbd3-423c-89d1-ea40c935b5a4,C0018787,C0206419,is in convalescent phase for patients recovered from ,Heart,Genus: Coronavirus,1,X,[bpoc],[virs],A07.541,B04.820.504.540.150
3f94801a-fbd3-423c-89d1-ea40c935b5a4,C0018787,C0206419,is in patients hospitalized with ,Heart,Genus: Coronavirus,1,X,[bpoc],[virs],A07.541,B04.820.504.540.150
3f94801a-fbd3-423c-89d1-ea40c935b5a4,C0018787,C0206419,are potential targets in ,Heart,Genus: Coronavirus,2,X,[bpoc],[virs],A07.541,B04.820.504.540.150
5c974b1b-f339-4b48-b93d-23784bd8f834,dataset,C0442540,provides four kinds of data ,dataset,Streams,4,X,????,[npop],????,G01.311.750;G16.500.275.280.650;N06.230.232.650
4b47cfb1-186b-43ce-ab5b-d2d02e6919fb,dataset,C1882932,provides four kinds of data ,dataset,Representation (action),2,X,????,[acty],????,
91dd4d11-47f6-4229-8714-73238e822ab6,dataset,C1175743,provides four kinds of data ,dataset,SARS coronavirus,8,X,????,[virs],????,B04.820.504.540.150.113.937
91dd4d11-47f6-4229-8714-73238e822ab6,dataset,C1175743,presents dataset ,dataset,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
8e82de90-0b71-49f6-89a9-4a5985b3eeb5,C0597357,C0022567,was found expressed on skin mainly on ,receptor,keratinocyte,3,X,[aapp/rcpt],[cell],,A11.409.500;A11.436.397
152becc5-2a69-4610-8d53-29a55f9bd872,C0206419,C0597295,determine ,Genus: Coronavirus,Protein Biosynthesis,2,X,[virs],[moft],B04.820.504.540.150,G02.111.660.871;G03.734.871;G05.297.670
85404aab-65f9-4f55-87a2-eed8d60570f0,C1175743,C0871208,have faster ,SARS coronavirus,Rating (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
ba04c339-539b-4f42-a3fe-87233491b29a,C0206419,RSCU,have high RSCU ,Genus: Coronavirus,RSCU,2,X,[virs],????,B04.820.504.540.150,????
8c43f491-9c39-4ea0-8322-63dcaa1e2c2e,C0206419,C0206422,have high RSCU ,Genus: Coronavirus,Human coronavirus,2,X,[virs],[virs],B04.820.504.540.150,
8c43f491-9c39-4ea0-8322-63dcaa1e2c2e,C0206419,C0206422,caused by novel ,Genus: Coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150,
de09816d-5013-4b20-83e3-67c071b5ec9d,C0871208,C1157569,is in zoonotic ,Rating (action),viral translation,1,X,[acty],[celf],,
cdd8689a-6ff5-442b-a845-6a792cda9a7c,C0004651,C0031676,has ,Bacteriophages,Phospholipids,4,X,[virs],[bacs/orch],B04.123,D10.570.755
2ab1ebd0-ce22-466a-99bc-7370d8c4b8ef,C2975867,C0031676,has ,GPI protein human,Phospholipids,4,X,[aapp/enzy],[bacs/orch],x.x.x.x,D10.570.755
04b110d2-9b67-49ff-9b17-89c2e6757325,C0004651,C1622204,has ,Bacteriophages,envelope,4,X,[virs],[celc],B04.123,
9809d81c-c8b6-4301-8d8a-8e37eb40af40,C2975867,C1622204,has ,GPI protein human,envelope,4,X,[aapp/enzy],[celc],x.x.x.x,
7038475f-b487-4d05-b9d4-43aa0af3d735,C2975867,C0086418,is used as surrogate for ,GPI protein human,Homo sapiens,8,X,[aapp/enzy],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
11693249-0fab-4731-8f8a-133ffc5cabe0,C2975867,C0005889,was suspended in ,GPI protein human,Body Fluids,4,X,[aapp/enzy],[bdsu],x.x.x.x,A12.207
9bc6cba6-ad7e-477d-9981-25f2b2ce1a08,C2975867,C0038239,inoculated onto cm coupons of ,GPI protein human,Steel,4,X,[aapp/enzy],[bodm/inch],x.x.x.x,D01.490.800;D01.552.033.847;D25.058.807;J01.637.051.058.807;x.x.x.x
70fb1a55-afbe-4db3-8ab3-072cdfc8e96c,C0337007,C0700308,declined compared to higher AH ,High humidity,Protium,5,X,[npop],[elii],,
e75dadfd-157f-4a23-af95-ce5ecfe7fd62,C0337007,C0012634,declined under ,High humidity,Disease,4,X,[npop],[dsyn],,C23.550.288
1c409768-a85f-4f3f-8f43-ff8887245dcc,C0337007,C0337008,declined under ,High humidity,Low humidity,1,X,[npop],[npop],,
050c891c-4923-4069-87b6-c4d45433367a,C0337007,C0871208,declined at slower ,High humidity,Rating (action),1,X,[npop],[acty],,
18c58c7b-987b-4021-93b4-3409f3a6ff01,C0337007,C0520510,declined at slower rate on ,High humidity,Materials,4,X,[npop],[sbst],,
f9a66fff-5a73-4669-ad0f-11c8eb339ec7,C0949892,C0012634,is in similar AH ,Ebolavirus,Disease,2,X,[virs],[dsyn],B04.820.455.300.200,C23.550.288
3d6b7158-930d-4550-a942-b81440bb8956,C2975867,C0949892,was found conservative surrogate for ,GPI protein human,Ebolavirus,18,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
3d6b7158-930d-4550-a942-b81440bb8956,C2975867,C0949892,was used as surrogate for persistence research related to ,GPI protein human,Ebolavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
3d6b7158-930d-4550-a942-b81440bb8956,C2975867,C0949892,assess suitability as surrogate for persistence research related to enveloped ,GPI protein human,Ebolavirus,3,X,[aapp/enzy],[virs],x.x.x.x,B04.820.455.300.200
7e047093-ea08-4250-97dd-5e6640194dd9,C2975867,C0337008,was found conservative surrogate under ,GPI protein human,Low humidity,12,X,[aapp/enzy],[npop],x.x.x.x,
8baa72b7-f0eb-408e-bea8-20561e083bab,C2975867,C0012634,was found conservative surrogate under ,GPI protein human,Disease,14,X,[aapp/enzy],[dsyn],x.x.x.x,C23.550.288
8baa72b7-f0eb-408e-bea8-20561e083bab,C2975867,C0012634,was found Under laboratory-simulated ,GPI protein human,Disease,4,X,[aapp/enzy],[dsyn],x.x.x.x,C23.550.288
becbc73e-03c4-469b-a5ed-0294a5d531c1,C0042776,C0949892, includes ,Virus,Ebolavirus,3,X,[virs],[virs],B04,B04.820.455.300.200
0008cfb4-a264-498c-a3aa-fc59cd34d067,C2975867,C0042776,was used as surrogate for persistence research related to ,GPI protein human,Virus,2,X,[aapp/enzy],[virs],x.x.x.x,B04
0008cfb4-a264-498c-a3aa-fc59cd34d067,C2975867,C0042776,assess suitability as surrogate for environmental persistence research related to ,GPI protein human,Virus,1,X,[aapp/enzy],[virs],x.x.x.x,B04
5229abf8-9c8b-49d6-b1a9-33a05a526124,C2975867,C1516048,was used to ,GPI protein human,Assessed,1,X,[aapp/enzy],[acty],x.x.x.x,
589f7a52-1323-4c6c-a848-bd486897a7c9,C0012634,C0015392,has spread across ,Disease,Eye,1,X,[dsyn],[bpoc],C23.550.288,A01.456.505.420;A09.371
589f7a52-1323-4c6c-a848-bd486897a7c9,C0012634,C0015392,impacted health care Xyzinclude0 practice throughout ,Disease,Eye,1,X,[dsyn],[bpoc],C23.550.288,A01.456.505.420;A09.371
4f86ea83-7137-41c3-acd1-fd97a5eec5f1,C0012634,C0006826,are common among older ,Disease,Malignant Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
4f86ea83-7137-41c3-acd1-fd97a5eec5f1,C0012634,C0006826, includes ,Disease,Malignant Neoplasms,1,X,[dsyn],[neop],C23.550.288,C04
e98d9e39-f0ae-4757-ad7e-df4df5d4edc0,C0012634,C1290884,are common among older ,Disease,Inflammatory disorder,2,X,[dsyn],[dsyn],C23.550.288,
de6d7080-6e15-417c-bf2e-ca050aad2ede,C0015259,C0021053,could result in ,Exercise,Immune System Diseases,2,X,[dora],[dsyn],G11.427.410.698.277;I03.350,C20
3e5482e0-f3cf-4b04-9ffd-c9dae6e70a3f,C2598152,C1516048,are performed in routine ,Pulmonary Function Tests:-:Point in time:^Patient:-,Assessed,2,X,[clna],[acty],,
fb45a65d-b160-4521-8698-97e91716e02e,C2598152,C0034060,are performed in routine ,Pulmonary Function Tests:-:Point in time:^Patient:-,Pulmonary Medicine,2,X,[clna],[bmod],,H02.403.429.675
f10ad8dc-270f-40d7-a27d-296d644cfcab,C2598152,C1707391,should should restricted to small patient population with ,Pulmonary Function Tests:-:Point in time:^Patient:-,Choose (action),1,X,[clna],[acty],,
f10ad8dc-270f-40d7-a27d-296d644cfcab,C2598152,C1707391,should should performed in ,Pulmonary Function Tests:-:Point in time:^Patient:-,Choose (action),1,X,[clna],[acty],,
6586a19a-3533-47c6-8151-c2670d8a5de3,C2598152,C0007018,Diffusion capacity of lung function for,Pulmonary Function Tests:-:Point in time:^Patient:-,Carbon Monoxide,2,X,[clna],[hops/inch],,D01.200.250;D01.362.200;D01.650.550.250
56f6c1d3-4769-484b-bc7c-77078d8868fd,C0026766,C0679215,are very serious ,Multiple Organ Failure,health and disease,2,X,[patf],[npop],C23.550.835.525,
41658886-07ac-4852-8841-83cc6b011c35,C2350332,C0024432,inducing anti-inflammatory ,Exosomes,macrophage,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
022206f3-b43b-4c62-8e2f-16f026d364b2,C2350332,C4330475,can affect ,Exosomes,Immune Cell,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
f16f6528-3456-4cbf-aa6b-53b291e5d1cf,C1257975,C4330475,can affect ,Mesenchymal Stem Cells,Immune Cell,2,X,[cell],[cell],A11.329.830.500;A11.872.590.500,
1615591b-27b2-4f4e-ad63-863306c0fec8,C2350332,C0004561,inducing ,Exosomes,B-Lymphocytes,2,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562
4e2d2e64-17cb-4dad-99e4-8f88c8953383,C1257975,C0039194,can inactivate ,Mesenchymal Stem Cells,T-Lymphocyte,1,X,[cell],[cell],A11.329.830.500;A11.872.590.500,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
a33a9e29-839d-4185-92e1-a9a1c6e04779,C0087111,C0553757,identify evidence in scientific literature about ,Therapeutic procedure,Olfaction Disorders,3,X,[topp],[dsyn],E02,C10.597.751.600;C23.888.592.763.550
e7c3239d-e2de-4a79-97d9-09adb41fdfea,C0237820,C0206419,usually happened after ,Recovery - action,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
35138f13-b719-482f-a04d-c1916aff66f5,C0553757,C1175743,are strong predictors of ,Olfaction Disorders,SARS coronavirus,12,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,B04.820.504.540.150.113.937
277cd945-6214-4f5e-bb34-29724b000183,C0553757,C0009450,is in ,Olfaction Disorders,Communicable Diseases,20,X,[dsyn],[dsyn],C10.597.751.600;C23.888.592.763.550,C01.539.221
a8a88851-bade-4e67-a753-9913ba2044f0,C0553757,C0599878,be should considered as part of ,Olfaction Disorders,disease characteristic,1,X,[dsyn],[patf],C10.597.751.600;C23.888.592.763.550,
4758b548-0b67-4547-840a-87fe7a6cd0cd,C0553757,C0206419,be should considered as part of ,Olfaction Disorders,Genus: Coronavirus,1,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,B04.820.504.540.150
439ad261-4028-4618-96da-7924e5a76217,C0009262,C0432616,combines Action with,Colchicine,Blood group antibody A,2,X,[orch/phsu],[aapp/imft],D03.132.225,
65a73b77-e6d1-4a16-8879-4054741f3c4e,C0009262,C3266814,combines ,Colchicine,Action,1,X,[orch/phsu],[acty],D03.132.225,
4198bd8c-5afa-4c74-b1dc-0467902351be,C0018787,C0012634,is in patients hospitalized with ,Heart,Disease,1,X,[bpoc],[dsyn],A07.541,C23.550.288
45099189-4c11-4132-ab09-43ee0eca68c1,C0011991,C0009262,was more frequent with ,Diarrhea,Colchicine,2,X,[sosy],[orch/phsu],C23.888.821.214,D03.132.225
7a546118-0aba-4417-b9e1-bb9332a57585,C1522002,C0206419,reaches levels after 4weeks ,RNA Recognition Motif,Genus: Coronavirus,1,X,[aapp/bacs],[virs],G02.111.570.820.709.275.500.869.500,B04.820.504.540.150
7a546118-0aba-4417-b9e1-bb9332a57585,C1522002,C0206419,counter effect of ,RNA Recognition Motif,Genus: Coronavirus,1,X,[aapp/bacs],[virs],G02.111.570.820.709.275.500.869.500,B04.820.504.540.150
cb4154fa-014c-492c-8be7-76f9585cce21,C1707391,3D,generate shape-based 3D ,Choose (action),3D,1,X,[acty],????,,????
28af85b0-c4b0-4f07-9783-d8380d536202,C0013227,C0033684,may act interfere with movements within ,Pharmaceutical Preparations,Proteins,6,X,[phsu],[aapp/bacs],D26,D12.776
842071db-3746-4e3a-a31c-a1b1d1f8edac,C0013227,C0745283,may act interfere with movements within ,Pharmaceutical Preparations,INFECTIOUS PROCESS,6,X,[phsu],[patf],D26,
0a90d659-c3f6-49c0-b60a-217831842ec5,C0013227,C0086418,already approved for use ,Pharmaceutical Preparations,Homo sapiens,3,X,[phsu],[humn],D26,B01.050.150.900.649.313.988.400.112.400.400
fc28b288-19c7-402b-b0fa-530db7f767f6,C0206419,C0242781,is emerging disease transmission with widespread,Genus: Coronavirus,disease transmission,2,X,[virs],[patf],B04.820.504.540.150,N06.850.310
fc28b288-19c7-402b-b0fa-530db7f767f6,C0206419,C0242781,shows higher ,Genus: Coronavirus,disease transmission,1,X,[virs],[patf],B04.820.504.540.150,N06.850.310
e09cb2e7-63c3-4ead-8fc0-0111546ccbee,C1880355,C1175743,reinforces their potentially critical role in ,Discover,SARS coronavirus,5,X,[acty],[virs],,B04.820.504.540.150.113.937
7828dd34-655e-4b37-8bf9-a51f7813999b,C1825598,C0206419,is essential Given pandemic of ,IMPACT gene,Genus: Coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150
cdbcd2f7-5cde-418b-936c-29c27ed34a87,C0162765,C1704259,is in endosomal ,Isoprenylation,Biochemical Pathway,1,X,[celf],[moft],G02.111.672;G03.804,
a3a32413-7fe9-4940-9ef4-bd68627b8c77,C0007595,C0024109,important in acute response in ,cell growth,Lung,1,X,[celf],[bpoc],,A04.411
2d766cff-d167-42b3-b805-7aedee2b8414,C0206419,C0014597,was found highly expressed in GI ,Genus: Coronavirus,Epithelial Cells,1,X,[virs],[cell],B04.820.504.540.150,A11.436
c34d8b92-a355-4775-a003-eef054d43eea,C0476288,C0206419,is in patients with ,Digestive symptom,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
b755080a-a636-473a-bdee-1d911dba78cf,C0815172,C0206419,is with ,patient characteristics,Genus: Coronavirus,3,X,[clna],[virs],,B04.820.504.540.150
e551e483-a98c-4b92-adda-4aae3bba690d,C1175743,C0038013,is with ,SARS coronavirus,Ankylosing spondylitis,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850
42b3c7f3-4dc9-4a64-a136-2d28f96cf128,C1175743,C3179547,is with ,SARS coronavirus,secukinumab,2,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,x.x.x.x
4cd2b749-e311-4e9e-a956-cd8202602c1f,C0242656,C0035436,is in patients with ,Disease Progression,Rheumatic Fever,4,X,[patf],[dsyn],C23.550.291.656,C01.252.410.890.731;C05.550.114.843;C05.799.825
37d88374-e77c-4abd-91dc-a385d816bcaa,C0206419,C0035436,is in patients with ,Genus: Coronavirus,Rheumatic Fever,2,X,[virs],[dsyn],B04.820.504.540.150,C01.252.410.890.731;C05.550.114.843;C05.799.825
6ac1862f-724a-4f3f-92a2-f9295e08a1f2,61-year,C0038013,is with ,61-year,Ankylosing spondylitis,2,X,????,[dsyn],????,C05.116.900.853.625.800.850;C05.550.069.680;C05.550.114.865.800.850
20f413f3-7f6f-4e5f-a2db-65c83f56c08f,C0384648,C0206419,has has related in ,Interleukin-17,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.517;D12.776.467.374.465.517;D23.529.374.465.517,B04.820.504.540.150
d0e9b4cb-3c4a-42b2-a527-96af43591b2e,C3653320,C0021368,were presented as promising targets for prevention of ,Interleukin inhibitors,Inflammation,1,X,[phsu],[patf],,C23.550.470
36359ccb-1163-4f23-baaa-38c016d50a99,C3653320,C0206419,were presented as promising targets for prevention of ,Interleukin inhibitors,Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
4653576b-e57f-40c1-ae0f-2d35f3df6da7,C3653320,C1175743,is in ,Interleukin inhibitors,SARS coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150.113.937
50971215-00b8-44e6-8235-63fe60bcb394,C0206422,C0032285,causing pandemic of severe ,Human coronavirus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
50971215-00b8-44e6-8235-63fe60bcb394,C0206422,C0032285,study ,Human coronavirus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
81831fe6-5fb0-45be-80ac-664e3740a3ab,C1175743,C0206422,is novel ,SARS coronavirus,Human coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.937,
81831fe6-5fb0-45be-80ac-664e3740a3ab,C1175743,C0206422,to SARS coronavirus is,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
81831fe6-5fb0-45be-80ac-664e3740a3ab,C1175743,C0206422,cause of ,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
81831fe6-5fb0-45be-80ac-664e3740a3ab,C1175743,C0206422,is emerging ,SARS coronavirus,Human coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
da9c1624-2028-4902-91dc-aee11db8fff9,C0524816,C1167395,were potential inhibitors of key component for response of,Nucleocapsid Proteins,Host (organism),2,X,[aapp/bacs],[orgm],D12.776.964.970.600,
a64cab17-8313-476c-9439-24a1335231e1,ORF8,C1167395,were potential inhibitors of key component for antiviral response of,ORF8,Host (organism),2,X,????,[orgm],????,
62c9282a-e165-4032-ac06-5f5757e37a54,ORF8,C2610474,were potential inhibitors of,ORF8,type I interferon signaling pathway,2,X,????,[celf],????,
62c9282a-e165-4032-ac06-5f5757e37a54,ORF8,C2610474,were In study potential ,ORF8,type I interferon signaling pathway,2,X,????,[celf],????,
355a9249-721c-4a54-9cc9-8f6a616d79ee,C2610474,C1167395,component for antiviral response of ,type I interferon signaling pathway,Host (organism),2,X,[celf],[orgm],,
870a157a-494f-492f-9b83-1900587c2d70,C0524816,C2610474,were potential inhibitors of,Nucleocapsid Proteins,type I interferon signaling pathway,2,X,[aapp/bacs],[celf],D12.776.964.970.600,
870a157a-494f-492f-9b83-1900587c2d70,C0524816,C2610474,were In study potential ,Nucleocapsid Proteins,type I interferon signaling pathway,2,X,[aapp/bacs],[celf],D12.776.964.970.600,
252bcf1b-9de1-4c48-aad8-72fcdd5fbb12,ORF8,C0243077,were In study potential ,ORF8,inhibitors,2,X,????,[chvf],????,
06224a00-38d0-49a3-8f67-bfc56100b2ea,C0524816,C0243077,were In study potential ,Nucleocapsid Proteins,inhibitors,2,X,[aapp/bacs],[chvf],D12.776.964.970.600,
184a0f8b-dae1-4f7b-9df6-0e80b8d1d864,ORF6,ISRE,inhibit ISRE,ORF6,ISRE,1,X,????,????,????,????
533c1229-bd54-4af5-85d2-306efeb8bd3c,C0033684,C1319860,inhibit Response Elements after,Proteins,Sendai virus infection,2,X,[aapp/bacs],[dsyn],D12.776,
533c1229-bd54-4af5-85d2-306efeb8bd3c,C0033684,C1319860,inhibit Response Elements after,Proteins,Sendai virus infection,2,X,[aapp/bacs],[dsyn],D12.776,
e92c19e3-87e8-4b26-9494-4e9a451c23aa,ORF6,C0015980,inhibit ISRE after treatment with ,ORF6,Interferon-beta,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
8f6f898c-9972-45cf-bc0e-395d806bab6e,C0033684,C3463820,showed strong ,Proteins,Inhibition,2,X,[aapp/bacs],[acty],D12.776,F01.145.544;F02.463.425.475;F02.739.794.405
8f6f898c-9972-45cf-bc0e-395d806bab6e,C0033684,C3463820,could could direct targets for ,Proteins,Inhibition,1,X,[aapp/bacs],[acty],D12.776,F01.145.544;F02.463.425.475;F02.739.794.405
f32a691e-c4c0-4bd9-b4fe-1ff94e707d1a,C0033684,C0021743,showed strong ,Proteins,Interferon Type I,2,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890
e3e39ff4-e754-4de6-841d-32926b5e01fc,C0033684,C3652465,inhibit ,Proteins,Interferon,4,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
4ea65852-bab5-4f25-b0a0-a027ecf55adb,C0033684,C1948023,inhibit ,Proteins,Stimulation (motivation),2,X,[aapp/bacs],[npop],D12.776,
8b24d97b-2e1d-4dfa-a260-ba93a85733a4,C0033684,C0600508,inhibit ,Proteins,Response Elements,2,X,[aapp/bacs],[bacs/nnon],D12.776,G02.111.570.080.689.330.700;G02.111.570.080.689.675.700;G05.360.080.689.330.700;G05.360.080.689.675.700;G05.360.340.024.340.137.750.249.765;G05.360.340.024.340.137.750.680.765
f5ba0ce4-551c-4453-956d-1d46dbc595fd,C1707455,C0225386,is with current protective ,Comparison,Breath,3,X,[acty],[bdsu],,
afad95be-6df7-45c7-a979-67d12bc1f872,C0206750,C0035204,is viral ,Coronavirus Infections,Respiration Disorders,11,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618
7f1f3d36-25e7-4eb4-ad95-a33218ea27b7,C0231528,C1457887,were most common clinical ,Myalgia,Symptoms,8,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,
43694bcb-4723-402b-80f2-6e27fa8b5995,C0038454,C0748159,extent of ,Cerebrovascular accident,pulmonary involvement,6,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
56c87674-6d3d-4e3a-8e15-141e3f60ee6b,C1175743,C1175175,caused ,SARS coronavirus,Severe Acute Respiratory Syndrome,6,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
56c87674-6d3d-4e3a-8e15-141e3f60ee6b,C1175743,C1175175,was causative Pharmacologic Substance of,SARS coronavirus,Severe Acute Respiratory Syndrome,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
56c87674-6d3d-4e3a-8e15-141e3f60ee6b,C1175743,C1175175,stands for ,SARS coronavirus,Severe Acute Respiratory Syndrome,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
56c87674-6d3d-4e3a-8e15-141e3f60ee6b,C1175743,C1175175,belonging as ,SARS coronavirus,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.600.550.200.750;C08.730.730
8e87f2f5-3bbf-46c6-a1cf-6c7e2cbbbaec,C0206419,C0035222,triggers mechanisms main ,Genus: Coronavirus,Respiratory Distress Syndrome Adult,4,X,[virs],[dsyn],B04.820.504.540.150,C08.381.840;C08.618.840
ef10b7a8-a0f8-4575-b89e-a8a9bb347bdd,C0007222,C0242656,are at higher risk of ,Cardiovascular Diseases,Disease Progression,4,X,[dsyn],[patf],C14,C23.550.291.656
ef10b7a8-a0f8-4575-b89e-a8a9bb347bdd,C0007222,C0242656,are Additionally risk factors for ,Cardiovascular Diseases,Disease Progression,1,X,[dsyn],[patf],C14,C23.550.291.656
9676646d-2dbc-4ab6-8f4e-b9efc8aefb02,C0007222,C0035204,are at higher risk to severe ,Cardiovascular Diseases,Respiration Disorders,4,X,[dsyn],[dsyn],C14,C08.618
7625c2d5-a121-4311-b0dc-f43a80de393a,C0007222,C0035222,are at higher risk to severe respiratory manifestations of ,Cardiovascular Diseases,Respiratory Distress Syndrome Adult,6,X,[dsyn],[dsyn],C14,C08.381.840;C08.618.840
b5935af5-c85c-4edf-8c4c-de79723dae0e,C0699748,C1705178,is in ,Pathogenesis,Order (action),6,X,[patf],[acty],,
7916d50a-ffa4-44fe-97f9-646fc789bf7a,C0699748,C1999230,is in ,Pathogenesis,Providing (action),1,X,[patf],[acty],,
359d2573-c363-41c3-ba28-42669fa25862,C1704259,C0012655,potentially links cardiovascular ,Biochemical Pathway,Disease susceptibility,6,X,[moft],[clna],,C23.550.291.687;G07.100.250
b0466549-3b1e-428f-8350-9d58ac8399cc,C1704259,C1175743,links outcome to ,Biochemical Pathway,SARS coronavirus,6,X,[moft],[virs],,B04.820.504.540.150.113.937
b0466549-3b1e-428f-8350-9d58ac8399cc,C1704259,C1175743,potentially links Disease susceptibility to,Biochemical Pathway,SARS coronavirus,6,X,[moft],[virs],,B04.820.504.540.150.113.937
b0466549-3b1e-428f-8350-9d58ac8399cc,C1704259,C1175743,support Organ Transplantation in even,Biochemical Pathway,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
b0466549-3b1e-428f-8350-9d58ac8399cc,C1704259,C1175743,are engaged by ,Biochemical Pathway,SARS coronavirus,2,X,[moft],[virs],,B04.820.504.540.150.113.937
3f488698-8857-4ec1-93c0-70fa3c73ad9f,C0009450,C0206419,is with novel ,Communicable Diseases,Genus: Coronavirus,11,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
3f488698-8857-4ec1-93c0-70fa3c73ad9f,C0009450,C0206419,should should considered in elderly patients with ,Communicable Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150
692631b5-a731-4e6a-9c71-4a942c64926a,C0009450,C1175175,results in moderate to ,Communicable Diseases,Severe Acute Respiratory Syndrome,11,X,[dsyn],[dsyn],C01.539.221,C02.782.600.550.200.750;C08.730.730
0dc40a20-02b0-4faa-ba2e-c91f143a318d,C0042776,C0032285,was identified in outbreak of ,Virus,Pneumonia,1,X,[virs],[dsyn],B04,C08.381.677;C08.730.610
0dc40a20-02b0-4faa-ba2e-c91f143a318d,C0042776,C0032285,leading to ,Virus,Pneumonia,3,X,[virs],[dsyn],B04,C08.381.677;C08.730.610
538e3272-9b68-49b6-b33c-cfe12521601e,C0017428,C0035668,is inscribed on single strand of ,Genome,RNA,5,X,[gngm],[nnon],G05.360.340,D13.444.735
34b9f150-e5cf-4515-9879-42226b0fc391,C0035243,C0086418,is in ,Respiratory Tract Infections,Homo sapiens,5,X,[dsyn],[humn],C01.539.739;C08.730,B01.050.150.900.649.313.988.400.112.400.400
0fdef9be-5e75-4331-b414-351494218e7d,C0221423,C1175175, includes ,Illness (finding),Severe Acute Respiratory Syndrome,5,X,[sosy],[dsyn],,C02.782.600.550.200.750;C08.730.730
0fdef9be-5e75-4331-b414-351494218e7d,C0221423,C1175175,is similar to high ,Illness (finding),Severe Acute Respiratory Syndrome,1,X,[sosy],[dsyn],,C02.782.600.550.200.750;C08.730.730
1ebb92fb-a152-49b8-a021-ee82e4b42b4f,C0178784,C0030054,suffer through lack of ,Organ,Oxygen,9,X,[bpoc],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
b7767f5f-4520-43d4-99d0-44a284d8b344,C0178784,C1880287,suffer through ,Organ,Deregulation,10,X,[bpoc],[acty],,
9cf5641b-e997-4ec5-a8a3-645792e4bfd3,C0178784,C0021368,suffer through ,Organ,Inflammation,10,X,[bpoc],[patf],,C23.550.470
028c3967-b6b0-468a-839b-949e27079a4c,C0042769,C0009450,is ,Virus Diseases,Communicable Diseases,4,X,[dsyn],[dsyn],C02,C01.539.221
c1e7a0cb-3a03-4547-8bf9-2728320ad8de,C0599878,C1707455,is in ,disease characteristic,Comparison,2,X,[patf],[acty],,
ac45a866-4495-487d-880e-171de1ab43c6,C0599878,C4522312,is in ,disease characteristic,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,2,X,[patf],[gngm],,
2aa4d27a-bd78-4776-be9d-4549725bb028,C1707455,C4522312,is with SN ,Comparison,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,4,X,[acty],[gngm],,
49d87c21-462f-4ff4-a929-038f2fb76547,C0206419,WBC,had more WBC CRP ,Genus: Coronavirus,WBC,1,X,[virs],????,B04.820.504.540.150,????
ca699411-4844-4444-80e5-e3ff39d98a48,C0206419,C0027950,had more WBC CRP ,Genus: Coronavirus,neutrophil,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
a3fdb957-a021-4b63-84e3-a68cc21c38d7,C0206419,CRP,had more WBC CRP ,Genus: Coronavirus,CRP,1,X,[virs],????,B04.820.504.540.150,????
6ee34d3e-4caa-43d7-b999-baa9ee9da330,C4522312,C0021368,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Inflammation,2,X,[gngm],[patf],,C23.550.470
fd22d2df-b83d-496d-ab13-a87767ce85f7,C4522312,C0206419,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
fd22d2df-b83d-496d-ab13-a87767ce85f7,C4522312,C0206419,more Inflammation than,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
c489a3bc-ca90-4b8b-a0f6-0c889d1d57c9,C0024264,COVID-19,were ,Lymphocyte,COVID-19,8,X,[cell],[virs],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C000657245
983952b6-2bce-472a-bb77-4248de4d3c9a,C0027950,COVID-19,are important indicators for ,neutrophil,COVID-19,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C000657245
983952b6-2bce-472a-bb77-4248de4d3c9a,C0027950,COVID-19,predict independently ,neutrophil,COVID-19,2,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C000657245
3a7a210f-262e-4e9d-be9d-a6494757096d,C0006560,COVID-19,were ,C-reactive protein,COVID-19,4,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C000657245
f897ac5a-3859-4f3d-b2c4-d47b1cb45900,NLR,COVID-19,are important indicators for ,NLR,COVID-19,1,X,????,[virs],????,C000657245
e0a9c6b7-9227-4d5b-b688-cd52b894b49d,C0077401,COVID-19,are important indicators for ,Troponin I,COVID-19,1,X,[aapp/bacs],[virs],D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925,C000657245
ceccff62-1f5c-47c3-93bc-df818283f692,C0010294,COVID-19,are important indicators for ,Creatinine,COVID-19,1,X,[bacs/orch],[virs],D03.383.129.308.207,C000657245
9d3dab77-7419-4a47-8f49-cda0cddfc733,C0600137,COVID-19,are important indicators for ,Blood Urea Nitrogen,COVID-19,1,X,[bacs/inch],[virs],E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115,C000657245
3bc1980b-b010-4dcf-93e7-9debe430c549,C0233697,C0003467,Anxiety about future sadness and,Obsessions,Anxiety,2,X,[mobd],[mobd],F01.145.126.950,F01.470.132
ed984728-39e7-4877-9d83-75137a939d5c,C0011570,C1707455,were lower ,Mental Depression,Comparison,1,X,[mobd],[acty],F01.145.126.350,
4ab888b6-7005-4860-83dc-a82e82765072,C4050231,C1707455,were lower ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Comparison,1,X,[clna],[acty],,
71fdc476-1cdc-4e65-8905-3c33f00a20f9,C0206419,C0588006,caused mild-level ,Genus: Coronavirus,Mild depression,1,X,[virs],[mobd],B04.820.504.540.150,
f68a294d-1319-4822-b386-1edc94c659cd,C0426576,C0206419,are are recognized in ,Gastrointestinal symptom,Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
f68a294d-1319-4822-b386-1edc94c659cd,C0426576,C0206419,could could used for prognostication in hospitalized patients with ,Gastrointestinal symptom,Genus: Coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150
581d4808-3ef7-4348-83fd-eaef5bb3b371,C0426576,C0012634,have have recognized as part of ,Gastrointestinal symptom,Disease,7,X,[sosy],[dsyn],,C23.550.288
581d4808-3ef7-4348-83fd-eaef5bb3b371,C0426576,C0012634,frequently reported in ,Gastrointestinal symptom,Disease,1,X,[sosy],[dsyn],,C23.550.288
03d9b4a7-a01f-4c0c-8ffa-00fa25a91339,C1856053,COVID-19,is with ,Hydranencephaly with Renal Aplasia-Dysplasia,COVID-19,1,X,[dsyn],[virs],x.x.x.x,C000657245
7d101ae4-35a8-4582-8851-4b5e7069e0bb,C0206419,C0426576,were Comparison with,Genus: Coronavirus,Gastrointestinal symptom,4,X,[virs],[sosy],B04.820.504.540.150,
3aa6be96-a8f7-42f7-9da9-c88ed5c748e2,C1707455,C0426576,is with ,Comparison,Gastrointestinal symptom,1,X,[acty],[sosy],,
879033bd-99f9-4303-ace2-690f3cc7b2ab,C0206419,COVID-19,designated as ,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
879033bd-99f9-4303-ace2-690f3cc7b2ab,C0206419,COVID-19,causing ,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
879033bd-99f9-4303-ace2-690f3cc7b2ab,C0206419,COVID-19,supporting Nucleoside Analogs as,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
879033bd-99f9-4303-ace2-690f3cc7b2ab,C0206419,COVID-19,is causative Agent of,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
879033bd-99f9-4303-ace2-690f3cc7b2ab,C0206419,COVID-19,was found in COVID19,Genus: Coronavirus,COVID-19,1,X,[virs],[virs],B04.820.504.540.150,C000657245
edc86384-8253-4b49-8bcc-88b7b5a01e0e,C0012634,COVID-19,was named ,Disease,COVID-19,9,X,[dsyn],[virs],C23.550.288,C000657245
2405ab5c-5233-4d47-a352-cb600a50a10d,C1706853,C0206419,minimize risk of exposure to ,Assembly (construction),Genus: Coronavirus,2,X,[acty],[virs],,B04.820.504.540.150
6815da90-3a0c-49be-aa2d-13d842bb9f80,C1706853,C0012634,minimize risk of exposure to ,Assembly (construction),Disease,2,X,[acty],[dsyn],,C23.550.288
a4c3c7bc-cd8a-414f-9093-43b47a3a8f62,C0027651,COVID-19,managing Neoplasms patients during,Neoplasms,COVID-19,2,X,[neop],[virs],C04,C000657245
e4debe0a-b529-4e06-95ab-71763fca58cb,SOPA,C0024501,ultimately contribute in ,SOPA,Maintenance,6,X,????,[acty],????,N02.628
d6863d00-e473-43de-93f5-b55e0172f591,SOPA,C0920425,ultimately contribute in ,SOPA,cancer therapy,6,X,????,[topp],????,
a3e3712e-faa0-4d1d-a0a0-8a6a4debe17f,C0319157,C1175743,causes ,AS virus,SARS coronavirus,4,X,[virs],[virs],,B04.820.504.540.150.113.937
7d6c74df-5b3f-4908-b565-0aea479d6909,C0319157,COVID-19,causes ,AS virus,COVID-19,3,X,[virs],[virs],,C000657245
7d6c74df-5b3f-4908-b565-0aea479d6909,C0319157,COVID-19,led ,AS virus,COVID-19,1,X,[virs],[virs],,C000657245
f34b345f-9e8d-4344-bc9d-c513e3018777,C0017428,C0033684,encodes numerous ,Genome,Proteins,3,X,[gngm],[aapp/bacs],G05.360.340,D12.776
78c9d4b6-7d8b-4e02-98b8-367170aecba9,C0033684,C0003451,might might targets for ,Proteins,Antiviral Agents,3,X,[aapp/bacs],[phsu],D12.776,D27.505.954.122.388
0531c5a4-47c3-40a6-9894-6b1fcfa2fb26,C0002520,C1175743,is in ,Amino Acids,SARS coronavirus,3,X,[aapp/bacs/phsu],[virs],D12.125,B04.820.504.540.150.113.937
c11108b5-6629-4e7d-aac5-7e6fe48c6e08,C0001461,C0206419,is important characteristic of beta ,Adenosine Diphosphate Ribose,Genus: Coronavirus,3,X,[bacs/nnon],[virs],D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125,B04.820.504.540.150
e77ac6ec-053a-46c7-a15e-863022f904be,C0683325,C0206419,were analyzed in relation to severity of ,clinical aspects,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
5af30c91-b13f-414a-8420-8b5c984d41ab,C0026764,COVID-19,diagnosed with ,Multiple Myeloma,COVID-19,2,X,[neop],[virs],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C000657245
04627e21-6a7a-418d-aa42-028ea5c118ef,C0020538,C1136084,was significantly associated In entire series of patients with ,Hypertensive disease,Plasma cell dyscrasia,4,X,[dsyn],[dsyn],C14.907.489,
3fada122-e00c-4d77-a042-fddb3ef126a1,C0026764,C0012634,compromised system due to ,Multiple Myeloma,Disease,3,X,[neop],[dsyn],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C23.550.288
ff7d2d7b-c09d-456e-ad01-7bc42fd7538f,C2348077,C1707455,to cohort is ,Date Fruit,Comparison,2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
76985513-9246-4a3a-89a7-503e36081f4a,C0812426,C0206750,may happen in patients with severe ,Kidney problem,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
0fef1c7d-ff6e-4c06-bb60-b0eb42593947,C0014544,C0206750,have ,Epilepsy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.490,C02.782.600.550.200
855f257d-dd30-4c05-859d-12a124c6e175,andit,C1831732,could could explained by ,andit,Blood-Brain Barrier Disruption,6,X,????,[topp],????,
6468f8d6-109b-41c0-84bf-d33a1a5a8c9c,andit,C0856169,could could explained by ,andit,endothelial dysfunction,3,X,????,[dsyn],????,
15c5592b-b435-4276-8134-286de8e21149,andit,C1175743,could could explained by ,andit,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
6bbd420d-c23b-425b-93c2-43eee4a1aa34,64-year,COVID-19,is with COVID19 ,64-year,COVID-19,3,X,????,[virs],????,C000657245
97952d45-1d28-4bd0-85bb-02071884c443,64-year,COVID19,is with COVID19 ,64-year,COVID19,3,X,????,????,????,????
368ddb76-af7b-4b30-9184-cb14dd18763a,64-year,C0009450,is with COVID19 ,64-year,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
358149b1-5859-4bdf-bfc8-65e12f5fb2eb,C0011849,C0012634,is ,Diabetes Mellitus,Disease,9,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C23.550.288
c132269b-d5fd-4a0b-b698-60e204bc159f,C0022671,C0206750,thought symptomatic for ,Kidney Transplantation,Coronavirus Infections,8,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,C02.782.600.550.200
338b61a2-b674-400e-9ce0-d0746306ad26,C0012634,C0037285,has associated ,Disease,Skin Manifestations,1,X,[dsyn],[sosy],C23.550.288,C23.888.885
3da119b2-c5f8-4888-9a61-2b9b58e12c33,C0007203,C1175743,is in patients with ,Cardiopulmonary Resuscitation,SARS coronavirus,1,X,[topp],[virs],E02.365.647.110,B04.820.504.540.150.113.937
79465f1c-1458-4a69-8076-5f6687bd1bdc,C0948008,C0021400,higher rate with cohort of patients with ,Ischemic stroke,Influenza,1,X,[dsyn],[dsyn],,C02.782.620.365;C08.730.310
48289ac8-283b-4e80-a5d9-94b8263e9491,IJMR,C0009450,trend of ,IJMR,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
bfe628ab-e839-4efc-a68e-dec03c9288fc,C1825598,C0206750,is essential Given pandemic of ,IMPACT gene,Coronavirus Infections,3,X,[gngm],[dsyn],,C02.782.600.550.200
bfe628ab-e839-4efc-a68e-dec03c9288fc,C1825598,C0206750,demographic characteristics of ,IMPACT gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
bfe628ab-e839-4efc-a68e-dec03c9288fc,C1825598,C0206750,is in severe ,IMPACT gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
261cdd44-dca7-4df2-b18f-cddce3b0c548,C0032098,C0012634,developing effective remedies against novel ,Plants,Disease,2,X,[plnt],[dsyn],B01.650,C23.550.288
603ef1c0-cf93-47eb-b430-555636368d43,C0439861,C0012634,developing effective remedies against novel ,Substance,Disease,2,X,[sbst],[dsyn],,C23.550.288
1aee94e8-9abd-416b-b7b2-0e263c47b51b,C0035452,C0206750,be at high risk from ,Rheumatology specialty,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.429.730,C02.782.600.550.200
1aee94e8-9abd-416b-b7b2-0e263c47b51b,C0035452,C0206750,received national ,Rheumatology specialty,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.429.730,C02.782.600.550.200
909abcf7-d218-4bfd-bf07-9446c24c504e,C0035452,C1875400,are considered hence have self ,Rheumatology specialty,ISOLATE COMPOUND,3,X,[bmod],[phsu],H02.403.429.730,
5903d8b6-b909-4945-96c8-ef4cacd0dc42,C1175743,C0010076,members of ,SARS coronavirus,Coronaviridae,3,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
5903d8b6-b909-4945-96c8-ef4cacd0dc42,C1175743,C0010076,are emerged ,SARS coronavirus,Coronaviridae,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
5903d8b6-b909-4945-96c8-ef4cacd0dc42,C1175743,C0010076,belongs to genus ,SARS coronavirus,Coronaviridae,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540
3e71261a-0173-47c3-84c4-3c1288089bdf,C2754943,C1175743,directed against ,IgG antibody,SARS coronavirus,2,X,[celc],[virs],,B04.820.504.540.150.113.937
198e7495-f04c-430d-9014-0e9d9920cfea,C0069228,C0033110,Group for Health of Italian Society of Hygiene ,O-(glucuronic acid 2-sulfate)-(1--4)-O-(25)-anhydromannitol 6-sulfate,preventive medicine specialty,3,X,[orch],[bmod],x.x.x.x,H02.403.720.750
bca46b50-78c0-48ca-8f08-5218e56f6b07,C0343844,C0033110,Group for Health of Italian Society of Hygiene ,Siti,preventive medicine specialty,3,X,[dsyn],[bmod],,H02.403.720.750
6bb79e88-bf62-463c-8224-c2f975d74467,C0026809,C0206750,exhibit pathologic findings found in ,Mus,Coronavirus Infections,4,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C02.782.600.550.200
6345b07b-b7ca-4b34-8f1c-8a7cc49f136a,C0042774,C0206750,is often followed In severe ,Virus Replication,Coronavirus Infections,11,X,[celf],[dsyn],G06.920.925,C02.782.600.550.200
0326b826-1c1d-4e1c-a403-fc4d3a64ed21,C0003261,C0206750,exhibit pathologic findings found in ,Antibody Formation,Coronavirus Infections,2,X,[biof],[dsyn],G12.070,C02.782.600.550.200
98a559a1-3d97-4757-8acf-04470fbbcb03,C0021743,C1175743,control CoV2 ,Interferon Type I,SARS coronavirus,6,X,[aapp/imft/phsu],[virs],D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,B04.820.504.540.150.113.937
f16b9375-bf58-4866-a14a-2fc3782c8180,C0021743,CoV2,control CoV2 ,Interferon Type I,CoV2,6,X,[aapp/imft/phsu],????,D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,????
fd84a61b-e31c-4dab-b401-13648fac9f7b,C0021743,C0598312,control CoV2 ,Interferon Type I,DNA Replication,6,X,[aapp/imft/phsu],[genf],D12.644.276.374.440.890;D12.776.467.374.440.890;D23.529.374.440.890,G02.111.225;G05.226
4e2e1c64-b383-42f7-8fba-5b0a781fd89d,hACE2,C1175175,enables Deploy for in-depth analysis following robust,hACE2,Severe Acute Respiratory Syndrome,3,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
4e2e1c64-b383-42f7-8fba-5b0a781fd89d,hACE2,C1175175,Thus enables Deploy for in-depth analysis following,hACE2,Severe Acute Respiratory Syndrome,2,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
5df95230-070b-472d-8a8d-6f9b6108a4f3,C1564874,C1175175,enables Deploy for in-depth analysis following robust,Adeno-Associated Virus,Severe Acute Respiratory Syndrome,3,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200.750;C08.730.730
5df95230-070b-472d-8a8d-6f9b6108a4f3,C1564874,C1175175,Thus enables Deploy for in-depth analysis following,Adeno-Associated Virus,Severe Acute Respiratory Syndrome,2,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200.750;C08.730.730
a7560ff5-e73a-4032-ac8e-aded82d4add2,C2986594,C1175175,enables Deploy for in-depth analysis following robust,Mouse Model,Severe Acute Respiratory Syndrome,3,X,[emod],[dsyn],,C02.782.600.550.200.750;C08.730.730
a7560ff5-e73a-4032-ac8e-aded82d4add2,C2986594,C1175175,Thus enables Deploy for in-depth analysis following,Mouse Model,Severe Acute Respiratory Syndrome,2,X,[emod],[dsyn],,C02.782.600.550.200.750;C08.730.730
066e7f24-89ee-4c32-a2fc-f37ad2a85b1c,C1175175,C0319157,is with authentic patient-derived ,Severe Acute Respiratory Syndrome,AS virus,4,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,
6f7f7bc4-ece7-463c-81bc-65a20b902ad6,C1175175,C0026809,is in ,Severe Acute Respiratory Syndrome,Mus,5,X,[dsyn],[mamm],C02.782.600.550.200.750;C08.730.730,B01.050.150.900.649.313.992.635.505.500
8b2bc69b-8a47-4c1a-a90c-494ab070342b,hACE2,C2825812,enables rapid ,hACE2,Deploy,12,X,????,[acty],????,
9e8915e8-972b-400d-a8d0-20e8acc90ed6,C1564874,C2825812,enables rapid ,Adeno-Associated Virus,Deploy,12,X,[virs],[acty],B04.280.580.650.170,
51d33145-bd39-4cf0-ab05-555ca10aca2d,C2986594,C2825812,enables rapid ,Mouse Model,Deploy,12,X,[emod],[acty],,
3f13bbc7-22de-49f1-82fa-8754d047526e,C0036537,C0028606,yielded positive results for ,Bodily secretions,Nucleic Acids,1,X,[bdsu],[bacs/nnon],A12.200,D13.444
ce46842a-7943-4f80-b045-a1edb8c7f1b3,C0599705,C0206750,observed as long-term ,perfusion (blood),Coronavirus Infections,3,X,[ortf],[dsyn],,C02.782.600.550.200
5bf423f5-0dc1-4877-bdd0-3ef1560c7c3f,C0027746,C0206750,observed as long-term ,Nerve Degeneration,Coronavirus Infections,3,X,[comd],[dsyn],C23.550.737,C02.782.600.550.200
89e8bf30-f20e-4747-8148-3ff5190ebf08,C0013227,C0003364,stratified by ,Pharmaceutical Preparations,Antihypertensive Agents,6,X,[phsu],[phsu],D26,D27.505.954.411.162
9303383f-1c4b-46f7-baac-0513d89292d5,C0003364,C0206750,risk of ,Antihypertensive Agents,Coronavirus Infections,3,X,[phsu],[dsyn],D27.505.954.411.162,C02.782.600.550.200
43a89f32-0add-4c7d-b194-fc1acf731935,C0012655,C0850624,is in patients with ,Disease susceptibility,cardiovascular risk factor,2,X,[clna],[dsyn],C23.550.291.687;G07.100.250,
83acd5fa-3e52-46f1-802e-abfb76ff9135,C0087111,C0013227,is with non-specific ,Therapeutic procedure,Pharmaceutical Preparations,1,X,[topp],[phsu],E02,D26
4c7707c8-91af-4914-9f3a-fbf936b0ec86,C0087111,C0678420,is with non-specific ,Therapeutic procedure,Cocktail,1,X,[topp],[food],E02,
7f7b824a-5bc5-42af-8a65-ac326de11422,C0025598,C0002055,seems as strong ,Metformin,Alkalies,1,X,[orch/phsu],[inch],D02.078.370.141.450,D01.045
eb0bf1f3-7472-4f17-b2b6-c30e8a97122a,C0074785,C0034069,Pharmacologic Substance for,Sodium-Hydrogen Antiporter,Pulmonary Fibrosis,1,X,[aapp/bacs],[dsyn],D12.776.157.530.450.162.775;D12.776.157.530.937.703;D12.776.543.550.190.775;D12.776.543.585.450.162.775;D12.776.543.585.937.828,C08.381.765
7c44475c-5046-49ed-a0da-6f5a77082e64,C0206750,C0872315,is ,Coronavirus Infections,Communicable Diseases Emerging,4,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.221.500
6be090fd-8de7-442b-9bc4-464c6007e089,C0032113,C0079189,significantly reduced inflammatory ,Plasma Exchange,cytokine,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374;D12.776.467.374;D23.529.374
6f2b5daf-5039-429c-ad24-442d7bbb3782,C0344211,C2919552,extend patients ,Supportive care,Survival time,1,X,[topp],[clna],,
bada81d6-50cd-4d08-aae7-c58b81ffda15,C0344211,C0087111,increase chance of ,Supportive care,Therapeutic procedure,1,X,[topp],[topp],,E02
81c3b1e1-9100-46a5-8be9-ea10ad5d3c2a,C0206750,C0278348,occurred amid ,Coronavirus Infections,Immunotherapy for cancer,1,X,[dsyn],[topp],C02.782.600.550.200,
a3ee7d7c-8af5-4797-b88c-c8c7c289d630,C4684977,C0346429,standard for ,Immune Checkpoint Inhibitor,Multiple malignancy,4,X,[imft/phsu],[neop],,
098496df-c5b5-4b68-a407-167f343f296a,C4684977,C0032285,are associated with peculiar ,Immune Checkpoint Inhibitor,Pneumonia,1,X,[imft/phsu],[dsyn],,C08.381.677;C08.730.610
dc33b24f-b8c6-4c83-8ced-88616a46fefd,C0319157,C0206750,causing 2019 ,AS virus,Coronavirus Infections,34,X,[virs],[dsyn],,C02.782.600.550.200
dc33b24f-b8c6-4c83-8ced-88616a46fefd,C0319157,C0206750,is named as novel 2019-nCoV ,AS virus,Coronavirus Infections,2,X,[virs],[dsyn],,C02.782.600.550.200
dc33b24f-b8c6-4c83-8ced-88616a46fefd,C0319157,C0206750,remained in ,AS virus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
dc33b24f-b8c6-4c83-8ced-88616a46fefd,C0319157,C0206750,underlying risk factors for ,AS virus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
de76d646-2277-44dc-85c3-961e07af2512,C0024264,C0206750,predict classification of ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
de76d646-2277-44dc-85c3-961e07af2512,C0024264,C0206750,are important indicators for severity grading in ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
de76d646-2277-44dc-85c3-961e07af2512,C0024264,C0206750,are vital in ,Lymphocyte,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
de76d646-2277-44dc-85c3-961e07af2512,C0024264,C0206750,comprehensive decrease of are In conclusion reliable indicators of ,Lymphocyte,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,C02.782.600.550.200
51597bee-feee-4194-8150-55d5fc85b593,C0279328,C0206750,improve hypoxemia for ,Hyperbaric Oxygen (substance),Coronavirus Infections,2,X,[phsu],[dsyn],,C02.782.600.550.200
16803c42-99e0-4051-808d-059c7845259c,C0020431,C0206750,improve hypoxemia for ,Hyperbaric oxygenation therapy,Coronavirus Infections,2,X,[topp],[dsyn],E02.880.690.490,C02.782.600.550.200
f95671e7-028c-4aec-b7e9-c5c4c50d09fe,C0279328,C0032285,improve hypoxemia for ,Hyperbaric Oxygen (substance),Pneumonia,3,X,[phsu],[dsyn],,C08.381.677;C08.730.610
1aaa8f88-45cf-46e8-8088-1b535671c604,C0020431,C0032285,improve hypoxemia for ,Hyperbaric oxygenation therapy,Pneumonia,3,X,[topp],[dsyn],E02.880.690.490,C08.381.677;C08.730.610
bfcb2d2d-ae99-42f3-aaef-a1420debff28,C0013404,C0020431,remarkably relieved after seven days of ,Dyspnea,Hyperbaric oxygenation therapy,2,X,[sosy],[topp],C08.618.326;C23.888.852.371,E02.880.690.490
cbf6c6d8-f8c8-481d-8f95-a127d2423379,C0060323,C0728936,corresponding to peripheral ,Fibrin fragment D,Disorder of circulatory system,3,X,[aapp/bacs],[dsyn],x.x.x.x,
1d1daa97-7381-4b39-ab54-8a0e9cd131e6,C0060323,C0012634,corresponding to peripheral ,Fibrin fragment D,Disease,3,X,[aapp/bacs],[dsyn],x.x.x.x,C23.550.288
fe998803-0c27-4770-866e-126ed1c7740b,C0206750,CBRN,can in respects can viewed as CBRN ,Coronavirus Infections,CBRN,1,X,[dsyn],????,C02.782.600.550.200,????
a59559ac-5ee9-470b-b694-cc80c924ab5f,FDP,C0030054,needed ,FDP,Oxygen,1,X,????,[bacs/elii/phsu],????,D01.268.185.550;D01.362.670;x.x.x.x
a9fa60b7-5a71-4180-ba3a-f8fae1bd813a,C0060323,C0030054,needed ,Fibrin fragment D,Oxygen,1,X,[aapp/bacs],[bacs/elii/phsu],x.x.x.x,D01.268.185.550;D01.362.670;x.x.x.x
fbc48305-ef01-4411-874f-7befe442af67,C0024312,COVID-19,were significantly common than ,Lymphopenia,COVID-19,4,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,C000657245
5f49534f-633e-4c92-9144-29889a42e12c,C0003467,C0206750,expected to ,Anxiety,Coronavirus Infections,2,X,[mobd],[dsyn],F01.470.132,C02.782.600.550.200
5f49534f-633e-4c92-9144-29889a42e12c,C0003467,C0206750,were common in patients with ,Anxiety,Coronavirus Infections,2,X,[mobd],[dsyn],F01.470.132,C02.782.600.550.200
399050ff-5eb3-4a3e-ac01-4e3e6ed7cfb0,C0011570,C0206750,expected to ,Mental Depression,Coronavirus Infections,2,X,[mobd],[dsyn],F01.145.126.350,C02.782.600.550.200
399050ff-5eb3-4a3e-ac01-4e3e6ed7cfb0,C0011570,C0206750,has has observed in ,Mental Depression,Coronavirus Infections,1,X,[mobd],[dsyn],F01.145.126.350,C02.782.600.550.200
207febfd-9d3a-4ea4-ae5a-0307a431e451,C0003467,C0001546,expected to ,Anxiety,Adjustment Disorders,2,X,[mobd],[mobd],F01.470.132,F03.950.500
f2b0bf9a-bd55-4840-9975-0324a79574e3,C0011570,C0001546,expected to ,Mental Depression,Adjustment Disorders,2,X,[mobd],[mobd],F01.145.126.350,F03.950.500
473cfc55-96cc-4261-969d-6a5d772f9542,C0161816,C0003811,include ,Cardiac complication,Cardiac Arrhythmia,4,X,[patf],[dsyn],,C14.280.067;C23.550.073
e7a31d95-99f3-441b-8d05-e2aee128c344,C0161816,C0011071,include even ,Cardiac complication,Sudden death,2,X,[patf],[patf],,C23.550.260.322
fe7c033f-af0a-4d4c-9aad-a08c18b28412,C0161816,C0036980,include ,Cardiac complication,Shock Cardiogenic,2,X,[patf],[patf],,C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550
eda694b2-bb4d-4ca8-897a-3f40bf9ca3dd,C0687133,C0003811,may place patient at risk for ,Drug Interactions,Cardiac Arrhythmia,2,X,[patf],[dsyn],G07.690.773.968,C14.280.067;C23.550.073
466034a6-6b06-46d4-8e00-8b75e0db7562,C0674607,C0015733,is in ,detox adjuvant,Feces,2,X,[aapp/imft/phsu],[bdsu],x.x.x.x,A12.459
8eadb2ed-75fe-42a4-8894-9cd72699f9b4,C0206750,C0038454,lower Lymphocyte than those without history of,Coronavirus Infections,Cerebrovascular accident,14,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.300.775;C14.907.253.855
d689ddd5-81fd-41a6-8aa9-ae27d4ddbdff,C0032310,C0038454,had ,Pneumonia Viral,Cerebrovascular accident,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C10.228.140.300.775;C14.907.253.855
b52ad438-5661-4ae7-a679-22b3afe59866,C0032310,C0011849,had ,Pneumonia Viral,Diabetes Mellitus,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C18.452.394.750;C19.246
9ca93b51-f41d-4989-abae-7c369007bc6d,C0032310,C0020538,had ,Pneumonia Viral,Hypertensive disease,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C14.907.489
5fb1d46d-e562-4045-85bb-fb5e9b7c6282,C0206750,C0085096,had ,Coronavirus Infections,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.617
c7de7ba7-00c9-4864-98d8-f69f2e9e609d,C0032310,C0085096,had ,Pneumonia Viral,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C14.907.617
1c25f11c-8a76-4163-8410-de35ed57ba9e,C0038454,C0011849,is with neurological deficits ,Cerebrovascular accident,Diabetes Mellitus,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C18.452.394.750;C19.246
7c05d8b3-d9a7-4ab8-9558-f495c344ca34,C0038454,C0020538,is with neurological deficits ,Cerebrovascular accident,Hypertensive disease,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C14.907.489
15e4de26-eb41-441b-858d-fec327fa189b,C0038454,C0085096,is with neurological deficits ,Cerebrovascular accident,Peripheral Vascular Diseases,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C14.907.617
32d23724-0961-4682-9dca-354ae3b266b3,C1856053,COVID,is with mild symptoms in Pediatric COVID ,Hydranencephaly with Renal Aplasia-Dysplasia,COVID,1,X,[dsyn],????,x.x.x.x,????
ea27b83c-f754-453c-97c4-4548c5d8d552,C0042029,C1856053,is in 6-week-old child admitted on ,Urinary tract infection,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C01.539.895;C12.777.892;C13.351.968.892,x.x.x.x
6df18de5-b2ab-4177-bd4c-ca379e855db8,C4048329,C0040732,leaves ,Immunosuppression,Transplantation,1,X,[dsyn],[topp],E02.095.465.425.450;E05.478.610,E04.936
0c3dc127-19d1-48c3-ac96-8a21b0d4f7ed,C4048329,C1175175,leaves ,Immunosuppression,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],E02.095.465.425.450;E05.478.610,C02.782.600.550.200.750;C08.730.730
c6ea3572-4c1e-49f6-b3ad-de64618d0854,C0024109,C0030858,intubate after ,Lung,Pentaerythritol Tetranitrate,1,X,[bpoc],[orch/phsu],A04.411,D02.033.455.706.690
815b783c-7254-4415-ad81-dd720da96d9d,C1155266,C0040732,was attenuated in ,inflammatory response,Transplantation,2,X,[patf],[topp],,E04.936
d4950ce8-7990-4f3a-b199-db6e72b644eb,C0040732,C0009450,be might susceptible to ,Transplantation,Communicable Diseases,1,X,[topp],[dsyn],E04.936,C01.539.221
7680e4a9-3bb7-4b4b-8589-fea8f8a3e19f,C0040732,C1175743,be might susceptible to ,Transplantation,SARS coronavirus,1,X,[topp],[virs],E04.936,B04.820.504.540.150.113.937
035be3d2-146a-4e2b-a267-b0657c5f33d5,C0009450,C1175743,prioritize clinical questions related to use of ,Communicable Diseases,SARS coronavirus,64,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150.113.937
78ca798b-2021-45c4-9e4c-ea60dc39556f,C0003241,C0085278,is in ,Antibodies,Antiphospholipid Syndrome,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C20.111.197
5b699b4b-2c64-4990-81a8-a918dbc8cb8e,C0030858,C0032105,were prospectively treated with ,Pentaerythritol Tetranitrate,Plasma,4,X,[orch/phsu],[bdsu],D02.033.455.706.690,A12.207.152.693;A12.207.270.695;A15.145.693
9463f4d8-4cd5-4846-9174-ddc788103161,C0030858,C0206750,were prospectively treated with ,Pentaerythritol Tetranitrate,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.033.455.706.690,C02.782.600.550.200
9463f4d8-4cd5-4846-9174-ddc788103161,C0030858,C0206750,distinguish ,Pentaerythritol Tetranitrate,Coronavirus Infections,6,X,[orch/phsu],[dsyn],D02.033.455.706.690,C02.782.600.550.200
9aa20f5c-7559-4e5b-abf1-af4e66068d69,hotspot,C0009450,different probability of ,hotspot,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
d7c78500-235c-466c-9709-4f89843fb640,C1515417,C0024109,has developed recommendations to guide decisions in ,Thoracic Oncology,Lung,3,X,[bmod],[bpoc],,A04.411
64a56899-1ce3-4f59-a97f-ee5e8edf9f90,C1515417,C0920425,has developed recommendations to guide decisions in ,Thoracic Oncology,cancer therapy,3,X,[bmod],[topp],,
60a5cbc2-8105-4954-874e-86c963b491e5,C1515417,C1175743,has developed recommendations during ,Thoracic Oncology,SARS coronavirus,3,X,[bmod],[virs],,B04.820.504.540.150.113.937
6eb65bf1-c1a5-4b6c-8e63-517e839f8e8a,C4281807,C1167622,mediates Host Cell entry by,Vitronectin human,Binding (Molecular Function),3,X,[aapp/bacs],[moft],,
cca0e758-6ea9-4305-9d94-02aaa2e2b00a,C4281807,C0022709,mediates Host Cell entry by,Vitronectin human,Peptidyl-Dipeptidase A,5,X,[aapp/bacs],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6cd515b2-fe4b-46ba-9f54-eb6c20b59570,C4281807,C1819995,mediates ,Vitronectin human,Host Cell,3,X,[aapp/bacs],[celc],,
8abdc05f-47b1-4ee2-88c9-022463d7199b,C2987482,C0087111,may may exploited by ,Animal Coat,Therapeutic procedure,3,X,[bpoc],[topp],,E02
23b9f3e9-fd5d-4351-8649-32273b462a96,C1175743,C0035668,2-positive at RT-PCR ,SARS coronavirus,RNA,2,X,[virs],[nnon],B04.820.504.540.150.113.937,D13.444.735
6cbcf6ad-e69d-47a6-9511-57f94b378b9d,C1175743,RT-PCR,2-positive at RT-PCR ,SARS coronavirus,RT-PCR,2,X,[virs],????,B04.820.504.540.150.113.937,????
6cbcf6ad-e69d-47a6-9511-57f94b378b9d,C1175743,RT-PCR,for Hypersensitivity is topic of particular importance given insufficient quantity of RT-PCR,SARS coronavirus,RT-PCR,3,X,[virs],????,B04.820.504.540.150.113.937,????
f0a7016d-3475-4793-989e-7d50bc9393d3,C0036745,C0035668,performed after RT-PCR ,Study of serum,RNA,3,X,[bmod],[nnon],H02.781,D13.444.735
cd14c919-37e0-42b4-bec2-e1d3d71ddcbe,C0036745,RT-PCR,performed after RT-PCR ,Study of serum,RT-PCR,3,X,[bmod],????,H02.781,????
6c3b77fb-0776-48f5-a54b-55aae39786e1,C0275518,C0009450,caused by ,Acute infectious disease,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
70c5a4d1-4881-480b-a722-ab5f68a58419,C0275518,C1175743,caused by ,Acute infectious disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
22ae06b9-a063-4f1f-abeb-1fb9db3d540b,C0206750,C0719214,is in ,Coronavirus Infections,century,1,X,[dsyn],[phsu/vita],C02.782.600.550.200,
0c45f704-3a75-4921-a881-f1c5f4f9be55,C0275518,C0206750,caused by ,Acute infectious disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
e79fb2af-5e34-479b-81ce-4fadc18d335c,C0275518,C0719214,caused by ,Acute infectious disease,century,1,X,[dsyn],[phsu/vita],,
9cc96760-e68e-44b5-8670-68ea4a410b1f,C0012634,C0035222,often evolves into ,Disease,Respiratory Distress Syndrome Adult,4,X,[dsyn],[dsyn],C23.550.288,C08.381.840;C08.618.840
55373c51-a08d-40a5-8e85-c508f2fb3dbd,C0206419,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Genus: Coronavirus,Dry cough,2,X,[virs],[sosy],B04.820.504.540.150,
b9fbaa5c-b7d4-4cc1-bd05-76e3f46caf97,C0015967,C0206419,varied spectra of ,Fever,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150
b9fbaa5c-b7d4-4cc1-bd05-76e3f46caf97,C0015967,C0206419,were most common Symptoms of,Fever,Genus: Coronavirus,2,X,[sosy],[virs],C23.888.119.344,B04.820.504.540.150
3380313a-65b3-4451-a655-7cdfb767848c,HRCT,C0206419,is in ,HRCT,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
0d1702f6-b6bb-46d4-828b-8df2b50c597f,C0549646,C0206419,is in ,chest disorders,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
539c75df-9b3a-4ad3-b931-bc99ad3495a7,C0850624,C0011849, includes ,cardiovascular risk factor,Diabetes Mellitus,2,X,[dsyn],[dsyn],,C18.452.394.750;C19.246
274cab57-465b-45ae-8f4b-bcd3b46cdb46,C0850624,C0010054, includes ,cardiovascular risk factor,Coronary Arteriosclerosis,2,X,[dsyn],[dsyn],,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
19ead563-718a-4e10-81c6-7937e237fd12,C3260929,C0206419,associated with ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Genus: Coronavirus,2,X,[clna],[virs],,B04.820.504.540.150
bf90ddcf-6992-4407-832b-fe8adf95cb4a,C0520510,C1705178,required in ,Materials,Order (action),3,X,[sbst],[acty],,
c69f6d63-920c-475e-8eda-d06493ca97cd,C0037285,C0206419,is in ,Skin Manifestations,Genus: Coronavirus,2,X,[sosy],[virs],C23.888.885,B04.820.504.540.150
c1926bfc-62b4-4592-9c87-64199dbae238,C0235267,C0043047,was commonest presenting complaint followed by ,Redness of eye,Water,3,X,[sosy],[inch/phsu],,D01.045.250.875;D01.248.497.158.459.650;D01.650.550.925;x.x.x.x
3018ece7-3114-46d5-8c60-a49cdeabbb65,C0039082,C0009763,was commonest diagnosis followed by ,Syndrome,Conjunctivitis,3,X,[dsyn],[dsyn],C23.550.288.500,C11.187.183
57b4418e-e79f-410a-88ce-5f552b6a35a0,2weeks,4weeks,patients operated in 4weeks,2weeks,4weeks,1,X,????,????,????,????
2cb98120-de04-4f5c-9f0c-10a1a9e6cb41,C1829939,C0038952,were older Compared with ,{Non-patient},Continuance of life,6,X,[clna],[acty],,I03.784
ff8a5c15-5061-48ad-8684-adf016e6d7c6,C1829939,C0199470,received more ,{Non-patient},Mechanical ventilation,3,X,[clna],[topp],,
f74481b9-7ec8-4a9e-9843-65cea200d6be,C0012634,C0010054,is with ,Disease,Coronary Arteriosclerosis,3,X,[dsyn],[dsyn],C23.550.288,C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260
a0e31443-8fd4-4058-a71f-cecb2d8ca647,C0040034,C0206419,is in ,Thrombocytopenia,Genus: Coronavirus,3,X,[dsyn],[virs],C15.378.140.855,B04.820.504.540.150
f8baa79d-4ef3-4e45-9f96-13d964fc4118,C1708476,C0206419,is discussed as model against ,Implementation,Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
f8baa79d-4ef3-4e45-9f96-13d964fc4118,C1708476,C0206419,will reduce ,Implementation,Genus: Coronavirus,3,X,[acty],[virs],,B04.820.504.540.150
f8baa79d-4ef3-4e45-9f96-13d964fc4118,C1708476,C0206419,convey level for ,Implementation,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
61482081-7b61-49c4-a554-1999d4ce1605,C0011682,C0012222,using sessile wetted ,Desiccation,Diffusion,3,X,[npop],[npop],E05.196.335;G02.176,G01.202;G02.196
0e8b38aa-b94b-4a31-8397-b4349bacce83,C0011682,C0596539,using sessile wetted ,Desiccation,evaporation,3,X,[npop],[npop],E05.196.335;G02.176,
d37047da-aebb-4579-89b0-d7b2c81c9f7d,C0011682,sessile,using sessile wetted ,Desiccation,sessile,3,X,[npop],????,E05.196.335;G02.176,????
d7fe8cd0-2959-4dfe-bc70-37a96e010bdf,IFSO,C0206750,navigating bariatric procedures in patients with ,IFSO,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
76423d85-4ad8-46e6-8ee8-f076ae394abc,C0003308,C0206750,is in Iranian ,Antifungal Agents,Coronavirus Infections,2,X,[phsu],[dsyn],D27.505.954.122.136,C02.782.600.550.200
9fa8d518-481a-4676-95ba-855a23b8fda3,C0012655,C0206750,is in Iranian ,Disease susceptibility,Coronavirus Infections,6,X,[clna],[dsyn],C23.550.291.687;G07.100.250,C02.782.600.550.200
b4813c13-9bc6-4d87-84e1-26844d463f7f,C0206750,C0919659,is with ,Coronavirus Infections,oropharyngeal candidiasis,5,X,[dsyn],[dsyn],C02.782.600.550.200,
eefaa3e7-8b53-438d-8b1d-95572bfcefeb,C0206750,C0007222,is with ,Coronavirus Infections,Cardiovascular Diseases,6,X,[dsyn],[dsyn],C02.782.600.550.200,C14
e11be83f-ac94-4672-92a7-767b6e6a6f3a,C0012634,C0919659,is In ,Disease,oropharyngeal candidiasis,2,X,[dsyn],[dsyn],C23.550.288,
ca635981-4f51-41bf-8795-e50ef6c2b013,C0006837,C.,followed by C. ,Candida albicans,C.,2,X,[fngs],????,B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326,????
d99ef5ab-f392-46f5-a97f-37b91ace0fef,C0006837,C1010126,followed by ,Candida albicans,Candida dubliniensis,2,X,[fngs],[fngs],B01.300.107.795.095.326;B01.300.381.147.326;B01.300.930.176.326,
56bc04a1-91ed-443b-af69-a2de48126e0f,C0960880,C1175743,is Receptor Cell for,angiotensin converting enzyme 2,SARS coronavirus,3,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
56bc04a1-91ed-443b-af69-a2de48126e0f,C0960880,C1175743,been has identified as ,angiotensin converting enzyme 2,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
3d24b38a-f0c1-4d6f-bf52-40631d3d6fae,C0960880,C1514760,is ,angiotensin converting enzyme 2,Receptor Cell,3,X,[aapp/enzy],[cell],x.x.x.x,
57704475-4466-444f-b9a0-2dbc92103436,C1515670,C0017471,was expressed in ,mRNA Expression,Germ Cells,3,X,[genf],[cell],,A05.360.490;A11.497
18fec7de-e1c0-4a36-a8cd-5707ca0a547f,C1175743,C1704259,cause Disease through,SARS coronavirus,Biochemical Pathway,3,X,[virs],[moft],B04.820.504.540.150.113.937,
18fec7de-e1c0-4a36-a8cd-5707ca0a547f,C1175743,C1704259,were similar to target ,SARS coronavirus,Biochemical Pathway,1,X,[virs],[moft],B04.820.504.540.150.113.937,
789c5160-a70d-4bca-a05c-453194b7c967,C1175743,C1422064,cause Disease through,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
789c5160-a70d-4bca-a05c-453194b7c967,C1175743,C1422064,use Complement Factor B in addition to,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
789c5160-a70d-4bca-a05c-453194b7c967,C1175743,C1422064,use Proteasome Pathway in addition to,SARS coronavirus,ACE2 gene,2,X,[virs],[gngm],B04.820.504.540.150.113.937,
bca5c278-d4e1-47b9-be21-ab73baf30b23,C1704259,C1422064,activated by ,Biochemical Pathway,ACE2 gene,1,X,[moft],[gngm],,
62bb16b5-c58d-4b83-8b6c-764447a40b01,C0236099,C0206750,induced by ,Disorder of male reproductive system,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
7966b89b-528a-40a0-bfae-240cfb59c725,C1424188,C1421479,is in ,PPP1R2C gene,WASF1 gene,1,X,[gngm],[gngm],,
194e0b24-ddba-4ecc-bcbd-7f864352efea,C1421479,C4082587,is in ,WASF1 gene,HLA Class II Histocompatibility Antigen Gamma Chain human,1,X,[gngm],[aapp/imft],,
393e4029-77fd-41f2-bcdc-edfa4874f3ff,C1424188,C4082587,is in ,PPP1R2C gene,HLA Class II Histocompatibility Antigen Gamma Chain human,1,X,[gngm],[aapp/imft],,
b52498a2-895f-4342-a5dc-55b0cd37f2ae,C0040300,C0349410,is main cause of multi ,Body tissue,Single organ dysfunction,5,X,[tisu],[sosy],A10,
9498f112-392a-40b0-be2a-566cd61eb6af,C0242184,C0349410,is main cause of multi ,Hypoxia,Single organ dysfunction,5,X,[patf],[sosy],C23.888.852.079,
7ba0695a-1d0b-4e6a-b04e-8e385d9b96dd,C0040300,C0243026,is main cause of multi ,Body tissue,Sepsis,4,X,[tisu],[dsyn],A10,C01.539.757;C23.550.470.790.500
35d21401-24e6-41bc-928d-991f2860ca7b,C0242184,C0243026,is main cause of multi ,Hypoxia,Sepsis,4,X,[patf],[dsyn],C23.888.852.079,C01.539.757;C23.550.470.790.500
857f7b45-bd1a-456c-9b50-16a053274dfd,C0040135,C0040300,has effects on immune system in infected ,Thyroid Hormones,Body tissue,2,X,[horm],[tisu],D06.472.931,A10
f2d70f91-a512-468a-92c9-aa1e952fa731,C0015190,C0243026,is common in ,Euthyroid Sick Syndromes,Sepsis,2,X,[dsyn],[dsyn],C19.874.255,C01.539.757;C23.550.470.790.500
4dd846ae-1fe8-400b-bb4d-3c09183d1aff,C0040135,C0010340,may Thus may treatment in setting of ,Thyroid Hormones,Critical Illness,2,X,[horm],[dsyn],D06.472.931,C23.550.291.625
a1a8ff0a-a81f-4d39-a45c-59ae76e36cfb,C0040135,C0042769,may Thus may treatment in setting of ,Thyroid Hormones,Virus Diseases,2,X,[horm],[dsyn],D06.472.931,C02
bc0141e1-3f06-4565-81b6-b88428f8189d,C0010340,C0700366,requiring Extra ,Critical Illness,body membrane,2,X,[dsyn],[tisu],C23.550.291.625,
210a9a04-cc6b-47e2-afe1-5efb6c75ceca,C0206750,C0700366,requiring Extra ,Coronavirus Infections,body membrane,2,X,[dsyn],[tisu],C02.782.600.550.200,
de6bca78-bf36-42dc-a72a-40c3df266a48,C0010340,C0282636,requiring Extra ,Critical Illness,Cell Respiration,2,X,[dsyn],[celf],C23.550.291.625,G03.197;G04.270
3c637827-fdf0-4dda-9499-1381eb7364d7,C0206750,C0282636,requiring Extra ,Coronavirus Infections,Cell Respiration,2,X,[dsyn],[celf],C02.782.600.550.200,G03.197;G04.270
bd5f84bd-7365-4fb7-b8e1-beb4fac941de,C0013230,C0001617,of trial is ,Investigational New Drugs,Adrenal Cortex Hormones,2,X,[phsu],[horm/orch/phsu],D26.371,D06.472.040
4ae1c43c-668c-4314-aab4-37301e2ecc94,C0304229,C0001617,of trial is ,Experimental drug,Adrenal Cortex Hormones,2,X,[phsu],[horm/orch/phsu],,D06.472.040
a1c0d5f1-68fb-4827-b731-4e5974286fcd,C0032042,C0439861,is with composition identical apart from active ,Placebos,Substance,2,X,[topp],[sbst],D26.660;E02.785,
9825ec77-39da-4197-b228-00173bf3c8c2,C0772289,IWRS,incorporating IWRS,corticotropin-releasing factor human,IWRS,2,X,[horm/orch/phsu],????,,????
122212ca-3f8d-405e-8682-d5c04b5516f1,C0772289,C1705178,incorporating IWRS in ,corticotropin-releasing factor human,Order (action),2,X,[horm/orch/phsu],[acty],,
8ac95047-19dc-4344-8996-53b199f738d2,C0012634,C1704259,leads with increasing evidence for ,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
8ac95047-19dc-4344-8996-53b199f738d2,C0012634,C1704259,may Lead to activated,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
8ac95047-19dc-4344-8996-53b199f738d2,C0012634,C1704259,may lead to activated immune-inflammatory ,Disease,Biochemical Pathway,1,X,[dsyn],[moft],C23.550.288,
4b5b3705-e299-4e40-8111-4619cbf9952b,C2931926,C4054044,proven in treatment of ,ruxolitinib,Secondary Hemophagocytic Lymphohistiocytosis,2,X,[orch/phsu],[dsyn],,
6c8428d3-9117-421d-975c-49db5954589b,C0450442,C1175175,appear promising in fight against ,Agent,Severe Acute Respiratory Syndrome,2,X,[chvf],[dsyn],,C02.782.600.550.200.750;C08.730.730
18034347-3f11-410c-b676-71b6f93fe451,C0027078,C0206750,were selected by multivariate analysis as candidates for prediction of disease severity in ,Myoglobin,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D12.776.210.500.588;D12.776.422.316.940,C02.782.600.550.200
bd774d50-6edf-45a1-a39f-ed4800b35236,C0012634,C0242781,is mainly ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
bd774d50-6edf-45a1-a39f-ed4800b35236,C0012634,C0242781,has attracted attention due to its ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
bd774d50-6edf-45a1-a39f-ed4800b35236,C0012634,C0242781,importance of route of ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
bd774d50-6edf-45a1-a39f-ed4800b35236,C0012634,C0242781,understanding temporal course of ,Disease,disease transmission,1,X,[dsyn],[patf],C23.550.288,N06.850.310
29caa1a5-66ff-49b6-bdd6-2c12014452fd,C0282682,C0597358,is with most against ,Antibodies Blocking,receptor binding,4,X,[aapp/imft/irda],[moft],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,
411937de-e8a5-43b8-b4a1-7bfcdb2a8872,C0032105,C0597358,differed in their degree of focus on ,Plasma,receptor binding,4,X,[bdsu],[moft],A12.207.152.693;A12.207.270.695;A15.145.693,
f29f967e-568e-4d90-a057-f27c15993743,C0032105,C0003316,differed in their degree of focus on ,Plasma,Epitopes,4,X,[bdsu],[imft],A12.207.152.693;A12.207.270.695;A15.145.693,D23.050.550
0cb0ded1-369c-4921-bfff-492967b618c7,C0524865,S1,showed recognition of S1,Reconstructive Surgical Procedures,S1,4,X,[topp],????,E04.680,????
4da67413-7349-4ba4-9429-226a8615de4a,C0003316,C1422064,blocks ,Epitopes,ACE2 gene,2,X,[imft],[gngm],D23.050.550,
bea39299-2309-43ba-979e-99160db03e5e,C0003316,C0597358,blocks ,Epitopes,receptor binding,4,X,[imft],[moft],D23.050.550,
834af074-83d4-41d8-b513-c3f53989a416,C0003316,C1522002,blocks ACE2 gene receptor binding on,Epitopes,RNA Recognition Motif,1,X,[imft],[aapp/bacs],D23.050.550,G02.111.570.820.709.275.500.869.500
834af074-83d4-41d8-b513-c3f53989a416,C0003316,C1522002,blocks Peptidyl-Dipeptidase A receptor binding on,Epitopes,RNA Recognition Motif,2,X,[imft],[aapp/bacs],D23.050.550,G02.111.570.820.709.275.500.869.500
86023b07-51a6-4e56-b76e-09602e1295ef,C0206750,H1N1,has spread rapidly like just H1N1 ,Coronavirus Infections,H1N1,4,X,[dsyn],????,C02.782.600.550.200,????
edf8ca7d-1790-4e8b-b1ca-408c599f84bb,C0012634,H1N1,has spread rapidly like just H1N1 ,Disease,H1N1,4,X,[dsyn],????,C23.550.288,????
f1c8a00d-3c1c-4cfe-942c-df6382dd581b,C0206750,C1135183,has spread rapidly like just H1N1 ,Coronavirus Infections,Sus scrofa,4,X,[dsyn],[mamm],C02.782.600.550.200,B01.050.150.900.649.313.500.880.399
16748aea-d274-42e9-8ade-2a007b999a1c,C0012634,C1135183,has spread rapidly like just H1N1 ,Disease,Sus scrofa,4,X,[dsyn],[mamm],C23.550.288,B01.050.150.900.649.313.500.880.399
0f4f021e-4ee0-4257-8078-9b933330e405,C0206750,C2076600,has spread rapidly like just H1N1 ,Coronavirus Infections,Influenza due to Influenza A virus subtype H1N1,4,X,[dsyn],[dsyn],C02.782.600.550.200,
0f4f021e-4ee0-4257-8078-9b933330e405,C0206750,C2076600,is severe than 2009 ,Coronavirus Infections,Influenza due to Influenza A virus subtype H1N1,2,X,[dsyn],[dsyn],C02.782.600.550.200,
cdee5d66-6ede-474b-bc73-9505aa82d18d,C0012634,C2076600,has spread rapidly like just H1N1 ,Disease,Influenza due to Influenza A virus subtype H1N1,4,X,[dsyn],[dsyn],C23.550.288,
487bc63f-a2a9-4a27-b8ac-40365a60c524,C0242648,C0206750,using Medical Subject terms ,Vertical Disease Transmission,Coronavirus Infections,4,X,[patf],[dsyn],N06.850.310.425,C02.782.600.550.200
2f44c3bb-ce09-4a17-ab96-e587fde79e29,C0439056,C0033727,were collected at ,Throat swab sample,Protons,6,X,[bdsu],[elii],,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
ec951a39-54a4-42bf-8234-bab8d4eb547d,C1511790,C0229671,is in neonates ,Detection,Serum,8,X,[topp],[bdsu],,A12.207.152.846;A15.145.846
d3ff3f3d-8917-435b-bad7-27d1b72d954a,C0039082,C0282686,concern only ,Syndrome,Respiratory System Agents,2,X,[dsyn],[phsu],C23.550.288.500,D27.505.954.796
3ffa23f8-fe57-4b1d-aa2e-a33ccd37949e,COVID,C0242821,numerous areas of ,COVID,Human body,4,X,????,[humn],????,I01.076.201.450.560;K01.093.378
88d466e4-eaa8-40c4-a3ae-e637e401ffd2,C1999230,C1707455,direct visualization of anatomic injury ,Providing (action),Comparison,1,X,[acty],[acty],,
a5e08a03-50a3-43bb-96eb-49b187c8120c,C0319157,C3697872,belongs to ,AS virus,Genus Betacoronavirus,3,X,[virs],[virs],,
763e0c4c-0575-4237-ab23-b36593a3bced,C0319157,C0010076,belongs to ,AS virus,Coronaviridae,3,X,[virs],[virs],,B04.820.504.540
992a8603-45b5-432d-aecc-64051e695733,C0221423,C0206419,with Genus: Coronavirus is,Illness (finding),Genus: Coronavirus,2,X,[sosy],[virs],,B04.820.504.540.150
992a8603-45b5-432d-aecc-64051e695733,C0221423,C0206419,caused by ,Illness (finding),Genus: Coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150
0967a81c-0e35-4a6c-930a-18fb248ae364,C1628478,C1550100,is in ,SARS coronavirus IgG,Specimen Type - Serum,2,X,[aapp/imft],[bdsu],,
6c9eafbe-f0d0-4d99-974f-424b9499602e,C1628478,C0086418,is in ,SARS coronavirus IgG,Homo sapiens,1,X,[aapp/imft],[humn],,B01.050.150.900.649.313.988.400.112.400.400
cc0813c9-90e2-41f2-b77c-fa1b5a3ee686,C0191234,C1883720,was performed with ,Pericardiocentesis,Removing (action),1,X,[topp],[acty],E01.370.225.998.329.620;E02.800.550.620;E04.100.376.745;E04.665.600.620;E04.928.220.620;E05.200.998.329.620,
b66aa7cc-34fe-45e2-b42c-0fddb69053ab,C0020452,C0206419,were reported in ,Hyperemia,Genus: Coronavirus,1,X,[dsyn],[virs],C14.907.474,B04.820.504.540.150
b90790e0-c242-4f20-8c7c-bf7ea3e57e7b,C0264545,C0206419,were reported in ,Thickening of pleura,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
74a25d23-f9e3-4c73-b5f6-0dd43d0bdb14,C0206419,C0032310,involvement with non-COVID ,Genus: Coronavirus,Pneumonia Viral,2,X,[virs],[dsyn],B04.820.504.540.150,C02.705;C08.381.677.807;C08.730.610.763
74a25d23-f9e3-4c73-b5f6-0dd43d0bdb14,C0206419,C0032310,emerged as ,Genus: Coronavirus,Pneumonia Viral,1,X,[virs],[dsyn],B04.820.504.540.150,C02.705;C08.381.677.807;C08.730.610.763
c0b846ed-cd83-405b-979a-a30270b81651,C0206419,C1707455,involvement of upper ,Genus: Coronavirus,Comparison,2,X,[virs],[acty],B04.820.504.540.150,
8463aca8-6118-4be2-932c-20380bd2f106,C0019682,C0206419,is with ,HIV,Genus: Coronavirus,3,X,[virs],[virs],B04.820.650.589.650.350,B04.820.504.540.150
e5b0d466-d352-47ac-b8ca-471d0742305f,C0019682,C1963724,had proportions on ,HIV,Antiretroviral therapy,1,X,[virs],[topp],B04.820.650.589.650.350,
c9b7c158-e398-4e83-9d93-b0e59de36090,C2948600,C0242821,review growing ,Aim,Human body,1,X,[inch/phsu],[humn],,I01.076.201.450.560;K01.093.378
3aa1fed0-fd1c-49e7-8585-2156e0724e3c,C2948600,C0242656,review growing ,Aim,Disease Progression,2,X,[inch/phsu],[patf],,C23.550.291.656
aef6b1cb-673e-424b-ba2f-82563a39d0f8,C2948600,C0035436,review growing ,Aim,Rheumatic Fever,1,X,[inch/phsu],[dsyn],,C01.252.410.890.731;C05.550.114.843;C05.799.825
bcc8a13a-bbde-4bed-97a5-a5bfae97bb2c,C1701790,C0206419,has has related to hyperinflammatory state in ,IL17A protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
dad4ba2d-7e0b-4958-8112-0b37892a8f01,C2364111,C1457887,was reported less frequently than other ,Ageusia,Symptoms,3,X,[sosy],[sosy],C10.597.751.861.184;C23.888.592.763.861.184,
e98d2fcf-a6ad-434e-8952-2818b367db08,C1457887,C1175743,predicting ,Symptoms,SARS coronavirus,3,X,[sosy],[virs],,B04.820.504.540.150.113.937
e98d2fcf-a6ad-434e-8952-2818b367db08,C1457887,C1175743,met in older adults infected with ,Symptoms,SARS coronavirus,4,X,[sosy],[virs],,B04.820.504.540.150.113.937
e98d2fcf-a6ad-434e-8952-2818b367db08,C1457887,C1175743,conduct surveillance for ,Symptoms,SARS coronavirus,1,X,[sosy],[virs],,B04.820.504.540.150.113.937
63fca819-523b-4982-b188-96fc6a1b9f49,C0013879,C0871208,promote similar -1 PRF ,Elements,Rating (action),2,X,[elii],[acty],D01.268,
9e1b79b9-408b-4dfa-99af-50801642b750,C0013879,C1538187,promote similar ,Elements,ZNF395 gene,1,X,[elii],[gngm],D01.268,
9e1b79b9-408b-4dfa-99af-50801642b750,C0013879,C1538187,similar Rating (action) of,Elements,ZNF395 gene,1,X,[elii],[gngm],D01.268,
0f271938-deb7-4392-be92-4c986d5103bb,C1519323,C1186763,is in three ,Silent Mutation,Stem of Organ,6,X,[genf],[bpoc],G05.365.590.803,
ece9b655-2681-446a-b094-a181ff179bf2,C1538187,C1175743,is in ,ZNF395 gene,SARS coronavirus,9,X,[gngm],[virs],,B04.820.504.540.150.113.937
55479809-7610-4e20-9f0a-eabab68d3d9c,C0243077,C0303231,Providing (action) promising,inhibitors,Lead compound,1,X,[chvf],[chvs],,
659b5dea-77af-43b1-bb69-31f7b316be7e,PRF,C1538187,was similarly effective against ,PRF,ZNF395 gene,6,X,????,[gngm],????,
bfa270f9-28c5-4544-8aa7-2146f6ae6bce,PRF,C1175743,was similarly effective against ,PRF,SARS coronavirus,6,X,????,[virs],????,B04.820.504.540.150.113.937
de4e1250-9f9d-471f-b21f-8becd7b6b65e,C0444279,C0206419,collected from confirmed ,Respiratory sample,Genus: Coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150
83baec20-9633-4257-9072-c701ae2f703c,C2985398,C1167395,regulating ,Intestinal Microbiome,Host (organism),1,X,[orgm],[orgm],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,
415abb76-4e5f-4d96-b25d-9a105ff3708e,C2985398,C0019868,regulating ,Intestinal Microbiome,Homeostasis,1,X,[orgm],[biof],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,G07.410
07eb8aa7-f72d-42aa-8bee-59f1f311ad4e,C2985398,C0024501,is closely related to ,Intestinal Microbiome,Maintenance,1,X,[orgm],[acty],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,N02.628
258d3409-62c7-4736-9458-b84225deca51,C2985398,C0024109,is closely related to ,Intestinal Microbiome,Lung,1,X,[orgm],[bpoc],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,A04.411
98e4df0c-781b-43a3-86c1-26935f920ab2,C0012155,C0870883,improving proportion of its ,Diet,Metabolite,1,X,[food],[bacs],G07.203.650.240,
183c0373-3a23-41c2-b8fa-b2d92387c7dd,C0012155,C0525033,improving proportion of its ,Diet,Probiotics,1,X,[food],[bact],G07.203.650.240,G07.203.300.456.500;J02.500.456.500
13b20384-8dfe-4f0c-9330-a5e29cb0cb90,C0012155,C2985398,improving composition of ,Diet,Intestinal Microbiome,1,X,[food],[orgm],G07.203.650.240,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
1b805833-3581-48f9-a3d4-958ebc38c6ab,C0012155,C0206419,prevent ,Diet,Genus: Coronavirus,1,X,[food],[virs],G07.203.650.240,B04.820.504.540.150
ec9e0ca2-62b3-483e-afff-1354a05a1061,C0022671,C0206419,thought symptomatic for ,Kidney Transplantation,Genus: Coronavirus,6,X,[topp],[virs],E02.870.500;E04.936.450.485;E04.950.774.400,B04.820.504.540.150
3d646a27-b221-4b48-8935-7aee70633700,C0027950,C0206419,predict independently classification of ,neutrophil,Genus: Coronavirus,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,B04.820.504.540.150
fdb2f0f3-c2dc-4a5f-b6f5-0d08c737b4b2,C1175743,C0035691,is new ,SARS coronavirus,RNA Viruses,5,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820
32e01d1b-2562-48cb-93c2-770d4f51241e,C1412002,C0026766,can progress to ,Atypical pneumonia,Multiple Organ Failure,5,X,[dsyn],[patf],,C23.550.835.525
9eeddd9e-ef97-44f5-8f4f-d6bac400b095,C0206419,C0024291,simulate ,Genus: Coronavirus,Lymphohistiocytosis Hemophagocytic,2,X,[virs],[dsyn],B04.820.504.540.150,C15.604.250.410.575
43a69e68-1e91-40a4-9ee7-86ec37071908,C1624602,C1609165, includes ,Anti-Antibodies,tocilizumab,4,X,[aapp/imft],[aapp/imft/phsu],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,x.x.x.x
837e9e60-a655-44a0-8e44-6b182fc2a723,C1624602,C1175743,play role in treatment with ,Anti-Antibodies,SARS coronavirus,6,X,[aapp/imft],[virs],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,B04.820.504.540.150.113.937
8a108450-5314-4a40-b6c0-571c93a42bae,C0063717,C1175743,play role in treatment with ,Interleukin 6 Receptor,SARS coronavirus,4,X,[aapp/imft/rcpt],[virs],D12.776.543.750.705.852.420.400,B04.820.504.540.150.113.937
88cee4aa-81bb-4fd7-8766-5a1c192c610a,C1609165,C1175743,play role in treatment with ,tocilizumab,SARS coronavirus,5,X,[aapp/imft/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
e3a5c574-3a30-4a84-af1f-894bd29587b8,C0035243,C1175743,is with ,Respiratory Tract Infections,SARS coronavirus,1,X,[dsyn],[virs],C01.539.739;C08.730,B04.820.504.540.150.113.937
135b71d3-2af9-47ae-b7bc-eeefe3239710,C1292459,C0206419,is with ,Specimen from patient,Genus: Coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150
a5dfc802-54c5-4fe4-9ecd-284e7f7ff6a4,C0026691,C0042769,suggest here hypothesis of new post-viral ,Mucocutaneous Lymph Node Syndrome,Virus Diseases,6,X,[dsyn],[dsyn],C14.907.940.560;C15.604.560;C17.800.862.560,C02
54a77080-b9e6-4584-b2b0-9be1bd9e6494,C1550661,C1175743,became for ,Specimen Type - Stool = Fecal,SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
10c53b6d-929f-46c3-bb85-c2183333a8ac,C1550661,C0444279,15days after first positive ,Specimen Type - Stool = Fecal,Respiratory sample,3,X,[bdsu],[bdsu],,
5c3add2e-8292-47f2-9b3d-5215acc1d267,C0265267,C0012634,is associated with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Disease,3,X,[dsyn],[dsyn],x.x.x.x,C23.550.288
8fb17cee-d146-4634-9efe-832d85d1ae92,NYSDOH,C0265267,definition for ,NYSDOH,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,2,X,????,[dsyn],????,x.x.x.x
f75d4998-a0c7-4045-a281-1071e919d997,NYSDOH,C1856053,definition for ,NYSDOH,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,????,[dsyn],????,x.x.x.x
d16093b6-163d-4020-af59-a2d50979bffb,C0426576,C1761613,had ,Gastrointestinal symptom,Conjunctival hyperemia,3,X,[sosy],[dsyn],,
be135911-cb1b-46ba-ad8a-ab30a2bd8756,C0426576,C0015230,had ,Gastrointestinal symptom,Exanthema,3,X,[sosy],[sosy],,C17.800.257
0490414e-bed0-4126-8748-770cb448aa36,C0007430,C0206419,was compared ,Catheterization,Genus: Coronavirus,1,X,[topp],[virs],E02.148;E05.157,B04.820.504.540.150
c5df1cf1-139f-4d28-9ea2-47f9efab2c17,C0917801,C0206419,experiencing high degree of threat from ,Sleeplessness,Genus: Coronavirus,1,X,[sosy],[virs],C10.886.425.800.800;F03.870.400.800.800,B04.820.504.540.150
4338d2e8-12a6-4c22-aaf7-083954247a1f,C0683325,C0026769,is in patients with ,clinical aspects,Multiple Sclerosis,1,X,[clna],[dsyn],,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
9f0af6e6-5ac3-44a1-b180-1be918edefdf,C0387382,C0206419,were independent risk factors for ,CI 4,Genus: Coronavirus,1,X,[aapp/phsu],[virs],,B04.820.504.540.150
223e80fc-a606-4d22-87d3-5b48f524ff58,C0028754,C0206419,were independent risk factors for ,Obesity,Genus: Coronavirus,1,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
223e80fc-a606-4d22-87d3-5b48f524ff58,C0028754,C0206419,also have worse outcomes with ,Obesity,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
223e80fc-a606-4d22-87d3-5b48f524ff58,C0028754,C0206419,BACKGROUND/During 2019 ,Obesity,Genus: Coronavirus,4,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
223e80fc-a606-4d22-87d3-5b48f524ff58,C0028754,C0206419,may contribute to ,Obesity,Genus: Coronavirus,2,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,B04.820.504.540.150
d4d3952b-15e5-4870-95b9-4fa56db671a2,EDSS,C0206419,was associated with highest variability of ,EDSS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
a3572aea-bd7f-4351-a2d1-af49337db9ea,C1415900,C0007600,is in ,IFNA1 gene,Cultured Cell Line,3,X,[gngm],[cell],,A11.251.210
453d43be-de1b-40ca-ad63-744e4010c908,C2931926,C1175743,boosted ,ruxolitinib,SARS coronavirus,6,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
a4d60382-5f78-4fe7-b441-bab1d2a6fa7d,C0007590,C1413097,is in IFN-competent ,Cell division,CALU gene,1,X,[celf],[gngm],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,
1277ea5b-48af-4d97-a0b7-495e0e87861d,C2931926,C3854325,Janus kinase inhibitor of IFN-triggered,ruxolitinib,Janus kinase inhibitor,3,X,[orch/phsu],[phsu],,D27.505.519.389.755.500
8a1ec3ad-8f5f-4ea4-9ec2-d659991e1295,C0020598,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Hypocalcemia,Genus: Coronavirus,4,X,[dsyn],[virs],C18.452.174.509;C18.452.950.509,B04.820.504.540.150
4bfb1894-a10a-4289-9f37-089bc6a72672,C0085680,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Hypochloremia (disorder),Genus: Coronavirus,4,X,[dsyn],[virs],,B04.820.504.540.150
42095aeb-3be6-43dd-a2b0-43c6535ef247,C1142578,C0206419,were independent risk factors associated with long-term hospitalization in patients with ,Bilateral pneumonia,Genus: Coronavirus,4,X,[dsyn],[virs],,B04.820.504.540.150
d6a3d4ea-9de5-406a-9a05-0fc7e7fd6534,studys,C0206419,apply morphoproteomics from forensic autopsy of untreated ,studys,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
279cc93f-c6f1-4b92-b777-edf9f02fd36e,studys,C0545747,apply morphoproteomics to ,studys,pulmonary artery and pulmonary artery,4,X,????,[bpoc],????,
97415e0e-b1f7-41cf-8217-72bdfc857021,C0225698,C2328510,is in ,Alveolar Epithelial Cells,Interstitium,4,X,[cell],[bpoc],A04.411.715.100;A11.436.081,
13166996-2052-44cb-a681-5fa8c1d85074,C0387583,C0225698,is in alveolar ,cyclooxygenase 2,Alveolar Epithelial Cells,4,X,[aapp/enzy],[cell],D08.811.600.720.750,A04.411.715.100;A11.436.081
0d2c9fc0-551e-47f9-bbaf-7248d0e1698a,C2985566,C0024115,could address ,Targeted Therapy,Lung diseases,4,X,[topp],[dsyn],,C08.381
1f6b505d-efef-42a6-9482-16f98991b4fe,C2985566,C0005532,could address ,Targeted Therapy,biology (field),4,X,[topp],[bmod],,H01.158.273
7f8cec01-9658-4466-bda2-b6c2dca95c03,C2985566,C0206419,could address ,Targeted Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
937bfc40-55af-40ca-a6a1-b3db0cea8060,C0033684,C0042776,collectively reveal map of ,Proteins,Virus,1,X,[aapp/bacs],[virs],D12.776,B04
6e830078-9d1d-4f65-a725-ffcd2c851423,C1167408,C0597357,is with ,immunoglobulin complex location,receptor,2,X,[celc],[aapp/rcpt],,
c069269c-141f-4103-8803-e2103a1cf01e,C1167408,C1328819,is with ,immunoglobulin complex location,Small Molecule,2,X,[celc],[orch],,
99d02c41-462d-409d-9d88-5d63056bdc0c,C0017968,C0376322,is with modeled ,Glycoproteins,Protein Glycosylation,2,X,[aapp/bacs],[moft],D09.400.430;D12.776.395,G02.111.158.812;G02.607.299;G03.191.812
29348e65-9072-4933-abf3-bd3af823327b,C0206419,C0264219,is causative agent of ,Genus: Coronavirus,Acute respiratory disease,2,X,[virs],[dsyn],B04.820.504.540.150,
29348e65-9072-4933-abf3-bd3af823327b,C0206419,C0264219,could cause ,Genus: Coronavirus,Acute respiratory disease,1,X,[virs],[dsyn],B04.820.504.540.150,
ddcb1335-e521-4bbf-86be-99b16052e6b8,C1175743,C0264219,is causative agent of ,SARS coronavirus,Acute respiratory disease,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,
ddcb1335-e521-4bbf-86be-99b16052e6b8,C1175743,C0264219,induces severe ,SARS coronavirus,Acute respiratory disease,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,
ddcb1335-e521-4bbf-86be-99b16052e6b8,C1175743,C0264219,commonly presents as severe ,SARS coronavirus,Acute respiratory disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
ef871573-ee30-43cb-8572-9fd8bfb4a21f,C0035668,C1511790,can can used for ,RNA,Detection,2,X,[nnon],[topp],D13.444.735,
ef871573-ee30-43cb-8572-9fd8bfb4a21f,C0035668,C1511790,was After resolution of ,RNA,Detection,1,X,[nnon],[topp],D13.444.735,
3282d27a-c66a-4a35-98b3-4c8e9f371f56,C0035668,C1764827,can can used for ,RNA,Isolate - microorganism,2,X,[nnon],[bacs],D13.444.735,
d53aa38e-132c-47e2-aae0-beec9eec6337,C0035668,SYBR,using low-cost SYBR ,RNA,SYBR,2,X,[nnon],????,D13.444.735,????
71a79050-d61a-4d08-b5a9-98d26a9abfc1,C1175743,C0599638,is in ,SARS coronavirus,Drinking Water,1,X,[virs],[sbst],B04.820.504.540.150.113.937,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
699d1ade-dfcc-444b-b6ee-8ce929d68aee,C1514562,C0206750,was significantly associated with ,Protein Domain,Coronavirus Infections,1,X,[amas],[dsyn],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,C02.782.600.550.200
4b280d84-f003-4a4b-9060-08e4fe1d0408,DRF,C0206750,understand ,DRF,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
11cc70f7-092e-48f1-847c-f2a5d331e0bd,DRF,C0699748,understand ,DRF,Pathogenesis,1,X,????,[patf],????,
4567c259-de64-400a-bdea-5305523538bb,DRF,C0023317,provides ,DRF,Lens Crystalline,1,X,????,[bpoc],????,A09.371.060.500
9fc47c0e-cb1a-4899-bb48-c1f2d7a5bc5e,C0011849,C0206750,were most prevalent comorbidities in ,Diabetes Mellitus,Coronavirus Infections,10,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C02.782.600.550.200
f6933922-b468-44f9-a9ce-04c87db253de,C0011849,C0948092,provides guidance recommendations for ,Diabetes Mellitus,diabetes mellitus management,4,X,[dsyn],[topp],C18.452.394.750;C19.246,
d91da416-324f-4345-ad24-ef3dd3a1328b,C0948092,C0206750,is in patients with ,diabetes mellitus management,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
b15896ce-f21b-4f37-93ba-2a358449d41c,C0037633,C0206750,literature on infection control practices in health care facilities against ,Solutions,Coronavirus Infections,1,X,[sbst],[dsyn],D26.776,C02.782.600.550.200
56f5cfe8-9a65-48da-b26f-18cf5361ddf5,C0206750,C0030664,has complex ,Coronavirus Infections,Pathology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
56f5cfe8-9a65-48da-b26f-18cf5361ddf5,C0206750,C0030664,is in children with underlying chronic renal ,Coronavirus Infections,Pathology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
56f5cfe8-9a65-48da-b26f-18cf5361ddf5,C0206750,C0030664,have course in children with underlying chronic ,Coronavirus Infections,Pathology,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.650
22438949-153d-4911-a4db-8816f879c6f4,C0012644,C1457887,can reflect clinical ,Animal Disease Models,Symptoms,1,X,[emod],[sosy],C22.232;E05.598.500;E05.599.395.080,
d5628105-171c-4bc5-a4b7-a4a873e7b32b,C0012644,C0206750,underlying etiopathogenesis similar to ,Animal Disease Models,Coronavirus Infections,1,X,[emod],[dsyn],C22.232;E05.598.500;E05.599.395.080,C02.782.600.550.200
7b866ddd-189c-4df3-95c6-93471340b68d,C0003015,C1175743,are associated with risk of Cov2 ,Angiotensin-Converting Enzyme Inhibitors,SARS coronavirus,2,X,[phsu],[virs],D27.505.519.389.745.085,B04.820.504.540.150.113.937
1bfa5dae-54d9-499a-82de-0a0f5f10823a,C0003015,Cov2,are associated with risk of Cov2 ,Angiotensin-Converting Enzyme Inhibitors,Cov2,2,X,[phsu],????,D27.505.519.389.745.085,????
c9fe627c-f73a-4da6-8d95-4f4f71d770e9,C2948600,C0700201,investigate prevalence of ,Aim,Dyssomnias,3,X,[inch/phsu],[mobd],,C10.886.425;F03.870.400
d264e342-cb01-487f-a6f0-93023c1bca86,C0086132,C0860603,reported ,Depressive Symptoms,Anxiety symptoms,2,X,[sosy],[sosy],F01.145.126.350,
d264e342-cb01-487f-a6f0-93023c1bca86,C0086132,C0860603,were related to ,Depressive Symptoms,Anxiety symptoms,6,X,[sosy],[sosy],F01.145.126.350,
5761947d-52e8-4f98-a671-9d2523b0cd2a,C0086132,C0700201,were associated with poor sleep quality ,Depressive Symptoms,Dyssomnias,3,X,[sosy],[mobd],F01.145.126.350,C10.886.425;F03.870.400
eeac1c00-0879-474b-be39-57c51dbae518,C0086132,C0011570,were associated with poor sleep quality ,Depressive Symptoms,Mental Depression,3,X,[sosy],[mobd],F01.145.126.350,F01.145.126.350
34a41bf0-7537-408a-aca9-aeed65a7243b,C0206750,C0006145,Available information on ,Coronavirus Infections,Breast Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C17.800.090
5644c8cd-ab43-448a-82d4-095f95b18a5a,C0012634,C0006145,Available information on ,Disease,Breast Diseases,1,X,[dsyn],[dsyn],C23.550.288,C17.800.090
74f28632-7c15-456c-b61e-4b281c46ed0e,C0206750,C0242656,is in ,Coronavirus Infections,Disease Progression,1,X,[dsyn],[patf],C02.782.600.550.200,C23.550.291.656
7d35732e-e859-4e6d-9cba-efa0e0a3044b,C0003015,C1422064,Top results for ,Angiotensin-Converting Enzyme Inhibitors,ACE2 gene,1,X,[phsu],[gngm],D27.505.519.389.745.085,
b57645bd-4bf9-4860-81ec-4aff83229468,C0003015,C1167622,Top results for ,Angiotensin-Converting Enzyme Inhibitors,Binding (Molecular Function),1,X,[phsu],[moft],D27.505.519.389.745.085,
cc3737e0-0149-4913-b882-83da7abe3d49,C1305855,kg/m,was 29.00 kg/m,Body mass index,kg/m,1,X,[clna],????,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,????
d7b82bb8-9c14-457b-bc78-97b630a0718a,C1305855,C0028754,was used as indicator of overall ,Body mass index,Obesity,2,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
b8f4f794-27a1-41aa-9390-83790053e25b,C1136170,C0012634,include lack of understanding of ,Virulence Factors,Disease,1,X,[bacs/hops/orch],[dsyn],D23.946.896,C23.550.288
c6e1b08d-8887-495b-85ba-93cbb3f8ff26,C0024312,C0225730,is in ,Lymphopenia,Left lung,2,X,[dsyn],[bpoc],C15.378.553.546.605;C20.673.627,
d9a25253-6693-481b-9379-10c9913b0c77,C0030054,C0020431,remarkably relieved after seven days of ,Oxygen,Hyperbaric oxygenation therapy,1,X,[bacs/elii/phsu],[topp],D01.268.185.550;D01.362.670;x.x.x.x,E02.880.690.490
26c47d89-072c-4588-b1af-7b9318f569c1,C0206750,C0024291,simulate ,Coronavirus Infections,Lymphohistiocytosis Hemophagocytic,2,X,[dsyn],[dsyn],C02.782.600.550.200,C15.604.250.410.575
57896e2e-edbb-40bb-b740-708b49e7eb2a,C1624602,C3873497,play role in treatment of ,Anti-Antibodies,Severe acute respiratory infection,3,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071,
edef47df-6c5b-4599-a4b4-9f277605834e,C0063717,C3873497,play role in treatment of ,Interleukin 6 Receptor,Severe acute respiratory infection,2,X,[aapp/imft/rcpt],[dsyn],D12.776.543.750.705.852.420.400,
9f1f0cfe-815a-446c-89d8-4997378a5d06,C1609165,C3873497,play role in treatment of ,tocilizumab,Severe acute respiratory infection,4,X,[aapp/imft/phsu],[dsyn],x.x.x.x,
1ca017ae-7adb-48c5-9a73-4a3bcde205d6,C1175743,C0003451,was refractory to ,SARS coronavirus,Antiviral Agents,9,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.122.388
f8701a5c-2c78-429b-83c8-29038756c877,C1175743,C0021755,was refractory with favourable outcome after treatment with anti ,SARS coronavirus,Interleukin-1,2,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400
0d19b549-27db-4caa-ba29-00ea739bbf16,C0052796,C0206750,is in hospitalized patients positive for ,Azithromycin,Coronavirus Infections,1,X,[antb/orch],[dsyn],D02.540.576.500.992.050,C02.782.600.550.200
dfd6d35d-33e6-4842-bdfa-687306120a58,C0206750,C3146294,has ,Coronavirus Infections,Generation (action),1,X,[dsyn],[acty],C02.782.600.550.200,
479fc97e-7788-42ac-a865-f8e3607412cd,C0040038,C0206750,are of utmost importance in ,Thromboembolism,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.590,C02.782.600.550.200
479fc97e-7788-42ac-a865-f8e3607412cd,C0040038,C0206750,have Despite severity of ,Thromboembolism,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.590,C02.782.600.550.200
8df80823-8ab1-4f89-8bad-7c4bdc738cab,C0005779,C0206750,is in ,Blood Coagulation Disorders,Coronavirus Infections,7,X,[dsyn],[dsyn],C15.378.100,C02.782.600.550.200
ed8cc2ad-16fe-4bc8-abcc-0c717f87b955,C0206750,C0199242,severe cases of be ,Coronavirus Infections,Anticoagulant prophylaxis,2,X,[dsyn],[topp],C02.782.600.550.200,
b3258cf1-3304-49ab-953d-9e6e12cbb15e,C0199242,C0019139,using ,Anticoagulant prophylaxis,Heparin Low-Molecular-Weight,1,X,[topp],[orch/phsu],,D09.698.373.400.300
320f5369-d62e-4622-a6d5-15b02da95127,C0014507,C1825598,been For analysis of ,Epidemiology,IMPACT gene,1,X,[bmod],[gngm],H02.403.720.500,
320f5369-d62e-4622-a6d5-15b02da95127,C0014507,C1825598,Considering ,Epidemiology,IMPACT gene,1,X,[bmod],[gngm],H02.403.720.500,
8ecff2a0-2d21-4979-b151-493ef6ffb4a2,C0030956,C1167622,provide highly specific ,Peptides,Binding (Molecular Function),1,X,[aapp/phsu],[moft],D12.644,
2866da7f-9b22-40a1-a988-37f3cfb86b4e,C0030956,C1175743,provide highly specific ,Peptides,SARS coronavirus,8,X,[aapp/phsu],[virs],D12.644,B04.820.504.540.150.113.937
cac9e72f-f95b-4551-a838-66ff5d2ff660,C0700271,C0960880,is with ,M Protein multiple myeloma,angiotensin converting enzyme 2,1,X,[aapp/imft],[aapp/enzy],x.x.x.x,x.x.x.x
6020eea5-b933-4b22-aced-bb1f739927f9,C0030956,C0960880,could inhibit ,Peptides,angiotensin converting enzyme 2,2,X,[aapp/phsu],[aapp/enzy],D12.644,x.x.x.x
c4ce5269-1940-466b-9754-92a60e1a6264,C0030956,C0700271,could inhibit ,Peptides,M Protein multiple myeloma,1,X,[aapp/phsu],[aapp/imft],D12.644,x.x.x.x
0a580254-af27-4404-ac5c-b301a0145439,C0030956,C1537068,thereby blocking cellular ,Peptides,Virus Internalization,2,X,[aapp/phsu],[biof],D12.644,G06.920.881
e5a5f96a-ee46-4bc6-b6f3-4da8b02f276d,C3463820,C1175743,be developed as anti ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
e5a5f96a-ee46-4bc6-b6f3-4da8b02f276d,C3463820,C1175743,caused by ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
e5a5f96a-ee46-4bc6-b6f3-4da8b02f276d,C3463820,C1175743,serving as ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
e5a5f96a-ee46-4bc6-b6f3-4da8b02f276d,C3463820,C1175743,may impair viral ,Inhibition,SARS coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150.113.937
9becf3c1-e0fc-45cf-a53b-24c9c4da3464,C3463820,C1254351,be developed as anti ,Inhibition,Pharmacologic Substance,1,X,[acty],[phsu],F01.145.544;F02.463.425.475;F02.739.794.405,
53d103cd-c370-4048-b6db-110fcd6bc7df,C0030956,C1254351,be developed as anti ,Peptides,Pharmacologic Substance,1,X,[aapp/phsu],[phsu],D12.644,
7af41ea5-780f-4149-9199-f933ff2664e5,C3463820,C1175175,be developed as anti ,Inhibition,Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C02.782.600.550.200.750;C08.730.730
e92da6d4-26b6-48f8-8d11-04b2c73aba53,C0030956,C1175175,be developed as anti ,Peptides,Severe Acute Respiratory Syndrome,1,X,[aapp/phsu],[dsyn],D12.644,C02.782.600.550.200.750;C08.730.730
6c958351-c087-4bb6-a6db-96be10440d77,C0206750,C0035222,presents as ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
6c958351-c087-4bb6-a6db-96be10440d77,C0206750,C0035222,resulting in ,Coronavirus Infections,Respiratory Distress Syndrome Adult,3,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
6c958351-c087-4bb6-a6db-96be10440d77,C0206750,C0035222, includes ,Coronavirus Infections,Respiratory Distress Syndrome Adult,5,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
6c958351-c087-4bb6-a6db-96be10440d77,C0206750,C0035222,may challenge so-called ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
6c958351-c087-4bb6-a6db-96be10440d77,C0206750,C0035222,can manifest with ,Coronavirus Infections,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.840;C08.618.840
b8905cbf-2102-4872-84c4-912b1452068b,C0185112,C0543419,counter negative ,Therapeutic Mobilization,Sequela of disorder,1,X,[topp],[patf],,
91e4073c-aa49-4152-b47d-bf984ff568bc,C4505065,C0206750,risk of ,Noncommunicable Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.750,C02.782.600.550.200
91e4073c-aa49-4152-b47d-bf984ff568bc,C4505065,C0206750,may influence Host (organism) Immune System Diseases to,Noncommunicable Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.750,C02.782.600.550.200
0a03db1d-9dd9-4334-89ec-c46f4ead427b,C0206750,C1170730,is ,Coronavirus Infections,wake ups,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,
e9533eda-faed-4485-b149-73eff0d69247,C0035668,C0598312,play roles in multiple aspects of ,RNA,DNA Replication,4,X,[nnon],[genf],D13.444.735,G02.111.225;G05.226
d1430393-0f63-4225-92d9-ee0c4cb13376,C0035668,C0017428,are pervasive throughout ,RNA,Genome,4,X,[nnon],[gngm],D13.444.735,G05.360.340
9374a317-b4e3-45d2-b920-f7dc08b2bd13,C0035668,C0042211,disruption of be Thus could strategy for generation of ,RNA,Vaccines Attenuated,4,X,[nnon],[imft/phsu],D13.444.735,D20.215.894.811
45c3b655-1a0c-4fd0-bee7-3cab98a0d09f,C0035668,C1175743,disruption of be Thus could strategy for generation of ,RNA,SARS coronavirus,4,X,[nnon],[virs],D13.444.735,B04.820.504.540.150.113.937
45c3b655-1a0c-4fd0-bee7-3cab98a0d09f,C0035668,C1175743,was However since ,RNA,SARS coronavirus,2,X,[nnon],[virs],D13.444.735,B04.820.504.540.150.113.937
b2aae049-bc4b-4623-8d64-8e4809cb2bfb,C0005768,C0206750,is in hospitalized ,In Blood,Coronavirus Infections,3,X,[bdsu],[dsyn],x.x.x.x.x,C02.782.600.550.200
b2aae049-bc4b-4623-8d64-8e4809cb2bfb,C0005768,C0206750,was statistically significantly more frequent among those infected with ,In Blood,Coronavirus Infections,1,X,[bdsu],[dsyn],x.x.x.x.x,C02.782.600.550.200
bbe65017-6ad8-4cfa-91c4-fdf3d98786c6,4weeks,C0206750,had 305 ,4weeks,Coronavirus Infections,3,X,????,[dsyn],????,C02.782.600.550.200
37da4db4-5b61-4ca9-b5c4-15a3f8835887,C0206750,C0005841,had significantly lower ,Coronavirus Infections,Blood Transfusion,2,X,[dsyn],[topp],C02.782.600.550.200,E02.095.135
37da4db4-5b61-4ca9-b5c4-15a3f8835887,C0206750,C0005841,required many fewer ,Coronavirus Infections,Blood Transfusion,3,X,[dsyn],[topp],C02.782.600.550.200,E02.095.135
78662e33-a6cc-45aa-b2b0-c080f6cee3c2,C0242656,C0032285,is in ,Disease Progression,Pneumonia,1,X,[patf],[dsyn],C23.550.291.656,C08.381.677;C08.730.610
d5f67c17-5d6f-450b-bda4-16871ba5fb6d,C0206750,C0032285,leading to ,Coronavirus Infections,Pneumonia,13,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.677;C08.730.610
ed2ba450-e5c3-46a8-af5f-3051c6adbd39,HRCT,C0032285,were when reached in ,HRCT,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
1b6ee08e-4d69-4372-a99f-ab70d2fb8437,HRCT,C0012634,is Demand (clinical) Given values of HRCT,HRCT,Disease,1,X,????,[dsyn],????,C23.550.288
7685790f-cbfd-4f26-b8e9-ed59ff96ff6d,HRCT,C0441516,is highly ,HRCT,Demand (clinical),1,X,????,[topp],????,
ae497aa0-4eef-46bc-a88a-1190507c942c,C0444190,C0009763,were collected from patients without ,Conjunctival swab (specimen),Conjunctivitis,8,X,[bdsu],[dsyn],,C11.187.183
473f5a53-8745-46d3-8d14-324ed15c3b08,C0444190,C1175743,detecting ,Conjunctival swab (specimen),SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
ae943861-a531-4bae-8752-e165936e8e9b,C0444190,C0035668,detecting ,Conjunctival swab (specimen),RNA,2,X,[bdsu],[nnon],,D13.444.735
4acb9c9d-0fd4-49e2-9753-f682fd3bceb5,C0035668,C0009763,was detected in one patient without ,RNA,Conjunctivitis,2,X,[nnon],[dsyn],D13.444.735,C11.187.183
a26d99f8-f797-4d30-ab3e-bf8aac5b0168,C1175743,C1521806,is in ,SARS coronavirus,Body Fluids and Substances,2,X,[virs],[tisu],B04.820.504.540.150.113.937,
3608a489-05bd-4e61-ae1b-c90fb4a1ee4e,C0337050,C0319157,stop spread of ,Rivers,AS virus,2,X,[npop],[virs],G01.311.750;G16.500.275.280.650;N06.230.232.650,
973614fe-89a7-4a02-819a-924d33aa1ed2,C0337050,C0034019,implemented first-level ,Rivers,public health medicine (field),2,X,[npop],[bmod],G01.311.750;G16.500.275.280.650;N06.230.232.650,H02.403.720;N01.400.550;N06.850
803f488b-83b8-4f44-aa67-e6623e3b45c0,C0337050,C2745965,implemented first-level ,Rivers,Emergencies [Disease/Finding],2,X,[npop],[patf],G01.311.750;G16.500.275.280.650;N06.230.232.650,C23.550.291.781;N06.230.100.083;N06.850.376
17e6967c-0f30-4d03-adb7-a57026b5db29,C0683325,C0032310,could differentiate between two types of ,clinical aspects,Pneumonia Viral,3,X,[clna],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
90e08ebf-63ba-4c9e-8607-410596b389f3,C0038056,C0206750,were most common symptoms of ,Sputum,Coronavirus Infections,4,X,[bdsu],[dsyn],A12.200.808,C02.782.600.550.200
21d7e697-e1d8-4ffc-8682-7ced21008720,C0231528,C0206750,were most common symptoms of ,Myalgia,Coronavirus Infections,3,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C02.782.600.550.200
966ec446-57b0-4eca-8a1b-96f1c71f530e,C0006560,C1615607,Elevation of was more common phenomenon than that in patients with ,C-reactive protein,Influenza A Virus H1N1 Subtype,3,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,B04.820.545.405.400.214
788bdec0-13c6-4d4f-b91d-628bf9b5b339,C0006560,C0032285,Elevation of was more common phenomenon than that in patients with ,C-reactive protein,Pneumonia,3,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C08.381.677;C08.730.610
196a1728-ad73-4776-b2e8-daa9b7f94bf8,C0026473,C0206750,was increased in ,Monocytes,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C02.782.600.550.200
c8611526-b4fb-4555-843b-3bad545f7c0b,C2676739,C0206750,is typical sign of ,Chromosome 2q32-Q33 Deletion Syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
9c9169cd-d9f0-4a98-8c87-a3828ff443b7,C0311437,C0206750,is typical sign of ,Exudation,Coronavirus Infections,2,X,[ortf],[dsyn],,C02.782.600.550.200
61a8096b-db31-4cb5-bd79-056a5f45616e,C0376537,C0029355,is in ,Evidence-Based Medicine,Orthopedics,2,X,[bmod],[bmod],H02.249.750;H02.403.200.400,H02.403.810.494
ab2e053c-eb6a-4c96-8df5-3bdb3b814988,C0032285,C0021368,often occurs in setting of increased ,Pneumonia,Inflammation,3,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.470
9487cc47-325c-4b40-b16a-7f0fa3bdf24a,TOCI,C0006560,had higher baseline ,TOCI,C-reactive protein,2,X,????,[aapp/imft],????,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
4638c261-7a9f-4849-b574-3295ef4c000d,TOCI,C0021760,had ,TOCI,Interleukin-6,3,X,????,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
28b9ede9-0d0b-4002-ad3f-77b711b23972,C0027950,TOCI,is with TOCI ,neutrophil,TOCI,3,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
9cd804fd-7a30-4a52-9024-02d06c471cd8,TOCI,C0027950,had higher TOCI ,TOCI,neutrophil,3,X,????,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
a39f7dc0-8277-4795-8373-2045702c7c98,C1516048,C1706374,is in late ,Assessed,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
a14c03e1-8ded-4bb6-9b24-379274631cc2,C0022709,C0242821,is In addition ,Peptidyl-Dipeptidase A,Human body,1,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,I01.076.201.450.560;K01.093.378
a14c03e1-8ded-4bb6-9b24-379274631cc2,C0022709,C0242821,is coronavirus receptor for,Peptidyl-Dipeptidase A,Human body,1,X,[aapp/enzy/imft],[humn],D08.811.277.656.350.350.687,I01.076.201.450.560;K01.093.378
34610837-72db-43e0-9816-2ea4a4ec6e75,C1175743,C0242821,is in ,SARS coronavirus,Human body,2,X,[virs],[humn],B04.820.504.540.150.113.937,I01.076.201.450.560;K01.093.378
ee34a6c3-546d-4b71-830e-2b4f00d49171,C0206419,C0033860,is with ,Genus: Coronavirus,Psoriasis,1,X,[virs],[dsyn],B04.820.504.540.150,C17.800.859.675
6eedbc58-3532-411e-8ce7-ae2a8d10f0eb,C1706005,C0085295,opsonizes ,CD40LG wt Allele,Interleukin-10,1,X,[gngm],[aapp/imft],,D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510
e13227e4-0b31-48dd-a30d-0f00e4d63c08,C1706005,C0599946,opsonizes ,CD40LG wt Allele,Attenuation,1,X,[gngm],[acty],,
33b4fd26-71a4-4386-a5f5-636115a5af23,C1706005,C0314597,opsonizes ,CD40LG wt Allele,Colony-stimulating factor granulocyte-monocyte,2,X,[gngm],[aapp/bacs],,
a0be47ed-8ac6-4a35-bbdb-b2fe987264c5,C1880355,C0301872,reinforces their potentially critical role in ,Discover,Immune response,4,X,[acty],[ortf],,
87e7bdec-7161-4a92-a734-a0acad645bb1,C0450254,C0206419,due to Genus: Coronavirus is,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
87e7bdec-7161-4a92-a734-a0acad645bb1,C0450254,C0206419, includes ,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
87e7bdec-7161-4a92-a734-a0acad645bb1,C0450254,C0206419,was soon identified as novel ,Pathogenic organism,Genus: Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150
98ff0642-a5e1-4bb8-a1b9-c0ddf78bf82f,C0080078,14days,commonly set at 14days,Range of Motion Articular,14days,2,X,[clna],????,E01.370.600.700;G11.427.760,????
695b2609-aad4-4039-901a-a3a90a9e09c6,C0034386,14days,commonly set at 14days,Quarantine,14days,2,X,[topp],????,N06.850.780.200.450.700,????
1014de75-39bd-4a91-8103-ee0ce8fc7d2c,C0080078,C0014507,defined according only incubation-based ,Range of Motion Articular,Epidemiology,2,X,[clna],[bmod],E01.370.600.700;G11.427.760,H02.403.720.500
a1df165f-34f7-4b3f-8e09-a63a0a5d26c7,C0034386,C0014507,defined according only incubation-based ,Quarantine,Epidemiology,2,X,[topp],[bmod],N06.850.780.200.450.700,H02.403.720.500
ab9d6d65-7d02-4b08-88ac-e4358db26d4e,C0036576,C1706202,were identified during electronic database ,Genetic Selection,Search - action,3,X,[genf],[acty],G05.783,
c40dfdf9-2c66-4eb8-863c-688b488ca76e,C2348077,19th,until Publications is 19th ,Date Fruit,19th,6,X,[food],????,B01.650.940.800.575.912.250.093.615,????
b624e22c-37df-4a33-8b2e-6687be3c2acd,C2348077,C1856053,until Publications is 19th ,Date Fruit,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,x.x.x.x
3e96a482-4481-4867-b78f-7cb6ee4a8320,acral,C0206419,have received attention worldwide Given their potential association with ,acral,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
2c00a6f1-24bd-47e2-950d-8289b63d21fd,C1175743,C0002199,generally exhibited ,SARS coronavirus,Interferon-alpha,2,X,[virs],[aapp/imft/phsu],B04.820.504.540.150.113.937,D12.644.276.374.440.890.250;D12.776.467.374.440.890.250;D23.529.374.440.890.250
f404c2a9-f7b4-4e84-b266-ca5a59ba4089,C2931926,C0007590,boosted ,ruxolitinib,Cell division,4,X,[orch/phsu],[celf],,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
a82798d5-6ce6-467d-ad6c-2b7d01084583,C0025124,C0280118,has has applied in ,Traditional Chinese Medicine,infection prophylaxis/management,2,X,[bmod],[topp],E02.190.488.585.520;I01.076.201.450.654.558.520,
4a2c9632-c3f3-403a-a6c1-a6f2bbe68de3,C0025124,C0003237,reduce use of ,Traditional Chinese Medicine,Antibiotics Antitubercular,2,X,[bmod],[antb],E02.190.488.585.520;I01.076.201.450.654.558.520,D27.505.954.122.085.255.135
2e690f38-b7d2-4eeb-bb34-5ddcb487cdb4,C1963758,C1155266, includes targeting ,Immunomodulation,inflammatory response,2,X,[topp],[patf],E02.095.465;G12.535,
6331bed7-2f4b-4e19-9cc5-2c5fc776cce0,C1963758,C0301872, includes targeting ,Immunomodulation,Immune response,2,X,[topp],[ortf],E02.095.465;G12.535,
c8272a08-f67d-4fa5-9393-dd3d9df9a863,C1167395,C0280274,are In absence of ,Host (organism),Antiviral Therapy,2,X,[orgm],[topp],,
2b24b7a4-fc11-4b34-877e-fd8baf66b708,C1963758,C0280274,are In absence of ,Immunomodulation,Antiviral Therapy,1,X,[topp],[topp],E02.095.465;G12.535,
8e994ca8-fae7-45c2-b6b6-492f35ba2c6c,C1155266,C0280274,are In absence of ,inflammatory response,Antiviral Therapy,1,X,[patf],[topp],,
437c5cad-6dea-4dfd-8e42-8546c11df251,C0301872,C0280274,are In absence of ,Immune response,Antiviral Therapy,1,X,[ortf],[topp],,
d61e41d3-ab46-44de-836d-7b0f28ae3b77,C0087111,C1167395,may affect clearance essential component of ,Therapeutic procedure,Host (organism),5,X,[topp],[orgm],E02,
8ff3c333-27d0-4ca9-a44f-339e5015362d,C0021368,C1167395,is essential component of ,Inflammation,Host (organism),5,X,[patf],[orgm],C23.550.470,
7adaff85-6ce4-4f55-8124-7538a268813a,C0021368,C0003451,is essential component of ,Inflammation,Antiviral Agents,4,X,[patf],[phsu],C23.550.470,D27.505.954.122.388
cae895a5-79be-4c76-b330-6043502a5b1f,C0087111,C0021368,targeting ,Therapeutic procedure,Inflammation,5,X,[topp],[patf],E02,C23.550.470
cae895a5-79be-4c76-b330-6043502a5b1f,C0087111,C0021368,have shown first promise in treatment of ,Therapeutic procedure,Inflammation,2,X,[topp],[patf],E02,C23.550.470
cae895a5-79be-4c76-b330-6043502a5b1f,C0087111,C0021368,could attenuate ,Therapeutic procedure,Inflammation,2,X,[topp],[patf],E02,C23.550.470
1e575707-f8b3-43ae-9482-12bc8de5e0cb,C4086768,C0042769,is associated with ,Reactivation,Virus Diseases,5,X,[acty],[dsyn],,C02
b1145885-06d0-496a-b75a-aa0141220ee9,C4086768,C0597177,is associated with ,Reactivation,Particle,5,X,[acty],[chvs],,
68be92fd-4fc4-4ad6-9db7-8bbb4593a9b9,C1175743,C0282686,primarily targets ,SARS coronavirus,Respiratory System Agents,6,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.796
68be92fd-4fc4-4ad6-9db7-8bbb4593a9b9,C1175743,C0282686,might attack ,SARS coronavirus,Respiratory System Agents,2,X,[virs],[phsu],B04.820.504.540.150.113.937,D27.505.954.796
81c663ac-9be5-4792-a687-4cd2ed8588ee,C0042776,C0007610,may enter system in nasal cavity in brainstem ,Virus,Cell Nucleus,5,X,[virs],[celc],B04,A11.284.430.106;A11.284.430.214.190.875.117
93a11e4a-b72e-4eb8-8ddf-46951eebd051,C0042776,C1656385,may enter system in nasal cavity in brainstem ,Virus,regulation of cellular respiration,5,X,[virs],[celf],B04,
ef913c40-f53d-4f01-8cde-c4cc085ef510,C0042776,C0028938,may enter system through ,Virus,Olfactory Nerve,5,X,[virs],[bpoc],B04,A08.800.800.120.640
e8279559-a5c2-40dd-8757-e61b6f6f608e,C1880019,C0007758,put - instruction imperative,Cessation,Cerebellar Ataxia,6,X,[acty],[dsyn],,C10.228.140.252.190;C10.597.350.090.500;C23.888.592.350.090.200
43a979ec-4736-4812-a524-76f0eb7274dc,C0206419,C1171362,control relative ,Genus: Coronavirus,protein expression,2,X,[virs],[genf],B04.820.504.540.150,
0cae8890-eb94-45c5-b4d3-17e431a58690,C0013879,PRF,promote similar -1 PRF ,Elements,PRF,5,X,[elii],????,D01.268,????
db98f6a2-0391-4f54-b43c-a908109f0cdc,C1519323,PRF,strongly ablate -1 PRF ,Silent Mutation,PRF,9,X,[genf],????,G05.365.590.803,????
c792d777-e455-42c4-8b29-3401140b4924,C0079380,C0206419,combat current ,Frameshift Mutation function,Genus: Coronavirus,1,X,[comd],[virs],G05.365.590.265,B04.820.504.540.150
73df8fdb-3f80-4385-b881-b95169b2b765,C0243077,C0206419,combat current ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
73df8fdb-3f80-4385-b881-b95169b2b765,C0243077,C0206419,also have high ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
73df8fdb-3f80-4385-b881-b95169b2b765,C0243077,C0206419,Furthermore interact with catalytic dyad ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
73df8fdb-3f80-4385-b881-b95169b2b765,C0243077,C0206419,have shown ,inhibitors,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
eadd99d0-2da4-4168-896d-45ca42a9c7dd,C0004936,C0009450,public awareness for ,Mental disorders,Communicable Diseases,4,X,[mobd],[dsyn],F03,C01.539.221
32cf4cee-9e0f-48c2-806e-a518ac4675df,C0013227,C0010357,are running in various stages of trials with ,Pharmaceutical Preparations,Cross Reactions,1,X,[phsu],[moft],D26,G12.122.281
e81e73ac-68f3-47cd-abb4-2399a34ab9fa,C0042210,C0010357,are running in various stages of trials with ,Vaccines,Cross Reactions,1,X,[aapp/imft/phsu],[moft],D20.215.894,G12.122.281
ec9f6abc-0ea0-4ebe-8dba-2f9252d48977,C0003241,C0010357,are running in various stages of preclinical/clinical trials with ,Antibodies,Cross Reactions,1,X,[aapp/imft/phsu],[moft],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,G12.122.281
e754d971-09c0-4f25-81b8-06fb716639dc,xe,C0010357,are running in various stages of preclinical/clinical trials with ,xe,Cross Reactions,1,X,????,[moft],????,G12.122.281
9ca2cea2-9098-45a2-a829-8aff4cdcffd5,ntity33,C0010357,are running in various stages of preclinical/clinical trials with ,ntity33,Cross Reactions,1,X,????,[moft],????,G12.122.281
d51bbfe5-6870-404c-a764-9faca9dfef98,C0087111,C0010357,are running in various stages of preclinical/clinical trials with ,Therapeutic procedure,Cross Reactions,1,X,[topp],[moft],E02,G12.122.281
7388f6c5-9788-4828-a60c-cfd064339e4c,C0010357,COVID-19,may ,Cross Reactions,COVID-19,1,X,[moft],[virs],G12.122.281,C000657245
8e790914-77e9-4d78-9aca-03e1c0d16bc6,C0206750,C0450254,is newly discovered highly ,Coronavirus Infections,Pathogenic organism,1,X,[dsyn],[orgm],C02.782.600.550.200,
d78dcdfa-002e-4fb7-9988-9ac834f27e6f,C0450254,C1856053,was declared in ,Pathogenic organism,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[orgm],[dsyn],,x.x.x.x
d566b591-5c80-464f-84d1-83ce0f717802,C0042776,C0282686,affects ,Virus,Respiratory System Agents,1,X,[virs],[phsu],B04,D27.505.954.796
7f4382d8-49a3-4311-ab15-2782a8b21a33,C1263722,C0028754, includes ,Chronic metabolic disorder,Obesity,2,X,[dsyn],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
84355e97-1a1e-49c3-b891-7938077497ba,C1263722,C0011849, includes ,Chronic metabolic disorder,Diabetes Mellitus,4,X,[dsyn],[dsyn],,C18.452.394.750;C19.246
07b7c644-d751-4300-93bb-f6849ff3926e,C1263722,C0020538, includes ,Chronic metabolic disorder,Hypertensive disease,2,X,[dsyn],[dsyn],,C14.907.489
65d038f0-7528-405a-b98e-7b5b9f21c3bd,C0206750,C1263722,takes course in individuals with ,Coronavirus Infections,Chronic metabolic disorder,1,X,[dsyn],[dsyn],C02.782.600.550.200,
35c8ce6b-db67-4532-a89b-2244dcfad501,C0206750,C0028754,takes course in individuals with ,Coronavirus Infections,Obesity,7,X,[dsyn],[dsyn],C02.782.600.550.200,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
4929653c-93c7-4892-a07a-d59a2bf58b00,C0025219,C0019932,is multifunctional signaling ,Melatonin,Hormones,1,X,[horm/orch/phsu],[horm],D03.633.100.473.914.481;D06.472.506,D06.472;D27.505.696.399.472
c4026db4-8918-4017-ad94-2b264ade7b1a,C0025219,C0031939,secreted primarily by ,Melatonin,Pineal gland,1,X,[horm/orch/phsu],[bpoc],D03.633.100.473.914.481;D06.472.506,A06.300.635;A06.688.733;A08.186.211.180.200.680;A08.186.211.200.317.200.620;A08.713.733
35238f84-692d-4ffb-9afb-72acd3eb89e4,C0003402,C0001272,is with immunomodulatory ,Antioxidants,Action Potentials,1,X,[phsu],[celf],D27.505.519.217;D27.505.696.706.125;D27.720.799.047,G04.580.100;G07.265.675.100;G11.561.570.100
f224df7a-0d51-48c8-a172-fa18fe6f7130,C0012634,C0003402,involve inflammation as powerful ,Disease,Antioxidants,1,X,[dsyn],[phsu],C23.550.288,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
fbf52060-9ee6-47f4-83be-5480a0ce026a,C0242606,C0028754,severe inflammation in people with ,Oxidative Stress,Obesity,1,X,[comd],[dsyn],G03.673;G07.775.750,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
c305d61c-abc5-4c45-9300-7fcb1a386fb3,C0011849,C0007637,anticipated ,Diabetes Mellitus,Inclusion Bodies,1,X,[dsyn],[celc],C18.452.394.750;C19.246,A11.284.420
a2bbec86-790e-4b1e-a342-5f343d0cd69a,C0011849,C0025219,anticipated ,Diabetes Mellitus,Melatonin,1,X,[dsyn],[horm/orch/phsu],C18.452.394.750;C19.246,D03.633.100.473.914.481;D06.472.506
b1f8908d-1e30-4598-996d-a478b438f918,C0025219,C1254351,is potential ,Melatonin,Pharmacologic Substance,1,X,[horm/orch/phsu],[phsu],D03.633.100.473.914.481;D06.472.506,
6fbe7363-e14d-4188-ba91-5e96fe807e60,C0003865,C0206750,is in ,Arthritis Adjuvant-Induced,Coronavirus Infections,1,X,[emod],[dsyn],C05.550.114.015;E05.598.500.249,C02.782.600.550.200
8acb5cfa-574b-4e50-a319-a268efbfa94d,C0003865,C0011849,is in ,Arthritis Adjuvant-Induced,Diabetes Mellitus,1,X,[emod],[dsyn],C05.550.114.015;E05.598.500.249,C18.452.394.750;C19.246
11d74fef-a92b-4653-9be1-b96a8fece26c,C0233401,COVID-19,rates of were ,Psychiatric symptom,COVID-19,8,X,[sosy],[virs],,C000657245
7b0b96c3-5c5f-46bf-ab5a-43c6945b394b,C0233401,C0003467,rates of were ,Psychiatric symptom,Anxiety,4,X,[sosy],[mobd],,F01.470.132
5d61ce3d-89db-408d-8f8b-1307dcffa320,COVID-19,C0086132,had risk for ,COVID-19,Depressive Symptoms,2,X,[virs],[sosy],C000657245,F01.145.126.350
ca62ee31-fab9-473a-961d-e38c1aa9e25c,COVID-19,C0917801,had ,COVID-19,Sleeplessness,1,X,[virs],[sosy],C000657245,C10.886.425.800.800;F03.870.400.800.800
657c6103-f720-40cc-90ee-0f5b3efa1206,C0086132,C0069590,of Depressive Symptoms is,Depressive Symptoms,ORALIT,1,X,[sosy],[inch/phsu],F01.145.126.350,x.x.x.x
7898274f-9440-4110-b0d7-7d774db0bb81,C0233401,C3714514,people with suspected ,Psychiatric symptom,Infection,1,X,[sosy],[patf],,C01.539
a0e061ad-2f99-43c2-b737-7a15abf3b1ce,C0221423,C0015967,leading to age of ,Illness (finding),Fever,1,X,[sosy],[sosy],,C23.888.119.344
259d7e93-70d7-4cbb-81dc-6087ecd9c19a,C0015967,C0021368,lasted laboratory evidence of ,Fever,Inflammation,2,X,[sosy],[patf],C23.888.119.344,C23.550.470
319ea4b0-5666-47c3-a725-47fabe36dafc,C3714514,C1175743,is with ,Infection,SARS coronavirus,4,X,[patf],[virs],C01.539,B04.820.504.540.150.113.937
2b8adc8a-c8db-4a3e-a123-3d2887ccf533,C0085297,C0017710,was used in ,Immunoglobulins Intravenous,Glucocorticoids,2,X,[aapp/imft/phsu],[horm/orch],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,D06.472.040.543;D27.505.696.399.472.488
3cc7a778-d01e-4fa3-a846-d1de36709b01,C0265267,C1175743,is in ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,SARS coronavirus,2,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150.113.937
8dc88337-8bc4-4870-adad-186d7cd8e9b7,C0028040,C0009324,is used in ,Nicotine,Ulcerative Colitis,2,X,[hops/orch],[dsyn],D03.132.760.570;D03.383.725.518,C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249
98045caf-5de7-4ab8-8a31-ca0d64e452cf,C0028040,C0021368,counteract ,Nicotine,Inflammation,2,X,[hops/orch],[patf],D03.132.760.570;D03.383.725.518,C23.550.470
1a699da2-a933-4923-8872-4505361ed95a,C0028040,C0948245,constitute novel potential ,Nicotine,Cytokine Release Syndrome,1,X,[hops/orch],[dsyn],D03.132.760.570;D03.383.725.518,
ba3534b2-0eaf-4394-b625-3ccdeb0f17d1,C0028040,C1175743,constitute novel potential CRS ,Nicotine,SARS coronavirus,2,X,[hops/orch],[virs],D03.132.760.570;D03.383.725.518,B04.820.504.540.150.113.937
21476e77-233e-4ae8-a50e-c28bcad28c91,C0948245,C1175743,is in severe ,Cytokine Release Syndrome,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
273c659e-b157-4679-895b-1443ca1700f2,C0191275,C0079850,undertaking ,Operation on skin,Mohs Surgery,2,X,[topp],[topp],,E04.494.575;E04.680.275.580
965a76cb-c127-45d8-9d82-8712d5293615,C0035222,C0398623,can predispose patients to ,Respiratory Distress Syndrome Adult,Thrombophilia,2,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C15.378.925
e0fd7c9c-7685-47be-812e-1422f530f710,C0035222,C0042487,can predispose patients with ,Respiratory Distress Syndrome Adult,Venous Thrombosis,2,X,[dsyn],[patf],C08.381.840;C08.618.840,C14.907.355.830.925
0b275836-22fe-46fe-a514-c95bded547e1,C0012655,C1184743,presents multifactorial physiopathology related to severe ,Disease susceptibility,bony process,1,X,[clna],[bpoc],C23.550.291.687;G07.100.250,
9507da9d-999c-4125-b0ee-39e51faf1d8f,C0012655,C0005789,presents multifactorial physiopathology related to severe ,Disease susceptibility,Blood Coagulation Factor,1,X,[clna],[aapp/bacs/phsu],C23.550.291.687;G07.100.250,D12.776.124.125;D23.119
4af61b1d-9f4e-4859-94fc-b2ced8af051a,C0021368,C0079189,accompanied by ,Inflammation,cytokine,2,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
4af61b1d-9f4e-4859-94fc-b2ced8af051a,C0021368,C0079189,caused by ,Inflammation,cytokine,1,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
4af61b1d-9f4e-4859-94fc-b2ced8af051a,C0021368,C0079189,sustained by ,Inflammation,cytokine,1,X,[patf],[aapp/imft],C23.550.470,D12.644.276.374;D12.776.467.374;D23.529.374
11e38f73-e3bf-4c50-9a18-3ea25a386a5a,C0003209,C0023821,changes in quantity of ,Anti-Inflammatory Agents,High Density Lipoproteins,2,X,[phsu],[aapp/bacs],D27.505.954.158,D10.532.432;D12.776.521.479
675f4581-5237-4acc-b92f-09db8f5cd0f5,C0003209,COVID-19,changes ,Anti-Inflammatory Agents,COVID-19,1,X,[phsu],[virs],D27.505.954.158,C000657245
7ca9b806-5497-4531-bd38-026690d51369,C0023820,C0178784,lead to virus-associated ,Lipoproteins,Organ,2,X,[aapp/bacs],[bpoc],D10.532;D12.776.521,
6b40e065-e40a-4bc1-8e29-125874c01b6a,C0023820,C0074129,lead to virus-associated ,Lipoproteins,scavenger receptor,2,X,[aapp/bacs],[aapp/rcpt],D10.532;D12.776.521,D12.776.543.750.705.940;D12.776.543.750.710.450.750
e95e8469-2d3e-4229-a519-bbcd5a7da7ca,C0023820,C0030011,is with ,Lipoproteins,Oxidation,2,X,[aapp/bacs],[moft],D10.532;D12.776.521,
8a7a3dba-7fc0-4e2d-97c8-47960623ef2a,C0023820,C0031676,is with ,Lipoproteins,Phospholipids,2,X,[aapp/bacs],[bacs/orch],D10.532;D12.776.521,D10.570.755
24e38798-3a64-4b2d-886c-89be5007484a,C1254351,C0475463,blocking scavenger receptor with,Pharmacologic Substance,Antibodies Neutralizing,1,X,[phsu],[aapp/imft],,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
d4e95498-7fe6-4165-9172-b7f4d81d98b2,C0085201,C1254351,raising ,Apolipoprotein A-I,Pharmacologic Substance,2,X,[aapp/bacs],[phsu],D10.532.091.200.100;D12.776.070.400.200.100;D12.776.521.120.200.100,
49ef5c14-f97a-41b5-a08b-2e51a49037af,C1254351,C0074129,blocking relevant ,Pharmacologic Substance,scavenger receptor,1,X,[phsu],[aapp/rcpt],,D12.776.543.750.705.940;D12.776.543.750.710.450.750
186efa1a-6b8b-4cb9-a31c-dd9286a8fde1,C0000936,C1947933,is in older adult ,Visual Accommodation,care activity,1,X,[ortf],[acty],G14.010,
48a69438-c5ff-4d0f-9ebf-10a6be9523c3,C0419193,COVID-19,is with ,Care of aged,COVID-19,4,X,[topp],[virs],,C000657245
65647604-8989-4e2b-8bfa-99a0496cf335,C1947933,amidst,would fit particular needs of older adults in settings amidst ,care activity,amidst,1,X,[acty],????,,????
65647604-8989-4e2b-8bfa-99a0496cf335,C1947933,amidst,would Seizures particular needs in settings amidst,care activity,amidst,1,X,[acty],????,,????
4f413107-f15e-4a6c-b9a9-ce4dfa204f26,CMH,C0011438,Institute of ,CMH,Dentistry,1,X,????,[bmod],????,E06;H02.163
c78bd5bb-4ab3-42a7-8853-3d55c5f2a51b,C2948600,C0041621,explore ,Aim,Ultrasonic Shockwave,1,X,[inch/phsu],[npop],,G01.750.770.776.891.500
ccc1b3d1-6606-4cd1-960d-11880ab3a844,C0032285,C0041621,underwent bedside ,Pneumonia,Ultrasonic Shockwave,1,X,[dsyn],[npop],C08.381.677;C08.730.610,G01.750.770.776.891.500
63123a1c-c6cd-4a58-8ca8-68b24fe451cb,C0041621,COVID-19,valid diagnostic aid in ,Ultrasonic Shockwave,COVID-19,3,X,[npop],[virs],G01.750.770.776.891.500,C000657245
c41217f0-1869-42a4-adc5-176fae1c385a,C0041621,C0032285,valid diagnostic aid in ,Ultrasonic Shockwave,Pneumonia,1,X,[npop],[dsyn],G01.750.770.776.891.500,C08.381.677;C08.730.610
c41217f0-1869-42a4-adc5-176fae1c385a,C0041621,C0032285,could represent ,Ultrasonic Shockwave,Pneumonia,1,X,[npop],[dsyn],G01.750.770.776.891.500,C08.381.677;C08.730.610
4bc78f32-7e15-4bca-adee-02611a35d60a,C2985398,C0026809,is in ,Intestinal Microbiome,Mus,2,X,[orgm],[mamm],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,B01.050.150.900.649.313.992.635.505.500
e9353f3a-7fae-457d-a72b-682f01bbd781,C0030664,C2985398,is in ,Pathology,Intestinal Microbiome,1,X,[bmod],[orgm],H02.403.650,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
5478ec1b-d556-489c-88fa-5612a4f96d63,C3888108,C0030664,cause ,Import into cell,Pathology,1,X,[celf],[bmod],,H02.403.650
246cc7ef-8afa-420a-a2d4-171b53e354a0,C3888108,C2985398,cause pathological changes in ,Import into cell,Intestinal Microbiome,2,X,[celf],[orgm],,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
4b070ec1-c0cc-4abb-ae81-3a7c322cca46,C3888108,C0026809,cause pathological changes in ,Import into cell,Mus,2,X,[celf],[mamm],,B01.050.150.900.649.313.992.635.505.500
8c986bd3-3965-49a9-97dd-f0babd4261ff,C0450254,C3536832,are typically sparse in ,Pathogenic organism,Air,2,X,[orgm],[inch/phsu],,G16.500.275.063.150;N06.230.300.100.150
0412a88a-af92-4d62-bbcd-77ae7651bd7d,C0038029,C0020517,may exacerbate ,Spores Fungal,Hypersensitivity,2,X,[fngs],[patf],A11.870.710;A19.374.500;B05.775.710,C20.543
9fc30b69-470a-4d2e-b016-cd91ba6a3113,C0038029,C0004096,may exacerbate ,Spores Fungal,Asthma,2,X,[fngs],[dsyn],A11.870.710;A19.374.500;B05.775.710,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
8dddc0b6-f058-4b8a-9675-c0a24046b20d,C0042776,C0004651, includes ,Virus,Bacteriophages,1,X,[virs],[virs],B04,B04.123
57f226d8-3fe7-4afe-8c3b-44ec29fba4b3,C0012634,C1145670,can lead to severe ,Disease,Respiratory Failure,1,X,[dsyn],[dsyn],C23.550.288,C08.618.846
c27d110d-e422-40df-9972-c80d153f4843,C0025124,C0199176,bringing new hope for ,Traditional Chinese Medicine,Prophylactic treatment,1,X,[bmod],[topp],E02.190.488.585.520;I01.076.201.450.654.558.520,
30ab06c5-cc14-41f7-b0f0-ec8b78564c4d,C0025124,C0206419,bringing new hope for ,Traditional Chinese Medicine,Genus: Coronavirus,1,X,[bmod],[virs],E02.190.488.585.520;I01.076.201.450.654.558.520,B04.820.504.540.150
30ab06c5-cc14-41f7-b0f0-ec8b78564c4d,C0025124,C0206419,is in Novel ,Traditional Chinese Medicine,Genus: Coronavirus,1,X,[bmod],[virs],E02.190.488.585.520;I01.076.201.450.654.558.520,B04.820.504.540.150
46771931-d294-4c6c-934c-b6f3e4d37acc,C1879848,C0024109,improvements in several clinical ,Biomedicine,Lung,2,X,[bmod],[bpoc],,A04.411
9e5e19e2-ff04-479e-b2d5-7d74e79e6384,C1707455,C0024109,has improvements in several ,Comparison,Lung,1,X,[acty],[bpoc],,A04.411
735f947c-e1d1-4909-952d-1bd424a48a43,C1273412,C0024109,has improvements in several ,Chinese herbal medicine,Lung,1,X,[topp],[bpoc],,A04.411
4f2cd431-8fbe-4a69-8d71-ce9d542cae87,C1273412,C0206419,could could used as potential candidates for ,Chinese herbal medicine,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
cb863bef-7d88-42b9-92b1-91f6455700ee,C0036974,C0026766,have Patients with ,Shock,Multiple Organ Failure,1,X,[patf],[patf],C23.550.835,C23.550.835.525
7aa9f9b1-a9b4-4f13-bef9-f6ce97e4f476,C0242966,C1457887,Recovery - action from,Systemic Inflammatory Response Syndrome,Symptoms,1,X,[dsyn],[sosy],C23.550.470.790;C23.550.835.900,
566d696d-a9f4-4d32-b01e-e264fb59f86a,C0605411,C0031350,is with ,austin,Pharyngitis,1,X,[orch],[dsyn],x.x.x.x,C07.550.781;C08.730.561;C09.775.649
f11976b2-a30c-48a6-8593-50a3dde239b5,C0605411,C0013404,is with ,austin,Dyspnea,1,X,[orch],[sosy],x.x.x.x,C08.618.326;C23.888.852.371
5568bb74-adec-4ed0-9158-f7a000ae0116,C0028677,C0037633,offering guidance for ,Discipline of Nursing,Solutions,2,X,[bmod],[sbst],H02.478;N04.452.758.377,D26.776
edeb104e-40c2-45ab-8b2a-2f353349b6df,C0520510,C0003451,were found more ,Materials,Antiviral Agents,6,X,[sbst],[phsu],,D27.505.954.122.388
347c566d-58b2-4817-816d-e9dfd8595080,C0520510,C3698360,were found more ,Materials,Middle East Respiratory Syndrome Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.750
347c566d-58b2-4817-816d-e9dfd8595080,C0520510,C3698360,be more Antiviral Agents activity than other morphologies against,Materials,Middle East Respiratory Syndrome Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150.113.750
3c6920c3-3bec-46b2-ac91-451fecf936f2,C0520510,C0206419,are positive affect against ,Materials,Genus: Coronavirus,3,X,[sbst],[virs],,B04.820.504.540.150
3c6920c3-3bec-46b2-ac91-451fecf936f2,C0520510,C0206419,included patients with diagnosis of ,Materials,Genus: Coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150
c76cff66-021b-4ca7-95f4-101eb8162f0d,C0271355,C0086418,is in previously healthy young ,Abducens Nerve Diseases,Homo sapiens,2,X,[dsyn],[humn],C10.292.150,B01.050.150.900.649.313.988.400.112.400.400
4aa6665e-a805-47ab-b0ce-667621f76c51,C0934029,C0011307,consistent with ,Left lateral rectus,Denervation,2,X,[bpoc],[topp],,E04.525.210
63132448-9dc6-4722-9e6e-1efd096bd662,C0934029,T2,was hyperintense on T2 ,Left lateral rectus,T2,2,X,[bpoc],????,,????
ec4d6fef-9ec3-4ea1-86c0-702fd44cb4b6,C0262576,C0042769,is suspected related to his ,Nerve palsy,Virus Diseases,4,X,[dsyn],[dsyn],,C02
7e9acfa0-835c-4657-b81c-ae3095eaa4bf,C0151311,C0027765,may represent part ,Cranial nerve palsies,nervous system disorder,1,X,[dsyn],[dsyn],,C10
83380fe9-def3-4c0c-a553-1615cd7a9f88,C0151311,C0206419,may represent part ,Cranial nerve palsies,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
66186465-8b43-494e-beac-d8d9e46c9178,C0028128,C0042774,inhibit early stage in ,Nitric Oxide,Virus Replication,2,X,[bacs/inch/phsu],[celf],D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600,G06.920.925
0d144be5-fcf4-44fc-b51b-36149c1e79e0,C0028128,C1175743,inhibits replication cycle of ,Nitric Oxide,SARS coronavirus,1,X,[bacs/inch/phsu],[virs],D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600,B04.820.504.540.150.113.937
9f08ff1b-bc26-4a9d-9f68-7df04eff49b5,C0239059,C1707455,contains Nitric Oxide as 160ppm,Cigarette smoke (substance),Comparison,1,X,[hops],[acty],,
c374486c-7c0d-4c6c-8e3c-eb6b504cc126,C0239059,160ppm,contains Nitric Oxide as 160ppm,Cigarette smoke (substance),160ppm,1,X,[hops],????,,????
4efbb69c-013a-4e88-a8df-b3ec6b590e7d,C0239059,C0028128,contains ,Cigarette smoke (substance),Nitric Oxide,1,X,[hops],[bacs/inch/phsu],,D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
d9d16c65-b8be-4e90-9349-a12772041169,C0028167,C0037366,is in mainstream ,Nitrogen Oxides,Smoke,1,X,[inch],[hops],D01.362.635;D01.625.550;D01.650.550.587,D20.633.937
ff00e227-c20e-4cd1-909b-1d0e581e3365,C0028167,C0028128,is ,Nitrogen Oxides,Nitric Oxide,1,X,[inch],[bacs/inch/phsu],D01.362.635;D01.625.550;D01.650.550.587,D01.339.387;D01.625.550.500;D01.625.700.500;D01.650.550.587.600
023333bb-8ea5-45b6-b2cc-4960cb7cfc08,C0021528,C0013227,provide ,Inosine,Pharmaceutical Preparations,1,X,[nnon/phsu],[phsu],D03.633.100.759.590.616;D13.570.583.616;D13.570.800.573;x.x.x.x,D26
57a96ca6-d327-4b85-8415-72f6637bf98c,C0021528,C0079483,provide Pharmaceutical Preparations without,Inosine,health hazards,1,X,[nnon/phsu],[hops],D03.633.100.759.590.616;D13.570.583.616;D13.570.800.573;x.x.x.x,
7dda54a1-3811-4cb0-9d08-c562ddf096ec,C0920687,C0206419,is impacted by ,cancer care,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
e615bf0e-eaed-4d24-9a47-ebb87294891b,C0920687,C0012634,is impacted by ,cancer care,Disease,1,X,[topp],[dsyn],,C23.550.288
04cd3c58-44b2-45d0-9115-5dacd6e5800d,C0023688,C0007382,conformation of ,Ligands,Catalysis,1,X,[chem],[npop],D27.720.470.480,G02.130
b51687dd-e588-4ed8-8d24-515f5b703580,C0023688,C0011334,conformation of ,Ligands,Dental caries,1,X,[chem],[dsyn],D27.720.470.480,C07.793.720.210
d8dccd99-fb50-46da-98ab-c6eb072ef977,C1707455,C0023688,is with previously reported low-temperature ,Comparison,Ligands,1,X,[acty],[chem],,D27.720.470.480
8c51f613-6b77-4195-b23e-ca80469f264c,C0450254,C1175743,relative of ,Pathogenic organism,SARS coronavirus,4,X,[orgm],[virs],,B04.820.504.540.150.113.937
8c51f613-6b77-4195-b23e-ca80469f264c,C0450254,C1175743,established ,Pathogenic organism,SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
8c51f613-6b77-4195-b23e-ca80469f264c,C0450254,C1175743,develop Communicable Diseases after intranasal,Pathogenic organism,SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
52f35bc2-a0ec-4ba9-9700-5a01f5e6ca52,C1947933,C0031843,inferring ,care activity,physiological aspects,4,X,[acty],[phsf],,x.x.x.x
d4a66808-b8bb-4952-aa37-1eb342c0a6e9,C0243083,C0087111,requires ,associated disease,Therapeutic procedure,1,X,[patf],[topp],,E02
a9448657-a6be-4bed-a4c7-823a1eac4007,C0206419,C0087111,requires ,Genus: Coronavirus,Therapeutic procedure,1,X,[virs],[topp],B04.820.504.540.150,E02
d575e5fd-dca8-49c9-a04e-a5071213f9be,C0087111,C1947933,be can translated to ,Therapeutic procedure,care activity,1,X,[topp],[acty],E02,
38912d37-aa72-4f27-87df-43a3db6c6493,C0022942,C1175175,is effective inhibitor of ,Lactoferrin,Severe Acute Respiratory Syndrome,1,X,[aapp/bacs],[dsyn],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,C02.782.600.550.200.750;C08.730.730
26e250c4-edf1-43d3-b96e-9d94c86beec1,C1175175,IC,is with IC ,Severe Acute Respiratory Syndrome,IC,1,X,[dsyn],????,C02.782.600.550.200.750;C08.730.730,????
9d5072e7-3071-4b3b-a225-fa96b6e033cb,C1175175,C0312860,is with IC ,Severe Acute Respiratory Syndrome,Neutrophil migration function,1,X,[dsyn],[celf],C02.782.600.550.200.750;C08.730.730,
9b5e0184-8474-4256-a339-77be7841f302,C0022942,C1819995,also stimulates antiviral ,Lactoferrin,Host Cell,1,X,[aapp/bacs],[celc],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,
0aa597c0-d033-42e3-9f4d-7fbc6d40037e,C0022942,C3463820,retains ,Lactoferrin,Inhibition,1,X,[aapp/bacs],[acty],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,F01.145.544;F02.463.425.475;F02.739.794.405
2fcb63f9-8ed5-4b98-919e-fa49ff489ee8,C0022942,C0225698,retains ,Lactoferrin,Alveolar Epithelial Cells,1,X,[aapp/bacs],[cell],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,A04.411.715.100;A11.436.081
a38cee15-afef-430e-92cb-4386d9126768,C3463820,C2717959,is in ,Inhibition,Induced Pluripotent Stem Cells,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A11.872.040.500;A11.872.700.500
41873166-b1c1-47bd-8bfd-591fd0688df0,C3463820,C0225698,is in ,Inhibition,Alveolar Epithelial Cells,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A04.411.715.100;A11.436.081
2777ed93-c723-48df-a979-bcef0db5fefb,C2717959,C0948192,model for ,Induced Pluripotent Stem Cells,primary infection nos,2,X,[cell],[dsyn],A11.872.040.500;A11.872.700.500,
ee366243-1819-4e12-b02c-7b6678377d43,C0225698,C0948192,model for ,Alveolar Epithelial Cells,primary infection nos,2,X,[cell],[dsyn],A04.411.715.100;A11.436.081,
477b8887-2881-4c67-81c4-fce404241c0b,C3166216,C0042769,exacerbate ,Prescribed medications,Virus Diseases,1,X,[phsu],[dsyn],,C02
27b400a6-51fa-4362-ab96-4a34bbaf06cc,C0003451,C1533157,is with potential to ,Antiviral Agents,Block Specimens,1,X,[phsu],[bdsu],D27.505.954.122.388,
cabafb7d-dfaf-4fa7-a134-36d4c480b246,C0013227,C0087111,used to ,Pharmaceutical Preparations,Therapeutic procedure,11,X,[phsu],[topp],D26,E02
f8f21402-832a-4c80-8e79-d9c47d78c891,C0003250,C0079189,targeting pro-inflammatory ,Monoclonal Antibodies,cytokine,2,X,[aapp/imft],[aapp/imft],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,D12.644.276.374;D12.776.467.374;D23.529.374
5751a961-5b4a-4c22-ae6d-f9dc2ce40200,C0087111,C0035245,could ameliorate ,Therapeutic procedure,Respiratory physiology,4,X,[topp],[phsf],E02,G09.772
9c3733a4-6e58-4302-a9aa-8631d7c87913,C0184661,C0013227,is with ,Interventional procedure,Pharmaceutical Preparations,1,X,[topp],[phsu],,D26
a864b643-ffb1-4783-87de-81d998a8cfad,C0206419,C0035204,is primarily ,Genus: Coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618
a864b643-ffb1-4783-87de-81d998a8cfad,C0206419,C0035204,is newly emerging life-threatening ,Genus: Coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618
7f59c086-55ad-4550-84d7-47ff6e7b0368,2D,C0206419,diagnose ,2D,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
2a293fa4-c29c-4fda-b859-6ecd4dc6386f,C0001527,C0206419,be ,Adipose tissue,Genus: Coronavirus,1,X,[tisu],[virs],A10.165.114,B04.820.504.540.150
b8560435-8db2-4d83-85f4-28fe9c13adc2,C1511790,C1175743,However is required for ,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
b8560435-8db2-4d83-85f4-28fe9c13adc2,C1511790,C1175743,is in CoV2,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
b8560435-8db2-4d83-85f4-28fe9c13adc2,C1511790,C1175743,was used for confirmation of ,Detection,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
6548d1a4-2d9c-4bc1-be8f-a334848b8e78,C1628478,C0206419,is in ,SARS coronavirus IgG,Genus: Coronavirus,1,X,[aapp/imft],[virs],,B04.820.504.540.150
a9ffec74-5e73-4df8-9d45-f81c62cd5b3e,C0871208,RT-PCR,was severe In RT-PCR ,Rating (action),RT-PCR,1,X,[acty],????,,????
541c92af-b81d-4055-af42-22f79b8a8f3b,C0871208,C1511790,was severe In RT-PCR ,Rating (action),Detection,1,X,[acty],[topp],,
ee2b925e-d75c-4a8b-8cc9-afe077e3b34a,C0020517,C0871208,produce probability ,Hypersensitivity,Rating (action),1,X,[patf],[acty],C20.543,
241fd082-f5d6-4638-9998-b28284cacebb,C0206419,C1443869,should take ,Genus: Coronavirus,Airborne precautions,1,X,[virs],[topp],B04.820.504.540.150,
8ed304e7-0fae-4142-b97a-274e933b6f58,C2188405,C0206419,suspected for ,urgent Operation,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
ce441ecc-b977-444f-bd4d-db763927bfff,C2948600,C0018837,compare ,Aim,Heat (physical force),2,X,[inch/phsu],[npop],,
d619ba01-34f9-4fb8-9446-c5950ef84fa1,C2948600,C0806140,compare ,Aim,Flow,2,X,[inch/phsu],[npop],,
d145f124-9f5f-4ff9-9faf-0e95d3f06587,C0020336,C1321301,is in target ,Hydroxychloroquine,Peripheral blood mononuclear cell (cell),2,X,[orch/phsu],[cell],D03.633.100.810.050.180.350,
9cda575a-dfa5-4d34-a3ff-bff2a92b31fd,C0057223,C0026056,using ,Cytochrome P-450 CYP2D6,Midazolam,2,X,[aapp/enzy],[orch/phsu],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D03.633.100.079.080.575
cb17d44c-4b10-4655-b1c9-bb799079c362,C0057223,C0724441,using ,Cytochrome P-450 CYP2D6,yohimbine,2,X,[aapp/enzy],[orch/phsu],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D03.132.436.681.933;D03.633.100.473.402.681.933
60e0ed07-36d9-4621-ae65-b9ba9be2f62b,C0057223,C0014442,using Midazolam as,Cytochrome P-450 CYP2D6,Enzymes,2,X,[aapp/enzy],[aapp/enzy],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D08.811
60e0ed07-36d9-4621-ae65-b9ba9be2f62b,C0057223,C0014442,using yohimbine as,Cytochrome P-450 CYP2D6,Enzymes,2,X,[aapp/enzy],[aapp/enzy],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,D08.811
25631789-0095-4fe0-a3d7-76e9160b3ebe,C0057223,C1513396,using Midazolam as,Cytochrome P-450 CYP2D6,Molecular Marker Activity,2,X,[aapp/enzy],[phsf],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,
25631789-0095-4fe0-a3d7-76e9160b3ebe,C0057223,C1513396,using yohimbine as,Cytochrome P-450 CYP2D6,Molecular Marker Activity,2,X,[aapp/enzy],[phsf],D08.244.453.005.600;D08.244.453.491.372;D08.811.682.690.708.170.010.600;D08.811.682.690.708.170.450.368;D12.776.422.220.453.010.600;D12.776.422.220.453.491.368,
4860a6e2-95ad-4b3d-94bd-0ea1befb2807,C0029456,C0206419,showed significant association with ,Osteoporosis,Genus: Coronavirus,2,X,[dsyn],[virs],C05.116.198.579;C18.452.104.579,B04.820.504.540.150
b7e8e9c9-9995-4207-9f35-baf9fb4f2c87,C0003873,C0206419,showed significant association with ,Rheumatoid Arthritis,Genus: Coronavirus,2,X,[dsyn],[virs],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,B04.820.504.540.150
4ff12f14-9053-43b1-a540-0b4cb27d5c69,C0237123,C0206419,showed significant association with ,Alcohol or Other Drugs use,Genus: Coronavirus,2,X,[mobd],[virs],,B04.820.504.540.150
7b5c276d-9815-4a81-8fa7-45826994a346,C0036341,C0206419,showed significant association with ,Schizophrenia,Genus: Coronavirus,2,X,[mobd],[virs],F03.700.750,B04.820.504.540.150
c3a8c2f4-fddc-448d-829e-b406795f80f1,RAAS,C0206419,be maintained in patients with ,RAAS,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
23b1e499-d9b4-4df9-b3e3-f6bd22b51692,C0035452,C0206419,be at high risk from ,Rheumatology specialty,Genus: Coronavirus,6,X,[bmod],[virs],H02.403.429.730,B04.820.504.540.150
fa275f52-f9f8-412e-8957-dfb1d474ff07,C0015230,C1609165,persisted despite ,Exanthema,tocilizumab,4,X,[sosy],[aapp/imft/phsu],C17.800.257,x.x.x.x
2977548a-4358-400e-82f7-f901479d0d29,C0015230,C1533734,persisted despite ,Exanthema,Administration procedure,3,X,[sosy],[topp],C17.800.257,
d8fcfaba-8859-43c7-a210-0f89cb06c37b,C0015230,C0206419,highly suggestive for ,Exanthema,Genus: Coronavirus,2,X,[sosy],[virs],C17.800.257,B04.820.504.540.150
b57b309e-d1d7-4acd-91ad-22da2e8b113e,C0206419,C0795934,has opened new ,Genus: Coronavirus,Digitorenocerebral Syndrome,3,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
b46f5791-0f75-4442-aff5-75b10f786d93,C0206419,C0003504,has opened new ,Genus: Coronavirus,Aortic Valve Insufficiency,3,X,[virs],[dsyn],B04.820.504.540.150,C14.280.484.095
98d9332d-4d3c-474d-adab-927e98d34daa,C0206419,C0013227,screened approximately 250 existing ,Genus: Coronavirus,Pharmaceutical Preparations,1,X,[virs],[phsu],B04.820.504.540.150,D26
48c16665-12db-4220-b4bc-68532d2b6c68,C0206419,C0441655,screened compounds for their ,Genus: Coronavirus,Activities,1,X,[virs],[acty],B04.820.504.540.150,
48c16665-12db-4220-b4bc-68532d2b6c68,C0206419,C0441655,halting worldwide principal income ,Genus: Coronavirus,Activities,2,X,[virs],[acty],B04.820.504.540.150,
37598ada-074a-4cce-9950-fef463c1b43f,C0206419,C0085306,screened compounds for their ,Genus: Coronavirus,Feline infectious peritonitis,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.600.550.200.360;C22.180.440
7961c8ad-f6ba-4a49-8cb3-291c08711a1e,C0206419,C0472699,was proliferated in feline Fcwf-4cells in ,Genus: Coronavirus,Hemopoietic stem cell transplant,1,X,[virs],[topp],B04.820.504.540.150,E02.095.147.500.500.500;E04.936.225.687.500
8ecdcc92-b33e-4fc5-9f0b-799a9eee14eb,C0524816,C0472699,is in ,Nucleocapsid Proteins,Hemopoietic stem cell transplant,3,X,[aapp/bacs],[topp],D12.776.964.970.600,E02.095.147.500.500.500;E04.936.225.687.500
f4d9294e-9a61-4f4a-8abb-b1f7c8678fea,C0013227,C1948030,of concentrations is ,Pharmaceutical Preparations,EC Regimen (Etoposide-Carboplatin),3,X,[phsu],[topp],D26,
74ae1daa-fad2-4762-98bf-091c93b8da74,8cells,C0017440,were measured by ,8cells,Gentian Violet,3,X,????,[irda/orch/phsu],????,D02.092.146.400
d5f9bd8c-9c93-4a45-94ba-f48083774cae,C0319157,C0009450, includes ,AS virus,Communicable Diseases,1,X,[virs],[dsyn],,C01.539.221
d5f9bd8c-9c93-4a45-94ba-f48083774cae,C0319157,C0009450,is highly ,AS virus,Communicable Diseases,3,X,[virs],[dsyn],,C01.539.221
fdae3a64-b810-47c8-8cc4-abf53fa63f35,C0035736,C0009450,Amplification of is current gold test for confirmation of ,RNA Viral,Communicable Diseases,2,X,[nnon],[dsyn],D13.444.735.828,C01.539.221
416debb6-2266-4838-ab62-2f142e9ec6e1,PCR,C1185740,performed on respiratory ,PCR,Tract,3,X,????,[bpoc],????,
468add2e-e721-4b8a-b61f-fe7b09e022c8,C0206074,C0444279,performed on respiratory ,Renal Replacement Therapy,Respiratory sample,2,X,[topp],[bdsu],E02.870,
46379788-f00e-405a-9735-1185c3dcff9d,PCR,C0444279,performed on respiratory ,PCR,Respiratory sample,2,X,????,[bdsu],????,
46379788-f00e-405a-9735-1185c3dcff9d,PCR,C0444279,detect Coronavirus Infections in,PCR,Respiratory sample,1,X,????,[bdsu],????,
22f3d559-36d5-451b-a233-8be50c0a0479,C0020452,C0206750,were reported in ,Hyperemia,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.907.474,C02.782.600.550.200
2d944b93-8f0f-4cc3-a1d7-27528b2f543f,C0264545,C0206750,were reported in ,Thickening of pleura,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
c0a0949b-ebd1-4bc6-a861-2dfaa3f5c344,C2825977,C1947933,predispose dental ,Dental Retraction (procedure),care activity,2,X,[topp],[acty],,
b8c5e464-1eec-4b9a-b0eb-a80737f2a86c,C0012682,C1947933,predispose dental ,Disinfectants,care activity,2,X,[sbst],[acty],D27.505.954.122.425;D27.720.274,
e4affbc7-84e5-4a10-bd2c-cad5db50dac0,C1947933,C0005889,consistent exposure to ,care activity,Body Fluids,2,X,[acty],[bdsu],,A12.207
c9c19fb0-f600-4d7f-9a7f-89a66bd75e61,C0242781,C3826466,is in ,disease transmission,Dentistry--Practice,2,X,[patf],[bmod],N06.850.310,
6645a071-0283-4d79-aad1-6095d84f87ef,C3826426,C3826466,is in ,Dynamics,Dentistry--Practice,2,X,[npop],[bmod],,
16e4b1cc-c2d0-4d6b-8454-8351e9b4343c,C0189573,hoc,were prioritized ad hoc,Cardiovascular procedures,hoc,2,X,[topp],????,,????
fbcbf64f-0faf-4761-ac73-eea55b534b82,C0189573,C0040861,be useful for fair ,Cardiovascular procedures,Triage,12,X,[topp],[topp],,N02.421.297.900
4a783c69-daaa-4ea6-9c46-b9ce24934d4e,C1293116,C0206750,aiding ,Introduction procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
9ffedba6-3f0d-494d-bb76-fad063ecf47f,C1293116,C0012634,aiding ,Introduction procedure,Disease,1,X,[topp],[dsyn],,C23.550.288
57d0d923-c977-4b9e-8156-f020afb4ee6f,C1293116,C1511790,aiding ,Introduction procedure,Detection,1,X,[topp],[topp],,
ab7c4cbd-9b75-4aba-80cf-cf79df488cf1,C0005818,C0206750,significantly lower Leukocytes in,Blood Platelet Disorders,Coronavirus Infections,2,X,[dsyn],[dsyn],C15.378.140,C02.782.600.550.200
8116a0ab-7585-4882-9173-14ed67c49b67,C0005818,C0032285,significantly lower Leukocytes in,Blood Platelet Disorders,Pneumonia,2,X,[dsyn],[dsyn],C15.378.140,C08.381.677;C08.730.610
cbbb6fcc-b0b2-4e36-b833-44330f6c2e97,C0700635,C0206750,is in severe ,Strudwick syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
3079ce1f-ed22-470e-ac86-563ffaea65c6,C0023516,C0009450,are markers of ,Leukocytes,Communicable Diseases,2,X,[cell],[dsyn],A11.118.637;A15.145.229.637;A15.382.490,C01.539.221
4a66613e-de8f-4ccf-8a25-a462375d540d,C1706374,C0206750,related to ,Tumor Necrosis Factor Ligand Superfamily Member 13,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,C02.782.600.550.200
1f50b0be-3d26-4fe9-a4ca-344b06f118e3,C1706374,C0242667,related to ,Tumor Necrosis Factor Ligand Superfamily Member 13,Reproductive Health,1,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,N01.400.625
57f86dbf-2f5e-4001-b281-75fe63a0ff02,C0206750,C0242667,is in ,Coronavirus Infections,Reproductive Health,1,X,[dsyn],[bmod],C02.782.600.550.200,N01.400.625
c4e14318-3e61-43e3-9e8f-494531aa5ce2,C1825598,C0015491,bathing ,IMPACT gene,factor IX,1,X,[gngm],[aapp/bacs/phsu],,D08.622.355;D12.776.124.125.375;D23.119.375
42a33ef8-34ee-4043-b038-3882c803fd0f,C0006141,babys,Symptoms of their babys,Breast,babys,1,X,[bpoc],????,A01.236,????
143b4980-6828-40ff-8707-fe5aa14ad1f3,C0006141,C0009450,Symptoms of their babys,Breast,Communicable Diseases,1,X,[bpoc],[dsyn],A01.236,C01.539.221
59468cb4-f28d-496f-b5ff-d2fb78e1ae31,C1871526,C0074558,are more effective drug candidates than ,raltegravir,sinefungin,3,X,[nnon/phsu],[antb/orch],,x.x.x.x
59468cb4-f28d-496f-b5ff-d2fb78e1ae31,C1871526,C0074558,Binding (Molecular Function) strongly to active site to,raltegravir,sinefungin,1,X,[nnon/phsu],[antb/orch],,x.x.x.x
538684b8-77ca-47a8-8cc4-1c92e41c8797,C1871526,C3463820,are more effective drug candidates than ,raltegravir,Inhibition,3,X,[nnon/phsu],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
b0372930-c8e5-46de-8533-7eef4c731d08,C1667052,C0074558,are more effective drug candidates than ,maraviroc,sinefungin,3,X,[orch/phsu],[antb/orch],D02.455.426.392.368.367.726;D03.383.129.799.682,x.x.x.x
b0372930-c8e5-46de-8533-7eef4c731d08,C1667052,C0074558,Binding (Molecular Function) strongly to active site to,maraviroc,sinefungin,1,X,[orch/phsu],[antb/orch],D02.455.426.392.368.367.726;D03.383.129.799.682,x.x.x.x
61cf4fe4-1314-4677-a34e-679041646b1f,C1667052,C3463820,are more effective drug candidates than ,maraviroc,Inhibition,3,X,[orch/phsu],[acty],D02.455.426.392.368.367.726;D03.383.129.799.682,F01.145.544;F02.463.425.475;F02.739.794.405
1041983f-a9b7-465a-95a9-1b729bab654d,C1667052,C0206750,may may used in treatment of ,maraviroc,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D02.455.426.392.368.367.726;D03.383.129.799.682,C02.782.600.550.200
4cf568f3-32cc-457b-8787-a05217b5957b,C1761613,C0271298,had ,Conjunctival hyperemia,Chemosis of conjunctiva,4,X,[dsyn],[patf],,
b54d2163-b9c5-4139-a954-a6480a5e5227,C0184904,C0011884,showed ,Slitting,Diabetic Retinopathy,4,X,[topp],[dsyn],,C11.768.257;C14.907.320.382;C19.246.099.500.382
88cc33ae-58ee-4c46-b183-2b0e8491d3fa,C4321457,C0011884,showed ,Examination,Diabetic Retinopathy,4,X,[acty],[dsyn],,C11.768.257;C14.907.320.382;C19.246.099.500.382
3f269baa-7aba-4ada-9ac3-7ba9a2b176d5,C0184904,C0086543,showed ,Slitting,Cataract,4,X,[topp],[acab],,C11.510.245
fdd9fdf6-6466-42e2-91cf-d728ed0a4fc0,C4321457,C0086543,showed ,Examination,Cataract,4,X,[acty],[acab],,C11.510.245
deca54a1-9a37-4a15-bb27-0d184f21906e,C0184904,C1761613,showed ,Slitting,Conjunctival hyperemia,4,X,[topp],[dsyn],,
6b0368bf-3fb1-4801-ac81-5a0fe00c08e9,C4321457,C1761613,showed ,Examination,Conjunctival hyperemia,4,X,[acty],[dsyn],,
87ec11d9-19bc-47ed-b4af-eaf532ef0f38,C0184904,C0271298,showed ,Slitting,Chemosis of conjunctiva,4,X,[topp],[patf],,
4d5d6444-bb69-4936-9292-9743191780b4,C4321457,C0271298,showed ,Examination,Chemosis of conjunctiva,4,X,[acty],[patf],,
30da33a3-5279-4d5b-a3ab-341d1810a5f6,C0239981,C1829939,occurred in ,Hypoalbuminemia,{Non-patient},8,X,[dsyn],[clna],C15.378.147.607.500,
8fda88e0-0bf7-4669-8fa0-5a2dd61f2d4d,C0239981,C1155266,are associated with exacerbation of disease-associated ,Hypoalbuminemia,inflammatory response,5,X,[dsyn],[patf],C15.378.147.607.500,
b9c2fe65-94c7-4f82-888e-e53e4339636b,C0239981,C0242656,are associated with exacerbation of disease-associated ,Hypoalbuminemia,Disease Progression,5,X,[dsyn],[patf],C15.378.147.607.500,C23.550.291.656
89c29ed4-8cdb-454a-aa5f-c94b4e1ad2e8,C1290884,C0302189,have have described in context of ,Inflammatory disorder,Cell Therapy,3,X,[dsyn],[topp],,E02.095.147
007da5c4-91ab-4ce2-9afc-5e6c576e1afa,C1619738,COVID-19,have COVID19,Immune Reconstitution Inflammatory Syndrome,COVID-19,6,X,[dsyn],[virs],C20.608,C000657245
803765e8-b490-4654-914b-7530148a9a14,C4054044,COVID-19,have COVID19,Secondary Hemophagocytic Lymphohistiocytosis,COVID-19,6,X,[dsyn],[virs],,C000657245
f7036c73-4aeb-4763-a2a7-22d7a681b520,C0948245,COVID19,have COVID19,Cytokine Release Syndrome,COVID19,6,X,[dsyn],????,,????
85781b44-33e2-424d-a933-901b23abae30,C1619738,COVID19,have COVID19,Immune Reconstitution Inflammatory Syndrome,COVID19,6,X,[dsyn],????,C20.608,????
0d995798-dd31-4437-be6a-200600ed617a,C4054044,COVID19,have COVID19,Secondary Hemophagocytic Lymphohistiocytosis,COVID19,6,X,[dsyn],????,,????
4ffd96ec-a0c7-48b7-ab15-b126249338e9,C2827774,C0206750,are are evaluated for treatment of ,Current Therapy,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
6689404c-83c2-4c63-be60-1d4d64bf5f4e,humoral,C0301872,revealed ,humoral,Immune response,1,X,????,[ortf],????,
abcad954-fceb-4a3b-a596-9e2ee81e3afe,humoral,C0282682,revealed notably enhanced ,humoral,Antibodies Blocking,1,X,????,[aapp/imft/irda],????,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
85c676f6-ef42-44c1-be7c-4ec60d2763ac,C0086418,C0009450,sustained loads upon intranasal ,Homo sapiens,Communicable Diseases,7,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C01.539.221
27e8eb3e-04fd-47ee-af9c-69fb44d986cd,C0305052,C0013227,can can considered as potential candidates for ,Gamma globulin serum,Pharmaceutical Preparations,2,X,[aapp/imft/phsu],[phsu],,D26
38477d02-779d-4115-a7b1-ac9b9875b1da,C0305052,C0087111,can can considered as potential candidates for ,Gamma globulin serum,Therapeutic procedure,2,X,[aapp/imft/phsu],[topp],,E02
8136c3a1-4565-4e8f-953c-d8f5bf314ec2,C0305052,C0206750,can can considered as potential candidates for ,Gamma globulin serum,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],,C02.782.600.550.200
772f41ec-c6ba-4f6f-baf4-e1738efda0cc,C2936405,C0206750,stands out as promising strategy for response in fight against novel ,Drug Repositioning,Coronavirus Infections,3,X,[topp],[dsyn],E05.290.875,C02.782.600.550.200
99d40516-c276-4e48-8841-ae728c25f72d,TLR3,C0013227,be considered as potential ,TLR3,Pharmaceutical Preparations,2,X,????,[phsu],????,D26
26d8d8f1-150d-4624-b210-83726ba0d8b4,C0243192,C0013227,be considered as potential ,agonists,Pharmaceutical Preparations,2,X,[phsu],[phsu],x.x.x,D26
16c7fdfc-cbc6-4fff-b2f3-71d28a55bccc,TLR3,C2936405,be considered as potential ,TLR3,Drug Repositioning,2,X,????,[topp],????,E05.290.875
fde581ad-3871-43b7-9d2f-2bc9aec74a99,C0243192,C2936405,be considered as potential ,agonists,Drug Repositioning,2,X,[phsu],[topp],x.x.x,E05.290.875
01d6b2fa-b259-4cef-ac7e-1433a4c67700,TLR3,C0206750,be considered as potential ,TLR3,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
6ae9ecb9-b687-4366-99af-c5fcff3f2477,C0243192,C0206750,be considered as potential ,agonists,Coronavirus Infections,1,X,[phsu],[dsyn],x.x.x,C02.782.600.550.200
7df9b0ee-9a25-4ad6-8e19-ea03e4cbb22c,C0206419,C0597404,are group of well-known ,Genus: Coronavirus,Respiratory viruses,3,X,[virs],[virs],B04.820.504.540.150,
7df9b0ee-9a25-4ad6-8e19-ea03e4cbb22c,C0206419,C0597404,are large family of respiratory ,Genus: Coronavirus,Respiratory viruses,3,X,[virs],[virs],B04.820.504.540.150,
8f28a4db-2dad-4c46-8add-3a4184b72e49,C0597404,C0339901,can cause ,Respiratory viruses,Acute respiratory infections,3,X,[virs],[dsyn],,
6a3e9259-b510-4508-9a76-4835c51e6ecf,C0206750,C1254351,is cited as most worldwide problematic ,Coronavirus Infections,Pharmacologic Substance,4,X,[dsyn],[phsu],C02.782.600.550.200,
bd49a72b-63be-4f28-a5cb-34024accd783,C0206750,C0282686,is cited as most worldwide problematic ,Coronavirus Infections,Respiratory System Agents,6,X,[dsyn],[phsu],C02.782.600.550.200,D27.505.954.796
bd49a72b-63be-4f28-a5cb-34024accd783,C0206750,C0282686,was initially characterized by mainly manifestations of ,Coronavirus Infections,Respiratory System Agents,1,X,[dsyn],[phsu],C02.782.600.550.200,D27.505.954.796
bc8518b3-76bf-4c06-8584-276acf017430,KCDC,C0242656,clearly distinguished improvement Coronaviridae from,KCDC,Disease Progression,1,X,????,[patf],????,C23.550.291.656
534548fc-6d29-4b54-8816-0dfcf3e718ca,C0021966,C0242656,clearly distinguished improvement Coronaviridae from,Iodides,Disease Progression,1,X,[inch],[patf],D01.248.497.158.490;D01.475.410,C23.550.291.656
a40ad976-31b0-4f9e-ab55-c21dead54533,KCDC,C0010076,clearly distinguished improvement Coronaviridae from,KCDC,Coronaviridae,1,X,????,[virs],????,B04.820.504.540
a40ad976-31b0-4f9e-ab55-c21dead54533,KCDC,C0010076,clearly distinguished improvement ,KCDC,Coronaviridae,1,X,????,[virs],????,B04.820.504.540
28207ca5-4e92-423d-8a18-2b4d0a3899ea,C0021966,C0010076,clearly distinguished improvement Coronaviridae from,Iodides,Coronaviridae,1,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04.820.504.540
28207ca5-4e92-423d-8a18-2b4d0a3899ea,C0021966,C0010076,clearly distinguished improvement ,Iodides,Coronaviridae,1,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04.820.504.540
5d71625e-a43d-4473-9311-d6989fecac01,KCDC,C1293130,clearly distinguished improvement ,KCDC,Stabilization,1,X,????,[topp],????,
172c770d-6e1b-46e0-9ba0-139a02651706,C0021966,C1293130,clearly distinguished improvement ,Iodides,Stabilization,1,X,[inch],[topp],D01.248.497.158.490;D01.475.410,
2629e838-a525-497b-ab7b-53b748cc180d,C0040861,C1521827,was ,Triage,Preparation,1,X,[topp],[acty],N02.421.297.900,
63db2960-7b87-4637-982b-e7b883f7b576,C0040861,C0206750,identify potential ,Triage,Coronavirus Infections,1,X,[topp],[dsyn],N02.421.297.900,C02.782.600.550.200
a3a9bff1-4c56-4e5c-a873-22e9099e336b,C1283174,C0206750,identify potential ,Checking (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
e3082e03-a491-41b5-82a6-f01c645954dd,C0333557,C0206750,is in patient with ,Watershed infarct,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
1c2f85c3-a0f5-49bf-916d-050e3d2dfe8c,C0039259,C0521530,is with focal distribution subpleural pleural ,Tail,Lung consolidation,1,X,[bpoc],[dsyn],A13.895,
a7c9a1f9-f42c-4484-9689-4616f1b7341a,C0039259,pleural,is with focal distribution subpleural pleural ,Tail,pleural,1,X,[bpoc],????,A13.895,????
3fc04cdc-2706-403e-b162-64c5f8377a56,C0017428,C0226993,characterized by ,Genome,Tooth Crowns,3,X,[gngm],[bpoc],G05.360.340,A14.549.167.900.710
b3893758-96a2-4a5f-b2e2-7cccf43f5401,C0036658,C0226993,characterized by ,Esthesia,Tooth Crowns,3,X,[ortf],[bpoc],F02.830.816;G11.561.790,A14.549.167.900.710
3b5a5ba3-0ecf-419d-ac27-80651d4b697e,C0035691,C0226993,characterized by ,RNA Viruses,Tooth Crowns,3,X,[virs],[bpoc],B04.820,A14.549.167.900.710
3b5a5ba3-0ecf-419d-ac27-80651d4b697e,C0035691,C0226993,containing ,RNA Viruses,Tooth Crowns,1,X,[virs],[bpoc],B04.820,A14.549.167.900.710
a8eee276-7313-4c79-b1cd-b425e4e08bfa,6LU7,C1519126,identity with ,6LU7,SARS Coronavirus Protease Pathway,2,X,????,[moft],????,
3a9d9cf1-772c-4f14-972e-10ebb5e09dc5,6LU7,C0598312,are playing role in ,6LU7,DNA Replication,3,X,????,[genf],????,G02.111.225;G05.226
7946ffa2-2e0a-4277-a5be-bbc0bf4a8881,C1167622,kcal,is with -8.2 kcal ,Binding (Molecular Function),kcal,3,X,[moft],????,,????
7946ffa2-2e0a-4277-a5be-bbc0bf4a8881,C1167622,kcal,was calculated -2.80 0.84 kcal ,Binding (Molecular Function),kcal,4,X,[moft],????,,????
1eef2a00-2cbb-4af1-b49d-10a0f0507e14,C1510827,kcal,is with -8.2 kcal ,Affinity,kcal,3,X,[npop],????,,????
d72e94d1-82c5-4de6-820d-baea7aed04df,C1167622,C0324740,is with -8.2 kcal ,Binding (Molecular Function),Talpidae,3,X,[moft],[mamm],,B01.050.150.900.649.473.450
d72e94d1-82c5-4de6-820d-baea7aed04df,C1167622,C0324740,was calculated -2.80 0.84 kcal ,Binding (Molecular Function),Talpidae,4,X,[moft],[mamm],,B01.050.150.900.649.473.450
d937f8d4-32ed-419d-9d18-2bb466e60d0d,C1510827,C0324740,is with -8.2 kcal ,Affinity,Talpidae,3,X,[npop],[mamm],,B01.050.150.900.649.473.450
9a89d36c-2273-4606-bbe8-9f0738bbc0fa,remdesivir,C1167622,having better ,remdesivir,Binding (Molecular Function),3,X,[clnd],[moft],,
f38a01ce-17a6-418b-b4cd-7f2ae0421270,remdesivir,C1510827,having better ,remdesivir,Affinity,3,X,[clnd],[npop],,
6c9bc821-d5aa-4cbb-a261-f67c71e0b7fb,remdesivir,C0035253,having better ,remdesivir,Rest,3,X,[clnd],[dora],,I03.450.769.647
75ef13e8-dc06-428f-8749-40814bcdce12,remdesivir,C0033607,having better ,remdesivir,Protease Inhibitors,3,X,[clnd],[phsu],,D27.505.519.389.745
9911fee9-f0fb-49dd-89de-ec0c2c6f99e6,remdesivir,C0087111,is potent ,remdesivir,Therapeutic procedure,3,X,[clnd],[topp],,E02
e87d3eb8-d8a7-4612-91f4-d0c830ff417d,C1145670,C0206750,lethal manifestation of ,Respiratory Failure,Coronavirus Infections,4,X,[dsyn],[dsyn],C08.618.846,C02.782.600.550.200
b438caa8-864a-4b51-9f47-fb477715e3e4,C0035222,C0281169,propose entity as remedy to ,Respiratory Distress Syndrome Adult,pulmonary complications,6,X,[dsyn],[patf],C08.381.840;C08.618.840,
cdf346c6-45ed-4fdb-9a63-d724ae96f901,C0002986,C0234221,include ,Fabry Disease,Acroparesthesia,2,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
53f88be5-891b-48a7-9c40-251c7509661a,C0002986,C0391845,is X-linked Fabry Disease due to,Fabry Disease,Lysosomal enzyme,2,X,[dsyn],[aapp/enzy],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
c9f85e69-4540-4622-b0d4-e7eea45d3eca,C0002986,C1457887,is X-linked Fabry Disease due to,Fabry Disease,Symptoms,2,X,[dsyn],[sosy],C10.228.140.163.100.435.825.200;C10.228.140.300.275.374;C14.907.253.329.374;C16.320.322.124;C16.320.565.189.435.825.200;C16.320.565.398.641.803.300;C16.320.565.595.554.825.200;C18.452.132.100.435.825.200;C18.452.584.687.803.300;C18.452.648.189.435.825.200;C18.452.648.398.641.803.300;C18.452.648.595.554.825.200,
e9ff2abf-1ce5-4b4c-afed-9738809c99de,C0319157,C0450254,has appeared as new ,AS virus,Pathogenic organism,1,X,[virs],[orgm],,
e9ff2abf-1ce5-4b4c-afed-9738809c99de,C0319157,C0450254,exerts its ,AS virus,Pathogenic organism,2,X,[virs],[orgm],,
5c2718b4-ea3a-4926-be72-4460e57440be,C0020974,C0319157,hold back mysterious ,passive immunization procedure,AS virus,1,X,[topp],[virs],E02.095.465.425.400.330;E05.478.550.520,
107a337b-e30d-41aa-9d8e-281fe21617e6,C0871189,C0206750,have have related to ,Psychotic symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
c60ecafc-df4c-451c-a4e0-1cda14be8ea4,C0338614,C0206750,is in ,Psychotic episodes,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
4f4f0940-afab-4435-92c3-2fee5b35a104,C0206750,C0960756,can develop as ,Coronavirus Infections,factor A,2,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
4f4f0940-afab-4435-92c3-2fee5b35a104,C0206750,C0960756,was related with ,Coronavirus Infections,factor A,6,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
4f4f0940-afab-4435-92c3-2fee5b35a104,C0206750,C0960756,combines multiplex ,Coronavirus Infections,factor A,1,X,[dsyn],[orch],C02.782.600.550.200,x.x.x.x
dd9da2c6-4f2c-409b-8664-ddbb5c869f74,C0003018,C0225336,is expressed in ,Angiotensins,Endothelial Cells,2,X,[aapp/bacs/phsu],[cell],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,A11.436.275
1ede00bd-b6f7-4b4d-bdea-01ffd63bb032,C0003018,C0162772,could could implicated in production of ,Angiotensins,Reactive Oxygen Species,2,X,[aapp/bacs/phsu],[bacs/elii],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,D01.339.431;D01.650.775
3d5b283d-fd33-4d8b-9cc5-909cc9d959ed,C0003018,C0856169,could could implicated in production of ,Angiotensins,endothelial dysfunction,2,X,[aapp/bacs/phsu],[dsyn],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,
e97b7f91-f6c8-4b66-9ebc-fe4c4f302687,A23403,C0028630,be most common ,A23403,Nucleotides,2,X,????,[nnon],????,D09.408.620;D13.695
f7eafb2b-9865-413f-83c9-08b6f1d28f5b,A23403,C3494870,be most common ,A23403,Viral isolate,2,X,????,[bacs],????,
ed93829b-6c8a-4f89-9f41-8320881f9865,C0020598,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Hypocalcemia,Coronavirus Infections,6,X,[dsyn],[dsyn],C18.452.174.509;C18.452.950.509,C02.782.600.550.200
28c6e8fc-bde4-4b3f-bbdc-a5e3936fdcb2,C0085680,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Hypochloremia (disorder),Coronavirus Infections,8,X,[dsyn],[dsyn],,C02.782.600.550.200
a898c98b-6c06-49c7-b6de-ef879aa79774,C1142578,C0206750,were independent risk factors associated with long-term hospitalization in patients with ,Bilateral pneumonia,Coronavirus Infections,7,X,[dsyn],[dsyn],,C02.782.600.550.200
77c62969-7a04-4f40-8c25-1865a29deb21,C3649547,C0178784,has become effective ,Continuous renal replacement therapy,Organ,1,X,[topp],[bpoc],,
39e0b7ae-b80d-4fd8-b5f7-8e805c1e056d,C3649547,C0206074,has become effective ,Continuous renal replacement therapy,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
39e0b7ae-b80d-4fd8-b5f7-8e805c1e056d,C3649547,C0206074,has become instead of single ,Continuous renal replacement therapy,Renal Replacement Therapy,1,X,[topp],[topp],,E02.870
66bebceb-af0c-40e5-8abc-d970ea934089,C0012634,C3649547, includes ,Disease,Continuous renal replacement therapy,1,X,[dsyn],[topp],C23.550.288,
cb249e12-1d94-4394-a8b5-2481caed1eb1,C3649547,C0206750,is in ,Continuous renal replacement therapy,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
b3ba335d-1100-4193-b235-7b4ddf1217ed,C0553741,C3649547,elaborate similarities between ,Fluid Management,Continuous renal replacement therapy,1,X,[topp],[topp],,
26cafa38-d393-4267-8e35-6b0fd59d6eb5,C0553741,C0206750,elaborate similarities between ,Fluid Management,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
76b10b8e-f041-4007-a6ff-03669a4c2412,C2745965,C0009450,is characterized by high ,Emergencies [Disease/Finding],Communicable Diseases,3,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C01.539.221
76b10b8e-f041-4007-a6ff-03669a4c2412,C2745965,C0009450,is Characterization by high,Emergencies [Disease/Finding],Communicable Diseases,2,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C01.539.221
5f947c52-438b-4d9f-8f7b-cb80777a6611,C0002520,C0206750,may affect ,Amino Acids,Coronavirus Infections,3,X,[aapp/bacs/phsu],[dsyn],D12.125,C02.782.600.550.200
0f5a7ca2-a2dc-4f82-b131-fb2c0045d519,C0282575,C0206750,may affect ,Micronutrients,Coronavirus Infections,3,X,[bacs],[dsyn],D27.505.696.377.683.500;G07.203.300.681.500;J02.500.681.500,C02.782.600.550.200
42587540-43bb-4b34-8f64-170780078cd6,C0319157,C0006255,is in lower ,AS virus,Bronchi,3,X,[virs],[bpoc],,A04.411.125
3873ba67-c97d-4cb9-9309-191c272b8f3f,C0225700,C0006255,is in lower ,Type-II Pneumocytes,Bronchi,5,X,[cell],[bpoc],A04.411.715.100;A11.436.081,A04.411.125
93c711f5-5039-4500-bd1a-3e3ce8a202e3,C0014442,C0040300,is widely expressed in numerous ,Enzymes,Body tissue,4,X,[aapp/enzy],[tisu],D08.811,A10
ab859c45-3208-4209-aeaf-98e836f8ab41,C1706079,C0206061,causes severe primary ,Arrival - action,Pneumonia Interstitial,10,X,[acty],[dsyn],,C08.381.483
40cc1a71-bd9e-480e-9022-3915a4cae59c,C0206061,C0079189,can lead to ,Pneumonia Interstitial,cytokine,5,X,[dsyn],[aapp/imft],C08.381.483,D12.644.276.374;D12.776.467.374;D23.529.374
82beb7e4-071f-413f-9f27-9d233ae1837b,C0206061,C1861452,can lead to ,Pneumonia Interstitial,Storm Syndrome,5,X,[dsyn],[dsyn],C08.381.483,x.x.x.x
1b4bcacc-b3c4-4382-8530-4f90683cf621,C0206061,C1155266,can lead to deadly uncontrolled systemic ,Pneumonia Interstitial,inflammatory response,5,X,[dsyn],[patf],C08.381.483,
907414c4-ffc5-45a6-8244-1c11dd8e737f,C0206061,C1512853,can lead to deadly uncontrolled systemic ,Pneumonia Interstitial,Interleukin Signaling Process,10,X,[dsyn],[phsf],C08.381.483,
d9a75d01-e672-4394-bc0e-ee8166d832af,C0012739,C0206750,are life-threatening for patients with ,Disseminated Intravascular Coagulation,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.100.220;C15.378.463.250;C15.378.925.220,C02.782.600.550.200
e0e46865-1174-43f2-9fc5-852f47c6d70d,C0597404,C0009264,replicate at ,Respiratory viruses,Cold Temperature,4,X,[virs],[npop],,G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300
e6eb42df-1184-4282-918e-7addadfe56df,C0042774,C0015219,risk of ,Virus Replication,Biological Evolution,5,X,[celf],[genf],G06.920.925,G05.045;G16.075
43c17705-2c86-457e-86c9-602282ac3829,C0597571,C2030271,is in ,thermostability,Humid heat,5,X,[npop],[topp],,
37ea7f8e-93fa-49a7-8555-b81fae281a98,C0597571,C0348007,is in ,thermostability,Laser ablation,5,X,[npop],[topp],,
dc2191cd-9d44-40c0-8c9c-0fec04cd74ab,C0042210,C0678544,affect first ,Vaccines,wave - physical agent,1,X,[aapp/imft/phsu],[npop],D20.215.894,
25ea3705-d383-4f51-b586-c8a585c4ee3a,C2926735,C0206419,is in children with ,Duration,Genus: Coronavirus,1,X,[orch/phsu],[virs],,B04.820.504.540.150
25ea3705-d383-4f51-b586-c8a585c4ee3a,C2926735,C0206419,is in patients infected with ,Duration,Genus: Coronavirus,2,X,[orch/phsu],[virs],,B04.820.504.540.150
b73d97b6-e360-42e6-b85c-dd8dae5ae9f2,vis,C0028754,is with multiple ,vis,Obesity,1,X,????,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
c72082d7-5df0-4290-a8b8-aa5d77dba429,C0038454,C0206419,is serious neurological comorbidity observed during ,Cerebrovascular accident,Genus: Coronavirus,2,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150
3af016ba-6959-4c12-b231-692f2e631943,C0038454,C2937358,includes ,Cerebrovascular accident,Cerebral Hemorrhage,2,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,C10.228.140.300.535.200;C14.907.253.573.200;C23.550.414.913.100
0e7140bc-7d1a-44dd-8f4f-2c3ba92ce0e7,C0038454,C0948008,includes ,Cerebrovascular accident,Ischemic stroke,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
6bb3d3e4-d11f-47af-933c-70ba2adebdd9,C0038454,C0151945,includes ,Cerebrovascular accident,Thrombosis of cerebral veins,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,
30b0c97e-2971-434c-8e57-ff7a1d988fad,C0206419,C0043047,is in ,Genus: Coronavirus,Water,1,X,[virs],[inch/phsu],B04.820.504.540.150,D01.045.250.875;D01.248.497.158.459.650;D01.650.550.925;x.x.x.x
a7cf857a-339a-423c-9438-3483d392941a,C0038443,C1825598,may have adverse ,Stress Psychological,IMPACT gene,2,X,[mobd],[gngm],F01.145.126.990;F02.830.900,
a7cf857a-339a-423c-9438-3483d392941a,C0038443,C1825598,have negative ,Stress Psychological,IMPACT gene,2,X,[mobd],[gngm],F01.145.126.990;F02.830.900,
180e4610-5ceb-4839-aab6-7a926fa37d9d,C0038443,C2700061,surrounding ,Stress Psychological,Transition (action),2,X,[mobd],[acty],F01.145.126.990;F02.830.900,
b98a5acc-eb9f-4498-8a07-f34f02289909,C0038443,C1457887,was associated with levels of vocal ,Stress Psychological,Symptoms,2,X,[mobd],[sosy],F01.145.126.990;F02.830.900,
2d3dcf8a-d2aa-426d-809d-6fc5dce844d9,C0162836,C0206419,capture data on risks clinical course and outcomes of ,Hidradenitis Suppurativa,Genus: Coronavirus,1,X,[dsyn],[virs],C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320,B04.820.504.540.150
5b53ed0d-ed64-44fd-8f06-6218877e5252,C0206419,C0162836,capture data on risks clinical course and outcomes of ,Genus: Coronavirus,Hidradenitis Suppurativa,1,X,[virs],[dsyn],B04.820.504.540.150,C01.252.825.420;C01.539.800.720.420;C01.539.830.499;C17.800.838.765.420;C17.800.946.315.320
9a500873-ae33-4cbd-a9ab-5820353150ab,C0206419,C1145670,is easily Communicable Diseases in its form characterized by,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
9a500873-ae33-4cbd-a9ab-5820353150ab,C0206419,C1145670,may cause ,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
9a500873-ae33-4cbd-a9ab-5820353150ab,C0206419,C1145670,is with severe ,Genus: Coronavirus,Respiratory Failure,1,X,[virs],[dsyn],B04.820.504.540.150,C08.618.846
bf33490c-0777-4c01-a52a-bc07a4e7a5aa,C0206419,C0079189,is easily Communicable Diseases in its form characterized by,Genus: Coronavirus,cytokine,3,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
bf33490c-0777-4c01-a52a-bc07a4e7a5aa,C0206419,C0079189,inducing ,Genus: Coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
bf33490c-0777-4c01-a52a-bc07a4e7a5aa,C0206419,C0079189,leads to ,Genus: Coronavirus,cytokine,3,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
bf33490c-0777-4c01-a52a-bc07a4e7a5aa,C0206419,C0079189,manifest ,Genus: Coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.644.276.374;D12.776.467.374;D23.529.374
1e5e906a-9354-41db-bfa0-ca4fb3fbada6,C0369718,C0002520,found highly conserved surface ,N not otherwise specified Antibody,Amino Acids,6,X,[aapp/imft],[aapp/bacs/phsu],,D12.125
057eb645-4fc6-4c8b-9ed6-36d6bc8c3b2f,C0017428,C1175743,is in ,Genome,SARS coronavirus,13,X,[gngm],[virs],G05.360.340,B04.820.504.540.150.113.937
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential missense variants from population databases within ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
66a45b58-ad08-444f-baa6-c51ad23117f4,C4553629,C0022709,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,xentit,1,X,[topp],????,,????
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,xentit,1,X,[topp],????,,????
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,xentit,1,X,[topp],????,,????
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,xentit,1,X,[topp],????,,????
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,xentit,1,X,[topp],????,,????
316f5504-7e1d-46d6-b3fc-b3e6cd802fad,C4553629,xentit,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,xentit,1,X,[topp],????,,????
35f55b51-a686-4ea4-9708-a60d46408141,C4553629,y384,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,y384,1,X,[topp],????,,????
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y384 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
883eeb61-d431-49ce-83cd-c3c4a4873f1a,C4553629,C0036734,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,Serine Endopeptidases,1,X,[topp],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
a9bf80fd-03e6-401b-924f-9fac024e3432,C3266262,C0206419,Cytomegalovirus Infections of only,Multiple Chronic Conditions,Genus: Coronavirus,1,X,[dsyn],[virs],C23.550.291.500.500,B04.820.504.540.150
90dfa11c-bc5d-4348-837d-f99b8acbce7d,C0206419,RT-PCR,ignoring potential for RT-PCR ,Genus: Coronavirus,RT-PCR,1,X,[virs],????,B04.820.504.540.150,????
90dfa11c-bc5d-4348-837d-f99b8acbce7d,C0206419,RT-PCR,based on RT-PCR,Genus: Coronavirus,RT-PCR,1,X,[virs],????,B04.820.504.540.150,????
df08ff81-1298-486f-9a0f-1d8d6b73096c,C0020517,C0801658,have ,Hypersensitivity,Diagnosis.primary:Impression/interpretation of study:Point in time:^Patient:Nominal,3,X,[patf],[clna],C20.543,
19fcd884-1088-4cec-8e8e-c4bbb2499888,C0020517,C0206419,was affected by increased resource use on ,Hypersensitivity,Genus: Coronavirus,4,X,[patf],[virs],C20.543,B04.820.504.540.150
2759305b-6187-4774-adfd-b682a757c6d2,C0013227,C0030946,were investigated against ,Pharmaceutical Preparations,Endopeptidases,1,X,[phsu],[aapp/enzy/phsu],D26,D08.811.277.656.300
b8332d16-1e52-4f0d-a185-0bd9ebed5fec,C0013227,C0012634,were investigated against ,Pharmaceutical Preparations,Disease,5,X,[phsu],[dsyn],D26,C23.550.288
e957d5e5-4a6e-4325-9060-0c6e2edbee06,C0030576,C1167622,have strong ,Paromomycin,Binding (Molecular Function),2,X,[antb/orch],[moft],D09.408.051.706,
7a4a71c2-0acf-4e13-852b-0f615f8ca866,C0030576,C1510827,have strong ,Paromomycin,Affinity,2,X,[antb/orch],[npop],D09.408.051.706,
a76c9752-c32f-4bfd-8631-daaee96b5aef,C0030576,C0206419,have strong ,Paromomycin,Genus: Coronavirus,1,X,[antb/orch],[virs],D09.408.051.706,B04.820.504.540.150
01fcf07c-bc21-4ed6-a681-d423dfda03a6,C0016452,C0012634,suppressing ,Food,Disease,4,X,[food],[dsyn],G07.203.300;J02.500,C23.550.288
37279ceb-34aa-4198-a3d7-aa8468c0a4d1,C1516924,C0206419,are important part of pathophysiology of ,Epigenetic Process,Genus: Coronavirus,1,X,[genf],[virs],G05.308.203,B04.820.504.540.150
2fe1c853-48f0-45ab-b9e5-1b417ba20b2a,MEDLINE,C1856053,Web for literature on use from their inception ,MEDLINE,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,????,[dsyn],????,x.x.x.x
0381b243-3b81-4ffa-9cd1-accaa6f42863,C0301872,C0079189,trigger ,Immune response,cytokine,2,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
0381b243-3b81-4ffa-9cd1-accaa6f42863,C0301872,C0079189,dysregulates ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
0381b243-3b81-4ffa-9cd1-accaa6f42863,C0301872,C0079189,developing ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
0381b243-3b81-4ffa-9cd1-accaa6f42863,C0301872,C0079189,orchestrated by inflammatory ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
0381b243-3b81-4ffa-9cd1-accaa6f42863,C0301872,C0079189,embodies in decrease of ,Immune response,cytokine,1,X,[ortf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
fdbbebf0-9475-424e-bc50-ca815f51eb0c,C0012634,C0393022,is with ,Disease,rituximab,2,X,[dsyn],[aapp/imft/phsu],C23.550.288,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
3d18f6f5-b177-4a03-a40e-2307b6ed330a,C0432618,C1254351,depleting ,Blood group antibody B,Pharmacologic Substance,2,X,[aapp/imft],[phsu],,
439d64da-fd80-41b4-8d3a-b2fee825bdac,CD20,C1254351,depleting ,CD20,Pharmacologic Substance,1,X,????,[phsu],????,
bbc02708-831a-430f-b23e-98541b5a06e8,C1413336,C1254351,depleting ,CEL gene,Pharmacologic Substance,1,X,[gngm],[phsu],,
56cf9ba6-04d9-4566-9cf1-a137fa2a9f52,C0393022,C0432618,with treatment is CD20 ,rituximab,Blood group antibody B,4,X,[aapp/imft/phsu],[aapp/imft],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,
40d349a7-057e-4da3-8abb-c922f488355f,C0393022,CD20,with treatment is CD20 ,rituximab,CD20,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,????
dff35864-7328-4a6d-bc6a-ddda089d899b,C0393022,C1413336,with treatment is CD20 ,rituximab,CEL gene,1,X,[aapp/imft/phsu],[gngm],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,
97b83746-6cdc-4560-b34f-ce24f538b989,C0026769,C0432618,for treatment is CD20 ,Multiple Sclerosis,Blood group antibody B,4,X,[dsyn],[aapp/imft],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,
71c1d5e5-047e-473d-b8cb-03c4d9fbd1e4,C0026769,CD20,for treatment is CD20 ,Multiple Sclerosis,CD20,2,X,[dsyn],????,C10.114.375.500;C10.314.350.500;C20.111.258.250.500,????
32905fd4-99a6-44e9-af1c-72e062b3436e,C0026769,C1413336,for treatment is CD20 ,Multiple Sclerosis,CEL gene,1,X,[dsyn],[gngm],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,
1c0e00d5-1119-4cc6-bdb4-5fed63a71c5f,C1457887,C0426576,were ,Symptoms,Gastrointestinal symptom,2,X,[sosy],[sosy],,
8a48f9db-c30a-45a5-8bf5-99858858a890,EMBASE,C1706202,were ,EMBASE,Search - action,1,X,????,[acty],????,
2ec09db4-adb9-4ee9-9674-7fee1a7650b5,MEDLINE,C1706202,were electronically ,MEDLINE,Search - action,2,X,????,[acty],????,
668be4a1-4aa0-43d4-bca1-2b0e2f156225,MEDLINE,C1706374,were Search - action through,MEDLINE,Tumor Necrosis Factor Ligand Superfamily Member 13,4,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
02f45bbf-5a14-4e36-9994-aa4644ccee93,EMBASE,C1706374,were Search - action through,EMBASE,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
d3afab87-9fa3-445a-840d-5d50a2c50002,C0036974,C0042397,resistant to ,Shock,Vasoconstrictor Agents,2,X,[patf],[phsu],C23.550.835,D27.505.954.411.793
d3afab87-9fa3-445a-840d-5d50a2c50002,C0036974,C0042397,requiring ,Shock,Vasoconstrictor Agents,1,X,[patf],[phsu],C23.550.835,D27.505.954.411.793
2d8d13c9-7844-4f0d-90eb-a04477861e1b,C0032604,C0079189,has has shown to adsorb ,Polystyrenes,cytokine,2,X,[bodm/orch],[aapp/imft],D02.455.426.559.389.150.750.800.830;D05.750.716.579;D25.720.716.579;J01.637.051.720.716.579,D12.644.276.374;D12.776.467.374;D23.529.374
754afc8d-17d6-413d-a172-4069d5d1524a,C0019010,C0010340,extracorporeal Excretory function in,Hemodynamics,Critical Illness,2,X,[ortf],[dsyn],G09.330.380,C23.550.291.625
8a695cb0-d0df-407b-b858-059025f02b54,C0019010,C0206750,extracorporeal Excretory function in,Hemodynamics,Coronavirus Infections,1,X,[ortf],[dsyn],G09.330.380,C02.782.600.550.200
4f9f5ccc-63ff-46bb-9ac2-a4c2e0c9a3e2,C0221102,C0019010,stabilize ,Excretory function,Hemodynamics,2,X,[phsf],[ortf],,G09.330.380
cafd1587-d2d9-4c58-9e5e-e918ae1a3427,C0221102,C0010340,is in ,Excretory function,Critical Illness,2,X,[phsf],[dsyn],,C23.550.291.625
d0fc2dd6-6dc7-4336-be02-5fb2f024a351,C0221102,C0206750,is in ,Excretory function,Coronavirus Infections,1,X,[phsf],[dsyn],,C02.782.600.550.200
e6b898e2-cfb8-4a75-afdd-2080883dcd03,C0019010,C0079189,extracorporeal Excretory function of,Hemodynamics,cytokine,2,X,[ortf],[aapp/imft],G09.330.380,D12.644.276.374;D12.776.467.374;D23.529.374
210fddae-a0fe-42de-9a20-539dce13670d,C1516048,C0007637,is done after ,Assessed,Inclusion Bodies,1,X,[acty],[celc],,A11.284.420
5b556f35-16b4-403d-b844-0f157e212e52,C0310367,C0036658,rebuild ,Today,Esthesia,2,X,[antb/orch],[ortf],,F02.830.816;G11.561.790
99e0e9f5-6a92-4354-b7ec-630282cd2737,C1175743,C1268456,Viral Components of,SARS coronavirus,Viral Components,2,X,[virs],[celc],B04.820.504.540.150.113.937,A21
36d191ac-4960-44fa-b9d3-55c1cc5a1fb8,C1175743,C2752522,site on ,SARS coronavirus,host cell surface,2,X,[virs],[celc],B04.820.504.540.150.113.937,
27b0b7d3-4172-4aae-bcc4-c10ae8ddf685,C1704241,C0597358,is with ,complex (molecular entity),receptor binding,1,X,[chvs],[moft],,
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,has radically shifted healthcare operations across ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,spread across ,Coronavirus Infections,Eye,5,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,is sweeping ,Coronavirus Infections,Eye,2,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,is currently impacting life around ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,has impacted research around ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
d51e73c9-e63a-4c7b-9c79-3da1cc6f4900,C0206750,C0015392,impacted health care Xyzinclude0 practice throughout ,Coronavirus Infections,Eye,1,X,[dsyn],[bpoc],C02.782.600.550.200,A01.456.505.420;A09.371
a8e2f306-8a21-4b2e-8955-1360ea52333e,C0013230,C1152412,having spectrum Antiviral Agents RNA-directed RNA polymerase activity with its target,Investigational New Drugs,RNA-directed RNA polymerase activity,4,X,[phsu],[genf],D26.371,
bd5c1334-a62f-4bc9-bf69-128d9c2777a7,remdesivir,C0013230,is ,remdesivir,Investigational New Drugs,2,X,[clnd],[phsu],,D26.371
583146ef-3c2a-4cc5-869f-3fd6a6f0abb6,C0013230,C0003451,having broad spectrum ,Investigational New Drugs,Antiviral Agents,2,X,[phsu],[phsu],D26.371,D27.505.954.122.388
056bb4c7-a52e-41b3-a85c-8f183494f489,remdesivir,vitro,had promising in vitro vivo,remdesivir,vitro,2,X,[clnd],????,,????
e4de7369-79b7-4df5-b639-dbb83af0e623,remdesivir,vivo,had promising in vitro vivo,remdesivir,vivo,2,X,[clnd],????,,????
85344fef-b5ad-4940-b551-2c3efda26cf5,C0518766,C0543467,were stable on first day after ,Vital signs,Operative Surgical Procedures,6,X,[clna],[topp],E01.370.600.875,E04
f1d64788-c37f-4297-bf3a-1a67cebee602,C0206750,C2359945,raised questions in patients about use of ,Coronavirus Infections,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[dsyn],[clna],C02.782.600.550.200,
ec617ca3-8ffc-4034-a847-5455b1aa4a99,C2745965,C0042776,has changed target of ,Emergencies [Disease/Finding],Virus,1,X,[patf],[virs],C23.550.291.781;N06.230.100.083;N06.850.376,B04
cb2da89c-ab3f-4428-821f-f7ba4addfac0,C0024128,C0042776,target of ,Lung Transplantation,Virus,2,X,[topp],[virs],E04.928.600.495;E04.936.450.495,B04
bfb8af85-0c0b-4105-b675-1e66f93e6520,C0673477,C0019134,is with end point-attached ,ultra-high molecular weight polyethylene,heparin,1,X,[orch],[bacs/orch/phsu],x.x.x.x,D09.698.373.400
6dedcdf5-0f37-400d-b2cc-56e291937b5c,C0004611,C0699040,Binding (Molecular Function) in similar way to interaction on,Bacteria,Cell surface,1,X,[bact],[celc],B03,
c02327a7-7f9f-4415-a527-93d5b466e8c3,C0016832,C0699040,Binding (Molecular Function) in similar way to interaction on,Fungi,Cell surface,1,X,[fngs],[celc],B01.300,
5d28036c-42ad-425a-a330-4836e3ee10a8,C0040549,C0699040,Binding (Molecular Function) in similar way to interaction on,Toxin,Cell surface,1,X,[bacs/hops],[celc],D23.946,
dc0ec972-c043-4d6a-b93e-6361dbce2f4f,C0004611,C0019134,Binding (Molecular Function) to immobilized,Bacteria,heparin,1,X,[bact],[bacs/orch/phsu],B03,D09.698.373.400
b11f36b6-c64f-41e2-aa67-9667a9bf391e,C0016832,C0019134,Binding (Molecular Function) to immobilized,Fungi,heparin,1,X,[fngs],[bacs/orch/phsu],B01.300,D09.698.373.400
fc1e8bb2-5aee-4912-ad86-60e50beb2722,C0040549,C0019134,Binding (Molecular Function) to immobilized,Toxin,heparin,1,X,[bacs/hops],[bacs/orch/phsu],D23.946,D09.698.373.400
74b69561-68e2-4782-b724-bb1641059bf7,C0450254,C0005775,are removed from ,Pathogenic organism,Blood Circulation,2,X,[orgm],[phsf],,G09.330.100
98cf3eb7-d4b9-41e4-9156-453699538df7,C0042071,COVID-19,Dysregulation of were ,Urokinase,COVID-19,1,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300.760.910;D08.811.277.656.959.350.910;D12.776.124.125.662.884,C000657245
b64cb48c-8509-4258-abaf-e762ef024c08,C1704259,COVID-19,is in ,Biochemical Pathway,COVID-19,2,X,[moft],[virs],,C000657245
7cb8377a-5029-4e1d-a454-f3f8baaf94ca,C0005778,COVID-19,is in ,Blood coagulation,COVID-19,2,X,[ortf],[virs],G09.188.390.150,C000657245
3d9ab69c-6219-4cdf-9c94-254f711a6912,C4521503,10th,Delhi between 10th ,CCDC26 wt Allele,10th,1,X,[gngm],????,,????
920e01e1-6aef-4d61-8167-cd691e915bcf,C4521503,C1706374,Delhi between 10th ,CCDC26 wt Allele,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[gngm],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
bc19535e-edc6-48db-ae72-a83fb4d9f494,C0011849,C0221423,were most common co-existing ,Diabetes Mellitus,Illness (finding),1,X,[dsyn],[sosy],C18.452.394.750;C19.246,
f4b8c458-8759-4f53-b9d5-d2b68275b221,C0020538,C0221423,were most common co-existing ,Hypertensive disease,Illness (finding),1,X,[dsyn],[sosy],C14.907.489,
508ca307-2b48-4066-8e2f-0e73cd436df6,C0024117,C0221423,were most common co-existing ,Chronic Obstructive Airway Disease,Illness (finding),1,X,[dsyn],[sosy],C08.381.495.389,
4d1aa8fd-a6e6-4f59-b9ef-68620eae3dce,C1457887,C0013404,were ,Symptoms,Dyspnea,12,X,[sosy],[sosy],,C08.618.326;C23.888.852.371
9617f0b3-8ad8-4b74-b682-e70cf7831afc,C0023530,C0024312,was present with majority of patients presenting with ,Leukopenia,Lymphopenia,1,X,[dsyn],[dsyn],C15.378.553.546,C15.378.553.546.605;C20.673.627
7398281b-969d-4390-8078-b534f3b3090a,C0040034,C0030312,was seen in ,Thrombocytopenia,Pancytopenia,1,X,[dsyn],[dsyn],C15.378.140.855,C15.378.700
cddd23c6-2fc4-4d2b-960c-e92139662e78,C0036974,C0476273,is in higher ,Shock,Respiratory distress,1,X,[patf],[sosy],C23.550.835,
7840d792-97fb-41a5-92ef-a7b25b558b9b,C0206419,C0032285,presented in severe ,Genus: Coronavirus,Pneumonia,11,X,[virs],[dsyn],B04.820.504.540.150,C08.381.677;C08.730.610
d2dedce3-b329-40b0-a800-16a2e772d824,C0699748,COVID-19,is in ,Pathogenesis,COVID-19,3,X,[patf],[virs],,C000657245
3f63a4ef-c9d9-4c81-a867-e89f73d83634,C2267116,C0017110,is in ,Vascular Alterations,Gases,3,X,[phsf],[chvs],,D01.362
7d4dc727-c7e9-48b0-a5e0-980f05349bc0,C3694279,C4284302,were In ,Middle East Respiratory Syndrome,EHD1 wt Allele,7,X,[dsyn],[gngm],C02.782.600.550.200,
897c5337-5c9e-4972-9d9c-e01a14e15d76,C0035203,C0007610,is with ,Respiration,Cell Nucleus,3,X,[phsf],[celc],G09.772.705,A11.284.430.106;A11.284.430.214.190.875.117
4a7bfad3-5aea-462f-8141-698d3bf3091d,C0028754,C0022709,develop COVID-19 outcome due to role of ,Obesity,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D08.811.277.656.350.350.687
4a7bfad3-5aea-462f-8141-698d3bf3091d,C0028754,C0022709,generally led to higher expression of ,Obesity,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D08.811.277.656.350.350.687
6564eefd-ce92-4f46-a2a5-c5dcb872af4b,C0028754,C0042769,develop COVID-19 outcome due to role of ,Obesity,Virus Diseases,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02
6564eefd-ce92-4f46-a2a5-c5dcb872af4b,C0028754,C0042769,develop Coronavirus Infections outcome due to role in,Obesity,Virus Diseases,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C02
4dabaa87-cf63-4e81-a5d3-5a342cdab8ba,C0028754,COVID-19,may Contribution to,Obesity,COVID-19,7,X,[dsyn],[virs],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C000657245
d4a4547f-7076-4496-8941-a2d273d74933,C0022709,C0017337,is regulated in human cells by ,Peptidyl-Dipeptidase A,Genes,6,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,G05.360.340.024.340
e6bad1f9-7e5b-48b3-aff4-5db6161b7758,C0022709,C0042774,decreased ,Peptidyl-Dipeptidase A,Virus Replication,3,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G06.920.925
55cf110f-93eb-4353-8e5e-93d151a3e684,C0022709,C1423053,decreased ,Peptidyl-Dipeptidase A,TAS2R13 gene,3,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,
b2a429ee-9901-404f-afb5-23f43320c79a,C0206131,C0017337, includes ,Adipocytes,Genes,6,X,[cell],[gngm],A11.329.114,G05.360.340.024.340
22ab343f-8e13-4f3c-9c57-8a5ace7c8895,C0017337,C0086418,expressed in ,Genes,Homo sapiens,6,X,[gngm],[humn],G05.360.340.024.340,B01.050.150.900.649.313.988.400.112.400.400
e5311f61-c4c7-47b3-baa9-183f8d2f03ab,C0017337,C0206131,expressed in ,Genes,Adipocytes,3,X,[gngm],[cell],G05.360.340.024.340,A11.329.114
b4ffa6e9-bc82-4210-92e8-c14900b3fa74,C0035668,C0017337,revealed ,RNA,Genes,9,X,[nnon],[gngm],D13.444.735,G05.360.340.024.340
b4ffa6e9-bc82-4210-92e8-c14900b3fa74,C0035668,C0017337,identified ,RNA,Genes,4,X,[nnon],[gngm],D13.444.735,G05.360.340.024.340
89a02e4b-c366-4a53-9eb6-ec0a4d10bb82,C0035668,C0086418,revealed ,RNA,Homo sapiens,6,X,[nnon],[humn],D13.444.735,B01.050.150.900.649.313.988.400.112.400.400
e18f7c10-2916-4335-9ff7-5e5f74234bc7,C0035668,C0206131,revealed ,RNA,Adipocytes,3,X,[nnon],[cell],D13.444.735,A11.329.114
daffb648-f0f8-4297-821b-d8b1711269e8,C1426803,3-fold,increased by 3-fold ,FNDC5 gene,3-fold,3,X,[gngm],????,,????
22a3ae00-928e-4475-9879-6394267d1fa5,C1426803,C1423053,increased by 3-fold ,FNDC5 gene,TAS2R13 gene,3,X,[gngm],[gngm],,
f75667eb-3690-4215-bb32-be985774e4f7,C1426803,C1519595,increased by 3-fold ,FNDC5 gene,Transcript,3,X,[gngm],[nnon],,
da556113-ad39-4289-b501-ffac52dc7331,C0042769,C0001527,is in ,Virus Diseases,Adipose tissue,2,X,[dsyn],[tisu],C02,A10.165.114
f7050279-a90a-43de-b080-ff34af19b39a,C0003504,C0206419,identify ,Aortic Valve Insufficiency,Genus: Coronavirus,1,X,[dsyn],[virs],C14.280.484.095,B04.820.504.540.150
a9aa101a-593b-4a4c-ab0e-850fdf2e5315,studys,COVID-19,apply morphoproteomics from ,studys,COVID-19,2,X,????,[virs],????,C000657245
66297575-346f-44be-9c30-75efa22c4571,PD-1,C1570089,abundance of intra-alveolar interstitial ,PD-1,CD163 protein human,1,X,????,[aapp/imft],????,
4eb0644d-f018-445c-b762-f4985bf542b7,PD-1,C0041484,nuclear expression of ,PD-1,MONOPHENOL MONOOXYGENASE,1,X,????,[aapp/enzy],????,D08.811.682.690.708.125.500
bb384d09-f01a-4255-b931-d3fd59009abe,PD-1,C0253050,nuclear expression of p ,PD-1,Stat3 protein,1,X,????,[aapp/bacs],????,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
96752949-fd5e-4866-bdfc-cb8c53407172,PD-1,C4322733,absence of ,PD-1,CD56+ NK cell,2,X,????,[cell],????,
1968d715-64fd-4b01-be07-4214575159a3,PD-1,C0242629,relative paucity of ,PD-1,CD8-Positive T-Lymphocytes,2,X,????,[cell],????,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
18744ab3-6657-4489-9dd0-c189ccc451e0,C2985566,COVID-19,could address ,Targeted Therapy,COVID-19,2,X,[topp],[virs],,C000657245
76958120-7c63-4e46-868a-7a59edb4204a,C2985566,C0032285,could address ,Targeted Therapy,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
68958e2d-4386-408a-93b9-54fd87c83bf6,C2985566,C0242656,prevent its ,Targeted Therapy,Disease Progression,2,X,[topp],[patf],,C23.550.291.656
cd4a54e8-27f5-4f82-94d2-283305f5058e,C0278347,C0815172,radiologic patient characteristics of 1 568,Transfusion of plasma,patient characteristics,2,X,[topp],[clna],,
89e63e29-6440-4f3f-b152-f174f6dd675b,C0028754,renin,is associated with dysregulated renin ,Obesity,renin,2,X,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,????
8719e96b-7168-4d2f-b309-28fa1e37359c,C0028754,C0003018,is associated with dysregulated renin ,Obesity,Angiotensins,2,X,[dsyn],[aapp/bacs/phsu],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
9e13b270-c81f-4fce-8761-f3dcf6cc8314,C0028754,C0004457,is associated with dysregulated renin ,Obesity,Axis vertebra,2,X,[dsyn],[bpoc],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,A02.835.232.834.151.383
9356bbcd-7ecf-46fc-98ec-5bfb8f255dc4,CoV2,C1167622,uses membrane ,CoV2,Binding (Molecular Function),1,X,????,[moft],????,
8af8ee43-8367-48ce-b0e4-0b3fb2db7e8d,CoV2,C0022709,uses membrane-bound form of ,CoV2,Peptidyl-Dipeptidase A,5,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
7c004916-1d3a-45d8-8666-7ef08c3896cc,CoV2,C1514760,uses membrane- form as,CoV2,Receptor Cell,3,X,????,[cell],????,
0f94cffe-6813-4bed-a576-e2a69d59ba95,CoV2,C0007634,uses membrane- form as,CoV2,Cells,1,X,????,[cell],????,A11
9e87897d-14fb-4560-bef5-f88656ec78f8,C0022709,C1325584,is protective lateral element of,Peptidyl-Dipeptidase A,lateral element,4,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
0606801b-9c53-4be4-bb59-a5b3fd28837d,C0022709,C0003018,is protective lateral element of,Peptidyl-Dipeptidase A,Angiotensins,2,X,[aapp/enzy/imft],[aapp/bacs/phsu],D08.811.277.656.350.350.687,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
255c596b-9e5c-4375-b76e-6a1ec40783c1,C0022709,CoV2,is downregulated after CoV2 ,Peptidyl-Dipeptidase A,CoV2,2,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
255c596b-9e5c-4375-b76e-6a1ec40783c1,C0022709,CoV2,enable CoV2,Peptidyl-Dipeptidase A,CoV2,1,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
e781d8d6-ddac-49de-89e9-094c2894d5e5,C0003018,C0028754,could could link between ,Angiotensins,Obesity,2,X,[aapp/bacs/phsu],[dsyn],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
14538f35-843b-419e-a255-6e8dc58b8f67,C0004457,C0028754,could could link between ,Axis vertebra,Obesity,2,X,[bpoc],[dsyn],A02.835.232.834.151.383,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
0330d0de-789a-4d03-bd79-d5e055fe6b2b,C1145670,C0206419,is with ,Respiratory Failure,Genus: Coronavirus,4,X,[dsyn],[virs],C08.618.846,B04.820.504.540.150
7e7d09d7-2427-4880-b8d7-2fff10b480c4,DCPEM,C1319405,initiated surveillance program in close collaboration with Department of ,DCPEM,Clinical microbiology,1,X,????,[bmod],????,
8a150109-df6b-441a-abe6-2300595e6dee,DOH,C1319405,initiated surveillance program in close collaboration with Department of ,DOH,Clinical microbiology,3,X,????,[bmod],????,
c451f3bd-2f23-436b-8190-185a88cd0ea8,COVID-19,C0221423,can cause severe respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
c451f3bd-2f23-436b-8190-185a88cd0ea8,COVID-19,C0221423,is new clinical syndrome from upper respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
c451f3bd-2f23-436b-8190-185a88cd0ea8,COVID-19,C0221423,is new syndrome from mild upper respiratory ,COVID-19,Illness (finding),1,X,[virs],[sosy],C000657245,
9dacf5ba-79b0-4503-a232-a4b8849e6e3a,C0319157,C0042542,is in ,AS virus,Vero Cells,1,X,[virs],[cell],,A11.251.210.955;A11.436.955
91b50b8d-5a20-41b7-825e-6f7c22046250,C0319157,C0007537,is in ,AS virus,Cefaclor,1,X,[virs],[antb/orch],,D02.065.589.099.249.200.155;D02.886.665.074.200.155;D03.633.100.300.249.200.155
c180778d-49dd-4240-9a1f-986370b8df92,C0003320,C0319157,propagating ,Antigens,AS virus,1,X,[imft],[virs],D23.050,
79b83d26-a0ef-442a-b61f-8545de9e2ac3,C1511790,C1550100,is in ,Detection,Specimen Type - Serum,2,X,[topp],[bdsu],,
744a7488-093f-41ff-b270-27cc439294e4,C1511790,C0086418,is in ,Detection,Homo sapiens,1,X,[topp],[humn],,B01.050.150.900.649.313.988.400.112.400.400
b703e9d5-7872-4f50-8ee7-5a4213f5c9c6,C0450254,C0206750,due to Coronavirus Infections is,Pathogenic organism,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
b703e9d5-7872-4f50-8ee7-5a4213f5c9c6,C0450254,C0206750,has has recently recognized as cause of ,Pathogenic organism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
0a1be959-2d43-48c0-9b6a-d148a7e11c09,C0063034,C2745965,guarantee ,huperzine B,Emergencies [Disease/Finding],5,X,[orch/phsu],[patf],x.x.x.x,C23.550.291.781;N06.230.100.083;N06.850.376
ed27d334-5e6c-44ed-b12b-25f4c8361b3a,C0063034,C0038897,guarantee ,huperzine B,Cardiovascular Surgical Procedures,5,X,[orch/phsu],[topp],x.x.x.x,E04.100
685d006d-7a24-4ce6-b172-84def830abc9,C0063034,C2188405,guarantee ,huperzine B,urgent Operation,5,X,[orch/phsu],[topp],x.x.x.x,
2c7823da-5fd7-4676-b6f5-b37ac2e02392,C0063034,C0018787,efficiently safeguards access to ,huperzine B,Heart,9,X,[orch/phsu],[bpoc],x.x.x.x,A07.541
6db79977-d178-40b8-8c9b-36f5ad94655c,C0206422,C0206750,has has recognized as cause of ,Human coronavirus,Coronavirus Infections,2,X,[virs],[dsyn],,C02.782.600.550.200
6db79977-d178-40b8-8c9b-36f5ad94655c,C0206422,C0206750,latest version of be ,Human coronavirus,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
c5f1feb5-a508-4db5-9b7a-60e3423317e3,C0014507,C0007222,suggest association between ,Epidemiology,Cardiovascular Diseases,2,X,[bmod],[dsyn],H02.403.720.500,C14
a245c2f1-e42d-4b40-af6f-b7bd166f0784,C0014507,C0683325,suggest association between ,Epidemiology,clinical aspects,2,X,[bmod],[clna],H02.403.720.500,
12e333b6-e15e-44a9-9ac9-79536de7452e,C0018787,C0007222,outcome for patients with underlying ,Heart,Cardiovascular Diseases,1,X,[bpoc],[dsyn],A07.541,C14
f07da980-9488-4542-9d72-63f96584d55e,C1853193,C1290884,followed by ,Recurrent skin infections,Inflammatory disorder,1,X,[dsyn],[dsyn],,
8fef9d7d-994e-47db-8aa4-a39b80c8051b,C1947933,C0037274,improves diagnostic accuracy in ,care activity,Dermatologic disorders,1,X,[acty],[dsyn],,C17.800
8fd920c1-dffa-4926-98f9-83334db120dd,C4321457,C0037274,improves diagnostic accuracy in ,Examination,Dermatologic disorders,1,X,[acty],[dsyn],,C17.800
03e6eac5-641c-45f0-b45d-6c12e767793a,C0206750,C0085593,presenting with ,Coronavirus Infections,Chills,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.208
9a5a00bf-2cc9-4bd2-8a92-5fe888f8e3e8,C1829939,C0037090,is with ,{Non-patient},Signs and Symptoms Respiratory,2,X,[clna],[sosy],,C23.888.852
28ca3377-8581-4dbc-8205-021bc43893b9,C1829939,C0206750,have ,{Non-patient},Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
752dbf83-7636-4b36-aeda-0da565842104,C0277554,C0184893,required ,primary disorders,Emergency operation,2,X,[dsyn],[topp],,
f930eb29-b288-4f76-beba-19934f623e31,C0883468,CD3,numbers of CD3,CD16+CD56+ cell,CD3,4,X,[cell],????,,????
fc1f1d36-d513-4730-b25c-4aa6d7cb41ae,C2709199,CD3,numbers of CD3,Natural killer,CD3,2,X,[cell],????,,????
5ffb7648-c388-49b8-aca8-529b49efaf9a,C0020639,C0005778,of presence is abnormal ,Hypoproteinemia,Blood coagulation,2,X,[dsyn],[ortf],C15.378.147.607,G09.188.390.150
d0c00415-e714-4599-96cc-966ddfa5aa57,C0020625,C0005778,of presence is abnormal ,Hyponatremia,Blood coagulation,2,X,[dsyn],[ortf],C18.452.950.620,G09.188.390.150
61e785b3-967b-4760-8aff-be5ee128eb6b,C0020598,C0005778,of presence is abnormal ,Hypocalcemia,Blood coagulation,2,X,[dsyn],[ortf],C18.452.174.509;C18.452.950.509,G09.188.390.150
4d758a7c-92ff-4892-a491-cd57bdb45c46,C0020639,C0031843,of presence is abnormal ,Hypoproteinemia,physiological aspects,2,X,[dsyn],[phsf],C15.378.147.607,x.x.x.x
8a394d55-7e64-487c-8497-a3cc3d8fd555,C0020625,C0031843,of presence is abnormal ,Hyponatremia,physiological aspects,2,X,[dsyn],[phsf],C18.452.950.620,x.x.x.x
4593888e-bb0b-45e2-a7dd-a3fc77bdc026,C0020598,C0031843,of presence is abnormal ,Hypocalcemia,physiological aspects,2,X,[dsyn],[phsf],C18.452.174.509;C18.452.950.509,x.x.x.x
85c0d89e-0901-41be-ba7b-a5a2ddbf2088,C1856053,C0206750,included attitudes toward ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
85c0d89e-0901-41be-ba7b-a5a2ddbf2088,C1856053,C0206750,is in World Health Organization ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
85c0d89e-0901-41be-ba7b-a5a2ddbf2088,C1856053,C0206750,established ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
85c0d89e-0901-41be-ba7b-a5a2ddbf2088,C1856053,C0206750,2020 during ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
85c0d89e-0901-41be-ba7b-a5a2ddbf2088,C1856053,C0206750,lowered compound growth rate of ,Hydranencephaly with Renal Aplasia-Dysplasia,Coronavirus Infections,2,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
6dea00e6-e7dc-463e-bc80-4c66641710f0,C1422064,C0034800,is in conveyor ,ACE2 gene,Receptors Cell Surface,4,X,[gngm],[aapp/rcpt],,D12.776.543.750
88d9f058-ffa6-41ee-9c9c-8b40f03fc4b5,C0004096,C0206750,constitutes risk factor for ,Asthma,Coronavirus Infections,4,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C02.782.600.550.200
88d9f058-ffa6-41ee-9c9c-8b40f03fc4b5,C0004096,C0206750,is in 11/46 children hospitalized for ,Asthma,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C02.782.600.550.200
a7d3002b-c7ae-43f0-9d36-04562b38e685,C1175743,C0679381,is in ,SARS coronavirus,Pediatric Disorder,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,
48469be3-aecd-4dc4-86d4-43213f23e474,C0679381,C1175743,in SARS coronavirus is,Pediatric Disorder,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
f85b4267-b9e2-4c85-bfeb-89f41db048bf,C1155266,C0035243,occurs in addition to ,inflammatory response,Respiratory Tract Infections,3,X,[patf],[dsyn],,C01.539.739;C08.730
536a30b5-ad74-4201-8f70-426250008685,C1155266,C0005779,leads to ,inflammatory response,Blood Coagulation Disorders,3,X,[patf],[dsyn],,C15.378.100
17cd2729-807a-4764-a499-3bd3c17f9ab1,C0242781,C1708476,was documented before ,disease transmission,Implementation,1,X,[patf],[acty],N06.850.310,
44b2dd95-a79c-4ba1-a2fc-234f89146655,C1999230,C0020405,importance of rigorous ,Providing (action),Hygiene,1,X,[acty],[bmod],,E02.547;N06.850.670
84940cd1-a44d-44c4-b919-28aa6b462b9a,PWH,C0005516,had higher levels of ,PWH,Biological Markers,1,X,????,[clna],????,D23.101
3e2bb52b-ff11-4935-b070-659202b4571b,PWH,COVID-19,remain at ,PWH,COVID-19,1,X,????,[virs],????,C000657245
f5e515e8-4870-47ef-ba3c-0c9a02008c73,C1707455,C1742865,is with positive control ,Comparison,TMPRSS2 protein human,1,X,[acty],[aapp/enzy],,x.x.x.x
7c6ada40-09d6-4c14-8ea9-de258aa5211a,C1742865,C0385178,as compound is ,TMPRSS2 protein human,benzquercin,1,X,[aapp/enzy],[orch/phsu],x.x.x.x,x.x.x.x
ead356e9-0cbc-4d22-aec3-1c3e3414df76,C0243052,C1175743, includes ,Virus Physiological Phenomena,SARS coronavirus,1,X,[npop],[virs],G06.920,B04.820.504.540.150.113.937
f4c09190-737c-455a-bd20-316ffc0564c0,C0243052,C0086418, includes ,Virus Physiological Phenomena,Homo sapiens,1,X,[npop],[humn],G06.920,B01.050.150.900.649.313.988.400.112.400.400
ba2a959f-7c7c-419c-8fa6-17c9a7eba0ed,C0061751,C0243052,has shown ,Glycyrrhizic Acid,Virus Physiological Phenomena,5,X,[orch/phsu],[npop],D02.455.849.919.530.466,G06.920
1e14331a-4aef-4e02-ab7a-4ac5d7e1b4fb,C0061751,C1175743,has shown ,Glycyrrhizic Acid,SARS coronavirus,2,X,[orch/phsu],[virs],D02.455.849.919.530.466,B04.820.504.540.150.113.937
1e14331a-4aef-4e02-ab7a-4ac5d7e1b4fb,C0061751,C1175743,good candidate tested against ,Glycyrrhizic Acid,SARS coronavirus,8,X,[orch/phsu],[virs],D02.455.849.919.530.466,B04.820.504.540.150.113.937
69e601ea-089f-4327-b038-46c48d549305,C0061751,C0086418,has shown ,Glycyrrhizic Acid,Homo sapiens,2,X,[orch/phsu],[humn],D02.455.849.919.530.466,B01.050.150.900.649.313.988.400.112.400.400
e712d35e-5008-432f-97b7-77dc6851d73b,C0061751,C0520481,is non-hemolytic ,Glycyrrhizic Acid,Saponin,2,X,[orch/phsu],[orch],D02.455.849.919.530.466,D09.408.782
f9830811-2125-4873-8656-b86b4f908b98,C0061751,C0008377,induces ,Glycyrrhizic Acid,Cholesterol,2,X,[orch/phsu],[bacs/orch],D02.455.849.919.530.466,D04.210.500.247.222.284;D04.210.500.247.808.197;D10.570.938.208
2bc5057a-ab1a-4351-9c38-bb84d05803eb,C0061751,C1167250,induces ,Glycyrrhizic Acid,lipid raft,2,X,[orch/phsu],[celc],D02.455.849.919.530.466,
f6769023-2b1f-444d-94a5-f4a57239492b,C0061751,C0596901,induces disorganization At ,Glycyrrhizic Acid,Membrane,2,X,[orch/phsu],[celc],D02.455.849.919.530.466,A10.615
3480d939-ec35-43dc-ac8b-3a82df305d9b,C0061751,C0019534,can CD40LG wt Allele,Glycyrrhizic Acid,High Mobility Group Proteins,2,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.660.235.400;D12.776.664.235.400
3480d939-ec35-43dc-ac8b-3a82df305d9b,C0061751,C0019534,can trap ,Glycyrrhizic Acid,High Mobility Group Proteins,2,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.660.235.400;D12.776.664.235.400
b5610fac-6bef-4e43-a760-ed46c4907635,C0061751,C3891560,thus blocks ,Glycyrrhizic Acid,Alarmins,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D23.035
b5610fac-6bef-4e43-a760-ed46c4907635,C0061751,C3891560,thus Obstruction,Glycyrrhizic Acid,Alarmins,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D23.035
31031b83-cd59-4d49-a656-828b15aae5f1,C0061751,C0019796,thus blocks ,Glycyrrhizic Acid,HMGB1 Protein,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.260.356.300;D12.776.660.235.400.600.300;D12.776.664.235.400.600.300
31031b83-cd59-4d49-a656-828b15aae5f1,C0061751,C0019796,thus Obstruction,Glycyrrhizic Acid,HMGB1 Protein,1,X,[orch/phsu],[aapp/bacs],D02.455.849.919.530.466,D12.776.260.356.300;D12.776.660.235.400.600.300;D12.776.664.235.400.600.300
6ffbdf05-07e0-4188-99db-cd8e52cd32cb,C3540027,C0008269,is with ,Adrenergic and dopaminergic agents combinations,Chloroquine,2,X,[phsu],[orch/phsu],,D03.633.100.810.050.180
c364b9b1-b16b-4d02-8b43-4257fd83441f,COVID-19,C1947933,opportunity for reformation of disabilities ,COVID-19,care activity,2,X,[virs],[acty],C000657245,
c364b9b1-b16b-4d02-8b43-4257fd83441f,COVID-19,C1947933,has dramatically changed practice in favor of ,COVID-19,care activity,1,X,[virs],[acty],C000657245,
c364b9b1-b16b-4d02-8b43-4257fd83441f,COVID-19,C1947933,presented for ,COVID-19,care activity,1,X,[virs],[acty],C000657245,
e1120870-98e1-47da-bf6b-d8fbe6c1dfdc,C1999230,C1947933,opportunity for reformation of disabilities ,Providing (action),care activity,2,X,[acty],[acty],,
e1120870-98e1-47da-bf6b-d8fbe6c1dfdc,C1999230,C1947933,is essential ,Providing (action),care activity,2,X,[acty],[acty],,
54677ecf-7441-40f6-b99b-ea08c8cbf1f5,C0020517,COVID-19,is with ,Hypersensitivity,COVID-19,2,X,[patf],[virs],C20.543,C000657245
8b804f32-46f2-42f0-8395-6011cf6dc521,COVID-19,C0278996,has altered healthcare environment for management ,COVID-19,Malignant Head and Neck Neoplasm,4,X,[virs],[neop],C000657245,
0e677be9-f6d2-4cd3-b8ce-60ec095e390d,C0206419,C0035920,is ,Genus: Coronavirus,Rubella,1,X,[virs],[dsyn],B04.820.504.540.150,C02.782.930.700.700
10b780c8-258f-4911-abdc-536f7caaae87,C0012634,C0035920,is ,Disease,Rubella,1,X,[dsyn],[dsyn],C23.550.288,C02.782.930.700.700
adf148fc-c29b-40c5-a4da-59006e25d502,C0237820,C1628327,is ,Recovery - action,Zoonotic pathogen,1,X,[acty],[orgm],,
fc60da16-8428-4323-871f-93ce47b0f261,C0237820,C3694279,is ,Recovery - action,Middle East Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200
7f64e6af-a87a-46d7-9c99-52408d103026,C0025241,C1504389,is with autologous ,Melphalan,Stem cell transplant,1,X,[aapp/phsu],[topp],D02.455.526.728.650.594;D12.125.072.050.685.500,E02.095.147.500.500;E04.936.225.687
fd8f7290-dfc7-4aad-a931-f68c54f62952,C0034019,C0719214,is in ,public health medicine (field),century,1,X,[bmod],[phsu/vita],H02.403.720;N01.400.550;N06.850,
e9bad1d9-ef22-4043-9e90-452d3c832e2f,C0341073,COVID-19,is useful for ,Percutaneous cholecystostomy,COVID-19,1,X,[topp],[virs],,C000657245
84aac241-4f95-421a-a206-8f954f26bf95,C0341073,C0149520,is useful for ,Percutaneous cholecystostomy,Acute Cholecystitis,1,X,[topp],[dsyn],,C06.130.564.263.500
e2d5bd07-d967-4ab1-a132-56204ac1fac7,C0149520,COVID-19,is in ,Acute Cholecystitis,COVID-19,1,X,[dsyn],[virs],C06.130.564.263.500,C000657245
98a646e0-05e2-47d0-818f-ef5a656fd6c4,dataset,C0028630,determine separately ,dataset,Nucleotides,1,X,????,[nnon],????,D09.408.620;D13.695
facd929a-f121-44f4-b4d9-ccdf6eeec2bc,dataset,C0026882,determine separately ,dataset,Mutation,1,X,????,[genf],????,G05.365.590
facd929a-f121-44f4-b4d9-ccdf6eeec2bc,dataset,C0026882,determine codon ,dataset,Mutation,1,X,????,[genf],????,G05.365.590
09a257b8-734f-4d85-8ebd-f990e41482c7,C0040034,C1175743,were significantly more common in ,Thrombocytopenia,SARS coronavirus,4,X,[dsyn],[virs],C15.378.140.855,B04.820.504.540.150.113.937
7ce787fc-ba3c-4816-9869-1191b75dbfb4,et,C0018943,conducted meta-analysis In recent paper published in Journal of ,et,Hematology (discipline),2,X,????,[bmod],????,H02.403.429.445
6d2cbdeb-3f90-488d-9b48-6e234dab774b,al,C0018943,conducted meta-analysis In recent paper published in Journal of ,al,Hematology (discipline),2,X,????,[bmod],????,H02.403.429.445
8e6e0b35-9c0a-433d-9f7b-a2f5c596d573,C0235029,C0038454,include ,neurological complication,Cerebrovascular accident,2,X,[patf],[dsyn],,C10.228.140.300.775;C14.907.253.855
b70c754a-58eb-42d0-9a13-5ebf2b34fb0e,C0235029,C0009450,associated with ,neurological complication,Communicable Diseases,2,X,[patf],[dsyn],,C01.539.221
0908c49c-b4d6-4f8c-9b98-9fdb4b44c85a,C0235029,C1175743,associated with ,neurological complication,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
660be14b-e6eb-44a2-828b-2027a7b63377,C0038454,C1155266,may result from dysregulated ,Cerebrovascular accident,inflammatory response,2,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,
47ebb283-602f-4e3e-ad59-8342934cdc40,C0038454,C0009450,may result from dysregulated ,Cerebrovascular accident,Communicable Diseases,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
47ebb283-602f-4e3e-ad59-8342934cdc40,C0038454,C0009450,should closely Assessed lung apices,Cerebrovascular accident,Communicable Diseases,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C01.539.221
9f11819a-c919-475b-b14c-8ee8f9d0f3b6,C1276305,C0206419,is In early stage ,Curative - procedure intent,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
bfd3ef7e-77bd-4ce4-b811-d86726f02c92,C0012634,C0037090,causes Signs and Symptoms Respiratory Illness (finding) with,Disease,Signs and Symptoms Respiratory,4,X,[dsyn],[sosy],C23.550.288,C23.888.852
91454084-954e-4acf-8a5f-c60a7b16d18d,C0012634,C0850149,causes Signs and Symptoms Respiratory Illness (finding) with,Disease,Dry cough,2,X,[dsyn],[sosy],C23.550.288,
287b45a4-af9e-434e-b483-7bf43f8d054e,C0022709,C0225336,is expressed in ,Peptidyl-Dipeptidase A,Endothelial Cells,3,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436.275
c23d840c-7299-46bc-a76b-b2bbbe8a37f0,C0022709,C0162772,could could implicated in production of ,Peptidyl-Dipeptidase A,Reactive Oxygen Species,3,X,[aapp/enzy/imft],[bacs/elii],D08.811.277.656.350.350.687,D01.339.431;D01.650.775
02f2523c-0e04-493b-9cee-fa955b1929f4,C0022709,C0856169,could could implicated in production of ,Peptidyl-Dipeptidase A,endothelial dysfunction,3,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,
348bd15d-d459-4f04-a651-f0def9574ae2,C0751956,C0206419,may have undiagnosed ,Acute Cerebrovascular Accidents,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150
c10d6adb-5776-416e-9fea-5b9f9605a89e,C0206419,C0275522,can cause spectrum of presentations ranging from ,Genus: Coronavirus,Asymptomatic Infections,5,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.187.500
975e9dd7-b83c-4f5c-8e10-24393e62ebbf,C0949880,C0041912,typically cause mild ,Human coronavirus 229E,Upper Respiratory Infections,5,X,[virs],[dsyn],B04.820.504.540.150.075.750,C01.539.739;C08.730
7aa2cbca-a2cc-4870-b583-318e4a38a517,C1412384,C0265267,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects in,AMH gene,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,1,X,[gngm],[dsyn],,x.x.x.x
493b9b0c-08a5-4a46-91f1-76a200839d77,C0054943,C0030755,Academy of ,ALANINE AMINOPEPTIDASE,Pediatrics,5,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.100.160;D08.811.277.656.350.555.100;D08.811.277.656.675.555.100;D23.050.301.264.894.113;D23.101.100.894.113,H02.403.670
23eadc8a-131b-4417-bd28-54df1496c8de,C0034019,C0699680,should report country-specific ,public health medicine (field),Metric,1,X,[bmod],[orch/phsu],H02.403.720;N01.400.550;N06.850,D02.640.672.500;D03.383.129.308.658.500
c6525e5b-a4eb-4a5a-903f-b5188b733717,C0086418,C0035804,is in ,Homo sapiens,Rodent,2,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,B01.050.150.900.649.313.992
90535397-fcbb-4983-a6af-97bbedc6059f,C0004626,C1521863,were conducted in pre-antibiotic ,Pneumonia Bacterial,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C01.252.620;C08.381.677.540;C08.730.610.540,x.x.x.x
66365baa-8ba7-44b0-8085-5d40ab194961,C1518010,C0029408,is when applied to subacute ,Low Dose Radiation Therapy,Degenerative polyarthritis,4,X,[topp],[dsyn],,C05.550.114.606;C05.799.613
61848069-ea9d-4f53-93b5-9a1fbe0a6dd1,C1518010,C0024109,produces effects in inflamed ,Low Dose Radiation Therapy,Lung,2,X,[topp],[bpoc],,A04.411
0d71af53-f493-4625-8830-b058a48d8255,C1518010,COVID-19,exacerbates ,Low Dose Radiation Therapy,COVID-19,2,X,[topp],[virs],,C000657245
01d753ca-e42e-472f-9a68-659b576a7bfe,COVID-19,C0042769,is new ,COVID-19,Virus Diseases,1,X,[virs],[dsyn],C000657245,C02
01d753ca-e42e-472f-9a68-659b576a7bfe,COVID-19,C0042769,is due to mainly ,COVID-19,Virus Diseases,1,X,[virs],[dsyn],C000657245,C02
bab5b228-41d0-48ad-90fa-70130bcdef70,COVID-19,C0458827,can affect ,COVID-19,Airway structure,1,X,[virs],[bpoc],C000657245,
ecd84646-842c-4b33-b2ac-99485af8032e,COVID-19,C0024109,can affect ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
ecd84646-842c-4b33-b2ac-99485af8032e,COVID-19,C0024109,cause severe ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
ecd84646-842c-4b33-b2ac-99485af8032e,COVID-19,C0024109,is new clinical syndrome from upper respiratory ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
ecd84646-842c-4b33-b2ac-99485af8032e,COVID-19,C0024109,aggravated in ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
ecd84646-842c-4b33-b2ac-99485af8032e,COVID-19,C0024109,directly targets ,COVID-19,Lung,1,X,[virs],[bpoc],C000657245,A04.411
e2851bbe-902a-4425-bd13-3256900de79e,C0040300,C0024109, includes ,Body tissue,Lung,6,X,[tisu],[bpoc],A10,A04.411
4f39f11a-f66f-4d7e-a2c7-f09032dcb9cc,C0040300,C0022646, includes ,Body tissue,Kidney,6,X,[tisu],[bpoc],A10,A05.810.453
74d404ca-5276-474b-9a4d-6dc690d8cc36,C0040300,C0021852, includes ,Body tissue,Intestines Small,6,X,[tisu],[bpoc],A10,A03.556.124.684
5cfe7820-cd60-46a3-aade-c6b687d8b22a,C0040300,C0018787, includes ,Body tissue,Heart,6,X,[tisu],[bpoc],A10,A07.541
149ce5af-57fd-4819-916b-0ed5cdb83822,C0022709,C0040300,were widely disturbed among ,Peptidyl-Dipeptidase A,Body tissue,7,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10
57f3ff5a-cfd4-4ec8-8fda-b1d83f7e9c7f,C0597357,C0040300,were widely disturbed among ,receptor,Body tissue,9,X,[aapp/rcpt],[tisu],,A10
57f3ff5a-cfd4-4ec8-8fda-b1d83f7e9c7f,C0597357,C0040300,is present on ,receptor,Body tissue,1,X,[aapp/rcpt],[tisu],,A10
57f3ff5a-cfd4-4ec8-8fda-b1d83f7e9c7f,C0597357,C0040300,is widely expressed in numerous ,receptor,Body tissue,1,X,[aapp/rcpt],[tisu],,A10
1fdae36d-6611-44ca-adca-0c6b293595af,C0022709,C0022646,were widely disturbed among ,Peptidyl-Dipeptidase A,Kidney,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.810.453
1fdae36d-6611-44ca-adca-0c6b293595af,C0022709,C0022646,effect on ,Peptidyl-Dipeptidase A,Kidney,6,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A05.810.453
0e2bc90c-61e1-43c5-88e7-b90f3e99b03c,C0597357,C0022646,were widely disturbed among ,receptor,Kidney,6,X,[aapp/rcpt],[bpoc],,A05.810.453
0e2bc90c-61e1-43c5-88e7-b90f3e99b03c,C0597357,C0022646,is present on ,receptor,Kidney,1,X,[aapp/rcpt],[bpoc],,A05.810.453
bf0535a8-bf43-42c1-b60a-28b26663853c,C0022709,C0021852,were widely disturbed among ,Peptidyl-Dipeptidase A,Intestines Small,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A03.556.124.684
16d3f16d-0a75-4e75-9ea2-808e3cde20dc,C0597357,C0021852,were widely disturbed among ,receptor,Intestines Small,6,X,[aapp/rcpt],[bpoc],,A03.556.124.684
a83bb246-1ae0-4fac-9b43-21d39f51a91f,C0597357,C0018787,were widely disturbed among ,receptor,Heart,6,X,[aapp/rcpt],[bpoc],,A07.541
a83bb246-1ae0-4fac-9b43-21d39f51a91f,C0597357,C0018787,is present on ,receptor,Heart,1,X,[aapp/rcpt],[bpoc],,A07.541
6d8abb97-aadb-4065-bff5-f5d905e152f0,C0597357,COVID-19,considered ,receptor,COVID-19,3,X,[aapp/rcpt],[virs],,C000657245
596697a7-b4f4-4965-b313-5838f84400bb,C0127400,NF-B,Up-Regulation (Physiology) of NF-B,Mediator brand of benfluorex hydrochloride,NF-B,3,X,[orch/phsu],????,,????
620c3d52-d0c3-42f5-94a9-c452b3d0a716,C0127400,C1704259,Up-Regulation (Physiology) of NF-B,Mediator brand of benfluorex hydrochloride,Biochemical Pathway,3,X,[orch/phsu],[moft],,
783f8d9a-99b2-4c2a-99e6-dc1657386d82,C0118522,C0432616,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Blood group antibody A,6,X,[aapp/bacs],[aapp/imft],D12.776.260.615.249;D12.776.930.618.249,
4b9b97dd-0b5b-4a70-94c1-ab29e975c47b,C0118522,C0085403,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Oxidants,3,X,[aapp/bacs],[chvf],D12.776.260.615.249;D12.776.930.618.249,D27.720.642;D27.888.569.540
17eafe80-43b6-4ca9-b83a-260f6d9fe681,C0118522,C0014442,was TRANSCRIPTION FACTOR play,GA-Binding Protein Transcription Factor,Enzymes,2,X,[aapp/bacs],[aapp/enzy],D12.776.260.615.249;D12.776.930.618.249,D08.811
55115735-f7ff-456a-aaf1-02f08c06cde7,C0118522,C0040648,was ,GA-Binding Protein Transcription Factor,TRANSCRIPTION FACTOR,6,X,[aapp/bacs],[aapp/bacs],D12.776.260.615.249;D12.776.930.618.249,D12.776.930
5f0a9a5f-0fe1-4d21-921a-871ff794c087,C0432616,C0085403,is in generation of ,Blood group antibody A,Oxidants,3,X,[aapp/imft],[chvf],,D27.720.642;D27.888.569.540
b12d03bb-304f-46cb-8542-0e116ea95fe4,C0432616,C0014442,is in generation of ,Blood group antibody A,Enzymes,2,X,[aapp/imft],[aapp/enzy],,D08.811
288829ca-44ab-4476-8136-9fbd44972526,C0127400,C1310468, includes ,Mediator brand of benfluorex hydrochloride,DDX58 protein human,2,X,[orch/phsu],[aapp/enzy],,x.x.x.x
56514f71-5908-4609-a11f-531084f904db,TRMPSS2,C0085403,induce anti ,TRMPSS2,Oxidants,1,X,????,[chvf],????,D27.720.642;D27.888.569.540
9731d984-f63d-492c-80ec-068981ca373f,TRMPSS2,C0014442,induce anti ,TRMPSS2,Enzymes,1,X,????,[aapp/enzy],????,D08.811
390920c8-f766-48d8-a167-be87e5e86b26,TRMPSS2,C1160700,induce ,TRMPSS2,viral gene expression,2,X,????,[celf],????,
5ffa038d-aa95-4db2-ab62-716e6b6d76b2,TRMPSS2,C0127400,induce ,TRMPSS2,Mediator brand of benfluorex hydrochloride,1,X,????,[orch/phsu],????,
ef634e42-2fef-4ea3-9ab7-47961133344a,TRMPSS2,C1310468,induce ,TRMPSS2,DDX58 protein human,1,X,????,[aapp/enzy],????,x.x.x.x
93f501c6-e134-428a-8313-33626ad5c799,TRMPSS2,C0022709,Up-Regulation (Physiology) of,TRMPSS2,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
af8c157d-4962-4e70-aea8-b38961ef96d5,C0017262,C1336763,Apoptosis Regulatory Proteins of,Gene Expression,Toll-Like Receptor Family Gene,1,X,[genf],[gngm],G05.297,
e50e420e-9ff2-49fd-a667-c76cb0cd95a3,TRMPSS2,C1564881,inhibit ,TRMPSS2,Apoptosis Regulatory Proteins,1,X,????,[aapp/bacs],????,D12.644.360.075;D12.776.476.075
0fa831de-6828-46c0-a04e-21cb7a4ab7a1,TRMPSS2,C1336763,inhibit ,TRMPSS2,Toll-Like Receptor Family Gene,1,X,????,[gngm],????,
a4ba5c0d-b803-4252-818c-f8357120b26e,C0058218,COVID-19,is in ,dimethyl fumarate,COVID-19,3,X,[imft/orch/phsu],[virs],D02.241.081.337.302.500,C000657245
2c2b74b7-de3e-4aa2-9456-be6226079a2c,COVID-19,C0009528,could therefore could caused by overactivation of ,COVID-19,Complement Activation,1,X,[virs],[moft],C000657245,G12.274
fbb72f45-7d2e-47ad-8b55-c7448438a2cb,C0302148,C0009528,could therefore could caused by overactivation of ,Blood Clot,Complement Activation,1,X,[patf],[moft],C14.907.355.830,G12.274
26305249-17fa-416e-9783-3167fe828f00,C0009528,C0206750,is in ,Complement Activation,Coronavirus Infections,2,X,[moft],[dsyn],G12.274,C02.782.600.550.200
8ae7ad42-8729-4d08-b681-16f090f2a5ac,C0009498,C0005821,Activation action,Complement System Proteins,Blood Platelets,2,X,[aapp/imft],[cell],D12.776.124.486.274,A11.118.188;A15.145.229.188
5ab63371-8061-4f6e-a14c-abdb858b17d0,C0009498,C0005778,Activation action,Complement System Proteins,Blood coagulation,2,X,[aapp/imft],[ortf],D12.776.124.486.274,G09.188.390.150
52bffbdd-ccb3-4a73-883f-7b8f39a714e2,C1452534,C3655548,is Height Kidney in,ACE protein human,Height Kidney,15,X,[aapp/bacs],[clna],x.x.x.x,
f1512aec-f35f-4b7e-a372-ae5703f3cb1c,C1452534,C0026809,is Height Kidney with female,ACE protein human,Mus,7,X,[aapp/bacs],[mamm],x.x.x.x,B01.050.150.900.649.313.992.635.505.500
3db1e7e7-f31a-478e-813b-9b9aa420a195,C0574032,C1439284,reduced glomerular ,Infusion procedures,AGTR1 gene,2,X,[topp],[gngm],,
616e5f0f-e821-4c56-9c31-be1859f51a10,C0574032,C1167622,reduced glomerular ,Infusion procedures,Binding (Molecular Function),2,X,[topp],[moft],,
32ff2f2d-37bf-45e3-888f-1d6fab387f64,C0574032,C1883559,reduced AGTR1 gene Binding (Molecular Function) in,Infusion procedures,Wild Type,2,X,[topp],[gngm],,
9817e085-7386-4592-99c9-aa26f29579a9,C0574032,C0026809,reduced AGTR1 gene Binding (Molecular Function) in,Infusion procedures,Mus,2,X,[topp],[mamm],,B01.050.150.900.649.313.992.635.505.500
cc84b5c2-4fc5-40a6-a3c9-81f9d73e90c8,C0574032,C0533668,effect of ,Infusion procedures,ANGPT1 protein human,5,X,[topp],[aapp/bacs],,x.x.x.x
f416c4cf-be50-42ff-aa5c-dfdd349d42a2,C0022709,C1171362,effect on ,Peptidyl-Dipeptidase A,protein expression,6,X,[aapp/enzy/imft],[genf],D08.811.277.656.350.350.687,
cc9bdaed-bc84-4b07-9087-042e94fbfc14,C0022709,C0025250,effect on ,Peptidyl-Dipeptidase A,Neprilysin,6,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,D08.811.277.656.300.480.600;D08.811.277.656.675.374.600;D23.050.285.550;D23.101.140.500
2343c9d2-23d0-4647-8eb0-7ade51c7bfdc,C0022709,C3887624,effect on ,Peptidyl-Dipeptidase A,Human Neprilysin,6,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,
73a13e43-655d-41cf-8247-9e8a64fa2d5d,C0014442,C0533668,catabolizes precursor of ,Enzymes,ANGPT1 protein human,6,X,[aapp/enzy],[aapp/bacs],D08.811,x.x.x.x
eb70922e-9f1e-40f6-a066-ec16ff83b623,C3887624,C1883559,is in ,Human Neprilysin,Wild Type,6,X,[aapp/enzy],[gngm],,
035dccf6-75ed-4301-b7ef-bdc36050b2d5,C3887624,C0026809,is in ,Human Neprilysin,Mus,6,X,[aapp/enzy],[mamm],,B01.050.150.900.649.313.992.635.505.500
d59bec39-7766-4de5-a7b2-575f104c9be9,C1511760,C3887624,resulted in lowered ,Deletion Mutation,Human Neprilysin,6,X,[comd],[aapp/enzy],G05.365.590.762;G05.558.800,
67d3746c-898a-4ea2-b6ec-287abe312da8,C1511760,C0533668,resulted in lowered ,Deletion Mutation,ANGPT1 protein human,6,X,[comd],[aapp/bacs],G05.365.590.762;G05.558.800,x.x.x.x
f75849c8-cdae-483e-abe1-363330c93b80,C0022709,C0533668,contributes to female protection from ,Peptidyl-Dipeptidase A,ANGPT1 protein human,3,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
bce190b8-9b1f-4a25-a1b1-23d7248cd1fe,C0041912,C0009443, includes ,Upper Respiratory Infections,Common Cold,8,X,[dsyn],[dsyn],C01.539.739;C08.730,C02.782.687.207;C08.730.162
d60ed337-e37a-4790-87b2-121ffbef5658,C0206419,C0041912,were assumed associated with mild ,Genus: Coronavirus,Upper Respiratory Infections,10,X,[virs],[dsyn],B04.820.504.540.150,C01.539.739;C08.730
5c73cf58-0b41-4bd9-8448-41322dd2e509,C0206419,C0009443,were assumed associated with mild ,Genus: Coronavirus,Common Cold,8,X,[virs],[dsyn],B04.820.504.540.150,C02.782.687.207;C08.730.162
c087c2bd-523c-42cf-90ee-718d5a01376a,C3694279,C3698360,caused by ,Middle East Respiratory Syndrome,Middle East Respiratory Syndrome Coronavirus,5,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113.750
2b1d3f0f-6b0b-4e98-8af1-60a6f1c82795,C0032310,C0242656,is with risk of ,Pneumonia Viral,Disease Progression,6,X,[dsyn],[patf],C02.705;C08.381.677.807;C08.730.610.763,C23.550.291.656
dccbdb9c-82d8-45e4-8a6c-70d4c2ff4642,C0032310,C1145670,is with risk of ,Pneumonia Viral,Respiratory Failure,6,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C08.618.846
95c122c7-2d86-4c62-bd04-a3caaff00206,C0419787,C0304066,is in ,Surveillance of contact,Cork,4,X,[topp],[orch],,
f85085bd-fb81-4976-93f8-dec04491290c,C1457887,C0019159, includes ,Symptoms,Hepatitis A,4,X,[sosy],[dsyn],,C02.440.420;C02.782.687.359.500;C06.552.380.705.422
7b2edf67-048d-4aeb-9d35-46f9da57bd58,C1457887,C0014038,extrapulmonary signs ,Symptoms,Encephalitis,1,X,[sosy],[dsyn],,C10.228.140.430
49b68d49-d307-4ba4-983c-0939967f977c,C0019159,C0014038,extrapulmonary signs ,Hepatitis A,Encephalitis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C10.228.140.430
eb343d01-c30d-4274-b864-4a71b51bb0b0,C1457887,C0027121,extrapulmonary signs ,Symptoms,Myositis,1,X,[sosy],[dsyn],,C05.651.594;C10.668.491.562
b53c5ccf-8b47-492e-baef-99ac698eb37b,C0019159,C0027121,extrapulmonary signs ,Hepatitis A,Myositis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C05.651.594;C10.668.491.562
8db0138e-4607-4000-ac36-23e864ae55d1,C1457887,C0017160,extrapulmonary signs ,Symptoms,Gastroenteritis,1,X,[sosy],[dsyn],,C06.405.205
f49a81c3-4076-4ad3-bece-33df9010db2f,C0019159,C0017160,extrapulmonary signs ,Hepatitis A,Gastroenteritis,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C06.405.205
eabe55b9-94a7-4ddc-baa8-3bbdf4b284bc,C1457887,C0022660,extrapulmonary signs ,Symptoms,Kidney Failure Acute,1,X,[sosy],[dsyn],,C12.777.419.780.050;C13.351.968.419.780.050
779cbc57-d1b8-4ef1-bda3-d6995d9a69d4,C0019159,C0022660,extrapulmonary signs ,Hepatitis A,Kidney Failure Acute,1,X,[dsyn],[dsyn],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,C12.777.419.780.050;C13.351.968.419.780.050
c3993d0c-ad5e-4f5a-bb29-8a3657b9d2e7,C0011682,C0011121,appear viable options for successful ,Desiccation,Decontamination,1,X,[npop],[topp],E05.196.335;G02.176,N06.850.780.325
6a98f09e-1ade-4693-87ea-c4ee55f78f2f,C0206419,C1160716,owing to nature ,Genus: Coronavirus,viral transmission,1,X,[virs],[celf],B04.820.504.540.150,
025a9be5-8009-4d96-a6e7-fc6a8608e81d,C0206419,C0458578,owing to nature possible airborne transmission ,Genus: Coronavirus,Upper respiratory tract,2,X,[virs],[bpoc],B04.820.504.540.150,
ce57b3ac-4787-4809-9d2f-0e4953884462,C0001617,C0677850,are commonly used as ,Adrenal Cortex Hormones,adjuvant therapy,2,X,[horm/orch/phsu],[topp],D06.472.040,
68a18d70-26dd-4da0-9d16-817a60d6c24c,C0001617,C0032310,However is controversial for patients with severe ,Adrenal Cortex Hormones,Pneumonia Viral,2,X,[horm/orch/phsu],[dsyn],D06.472.040,C02.705;C08.381.677.807;C08.730.610.763
543438b9-ebfd-4599-af04-96e2a270f390,C0001617,C0021403,was associated with increased mortality for ,Adrenal Cortex Hormones,Influenza virus vaccine,2,X,[horm/orch/phsu],[imft/phsu],D06.472.040,D20.215.894.899.302
e4496289-6ae2-4176-af8a-13806aef729f,C0024312,C0206419,might might factors associated with severity of from ,Lymphopenia,Genus: Coronavirus,2,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,B04.820.504.540.150
c65de2a8-16f1-4020-8ac2-8769e4f7fefb,C1155266,C0206419,might might factors associated with severity of from ,inflammatory response,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
c65de2a8-16f1-4020-8ac2-8769e4f7fefb,C1155266,C0206419,are hallmarks of severe ,inflammatory response,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
555876a3-19e3-4725-ad32-009f918b1525,C1527344,4-point,were self-assessed through 4-point ,Dysphonia,4-point,1,X,[mobd],????,C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,????
8df8d8ef-52c9-4c94-bfa1-755df87351b1,C1527344,C0206419,may may encountered in quarter of patients with ,Dysphonia,Genus: Coronavirus,1,X,[mobd],[virs],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,B04.820.504.540.150
7e5c7440-2240-45f6-8320-58b8ae04aa79,C1527344,C1457887,be should considered as ,Dysphonia,Symptoms,1,X,[mobd],[sosy],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,
10917089-a407-4264-998e-5ff2091cc688,C1527344,C0009450,be should considered as ,Dysphonia,Communicable Diseases,1,X,[mobd],[dsyn],C08.360.940.325;C09.400.940.325;C10.597.975.325;C23.888.592.979.325,C01.539.221
b05c1045-8b96-4103-a12a-1dfddb77ea9b,C0036087,C0242781,is hence potential source for infection given possible ,saliva,disease transmission,2,X,[bdsu],[patf],A12.200.666,N06.850.310
68d26799-d75e-45af-ab82-374599933459,C0242781,C0036087,is through ,disease transmission,saliva,9,X,[patf],[bdsu],N06.850.310,A12.200.666
1a0912cc-c7f9-4dd1-866c-0502912e6e4c,ity224,C0036087,is near ubiquitously present in ,ity224,saliva,1,X,????,[bdsu],????,A12.200.666
c57fa8e4-21a3-4d7a-a153-a29f4ede83d9,C2598130,C0031765, includes ,Major Treatments,Phototherapy,2,X,[topp],[topp],,E02.774
f911be95-752f-4992-9a30-e02f8c75bfe4,C0206419,C2598130,has ,Genus: Coronavirus,Major Treatments,6,X,[virs],[topp],B04.820.504.540.150,
cf95380e-5542-418c-bddd-79f227680e9b,C0206419,C0011627,has ,Genus: Coronavirus,Dermatology field,4,X,[virs],[bmod],B04.820.504.540.150,H02.403.225
dab5339f-8f3c-4030-ace4-31ac78b9dce5,C0206419,C0031765,has ,Genus: Coronavirus,Phototherapy,2,X,[virs],[topp],B04.820.504.540.150,E02.774
3641695a-ef26-4c0a-9a1d-5e2c1b5ffe43,C1184743,C0206419,understanding public response to ,bony process,Genus: Coronavirus,2,X,[bpoc],[virs],,B04.820.504.540.150
5a15d0b2-629d-4e4b-8601-ce7334eaa1e2,C0450254,C0949892, includes ,Pathogenic organism,Ebolavirus,1,X,[orgm],[virs],,B04.820.455.300.200
926119cc-3b99-4d04-bf2d-5a9743716dff,C0450254,C0318793, includes ,Pathogenic organism,Zika Virus,1,X,[orgm],[virs],,B04.820.250.350.995
24edc39a-4e09-40bc-95ff-b880340f4948,C0450254,C0751673, includes ,Pathogenic organism,Nipah Virus,1,X,[orgm],[virs],,B04.820.455.600.650.400.550
b3206011-b055-4a8e-bc8c-0544c39b0daf,C0012634,C0450254,have emerged with ,Disease,Pathogenic organism,1,X,[dsyn],[orgm],C23.550.288,
4d6fbd6f-9e15-4739-a927-5b639a829939,C0012634,C0949892,have emerged with ,Disease,Ebolavirus,1,X,[dsyn],[virs],C23.550.288,B04.820.455.300.200
7453161a-28bf-45fc-b7d9-84bb7660c14a,C0012634,C0318793,have emerged with ,Disease,Zika Virus,1,X,[dsyn],[virs],C23.550.288,B04.820.250.350.995
4392e8da-b030-48f6-a593-7f1cf943bd53,C0012634,C0751673,have emerged with ,Disease,Nipah Virus,1,X,[dsyn],[virs],C23.550.288,B04.820.455.600.650.400.550
c9a0ed02-ea4f-448e-9e93-6ecef7345c58,C0042776,C0003062,has has transferred from ,Virus,Animals,2,X,[virs],[anim],B04,B01.050
c9a0ed02-ea4f-448e-9e93-6ecef7345c58,C0042776,C0003062, includes ,Virus,Animals,2,X,[virs],[anim],B04,B01.050
cbd3ef53-af87-48ea-8e05-5c03cc93d822,C0042776,C0008139,has has transferred from ,Virus,Chiroptera,1,X,[virs],[mamm],B04,B01.050.150.900.649.313.937
c4487c46-8b35-4b4e-abc3-bf46cd06f6c5,C0003451,C0087111,prevent potential ,Antiviral Agents,Therapeutic procedure,1,X,[phsu],[topp],D27.505.954.122.388,E02
c4487c46-8b35-4b4e-abc3-bf46cd06f6c5,C0003451,C0087111,could Also could guide for potential ,Antiviral Agents,Therapeutic procedure,3,X,[phsu],[topp],D27.505.954.122.388,E02
c1c1836c-c190-45d5-9033-fcc7bbb5df6a,C0038056,C1457887,were most common ,Sputum,Symptoms,1,X,[bdsu],[sosy],A12.200.808,
4eb205fd-d239-4c8a-9934-79a072d9b0c6,C0038056,C0206419,were most common Symptoms of,Sputum,Genus: Coronavirus,2,X,[bdsu],[virs],A12.200.808,B04.820.504.540.150
16f8e6af-708c-4a80-9fa3-2613c0221700,C0231528,C0206419,were most common Symptoms of,Myalgia,Genus: Coronavirus,2,X,[sosy],[virs],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,B04.820.504.540.150
eebc3f09-6d19-4f78-aaf3-d66585c201a2,C0006560,C0206419,Elevation of was more common phenomenon in patients with ,C-reactive protein,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,B04.820.504.540.150
1b4f5085-39be-4928-95da-b7bddba29676,C0026473,C0206419,was increased in ,Monocytes,Genus: Coronavirus,1,X,[cell],[virs],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,B04.820.504.540.150
ef4f3e15-16f1-4220-a945-bd9e96db94b1,C2676739,C0206419,is typical sign of ,Chromosome 2q32-Q33 Deletion Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
de0440af-a4d7-462c-a1e0-ce17684eed07,C0311437,C0206419,is typical sign of ,Exudation,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
82ea5259-6593-45e8-b262-9a78cf93c7cc,C1175743,C0277554,Organism in,SARS coronavirus,primary disorders,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
c63511d7-1bf0-43cd-89ef-6a309f642892,C0087162,C0040808,should Hence should incorporated in ,Vitamin B6,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.383.725.676.925,E02.183;N05.715.360.330.125
662d51e2-05d9-4bfa-a5ea-44ff9671f2d5,C0016410,C0040808,should Hence should incorporated in ,Folic Acid,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.633.100.733.631.400,E02.183;N05.715.360.330.125
2a3fffcd-bc55-4afa-b18f-99849537fbe0,C0042845,C0040808,should Hence should incorporated in ,Vitamin B 12,Treatment Protocols,2,X,[orch/phsu/vita],[topp],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,E02.183;N05.715.360.330.125
b7afa1d0-abbe-4afc-a719-84b3366f67e4,C0087162,C1175175,should Hence should incorporated in ,Vitamin B6,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.383.725.676.925,C02.782.600.550.200.750;C08.730.730
dd71d6ae-a8dd-498e-ab63-e5e66c2d800b,C0016410,C1175175,should Hence should incorporated in ,Folic Acid,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.633.100.733.631.400,C02.782.600.550.200.750;C08.730.730
000c9e5c-a119-492b-bd0f-a90da5247677,C0042845,C1175175,should Hence should incorporated in ,Vitamin B 12,Severe Acute Respiratory Syndrome,1,X,[orch/phsu/vita],[dsyn],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,C02.782.600.550.200.750;C08.730.730
c81ea82e-dfb6-4c05-b7da-e5aac0169069,C0042776,C3826603,mediates altered ,Virus,Cell metabolism,2,X,[virs],[cell],B04,
9e232ecc-4615-458a-9ab7-603998962b23,C0206419,C1305430,activate multiple ,Genus: Coronavirus,complement pathway,2,X,[virs],[moft],B04.820.504.540.150,
fbbb3b58-00ac-422f-97b7-b6d26f947be4,C0206419,C2806453,is ,Genus: Coronavirus,Betacoronavirus,1,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540.150.113
4b06849b-41a8-40c3-bcf8-dd72baae66d0,C4506270,C2806453,have anti ,Gene-Eden-VIR,Betacoronavirus,4,X,[phsu],[virs],x.x.x.x,B04.820.504.540.150.113
870e70aa-3bcd-4cd8-a7da-be97bd493d22,C1550600,C2806453,have anti ,Ingredient,Betacoronavirus,2,X,[chvf],[virs],,B04.820.504.540.150.113
00aa6d27-333e-4256-bc40-27d28d71af39,C0040038,C0012634,Disseminated Intravascular Coagulation represent causes during,Thromboembolism,Disease,1,X,[patf],[dsyn],C14.907.355.590,C23.550.288
52e7509c-86dc-40af-8ccf-57a4cb3956b1,C0012655,C0005778,is due to multiple derangements of ,Disease susceptibility,Blood coagulation,8,X,[clna],[ortf],C23.550.291.687;G07.100.250,G09.188.390.150
376dcac8-ce81-47f2-b857-a61a955013a2,C0012655,C0060323,is due to multiple derangements of ,Disease susceptibility,Fibrin fragment D,8,X,[clna],[aapp/bacs],C23.550.291.687;G07.100.250,x.x.x.x
72ec49dd-48fb-41d6-ab53-b2cbb4533e19,C0060323,C0038952,correlate with ,Fibrin fragment D,Continuance of life,4,X,[aapp/bacs],[acty],x.x.x.x,I03.784
aeddd3ba-3376-4b68-a024-24807af6e4bc,C0409983,C0012739,eventually development of ,Secondary antiphospholipid syndrome,Disseminated Intravascular Coagulation,4,X,[dsyn],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
c3797901-1560-4dcd-b005-9c9eb01b22c2,C0409983,C0009450,eventually development of ,Secondary antiphospholipid syndrome,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
c3797901-1560-4dcd-b005-9c9eb01b22c2,C0409983,C0009450,is responsible for ,Secondary antiphospholipid syndrome,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
e36056e5-a082-4ef7-b3fb-c4c2fceba246,C0040038,C0409983,represent ,Thromboembolism,Secondary antiphospholipid syndrome,4,X,[patf],[dsyn],C14.907.355.590,
fc156939-abb7-4f4b-a172-c38c40cde23c,C0040038,C0012739,eventually development of ,Thromboembolism,Disseminated Intravascular Coagulation,4,X,[patf],[dsyn],C14.907.355.590,C15.378.100.220;C15.378.463.250;C15.378.925.220
fc156939-abb7-4f4b-a172-c38c40cde23c,C0040038,C0012739,may lead to ,Thromboembolism,Disseminated Intravascular Coagulation,3,X,[patf],[dsyn],C14.907.355.590,C15.378.100.220;C15.378.463.250;C15.378.925.220
ba346f66-e061-4785-adfa-16c7832508ef,C0040038,C0009450,eventually development of ,Thromboembolism,Communicable Diseases,4,X,[patf],[dsyn],C14.907.355.590,C01.539.221
a138500a-cc31-45ed-a01a-12e81c640393,C0409983,C0005779,is responsible for ,Secondary antiphospholipid syndrome,Blood Coagulation Disorders,4,X,[dsyn],[dsyn],,C15.378.100
ecf4bd07-11ea-4bab-a551-81148af98799,C0409983,C0242656,is responsible for ,Secondary antiphospholipid syndrome,Disease Progression,4,X,[dsyn],[patf],,C23.550.291.656
9a5f4c4c-9a53-4d39-a15c-8634f305d06e,C0409983,C0206750,is responsible for ,Secondary antiphospholipid syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
a04e6eb5-53fa-4c39-8a3d-d33d80392ed4,C0009450,C4287874,may have ,Communicable Diseases,Droplet Transmission,2,X,[dsyn],[patf],C01.539.221,
8ed51293-b418-47fe-ab06-1807279bd02f,C0035222,COVID-19,is leading cause of ,Respiratory Distress Syndrome Adult,COVID-19,4,X,[dsyn],[virs],C08.381.840;C08.618.840,C000657245
cdb56e8d-eff7-463a-a4f6-255ba4683b9d,C0035222,C0021368,characterized by rapid onset of generalized ,Respiratory Distress Syndrome Adult,Inflammation,1,X,[dsyn],[patf],C08.381.840;C08.618.840,C23.550.470
cf0f9cd0-6ed7-4026-b19b-ee95d24604de,C0242656,COVID-19,is in ,Disease Progression,COVID-19,1,X,[patf],[virs],C23.550.291.656,C000657245
1b9d0688-50e2-4412-bc76-defaf222b34e,C0072027,COVID-19,were ,procalcitonin,COVID-19,6,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,C000657245
83f7d4e5-a0b9-41be-96ba-2711e46bcef3,C0072027,C0242656,were associated with risk for ,procalcitonin,Disease Progression,3,X,[aapp/bacs],[patf],D06.472.699.666;D12.644.548.744;D12.776.811.555,C23.550.291.656
a8b6b72a-8513-490c-ad2d-1d2f4d8de359,C0024264,C0005516,Furthermore can also help as novel ,Lymphocyte,Biological Markers,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,D23.101
5d77ece2-aba6-4c47-b3d4-2ec50fa95e39,C0024264,C1155266,Furthermore can also help as novel ,Lymphocyte,inflammatory response,1,X,[cell],[patf],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
e3f6d90c-22ce-497f-aa76-8a40c3f52bcb,C0023516,COVID-19,is with ,Leukocytes,COVID-19,2,X,[cell],[virs],A11.118.637;A15.145.229.637;A15.382.490,C000657245
836bfe09-cebc-414b-baf8-78134917557b,C0024264,C0027950,has taken levels of ,Lymphocyte,neutrophil,1,X,[cell],[cell],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
725abc53-88bc-4d23-bb35-3101b65946c8,C0024264,C2741673,has taken levels of ,Lymphocyte,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
e1d68c59-5c4a-4edd-880b-c0ecadf10626,C0206750,C0029216,has evolved into abdominal ,Coronavirus Infections,Organ Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936.450
8da236dd-8537-45b7-9665-05583bb31bbe,C0012634,C0029216,has evolved into abdominal ,Disease,Organ Transplantation,1,X,[dsyn],[topp],C23.550.288,E04.936.450
40291464-bbb1-4c01-9cae-381ee287cc13,C0206750,C0040732,has evolved into abdominal ,Coronavirus Infections,Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936
40291464-bbb1-4c01-9cae-381ee287cc13,C0206750,C0040732,had fatality rate Among ,Coronavirus Infections,Transplantation,2,X,[dsyn],[topp],C02.782.600.550.200,E04.936
40291464-bbb1-4c01-9cae-381ee287cc13,C0206750,C0040732,poses increasing challenge for ,Coronavirus Infections,Transplantation,1,X,[dsyn],[topp],C02.782.600.550.200,E04.936
74162647-4e02-4b77-bd72-15e7d9ad8a62,C0012634,C0040732,has evolved into abdominal ,Disease,Transplantation,1,X,[dsyn],[topp],C23.550.288,E04.936
6410bd41-122b-498c-8a44-7567b943b66f,C0029216,COVID-19,is in ,Organ Transplantation,COVID-19,1,X,[topp],[virs],E04.936.450,C000657245
53eebc01-7261-4355-9856-89044e501822,C0040732,COVID-19,was ,Transplantation,COVID-19,3,X,[topp],[virs],E04.936,C000657245
722b253d-52d9-48ca-9531-cf09b5500301,C0029216,C1521863,is in ,Organ Transplantation,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.936.450,x.x.x.x
058d7b53-a178-49a4-ab9c-9ac7c2356306,C0040732,C1521863,is in ,Transplantation,estrogen receptor alpha human,2,X,[topp],[aapp/rcpt],E04.936,x.x.x.x
909e8af2-bd14-4559-ad66-c792cccf9b0e,C0597357,C0225336,is present on ,receptor,Endothelial Cells,1,X,[aapp/rcpt],[cell],,A11.436.275
ef63e9f8-25af-4be9-a72b-d08ff5dffc4f,C0225336,C0024109,is in ,Endothelial Cells,Lung,1,X,[cell],[bpoc],A11.436.275,A04.411
03115a55-d079-44c1-8fe9-9e6e38ad8341,C0225336,C0018787,is in ,Endothelial Cells,Heart,1,X,[cell],[bpoc],A11.436.275,A07.541
ea4c0648-71b2-41e5-849c-ad36a6cedd2f,C0225336,C0022646,is in ,Endothelial Cells,Kidney,1,X,[cell],[bpoc],A11.436.275,A05.810.453
a3900e06-af51-437c-9169-a57c6a172ea3,C0225336,C0040300,is in ,Endothelial Cells,Body tissue,1,X,[cell],[tisu],A11.436.275,A10
39b36d65-c46b-4bea-9d31-706a7ca3b014,C1175175,C0024109,is in ,Severe Acute Respiratory Syndrome,Lung,5,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A04.411
9257624a-7f7a-4f1c-a01e-e4ede6c83dc0,C1175175,C0031001,has component of ,Severe Acute Respiratory Syndrome,Perfusion (procedure),2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E05.680
6d5b9eb4-75f0-4b99-b4b8-12298f10f76d,C0087111,C0022709,increase ,Therapeutic procedure,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],E02,D08.811.277.656.350.350.687
cf69c0a2-d892-44cc-9414-352851248e6b,C0020517,C0450254,is with other ,Hypersensitivity,Pathogenic organism,1,X,[patf],[orgm],C20.543,
8c284e20-b850-46c7-8ca3-16af7ffc830e,C0033860,C1290884,is systemic immune-mediated ,Psoriasis,Inflammatory disorder,2,X,[dsyn],[dsyn],C17.800.859.675,
410a5001-23e7-449b-8724-fc3b818b99b1,C0033860,C0442893,is systemic immune-mediated ,Psoriasis,Systemic disease,2,X,[dsyn],[dsyn],C17.800.859.675,
a4dc6348-7ebb-4d1a-9332-297cb3f2652d,C0010076,C0035204,causes ,Coronaviridae,Respiration Disorders,2,X,[virs],[dsyn],B04.820.504.540,C08.618
8f87dfd7-ebd4-44fc-9677-1e8bb4ad79ad,C0079189,C0032285,can induce ,cytokine,Pneumonia,8,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.677;C08.730.610
9ef6d2d9-8a77-4895-9200-f0cdfb9bd63e,C2248778,C0021368,suppress ,cyclic nucleotide-gated mechanosensitive ion channel activity,Inflammation,2,X,[moft],[patf],,C23.550.470
88b84cec-80c1-4c94-a6b2-8ade5bc76468,nt,C1516348,have problems associated to ,nt,Cell Maintenance,2,X,????,[celf],????,
f86e508c-c08c-4ee1-b152-1f08f4119f07,C2350332,C2248778,apply same repair effects of ,Exosomes,cyclic nucleotide-gated mechanosensitive ion channel activity,2,X,[celc],[moft],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
64cb31a1-4e21-4c07-8722-c504c04904bb,C2350332,C1550101,should Then should isolated from ,Exosomes,Supernatant,2,X,[celc],[bdsu],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,
d0bee461-a99d-4b6f-b6f9-2b5210635613,C2350332,C0003069,should ,Exosomes,Animals Transgenic,2,X,[celc],[anim],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,B01.050.050.136;B05.620.136
4b480313-4779-4b99-b3cd-a362527c9261,C0699748,C0035222,can cause lung injury with ,Pathogenesis,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
e02dc2ca-2baf-4133-bd74-0c31f8aa37b7,C0035222,C0087111,finding novel ,Respiratory Distress Syndrome Adult,Therapeutic procedure,2,X,[dsyn],[topp],C08.381.840;C08.618.840,E02
2298f074-d07f-468c-9d4b-9b6e88575ee5,C0035222,C0012634,finding novel ,Respiratory Distress Syndrome Adult,Disease,2,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C23.550.288
36a04d0d-2d07-432f-8f96-2615f8d96929,C4061114,C0035222,varies from mild to life-threatening ,Acute illness,Respiratory Distress Syndrome Adult,2,X,[patf],[dsyn],,C08.381.840;C08.618.840
aae55cc2-f608-4ab0-9cf3-dbbfea10b567,C0009498,C0172217,is part of innate ,Complement System Proteins,arsenal,2,X,[aapp/imft],[orch/phsu],D12.776.124.486.274,
6abca946-5572-4e28-a005-3ac48fae4e4c,C0009498,C0450254,is part of innate ,Complement System Proteins,Pathogenic organism,2,X,[aapp/imft],[orgm],D12.776.124.486.274,
49946271-8b89-4575-a453-f1cb68053041,C0042776,C0007634,mediate ,Virus,Cells,1,X,[virs],[cell],B04,A11
49946271-8b89-4575-a453-f1cb68053041,C0042776,C0007634,entered ,Virus,Cells,1,X,[virs],[cell],B04,A11
49946271-8b89-4575-a453-f1cb68053041,C0042776,C0007634,are taken up into ,Virus,Cells,1,X,[virs],[cell],B04,A11
d5c4b9f9-d1ce-4190-bfdb-1bd14bc5427c,C0596756,C1879547,can can directly ,immunopathology specialty,Activation action,2,X,[bmod],[acty],,
def931ab-50e9-4cb9-8f96-d66079217f72,C0596756,C0312743,can can directly ,immunopathology specialty,Complement component,1,X,[bmod],[aapp/imft],,
e029d087-4698-4a92-83d1-96ca7d0c8a4a,C0596756,C0079189,can can directly ,immunopathology specialty,cytokine,2,X,[bmod],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
23cc9492-1a81-41f8-856c-c24dd3426d2b,C0398623,C0009450,related to ,Thrombophilia,Communicable Diseases,2,X,[dsyn],[dsyn],C15.378.925,C01.539.221
eb666ee1-6341-4b81-827d-f8262716a09d,C1175743,C0009450,is responsible for ,SARS coronavirus,Communicable Diseases,4,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
eb666ee1-6341-4b81-827d-f8262716a09d,C1175743,C0009450,is etiological Agent of highly contagious,SARS coronavirus,Communicable Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
eb666ee1-6341-4b81-827d-f8262716a09d,C1175743,C0009450,has become pandemic ,SARS coronavirus,Communicable Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.221
b877abdc-729f-41bd-a9ee-1db225ef02e1,C2948600,C0023884,provide information in healthy ,Aim,Liver,2,X,[inch/phsu],[bpoc],,A03.620
b877abdc-729f-41bd-a9ee-1db225ef02e1,C2948600,C0023884,illustrate clinical implications on ,Aim,Liver,2,X,[inch/phsu],[bpoc],,A03.620
87367500-37ac-47b7-80a6-9611d0d99c77,C0023890,C0020964,has recognized ,Liver Cirrhosis,Immunity,6,X,[dsyn],[phsf],C06.552.630,G12.450
85d72837-958e-4b5b-b56e-0123ae412e79,C0020964,C1175175,making more susceptible to ,Immunity,Severe Acute Respiratory Syndrome,2,X,[phsf],[dsyn],G12.450,C02.782.600.550.200.750;C08.730.730
8284e7a3-1598-4e17-8f05-74a3b1758f15,C0020964,C0021051,includes ,Immunity,Immunologic Deficiency Syndromes,3,X,[phsf],[dsyn],G12.450,C20.673
d6374a39-9d31-4007-8acc-4d61d7200f83,C0020964,C0021368,includes ,Immunity,Inflammation,3,X,[phsf],[patf],G12.450,C23.550.470
94cad621-3110-4f77-94bc-2aa571c7acfc,C2364082,COVID-19,can ,Sense of smell impaired,COVID-19,1,X,[sosy],[virs],,C000657245
1ce66846-d62d-4887-9cd1-84217559a218,C2364082,C0018563,can ,Sense of smell impaired,Hand,1,X,[sosy],[bpoc],,A01.378.800.667
c48110aa-fc9e-4b37-8173-0a280df7d143,C2364082,C1457887,have have identified as highly prevalent ,Sense of smell impaired,Symptoms,2,X,[sosy],[sosy],,
b0d2bf7a-a49f-490f-839f-d1b87ecc2fa4,COVID-19,C0014038,is with ,COVID-19,Encephalitis,1,X,[virs],[dsyn],C000657245,C10.228.140.430
0ad791e6-f2e6-4cc5-8991-d1c5cdbae8bc,C0068450,COVID-19,exert Therapeutic Effect through,naringenin,COVID-19,3,X,[orch/phsu],[virs],x.x.x.x,C000657245
0ad791e6-f2e6-4cc5-8991-d1c5cdbae8bc,C0068450,COVID-19,might exert ,naringenin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
0ad791e6-f2e6-4cc5-8991-d1c5cdbae8bc,C0068450,COVID-19,could ,naringenin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
1a3a591b-7ad1-46e6-b138-59aac0d80946,C0683325,COVID-19,key Epidemiology of,clinical aspects,COVID-19,3,X,[clna],[virs],,C000657245
db8a93e8-f6ea-4842-83b6-69f97f527b7e,C0310367,C0206419,is rapid outbreak of ,Today,Genus: Coronavirus,3,X,[antb/orch],[virs],,B04.820.504.540.150
2036f248-5ece-405b-8a27-5394fc7d9827,C0545747,COVID-19,are at ,pulmonary artery and pulmonary artery,COVID-19,1,X,[bpoc],[virs],,C000657245
940326df-7007-4e00-b95c-6bf8e821a09d,C0545747,C0009450,are at also risk of severe ,pulmonary artery and pulmonary artery,Communicable Diseases,2,X,[bpoc],[dsyn],,C01.539.221
fff962a8-a62b-453a-a24d-95e1d859781f,C1175175,COVID-19,is in ,Severe Acute Respiratory Syndrome,COVID-19,3,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,C000657245
bb40b08e-8795-457d-8e97-d58649c74f9c,C0008139,C0206419,are presumed reservoirs of diverse ,Chiroptera,Genus: Coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.937,B04.820.504.540.150
4f751b90-d8f3-4cab-ae3d-7eee8c95c2c3,C0008139,C1175175,are presumed reservoirs of diverse ,Chiroptera,Severe Acute Respiratory Syndrome,1,X,[mamm],[dsyn],B01.050.150.900.649.313.937,C02.782.600.550.200.750;C08.730.730
a302bcdb-3c60-429e-a953-0ef938e92cdb,C1175743,C1265469,is in ,SARS coronavirus,Rhinolophus,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.937
e636c284-f002-4957-96a0-91cb0ef56aaa,C1175743,C0074992,is in ,SARS coronavirus,sphingosine 1-phosphate,1,X,[virs],[orch],B04.820.504.540.150.113.937,x.x.x.x
38c72ee0-6877-413b-aa8e-cb1d5903cfd7,COVID-19,C1609165,were treated with ,COVID-19,tocilizumab,1,X,[virs],[aapp/imft/phsu],C000657245,x.x.x.x
fda6deea-974f-4021-8329-e789db037f11,C0235031,24h,greater than 24h,Neurologic Symptoms,24h,2,X,[sosy],????,C10.597;C23.888.592,????
869aec5a-4c3a-4cfe-ad67-3ccf1c573ee9,COVID-19,C0035298,is in ,COVID-19,Retina,1,X,[virs],[bpoc],C000657245,A09.371.729
3612fe7c-d787-4cfd-b11b-581b2a7402ba,C0242781,C0015392,is in ,disease transmission,Eye,1,X,[patf],[bpoc],N06.850.310,A01.456.505.420;A09.371
5f3639e9-615c-4d87-bae5-ed68ee280b31,IRB,C0085076,was conducted to detail novel same-day ,IRB,Mammaplasty,2,X,????,[topp],????,E02.218.565;E04.680.500
62dda1d7-db02-4271-acd4-66d84ebac62e,C0085076,C0184661,can can definitive ,Mammaplasty,Interventional procedure,2,X,[topp],[topp],E02.218.565;E04.680.500,
6f460598-f696-458e-a62d-a67d46e64459,C0085076,C0524865,be used as bridge to autologous ,Mammaplasty,Reconstructive Surgical Procedures,2,X,[topp],[topp],E02.218.565;E04.680.500,E04.680
a3e1de8c-39b8-40a8-b6b6-8d6ddeb37b86,C1000689,C1175743,M of ,Clerodendrum,SARS coronavirus,5,X,[plnt],[virs],B01.650.940.800.575.912.250.583.520.121,B04.820.504.540.150.113.937
057aefd2-5bc3-4965-881a-d4fdb0cecfb1,C0075816,C1167622,exhibited better ,taraxerol,Binding (Molecular Function),6,X,[orch/phsu],[moft],x.x.x.x,
27fd269f-6102-406a-8584-20ec61413db6,C0075816,C0042736,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Viral Proteins,6,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.964
33133d84-c280-4250-801c-b611bf5e9f0c,C0075816,C3687832,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Drugs - dental services,3,X,[orch/phsu],[topp],x.x.x.x,
bda6aa31-a41e-4c60-a26f-1d0a2d129cc7,COVID-19,C0543467,underwent ,COVID-19,Operative Surgical Procedures,2,X,[virs],[topp],C000657245,E04
bda6aa31-a41e-4c60-a26f-1d0a2d129cc7,COVID-19,C0543467,has dramatically changed practice in favor of ,COVID-19,Operative Surgical Procedures,1,X,[virs],[topp],C000657245,E04
143ae2b8-d0fe-4477-9dd4-a4342707fcbf,C2936287,C1533734,requiring prolonged ,Chemical Oxygen Demand,Administration procedure,3,X,[biof],[topp],N06.850.460.350.080.500;N06.850.780.375.349,
24fb39be-2560-4270-ae27-44e19ad94c2a,C2936287,C0184633,requiring prolonged ,Chemical Oxygen Demand,Oxygen Therapy Care,3,X,[biof],[topp],N06.850.460.350.080.500;N06.850.780.375.349,E02.880.690
afd8b65b-3710-41e6-a4fc-1b99ea713946,C0086418,C0206419,ventilated due to ,Homo sapiens,Genus: Coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
afd8b65b-3710-41e6-a4fc-1b99ea713946,C0086418,C0206419,is with severe ,Homo sapiens,Genus: Coronavirus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
afd8b65b-3710-41e6-a4fc-1b99ea713946,C0086418,C0206419,is in development of vaccine against ,Homo sapiens,Genus: Coronavirus,2,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04.820.504.540.150
cfd0b45a-579e-44f0-a1a9-b56a48388a78,C1999230,COVID-19,is in ,Providing (action),COVID-19,1,X,[acty],[virs],,C000657245
90a55bfc-98b6-4c03-8609-87e4e7f62b1e,C0034991,COVID-19,is in ,Rehabilitation therapy,COVID-19,1,X,[topp],[virs],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C000657245
cc4d5ecc-8770-4a77-86dd-11a84a6f9e44,C0034991,C1175175,is in ,Rehabilitation therapy,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200.750;C08.730.730
036a08a3-b459-4557-89ff-1431b3bb22b0,C0005802,COVID-19,increase ,Blood Glucose,COVID-19,1,X,[orch],[virs],D09.947.875.359.448.500,C000657245
a2143093-eeb7-40d3-919a-438b014640fb,C0011849,COVID-19,is in ,Diabetes Mellitus,COVID-19,3,X,[dsyn],[virs],C18.452.394.750;C19.246,C000657245
9169473f-97dc-4f17-8304-c1a2f5c189e5,C0021440,C3669205,is with hourly ,Intravenous infusion procedures,Blood glucose monitoring (regime/therapy),4,X,[topp],[topp],E02.319.267.082.500;E02.319.267.510.590,
b8e693ca-3520-4905-b587-f8fa9471131d,C0021641,C3669205,is with hourly ,Insulin,Blood glucose monitoring (regime/therapy),2,X,[aapp/horm/phsu],[topp],D06.472.699.587.200.500.625;D12.644.548.586.200.500.625,
fd1c202d-abc1-422d-89ca-739acdb8066a,C0007430,COVID-19,was ,Catheterization,COVID-19,1,X,[topp],[virs],E02.148;E05.157,C000657245
97b06193-9c2a-48c2-9293-f2d075d7c778,C4553629,y245,elucidated potential functional missense variants from databases within xentit y245 ,MATRix Regimen,y245,1,X,[topp],????,,????
6f55046f-e8ef-4fd0-bede-10c273096ec6,C0369718,C0010340,had ,N not otherwise specified Antibody,Critical Illness,2,X,[aapp/imft],[dsyn],,C23.550.291.625
cde3db46-6eec-4430-a935-65f624f3862a,C3887843,COVID-19,is in ,Microbiota (environment),COVID-19,1,X,[orgm],[virs],G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500,C000657245
c26d03aa-3bde-4591-8ec2-82e77f48ff73,COVID-19,C0683325,share similar ,COVID-19,clinical aspects,1,X,[virs],[clna],C000657245,
0aea3561-132a-49c6-b47b-6127df02c19e,C1175743,C0683325,share similar ,SARS coronavirus,clinical aspects,1,X,[virs],[clna],B04.820.504.540.150.113.937,
c7226aaa-4d3e-4696-87fd-758d1d726a96,C0022709,C4018878,regulates ,Peptidyl-Dipeptidase A,Gastrointestinal Microbiome,1,X,[aapp/enzy/imft],[orgm],D08.811.277.656.350.350.687,G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250
86a80b69-b913-4943-8793-46b9328725c2,C0022709,C1819788,indirectly controlling ,Peptidyl-Dipeptidase A,antimicrobial peptide secretion,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,
4b485896-3603-4f13-b35a-59b33ce0cfae,C4018878,C0003451,enhances ,Gastrointestinal Microbiome,Antiviral Agents,2,X,[orgm],[phsu],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,D27.505.954.122.388
2de8ee42-b632-490b-b08f-2e8db635be2a,C4018878,C0678209,enhances Antiviral Agents Adaptive Immunity by,Gastrointestinal Microbiome,Adaptive Immunity,3,X,[orgm],[phsf],G06.591.375;G16.500.275.157.049.100.500.375;N06.230.124.049.100.500.250,G12.450.050
d94cb7d9-d0fb-4b7a-bf1a-d754d8cfc1a9,C0597404,C0024109,influence composition in ,Respiratory viruses,Lung,1,X,[virs],[bpoc],,A04.411
2010b168-9c06-4b44-ab20-0ee32c75bde7,C1457887,C1260880, includes ,Symptoms,Rhinorrhea,4,X,[sosy],[sosy],,
045f8886-55f9-40fd-a72a-dcf27aa00e9e,C1457887,C0012833, includes ,Symptoms,Dizziness,6,X,[sosy],[sosy],,C23.888.592.763.237
56bc7f56-b041-46f3-b89b-6c806ccf1960,C1457887,C0085593, includes ,Symptoms,Chills,4,X,[sosy],[sosy],,C23.888.208
aece7aec-1ec4-4a7f-8f30-315a5f323f16,C0242656,C0009566,was most common ,Disease Progression,Complication,4,X,[patf],[patf],C23.550.291.656,
02e4f4e0-4f1c-41aa-bc52-79d0fa1961f5,C0005525,C4524578,is with ,Biological Response Modifiers,Recovered Plasma,4,X,[imft/phsu],[phsu],D27.505.696.477,
4713a3b7-81d2-422c-a270-d262c8e12081,C1292533,C1510711,were obtained during emergent ,Tissue specimen,Abdominal Surgical Procedure,3,X,[tisu],[topp],,
d849c859-bdc8-4ea0-a6e8-18e7b5c418b3,C1292533,C0206419,were obtained during emergent ,Tissue specimen,Genus: Coronavirus,1,X,[tisu],[virs],,B04.820.504.540.150
4d7fd05b-5ca0-4b7f-8989-b2eeadf7f635,C1510711,C0206419,is in four patients with ,Abdominal Surgical Procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1e9a5a8d-b0fc-4f39-82d9-8b0b5c22e7f4,C1292533,C0040300,were obtained examine for ,Tissue specimen,Body tissue,6,X,[tisu],[tisu],,A10
4c215376-1411-4aec-bdbf-c8c3cf386fbb,C1292533,C1175743,were obtained examine for ,Tissue specimen,SARS coronavirus,6,X,[tisu],[virs],,B04.820.504.540.150.113.937
b810ce32-1375-4f03-8fdf-45ab4c955579,C0149725,C0041912,occurs in ,Lower respiratory tract infection,Upper Respiratory Infections,6,X,[dsyn],[dsyn],,C01.539.739;C08.730
989a557e-d09b-4e5c-b1d5-5528800b0763,C1511790,C0006279,is in ,Detection,Bronchoalveolar Lavage Fluid,6,X,[topp],[bdsu],,E05.927.100.500
248db490-4643-448d-a049-b956a6a3fc63,C0041912,C0456204,is with clinical testing ,Upper Respiratory Infections,Specimen type,6,X,[dsyn],[clna],C01.539.739;C08.730,
56fbd8ef-e3fa-40dd-be92-7181d4107766,C0149725,C0006279,Detection in,Lower respiratory tract infection,Bronchoalveolar Lavage Fluid,3,X,[dsyn],[bdsu],,E05.927.100.500
a9ffdcaf-d4f3-4201-9fcf-dd5f40e2b4bc,C1175743,C0024115,may trigger severe ,SARS coronavirus,Lung diseases,3,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381
6d76ba1f-5f0f-4075-b97e-cad52f5b4397,C0751982,C0024109,is in ,Neutrophil Infiltration,Lung,1,X,[phsf],[bpoc],G12.632,A04.411
053d37ca-769d-47c9-b8df-52ca836b36a8,C1879547,C3850088,releasing ,Activation action,Neutrophil Extracellular Traps,2,X,[acty],[celc],,A11.284.295.495
7aadcc64-692c-498a-8ef4-1dbdc6da5859,C0027950,C3850088,releasing ,neutrophil,Neutrophil Extracellular Traps,2,X,[cell],[celc],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A11.284.295.495
6c1e3f07-7763-4aaa-bfe3-91c70111d754,C1879547,C0021368,induce ,Activation action,Inflammation,2,X,[acty],[patf],,C23.550.470
6c1e3f07-7763-4aaa-bfe3-91c70111d754,C1879547,C0021368,protecting system from ,Activation action,Inflammation,1,X,[acty],[patf],,C23.550.470
69cb6773-7608-4dc2-8053-c2f36e417aa0,C0027950,C0021368,induce ,neutrophil,Inflammation,2,X,[cell],[patf],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C23.550.470
e66ce4dd-b6c2-49c9-89ca-20bd4707aa37,C1135662,C0010674,is FDA-approved for ,Dornase Alfa,Cystic Fibrosis,3,X,[aapp/enzy/phsu],[dsyn],x.x.x.x,C06.689.202;C08.381.187;C16.320.190;C16.614.213
cfa05416-5043-40c4-9861-0a7f611d783f,C1135662,C0225698,reducing -induced toxicity on alveolar,Dornase Alfa,Alveolar Epithelial Cells,2,X,[aapp/enzy/phsu],[cell],x.x.x.x,A04.411.715.100;A11.436.081
50bc1856-eb62-4a93-8c63-af3b184661f2,C1135662,C3850088,reducing ,Dornase Alfa,Neutrophil Extracellular Traps,2,X,[aapp/enzy/phsu],[celc],x.x.x.x,A11.284.295.495
50bc1856-eb62-4a93-8c63-af3b184661f2,C1135662,C3850088,targeting ,Dornase Alfa,Neutrophil Extracellular Traps,1,X,[aapp/enzy/phsu],[celc],x.x.x.x,A11.284.295.495
8ff26e1e-61bb-47f4-9776-67dde287e2e1,C0010674,C4289789,may break up ,Cystic Fibrosis,Cell-Free DNA,2,X,[dsyn],[bacs/nnon],C06.689.202;C08.381.187;C16.320.190;C16.614.213,D13.444.154
326511fc-70d7-45d9-b608-fdd5687e0694,COVID-19,C0035222,is with large number of ,COVID-19,Respiratory Distress Syndrome Adult,3,X,[virs],[dsyn],C000657245,C08.381.840;C08.618.840
3cc6c682-1cad-4429-a0df-b0ca9be10d27,C0013227,C1960499,promoting improved ,Pharmaceutical Preparations,Clearance of secretions of respiratory tract,4,X,[phsu],[topp],D26,
143eede5-28c5-4e33-8580-b616c35aa0d2,C0013227,C0024109,might make ,Pharmaceutical Preparations,Lung,2,X,[phsu],[bpoc],D26,A04.411
143eede5-28c5-4e33-8580-b616c35aa0d2,C0013227,C0024109,preventing further damage to ,Pharmaceutical Preparations,Lung,1,X,[phsu],[bpoc],D26,A04.411
ea41c7e2-dcdb-41f3-9669-0d1a3eee2104,C0013227,C0026727,might make ,Pharmaceutical Preparations,Mucous body substance,2,X,[phsu],[bdsu],D26,A12.200.503
e26ce211-8036-4c00-bd7b-70ab5ec164a7,C0026727,C1515933,reduce extracellular hyperinflammation in ,Mucous body substance,Alveolus,3,X,[bdsu],[bpoc],A12.200.503,
e35a3232-ac2c-487b-8c72-ed4d07a9d6b0,C0012854,C1515933,is in ,DNA,Alveolus,2,X,[bacs/nnon],[bpoc],D13.444.308,
e6945119-a168-4eb7-80f6-75e89359534e,C0026727,C0024109,preventing further damage to ,Mucous body substance,Lung,1,X,[bdsu],[bpoc],A12.200.503,A04.411
38d7f99b-e5b3-4429-b5c5-8942e0cf778a,C0850149,C0032310,can progress to severe ,Dry cough,Pneumonia Viral,3,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
bd89bdda-9fe3-4912-8ec0-a1211791f63f,C0013404,C0032310,can progress to severe ,Dyspnea,Pneumonia Viral,3,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.705;C08.381.677.807;C08.730.610.763
bd89bdda-9fe3-4912-8ec0-a1211791f63f,C0013404,C0032310,were main Symptoms in groups with,Dyspnea,Pneumonia Viral,1,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.705;C08.381.677.807;C08.730.610.763
dbd9d567-4cd5-4e20-9d07-25ccdb004dfe,C4287874,C0242781,be main route ,Droplet Transmission,disease transmission,6,X,[patf],[patf],,N06.850.310
7aa940e0-010e-4b3d-9494-45fbb893f5b7,C4287874,C0206419,be main route ,Droplet Transmission,Genus: Coronavirus,6,X,[patf],[virs],,B04.820.504.540.150
8c9f6adc-695f-4ecc-9457-b275a0aa4dd7,C0206750,WBC,had more WBC CRP ,Coronavirus Infections,WBC,1,X,[dsyn],????,C02.782.600.550.200,????
6925455e-c237-479b-ab6f-fcc733ca9dd7,C0206750,C0027950,had more WBC CRP ,Coronavirus Infections,neutrophil,1,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
6b6b945a-1698-4e41-b5f0-8a2935749f2a,C0206750,CRP,had more WBC CRP ,Coronavirus Infections,CRP,1,X,[dsyn],????,C02.782.600.550.200,????
c8385edf-24cb-4389-a765-e515db17a0fe,C4522312,C0206750,showed more ,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
c8385edf-24cb-4389-a765-e515db17a0fe,C4522312,C0206750,more Inflammation than,CYCLASE-ASSOCIATED ACTIN CYTOSKELETON REGULATORY PROTEIN 1,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
e10a0205-4a17-40d3-b010-9b0bfbd950c4,C0027950,C0206750,are important indicators for severity grading in ,neutrophil,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
e10a0205-4a17-40d3-b010-9b0bfbd950c4,C0027950,C0206750,predicting ,neutrophil,Coronavirus Infections,3,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
e10a0205-4a17-40d3-b010-9b0bfbd950c4,C0027950,C0206750,were significantly associated with outcomes of ,neutrophil,Coronavirus Infections,2,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02.782.600.550.200
3eeb06d6-1afa-49f0-a542-baf34ef03a03,C0006560,C0206750,are important indicators for severity grading in ,C-reactive protein,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,C02.782.600.550.200
5d309752-fe88-412e-996e-c2f14231e6ca,NLR,C0206750,are important indicators for severity grading in ,NLR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
5d309752-fe88-412e-996e-c2f14231e6ca,NLR,C0206750,may serve as useful ,NLR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
5386bd43-3429-49b0-a83c-c5acd2b57cba,C0077401,C0206750,are important indicators for severity grading in ,Troponin I,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925,C02.782.600.550.200
67f20552-dbdb-404f-b82d-68020980ce4c,C0010294,C0206750,are important indicators for severity grading in ,Creatinine,Coronavirus Infections,1,X,[bacs/orch],[dsyn],D03.383.129.308.207,C02.782.600.550.200
db272e08-d16a-4eac-9051-e18ffbd7d456,C0600137,C0206750,are important indicators for severity grading in ,Blood Urea Nitrogen,Coronavirus Infections,1,X,[bacs/inch],[dsyn],E01.370.225.124.100.115;E01.370.390.400.100;E05.200.124.100.115,C02.782.600.550.200
88556a49-09a1-4a0b-acca-139dc2a0fdd4,C0314732,C0206750,responsible for ,Infectious agent,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
0d4152de-0c63-4038-8f7e-5d449e0cb5d9,C3037,C0028630,were found most common ,C3037,Nucleotides,3,X,????,[nnon],????,D09.408.620;D13.695
3714abd8-8f16-491f-8675-3223d126cacf,C3037,C3494870,were found most common ,C3037,Viral isolate,3,X,????,[bacs],????,
52b5e9e8-17dd-4ab6-87eb-a7eb14c332e5,C0035736,C0319157,yielding Hippocampus Proper with evidence of,RNA Viral,AS virus,2,X,[nnon],[virs],D13.444.735.828,
f87360d5-7174-460e-bde9-9476982a8529,C1720950,C0206750,identify possible ,Gene Regulatory Networks,Coronavirus Infections,3,X,[moft],[dsyn],G05.360.080.689.360,C02.782.600.550.200
c0a148bd-4bf6-4c5a-9513-a757a77ef197,C1720950,C0017337,identify bioactive ,Gene Regulatory Networks,Genes,3,X,[moft],[gngm],G05.360.080.689.360,G05.360.340.024.340
e09a3a44-41b2-4f8b-bac8-9fbe36423f36,C0007634,C0041904,identified ,Cells,Up-Regulation (Physiology),8,X,[cell],[moft],A11,G02.111.905;G05.308.850;G07.690.773.998
ce73f14f-4b63-46c5-9738-f75cf7ea9961,C0035668,C0041904,identified ,RNA,Up-Regulation (Physiology),4,X,[nnon],[moft],D13.444.735,G02.111.905;G05.308.850;G07.690.773.998
699ceaeb-0ad4-46fd-83ec-681cbb34112c,C0007634,C0027950,identified ,Cells,neutrophil,8,X,[cell],[cell],A11,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
699ceaeb-0ad4-46fd-83ec-681cbb34112c,C0007634,C0027950,expressed ,Cells,neutrophil,1,X,[cell],[cell],A11,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
1f474e07-17ab-4aa8-b24f-abb5d7b296e5,C0035668,C0027950,identified ,RNA,neutrophil,4,X,[nnon],[cell],D13.444.735,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689
106dd5b3-5db6-46ef-a75a-2ddd6e6a53ad,C0007634,C0017337,identified ,Cells,Genes,8,X,[cell],[gngm],A11,G05.360.340.024.340
ad46a814-c4da-4958-bfc2-e96647e3b128,C1175743,C1533724,be acquired by exposure to ,SARS coronavirus,Fomes,1,X,[virs],[fngs],B04.820.504.540.150.113.937,B01.300.179.120.174
c753c208-687e-48f3-bd72-b1492892a294,C3710940,C1705178,must implement form in ,STS protein human,Order (action),3,X,[aapp/enzy],[acty],x.x.x.x,
3ffe57a4-3b95-4940-9c02-269585804e80,C0206750,C0026882,form escape ,Coronavirus Infections,Mutation,2,X,[dsyn],[genf],C02.782.600.550.200,G05.365.590
67cc2317-69ec-45d4-923e-5ed60623f0ad,C0026882,C1149306,may correspond to reduction in ,Mutation,immunoglobulin binding,4,X,[genf],[moft],G05.365.590,
3b97274d-05e7-49a4-891f-fb232b17d122,C0301872,C0682639,is with formation of CD8,Immune response,Memory T-Lymphocyte,4,X,[ortf],[cell],,
0e2cb4d1-7abc-4ff7-8662-b74cc8225357,C0301872,CD8,is with formation of CD8,Immune response,CD8,4,X,[ortf],????,,????
11a542e2-361e-4e2d-b8d8-32526b8b5c27,C0599878,C0037090,is with non ,disease characteristic,Signs and Symptoms Respiratory,1,X,[patf],[sosy],,C23.888.852
ce261caf-8200-42f0-a26b-4b82ec19a1e0,C2948600,C1175175,describe demographic baseline clinical characteristics of cohort with ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ce261caf-8200-42f0-a26b-4b82ec19a1e0,C2948600,C1175175,summarize data on treatment of ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ce261caf-8200-42f0-a26b-4b82ec19a1e0,C2948600,C1175175,emphasize mechanism due to ,Aim,Severe Acute Respiratory Syndrome,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ce261caf-8200-42f0-a26b-4b82ec19a1e0,C2948600,C1175175,systematically review main ,Aim,Severe Acute Respiratory Syndrome,1,X,[inch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
ae5ea3ad-f394-4bd3-993b-8bd1e76d29d7,C0206750,C0871208,was associated with overall fatality ,Coronavirus Infections,Rating (action),2,X,[dsyn],[acty],C02.782.600.550.200,
ae5ea3ad-f394-4bd3-993b-8bd1e76d29d7,C0206750,C0871208,assess ,Coronavirus Infections,Rating (action),1,X,[dsyn],[acty],C02.782.600.550.200,
158f8e69-713a-43cc-af4b-e64cd3de46fe,C1708476,C1706374,is in specific community setting among community-dwelling individuals exposed to from January to ,Implementation,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
158f8e69-713a-43cc-af4b-e64cd3de46fe,C1708476,C1706374,of weeks is ,Implementation,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
d3563606-5cbb-427f-b912-f554e0924c69,C0439056,C1175743,were positive for ,Throat swab sample,SARS coronavirus,3,X,[bdsu],[virs],,B04.820.504.540.150.113.937
85c5fdc3-8e35-4e91-80b4-679caf855ab2,C3274800,C0206750,prevalence of ,Disease Presentation,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
f63fa755-c294-42fe-8eb5-3cbe57bf21c6,C0010340,C0199470,requiring ,Critical Illness,Mechanical ventilation,2,X,[dsyn],[topp],C23.550.291.625,
add32fea-892b-4efc-989d-16c9e04846fd,C0010340,C0015357,requiring ,Critical Illness,Extracorporeal Membrane Oxygenation,2,X,[dsyn],[topp],C23.550.291.625,E02.880.301;E04.292.451
cfa3e6dc-6c84-4e29-99b0-b54314b59312,C0871208,C1175743,was low In large cohort of patients tested for ,Rating (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
efc80d3d-7a5f-4c3e-9298-361ba0c4689a,C0206750,C0851312,may exacerbate delays in time to ,Coronavirus Infections,Breast surgery specialty,6,X,[dsyn],[bmod],C02.782.600.550.200,
cb3611fd-3d46-42ea-ba00-aaf000c13cf0,C0042774,C0079189,is often followed by ,Virus Replication,cytokine,3,X,[celf],[aapp/imft],G06.920.925,D12.644.276.374;D12.776.467.374;D23.529.374
811ae48e-529e-43c7-9bf3-ccde92ab45d2,C0042774,C1861452,is often followed by ,Virus Replication,Storm Syndrome,3,X,[celf],[dsyn],G06.920.925,x.x.x.x
072275d3-71c5-40d1-9253-764a982acee8,C0032310,C0206750, includes ,Pneumonia Viral,Coronavirus Infections,6,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C02.782.600.550.200
3502373f-27d7-4275-a0df-68a207adc175,C0042774,C0032310,is often followed In severe ,Virus Replication,Pneumonia Viral,6,X,[celf],[dsyn],G06.920.925,C02.705;C08.381.677.807;C08.730.610.763
dfc1d71a-e544-4691-9030-68d82363a794,C0042774,C0012634,is often followed In severe ,Virus Replication,Disease,12,X,[celf],[dsyn],G06.920.925,C23.550.288
98bcc945-4a47-4606-b9f5-800ecdb91467,C1861452,C0035222,leads to ,Storm Syndrome,Respiratory Distress Syndrome Adult,3,X,[dsyn],[dsyn],x.x.x.x,C08.381.840;C08.618.840
80a0ec53-9722-467b-b780-cefb1235daf7,C0725685,C0841874,is with provisions for ,Compleat Liquid Nutrition,dental emergency,2,X,[food],[topp],,
04d27500-deff-4370-98d8-f4cc6751c2e3,C1704330,C1999230,Coronavirus Infections,Dental Diseases,Providing (action),1,X,[dsyn],[acty],C07,
8bb394aa-ef99-4925-8195-a235c0ce6cbe,C1999230,C0087111,update on ,Providing (action),Therapeutic procedure,2,X,[acty],[topp],,E02
19c5a16f-b4c6-4e6c-a41d-fb1ca3d6851f,C2754943,C0039082,directed against ,IgG antibody,Syndrome,1,X,[celc],[dsyn],,C23.550.288.500
ccdbd2d3-ccb2-42f4-be74-2cd567f70dba,C0007876,C0028773,is in our ,Cesarean section,Discipline of obstetrics,1,X,[topp],[bmod],E04.520.252.500,H02.403.810.450
2228209e-b41c-4150-94fe-bb17de1ef90e,C0039082,C0028429,is in asymptomatic woman with positive ,Syndrome,Nose,1,X,[dsyn],[bpoc],C23.550.288.500,A01.456.505.733;A04.531;A09.531
e6b020f9-0258-4e6e-8e1c-1748ad30ef16,C0039082,C0439056,is in asymptomatic woman with positive ,Syndrome,Throat swab sample,1,X,[dsyn],[bdsu],C23.550.288.500,
5bfe8647-82ae-4d07-a028-ce614248343e,C0206750,C1521863,is now global pandemic with highest number of affected individuals in modern ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
5bfe8647-82ae-4d07-a028-ce614248343e,C0206750,C1521863,self-protection and prompt diagnosis in ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
5bfe8647-82ae-4d07-a028-ce614248343e,C0206750,C1521863,ensure self-protection diagnosis in ,Coronavirus Infections,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,x.x.x.x
a06f08c7-a9cd-43a9-8583-a55eb4437910,C0018787,C0155686,include ,Heart,Acute myocarditis,1,X,[bpoc],[dsyn],A07.541,
84cdb838-c178-439d-a01a-56b1aa22786e,C0018787,C0027051,include ,Heart,Myocardial Infarction,1,X,[bpoc],[dsyn],A07.541,C14.280.647.500;C14.907.585.500
f5f143df-5043-48f5-978d-229abfea501a,C0018787,C0003811,include ,Heart,Cardiac Arrhythmia,1,X,[bpoc],[dsyn],A07.541,C14.280.067;C23.550.073
961591db-ce7f-4e74-92c4-a074c588690c,C0027765,C0206750,nervous system disorder,nervous system disorder,Coronavirus Infections,5,X,[dsyn],[dsyn],C10,C02.782.600.550.200
3f0789a3-8d56-45d5-81e3-8b12ff4cdb58,C0206750,C3542961,attack ,Coronavirus Infections,NERVOUS SYSTEM DRUGS,1,X,[dsyn],[phsu],C02.782.600.550.200,
9779119b-371f-4190-915d-59ccaff073ae,C1327414,C3542961,are among most possible routes into ,cytokine secretion,NERVOUS SYSTEM DRUGS,2,X,[celf],[phsu],,
3e32dfb5-870b-4ea0-9b32-0b42c75de3c0,C0005775,C3542961,are among most possible routes into ,Blood Circulation,NERVOUS SYSTEM DRUGS,2,X,[phsf],[phsu],G09.330.100,
8eeebaa3-dd0a-45ca-9396-3b41f58dcea9,C1825598,C0948089,is in particularly field of ,IMPACT gene,Acute Coronary Syndrome,3,X,[gngm],[dsyn],,C14.280.647.124;C14.907.585.124
e055af7a-b199-4281-a8b7-06e9659007bc,C4554533,C0206750,is in ,Trend:Type:Point in time:^Patient:Nominal,Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
519c75e7-c68a-4119-8b1d-526358aab1b1,C4554533,C2348077,analyzed literature data published since beginning to ,Trend:Type:Point in time:^Patient:Nominal,Date Fruit,2,X,[clna],[food],,B01.650.940.800.575.912.250.093.615
abfef92e-13eb-4039-9deb-cea8ae7847a5,C2806453,C0450254,is ,Betacoronavirus,Pathogenic organism,7,X,[virs],[orgm],B04.820.504.540.150.113,
57464a40-8d0c-4f85-89cd-9e16eae25ddc,C2806453,C0009450,has has recognized as ,Betacoronavirus,Communicable Diseases,5,X,[virs],[dsyn],B04.820.504.540.150.113,C01.539.221
e15c4ec9-0c40-45ac-8da9-ed08548d443d,C1422064,C0030664,is in various neoplastic ,ACE2 gene,Pathology,2,X,[gngm],[bmod],,H02.403.650
49e7e0e6-943d-46fc-90a7-b931d96d2baf,C0034848,C0030664,is in various neoplastic ,Receptors Virus,Pathology,4,X,[aapp/rcpt],[bmod],D12.776.543.750.830,H02.403.650
511e4aa7-0660-4b15-859e-36f3b0ee3105,C0079189,C0009450,could have in vulnerability to ,cytokine,Communicable Diseases,6,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C01.539.221
4659f89d-7e40-46f4-a6c9-ccc63caebadc,C0025268,C0042542,is in ,Multiple Endocrine Neoplasia Type 2a,Vero Cells,2,X,[neop],[cell],C04.588.322.400.505;C04.651.600.505;C04.700.630.505;C16.320.700.630.505;C19.344.400.505,A11.251.210.955;A11.436.955
a1e64b63-05a2-40b8-890e-6232aafbf2b4,C0003451,C0042542,is in ,Antiviral Agents,Vero Cells,2,X,[phsu],[cell],D27.505.954.122.388,A11.251.210.955;A11.436.955
e3b2d60a-ef8b-4e86-91a2-faaa29d98837,C0025268,C1335332,is in ,Multiple Endocrine Neoplasia Type 2a,Papillomavirus Transforming Protein E6,1,X,[neop],[aapp/bacs],C04.588.322.400.505;C04.651.600.505;C04.700.630.505;C16.320.700.630.505;C19.344.400.505,
9737d18c-f443-4e8a-b2e3-e9fa2524771f,C0003451,C1335332,is in ,Antiviral Agents,Papillomavirus Transforming Protein E6,1,X,[phsu],[aapp/bacs],D27.505.954.122.388,
a60b3b9b-82f6-4fc2-8ca0-c63265681b68,C0206750,C0275518,is novel ,Coronavirus Infections,Acute infectious disease,5,X,[dsyn],[dsyn],C02.782.600.550.200,
b0329458-877d-4df0-b7d8-984e9291089f,C0064906,C1167622,affirmed ,Nafarelin,Binding (Molecular Function),1,X,[aapp/phsu],[moft],D06.472.699.327.740.320.580;D12.644.400.400.740.320.580;D12.644.456.460.600;D12.644.548.365.740.320.580;D12.776.631.650.405.740.320.580,
d1b28942-7118-4536-b0d3-c86427dd26cf,C0064906,C0324740,affirmed ,Nafarelin,Talpidae,1,X,[aapp/phsu],[mamm],D06.472.699.327.740.320.580;D12.644.400.400.740.320.580;D12.644.456.460.600;D12.644.548.365.740.320.580;D12.776.631.650.405.740.320.580,B01.050.150.900.649.473.450
c815832d-2aa3-4803-a4b7-d667673281f3,C0246269,C1167622,affirmed ,icatibant,Binding (Molecular Function),1,X,[aapp/phsu],[moft],x.x.x.x,
909ec787-0ca1-41cb-9672-b9172e659a3b,C0246269,C0324740,affirmed ,icatibant,Talpidae,1,X,[aapp/phsu],[mamm],x.x.x.x,B01.050.150.900.649.473.450
a65ce9a6-58d2-4c41-937e-449df03b4886,C0936079,C0242402,mentioning ,Cannabis,Opioids,1,X,[plnt],[hops/orch/phsu],B01.650.940.800.575.912.250.859.937.055.500,D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
5ad128b4-4849-4835-99bb-5c7724fcc016,C0936079,C0206750,mentioning Opioids from,Cannabis,Coronavirus Infections,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.859.937.055.500,C02.782.600.550.200
eadb3019-2db9-46c2-859a-5fb23e8e11e4,C0936079,C0227813,mentioning Opioids from,Cannabis,Body of uterus,1,X,[plnt],[bpoc],B01.650.940.800.575.912.250.859.937.055.500,
a94c03bd-4bba-4983-b2ce-8b499297d93f,C2948600,C0086132,analyze ,Aim,Depressive Symptoms,1,X,[inch/phsu],[sosy],,F01.145.126.350
1fcc8b9a-5c3f-4047-9033-0d685b2feed9,C2948600,C0003467,analyze ,Aim,Anxiety,1,X,[inch/phsu],[mobd],,F01.470.132
1fcc8b9a-5c3f-4047-9033-0d685b2feed9,C2948600,C0003467,enhancing ,Aim,Anxiety,1,X,[inch/phsu],[mobd],,F01.470.132
5258c5a1-a116-4823-802c-a26ed633403c,C0206750,C0042769,is viral ,Coronavirus Infections,Virus Diseases,12,X,[dsyn],[dsyn],C02.782.600.550.200,C02
9c11d3dd-af66-4b8d-b08b-86b6e7bb0bd3,C0086418,C1292533,Lacking clear information about load on ,Homo sapiens,Tissue specimen,2,X,[humn],[tisu],B01.050.150.900.649.313.988.400.112.400.400,
67ad21c5-803a-4a19-a14c-cbaca786a849,C0370003,C1292533,Lacking clear information about load on ,Specimen,Tissue specimen,2,X,[sbst],[tisu],,
a4daf4bf-3019-4690-9da5-1012e8092b22,C1947904,C1328821,determining ,Attachment (action),tissue tropism,1,X,[acty],[phsf],,
2f641ed7-f59a-4fca-87c0-72f97cca0ddf,C1947904,C1167395,determining ,Attachment (action),Host (organism),1,X,[acty],[orgm],,
53034467-fcc5-41d9-8d2c-2365c32282d6,C0009450,C0025255,fusion of viral ,Communicable Diseases,Tissue membrane,1,X,[dsyn],[tisu],C01.539.221,A10.615
97eb71e1-a9c2-4c89-81e6-e3caa9642d60,C1175743,C0475463,is main target of ,SARS coronavirus,Antibodies Neutralizing,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
c687ef6f-4a17-49cc-abc9-93c9b4c70bb0,C3826426,C0475463,are limiting factors main target of ,Dynamics,Antibodies Neutralizing,1,X,[npop],[aapp/imft],,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
a2c945d9-aee1-46a4-b865-7bffdc37d41c,C0020964,C0206750,is in ,Immunity,Coronavirus Infections,1,X,[phsf],[dsyn],G12.450,C02.782.600.550.200
365a74f5-d0f9-4bb6-ba99-19984cb98825,C0020964,C0024264,count of ,Immunity,Lymphocyte,1,X,[phsf],[cell],G12.450,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
51263b77-f0d0-40c0-aa3e-c127278cf8ec,C0024264,C1879547,lead to compensatory CD8 ,Lymphocyte,Activation action,1,X,[cell],[acty],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
74406762-dc1b-481b-b9c1-e0ace345ad52,C0024264,CD8,lead to compensatory CD8 ,Lymphocyte,CD8,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
74406762-dc1b-481b-b9c1-e0ace345ad52,C0024264,CD8,increased CD8 ,Lymphocyte,CD8,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
dfb62954-3bb5-4af8-b13d-0c7ad2ee0643,C0024264,C2603360,lead to compensatory CD8 ,Lymphocyte,T prime,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
c8706420-56bc-4f02-9686-04c5c3e8b7a2,MAFLD,C0206750,is with ,MAFLD,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
b15ce11b-4b04-4a16-b48f-f4352407a692,C0243077,C0042774,reduce ,inhibitors,Virus Replication,1,X,[chvf],[celf],,G06.920.925
343e4335-3ad8-496e-b1ca-7d03c87b0d6d,C0205721,C0206750,accounted for ,Infections Hospital,Coronavirus Infections,1,X,[dsyn],[dsyn],C01.539.248;C23.550.291.875.500,C02.782.600.550.200
9ff6fff3-a64e-4d18-bf06-af07b4070de9,C0032105,C3277428,increase survival rates in other ,Plasma,Severe viral infections,2,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,
7db39d3d-9b99-43d7-b667-d4f868887371,C0034535,C0206750,is in ,Radiation Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,C02.782.600.550.200
0eb9eae8-c22b-4c79-b746-69c09c21a729,C0027651,C0206750,is in ,Neoplasms,Coronavirus Infections,1,X,[neop],[dsyn],C04,C02.782.600.550.200
999515db-f2b9-4f45-acd6-021dc6f992ff,C0034535,C0012634,is in ,Radiation Syndrome,Disease,2,X,[dsyn],[dsyn],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,C23.550.288
d2ca8df4-44a2-41a6-8eee-993f38326877,C0027651,C0012634,was converted into 22-inpatient bedcoronavirus ,Neoplasms,Disease,4,X,[neop],[dsyn],C04,C23.550.288
a37ef04c-63ff-47ad-91fe-a733d0629391,C0278996,C0034535,is in ,Malignant Head and Neck Neoplasm,Radiation Syndrome,2,X,[neop],[dsyn],,C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360
1d08e556-66d8-497b-88be-9e36d55bb67a,C0278996,C0027651,is in ,Malignant Head and Neck Neoplasm,Neoplasms,2,X,[neop],[neop],,C04
40389087-3d3e-4f22-8ae8-c93ade9a0637,C3887461,C0206750,were proven as ,Head and Neck Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],,C02.782.600.550.200
40389087-3d3e-4f22-8ae8-c93ade9a0637,C3887461,C0206750,is high risk ,Head and Neck Carcinoma,Coronavirus Infections,2,X,[neop],[dsyn],,C02.782.600.550.200
2fef0827-3140-4bf4-8f34-f5be55344131,C0025242,C1422064,may decrease ,Memantine,ACE2 gene,1,X,[orch/phsu],[gngm],D02.455.426.100.050.035.500,
72a3845c-6495-4479-89ed-e7999af650c0,C0025242,C0597360,may decrease ,Memantine,receptor expression,2,X,[orch/phsu],[genf],D02.455.426.100.050.035.500,
e5754035-bc91-4757-bf63-6eb17df1743f,C0025242,C0231491,may decrease ACE2 gene receptor expression as,Memantine,Antagonist muscle action,1,X,[orch/phsu],[ortf],D02.455.426.100.050.035.500,
e5754035-bc91-4757-bf63-6eb17df1743f,C0025242,C0231491,may decrease Peptidyl-Dipeptidase A receptor expression as,Memantine,Antagonist muscle action,1,X,[orch/phsu],[ortf],D02.455.426.100.050.035.500,
c2d817cb-9b8d-463c-b6de-c73223409685,C0025242,C1148665,may decrease ACE2 gene receptor expression as,Memantine,nicotinic acetylcholine-activated cation-selective channel activity,1,X,[orch/phsu],[moft],D02.455.426.100.050.035.500,
c2d817cb-9b8d-463c-b6de-c73223409685,C0025242,C1148665,may decrease Peptidyl-Dipeptidase A receptor expression as,Memantine,nicotinic acetylcholine-activated cation-selective channel activity,1,X,[orch/phsu],[moft],D02.455.426.100.050.035.500,
ccdb89da-3af2-4e69-9640-762181b78f6a,C0231491,C0021368,reduce ,Antagonist muscle action,Inflammation,1,X,[ortf],[patf],,C23.550.470
51579bd2-ccdf-4d4f-bf5a-15ad004be539,C0231491,C0242606,reduce ,Antagonist muscle action,Oxidative Stress,1,X,[ortf],[comd],,G03.673;G07.775.750
3404555b-e435-44ff-a201-d838b7b2fcdf,C0025242,C1175743,may reduce ,Memantine,SARS coronavirus,2,X,[orch/phsu],[virs],D02.455.426.100.050.035.500,B04.820.504.540.150.113.937
28e8c0a1-661f-4a7b-bb64-05a05ca7098e,C1096155,C0012634,is in pandemic ,Macrophage Activation Syndrome,Disease,5,X,[dsyn],[dsyn],C20.683.515.800,C23.550.288
fb86fba5-e51f-4c88-a7e3-cd2f8dd7a90f,C1096155,C0206750,is in pandemic ,Macrophage Activation Syndrome,Coronavirus Infections,2,X,[dsyn],[dsyn],C20.683.515.800,C02.782.600.550.200
478e2463-9c57-4232-aa5d-76bc8711e7c7,C1707455,C1175175,is with other pandemic strains such that of ,Comparison,Severe Acute Respiratory Syndrome,2,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
40f00c54-f185-4171-81c0-520b53a7cb0e,C0033873,C0206750,effectively provided care services during early phase of New York Citys ,Psychiatry Specialty,Coronavirus Infections,1,X,[bmod],[dsyn],F04.096.544;H02.403.690,C02.782.600.550.200
bcc59713-57ee-4bfb-996b-bc52b2cf9619,C4300185,C0206750,effectively provided care services during early phase of New York Citys ,Palliative care.team,Coronavirus Infections,2,X,[bmod],[dsyn],,C02.782.600.550.200
297d868c-e1aa-4aef-a085-b57c7149160d,C4300185,C1273400,thereby enabling ,Palliative care.team,Specialist palliative care,1,X,[bmod],[bmod],,
2efeb0a0-a7e8-4edd-924a-afa977f12ccb,C0033873,C0557533,is in specific ,Psychiatry Specialty,Hospice and Palliative Care Nursing,1,X,[bmod],[bmod],F04.096.544;H02.403.690,H02.478.676.350;N02.421.533.390
895aaa15-0e1a-44f3-82fc-07e56c043e62,C0206419,C2348077,has ,Genus: Coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150,B01.650.940.800.575.912.250.093.615
70a4c51b-1aed-4c55-bdf6-8f0d36fbbe18,C0206419,C2745965,was declared global health ,Genus: Coronavirus,Emergencies [Disease/Finding],9,X,[virs],[patf],B04.820.504.540.150,C23.550.291.781;N06.230.100.083;N06.850.376
3421cdaf-f5f0-46f0-b272-b6256e48f612,C0264361,C0796494,is with over ,Traction bronchiectasis,lobe,4,X,[dsyn],[bpoc],,
5532e4b5-34f2-4ddd-ac1a-cc6e9eae4b1b,ANCC,C2700061,is in Practice ,ANCC,Transition (action),1,X,????,[acty],????,
0b6a9f84-0e11-453d-b18d-95b5dbc47110,C0206419,C0042769,is new ,Genus: Coronavirus,Virus Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C02
1089fb4e-5b6f-433f-92e3-0d67e2b37bcd,C1422064,C0022646,were widely disturbed among ,ACE2 gene,Kidney,4,X,[gngm],[bpoc],,A05.810.453
1089fb4e-5b6f-433f-92e3-0d67e2b37bcd,C1422064,C0022646,effect on ,ACE2 gene,Kidney,6,X,[gngm],[bpoc],,A05.810.453
cdf0178a-b834-4540-aa7c-5d2b7a57f620,C1422064,C0021852,were widely disturbed among ,ACE2 gene,Intestines Small,4,X,[gngm],[bpoc],,A03.556.124.684
2caa6231-9da8-4551-a927-d5c85a5f7bcd,TRMPSS2,C1422064,Up-Regulation (Physiology) of,TRMPSS2,ACE2 gene,2,X,????,[gngm],????,
bb73b35c-cd87-4c51-8f4b-073775e94439,C0162633,C0005768,is in ,Viral Shedding,In Blood,1,X,[patf],[bdsu],G07.925,x.x.x.x.x
c6ef4a7e-72b3-4bbc-a4df-085afcb2171f,C0031843,C0206419,thus seem important to ,physiological aspects,Genus: Coronavirus,6,X,[phsf],[virs],x.x.x.x,B04.820.504.540.150
b481261a-bea9-462c-a9dd-5f0687210fcf,C0013982,C1175743,inhibit ,Emodin,SARS coronavirus,2,X,[bacs/orch/phsu],[virs],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,B04.820.504.540.150.113.937
086d165e-e82e-443c-9ae7-8e0a7eab1d04,C0013982,C1167622,inhibit SARS coronavirus entry by apparently,Emodin,Binding (Molecular Function),1,X,[bacs/orch/phsu],[moft],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
9ebfd087-ec48-433b-8b9b-0ddef10f8fca,C0013982,C1422064,inhibit SARS coronavirus entry by apparently,Emodin,ACE2 gene,1,X,[bacs/orch/phsu],[gngm],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
cfbb1f83-6bf3-4095-8995-530ad9f27acf,C0014442,C0599740,is argued convenient model ,Enzymes,pharmacophore,4,X,[aapp/enzy],[rcpt],D08.811,
f2f6547f-6458-4656-9c93-98eb9d2095a7,C0044707,C0599740,is argued convenient model ,11-beta-Hydroxysteroid Dehydrogenases,pharmacophore,4,X,[aapp/enzy],[rcpt],D08.811.682.047.436.174;D08.811.682.047.820.100,
6c93997d-80de-44ce-8666-994981fbc324,C0009450,C0038454,represents independent ,Communicable Diseases,Cerebrovascular accident,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
b5046f52-a810-4951-9269-b584fc15792a,C0042776,C0333355,Inflammatory disease of mucous membrane of,Virus,Inflammatory disease of mucous membrane,2,X,[virs],[patf],B04,C06.405.205.798;C07.465.584
b5046f52-a810-4951-9269-b584fc15792a,C0042776,C0333355,produce ,Virus,Inflammatory disease of mucous membrane,4,X,[virs],[patf],B04,C06.405.205.798;C07.465.584
afd2a784-03f7-433f-a491-5b41c06c4360,C0039336,C1175743,is in ,Taste Perception,SARS coronavirus,2,X,[ortf],[virs],F02.830.816.724;G11.561.790.724,B04.820.504.540.150.113.937
aa278df1-0939-4a49-a6b1-4e5db8dd2bd5,C1175743,C1825598,is having profound ,SARS coronavirus,IMPACT gene,8,X,[virs],[gngm],B04.820.504.540.150.113.937,
d159c950-0a35-4288-9177-0bc5dd662534,C0441655,C0018563,studying on other ,Activities,Hand,1,X,[acty],[bpoc],,A01.378.800.667
3bc723ab-3af4-46e8-900d-61cc9547b3bd,C1457887,C0562483,was ,Symptoms,Persistent cough,4,X,[sosy],[sosy],,
d7d9329e-1ed3-40f7-b6e6-11cff61752d6,C0010200,C0015967,was more common than ,Coughing,Fever,4,X,[sosy],[sosy],C08.618.248;C23.888.852.293,C23.888.119.344
68957966-1428-4fbf-b2c5-4ef82cadaec6,C3825816,C0206419,is with ,Pneumonia in children,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
40525190-a4fa-4dfd-9ad8-f6bb13f93476,C3825816,C0012634,is with ,Pneumonia in children,Disease,3,X,[dsyn],[dsyn],,C23.550.288
5ad4ebda-a09e-4355-aedf-a93df5fe9b45,C0021054,C0206419,is in children with ,Immunologic Factors,Genus: Coronavirus,1,X,[imft],[virs],D27.505.696.477,B04.820.504.540.150
5ad4ebda-a09e-4355-aedf-a93df5fe9b45,C0021054,C0206419,participate in ,Immunologic Factors,Genus: Coronavirus,2,X,[imft],[virs],D27.505.696.477,B04.820.504.540.150
a354d8fc-308d-4bf7-b4eb-18ab8c277184,C0021054,C0699748,participate in ,Immunologic Factors,Pathogenesis,6,X,[imft],[patf],D27.505.696.477,
b865fb97-a2c5-46d8-bb31-2639df7b7621,C0021054,C0032285,participate in ,Immunologic Factors,Pneumonia,6,X,[imft],[dsyn],D27.505.696.477,C08.381.677;C08.730.610
fbbb4633-779c-44b3-9515-329f83f3fb65,C0699748,C0206419,is in children with ,Pathogenesis,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
130e13c8-a77b-4f7f-ae6e-4cd1e091aa29,C0597357,C0206750,make patients susceptible to ,receptor,Coronavirus Infections,2,X,[aapp/rcpt],[dsyn],,C02.782.600.550.200
1965d100-5643-4e80-a244-21c6088e98c1,C1999230,C0032105,lead clinical use of ,Providing (action),Plasma,3,X,[acty],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
ae255bcd-56db-4ccb-a13b-035ae448f869,C4554533,C2745965,seen in ,Trend:Type:Point in time:^Patient:Nominal,Emergencies [Disease/Finding],4,X,[clna],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
ccfd6a3e-b1b7-4c02-9d70-8f927fe0703b,C1706005,C1175743,were negative for ,CD40LG wt Allele,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
ccfd6a3e-b1b7-4c02-9d70-8f927fe0703b,C1706005,C1175743,for assay is ,CD40LG wt Allele,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
ccfd6a3e-b1b7-4c02-9d70-8f927fe0703b,C1706005,C1175743,be useful test for diagnosis of active ,CD40LG wt Allele,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
b631ad48-d834-4cc9-a873-b4c5b28b7afd,titers,C1175743,were negative for ,titers,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
3319ef30-c4e7-48e5-aa85-902c4fa8bc45,C0319157,C0598197,is highly ,AS virus,contagion,1,X,[virs],[npop],,
775d9e14-778a-43cb-8290-64a79d2c910d,C0162429,C0039082,of Lung is,Malnutrition,Syndrome,1,X,[dsyn],[dsyn],C18.654.521,C23.550.288.500
a61bf605-828f-4919-901a-62ee52b09dd9,C0024109,C0042740,Viral syndrome of epidemic,Lung,Viral syndrome,2,X,[bpoc],[dsyn],A04.411,
de855de4-79b5-4d8a-bc98-d8ff4a0ac5b8,C0018837,C0039082,of Xyzinclude3 is ,Heat (physical force),Syndrome,1,X,[npop],[dsyn],,C23.550.288.500
495ea428-5f69-4df2-a00e-671af22b4912,C0039082,C3891560,Syndrome of,Syndrome,Alarmins,2,X,[dsyn],[aapp/bacs],C23.550.288.500,D23.035
88fc1d45-ae2b-4cad-82c0-2a0f6ab56a74,C0039082,C0018837,Syndrome of,Syndrome,Heat (physical force),2,X,[dsyn],[npop],C23.550.288.500,
96ef3682-dca6-4d08-bbb9-ad3df80d19c1,C0162429,C0042740,of Lung is,Malnutrition,Viral syndrome,1,X,[dsyn],[dsyn],C18.654.521,
8a0acfaa-4415-4280-83ed-42df994cf5af,C0042740,C0018837,Syndrome of pathogenic,Viral syndrome,Heat (physical force),1,X,[dsyn],[npop],,
a7cce6e0-0597-47d7-914b-8ca0893ce26c,C0024109,C0018837,Syndrome of pathogenic,Lung,Heat (physical force),3,X,[bpoc],[npop],A04.411,
2ffeb96f-b44d-4dd0-b755-363d195b21d8,C1457887,C0042740,were clustered including ,Symptoms,Viral syndrome,2,X,[sosy],[dsyn],,
d769e891-bf48-4c4f-a507-768dc51ee78c,C1457887,C0024109,were clustered including ,Symptoms,Lung,1,X,[sosy],[bpoc],,A04.411
d769e891-bf48-4c4f-a507-768dc51ee78c,C1457887,C0024109,stagnating in ,Symptoms,Lung,1,X,[sosy],[bpoc],,A04.411
8ab13854-6c83-4fc1-a723-84f3db6dcc84,C0039082,C0042740,Viral syndrome of epidemic,Syndrome,Viral syndrome,1,X,[dsyn],[dsyn],C23.550.288.500,
37687c57-d038-4cf5-9e3a-5d431ccc74a1,C0039082,C0024109,Viral syndrome of epidemic,Syndrome,Lung,1,X,[dsyn],[bpoc],C23.550.288.500,A04.411
37687c57-d038-4cf5-9e3a-5d431ccc74a1,C0039082,C0024109,is with limited damage to ,Syndrome,Lung,2,X,[dsyn],[bpoc],C23.550.288.500,A04.411
663543be-9143-4f7e-b894-86c1fe1093de,C0729650,C0039082,with Syndrome is,Constituents,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
08c81d52-52c7-466b-9dab-5e4b260e9698,C0729650,C3891560,with Syndrome is,Constituents,Alarmins,1,X,[sbst],[aapp/bacs],,D23.035
6003fb8b-57dc-44d0-9da9-02e0123d2510,C0729650,C0018837,with Syndrome is,Constituents,Heat (physical force),1,X,[sbst],[npop],,
66c665f6-7dbb-4c15-ae59-d426f7feaae8,C0039082,C0729650,is with ,Syndrome,Constituents,1,X,[dsyn],[sbst],C23.550.288.500,
32f21944-f8db-4d0b-adef-adc8d7f3eece,C0729650,C0042740,with Syndrome is,Constituents,Viral syndrome,2,X,[sbst],[dsyn],,
b06afea9-c924-49ff-8851-5f7dcac5b3ab,C0729650,C0024109,with Syndrome is,Constituents,Lung,1,X,[sbst],[bpoc],,A04.411
c87505c9-c391-411d-9373-da778bd299d7,C0024109,C0162429,Syndrome of Qi,Lung,Malnutrition,1,X,[bpoc],[dsyn],A04.411,C18.654.521
d4ca21c3-ffcd-4ce4-a80c-fc89d03ac50f,C0009264,C0242821,to Aversion is,Cold Temperature,Human body,2,X,[npop],[humn],G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300,I01.076.201.450.560;K01.093.378
9fe9aceb-3152-46d0-b996-c57f6f4c59ec,C0687681,C0682477,is in ,Feeling feverish,Arecaceae,1,X,[sosy],[plnt],,B01.650.940.800.575.912.250.093
42190d4b-c226-4e30-a6de-5d5e6b10c82f,C0024109,C0009264,Syndrome of,Lung,Cold Temperature,1,X,[bpoc],[npop],A04.411,G01.906.595.272;G16.500.275.063.725.710.300;G16.500.750.775.710.300;N06.230.300.100.725.154;N06.230.300.100.725.710.300
fb73104c-1de9-4c7f-a05b-6a4704a53c6f,C0024109,C3891560,Syndrome of,Lung,Alarmins,2,X,[bpoc],[aapp/bacs],A04.411,D23.035
49888c24-b464-4094-b115-35feffb00882,C0370003,C0033727,were collected at ,Specimen,Protons,1,X,[sbst],[elii],,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
c9e978e4-9175-4261-97e2-ec9efd3c45d0,C1175743,C0015296,is seventh in ,SARS coronavirus,Exonuclease,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.352.365
dcbde01f-2f71-4de9-a051-c4d64c6f6b9d,C1175743,C0440471,repairing mismatches in newly transcribed ,SARS coronavirus,Genetic Materials,1,X,[virs],[gngm],B04.820.504.540.150.113.937,G05.360.340.024.340
8d0f3ee6-366d-4099-a4a1-f5efdebc60d8,C0206750,C0015296,is with unique ,Coronavirus Infections,Exonuclease,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.277.352.365
3f3a2fd7-bcac-4db3-9ca3-6a6f66831923,C0920474,C0319157,eliminate ,drug mechanism,AS virus,1,X,[patf],[virs],,
8d59c06c-2043-4c8c-bed9-700530179679,C0596957,C0013227,concluded three ,Molecular Dynamics,Pharmaceutical Preparations,2,X,[moft],[phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D26
aa3fc4dc-478b-4282-9214-9f27ed2dbb65,C0013227,C1167622,is from PubChem database with docking scores with its ,Pharmaceutical Preparations,Binding (Molecular Function),1,X,[phsu],[moft],D26,
aa3fc4dc-478b-4282-9214-9f27ed2dbb65,C0013227,C1167622,shows good ,Pharmaceutical Preparations,Binding (Molecular Function),3,X,[phsu],[moft],D26,
e27243ef-6cfe-405a-a002-9558365e142e,C0013227,C0678591,is from PubChem database with docking scores with its ,Pharmaceutical Preparations,free energy,1,X,[phsu],[npop],D26,
bc541557-bc4e-4b8f-bf20-322d776c184b,C1947933,C0012634,preventing further health outcomes from ,care activity,Disease,1,X,[acty],[dsyn],,C23.550.288
bc541557-bc4e-4b8f-bf20-322d776c184b,C1947933,C0012634,are added ,care activity,Disease,2,X,[acty],[dsyn],,C23.550.288
1e742394-243a-4846-9c22-848e40023eed,C0206750,C0010356,is in ,Coronavirus Infections,Cross Infection,1,X,[dsyn],[patf],C02.782.600.550.200,C01.539.248;C23.550.291.875.500
0779051a-09e6-4828-84cd-b8d535e72cab,C0036087,C1511790,is acceptable Specimen to nasopharyngeal specimen for,saliva,Detection,2,X,[bdsu],[topp],A12.200.666,
622d1d6b-c705-4072-b91f-8453a95468f1,C0036087,C1175743,is acceptable Specimen to nasopharyngeal specimen for,saliva,SARS coronavirus,2,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
622d1d6b-c705-4072-b91f-8453a95468f1,C0036087,C1175743,detecting ,saliva,SARS coronavirus,2,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
622d1d6b-c705-4072-b91f-8453a95468f1,C0036087,C1175743,were sufficient for use in tests of ,saliva,SARS coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
622d1d6b-c705-4072-b91f-8453a95468f1,C0036087,C1175743,are suitable for testing for ,saliva,SARS coronavirus,1,X,[bdsu],[virs],A12.200.666,B04.820.504.540.150.113.937
1f9366c0-0a4f-4cdb-97ff-cddc4ce10bb3,C0036087,C0370003,is acceptable ,saliva,Specimen,2,X,[bdsu],[sbst],A12.200.666,
9429ef84-5d48-48df-b6a8-40a479213bf2,C1708476,C0162429,rapid diagnosis of ,Implementation,Malnutrition,5,X,[acty],[dsyn],,C18.654.521
e6277ea7-c9b3-479d-b924-a93968f7fe4d,C0441655,C0030547,are crucial According to specialists from Chinese Medical Association for ,Activities,Parenteral Nutrition,5,X,[acty],[topp],,E02.421.505;E02.642.500.505
a29b1649-bf6d-477c-a11d-00f105a33ccc,C0013879,C0206750,is in patients with ,Elements,Coronavirus Infections,6,X,[elii],[dsyn],D01.268,C02.782.600.550.200
90abb06a-a42a-4281-9873-f4fc2b025cf3,COVID19,C0206750,of propagation is ,COVID19,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
f946e922-c624-43ce-8ef9-2ac65f11bee7,COVID19,C0012634,of propagation is ,COVID19,Disease,3,X,????,[dsyn],????,C23.550.288
b27e720f-99a4-40a3-beb6-5269c26d9eeb,C0018581,C0042210,represent weapons in absence of ,Handwashing,Vaccines,2,X,[acty],[aapp/imft/phsu],N06.850.670.150.500,D20.215.894
98725320-d506-4ffc-8c52-26bb20fc1ee7,C0020405,C0042210,represent weapons in absence of ,Hygiene,Vaccines,1,X,[bmod],[aapp/imft/phsu],E02.547;N06.850.670,D20.215.894
d4273d9d-3bca-4cf5-afcc-1ca67215e2cb,C0086418,C3658340,was admitted to Hubei Provincial 1day 1week,Homo sapiens,Hospital Medicine,3,X,[humn],[bmod],B01.050.150.900.649.313.988.400.112.400.400,H02.403.377
bc4ffcd2-2449-48eb-b844-e5eeb9b5beba,C0086418,1day,was admitted to Hubei Provincial 1day 1week,Homo sapiens,1day,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
bc4ffcd2-2449-48eb-b844-e5eeb9b5beba,C0086418,1day,was admitted due to right limb weakness for 1day 1week,Homo sapiens,1day,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
2bc84692-2e8d-47a7-ad0e-0ecce2b183f1,C0428692,COVID-19,have effect on ,Ambient temperature,COVID-19,1,X,[npop],[virs],,C000657245
2475f600-35ab-4620-8e38-5c4ac9f4029f,C0428692,C0242781,have effect on ,Ambient temperature,disease transmission,1,X,[npop],[patf],,N06.850.310
64c92aa1-5a8f-4fb0-8aae-514fbdea04bb,C1963758,C0015967,is often considered for ,Immunomodulation,Fever,1,X,[topp],[sosy],E02.095.465;G12.535,C23.888.119.344
2870c488-d3c2-4fc9-b06b-262b06e40814,C0042164,C1963758,generated consensus statements for ,Uveitis,Immunomodulation,1,X,[dsyn],[topp],C11.941.879,E02.095.465;G12.535
2387c8fd-ff80-411d-b308-99cdb5c2b2e8,C2825347,C0020517,was demonstrated ,Immunoglobulin A Human,Hypersensitivity,8,X,[imft/phsu],[patf],,C20.543
c0141fc9-74d9-43fb-9f35-f7c42123ac7f,C2825347,C0005516,was demonstrated ,Immunoglobulin A Human,Biological Markers,8,X,[imft/phsu],[clna],,D23.101
cb0063ca-aa58-48f5-82d7-dc567f94c80b,C2825347,C0009450,was demonstrated ,Immunoglobulin A Human,Communicable Diseases,8,X,[imft/phsu],[dsyn],,C01.539.221
22873e5e-b60e-40fe-a9b7-afc567255dc6,studys,C0152060,apply morphoproteomics to ,studys,Transection (procedure),2,X,????,[topp],????,
a785c948-e7d1-4cf3-8fbf-c851e670e585,C0387583,C1440080,is in ,cyclooxygenase 2,Alveolar,1,X,[aapp/enzy],[bpoc],D08.811.600.720.750,
eb48d5a4-9089-4099-b596-14a96f97d585,C0152060,C0242629,rare PD-1 as ,Transection (procedure),CD8-Positive T-Lymphocytes,2,X,[topp],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
eb48d5a4-9089-4099-b596-14a96f97d585,C0152060,C0242629,relative paucity of ,Transection (procedure),CD8-Positive T-Lymphocytes,2,X,[topp],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
57271bce-7056-4ef0-bc1f-326f02e6c2e9,C0032285,C1457887,appeared with clinical ,Pneumonia,Symptoms,2,X,[dsyn],[sosy],C08.381.677;C08.730.610,
e009d152-887e-48a4-abe2-320d6aff55c4,C0032285,C0543829,appeared with clinical ,Pneumonia,pneumonia clinical,2,X,[dsyn],[dsyn],C08.381.677;C08.730.610,
e4abddaa-4b0c-478f-a1e4-4ed59072f0f9,WONCA,C0015607,is in ,WONCA,family medicine (field),2,X,????,[bmod],????,H02.403.340.500
4fa910c9-00d0-4ea0-88ca-ba3388b96048,C1705648,C1824356,be concerns than ,Dropping,KIAA1551 gene,4,X,[acty],[gngm],,
8554c562-020a-4542-b12a-fd67fd523b28,C0376637,C0023175,was described as ,Indinavir,Lead,2,X,[orch/phsu],[elii/hops],D03.383.725.385,D01.268.556.435;D01.552.544.435;x.x.x.x
9c7fecbc-12d2-47a6-ad22-020294293609,C0376637,C0013227,was described as ,Indinavir,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D03.383.725.385,D26
1ef108fd-60ae-41ad-847b-b605b3049f67,C0376637,C4050231,was described as ,Indinavir,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[orch/phsu],[clna],D03.383.725.385,
6a811d35-ef73-48c5-bba1-e64038fcdeec,C0023175,C4050231,is with docking ,Lead,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[elii/hops],[clna],D01.268.556.435;D01.552.544.435;x.x.x.x,
dd380221-b911-4f6e-86e0-0034cc5051f4,C0013227,C4050231,is with docking ,Pharmaceutical Preparations,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[phsu],[clna],D26,
797d3e65-e40b-4b51-9f13-1644a60be94b,C0376637,C0599740,possesses important ,Indinavir,pharmacophore,2,X,[orch/phsu],[rcpt],D03.383.725.385,
787e2a7b-2701-4dcd-a4be-9f4adf04a9b1,C4082587,COVID-19,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,COVID-19,1,X,[aapp/imft],[virs],,C000657245
38d9cb0b-05c9-4779-afae-6eb5fb4721c7,C4082587,C0087111,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,Therapeutic procedure,1,X,[aapp/imft],[topp],,E02
53f93dd8-652d-418c-a275-e6f3ee4f3651,C4082587,C1880355,suggesting ,HLA Class II Histocompatibility Antigen Gamma Chain human,Discover,1,X,[aapp/imft],[acty],,
528669c3-25dc-43ec-8df2-b9587588e033,C0206750,C1516048,were ,Coronavirus Infections,Assessed,2,X,[dsyn],[acty],C02.782.600.550.200,
c9306b69-777c-49bf-b0e8-1aae29623c0d,C0547605,C0042769,is in corona ,prevention of infection,Virus Diseases,1,X,[topp],[dsyn],,C02
c289b603-e31c-45a9-830f-946c1e822633,C0596197,COVID-19,is in ,blood treatment,COVID-19,2,X,[topp],[virs],,C000657245
c5c99879-49c7-4082-a709-cdc7a1f33aa2,C0030693,C0596197,received bedside ,Patient Isolation,blood treatment,3,X,[topp],[topp],E02.770;N06.850.780.200.450.650,
6523d204-26ee-41b3-b559-59927f29607f,C0030693,C0005768,received ,Patient Isolation,In Blood,1,X,[topp],[bdsu],E02.770;N06.850.780.200.450.650,x.x.x.x.x
e8c88c50-c6f3-4936-ac86-4d49e600cdfd,C0439056,COVID-19,is in ,Throat swab sample,COVID-19,1,X,[bdsu],[virs],,C000657245
48eeadfe-cc70-41c4-861d-5757875faf85,C0439056,C0319157,is in ,Throat swab sample,AS virus,1,X,[bdsu],[virs],,
863a0b2b-c5fa-499a-bbc8-9bdfa3590812,C0439056,C0028606,is in ,Throat swab sample,Nucleic Acids,1,X,[bdsu],[bacs/nnon],,D13.444
82ffb5a5-e171-4f71-945b-13cfd72f4e30,C0005768,C0009450,control of patients in ,In Blood,Communicable Diseases,1,X,[bdsu],[dsyn],x.x.x.x.x,C01.539.221
cacc1d77-2a19-4e4e-bbfc-e6cd358883e7,COVID-19,C0010356,in treatment is occurrence of ,COVID-19,Cross Infection,1,X,[virs],[patf],C000657245,C01.539.248;C23.550.291.875.500
00535467-9efb-4aa9-9ea2-85bfe663077a,C0005768,C0010356,occurrence of ,In Blood,Cross Infection,1,X,[bdsu],[patf],x.x.x.x.x,C01.539.248;C23.550.291.875.500
914a5457-c4ff-4bec-84a5-bb109806c869,C0949880,C0035204,cause mild ,Human coronavirus 229E,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150.075.750,C08.618
718dc692-e021-4716-a4d5-9452a16b353a,C0206750,C0021400,has emerged Like severe ,Coronavirus Infections,Influenza,2,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.620.365;C08.730.310
c9448b00-5c31-4807-9082-8fd772b91f7b,C0012634,C2350530,predisposes patients to secondary ,Disease,Bronchopulmonary Aspergillosis,2,X,[dsyn],[dsyn],C23.550.288,C01.703.080.768;C08.381.472.850
e32dd9b7-b6a4-453f-9ff6-6f4f32f8404a,C1290884,C2350530,are predisposing risk factors for ,Inflammatory disorder,Bronchopulmonary Aspergillosis,2,X,[dsyn],[dsyn],,C01.703.080.768;C08.381.472.850
bd1f5f62-c793-42b2-92d2-daa72c83b2b1,C1175743,C1145701,may challenge use of ,SARS coronavirus,amphotericin B liposomal,2,X,[virs],[antb/orch],B04.820.504.540.150.113.937,x.x.x.x
ac80e534-559e-48ef-b1da-f75f8df3d910,C0597357,C0014597,was found highly expressed in GI ,receptor,Epithelial Cells,2,X,[aapp/rcpt],[cell],,A11.436
10db19eb-44da-4529-bbe7-1d4461945fca,C0022709,C0014597,was found highly expressed in GI ,Peptidyl-Dipeptidase A,Epithelial Cells,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
10db19eb-44da-4529-bbe7-1d4461945fca,C0022709,C0014597,are differentially expressed in respiratory ,Peptidyl-Dipeptidase A,Epithelial Cells,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
10db19eb-44da-4529-bbe7-1d4461945fca,C0022709,C0014597,identified on ,Peptidyl-Dipeptidase A,Epithelial Cells,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
10db19eb-44da-4529-bbe7-1d4461945fca,C0022709,C0014597,is in primary ,Peptidyl-Dipeptidase A,Epithelial Cells,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11.436
c1984e0c-26e9-4109-a485-ffd5ab97a09d,C0597357,C1999230,be highly expressed in ,receptor,Providing (action),1,X,[aapp/rcpt],[acty],,
7654b34b-4df7-4998-a9b3-54b29fb0823e,C0022709,C1999230,be highly expressed in ,Peptidyl-Dipeptidase A,Providing (action),1,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
480a7c61-1a02-4ee0-972e-d732ece86708,C0476288,C0206750,is in patients with ,Digestive symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
432050a9-be57-4844-9563-c68e3e3df52c,C0030664,C0815172,is in ,Pathology,patient characteristics,1,X,[bmod],[clna],H02.403.650,
4abdd0c9-0907-43b0-8f9c-da421246dc97,C0030664,C0206750,is in ,Pathology,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.650,C02.782.600.550.200
4eb0d731-f45e-4a76-a20a-a4061502e79a,C0020311,C0012634,affect main manifestations of ,Hydrotherapy,Disease,2,X,[topp],[dsyn],E02.779.492;E02.831.535.492,C23.550.288
a28335ad-7288-431d-9258-223245bbffc8,C0014507,C0337005,is in ,Epidemiology,Cold weather,1,X,[bmod],[npop],H02.403.720.500,
8b454617-e7b5-40fb-a5b2-7bb2329821e7,C2745965,C0023693,trends brought to ,Emergencies [Disease/Finding],Light,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
8b454617-e7b5-40fb-a5b2-7bb2329821e7,C2745965,C0023693,attitudes brought to ,Emergencies [Disease/Finding],Light,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
afd66380-e214-4761-a2fe-d7a39e0da8d6,cov,C0206750,is member of ,cov,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
e7c00d3a-dd24-4477-a212-98e29ed7228f,COVID-19,C3536832,could have ,COVID-19,Air,2,X,[virs],[inch/phsu],C000657245,G16.500.275.063.150;N06.230.300.100.150
32a70c87-86a8-40ba-bd04-fe92a9c163a2,COVID-19,C0242781,could have ,COVID-19,disease transmission,2,X,[virs],[patf],C000657245,N06.850.310
a5617c03-2c4b-4350-ab13-9e1905e4516e,COVID-19,C1720884,could have atmospheric ,COVID-19,Particulate Matter,2,X,[virs],[sbst],C000657245,D20.633
c8c9101a-8db1-43db-bc23-49f2840d9c8a,C1720884,C0032285,induces Pneumonia in,Particulate Matter,Pneumonia,6,X,[sbst],[dsyn],D20.633,C08.381.677;C08.730.610
15ce717f-56ca-4885-8aab-f727e23838d5,C0012634,C0719214,is in twentieth ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
15ce717f-56ca-4885-8aab-f727e23838d5,C0012634,C0719214,has emerged as once in a ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
15ce717f-56ca-4885-8aab-f727e23838d5,C0012634,C0719214,is considered as major health ,Disease,century,1,X,[dsyn],[phsu/vita],C23.550.288,
ddf23a76-4cf0-41c7-a8cb-ea2d3628a683,C0206750,C1457887,results after resolution of ,Coronavirus Infections,Symptoms,10,X,[dsyn],[sosy],C02.782.600.550.200,
e6d0a249-791a-431b-b06f-a28ab5c6c844,C0024115,C1457887,could lead to serious of clinical ,Lung diseases,Symptoms,2,X,[dsyn],[sosy],C08.381,
f23c165d-83c2-4e59-a8be-78e54967c3e0,C0748168,C0206750,is in ,Pulmonary Pathology,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
5f9394f3-d743-425d-b41d-478a58bf40dc,C0002808,C0451610,were Patient review on,Science of Anatomy,Patient review,6,X,[bmod],[topp],H01.158.100,
15c51898-e8c6-4ce6-aee8-167fadf0aafb,C0001933,C0026727,were performed for examinations of ,Alcian Blue,Mucous body substance,1,X,[irda/orch],[bdsu],D03.633.100.473.050;x.x.x.x,A12.200.503
217ee714-e1be-4469-9a53-44847c8aa75a,C0001933,C0819757,were performed for examinations of ,Alcian Blue,Structure of parenchyma of lung,2,X,[irda/orch],[tisu],D03.633.100.473.050;x.x.x.x,
e91f6113-ceeb-410d-96c7-357ba7d8b142,PCR,C1175743,detect ,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
e91f6113-ceeb-410d-96c7-357ba7d8b142,PCR,C1175743,by SARS coronavirus is,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
e91f6113-ceeb-410d-96c7-357ba7d8b142,PCR,C1175743,positive for CoV2,PCR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
e91f6113-ceeb-410d-96c7-357ba7d8b142,PCR,C1175743,is currently standard for ,PCR,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
c313693f-02ec-44f8-a806-1aa51dde6074,C0030664,C0024109,is in ,Pathology,Lung,1,X,[bmod],[bpoc],H02.403.650,A04.411
18c30821-d2a6-47f9-8b83-40bc33e7e290,C0333977,C0021966,extensive impairment of type ,Atypical hyperplasia,Iodides,2,X,[patf],[inch],,D01.248.497.158.490;D01.475.410
a3e77771-51af-4676-ba1c-4758829b3d30,C0333977,C1440080,extensive impairment of type ,Atypical hyperplasia,Alveolar,2,X,[patf],[bpoc],,
731d3c83-905f-4b6b-a796-3507bc7c19ab,C0026727,C0015388,is with fibrinous ,Mucous body substance,Exudate,2,X,[bdsu],[bdsu],A12.200.503,A12.383
29a4cdc6-86ff-4a9a-8b93-f3843b17e146,C0225700,C1175743,were infected by ,Type-II Pneumocytes,SARS coronavirus,2,X,[cell],[virs],A04.411.715.100;A11.436.081,B04.820.504.540.150.113.937
21fddc89-7e8c-448a-b8d2-01a5aaaf1872,C0225700,C0085236,is in ,Type-II Pneumocytes,Macrophages Alveolar,2,X,[cell],[cell],A04.411.715.100;A11.436.081,A11.329.372.600;A11.627.482.600;A11.733.397.600;A15.382.670.522.600;A15.382.680.397.600
a6042b80-45f7-4c7f-8c9d-775cabe3ee37,C0206750,C1254373,emerged as ,Coronavirus Infections,etiologic agent,1,X,[dsyn],[sbst],C02.782.600.550.200,
27e11157-f2f9-4ddd-9c09-0440c8f29fdd,C0020517,C0206750,were conducted to ,Hypersensitivity,Coronavirus Infections,6,X,[patf],[dsyn],C20.543,C02.782.600.550.200
e4214ae1-1698-4e94-b778-6b358f52fc67,C0206750,C0085306,screened compounds for their ,Coronavirus Infections,Feline infectious peritonitis,2,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200.360;C22.180.440
fe7a4f53-65bf-4fc8-a52d-534254602c3e,C0206750,C0472699,was proliferated in feline Fcwf-4cells in human ,Coronavirus Infections,Hemopoietic stem cell transplant,2,X,[dsyn],[topp],C02.782.600.550.200,E02.095.147.500.500.500;E04.936.225.687.500
6bd7388e-707a-4444-8068-1a086751f789,C2741673,C0012634,is in response of patients to ,Account number:Identifier:Point in time:^Patient:Nominal,Disease,2,X,[clna],[dsyn],,C23.550.288
7e83d10d-5eae-4d98-8eea-1aa8b89d3f51,C0023895,C0010827,could could multifactorial related to any of ,Liver diseases,Cytopathogenic Effect Viral,2,X,[dsyn],[comd],C06.552,E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190
3178305b-c911-43eb-907c-fe8d9d02a35e,C0023895,C0206750,is in ,Liver diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C06.552,C02.782.600.550.200
24a92a50-27ca-497f-a2a6-e01f6f8a5f44,C0022709,C1440080,are present in type ,Peptidyl-Dipeptidase A,Alveolar,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
95025473-a688-4cd7-a4e4-8ae0bd7f8e47,C0597360,C0023884,were identified in gastrointestinal tract of ,receptor expression,Liver,2,X,[genf],[bpoc],,A03.620
88712827-85e0-4378-b8b9-aa266542b8f9,C2717801,C1537068,govern ,Viral Tropism,Virus Internalization,2,X,[phsf],[biof],G06.099.925;G06.920.863,G06.920.881
8350833e-eb25-46f3-bcfc-3728686b9302,C2717801,C0284778,govern Virus Internalization in,Viral Tropism,RNA Small Cytoplasmic,2,X,[phsf],[bacs/nnon],G06.099.925;G06.920.863,D13.444.735.790.552.750
f4afb0b0-9b80-42ae-90fe-7bb232de8b65,C0022709,C0284778,govern Virus Internalization in,Peptidyl-Dipeptidase A,RNA Small Cytoplasmic,2,X,[aapp/enzy/imft],[bacs/nnon],D08.811.277.656.350.350.687,D13.444.735.790.552.750
56f60c95-85e7-46f5-83fc-cce28933dbb6,C2717801,C0007634,govern Virus Internalization in single,Viral Tropism,Cells,2,X,[phsf],[cell],G06.099.925;G06.920.863,A11
7fe100c2-18a4-46f5-94c9-97fe1caee2dc,C0022709,C0007634,was expressed in ,Peptidyl-Dipeptidase A,Cells,12,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A11
5b22e1eb-2748-4d2a-a660-cc437289b6ad,C0014597,C0022709,display highest ,Epithelial Cells,Peptidyl-Dipeptidase A,2,X,[cell],[aapp/enzy/imft],A11.436,D08.811.277.656.350.350.687
1329f8c4-96df-473a-a842-01b9531f3ff9,C0206750,C0275522,investigate prevalence in ,Coronavirus Infections,Asymptomatic Infections,3,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.187.500
1329f8c4-96df-473a-a842-01b9531f3ff9,C0206750,C0275522,vary from ,Coronavirus Infections,Asymptomatic Infections,2,X,[dsyn],[dsyn],C02.782.600.550.200,C23.550.291.187.500
a603923d-fc75-4b93-8dba-de6089068b31,C0002871,C0596448,increased D ,Anemia,dimer,2,X,[dsyn],[chvs],C15.378.071,
946b1ab8-6722-4bc1-bc32-be74cefbe1a5,C0002871,C0021760,increased ,Anemia,Interleukin-6,2,X,[dsyn],[aapp/imft],C15.378.071,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
73ebc9b7-455f-4469-b5a6-d4e364fa8e0c,C1704241,RBD,is with RBD,complex (molecular entity),RBD,1,X,[chvs],????,,????
105a9137-19e3-42b6-9620-b75909090774,C0013982,C1149286,inhibit SARS coronavirus entry by apparently,Emodin,enzyme binding,1,X,[bacs/orch/phsu],[moft],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,
0ff0ca61-466a-46b5-8a03-1988fa13eb84,C0013982,C0003018,inhibit SARS coronavirus entry by apparently,Emodin,Angiotensins,1,X,[bacs/orch/phsu],[aapp/bacs/phsu],D02.455.426.559.847.117.159.205.400;D02.806.100.205.400;D04.615.117.159.205.400,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
1945f593-417a-472c-bb01-429cd0b8bcf3,C0920687,C0023693,is in ,cancer care,Light,2,X,[topp],[npop],,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
e387ce50-f9ce-4367-9a12-f3a5322cd775,C1167395,C0597357,activate ,Host (organism),receptor,2,X,[orgm],[aapp/rcpt],,
10a73f09-6c19-44b2-b0c2-05f8ab116db1,C0014442,C0597357,activate ,Enzymes,receptor,2,X,[aapp/enzy],[aapp/rcpt],D08.811,
7791ec9f-df28-4302-a1ac-d77fd0682f4f,C0287990,C0597357,activate ,paired basic amino acid cleaving enzyme,receptor,2,X,[aapp/enzy],[aapp/rcpt],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
483a8180-a6bb-4487-a980-36f7c4c21404,C1167395,C1514535,activate ,Host (organism),Protein Binding Motif,2,X,[orgm],[amas],,
4c791084-2e6d-4418-8d20-50c7883b7b75,C0014442,C1514535,activate ,Enzymes,Protein Binding Motif,2,X,[aapp/enzy],[amas],D08.811,
e2469466-81de-4df1-a1f0-a64749659c8f,C0287990,C1514535,activate ,paired basic amino acid cleaving enzyme,Protein Binding Motif,2,X,[aapp/enzy],[amas],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
f4fe86bd-5b9f-4be8-8c7e-c61933f8482d,C1167395,C0597358,activate ,Host (organism),receptor binding,2,X,[orgm],[moft],,
f7a3d612-8182-431f-ae39-b3fbd2c5c7e1,C0014442,C0597358,activate ,Enzymes,receptor binding,2,X,[aapp/enzy],[moft],D08.811,
9e2d35af-adf2-4598-a8a6-0d96b56ae9c1,C0287990,C0597358,activate ,paired basic amino acid cleaving enzyme,receptor binding,2,X,[aapp/enzy],[moft],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
cba706e0-8664-47af-8c9a-d191273f4403,C0040300,C0287990,higher expression of ,Body tissue,paired basic amino acid cleaving enzyme,6,X,[tisu],[aapp/enzy],A10,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
5fa0e14b-57c5-4a1f-a866-069cb502ef50,C0220641,C0287990,exhibit higher expression of ,Lip and Oral Cavity Carcinoma,paired basic amino acid cleaving enzyme,2,X,[neop],[aapp/enzy],,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
0579dae4-65f6-4ca4-913c-74cfb87e2885,C0220641,C0206750,require attention during ,Lip and Oral Cavity Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],,C02.782.600.550.200
04016967-1c97-48e3-a2aa-7063c0fc0c8e,C0220641,C0027651,require attention during ,Lip and Oral Cavity Carcinoma,Neoplasms,2,X,[neop],[neop],,C04
9a95bab6-a156-4dbd-858a-cc930b6ed3ae,C0075816,C0013227,exhibited Binding (Molecular Function) energy scores with concerned,taraxerol,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],x.x.x.x,D26
1bffb21f-6c17-4272-8ead-26b221bde981,C1707455,C1275589,were distributed in fewer ,Comparison,Lobular pneumonia,1,X,[acty],[dsyn],,
911efcd5-399a-49d9-afdf-e59212087450,C0599878,GGO,are multiple areas of GGO ,disease characteristic,GGO,2,X,[patf],????,,????
7f820443-a3a9-48f5-bc14-3917b7a14595,C1175743,C1879547,cause Disease through,SARS coronavirus,Activation action,1,X,[virs],[acty],B04.820.504.540.150.113.937,
0c053fbd-4f43-4dde-af7b-824ed0353b97,C0236099,C0206419,induced by ,Disorder of male reproductive system,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
ce488f16-4156-4c0a-9624-830d426f5d57,C1707391,C1706202,were identified during electronic database ,Choose (action),Search - action,3,X,[acty],[acty],,
8a21d017-7f12-4c99-b2fc-50b47482713c,C2948600,C0063034,analyse results of ,Aim,huperzine B,2,X,[inch/phsu],[orch/phsu],,x.x.x.x
7046e267-5bdb-45a7-ade0-f29c94fd9310,C0301630,C0012634,are among consequences of ,Reduction (chemical),Disease,2,X,[npop],[dsyn],,C23.550.288
df569ac0-d068-4347-95ed-199c7ca75f2a,C0028754,C0012634,BACKGROUND/During 2019 ,Obesity,Disease,4,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
df569ac0-d068-4347-95ed-199c7ca75f2a,C0028754,C0012634,has In addition has correlated with mortality rates after ,Obesity,Disease,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
df569ac0-d068-4347-95ed-199c7ca75f2a,C0028754,C0012634,increase chances of ,Obesity,Disease,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
df569ac0-d068-4347-95ed-199c7ca75f2a,C0028754,C0012634,risk in patients with ,Obesity,Disease,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C23.550.288
0e7ae6c3-7fce-494b-ac9f-c0c0fc30af01,ALF,C0001899,was determined as 40U/L,ALF,Alanine Transaminase,4,X,????,[aapp/enzy],????,D08.811.913.477.700.100
6c9863e4-4780-4379-b949-ef986fea7219,ALF,40U/L,was determined as 40U/L,ALF,40U/L,4,X,????,????,????,????
d818e9e3-c7a1-4f21-bc9c-528ab7272116,C0028754,C1305855,was determined as 24kg/m,Obesity,Body mass index,5,X,[dsyn],[clna],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175
b7e3115e-6b49-4afb-95ca-ba01180dbfd9,C0028754,24kg/m,was determined as 24kg/m,Obesity,24kg/m,3,X,[dsyn],????,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,????
2c297483-ab55-48b8-9de4-cb9857586f83,C2926735,C0028754,was increased to those with overweight ,Duration,Obesity,20,X,[orch/phsu],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
b9a22b56-b1d9-495a-8202-b58c7612e97a,ALF,C0012634,predicting probability of prolonged hospitalization in patients with ,ALF,Disease,2,X,????,[dsyn],????,C23.550.288
149f7d69-fe05-4375-a279-f242bd1f2b3b,C2948600,C0242781,reducing ,Aim,disease transmission,1,X,[inch/phsu],[patf],,N06.850.310
149f7d69-fe05-4375-a279-f242bd1f2b3b,C2948600,C0242781,slow ,Aim,disease transmission,2,X,[inch/phsu],[patf],,N06.850.310
04b86e23-8496-4743-8578-40b165b736df,C1706202,C1330330,succinctly summarize primary active ingredients of action of ,Search - action,Hand Sanitizers,2,X,[acty],[phsu],,D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650
8ba5ccf0-6eae-4d22-87f9-0fe83ef9854b,C0001962,C1175743,be effective against ,Ethanol,SARS coronavirus,20,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04.820.504.540.150.113.937
29af1814-573d-4e8d-9d61-2c7b75571c99,C0242781,C1175743,be effective against ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
29af1814-573d-4e8d-9d61-2c7b75571c99,C0242781,C1175743,are responsible for three disease outbreaks since 2002 caused by ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
29af1814-573d-4e8d-9d61-2c7b75571c99,C0242781,C1175743,Zoonotically are responsible for three disease outbreaks caused by ,disease transmission,SARS coronavirus,1,X,[patf],[virs],N06.850.310,B04.820.504.540.150.113.937
642b515b-5e7b-4e6d-a369-310fab7503ce,C1330330,C1175743,be effective against ,Hand Sanitizers,SARS coronavirus,2,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04.820.504.540.150.113.937
07617e37-4719-488c-b8f8-6bf3616d7b27,C0360714,C1537068,modulating ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Virus Internalization,2,X,[orch/phsu],[biof],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G06.920.881
43d3d6d5-e57a-4ce7-ba60-04ee79f4b742,C0360714,C1175743,could act acting on ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,SARS coronavirus,4,X,[orch/phsu],[virs],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,B04.820.504.540.150.113.937
be824261-2a4c-4711-949a-98d3a1b6ba2d,C0360714,C0174990,acting on ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,x.x.x.x
a36aad5c-31a6-43f2-9a54-3c615df99632,C0360714,C0042774,could regulate ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Virus Replication,2,X,[orch/phsu],[celf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G06.920.925
7c678ce7-fef9-49d2-bc70-486764955e39,C0360714,C0004391,inducing ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Autophagy,2,X,[orch/phsu],[celf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,G04.146.399;G04.417.350.091
35f43551-eb93-4091-8e70-5182e87e939d,C0360714,C1879547,inducing ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Activation action,2,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
e35aca5a-1ce9-4358-9a05-66a72b3a2901,C0360714,C0206419,improve ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Genus: Coronavirus,1,X,[orch/phsu],[virs],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,B04.820.504.540.150
a0ba7511-501b-4493-b9d4-7d56017553ba,C2259033,C0206419,improve ,activation of coagulation,Genus: Coronavirus,2,X,[phsf],[virs],,B04.820.504.540.150
a690c703-d920-4611-9f62-5cb8507fea0b,C0233514,C0440283,consuming ,Abnormal behavior,Citrus limon plant,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,
0f4495e8-e0fc-4507-ad8a-0439d1893321,C0233514,C0017102,consuming ,Abnormal behavior,Allium sativum,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,B01.650.940.800.575.912.250.618.100.050.060.300
af0a2f12-f4bf-4f0f-a688-34ed87fe37c2,C0233514,C0019240,consuming ,Abnormal behavior,Herb,3,X,[mobd],[plnt],F01.145.126.972;F01.145.179.750,
d361a297-7493-4b0c-9ddc-191eec9aa42e,C0233514,C0439861,consuming ,Abnormal behavior,Substance,3,X,[mobd],[sbst],F01.145.126.972;F01.145.179.750,
1f7d5b35-4eb6-4158-941e-8bceb83d7fe9,C0301630,CoV2,have have implemented in countries with outbreaks of CoV2,Reduction (chemical),CoV2,4,X,[npop],????,,????
83f49444-2c62-4965-8db7-c54bd9109d66,C0038164,C0699748,gain insights into mechanism of ,Staphylococcal Protein A,Pathogenesis,4,X,[aapp/imft/irda],[patf],D12.776.097.820;D23.050.161.821,
5398ea7e-8ed4-4460-829c-2677a96f20e2,C0204514,C0699748,gain insights into mechanism of ,Structural analysis,Pathogenesis,4,X,[topp],[patf],,
abf5b85a-541a-4ce5-89bf-3c24cae3e33a,C0037083,C1175743,are different in case of ,Signal Transduction,SARS coronavirus,4,X,[celf],[virs],G02.111.820;G04.835,B04.820.504.540.150.113.937
fdbba641-f880-4164-abdb-748ca3555554,C0042333,C0017428,is in ,Variation (Genetics),Genome,4,X,[npop],[gngm],G05.365,G05.360.340
af2bb7cb-b383-4f0d-b07a-7b3bf95a915c,C0042333,C1175743,is in ,Variation (Genetics),SARS coronavirus,4,X,[npop],[virs],G05.365,B04.820.504.540.150.113.937
22a95bca-6bff-458c-9275-8c434d303ad3,C0006786,C0001272,have IC ,Calpain II,Action Potentials,2,X,[aapp/bacs],[celf],D08.811.277.656.262.500.120;D08.811.277.656.300.200.120,G04.580.100;G07.265.675.100;G11.561.570.100
41e1722e-0e91-43a0-b8ff-8fbddf407930,C0243077,C0001272,have IC ,inhibitors,Action Potentials,1,X,[chvf],[celf],,G04.580.100;G07.265.675.100;G11.561.570.100
e8e9920d-5c35-47f0-b1e4-3768ef396bef,C0006786,IC,have IC ,Calpain II,IC,2,X,[aapp/bacs],????,D08.811.277.656.262.500.120;D08.811.277.656.300.200.120,????
f0fb2cb8-72eb-4e3f-a9e9-5bf840a08a2f,C0243077,IC,have IC ,inhibitors,IC,1,X,[chvf],????,,????
2c491c36-66ab-494e-b529-145bfc88d6bd,C0001272,IC,is with single-digit to submicromolar IC ,Action Potentials,IC,4,X,[celf],????,G04.580.100;G07.265.675.100;G11.561.570.100,????
b11c71e6-2cb3-475f-9036-0642b66229b8,C0007590,C0040676,is with ,Cell division,Transferase,6,X,[celf],[aapp/enzy],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,D08.811.913
24a8e0af-1cf8-4003-bdfa-ddd8a6e01cbb,C1175743,C0007590,is in ,SARS coronavirus,Cell division,3,X,[virs],[celf],B04.820.504.540.150.113.937,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
2d455ec6-5533-491d-95b5-0ec1be6cd69b,C0040676,C0007590,is in ,Transferase,Cell division,3,X,[aapp/enzy],[celf],D08.811.913,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
de8f6352-7083-4ac0-bf52-3d6dece26c90,C1175743,C0040676,is in ,SARS coronavirus,Transferase,3,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.913
7b70f717-c41f-4297-8633-7cbce9cff37d,C3891814,C1175743,provide points for further development of ,Substrate,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
e7a46196-1ad3-46ba-ab07-208664450dc8,C1167622,C1175743,provide points for further development of ,Binding (Molecular Function),SARS coronavirus,7,X,[moft],[virs],,B04.820.504.540.150.113.937
14096f6c-0c12-4d47-9eea-1a3e99e69847,C0235029,C0206419,is in patients with ,neurological complication,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
cf8038d7-c6eb-497f-8b13-373550ce901f,C0497552,C1175743,are caused by Cov2 ,Congenital neurologic anomalies,SARS coronavirus,3,X,[cgab],[virs],C10.500;C16.131.666,B04.820.504.540.150.113.937
613d75ce-149e-4a60-9e64-24a0e387c170,C0497552,Cov2,are caused by Cov2 ,Congenital neurologic anomalies,Cov2,3,X,[cgab],????,C10.500;C16.131.666,????
02e535cd-62aa-4add-9cff-9f352df21a4b,C0497552,C0206419,is in ,Congenital neurologic anomalies,Genus: Coronavirus,1,X,[cgab],[virs],C10.500;C16.131.666,B04.820.504.540.150
c1c38b7e-da82-49dd-ad5d-92fb8a24aa55,C0206419,C0011570, includes ,Genus: Coronavirus,Mental Depression,1,X,[virs],[mobd],B04.820.504.540.150,F01.145.126.350
d642f0be-4689-4208-b880-65250a33546a,C0030567,C0206419,long-term sequalae of ,Parkinson Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,B04.820.504.540.150
ed765773-a812-4a03-b50d-22d0bc033429,C0002395,C0206419,long-term sequalae of ,Alzheimer's Disease,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,B04.820.504.540.150
40109d95-e88a-446a-a41b-3e1ed7651958,C0030567,C0011570,long-term sequalae of ,Parkinson Disease,Mental Depression,2,X,[dsyn],[mobd],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,F01.145.126.350
9b6401f1-38f4-481d-9d54-83842114391d,C0002395,C0011570,long-term sequalae of ,Alzheimer's Disease,Mental Depression,2,X,[dsyn],[mobd],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,F01.145.126.350
94c452ed-ac01-4fb2-835b-19779fff7d5b,C0021747,C1175743,controlling ,Interferons,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
4bf5e22c-767b-4877-90ef-f09bb73e62d6,C0021747,C0598312,controlling ,Interferons,DNA Replication,1,X,[aapp/imft],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G02.111.225;G05.226
a8a24860-3c9d-4337-b34e-84e9da8aa7ee,C0021747,de,controlling de ,Interferons,de,1,X,[aapp/imft],????,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,????
03ae0a4c-c6ca-4b7d-9442-c449c05a4d22,C0021747,C0042776,controlling de ,Interferons,Virus,1,X,[aapp/imft],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04
8fe07e99-e15b-4bb8-84eb-fc76648b1932,C3273807,C1547282,were recently ,Sodium-Glucose Transporter 2 Inhibitors,Show,3,X,[orch/phsu],[anim],D27.505.519.936;D27.505.696.422.750,
4713b5e2-6b0a-4fff-90ff-433f975eab9d,C0178784,C0206750,may explain pulmonary deficits seen in ,Organ,Coronavirus Infections,9,X,[bpoc],[dsyn],,C02.782.600.550.200
02e61a3a-baee-4025-b0c5-a39990e2bd56,C1547282,C1819995,could could potential ,Show,Host Cell,1,X,[anim],[celc],,
6ad78d0a-f88c-48ed-94c8-438c7dbdf071,C1547282,C1175743,could could potential ,Show,SARS coronavirus,1,X,[anim],[virs],,B04.820.504.540.150.113.937
39404795-fcac-4264-a638-8b49db98103c,C0007600,C1819995,are genetically and phenotypically different from ,Cultured Cell Line,Host Cell,6,X,[cell],[celc],A11.251.210,
8f6714c4-edfb-4f47-923b-19e2488e6681,C0178708,C1819995,are genetically and phenotypically different from ,immortalized cell,Host Cell,2,X,[cell],[celc],,
5b1195cc-31bd-401a-87ae-e94f085b333c,C1182792,2D,is in 2D,Epithelial cell of proximal tubule,2D,4,X,[cell],????,,????
d182fe8b-cb9d-496d-b7bb-a77adaca703b,C0086418,2D,is in 2D,Homo sapiens,2D,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
0a8c3342-077e-45b3-901a-abc2fc876e8e,C0022646,2D,is in 2D,Kidney,2D,2,X,[bpoc],????,A05.810.453,????
e0bb7de8-6535-4a95-9f09-edee78d23829,C0022677,C0596902,Importantly maintained lineage physiological aspects with expression of,Kidney Tubules Proximal,Membrane Transport Proteins,1,X,[bpoc],[aapp/bacs],A05.810.453.736.560.570,D12.776.157.530;D12.776.543.585
e0bb7de8-6535-4a95-9f09-edee78d23829,C0022677,C0596902,maintained lineage physiological aspects with expression of specific,Kidney Tubules Proximal,Membrane Transport Proteins,1,X,[bpoc],[aapp/bacs],A05.810.453.736.560.570,D12.776.157.530;D12.776.543.585
abc234ee-6092-4295-b4ca-b574f15be291,C0022677,C0031843,maintained lineage ,Kidney Tubules Proximal,physiological aspects,4,X,[bpoc],[phsf],A05.810.453.736.560.570,x.x.x.x
5e87d8f9-828a-4813-bd5f-f0a330f6e427,C1452534,C1175743,receptor for,ACE protein human,SARS coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
5e87d8f9-828a-4813-bd5f-f0a330f6e427,C1452534,C1175743,is entry ,ACE protein human,SARS coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
e94308ac-a6dc-45d4-98c2-3919248177fc,C1452534,2DCR,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,2DCR,3,X,[aapp/bacs],????,x.x.x.x,????
4ec59343-b6a8-49ad-bb9d-bbd15e1e735c,C1452534,C0012634,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,Disease,3,X,[aapp/bacs],[dsyn],x.x.x.x,C23.550.288
03b2a7ba-55dd-4414-9f10-e4a6ca864099,C1452534,C1707455,was Very interestingly twofold higher in 3Dorganoids culture 2DCR ,ACE protein human,Comparison,5,X,[aapp/bacs],[acty],x.x.x.x,
8d410ca3-0b2f-4a6e-81da-5f8b23a74097,C4281807,C0024075,enter Cellular Reprogramming with,Vitronectin human,Luciferases,2,X,[aapp/bacs],[aapp/enzy/irda],,D08.811.682.517;D12.776.532.510
2d2c6d5e-b808-4945-a5a4-4fb4d3c1dcbd,C4281807,C3850096,enter ,Vitronectin human,Cellular Reprogramming,2,X,[aapp/bacs],[celf],,G04.152.262;G05.135
d63098ec-7947-47c1-8b13-17f8cd10a311,C0017428,C0042765,decrease its inocula,Genome,Virulence,2,X,[gngm],[biof],G05.360.340,G06.930
cece6212-0f07-473a-8dd9-3c3578c8933d,C0017428,C0319157,decrease its inocula,Genome,AS virus,3,X,[gngm],[virs],G05.360.340,
083cdc8f-0143-47bb-b463-a21ec3be4e0d,C0017428,inocula,decrease its inocula,Genome,inocula,2,X,[gngm],????,G05.360.340,????
4d9e0e05-7c8c-4d2c-a5bc-a1fee28edd0b,C1707455,C1452534,demonstrated moderately lower risk with ,Comparison,ACE protein human,2,X,[acty],[aapp/bacs],,x.x.x.x
5c6a618b-4eac-4121-9382-696b9b3d8e5e,C3888198,C1452534,demonstrated moderately lower risk with ,BESTROPHINOPATHY AUTOSOMAL RECESSIVE,ACE protein human,2,X,[dsyn],[aapp/bacs],,x.x.x.x
d8fec4bd-cfbd-4084-8884-83fc308bbd6b,nt,C1167395,would of would threat to ,nt,Host (organism),3,X,????,[orgm],????,
2e5f3405-047e-4b27-92fc-4d72a4ee0167,C0042776,C0023779,interacting with ,Virus,Lipids,6,X,[virs],[orch],B04,D10
33405ffc-0d63-443c-9e5c-936fc88af462,C0042776,C0596901,interacting with ,Virus,Membrane,6,X,[virs],[celc],B04,A10.615
3faf60eb-bcbc-4b32-9e19-ef29fe23b338,C0042776,C0178784,could also affect human internal ,Virus,Organ,3,X,[virs],[bpoc],B04,
291b34a5-a371-4936-a609-cf22654114ee,C1175743,C0025249,is in case detrimentally dependent on integrity of its ,SARS coronavirus,Membrane Lipids,6,X,[virs],[orch],B04.820.504.540.150.113.937,D10.570
e6bd50f4-cec7-4932-bb6a-1cc2c4e5dd95,C0206750,C0043528,is new ,Coronavirus Infections,Zoonoses,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.908;C02.968;C03.908;C22.969
b8cf9239-3bee-4c72-aa1e-d6a3dc05f279,C0012634,C0043528,is new ,Disease,Zoonoses,1,X,[dsyn],[dsyn],C23.550.288,C01.908;C02.968;C03.908;C22.969
aab18e0c-c7d3-4135-925c-edab511ac9f6,C0012634,C0282686,IMPACT gene of be may,Disease,Respiratory System Agents,1,X,[dsyn],[phsu],C23.550.288,D27.505.954.796
aab18e0c-c7d3-4135-925c-edab511ac9f6,C0012634,C0282686,was initially characterized by mainly manifestations of ,Disease,Respiratory System Agents,1,X,[dsyn],[phsu],C23.550.288,D27.505.954.796
6116883b-965e-4759-9e34-35d90eaf9ce2,C1825598,C0282686,may beyond may ,IMPACT gene,Respiratory System Agents,1,X,[gngm],[phsu],,D27.505.954.796
350a76c9-3d73-43c5-8e8e-db0f5d0c547c,C0042774,C0301872,are when prevalent under insufficient ,Virus Replication,Immune response,8,X,[celf],[ortf],G06.920.925,
59064821-7250-4447-b429-d7811c11a7a7,C0072393,C1537068,allowing ,Protein S,Virus Internalization,2,X,[aapp/bacs],[biof],D12.776.124.670;D12.776.395.642;D23.113.725,G06.920.881
eb2381c2-33e2-42b7-92ab-f9a3cc1353ec,C2249699,C1537068,allowing ,activation of proteolysis,Virus Internalization,2,X,[moft],[biof],,G06.920.881
530b65cf-76cc-4049-9b9c-1d0dd1462e04,C0072393,C0221284,allowing Virus Internalization into,Protein S,Leptocyte,2,X,[aapp/bacs],[cell],D12.776.124.670;D12.776.395.642;D23.113.725,
925714bb-1779-411a-8cc4-6ae95c86ead1,C2249699,C0221284,allowing Virus Internalization into,activation of proteolysis,Leptocyte,2,X,[moft],[cell],,
30390e79-4229-43ae-ad5d-0ecbcbc01442,C0243077,C0007634,is in ,inhibitors,Cells,1,X,[chvf],[cell],,A11
940adea5-08e5-4db5-b981-96f5a5f22b22,C1160657,C0007634,is in ,Virus Uncoating,Cells,1,X,[celf],[cell],G06.920.950,A11
921c9f69-a537-4fcc-a54d-97c8c108d427,C0243077,C0034850,is in cellular ,inhibitors,Endosomes,2,X,[chvf],[celc],,A11.284.430.214.190.875.190.880.337
cd627d83-4913-454b-a423-007e615ffb0f,C1160657,C0034850,is in cellular ,Virus Uncoating,Endosomes,2,X,[celf],[celc],G06.920.950,A11.284.430.214.190.875.190.880.337
22106b7e-3fa5-44d6-b706-7c779d369484,C0206750,C2745965,was declared ,Coronavirus Infections,Emergencies [Disease/Finding],24,X,[dsyn],[patf],C02.782.600.550.200,C23.550.291.781;N06.230.100.083;N06.850.376
ccc47816-cefa-45d1-8517-b5434681a091,C0012634,C2745965,is serious ,Disease,Emergencies [Disease/Finding],8,X,[dsyn],[patf],C23.550.288,C23.550.291.781;N06.230.100.083;N06.850.376
c3ffde8a-1db6-4b4b-b697-681e857a6b47,C1824986,C2945744,is in ,DUOXA1 gene,Bud - CHV concept,1,X,[gngm],[anst],,
6d494e9a-0a8f-4920-b10c-500f68557f03,C0206750,C2945744,is in ,Coronavirus Infections,Bud - CHV concept,1,X,[dsyn],[anst],C02.782.600.550.200,
6584cc44-76e4-4c99-adbd-039c8f180e09,C1706202,C0022671,included ,Search - action,Kidney Transplantation,2,X,[acty],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
6584cc44-76e4-4c99-adbd-039c8f180e09,C1706202,C0022671,was performed ,Search - action,Kidney Transplantation,1,X,[acty],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
f11ef2b6-73ba-4182-ab6d-58408e10f565,C0022671,C4048329,potential risk for infection non-negligible comorbidity and exposure to long-term ,Kidney Transplantation,Immunosuppression,2,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,E02.095.465.425.450;E05.478.610
d4a184e2-ebf9-4ee2-973a-7bb629036a2e,C1457887,C0022671,is in ,Symptoms,Kidney Transplantation,2,X,[sosy],[topp],,E02.870.500;E04.936.450.485;E04.950.774.400
c8386b6b-74ef-468e-94ed-227078d21230,C0024109,C0178784,are main ,Lung,Organ,2,X,[bpoc],[bpoc],A04.411,
3e442619-85dc-4e6a-870c-2776753b636c,C0024109,C0035222,are main ,Lung,Respiratory Distress Syndrome Adult,2,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
3e442619-85dc-4e6a-870c-2776753b636c,C0024109,C0035222,involved in ,Lung,Respiratory Distress Syndrome Adult,1,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
3e442619-85dc-4e6a-870c-2776753b636c,C0024109,C0035222,can can used only in patients with L phenotype ,Lung,Respiratory Distress Syndrome Adult,1,X,[bpoc],[dsyn],A04.411,C08.381.840;C08.618.840
28524765-696b-4ab2-8a16-2f2228d8fcbc,C0024109,C0206750,is with acute lung injury post ,Lung,Coronavirus Infections,5,X,[bpoc],[dsyn],A04.411,C02.782.600.550.200
013392c2-eb78-46d4-b934-80a427b60d7a,C0013227,C0939237,include ,Pharmaceutical Preparations,lopinavir / Ritonavir,2,X,[phsu],[phsu],D26,
89bc12b6-7861-451d-9915-757f39fabe18,C0013227,C0021747,include ,Pharmaceutical Preparations,Interferons,1,X,[phsu],[aapp/imft],D26,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
50494964-be37-4102-bc68-8d4f5575c11f,C0013227,C0032105,include ,Pharmaceutical Preparations,Plasma,2,X,[phsu],[bdsu],D26,A12.207.152.693;A12.207.270.695;A15.145.693
7471c7e0-fb09-4ef2-a281-d1d54f743990,C0013227,C0003250,include ,Pharmaceutical Preparations,Monoclonal Antibodies,2,X,[phsu],[aapp/imft],D26,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
32529c1f-5c72-4770-99fa-d497bced0873,C0939237,C0021747,combined with ,lopinavir / Ritonavir,Interferons,1,X,[phsu],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
21ff4604-6050-4ce0-b7e2-df000ed538fe,C0939237,C0032105,combined with ,lopinavir / Ritonavir,Plasma,2,X,[phsu],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
b65618c0-4ba9-4b03-af7e-215e4b12782c,C0939237,C0003250,combined with ,lopinavir / Ritonavir,Monoclonal Antibodies,2,X,[phsu],[aapp/imft],,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
300cae6c-c40a-470b-9074-4ae251da252b,C0007820,C0871208,has disability ,Cerebrovascular Disorders,Rating (action),1,X,[dsyn],[acty],C10.228.140.300;C14.907.253,
300cae6c-c40a-470b-9074-4ae251da252b,C0007820,C0871208,has fatality ,Cerebrovascular Disorders,Rating (action),1,X,[dsyn],[acty],C10.228.140.300;C14.907.253,
c23a869c-0155-45bb-b46f-59bbe77850b7,C0206750,EGID,is in EGID ,Coronavirus Infections,EGID,1,X,[dsyn],????,C02.782.600.550.200,????
05de488a-77d4-49c2-97ce-2c4b81f755e3,C0206419,C0230425,is in patients with first negative PCR ,Genus: Coronavirus,Structure of right thigh,1,X,[virs],[bpoc],B04.820.504.540.150,
0c688c06-c228-49b3-97bc-76c706767e19,C0206419,PCR,is in patients with first negative PCR ,Genus: Coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150,????
54bbc85d-225d-4ca7-9583-2b768606d2c7,remdesivir,C0206419,received emergency use authorization recently for use in patients hospitalized with ,remdesivir,Genus: Coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150
54bbc85d-225d-4ca7-9583-2b768606d2c7,remdesivir,C0206419,have shown ,remdesivir,Genus: Coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150
2a804ab8-56c9-4404-b559-76ce4b3982cd,C1742865,C0319157,used by ,TMPRSS2 protein human,AS virus,1,X,[aapp/enzy],[virs],x.x.x.x,
7a91a31c-079e-4c12-835f-558c26926ea5,C1742865,C1175743,are Proteins to,TMPRSS2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
7a91a31c-079e-4c12-835f-558c26926ea5,C1742865,C1175743,are key ,TMPRSS2 protein human,SARS coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
7a91a31c-079e-4c12-835f-558c26926ea5,C1742865,C1175743,chemical cofactor for CoV2,TMPRSS2 protein human,SARS coronavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
3224ec74-9d07-4b6b-8043-6e18a1abd601,C1742865,C0033684,are key ,TMPRSS2 protein human,Proteins,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,D12.776
59712c82-9370-43e0-9983-117e3a5a5159,C0033147,C1175175,be also susceptible to ,Primates,Severe Acute Respiratory Syndrome,2,X,[mamm],[dsyn],B01.050.150.900.649.313.988,C02.782.600.550.200.750;C08.730.730
7f8b7073-4496-40ce-a51b-70c9325246df,C0033147,C0012634,be also susceptible to ,Primates,Disease,2,X,[mamm],[dsyn],B01.050.150.900.649.313.988,C23.550.288
18608d81-224f-4789-9adf-6abc3b92dcdc,C0086418,C1254351,is with well-established potential as bi-directional zoonotic/anthroponotic ,Homo sapiens,Pharmacologic Substance,1,X,[humn],[phsu],B01.050.150.900.649.313.988.400.112.400.400,
cb0e13f0-4c6a-439f-b460-cf1245e01f9d,C0033147,C1254351,is with well-established potential as bi-directional zoonotic/anthroponotic ,Primates,Pharmacologic Substance,1,X,[mamm],[phsu],B01.050.150.900.649.313.988,
6ccea81e-3c94-49e3-99a7-a98309745e37,C0033147,C0086418,is with well-established potential as bi-directional zoonotic/anthroponotic ,Primates,Homo sapiens,1,X,[mamm],[humn],B01.050.150.900.649.313.988,B01.050.150.900.649.313.988.400.112.400.400
f49fa22d-c620-4b15-b159-6c20675fcdc0,C4045971,C0026447, includes wild ,Savannah Monkey,Monkeys,1,X,[mamm],[mamm],B01.050.150.900.649.313.988.400.112.199.120.126.110,B01.050.150.900.649.313.988.400
8c469e1b-2b24-4205-80a6-40a333f63a95,C1742865,C0017428,inspected recently published ,TMPRSS2 protein human,Genome,2,X,[aapp/enzy],[gngm],x.x.x.x,G05.360.340
431a370f-7d4e-4f9f-b5b6-6f85156cbec7,C1742865,C4045971,inspected recently published ,TMPRSS2 protein human,Savannah Monkey,1,X,[aapp/enzy],[mamm],x.x.x.x,B01.050.150.900.649.313.988.400.112.199.120.126.110
34ace402-966a-4a18-892d-fe7b00694087,C1742865,C0026447,inspected recently published ,TMPRSS2 protein human,Monkeys,1,X,[aapp/enzy],[mamm],x.x.x.x,B01.050.150.900.649.313.988.400
be320c39-3cde-4f6e-9c42-fda740398d55,sabaeus,VRC,are present in VRC,sabaeus,VRC,1,X,????,????,????,????
086a952c-8d25-4d7a-b3ba-bec8725806c9,C0277548,C0086418,is in communities with frequent ,Epidemic disease,Homo sapiens,1,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e2bdb1ea-49c4-4eb0-b03d-54d0cbabe8fe,C0206419,C0033147,is in communities with frequent ,Genus: Coronavirus,Primates,1,X,[virs],[mamm],B04.820.504.540.150,B01.050.150.900.649.313.988
c414dab2-f678-4573-9691-a9b0ddf72bca,C0277548,C0033147,is in communities with frequent ,Epidemic disease,Primates,1,X,[dsyn],[mamm],,B01.050.150.900.649.313.988
ec4a3b1f-2835-4937-835f-119dba9daa86,C0017710,C0024115,are used in treatment of ,Glucocorticoids,Lung diseases,2,X,[horm/orch],[dsyn],D06.472.040.543;D27.505.696.399.472.488,C08.381
41180b15-0330-4c99-afb4-a656485ecdcd,C0744425,C0206419,be considered for patients with ,glucocorticoid therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1a7d9a41-ff73-4dda-b614-18976efd00ed,C1515119,C0206419,be considered for patients with ,systemic therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
2fee363f-38a0-43a5-94ce-caa7a48f7606,C0744425,C0012634,be considered for patients with ,glucocorticoid therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
7da2929b-1f27-48fe-acf6-da6392774f10,C1515119,C0012634,be considered for patients with ,systemic therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
b7cd3bce-7dda-4dd8-9efe-c94d15fecc40,C0319157,C0037090,causes severe ,AS virus,Signs and Symptoms Respiratory,1,X,[virs],[sosy],,C23.888.852
302d4416-9fb3-4b0c-8932-f68e4352220e,C0206419,C0003451,great need for ,Genus: Coronavirus,Antiviral Agents,1,X,[virs],[phsu],B04.820.504.540.150,D27.505.954.122.388
1e241d42-93a9-422b-83dd-7341fdd2d285,C0042210,C0009426,show promise in ,Vaccines,Combat Disorders,1,X,[aapp/imft/phsu],[mobd],D20.215.894,F03.950.750.249
0714bddd-1fe5-4e83-805c-dda52429700a,C1175175,C0042542,is in ,Severe Acute Respiratory Syndrome,Vero Cells,8,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11.251.210.955;A11.436.955
327ddba0-0080-4d84-a07c-1c232fe33b0b,C1175175,C1335332,is in ,Severe Acute Respiratory Syndrome,Papillomavirus Transforming Protein E6,4,X,[dsyn],[aapp/bacs],C02.782.600.550.200.750;C08.730.730,
4e077001-e415-41da-b73d-ec7bccbab58c,COVID19,C0206419,of propagation is ,COVID19,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
d944cfa8-10d8-4efa-8995-3700015ba287,C0006145,C0206419,thin-section CT of ,Breast Diseases,Genus: Coronavirus,2,X,[dsyn],[virs],C17.800.090,B04.820.504.540.150
7d0994b5-4280-46a5-a02a-c4a4c03fd9e7,COVID-19,C0003018,Peptidyl-Dipeptidase A,COVID-19,Angiotensins,1,X,[virs],[aapp/bacs/phsu],C000657245,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
5ef03741-2392-4a64-a858-4d8461d18e3c,C0042776,C0003018,Peptidyl-Dipeptidase A,Virus,Angiotensins,1,X,[virs],[aapp/bacs/phsu],B04,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
825795fb-78b1-4973-8380-f2437a4fac94,COVID-19,C0751956,had significant independent association with ,COVID-19,Acute Cerebrovascular Accidents,2,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
825795fb-78b1-4973-8380-f2437a4fac94,COVID-19,C0751956,is significantly associated with imaging confirmation of ,COVID-19,Acute Cerebrovascular Accidents,2,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
cce74350-4881-4357-8995-b57d242eefdf,C0009450,C0751956,had significant independent association with ,Communicable Diseases,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
cce74350-4881-4357-8995-b57d242eefdf,C0009450,C0751956,is significantly associated with imaging confirmation of ,Communicable Diseases,Acute Cerebrovascular Accidents,2,X,[dsyn],[dsyn],C01.539.221,C10.228.140.300.775;C14.907.253.855
1fd2a643-3477-4eb4-8af3-fea1e9a694ab,C0333557,COVID-19,is in ,Watershed infarct,COVID-19,1,X,[patf],[virs],,C000657245
2900c9aa-1918-4b1e-a661-daf1fe44f70d,C1292533,C0206750,were obtained during emergent ,Tissue specimen,Coronavirus Infections,2,X,[tisu],[dsyn],,C02.782.600.550.200
88164b49-cb97-4998-b1c0-aa6d75be387c,C1510711,C0206750,is in four patients with ,Abdominal Surgical Procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
fcb1ce95-2905-4d3c-9e0d-d6d28a8884b7,C0042776,C1267213,is disease transmission through directly or,Virus,Upper aerodigestive tract,1,X,[virs],[bpoc],B04,
5a727af4-85a6-4899-b630-3fb16357d41c,C0220641,COVID-19,require attention during ,Lip and Oral Cavity Carcinoma,COVID-19,1,X,[neop],[virs],,C000657245
62bcd889-da1c-4b32-8980-db1862f21f17,COVID-19,C0027651,is in oral ,COVID-19,Neoplasms,1,X,[virs],[neop],C000657245,C04
4eb24a6f-8f03-463b-8ae0-9cfaa0fd9e42,C0232741,C0341439,is in patients with ,Liver function,Chronic liver disease,2,X,[ortf],[dsyn],,
a53a450a-7677-44cc-a49d-8ad85d715e53,COVID-19,C0524909,is with ,COVID-19,Hepatitis B Chronic,4,X,[virs],[dsyn],C000657245,C02.256.430.400.100;C02.440.435.100;C06.552.380.350.100;C06.552.380.705.437.100
52046e2c-c255-4cdf-a6fa-613392f704a3,COVID-19,C1825598,is having significant ,COVID-19,IMPACT gene,2,X,[virs],[gngm],C000657245,
52046e2c-c255-4cdf-a6fa-613392f704a3,COVID-19,C1825598,has demonstrated ,COVID-19,IMPACT gene,1,X,[virs],[gngm],C000657245,
32cbbc09-6248-4350-9a49-2524ee7c9039,COVID-19,C0700431,is having significant ,COVID-19,Cardiac rehabilitation,1,X,[virs],[topp],C000657245,E02.760.169.063.500.185;E02.831.185;H02.403.680.600.250;N02.421.784.244
e5ab2ef8-6aac-4ff0-a91d-b170d564a697,C0206750,C0040038,is known associated with risk of ,Coronavirus Infections,Thromboembolism,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.590
e5ab2ef8-6aac-4ff0-a91d-b170d564a697,C0206750,C0040038,be associated with heightened risk of ,Coronavirus Infections,Thromboembolism,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.590
34df1222-dde5-489e-9472-ea1907b1da5f,C0598197,C3826426,understand ,contagion,Dynamics,4,X,[npop],[npop],,
5a5c7e7a-dbeb-4c80-9486-141a9b825a79,C0598197,C0012634,understand ,contagion,Disease,4,X,[npop],[dsyn],,C23.550.288
eb63987e-389b-49b2-ab6c-af8486ebe5b5,C1457887,C0015672,were ,Symptoms,Fatigue,10,X,[sosy],[sosy],,C23.888.369
8eb2061c-2156-433e-8b7f-6320496c20c8,C1457887,C0850149,were ,Symptoms,Dry cough,5,X,[sosy],[sosy],,
5f383329-724e-41e9-b394-3ec6837eac20,C1457887,C0031350,can can complicated with ,Symptoms,Pharyngitis,3,X,[sosy],[dsyn],,C07.550.781;C08.730.561;C09.775.649
9d2fd44d-65aa-4b0b-ad4f-47155b257e4b,C0231918,C1260880, includes stuffy ,Nose symptoms,Rhinorrhea,1,X,[sosy],[sosy],,
60d9c056-037a-43a3-8007-74f9184bfd5d,C0231918,C0011991, includes stuffy ,Nose symptoms,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
f8f9415b-324e-422a-aa17-7b7c91e42729,C0206061,C3489532, includes fibrous ,Pneumonia Interstitial,Cone-Rod Dystrophy 2,2,X,[dsyn],[dsyn],C08.381.483,C11.270.152;C11.768.585.658.250;C16.320.290.152
de77f49f-fea4-416d-90c0-c860a5c51655,posedan,C3714514,is with more eight million ,posedan,Infection,1,X,????,[patf],????,C01.539
48ffc50c-e934-448e-9c14-3030b678940a,C0086418,C0043031,is with history of atrial fibrillation on ,Homo sapiens,Warfarin,1,X,[humn],[hops/orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D03.383.663.283.446.520.914;D03.633.100.150.446.520.914
29650278-7942-46a3-bb4b-923ea39218d5,C1145670,C1265800,is with ,Respiratory Failure,Multiple emboli,2,X,[dsyn],[patf],C08.618.846,
29424aba-adc9-40be-87d8-da2b74e4aa76,C1145670,C0024109,is with ,Respiratory Failure,Lung,1,X,[dsyn],[bpoc],C08.618.846,A04.411
488a9b92-241b-4237-ad3b-67cdde8968ec,C0199470,C0038317,was started on ,Mechanical ventilation,Steroids,1,X,[topp],[orch/phsu],,D04.210.500
6e7b9cb5-95b3-46ea-987c-91b89590a305,C0013404,C0037088,were most frequent ,Dyspnea,Signs and Symptoms,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C23.888
6784df24-b40d-4b78-9c81-5308290f36d4,C0015967,C0037088,were most frequent ,Fever,Signs and Symptoms,1,X,[sosy],[sosy],C23.888.119.344,C23.888
58282a3f-fba2-42b2-af9c-d6202c9e0d59,C0010200,C0037088,were most frequent ,Coughing,Signs and Symptoms,1,X,[sosy],[sosy],C08.618.248;C23.888.852.293,C23.888
d5d14dee-6f0c-442a-ad8e-f6d0396e966a,C0020517,C1705178,is in ,Hypersensitivity,Order (action),1,X,[patf],[acty],C20.543,
7ba7c5b7-9bdc-475d-8e52-d3da2645f34e,C0020517,C1457887,considering diversity of ,Hypersensitivity,Symptoms,1,X,[patf],[sosy],C20.543,
7ba7c5b7-9bdc-475d-8e52-d3da2645f34e,C0020517,C1457887,improved in patients with longer existing ,Hypersensitivity,Symptoms,2,X,[patf],[sosy],C20.543,
fc8b490b-9b18-493d-bd22-21cbd0472203,C1880355,C0206419,is in ,Discover,Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
0217e0d3-6a61-49aa-b4cb-c87012d25311,C0035253,C0206419,have have hit during crisis due ,Rest,Genus: Coronavirus,1,X,[dora],[virs],I03.450.769.647,B04.820.504.540.150
cd58d030-a569-4337-8b76-53a63d32a13e,C0242781,C0319157,is easy in context of contagious ,disease transmission,AS virus,1,X,[patf],[virs],N06.850.310,
576b19f2-05b8-42ac-914c-c17954a0d098,C0206419,C0034991,is essential for their ,Genus: Coronavirus,Rehabilitation therapy,2,X,[virs],[topp],B04.820.504.540.150,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
11016977-87f4-46c3-83e3-6536b57f340a,C1158478,C1999230,was effective in ,DNA Integration,Providing (action),2,X,[genf],[acty],,
c4e9581f-11b3-4021-bda2-19388bc47058,C0206419,C0004364,is with ,Genus: Coronavirus,Autoimmune Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C20.111
365d7467-a116-489e-ad1f-46e100e3dfd6,C0221102,C0206419,is in ,Excretory function,Genus: Coronavirus,1,X,[phsf],[virs],,B04.820.504.540.150
a4926333-f6db-4d15-b1de-50ec413a5649,C0019010,C0206419,extracorporeal Excretory function in,Hemodynamics,Genus: Coronavirus,1,X,[ortf],[virs],G09.330.380,B04.820.504.540.150
aef5eb21-7282-4565-9073-18a5f85056ad,C1175743,C0006560,for test is mg/l,SARS coronavirus,C-reactive protein,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
8b9d5e6b-e3f1-4c67-972a-8f314480eaad,C1175743,mg/l,for test is mg/l,SARS coronavirus,mg/l,1,X,[virs],????,B04.820.504.540.150.113.937,????
67cbb84e-c079-4a61-93ae-782c9b29ba08,C0318793,C4035700,tested health systems for particularly ,Zika Virus,Maternal-Child Health,2,X,[virs],[bmod],B04.820.250.350.995,
030b011b-6122-4d74-9915-76ff63506417,C0700271,C1175743,development for ,M Protein multiple myeloma,SARS coronavirus,4,X,[aapp/imft],[virs],x.x.x.x,B04.820.504.540.150.113.937
030b011b-6122-4d74-9915-76ff63506417,C0700271,C1175743,is Homologous Protein of,M Protein multiple myeloma,SARS coronavirus,1,X,[aapp/imft],[virs],x.x.x.x,B04.820.504.540.150.113.937
1eb6fb69-ed5e-4537-a3e3-d2941299384c,C0038164,C1175743,development for ,Staphylococcal Protein A,SARS coronavirus,4,X,[aapp/imft/irda],[virs],D12.776.097.820;D23.050.161.821,B04.820.504.540.150.113.937
65b16595-5f3e-434c-a285-67d15d5a4c93,C1273412,C1947933,is in than standard ,Chinese herbal medicine,care activity,1,X,[topp],[acty],,
3f069195-3e91-478d-a820-c28eb85f0dfa,C1433062,C1268456,Viral Components of,3C-like protease SARS coronavirus,Viral Components,3,X,[aapp/enzy],[celc],x.x.x.x,A21
6741415d-a6d8-435a-8b4d-37608c421c0f,C1433062,C0598312,Viral Components of,3C-like protease SARS coronavirus,DNA Replication,3,X,[aapp/enzy],[genf],x.x.x.x,G02.111.225;G05.226
832921e6-4ca2-4084-a5c7-0e22c8492b2c,C1433062,C0206419,is considered as prime target for anti ,3C-like protease SARS coronavirus,Genus: Coronavirus,1,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150
4c06d8ba-2db6-4911-bd08-207b774930e5,C1433062,C0872152,is considered as prime target for anti ,3C-like protease SARS coronavirus,Drug Development,3,X,[aapp/enzy],[bmod],x.x.x.x,E05.290;H01.158.703.007.338;H01.181.466.338
f98c8f8f-7a2c-48b8-ae47-1a3233ff1682,C0071649,C1621837,exhibit good ,polyphenols,protease binding,3,X,[orch/phsu],[moft],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
97246911-4aee-4056-8b05-a370488132e7,C0071649,C1510827,exhibit good ,polyphenols,Affinity,3,X,[orch/phsu],[npop],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
af3dbc8c-b800-4c54-9134-222d56bc4124,C0071649,C0013227,possess favorable ,polyphenols,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,D26
6494e227-1efa-4b1c-966a-ad1cd2bfcf79,C0071649,C3469597,are promising ,polyphenols,Administration of medication,4,X,[orch/phsu],[topp],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
e41ed562-b340-4207-b36b-92f04f7b7f2e,C0071649,C0206419,are promising ,polyphenols,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,B04.820.504.540.150
99bf3e7b-1c24-4488-8c47-9da6420dc9be,C0071649,C0243077,can Altogether can used as potential ,polyphenols,inhibitors,3,X,[orch/phsu],[chvf],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
af28474a-dce2-46a7-94f0-534912dc6cc5,C0071649,C1433062,can Altogether can used as potential ,polyphenols,3C-like protease SARS coronavirus,3,X,[orch/phsu],[aapp/enzy],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,x.x.x.x
ea5f5a66-e6df-4ceb-a2b0-d42ddf766824,C0230425,C0242781,has raised possibility of ,Structure of right thigh,disease transmission,1,X,[bpoc],[patf],,N06.850.310
ff95689f-6ed1-4f3e-91cc-d9ad4e0ef3f6,C0032521,C0242781,has raised possibility of ,Polymers,disease transmission,1,X,[bodm/chvs],[patf],D05.750;D25.720;J01.637.051.720,N06.850.310
703cb942-c439-4ee3-b6b1-9f2150a41906,C0230425,C0015733,is in ,Structure of right thigh,Feces,1,X,[bpoc],[bdsu],,A12.459
a755b04d-8da7-4f47-84fc-f3d5e9093ff3,C0032521,C0015733,is in ,Polymers,Feces,1,X,[bodm/chvs],[bdsu],D05.750;D25.720;J01.637.051.720,A12.459
2b54e2e9-80ba-4460-a7ae-7c0a4f1f39bf,C0599779,C2936609,demonstrate strong anti-inflammatory effects of ,Animal Model,Phosphodiesterase 4 Inhibitors,2,X,[anim],[phsu],E05.598,D27.505.519.389.735.374
95ef7640-4586-4734-b233-3de076303472,C2936609,C0206419,is in ,Phosphodiesterase 4 Inhibitors,Genus: Coronavirus,2,X,[phsu],[virs],D27.505.519.389.735.374,B04.820.504.540.150
0ddf496c-91fa-4ba3-8bd7-4b3649d4fd2a,C2936609,C0242634,is in ,Phosphodiesterase 4 Inhibitors,Primate Diseases,2,X,[phsu],[dsyn],D27.505.519.389.735.374,C22.735
3eb41c37-9993-42c3-9faf-2d50706b31b7,C1704259,C0242634,is in ,Biochemical Pathway,Primate Diseases,2,X,[moft],[dsyn],,C22.735
8c4a9b92-5796-4164-8e21-40971befbe86,C0003451,C0038952,may pose risk to patient ,Antiviral Agents,Continuance of life,1,X,[phsu],[acty],D27.505.954.122.388,I03.784
5b1837f8-ab3f-4212-9a19-8e1cda513727,C0301872,C0038952,may pose risk to patient ,Immune response,Continuance of life,1,X,[ortf],[acty],,I03.784
7fb5ec03-d760-4f04-b70c-30194a9d8543,C0003451,C0021368,may pose risk to patient ,Antiviral Agents,Inflammation,1,X,[phsu],[patf],D27.505.954.122.388,C23.550.470
fc11dcab-a68c-4aba-9954-9aae3d35e750,C0301872,C0021368,may pose risk to patient ,Immune response,Inflammation,1,X,[ortf],[patf],,C23.550.470
cb4afc75-cadb-4708-816d-e371b6457d28,C0003451,C2936609,may pose risk to patient ,Antiviral Agents,Phosphodiesterase 4 Inhibitors,1,X,[phsu],[phsu],D27.505.954.122.388,D27.505.519.389.735.374
150ddcf2-9bca-403b-bd5a-6e6026fedfed,C0301872,C2936609,may pose risk to patient ,Immune response,Phosphodiesterase 4 Inhibitors,1,X,[ortf],[phsu],,D27.505.519.389.735.374
7f65da22-c64a-4466-8c7f-0074d0db9eed,C0301872,C0206419,is in older patients with ,Immune response,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
f34594db-ba06-45a9-9a90-f34a05eaca56,C0301872,C0003451,may pose risk with especially ,Immune response,Antiviral Agents,1,X,[ortf],[phsu],,D27.505.954.122.388
198933b6-a7b8-4f8d-9f1a-da09a8480ce5,C0021368,C2936609,is with ,Inflammation,Phosphodiesterase 4 Inhibitors,1,X,[patf],[phsu],C23.550.470,D27.505.519.389.735.374
fd3f00c6-9b73-4bb3-be88-cb6bfdc7383e,C0041625,C0003451,has well-known ,Ultraviolet Rays,Antiviral Agents,1,X,[npop],[phsu],G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600,D27.505.954.122.388
f4918709-4e42-4394-8b0c-1944cb698635,C0206419,C0041625,is with ,Genus: Coronavirus,Ultraviolet Rays,3,X,[virs],[npop],B04.820.504.540.150,G01.358.500.505.650.891;G01.590.540.891;G01.750.250.650.891;G01.750.750.659;G01.750.770.578.891;G16.500.275.063.725.525.600;G16.500.750.775.525.600;N06.230.300.100.725.525.600
96975fcb-7057-48ad-852b-55b1932402c6,C0206419,C2169144,determine ,Genus: Coronavirus,Radiation dose,1,X,[virs],[topp],B04.820.504.540.150,
be268f48-b342-4952-97c3-367be7ba517a,C0206419,C0319157,determine ,Genus: Coronavirus,AS virus,1,X,[virs],[virs],B04.820.504.540.150,
129419da-9cb0-4297-a9c7-33dedbc95bc4,C0206419,C0035668,have similar ,Genus: Coronavirus,RNA,1,X,[virs],[nnon],B04.820.504.540.150,D13.444.735
129419da-9cb0-4297-a9c7-33dedbc95bc4,C0206419,C0035668,are large family of respiratory ,Genus: Coronavirus,RNA,3,X,[virs],[nnon],B04.820.504.540.150,D13.444.735
7cd53eb0-67ef-47f3-862a-ddaae0b3f09c,C0206419,C0020517,seems ,Genus: Coronavirus,Hypersensitivity,4,X,[virs],[patf],B04.820.504.540.150,C20.543
5de189ef-ca0c-4657-9873-deae768499b6,C0035204,C0206419,caused by novel ,Respiration Disorders,Genus: Coronavirus,2,X,[dsyn],[virs],C08.618,B04.820.504.540.150
da780268-3743-419e-91fa-5ae7ff3a4237,C0042210,C1824356,prevent person from ,Vaccines,KIAA1551 gene,1,X,[aapp/imft/phsu],[gngm],D20.215.894,
900efc68-8b29-4386-b55f-c88f0aca0d54,C0596957,C0040300,predict macrocyclic ,Molecular Dynamics,Body tissue,2,X,[moft],[tisu],E05.599.595.500;G02.111.570.895;L01.224.160.500,A10
90ef2737-f18a-4c5e-a7f6-5c7731124f5c,C0596957,C0015505,predict macrocyclic ,Molecular Dynamics,Factor VIIa,4,X,[moft],[aapp/enzy/phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.300.760.300;D08.811.277.656.959.350.300;D12.776.124.125.325.300;D23.119.325.300
059a7576-8063-4733-8ec0-830e790b8481,C0596957,C0030946,predict macrocyclic ,Molecular Dynamics,Endopeptidases,1,X,[moft],[aapp/enzy/phsu],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.300
417fb25e-b071-4981-97ab-10a516c4468a,C4048299,C0005778,prevent ,Tissue Factor,Blood coagulation,4,X,[aapp/imft],[ortf],D12.776.124.125.900;D23.119.965,G09.188.390.150
9517ade7-6738-4ef0-8f16-afd7b5f2f135,C0243077,C0005778,prevent ,inhibitors,Blood coagulation,4,X,[chvf],[ortf],,G09.188.390.150
6327404a-551c-4425-9055-be73f5b408f2,C0243077,C0003451,have ,inhibitors,Antiviral Agents,1,X,[chvf],[phsu],,D27.505.954.122.388
0d85cd34-bf94-4b5c-b76a-e821c2e7a729,C0243077,C1510827,also have high ,inhibitors,Affinity,2,X,[chvf],[npop],,
508c26ae-b284-433e-9585-35bdc2aa9828,C0243077,C0030946,also have high ,inhibitors,Endopeptidases,2,X,[chvf],[aapp/enzy/phsu],,D08.811.277.656.300
508c26ae-b284-433e-9585-35bdc2aa9828,C0243077,C0030946,Furthermore interact with dyad ,inhibitors,Endopeptidases,2,X,[chvf],[aapp/enzy/phsu],,D08.811.277.656.300
ddf4adc5-b5a2-4243-9fea-fadb3fd93ea4,C0243077,dyad,Furthermore interact with dyad ,inhibitors,dyad,2,X,[chvf],????,,????
14445f2c-36fc-4b38-9348-4d702469368e,dyad,C0206419,is in active site of ,dyad,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
c2b00139-2798-4afd-853e-36405c8005d3,dyad,C0030946,is in active site of ,dyad,Endopeptidases,2,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
848f9c17-1ff2-4bf0-b2bc-752039243ad8,C0030946,C0042774,is important in ,Endopeptidases,Virus Replication,2,X,[aapp/enzy/phsu],[celf],D08.811.277.656.300,G06.920.925
f12855c9-e7d6-48b9-9dd7-11759282a2f2,C0086168,C0033607,are found very similar to experimental ,Dissociation,Protease Inhibitors,2,X,[mobd],[phsu],F03.300,D27.505.519.389.745
3ceaf978-bfc7-46e2-8b91-4831aac40568,C0034019,C0242781,curtail ,public health medicine (field),disease transmission,2,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,N06.850.310
3ceaf978-bfc7-46e2-8b91-4831aac40568,C0034019,C0242781,significantly reduced ,public health medicine (field),disease transmission,1,X,[bmod],[patf],H02.403.720;N01.400.550;N06.850,N06.850.310
98e5ff07-64cf-4b0b-87c0-bbdf8f609eb2,C0020517,C0699680,were test ,Hypersensitivity,Metric,1,X,[patf],[orch/phsu],C20.543,D02.640.672.500;D03.383.129.308.658.500
12d90a64-aff5-4bab-99da-a6e3bb41a2eb,C0012634,C0039082,is caused by ,Disease,Syndrome,4,X,[dsyn],[dsyn],C23.550.288,C23.550.288.500
7136ca7b-2f9c-4db9-9101-20d2e1082b86,1a,C0032105,anti- effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
7136ca7b-2f9c-4db9-9101-20d2e1082b86,1a,C0032105,anti- effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
7136ca7b-2f9c-4db9-9101-20d2e1082b86,1a,C0032105,anti- effects of convalescent,1a,Plasma,1,X,????,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693
22f7ef15-653c-4560-a006-d61268a797eb,C0206750,C0040802,leading to widespread ,Coronavirus Infections,travel,7,X,[dsyn],[dora],C02.782.600.550.200,I03.883
5024fd50-3820-43fc-8f83-45c7c0e99163,C0683325,C0206750,were analyzed in relation to severity of ,clinical aspects,Coronavirus Infections,7,X,[clna],[dsyn],,C02.782.600.550.200
497acd4d-b019-4223-a827-9f9f6cc95b9c,C0013404,C0012634,was only ,Dyspnea,Disease,14,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C23.550.288
a807d8ab-74a0-403e-bab4-3a3ef94a745e,C0035473,C0039082,are typically explained in case of ,Rhinovirus,Syndrome,2,X,[virs],[dsyn],B04.820.565.775,C23.550.288.500
869a228f-7ddf-4626-9575-69fe6149f1cc,C0029341,C0039082,are typically explained in case of ,Orthomyxoviridae,Syndrome,2,X,[virs],[dsyn],B04.820.545,C23.550.288.500
07963cc7-eafe-47ea-9476-1bd6cf6469b4,C0302507,C0039082,are typically explained in case of ,Parainfluenza Virus Infections,Syndrome,2,X,[dsyn],[dsyn],C02.782.580.600,C23.550.288.500
c368d362-3c4f-4a3d-a983-24291a527c44,C0035473,C0026727,are typically explained by nasal obstruction with ,Rhinovirus,Mucous body substance,9,X,[virs],[bdsu],B04.820.565.775,A12.200.503
3403f43f-f2bf-46d6-a020-3cf88387a3ab,C0029341,C0026727,are typically explained by nasal obstruction with ,Orthomyxoviridae,Mucous body substance,9,X,[virs],[bdsu],B04.820.545,A12.200.503
bec82e0a-fc1f-43ae-8c9f-5dfe444a2670,C0302507,C0026727,are typically explained by nasal obstruction with ,Parainfluenza Virus Infections,Mucous body substance,9,X,[dsyn],[bdsu],C02.782.580.600,A12.200.503
cbd074c7-b8a9-42d9-b6ce-9c239f2853fb,C0039082,C1705178,is in ,Syndrome,Order (action),1,X,[dsyn],[acty],C23.550.288.500,
96c75195-1552-4b93-9ba3-a159b3083f69,C0036563,C0441655,restarting endoscopic ,Plant seeds,Activities,1,X,[plnt],[acty],A18.024.500.750;G07.203.300.775;J02.500.775,
0c87971b-a400-4668-81a2-f5592191037a,C1550100,C0806140,using four point-of-care ,Specimen Type - Serum,Flow,1,X,[bdsu],[npop],,
0c87971b-a400-4668-81a2-f5592191037a,C1550100,C0806140,using four lateral ,Specimen Type - Serum,Flow,1,X,[bdsu],[npop],,
5abccaf4-6a8b-455d-ab9d-56024533577b,C1550100,C0003261,tested for ,Specimen Type - Serum,Antibody Formation,2,X,[bdsu],[biof],,G12.070
b96a46d7-f1bc-43c0-aa3d-24224ea15498,POC,LFIA,based on LFIA,POC,LFIA,2,X,????,????,????,????
23bdae35-7f1d-439d-bf86-e6d2da658984,C0003241,LFIA,based on LFIA,Antibodies,LFIA,2,X,[aapp/imft/phsu],????,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,????
b59fcdee-3522-4e4a-a0e1-53ad0a72b2c1,POC,C0039082,showed performance in detection of ,POC,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
51193f91-5105-4c99-a463-ecbca138db46,C0003241,C0039082,showed performance in detection of ,Antibodies,Syndrome,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114,C23.550.288.500
3f9e939c-6048-40ce-b901-e50413e21c36,C0206750,C0003242,exhibited earlier ,Coronavirus Infections,Antibodies Anti-Idiotypic,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
0e1147db-2b05-494f-86ad-4143ec66fdf3,C1999230,C0302148,is in field of ,Providing (action),Blood Clot,4,X,[acty],[patf],,C14.907.355.830
0e2b8086-793f-4cea-bad1-9e8c6b4465b0,C0005779,C0596448,includes exceptionally high levels of D ,Blood Coagulation Disorders,dimer,5,X,[dsyn],[chvs],C15.378.100,
71f4e44f-9330-4c85-87e6-e9ce739deb32,C0060323,C0005516,were related with ,Fibrin fragment D,Biological Markers,9,X,[aapp/bacs],[clna],x.x.x.x,D23.101
73bf7974-df81-469e-aca4-3c63e9e57e1a,C0040044,C0012634,might offer hope for patients with ,Thrombolytic Therapy,Disease,5,X,[topp],[dsyn],E02.319.913,C23.550.288
ebd38b2b-9104-4573-8585-d14ef840e332,C0016016,C0206750,can where can deleterious in ,Plasmin,Coronavirus Infections,4,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.330;D08.811.277.656.959.350.330,C02.782.600.550.200
402414fb-4c9b-4096-9b22-24daf68a2944,C0220781,C0206750,can where can deleterious in ,Anabolism,Coronavirus Infections,1,X,[biof],[dsyn],G03,C02.782.600.550.200
d9930dcc-afcc-4808-a1b3-bb0161a05ce9,C0012634,C0524850,is in department of ,Disease,Neurosurgical Procedures,1,X,[dsyn],[topp],C23.550.288,E04.525
d1930db7-d713-4bdd-a577-78ded6cc6f4b,C0087111,C1705178,is in ,Therapeutic procedure,Order (action),2,X,[topp],[acty],E02,
e97fdee7-a41d-429d-bb85-7d19e7bee86b,C0206750,C0017181,is with ,Coronavirus Infections,Gastrointestinal Hemorrhage,3,X,[dsyn],[patf],C02.782.600.550.200,C06.405.227;C23.550.414.788
abba40ae-d95e-4fca-8915-a020ee055224,C1175175,C1880022,was ,Severe Acute Respiratory Syndrome,Characterization,1,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
28e4e861-0fd1-4499-92cc-f4a2e5eeb2a0,C1175175,C0206061,was ,Severe Acute Respiratory Syndrome,Pneumonia Interstitial,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381.483
dfa8f0af-4c1e-4e78-ae49-19ac76d5f303,C2349975,humoral,Comparing humoral ,Enhance (action),humoral,1,X,[acty],????,,????
1cb4359f-67d1-4b64-837c-7eeae348764e,C0282682,humoral,Comparing humoral ,Antibodies Blocking,humoral,1,X,[aapp/imft/irda],????,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,????
2251fa52-eeff-4c71-8a0a-f0b963d85207,COVID-19,C0013404,share Xyzinclude1 in ,COVID-19,Dyspnea,1,X,[virs],[sosy],C000657245,C08.618.326;C23.888.852.371
2251fa52-eeff-4c71-8a0a-f0b963d85207,COVID-19,C0013404,share similar fever ,COVID-19,Dyspnea,1,X,[virs],[sosy],C000657245,C08.618.326;C23.888.852.371
2e9e58ff-ae69-412c-81b2-df338e826261,COVID-19,C0010200,share similar fever ,COVID-19,Coughing,1,X,[virs],[sosy],C000657245,C08.618.248;C23.888.852.293
afeff278-7d79-4e79-bb90-be3c0cc947ff,C0026056,C0011744,of AUC is ,Midazolam,Deuterium,2,X,[orch/phsu],[elii],D03.633.100.079.080.575,D01.268.406.500;D01.362.340.500;D01.496.289;x.x.x.x
027d2de9-7451-4804-ba07-6f1ab1e7de44,C0185112,C0087111,is in worldwide race towards ,Therapeutic Mobilization,Therapeutic procedure,1,X,[topp],[topp],,E02
1f11ce70-2244-46a1-9a04-1cbc10693ffe,C0037633,C0242781,reduce further ,Solutions,disease transmission,1,X,[sbst],[patf],D26.776,N06.850.310
10cfa6a9-f190-4f83-bb6d-2424bc1576f0,C0037633,C0086418,reduce ,Solutions,Homo sapiens,1,X,[sbst],[humn],D26.776,B01.050.150.900.649.313.988.400.112.400.400
f681e19d-08e7-493a-88db-4ec801ba621d,C3463820,C2931926,is with ,Inhibition,ruxolitinib,2,X,[acty],[orch/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,
e1fa9a95-d6d1-4acb-b683-3fa94d7abf1a,C2931926,C0079189,reduce ,ruxolitinib,cytokine,2,X,[orch/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
ec9a1daf-bf71-4f5d-8418-43f97ddbe2e6,COVID-19,C1175175,is caused by ,COVID-19,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],C000657245,C02.782.600.550.200.750;C08.730.730
a1005b16-e9aa-4b0f-aebb-e098b4226529,COVID-19,C3272452,is caused by ,COVID-19,Single-Stranded RNA,1,X,[virs],[nnon],C000657245,
5793f9ff-b0cd-46c1-8e6c-85d5066b01a8,COVID-19,C0017428,is caused by ,COVID-19,Genome,1,X,[virs],[gngm],C000657245,G05.360.340
3b3c8ba7-368a-4db1-8ea1-5cc6f4cc2f2f,C0042736,C0034800,interact with ,Viral Proteins,Receptors Cell Surface,3,X,[aapp/bacs],[aapp/rcpt],D12.776.964,D12.776.543.750
3fd52263-ed86-4dfb-b6e0-6e3f83a25e5f,C0023688,C0034800,interact with ,Ligands,Receptors Cell Surface,3,X,[chem],[aapp/rcpt],D27.720.470.480,D12.776.543.750
12f5e931-faa5-40eb-aa03-b9fd1cbc1323,C0042736,C0042776,interact with ,Viral Proteins,Virus,2,X,[aapp/bacs],[virs],D12.776.964,B04
2ada4338-30e7-4e78-ac40-cb8284a449a3,C0023688,C0042776,interact with ,Ligands,Virus,2,X,[chem],[virs],D27.720.470.480,B04
2d622831-4f01-4329-b42e-84c7ca2a8332,C0024109,C0038952,affect ,Lung,Continuance of life,3,X,[bpoc],[acty],A04.411,I03.784
bb4f0553-fb4e-4d19-b859-42c8e86a0065,C1167395,C0038952,affect ,Host (organism),Continuance of life,3,X,[orgm],[acty],,I03.784
79581e51-c0ef-4ef1-a6af-036637b82631,C0022942,C0678695,is ,Lactoferrin,Nutrients,3,X,[aapp/bacs],[food],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,D27.505.696.377.683;G07.203.300.681;J02.500.681
7ca14a5d-380b-4bc7-bca9-7ca6d803f0f2,C0022942,C0026131,is ,Lactoferrin,Milk (body substance),3,X,[aapp/bacs],[bdsu],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,A12.200.455;G07.203.100.700;G07.203.300.350.525;J02.200.700;J02.500.350.525
584e0851-a7c5-41ad-a958-c4dc86d42f6a,C1175743,C0441655,Heparan Sulfate Proteoglycans based on other,SARS coronavirus,Activities,3,X,[virs],[acty],B04.820.504.540.150.113.937,
0374d8c5-a078-4021-b9d8-fa54faafdd62,C1175743,C0022942,Heparan Sulfate Proteoglycans based on other,SARS coronavirus,Lactoferrin,3,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
4d424458-3c99-425f-93a7-f644a325a122,C0062503,C1819995,prevent SARS coronavirus attaching to,Heparan Sulfate Proteoglycans,Host Cell,4,X,[aapp/bacs],[celc],D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350,
7521d96b-7c88-4009-8c22-09991ae22673,C1167395,C1175743,prevent ,Host (organism),SARS coronavirus,6,X,[orgm],[virs],,B04.820.504.540.150.113.937
7521d96b-7c88-4009-8c22-09991ae22673,C1167395,C1175743,utilizing publicly available high throughput ,Host (organism),SARS coronavirus,2,X,[orgm],[virs],,B04.820.504.540.150.113.937
c062d4d0-a063-41d7-95cf-828a2bedb09b,C1167395,C1819995,prevent SARS coronavirus attaching to,Host (organism),Host Cell,5,X,[orgm],[celc],,
afbc2b8e-aa0d-4a43-978e-58bf8b1e18b5,C0597357,C1819995,prevent SARS coronavirus attaching to,receptor,Host Cell,5,X,[aapp/rcpt],[celc],,
9d050085-fd46-4b5e-971d-c25412c9d654,C1167395,C0441655,Heparan Sulfate Proteoglycans based on,Host (organism),Activities,2,X,[orgm],[acty],,
e1fc6fcd-6ce3-4ebc-a7ca-6ea480fb7c9d,C0597357,C0441655,Heparan Sulfate Proteoglycans based on,receptor,Activities,2,X,[aapp/rcpt],[acty],,
71aab41f-6346-40ae-8855-c1601aa57764,C0022709,C0441655,Heparan Sulfate Proteoglycans based on,Peptidyl-Dipeptidase A,Activities,2,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
64b74059-663f-4bb7-a8fb-32394d938b34,C1167395,C0022942,Heparan Sulfate Proteoglycans based on,Host (organism),Lactoferrin,2,X,[orgm],[aapp/bacs],,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
9d179466-e744-47da-b1fe-7fdd8aed9885,C0597357,C0022942,Heparan Sulfate Proteoglycans based on,receptor,Lactoferrin,2,X,[aapp/rcpt],[aapp/bacs],,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
7e18d26c-3c23-4430-9b7a-da6cc9e227e9,C0022709,C0022942,Heparan Sulfate Proteoglycans based on,Peptidyl-Dipeptidase A,Lactoferrin,2,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249
f3f28057-7aba-486e-bb80-1668137c0e4d,C0062503,C1175743,prevent ,Heparan Sulfate Proteoglycans,SARS coronavirus,6,X,[aapp/bacs],[virs],D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350,B04.820.504.540.150.113.937
2b61307a-6edf-4418-9b22-ad589c025fa1,C0022942,COVID-19,may of ,Lactoferrin,COVID-19,2,X,[aapp/bacs],[virs],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,C000657245
e00412aa-7b46-4e92-b1b6-8fc760ad97d5,C0151942,CAC,are more frequent in CAC,Arterial thrombosis,CAC,1,X,[patf],????,,????
accf44a0-6d71-4cc7-90d2-5518ae34df95,C1861172,CAC,are more frequent in CAC,Venous Thromboembolism,CAC,2,X,[dsyn],????,C14.907.355.590.700,????
dc29d1b9-670c-4ed2-8e0a-507010660a76,C0151942,C0005779,are frequent compared to ,Arterial thrombosis,Blood Coagulation Disorders,1,X,[patf],[dsyn],,C15.378.100
7fa9cfee-08f6-4f28-a7da-4e705587db5e,C0151942,C0012739,are frequent compared to ,Arterial thrombosis,Disseminated Intravascular Coagulation,1,X,[patf],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
00512e33-5c2a-431f-ada9-5588137ee396,C1861172,C0005779,are frequent compared to ,Venous Thromboembolism,Blood Coagulation Disorders,1,X,[dsyn],[dsyn],C14.907.355.590.700,C15.378.100
fa9293df-563b-4ff4-b755-ac63abdd0897,C1861172,C0012739,are frequent compared to ,Venous Thromboembolism,Disseminated Intravascular Coagulation,1,X,[dsyn],[dsyn],C14.907.355.590.700,C15.378.100.220;C15.378.463.250;C15.378.925.220
e74fe4c1-0743-418c-81df-d2937d4b8475,C0042769,C0011311, includes ,Virus Diseases,Dengue Fever,3,X,[dsyn],[dsyn],C02,C02.081.270;C02.782.350.250.214;C02.782.417.214
bf696177-0e80-4f5c-be00-f79ba5c9cebf,C0206750,C0011311,is with false-positive ,Coronavirus Infections,Dengue Fever,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.081.270;C02.782.350.250.214;C02.782.417.214
908d56fa-321e-4116-8afc-dd525447a9c7,C0206750,C0036745,is with false-positive ,Coronavirus Infections,Study of serum,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.781
2b645b8a-94eb-4c2d-96ab-0d0ba9351982,C0024109,COVID-19,is with ,Lung,COVID-19,4,X,[bpoc],[virs],A04.411,C000657245
097d6e93-cde6-4e7a-9179-7f575bca5551,C0009450,C0034019,has become serious ,Communicable Diseases,public health medicine (field),3,X,[dsyn],[bmod],C01.539.221,H02.403.720;N01.400.550;N06.850
fec23c21-b362-4d68-8a13-f97ca61940a6,C1512523,C3854325,is broad spectrum ,hydrochloride,Janus kinase inhibitor,1,X,[inch/phsu],[phsu],,D27.505.519.389.755.500
bef2c261-9fe7-4f87-8633-9cd3832fec4d,C1512523,C0206750,has great potential for treatment of patients with ,hydrochloride,Coronavirus Infections,2,X,[inch/phsu],[dsyn],,C02.782.600.550.200
3c94e9bf-a1ae-4677-8e95-271c7b6cc751,C1512523,C0012634,has great potential for treatment of patients with ,hydrochloride,Disease,3,X,[inch/phsu],[dsyn],,C23.550.288
09669283-6e0d-4de6-ad0d-069276d241cd,C0441655,C0206750,is in ,Activities,Coronavirus Infections,3,X,[acty],[dsyn],,C02.782.600.550.200
07daa252-c0f0-4ecd-85f8-62f8939c296b,C0699748,C0206750,may behind may ,Pathogenesis,Coronavirus Infections,4,X,[patf],[dsyn],,C02.782.600.550.200
fc58ac77-1033-48c7-ab92-64ba16a0cb81,C2267116,C0206750,is in ,Vascular Alterations,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
b02fe93d-a30e-45b9-b11f-4cd1c48bc343,C0035216,C0007682,is in ,Respiratory Center,CNS disorder,4,X,[bpoc],[dsyn],A08.186.211.132.772.646,C10.228
695423a2-eea7-4cec-91cc-d2edc84dfa85,C0003316,C1114743,outshine Among ,Epitopes,Type:ID:Pt:Vaccine:Nom,6,X,[imft],[clna],D23.050.550,
5eaf587c-c037-486c-a359-661c2dce6f0d,C0599934,C1114743,outshine Among ,Vaccines Peptide,Type:ID:Pt:Vaccine:Nom,6,X,[imft/phsu],[clna],D20.215.894.860,
f1abc660-5661-4025-8246-cf79acf06d99,C0042760,C0599444,were found in ,Virion,Cell body of neuron,1,X,[celc],[celc],A21.249;B04.950,
1c96a468-5cf9-4007-9ac2-6e2471f6aa23,C0042760,C0085103,were found in ,Virion,Neurites,1,X,[celc],[celc],A21.249;B04.950,A08.675.256.500;A08.675.542.145.500;A11.284.180.610;A11.671.501.145.500;A11.671.543
95ca27ee-39ca-4d0f-b57c-ab11e8c2797e,PCR,C0042776,suggesting at least increase in ,PCR,Virus,1,X,????,[virs],????,B04
02c96c8a-6b62-4719-85e6-795ea7a46c1e,PCR,C0042774,corroborated ,PCR,Virus Replication,2,X,????,[celf],????,G06.920.925
f931f1f1-909f-434b-8189-4ef69a93a1f2,C0003504,C0206750,identify ,Aortic Valve Insufficiency,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.280.484.095,C02.782.600.550.200
c7ec3e71-c297-40c9-a409-53d8e160d85e,C1175175,C0349410,causes multiple ,Severe Acute Respiratory Syndrome,Single organ dysfunction,4,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
0d930ca1-d883-4fb7-9090-a769ae4f47d5,C0034019,C0018563,have on other ,public health medicine (field),Hand,2,X,[bmod],[bpoc],H02.403.720;N01.400.550;N06.850,A01.378.800.667
e5653dd9-d550-430d-91f3-56ab9c9924cb,C0242821,C0018563,have on other ,Human body,Hand,2,X,[humn],[bpoc],I01.076.201.450.560;K01.093.378,A01.378.800.667
487df62b-48a3-4cb8-ac0c-a222720b3c07,C0034386,C1705178,is in ,Quarantine,Order (action),1,X,[topp],[acty],N06.850.780.200.450.700,
cbf7338c-4eee-4468-b01d-443ecd7ed9ef,C0037633,C0012634,address mental health issues of patients affected by ,Solutions,Disease,1,X,[sbst],[dsyn],D26.776,C23.550.288
24c71204-4979-4dce-bf57-e2d201651bb6,C0037633,C1882509,have in have ,Solutions,put - instruction imperative,2,X,[sbst],[acty],D26.776,
146bb3e0-97f4-4d53-973b-8d9167ed6df7,C0206750,C2806453,is ,Coronavirus Infections,Betacoronavirus,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540.150.113
b223b141-8e90-4418-a6ea-c4f9c1f4682d,C0206750,C3272275,created ,Coronavirus Infections,Urgent Procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
314a309e-889b-4627-8a7f-2567470441ff,C0683325,C0015967,is in ,clinical aspects,Fever,3,X,[clna],[sosy],,C23.888.119.344
5b57b478-f7f5-4a15-8ba7-1b188c5a1395,C0014507,C0206750,were compared between ,Epidemiology,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
5b57b478-f7f5-4a15-8ba7-1b188c5a1395,C0014507,C0206750,include data on sociodemographic ,Epidemiology,Coronavirus Infections,3,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
5b57b478-f7f5-4a15-8ba7-1b188c5a1395,C0014507,C0206750,include number of recovered ,Epidemiology,Coronavirus Infections,6,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
5b57b478-f7f5-4a15-8ba7-1b188c5a1395,C0014507,C0206750,Considering ,Epidemiology,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200
f1a88d03-3e9e-48f4-bb36-a9efd129f4b8,C1175743,C0015967,is in outpatients from our ,SARS coronavirus,Fever,3,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.119.344
e975b032-00ff-4438-a344-a86c506cecee,C0015967,C0010200,followed by ,Fever,Coughing,4,X,[sosy],[sosy],C23.888.119.344,C08.618.248;C23.888.852.293
e975b032-00ff-4438-a344-a86c506cecee,C0015967,C0010200,42-year-old male patient with ,Fever,Coughing,1,X,[sosy],[sosy],C23.888.119.344,C08.618.248;C23.888.852.293
f8f905df-2a12-47cb-8b94-86ff667a7218,C0015967,C0012634,are probably valuable indicator of ,Fever,Disease,3,X,[sosy],[dsyn],C23.888.119.344,C23.550.288
202fdef2-6cba-4cb6-95b4-520f300797e5,C2948600,C0220781,provide rapid ,Aim,Anabolism,1,X,[inch/phsu],[biof],,G03
c43ebb98-d61c-440c-998b-da90ab680354,C1175743,C0242781,was obtained given rampant community ,SARS coronavirus,disease transmission,4,X,[virs],[patf],B04.820.504.540.150.113.937,N06.850.310
1c2483b5-cfc1-498b-8e46-b51f3e4d53fa,CoV2,C0242781,is ,CoV2,disease transmission,2,X,????,[patf],????,N06.850.310
f08ae10d-59ad-43b8-a2ee-a355cfbdb1e1,C4284286,C0041612,Evacuation procedure through,C2 wt Allele,Ultrafiltration (procedure),2,X,[gngm],[topp],,E04.292.975;E05.196.454.807;G01.280.807;G02.263.807
7cfd506c-bfce-49fe-b60e-ec9f682c6f47,C0441655,C3272275,specific recommendations for most frequent ,Activities,Urgent Procedure,4,X,[acty],[topp],,
9289e012-621b-45a5-b90f-00d348ffa467,C0152097,C0028768, includes ,Disease of diaphragm,Obsessive-Compulsive Disorder,3,X,[dsyn],[mobd],,F03.080.600
439fa514-1834-419d-be92-6ac880a5b7ce,C0034386,C0028768,were significantly associated with more elevated ,Quarantine,Obsessive-Compulsive Disorder,3,X,[topp],[mobd],N06.850.780.200.450.700,F03.080.600
d8ca8b66-4a48-41ce-b01d-01f2c1c7db60,C0034386,C1457887,were significantly associated with more elevated ,Quarantine,Symptoms,3,X,[topp],[sosy],N06.850.780.200.450.700,
77e6de0f-5a27-4ada-b2fc-88dda281de24,C0009450,C0302113,should should considered in elderly patients with ,Communicable Diseases,Fragility,1,X,[dsyn],[comd],C01.539.221,
3cf0c2fb-dfc1-4ebb-885c-ae76afe6f819,C1004593,C1856053,were Search - action up up,Scopus,Hydranencephaly with Renal Aplasia-Dysplasia,3,X,[bird],[dsyn],,x.x.x.x
ed62a42c-a45b-4f62-89ed-e6055713c1a7,C0872147,C1856053,were Search - action up up,DNA Library,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[gngm/nnon],[dsyn],G05.360.325,x.x.x.x
8b4f031d-075c-4bf2-8c91-1a1f448539ae,C0872147,C1706202,were ,DNA Library,Search - action,3,X,[gngm/nnon],[acty],G05.360.325,
45799faf-a457-4a34-81ce-2ffd187ffdce,C1004593,C1706202,were ,Scopus,Search - action,2,X,[bird],[acty],,
ee8cd051-1b78-4f45-9622-1f9fc34c377c,C0024109,C0015982,often reveals ,Lung,Fibrin,3,X,[bpoc],[aapp/bacs/phsu],A04.411,D12.776.124.270
cb90d22f-297b-439b-9ffe-64dcf8cd21dd,C0024109,C0011382,often reveals ,Lung,Dental Occlusion,3,X,[bpoc],[ortf],A04.411,E06.276;G10.549.208
b690ca59-2935-4b17-af97-aacac1af420b,C0024109,C1096458,often reveals ,Lung,Vascular occlusion,2,X,[bpoc],[dsyn],A04.411,
bae59932-09d3-4ec2-bb15-fca29aeb0d63,C0085278,C0398623,is acquired ,Antiphospholipid Syndrome,Thrombophilia,3,X,[dsyn],[dsyn],C20.111.197,C15.378.925
f4e97019-b575-48e8-aa3e-c67eaffe2244,C0021053,C0178784,is in severe multi ,Immune System Diseases,Organ,1,X,[dsyn],[bpoc],C20,
e7e4c496-adcb-44f1-9cec-573d589c0a5c,C0178784,C0024109, includes ,Organ,Lung,1,X,[bpoc],[bpoc],,A04.411
e7e4c496-adcb-44f1-9cec-573d589c0a5c,C0178784,C0024109,may explain ,Organ,Lung,4,X,[bpoc],[bpoc],,A04.411
ce347b57-4723-4d6d-838d-fd83339e44ff,C0023693,C0440744,efficiently kills Pathogenic organism without harm to,Light,Human tissue,3,X,[npop],[tisu],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
c36408b6-adc8-490b-b0cf-17f6e79d9079,C0023693,C0450254,efficiently kills potentially ,Light,Pathogenic organism,3,X,[npop],[orgm],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
5a414fc9-649f-41e2-b801-2f313a0591be,C0312860,C0029341,efficiently kills airborne ,Neutrophil migration function,Orthomyxoviridae,3,X,[celf],[virs],,B04.820.545
54c7488e-08d2-4aa3-87d9-89f68ea44d00,C0023693,C0029341,efficiently kills airborne ,Light,Orthomyxoviridae,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,B04.820.545
3314429c-6bb8-4661-8b22-df54eabbc932,C0206422,genomic,have similar genomic ,Human coronavirus,genomic,1,X,[virs],????,,????
64cccc7f-25c7-4fde-86fa-c93f482416d5,C0206422,C1175743, includes ,Human coronavirus,SARS coronavirus,3,X,[virs],[virs],,B04.820.504.540.150.113.937
e9e33d7e-518b-441e-a39e-1962b7d6314b,C0023693,C0206422,show similar inactivation efficiency against other ,Light,Human coronavirus,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,
5014bfcc-079d-44cc-910c-8492eb107b26,C0023693,C1175743,show similar inactivation efficiency against other ,Light,SARS coronavirus,3,X,[npop],[virs],G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578,B04.820.504.540.150.113.937
52b4df43-c2a5-4264-99bb-b1af889445b7,C0206419,C1861452,are characterized with ,Genus: Coronavirus,Storm Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,x.x.x.x
5d1e5b78-3369-4220-9d40-7bd84b9a178e,C1861452,C0178784,can cause severe damage to ,Storm Syndrome,Organ,4,X,[dsyn],[bpoc],x.x.x.x,
a021e9fb-cb00-44b1-bef1-c58fe6b6abd9,C1861452,C0026766,can cause severe damage to ,Storm Syndrome,Multiple Organ Failure,3,X,[dsyn],[patf],x.x.x.x,C23.550.835.525
d7f11dc5-1ad2-40ca-a735-2bed810a44f1,C0424295,C0206419,is in ,Hyperactive behavior,Genus: Coronavirus,2,X,[mobd],[virs],,B04.820.504.540.150
d9c97032-3d1b-4123-a180-3c10df74ec0d,C1285338,C0206419,is in ,Inflammatory disorder of immune system,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
83bf5e6e-863d-46a7-8db6-613ff3eae377,C0004897,C0042105,is rich in ,Ursidae Family,Ursodiol,4,X,[mamm],[bacs/orch/phsu],B01.050.150.900.649.313.750.250.761,D04.210.500.105.225.272.962;D04.210.500.221.430.342.925
84f69eb5-6315-4ff4-b0bb-f6bbdd5e9be6,C0005388,C0042105,is rich in ,Bile fluid,Ursodiol,4,X,[bdsu],[bacs/orch/phsu],A12.200.087,D04.210.500.105.225.272.962;D04.210.500.221.430.342.925
41d13823-e799-4c70-b652-45c54ae14934,C0042105,C0035139,is logical ,Ursodiol,Surgical Replantation,4,X,[bacs/orch/phsu],[topp],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,E04.936.494
59a26403-71e0-4701-8e92-558d0d245c5e,C0042105,C0004897,is logical and attainable Surgical Replantation for,Ursodiol,Ursidae Family,4,X,[bacs/orch/phsu],[mamm],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,B01.050.150.900.649.313.750.250.761
07ceeb0e-b529-45d4-a28f-bd97ce3a703b,C0042105,C0005388,is logical and attainable Surgical Replantation for,Ursodiol,Bile fluid,4,X,[bacs/orch/phsu],[bdsu],D04.210.500.105.225.272.962;D04.210.500.221.430.342.925,A12.200.087
ead9d5ef-078a-4fe8-91c2-857cecd991de,C0005388,C0009905,is available in ,Bile fluid,Contraceptives Oral,4,X,[bdsu],[phsu],A12.200.087,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
76c09dd1-8364-4f0a-9938-f67dcbf12da1,MAFLD,C0206419,is with ,MAFLD,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
3a89fc1b-53a8-49f5-aac2-5031d1f00e7f,C0206277,C0221423,characteristics of highly ,Fatal Outcome,Illness (finding),3,X,[patf],[sosy],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,
4f1e8bd4-de0a-4d7d-9b3b-207fdbf354ed,C0206419,C0022661,brought challenges to patients with ,Genus: Coronavirus,Kidney Failure Chronic,1,X,[virs],[dsyn],B04.820.504.540.150,C12.777.419.780.750.500;C13.351.968.419.780.750.500
c2cce601-a7c2-4c4b-a2a3-47f750085153,C2720167,COVID-19,is in ,Sirtuin 1,COVID-19,1,X,[aapp/enzy],[virs],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C000657245
7b27ac8f-42e7-4c88-b74b-3651bf8ff92a,C3463820,COVID-19,is in ,Inhibition,COVID-19,3,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,C000657245
86da88b8-70f9-452e-b27f-9edd423f35af,C2720167,C0206419,is in ,Sirtuin 1,Genus: Coronavirus,1,X,[aapp/enzy],[virs],D08.811.277.087.520.200.650.100;D12.776.476.900.100,B04.820.504.540.150
ab66111f-24dd-4ece-b314-cd6b01294beb,C3463820,C0206419,is in ,Inhibition,Genus: Coronavirus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,B04.820.504.540.150
4063daf0-7f16-4e34-a5cc-b815f3e3721b,C2720167,C0012634,is in ,Sirtuin 1,Disease,1,X,[aapp/enzy],[dsyn],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C23.550.288
30d9f157-e187-4d83-9c37-55c606f53795,C3463820,C0012634,is in ,Inhibition,Disease,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C23.550.288
df25e46e-a26f-4716-a2f7-136c65f6d2f9,C2720167,CD8,reduces CD8 ,Sirtuin 1,CD8,1,X,[aapp/enzy],????,D08.811.277.087.520.200.650.100;D12.776.476.900.100,????
e62f5213-54b4-4916-b12f-d705682d7638,C3463820,CD8,reduces CD8 ,Inhibition,CD8,1,X,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405,????
faebadc6-5cc3-485e-986c-05929c36d60f,C2720167,C0039195,reduces CD8 ,Sirtuin 1,Cytotoxic T-Lymphocytes,1,X,[aapp/enzy],[cell],D08.811.277.087.520.200.650.100;D12.776.476.900.100,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
74d8ff85-1c9b-4525-9d51-c024b836c320,C3463820,C0039195,reduces CD8 ,Inhibition,Cytotoxic T-Lymphocytes,1,X,[acty],[cell],F01.145.544;F02.463.425.475;F02.739.794.405,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
0059c3de-a347-4a0f-8833-d6a211fbfc1c,C2720167,C0024131,reduces CD8 Cytotoxic T-Lymphocytes in patients with systemic erythematosus,Sirtuin 1,Lupus Vulgaris,1,X,[aapp/enzy],[dsyn],D08.811.277.087.520.200.650.100;D12.776.476.900.100,C01.252.410.040.552.846.583.470;C01.252.825.820.470;C01.539.800.720.820.470;C17.800.838.765.820.470
479af2c1-0721-407f-a307-d4185bf04e9f,C3463820,C0024131,reduces CD8 Cytotoxic T-Lymphocytes in patients with systemic erythematosus,Inhibition,Lupus Vulgaris,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.252.410.040.552.846.583.470;C01.252.825.820.470;C01.539.800.720.820.470;C17.800.838.765.820.470
67fcfc4a-b946-4c57-97c3-b67a38b36bde,C2720168,C0014467,is regulated by ,Sirtuin 2,eosinophil,2,X,[aapp/enzy],[cell],D08.811.277.087.520.200.650.200;D08.811.913.400.725.115.961.200;D12.776.476.900.200,A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251
29fea6a9-a207-4619-bd2f-18125dffc6b5,C2720168,C3156663,is regulated by ,Sirtuin 2,interleukin-4 secretion,4,X,[aapp/enzy],[celf],D08.811.277.087.520.200.650.200;D08.811.913.400.725.115.961.200;D12.776.476.900.200,
bbaa1fb0-d317-4be7-bb24-73bf1ab0d136,C2720169,C0302600,promotes ,Sirtuin 3,Angiogenic Process,1,X,[aapp/enzy],[ortf],D08.811.277.087.520.200.650.600;D08.811.913.400.725.115.961.600;D12.776.476.900.600;D12.776.575.875,
8b49bf52-53d6-4df4-b6a7-915c3d960e9e,C1423064,C1423065,is Tumor Suppressor Genes in contrastto,SIRT4 gene,SIRT5 gene,1,X,[gngm],[gngm],,
3b32bca3-ec67-4c8b-aa35-0ea8395f5108,C0079427,C1423065,is in contrastto ,Tumor Suppressor Genes,SIRT5 gene,1,X,[gngm],[gngm],G05.360.340.024.340.375.249;G05.360.340.024.340.415.400,
4717785b-941c-4b2e-82c1-e652d8b1a851,C1423064,C0079427,is ,SIRT4 gene,Tumor Suppressor Genes,1,X,[gngm],[gngm],,G05.360.340.024.340.375.249;G05.360.340.024.340.415.400
4f09f2af-a12e-46c0-8eb5-1c55a60e7891,C0596290,C1527249,causing ,Cell Proliferation,Colorectal Cancer,1,X,[celf],[neop],G04.161.750;G07.345.249.410.750,C04.588.274.476.411.307;C06.301.371.411.307;C06.405.249.411.307;C06.405.469.158.356;C06.405.469.491.307;C06.405.469.860.180
846a7352-bd1c-4c05-adf0-9298cfee099d,C1423066,C0206558,attenuates ,SIRT6 gene,Simplexvirus,1,X,[gngm],[virs],,B04.280.382.100.750
1ec386ee-3988-4705-9bfd-f0bbab942645,C1423066,C0036220,attenuates ,SIRT6 gene,Kaposi Sarcoma,1,X,[gngm],[neop],,C02.256.466.860;C04.557.450.795.850;C04.557.645.750
6a8f8f9d-279a-4e32-8e37-d5675b415270,C1423065,C0596290,promotes ,SIRT5 gene,Cell Proliferation,1,X,[gngm],[celf],,G04.161.750;G07.345.249.410.750
f2940b82-dabb-4593-a2c0-509c9f5e21fe,C0206558,C0036220,associated with ,Simplexvirus,Kaposi Sarcoma,1,X,[virs],[neop],B04.280.382.100.750,C02.256.466.860;C04.557.450.795.850;C04.557.645.750
62d8e1ed-0d58-42d1-ab08-848d8be35238,C0206558,C0376526,associated with ,Simplexvirus,human herpesvirus 8,1,X,[virs],[virs],B04.280.382.100.750,B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330
caf80334-e2d2-4ef5-97f1-7da44b6bbdd3,C0598312,C0334227,Apoptosis of,DNA Replication,Tumor cells malignant,1,X,[genf],[cell],G02.111.225;G05.226,
f259f742-fb41-496a-bbcd-341130d3ccc8,C0162638,C0598312,attenuates ,Apoptosis,DNA Replication,1,X,[celf],[genf],G04.146.160,G02.111.225;G05.226
967a8624-663e-435a-b096-855b7ce9222f,C0162638,C0376526,attenuates ,Apoptosis,human herpesvirus 8,1,X,[celf],[virs],G04.146.160,B04.280.210.400.700.330;B04.280.382.400.700.330;B04.613.204.500.700.330
94998666-0c20-43eb-afcb-4c7bcf64d5f2,C0598312,C3463820,is associated with ,DNA Replication,Inhibition,1,X,[genf],[acty],G02.111.225;G05.226,F01.145.544;F02.463.425.475;F02.739.794.405
34238273-595f-4d03-b268-a4eec355702a,C0598312,C2720167,is associated with ,DNA Replication,Sirtuin 1,1,X,[genf],[aapp/enzy],G02.111.225;G05.226,D08.811.277.087.520.200.650.100;D12.776.476.900.100
68f63945-0db4-4b61-a75a-fb6d7ec64359,C0162638,C3463820,is associated with ,Apoptosis,Inhibition,1,X,[celf],[acty],G04.146.160,F01.145.544;F02.463.425.475;F02.739.794.405
f11e6179-58c1-4073-bbeb-bbb9be9cc38b,C0162638,C2720167,is associated with ,Apoptosis,Sirtuin 1,1,X,[celf],[aapp/enzy],G04.146.160,D08.811.277.087.520.200.650.100;D12.776.476.900.100
c382e8f6-c5a6-49e1-9889-5c9afead65b0,C0162638,C0206419,attenuates DNA Replication in addition to molecular pathology pathway of,Apoptosis,Genus: Coronavirus,1,X,[celf],[virs],G04.146.160,B04.820.504.540.150
a47bd084-5a58-4cca-9f2c-f1448933d6b3,C1175743,C0596756,is driving ,SARS coronavirus,immunopathology specialty,1,X,[virs],[bmod],B04.820.504.540.150.113.937,
eca9aa7b-a85d-4cb8-8a1b-60de44519b0e,C0596756,C0002390,strongly resembles severe form of ,immunopathology specialty,Extrinsic allergic alveolitis,2,X,[bmod],[dsyn],,C08.381.483.125;C08.674.055;C20.543.480.680.075
e59154dd-b19c-4f18-af9f-a9d40a026cde,C0596756,C0032285,strongly resembles severe form of ,immunopathology specialty,Pneumonia,2,X,[bmod],[dsyn],,C08.381.677;C08.730.610
bdc1cacc-c2ed-49a9-ad77-66b58d13bfa4,C0600327,C1175743,is in setting of ,Toxic Shock Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712,B04.820.504.540.150.113.937
fbaf55a2-5b10-47be-ae65-7d173e5ec897,C1175743,C0032285,led to outbreak of ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
fbaf55a2-5b10-47be-ae65-7d173e5ec897,C1175743,C0032285,causes novel ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
fbaf55a2-5b10-47be-ae65-7d173e5ec897,C1175743,C0032285,include ,SARS coronavirus,Pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.677;C08.730.610
f50fb1f0-04a4-4400-9606-49d5d7e95a81,C1185738,C0003467,focuses on neurobiological explanations for ,Column (anatomic),Anxiety,1,X,[bpoc],[mobd],,F01.470.132
f1b0c84e-1637-40d5-a2c3-056be0259cd2,COVID-19,C0011991,been associated disease with,COVID-19,Diarrhea,1,X,[virs],[sosy],C000657245,C23.888.821.214
529a6fa3-eea4-4c63-bdfd-ac1bb196996e,COVID-19,C0243083,been associated disease with,COVID-19,associated disease,2,X,[virs],[patf],C000657245,
0af4e0a2-eeb1-49ba-8e81-1dcf9ac96cf3,C0042776,COVID-19,associated with ,Virus,COVID-19,2,X,[virs],[virs],B04,C000657245
0b456753-938e-415c-8c85-21965eb601a7,CBLL,C0037284,accounted for for ,CBLL,Skin lesion,2,X,????,[dsyn],????,
81e3e9b8-6890-4bbf-8581-c351c72bccc5,CBLL,C0242656,appear late in ,CBLL,Disease Progression,2,X,????,[patf],????,C23.550.291.656
0b01ad1a-781a-46eb-be98-fa5bb32780f5,C1175743,C0035242,has has identified as agent of global outbreak of ,SARS coronavirus,Respiratory Tract Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08
31716717-9e17-456d-9993-25862ea4353e,C0009450,C0035222,results in moderate to ,Communicable Diseases,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C01.539.221,C08.381.840;C08.618.840
0df1ec90-f4a4-4793-ae0f-7ffaa5a44c11,C0009450,C1868981,requiring ,Communicable Diseases,Invasive mechanical ventilation NOS,1,X,[dsyn],[topp],C01.539.221,
376d0209-b31f-437e-b8dd-23b50ea80a49,C1175743,C0010357,is indicative of ,SARS coronavirus,Cross Reactions,1,X,[virs],[moft],B04.820.504.540.150.113.937,G12.122.281
e1731d0b-627c-4abb-8f0e-2009ceb45d9b,C1175743,C0009443,is indicative of ,SARS coronavirus,Common Cold,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02.782.687.207;C08.730.162
46514fee-db76-4233-84c5-e04eb3929f17,C0039194,C0025248,were directed to spike ,T-Lymphocyte,Membrane Glycoproteins,1,X,[cell],[aapp/bacs],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D12.776.395.550;D12.776.543.550
477faf6a-3ccc-4ba9-9bda-124a2c4a4645,C1175743,C0079189,predominantly produced effector ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
477faf6a-3ccc-4ba9-9bda-124a2c4a4645,C1175743,C0079189,is characterized by overwhelming ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
477faf6a-3ccc-4ba9-9bda-124a2c4a4645,C1175743,C0079189,may cause reaction through release of ,SARS coronavirus,cytokine,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D12.644.276.374;D12.776.467.374;D23.529.374
07e49075-b6f1-4e31-8b93-c38c6f5fc66e,C0039194,C0079189,predominantly produced effector ,T-Lymphocyte,cytokine,1,X,[cell],[aapp/imft],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D12.644.276.374;D12.776.467.374;D23.529.374
ebf9587e-87bf-4b20-9609-bf758e25930c,C0553757,COVID-19,beginning before ,Olfaction Disorders,COVID-19,2,X,[dsyn],[virs],C10.597.751.600;C23.888.592.763.550,C000657245
58b85d6c-5be7-4044-ab55-8bfc464f4469,C0553757,C0037088,beginning before ,Olfaction Disorders,Signs and Symptoms,2,X,[dsyn],[sosy],C10.597.751.600;C23.888.592.763.550,C23.888
0ed23976-94f5-43fb-a6e9-d48a0bd4d96d,C0237820,COVID-19,usually happened after ,Recovery - action,COVID-19,2,X,[acty],[virs],,C000657245
be1be528-1eac-492d-ab60-56315194eae4,C0149783,C0395797,is in ,Steroid therapy,Ear nose and throat disorder,6,X,[topp],[dsyn],,
2d517cc3-05d9-454b-a186-8e5ba5cf52d2,C1523273,C0062503,Viral Interference with,protein complex oligomerization,Heparan Sulfate Proteoglycans,2,X,[moft],[aapp/bacs],,D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350
f2ecf280-f717-41aa-a90a-65b2cf139780,C1523273,C0042730,Viral Interference with,protein complex oligomerization,Viral Interference,2,X,[moft],[npop],,G06.920.800
2205fa9c-9eb1-43f2-b1dd-314c64acd4e6,C1523273,C4551660,outcompeting ,protein complex oligomerization,Virus Host Interactions,4,X,[moft],[npop],,G06.373;G16.527
76136c6a-6fc8-4366-b87d-aa1c83975367,C1523273,C0032594,outcompeting ,protein complex oligomerization,Polysaccharides,2,X,[moft],[orch/phsu],,D09.698
6376a8c0-3833-4e15-bfd3-8813c0651d49,C0042730,C0062503,is with ,Viral Interference,Heparan Sulfate Proteoglycans,2,X,[npop],[aapp/bacs],G06.920.800,D09.698.373.425.500;D09.698.735.400;D12.776.395.650.350
0949ccfc-23d0-4eb3-8f3f-04628c5d7657,C1609165,C0035222,were reported in ,tocilizumab,Respiratory Distress Syndrome Adult,1,X,[aapp/imft/phsu],[dsyn],x.x.x.x,C08.381.840;C08.618.840
4ce1fc6b-b58b-4815-95b4-1ae014a1cf84,C0229671,C1609165,were assayed at time of first ,Serum,tocilizumab,1,X,[bdsu],[aapp/imft/phsu],A12.207.152.846;A15.145.846,x.x.x.x
6512c8c6-ed58-4f96-93db-eb1871539a24,C0024312,C4019050,was reversed at_time days after ,Lymphopenia,tocilizumab Injection,1,X,[dsyn],[clnd],C15.378.553.546.605;C20.673.627,
23137fd1-6a31-48dd-996e-e621199c92a1,COVID-19,C0011945,occur among patients on ,COVID-19,Physical Dialysis,1,X,[virs],[npop],C000657245,E05.196.353;G02.186
cc3cf9b5-d015-449f-948d-8a91f22b50ba,C0009450,C0011945,occur among patients on ,Communicable Diseases,Physical Dialysis,2,X,[dsyn],[npop],C01.539.221,E05.196.353;G02.186
996a23bd-64b2-4c56-9661-81e63fdf9861,C0009450,C1707455,occur among patients on ,Communicable Diseases,Comparison,1,X,[dsyn],[acty],C01.539.221,
d1a86a2b-edc6-446f-85ca-4f6375cc9f43,C0034535,C0206419,is in ,Radiation Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,B04.820.504.540.150
d669f62b-9e2b-47d3-87b4-77b771b276cf,C0027651,C0206419,managing Neoplasms patients during,Neoplasms,Genus: Coronavirus,4,X,[neop],[virs],C04,B04.820.504.540.150
6938d87e-a166-4008-b2cc-7a4205951e52,C0034535,C1521863,is in ,Radiation Syndrome,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C26.733;G01.750.748.500;N06.850.460.350.850.500;N06.850.810.300.360,x.x.x.x
7485cf53-6190-4644-8d62-af21ae5de933,C0027651,C1521863,is in ,Neoplasms,estrogen receptor alpha human,1,X,[neop],[aapp/rcpt],C04,x.x.x.x
f386bec5-fa5b-42a5-8842-74265b35c7d0,C0232741,COVID-19,should ,Liver function,COVID-19,1,X,[ortf],[virs],,C000657245
d0aaeeaf-1681-44fa-afe0-a371ffae5385,C1179870,C0032930,inflammatory damage of are possible ,Nodal myocyte,Precipitating Factors,1,X,[cell],[clna],,N05.715.350.200.650;N06.850.490.625.500
258bdde1-d5b7-455c-8708-0d963956ccdd,C0003130,C0032930,are possible ,Anoxia,Precipitating Factors,1,X,[patf],[clna],C23.888.852.079,N05.715.350.200.650;N06.850.490.625.500
c1864040-de30-4d79-8832-33eb16b80f5d,C0037088,C0206419,is in inpatient ,Signs and Symptoms,Genus: Coronavirus,1,X,[sosy],[virs],C23.888,B04.820.504.540.150
9774473d-ee49-41c5-8935-d6bd8e4f1470,C0037088,C0012634,is in inpatient ,Signs and Symptoms,Disease,2,X,[sosy],[dsyn],C23.888,C23.550.288
cde6571e-fbd9-45ff-8658-74aad602cb9d,C0024115,COVID-19,is in ,Lung diseases,COVID-19,3,X,[dsyn],[virs],C08.381,C000657245
02052fff-c871-49d0-9b1b-d4e1f4bdd16d,C0032529,C0017337,is in ,Genetic Polymorphism,Genes,2,X,[genf],[gngm],G05.365.795,G05.360.340.024.340
3f7d9a5f-e114-463e-9132-5cebe73027db,C0032529,C1422064,is in ,Genetic Polymorphism,ACE2 gene,1,X,[genf],[gngm],G05.365.795,
27164446-a942-4ecc-b6af-c895234de638,C0032529,C0678951,is in ,Genetic Polymorphism,gene polymorphism,1,X,[genf],[genf],G05.365.795,
d3fec9a9-6e19-42ab-837f-63444598f50b,C0032529,C0598312,could affect ,Genetic Polymorphism,DNA Replication,2,X,[genf],[genf],G05.365.795,G02.111.225;G05.226
24f35a2e-e7bb-4706-83b9-9ad3db45aa1b,C0032529,C1537068,could affect ,Genetic Polymorphism,Virus Internalization,2,X,[genf],[biof],G05.365.795,G06.920.881
31808014-4543-4f20-a846-e13d99d5d4d6,C0020167,C0301872,can influence ,Humidity,Immune response,4,X,[npop],[ortf],G16.500.275.063.725.310;G16.500.750.775.310;N06.230.150.372;N06.230.300.100.725.310,
7dbbf6c1-c5a6-40ea-a340-8ee6f09b34de,C0020167,C0038952,can influence viral ,Humidity,Continuance of life,2,X,[npop],[acty],G16.500.275.063.725.310;G16.500.750.775.310;N06.230.150.372;N06.230.300.100.725.310,I03.784
b546e766-11ad-4a8c-b5f1-7016cd1bd620,C1708476,C0012634,has also Contribution to less,Implementation,Disease,2,X,[acty],[dsyn],,C23.550.288
d8c4d3e1-9808-42de-8266-adc7043bce28,C1335439,C0003451,is promising ,Polymerase,Antiviral Agents,1,X,[aapp/enzy],[phsu],,D27.505.954.122.388
d23b4279-02ce-44b4-9c62-f8a754ac3271,C0854532,C0009450,remains prominent ,Myopericarditis,Communicable Diseases,4,X,[dsyn],[dsyn],,C01.539.221
203d4a84-d8a2-4a3d-87d5-89a578295944,C1520005,C0854532,be leading contributors ,Viral Pathogenesis,Myopericarditis,2,X,[patf],[dsyn],,
6c118058-bdef-41af-bc2c-97fec67f76a3,NYSDOH,C0282624,definition for ,NYSDOH,Minimally Invasive Surgical Procedures,1,X,????,[topp],????,E04.502
52535c7b-7ef5-4c97-a15b-604a28f83855,C0751973,C1175743,dynamicome-level understanding of ,Proteome,SARS coronavirus,4,X,[aapp/bacs],[virs],D12.776.817,B04.820.504.540.150.113.937
bc3ce62c-2594-4d33-9622-4117f9abca94,C4553629,y216,elucidated potential functional missense variants from databases within xentit y216 ,MATRix Regimen,y216,1,X,[topp],????,,????
9b5e2686-a365-4a81-bf18-3a4709e43e5b,C0009450,C1880355,caused by newly ,Communicable Diseases,Discover,1,X,[dsyn],[acty],C01.539.221,
9b5e2686-a365-4a81-bf18-3a4709e43e5b,C0009450,C1880355,has spread worldwide Since December 2019 ,Communicable Diseases,Discover,1,X,[dsyn],[acty],C01.539.221,
36491603-35f6-44a6-b443-886ec9d4cd10,C0033684,C0319157,collectively reveal map of ,Proteins,AS virus,1,X,[aapp/bacs],[virs],D12.776,
e62757a5-72b5-4ecd-9ed7-3ba630975ee0,C0162595,C0850624,are considered as ,Antiphospholipid Antibodies,cardiovascular risk factor,2,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,
af06ce1d-fb70-43b4-b8f8-badf5b22b57e,C0162595,C0005516,are essential ,Antiphospholipid Antibodies,Biological Markers,2,X,[aapp/imft],[clna],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,D23.101
c79c779c-44c9-4243-9361-4b9c8eab64f6,C0162595,C0085278,are essential Biological Markers for,Antiphospholipid Antibodies,Antiphospholipid Syndrome,2,X,[aapp/imft],[dsyn],D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210,C20.111.197
62ef142e-8889-4e71-a1eb-53a45a4e670e,C0003209,C0001617, includes ,Anti-Inflammatory Agents,Adrenal Cortex Hormones,4,X,[phsu],[horm/orch/phsu],D27.505.954.158,D06.472.040
801c2d4a-64dc-4abc-a707-c470200885d3,C0003209,C0079189,effectively reduce effect of ,Anti-Inflammatory Agents,cytokine,2,X,[phsu],[aapp/imft],D27.505.954.158,D12.644.276.374;D12.776.467.374;D23.529.374
f0080b22-4412-4d43-957d-15ffad6ef2f9,C0001617,C0079189,effectively reduce effect of ,Adrenal Cortex Hormones,cytokine,2,X,[horm/orch/phsu],[aapp/imft],D06.472.040,D12.644.276.374;D12.776.467.374;D23.529.374
f0080b22-4412-4d43-957d-15ffad6ef2f9,C0001617,C0079189,is In other very similar ,Adrenal Cortex Hormones,cytokine,2,X,[horm/orch/phsu],[aapp/imft],D06.472.040,D12.644.276.374;D12.776.467.374;D23.529.374
c188c71b-29ca-4990-8cfa-0ed30fc44016,C1533734,C0010340,reduce effect of ,Administration procedure,Critical Illness,2,X,[topp],[dsyn],,C23.550.291.625
133389d4-123a-4e7b-9f4c-2e4374207994,C1533734,C0021027,is in combination with IV ,Administration procedure,Immunoglobulins,2,X,[topp],[aapp/imft],,D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548
a23c09f2-1bdf-4fcd-95d4-4447cddab4e5,C1879547,C0319157,causes in addition to direct injury from se,Activation action,AS virus,1,X,[acty],[virs],,
bc2d8e63-7c19-45da-9836-78b034d77a3e,C1879547,se,causes in addition to direct injury from se,Activation action,se,1,X,[acty],????,,????
803fb5bd-f2cb-482a-be38-1ed797bb0e10,C0079189,C0319157,causes in addition to direct injury from se,cytokine,AS virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,
064aafff-3272-4b7f-908f-54d0e0d58972,C0079189,se,causes in addition to direct injury from se,cytokine,se,2,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
26c468e3-4894-48da-a7d9-6dd58bbdb533,C1175743,C2348077,are warranted To ,SARS coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150.113.937,B01.650.940.800.575.912.250.093.615
26c468e3-4894-48da-a7d9-6dd58bbdb533,C1175743,C2348077,2-positive results to ,SARS coronavirus,Date Fruit,1,X,[virs],[food],B04.820.504.540.150.113.937,B01.650.940.800.575.912.250.093.615
2354f8ae-8c6f-4d57-8b91-bc8a509c4e18,C0087111,C2348077,are warranted To ,Therapeutic procedure,Date Fruit,2,X,[topp],[food],E02,B01.650.940.800.575.912.250.093.615
6d592375-841e-40e3-b3bb-d300ad1188d1,C3687832,C1175743,However may have risks beyond anti ,Drugs - dental services,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
6d592375-841e-40e3-b3bb-d300ad1188d1,C3687832,C1175743,have have tested as new ,Drugs - dental services,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
6d592375-841e-40e3-b3bb-d300ad1188d1,C3687832,C1175743,entry of ,Drugs - dental services,SARS coronavirus,2,X,[topp],[virs],,B04.820.504.540.150.113.937
52beeb99-b46e-42e6-a3d9-e93bb9e18759,C3687832,C0232217,especially altering ,Drugs - dental services,Cardiac conduction,1,X,[topp],[ortf],,
39f9eb1f-2acc-4e86-8516-503210cb52fe,C0035204,C0206061,occurred with ,Respiration Disorders,Pneumonia Interstitial,3,X,[dsyn],[dsyn],C08.618,C08.381.483
2d0dd273-94ff-48fa-b9fd-bdad4bb5d170,C0035668,C0178784,is in ,RNA,Organ,3,X,[nnon],[bpoc],D13.444.735,
81c9ee4a-e8aa-47b3-a822-ad76c2566f2e,C0035204,C0026179,occurred in ,Respiration Disorders,Mink,3,X,[dsyn],[mamm],C08.618,B01.050.150.900.649.313.750.250.575.500
46d71ea6-01b4-4271-8e9f-f2f66a9727e1,C0013330,C0035736,contained ,Dust,RNA Viral,3,X,[sbst],[nnon],D20.633.222,D13.444.735.828
f3816195-9627-4c38-ab39-087d17a07158,C4321457,C0024115,rule out incidental finding ,Examination,Lung diseases,1,X,[acty],[dsyn],,C08.381
ddbb28c5-5bb6-4932-8686-6b09fa51fa8d,C4321457,C0156149,rule out ,Examination,Gastrointestinal tract vascular insufficiency,1,X,[acty],[dsyn],,
d14995ba-da98-4724-97e3-a9e9626dabbb,C0282624,C4283938,is associated with shorter hospital stay than ,Minimally Invasive Surgical Procedures,Open Surgical Procedure,3,X,[topp],[topp],E04.502,
d14995ba-da98-4724-97e3-a9e9626dabbb,C0282624,C4283938,reconverted to ,Minimally Invasive Surgical Procedures,Open Surgical Procedure,3,X,[topp],[topp],E04.502,
40327f86-6f8e-4c94-b39e-14f4728cf60f,C1175743,C1705178,recommended in ,SARS coronavirus,Order (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
aaf618ee-5e1d-42f5-aa7d-57f96edc6c8f,C1175743,C3714514,prevent professional ,SARS coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150.113.937,C01.539
aaf618ee-5e1d-42f5-aa7d-57f96edc6c8f,C1175743,C3714514,has caused about million ,SARS coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150.113.937,C01.539
f656d04d-7c82-4009-a875-76a8d242c2e1,C0282624,C0206419,reconverted during ,Minimally Invasive Surgical Procedures,Genus: Coronavirus,1,X,[topp],[virs],E04.502,B04.820.504.540.150
e604b725-e61c-4db8-8fac-cecc76b4dcf3,C1175743,C0189341,is in anticipation of ,SARS coronavirus,Planned tracheostomy,2,X,[virs],[topp],B04.820.504.540.150.113.937,
e360971d-7ec2-4417-af4f-4740fbef0e58,C3176469,silico,readily bind in silico,Over the counter medications,silico,1,X,[phsu],????,,????
280981a6-747c-4191-b952-f01a6559e28e,C0020538,C1707455,occurred more commonly in elderly group ,Hypertensive disease,Comparison,1,X,[dsyn],[acty],C14.907.489,
27003f71-a52d-488c-bce0-57e773bd3914,C0011849,C1707455,occurred commonly in elderly group ,Diabetes Mellitus,Comparison,1,X,[dsyn],[acty],C18.452.394.750;C19.246,
27003f71-a52d-488c-bce0-57e773bd3914,C0011849,C1707455,frequency of was ,Diabetes Mellitus,Comparison,1,X,[dsyn],[acty],C18.452.394.750;C19.246,
cd77a380-e034-4307-ad90-c2f6511678e7,C0006560,C4551752,percentage of ,C-reactive protein,Abnormal Lymphocyte cell,1,X,[aapp/imft],[cell],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,
c117d3b1-9433-4f7d-91ae-8cbe99b7d8bb,C1704259,C0233514,are associated with major ,Biochemical Pathway,Abnormal behavior,5,X,[moft],[mobd],,F01.145.126.972;F01.145.179.750
3a9544b7-1efb-4177-aa99-57a25ef65508,C1817997,C0012634,be crucially involved in manifestation in individuals with ,chronic inflammatory response,Disease,2,X,[patf],[dsyn],,C23.550.288
b1f67249-6ba1-4325-bc30-5d18e4229ff4,C0206750,C0004936,is with prior ,Coronavirus Infections,Mental disorders,2,X,[dsyn],[mobd],C02.782.600.550.200,F03
b1f67249-6ba1-4325-bc30-5d18e4229ff4,C0206750,C0004936,could specially affect people with ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
b1f67249-6ba1-4325-bc30-5d18e4229ff4,C0206750,C0004936,is with its subsequent ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
b1f67249-6ba1-4325-bc30-5d18e4229ff4,C0206750,C0004936,possesses challenges for individuals with preexisting ,Coronavirus Infections,Mental disorders,1,X,[dsyn],[mobd],C02.782.600.550.200,F03
40a4924f-3eab-4299-83a4-6dbf05347ad2,C0013227,C0030664,already used in clinical setting for ,Pharmaceutical Preparations,Pathology,1,X,[phsu],[bmod],D26,H02.403.650
10a3f909-be84-4c95-9037-99c9af0f7b3f,C1856053,C1845118,as of Institute is ,Hydranencephaly with Renal Aplasia-Dysplasia,SHORT STATURE IDIOPATHIC X-LINKED,1,X,[dsyn],[cgab],x.x.x.x,x.x.x.x
5bdeac37-a108-4266-a5b1-4e37702c2459,DCC19,C0206750,assist GPs for patients with suspected ,DCC19,Coronavirus Infections,4,X,????,[dsyn],????,C02.782.600.550.200
31d0400a-df7d-4c27-90df-9440012c7ce3,DCC19,C1999230,assist GPs in ,DCC19,Providing (action),5,X,????,[acty],????,
3262ccbc-7d09-4293-9902-28d16864805f,C0301630,C0004610,is in rates of ,Reduction (chemical),Bacteremia,4,X,[npop],[dsyn],,C01.252.100;C01.539.757.100;C23.550.470.790.500.100
b27e0c0c-fd13-47f8-9dd6-51fb22f69098,C0743841,C0301630,continues Despite dramatic 1980s,Disorder characterized by fever,Reduction (chemical),4,X,[dsyn],[npop],,
2b0bd24a-26b3-4680-bcb2-627485853680,C0743841,C0004610,continues Despite dramatic 1980s,Disorder characterized by fever,Bacteremia,2,X,[dsyn],[dsyn],,C01.252.100;C01.539.757.100;C23.550.470.790.500.100
ada8d304-6404-439c-b3d1-95a91dbd5e91,C0743841,1980s,continues Despite dramatic 1980s,Disorder characterized by fever,1980s,4,X,[dsyn],????,,????
180a349c-aca3-480b-9a5d-e6357cbee435,C0009450,C0425716,include delayed ,Communicable Diseases,Capillary filling function (observable entity),2,X,[dsyn],[ortf],C01.539.221,
3dae4580-2331-496a-8d1a-8f326b0b9018,C0009450,C1516048,include overall physician ,Communicable Diseases,Assessed,3,X,[dsyn],[acty],C01.539.221,
d2c6e6da-2b3b-473c-92bc-a6994db39b80,C0009450,C0241144,include ,Communicable Diseases,Petechiae of skin,2,X,[dsyn],[sosy],C01.539.221,
53e631c6-e01f-48c5-86f4-9e94ae00cfce,C0042029,C3826128,are most common serious bacterial ,Urinary tract infection,Infection in children,4,X,[dsyn],[dsyn],C01.539.895;C12.777.892;C13.351.968.892,
a1e89092-c04f-47c4-875d-8e411c309f13,C0003237,C0007561,include ,Antibiotics Antitubercular,Ceftriaxone,4,X,[antb],[antb/orch],D27.505.954.122.085.255.135,D02.065.589.099.249.190.190.155;D02.886.665.074.190.190.155;D03.633.100.300.249.190.190.155
fcb57932-b2cf-4881-a648-a5f0a7eba8e5,C0002680,C0007554,is with ,Ampicillin,Cefotaxime,4,X,[antb/orch],[antb/orch],D02.065.589.099.750.750.050;D02.886.108.750.750.050;D03.633.100.300.750.750.050,D02.065.589.099.249.190.190;D02.886.665.074.190.190;D03.633.100.300.249.190.190
75741013-49f0-44f5-b316-acf1816fe84e,C0002680,C3854019,is with ,Ampicillin,Gentamicin,4,X,[antb/orch],[antb/orch],D02.065.589.099.750.750.050;D02.886.108.750.750.050;D03.633.100.300.750.750.050,D09.408.051.374
50a67e87-6ac6-49f7-b7f9-37dafce74584,C0003237,C0060400,are ,Antibiotics Antitubercular,Cefixime,5,X,[antb],[antb/orch],D27.505.954.122.085.255.135,D02.065.589.099.249.190.190.115;D02.886.665.074.190.190.115;D03.633.100.300.249.190.190.115
48eab315-e1fe-464b-bf22-d2264b50e3f3,C0003237,C0054066,are ,Antibiotics Antitubercular,Amoxicillin / Clavulanate,3,X,[antb],[phsu],D27.505.954.122.085.255.135,D02.065.589.099.374.160.060;D02.065.589.099.750.750.050.050.060;D02.886.108.750.750.050.050.060;D03.633.100.300.374.160.060;D03.633.100.300.750.750.050.050.500;D26.310.102
5f8f72c6-2640-4ca0-88a5-fc65689474f4,C0003237,C0041044,are ,Antibiotics Antitubercular,Trimethoprim-Sulfamethoxazole Combination,3,X,[antb],[phsu],D27.505.954.122.085.255.135,D02.065.884.725.867.500;D02.092.146.807.867.500;D02.886.590.700.725.867.500;D03.383.742.906.500;D26.310.875
8f8d7354-9606-4512-b248-e9c6edb0b3c5,C0206750,C0877373,patients with ,Coronavirus Infections,advanced cancer,4,X,[dsyn],[neop],C02.782.600.550.200,
b493500d-123e-4a60-8940-7e26bcb34e8b,C0206750,C0751569,patients with ,Coronavirus Infections,Genitourinary Cancer,2,X,[dsyn],[neop],C02.782.600.550.200,C04.588.945;C12.758;C13.351.937
9158c256-1ded-4d85-8afe-58d68a22ff06,C1537068,C0242821,is in ,Virus Internalization,Human body,4,X,[biof],[humn],G06.920.881,I01.076.201.450.560;K01.093.378
89c7242b-6deb-4fb6-bcf1-993fd4d1ddbf,C0206750,C0857828,is in ,Coronavirus Infections,infection in the elderly,2,X,[dsyn],[dsyn],C02.782.600.550.200,
d5987b6c-6c23-4d95-b490-87586aded7a3,C0206750,C0277562,is in young ,Coronavirus Infections,Adult disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
dfb43bbd-9f32-4de8-9224-299d5f152299,C0857828,C0277562,is in ,infection in the elderly,Adult disease,3,X,[dsyn],[dsyn],,
47ddcd33-372c-439b-851b-aeb357ed7eb5,C0206750,C0023175,is in ,Coronavirus Infections,Lead,2,X,[dsyn],[elii/hops],C02.782.600.550.200,D01.268.556.435;D01.552.544.435;x.x.x.x
fd2343d6-6a1f-4f7b-b0df-457a756b545c,C0857828,C0023175,is in ,infection in the elderly,Lead,1,X,[dsyn],[elii/hops],,D01.268.556.435;D01.552.544.435;x.x.x.x
d10a4db6-2c92-4d95-a24a-d8a072c4d399,C0079189,C0035222,can induce ,cytokine,Respiratory Distress Syndrome Adult,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
d10a4db6-2c92-4d95-a24a-d8a072c4d399,C0079189,C0035222,leading to ,cytokine,Respiratory Distress Syndrome Adult,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
d10a4db6-2c92-4d95-a24a-d8a072c4d399,C0079189,C0035222,followed by ,cytokine,Respiratory Distress Syndrome Adult,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381.840;C08.618.840
1215939a-ba6f-4fc9-a0b2-f33093045a7c,C0079189,C0026766,can induce ,cytokine,Multiple Organ Failure,4,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.835.525
1215939a-ba6f-4fc9-a0b2-f33093045a7c,C0079189,C0026766,lead to ,cytokine,Multiple Organ Failure,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.835.525
00d4c87a-c076-441d-ad74-4a610d930e63,C0206750,C0007682,is in ,Coronavirus Infections,CNS disorder,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228
25c620b9-655b-4d7d-bcf4-4bf4a8eacda7,C0011849,C0301889,has ,Diabetes Mellitus,Immune defect,1,X,[dsyn],[patf],C18.452.394.750;C19.246,
d54c2aeb-738c-4050-a2ec-81ab4dcaf52c,covid,C0342303,Also can cause ,covid,Metabolic stress hyperglycemia,1,X,????,[patf],????,
02a5e643-fc04-4de3-a9ac-6646e841b78e,C0024115,C0012634,be associated with higher risk of hospitalization with ,Lung diseases,Disease,1,X,[dsyn],[dsyn],C08.381,C23.550.288
dd7b63b8-ecfb-4c92-b49c-333f32df269b,C0013227,C0004096,is in patients with ,Pharmaceutical Preparations,Asthma,1,X,[phsu],[dsyn],D26,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
e8202cc3-5714-452b-872a-2bde1b9bb495,C0001617,C0013227,are most commonly used controller ,Adrenal Cortex Hormones,Pharmaceutical Preparations,3,X,[horm/orch/phsu],[phsu],D06.472.040,D26
bfc59af4-199d-4c87-a411-f669e3d219b4,C0001617,C0004096,are most commonly used controller ,Adrenal Cortex Hormones,Asthma,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
15ef6c47-e9ab-432a-b777-a384d75d8c70,C0232804,C0020538,independently predicted mortality at_time ,Renal function,Hypertensive disease,1,X,[ortf],[dsyn],,C14.907.489
10c6c1a9-7058-45d7-9dfd-c738b4c01cfb,C0282687,C0318793,is with ,Hemorrhagic Fever Ebola,Zika Virus,1,X,[dsyn],[virs],C02.782.417.415;C02.782.580.250.400,B04.820.250.350.995
0fd7c0f3-79d3-4405-af30-665e11121276,C0003451,C1705178,be integrated into control measures in ,Antiviral Agents,Order (action),2,X,[phsu],[acty],D27.505.954.122.388,
54a4eca8-74c6-4899-b1af-501c12a6cd32,C0003451,C0034386,result in combination with contact tracing ,Antiviral Agents,Quarantine,2,X,[phsu],[topp],D27.505.954.122.388,N06.850.780.200.450.700
0cfb1a61-2ae8-49dd-bf43-195692f7eb10,C1533734,C0034386,is shown together ,Administration procedure,Quarantine,2,X,[topp],[topp],,N06.850.780.200.450.700
2db23241-ac9b-4f93-b874-65121ab16307,C0444190,C1628999,detecting ,Conjunctival swab (specimen),SARS coronavirus RNA,1,X,[bdsu],[nnon],,
2cde514b-88a1-46b7-8feb-fcce6a89a2de,C1628999,C0009763,Likewise was detected in one patient without ,SARS coronavirus RNA,Conjunctivitis,1,X,[nnon],[dsyn],,C11.187.183
540177c6-8f68-4a21-b40d-4afd06a47f23,C0596448,C0012634,is in patients with ,dimer,Disease,1,X,[chvs],[dsyn],,C23.550.288
d215d2fa-b832-4442-bc96-9a5bd6327e05,C1707455,C0596448,is with normal D ,Comparison,dimer,1,X,[acty],[chvs],,
747ca3c2-6f76-49c6-97cc-d4cc8d101f06,C0060323,C1416903,was related with ,Fibrin fragment D,LPO gene,1,X,[aapp/bacs],[gngm],x.x.x.x,
2721419d-48d4-452d-aa0c-5b7cc4e9d02d,C0060323,C0232117,was negatively related with ,Fibrin fragment D,Pulse Rate,2,X,[aapp/bacs],[clna],x.x.x.x,E01.370.600.875.500;G09.330.380.500
b4288d07-27e2-4796-806c-5f3bda983be7,C0060323,C0369768,was negatively related with ,Fibrin fragment D,Molecular oxygen saturation,2,X,[aapp/bacs],[moft],x.x.x.x,
3e2d226d-eebb-4de2-8d57-8567396d2459,C0060323,C0522534,was negatively related with ,Fibrin fragment D,Saturated,2,X,[aapp/bacs],[npop],x.x.x.x,
f81a28ec-e20e-46d9-86d7-7105120ef4f6,C0060323,C0231832,was related with ,Fibrin fragment D,Respiratory rate,2,X,[aapp/bacs],[clna],x.x.x.x,E01.370.600.875.875;G09.772.705.730
02187261-f9a4-478f-935e-3f1bb4d024b6,C0060323,C0206750,were related in ,Fibrin fragment D,Coronavirus Infections,7,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
005e2dfd-1324-42bb-ab4f-aee7bd19d640,MSC,C0035222,have shown first promise in treatment of ,MSC,Respiratory Distress Syndrome Adult,2,X,????,[dsyn],????,C08.381.840;C08.618.840
abd69bf7-10b2-4a57-8d39-8c417c9bff07,MSC,C0032285,have shown first promise in treatment of ,MSC,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
a6a8def6-b3c6-4dff-8b6e-fc6798925cf2,C0087111,C0032285,have shown first promise in treatment of ,Therapeutic procedure,Pneumonia,2,X,[topp],[dsyn],E02,C08.381.677;C08.730.610
a98f23f2-8031-482f-9fef-0ffc15176147,MSC,C0021368,have shown first promise in treatment of ,MSC,Inflammation,2,X,????,[patf],????,C23.550.470
468870c6-5535-4974-b857-115075edce13,MSC,C0243026,have shown first promise in treatment of ,MSC,Sepsis,2,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
a2cd45b8-bd62-4d11-b92c-cbfad2c4f83a,C0087111,C0243026,have shown first promise in treatment of ,Therapeutic procedure,Sepsis,2,X,[topp],[dsyn],E02,C01.539.757;C23.550.470.790.500
9c1b160f-bb69-4124-9ef5-dbf653d834c9,C0243026,C0206750,are among leading causes of mortality in ,Sepsis,Coronavirus Infections,2,X,[dsyn],[dsyn],C01.539.757;C23.550.470.790.500,C02.782.600.550.200
c8143d2b-c3ff-463e-8948-da5ee50d4c9e,C1880022,C4048299,is with unchecked CD142 ,Characterization,Tissue Factor,2,X,[acty],[aapp/imft],,D12.776.124.125.900;D23.119.965
b8445cc2-df28-4c47-9b74-2069d4be5737,MSC,C4048299,is with unchecked CD142 ,MSC,Tissue Factor,2,X,????,[aapp/imft],????,D12.776.124.125.900;D23.119.965
73cd7851-5d4d-4508-8b78-5f1c8bb46be1,C1880022,CD142,is with unchecked CD142 ,Characterization,CD142,2,X,[acty],????,,????
534f0c91-dad7-4596-9e5c-dcaf721a0910,MSC,CD142,is with unchecked CD142 ,MSC,CD142,2,X,????,????,????,????
578bba81-7b13-4066-adcf-f9d5a72d18a4,C1880022,C0178784,inducing ,Characterization,Organ,2,X,[acty],[bpoc],,
d5f2ad53-0951-416e-a236-567bbf5c81fc,MSC,C0206750,is in ,MSC,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
56ba2917-0f95-4d54-97bd-3d7b8395f7a4,C0872315,C1175743,caused by ,Communicable Diseases Emerging,SARS coronavirus,1,X,[dsyn],[virs],C01.539.221.500,B04.820.504.540.150.113.937
d83e8fea-0c62-49a6-b846-57de7a64376d,C0079189,C1175743,is in asymptomatic ,cytokine,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150.113.937
d83e8fea-0c62-49a6-b846-57de7a64376d,C0079189,C1175743,were seen in ,cytokine,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04.820.504.540.150.113.937
f207b05d-34e3-49e5-9fb5-21b45a96f5c6,C0012634,C0679215,became reportable ,Disease,health and disease,2,X,[dsyn],[npop],C23.550.288,
f207b05d-34e3-49e5-9fb5-21b45a96f5c6,C0012634,C0679215,reportable health and disease of public,Disease,health and disease,1,X,[dsyn],[npop],C23.550.288,
f207b05d-34e3-49e5-9fb5-21b45a96f5c6,C0012634,C0679215,can lead to serious problems like ,Disease,health and disease,1,X,[dsyn],[npop],C23.550.288,
90661beb-58fe-42d4-9aea-391e89da71e0,C0034019,C1175743,were Providing (action) with guidance on entry of patients tested for,public health medicine (field),SARS coronavirus,1,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,B04.820.504.540.150.113.937
021c31e9-9e82-4859-af75-62d8c644a9e6,C0441655,C0018837,protect health during periods of ,Activities,Heat (physical force),1,X,[acty],[npop],,
e4f4905a-7d55-4825-bf5d-883317c2f4ba,C0319157,C0678568,causes Coronavirus Infections into,AS virus,Cool - action,1,X,[virs],[npop],,
d0580c68-0815-4d87-ad3c-004a5f6dd68f,C1186763,C2828389,got ,Stem of Organ,Exclusion,1,X,[bpoc],[acty],,
d89c15ab-e059-47fe-901d-b52d26a5b7c8,C1184743,C2828389,got ,bony process,Exclusion,1,X,[bpoc],[acty],,
14cf0368-68fb-45da-9437-b2ef2999f6cb,C1186763,C0012634,got ,Stem of Organ,Disease,1,X,[bpoc],[dsyn],,C23.550.288
4ee86e2d-5470-40f8-84e2-efaa0529d731,C1184743,C0012634,got ,bony process,Disease,1,X,[bpoc],[dsyn],,C23.550.288
bee986f9-c8d2-461f-8224-a26298399afe,RT-PCR,C0206750,detect ,RT-PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
4f3c05d4-12db-4f76-bff9-2229d6a88464,C0012634,C0014338,is in ,Disease,Coronavirus Turkey,1,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.400.500
d5753832-7ddc-4438-a4d1-3a4803d40fae,C1280903,C0206750,is in severe ,Exploration procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
7c50ff81-06e3-4808-a96b-26f46563ddd7,C0024264,C4048285,is with higher levels of ,Lymphocyte,C-Reactive Protein human,1,X,[cell],[aapp/imft],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
e388f35f-c5e6-49c3-8eaa-b40d15c5d58e,C0021368,C0744673,is with induced ,Inflammation,heart inflammation,3,X,[patf],[dsyn],C23.550.470,
9118ab12-9319-4cb6-b6b0-5c3e2b330734,C0751956,C2745965,continues treatable medical ,Acute Cerebrovascular Accidents,Emergencies [Disease/Finding],8,X,[dsyn],[patf],C10.228.140.300.775;C14.907.253.855,C23.550.291.781;N06.230.100.083;N06.850.376
20ef1d03-cf7e-4b1d-923f-5053fc15e9a4,C0751956,C1175743,be treatable medical Emergencies [Disease/Finding] also during,Acute Cerebrovascular Accidents,SARS coronavirus,4,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150.113.937
20ef1d03-cf7e-4b1d-923f-5053fc15e9a4,C0751956,C1175743,continues treatable medical ,Acute Cerebrovascular Accidents,SARS coronavirus,4,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,B04.820.504.540.150.113.937
d22feb01-3cb5-4578-8d94-add814077a29,C0009566,C0206750,is in severe cases of ,Complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
d22feb01-3cb5-4578-8d94-add814077a29,C0009566,C0206750,is in patients with severe ,Complication,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
d22feb01-3cb5-4578-8d94-add814077a29,C0009566,C0206750,associated with ,Complication,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
d22feb01-3cb5-4578-8d94-add814077a29,C0009566,C0206750,were found during ,Complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
9f9b8dfc-5573-43b8-b732-21d631a62091,C0699748,C0948008,may behind may ,Pathogenesis,Ischemic stroke,2,X,[patf],[dsyn],,
10d14b18-775a-41d1-8f74-b40f165b7201,C0948008,C0206750,may result from ,Ischemic stroke,Coronavirus Infections,4,X,[dsyn],[dsyn],,C02.782.600.550.200
d28be2ed-59c3-4b77-8a17-67fe75f89bec,C0079189,C0729531,frequently exacerbates Lung tissue damage during,cytokine,Viral respiratory infection,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
fe63c5cf-fecb-4c70-a2a3-fb5aa1e72d16,C0037083,C0729531,frequently exacerbates Lung tissue damage during,Signal Transduction,Viral respiratory infection,2,X,[celf],[dsyn],G02.111.820;G04.835,
401c269f-9f1a-4a25-9bed-0dec3e397168,C0079189,C0024109,frequently exacerbates ,cytokine,Lung,2,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,A04.411
185cd69e-bfcc-4ee5-9465-54a67889ca00,C0037083,C0024109,frequently exacerbates ,Signal Transduction,Lung,2,X,[celf],[bpoc],G02.111.820;G04.835,A04.411
fffdeedc-a8b0-4c04-aded-696b133ea89d,C0021747,C1167395,are ,Interferons,Host (organism),2,X,[aapp/imft],[orgm],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
db280a79-5498-4734-8e93-2d1b7a41eb85,C0021747,C0003451,are ,Interferons,Antiviral Agents,2,X,[aapp/imft],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D27.505.954.122.388
e4614978-6a58-4e55-93bc-80d246b3ac28,C0021747,C0079189,are ,Interferons,cytokine,2,X,[aapp/imft],[aapp/imft],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D12.644.276.374;D12.776.467.374;D23.529.374
76ea4e68-7938-41c4-9773-b2bfef1a5876,IFN,C0014609,is in ,IFN,Epithelium,2,X,????,[tisu],????,A10.272
728359a7-dfb0-432b-bbbb-326b4373672e,IFN,C0003451,inducing localized ,IFN,Antiviral Agents,2,X,????,[phsu],????,D27.505.954.122.388
ba38e464-8e3d-4e27-81c0-bf283351d89e,IFN,C0020964,inducing localized ,IFN,Immunity,2,X,????,[phsf],????,G12.450
4e910f74-7d74-472a-b552-934bb914eaf2,C0037083,IFN,interferes with IFN,Signal Transduction,IFN,2,X,[celf],????,G02.111.820;G04.835,????
53d55b0b-8a47-49ef-b549-7a1cd4333702,C0037083,C0021403,interferes during ,Signal Transduction,Influenza virus vaccine,2,X,[celf],[imft/phsu],G02.111.820;G04.835,D20.215.894.899.302
66f58118-2e88-43f6-8cf1-e67b787d06a2,C0037083,C0237820,interferes during ,Signal Transduction,Recovery - action,2,X,[celf],[acty],G02.111.820;G04.835,
d2af75e7-59cc-46ee-900b-b3e29e09b770,C0037083,C0189537,interferes with ,Signal Transduction,Repair of lung,2,X,[celf],[topp],G02.111.820;G04.835,
44ff93c6-2d14-49f5-aea9-fe4562d84e50,C0079419,C0038826,Disease susceptibility to bacterial,TP53 gene,Superinfection,2,X,[gngm],[dsyn],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,C01.539.597.880;C02.597.880;C03.684.880
9226029c-ea01-4425-913f-e082fe2fd83c,C0079419,C0007589,directly reduces ,TP53 gene,Cell Differentiation process,2,X,[gngm],[celf],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,G04.152
02c964c2-aac3-4170-83d9-2a246cad467c,C0079419,C0334097,directly reduces ,TP53 gene,Epithelial proliferation,2,X,[gngm],[patf],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,
1f293122-98f4-44f7-9276-3dd90cebd54d,C2926735,IFN,are Therefore parameters of IFN ,Duration,IFN,3,X,[orch/phsu],????,,????
1f293122-98f4-44f7-9276-3dd90cebd54d,C2926735,IFN,be considered for IFN ,Duration,IFN,1,X,[orch/phsu],????,,????
321cc8b3-3aa3-4d22-9621-8096f3b2dd94,C0206750,C0588006,caused mild-level ,Coronavirus Infections,Mild depression,1,X,[dsyn],[mobd],C02.782.600.550.200,
f57767bc-3188-4b3a-84ed-72c91fc093a6,C0029456,C0206750,showed significant association with ,Osteoporosis,Coronavirus Infections,2,X,[dsyn],[dsyn],C05.116.198.579;C18.452.104.579,C02.782.600.550.200
f57767bc-3188-4b3a-84ed-72c91fc093a6,C0029456,C0206750,pose challenge during ,Osteoporosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C05.116.198.579;C18.452.104.579,C02.782.600.550.200
200f257b-6963-4581-bd83-ab5ecc293f3a,C0003873,C0206750,showed significant association with ,Rheumatoid Arthritis,Coronavirus Infections,2,X,[dsyn],[dsyn],C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199,C02.782.600.550.200
aee31a32-b401-4937-abfa-d7eb42db8ba7,C0237123,C0206750,showed significant association with ,Alcohol or Other Drugs use,Coronavirus Infections,2,X,[mobd],[dsyn],,C02.782.600.550.200
93a8a986-0589-4fdb-b13f-b783033af74f,C0036341,C0206750,showed significant association with ,Schizophrenia,Coronavirus Infections,2,X,[mobd],[dsyn],F03.700.750,C02.782.600.550.200
e415d68a-f28c-4f8b-923f-ec0c666dabb3,C0032227,C3536832,reversed ,Pleural effusion disorder,Air,1,X,[dsyn],[inch/phsu],C08.528.652,G16.500.275.063.150;N06.230.300.100.150
268c0edd-8d3c-4e5e-8b7b-84df9bc6b2cc,C0032227,C0011334,reversed ,Pleural effusion disorder,Dental caries,1,X,[dsyn],[dsyn],C08.528.652,C07.793.720.210
0399ceed-0bfa-48b4-af1a-6930419abf62,C0032227,C0235593,reversed ,Pleural effusion disorder,Thoracic lymphadenopathy,1,X,[dsyn],[dsyn],C08.528.652,
c2e72390-50f9-40a1-aa6f-33f7edfcec4f,C0032227,C1868833,reversed ,Pleural effusion disorder,Bronchial wall thickening,1,X,[dsyn],[dsyn],C08.528.652,
4d7cc63f-9170-4596-8dad-ef7568cf7e2b,C0032227,C0233205,reversed ,Pleural effusion disorder,Halo sign,4,X,[dsyn],[sosy],C08.528.652,
9ce0db55-a39e-4d44-9683-d9f0b7c1d088,C1514593,C1306597,has has additionally documented together with most relevant ,Psychological Impact,Psychiatric problem,1,X,[clna],[mobd],,
d0340501-da9d-47ae-8751-ee2ad830a611,C1306597,C0206750,is in general population related to ,Psychiatric problem,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
bd8783d9-fde1-4a2d-9da6-b880a1fd811d,C2077218,C0264490,induced ,Injury care,Acute respiratory failure,1,X,[topp],[dsyn],,
52489e9c-52fc-4303-9ad4-03865b7f0ec2,C2077218,C0024115,induced ,Injury care,Lung diseases,1,X,[topp],[dsyn],,C08.381
0baa8d16-a5b3-437f-b922-88294c18a0f9,C3463820,C0700271,caused by ,Inhibition,M Protein multiple myeloma,1,X,[acty],[aapp/imft],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
835dd0ee-5f16-4eee-9701-faef2e11f523,C3260929,C0206750,is in patients with ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Coronavirus Infections,5,X,[clna],[dsyn],,C02.782.600.550.200
66a16f9f-41ac-404e-aec7-80243bdf70e0,C0221284,C2937290,is in HCC515 ,Leptocyte,COL-3,1,X,[cell],[antb/orch],,
190943cd-6db2-435d-a23d-324e67f99d38,C0221284,HCC515,is in HCC515 ,Leptocyte,HCC515,1,X,[cell],????,,????
ed1d5bce-c88a-4758-956a-fa8419eff1a9,C1704259,C0221284,are Leptocyte in HCC515,Biochemical Pathway,Leptocyte,2,X,[moft],[cell],,
1d63f15c-8fb1-43d9-bdf6-32de43985af0,C1704259,C2937290,are Leptocyte in HCC515,Biochemical Pathway,COL-3,1,X,[moft],[antb/orch],,
20999fdd-f247-48ae-baa1-cb040d84159a,C1704259,HCC515,are Leptocyte in HCC515,Biochemical Pathway,HCC515,1,X,[moft],????,,????
533334b4-f483-43eb-8f83-cbf65895601b,C1332838,C0084340, includes ,Candidate Disease Gene,rhoA GTP-Binding Protein,1,X,[gngm],[aapp/enzy],,D08.811.277.040.330.300.400.700.200;D12.644.360.525.700.200;D12.776.157.325.515.700.200;D12.776.476.525.700.200
717d9ad2-21e4-45c8-ab8a-60c9a5b9251a,C2937290,C1332838,is with common ,COL-3,Candidate Disease Gene,1,X,[antb/orch],[gngm],,
13d92e13-ef93-4745-a8b8-71b19a7fe6a9,C2937290,C0084340,is with common ,COL-3,rhoA GTP-Binding Protein,1,X,[antb/orch],[aapp/enzy],,D08.811.277.040.330.300.400.700.200;D12.644.360.525.700.200;D12.776.157.325.515.700.200;D12.776.476.525.700.200
cd236233-386d-422e-b1ac-1842b8f688b5,C1571058,C2937290,is with ,CGP 60474,COL-3,1,X,[orch],[antb/orch],,
a1ebc305-6051-41f4-892d-248985d2fa3f,C0017337,C1413096,related to lung ,Genes,CALR gene,1,X,[gngm],[gngm],G05.360.340.024.340,
e33a2b31-9eda-4eda-bc1c-6500313f38fd,C1571058,C0013227,have potential as ,CGP 60474,Pharmaceutical Preparations,1,X,[orch],[phsu],,D26
3fba12ae-a048-4fc2-a59b-9faa27455c22,C2937290,C0013227,have potential as ,COL-3,Pharmaceutical Preparations,2,X,[antb/orch],[phsu],,D26
b520a4c8-d931-49de-b87c-56b44c5b3122,C0022709,C0206750,is likely part of mechanisms leading to lung injury in ,Peptidyl-Dipeptidase A,Coronavirus Infections,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
b520a4c8-d931-49de-b87c-56b44c5b3122,C0022709,C0206750,was increased in demographic with incidence of severe ,Peptidyl-Dipeptidase A,Coronavirus Infections,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
b520a4c8-d931-49de-b87c-56b44c5b3122,C0022709,C0206750,causing ,Peptidyl-Dipeptidase A,Coronavirus Infections,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
b520a4c8-d931-49de-b87c-56b44c5b3122,C0022709,C0206750,underlying risk factors for ,Peptidyl-Dipeptidase A,Coronavirus Infections,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C02.782.600.550.200
5eb5b4de-cba4-42b5-85c0-4be6fe3c58e0,C0150126,C0184661,is aerosol-producing high-risk ,Airway Management,Interventional procedure,3,X,[topp],[topp],E02.041,
b129a141-11d6-40d8-afeb-72f3dbd4dadb,C1512523,C0597721,is broad spectrum ,hydrochloride,Janus kinase,2,X,[inch/phsu],[aapp/enzy],,D08.811.913.696.620.682.725.124;D12.776.476.393
34f5170d-92af-4d02-bfa0-781ba53230a4,C0031336,veryday,required for patients veryday ,Pharmacy (field),veryday,3,X,[bmod],????,H02.646,????
566e7b81-6084-41e0-9764-0e13d610f51f,C0035028,C0003467,may Representation (action) Exercise cope with,Relaxation,Anxiety,2,X,[acty],[mobd],I03.450.769,F01.470.132
3bf4570c-7e2d-4ddb-8168-480261af16e0,C0035028,C0015259,may Representation (action) helpful,Relaxation,Exercise,1,X,[acty],[dora],I03.450.769,G11.427.410.698.277;I03.350
65f25dd2-18d9-4dd4-a126-344190280ba2,C0037709,C2984554,improved ,Sound - physical agent,Emotional Well-being,1,X,[npop],[clna],G01.750.770.776,
a6e83832-2ee6-408f-b7d2-4624bf81c854,C0037709,C0206750,reduce preoccupation related to ,Sound - physical agent,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776,C02.782.600.550.200
c88a9fa8-ace3-4889-b672-3b3285dee9ad,C0037709,C0012634,reduce preoccupation related to ,Sound - physical agent,Disease,1,X,[npop],[dsyn],G01.750.770.776,C23.550.288
bcf59066-23f7-4e5c-9705-e9906233f680,C0037709,C1879547,reduce psychomotor ,Sound - physical agent,Activation action,1,X,[npop],[acty],G01.750.770.776,
1443d74b-2f73-4274-880b-712f34ae2fd9,C0547605,C0206750,is with risk of ,prevention of infection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
1443d74b-2f73-4274-880b-712f34ae2fd9,C0547605,C0206750,prevent spread of ,prevention of infection,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
1443d74b-2f73-4274-880b-712f34ae2fd9,C0547605,C0206750,becoming independent ,prevention of infection,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
542f039f-bb25-4c23-a150-e990506ccb6b,C0441655,C1175743,are needed for ,Activities,SARS coronavirus,3,X,[acty],[virs],,B04.820.504.540.150.113.937
1e3412ee-03b0-4016-9c0a-913e11b1954d,C0598312,C1175743,entry of ,DNA Replication,SARS coronavirus,3,X,[genf],[virs],G02.111.225;G05.226,B04.820.504.540.150.113.937
d03fb3a6-7010-4d5a-845d-ff6ec22f028e,C0035078,C0599878,are among gravest ,Kidney Failure,disease characteristic,3,X,[dsyn],[patf],C12.777.419.780;C13.351.968.419.780,
c4c63c73-b0ba-4f97-9c98-14cc42ee6c27,C0035078,C0206750,are among gravest ,Kidney Failure,Coronavirus Infections,2,X,[dsyn],[dsyn],C12.777.419.780;C13.351.968.419.780,C02.782.600.550.200
def003ea-abe2-4ca3-a1a3-e64888e2c789,C0079613,C0178784,is in other target ,Adoptive Immunotherapy,Organ,3,X,[topp],[bpoc],E02.095.465.425.400.330.050.400;E05.478.550.520.050.400,
39bdaf58-0091-419e-836e-54d87f2e3856,C0022709,C4689723,also serves as ,Peptidyl-Dipeptidase A,glycoprotein binding,5,X,[aapp/enzy/imft],[moft],D08.811.277.656.350.350.687,
34ee919a-1c42-4f93-936e-846018c69294,C0022709,C0034848,is regarded as ,Peptidyl-Dipeptidase A,Receptors Virus,8,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750.830
584c3bf0-640a-4526-a939-ec6654927ae3,C0022709,C1947904,enabling its ,Peptidyl-Dipeptidase A,Attachment (action),3,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
bea1ed2b-36b2-4253-843d-a5e301db2642,ity212,C0022709,widely expressing ,ity212,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
fc100731-6ae5-452b-b9f4-4e2ae599e609,C0887869,C0022709,widely expressing ,Cell-Matrix Junction,Peptidyl-Dipeptidase A,3,X,[celc],[aapp/enzy/imft],A11.284.149.165.165,D08.811.277.656.350.350.687
8e9f6f1f-f4de-45e4-80c3-ce3d7583640d,C0024432,C0003451,play role in ,macrophage,Antiviral Agents,2,X,[cell],[phsu],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,D27.505.954.122.388
0ebe47c5-de6e-4a94-bb74-07e508588f72,C0225385,C0227261,Small intestine mucous membrane,Structure of respiratory epithelium,Small intestine mucous membrane,5,X,[tisu],[tisu],,
d43400cb-b557-4774-82f5-f3172e263468,C1175743,C2699153,capacity for ,SARS coronavirus,Cell Invasion,8,X,[virs],[patf],B04.820.504.540.150.113.937,
2d18dad0-828f-4f04-8213-9a6f545c823a,C0033684,C1819995,enable Virus Internalization into,Proteins,Host Cell,5,X,[aapp/bacs],[celc],D12.776,
2d18dad0-828f-4f04-8213-9a6f545c823a,C0033684,C1819995,may use same ,Proteins,Host Cell,2,X,[aapp/bacs],[celc],D12.776,
2d18dad0-828f-4f04-8213-9a6f545c823a,C0033684,C1819995,entering ,Proteins,Host Cell,2,X,[aapp/bacs],[celc],D12.776,
119bfe54-a099-469d-b8ea-b6b438635a7a,C0033684,C1537068,enable ,Proteins,Virus Internalization,10,X,[aapp/bacs],[biof],D12.776,G06.920.881
a468ce9d-0460-4675-a910-d615a52448b1,C0033684,C0042210,synthesize ,Proteins,Vaccines,5,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D20.215.894
0fdfcb78-94e6-4aee-94c8-0398296dc499,C0033684,C0003250,synthesize ,Proteins,Monoclonal Antibodies,5,X,[aapp/bacs],[aapp/imft],D12.776,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
131def91-aa4b-4af1-8889-f48d01b98163,C0040300,C0022709,express ,Body tissue,Peptidyl-Dipeptidase A,5,X,[tisu],[aapp/enzy/imft],A10,D08.811.277.656.350.350.687
128b68bd-aa42-4a14-97ea-9696436686a1,C0040300,C0700271,performed in-depth analysis like sequence alignments of ,Body tissue,M Protein multiple myeloma,5,X,[tisu],[aapp/imft],A10,x.x.x.x
976e1ee6-42c6-4101-bca3-776d60bebeab,C0040300,C1175743,performed in-depth analysis like sequence alignments of ,Body tissue,SARS coronavirus,5,X,[tisu],[virs],A10,B04.820.504.540.150.113.937
e782fc83-0428-425b-8f27-2e826df97540,C0034788,C0003250,synthesize ,Receptors Antigen,Monoclonal Antibodies,5,X,[aapp/imft/rcpt],[aapp/imft],D12.776.543.750.705.816,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
004a228d-d2c4-4068-88c8-45f3aecf42ce,C0034788,C0042210,synthesize ,Receptors Antigen,Vaccines,5,X,[aapp/imft/rcpt],[aapp/imft/phsu],D12.776.543.750.705.816,D20.215.894
69ac5320-c084-4bc7-99f7-5ae84d8a7ec2,C0022709,C0178784,is widely expressed in ,Peptidyl-Dipeptidase A,Organ,5,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
69ac5320-c084-4bc7-99f7-5ae84d8a7ec2,C0022709,C0178784,plays role in practically ,Peptidyl-Dipeptidase A,Organ,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
bc3c29c2-7068-4cc7-baaa-c1488b281689,C3711684,C0597358,has regions in ,S protein severe acute respiratory syndrome coronavirus,receptor binding,3,X,[aapp/bacs],[moft],x.x.x.x,
f886eb5e-098e-48b1-b289-1a4ba8cb8773,C0030956,C0597358,is in ,Peptides,receptor binding,5,X,[aapp/phsu],[moft],D12.644,
a9241014-f1a6-4650-90c0-76ea40a9ee50,C1175743,C4049595,can Binding (Molecular Function) to,SARS coronavirus,HLA Complex,4,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,
a773eed5-2ceb-463c-b2d3-51b9e4de579c,C1175743,C0002085,can Binding (Molecular Function) to,SARS coronavirus,Alleles,4,X,[virs],[gngm],B04.820.504.540.150.113.937,G05.360.340.024.340.030
c097fb3d-207d-47cd-9646-e683dca09fa6,C1175743,C0003316,serve as effective ,SARS coronavirus,Epitopes,4,X,[virs],[imft],B04.820.504.540.150.113.937,D23.050.550
8f5b1214-8e8a-4733-aa17-9ce8a2268957,C1175743,C0042210,serve as effective ,SARS coronavirus,Vaccines,4,X,[virs],[aapp/imft/phsu],B04.820.504.540.150.113.937,D20.215.894
8dcdf5f5-1984-4c16-96c7-38110b9f40a2,C0030858,COVID-19,distinguish Coronavirus Infections from,Pentaerythritol Tetranitrate,COVID-19,1,X,[orch/phsu],[virs],D02.033.455.706.690,C000657245
593e17d6-906c-4e16-98e7-d0814eb49578,C0162429,COVID-19,treating ,Malnutrition,COVID-19,1,X,[dsyn],[virs],C18.654.521,C000657245
a627b7fd-059e-40d5-a7af-f955316ac694,C1533734,C0543419,serve as preventive measure against ,Administration procedure,Sequela of disorder,2,X,[topp],[patf],,
ac011003-e136-4864-a275-4903550a7fac,C1533734,C0206750,serve as preventive measure against ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
ac011003-e136-4864-a275-4903550a7fac,C1533734,C0206750,improves clinical outcome of patients with ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
ac011003-e136-4864-a275-4903550a7fac,C1533734,C0206750,is safe treatment option for those with ,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
ac011003-e136-4864-a275-4903550a7fac,C1533734,C0206750,optimize Biochemical Pathway during current,Administration procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
025cc579-523f-4aab-978a-e6b3483fef8d,C0042211,C1819995,inducing trained ,Vaccines Attenuated,Host Cell,6,X,[imft/phsu],[celc],D20.215.894.811,
22888a7b-cf83-4f2b-b0cd-fbbb630c1e33,C0042211,C3714514,inducing trained ,Vaccines Attenuated,Infection,3,X,[imft/phsu],[patf],D20.215.894.811,C01.539
bec68e91-5056-4c10-9ece-f5f9f94db703,C0042211,C0150259,nonspecific Infection protection against lethal,Vaccines Attenuated,Infection protection,3,X,[imft/phsu],[topp],D20.215.894.811,
bec68e91-5056-4c10-9ece-f5f9f94db703,C0042211,C0150259,provide nonspecific ,Vaccines Attenuated,Infection protection,6,X,[imft/phsu],[topp],D20.215.894.811,
f58458f2-b9c3-4b05-8a5a-d2354a9bef5f,C0042211,C0450254,nonspecific Infection protection against lethal,Vaccines Attenuated,Pathogenic organism,3,X,[imft/phsu],[orgm],D20.215.894.811,
34c159dd-b365-4d52-a824-b60fbf523136,C0042211,C0042210,nonspecific Infection protection against lethal,Vaccines Attenuated,Vaccines,3,X,[imft/phsu],[aapp/imft/phsu],D20.215.894.811,D20.215.894
690e67e5-6545-4c9b-95b9-31348aa86a5e,C2926735,C3687742,is in nasopharyngeal ,Duration,Oropharyngeal swab,2,X,[orch/phsu],[bdsu],,
0106d8e2-c52c-404a-b3ee-70704aba66ac,C0031740,C0309872,mitigate Coronavirus Infections to either,Photochemotherapy,PREVENT (product),1,X,[topp],[phsu],E02.186.500;E02.319.685;E02.774.722,
2fe2cd5e-f886-4279-a90a-1ba36a8b1606,C0031740,C3714514,mitigate Coronavirus Infections to either,Photochemotherapy,Infection,1,X,[topp],[patf],E02.186.500;E02.319.685;E02.774.722,C01.539
72fb89f9-f102-440c-a5f6-15bad2598207,C0031740,C0206750,mitigate ,Photochemotherapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.186.500;E02.319.685;E02.774.722,C02.782.600.550.200
737327ff-8284-411f-b12b-041fa2246ef3,C0035253,C1705178,is in ,Rest,Order (action),3,X,[dora],[acty],I03.450.769.647,
6516dad9-988b-4564-9350-27f15ffd32f0,71-year,C1175743,was hospitalized at University of Bologna for ,71-year,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
790cdf5d-d2f7-424c-82f3-699b01401199,71-year,C0009450,was hospitalized at ,71-year,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
c8a16f5c-5d9e-4851-ae49-0167ac1a9cf3,71-year,C0003842,is with history of ,71-year,Arteries,2,X,????,[bpoc],????,A07.015.114
d1f26c47-f53c-41cd-ac69-b0ad3e96832d,C1696945,C0543467,showing statistically significant reduction in ,Burnout Psychological,Operative Surgical Procedures,1,X,[mobd],[topp],F01.145.126.990.367;F02.830.900.333,E04
9e3fd56e-8872-4b78-a3af-efa2676dd08b,C0599878,C0206750,is in early phase of ,disease characteristic,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
9e3fd56e-8872-4b78-a3af-efa2676dd08b,C0599878,C0206750,on data is number of recovered ,disease characteristic,Coronavirus Infections,8,X,[patf],[dsyn],,C02.782.600.550.200
bb0b7844-6357-4bdf-a73f-428eac2e1200,C1167622,C0542479,were found by molecular docking approaches with ,Binding (Molecular Function),Energy Physics,2,X,[moft],[npop],,
5466f640-1c5d-4e13-8814-91b1578f0ef8,C0206750,C0795934,has opened new ,Coronavirus Infections,Digitorenocerebral Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
1a6e5bfc-f417-4ea7-ad86-33383043d08c,C0206750,C0003504,has opened new ,Coronavirus Infections,Aortic Valve Insufficiency,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.484.095
e6eb2f86-66cc-472d-ba52-215b545661c0,C0243077,C0206750,are related to ,inhibitors,Coronavirus Infections,1,X,[chvf],[dsyn],,C02.782.600.550.200
e6eb2f86-66cc-472d-ba52-215b545661c0,C0243077,C0206750,combat current ,inhibitors,Coronavirus Infections,3,X,[chvf],[dsyn],,C02.782.600.550.200
61f290d0-d443-4340-9dd4-845a227ba7aa,C1533734,C0079189,reduce effect of ,Administration procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
584a8032-42ee-4f0c-8b5f-9513ce7f8310,C3266262,C0206655,is with three parallel ,Multiple Chronic Conditions,Alveolar rhabdomyosarcoma,1,X,[dsyn],[neop],C23.550.291.500.500,C04.557.450.590.550.660.665;C04.557.450.795.550.660.665
afac04d6-29f8-4e3c-a5e1-bc944b46bdd8,C0021361,C3839507,is with ,Female infertility,Diminished ovarian reserve,3,X,[patf],[dsyn],C13.351.500.365.700,
36dc2be8-3847-41cd-a2ca-1db75cf4ed4f,C0404268,C0013938,is with planned fresh ,Oocyte Retrieval,Embryo transfer (procedure),3,X,[topp],[topp],E02.875.800.976;E04.936.537.625;E05.820.800.976,E02.875.800.500;E05.820.800.500
2dd04594-4b16-471b-bd15-4f985b22af33,C2751898,C3839507,is in patients with ,Ventricular Fibrillation Paroxysmal Familial 1,Diminished ovarian reserve,3,X,[dsyn],[dsyn],x.x.x.x,
75e109da-22f0-4030-9b43-0330188c4e60,C2948600,C0028754,investigate whether ,Aim,Obesity,1,X,[inch/phsu],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
171eacc2-6ee7-4b41-b95f-1c6e218f2985,C0005516,C0369718,were higher than ,Biological Markers,N not otherwise specified Antibody,8,X,[clna],[aapp/imft],D23.101,
8570c8af-e013-4a6f-8a91-9e04437049d2,C0079189,C0544688,is serious ,cytokine,complication of disease,4,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
c52d2034-19ac-4414-8763-781a9b9f0405,C1861452,C0544688,is serious ,Storm Syndrome,complication of disease,4,X,[dsyn],[patf],x.x.x.x,
e31b41d4-1b64-4e85-bc72-a40c5a421e8c,C1861452,C0206750,is serious ,Storm Syndrome,Coronavirus Infections,4,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
e31b41d4-1b64-4e85-bc72-a40c5a421e8c,C1861452,C0206750,is considered as leading cause of mortality in ,Storm Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
0cc3467e-6ead-432c-9df0-cd9ee242dc8a,C0001617,C1096155,is In other very similar ,Adrenal Cortex Hormones,Macrophage Activation Syndrome,4,X,[horm/orch/phsu],[dsyn],D06.472.040,C20.683.515.800
e93052bd-67c3-4fc3-a5e2-aa636eca9ffb,C1700396,C0017710,early use of ,CCL21 protein human,Glucocorticoids,4,X,[aapp/bacs],[horm/orch],x.x.x.x,D06.472.040.543;D27.505.696.399.472.488
abc9f2bd-5e19-4bf6-a870-6b6807985878,C0040038,C0947751,is highly suspected through COV2,Thromboembolism,vascular inflammations,8,X,[patf],[dsyn],C14.907.355.590,
a7ed3037-0956-48b6-9209-7313e27ce899,C0040038,C1175743,is highly suspected through COV2,Thromboembolism,SARS coronavirus,8,X,[patf],[virs],C14.907.355.590,B04.820.504.540.150.113.937
f5e27456-3316-47d4-a28a-cd23d46da83c,C0040038,COV2,is highly suspected through COV2,Thromboembolism,COV2,8,X,[patf],????,C14.907.355.590,????
8ebf50f1-7bad-42d9-a10b-46541cddde08,LTCF,C0206750,are why resilient to ,LTCF,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
61125f50-d9ea-4001-9fe5-db174bf3b181,C1175743,7days,showed sensitivity before 7days,SARS coronavirus,7days,1,X,[virs],????,B04.820.504.540.150.113.937,????
c5a89418-80fd-4b5c-af55-016a69011806,C0683174,COVID-19,provides ,topical application,COVID-19,1,X,[topp],[virs],,C000657245
79aa6cbf-f77d-4a0f-a0cf-936e260f0618,C0683174,C0184661,provides ,topical application,Interventional procedure,1,X,[topp],[topp],,
a6656504-8943-49e6-82d6-c4f23bca71ed,C3714514,C0012634,enter phase of control of spread of ,Infection,Disease,1,X,[patf],[dsyn],C01.539,C23.550.288
c24bab3f-ae0f-411b-8678-1363c397fb62,C0242781,C0037778,is in specific context of development of our ,disease transmission,Medical Specialities,1,X,[patf],[bmod],N06.850.310,H02.403
6902d342-ccdf-43e8-b930-8ec6e5ff3d17,C0040590,C0184661,is aerosol-generating ,Tracheostomy procedure,Interventional procedure,1,X,[topp],[topp],E02.041.750;E04.579.935;E04.580.900;E04.928.780,
ba2c3139-b57e-4f63-9a61-2ae3f83b0513,C0040590,C1160716,poses significant risk ,Tracheostomy procedure,viral transmission,1,X,[topp],[celf],E02.041.750;E04.579.935;E04.580.900;E04.928.780,
ccddfbeb-488f-47df-8c91-7c70f4bd5c77,C0040590,14th,was carried out on 14th ,Tracheostomy procedure,14th,1,X,[topp],????,E02.041.750;E04.579.935;E04.580.900;E04.928.780,????
8195f3d3-c177-4627-b03d-0777be1170d8,C0040590,C0021925,was carried out on 14th ,Tracheostomy procedure,Intubation,1,X,[topp],[topp],E02.041.750;E04.579.935;E04.580.900;E04.928.780,E02.585;E05.497
2ccfdef5-a64e-43d2-a100-467cf5589815,C0022709,C0034987,is key counter ,Peptidyl-Dipeptidase A,Regulatory Sequences Nucleic Acid,2,X,[aapp/enzy/imft],[bacs/nnon],D08.811.277.656.350.350.687,G02.111.570.080.689;G05.360.080.689
8f98286a-7538-4729-bb10-4e8f97e48d01,C0103306,C0003009,proinflammatory and prothrombotic effects of ,angiotensin I (1-7),angiotensin II,1,X,[aapp/phsu],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
4650d969-ad8b-49fc-a097-ef8f9ab2d0e8,C4082587,C0003009,proinflammatory and prothrombotic effects of ,HLA Class II Histocompatibility Antigen Gamma Chain human,angiotensin II,1,X,[aapp/imft],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
d3e2aaac-863b-4cd9-986d-7f604f946b76,C0022709,C0103306,converts ,Peptidyl-Dipeptidase A,angiotensin I (1-7),2,X,[aapp/enzy/imft],[aapp/phsu],D08.811.277.656.350.350.687,x.x.x.x
66473bdc-71f7-4831-9607-3d72ac49ac7d,C0022709,C4082587,converts ,Peptidyl-Dipeptidase A,HLA Class II Histocompatibility Antigen Gamma Chain human,2,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,
70e87ec0-d5f1-483c-81db-be402c40b883,C0022709,C1656555,also facilitates ,Peptidyl-Dipeptidase A,viral entry into host cell,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,
77eb8f81-5af3-43fe-8e87-ab2070b62cec,C3687832,COVID-19,may IMPACT gene,Drugs - dental services,COVID-19,1,X,[topp],[virs],,C000657245
7c7ec85f-336e-47f0-bb92-4a5b57fab53a,C3687832,C0699748,may IMPACT gene,Drugs - dental services,Pathogenesis,1,X,[topp],[patf],,
e3ab2f8f-efc8-4a15-b7cd-fbbdaeff1753,C3687832,C0022709,may IMPACT gene,Drugs - dental services,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
e3ab2f8f-efc8-4a15-b7cd-fbbdaeff1753,C3687832,C0022709,targeting ,Drugs - dental services,Peptidyl-Dipeptidase A,1,X,[topp],[aapp/enzy/imft],,D08.811.277.656.350.350.687
36e173ee-82d6-4033-8d42-520430738c7f,COVID-19,C0023530,showed ,COVID-19,Leukopenia,1,X,[virs],[dsyn],C000657245,C15.378.553.546
00072edf-d1db-4554-968f-a7ca2ea37086,C0028754,C0242781,may Contribution to,Obesity,disease transmission,2,X,[dsyn],[patf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,N06.850.310
bc64b945-190d-4a99-a985-7a906b354aa6,C2926735,COVID-19,were similar in ,Duration,COVID-19,3,X,[orch/phsu],[virs],,C000657245
c0bceaef-5bf7-4dc5-b5bd-47ca99623ad1,COVID-19,C0344211,Management of is mainly ,COVID-19,Supportive care,1,X,[virs],[topp],C000657245,
2d47d42f-37cd-489e-9354-1cc450d1636d,C0035222,C0079189,is characterized by severe ,Respiratory Distress Syndrome Adult,cytokine,1,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374;D12.776.467.374;D23.529.374
2d47d42f-37cd-489e-9354-1cc450d1636d,C0035222,C0079189,sustained by uncontrolled inflammatory ,Respiratory Distress Syndrome Adult,cytokine,1,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374;D12.776.467.374;D23.529.374
f7a20609-3700-4abb-ba1d-f4c8eb463474,C0151467,C0001623,is in patients with ,Addisonian crisis,Adrenal gland hypofunction,1,X,[dsyn],[dsyn],,C19.053.500
6152c2dc-a752-4f9e-bce1-18e668940437,C0151467,C2745965,is medical ,Addisonian crisis,Emergencies [Disease/Finding],1,X,[dsyn],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
ce85f943-5e65-4118-b9f0-115db0ef718c,C0001623,C0017710,with patients is dose of ,Adrenal gland hypofunction,Glucocorticoids,1,X,[dsyn],[horm/orch],C19.053.500,D06.472.040.543;D27.505.696.399.472.488
c16b9539-8bb1-4816-a2ef-aef3d04edadc,C0001623,C0279033,with patients is dose of ,Adrenal gland hypofunction,Replacement therapy,1,X,[dsyn],[topp],C19.053.500,
00cd1e08-cf09-4671-98e1-73a36e903a39,C0001623,C0744425,with patients is dose of ,Adrenal gland hypofunction,glucocorticoid therapy,1,X,[dsyn],[topp],C19.053.500,
42406bba-8459-4f4c-a9ee-9d9a148eb50f,C0015967,C0073187,was On 8 ,Fever,Blood group antigen D,3,X,[sosy],[aapp/imft],C23.888.119.344,x.x.x.x
b9a91f7c-8fc9-450c-98f2-1f1d09ace559,C0369768,C2964138,was despite high ,Molecular oxygen saturation,Inspiratory flow,6,X,[moft],[clna],,
84b15eeb-18ae-44b7-99a4-1c700a1ed612,C0369768,C0030054,was despite high ,Molecular oxygen saturation,Oxygen,3,X,[moft],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
64056dac-f5c8-426a-906f-e49802dd68c6,C0003451,C0030054,were used In addition to nasal catheter ,Antiviral Agents,Oxygen,3,X,[phsu],[bacs/elii/phsu],D27.505.954.122.388,D01.268.185.550;D01.362.670;x.x.x.x
b48dcaf7-75e6-471b-8b18-8fdbcda0a6d6,C4720089,C0073187,were given orally for ,Oseltamivir Phosphate Capsules,Blood group antigen D,6,X,[clnd],[aapp/imft],,x.x.x.x
4dbe2ed2-2b4c-48ec-aaeb-41709c2cc322,C0021027,C0021440,was administered by intravenous drip ,Immunoglobulins,Intravenous infusion procedures,3,X,[aapp/imft],[topp],D12.776.124.486.485;D12.776.124.790.651;D12.776.377.715.548,E02.319.267.082.500;E02.319.267.510.590
1f30fb8b-66c3-4372-840b-398d19858528,C0025815,C0033727,was given once ,Methylprednisolone,Protons,3,X,[horm/orch/phsu],[elii],D04.210.500.745.432.769.795.539,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
becb18bf-8c07-48b0-8fa6-1b27027c6d78,C0040106,C0005525,once daily combined with ,Thymosin,Biological Response Modifiers,3,X,[aapp/horm],[imft/phsu],D06.472.910.850;D12.644.548.869;D12.776.922;x.x.x.x,D27.505.696.477
c481f5b0-240b-4d45-ab5c-1cd725da8a0e,C0031354,C0206750,were negative for novel ,Pharyngeal structure,Coronavirus Infections,1,X,[bpoc],[dsyn],A03.556.750;A04.623;A14.724,C02.782.600.550.200
a22992f1-f794-4da7-a47f-ebb13cee48e2,C0031354,C0028606,were negative for novel ,Pharyngeal structure,Nucleic Acids,1,X,[bpoc],[bacs/nnon],A03.556.750;A04.623;A14.724,D13.444
5ee6d1e4-57ba-44cb-a0d7-3165fc19610c,C0072027,C1175743,determining severity of patients infected with ,procalcitonin,SARS coronavirus,3,X,[aapp/bacs],[virs],D06.472.699.666;D12.644.548.744;D12.776.811.555,B04.820.504.540.150.113.937
1d1c0a56-ccc1-4d51-ba4d-85bf98a053fb,C0037633,C1955980,proposed in ,Solutions,Disaster Medicine,1,X,[sbst],[bmod],D26.776,H02.403.230
8285ff51-f840-4bc5-a09d-78f02a3bc965,C0040861,C0806140,manage Emergency Department ,Triage,Flow,1,X,[topp],[npop],N02.421.297.900,
aec5447a-d953-456f-8997-fe29d8330c35,C1856053,C0040861,established ,Hydranencephaly with Renal Aplasia-Dysplasia,Triage,1,X,[dsyn],[topp],x.x.x.x,N02.421.297.900
32e5305e-5d4f-488b-806d-fd0f2a036639,C0040861,C1829939,prevent spread among ,Triage,{Non-patient},2,X,[topp],[clna],N02.421.297.900,
a8e14e92-3a88-4450-9f13-78c730b6c42b,C0557061,C3203533,will focus lockdown policies on ,Discussion (procedure),Psychological Trauma,1,X,[topp],[mobd],,F03.950.750.375
486d552f-4e84-4366-afcb-724f948517eb,C0557061,C0206750,will focus poorly equipped health care system dealing with spread of ,Discussion (procedure),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
42f34250-30b1-4b36-8464-0b9617a582fd,C3203533,C0020701,types of were social withdrawal ,Psychological Trauma,Hysteria,1,X,[mobd],[mobd],F03.950.750.375,F03.675.400.500
ba5a39da-89bc-4535-8a7d-d7cf260f58be,C3203533,C0042693,types of were social withdrawal ,Psychological Trauma,Violence,2,X,[mobd],[mobd],F03.950.750.375,I01.198.240.856;I01.880.735.900
ef6d1308-cf29-45b6-ba6f-8be2b5a62ac4,C2948600,C0007634,investigate Binding (Molecular Function) together with,Aim,Cells,1,X,[inch/phsu],[cell],,A11
e5477274-75d9-4760-8a39-62dae6b6d848,C3266262,C0265267,is in ,Multiple Chronic Conditions,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,1,X,[dsyn],[dsyn],C23.550.291.500.500,x.x.x.x
f2bd568f-3612-4859-b2e8-9d7794f1d9b8,C0027424,C0026727,is with ,Nasal congestion (finding),Mucous body substance,1,X,[sosy],[bdsu],,A12.200.503
8e6ab0b2-9357-4451-9ad5-46055440be9a,C0035473,C1175743,are typically explained in case of ,Rhinovirus,SARS coronavirus,8,X,[virs],[virs],B04.820.565.775,B04.820.504.540.150.113.937
87718b84-8995-4311-b955-abed114e31b0,C0029341,C1175743,are typically explained in case of ,Orthomyxoviridae,SARS coronavirus,8,X,[virs],[virs],B04.820.545,B04.820.504.540.150.113.937
e0888282-3f62-4b0d-b0f1-0c2e7bc0650f,C0302507,C1175743,are typically explained in case of ,Parainfluenza Virus Infections,SARS coronavirus,8,X,[dsyn],[virs],C02.782.580.600,B04.820.504.540.150.113.937
c45f8eec-42de-4a6f-91b1-968e515d6e1c,C1175175,C1705178,is in ,Severe Acute Respiratory Syndrome,Order (action),4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
5b4f6386-ee15-4815-bd46-4d2e05cbf59a,C0018943,C0206750,is in patients with ,Hematology (discipline),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.429.445,C02.782.600.550.200
a4c3f4ba-975b-4bbf-959e-a26f361dea09,C2948600,C0018943,investigate characteristics of ,Aim,Hematology (discipline),1,X,[inch/phsu],[bmod],,H02.403.429.445
48bb1e99-d4a8-4a99-80a7-a38f86bdd617,C0020517,C0024264,followed by combined parameter ,Hypersensitivity,Lymphocyte,1,X,[patf],[cell],C20.543,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
71b88494-8735-46cc-9b3f-781322f4a59d,C0024264,C0018943,is best ,Lymphocyte,Hematology (discipline),1,X,[cell],[bmod],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,H02.403.429.445
fe75900e-b921-4162-9989-60db2396d84b,RDW-SD,C0018943,is best ,RDW-SD,Hematology (discipline),1,X,????,[bmod],????,H02.403.429.445
beae9626-0460-445f-9f54-b63bb8edd33c,C0014507,C0150638,should should focused on ,Epidemiology,Preventing injury,2,X,[bmod],[topp],H02.403.720.500,
e38920c1-3db7-40e7-a7c7-442032fca9b0,C0597357,C0012634,make patients susceptible to ,receptor,Disease,1,X,[aapp/rcpt],[dsyn],,C23.550.288
98a1f09e-118d-47c8-bb94-bc766fca9411,C0206750,C0012655,is In nested case-control ,Coronavirus Infections,Disease susceptibility,2,X,[dsyn],[clna],C02.782.600.550.200,C23.550.291.687;G07.100.250
98a1f09e-118d-47c8-bb94-bc766fca9411,C0206750,C0012655,raised many questions about higher ,Coronavirus Infections,Disease susceptibility,1,X,[dsyn],[clna],C02.782.600.550.200,C23.550.291.687;G07.100.250
a244af73-d935-4f1b-b99f-4691ef9daed3,C1707455,C0012655,is In nested case-control analysis of ,Comparison,Disease susceptibility,2,X,[acty],[clna],,C23.550.291.687;G07.100.250
2b878c5b-2a24-4786-830f-8f1ad6c5ac7d,C4288399,C0206750,are indicated in context of ,Pharmacotherapy Discontinuation,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
2d9a5df9-41e9-4ec2-903d-5df00ea1c063,C0020517,RT-PCR,topic given insufficient quantity of RT-PCR ,Hypersensitivity,RT-PCR,3,X,[patf],????,C20.543,????
d3649252-433b-4e1b-b471-1389efe5dfde,C0020517,C1707455,was For chest CT ,Hypersensitivity,Comparison,4,X,[patf],[acty],C20.543,
db7b0994-58f1-4474-aa3b-04b05b7cf1c4,RT-PCR,C1707455,Hypersensitivity of was,RT-PCR,Comparison,2,X,????,[acty],????,
c413ddfd-6ee9-4b0e-855d-23b906a496b2,C0947647,C0242781,increase likelihood of ,Manipulation procedure,disease transmission,2,X,[topp],[patf],,N06.850.310
c5fd5385-eabe-4fb5-917c-c2ce83f7faf3,C0947647,C0184661,therefore is considered high-risk ,Manipulation procedure,Interventional procedure,2,X,[topp],[topp],,
3b60e34b-7ee7-4fbf-844e-c4c56da6db15,C0038056,C1175743,was positive for PCR,Sputum,SARS coronavirus,2,X,[bdsu],[virs],A12.200.808,B04.820.504.540.150.113.937
99f522ed-7c85-4e46-9023-c131acbd1707,C0038056,PCR,was positive for PCR,Sputum,PCR,2,X,[bdsu],????,A12.200.808,????
92750db9-59d6-46fc-9934-a2d28e6322d7,C1532372,C0028606,were tested for ,Respiratory secretion,Nucleic Acids,4,X,[bdsu],[bacs/nnon],,D13.444
48552e1c-4301-4329-9187-fc5d081bb612,C4050231,C1861172,identify patients at risk for ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Venous Thromboembolism,2,X,[clna],[dsyn],,C14.907.355.590.700
8a3a6f18-2aa0-4982-b08d-4d11dbd43877,C1707455,C0694549,is with ,Comparison,Community acquired pneumonia,2,X,[acty],[dsyn],,
a63fa31c-af6a-4857-a2dc-bfdd443df631,C0060323,C0694549,Comparison with,Fibrin fragment D,Community acquired pneumonia,2,X,[aapp/bacs],[dsyn],x.x.x.x,
a6a41865-44dc-439f-bfdb-cf10b2aa5499,C0060323,C0021368,were related with ,Fibrin fragment D,Inflammation,3,X,[aapp/bacs],[patf],x.x.x.x,C23.550.470
25dbb68f-86fe-4f14-83d0-f775627332ed,C4050231,C0206750,is in ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
9003b59a-b6cf-4a5c-8ff7-759aef81b9b0,C0040590,C1145670,were performed on patients with ,Tracheostomy procedure,Respiratory Failure,1,X,[topp],[dsyn],E02.041.750;E04.579.935;E04.580.900;E04.928.780,C08.618.846
8ef97df5-cfe6-4afa-9083-da2522a3a6d6,C0040590,C1175175,were performed on patients with ,Tracheostomy procedure,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],E02.041.750;E04.579.935;E04.580.900;E04.928.780,C02.782.600.550.200.750;C08.730.730
36297fcf-2efe-4705-acc8-12570a39d2c8,C0206419,C0015392,is rapidly spreading across ,Genus: Coronavirus,Eye,1,X,[virs],[bpoc],B04.820.504.540.150,A01.456.505.420;A09.371
36297fcf-2efe-4705-acc8-12570a39d2c8,C0206419,C0015392,is sweeping ,Genus: Coronavirus,Eye,1,X,[virs],[bpoc],B04.820.504.540.150,A01.456.505.420;A09.371
b7dc3c30-3e69-45f7-8993-c310f694f95e,C0206419,C2825812,has posed barriers to communication ,Genus: Coronavirus,Deploy,1,X,[virs],[acty],B04.820.504.540.150,
dad4cee9-ac33-4143-9b08-3a3aab151f26,C0206419,C0003467,has posed barriers to communication ,Genus: Coronavirus,Anxiety,1,X,[virs],[mobd],B04.820.504.540.150,F01.470.132
59f556d9-c0b2-4b43-b550-455ef82ae234,C0079460,C1440080,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,Alveolar,2,X,[aapp/imft],[bpoc],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
b4906e36-1a5a-478d-94e4-d291897ee038,C0079460,C3820859,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,macrophage homeostasis,2,X,[aapp/imft],[celf],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
608fdda2-7089-4ca8-9712-1cc4fdbde9cd,C0079460,C0019868,plays role in ,Granulocyte-Macrophage Colony-Stimulating Factor,Homeostasis,2,X,[aapp/imft],[biof],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,G07.410
14088043-5067-497b-b3a9-4dcbd65756de,C4684977,C0007131,have revolutionized management of fit patients with ,Immune Checkpoint Inhibitor,Non-Small Cell Lung Carcinoma,1,X,[imft/phsu],[neop],,C04.588.894.797.520.109.220.249;C08.381.540.140.500;C08.785.520.100.220.500
ce15b430-5a0d-4dfd-a700-5922512b2d06,C0279025,C0206419,acts during ,Hormone Therapy,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
cd1f8f23-528e-48e7-b2fe-392c9f274e4a,coldand,C0042776,transmitting ,coldand,Virus,1,X,????,[virs],????,B04
d1b202e2-0717-4591-bdb4-7f0f165a9063,C0206419,C0017968,presents with S ,Genus: Coronavirus,Glycoproteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D09.400.430;D12.776.395
7fd4998a-6137-4295-9666-764106b56bbf,C0206419,C0596901,presents with S ,Genus: Coronavirus,Membrane,1,X,[virs],[celc],B04.820.504.540.150,A10.615
b7854745-4512-4ce0-ad92-9bd65b06c4b4,C0596901,C0022709,plays role with ,Membrane,Peptidyl-Dipeptidase A,1,X,[celc],[aapp/enzy/imft],A10.615,D08.811.277.656.350.350.687
cbe1c00f-0f5a-423c-b815-2ae2fe937a16,C0596901,C0597357,plays role with ,Membrane,receptor,1,X,[celc],[aapp/rcpt],A10.615,
b2472f83-61fc-4e01-8d41-00769f919f79,C0596901,C1721019,plays role in ,Membrane,Virus Attachment,1,X,[celc],[biof],A10.615,G06.920.868
8af51426-f8b7-440e-8cf4-b6ca4514b0e1,C0042776,C1824356,replicate after ,Virus,KIAA1551 gene,1,X,[virs],[gngm],B04,
3ac6a9e7-1884-43c8-8fd2-f4b5ba28d894,C0042776,C0010834,replicate after ,Virus,Cytoplasm,1,X,[virs],[celc],B04,A11.284.430.214
e56d3d08-6886-4567-820b-19ae0518bb85,C0022709,C0225700,is intramembrane receptor on,Peptidyl-Dipeptidase A,Type-II Pneumocytes,1,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,A04.411.715.100;A11.436.081
abf7c07a-2d31-40d0-a944-f7639165c43d,C0597357,C0225700,is intramembrane receptor on,receptor,Type-II Pneumocytes,1,X,[aapp/rcpt],[cell],,A04.411.715.100;A11.436.081
56ea1d2f-37fe-440b-a126-2b79d1663246,C2936405,C1175743,is widely used for rapid identification of potential ,Drug Repositioning,SARS coronavirus,3,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
56ea1d2f-37fe-440b-a126-2b79d1663246,C2936405,C1175743,is In scenario widely used for identification of potential ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
56ea1d2f-37fe-440b-a126-2b79d1663246,C2936405,C1175743,utilizing publicly available high throughput ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
56ea1d2f-37fe-440b-a126-2b79d1663246,C2936405,C1175743,stands out Due to evidence of ,Drug Repositioning,SARS coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
56ea1d2f-37fe-440b-a126-2b79d1663246,C2936405,C1175743,is In scenario used for rapid identification against ,Drug Repositioning,SARS coronavirus,1,X,[topp],[virs],E05.290.875,B04.820.504.540.150.113.937
0e0c65ab-c785-42aa-9805-7e3d0f746ff1,C1167395,C0017262,utilizing publicly available high throughput ,Host (organism),Gene Expression,2,X,[orgm],[genf],,G05.297
fb43c070-3834-4023-938f-3aa70616796c,C2936405,C0017262,utilizing publicly available high throughput ,Drug Repositioning,Gene Expression,2,X,[topp],[genf],E05.290.875,G05.297
6daaba01-cfff-4987-95db-b93b35dadccd,C1333327,C0009450,were identified in early ,TYMP gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
1e5961e1-5934-4ff2-aa6c-9909d4f2bdf9,C0387583,C0009450,were identified in early ,cyclooxygenase 2,Communicable Diseases,3,X,[aapp/enzy],[dsyn],D08.811.600.720.750,C01.539.221
f2ce88a7-30da-47cc-9cc0-754ed847c321,C1412937,C0009450,were identified in early ,C1S gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
678a938d-f259-4213-9502-25dfc8018a89,C0009002,C0009450,were identified in early ,Clofibrate,Communicable Diseases,3,X,[orch/phsu],[dsyn],D02.241.081.114.968.500.500.195;D02.355.726.305.500.195;D02.455.426.559.389.657.654.305.500.195,C01.539.221
16e7550f-7ecc-461b-93ab-e063f9cd69b4,C1424650,C0009450,were identified in early ,IFI44 gene,Communicable Diseases,3,X,[gngm],[dsyn],,C01.539.221
d94fdb38-4b4a-4b17-9526-40fb085eac12,C1447833,C0009450,were identified in early ,HSXIAPAF1 protein human,Communicable Diseases,3,X,[aapp/bacs],[dsyn],x.x.x.x,C01.539.221
2ef957cc-7f5b-4c90-83a4-0e4fd9cfe543,CXCL2,C0009450,were identified in early ,CXCL2,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
4d232cc1-24fc-403b-acf6-c1766c78ad27,CXCL3,C0009450,were identified in early ,CXCL3,Communicable Diseases,3,X,????,[dsyn],????,C01.539.221
7e0e4ac7-75d4-4d85-9c62-7bd8755e3c46,C1333327,C1175743,were identified in early ,TYMP gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
018e6366-01d4-4de9-86ad-47a3ad9ad0d0,C0387583,C1175743,were identified in early ,cyclooxygenase 2,SARS coronavirus,3,X,[aapp/enzy],[virs],D08.811.600.720.750,B04.820.504.540.150.113.937
483c8c91-5325-4336-a6bb-244ac1a73151,C1412937,C1175743,were identified in early ,C1S gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
06b64b71-8a6f-4881-b7a8-76631269879f,C0009002,C1175743,were identified in early ,Clofibrate,SARS coronavirus,3,X,[orch/phsu],[virs],D02.241.081.114.968.500.500.195;D02.355.726.305.500.195;D02.455.426.559.389.657.654.305.500.195,B04.820.504.540.150.113.937
6e818fc6-0f2f-4511-a40b-6ea6c58bb431,C1424650,C1175743,were identified in early ,IFI44 gene,SARS coronavirus,3,X,[gngm],[virs],,B04.820.504.540.150.113.937
447d2322-2fea-4e25-bc15-1b1705e0e738,C1447833,C1175743,were identified in early ,HSXIAPAF1 protein human,SARS coronavirus,3,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150.113.937
afe6579a-83ca-42ee-b816-108cb977939f,CXCL2,C1175743,were identified in early ,CXCL2,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
bc05b8c2-b178-4294-8d9a-e9ad4053032e,CXCL3,C1175743,were identified in early ,CXCL3,SARS coronavirus,3,X,????,[virs],????,B04.820.504.540.150.113.937
96dfaa51-5213-407b-942e-f28c8c35bd5e,C1880157,C0206419,could propose candidate drugs against ,Computation (action),Genus: Coronavirus,2,X,[acty],[virs],,B04.820.504.540.150
73220dc4-212b-454e-bfd5-3e2e2279f374,C0028630,C1175743,inhibit ,Nucleotides,SARS coronavirus,1,X,[nnon],[virs],D09.408.620;D13.695,B04.820.504.540.150.113.937
dc558df0-2818-4685-a04f-7410f160eb08,C0243071,C1175743,inhibit ,Analog,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
08640d57-77ff-4594-82b0-02693ac392b8,C0028630,C0035685,inhibit ,Nucleotides,RNA-Directed RNA Polymerase,1,X,[nnon],[aapp/enzy],D09.408.620;D13.695,D08.811.913.696.445.735.780
4fdc6d34-c1df-468b-9a2c-863e9166c45a,C0243071,C0035685,inhibit ,Analog,RNA-Directed RNA Polymerase,1,X,[chvs],[aapp/enzy],,D08.811.913.696.445.735.780
00fd17c5-0c16-4726-a584-592e642c2fb4,C0028630,C0146894,inhibit ,Nucleotides,triphosphate,1,X,[nnon],[inch],D09.408.620;D13.695,
5a81d9f6-5ee1-4129-a532-9d44071551b2,C0243071,C0146894,inhibit ,Analog,triphosphate,1,X,[chvs],[inch],,
f85b712f-82fb-4f25-a458-dc7ccb197af6,C0028630,C2976303,inhibit ,Nucleotides,sofosbuvir,1,X,[nnon],[nnon/phsu],D09.408.620;D13.695,D03.383.742.686.850.877.500;D13.695.740.850.877.500;D13.695.827.919.877.500
25f1286f-540b-4106-b4ae-85c14e415554,C0243071,C2976303,inhibit ,Analog,sofosbuvir,1,X,[chvs],[nnon/phsu],,D03.383.742.686.850.877.500;D13.695.740.850.877.500;D13.695.827.919.877.500
dcd54dc2-9f12-4850-a43a-ff83fc11b7f4,C0146894,C1152412,including RNA-Directed RNA Polymerase is,triphosphate,RNA-directed RNA polymerase activity,1,X,[inch],[genf],,
eabc4f09-a9c2-4c2f-b970-074ff41244f0,C1328948,C0206419,catalyzed by ,RNA biosynthesis,Genus: Coronavirus,1,X,[moft],[virs],,B04.820.504.540.150
11868682-e24e-4f50-a260-2d4a0f59c336,C1328948,C1152412,catalyzed by ,RNA biosynthesis,RNA-directed RNA polymerase activity,1,X,[moft],[genf],,
852decac-72ba-4aa6-a8b3-90085356fa37,C1152412,C1335439,is in ,RNA-directed RNA polymerase activity,Polymerase,1,X,[genf],[aapp/enzy],,
b3be52d8-7ff2-4fcd-8e31-cc818b4dbc87,C1335439,C0081912,carbovir triphosphate of,Polymerase,carbovir triphosphate,1,X,[aapp/enzy],[nnon/phsu],,x.x.x.x
eef773e2-bd01-4277-b9a5-47f175870c94,C0206419,C0015296,possess ,Genus: Coronavirus,Exonuclease,1,X,[virs],[aapp/enzy],B04.820.504.540.150,D08.811.277.352.365
a31f5aa3-3e40-4a7a-a243-736d59357454,C0015296,C0220853,apparently requires 2 ,Exonuclease,Hydroxide Ion,1,X,[aapp/enzy],[elii],D08.811.277.352.365,x.x.x.x
8142c22a-e865-4a6c-bb2b-64d324a883de,C0015296,C0035668,apparently requires 2 ,Exonuclease,RNA,1,X,[aapp/enzy],[nnon],D08.811.277.352.365,D13.444.735
89c6d3f9-66bc-42ae-a9b5-697729c17ed8,C0028630,C0220853,lack 2 ,Nucleotides,Hydroxide Ion,1,X,[nnon],[elii],D09.408.620;D13.695,x.x.x.x
1363a99a-bb52-44b6-b733-b5dc1c4a9eae,C0243071,C0220853,lack 2 ,Analog,Hydroxide Ion,1,X,[chvs],[elii],,x.x.x.x
1b07f6f6-c588-43ae-807f-258c0c941add,C0033262,C3469597,are Administration of medication for,Prodrugs,Administration of medication,1,X,[chvf],[topp],D26.675,
1b07f6f6-c588-43ae-807f-258c0c941add,C0033262,C3469597,are FDA-approved ,Prodrugs,Administration of medication,1,X,[chvf],[topp],D26.675,
47d8ef7e-8c56-472b-a648-d2700f21d5dc,C0033262,C0042769,are Administration of medication for,Prodrugs,Virus Diseases,1,X,[chvf],[dsyn],D26.675,C02
2cc2896b-b8c8-4a16-acef-296425a6b3bf,C0567416,C0087111,can can evaluated as potential ,Molecule,Therapeutic procedure,1,X,[sbst],[topp],,E02
b52c8de3-2b61-4f97-8aab-4e603c383b04,C0567416,C0206419,can can evaluated as potential ,Molecule,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
5067f52f-8210-4f78-90df-b159602f20dd,C0567416,C3463820,demonstrating potency in ,Molecule,Inhibition,1,X,[sbst],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
9aa49081-7bfb-483c-ac2a-f607fb8da0a9,C0567416,C0007590,demonstrating potency in ,Molecule,Cell division,2,X,[sbst],[celf],,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
6cc2a97e-797c-47be-8daf-811343643717,C0150593,C0040210,was modeled after ,game,Tidal Volume,2,X,[dora],[clna],,E01.370.386.700.485.750.900.350.750;G09.772.850.970.500.700
9a521a84-0b75-4cad-ba3b-67609a069c5d,C0150593,C2350169,was modeled with ,game,Warm-Up Exercise,2,X,[dora],[dora],,G11.427.410.698.277.968;I03.350.968
30d16663-a79c-44ef-9c1c-8192299b6346,C0018799,C0235974,Heart Diseases ischemic,Heart Diseases,Pancreatic carcinoma,1,X,[dsyn],[neop],C14.280,x.x.x.x
e8b302a5-49df-4144-870c-51039e08a352,C0018799,C0023418,Heart Diseases ischemic,Heart Diseases,leukemia,1,X,[dsyn],[neop],C14.280,C04.557.337
ba3c6c01-86a7-441f-b281-c22ef94a0cc3,C0206419,C0729531,is acute ,Genus: Coronavirus,Viral respiratory infection,1,X,[virs],[dsyn],B04.820.504.540.150,
c4b94d70-f0f7-464e-9fd5-b56c40a6cbe7,C0206419,C0339901,is acute ,Genus: Coronavirus,Acute respiratory infections,1,X,[virs],[dsyn],B04.820.504.540.150,
71c383d5-0ffa-456b-9c39-f055497a2c72,C0729531,C1175743,caused by ,Viral respiratory infection,SARS coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150.113.937
8df7c6d0-c43b-49f5-beac-afa7a084d1f5,C0339901,C1175743,caused by ,Acute respiratory infections,SARS coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150.113.937
ca3d2f3c-3e07-449b-aba2-cf92b838acb0,C2986592,C0042210,are uncovered such as ,Definitive Treatment,Vaccines,3,X,[topp],[aapp/imft/phsu],,D20.215.894
d85021fe-fa89-4422-9ad1-2b14ebd22a02,C3274800,C0035243,is common to other ,Disease Presentation,Respiratory Tract Infections,2,X,[clna],[dsyn],,C01.539.739;C08.730
17384476-58d9-4c3d-9aa2-b083322256c9,C0599878,C2676739,were grand ,disease characteristic,Chromosome 2q32-Q33 Deletion Syndrome,2,X,[patf],[dsyn],,x.x.x.x
d95db4c9-ec2a-4e8a-8ab5-a81e64676690,C0599878,C1265876,were grand ,disease characteristic,Abnormally opaque structure (morphologic abnormality),2,X,[patf],[patf],,
ba81f74d-1c98-45c8-b867-64a8daf60a95,C0012634,C1825598,has had substantial ,Disease,IMPACT gene,4,X,[dsyn],[gngm],C23.550.288,
ba81f74d-1c98-45c8-b867-64a8daf60a95,C0012634,C1825598,is causing insurmountable psychosocial ,Disease,IMPACT gene,2,X,[dsyn],[gngm],C23.550.288,
ba81f74d-1c98-45c8-b867-64a8daf60a95,C0012634,C1825598,is now epidemic of proportion with major adverse ,Disease,IMPACT gene,1,X,[dsyn],[gngm],C23.550.288,
ba81f74d-1c98-45c8-b867-64a8daf60a95,C0012634,C1825598,has had extraordinary ,Disease,IMPACT gene,1,X,[dsyn],[gngm],C23.550.288,
520a6ccc-fcac-41fc-893c-71fec0bd599f,C0206419,C0039082,is acute ,Genus: Coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288.500
520a6ccc-fcac-41fc-893c-71fec0bd599f,C0206419,C0039082,caused by ,Genus: Coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.288.500
40b40661-065a-47e2-9d75-413506125823,C0013227,C0034991,promote ,Pharmaceutical Preparations,Rehabilitation therapy,5,X,[phsu],[topp],D26,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
d2f5f173-eac8-4ad6-b022-33c2492985be,C0206750,C1706214,is ,Coronavirus Infections,Creation,2,X,[dsyn],[acty],C02.782.600.550.200,
7a595c83-179a-441e-a1f3-65a30765a52d,C3241973,C0027651, includes ,Pediatric Surgical Procedures,Neoplasms,2,X,[topp],[neop],,C04
977d9d30-4964-4c04-b8b5-fac0eed7806e,C0020336,C0559546,causing cardiovascular ,Hydroxychloroquine,Adverse reactions,1,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,
68d83001-569b-447f-beec-8a7881105726,C0020336,C0162770,was associated with higher reporting of ,Hydroxychloroquine,Right Ventricular Hypertrophy,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.195.410;C23.300.775.250.401
7860429e-0200-40ce-a193-2fa9e5571081,C0040479,C0206750,are relevant to ,Torsades de Pointes,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700,C02.782.600.550.200
1b58fb94-56e6-4e09-ad84-e512de8fa45c,C0040479,C2348331,are relevant to ,Torsades de Pointes,Dose Regimen,1,X,[dsyn],[topp],C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700,
cd424b4a-950c-474a-b912-93c5ccc2c9a7,30-day,C0035222,is in ,30-day,Respiratory Distress Syndrome Adult,1,X,????,[dsyn],????,C08.381.840;C08.618.840
d18a8cf4-5b3f-4ce0-9eda-3e5259bcea82,C0207682,C3698360,effectively blocked ,nafamostat mesilate,Middle East Respiratory Syndrome Coronavirus,2,X,[orch/phsu],[virs],,B04.820.504.540.150.113.750
d18a8cf4-5b3f-4ce0-9eda-3e5259bcea82,C0207682,C3698360,inhibited ,nafamostat mesilate,Middle East Respiratory Syndrome Coronavirus,4,X,[orch/phsu],[virs],,B04.820.504.540.150.113.750
9294c9f1-df70-4d45-9a99-f881d0beb361,C0207682,C0072330,effectively blocked ,nafamostat mesilate,protease S,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
9294c9f1-df70-4d45-9a99-f881d0beb361,C0207682,C0072330,targeting ,nafamostat mesilate,protease S,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
b26d7fc2-ec21-4e9d-984c-a94414aa6149,C0207682,C0021699,effectively blocked ,nafamostat mesilate,Integral Membrane Proteins,5,X,[orch/phsu],[aapp],,D12.776.543
b26d7fc2-ec21-4e9d-984c-a94414aa6149,C0207682,C0021699,targeting ,nafamostat mesilate,Integral Membrane Proteins,4,X,[orch/phsu],[aapp],,D12.776.543
29ef200e-7bb9-4788-9185-30eebfc76058,C0207682,C1742865,targeting ,nafamostat mesilate,TMPRSS2 protein human,4,X,[orch/phsu],[aapp/enzy],,x.x.x.x
581dc435-43ee-4fc9-9a80-caa21b999935,C0013227,C0012739,used for ,Pharmaceutical Preparations,Disseminated Intravascular Coagulation,4,X,[phsu],[dsyn],D26,C15.378.100.220;C15.378.463.250;C15.378.925.220
893c0eda-a078-440c-bc75-256848082006,C0207682,C0036720,targeting ,nafamostat mesilate,Serine,4,X,[orch/phsu],[aapp/bacs/phsu],,D12.125.154.800
fe7d6751-0b21-48d9-ae7c-4932f5fbad16,C0207682,C0024109,inhibited ,nafamostat mesilate,Lung,4,X,[orch/phsu],[bpoc],,A04.411
581fc7d2-e5f3-4d20-9a90-dcb9872530e7,C0207682,C0014609,inhibited ,nafamostat mesilate,Epithelium,3,X,[orch/phsu],[tisu],,A10.272
6517be8a-f7ba-4c1c-a1fd-1cb7b0667b1a,C0207682,C1413097,inhibited ,nafamostat mesilate,CALU gene,4,X,[orch/phsu],[gngm],,
6517be8a-f7ba-4c1c-a1fd-1cb7b0667b1a,C0207682,C1413097,blocked 2 ,nafamostat mesilate,CALU gene,4,X,[orch/phsu],[gngm],,
050ee4a4-c4b5-4138-9ca2-cad2403becaf,C0108225,10-fold,was about 10-fold ,camostate-mesilate,10-fold,6,X,[orch/phsu],????,,????
ef2ba4e5-184d-4fb7-9018-7fc41c08cf05,C0207682,10-fold,potently inhibited fusion about 10-fold ,nafamostat mesilate,10-fold,4,X,[orch/phsu],????,,????
493448d9-7071-4331-b19c-a919fd67c691,C0207682,C1175743,blocked ,nafamostat mesilate,SARS coronavirus,8,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
493448d9-7071-4331-b19c-a919fd67c691,C0207682,C1175743,potently inhibits ,nafamostat mesilate,SARS coronavirus,7,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
493448d9-7071-4331-b19c-a919fd67c691,C0207682,C1175743,also inhibits 2 ,nafamostat mesilate,SARS coronavirus,3,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
74bcccc6-1b42-429b-8a7c-9f013341e499,C0312860,C0005768,is below its average ,Neutrophil migration function,In Blood,4,X,[celf],[bdsu],,x.x.x.x.x
157472f4-8076-48c0-88fb-80b6dacaf812,C0312860,C1511497,is below its average ,Neutrophil migration function,Continuous Intravenous Infusion,8,X,[celf],[topp],,
0bc268b5-e8a2-47a7-a8d6-9794cbe71c7a,C0312860,C0574032,is below its average ,Neutrophil migration function,Infusion procedures,4,X,[celf],[topp],,
c48d7c1f-d6fb-4e67-9fda-07221a719749,C0009450,C0020405,of spread is greater attention to endoscopic room ,Communicable Diseases,Hygiene,4,X,[dsyn],[bmod],C01.539.221,E02.547;N06.850.670
ece9cbf1-4199-4181-9364-6fa822ecaf98,C0596577,C0005532,have attracted attention due to their various ,Flavonoids,biology (field),1,X,[orch],[bmod],D03.383.663.283.266.450;D03.633.100.150.266.450,H01.158.273
185a5915-d7ad-4f25-8c43-be650d440e5b,C0015230,C0206750,highly suggestive for ,Exanthema,Coronavirus Infections,2,X,[sosy],[dsyn],C17.800.257,C02.782.600.550.200
45b5299c-f9ea-4e51-80ea-32a2781a1ff7,C0206750,C4321457,diagnosed in our hospital ,Coronavirus Infections,Examination,3,X,[dsyn],[acty],C02.782.600.550.200,
357a552c-d85d-4826-abf9-73c060d0ec43,C0009450,C4321457,diagnosed in our hospital ,Communicable Diseases,Examination,3,X,[dsyn],[acty],C01.539.221,
357a552c-d85d-4826-abf9-73c060d0ec43,C0009450,C4321457,can can used as ,Communicable Diseases,Examination,2,X,[dsyn],[acty],C01.539.221,
2772481f-b13e-44a5-abae-c9ddbfda3455,C0009429,C0206750,be considered as preferred treatment approach to severe ,Combined Modality Therapy,Coronavirus Infections,3,X,[topp],[dsyn],E02.186,C02.782.600.550.200
2772481f-b13e-44a5-abae-c9ddbfda3455,C0009429,C0206750,affect ,Combined Modality Therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.186,C02.782.600.550.200
10969e5f-a395-4f96-866b-b3302e67150f,C0033972,C0206750,is in patients with ,Psychotherapy Multiple,Coronavirus Infections,3,X,[topp],[dsyn],F04.754.766,C02.782.600.550.200
4c48dce5-8003-45eb-aa19-e5fa330198a6,C0001962,C0042776,inactivating enveloped ,Ethanol,Virus,1,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04
c029685f-cf2c-42ca-8226-08a3271f68e1,C1330330,C0042776,inactivating enveloped ,Hand Sanitizers,Virus,1,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04
e69e06ac-65de-40e3-94b3-593a97cbdcd4,C0001962,C0206419,inactivating enveloped ,Ethanol,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.033.375;x.x.x.x,B04.820.504.540.150
6e067219-0e4c-425e-96ce-7b70bffeb6c0,C1330330,C0206419,inactivating enveloped ,Hand Sanitizers,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650,B04.820.504.540.150
696de706-9084-48c5-b1d5-33977fa1653a,C0042776,C2717802,extrapolating effectiveness on ,Virus,Viral Structures,2,X,[virs],[anst],B04,A21
257952ca-ed3f-4f92-ba65-a6eaa2ffb372,C0042776,C1330330,extrapolating effectiveness of ,Virus,Hand Sanitizers,1,X,[virs],[phsu],B04,D27.505.954.122.187.500;D27.505.954.122.425.650;D27.720.274.650
f23e231e-b797-4775-91fc-87a78632b636,C0079189,C0042776,causes in addition to direct injury from se,cytokine,Virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04
f23e231e-b797-4775-91fc-87a78632b636,C0079189,C0042776,are responsible for poor humoral ,cytokine,Virus,1,X,[aapp/imft],[virs],D12.644.276.374;D12.776.467.374;D23.529.374,B04
386fea14-be21-446c-b315-f8bca8f99817,C0013227,C0232217,especially altering ,Pharmaceutical Preparations,Cardiac conduction,1,X,[phsu],[ortf],D26,
5f7a1a61-ffd8-477c-99da-bc1d21a28418,C0015967,C0013404,stuffed ,Fever,Dyspnea,1,X,[sosy],[sosy],C23.888.119.344,C08.618.326;C23.888.852.371
99685f6b-f35d-4bc4-9b51-171a00599a9e,C0015672,C0206750,were identified as prognostic symptoms of ,Fatigue,Coronavirus Infections,2,X,[sosy],[dsyn],C23.888.369,C02.782.600.550.200
c95650b1-261e-4540-a78c-9b20bbe8140f,C0028429,C0206750,were identified as prognostic symptoms of ,Nose,Coronavirus Infections,2,X,[bpoc],[dsyn],A01.456.505.733;A04.531;A09.531,C02.782.600.550.200
3bd5193d-2917-4d1b-b4a1-38735b8346b4,C0038056,C1514474,was sole ,Sputum,Prognostic Factors,2,X,[bdsu],[clna],A12.200.808,E01.789
45a1ad4b-8a8b-4e05-b471-9b8436cc3b78,C0161816,C0020538, includes ,Cardiac complication,Hypertensive disease,4,X,[patf],[dsyn],,C14.907.489
3babf157-ed3a-481a-9ae3-e789ed40fd12,C0038056,C0161816,was sole Prognostic Factors for patients with,Sputum,Cardiac complication,2,X,[bdsu],[patf],A12.200.808,
cf5e4ee9-5583-4d0c-91f0-f1ffe389fcc9,C0038056,C0020538,was sole Prognostic Factors for patients with,Sputum,Hypertensive disease,2,X,[bdsu],[dsyn],A12.200.808,C14.907.489
f2867613-ce1c-4c72-8c52-a00617bc6c63,C0007222,C0020538, includes ,Cardiovascular Diseases,Hypertensive disease,2,X,[dsyn],[dsyn],C14,C14.907.489
e4ddb990-7c4b-42cd-9d33-f75105e3a55c,C0013404,C0009450,is prognostic of severe ,Dyspnea,Communicable Diseases,2,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C01.539.221
b8a8724a-7b2f-4dc4-9c01-f1e109ae18bd,C0027497,C1514474,are favorable ,Nausea,Prognostic Factors,2,X,[sosy],[clna],C23.888.821.712,E01.789
d7704685-1645-449c-af2b-c83dad082e96,C0027497,C0009450,are favorable Prognostic Factors of severe,Nausea,Communicable Diseases,4,X,[sosy],[dsyn],C23.888.821.712,C01.539.221
0d8bcd84-7d29-4a75-b6fa-f386698bc175,C0028429,C1514474,are favorable ,Nose,Prognostic Factors,2,X,[bpoc],[clna],A01.456.505.733;A04.531;A09.531,E01.789
b167c700-0013-449c-9ed4-f1474e4d88e2,C0028429,C0009450,are favorable Prognostic Factors of severe,Nose,Communicable Diseases,3,X,[bpoc],[dsyn],A01.456.505.733;A04.531;A09.531,C01.539.221
dc6694c3-31ca-4554-9ad0-f9e341c588a2,C0264219,C0086418,is threat to ,Acute respiratory disease,Homo sapiens,2,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
c9eece4f-fe65-4a39-9fec-b3c7af93d745,C3698360,C3697872,belong to same ,Middle East Respiratory Syndrome Coronavirus,Genus Betacoronavirus,2,X,[virs],[virs],B04.820.504.540.150.113.750,
6759c280-b7d6-48ba-9e2a-d99b0534f4e0,C0030946,C0206750,is essential for ,Endopeptidases,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C02.782.600.550.200
6759c280-b7d6-48ba-9e2a-d99b0534f4e0,C0030946,C0206750,is considered important ,Endopeptidases,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C02.782.600.550.200
38a38cbb-cc07-4f55-bf89-7935b7a17757,C0030946,C0598312,is essential for ,Endopeptidases,DNA Replication,2,X,[aapp/enzy/phsu],[genf],D08.811.277.656.300,G02.111.225;G05.226
e16f9fec-2402-463f-a548-5e39e918eeb0,C0030946,C0087111,is considered important ,Endopeptidases,Therapeutic procedure,4,X,[aapp/enzy/phsu],[topp],D08.811.277.656.300,E02
4bd2c101-43d7-4e51-93da-86f3f1b28da0,C0030946,C0012634,is considered important ,Endopeptidases,Disease,4,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300,C23.550.288
002615cc-d9c4-4feb-8543-66efca0550f3,C0030946,C0206419,is essential for ,Endopeptidases,Genus: Coronavirus,5,X,[aapp/enzy/phsu],[virs],D08.811.277.656.300,B04.820.504.540.150
8fc6544e-9aa8-4339-b961-470c9eb9bbe9,C0031843,C0206750,makes ,physiological aspects,Coronavirus Infections,5,X,[phsf],[dsyn],x.x.x.x,C02.782.600.550.200
90239ced-e827-45c2-b720-fbe44cda01f5,C0031843,C0598312,is in ,physiological aspects,DNA Replication,2,X,[phsf],[genf],x.x.x.x,G02.111.225;G05.226
65ed071f-0d28-4e31-adf8-1729f9705059,C0206058,C1705178,is in ,Elective Surgical Procedures,Order (action),8,X,[topp],[acty],E04.249,
aae66368-68d5-4b48-b130-01b194406a3d,C0018821,C1705178,have have postponed in ,Cardiac Surgery procedures,Order (action),3,X,[topp],[acty],E04.100.376;E04.928.220,
5e091e0e-e835-4ba7-a306-728ae0a70639,C0206058,C0242781,reduce ,Elective Surgical Procedures,disease transmission,6,X,[topp],[patf],E04.249,N06.850.310
ff1744b1-e896-4692-977d-7c6381663843,C0018821,C0242781,reduce ,Cardiac Surgery procedures,disease transmission,3,X,[topp],[patf],E04.100.376;E04.928.220,N06.850.310
b531bbdd-6833-4a68-8e21-399ec24f55ef,C0012634,C0018799,is in setting of emergent ,Disease,Heart Diseases,4,X,[dsyn],[dsyn],C23.550.288,C14.280
ff76ee0c-ba14-489d-bbdf-66e847ddf740,C3272275,C0206750,is with active/recent ,Urgent Procedure,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
6d7f24b0-e3c4-4390-8dd9-d0d47b2b6f80,22nd,C0374505,divided into routine ,22nd,Group Therapies,2,X,????,[topp],????,
50031e6a-b84b-4791-901d-59dbec172b7c,22nd,C1415068,divided by ,22nd,GJA1 gene,2,X,????,[gngm],????,
0c224d86-9f69-4510-950e-edfb398cca5b,C0052432,C0559546,eliminate Pathogenic organism with fewer,artesunate,Adverse reactions,2,X,[orch/phsu],[patf],D01.248.497.158.685.750.212.500;D01.339.431.374.212.500;D01.650.550.750.200.500;D02.389.338.055.500;D02.455.849.765.211.500,
bb252d32-e184-40fd-916e-e5c887f5c505,C0052432,C0450254,eliminate ,artesunate,Pathogenic organism,2,X,[orch/phsu],[orgm],D01.248.497.158.685.750.212.500;D01.339.431.374.212.500;D01.650.550.750.200.500;D02.389.338.055.500;D02.455.849.765.211.500,
93206b2c-effe-46ff-807d-5f6d465dc1f4,C0021966,C0206750,emphasize significance due to previous exposure to seasonal ,Iodides,Coronavirus Infections,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C02.782.600.550.200
93206b2c-effe-46ff-807d-5f6d465dc1f4,C0021966,C0206750,is in completo isolamento durante da ,Iodides,Coronavirus Infections,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C02.782.600.550.200
9e257d62-164e-4521-9d29-0bb8fe390efc,C0021966,C0178575,emphasize significance of ,Iodides,cross immunity,2,X,[inch],[moft],D01.248.497.158.490;D01.475.410,
89a5c102-2743-4f65-a36b-fdf375a3edb8,COVID-19,CBRN,can in certain respects can viewed as CBRN ,COVID-19,CBRN,1,X,[virs],????,C000657245,????
33b8c395-6384-4b9b-afee-1ed5eecaa77d,C2948600,7-day,evaluate 7-day HCP ,Aim,7-day,2,X,[inch/phsu],????,,????
b2231aa5-609a-4e61-a8c9-45bca5b79b52,C2948600,C2828389,evaluate 7-day HCP ,Aim,Exclusion,2,X,[inch/phsu],[acty],,
a1ab4874-ac2b-4d74-8af7-8413d1584f02,C2948600,HCP,evaluate 7-day HCP ,Aim,HCP,1,X,[inch/phsu],????,,????
16b9feeb-0147-4479-9b6a-33e0d7980200,COVID-19,C1521863,is in burgeoning ,COVID-19,estrogen receptor alpha human,2,X,[virs],[aapp/rcpt],C000657245,x.x.x.x
af6facdd-6de4-4867-8ea3-9183231b1ba7,C0032285,C1521863,is in burgeoning ,Pneumonia,estrogen receptor alpha human,2,X,[dsyn],[aapp/rcpt],C08.381.677;C08.730.610,x.x.x.x
3806015a-07de-4b88-bf98-157511b306dc,COVID-19,C2718059,is in burgeoning ,COVID-19,Precision Medicine,2,X,[virs],[topp],C000657245,E02.574;H02.403.200.700
f5737376-1b3e-4ebd-9061-2a2d7426d3bd,C0032285,C2718059,is in burgeoning ,Pneumonia,Precision Medicine,2,X,[dsyn],[topp],C08.381.677;C08.730.610,E02.574;H02.403.200.700
d9aa12ce-78ce-43f3-a6ba-5e14c898be78,COVID-19,C0037054,is in ,COVID-19,Sickle Cell Trait,2,X,[virs],[dsyn],C000657245,C15.378.071.141.150.150.670;C15.378.420.155.668;C16.320.070.150.670;C16.320.365.155.668
6f8b4c92-6181-4b23-89a6-dc1c608240d8,C0032285,C0037054,is in ,Pneumonia,Sickle Cell Trait,2,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C15.378.071.141.150.150.670;C15.378.420.155.668;C16.320.070.150.670;C16.320.365.155.668
5fd479b0-8b51-46c3-b680-fb4f0e70b0f5,C0005821,C1175743,is in patients infected with ,Blood Platelets,SARS coronavirus,2,X,[cell],[virs],A11.118.188;A15.145.229.188,B04.820.504.540.150.113.937
6ec720bf-7537-4fa4-88fb-78893686f345,C0017262,C1175743,is in patients infected with ,Gene Expression,SARS coronavirus,2,X,[genf],[virs],G05.297,B04.820.504.540.150.113.937
a7c63b53-9a03-4e47-b8aa-7342e451b9da,C3641730,COVID-19,demonstrated ,Cell-Free RNA,COVID-19,1,X,[nnon],[virs],D13.444.154,C000657245
7eedd3e6-df3d-48d5-a77a-e72fa4fba02b,C3641730,C0005821,demonstrated ,Cell-Free RNA,Blood Platelets,1,X,[nnon],[cell],D13.444.154,A11.118.188;A15.145.229.188
f2554092-d0bf-4c0b-9ea4-0d274f2945cd,C1519516,C1704259,is in ,Tissue-Specific Gene Expression,Biochemical Pathway,2,X,[genf],[moft],,
7c76fad0-f456-474e-9b04-3b7df1556118,C1519516,C1519751,is in ,Tissue-Specific Gene Expression,Ubiquitination,2,X,[genf],[moft],,G02.111.660.871.790.600.925;G02.111.691.600.775;G03.734.871.790.600.831;G05.308.670.600.831
78e93b19-f078-4bf4-a4aa-389e557c598d,C0005821,C0134835,had increased ,Blood Platelets,P-Selectin,1,X,[cell],[aapp/imft],A11.118.188;A15.145.229.188,D12.776.395.550.200.700.775;D12.776.395.550.625.905;D12.776.503.843.775;D12.776.543.550.200.700.775;D12.776.543.550.625.905;D23.050.301.350.700.775
cdfc9148-53cf-4456-a52d-a96b673ac608,C0039194,COVID-19,were significantly elevated in ,T-Lymphocyte,COVID-19,1,X,[cell],[virs],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,C000657245
93cecbb5-1fb0-44f8-84dd-f33a5e6c683b,C0051979,C0009359,is with ,anti-IgG,Gold Colloid,2,X,[aapp/imft],[inch/phsu],x.x.x.x,D01.379.400
99f8efc2-00c6-4a90-a177-663209d9e9f0,C0086418,C0009359,is with ,Homo sapiens,Gold Colloid,1,X,[humn],[inch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D01.379.400
47992b17-86a1-4a61-867e-7dddbbd3eb6e,C1511790,C1524029,took 15 20 ,Detection,Mouse MIN NOS,2,X,[topp],[neop],,
1ef9a406-0667-46cd-9fc1-6a1e610d8374,C0034019,COVID-19,would reduce ,public health medicine (field),COVID-19,3,X,[bmod],[virs],H02.403.720;N01.400.550;N06.850,C000657245
55acf1b3-1b3c-459c-a138-91e30593d984,C0034019,C1521827,is in ,public health medicine (field),Preparation,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
8b003974-7762-482d-9046-a58de6b7518c,C0034019,C1421479,is in ,public health medicine (field),WASF1 gene,1,X,[bmod],[gngm],H02.403.720;N01.400.550;N06.850,
26460893-48c8-4857-b11c-69f44f93f9b0,C0020336,C1175743,could potently inhibit ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
26460893-48c8-4857-b11c-69f44f93f9b0,C0020336,C1175743,is effective against ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
26460893-48c8-4857-b11c-69f44f93f9b0,C0020336,C1175743,is more potent than CQ ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
26460893-48c8-4857-b11c-69f44f93f9b0,C0020336,C1175743,exhibited anti ,Hydroxychloroquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180.350,B04.820.504.540.150.113.937
c23cd403-48fa-4a47-9853-3b2fe454f363,C0023530,C0086418,is in 65-year-old Chinese ,Leukopenia,Homo sapiens,1,X,[dsyn],[humn],C15.378.553.546,B01.050.150.900.649.313.988.400.112.400.400
c44b4850-f654-43ad-aa78-ae51106f549b,C0086418,COVID-19,was diagnosed with ,Homo sapiens,COVID-19,4,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,C000657245
d38108f3-f414-4b2c-b67f-845a121f3c15,C0030069,CP,decreased on day after CP ,Oxyhemoglobin,CP,1,X,[aapp/bacs],????,D12.776.124.400.707;D12.776.422.316.762.687,????
ba2c4a08-b060-4bdc-a366-6f745ab5b549,C0522534,CP,decreased on day after CP ,Saturated,CP,1,X,[npop],????,,????
f6e2c39b-d2c3-4974-a853-cf2815778e1c,C0064582,C0030069,remained arterial CP ,Lactic acid,Oxyhemoglobin,1,X,[bacs/orch/phsu],[aapp/bacs],D02.241.511.459.450,D12.776.124.400.707;D12.776.422.316.762.687
39cd1b69-31d8-4905-a61a-ea231006ab2d,C0064582,C0522534,remained arterial CP ,Lactic acid,Saturated,1,X,[bacs/orch/phsu],[npop],D02.241.511.459.450,
690c41ff-b1c8-4d66-8a2c-8a63d8daf185,C0064582,CP,remained arterial CP ,Lactic acid,CP,1,X,[bacs/orch/phsu],????,D02.241.511.459.450,????
e884c7c8-6ee0-4405-a162-3dea21bc1029,C0035668,C0439056,remained in ,RNA,Throat swab sample,3,X,[nnon],[bdsu],D13.444.735,
797fbabc-0eed-4ee1-9885-53ee112f377f,C1175743,MEO,was performed in MEO,SARS coronavirus,MEO,2,X,[virs],????,B04.820.504.540.150.113.937,????
4fc37a79-d402-45b0-a205-5214a59e288b,C1450224,COVID-19,successfully navigating ,forensic pathology discipline,COVID-19,1,X,[bmod],[virs],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C000657245
98497b66-2573-4490-9c04-747fb7496f66,C1450224,C0012634,successfully navigating emerging ,forensic pathology discipline,Disease,2,X,[bmod],[dsyn],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C23.550.288
df9ebf5a-c4f3-4269-bfb3-58304e989c9d,COVID-19,C0036974,cause economic ,COVID-19,Shock,1,X,[virs],[patf],C000657245,C23.550.835
4e0d4bad-62e8-4ed1-b52c-069a71263a81,C0011570,1930s,is in 1930s,Mental Depression,1930s,1,X,[mobd],????,F01.145.126.350,????
e09e6e77-6568-4314-b249-115d4ba9a6cf,C0012634,C2806453,caused by ,Disease,Betacoronavirus,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540.150.113
ec3f2f44-8b8f-4588-b096-32b995005164,C0012634,C0020517,was shown temperature ,Disease,Hypersensitivity,4,X,[dsyn],[patf],C23.550.288,C20.543
21bf39b4-0e8d-46c7-ba0f-b0ece19ec821,C1160716,C0015392,are proposed with highlight on system as conduit between ,viral transmission,Eye,2,X,[celf],[bpoc],,A01.456.505.420;A09.371
a3ed64ac-c3a4-428e-b197-5bc37628cf53,C1511790,C0036537,is in ocular ,Detection,Bodily secretions,1,X,[topp],[bdsu],,A12.200
c7bdf4f6-057d-4970-a8a5-811916d546b8,C0024109,C0079189,is key target of ,Lung,cytokine,1,X,[bpoc],[aapp/imft],A04.411,D12.644.276.374;D12.776.467.374;D23.529.374
341d1dd0-f2ba-4101-a88a-61fec995f823,C2755994,C0079189,heavy burden of ,intracellular signal transduction pathway,cytokine,1,X,[celf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
34152b38-907c-4b41-b648-e6d38a30f081,C1511617,C0079189,heavy burden of ,Cytokine Signaling,cytokine,1,X,[moft],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
7d60a424-55fa-4b1e-9327-dea05c6ecbe4,C0079189,C2985566,can Therefore can ,cytokine,Targeted Therapy,2,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
67e43ddb-ed00-4ae9-ae89-4c35089a077f,C0079189,C2948600,can Therefore can ,cytokine,Aim,1,X,[aapp/imft],[inch/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,
30bad1ac-76d7-47fe-98a3-2b4c0b960019,C0013227,C1521827,be ,Pharmaceutical Preparations,Preparation,1,X,[phsu],[acty],D26,
fbe7d02e-cb91-4cce-b3a9-d0db815706b1,hadto,C1521827,be ,hadto,Preparation,1,X,????,[acty],????,
6b7816dc-5606-4d1d-9d5c-4e0461c4960d,C0037778,COVID-19,is In ,Medical Specialities,COVID-19,1,X,[bmod],[virs],H02.403,C000657245
f4d36f43-79ec-4a9f-83b0-451be6e81adc,C0037778,C1521863,is In ,Medical Specialities,estrogen receptor alpha human,1,X,[bmod],[aapp/rcpt],H02.403,x.x.x.x
27bee679-4d0a-44c2-bdd6-09d24ebae532,C0815172,C0015967,is in ,patient characteristics,Fever,3,X,[clna],[sosy],,C23.888.119.344
28e8e5c8-18ed-4283-b81f-cc59524d82bd,C2348077,C1705178,was defined In ,Date Fruit,Order (action),2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
67998269-cd0e-465d-a212-7f557c28fc07,C2348077,C2741673,was defined In ,Date Fruit,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[food],[clna],B01.650.940.800.575.912.250.093.615,
fc1032d9-9184-4cf0-8488-cf82e42ffe71,C0442886,C0206750,occurred in in critical ill patients with ,Secondary Infections,Coronavirus Infections,1,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,C02.782.600.550.200
95da6b0c-c0a2-4dae-80d9-65119da0ec8c,C0042487,C0206750,was identified in patients with critically ill ,Venous Thrombosis,Coronavirus Infections,3,X,[patf],[dsyn],C14.907.355.830.925,C02.782.600.550.200
95da6b0c-c0a2-4dae-80d9-65119da0ec8c,C0042487,C0206750,is in intensive care unit with severe ,Venous Thrombosis,Coronavirus Infections,2,X,[patf],[dsyn],C14.907.355.830.925,C02.782.600.550.200
fc3ad656-8738-4483-b852-fa474d64e6c0,C0042487,C0199242,is in critically ill ,Venous Thrombosis,Anticoagulant prophylaxis,1,X,[patf],[topp],C14.907.355.830.925,
7d327c88-8d0e-496a-b514-3a2000d05356,C0042487,C0679698,is in critically ill ,Venous Thrombosis,disease prevention,1,X,[patf],[topp],C14.907.355.830.925,
575bb778-d080-4bed-8d98-86f8c7c44f74,C0206750,C0679698,is with ,Coronavirus Infections,disease prevention,1,X,[dsyn],[topp],C02.782.600.550.200,
f1696a8a-2b17-458c-a296-948c6d839471,C0042487,C0149871,occurred in distal ,Venous Thrombosis,Deep Vein Thrombosis,2,X,[patf],[dsyn],C14.907.355.830.925,C14.907.355.830.925
e9792925-01c6-4dc4-ac26-0726efeb42aa,DVT,C0149871,occurred in distal ,DVT,Deep Vein Thrombosis,2,X,????,[dsyn],????,C14.907.355.830.925
e1c3b732-6615-4ffd-9d3e-0b94bf689292,C0239981,C0149871,presence of were significantly independent risk factors of ,Hypoalbuminemia,Deep Vein Thrombosis,1,X,[dsyn],[dsyn],C15.378.147.607.500,C14.907.355.830.925
9ecd4552-ddb5-4fc8-8ab1-b2f7de8bce86,C0036770,C1175175,suggests potential vulnerability to ,Structure of sertoli cell,Severe Acute Respiratory Syndrome,1,X,[cell],[dsyn],A05.360.444.849.789;A11.382.952;A11.436.837,C02.782.600.550.200.750;C08.730.730
2e29c692-d885-40fc-a867-9effca44f1e0,C1511790,C0444176,is in ,Detection,Seminal fluid specimen,1,X,[topp],[bdsu],,
37539107-4cc8-4d3c-b737-c3236891a0b8,C0149871,C0206750,is in patients with ,Deep Vein Thrombosis,Coronavirus Infections,2,X,[dsyn],[dsyn],C14.907.355.830.925,C02.782.600.550.200
645efd54-eddc-46fa-92c8-333a7ba2d6ee,C0206750,C0149871,is with ,Coronavirus Infections,Deep Vein Thrombosis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.355.830.925
a72a4954-6270-4704-9c80-fab5afe203a0,C0206750,C0596448,had average in-hospital D ,Coronavirus Infections,dimer,1,X,[dsyn],[chvs],C02.782.600.550.200,
a72a4954-6270-4704-9c80-fab5afe203a0,C0206750,C0596448,= 3D ,Coronavirus Infections,dimer,1,X,[dsyn],[chvs],C02.782.600.550.200,
28e7bcff-28d6-43ab-8f55-73abee0f49a6,C0204819,C0700184,can also cause ,Intubation Nasogastric,Throat irritation,2,X,[topp],[sosy],E02.585.412;E05.497.412,
d55c9c12-7a7a-4174-9c83-31cadbdbeaa7,C0204819,C0010200,resulting in ,Intubation Nasogastric,Coughing,2,X,[topp],[sosy],E02.585.412;E05.497.412,C08.618.248;C23.888.852.293
c6f10deb-7c97-435a-8e4e-426433c01cf4,C0444279,C0206750,collected from confirmed ,Respiratory sample,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
54255cae-c4cf-42e7-9d36-518ce89dcad0,C2948600,C0422833,investigate transversally ,Aim,ENT symptoms,4,X,[inch/phsu],[sosy],,
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,investigate transversally ,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,report radiological ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,evaluate Clinical Treatment implications with ACEI,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,evaluate results of protocol established in advanced ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,describe clinical presentation of patients aged 80 years with ,Aim,Disease,2,X,[inch/phsu],[dsyn],,C23.550.288
75470cab-777e-4040-924e-dd1f19055be0,C2948600,C0012634,investigate correlations between serum calcium in patients with ,Aim,Disease,1,X,[inch/phsu],[dsyn],,C23.550.288
d6c8910c-1015-4da7-add6-53ddbcd3514e,C0004093,C1457887,were most prevalent ,Asthenia,Symptoms,2,X,[sosy],[sosy],C23.888.089,
e909f2d1-fc1d-4638-bbe9-3c066a7393ef,C1457887,C1518304,probably linked to ,Symptoms,Neurotropism,2,X,[sosy],[patf],,
4d572c21-8ef1-429c-8d67-c796be869637,C1457887,C0319157,probably linked to ,Symptoms,AS virus,1,X,[sosy],[virs],,
368309ad-eae1-4ab8-807b-0c7c5efad90a,anosmia,C1457887,are Furthermore ,anosmia,Symptoms,2,X,????,[sosy],????,
368309ad-eae1-4ab8-807b-0c7c5efad90a,anosmia,C1457887,have have identified as highly prevalent ,anosmia,Symptoms,1,X,????,[sosy],????,
2e34431c-1672-404e-9f08-56417d86b4db,anosmia,C0206750,are early Symptoms of,anosmia,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
2e34431c-1672-404e-9f08-56417d86b4db,anosmia,C0206750,are frequent early symptoms of ,anosmia,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
2e34431c-1672-404e-9f08-56417d86b4db,anosmia,C0206750,are Furthermore ,anosmia,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
378b3254-33cf-4378-86d4-637627ab8bd6,C0199529,C0206750,is in patients with ,Pulmonary rehabilitation (procedure),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
7306ea39-23f1-47d6-af27-e6d61d95c924,C0206750,C0344211,Management of is mainly ,Coronavirus Infections,Supportive care,1,X,[dsyn],[topp],C02.782.600.550.200,
e607ac2f-90a4-4d55-9196-16e6d0ee466b,C0476474,C0206750,is with suspected association to ,persistent fever,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
81858d7a-027a-4733-b268-df14ac227e7b,C2948600,C0815172,report radiological ,Aim,patient characteristics,1,X,[inch/phsu],[clna],,
13b07cd0-7594-4f37-9616-6ebbe75f4c88,C0036658,C0017428,is with largest RNA ,Esthesia,Genome,2,X,[ortf],[gngm],F02.830.816;G11.561.790,G05.360.340
b756ef97-dd8a-49bd-bf5e-fe46860fd49d,C3272452,C0017428,is with largest RNA ,Single-Stranded RNA,Genome,2,X,[nnon],[gngm],,G05.360.340
aa63fe39-015e-428a-8925-8cd534998b58,C0567416,C0003451,exhibit significant ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
aa63fe39-015e-428a-8925-8cd534998b58,C0567416,C0003451,is with well-known broad-spectrum ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
aa63fe39-015e-428a-8925-8cd534998b58,C0567416,C0003451,elicit ,Molecule,Antiviral Agents,1,X,[sbst],[phsu],,D27.505.954.122.388
52a4b590-91a0-4f06-9272-c6d10468671f,C0567416,C1175743,exhibit significant ,Molecule,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
52a4b590-91a0-4f06-9272-c6d10468671f,C0567416,C1175743,prevent ,Molecule,SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
fbbc633a-ccd1-4960-a280-eb05bd9a743d,C0567416,C1705178,are In present review discussed in ,Molecule,Order (action),1,X,[sbst],[acty],,
a0aca773-fc31-4b81-b9c4-2997fe9e46b3,C0032081,C0441655,is with mentioned ,Plant Extracts,Activities,1,X,[bacs/phsu],[acty],D20.215.784.500;D26.667,
f40a53f2-52bf-4b1a-9da2-2710ddffc2c8,C0600558,C0280220,is in advanced ,Neoadjuvant Therapy,stage ovarian epithelial cancer,2,X,[topp],[neop],E02.186.450,
ce011581-0b4f-4107-91f2-5f89a8354479,C0677962,C0195495,is with ,Total hysterectomy (procedure),Bilateral salpingectomy with oophorectomy,2,X,[topp],[topp],,
cec86386-7b06-4704-a27c-976950958c1a,C0035124,C1947933,is measure of ,Reperfusion Therapy,care activity,2,X,[topp],[acty],E04.100.700;E05.680.730,
b9b446d1-bd90-431d-a9f2-be51ebc3c1db,C0035124,C1536220,is measure of ,Reperfusion Therapy,ST segment elevation myocardial infarction,2,X,[topp],[dsyn],E04.100.700;E05.680.730,C14.280.647.500.875;C14.907.585.500.875
26e4b62b-4a9f-421c-a475-96455f9d8639,C1947933,C1536220,is in patients with ,care activity,ST segment elevation myocardial infarction,2,X,[acty],[dsyn],,C14.280.647.500.875;C14.907.585.500.875
bcb2c39f-f26d-4445-8fa5-903d20f3d176,C0035124,C0040044,is focused on ,Reperfusion Therapy,Thrombolytic Therapy,2,X,[topp],[topp],E04.100.700;E05.680.730,E02.319.913
bcb2c39f-f26d-4445-8fa5-903d20f3d176,C0035124,C0040044,is in patients with ,Reperfusion Therapy,Thrombolytic Therapy,2,X,[topp],[topp],E04.100.700;E05.680.730,E02.319.913
1f11f3a8-59b9-4ac1-8e9e-8f130dd75be8,C0035124,C1175175,is in patients with ,Reperfusion Therapy,Severe Acute Respiratory Syndrome,4,X,[topp],[dsyn],E04.100.700;E05.680.730,C02.782.600.550.200.750;C08.730.730
86f0aad4-de58-4d14-90ff-ad7670673281,PCR,C0370003,also remained from lower respiratory tract ,PCR,Specimen,2,X,????,[sbst],????,
86f0aad4-de58-4d14-90ff-ad7670673281,PCR,C0370003,performed on respiratory ,PCR,Specimen,1,X,????,[sbst],????,
8f1d9a86-85d8-4ab1-9652-b87e29a9342b,PCR,C0444159,qualified ,PCR,Sputum specimen,2,X,????,[bdsu],????,
220ad0e1-1ca3-4cd8-965f-90911ff90272,C0003451,C0199848,are needed for ,Antiviral Agents,Coronavirus vaccination,2,X,[phsu],[topp],D27.505.954.122.388,
a492329a-34e7-4e8d-8521-bd2dbb4f64b1,C0441655,C0199848,are needed for ,Activities,Coronavirus vaccination,1,X,[acty],[topp],,
f86b7f94-e5e6-4483-9315-6352c29e7f4e,C1708476,C0206750,is discussed as model against ,Implementation,Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
f86b7f94-e5e6-4483-9315-6352c29e7f4e,C1708476,C0206750,will reduce ,Implementation,Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
37ec583c-4d12-4f7e-bd00-42c27f64e582,C0282572,C1171362,control relative ,Frameshifting Ribosomal,protein expression,8,X,[genf],[genf],G02.111.660.871.200;G03.734.871.200;G05.308.215,
0096909d-8948-4fe5-84aa-a3592c8f8d8c,C0042774,PRF,Altering -1 PRF ,Virus Replication,PRF,2,X,[celf],????,G06.920.925,????
eb4c9496-32e4-4d0b-99c1-fb39a6ddac9f,C0042774,C0441655,Altering -1 PRF ,Virus Replication,Activities,2,X,[celf],[acty],G06.920.925,
37e981f3-f0aa-43e0-a106-75a6b43657c6,C1519323,C0441655,strongly ablate -1 PRF ,Silent Mutation,Activities,3,X,[genf],[acty],G05.365.590.803,
d66babbf-4335-4807-a329-07233ca92c25,C0441655,C0042776,is also retained in ,Activities,Virus,4,X,[acty],[virs],,B04
85b0ad8f-cb3d-45c1-a1fe-548478efe08a,C0010200,C1175175,stands for ,Coughing,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.782.600.550.200.750;C08.730.730
c3fa9c65-cd19-46c9-b22e-c1548d8a5711,C0015967,C1175175,stands for ,Fever,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C23.888.119.344,C02.782.600.550.200.750;C08.730.730
9cbf533c-db3f-4f9d-bc0e-8644c746b2cd,C0013404,C1175175,stands for ,Dyspnea,Severe Acute Respiratory Syndrome,2,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C02.782.600.550.200.750;C08.730.730
bae84d52-4f69-4335-badf-7569fa7533b2,C0010200,C1175743,stands for ,Coughing,SARS coronavirus,2,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150.113.937
bae84d52-4f69-4335-badf-7569fa7533b2,C0010200,C1175743,are most prevalent Symptoms of adults infected by,Coughing,SARS coronavirus,1,X,[sosy],[virs],C08.618.248;C23.888.852.293,B04.820.504.540.150.113.937
13d7b86f-1ec5-4df5-af25-e97b59f2b849,C0013404,C1175743,stands for ,Dyspnea,SARS coronavirus,2,X,[sosy],[virs],C08.618.326;C23.888.852.371,B04.820.504.540.150.113.937
2e5cacd0-2f77-4aa1-ba10-6bfcc0b7c7d8,hisskin,sclera,was jaundiced with sclera ,hisskin,sclera,4,X,????,????,????,????
4df60ef6-d505-49bb-a922-c802820bcfce,hisskin,C0004002,was jaundiced with sclera ,hisskin,Aspartate Transaminase,2,X,????,[aapp/enzy],????,D08.811.913.477.700.225
4df60ef6-d505-49bb-a922-c802820bcfce,hisskin,C0004002,was jaundiced with very high levels of ,hisskin,Aspartate Transaminase,2,X,????,[aapp/enzy],????,D08.811.913.477.700.225
64670171-ec19-447f-872e-424602724e5c,hisskin,icteric,was jaundiced with icteric sclera ,hisskin,icteric,3,X,????,????,????,????
119d36ff-bf79-41d5-a1e7-c2ceea2cde59,C0118522,C0003451,regulates expression of wide array of genes including ,GA-Binding Protein Transcription Factor,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.776.260.615.249;D12.776.930.618.249,D27.505.954.122.388
88dce1c1-3410-45d6-98ee-f1eafa63c29b,C0118522,C0030012,regulates cellular ,GA-Binding Protein Transcription Factor,Oxidation-Reduction,3,X,[aapp/bacs],[moft],D12.776.260.615.249;D12.776.930.618.249,G02.700;G03.295.531
ba611a48-a03d-47ed-af5e-db794403098f,C0118522,C0012634,making elderly susceptible to ,GA-Binding Protein Transcription Factor,Disease,3,X,[aapp/bacs],[dsyn],D12.776.260.615.249;D12.776.930.618.249,C23.550.288
714d4fd7-02b9-4079-85f9-34106141350b,C0441655,C0012634,making elderly susceptible to ,Activities,Disease,2,X,[acty],[dsyn],,C23.550.288
937fc17f-7efa-4844-b2a9-2e8c99384413,C0012634,C0021376,include type diabetes ,Disease,Chronic inflammation,3,X,[dsyn],[patf],C23.550.288,
856e2842-6622-47d1-a731-8dc1c6da2010,C0012634,C0042769,is viral ,Disease,Virus Diseases,6,X,[dsyn],[dsyn],C23.550.288,C02
fae54b09-28ea-4c61-93b3-168dadbd6d0c,C0118522,C1422064,downregulates ,GA-Binding Protein Transcription Factor,ACE2 gene,2,X,[aapp/bacs],[gngm],D12.776.260.615.249;D12.776.930.618.249,
19b63ddd-858c-4fe6-a70b-888ec687bb7e,C1879547,C1422064,downregulates ,Activation action,ACE2 gene,2,X,[acty],[gngm],,
a02be921-9161-42d2-872c-0b1c24a119f3,PB125,C1422064,downregulates ,PB125,ACE2 gene,2,X,????,[gngm],????,
d1aa1e60-953f-4852-b0d3-22a9e04d644d,C0118522,C1515670,downregulates ,GA-Binding Protein Transcription Factor,mRNA Expression,3,X,[aapp/bacs],[genf],D12.776.260.615.249;D12.776.930.618.249,
913ec574-0ff2-4aa6-a189-01219bcecf89,C1879547,C1515670,downregulates ,Activation action,mRNA Expression,3,X,[acty],[genf],,
a97a4f12-0848-4692-af96-27f65e70a2af,PB125,C1515670,downregulates ,PB125,mRNA Expression,3,X,????,[genf],????,
0a17b86e-fe50-4a19-81f0-a55e3f1bcca5,C0118522,C0086418,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Homo sapiens,2,X,[aapp/bacs],[humn],D12.776.260.615.249;D12.776.930.618.249,B01.050.150.900.649.313.988.400.112.400.400
0a17b86e-fe50-4a19-81f0-a55e3f1bcca5,C0118522,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Homo sapiens,1,X,[aapp/bacs],[humn],D12.776.260.615.249;D12.776.930.618.249,B01.050.150.900.649.313.988.400.112.400.400
f9c5e120-a422-4202-834c-20301cb69d15,C1879547,C0086418,downregulates ACE2 gene mRNA Expression in,Activation action,Homo sapiens,2,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
f9c5e120-a422-4202-834c-20301cb69d15,C1879547,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Homo sapiens,1,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
f513d879-2d13-46ed-8b05-6c9eaa4f5f46,PB125,C0086418,downregulates ACE2 gene mRNA Expression in,PB125,Homo sapiens,2,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
f513d879-2d13-46ed-8b05-6c9eaa4f5f46,PB125,C0086418,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
83ac327c-65a5-4fdc-9f40-7cf578fdcc6a,C0118522,C0023884,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Liver,1,X,[aapp/bacs],[bpoc],D12.776.260.615.249;D12.776.930.618.249,A03.620
83ac327c-65a5-4fdc-9f40-7cf578fdcc6a,C0118522,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Liver,1,X,[aapp/bacs],[bpoc],D12.776.260.615.249;D12.776.930.618.249,A03.620
544878ed-d4d4-4c3c-86a4-3583056f8dd9,C1879547,C0023884,downregulates ACE2 gene mRNA Expression in,Activation action,Liver,1,X,[acty],[bpoc],,A03.620
544878ed-d4d4-4c3c-86a4-3583056f8dd9,C1879547,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Liver,1,X,[acty],[bpoc],,A03.620
66aea551-cff6-4f4d-93b6-b3dc598df450,PB125,C0023884,downregulates ACE2 gene mRNA Expression in,PB125,Liver,1,X,????,[bpoc],????,A03.620
66aea551-cff6-4f4d-93b6-b3dc598df450,PB125,C0023884,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Liver,1,X,????,[bpoc],????,A03.620
a98d3633-d572-42a6-897c-a03d2da64f0f,C0118522,C2717940,downregulates ACE2 gene mRNA Expression in,GA-Binding Protein Transcription Factor,Hep G2 Cells,2,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11.251.860.180.432;A11.436.348.500
a98d3633-d572-42a6-897c-a03d2da64f0f,C0118522,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,GA-Binding Protein Transcription Factor,Hep G2 Cells,1,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11.251.860.180.432;A11.436.348.500
1d4c4ecb-a868-4fff-8097-ffec9320d8dd,C1879547,C2717940,downregulates ACE2 gene mRNA Expression in,Activation action,Hep G2 Cells,2,X,[acty],[cell],,A11.251.860.180.432;A11.436.348.500
1d4c4ecb-a868-4fff-8097-ffec9320d8dd,C1879547,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,Activation action,Hep G2 Cells,1,X,[acty],[cell],,A11.251.860.180.432;A11.436.348.500
7eb3cf7e-1497-4978-9a8e-4c16171d4fc7,PB125,C2717940,downregulates ACE2 gene mRNA Expression in,PB125,Hep G2 Cells,2,X,????,[cell],????,A11.251.860.180.432;A11.436.348.500
7eb3cf7e-1497-4978-9a8e-4c16171d4fc7,PB125,C2717940,downregulates Peptidyl-Dipeptidase A mRNA Expression in,PB125,Hep G2 Cells,1,X,????,[cell],????,A11.251.860.180.432;A11.436.348.500
b3f885b4-5e54-4351-94d7-99f4e202c727,C1422064,C0597357,is surface ,ACE2 gene,receptor,2,X,[gngm],[aapp/rcpt],,
1e097e42-f419-4c54-9cfa-dfd38d9e89be,C0028606,C0020538,is with ,Nucleic Acids,Hypertensive disease,2,X,[bacs/nnon],[dsyn],D13.444,C14.907.489
fc674a9f-67f5-47e9-aa0f-2cd5c2f2b463,C0206750,C0034819,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin 2 Receptor,2,X,[dsyn],[aapp/imft/rcpt],C02.782.600.550.200,D12.776.543.750.705.852.420.320
765b1aa5-c786-4f5c-8d2f-0969f8d1df06,C0206750,C0021760,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin-6,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
cc3ecfb7-91e8-4daa-99bf-e40e3d16bf7b,C0206750,C0085295,In age is low lymphocyte count myocardial injury and abnormal increase of ,Coronavirus Infections,Interleukin-10,2,X,[dsyn],[aapp/imft],C02.782.600.550.200,D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510
6318d4e7-b2e1-4ee2-9f81-38667cae68b5,C0013404,C0010200,followed by ,Dyspnea,Coughing,5,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C08.618.248;C23.888.852.293
b111f9f8-b2dd-421a-87bc-e3cf42b8d9c3,C0030193,C0005768,factors elevated ,Pain,In Blood,1,X,[sosy],[bdsu],C23.888.592.612;F02.830.816.444;G11.561.790.444,x.x.x.x.x
b111f9f8-b2dd-421a-87bc-e3cf42b8d9c3,C0030193,C0005768,associated elevated white ,Pain,In Blood,1,X,[sosy],[bdsu],C23.888.592.612;F02.830.816.444;G11.561.790.444,x.x.x.x.x
9caadb3a-6402-49dd-9aee-4714e8231d74,C0030193,C0013404,factors ,Pain,Dyspnea,1,X,[sosy],[sosy],C23.888.592.612;F02.830.816.444;G11.561.790.444,C08.618.326;C23.888.852.371
9caadb3a-6402-49dd-9aee-4714e8231d74,C0030193,C0013404,associated ,Pain,Dyspnea,1,X,[sosy],[sosy],C23.888.592.612;F02.830.816.444;G11.561.790.444,C08.618.326;C23.888.852.371
f1911f6d-dcd3-4654-9ef4-20510943b6bb,C0023884,C0206419,were common in ,Liver,Genus: Coronavirus,2,X,[bpoc],[virs],A03.620,B04.820.504.540.150
d694b0aa-20bc-4a8c-961b-3c4ff2bb7952,C0030193,C0023884,associated with elevated ,Pain,Liver,1,X,[sosy],[bpoc],C23.888.592.612;F02.830.816.444;G11.561.790.444,A03.620
76774282-1467-4848-9752-578e13da0592,C0030193,C0206419,associated with elevated ,Pain,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.592.612;F02.830.816.444;G11.561.790.444,B04.820.504.540.150
15b388aa-fd3b-4cfa-9f95-08c353b4c7a2,C0174990,C0206419,Agent of,coronavirus receptor,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],x.x.x.x,B04.820.504.540.150
d3c4986f-b47a-4dfe-88d3-bc0dbccdb159,C1452534,C0174990,is entry ,ACE protein human,coronavirus receptor,2,X,[aapp/bacs],[aapp/rcpt],x.x.x.x,x.x.x.x
ad428248-2ba3-4a09-8f54-aa7377450f1e,C1452534,C0206419,decreases during ,ACE protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
3eb9bb3d-85fd-41e2-8755-a69494c1e0ca,C1452534,C0035222,leads to ,ACE protein human,Respiratory Distress Syndrome Adult,1,X,[aapp/bacs],[dsyn],x.x.x.x,C08.381.840;C08.618.840
524b08db-29c7-4235-acc9-9032c307f83d,C0277564,C1882509,are ,Acquired disease,put - instruction imperative,1,X,[dsyn],[acty],,
37539a48-6cbb-4693-9a93-9d7fb6838914,C0222045,C0960756,is in ,Integumentary scale,factor A,2,X,[bpoc],[orch],,x.x.x.x
ed05e25e-367a-4cf4-9aad-ddbda53fd33b,C1177210,8-fold,is with 8-fold ,cupric cation,8-fold,2,X,[inch/phsu],????,,????
80756796-6525-4cab-bff9-94c189c6dda7,C2700061,8-fold,is with 8-fold ,Transition (action),8-fold,2,X,[acty],????,,????
3c7030cd-5de2-427b-b245-48f8dcc3f614,C1177210,C0002055,is with 8-fold ,cupric cation,Alkalies,2,X,[inch/phsu],[inch],,D01.045
0bb6af8d-5190-4ea8-93be-9dceb052e77c,C2700061,C0002055,is with 8-fold ,Transition (action),Alkalies,2,X,[acty],[inch],,D01.045
d99c8049-c9d1-46fb-9484-3580ff89dc6a,C1177210,C1175743,underpinned almost one-half of amino acid differences between ,cupric cation,SARS coronavirus,2,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
340b9725-91c7-480b-b42f-db363eb85990,C2700061,C1175743,underpinned almost one-half of amino acid differences between ,Transition (action),SARS coronavirus,2,X,[acty],[virs],,B04.820.504.540.150.113.937
d800d627-3978-4d03-b60d-06dff5d28b5f,C2700061,U/A,occurred preferentially in U/A ,Transition (action),U/A,2,X,[acty],????,,????
5abc73d9-7863-4aec-ae07-bdd30154c6b9,C2700061,C1514562,occurred preferentially in U/A ,Transition (action),Protein Domain,2,X,[acty],[amas],,G02.111.570.820.709.275.750;G02.111.570.820.709.610.500
c6c75fc5-b1e4-427d-920d-ace5c40592b2,C2700061,C1609158,occurred preferentially in U/A ,Transition (action),APOBEC3 protein human,2,X,[acty],[aapp/enzy],,x.x.x.x
3d613ad3-8b12-4c3b-acdf-7ba8d40ca053,C0002055,C1177210,may represent long-term effects of prolonged ,Alkalies,cupric cation,2,X,[inch],[inch/phsu],D01.045,
e22dd554-df64-45d6-bfb7-63be27a670d2,C0002055,C1167395,may represent effects in their ,Alkalies,Host (organism),2,X,[inch],[orgm],D01.045,
8bfa1ef2-515d-410f-8d46-a9a89ba1767b,C0002055,C0206422,observed in nonpandemic ,Alkalies,Human coronavirus,2,X,[inch],[virs],D01.045,
86b6e2e7-9981-4ec9-83cf-da5bd4972cba,C0002520,C0042776,is with adaptive value for ,Amino Acids,Virus,1,X,[aapp/bacs/phsu],[virs],D12.125,B04
eb5eb5f6-d02a-47c6-bdcf-2b08dd91894c,C1177210,C1167395,is in ,cupric cation,Host (organism),2,X,[inch/phsu],[orgm],,
b37ab450-07f2-41f4-833a-89cc16a10373,C0026882,C1167395,is in ,Mutation,Host (organism),2,X,[genf],[orgm],G05.365.590,
51041017-6d44-435f-8ef1-e90c3a77dae0,C1177210,C1325696,is in ,cupric cation,apolipoprotein B mRNA editing enzyme complex,2,X,[inch/phsu],[celc],,
5fe1c3f2-4c34-4ced-ba27-f7091920cfa4,C0026882,C1325696,is in ,Mutation,apolipoprotein B mRNA editing enzyme complex,2,X,[genf],[celc],G05.365.590,
2bb5bccb-45cf-4cfd-9f98-f4f28dcb2394,C0886515,C0087111,more recently are emerging as new promising ,Secretory Vesicles,Therapeutic procedure,4,X,[celc],[topp],A11.284.430.214.190.875.190.880.810,E02
02ebc91c-d778-490a-917a-2c2f714df6ed,C3894683,C0087111,more recently are emerging as new promising ,Extracellular Vesicles,Therapeutic procedure,2,X,[celc],[topp],A11.284.295.588,E02
af203dc2-73b8-44a2-a740-af2c3e701b65,C0087111,C0024109,also regenerate ,Therapeutic procedure,Lung,2,X,[topp],[bpoc],E02,A04.411
af203dc2-73b8-44a2-a740-af2c3e701b65,C0087111,C0024109,diminished ,Therapeutic procedure,Lung,1,X,[topp],[bpoc],E02,A04.411
e522cd5d-74e7-41a2-9f4c-f30731cbfb24,C0038250,C1527144,exert their immunomodulatory ,Stem cells,Therapeutic Effect,2,X,[cell],[clna],A11.872,
f56d13a6-9799-452d-8b03-ae8c24791be8,C0699748,C0237820,seems most effective way for patients ,Pathogenesis,Recovery - action,2,X,[patf],[acty],,
ee2ca6d2-2253-4d28-8da2-d58cc2ef3520,C0087111,C0237820,seems most effective way for patients ,Therapeutic procedure,Recovery - action,2,X,[topp],[acty],E02,
62abdd5d-86db-46dd-b646-ac4fd8f8fef7,C0282636,C0237820,seems most effective way for patients ,Cell Respiration,Recovery - action,2,X,[celf],[acty],G03.197;G04.270,
e3b36923-336d-41fa-8d1f-45c87521560f,C0003209,C0237820,seems most effective way for patients ,Anti-Inflammatory Agents,Recovery - action,2,X,[phsu],[acty],D27.505.954.158,
1cf1e7fc-9bb7-418c-9654-eee63fd2dc15,C1261096,C0237820,seems most effective way for patients ,Extracorporeal blood,Recovery - action,1,X,[bdsu],[acty],,
6062bfc8-2a2f-4bd4-bdbe-d25a38b279e8,C0013227,HPLC,using validated HPLC ,Pharmaceutical Preparations,HPLC,2,X,[phsu],????,D26,????
e24a68db-0b6c-42dd-9a01-f7605b8fb726,C0008269,C0206419,were removed by treatment with Seraph dose adjustments in ,Chloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150
e24a68db-0b6c-42dd-9a01-f7605b8fb726,C0008269,C0206419,are are repurposed for treatment of ,Chloroquine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.180,B04.820.504.540.150
babce58e-94b4-4b9d-afe4-6f8603245c38,C0026652,C0203597,were higher than than ,Moxibustion,hyperthermia treatment,5,X,[topp],[topp],E02.190.044.588,
babce58e-94b4-4b9d-afe4-6f8603245c38,C0026652,C0203597,were lower than than ,Moxibustion,hyperthermia treatment,10,X,[topp],[topp],E02.190.044.588,
848f2ab4-7e32-42fe-a014-3e799ebceb52,C0026652,C0020517,were higher than than ,Moxibustion,Hypersensitivity,4,X,[topp],[patf],E02.190.044.588,C20.543
848f2ab4-7e32-42fe-a014-3e799ebceb52,C0026652,C0020517,were lower than than ,Moxibustion,Hypersensitivity,4,X,[topp],[patf],E02.190.044.588,C20.543
85f6adb3-8085-4555-8a76-6a8f2db4e764,C0026652,C0018837,was higher than than ,Moxibustion,Heat (physical force),2,X,[topp],[npop],E02.190.044.588,
a37c6af8-163f-469f-84db-c7389f7bb7fe,C0026652,C1457887,improve ,Moxibustion,Symptoms,3,X,[topp],[sosy],E02.190.044.588,
dc5f1e12-c078-4d6b-9f00-8c7f8e5753db,C0026652,C0206419,improve Symptoms with,Moxibustion,Genus: Coronavirus,1,X,[topp],[virs],E02.190.044.588,B04.820.504.540.150
121f411d-847a-4fbb-bac6-ba5240125c36,C0700271,C1707455,is in ,M Protein multiple myeloma,Comparison,1,X,[aapp/imft],[acty],x.x.x.x,
54623684-cd5e-4c64-84b8-cbcaf80094c9,C0042776,C1422064,recognizes other ,Virus,ACE2 gene,1,X,[virs],[gngm],B04,
b69d2ed5-f05c-4fd9-bc3d-b4e80cdb38f5,C0027794,C0597358,contains ,Neural Tube Defects,receptor binding,1,X,[cgab],[moft],C10.500.680;C16.131.666.680,
a3894120-5a46-4041-a125-68d8a9899eb4,C0027794,C1175743,contains ,Neural Tube Defects,SARS coronavirus,1,X,[cgab],[virs],C10.500.680;C16.131.666.680,B04.820.504.540.150.113.937
4e2831f8-c007-430b-9b2d-16bf023da10a,C0597358,C1175743,Protein Domain different from that of,receptor binding,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
02a93da0-97d9-48a3-b69f-36feb3ed9812,C1514562,C0042738,been In particular have found in ,Protein Domain,Viral Structural Proteins,2,X,[amas],[aapp/bacs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D12.776.964.970
00c69087-ceda-4bc3-b416-4f9e8eef2502,C1457887,C0231528,were ,Symptoms,Myalgia,7,X,[sosy],[sosy],,C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500
273b2b9f-34a8-480a-82cd-daaf2a3742f0,C1457887,C0038056,was ,Symptoms,Sputum,3,X,[sosy],[bdsu],,A12.200.808
d287a961-fcfb-4e8f-a556-41afea1f805c,C0206419,C4552744,has enforced dramatic changes to ,Genus: Coronavirus,Daily Living,1,X,[virs],[dora],B04.820.504.540.150,
f56e1a75-511a-4576-9df0-17ea04b6d2c9,C0243082,C0206750,were reported During ,associated conditions,Coronavirus Infections,3,X,[patf],[dsyn],,C02.782.600.550.200
aa97d989-598a-4c25-9324-a79c7d506db9,C0012655,C0596448,is with high D ,Disease susceptibility,dimer,3,X,[clna],[chvs],C23.550.291.687;G07.100.250,
a7d1bfc0-4ac3-469c-88ee-d28202c63759,C0005779,C0012634,are associated with ,Blood Coagulation Disorders,Disease,1,X,[dsyn],[dsyn],C15.378.100,C23.550.288
a7d1bfc0-4ac3-469c-88ee-d28202c63759,C0005779,C0012634,induced by ,Blood Coagulation Disorders,Disease,2,X,[dsyn],[dsyn],C15.378.100,C23.550.288
a7d1bfc0-4ac3-469c-88ee-d28202c63759,C0005779,C0012634,has recently emerged as major component of ,Blood Coagulation Disorders,Disease,3,X,[dsyn],[dsyn],C15.378.100,C23.550.288
027eb703-a2dc-475a-bc45-f8fa870ecc8b,C0005779,C1175743,are associated with ,Blood Coagulation Disorders,SARS coronavirus,1,X,[dsyn],[virs],C15.378.100,B04.820.504.540.150.113.937
7dc4a557-273c-4d9f-aa36-fc02bf1eb402,C0302148,C2586211,is in small ,Blood Clot,Thrombosis of blood vessel,3,X,[patf],[patf],C14.907.355.830,
947c049f-3fbd-4331-8dae-f600e559df59,C2350571,C0024109,is in ,Microvascular Network,Lung,3,X,[bpoc],[bpoc],A07.015.461,A04.411
9c760ec3-c5b2-456b-a803-5816097669b2,C1861172,C0206750,is in hospitalised ,Venous Thromboembolism,Coronavirus Infections,3,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
9c760ec3-c5b2-456b-a803-5816097669b2,C1861172,C0206750,has has frequently reported in patients with ,Venous Thromboembolism,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
9c760ec3-c5b2-456b-a803-5816097669b2,C1861172,C0206750,has emerged as important consideration in management of patients with ,Venous Thromboembolism,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.355.590.700,C02.782.600.550.200
260d1f25-ce83-482b-8175-612055300b2c,C2348077,C1947933,personalized ,Date Fruit,care activity,2,X,[food],[acty],B01.650.940.800.575.912.250.093.615,
6691c838-715e-4d74-ba70-64110af2520e,PCR,C0242781,has raised possibility of feco-oral ,PCR,disease transmission,3,X,????,[patf],????,N06.850.310
07dbfff4-2ecf-4ba0-83d8-ece866fe534d,PCR,C0015733,is in ,PCR,Feces,3,X,????,[bdsu],????,A12.459
5fc53c01-9e66-48ff-8c07-cc427d494adf,C0360714,C0206750,improve ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,C02.782.600.550.200
92560d88-c677-4230-bbd4-3ce17bf57f08,C2259033,C0206750,improve ,activation of coagulation,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
ea1c1060-9d8c-42d5-b210-9012eb85849a,C1511790,C0038056,is in ,Detection,Sputum,1,X,[topp],[bdsu],,A12.200.808
4ecb0351-9950-4572-abe5-583bceae0d1a,C0206750,C1608239,was found in ,Coronavirus Infections,Specimen Type - Bile fluid,2,X,[dsyn],[bdsu],C02.782.600.550.200,
64780946-dc04-4d97-84af-276f487757db,C0206750,RTPCR,was In case report found in RTPCR,Coronavirus Infections,RTPCR,1,X,[dsyn],????,C02.782.600.550.200,????
64780946-dc04-4d97-84af-276f487757db,C0206750,RTPCR,was found by realtime RTPCR,Coronavirus Infections,RTPCR,1,X,[dsyn],????,C02.782.600.550.200,????
6606c7f1-24b8-4af6-afe4-f3fb55cc720b,C0086312,C1705178,predict compound growth rate after SIP ,Forests,Order (action),2,X,[npop],[acty],G16.500.275.157.437;N06.230.124.343,
8562eb1c-2b95-473e-94a2-eb0fce1de7dc,C0948245,C3714514,is systemic inflammatory response can triggered by,Cytokine Release Syndrome,Infection,2,X,[dsyn],[patf],,C01.539
4658cba0-0edc-444e-af7d-cc2e990e1929,C0948245,C1155266,is systemic ,Cytokine Release Syndrome,inflammatory response,4,X,[dsyn],[patf],,
7d6352a5-50a7-433c-a6f9-489d7015d335,C0948245,C0206750,is in patients with ,Cytokine Release Syndrome,Coronavirus Infections,6,X,[dsyn],[dsyn],,C02.782.600.550.200
4dfc6bf7-15fe-4e7a-8b6e-920772930ab1,C0948245,C0012634,is in patients with ,Cytokine Release Syndrome,Disease,2,X,[dsyn],[dsyn],,C23.550.288
7aacb1f1-c782-4c04-b375-72fa1e5360c9,C1155266,C0206750,can can triggered by ,inflammatory response,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
7aacb1f1-c782-4c04-b375-72fa1e5360c9,C1155266,C0206750,are hallmarks of severe ,inflammatory response,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
7aacb1f1-c782-4c04-b375-72fa1e5360c9,C1155266,C0206750,has direct ,inflammatory response,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
5d82b89f-6012-47df-8172-3389d018b057,C1155266,C0948245,can can triggered by ,inflammatory response,Cytokine Release Syndrome,2,X,[patf],[dsyn],,
d41f95f2-f426-4d9b-9b07-a3f6e3b1fd29,C0206277,C0032962,is in ,Fatal Outcome,Pregnancy Complications,1,X,[patf],[patf],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,C13.703
28accdf3-c6bc-4c25-934a-0d995faf5de4,C1817959,C0035222,will reduce frequency of ,tolerance induction,Respiratory Distress Syndrome Adult,1,X,[biof],[dsyn],,C08.381.840;C08.618.840
868f46af-5489-4df0-820c-2de3d4ad02b5,COVID-19,C0079189,can manifest with ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
868f46af-5489-4df0-820c-2de3d4ad02b5,COVID-19,C0079189,are characterized with ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
868f46af-5489-4df0-820c-2de3d4ad02b5,COVID-19,C0079189,leads to ,COVID-19,cytokine,1,X,[virs],[aapp/imft],C000657245,D12.644.276.374;D12.776.467.374;D23.529.374
f5160c96-f7ae-4c57-92d3-195999be391c,C0389003,C0041755,is known as ideal target for next generation without ,cyclooxygenase 1,Adverse reaction to drug,2,X,[aapp/enzy],[patf],D08.811.600.720.500,C25.100
347a9b82-1b4d-40a3-81dd-ac2fc1cb31fa,C1412677,C0041755,is known as ideal target for next generation without ,ATP6V1E1 gene,Adverse reaction to drug,1,X,[gngm],[patf],,C25.100
76d6cb72-7305-4609-83b9-c07ea4a10cbe,C1506770,C1424489,using DREAM in ,lapatinib,BCAP31 gene,1,X,[orch/phsu],[gngm],D03.633.100.786.516,
9bb683e6-f398-479f-b429-edd10fc879e0,C1506770,C0033555,has has identified as ,lapatinib,Prostaglandins A,2,X,[orch/phsu],[orch/phsu],D03.633.100.786.516,D10.251.355.255.550.100;D23.469.050.175.725.100
99e03ce1-0300-4017-904f-941288c5194c,C1424489,C1718097,repurpose New medications for various,BCAP31 gene,New medications,1,X,[gngm],[phsu],,
99e03ce1-0300-4017-904f-941288c5194c,C1424489,C1718097,repurpose FDA-approved ,BCAP31 gene,New medications,1,X,[gngm],[phsu],,
b58e3139-e0fe-4604-bd1b-8461722caa68,C1424489,C0087111,repurpose New medications for various,BCAP31 gene,Therapeutic procedure,1,X,[gngm],[topp],,E02
d4c3fa0b-a4e2-4409-910b-7230ec52e2cd,C0036974,COVID-19,is known as ,Shock,COVID-19,2,X,[patf],[virs],C23.550.835,C000657245
c45db742-788a-4cbd-ac9d-e9241f51985f,C3714634,C0242781,underpin ,Biological Processes,disease transmission,2,X,[biof],[patf],G16,N06.850.310
0bcfdc92-1cc4-4d59-8962-d38ed2a8efaf,C3714634,C0012634,underpin population-level dynamics of ,Biological Processes,Disease,2,X,[biof],[dsyn],G16,C23.550.288
9e4c560d-2c17-4272-818b-c1b3563f4a2c,C0031843,C0014442,makes ,physiological aspects,Enzymes,3,X,[phsf],[aapp/enzy],x.x.x.x,D08.811
934bb026-51c6-4a80-b22b-d0d06a47f4bd,C0031843,C0243077,makes ,physiological aspects,inhibitors,2,X,[phsf],[chvf],x.x.x.x,
12e0fc77-791d-46c3-9100-606ab8fc25c6,C0031843,C0087111,makes ,physiological aspects,Therapeutic procedure,3,X,[phsf],[topp],x.x.x.x,E02
e0bc1df0-7738-4e09-b5f3-8816c2e79737,C0014442,C0243077,promising target for ,Enzymes,inhibitors,3,X,[aapp/enzy],[chvf],D08.811,
8957be5c-41f6-41df-95c7-5ac652e5618c,C0014442,C0087111,promising target to ,Enzymes,Therapeutic procedure,3,X,[aapp/enzy],[topp],D08.811,E02
8f62be90-200c-4e5d-985b-2b44a2752b89,C0014442,C0206750,promising target to ,Enzymes,Coronavirus Infections,3,X,[aapp/enzy],[dsyn],D08.811,C02.782.600.550.200
424149ee-8488-4e15-b552-f5b2cb7ee16e,C0031843,C0042774,is in ,physiological aspects,Virus Replication,3,X,[phsf],[celf],x.x.x.x,G06.920.925
6dc7020d-a427-4bff-bdb1-a8d975e98bee,C1510827,C1175743,is in ,Affinity,SARS coronavirus,3,X,[npop],[virs],,B04.820.504.540.150.113.937
e41a2d6f-f99d-4918-b9c6-8fffc9180217,C0319157,C0008139,is related to SL ,AS virus,Chiroptera,2,X,[virs],[mamm],,B01.050.150.900.649.313.937
3de62d08-b1ca-43b6-a114-a5485d9241fe,C0319157,SL,is related to SL ,AS virus,SL,2,X,[virs],????,,????
a9e03b62-ab0e-4e69-b0e3-8e803eeb9938,C0030858,C0013227,shows Binding (Molecular Function) Affinity among,Pentaerythritol Tetranitrate,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D02.033.455.706.690,D26
b4f0f010-52fc-4835-a9f2-577a057c693c,C0030858,C1167622,shows good ,Pentaerythritol Tetranitrate,Binding (Molecular Function),3,X,[orch/phsu],[moft],D02.033.455.706.690,
db54fcf9-c1ac-4f4e-9b2f-266dd6197ca8,C0030858,C1510827,shows good ,Pentaerythritol Tetranitrate,Affinity,3,X,[orch/phsu],[npop],D02.033.455.706.690,
3b941e0c-edb7-45fa-aab7-c8799bcfb4e0,C0013227,C1510827,shows good ,Pharmaceutical Preparations,Affinity,3,X,[phsu],[npop],D26,
3b941e0c-edb7-45fa-aab7-c8799bcfb4e0,C0013227,C1510827,evaluate ,Pharmaceutical Preparations,Affinity,1,X,[phsu],[npop],D26,
ffb7cc49-7a7f-4491-b7d7-fa985ab08826,C1167622,C1433062,is with ,Binding (Molecular Function),3C-like protease SARS coronavirus,6,X,[moft],[aapp/enzy],,x.x.x.x
15b1c5ef-41f6-43b8-9825-6040690ad2c8,C1175743,C0021368,leads to ,SARS coronavirus,Inflammation,1,X,[virs],[patf],B04.820.504.540.150.113.937,C23.550.470
5f0a65fd-a00f-49dd-bcfa-a8a22796ff17,C0085405,C0032143,is with ,Salvage Therapy,alteplase,1,X,[topp],[aapp/enzy/phsu],E02.895,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
021efbe5-6751-47b8-a9df-247a17ba5f7f,C2370955,C0089147,using ,Smell function,butyl alcohol,1,X,[phsf],[orch],,D02.033.415.110.175;D10.289.110.175
85a9f09d-45bc-4406-a549-b5a390bc86e5,C0003342,COVID-19,contribute to ,Antigens Viral,COVID-19,1,X,[imft],[virs],D23.050.327,C000657245
6c070388-860d-408d-93c7-a5e1bba10ea6,C0450254,C0020517,established ,Pathogenic organism,Hypersensitivity,2,X,[orgm],[patf],,C20.543
856692da-a307-46c3-8a24-ecb49e871358,C0450254,C0206415,screened ,Pathogenic organism,Oligonucleotide Primers,2,X,[orgm],[nnon],,D13.695.578.424.450.275;D27.720.470.530.600.223.600
65db04dd-f8e2-4543-99f7-2d1394fa2ccb,LOD,C1175743,Using two fold diluted ,LOD,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
65db04dd-f8e2-4543-99f7-2d1394fa2ccb,LOD,C1175743,reported in RealTime ,LOD,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
9b87ea81-789e-4e17-a73a-6356fec1b67e,C0017337,C1511790,be used for rapid ,Genes,Detection,2,X,[gngm],[topp],G05.360.340.024.340,
9b87ea81-789e-4e17-a73a-6356fec1b67e,C0017337,C1511790,could With advantage of CoV2 ,Genes,Detection,2,X,[gngm],[topp],G05.360.340.024.340,
060afda8-baa0-4a26-b43b-dd830586bdda,C0017337,C1175743,be used for rapid ,Genes,SARS coronavirus,2,X,[gngm],[virs],G05.360.340.024.340,B04.820.504.540.150.113.937
060afda8-baa0-4a26-b43b-dd830586bdda,C0017337,C1175743,could With advantage of CoV2 ,Genes,SARS coronavirus,2,X,[gngm],[virs],G05.360.340.024.340,B04.820.504.540.150.113.937
0924b00f-4419-4be4-b74d-717f76b01a2b,C0017337,CoV2,could With advantage of CoV2 ,Genes,CoV2,2,X,[gngm],????,G05.360.340.024.340,????
2ad9f245-e03b-44fb-835c-01462b7ccaaf,C0812928,COVID-19,uniquely exposes providers to ,Oral and maxillofacial surgery (qualifier value),COVID-19,1,X,[topp],[virs],,C000657245
7bfce844-1530-4e3d-a1d3-2841bddd82a3,C0035452,COVID-19,received ,Rheumatology specialty,COVID-19,1,X,[bmod],[virs],H02.403.429.730,C000657245
edad35b0-04eb-4593-93fc-6af7130c02af,C0007430,C0543467,maintain their ,Catheterization,Operative Surgical Procedures,1,X,[topp],[topp],E02.148;E05.157,E04
c9faf13c-12ee-473f-ae11-e8cf8159298b,C1829939,C0679225,showed frequently several ,{Non-patient},multiple pathologies,4,X,[clna],[dsyn],,
7589aaae-bb71-408f-aa3a-e2c21c939d34,C1829939,C0020538,showed frequently several ,{Non-patient},Hypertensive disease,2,X,[clna],[dsyn],,C14.907.489
3b678322-8d39-4396-a0b7-c84afa74960d,C0679225,C0020538,is with ,multiple pathologies,Hypertensive disease,2,X,[dsyn],[dsyn],,C14.907.489
d8b53fd2-c569-4dcf-bfde-b302d9fbeffe,C0020538,C0679225,was most common ,Hypertensive disease,multiple pathologies,1,X,[dsyn],[dsyn],C14.907.489,
eb2076ad-3c4f-4119-bc8e-1cf729266e89,C3887642,C0319157,is with evidence of ,Hippocampus Proper,AS virus,2,X,[bpoc],[virs],A08.186.211.180.405;A08.186.211.200.885.287.500.345,
1bda7c48-b9db-4f16-9b86-e8547b05a4cc,C0039082,C0302189,have have described in context of ,Syndrome,Cell Therapy,1,X,[dsyn],[topp],C23.550.288.500,E02.095.147
85b2d410-688d-4cd2-a92a-84ee6bb2ebe5,C1619738,C0206750,have disease characteristic in common with,Immune Reconstitution Inflammatory Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C20.608,C02.782.600.550.200
7986ffb8-2be2-4c28-9ed8-fd9b8dfdfe73,C4054044,C0206750,have disease characteristic in common with,Secondary Hemophagocytic Lymphohistiocytosis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
64408927-b204-419a-8594-f46194563fd6,C0948245,C0599878,have clinical ,Cytokine Release Syndrome,disease characteristic,2,X,[dsyn],[patf],,
a3a368f5-877b-4531-bf9d-ddf5cf87a6d6,C1619738,C0599878,have clinical ,Immune Reconstitution Inflammatory Syndrome,disease characteristic,2,X,[dsyn],[patf],C20.608,
0bd8d65e-1496-4a7d-8e4c-3fb2dfe99748,C4054044,C0599878,have clinical ,Secondary Hemophagocytic Lymphohistiocytosis,disease characteristic,2,X,[dsyn],[patf],,
01830800-9da2-458f-bdf5-f3d0d7fe3cf9,C0086418,C1856053,China until ,Homo sapiens,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,x.x.x.x
01830800-9da2-458f-bdf5-f3d0d7fe3cf9,C0086418,C1856053,was diagnosed with ,Homo sapiens,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,x.x.x.x
c8599182-1e9b-4fdb-9482-0aeca093058a,C0206750,C0439056,was positive for ,Coronavirus Infections,Throat swab sample,1,X,[dsyn],[bdsu],C02.782.600.550.200,
b5cfdffc-ec96-463f-8527-638a7810be40,C3687832,C0087111,have have tested as new ,Drugs - dental services,Therapeutic procedure,1,X,[topp],[topp],,E02
65033921-6cc2-49cb-9d38-d179b9ba6a35,C3687832,C0030664,already used in clinical setting for ,Drugs - dental services,Pathology,1,X,[topp],[bmod],,H02.403.650
06efdff8-f452-462a-86a5-66475908a985,C0019682,C1175743,tested positive for ,HIV,SARS coronavirus,2,X,[virs],[virs],B04.820.650.589.650.350,B04.820.504.540.150.113.937
bc2fbef5-c604-4109-a605-4e5518507b3a,C0019682,C0444192,tested positive for ,HIV,Nasopharyngeal swab (specimen),2,X,[virs],[bdsu],B04.820.650.589.650.350,
0dce3d8f-bb0e-466e-9e86-ee7947990f10,C0235029,C0206750,is in patients with ,neurological complication,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
9bd21a51-2429-4536-a0b2-6a7163c6e828,C0497552,C0206750,is in ,Congenital neurologic anomalies,Coronavirus Infections,1,X,[cgab],[dsyn],C10.500;C16.131.666,C02.782.600.550.200
9cb9f989-b8e7-4319-b075-77fc139056fe,C0206750,C0011570, includes ,Coronavirus Infections,Mental Depression,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.145.126.350
af041f72-1ece-4311-9ad2-4ac666f37684,C0030567,C0206750,long-term sequalae of ,Parkinson Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,C02.782.600.550.200
899e44e3-4f07-4568-b07d-3c8a4388d6b1,C0002395,C0206750,long-term sequalae of ,Alzheimer's Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,C02.782.600.550.200
cabb89bf-154a-4ba9-a406-154037a65e0b,C0815107,C0206750,people with ,psychological distress,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
e720288b-8cce-4bdc-8166-f14d0d6decbb,C0683587,COVID-19,are ,tourism,COVID-19,1,X,[dora],[virs],,C000657245
c37e75ba-530f-4126-9c1b-988c9d417469,C0683587,C0025874,are worldwide research gap ,tourism,Metrorrhagia,3,X,[dora],[patf],,C13.351.500.852.691.622;C23.550.414.993.700
696ec463-ea9b-4dc7-824d-e503471b2637,C0008151,C0035243,importantly reduce healthcare worker exposure to ,Chlamydia trachomatis,Respiratory Tract Infections,1,X,[bact],[dsyn],B03.440.190.190.190.750,C01.539.739;C08.730
28f7d4ef-bfcc-4c7b-81dd-c91a7494d6b2,C1175175,C0598197,is highly ,Severe Acute Respiratory Syndrome,contagion,1,X,[dsyn],[npop],C02.782.600.550.200.750;C08.730.730,
b166cb56-22a1-4484-a171-73c4a6ebbfce,C1999230,C1424721,structured information on prevention in ,Providing (action),FAIM2 gene,1,X,[acty],[gngm],,
6b6ad969-f7c8-494b-a6d1-98b5466e0bc0,C0009450,C0015967,mainly presents as ,Communicable Diseases,Fever,2,X,[dsyn],[sosy],C01.539.221,C23.888.119.344
c3321374-16b5-497b-a1fe-13cfe95837dc,C0009450,C0013404,mainly presents as ,Communicable Diseases,Dyspnea,2,X,[dsyn],[sosy],C01.539.221,C08.618.326;C23.888.852.371
0a111853-cee3-47b5-951f-668c51c51d6a,AKI,COVID-19,is in ,AKI,COVID-19,3,X,????,[virs],????,C000657245
b3163b40-2a07-45b6-be48-ddf33a363618,AKI,C0009450,is in ,AKI,Communicable Diseases,2,X,????,[dsyn],????,C01.539.221
406b399e-33fe-4d3e-bd17-53419efe4170,C3649547,C0005768,is most used ,Continuous renal replacement therapy,In Blood,2,X,[topp],[bdsu],,x.x.x.x.x
f2e00897-6e19-4793-8fdd-923333f4349a,COVID-19,C0870392,is under In addition still ,COVID-19,debate,2,X,[virs],[acty],C000657245,
bdb52fdf-e962-46f5-a88f-4b766575aaa3,C0024501,C0870392,is under In addition ,Maintenance,debate,2,X,[acty],[acty],N02.628,
4eead027-8aae-4e4c-9006-1d096739aa87,C0021079,C0870392,is under In addition ,Therapeutic immunosuppression,debate,1,X,[topp],[acty],E02.095.465.425.450;E05.478.610,
542bb3c3-15a4-45ca-84a3-5aaad34078f8,C1175175,C0022646,is in ,Severe Acute Respiratory Syndrome,Kidney,2,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,A05.810.453
8793181e-7fec-435c-aea7-b973723d02eb,C1175175,C0206277,is in ,Severe Acute Respiratory Syndrome,Fatal Outcome,2,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325
ee997530-2f9d-45fa-9bfd-3deb8af3cc1d,PCR,C0206750,analyzing DNA during especially now,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
ee997530-2f9d-45fa-9bfd-3deb8af3cc1d,PCR,C0206750,development of positive ,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
ee997530-2f9d-45fa-9bfd-3deb8af3cc1d,PCR,C0206750,detect new ,PCR,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
86b9de46-71a1-4b45-80bc-f31805265d02,PCR,C0012854,analyzing ,PCR,DNA,1,X,????,[bacs/nnon],????,D13.444.308
d4497f16-6005-4f6b-ae12-b8e7e6599b52,C0042720,C0065827,contains distinctive features including fragment within spike ,Viral Genome,Measles Virus Nucleoprotein,1,X,[gngm],[aapp/bacs],G05.360.340.358.840,x.x.x.x
fa2e928e-2537-44aa-93c2-873d2a8ae31d,C0065827,C0206750,allows ,Measles Virus Nucleoprotein,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
fa2e928e-2537-44aa-93c2-873d2a8ae31d,C0065827,C0206750,is important Antigens for,Measles Virus Nucleoprotein,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
2bcb300d-3840-46e2-92ec-08aea6eb2cd4,C0065827,C1947904,allows ,Measles Virus Nucleoprotein,Attachment (action),1,X,[aapp/bacs],[acty],x.x.x.x,
c515ca59-2c9c-49a1-966f-5c44d1df3bbb,C0206750,C3536832,might might ongoing during summer ,Coronavirus Infections,Air,1,X,[dsyn],[inch/phsu],C02.782.600.550.200,G16.500.275.063.150;N06.230.300.100.150
e009cbcb-fbf7-4727-8e1d-0079bcf1e73f,COVID-19,C0009079,suggest continuing with ,COVID-19,Clozapine,2,X,[virs],[orch/phsu],C000657245,D03.633.300.240.220
b98354d8-cb68-45ec-80e8-a4dd13b9d63c,C0035243,C0009079,recommend use in ,Respiratory Tract Infections,Clozapine,1,X,[dsyn],[orch/phsu],C01.539.739;C08.730,D03.633.300.240.220
286c6194-1aed-46ea-b7c9-8626d419ce2c,C0543467,C0751429,collected during different ,Operative Surgical Procedures,Surgical Procedures Laparoscopic,1,X,[topp],[topp],E04,E01.370.388.250.520;E04.502.250.520
8a60fac7-a779-43f3-b611-eaa31f8dc0a0,C0037366,C0751429,collected during different ,Smoke,Surgical Procedures Laparoscopic,1,X,[hops],[topp],D20.633.937,E01.370.388.250.520;E04.502.250.520
c5f12a40-b50a-4f40-8259-9b08a8b0e086,C0019169,C0042776,was identified About other ,Hepatitis B Virus,Virus,2,X,[virs],[virs],B04.280.375.650.425;B04.450.390.650.425,B04
e88cc86a-5852-42b9-a8ef-5cd82126919d,C0019169,C0543467,was identified in ,Hepatitis B Virus,Operative Surgical Procedures,2,X,[virs],[topp],B04.280.375.650.425;B04.450.390.650.425,E04
ab4730e6-b87a-4087-9ef5-8534dfceac2e,C0019169,C0037366,was identified in ,Hepatitis B Virus,Smoke,2,X,[virs],[hops],B04.280.375.650.425;B04.450.390.650.425,D20.633.937
f5285b46-dd10-43ae-ba0f-68d306443ae5,C0019169,C0751429,was identified in ,Hepatitis B Virus,Surgical Procedures Laparoscopic,2,X,[virs],[topp],B04.280.375.650.425;B04.450.390.650.425,E01.370.388.250.520;E04.502.250.520
bf0fd314-681a-423c-9160-25ba521f9c20,C0343641,C0543467,is in ,Human papilloma virus infection,Operative Surgical Procedures,1,X,[dsyn],[topp],C02.256.650;C02.928.725,E04
06a59f49-4d0a-481b-bc54-00321af68ccf,C0021344,C0242781,have high risk of ,Human Papillomavirus,disease transmission,1,X,[virs],[patf],,N06.850.310
89ec6930-388d-4a66-8747-c48c2f9636d7,C0298067,C1254351,is recognized as antifibrotic ,pirfenidone,Pharmacologic Substance,2,X,[orch/phsu],[phsu],x.x.x.x,
1e015948-e7e4-4cc0-b2dd-21c6f6d18d2f,C0298067,C1800706,is recognized as antifibrotic ,pirfenidone,Idiopathic Pulmonary Fibrosis,2,X,[orch/phsu],[dsyn],x.x.x.x,C08.381.483.487.500;C08.381.765.500
f3a4fac7-da44-47db-ab82-2c266ca59903,C0298067,C0206750,has Recently has launched for treatment of ,pirfenidone,Coronavirus Infections,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
71ee73a6-fd12-43f1-9780-15cf2d7971d2,C0298067,C0012634,has Recently has launched for treatment of ,pirfenidone,Disease,2,X,[orch/phsu],[dsyn],x.x.x.x,C23.550.288
3f047b70-de8c-482a-92a3-996ca507826d,C0011570,C0665820,is in amplitude of ,Mental Depression,DMBT1 protein human,2,X,[mobd],[aapp/bacs],F01.145.126.350,x.x.x.x
a5a9c6ad-c524-46dc-8782-dcaef3a9e19a,C0298067,C0162585,perturbing specific ,pirfenidone,Ion Transport,2,X,[orch/phsu],[celf],x.x.x.x,G03.143.500
3d23c699-41ea-4cdf-986e-ae8b0b55ffd9,COVID-19,C2745965,is world health ,COVID-19,Emergencies [Disease/Finding],2,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
3d23c699-41ea-4cdf-986e-ae8b0b55ffd9,COVID-19,C2745965,has demonstrated ,COVID-19,Emergencies [Disease/Finding],1,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
3d23c699-41ea-4cdf-986e-ae8b0b55ffd9,COVID-19,C2745965,IMPACT gene of large-scale health,COVID-19,Emergencies [Disease/Finding],1,X,[virs],[patf],C000657245,C23.550.291.781;N06.230.100.083;N06.850.376
398e3e6d-2ea5-4873-a860-1cf69f3a00be,C0036421,C1947933,need ,Systemic Scleroderma,care activity,3,X,[dsyn],[acty],C17.300.799;C17.800.784,
ba822cd0-c5f4-4c94-b499-68d294966da5,COVID-19,C0024115,might complicate ,COVID-19,Lung diseases,6,X,[virs],[dsyn],C000657245,C08.381
87781b3b-f054-45a5-b1bf-a75849f94b81,C0009450,C0024115,might complicate ,Communicable Diseases,Lung diseases,6,X,[dsyn],[dsyn],C01.539.221,C08.381
f411dcf6-b17e-4b8e-a9ba-268242985d80,COVID-19,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,COVID-19,Systemic Scleroderma,2,X,[virs],[dsyn],C000657245,C17.300.799;C17.800.784
6745c47f-d68e-4c5d-a821-2142729195a3,C0009450,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,Communicable Diseases,Systemic Scleroderma,2,X,[dsyn],[dsyn],C01.539.221,C17.300.799;C17.800.784
c0a5a380-9ad5-47e8-bd34-d51152485d10,COVID-19,C1705178,is in ,COVID-19,Order (action),2,X,[virs],[acty],C000657245,
87594dd4-e608-4f94-8394-a8bd069c4d73,C0009450,C1705178,is in ,Communicable Diseases,Order (action),2,X,[dsyn],[acty],C01.539.221,
b29c6e35-07d7-4e0c-9e8c-d22d36addf1c,COVID-19,C0206062,distinguish from ,COVID-19,Lung Diseases Interstitial,2,X,[virs],[dsyn],C000657245,C08.381.483
f4333303-551b-4262-a8d3-21e7a0a3ed8e,C1550661,C1628999,became for ,Specimen Type - Stool = Fecal,SARS coronavirus RNA,1,X,[bdsu],[nnon],,
37cf9cb9-2ff4-47f1-9609-d03efbe7b0d3,C0370003,C0035668,remained positive for ,Specimen,RNA,1,X,[sbst],[nnon],,D13.444.735
20db4d81-5dd4-402d-843c-28d3123e51cc,C2948600,C1516635,evaluate ,Aim,Clinical Treatment,4,X,[inch/phsu],[topp],,
d9c225ed-386f-4e87-b761-7fed092874c4,C2948600,ACEI,evaluate Clinical Treatment implications with ACEI,Aim,ACEI,1,X,[inch/phsu],????,,????
845633a1-60b6-4212-8c80-65933b291b9e,C2948600,C3888198,evaluate Clinical Treatment implications with ACEI,Aim,BESTROPHINOPATHY AUTOSOMAL RECESSIVE,1,X,[inch/phsu],[dsyn],,
bb7fa424-cb76-4600-84eb-25d9ae8510b3,C0007430,C1707455,was ,Catheterization,Comparison,1,X,[topp],[acty],E02.148;E05.157,
57645d56-f2fa-46ad-b5cc-b81bee00eaf6,C0007430,C0206750,was ,Catheterization,Coronavirus Infections,1,X,[topp],[dsyn],E02.148;E05.157,C02.782.600.550.200
6cec08ad-b9d1-4542-9e70-ddf07300bfcd,C4553629,y144,elucidated potential missense variants from databases within xentit y144 ,MATRix Regimen,y144,1,X,[topp],????,,????
779e63b3-769b-48ec-90a6-453cd6e2b0b0,C0026780,C0282682,provide broad ,Mumps,Antibodies Blocking,4,X,[dsyn],[aapp/imft/irda],C02.782.580.600.680.500;C07.465.815.470.800.630,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
0f1f580a-4810-456d-b5e2-60bc52910bb2,C0026780,C0012634,provide broad ,Mumps,Disease,2,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C23.550.288
0f1f580a-4810-456d-b5e2-60bc52910bb2,C0026780,C0012634,broad Antibodies Blocking against numbers of,Mumps,Disease,1,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C23.550.288
dda6e4b3-4df6-4773-82cd-9faf1d0c3251,C0026780,C0206750,provide broad ,Mumps,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C02.782.600.550.200
dda6e4b3-4df6-4773-82cd-9faf1d0c3251,C0026780,C0206750,broad Antibodies Blocking against numbers of,Mumps,Coronavirus Infections,1,X,[dsyn],[dsyn],C02.782.580.600.680.500;C07.465.815.470.800.630,C02.782.600.550.200
5b528499-0e84-40fc-bbd4-8637869c239d,C0025007,C0282682,provide broad ,Measles,Antibodies Blocking,4,X,[dsyn],[aapp/imft/irda],C02.782.580.600.500.500,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
61962802-cb78-4204-947e-9af25df47060,C0025007,C0012634,provide broad ,Measles,Disease,2,X,[dsyn],[dsyn],C02.782.580.600.500.500,C23.550.288
61962802-cb78-4204-947e-9af25df47060,C0025007,C0012634,broad Antibodies Blocking against numbers of,Measles,Disease,1,X,[dsyn],[dsyn],C02.782.580.600.500.500,C23.550.288
760318fa-a2b1-4538-a764-d9cde413e3ab,C0025007,C0206750,provide broad ,Measles,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.580.600.500.500,C02.782.600.550.200
760318fa-a2b1-4538-a764-d9cde413e3ab,C0025007,C0206750,broad Antibodies Blocking against numbers of,Measles,Coronavirus Infections,1,X,[dsyn],[dsyn],C02.782.580.600.500.500,C02.782.600.550.200
9717f91c-4995-4f8f-9ae4-c5654d1e96e2,C0035923,C0012634,broad Antibodies Blocking against numbers of,Rubella virus vaccine,Disease,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C23.550.288
9717f91c-4995-4f8f-9ae4-c5654d1e96e2,C0035923,C0012634,provide broad ,Rubella virus vaccine,Disease,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C23.550.288
6de7134c-5918-45d2-be7c-6b6db7dd6c7e,C0035923,C0206750,broad Antibodies Blocking against numbers of,Rubella virus vaccine,Coronavirus Infections,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C02.782.600.550.200
6de7134c-5918-45d2-be7c-6b6db7dd6c7e,C0035923,C0206750,provide broad ,Rubella virus vaccine,Coronavirus Infections,4,X,[aapp/imft/phsu],[dsyn],D20.215.894.899.779,C02.782.600.550.200
6d88e143-f0f1-41df-92b4-cf4eeeb7b8c5,C0035923,C0282682,provide broad ,Rubella virus vaccine,Antibodies Blocking,8,X,[aapp/imft/phsu],[aapp/imft/irda],D20.215.894.899.779,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
c3276618-e6e0-4c86-b88b-9b9f331ca219,C0003316,C0025007,is in ,Epitopes,Measles,2,X,[imft],[dsyn],D23.050.550,C02.782.580.600.500.500
2baf4e3e-e6bb-4bef-9163-f614884d9fc1,humoral,C0206750,children with advantageous protection against ,humoral,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
99db8a23-17bf-41a4-bff5-1d5e2604f58d,C1175743,C0849867,cause ,SARS coronavirus,Widespread Disease,7,X,[virs],[dsyn],B04.820.504.540.150.113.937,
99db8a23-17bf-41a4-bff5-1d5e2604f58d,C1175743,C0849867,is responsible for unprecedented ,SARS coronavirus,Widespread Disease,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
cfb16a8d-f323-4a4e-b4de-7f3ff02d0661,C0055673,C0042774,Enzymes for,Chymase,Virus Replication,4,X,[aapp/enzy],[celf],D08.811.277.656.300.760.103;D08.811.277.656.959.350.103,G06.920.925
ad934ad9-5e20-4359-83f0-4442d1b06ab4,C0596391,C0038734,is with reactive Cys145,covalent bond,Sulfhydryl Compounds,4,X,[npop],[orch],,D02.886.489
b08df8b2-26ba-47b5-b141-7dceab9d4726,C0596391,Cys145,is with reactive Cys145,covalent bond,Cys145,4,X,[npop],????,,????
ba028b5a-ac09-429b-8cff-5c3e265f18c2,C3864824,C0243077,were Moreover identified as potential ,paritaprevir,inhibitors,4,X,[orch/phsu],[chvf],,
2d015416-f1d9-4ac6-80f1-b6f7cd4507fe,C3864824,C1175743,were Moreover identified as potential ,paritaprevir,SARS coronavirus,4,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
18343ae7-c8bf-44fc-a9ea-0969c1f8297a,C0432626,C0087111,could Importantly could ready for trials to ,Blood group antibody c,Therapeutic procedure,6,X,[aapp/imft],[topp],,E02
1822f8f1-96db-4097-a445-af525ff778bf,C0019159,C0087111,could Importantly could ready for trials to ,Hepatitis A,Therapeutic procedure,3,X,[dsyn],[topp],C02.440.420;C02.782.687.359.500;C06.552.380.705.422,E02
15b8ed37-c5c1-4db7-a96e-d450cb0a0ed3,C0319157,C0087111,could Importantly could ready for trials to ,AS virus,Therapeutic procedure,3,X,[virs],[topp],,E02
45cd600c-9474-4cde-8f2d-3fc2977e9e92,C0206750,C0264219,is causative agent of ,Coronavirus Infections,Acute respiratory disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
45cd600c-9474-4cde-8f2d-3fc2977e9e92,C0206750,C0264219,could In cases could complicated by ,Coronavirus Infections,Acute respiratory disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
611e9e26-31ed-4a7e-8105-9e323d91b358,RT-PCR,C2347609,using ,RT-PCR,Chemical Probe,2,X,????,[chvf],????,
d0d49586-4e51-4588-9d35-4f31f08d16f6,RT-PCR,C0206415,using multiple ,RT-PCR,Oligonucleotide Primers,2,X,????,[nnon],????,D13.695.578.424.450.275;D27.720.470.530.600.223.600
5687199e-80ce-4057-801f-d14598338937,C1628999,SYBR,using low-cost SYBR ,SARS coronavirus RNA,SYBR,1,X,[nnon],????,,????
5ac95a4a-e103-4471-8e66-625f2f311e95,C1628999,C1511790,can can used for ,SARS coronavirus RNA,Detection,1,X,[nnon],[topp],,
7bcb799b-742e-422d-addb-7c9457416d52,C1628999,C1764827,can can used for ,SARS coronavirus RNA,Isolate - microorganism,1,X,[nnon],[bacs],,
ddece495-449f-49ec-b8da-0a2f116f852f,C0597404,C4284302,can cause Infection we have seen in,Respiratory viruses,EHD1 wt Allele,3,X,[virs],[gngm],,
93a48a95-fda9-407c-88dc-191c0a7ea5d5,C0597404,C3714514,can cause severe ,Respiratory viruses,Infection,3,X,[virs],[patf],,C01.539
3c80d52c-da16-4e0f-abe7-1b919acd891a,C0597404,C0458827,can cause severe ,Respiratory viruses,Airway structure,3,X,[virs],[bpoc],,
37593a2b-8fe5-441b-be83-da414b7aa7b6,C0242781,C0234856,produced by ,disease transmission,Speaking (activity),9,X,[patf],[dora],N06.850.310,
7cb9b9d4-1b3a-48e8-92e8-78f2f7ca9446,C0030106,C0242656,could of could help in control of ,Ozone,Disease Progression,3,X,[chem],[patf],D01.362.670.600;x.x.x.x,C23.550.291.656
d7d351e7-2348-4652-ba9e-8a3c7edb9eaa,U.S.,remdesivir,has granted Emergency Use Authorization for ,U.S.,remdesivir,1,X,????,[clnd],????,
f9df1098-19d7-4e49-92c8-c7c75ad2e9ac,U.S.,C0087111,has granted Emergency Use Authorization for ,U.S.,Therapeutic procedure,1,X,????,[topp],????,E02
86584519-759e-4100-bb24-58dd4abc5ffd,U.S.,C0206750,has granted Emergency Use Authorization for ,U.S.,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
86584519-759e-4100-bb24-58dd4abc5ffd,U.S.,C0206750,onboard developed ,U.S.,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
57d86e00-a2f2-442b-a31c-d3f875ec772c,C0019134,C0003280,may Given complications may choice of ,heparin,Anticoagulants,1,X,[bacs/orch/phsu],[phsu],D09.698.373.400,D27.505.954.502.119
57d86e00-a2f2-442b-a31c-d3f875ec772c,C0019134,C0003280,may Given complications specific to ,heparin,Anticoagulants,1,X,[bacs/orch/phsu],[phsu],D09.698.373.400,D27.505.954.502.119
5b319ba1-917d-47c8-822a-e355cc050802,C0003280,C0522794,is discussed as possible potentiate for ,Anticoagulants,Heparin therapy,2,X,[phsu],[topp],D27.505.954.502.119,
cb453a45-ad9c-4ece-a5aa-7327e9ac1f50,C0206750,C0021368,aggravates ,Coronavirus Infections,Inflammation,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.470
c29f0cd5-0020-4c00-a359-366500a563cd,C0206750,C0003130,aggravates ,Coronavirus Infections,Anoxia,2,X,[dsyn],[patf],C02.782.600.550.200,C23.888.852.079
c29f0cd5-0020-4c00-a359-366500a563cd,C0206750,C0003130,Affinity to,Coronavirus Infections,Anoxia,1,X,[dsyn],[patf],C02.782.600.550.200,C23.888.852.079
cd1f977d-753c-47c9-92e3-1a344e0efe38,C0028754,C0221423,can lead to severe ,Obesity,Illness (finding),2,X,[dsyn],[sosy],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
33e8fbaf-c066-4abb-be14-171dd7914d8f,C0021760,C0242656,play role in ,Interleukin-6,Disease Progression,2,X,[aapp/imft],[patf],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.550.291.656
33e8fbaf-c066-4abb-be14-171dd7914d8f,C0021760,C0242656,were associated with ,Interleukin-6,Disease Progression,1,X,[aapp/imft],[patf],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C23.550.291.656
a6c92ce4-142a-40be-a1de-06b93b034c25,C0021760,C0206750,were elevated in patients with ,Interleukin-6,Coronavirus Infections,9,X,[aapp/imft],[dsyn],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,C02.782.600.550.200
a5af5347-06bf-4d7d-abb6-02e7fa7211ba,C0079189,C0242656,play role in ,cytokine,Disease Progression,2,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.291.656
a5af5347-06bf-4d7d-abb6-02e7fa7211ba,C0079189,C0242656,is in female patients associated with worse ,cytokine,Disease Progression,3,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.291.656
0e17ab5d-dae0-44c0-b9eb-55ca5818eddb,C0028754,C0011849, includes ,Obesity,Diabetes Mellitus,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C18.452.394.750;C19.246
4ad36bc2-3bd3-4107-86b7-4365e11ff83d,C1155266,C0028754,may predispose to complications of ,inflammatory response,Obesity,2,X,[patf],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
5477f12f-f2fa-452a-97f4-2ced6c2ce616,C1155266,C0011849,may predispose to complications of ,inflammatory response,Diabetes Mellitus,2,X,[patf],[dsyn],,C18.452.394.750;C19.246
e591f376-4a41-449a-ad22-f398c475a99c,C0026652,C0920467,has wealth in prevention of ,Moxibustion,disorder control (procedure),3,X,[topp],[topp],E02.190.044.588,
d71df43f-27d4-47db-bf4f-fddd9381beeb,C0394664,C0920467,has wealth in prevention of epidemic ,Acupuncture procedure,disorder control (procedure),3,X,[topp],[topp],E02.190.044,
35ff8a01-af7c-49df-9ce8-99ca153abad6,C0020164,C0185451,was During period third most common ,Bone structure of humerus,Osteoclasis,3,X,[bpoc],[topp],A02.835.232.087.090.400,
35ff8a01-af7c-49df-9ce8-99ca153abad6,C0020164,C0185451,was third most common Osteoclasis for,Bone structure of humerus,Osteoclasis,2,X,[bpoc],[topp],A02.835.232.087.090.400,
22285d8e-9012-463f-95ce-8a33e99f7018,C0016641,C0185451,was During period third most common ,Fracture Fixation,Osteoclasis,3,X,[topp],[topp],E04.555.300,
22285d8e-9012-463f-95ce-8a33e99f7018,C0016641,C0185451,was third most common Osteoclasis for,Fracture Fixation,Osteoclasis,2,X,[topp],[topp],E04.555.300,
e917a16d-00db-43be-8b3d-fdfc8547f9f3,C0185023,C0185451,was During period third most common ,Fixation - action,Osteoclasis,3,X,[topp],[topp],,
e917a16d-00db-43be-8b3d-fdfc8547f9f3,C0185023,C0185451,was third most common Osteoclasis for,Fixation - action,Osteoclasis,2,X,[topp],[topp],,
e687573e-0fac-433f-a387-80d60b9c5b98,C0039194,C0301872,induce Immune response in,T-Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
e687573e-0fac-433f-a387-80d60b9c5b98,C0039194,C0301872,induce protective ,T-Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
e687573e-0fac-433f-a387-80d60b9c5b98,C0039194,C0301872,suggesting dysregulated ,T-Lymphocyte,Immune response,1,X,[cell],[ortf],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,
1025d355-2345-4e32-b031-3bacf53385c5,C1167622,C0024518,is with ,Binding (Molecular Function),Major Histocompatibility Complex,2,X,[moft],[gngm],,G05.360.340.024.340.610;G05.360.340.024.380.500;G12.500.500
4171d0be-f007-446e-80d5-be65661743e7,C0079600,C0003241,could enable generation of ,Immunodominant Epitopes,Antibodies,2,X,[imft],[aapp/imft/phsu],D23.050.550.500,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
73f35436-9c4f-46d3-a8ee-4ecc52e54b85,C1265876,15days,increase beyond 15days ,Abnormally opaque structure (morphologic abnormality),15days,4,X,[patf],????,,????
68dcfd8f-f005-4798-adf3-52d174c364be,C1265876,C0010340,increase beyond 15days ,Abnormally opaque structure (morphologic abnormality),Critical Illness,2,X,[patf],[dsyn],,C23.550.291.625
36e5bf73-7766-4f94-85ff-84a32ce14990,15days,C0010340,is in severe ,15days,Critical Illness,1,X,????,[dsyn],????,C23.550.291.625
f6f49e83-8cb5-4694-a20f-55e362187092,C1265876,C0231218,drop for moderately ,Abnormally opaque structure (morphologic abnormality),Malaise,2,X,[patf],[sosy],,
08777fe3-c6d2-4409-b21d-4b6c2f3d13fc,C0015219,C0206750,varied with disease severity in ,Biological Evolution,Coronavirus Infections,1,X,[genf],[dsyn],G05.045;G16.075,C02.782.600.550.200
78b2a6fc-a302-4a98-8b4b-8e2a8d4e5801,C0206750,C0440790,is in ,Coronavirus Infections,Solid organ,2,X,[dsyn],[bpoc],C02.782.600.550.200,
337ef0c1-202f-499c-bcf9-412c499583ea,C1537065,C0440790,is in ,transplantation infection,Solid organ,2,X,[patf],[bpoc],,
83367ec4-756c-451a-adb2-6a4002e48d7b,C0206750,C1537065,is in ,Coronavirus Infections,transplantation infection,2,X,[dsyn],[patf],C02.782.600.550.200,
0a903653-baab-4d0d-b76e-6de88f7a2eb6,C1706374,RT-PCR,indicated nasopharyngeal swab RT-PCR ,Tumor Necrosis Factor Ligand Superfamily Member 13,RT-PCR,2,X,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,????
0b69ff9b-1eb4-4a10-ab02-6d12846ab517,C1706374,C0029355,indicated nasopharyngeal swab RT-PCR ,Tumor Necrosis Factor Ligand Superfamily Member 13,Orthopedics,2,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,H02.403.810.494
725db467-befe-4042-ae8f-4590c59be4c1,C0086418,C0011991,is with ,Homo sapiens,Diarrhea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C23.888.821.214
8c65a745-8fb4-4ba3-bbfa-6062c5844aca,C0086418,C0018787,is with ,Homo sapiens,Heart,1,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A07.541
f45d9ef8-f005-41f8-b7fe-891dcc2dbe31,C0206419,C0018787,Homo sapiens with,Genus: Coronavirus,Heart,1,X,[virs],[bpoc],B04.820.504.540.150,A07.541
f45d9ef8-f005-41f8-b7fe-891dcc2dbe31,C0206419,C0018787, includes ,Genus: Coronavirus,Heart,2,X,[virs],[bpoc],B04.820.504.540.150,A07.541
46ff705f-52ba-46ba-ac75-9b2ce9212659,C2939465,C0026882,is common X-linked ,Deficiency of glucose-6-phosphate dehydrogenase,Mutation,4,X,[dsyn],[genf],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,G05.365.590
85470414-7de6-4930-b906-17e7bf55a5c6,C0206419,C0302110,may cause ,Genus: Coronavirus,Hemolytic crisis,1,X,[virs],[comd],B04.820.504.540.150,
35406450-4d01-4723-91d5-783467b23d55,C0042769,C0302110,may cause ,Virus Diseases,Hemolytic crisis,2,X,[dsyn],[comd],C02,
90413289-b151-4188-a51d-59612acc2769,C0206750,C0302110,may cause ,Coronavirus Infections,Hemolytic crisis,4,X,[dsyn],[comd],C02.782.600.550.200,
001c0c8f-7038-428a-90c5-600c1761d563,C0206419,C2939465,may cause outcome in presence ,Genus: Coronavirus,Deficiency of glucose-6-phosphate dehydrogenase,1,X,[virs],[dsyn],B04.820.504.540.150,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
247004f2-852c-487f-b311-bc4cdca785d4,C0042769,C2939465,may cause outcome in presence ,Virus Diseases,Deficiency of glucose-6-phosphate dehydrogenase,2,X,[dsyn],[dsyn],C02,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
ffe6e58d-6ce2-4461-b854-22f992e41847,C0206750,C2939465,may cause outcome in presence ,Coronavirus Infections,Deficiency of glucose-6-phosphate dehydrogenase,4,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402
6389af22-06b9-4390-8302-147fb0a38e47,C2939465,C0206419,is in ,Deficiency of glucose-6-phosphate dehydrogenase,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,B04.820.504.540.150
f8bb476f-d095-4abe-af6d-65b5782ce11f,C0013879,C0206419,is in ,Elements,Genus: Coronavirus,1,X,[elii],[virs],D01.268,B04.820.504.540.150
26bfe2b7-5421-459e-8d4c-834838f9444b,C1707455,C0700308,is with decay rate of 0.65 logPFU ,Comparison,Protium,4,X,[acty],[elii],,
15d9a3ad-693b-4628-882d-acf53d04b013,C0337007,C1707455,declined as ,High humidity,Comparison,2,X,[npop],[acty],,
fb8e200b-6a82-467a-aa1f-f0559b882451,C0852312,C0206419,is in ,gender disorders,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
6899b101-e506-48cf-a0f8-a5216bcc438d,C0185117,C0024109,is in ,Expression procedure,Lung,2,X,[topp],[bpoc],,A04.411
f3ec8ab3-8b9b-4d45-b128-93794909caac,C0748168,C0206419,is in ,Pulmonary Pathology,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
4cf54ba8-0ddc-4919-aee0-d8d51f4866e0,PCR,C1175175,detect ,PCR,Severe Acute Respiratory Syndrome,2,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
a823a6af-c9bf-4e93-9568-93ecf9e3657c,C0185117,C0242210,direct Binding Proteins of S,Expression procedure,Binding Proteins,1,X,[topp],[aapp/bacs],,D12.776.157
8177cf54-f50b-45c0-b8ac-ce14e08b9c62,C0009450,C0026766,leading to ,Communicable Diseases,Multiple Organ Failure,2,X,[dsyn],[patf],C01.539.221,C23.550.835.525
0bd9145a-8121-46de-b260-01a0d589929b,C0003018,C0206419,has attracted interest as potential regulator of ,Angiotensins,Genus: Coronavirus,1,X,[aapp/bacs/phsu],[virs],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,B04.820.504.540.150
1ed8ffa5-b92e-4d49-a3ac-5535c63d59bd,C0206419,C0740766,is acute viral ,Genus: Coronavirus,acute pneumonia,1,X,[virs],[dsyn],B04.820.504.540.150,
2805b1f0-afe4-4c56-8e85-c9e6e5f33af8,C0743841,C0037090,is with ,Disorder characterized by fever,Signs and Symptoms Respiratory,1,X,[dsyn],[sosy],,C23.888.852
0ade7f23-1f7f-47d9-9120-183fd3fd9d5e,C0042776,C1707391,Outpatient management of ,Virus,Choose (action),1,X,[virs],[acty],B04,
218fdca4-9735-489d-9b61-7fb1573daa06,POC,C1175743,showed performance in detection of ,POC,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
53c4fa67-f442-441f-a704-fe4cacd843e1,C0206419,C0003242,exhibited earlier ,Genus: Coronavirus,Antibodies Anti-Idiotypic,1,X,[virs],[aapp/imft],B04.820.504.540.150,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
fb0d3b16-498a-4d7b-96fa-d5a789e1a16e,C0243077,remdesivir, includes ,inhibitors,remdesivir,3,X,[chvf],[clnd],,
627c923c-c7b1-404f-af36-f77f5cba9012,C0597107,C0035685,have shown this despite understanding of viral nsp12 ,nucleotide analog,RNA-Directed RNA Polymerase,2,X,[nnon],[aapp/enzy],,D08.811.913.696.445.735.780
a124c1ac-6bd0-493f-bbc9-a5f047b8485e,C0243077,C0035685,have shown this despite understanding of viral nsp12 ,inhibitors,RNA-Directed RNA Polymerase,1,X,[chvf],[aapp/enzy],,D08.811.913.696.445.735.780
66a53b20-e969-47d8-92ac-04d14ce8bca9,C0597107,nsp12,have shown this despite understanding of viral nsp12 ,nucleotide analog,nsp12,2,X,[nnon],????,,????
b5e71b22-b222-4f94-8942-b125d8ed4d9a,C0243077,nsp12,have shown this despite understanding of viral nsp12 ,inhibitors,nsp12,1,X,[chvf],????,,????
8390fb62-6cdd-4e17-adc4-661bcd621fa9,C0597107,C0687133,have shown this despite understanding of viral nsp12 ,nucleotide analog,Drug Interactions,2,X,[nnon],[patf],,G07.690.773.968
afa2e985-3e3d-42c1-89c3-3ff24c35662f,C0243077,C0687133,have shown this despite understanding of viral nsp12 ,inhibitors,Drug Interactions,1,X,[chvf],[patf],,G07.690.773.968
cb9524e2-cd30-41a0-b5d7-2ace14c27bce,remdesivir,C0035685,have shown this despite understanding of viral nsp12 ,remdesivir,RNA-Directed RNA Polymerase,1,X,[clnd],[aapp/enzy],,D08.811.913.696.445.735.780
f5064eb5-55dc-4c17-8b82-9a46863fbd4e,remdesivir,nsp12,have shown this despite understanding of viral nsp12 ,remdesivir,nsp12,1,X,[clnd],????,,????
2fb9db03-bddf-4491-ac66-e342ce40aa1d,remdesivir,C0687133,have shown this despite understanding of viral nsp12 ,remdesivir,Drug Interactions,1,X,[clnd],[patf],,G07.690.773.968
8f34303d-b71a-42d2-8f55-fa887440db1c,C1138226,C0035685,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,RNA-Directed RNA Polymerase,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,D08.811.913.696.445.735.780
6337c73c-8dab-440a-959b-b4c3be16eb87,C1138226,nsp12,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,nsp12,1,X,[orch/phsu],????,x.x.x.x,????
0653106c-621b-4ab9-b881-34c03f357c1d,C1138226,C0687133,have shown this despite mechanistic understanding of viral nsp12 ,favipiravir,Drug Interactions,1,X,[orch/phsu],[patf],x.x.x.x,G07.690.773.968
e936260c-9306-4d04-aa24-20d0b3ff3164,C0597107,invitro,have shown promise in invitro ,nucleotide analog,invitro,2,X,[nnon],????,,????
a0d73c4a-a5a1-41ea-ba42-fd3039d22a93,C0243077,invitro,have shown promise in invitro ,inhibitors,invitro,1,X,[chvf],????,,????
1aef763e-c5b7-4daf-9620-edb0d6217291,remdesivir,invitro,have shown promise in invitro ,remdesivir,invitro,1,X,[clnd],????,,????
9f42e33f-66ad-49b3-b6c1-b77e8c86604e,C1138226,C1516635,have shown ,favipiravir,Clinical Treatment,2,X,[orch/phsu],[topp],x.x.x.x,
8517c240-6db1-480f-960d-fe406ee43690,C1138226,C0206419,have shown ,favipiravir,Genus: Coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150
8517c240-6db1-480f-960d-fe406ee43690,C1138226,C0206419,has has experimentally used for ,favipiravir,Genus: Coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150
3a6cc76e-eaf6-40a4-8f2f-419bc1fc5eab,C0597107,C1516635,have shown ,nucleotide analog,Clinical Treatment,4,X,[nnon],[topp],,
3ba8e572-246f-4bb9-adf9-da01337c917e,C0243077,C1516635,have shown ,inhibitors,Clinical Treatment,2,X,[chvf],[topp],,
debfe9b6-4920-423b-9196-1a5115fd1583,C0597107,C0206419,have shown ,nucleotide analog,Genus: Coronavirus,2,X,[nnon],[virs],,B04.820.504.540.150
37bc35cd-dca2-4b7c-936c-d5a8a706519b,remdesivir,C1516635,have shown ,remdesivir,Clinical Treatment,2,X,[clnd],[topp],,
4ee7f771-8af4-480f-a81a-5838d52b4042,C1138226,invitro,have shown promise in invitro ,favipiravir,invitro,1,X,[orch/phsu],????,x.x.x.x,????
c794eb98-ce33-46eb-8bca-c4362ea7efee,C1707455,apo,is with apo ,Comparison,apo,1,X,[acty],????,,????
37091147-c74d-43b5-bdb6-a13030338c91,C1707455,C1704241,is with apo ,Comparison,complex (molecular entity),1,X,[acty],[chvs],,
1a41b93c-002b-47b2-89e7-b4ecdbdc25f2,C2700061,C0206419,provide clues for understanding of ,Transition (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
bc977416-7951-4514-b5e7-81168aa37dd5,C2700061,C0040649,provide clues for understanding of ,Transition (action),Transcription Genetic,1,X,[acty],[genf],,G02.111.873;G05.297.700
52c84961-f975-4711-abc0-0b0bbf69da67,C0021760,C0206419,are elevated In ,Interleukin-6,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,B04.820.504.540.150
52c84961-f975-4711-abc0-0b0bbf69da67,C0021760,C0206419,is in patients with ,Interleukin-6,Genus: Coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,B04.820.504.540.150
77b6a841-7812-4499-b5cb-04deac4d48b4,C1514562,C1175743,can can related to pathogenicity of ,Protein Domain,SARS coronavirus,1,X,[amas],[virs],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,B04.820.504.540.150.113.937
a452d247-d2b9-450c-b50c-7f2386949bb5,C1175743,C1707391,were similar to target ,SARS coronavirus,Choose (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
2492e4a3-d46f-46b6-bfbd-95f95e546519,C1101610,C0206419,may constitute potential therapeutic approaches in ,MicroRNAs,Genus: Coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150
55907fdf-70b9-4f47-aef6-47b46a184dd7,C0037633,C0206419,literature on infection control practices in health care facilities against ,Solutions,Genus: Coronavirus,1,X,[sbst],[virs],D26.776,B04.820.504.540.150
21df0562-2d62-4db1-8bc9-61e92e1cd8e7,C0545747,C0206419,are at also risk of severe ,pulmonary artery and pulmonary artery,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
41abaa3e-b694-46f8-ada6-bde55025c4f1,C0279328,C0206419,improve hypoxemia for ,Hyperbaric Oxygen (substance),Genus: Coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150
7510fdeb-e8b5-4b83-ab1a-558715564ade,C0020431,C0206419,improve hypoxemia for ,Hyperbaric oxygenation therapy,Genus: Coronavirus,1,X,[topp],[virs],E02.880.690.490,B04.820.504.540.150
c6bdbc18-359d-4e23-9014-241331eecbea,C4086508,C1609165, includes ,IL6 Receptor Antibody,tocilizumab,6,X,[aapp/imft],[aapp/imft/phsu],,x.x.x.x
64134b6a-0dbb-44b8-8d9a-21ec6c354a87,C4086508,C3873497,play role in treatment of ,IL6 Receptor Antibody,Severe acute respiratory infection,3,X,[aapp/imft],[dsyn],,
ea64dd29-a2cf-4d06-944b-62b59bc2515c,C4086508,C1175743,play role in treatment of ,IL6 Receptor Antibody,SARS coronavirus,3,X,[aapp/imft],[virs],,B04.820.504.540.150.113.937
d8f86265-6164-4c9a-8260-7d62dac25a0b,C0034386,C1160716,prevent onward viral transmission during,Quarantine,viral transmission,2,X,[topp],[celf],N06.850.780.200.450.700,
a6c4f0bf-e6a5-47c4-b12e-3f8ace083718,C0206419,C2359945,raised questions in patients about use of ,Genus: Coronavirus,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[virs],[clna],B04.820.504.540.150,
0a0bf5be-768d-4670-8e06-557f0dc1c655,C1511790,C0009359,evaluate differences between ,Detection,Gold Colloid,2,X,[topp],[inch/phsu],,D01.379.400
2ca88589-13fa-4231-bd6b-04f01255ea05,C1706005,C0206419,is in patients with ,CD40LG wt Allele,Genus: Coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150
2ca88589-13fa-4231-bd6b-04f01255ea05,C1706005,C0206419,were negative for ,CD40LG wt Allele,Genus: Coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150
01d72cfd-7733-4d1f-bd62-8219f199cff2,C1706005,C0012634,is in patients with ,CD40LG wt Allele,Disease,2,X,[gngm],[dsyn],,C23.550.288
fc922d4d-3ce2-4c6b-a549-b3969cbd5732,C0162524,C2584300,showed positive rate ,Chemiluminescence,Climbing,2,X,[npop],[dora],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,
4f2323a7-1db3-46d3-9549-ca4d5a6a4432,C0162524,C0009359,showed positive rate ,Chemiluminescence,Gold Colloid,2,X,[npop],[inch/phsu],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,D01.379.400
ea5eddf9-62e2-49be-8ff3-44c738fb15f0,C0162524,C2754943,showed rate Climbing For,Chemiluminescence,IgG antibody,1,X,[npop],[celc],G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665,
b394e410-a899-4a6e-a320-2b83f63880c6,C0009359,C0162524,is less Hypersensitivity than,Gold Colloid,Chemiluminescence,2,X,[inch/phsu],[npop],D01.379.400,G01.358.500.505.650.665;G01.590.540.665;G01.750.250.650.665;G01.750.770.578.665
fc56bfbc-d3d5-4d6e-93f5-ddd780e2b459,C0009359,C0020517,is generally less ,Gold Colloid,Hypersensitivity,2,X,[inch/phsu],[patf],D01.379.400,C20.543
bf271a69-9d56-4f70-9cca-e82269293193,C0010200,C0040590,increases aerosol production via particularly ,Coughing,Tracheostomy procedure,1,X,[sosy],[topp],C08.618.248;C23.888.852.293,E02.041.750;E04.579.935;E04.580.900;E04.928.780
6c1270e3-2987-40b9-bd67-f27be4c0bff8,C1880355,C0042769,repurposing those already in use for other ,Discover,Virus Diseases,1,X,[acty],[dsyn],,C02
3ab42f26-d863-405a-bfb7-2770a281b002,C1175743,C0920283,over non- is,SARS coronavirus,DNA Helicases,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.040.025.159;D08.811.399.340
4ec28d1f-5e5e-4c46-a6ff-b7b8415a6f98,C0683949,C0022322,revealed broad range of antiviral effects of ,animal study,Ivermectin,2,X,[anim],[orch/phsu],,D02.540.576.500.997;x.x.x.x
07d8992a-6e73-4a08-a4f1-5a388fa10690,LTCF,C0206419,are why resilient to ,LTCF,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
be28950c-1dde-4dee-8c78-5d37e452afd9,C1516048,C0012634,is important component of diagnosis of ,Assessed,Disease,3,X,[acty],[dsyn],,C23.550.288
c130cdac-36f8-4ae8-82f4-d99b217deeb1,C3714798,C0724441,using ,Cytochrome P-450 CYP3A4,yohimbine,1,X,[aapp/enzy],[orch/phsu],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D03.132.436.681.933;D03.633.100.473.402.681.933
300f9a80-41ed-474f-bb0f-21a5fa57d222,C3714798,C0014442,using yohimbine as,Cytochrome P-450 CYP3A4,Enzymes,1,X,[aapp/enzy],[aapp/enzy],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D08.811
300f9a80-41ed-474f-bb0f-21a5fa57d222,C3714798,C0014442,using Midazolam as,Cytochrome P-450 CYP3A4,Enzymes,1,X,[aapp/enzy],[aapp/enzy],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D08.811
3f787a0f-70af-4d11-be86-85f87c234480,C3714798,C1513396,using yohimbine as,Cytochrome P-450 CYP3A4,Molecular Marker Activity,1,X,[aapp/enzy],[phsf],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,
3f787a0f-70af-4d11-be86-85f87c234480,C3714798,C1513396,using Midazolam as,Cytochrome P-450 CYP3A4,Molecular Marker Activity,1,X,[aapp/enzy],[phsf],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,
3c12ec5d-225a-4838-9f29-364490bae778,C3714798,C0026056,using ,Cytochrome P-450 CYP3A4,Midazolam,1,X,[aapp/enzy],[orch/phsu],D08.244.453.860.500;D08.811.682.662.582.353;D08.811.682.690.708.170.495.500;D12.776.422.220.453.860.500,D03.633.100.079.080.575
1566d3a6-bbd3-453f-93be-499a0d9bfce3,C0035078,C0206419,are among gravest ,Kidney Failure,Genus: Coronavirus,1,X,[dsyn],[virs],C12.777.419.780;C13.351.968.419.780,B04.820.504.540.150
e3743d2c-dc11-436f-b21b-861c22ae8332,C0022709,C1325834,also serves as ,Peptidyl-Dipeptidase A,viral glycoprotein,1,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
2919da89-5c46-4014-939f-24fc4265c700,ity164,C0022709,widely expressing ,ity164,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
9193dd00-c486-4d0c-9590-cfbe8c940500,C0039082,C0597357,utilize same ,Syndrome,receptor,1,X,[dsyn],[aapp/rcpt],C23.550.288.500,
50d56f6a-5807-462e-bf7f-a077700d1358,C0039082,C1167395,utilize same ,Syndrome,Host (organism),1,X,[dsyn],[orgm],C23.550.288.500,
82216d7b-5d03-4ba3-a4bd-125e41cb9e3d,COVID-19,C0039082,caused by ,COVID-19,Syndrome,1,X,[virs],[dsyn],C000657245,C23.550.288.500
ed4d86e8-fd0e-4783-b84d-64b7080f349d,C3540469,silico,of in silico ,AICDA wt Allele,silico,2,X,[gngm],????,,????
b8213807-c5a3-4bd2-a2f7-01fa42b5ed09,C0872152,C0206419,combat ,Drug Development,Genus: Coronavirus,1,X,[bmod],[virs],E05.290;H01.158.703.007.338;H01.181.466.338,B04.820.504.540.150
7965d31e-8485-4894-a65c-65ec6149ab76,C0872152,C0012634,combat ,Drug Development,Disease,2,X,[bmod],[dsyn],E05.290;H01.158.703.007.338;H01.181.466.338,C23.550.288
4c20c2b3-dd81-4182-b293-7b729a806861,C1704259,C3813209,discuss ,Biochemical Pathway,PROS1 wt Allele,2,X,[moft],[gngm],,
b24cc54e-6584-4431-a5e0-52081a0fcfb2,C0221423,C0009450,caused by ,Illness (finding),Communicable Diseases,2,X,[sosy],[dsyn],,C01.539.221
40c9faa5-03d3-4657-932f-7a2102f1e703,C0221423,C0039082,caused by ,Illness (finding),Syndrome,1,X,[sosy],[dsyn],,C23.550.288.500
17f41c42-7633-4fe0-9b81-f65590ee8967,C0009450,C0039082,is with novel ,Communicable Diseases,Syndrome,1,X,[dsyn],[dsyn],C01.539.221,C23.550.288.500
03b4d4c3-5887-4141-98df-e6abfab83f08,C0243052,C0206419,candidate against ,Virus Physiological Phenomena,Genus: Coronavirus,6,X,[npop],[virs],G06.920,B04.820.504.540.150
2eaafd77-22de-479e-a43d-d093e12e1043,C0243052,C0039082,candidate against ,Virus Physiological Phenomena,Syndrome,2,X,[npop],[dsyn],G06.920,C23.550.288.500
7b6bb08b-c3f1-4e2e-bc76-cf8535baa69a,C0600334,C0206419,of Virus Physiological Phenomena is potential drug candidate against,silybin,Genus: Coronavirus,3,X,[orch/phsu],[virs],D03.383.663.283.266.450.268.777.500;D03.633.100.150.266.450.268.777.500,B04.820.504.540.150
c26cb02d-ec17-43a1-ac74-db7097fa05de,C0600334,C0039082,of Virus Physiological Phenomena is potential drug candidate against,silybin,Syndrome,1,X,[orch/phsu],[dsyn],D03.383.663.283.266.450.268.777.500;D03.633.100.150.266.450.268.777.500,C23.550.288.500
85debc2c-d38b-4d6d-b74d-7d3dd2e60b77,C1325583,C0035685,is expected As computationally predicted inhibitor of ,central element,RNA-Directed RNA Polymerase,2,X,[celc],[aapp/enzy],,D08.811.913.696.445.735.780
55b2bc87-dfdc-4286-9f44-1097e5e476a1,C2936405,C0206419,stands out as promising strategy for short-term response in fight against ,Drug Repositioning,Genus: Coronavirus,2,X,[topp],[virs],E05.290.875,B04.820.504.540.150
55b2bc87-dfdc-4286-9f44-1097e5e476a1,C2936405,C0206419,novel Agent as,Drug Repositioning,Genus: Coronavirus,1,X,[topp],[virs],E05.290.875,B04.820.504.540.150
cd1eefdc-7cd6-4d06-9a3f-ad61e7d02da2,C2936405,C0040616,stands out Due to evidence of ,Drug Repositioning,Anti-Anxiety Agents,4,X,[topp],[phsu],E05.290.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
f1bfeca3-7f13-4c00-9635-6100479fe225,C2936405,C0039082,stands out Due to evidence of ,Drug Repositioning,Syndrome,2,X,[topp],[dsyn],E05.290.875,C23.550.288.500
1b4af70d-0170-484f-bcb7-669ae381057c,C0010340,C1868981,associated with high frequency ,Critical Illness,Invasive mechanical ventilation NOS,1,X,[dsyn],[topp],C23.550.291.625,
a2bae534-d415-49fa-91d5-cdc4e34cb8e9,C0206750,C0151763,induce some ,Coronavirus Infections,Liver damage,4,X,[dsyn],[patf],C02.782.600.550.200,
11e9c55c-2fc7-4ad5-8b2d-ede0d3b788db,C0206750,C0031843,induce some ,Coronavirus Infections,physiological aspects,2,X,[dsyn],[phsf],C02.782.600.550.200,x.x.x.x
ed2e1c99-7566-44d2-8184-dd92293b3cc7,C1706214,C0009676,is in our ,Creation,Confusion,1,X,[acty],[mobd],,C10.597.606.337;C23.888.592.604.339;F01.700.250
d3790492-d65d-4920-8432-bac97964ea36,C0003451,C0013227,are among ,Antiviral Agents,Pharmaceutical Preparations,3,X,[phsu],[phsu],D27.505.954.122.388,D26
ced2466f-0323-4f52-ab97-9d056673f4ce,C0018939,C0206750,is in ,Hematological Disease,Coronavirus Infections,3,X,[dsyn],[dsyn],C15.378,C02.782.600.550.200
22d9faa5-82ca-42d6-81d2-3441f67bd914,C0237873,C0206750,is in ,Physiological Sexual Disorders,Coronavirus Infections,3,X,[patf],[dsyn],C12.294.644;C13.351.500.665,C02.782.600.550.200
977003a9-a576-4c71-a466-9e597f540d74,C2948600,C0010356,simultaneously prevent ,Aim,Cross Infection,1,X,[inch/phsu],[patf],,C01.539.248;C23.550.291.875.500
c9547661-118f-4a26-8d57-1173e8b48793,C0815172,C1175743,is with ,patient characteristics,SARS coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.937
71611244-f029-460f-a4e0-a1067c363656,C0086418,7days,developed fever after 7days ,Homo sapiens,7days,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
71611244-f029-460f-a4e0-a1067c363656,C0086418,7days,developed Coughing after 7days,Homo sapiens,7days,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
3fbe341d-5381-4160-82ad-045e07ed39c5,C0040802,7days,developed fever after 7days ,travel,7days,1,X,[dora],????,I03.883,????
3fbe341d-5381-4160-82ad-045e07ed39c5,C0040802,7days,developed Coughing after 7days,travel,7days,1,X,[dora],????,I03.883,????
58903612-81a2-482f-92d9-74e0c4046632,C0086418,C4275242,developed fever after 7days ,Homo sapiens,Sudden sensorineural hearing loss,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
58903612-81a2-482f-92d9-74e0c4046632,C0086418,C4275242,developed Coughing after 7days,Homo sapiens,Sudden sensorineural hearing loss,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
4b5c4f9d-8bc7-45ef-b72f-f78473a0c7dc,C0040802,C4275242,developed fever after 7days ,travel,Sudden sensorineural hearing loss,1,X,[dora],[dsyn],I03.883,
4b5c4f9d-8bc7-45ef-b72f-f78473a0c7dc,C0040802,C4275242,developed Coughing after 7days,travel,Sudden sensorineural hearing loss,1,X,[dora],[dsyn],I03.883,
9f83d70e-8c8a-43dc-ab79-fdffd13136ed,C0086418,C0013404,developed ,Homo sapiens,Dyspnea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.326;C23.888.852.371
9f83d70e-8c8a-43dc-ab79-fdffd13136ed,C0086418,C0013404,presented with ,Homo sapiens,Dyspnea,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.326;C23.888.852.371
f01909bd-1479-4936-86eb-31762a6b953f,C0040802,C0013404,developed ,travel,Dyspnea,1,X,[dora],[sosy],I03.883,C08.618.326;C23.888.852.371
db0def03-5f0a-4849-9536-665bad4d07c6,C0086418,C0010200,developed ,Homo sapiens,Coughing,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
db0def03-5f0a-4849-9536-665bad4d07c6,C0086418,C0010200,presented with ,Homo sapiens,Coughing,1,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
db0def03-5f0a-4849-9536-665bad4d07c6,C0086418,C0010200,was brought with 3-week ,Homo sapiens,Coughing,2,X,[humn],[sosy],B01.050.150.900.649.313.988.400.112.400.400,C08.618.248;C23.888.852.293
455652eb-2e6a-41e1-bb60-0c09db6747c9,C0040802,C0010200,developed ,travel,Coughing,1,X,[dora],[sosy],I03.883,C08.618.248;C23.888.852.293
9e709525-425e-4028-a598-b85b213543a6,C0086418,C0149783,developed Coughing after 7days,Homo sapiens,Steroid therapy,1,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,
f7072104-3708-4901-9119-964829f0c8a2,C0040802,C0149783,developed Coughing after 7days,travel,Steroid therapy,1,X,[dora],[topp],I03.883,
5745414f-0f86-4089-910a-ccfb8970f6b8,C0035203,C0087111,deteriorated despite ,Respiration,Therapeutic procedure,1,X,[phsf],[topp],G09.772.705,E02
de263fdc-38d8-4887-b02e-1d0a40f5a205,C0035203,C0939237,deteriorated despite ,Respiration,lopinavir / Ritonavir,1,X,[phsf],[phsu],G09.772.705,
e41d3955-f1c8-4941-8a9b-240cc71d9a3c,C0087111,C0939237,is with ,Therapeutic procedure,lopinavir / Ritonavir,1,X,[topp],[phsu],E02,
682d8e0a-d523-4c76-96b9-9b9cb35f99ea,C4058719,C0280274,enhance ,interferon beta-1b Injection,Antiviral Therapy,2,X,[clnd],[topp],,
4f449cca-fff3-4242-8cf0-96bd3afe21e9,C0242656,C0028351,necessitated inhalation Nitrogen Oxides for,Disease Progression,Norepinephrine,1,X,[patf],[horm/orch/phsu],C23.550.291.656,D02.033.100.291.502;D02.092.063.480;D02.092.211.215.746;D02.092.311.830;D02.455.426.559.389.657.166.175.830
aec3db1a-f631-4f72-ba0d-1d6c11ad9fa1,C0242656,C0028167,necessitated inhalation ,Disease Progression,Nitrogen Oxides,1,X,[patf],[inch],C23.550.291.656,D01.362.635;D01.625.550;D01.650.550.587
88de6648-4e7e-4d22-9aa4-8fc3f53715bf,C0178913,C0042749,indicating IL-6 ,Blood specimen,Viremia,1,X,[bdsu],[dsyn],,C02.937;C23.550.470.790.500.900
143b5938-d5ba-4129-bfd1-8b108274bc41,PCR,C0042749,indicating IL-6 ,PCR,Viremia,1,X,????,[dsyn],????,C02.937;C23.550.470.790.500.900
dedd4e97-8b25-4954-8e2b-c0983a2a267f,C0178913,IL-6,indicating IL-6 ,Blood specimen,IL-6,1,X,[bdsu],????,,????
deb6d3e4-fd96-4784-87d3-b3b32c5425af,PCR,IL-6,indicating IL-6 ,PCR,IL-6,1,X,????,????,????,????
648e72ba-7738-4a07-9ec0-d07c49b123c9,C0042216,C0282636,maintain ,Vaccinia virus,Cell Respiration,1,X,[virs],[celf],B04.280.650.160.650.900,G03.197;G04.270
46ba04a1-32fd-4d64-a84d-e949c7dc7009,C0015357,C0282636,maintain ,Extracorporeal Membrane Oxygenation,Cell Respiration,1,X,[topp],[celf],E02.880.301;E04.292.451,G03.197;G04.270
51f2fa0e-710a-4550-8fa2-a0119d22f4eb,C0079189,C0178784,requiring vigorous ,cytokine,Organ,1,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,
0d446eb3-a7c8-43ae-ae3b-11932854191e,C0079189,C0087111,requiring vigorous ,cytokine,Therapeutic procedure,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,E02
f2650a9e-f188-4a0c-af68-4d6e5d740350,C0178784,C0038952,allow for ,Organ,Continuance of life,1,X,[bpoc],[acty],,I03.784
b594f8e0-aa38-4f0f-916f-4265b6d36322,C0087111,C0038952,allow for ,Therapeutic procedure,Continuance of life,1,X,[topp],[acty],E02,I03.784
b594f8e0-aa38-4f0f-916f-4265b6d36322,C0087111,C0038952,could increase ,Therapeutic procedure,Continuance of life,1,X,[topp],[acty],E02,I03.784
ba615409-0ffb-4784-8a75-4b16146a9ebb,C0178784,C0349410,allow for ,Organ,Single organ dysfunction,1,X,[bpoc],[sosy],,
27650b0e-ebf2-4e24-bcc8-9f61f67674df,C0087111,C0349410,allow for ,Therapeutic procedure,Single organ dysfunction,1,X,[topp],[sosy],E02,
3435be7f-536f-4d9d-a7bd-d7cb938abb98,C0563597,C1874964,is in ,Momentum,DELIVER (Dietary Supplement),1,X,[npop],[phsu],,
3cf88e1e-7782-4366-af56-a161e5ef08d2,C0206750,C0023693,is important to high ,Coronavirus Infections,Light,1,X,[dsyn],[npop],C02.782.600.550.200,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
62821485-4520-4999-a9a3-e98aa16e4342,C0009450,C0683325,resulting in wide range ,Communicable Diseases,clinical aspects,1,X,[dsyn],[clna],C01.539.221,
903437f3-cb3b-4b25-b7f9-ce8be2a85892,C1511790,C0225778,is in ,Detection,Pleural fluid,1,X,[topp],[bdsu],,
66092a28-6515-4809-b540-dd202b5d5996,C0027950,C0319157,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,AS virus,1,X,[cell],[virs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,
048d04a4-d5cc-474b-a95a-1c8037b55e49,C0027950,2weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,2weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
89fe4318-e302-4739-a24a-2711a39e0b7e,C0027950,3weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,3weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
402a3055-ad4d-470a-8e4a-ccb034f6b270,C0027950,4weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,4weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
8c6c2455-a53e-4c55-aaa8-cae049e1ec7e,C0027950,5weeks,predicting 2weeks 3weeks 4weeks 5weeks,neutrophil,5weeks,1,X,[cell],????,A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,????
f5fec034-d8ab-4cfb-90dd-2fa325d4566d,C0027950,C0042769,predicting ,neutrophil,Virus Diseases,1,X,[cell],[dsyn],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,C02
52087b14-f443-4377-b8c5-a475669ea9a5,et,COVID-19,reviewed COVID19 ,et,COVID-19,1,X,????,[virs],????,C000657245
1c2c823b-7f75-472b-9ab3-3ba2cf6fb6a3,al,COVID-19,reviewed COVID19 ,al,COVID-19,1,X,????,[virs],????,C000657245
135f19a4-d444-4fbb-92ed-c37b2eeba963,et,C1160716,reviewed COVID19 ,et,viral transmission,2,X,????,[celf],????,
a630d92a-8495-4689-81b1-ee13c2ac560c,al,C1160716,reviewed COVID19 ,al,viral transmission,2,X,????,[celf],????,
83275edf-561e-476d-8257-1b7ab4facb5a,et,COVID19,reviewed COVID19 ,et,COVID19,1,X,????,????,????,????
f5c0d667-15f3-4445-b61f-65c66b4563ef,al,COVID19,reviewed COVID19 ,al,COVID19,1,X,????,????,????,????
1684bfd6-f22d-4184-bd0c-5a24d51f9abc,C0013879,C1175743,have become universal besides ,Elements,SARS coronavirus,2,X,[elii],[virs],D01.268,B04.820.504.540.150.113.937
223d0514-a073-4b10-9aa6-74f8ff867b5b,C1414683,C3B6,is in C3B6 ,FOXJ1 gene,C3B6,1,X,[gngm],????,,????
793e0a26-d24b-4f17-a0e7-375aca9417c3,C0086418,C3B6,is in C3B6 ,Homo sapiens,C3B6,1,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
d6c9283b-6e23-4db3-9132-d2b797b0d245,C1414683,C0026809,is in C3B6 ,FOXJ1 gene,Mus,1,X,[gngm],[mamm],,B01.050.150.900.649.313.992.635.505.500
f4beceee-8370-4773-81ee-9e1cb9f68feb,C0086418,C0026809,is in C3B6 ,Homo sapiens,Mus,1,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,B01.050.150.900.649.313.992.635.505.500
fd7bd1c5-24ee-4924-9dca-c72f1f85791c,C0026809,C1800706,generated ,Mus,Idiopathic Pulmonary Fibrosis,1,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C08.381.483.487.500;C08.381.765.500
824d021a-feed-4e85-9fe5-3f38c50e05a2,C0035736,C0015392,could could found in ,RNA Viral,Eye,1,X,[nnon],[bpoc],D13.444.735.828,A01.456.505.420;A09.371
0120f2d6-8265-4e57-9a3d-8e33d6f3de04,C0035736,C0018787,could could found in ,RNA Viral,Heart,1,X,[nnon],[bpoc],D13.444.735.828,A07.541
b0693299-8ea5-4ae6-bc65-c27b88f491e0,C0035736,C1521713,could could found in ,RNA Viral,CNS - Brain (MMHCC),2,X,[nnon],[tisu],D13.444.735.828,
ef7af9ab-c39b-4eb2-bcd0-e9964f4cb910,C0035435,C0024432, includes ,Rheumatism,macrophage,4,X,[dsyn],[cell],C05.799;C17.300.775,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
30f75bee-e207-4ab8-acd3-a45036effaa4,C0005522,C0035435,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Rheumatism,2,X,[bacs/phsu],[dsyn],D20.215,C05.799;C17.300.775
44a6236a-60a2-425e-9986-3a7accf5810f,C0005522,C0039082,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Syndrome,4,X,[bacs/phsu],[dsyn],D20.215,C23.550.288.500
ea9844fd-d8e6-455b-a0bb-4d04732361b6,C0005522,C0024432,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,macrophage,2,X,[bacs/phsu],[cell],D20.215,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
cb3fa2c2-cca3-420a-97cb-4d66d7cc3a7a,C1155266,C1175743,induced by ,inflammatory response,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
0b32691d-effe-4f24-8799-0510ee3222ac,C0038952,C1565830,followed by ,Continuance of life,PTGS1 protein human,1,X,[acty],[aapp/enzy],I03.784,x.x.x.x
29d0e332-7d8c-4ce3-a53a-3606adcb2261,C0021368,C0012634,adjusting for ,Inflammation,Disease,1,X,[patf],[dsyn],C23.550.470,C23.550.288
29d0e332-7d8c-4ce3-a53a-3606adcb2261,C0021368,C0012634,is in severe ,Inflammation,Disease,2,X,[patf],[dsyn],C23.550.470,C23.550.288
6e33a582-c19c-48fd-9d76-fcb331901fd5,C0021368,C4050231,adjusting for ,Inflammation,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[patf],[clna],C23.550.470,
d580e713-07ad-4442-a552-7775886ac30b,C3540676,C0012634,is in ,Blockade,Disease,1,X,[elii/phsu],[dsyn],,C23.550.288
e3d56c4d-b3ef-4fd3-844f-cd0a12662bc0,C0007634,C0282554,expressed ,Cells,chemokine,1,X,[cell],[aapp/imft],A11,D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200
ca65dc64-2b76-43ec-aa25-959cdfa64d55,C0206750,C3272452,is caused by ,Coronavirus Infections,Single-Stranded RNA,1,X,[dsyn],[nnon],C02.782.600.550.200,
269b1115-d1d2-41b7-ab3f-11078f09d375,C0206750,C0017428,is caused by enveloped ,Coronavirus Infections,Genome,2,X,[dsyn],[gngm],C02.782.600.550.200,G05.360.340
476a6aa2-9fff-41a8-bbd0-19b3b49e5c38,C0042736,C0319157,interact with ,Viral Proteins,AS virus,1,X,[aapp/bacs],[virs],D12.776.964,
8bbdda3a-d7c9-4dbf-ba6b-090085ac60da,C0023688,C0319157,interact with ,Ligands,AS virus,1,X,[chem],[virs],D27.720.470.480,
e45ca9fc-f4bb-4fcd-a86e-8691d975ba8e,C1514593,C0206750,has has additionally documented together with relevant reactions in population related to ,Psychological Impact,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
ddee8545-5b90-4f40-8324-ef1a7c6f7e6c,C0001924,C0369768,more likely ,Albumins,Molecular oxygen saturation,8,X,[aapp/bacs],[moft],D12.776.034,
ede5e502-53dd-4ce5-b37b-0fa9a6c16487,C0001924,C0024264,low levels of ,Albumins,Lymphocyte,3,X,[aapp/bacs],[cell],D12.776.034,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
0315ad36-4d04-4c8b-b0d3-375f8f3fa670,C1947933,C0815172,were collected on key ,care activity,patient characteristics,4,X,[acty],[clna],,
5af4c6af-8bbb-45f4-8b1c-bf3e387f48e6,C1704259,C0815172,were collected on key ,Biochemical Pathway,patient characteristics,4,X,[moft],[clna],,
275bca06-cba0-4ccc-8b83-ccff004650d3,centre,C1704259,effectively managed Emergency treatment with appropriate patient,centre,Biochemical Pathway,1,X,????,[moft],????,
275bca06-cba0-4ccc-8b83-ccff004650d3,centre,C1704259,effectively managed Emergency Care with appropriate patient,centre,Biochemical Pathway,1,X,????,[moft],????,
c0a63e95-1076-4772-8e33-fdb6e7396a41,centre,C0013969,effectively managed urgent ,centre,Emergency treatment,1,X,????,[topp],????,E02.365
22d9ff82-69a2-4c84-8bf2-d78691bf6d92,C0005779,C0021368,is common abnormality in patients with ,Blood Coagulation Disorders,Inflammation,2,X,[dsyn],[patf],C15.378.100,C23.550.470
27572b1f-c498-4a36-b0dd-42759b8e6afc,C0040038,C0524702, includes ,Thromboembolism,Pulmonary Thromboembolisms,2,X,[patf],[dsyn],C14.907.355.590,C08.381.746;C14.907.355.350.700
b837d03a-d893-4a76-9be4-637a0b0bc5c9,C1175743,C1550661,was detected in their nasopharyngeal swabs ,SARS coronavirus,Specimen Type - Stool = Fecal,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
599ba022-fe14-4271-8585-9c2925a6b18c,C1175743,C3687742,was detected in their nasopharyngeal swabs ,SARS coronavirus,Oropharyngeal swab,2,X,[virs],[bdsu],B04.820.504.540.150.113.937,
14b93261-00a9-43f8-ad04-03dc74584bdc,C0029892,C0037778,producing resources for ,Otolaryngology specialty,Medical Specialities,2,X,[bmod],[bmod],H02.403.810.526,H02.403
ec6cfedb-96aa-4c80-8c4e-dd952462150e,ACE2,C0007634,of levels is ,ACE2,Cells,1,X,????,[cell],????,A11
e0efaaf1-6355-48e8-98d3-731bbae414dd,ACE2,C0206750,of levels is ,ACE2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
d29cade1-6165-40c3-9118-0ebd82202332,ACE2,C1175743,point for ,ACE2,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
0ee5009b-974f-4a7c-b5ab-97f40f606605,AGES-RS,C0003015,was stratified by ,AGES-RS,Angiotensin-Converting Enzyme Inhibitors,3,X,????,[phsu],????,D27.505.519.389.745.085
1c07576b-d997-4165-9de1-95058611ecfe,C0035100,C0229671,were significantly raised in ,Chymosin,Serum,3,X,[aapp/enzy],[bdsu],D08.811.277.656.074.500.200;D08.811.277.656.300.048.200,A12.207.152.846;A15.145.846
add99885-96db-438f-9f0c-80fc3bf402de,C0035100,C0003015,were significantly raised in ,Chymosin,Angiotensin-Converting Enzyme Inhibitors,3,X,[aapp/enzy],[phsu],D08.811.277.656.074.500.200;D08.811.277.656.300.048.200,D27.505.519.389.745.085
173e2780-5bf5-4659-9b39-c453c5b4dc82,C1422064,C1171362,effect on ,ACE2 gene,protein expression,6,X,[gngm],[genf],,
e547a068-285e-4f9d-b5ce-ed166d235212,C1422064,C0025250,effect on ,ACE2 gene,Neprilysin,6,X,[gngm],[aapp/enzy],,D08.811.277.656.300.480.600;D08.811.277.656.675.374.600;D23.050.285.550;D23.101.140.500
513f5328-2f2d-4f7f-bef6-20b44f9fec89,C1422064,C3887624,effect on ,ACE2 gene,Human Neprilysin,6,X,[gngm],[aapp/enzy],,
6d7cca45-549a-4df2-9e9b-851e614ddcd4,C0574032,C3887624,downregulated ,Infusion procedures,Human Neprilysin,2,X,[topp],[aapp/enzy],,
9f79dd59-fa84-40b9-b1d0-5a08fbbd4453,C0574032,C1171362,downregulated ,Infusion procedures,protein expression,2,X,[topp],[genf],,
69a9f515-ff74-4e7a-9d14-096eefe7a947,C1422064,C0533668,contributes to female protection from ,ACE2 gene,ANGPT1 protein human,3,X,[gngm],[aapp/bacs],,x.x.x.x
c9d658fb-4365-4cac-880a-dc88c7481ab9,C0151864,C0206750,is in ,Disorder of pregnancy,Coronavirus Infections,5,X,[dsyn],[dsyn],,C02.782.600.550.200
301d959c-1b17-4748-b5f8-b81085a7ff78,C0151864,C1521863,is in ,Disorder of pregnancy,estrogen receptor alpha human,5,X,[dsyn],[aapp/rcpt],,x.x.x.x
a6557745-10c6-4774-ac9d-9ef315c26c8c,C0010200,GLCM,was negatively correlated with GLCM offset4,Coughing,GLCM,5,X,[sosy],????,C08.618.248;C23.888.852.293,????
f3a02b1e-cbec-4c39-8cd3-3161a3febf91,C0010200,offset4,was negatively correlated with GLCM offset4,Coughing,offset4,5,X,[sosy],????,C08.618.248;C23.888.852.293,????
7b2d85d2-8e7a-4f69-b548-44d14f62e400,C0006560,C2699239,offset 4 _ ,C-reactive protein,SD Rat Strain,5,X,[aapp/imft],[mamm],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,
ff2c655f-44ce-4851-b174-4a18285affa4,C1514562,C0024109,changes of ,Protein Domain,Lung,5,X,[amas],[bpoc],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,A04.411
18a5104d-59cd-4ead-b3e7-aeeb1e9e1e6c,C0028754,C0061355, includes ,Obesity,Glucagon-Like Peptide 1,2,X,[dsyn],[aapp],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,D06.472.317.680.500.500
0e00efb5-6e64-4a9e-b427-22a0e2a5c7fb,C0087111,C0028754,is with ,Therapeutic procedure,Obesity,1,X,[topp],[dsyn],E02,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
299d8ec9-8024-405b-8dcf-45d64d940211,C0087111,C0243071,is with ,Therapeutic procedure,Analog,2,X,[topp],[chvs],E02,
371c8fa0-473f-4f66-9cea-b1d63837f32c,C0087111,C0360714,is with ,Therapeutic procedure,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[topp],[orch/phsu],E02,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
fbc5a89c-fa72-477c-915f-d06e85aa6b02,C0087111,C0085826,is with ,Therapeutic procedure,Antiplatelet Agents,2,X,[topp],[phsu],E02,D27.505.954.502.780
f6b1c311-ad6c-4e37-92a8-9bca12008cf0,C0087111,C0061355,is with ,Therapeutic procedure,Glucagon-Like Peptide 1,1,X,[topp],[aapp],E02,D06.472.317.680.500.500
15c25dc0-7f32-4989-8bda-da4e065bfe53,C0013227,C0028754,used to ,Pharmaceutical Preparations,Obesity,1,X,[phsu],[dsyn],D26,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
5d0effc9-8570-4a36-b314-5d4fdd201434,C0013227,C0243071,used to ,Pharmaceutical Preparations,Analog,2,X,[phsu],[chvs],D26,
6d9bc316-d15c-4ad3-850e-d6d55f284184,C0013227,C0360714,used to ,Pharmaceutical Preparations,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[phsu],[orch/phsu],D26,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
4f2cb892-b3ae-4935-a89f-afeb8a4f82da,C0013227,C0085826,used to ,Pharmaceutical Preparations,Antiplatelet Agents,2,X,[phsu],[phsu],D26,D27.505.954.502.780
18cf1ddc-79f3-463c-a780-4bbab4e5161a,C0013227,C0061355,used to ,Pharmaceutical Preparations,Glucagon-Like Peptide 1,1,X,[phsu],[aapp],D26,D06.472.317.680.500.500
c07e849c-3676-4fc5-8d9d-33984402a46d,C1706202,11th,has increased significantly since February 11th,Search - action,11th,1,X,[acty],????,,????
d0a23efa-9b78-4a2b-bfea-c0697cda405e,C1175743,C0013227,have far-reaching ,SARS coronavirus,Pharmaceutical Preparations,6,X,[virs],[phsu],B04.820.504.540.150.113.937,D26
b8944b5b-c2e9-481d-9896-ece559ee968c,C0021966,C0042776,was aware of my risk of exposure to ,Iodides,Virus,3,X,[inch],[virs],D01.248.497.158.490;D01.475.410,B04
652b7d01-b964-45a1-b6a5-6f43e118158c,C0021966,C4048158,assumed that as ,Iodides,Convulsions,2,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C10.597.742;C23.888.592.742
c02cfdbd-aa60-4f8e-84de-cbd83c34b77f,C0021966,C0021932,necessitating ,Iodides,Intubation Intratracheal,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,E02.041.500;E02.585.578;E05.497.578
b0b69b78-6e14-475b-9fdc-02d65346437f,C0021966,C0199470,necessitating ,Iodides,Mechanical ventilation,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,
83d745c2-d053-4e22-aaee-38aa536e23c9,C0021966,C0034991,was discharged home After two further days of ,Iodides,Rehabilitation therapy,3,X,[inch],[topp],D01.248.497.158.490;D01.475.410,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
e3b360a6-cbad-488f-883a-af4ca694212a,C0524816,C0017968,is in spike ,Nucleocapsid Proteins,Glycoproteins,3,X,[aapp/bacs],[aapp/bacs],D12.776.964.970.600,D09.400.430;D12.776.395
4725c526-58dd-45bd-970b-5db0d4c84d1a,C0525021,C0524816,is in ,Nuclear Localization Signals,Nucleocapsid Proteins,3,X,[amas],[aapp/bacs],D12.644.770.610;G02.111.570.060.670.610,D12.776.964.970.600
ccda6e39-bb7b-4ce3-9ace-b84e75dd24ff,C0017968,C0206419,be associated with high case fatality rate of ,Glycoproteins,Genus: Coronavirus,6,X,[aapp/bacs],[virs],D09.400.430;D12.776.395,B04.820.504.540.150
61e76ef4-ec50-4095-8ae0-dffa528c3315,C0035243,C1856053,be ultimately declared pandemic by World Health Organization on ,Respiratory Tract Infections,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,x.x.x.x
61c453f6-f0ec-474e-8fb9-d65f553a8d0e,C0035243,C0015392,has since spread across ,Respiratory Tract Infections,Eye,1,X,[dsyn],[bpoc],C01.539.739;C08.730,A01.456.505.420;A09.371
b561cbe0-e040-480c-8919-d8eabe7a1af5,C1267213,C0242781,is portal of ,Upper aerodigestive tract,disease transmission,2,X,[bpoc],[patf],,N06.850.310
826e1592-6665-44ca-b4ae-916bcc49cf51,C1267213,C0042774,is portal of ,Upper aerodigestive tract,Virus Replication,4,X,[bpoc],[celf],,G06.920.925
c7c46831-a8ef-48fa-b9e8-bc42333c3b56,C2745965,C0029892,is in ,Emergencies [Disease/Finding],Otolaryngology specialty,2,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,H02.403.810.526
f90f1eda-72e7-47e9-a058-f8845e007d36,C1533734,C0237798,is in ,Administration procedure,Nonhuman primate,2,X,[topp],[mamm],,
14383c42-59d8-41b8-bd0c-ab5552ef774a,C1533734,C0003261,is in ,Administration procedure,Antibody Formation,3,X,[topp],[biof],,G12.070
acdb6d57-6ef0-418d-b746-f3fc961a8809,C0003261,C1175743,potently neutralized ,Antibody Formation,SARS coronavirus,2,X,[biof],[virs],G12.070,B04.820.504.540.150.113.937
4ba598b3-38b7-4d06-9c2c-7a4c5cb1e594,C0012655,C0012634,are associated with ,Disease susceptibility,Disease,1,X,[clna],[dsyn],C23.550.291.687;G07.100.250,C23.550.288
abbfe8ee-b681-4d20-988f-aa06d613c449,C0012655,C1175743,are associated with ,Disease susceptibility,SARS coronavirus,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540.150.113.937
e599241b-34ac-47b1-be38-51268191a7cd,C0007222,C0683325,is in term of ,Cardiovascular Diseases,clinical aspects,1,X,[dsyn],[clna],C14,
969bf470-b8f5-4d33-abf7-28afbd923f7a,C2948600,C0599878,describe cardiological ,Aim,disease characteristic,4,X,[inch/phsu],[patf],,
fdf94e51-42ca-41f7-822e-38578180f652,C2948600,C0007222,describe clinical outcome for patients with ,Aim,Cardiovascular Diseases,1,X,[inch/phsu],[dsyn],,C14
0ff7d199-c041-4a4f-a34a-3348bb9705d5,C0596197,C0206750,is in patients with ,blood treatment,Coronavirus Infections,3,X,[topp],[dsyn],,C02.782.600.550.200
830da6f9-57af-443e-9650-32c9d64c8dd3,C0152025,C0225990,Occlusive stroke from,Polyneuropathy,Large blood vessel structure,1,X,[dsyn],[bpoc],C10.668.829.800,
13f0107f-052d-48c8-9f96-24e2c147b76c,C0152025,C1298680,Occlusive stroke from,Polyneuropathy,Occlusive stroke,1,X,[dsyn],[dsyn],C10.668.829.800,
42850c74-9535-4ead-a353-84425ad303f0,C0079102,C0206750,may complicate initial clinical presentation of ,Cerebral Thrombosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,C02.782.600.550.200
9fe684be-0ab7-4477-84f1-8ce69bde6a49,C0035668,C0037088,was Detection After resolution of,RNA,Signs and Symptoms,2,X,[nnon],[sosy],D13.444.735,C23.888
3a921aad-9ced-4694-872f-5f0c061047be,C0524865,C2700061,initiate great green ,Reconstructive Surgical Procedures,Transition (action),1,X,[topp],[acty],E04.680,
e95cf956-3b9e-4116-b4bb-e1c7e804f462,C2728259,C2700061,initiate great green ,Program,Transition (action),1,X,[orch/phsu],[acty],V02.355.750,
f826be2d-ca2f-43b0-b4ce-032aa81e3bae,C0694549,C1175743, includes CoV2,Community acquired pneumonia,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
71f551e6-1cf5-451c-ab98-9c358a50e208,C0694549,CoV2, includes CoV2,Community acquired pneumonia,CoV2,1,X,[dsyn],????,,????
12aa2c8a-4668-4ed9-957b-4f52a225e4a6,C0857828,C0079189,leads to ,infection in the elderly,cytokine,3,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
6a3705be-71d6-42b4-b770-e45b79df3651,C0206750,CD8,characterize CD8 ,Coronavirus Infections,CD8,1,X,[dsyn],????,C02.782.600.550.200,????
6a3705be-71d6-42b4-b770-e45b79df3651,C0206750,CD8,decreased CD8 ,Coronavirus Infections,CD8,2,X,[dsyn],????,C02.782.600.550.200,????
427e926c-2bab-4088-9292-05ebce4205b7,CD8,C1175743,is in ,CD8,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
d74612c4-7894-4a94-8647-83c10a32bc5c,C0282580,C1175743,CD8 in ,Epitopes T-Lymphocyte,SARS coronavirus,1,X,[imft],[virs],D23.050.550.402,B04.820.504.540.150.113.937
f243522c-0335-4f56-b995-ce5c4350aafe,C0043309,3D,derive physically realistic 3D ,Roentgen Rays,3D,1,X,[npop],????,G01.358.500.505.970;G01.750.250.970;G01.750.750.918,????
aba6a1b8-0afd-4cb4-9572-f93e9f644f89,C0043309,C1175743,derive physically realistic 3D ,Roentgen Rays,SARS coronavirus,1,X,[npop],[virs],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,B04.820.504.540.150.113.937
01c5154b-8bd1-4ab7-ad1a-f0eaf6cec3ce,C0206419,C1947932,later identified as quickly ,Genus: Coronavirus,Smear - instruction imperative,1,X,[virs],[acty],B04.820.504.540.150,
b3e89bd8-5bf8-41a6-9ed1-a64c730802c2,C1175743,C1947932,has worldwide ,SARS coronavirus,Smear - instruction imperative,2,X,[virs],[acty],B04.820.504.540.150.113.937,
daa6e756-992f-4dd4-b88d-c4f6c8d816c4,C0018787,C0960880,caused by ,Heart,angiotensin converting enzyme 2,2,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
daa6e756-992f-4dd4-b88d-c4f6c8d816c4,C0018787,C0960880,have have direct ,Heart,angiotensin converting enzyme 2,1,X,[bpoc],[aapp/enzy],A07.541,x.x.x.x
c13ad6e4-af4a-4b10-a8ac-da9464995b11,C3260929,C0960880,caused by ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,angiotensin converting enzyme 2,1,X,[clna],[aapp/enzy],,x.x.x.x
c13ad6e4-af4a-4b10-a8ac-da9464995b11,C3260929,C0960880,have have direct ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,angiotensin converting enzyme 2,1,X,[clna],[aapp/enzy],,x.x.x.x
a3b5e222-e645-401e-b145-2609026e8608,C3260929,C0018787,have have direct ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Heart,1,X,[clna],[bpoc],,A07.541
d98b2ca7-2b47-4617-bab9-8924b4097586,C0011389,C0005779,is with ,Dental Plaque,Blood Coagulation Disorders,2,X,[dsyn],[dsyn],C07.793.208.377,C15.378.100
8b4068cc-c197-481c-aa95-9afcecbd08d5,C1719472,C0264714,can lead to ,Stress induced cardiomyopathy,Acute heart failure,2,X,[dsyn],[dsyn],,
49fb826e-9587-4ce0-bf49-c9d08d153684,C1719472,C0018787,can lead with further ,Stress induced cardiomyopathy,Heart,1,X,[dsyn],[bpoc],,A07.541
78a0d2ba-c19d-4b3c-abab-f30b36209e0d,C1719472,C0012634,is in critically ill ,Stress induced cardiomyopathy,Disease,2,X,[dsyn],[dsyn],,C23.550.288
ad7bbcdf-0983-4e74-94b9-b65105ae6714,C0206419,C0026882,form escape ,Genus: Coronavirus,Mutation,2,X,[virs],[genf],B04.820.504.540.150,G05.365.590
f4cc3353-2648-438a-900b-c161617ee7a9,C1527075,C0226658,followed by specific considerations in ,Revision procedure,Structure of valve of coronary sinus,1,X,[topp],[bpoc],,
bae34ab5-1887-4e3f-bb55-54b18ce246f4,C0206419,C0010076,is ,Genus: Coronavirus,Coronaviridae,4,X,[virs],[virs],B04.820.504.540.150,B04.820.504.540
6cee7583-1911-402d-bc5d-eb161947fddb,C0012634,C0010076,is ,Disease,Coronaviridae,2,X,[dsyn],[virs],C23.550.288,B04.820.504.540
4f82359b-0878-441c-ab4f-acf9137f64f5,C1422064,C1440080,are present in type ,ACE2 gene,Alveolar,1,X,[gngm],[bpoc],,
ecd2c9e7-c7c6-4054-b209-e014ac578713,C2316160,C0206419,is in critically ill patients with ,Infection of bloodstream,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
e9b56788-b0b8-44ba-ae9c-595be4ca3a3b,C0003209,C2316160,was independently associated with development ,Anti-Inflammatory Agents,Infection of bloodstream,4,X,[phsu],[patf],D27.505.954.158,
aa347258-e81b-4837-ad1c-82474cf450a6,C1457887,C0458578,are those of ,Symptoms,Upper respiratory tract,2,X,[sosy],[bpoc],,
0448803d-6dca-432e-a475-71df85d41b8d,C0034019,C0450254,Increasingly are using genomic ,public health medicine (field),Pathogenic organism,1,X,[bmod],[orgm],H02.403.720;N01.400.550;N06.850,
915a5f1f-6ee1-4fae-aa9e-3f8cd1140354,C0034019,genomic,Increasingly are using genomic ,public health medicine (field),genomic,1,X,[bmod],????,H02.403.720;N01.400.550;N06.850,????
a0587f08-7cb4-4f88-bc19-c3ac99cc93a7,C0450254,C0034019,is in ,Pathogenic organism,public health medicine (field),1,X,[orgm],[bmod],,H02.403.720;N01.400.550;N06.850
aa22e5fc-a2f5-4360-9055-7027cd55a0d0,genomic,C0034019,is in ,genomic,public health medicine (field),1,X,????,[bmod],????,H02.403.720;N01.400.550;N06.850
fba1f2ed-5ec9-4f6d-892c-fb8287fd5e66,COVID-19,C1527075,has drawn attention experts calling for its ,COVID-19,Revision procedure,1,X,[virs],[topp],C000657245,
59635b63-4646-4efc-a706-f4431945fa29,COVID-19,C1334294,performs on PCR,COVID-19,JTB gene,1,X,[virs],[gngm],C000657245,
a39d6049-fb27-4af7-a4d1-a1c3e457ce45,COVID-19,C0230425,performs on PCR,COVID-19,Structure of right thigh,1,X,[virs],[bpoc],C000657245,
20dfdb08-715f-4740-a8e7-8ed898a97dd2,COVID-19,PCR,performs on PCR,COVID-19,PCR,1,X,[virs],????,C000657245,????
38c92f92-4b77-40ab-a13c-62979111fcf1,C1334294,COVID-19,is with PCR,JTB gene,COVID-19,1,X,[gngm],[virs],,C000657245
b42c92fb-e7d4-4f0f-8e8c-647c9d2fb69d,C1334294,C0230425,is with PCR,JTB gene,Structure of right thigh,1,X,[gngm],[bpoc],,
ee7bb01d-47bf-4937-82ef-d68c368e0b21,C1334294,PCR,is with PCR,JTB gene,PCR,1,X,[gngm],????,,????
3be54c92-4551-46e2-82b2-c711c92f8972,COVID-19,C0020517,has ,COVID-19,Hypersensitivity,2,X,[virs],[patf],C000657245,C20.543
ce9807b4-0682-4245-8222-5db6f4bc7b85,C0872079,C1413931,Genetic Polymorphism in,protein protein interaction,ACE gene,1,X,[moft],[gngm],,
3df28a8b-e20f-4d47-873a-0d1a50fd6043,C0032529,C0024109,contribute to ,Genetic Polymorphism,Lung,1,X,[genf],[bpoc],G05.365.795,A04.411
67ce2223-f575-4258-a381-220cf072ffc0,C0206750,60-year,with patient is 60-year ,Coronavirus Infections,60-year,2,X,[dsyn],????,C02.782.600.550.200,????
38cea766-b9dc-477a-b095-fc9d4e4067a1,C0012634,60-year,with patient is 60-year ,Disease,60-year,2,X,[dsyn],????,C23.550.288,????
559ff610-f0f8-4f8e-a4d2-c9a1cd9c2816,C0024432,C0950580,are ,macrophage,sentinel,2,X,[cell],[hops/orch],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,
2dc7c14f-d263-41a3-8b45-70a164d76476,C0011306,C0950580,are ,Dendritic Cells,sentinel,2,X,[cell],[hops/orch],A11.066.270;A11.436.270;A15.382.066.270;A15.382.670.260,
68bc4e40-48c4-487d-92bb-9142f0c1ee94,C0678209,C0699748,affect ,Adaptive Immunity,Pathogenesis,2,X,[phsf],[patf],G12.450.050,
1b461388-1342-4f30-8a79-b206639541a4,C0678209,C1175743,affect ,Adaptive Immunity,SARS coronavirus,2,X,[phsf],[virs],G12.450.050,B04.820.504.540.150.113.937
3531d374-5e63-494e-ae83-bb850311065b,C0026473,C1175175,were permissive to ,Monocytes,Severe Acute Respiratory Syndrome,4,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C02.782.600.550.200.750;C08.730.730
894d6122-c9dc-4ce0-a368-9a357cb67e9d,C0066350,C1175175,were permissive to ,methylene dimethanesulfonate,Severe Acute Respiratory Syndrome,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
8d4c34a2-2acd-4b70-b50e-de1a4b27d06b,C3652465,C0007634,is in ,Interferon,Cells,2,X,[aapp/imft/phsu],[cell],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,A11
00481696-293f-4c88-ba6b-b05b479d7456,C1721019,C0022709,locate at ,Virus Attachment,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.868,D08.811.277.656.350.350.687
cf57ca91-f26d-455d-8b22-90a38811e28d,C1721019,C0034987,locate at ,Virus Attachment,Regulatory Sequences Nucleic Acid,1,X,[biof],[bacs/nnon],G06.920.868,G02.111.570.080.689;G05.360.080.689
0c27bda7-1a4a-4821-882f-a10cc3c6e6d5,C0022709,C0011860,is reduced in ,Peptidyl-Dipeptidase A,Diabetes Mellitus Non-Insulin-Dependent,6,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C18.452.394.750.149;C19.246.300
7ca7e4c7-6786-4d8a-8220-0a35c8f13473,C0022709,C0079189,is reduced with inflammatory ,Peptidyl-Dipeptidase A,cytokine,6,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,D12.644.276.374;D12.776.467.374;D23.529.374
7ca7e4c7-6786-4d8a-8220-0a35c8f13473,C0022709,C0079189,was significantly negatively associated with type ,Peptidyl-Dipeptidase A,cytokine,1,X,[aapp/enzy/imft],[aapp/imft],D08.811.277.656.350.350.687,D12.644.276.374;D12.776.467.374;D23.529.374
b1245777-178b-46a0-a272-f305ce731b58,C3649547,C4547399,was required in ,Continuous renal replacement therapy,CI-2,1,X,[topp],[aapp/phsu],,
2be80b38-165c-471e-836f-dc2a0892c1ef,AKI,C0206750,is associated with severity of ,AKI,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
14130401-9067-44ab-80c2-d5ae86d07bf3,C0034019,C0275518,was classified as pandemic of ,public health medicine (field),Acute infectious disease,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,
236406e9-a2c1-4acc-bd27-33a0d052ce60,C0034019,C0206750,has has declared worldwide since ,public health medicine (field),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
236406e9-a2c1-4acc-bd27-33a0d052ce60,C0034019,C0206750,started following ,public health medicine (field),Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
236406e9-a2c1-4acc-bd27-33a0d052ce60,C0034019,C0206750,mitigate spread of ,public health medicine (field),Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C02.782.600.550.200
a6826685-147b-4603-a48b-c2cee720b1a8,C0034019,C0012634,has has declared worldwide since ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
a6826685-147b-4603-a48b-c2cee720b1a8,C0034019,C0012634,was key disproportionately affected by ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
a6826685-147b-4603-a48b-c2cee720b1a8,C0034019,C0012634,mitigate spread of ,public health medicine (field),Disease,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C23.550.288
6cea03c8-af4d-491e-bb6d-4802b67874e0,C0206750,C1704330,is in ,Coronavirus Infections,Dental Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07
a0186465-9a11-4219-a5eb-401c3504da94,C0040034,C1511790,was ,Thrombocytopenia,Detection,2,X,[dsyn],[topp],C15.378.140.855,
86e6e0c6-3807-479d-b8ec-e7618d83b00a,C0040034,C0206750,was Detection of patients with,Thrombocytopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.140.855,C02.782.600.550.200
98bd8c65-671a-4a88-987d-2191e062a7a0,C1706202,C1707391,resulted in ,Search - action,Choose (action),3,X,[acty],[acty],,
f9028311-054b-4b8b-8dbe-1824e6680041,C2948600,C0016059,evaluate efficacy in treatment of ,Aim,Fibrosis,2,X,[inch/phsu],[patf],,C23.550.355
016ecd98-c5d9-457d-852d-44cd9f684c72,C0016059,C0206750,is in patients with severe ,Fibrosis,Coronavirus Infections,2,X,[patf],[dsyn],C23.550.355,C02.782.600.550.200
016ecd98-c5d9-457d-852d-44cd9f684c72,C0016059,C0206750,direct future efforts towards its potential role in ,Fibrosis,Coronavirus Infections,1,X,[patf],[dsyn],C23.550.355,C02.782.600.550.200
615fe405-4fc9-40e5-8998-ba6ff4e39367,C0014898,C0016059,used other anti ,Esters,Fibrosis,2,X,[orch],[patf],D02.241.400,C23.550.355
913a679f-3cb0-427e-aa36-98c7ef4fd4dc,C0004482,C0016059,used other anti ,Azathioprine,Fibrosis,2,X,[hops/orch/phsu],[patf],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,C23.550.355
a4502c27-b2b7-4cde-a2f2-143929977825,C0010583,C0016059,used other anti ,Cyclophosphamide,Fibrosis,2,X,[orch/phsu],[patf],D02.455.526.728.650.730.243;D02.705.672.500.243,C23.550.355
fd5383b9-d063-4f78-91f2-d9487808f99f,C3652465,C0016059,used other anti ,Interferon,Fibrosis,2,X,[aapp/imft/phsu],[patf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,C23.550.355
ac5bd6f4-63d9-49b0-8ad5-e650ab76da06,C0025124,C0016059,used other anti ,Traditional Chinese Medicine,Fibrosis,2,X,[bmod],[patf],E02.190.488.585.520;I01.076.201.450.654.558.520,C23.550.355
0fc6663f-653d-48b7-a39b-c9726306315c,C0014898,C0034060,used other anti ,Esters,Pulmonary Medicine,2,X,[orch],[bmod],D02.241.400,H02.403.429.675
8ea59e04-44df-4c72-9cc5-c824b9a480ee,C0004482,C0034060,used other anti ,Azathioprine,Pulmonary Medicine,2,X,[hops/orch/phsu],[bmod],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,H02.403.429.675
a5d00ffc-19b9-4eb9-8144-fc6c1359bce2,C0010583,C0034060,used other anti ,Cyclophosphamide,Pulmonary Medicine,2,X,[orch/phsu],[bmod],D02.455.526.728.650.730.243;D02.705.672.500.243,H02.403.429.675
7878bed4-83ed-451d-9855-224ad3bf9683,C3652465,C0034060,used other anti ,Interferon,Pulmonary Medicine,2,X,[aapp/imft/phsu],[bmod],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,H02.403.429.675
3c175b2e-3fcf-43fe-ba87-a90de847f166,C0025124,C0034060,used other anti ,Traditional Chinese Medicine,Pulmonary Medicine,2,X,[bmod],[bmod],E02.190.488.585.520;I01.076.201.450.654.558.520,H02.403.429.675
0cc74089-f88e-4bee-9fcc-e32b3944dede,C0014898,C2930789,consider in past ,Esters,nintedanib,2,X,[orch],[orch/phsu],D02.241.400,x.x.x.x
8fe38d54-5933-4ea3-ac69-f8bea62ee19b,C0004482,C2930789,consider in past ,Azathioprine,nintedanib,2,X,[hops/orch/phsu],[orch/phsu],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,x.x.x.x
53e57c79-0a2d-429a-9417-9adf16a71b8e,C0010583,C2930789,consider in past ,Cyclophosphamide,nintedanib,2,X,[orch/phsu],[orch/phsu],D02.455.526.728.650.730.243;D02.705.672.500.243,x.x.x.x
56b81c5e-8a5f-405b-b9ad-df112055f177,C3652465,C2930789,consider in past ,Interferon,nintedanib,2,X,[aapp/imft/phsu],[orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,x.x.x.x
3bb6841b-9a39-4ebf-8da7-86e56f59f74c,C0025124,C2930789,consider in past ,Traditional Chinese Medicine,nintedanib,2,X,[bmod],[orch/phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,x.x.x.x
a9e10a5e-15e1-4353-a7c6-8763fdfccad5,C1254351,C0009905,is Anluohuaxian ,Pharmacologic Substance,Contraceptives Oral,1,X,[phsu],[phsu],,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
549e4706-dada-4407-a88c-998d61dc6db9,C1254351,C1136140,is Anluohuaxian ,Pharmacologic Substance,Long-Term Synaptic Depression,1,X,[phsu],[ortf],,G11.561.638.355
81b9b8df-853e-4de0-89b7-0bc26743803e,C1417168,HC,0.12 in HC,MID2 gene,HC,2,X,[gngm],????,,????
ae42f2db-fecd-4396-943a-676775bfad72,C1268822,HC,0.12 in HC,Optical density function,HC,2,X,[clna],????,,????
a5401ef3-07fc-4239-b72a-79f73656683d,C1417167,HC,is in HC S1 ,MID1 gene,HC,4,X,[gngm],????,,????
b7ec4ad0-0a93-4242-af97-4288f14bc1aa,C1417167,C0051980,is in HC S1 ,MID1 gene,anti-IgM,6,X,[gngm],[aapp/imft],,x.x.x.x
e0e5719b-3713-47ac-bb2c-41b705b34bce,C1417167,S1,is in HC S1 ,MID1 gene,S1,1,X,[gngm],????,,????
9620f086-de32-4775-9418-c901ccce9cff,C0254211,C0001551,combined with ,arbidol,Immunologic Adjuvants,1,X,[orch/phsu],[imft/phsu],x.x.x.x,D27.505.696.477.067
bd6293fd-0c92-488d-84b5-f20d2daf7e01,C0254211,C0033972,combined with ,arbidol,Psychotherapy Multiple,1,X,[orch/phsu],[topp],x.x.x.x,F04.754.766
0dec56c4-0183-4131-b802-b817d9680fc4,C0254211,C0743841,relieve ,arbidol,Disorder characterized by fever,1,X,[orch/phsu],[dsyn],x.x.x.x,
d3d98727-b897-4ce3-9b6b-17bb27d483b0,C0254211,C0206750,relieve ,arbidol,Coronavirus Infections,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
b62a30c7-34aa-49fd-9853-9f911ce4b06d,C0520510,C0441655,were found more ,Materials,Activities,3,X,[sbst],[acty],,
48b55b6e-6563-4895-92cf-7c5125caac92,C0151311,COVID-19,may Representation (action),Cranial nerve palsies,COVID-19,1,X,[dsyn],[virs],,C000657245
9d661aef-a7b0-426e-a8a7-d35561b4211c,C0151311,C1518256,may Representation (action),Cranial nerve palsies,Nervous System Part,2,X,[dsyn],[bpoc],,
08c08a6a-028f-44f6-8744-7480ce5d4e8c,C0677043,C0015982,often reveals ,Histopathology,Fibrin,1,X,[bmod],[aapp/bacs/phsu],,D12.776.124.270
dcd394af-8378-4b5b-91f8-bd2e2075cb40,C0677043,C0011382,often reveals ,Histopathology,Dental Occlusion,1,X,[bmod],[ortf],,E06.276;G10.549.208
0651eff1-3680-42f2-9821-e36482c17352,C0005841,C0005821,Comparison to non-COVID wards for RBCs ,Blood Transfusion,Blood Platelets,2,X,[topp],[cell],E02.095.135,A11.118.188;A15.145.229.188
9a4a1b8d-4b3c-4b91-9493-f05c21d1aa9c,C0005841,C0032105,Comparison to non-COVID wards for RBCs ,Blood Transfusion,Plasma,2,X,[topp],[bdsu],E02.095.135,A12.207.152.693;A12.207.270.695;A15.145.693
63125b8b-ed9d-4a3f-b994-b3682c06aa1e,COVID-19,C0007189,brings changes For ,COVID-19,Cardiology discipline,1,X,[virs],[bmod],C000657245,H02.403.429.163
52b5c3c0-ddac-4b50-b3e5-c1a836fa084c,COVID-19,C1861452,are characterized with ,COVID-19,Storm Syndrome,1,X,[virs],[dsyn],C000657245,x.x.x.x
f6b9ffee-57a0-4be8-b13b-74d8a097496d,C0424295,COVID-19,is in ,Hyperactive behavior,COVID-19,1,X,[mobd],[virs],,C000657245
20accdac-6837-47dc-b76d-85c08314f361,C0301872,COVID-19,is in ,Immune response,COVID-19,2,X,[ortf],[virs],,C000657245
ceacc8c7-a741-4834-8413-f8084663b0c8,C1155266,COVID-19,is in ,inflammatory response,COVID-19,2,X,[patf],[virs],,C000657245
184cdbfb-9e8e-4035-853b-f9a557f7e831,COVID-19,C0035204,is primarily ,COVID-19,Respiration Disorders,1,X,[virs],[dsyn],C000657245,C08.618
184cdbfb-9e8e-4035-853b-f9a557f7e831,COVID-19,C0035204,can result in severe ,COVID-19,Respiration Disorders,1,X,[virs],[dsyn],C000657245,C08.618
4273d677-2267-4783-be4d-79802c505485,COVID-19,C1880355,is primarily ,COVID-19,Discover,1,X,[virs],[acty],C000657245,
65b99f5b-bdac-480b-8eee-c5a574df9c8f,C4554533,COVID-19,is in ,Trend:Type:Point in time:^Patient:Nominal,COVID-19,1,X,[clna],[virs],,C000657245
9ed2d19e-9741-41a9-9630-2b6ed8ba831b,C0012634,C0008679,persons with ,Disease,Chronic disease,2,X,[dsyn],[dsyn],C23.550.288,C23.550.291.500
858eedde-63ee-452a-a9ea-a67ebdceed38,C1262020,C1292533,was main finding in lung ,diffuse alveolar damage,Tissue specimen,1,X,[dsyn],[tisu],,
d5787d26-e3f0-40da-a9a6-d8d6d3504983,C0700148,C0677043,were ,Congestion,Histopathology,1,X,[patf],[bmod],,
02d5fdbd-f5f9-413b-9753-0d4c99ec243d,C0225698,C0333865,in Alveolar Epithelial Cells is,Alveolar Epithelial Cells,Cytologic atypia,2,X,[cell],[comd],A04.411.715.100;A11.436.081,
09df21ba-17a1-4396-b46a-7f6ad45d30e0,C0005847,C0677043,Congestion of were other,Blood Vessel,Histopathology,1,X,[bpoc],[bmod],A07.015,
1f79e91f-5a51-47d3-a8a5-323347c4f7c1,C0005847,C0024109,Congestion of were other,Blood Vessel,Lung,1,X,[bpoc],[bpoc],A07.015,A04.411
1f79e91f-5a51-47d3-a8a5-323347c4f7c1,C0005847,C0024109,amount of was In ,Blood Vessel,Lung,2,X,[bpoc],[bpoc],A07.015,A04.411
76063710-187b-4084-828d-5b97dc52c7eb,C0024432,C0677043,accumulation of were ,macrophage,Histopathology,1,X,[cell],[bmod],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,
c4b37c31-3e63-430c-8366-a0e3f5c361cb,C0225698,C0677043,were ,Alveolar Epithelial Cells,Histopathology,1,X,[cell],[bmod],A04.411.715.100;A11.436.081,
90495b5f-ed8d-49a3-932e-05590c22b5b5,C0010054,C0018787,is most probable justification of observed pathologic changes in ,Coronary Arteriosclerosis,Heart,1,X,[dsyn],[bpoc],C14.280.647.250.260;C14.907.137.126.339;C14.907.585.250.260,A07.541
fe0a945b-aac6-47df-9491-c0539beca9ab,C1706202,C0599416,were performed in MEDLINE,Search - action,ovid,1,X,[acty],[mamm],,
1349adb2-8113-4d04-ae5c-9e6a068d96e0,C4086266,C0184633,invasive ventilation of ,Escalation,Oxygen Therapy Care,1,X,[acty],[topp],,E02.880.690
c96535cd-6b04-4f23-8d81-0b43f80e03bc,HFNC,C1145670,reduce ventilation in patients with ,HFNC,Respiratory Failure,1,X,????,[dsyn],????,C08.618.846
2b1cc59c-9431-48fb-b371-ad86d95fa972,HFNC,C0184633,reduce invasive ventilation of ,HFNC,Oxygen Therapy Care,2,X,????,[topp],????,E02.880.690
981fd7a1-729d-46e0-a20c-1f60be8d1e8e,C0806140,COVID-19,need with ,Flow,COVID-19,1,X,[npop],[virs],,C000657245
64e4dd06-356d-44dd-a817-bd1f475962c8,cannula,COVID-19,need with ,cannula,COVID-19,1,X,????,[virs],????,C000657245
d242c0ee-10b4-4676-a3a0-7036c873ae8b,C0806140,C0184633,need with ,Flow,Oxygen Therapy Care,1,X,[npop],[topp],,E02.880.690
0a17eda7-fd03-45bc-9738-ece5b4f300eb,cannula,C0184633,need with ,cannula,Oxygen Therapy Care,1,X,????,[topp],????,E02.880.690
043be8ae-118d-46d1-9c5c-1382d67f9f0a,C0806140,C4039867,need with ,Flow,Acute hypoxemic respiratory failure,1,X,[npop],[dsyn],,
e8b85995-f9ef-4aaf-b45f-43b482fe6375,cannula,C4039867,need with ,cannula,Acute hypoxemic respiratory failure,1,X,????,[dsyn],????,
b2cffacb-ebe9-41ac-8409-921f3213242d,COVID-19,C4039867,is with ,COVID-19,Acute hypoxemic respiratory failure,1,X,[virs],[dsyn],C000657245,
75e0da29-7f03-4131-8c1b-c27e917c510c,C0184633,COVID-19,is in ,Oxygen Therapy Care,COVID-19,1,X,[topp],[virs],E02.880.690,C000657245
463caf37-c2c4-4e9c-ad9e-d5c374b78d3e,C0184633,C4039867,is in ,Oxygen Therapy Care,Acute hypoxemic respiratory failure,1,X,[topp],[dsyn],E02.880.690,
548d2ef4-9f5c-4018-bbc8-be3c5cc0d442,C3714514,C4042908,were accounting to ,Infection,Seroconversion,2,X,[patf],[npop],C01.539,G12.800
b82dd619-a09c-4b04-8d2d-72fd8d38f830,C0917707,C1708476,arguably Representation (action) key steps for,Cannulation,Implementation,1,X,[topp],[acty],E02.148;E05.157,
24c63dda-bd47-4d62-a55d-a20ebc7b380b,C0917707,C0015357,arguably Representation (action) key steps for,Cannulation,Extracorporeal Membrane Oxygenation,1,X,[topp],[topp],E02.148;E05.157,E02.880.301;E04.292.451
41740fe7-b930-4351-a791-b1c8d391a88a,C0917707,cannula,ensuring appropriate cannula ,Cannulation,cannula,1,X,[topp],????,E02.148;E05.157,????
d2dc61d8-a2d6-40f1-9077-b53ca0c5eecd,C0005528,C0015357,implemented protocol for bedside ,Biological Transport,Extracorporeal Membrane Oxygenation,1,X,[celf],[topp],G03.143,E02.880.301;E04.292.451
10c36297-b796-470a-9407-3bcc33545329,C0005528,C0917707,implemented protocol for bedside ,Biological Transport,Cannulation,1,X,[celf],[topp],G03.143,E02.148;E05.157
2d67d400-5302-4b2b-8214-586fccb02493,C0023870,C0087111,is used to ,Lithium,Therapeutic procedure,1,X,[elii/phsu],[topp],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,E02
497f2f9f-67be-4e6f-844a-1a47e152c768,C0023870,C0005586,is used to ,Lithium,Bipolar Disorder,1,X,[elii/phsu],[mobd],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,F03.084.500
1d409896-8bd3-4205-a1a1-64bb5ea4ee10,C1861452,C0206419,patients with severe ,Storm Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
fcc4b79a-eed2-46af-908b-df621279b7e2,C2700061,C0441655,restrictions on non-essential ,Transition (action),Activities,1,X,[acty],[acty],,
a610d0cc-345b-4a2f-8e25-f4c4e1c4fb7a,C4082587,C0441655,restrictions on non-essential ,HLA Class II Histocompatibility Antigen Gamma Chain human,Activities,1,X,[aapp/imft],[acty],,
8f36e6e9-1c8f-43ae-b1e5-9b377b1bfbe6,C0206419,U.S.,is placing considerable strain on U.S. ,Genus: Coronavirus,U.S.,1,X,[virs],????,B04.820.504.540.150,????
0072b269-5e34-4b98-a2d7-a597a9ee654c,C0012634,U.S.,is placing considerable strain on U.S. ,Disease,U.S.,1,X,[dsyn],????,C23.550.288,????
638c2969-ada2-47b8-bac2-362f13c5767c,C0038952,COVID-19,is in ,Continuance of life,COVID-19,3,X,[acty],[virs],I03.784,C000657245
b10373ca-0707-474d-a26b-c99820125c12,C0007203,C0032285,is in cohort of similar critically ill patients with ,Cardiopulmonary Resuscitation,Pneumonia,3,X,[topp],[dsyn],E02.365.647.110,C08.381.677;C08.730.610
9f6bfb53-cf57-434a-a2a9-f531082868ca,C0030738,C0042397,were receiving ,Peas - dietary,Vasoconstrictor Agents,3,X,[food],[phsu],B01.650.940.800.575.912.250.401.630,D27.505.954.411.793
001619d3-fec7-4a11-b4b8-f0f6c416b8cc,C0450254,C0036974,caused ,Pathogenic organism,Shock,1,X,[orgm],[patf],,C23.550.835
2e0c2d97-790d-482a-99e4-b4bd9cdfc2f9,C0450254,C0003467,caused nationwide ,Pathogenic organism,Anxiety,1,X,[orgm],[mobd],,F01.470.132
cf259063-954d-4af9-b602-8d0c95245276,C0035222,C1175175,is in ,Respiratory Distress Syndrome Adult,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C02.782.600.550.200.750;C08.730.730
86d6f4d8-7f5f-42b0-8b7d-9f4ce480c3df,C0072027,C0206750,be indicator of disease severity in ,procalcitonin,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],D06.472.699.666;D12.644.548.744;D12.776.811.555,C02.782.600.550.200
e965bfb4-9674-4c0e-88d7-4c5d65ae16d8,C0229671,C1175743,collected from ,Serum,SARS coronavirus,1,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150.113.937
e965bfb4-9674-4c0e-88d7-4c5d65ae16d8,C0229671,C1175743,was significantly higher in ,Serum,SARS coronavirus,2,X,[bdsu],[virs],A12.207.152.846;A15.145.846,B04.820.504.540.150.113.937
3314aa47-0ba0-4d09-90a6-ab35fdaac7c4,C0022709,C0028429,is in ,Peptidyl-Dipeptidase A,Nose,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A01.456.505.733;A04.531;A09.531
29304c54-b3ce-4465-9549-3e3433360a16,C0035668,C0022709,revealed ,RNA,Peptidyl-Dipeptidase A,1,X,[nnon],[aapp/enzy/imft],D13.444.735,D08.811.277.656.350.350.687
6ba2dc48-d948-4d3b-a266-cc1c19908042,C0009450,C0024109,is in proximal ,Communicable Diseases,Lung,1,X,[dsyn],[bpoc],C01.539.221,A04.411
6ba2dc48-d948-4d3b-a266-cc1c19908042,C0009450,C0024109,requires collaboration of ,Communicable Diseases,Lung,2,X,[dsyn],[bpoc],C01.539.221,A04.411
dce8dd0e-beac-4c8a-a89a-af711b33b121,C0024109,C0012634,identified focal ,Lung,Disease,1,X,[bpoc],[dsyn],A04.411,C23.550.288
f574d566-a6bf-4652-bee8-1fb88f255c8c,C0700198,C1175743,is in ,Pulmonary aspiration,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
a5d320d6-9509-4e97-9189-db0d16c1c0cd,C1175743,C0700198,is with likely subsequent ,SARS coronavirus,Pulmonary aspiration,2,X,[virs],[patf],B04.820.504.540.150.113.937,
0c65bc94-2907-4e01-8df5-b81d23cf2426,C0011777,C0027497,delayed ,Dexamethasone,Nausea,2,X,[orch/phsu],[sosy],D04.210.500.745.432.769.344;D04.210.500.908.238,C23.888.821.712
aa57b5c2-baea-4d6d-801a-aa0d103ab4a6,C0011777,C0042963,delayed ,Dexamethasone,Vomiting,2,X,[orch/phsu],[sosy],D04.210.500.745.432.769.344;D04.210.500.908.238,C23.888.821.937
be6b2481-20a3-4a43-89fa-104f8fa78dac,C0677960,C4048329,may augment ,T-Cell Depletion Therapy,Immunosuppression,2,X,[topp],[dsyn],,E02.095.465.425.450;E05.478.610
d952b372-a15d-4ca1-8205-a3d4a8d271ce,C0024264,C0301872,are vital in ,Lymphocyte,Immune response,2,X,[cell],[ortf],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
2306092e-9244-4331-9088-e227f89cac6f,C0003297,C0206750,are available during ,Antiemetics,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.696.663.050.030;D27.505.954.427.095;D27.505.954.483.200,C02.782.600.550.200
1220e694-c6dc-4a59-85ed-0490bad4e4f1,C2948600,C0015397,describe demographics of patients with ,Aim,Disorder of eye,1,X,[inch/phsu],[dsyn],,C11
ad293cfd-921f-4987-9328-350b12e45b3d,C0242781,C4287874,mainly occurs by ,disease transmission,Droplet Transmission,4,X,[patf],[patf],N06.850.310,
e15bf967-991b-44dd-a187-8962e44cf857,C0032105,FFP2,Reprocess FFP2,Plasma,FFP2,2,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
e15bf967-991b-44dd-a187-8962e44cf857,C0032105,FFP2,allows to FFP2,Plasma,FFP2,1,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
2e7dc52a-1e45-465f-9d09-de9902cafe3e,C0038280,FFP2,Reprocess FFP2,Sterilization for infection control,FFP2,2,X,[topp],????,N06.850.780.200.450.850,????
2e7dc52a-1e45-465f-9d09-de9902cafe3e,C0038280,FFP2,allows to FFP2,Sterilization for infection control,FFP2,1,X,[topp],????,N06.850.780.200.450.850,????
0fd11c89-52ef-4de7-9f91-310ccbd7b08a,C0011121,C0017110,were further checked by single ,Decontamination,Gases,4,X,[topp],[chvs],N06.850.780.325,D01.362
0fd11c89-52ef-4de7-9f91-310ccbd7b08a,C0011121,C0017110,were further checked for residual ,Decontamination,Gases,1,X,[topp],[chvs],N06.850.780.325,D01.362
291b476c-fde9-4105-a568-02e478a815b5,C0011121,C0011744,were further checked for residual ,Decontamination,Deuterium,8,X,[topp],[elii],N06.850.780.325,D01.268.406.500;D01.362.340.500;D01.496.289;x.x.x.x
c5f2fa76-3ad7-4c52-9142-e5fd6eb82d31,C0011121,C0389006,were further checked for residual ,Decontamination,Growth Arrest-Specific Protein 2,8,X,[topp],[aapp/bacs],N06.850.780.325,
53128343-7fa4-4289-8685-af0abf6489b1,C0011121,C0031180,were further checked for residual ,Decontamination,Peroxides,12,X,[topp],[inch],N06.850.780.325,D01.248.497.158.685.750;D01.339.431.374;D01.650.550.750;D02.389.338
11f7450e-b98f-4535-b179-5cd801498706,C0015376,C0004178,was quantitatively tested with 10 test persons in ,Extravasation,Atmosphere planetary,4,X,[patf],[npop],,G16.500.275.063;N06.230.300.100
1e0ed43c-76e8-46ed-804f-38d5045cc25e,C0015376,C0030415,was quantitatively tested with 10 test persons in ,Extravasation,Paraffin,4,X,[patf],[bodm/orch],,D02.455.612
ed408b94-5c61-4d32-acc2-2dafccf42316,C0036572,C0015376,was calculated as inverse of total inward ,Seizures,Extravasation,1,X,[sosy],[patf],C10.597.742;C23.888.592.742,
23a11d4a-ad87-4af8-91f1-68030a6705f9,C0118522,C0020964,regulates expression of wide array of genes involved in ,GA-Binding Protein Transcription Factor,Immunity,2,X,[aapp/bacs],[phsf],D12.776.260.615.249;D12.776.930.618.249,G12.450
43260321-b3df-49d4-a225-097da30919d9,C0118522,C0007634,regulates ,GA-Binding Protein Transcription Factor,Cells,2,X,[aapp/bacs],[cell],D12.776.260.615.249;D12.776.930.618.249,A11
a9fbc4d8-a456-4314-8a41-a641ba40cbb6,C0021966,C0036572,assumed that as ,Iodides,Seizures,1,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C10.597.742;C23.888.592.742
1cfa1d9c-9a60-4549-8418-1a0dcf668607,C0021079,C1520005,contributes to ,Therapeutic immunosuppression,Viral Pathogenesis,4,X,[topp],[patf],E02.095.465.425.450;E05.478.610,
c8e4dd26-8386-4a41-8f4e-4e2ae9297342,C0002518,C1175743,is with ,Amino Acid Sequence,SARS coronavirus,2,X,[amas],[virs],G02.111.570.060;L01.453.245.667.060,B04.820.504.540.150.113.937
62fe4493-4b96-4e15-9165-09d62113876d,orf6,C1512835,demonstrated strongest ,orf6,Interferon Suppression,2,X,????,[phsf],????,
2a36b2c5-097c-420a-b9e6-3a1d7f741ce1,orf6,C0042736,demonstrated Interferon Suppression Among,orf6,Viral Proteins,2,X,????,[aapp/bacs],????,D12.776.964
520d3849-c262-45ce-b545-2431aaeb5ca0,C1175743,xenti,may may considered for development of intranasal live but xenti ,SARS coronavirus,xenti,2,X,[virs],????,B04.820.504.540.150.113.937,????
3ec99533-c30a-42ce-b9b0-2855ca7a96b0,C0230425,C4554533,had descending ,Structure of right thigh,Trend:Type:Point in time:^Patient:Nominal,3,X,[bpoc],[clna],,
bb4437f9-99fe-41d4-814b-7cd918f8328d,C3652465,C0017262,turns on ,Interferon,Gene Expression,2,X,[aapp/imft/phsu],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G05.297
f7169629-4166-4251-906d-177079aa0be6,C0206750,C0027270,also induces severe attack on ,Coronavirus Infections,Nicotinamide adenine dinucleotide (NAD),2,X,[dsyn],[bacs/nnon/phsu],C02.782.600.550.200,D03.633.100.759.646.138.694;D08.211.589;D13.695.667.138.694;D13.695.827.068.694
cd2237dd-fd30-4ee4-b3df-0cbcfe41450b,C0020281,C0450442,was minimally effective as viricidal ,Hydrogen Peroxide,Agent,2,X,[inch/irda/phsu],[chvf],D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253,
818e8276-83f5-441c-8f6c-d570ef769643,C1882955,C0020281,is in range of may preferred over ,Rinsing,Hydrogen Peroxide,1,X,[acty],[inch/irda/phsu],,D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253
5c194848-4041-4e09-b01c-dd30227a9e7d,C1882955,C0032857,is with diluted ,Rinsing,Povidone-Iodine,1,X,[acty],[orch/phsu],,D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745
d92debca-18f9-49a4-aaf4-18f03900cc0d,C1305855,C0007222,higher prevalence of ,Body mass index,Cardiovascular Diseases,1,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C14
bd147635-34c3-4a88-830f-932dc443bc55,C1305855,C0020538,higher prevalence of ,Body mass index,Hypertensive disease,1,X,[clna],[dsyn],E01.370.600.115.100.125;E05.041.124.125;G07.100.100.125;N06.850.505.200.100.175,C14.907.489
0e4eaceb-f179-4d93-be99-8812ae7cdc30,C1175743,N95,has caused severe shortage of N95 ,SARS coronavirus,N95,1,X,[virs],????,B04.820.504.540.150.113.937,????
b39687f8-27b5-463e-92f3-d7237877d8b6,C0011121,C0038280,must result in ,Decontamination,Sterilization for infection control,4,X,[topp],[topp],N06.850.780.325,N06.850.780.200.450.850
0e98fc07-bfde-417f-a533-6669d4de6433,C0206390,C1175743,surrogate for ,Phage MS2,SARS coronavirus,1,X,[virs],[virs],B04.123.205.600.500;B04.123.691.600.500;B04.820.410.500,B04.820.504.540.150.113.937
bb03f4a7-21a5-4c09-906b-83d17d568d93,C0543467,C0206058,plummeted due to reduction in ,Operative Surgical Procedures,Elective Surgical Procedures,2,X,[topp],[topp],E04,E04.249
66cfb3b7-0c83-41d5-acb9-5054d6eb2088,C1523935,C1175743,fight ,cellular catabolic process,SARS coronavirus,1,X,[celf],[virs],,B04.820.504.540.150.113.937
2c0fc2d0-5836-4e0c-b199-e82221c35b18,C1523935,C0004391,known as ,cellular catabolic process,Autophagy,2,X,[celf],[celf],,G04.146.399;G04.417.350.091
8aac9172-396d-45f5-9547-9ff52e17e60d,C1523935,C0206419,fight novel ,cellular catabolic process,Genus: Coronavirus,1,X,[celf],[virs],,B04.820.504.540.150
d5a579b5-6e16-44be-a422-753c6aacc502,C0034019,C1947932,would reduce risk of ,public health medicine (field),Smear - instruction imperative,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
c6062887-0f60-4652-90cc-90d26fd1070e,C0010076,C1706079,had more evidence of physiologic disturbances on ,Coronaviridae,Arrival - action,1,X,[virs],[acty],B04.820.504.540,
7ea44e4b-594c-4eae-91a7-b45f4ae9b348,C0012634,C1706079,had more evidence of physiologic disturbances on ,Disease,Arrival - action,1,X,[dsyn],[acty],C23.550.288,
ffffd9f0-bbad-4465-b32c-8ae32bbeb5b1,C0206419,C0439056,was positive for ,Genus: Coronavirus,Throat swab sample,1,X,[virs],[bdsu],B04.820.504.540.150,
a64c7b36-9b77-4865-9fe0-4ab58e0971a5,=-RRB-,C0032285,presented involvement Among those with ,=-RRB-,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
368b3f6f-3aaa-47f7-ad51-3c160031d002,=-RRB-,C0206061,had ,=-RRB-,Pneumonia Interstitial,2,X,????,[dsyn],????,C08.381.483
55b037e1-7860-445a-a558-7c7fb8c2f293,C0599878,C0030755,is in ,disease characteristic,Pediatrics,1,X,[patf],[bmod],,H02.403.670
e07c5afe-5956-4ac2-98e8-bf97abcfc69e,C3826426,C0012634,effective treatment of ,Dynamics,Disease,1,X,[npop],[dsyn],,C23.550.288
d1f73d20-902b-489f-9a60-c1998d41b69b,C1539479,C0013227,is in aquatic compartments of ,FATE1 gene,Pharmaceutical Preparations,1,X,[gngm],[phsu],,D26
94c9c1b1-3f9a-49fe-abaf-f3e0318e6528,C0016510,C0206419,be redefined during ,Foot Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C05.360;C17.800.321,B04.820.504.540.150
3ed8bf14-2f7a-4b2f-a230-8d99302bdf9a,C0206172,C0206419,been how affected by ,Diabetic Foot,Genus: Coronavirus,2,X,[dsyn],[virs],C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250,B04.820.504.540.150
d97f52d6-fee6-4294-a325-cc6ac735cd09,SEIR,C0948998,is well-known method used in simulations of ,SEIR,Viral Contagious disease,2,X,????,[dsyn],????,
c478affa-ff68-4618-86d4-e82150cbd219,SEIRS,C0012634,is with additional exit ,SEIRS,Disease,2,X,????,[dsyn],????,C23.550.288
53875623-dcff-4df8-9d6f-ac84a5caca5d,C1175743,C0878544,has shown association with acute myocardial injury ,SARS coronavirus,Cardiomyopathies,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.280.238
387e1e22-40c2-4b63-bf07-53f0875e95ee,C0009450,C0878544,has shown association with acute myocardial injury ,Communicable Diseases,Cardiomyopathies,2,X,[dsyn],[dsyn],C01.539.221,C14.280.238
db53cd99-82a5-4b86-85f4-2328aa076f24,C1175743,C0027059,has shown association with acute myocardial injury ,SARS coronavirus,Myocarditis,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C14.280.238.625
9c43af0c-8abe-491d-be94-7a27092fe630,C0009450,C0027059,has shown association with acute myocardial injury ,Communicable Diseases,Myocarditis,2,X,[dsyn],[dsyn],C01.539.221,C14.280.238.625
758d8f6a-d67b-4c70-bbec-ebb92a82c769,C0161816,C0206419,also occur in ,Cardiac complication,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
f2e385c4-8ad6-4ffc-a907-7a94c88c2c97,C0161816,C1155266,occur because of high ,Cardiac complication,inflammatory response,4,X,[patf],[patf],,
2734939a-0239-4f36-8a2b-abd1431e8a6c,C0021822,C3888108,evaluating resources in ,Interview,Import into cell,1,X,[acty],[celf],E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,
2734939a-0239-4f36-8a2b-abd1431e8a6c,C0021822,C3888108,evaluating obstacles in ,Interview,Import into cell,1,X,[acty],[celf],E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,
57e5c0da-e600-49b3-b1d4-a70156b0f14f,C0023660,C0003209,is known for its ,Lidocaine,Anti-Inflammatory Agents,1,X,[orch/phsu],[phsu],D02.065.199.092.500;D02.092.146.113.092.500,D27.505.954.158
9a5dac73-2779-4803-8545-401b929349a3,C0023660,C0010200,reduce ,Lidocaine,Coughing,1,X,[orch/phsu],[sosy],D02.065.199.092.500;D02.092.146.113.092.500,C08.618.248;C23.888.852.293
fd2f33c0-ea8b-4184-b4d4-d029f68f1c11,C0023660,C0037090,improve ,Lidocaine,Signs and Symptoms Respiratory,1,X,[orch/phsu],[sosy],D02.065.199.092.500;D02.092.146.113.092.500,C23.888.852
87079610-6017-412b-ab57-04b2c5b4d4fd,C0023660,C0079189,reducing ,Lidocaine,cytokine,1,X,[orch/phsu],[aapp/imft],D02.065.199.092.500;D02.092.146.113.092.500,D12.644.276.374;D12.776.467.374;D23.529.374
83d674e2-28be-43b6-b4f3-2ee9c0952226,C0023660,C0024109,protecting patients ,Lidocaine,Lung,1,X,[orch/phsu],[bpoc],D02.065.199.092.500;D02.092.146.113.092.500,A04.411
b3d89185-e2df-4450-9e3e-0fb7042bc421,C0023660,C0206419,is in ,Lidocaine,Genus: Coronavirus,1,X,[orch/phsu],[virs],D02.065.199.092.500;D02.092.146.113.092.500,B04.820.504.540.150
d6a88bf9-9a0e-4ddf-a307-7f50d9433851,C0035028,C0086418,can can viewed as Global ,Relaxation,Homo sapiens,2,X,[acty],[humn],I03.450.769,B01.050.150.900.649.313.988.400.112.400.400
71b724fe-f953-4e6c-aaae-29e641599f49,C1175743,C1522002,of M Protein multiple myeloma is,SARS coronavirus,RNA Recognition Motif,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,G02.111.570.820.709.275.500.869.500
b8e62904-65e8-4e94-b6f7-79cb570bf9ea,C0275522,C0206750,Patients with ,Asymptomatic Infections,Coronavirus Infections,2,X,[dsyn],[dsyn],C23.550.291.187.500,C02.782.600.550.200
b8e62904-65e8-4e94-b6f7-79cb570bf9ea,C0275522,C0206750,constitute substantial component of ,Asymptomatic Infections,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.187.500,C02.782.600.550.200
88a869aa-815e-4540-8a37-86a11cba99e8,C0042762,C0020517,management of patients with ,Science of Virology,Hypersensitivity,2,X,[bmod],[patf],H01.158.273.540.859,C20.543
89d69090-14f8-42cc-9acd-c56d163292bf,CT/MR,C0265085,showed common pattern ,CT/MR,Cortical hemorrhage,3,X,????,[patf],????,
d6e3d966-974b-40c7-b7cb-b08663af52c7,C0304925,C0003402,is Acute-Phase Proteins with,Albumin Human USP,Antioxidants,1,X,[aapp/phsu],[phsu],D12.776.034.841.603;D12.776.124.727.906,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
8b213fe4-b107-418c-a91c-1f387e2eafe5,C0001347,C0003402,is with ,Acute-Phase Proteins,Antioxidants,1,X,[aapp/bacs],[phsu],D12.776.124.050,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
3936101d-8509-4e73-8850-02e89bb8f514,C0304925,C0001347,is ,Albumin Human USP,Acute-Phase Proteins,1,X,[aapp/phsu],[aapp/bacs],D12.776.034.841.603;D12.776.124.727.906,D12.776.124.050
3836195a-f8ed-4fcc-87b3-855292630330,C0038952,C0206750,is in ,Continuance of life,Coronavirus Infections,1,X,[acty],[dsyn],I03.784,C02.782.600.550.200
d55fcddb-b212-4151-ba98-e605a919d8f4,C0001924,C1565830,were At ,Albumins,PTGS1 protein human,1,X,[aapp/bacs],[aapp/enzy],D12.776.034,x.x.x.x
fd394fea-ceec-4f4e-9bea-3057c5dcd986,C0304925,C0206750,identify patients at risk of death in ,Albumin Human USP,Coronavirus Infections,1,X,[aapp/phsu],[dsyn],D12.776.034.841.603;D12.776.124.727.906,C02.782.600.550.200
a1fe3ddc-8076-49c2-9595-f1a4ecd4fce0,C0199848,C0206750,for Coronavirus vaccination is causative agent of,Coronavirus vaccination,Coronavirus Infections,4,X,[topp],[dsyn],,C02.782.600.550.200
b454b7a1-acff-40cd-833e-cb719f80cbf4,C0042742,C0086418,have have licensed for use in ,Viral Vaccines,Homo sapiens,2,X,[imft/phsu],[humn],D20.215.894.899,B01.050.150.900.649.313.988.400.112.400.400
31c79b6e-b521-4b4e-a68a-96f603302f53,EULAR,C1175743,address several aspects of ,EULAR,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
3e4f0cf1-2861-4d18-b374-0aa71a712c53,C0022674,C1175743,targeted by ,Renal tubule structure,SARS coronavirus,1,X,[bpoc],[virs],A05.810.453.736.560,B04.820.504.540.150.113.937
3e4f0cf1-2861-4d18-b374-0aa71a712c53,C0022674,C1175743,be potential ,Renal tubule structure,SARS coronavirus,1,X,[bpoc],[virs],A05.810.453.736.560,B04.820.504.540.150.113.937
1e747a37-cbca-4ce4-9e1e-ef37fb08e132,C0022674,C1819995,be potential ,Renal tubule structure,Host Cell,1,X,[bpoc],[celc],A05.810.453.736.560,
f025f862-aeaa-4ebb-93ac-103e0013f635,C0022709,2DCR,was higher compared to that in 2DCR ,Peptidyl-Dipeptidase A,2DCR,3,X,[aapp/enzy/imft],????,D08.811.277.656.350.350.687,????
3c300862-3e64-4a15-ba5a-38c6292a6f62,C0022709,C0012634,was higher compared to that in 2DCR ,Peptidyl-Dipeptidase A,Disease,3,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C23.550.288
3c300862-3e64-4a15-ba5a-38c6292a6f62,C0022709,C0012634,may may ,Peptidyl-Dipeptidase A,Disease,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C23.550.288
e38d16d6-cad1-4978-9cf6-25e5ce6766b0,C0206419,C1167622,using high-throughput ,Genus: Coronavirus,Binding (Molecular Function),2,X,[virs],[moft],B04.820.504.540.150,
0b0617c0-ea93-46e1-ad54-9173291e3bb7,C0206419,C1510827,using high-throughput ,Genus: Coronavirus,Affinity,1,X,[virs],[npop],B04.820.504.540.150,
cf80eb94-dba1-42cc-9229-58ef920a1afe,C0012634,C0599779,was run on ,Disease,Animal Model,1,X,[dsyn],[anim],C23.550.288,E05.598
c9237fbc-a01b-43b9-86bf-ac4f94abcefa,Cov2,C0007634,uses Peptidyl-Dipeptidase A receptor as entry point to,Cov2,Cells,1,X,????,[cell],????,A11
868f46b9-1985-4c15-8eeb-c0a6a6763c38,Cov2,C0022709,uses ,Cov2,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
780df06a-4a58-4cf0-9852-37aafb2a569c,Cov2,C0597357,uses ,Cov2,receptor,1,X,????,[aapp/rcpt],????,
6e9a5cc7-76f8-409b-b972-eab03ef8ebd2,C0815017,C0206419,was associated with higher ,Angiotensin Receptor Antagonists,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.519.162,B04.820.504.540.150
823e6c30-950c-4546-925b-a3879719ee76,C2948600,C0683325,investigate ,Aim,clinical aspects,2,X,[inch/phsu],[clna],,
823e6c30-950c-4546-925b-a3879719ee76,C2948600,C0683325,describe specific ,Aim,clinical aspects,1,X,[inch/phsu],[clna],,
823e6c30-950c-4546-925b-a3879719ee76,C2948600,C0683325,systematically review main ,Aim,clinical aspects,1,X,[inch/phsu],[clna],,
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,investigate ,Aim,SARS coronavirus,2,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,minimize risk of transmission of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,summarize data on treatment of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,determine prevalence of symptoms among laboratory-confirmed ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,evaluate novel immunoassays for detection of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
2bf480a6-79e2-4912-81da-c631bea4aa39,C2948600,C1175743,examine seroprevalence of ,Aim,SARS coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150.113.937
43f4bcc9-7ed2-4843-82f0-dcddd892984c,C0683325,C1175743,is with ,clinical aspects,SARS coronavirus,2,X,[clna],[virs],,B04.820.504.540.150.113.937
6fefcb4e-4266-4a4b-809e-a6aff154aa3b,C0023530,C0004002,were For laboratory result indicators for pediatric inpatients followed by ,Leukopenia,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.546,D08.811.913.477.700.225
6fefcb4e-4266-4a4b-809e-a6aff154aa3b,C0023530,C0004002,were For laboratory result indicators followed by high ,Leukopenia,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.546,D08.811.913.477.700.225
a62ad928-360d-4638-916b-67454b2dcb00,C0024282,C0004002,were For laboratory result indicators for inpatients followed by ,Lymphocytosis,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.475.604,D08.811.913.477.700.225
a62ad928-360d-4638-916b-67454b2dcb00,C0024282,C0004002,were For laboratory result indicators followed by high ,Lymphocytosis,Aspartate Transaminase,1,X,[dsyn],[aapp/enzy],C15.378.553.475.604,D08.811.913.477.700.225
3de431ac-57fb-49b2-a019-727ad2b14306,C1135927,C0026769,have developed protocol for management of ,Immunity Herd,Multiple Sclerosis,2,X,[phsf],[dsyn],G12.450.400,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
485d3984-9b05-4eb5-8243-f3d2c6475c36,C0042075,C1704272, includes ,Urologic Diseases,Benign Prostatic Hyperplasia,2,X,[dsyn],[dsyn],C12.777;C13.351.968,C12.294.565.500
2adefc94-28d2-4d1e-911f-b3c2662d885c,C0015967,C3714514,can occur along with urological ,Fever,Infection,1,X,[sosy],[patf],C23.888.119.344,C01.539
ed74b65e-3c4e-4c0c-a05b-5248149379c5,C0010076,C1175743,designated SARS coronavirus as,Coronaviridae,SARS coronavirus,2,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150.113.937
ed74b65e-3c4e-4c0c-a05b-5248149379c5,C0010076,C1175743,find ,Coronaviridae,SARS coronavirus,1,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150.113.937
20802324-a03f-4d6f-8f3d-f8aa812b8faa,C0010076,C0206419,designated SARS coronavirus as,Coronaviridae,Genus: Coronavirus,1,X,[virs],[virs],B04.820.504.540,B04.820.504.540.150
f6a0d127-54cb-4a60-af84-54a397aacd35,C0008139,C4086523,being ,Chiroptera,Intermediate Host,1,X,[mamm],[orgm],B01.050.150.900.649.313.937,
6272f11c-c926-42ec-8ef7-a14de1d82962,COVID-19,C1706374,has led by end of ,COVID-19,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],C000657245,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
6272f11c-c926-42ec-8ef7-a14de1d82962,COVID-19,C1706374,were collected up to ,COVID-19,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],C000657245,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
8a9aacb1-b23e-4954-98dd-78926bad65a3,C0003451,C3652465,included abidol ,Antiviral Agents,Interferon,2,X,[phsu],[aapp/imft/phsu],D27.505.954.122.388,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
27dc44af-6039-464c-9229-287026f01072,C0003451,C0939237,included abidol ,Antiviral Agents,lopinavir / Ritonavir,2,X,[phsu],[phsu],D27.505.954.122.388,
bfff2802-0874-4815-93fb-98bc9e1a44be,C0003451,abidol,included abidol ,Antiviral Agents,abidol,2,X,[phsu],????,D27.505.954.122.388,????
3b80becb-50c2-42ab-9397-292b04c10bfe,C0003451,C0035525,included abidol ,Antiviral Agents,Ribavirin,2,X,[phsu],[nnon/phsu],D27.505.954.122.388,D13.570.800.790
ecbeb7fd-740b-42ae-bf0d-71b9d61fb978,C0085278,C0005516,Obtaining serial ,Antiphospholipid Syndrome,Biological Markers,1,X,[dsyn],[clna],C20.111.197,D23.101
3a3d8121-bcea-46dc-8ad5-f98fb3fa2ee1,C0085278,C0162595,Obtaining Biological Markers in conjunction with,Antiphospholipid Syndrome,Antiphospholipid Antibodies,1,X,[dsyn],[aapp/imft],C20.111.197,D12.776.124.486.485.114.323.210;D12.776.124.790.651.114.323.210;D12.776.377.715.548.114.323.210
5c586ec5-a567-41b9-b0ec-852a5f2fdaa2,C0085278,C1175743,observed in ,Antiphospholipid Syndrome,SARS coronavirus,1,X,[dsyn],[virs],C20.111.197,B04.820.504.540.150.113.937
c60ccae5-f283-4b4c-8476-fcf48ba01789,C0010076,C0056912,find ,Coronaviridae,cytidylyl-3'-5'-guanosine,1,X,[virs],[bacs/nnon],B04.820.504.540,x.x.x.x
719113d1-a5f9-4747-8340-73c601cc9dfe,C0056912,C0242972,are Diet Protein-Restricted for spike,cytidylyl-3'-5'-guanosine,Diet Protein-Restricted,2,X,[bacs/nnon],[topp],x.x.x.x,E02.642.249.280;G07.203.650.240.280
affee252-e0d5-4e15-9cc3-65f060f66402,C0206419,HKU1, includes HKU1,Genus: Coronavirus,HKU1,2,X,[virs],????,B04.820.504.540.150,????
ff429bcf-13a2-442b-a28a-8338e49f2c8a,C0206419,3-end,are greater for 3-end ,Genus: Coronavirus,3-end,1,X,[virs],????,B04.820.504.540.150,????
bf5b9fd6-2392-4d42-bb55-dad5d40ad6ef,C0206419,C0042720,are greater for 3-end ,Genus: Coronavirus,Viral Genome,1,X,[virs],[gngm],B04.820.504.540.150,G05.360.340.358.840
d6998f15-c9c0-409d-94bd-6522538a874d,HKU1,3-end,are greater for 3-end ,HKU1,3-end,1,X,????,????,????,????
007c7777-8eb1-4ed4-997d-4599f7be28c3,HKU1,C0042720,are greater for 3-end ,HKU1,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
f4cbef0b-81b0-43d0-ade5-1acdf7e36d10,C1519323,C0056912,seem driven by value of ,Silent Mutation,cytidylyl-3'-5'-guanosine,1,X,[genf],[bacs/nnon],G05.365.590.803,x.x.x.x
f4cbef0b-81b0-43d0-ade5-1acdf7e36d10,C1519323,C0056912,driven by high value of ,Silent Mutation,cytidylyl-3'-5'-guanosine,1,X,[genf],[bacs/nnon],G05.365.590.803,x.x.x.x
4b1b2d85-40d2-41c6-91f3-54fc3eb83058,C1519323,C0065827,seem driven by value of ,Silent Mutation,Measles Virus Nucleoprotein,1,X,[genf],[aapp/bacs],G05.365.590.803,x.x.x.x
4b1b2d85-40d2-41c6-91f3-54fc3eb83058,C1519323,C0065827,driven by high value of ,Silent Mutation,Measles Virus Nucleoprotein,1,X,[genf],[aapp/bacs],G05.365.590.803,x.x.x.x
cb3565d2-5d97-4e58-a000-7895c8f8f82e,C1519323,C0012476,Using application on ,Silent Mutation,Dinucleoside Phosphates,1,X,[genf],[nnon],G05.365.590.803,D13.695.250
f3aa6a6b-3276-43e2-a010-388a1759f1e9,C0056912,C0065827,is in ,cytidylyl-3'-5'-guanosine,Measles Virus Nucleoprotein,1,X,[bacs/nnon],[aapp/bacs],x.x.x.x,x.x.x.x
73c8afee-f9f9-48fb-ab81-31947958a524,C1519323,C1707391,Using new application of ,Silent Mutation,Choose (action),1,X,[genf],[acty],G05.365.590.803,
f3817b9b-a242-45d7-afd0-61139ad747a7,C1514562,C1167622,match recently identified ,Protein Domain,Binding (Molecular Function),1,X,[amas],[moft],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
9485f785-73f7-4c7b-ac57-d0f0cfce1838,C1514562,C1428222,match recently identified ,Protein Domain,ZC3HAV1 gene,1,X,[amas],[gngm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
ae0d33a0-c283-44c8-b243-672e9dd84099,subtype,C0037090,is with prominent ,subtype,Signs and Symptoms Respiratory,2,X,????,[sosy],????,C23.888.852
3b4afe96-1357-457a-a076-e6d5f7936dbb,C0037090,C1327613,is characterized by ,Signs and Symptoms Respiratory,fear response,2,X,[sosy],[phsf],C23.888.852,
f18ed9f2-84cd-43ea-bcfc-93a7bfcb6159,C0037090,C0036658,is characterized by ,Signs and Symptoms Respiratory,Esthesia,2,X,[sosy],[ortf],C23.888.852,F02.830.816;G11.561.790
eedfc8e8-0c0f-4110-ac1b-acd1223d45e3,C0037090,C0010200, includes ,Signs and Symptoms Respiratory,Coughing,2,X,[sosy],[sosy],C23.888.852,C08.618.248;C23.888.852.293
54e0499b-0481-4f07-8b6c-c5951655b7ba,C0037090,C0221423,are Indeed associated with poor ,Signs and Symptoms Respiratory,Illness (finding),2,X,[sosy],[sosy],C23.888.852,
7a03db49-0527-4427-a7b7-52059169948e,C0010200,C0221423,are Indeed associated with poor ,Coughing,Illness (finding),2,X,[sosy],[sosy],C08.618.248;C23.888.852.293,
317e2751-cfee-46a4-a664-1bca064be5e1,C1099456,C0030319,are First line treatment for,Escitalopram,Panic Disorder,2,X,[orch/phsu],[mobd],D02.092.831.170;D02.626.320;D03.633.100.127.187,F03.080.700
7a21ab77-63c1-4adf-bce5-fd17bc38e068,C1099456,C1708063,are ,Escitalopram,First line treatment,2,X,[orch/phsu],[topp],D02.092.831.170;D02.626.320;D03.633.100.127.187,
317da788-5c66-4221-8fbd-0281edd8fbd2,C0020404,C0150135,aiming at ,Hydroxyzine,Alleviating anxiety,2,X,[orch/phsu],[topp],D03.383.606.515,
7542dbed-376b-4716-9a7a-615db11f98d6,C0079460,C0003451,profound effects on ,Granulocyte-Macrophage Colony-Stimulating Factor,Antiviral Agents,8,X,[aapp/imft],[phsu],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,D27.505.954.122.388
586bdb56-bdcb-4f6b-b203-1d30464e2a39,C0079460,C0020964,profound effects on ,Granulocyte-Macrophage Colony-Stimulating Factor,Immunity,8,X,[aapp/imft],[phsf],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,G12.450
43e31865-3a14-4226-a1c9-e11464dbe0b2,C0079460,C0189537,can promote ,Granulocyte-Macrophage Colony-Stimulating Factor,Repair of lung,4,X,[aapp/imft],[topp],D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375,
5773d24d-355d-4462-aec4-50fcab9a3de3,C0216231,C0038164,is made form of naturally-occurring,sargramostim,Staphylococcal Protein A,8,X,[aapp/imft/phsu],[aapp/imft/irda],x.x.x.x,D12.776.097.820;D23.050.161.821
9f91114b-0a74-4ac8-8690-f127fd6f98b6,C0216231,C0079460,is made form of naturally-occurring,sargramostim,Granulocyte-Macrophage Colony-Stimulating Factor,4,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.644.276.374.410.240.375;D12.776.395.240.300;D12.776.467.374.410.240.375;D23.529.374.410.240.375
2cc52060-9135-4e29-b962-20292c03bf3e,COVID-19,C1524029,is with ,COVID-19,Mouse MIN NOS,2,X,[virs],[neop],C000657245,
974e2da7-9213-4d81-9d6d-5a31a1096a7e,C0216231,C0242656,will Upon g/m ,sargramostim,Disease Progression,7,X,[aapp/imft/phsu],[patf],x.x.x.x,C23.550.291.656
b6b1b5f6-59f5-4566-89ac-ac10a5b4a7b2,C0282636,C0184661,primary endpoint of ,Cell Respiration,Interventional procedure,3,X,[celf],[topp],G03.197;G04.270,
b2afece1-926d-4cdc-b848-6829ce889a4b,C2949735,C1856053,started on ,Recruitment,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[acty],[dsyn],,x.x.x.x
542c5623-10e0-46a7-808d-c3ccb2c1e1bf,C0003316,C0022709,blocks ,Epitopes,Peptidyl-Dipeptidase A,2,X,[imft],[aapp/enzy/imft],D23.050.550,D08.811.277.656.350.350.687
035b6e57-c319-4661-a583-28c932f69252,6LU7,C0039082,identity with ,6LU7,Syndrome,2,X,????,[dsyn],????,C23.550.288.500
9d3eb9d5-13e4-4567-b8d5-5303aa2dc9a9,6LU7,C0030946,identity with ,6LU7,Endopeptidases,4,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
7ccc69fd-a55c-4595-8366-2d20dc7235f9,C0022709,C0034800,is in conveyor ,Peptidyl-Dipeptidase A,Receptors Cell Surface,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750
6a120f90-2d64-4799-a976-41e16461670f,C0242781,C0035253,differ considerably from those in ,disease transmission,Rest,2,X,[patf],[dora],N06.850.310,I03.450.769.647
3c0b8737-dcb1-40ea-8af5-42a90251863c,C3826426,C0035253,differ considerably from those in ,Dynamics,Rest,2,X,[npop],[dora],,I03.450.769.647
ad238970-7c52-4637-ab24-555e9c576e13,C0543467,twith,be how deal twith,Operative Surgical Procedures,twith,2,X,[topp],????,E04,????
0cb6f7f2-1837-444e-9171-70d737250682,C0441655,twith,be how deal twith,Activities,twith,1,X,[acty],????,,????
2ce81150-6495-400d-be42-6e34bce9f491,nt,C0398623,have COVID ,nt,Thrombophilia,2,X,????,[dsyn],????,C15.378.925
554f3450-a40d-4d35-8b50-87e32527b333,nt,C0034065,have COVID ,nt,Pulmonary Embolism,2,X,????,[patf],????,C08.381.746;C14.907.355.350.700
d790476a-eb0c-4713-96d0-4812e32c4617,nt,COVID,have COVID ,nt,COVID,2,X,????,????,????,????
861617bf-4229-4cf6-a42a-fff2e65f73c3,nt,C3714514,have COVID ,nt,Infection,1,X,????,[patf],????,C01.539
5b129a17-1826-436b-a945-155ef5390b73,C0011849,C0008679,is ,Diabetes Mellitus,Chronic disease,1,X,[dsyn],[dsyn],C18.452.394.750;C19.246,C23.550.291.500
cd35da1c-18f7-4e5b-a014-2f546644f68d,C0011849,C0596620,is ,Diabetes Mellitus,glucose metabolism,2,X,[dsyn],[moft],C18.452.394.750;C19.246,
d36acd52-ddb0-4a83-9a68-f6d48d895386,C0008679,C0012655,is associated with increased ,Chronic disease,Disease susceptibility,1,X,[dsyn],[clna],C23.550.291.500,C23.550.291.687;G07.100.250
c7c455ef-cd52-4b3d-b918-978959b79ea4,C0008679,C3714514,is associated with increased ,Chronic disease,Infection,1,X,[dsyn],[patf],C23.550.291.500,C01.539
c9934747-ed50-48d6-83fa-ac07ac2c252f,C0020456,C3714514,worsens course of ,Hyperglycemia,Infection,1,X,[dsyn],[patf],C18.452.394.952,C01.539
c9e00010-a524-4914-acb2-ddeeae3803fe,C1516048,C0086418,is in normal ,Assessed,Homo sapiens,1,X,[acty],[humn],,B01.050.150.900.649.313.988.400.112.400.400
a5b64712-0a9a-4af1-831d-fb0ebf090525,C1516048,C1292563,is in normal ,Assessed,Myocardial specimen,1,X,[acty],[tisu],,
99ebca38-42d9-418f-a310-714b900d1100,C0022709,C1292563,is in normal ,Peptidyl-Dipeptidase A,Myocardial specimen,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,
87731460-3e53-48f4-b4f3-3ed15d4f0061,C1516048,C0012173,is in normal ,Assessed,Dietary Fiber,1,X,[acty],[food],,D09.301.416;G07.203.300.400;J02.500.400
6334d6a0-2bbf-4797-b426-bb3ac5b9549e,C0022709,C0012173,is in normal ,Peptidyl-Dipeptidase A,Dietary Fiber,1,X,[aapp/enzy/imft],[food],D08.811.277.656.350.350.687,D09.301.416;G07.203.300.400;J02.500.400
94e3ba33-1d0a-4acc-aaad-046d56832198,C0370003,C1999230,across technologies is ,Specimen,Providing (action),3,X,[sbst],[acty],,
719fae79-f4c8-4b41-86dc-0eba05e066e4,C0683201,C3652465,is in ,specific immunity,Interferon,2,X,[ortf],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
8538a7ff-68a4-4b9e-9ec1-651ccb569b52,C0037090,C0206419,were suspected for ,Signs and Symptoms Respiratory,Genus: Coronavirus,1,X,[sosy],[virs],C23.888.852,B04.820.504.540.150
c405b066-500e-4784-96b8-5557581cefbf,C0017337,C0020517,was found most ,Genes,Hypersensitivity,3,X,[gngm],[patf],G05.360.340.024.340,C20.543
5002fd22-bf06-40b1-98f1-b6e0bc0b2f82,C1706005,C0020517,had ,CD40LG wt Allele,Hypersensitivity,2,X,[gngm],[patf],,C20.543
755d5542-a1c5-47fc-a356-c480a83ba73b,LFA,C0020517,had ,LFA,Hypersensitivity,2,X,????,[patf],????,C20.543
5685b8be-e0da-431c-ab07-f534da8d7b08,C0020517,7days,increased in patients with 7days ,Hypersensitivity,7days,4,X,[patf],????,C20.543,????
cfda3614-cb85-42dc-a49a-a852e98817cd,C0543467,C1882509,is considered as ,Operative Surgical Procedures,put - instruction imperative,2,X,[topp],[acty],E04,
00979050-0c95-496d-8a96-647aff4e73ac,C0543467,C0010356,is considered as ,Operative Surgical Procedures,Cross Infection,2,X,[topp],[patf],E04,C01.539.248;C23.550.291.875.500
a471d18a-1e86-4b3a-aaf9-2fcbe9113348,C1882509,C0010356,is with high risk of ,put - instruction imperative,Cross Infection,1,X,[acty],[patf],,C01.539.248;C23.550.291.875.500
7ea965ac-7ec6-4426-b4a6-9ed0be30b349,C0206750,C0277548,is in especially early phase of ,Coronavirus Infections,Epidemic disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
7ea965ac-7ec6-4426-b4a6-9ed0be30b349,C0206750,C0277548,is ongoing Epidemic disease of,Coronavirus Infections,Epidemic disease,3,X,[dsyn],[dsyn],C02.782.600.550.200,
34b1e7db-16a7-49c8-8e18-1b563cc8ee91,C0270724,C0206750,support health during ,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
34b1e7db-16a7-49c8-8e18-1b563cc8ee91,C0270724,C0206750,mitigate effect of ,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
34b1e7db-16a7-49c8-8e18-1b563cc8ee91,C0270724,C0206750,use Extracorporeal Membrane Oxygenation Biological Transport for,Infantile Neuroaxonal Dystrophy,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140.744,C02.782.600.550.200
1f0e27fe-c5d4-48d3-b579-ac0a87687006,C0206750,C0458827,can affect ,Coronavirus Infections,Airway structure,1,X,[dsyn],[bpoc],C02.782.600.550.200,
49f37a19-717f-4226-95aa-b8fba6b4a714,C0009450,C0079189,is characterized by overwhelming ,Communicable Diseases,cytokine,1,X,[dsyn],[aapp/imft],C01.539.221,D12.644.276.374;D12.776.467.374;D23.529.374
322ca4b4-9322-42c4-acf5-c47d5cc5742d,C0086418,C0018823,is with ,Homo sapiens,Heart Transplantation,1,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,E04.100.376.475;E04.928.220.390;E04.936.450.475
0668bdec-3356-4f74-a601-c6b0bfd93883,C1609165,C1999230,was in low ,tocilizumab,Providing (action),1,X,[aapp/imft/phsu],[acty],x.x.x.x,
81c55238-960e-4c06-8452-7b7c09d73cd0,PCR,C4282212,development of positive ,PCR,IgG.serum,2,X,????,[imft],????,
36205d3e-2b0b-4226-8823-0b5bc445b1a7,C4077748,C2983957,is Monoclonal Antibodies against,clazakizumab,Interleukin-6 human,1,X,[aapp/imft],[aapp/imft/phsu],x.x.x.x,
ce644147-49a9-4200-9472-310c47a080ea,C4077748,C0003250,is ,clazakizumab,Monoclonal Antibodies,1,X,[aapp/imft],[aapp/imft],x.x.x.x,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
3aff35fb-94cb-4940-8e51-b2c0a4c1aa8a,C2247677,C0206750,is in ,response to cytokine,Coronavirus Infections,1,X,[celf],[dsyn],,C02.782.600.550.200
08da54dd-ebfe-435c-aa46-35a6b449490d,C0206750,C0023882,know ,Coronavirus Infections,Little's Disease,2,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.140.140.254
bcc01010-c228-4736-a42b-074ff7e49f85,C1457887,C2945704,is with ,Symptoms,Conventional Treatment,1,X,[sosy],[topp],,
a44ac791-5a10-4b66-b2ab-e4927daaab97,C0021081,C0242656,have have ceased during ,Immunosuppressive Agents,Disease Progression,1,X,[imft/phsu],[patf],D27.505.696.477.656,C23.550.291.656
9ec29884-dd5b-431d-8094-afe94ee10aec,C0235031,C0085584, includes ,Neurologic Symptoms,Encephalopathies,2,X,[sosy],[dsyn],C10.597;C23.888.592,C10.228.140
40dfbd6c-b717-4730-b584-32f43b8bf69c,C0036572,C3274800,be initial ,Seizures,Disease Presentation,1,X,[sosy],[clna],C10.597.742;C23.888.592.742,
1b70bffe-3334-4b4e-a172-6bf88ee944f2,C0235031,C3274800,be initial ,Neurologic Symptoms,Disease Presentation,1,X,[sosy],[clna],C10.597;C23.888.592,
28495017-68ee-4b01-805b-7b5b47ffa315,C0085584,C3274800,be initial ,Encephalopathies,Disease Presentation,1,X,[dsyn],[clna],C10.228.140,
023b6e1d-4bd6-4905-b60b-ee19bdba75e6,C0036572,C0206750,be initial Disease Presentation of,Seizures,Coronavirus Infections,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C02.782.600.550.200
410ac38b-2549-4515-81fd-d0c7d137ae2c,C0021368,C0027765,may associate with ,Inflammation,nervous system disorder,2,X,[patf],[dsyn],C23.550.470,C10
028842f3-575d-4134-81a2-b420f7e5799a,C0206750,NYS,is in NYS,Coronavirus Infections,NYS,1,X,[dsyn],????,C02.782.600.550.200,????
a8b6625e-cb84-4b89-a34f-32e51ea4123b,C0042776,C1413336,entered ,Virus,CEL gene,1,X,[virs],[gngm],B04,
a8b6625e-cb84-4b89-a34f-32e51ea4123b,C0042776,C1413336,mediate ,Virus,CEL gene,1,X,[virs],[gngm],B04,
a938a767-80f7-4399-8eac-34a7085b02f3,C1175743,C1752727,use ,SARS coronavirus,Proteasome Pathway,2,X,[virs],[moft],B04.820.504.540.150.113.937,
c2cc16d5-8f8f-4d22-bfd1-b8351db3de5c,C1175743,C0599689,use ,SARS coronavirus,Lipoxins,2,X,[virs],[bacs/orch],B04.820.504.540.150.113.937,D10.251.355.255.375
ef525ae1-7e7c-45d3-bfd9-18d14af9eafc,C1175743,C0036734,use ,SARS coronavirus,Serine Endopeptidases,2,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811.277.656.300.760;D08.811.277.656.959.350
35b348b5-9f7c-41b5-8c96-6ab222a5d59c,C1175743,C0008905,use ,SARS coronavirus,Clathrin,2,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.543.990.200
d533b495-c057-4dd7-b552-8d258cd716f0,C1175743,C0033453,use nuclear ,SARS coronavirus,Complement Factor B,2,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,D08.622.200;D08.811.277.656.300.760.198;D08.811.277.656.959.350.198;D12.776.124.486.274.900
0ddc218d-2513-46c0-89b5-a9356d26c20e,C0013227,C1704259,inhibit ,Pharmaceutical Preparations,Biochemical Pathway,1,X,[phsu],[moft],D26,
80b05426-9e1e-488a-8afd-4cf0a09c41fe,C0206750,C1520005,triggers inflammatory response Along with direct,Coronavirus Infections,Viral Pathogenesis,1,X,[dsyn],[patf],C02.782.600.550.200,
9e3a4aad-55d3-4174-867c-6b49e0dc6b13,C0206750,C0005525,may represent threat In patients with cancer treated with ,Coronavirus Infections,Biological Response Modifiers,1,X,[dsyn],[imft/phsu],C02.782.600.550.200,D27.505.696.477
4895badd-5c3a-4225-9b3e-066919ea0d22,C1533734,C0032285,improves clinical outcome of patients with severe ,Administration procedure,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
58a19a8f-553a-4bf1-808c-8c84eebc631d,MSC,C1257975,has emerged despite lack of data of ,MSC,Mesenchymal Stem Cells,1,X,????,[cell],????,A11.329.830.500;A11.872.590.500
6ed13bd9-47fd-4b13-a899-7ae342919d2f,MSCT,C0018133,be reported with first use of MSCT ,MSCT,Graft-vs-Host Disease,2,X,????,[dsyn],????,C20.452
8b1b01dd-fcd5-47ba-942c-77e535e69912,MSCT,C0024117,is in noninfectious-including ,MSCT,Chronic Obstructive Airway Disease,1,X,????,[dsyn],????,C08.381.495.389
3244ff27-2731-42be-94c4-aa23f6171467,MSCT,C0004096,is in noninfectious-including ,MSCT,Asthma,1,X,????,[dsyn],????,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
2afc5ba4-3351-4b5b-91ec-eb2251fe3a6c,MSCT,C1800706,is in noninfectious-including ,MSCT,Idiopathic Pulmonary Fibrosis,1,X,????,[dsyn],????,C08.381.483.487.500;C08.381.765.500
7fc74194-cdce-417a-8a94-25b9aa522f20,C0043481,C0237820,playing role in clinical ,Zinc,Recovery - action,1,X,[bacs/elii/phsu],[acty],D01.268.556.940;D01.268.956.906;D01.552.544.940,
62b9cc88-ea94-4255-b9f6-dd93dc7c32c5,C0206750,C0005516,combines multiplex ,Coronavirus Infections,Biological Markers,1,X,[dsyn],[clna],C02.782.600.550.200,D23.101
24902192-a501-433e-96f2-796916f9c315,C3887461,C0184661,is high risk ,Head and Neck Carcinoma,Interventional procedure,2,X,[neop],[topp],,
68556325-44de-466c-a8db-ec93e249bc1e,C0003451,C0042210,are needed for ,Antiviral Agents,Vaccines,4,X,[phsu],[aapp/imft/phsu],D27.505.954.122.388,D20.215.894
902f7ae0-e148-444f-aeb1-455133b111db,C0441655,C0042210,are needed for ,Activities,Vaccines,1,X,[acty],[aapp/imft/phsu],,D20.215.894
b8c3ee00-d055-4268-8b8f-d0e7f50ab1d1,C0700271,C1512488,is Homologous Protein of,M Protein multiple myeloma,Homologous Protein,1,X,[aapp/imft],[aapp],x.x.x.x,
358eb485-e577-4743-998d-7db5e9f757be,C1175743,C1512488,M Protein multiple myeloma of is,SARS coronavirus,Homologous Protein,1,X,[virs],[aapp],B04.820.504.540.150.113.937,
5b283c79-1c0a-4e13-9417-2fcebe4547ef,C0597358,C4049595,can Binding (Molecular Function) to,receptor binding,HLA Complex,1,X,[moft],[aapp/imft],,
89a2d84e-5aac-41df-9da9-58a1d8668c8c,C0597358,C0002085,can Binding (Molecular Function) to,receptor binding,Alleles,1,X,[moft],[gngm],,G05.360.340.024.340.030
4fde591d-9759-4f9a-b70e-67a8019134f8,C0597358,C0003316,serve as effective ,receptor binding,Epitopes,1,X,[moft],[imft],,D23.050.550
9eb952c7-5865-4731-951a-ce4cbc1c9c90,C0597358,C0042210,serve as effective ,receptor binding,Vaccines,1,X,[moft],[aapp/imft/phsu],,D20.215.894
3b49135f-5cf1-4ecf-8539-43e71d233426,C0042776,C0006255,is in lower ,Virus,Bronchi,2,X,[virs],[bpoc],B04,A04.411.125
b64affe9-089e-459d-80e7-a1d9cb91850a,C0185112,C1708476,facilitated synchronous ,Therapeutic Mobilization,Implementation,5,X,[topp],[acty],,
c5b87f2e-002f-4e80-8675-10effeda4895,C0556030,C1718097,deploy existing licensed ,Repositioning (procedure),New medications,6,X,[topp],[phsu],,
b762742f-dbfe-4d98-8af4-cf763785a758,C0556030,C2700061,provides quickest possible ,Repositioning (procedure),Transition (action),3,X,[topp],[acty],,
94325d2d-45ab-4381-9da1-fc9474dd4342,C0026187,C0450442,offers advantages compared to ,Minocycline,Agent,2,X,[antb/orch],[chvf],D02.455.426.559.847.562.900.550;D04.615.562.900.550,
5b7b3b14-6b0a-4194-9141-8939a8a58522,C0026187,C0035222,offers advantages in terms of potential efficacy in patients with ,Minocycline,Respiratory Distress Syndrome Adult,1,X,[antb/orch],[dsyn],D02.455.426.559.847.562.900.550;D04.615.562.900.550,C08.381.840;C08.618.840
abd296ac-3239-46e9-b25f-5b51e296122a,C0039986,C0206750,is in children with ,Thoracic Surgery Specialty,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.810.803,C02.782.600.550.200
2b538809-2d4d-4a6a-8421-64889c72a148,C0039986,C0012634,is in children with ,Thoracic Surgery Specialty,Disease,1,X,[bmod],[dsyn],H02.403.810.803,C23.550.288
a405be8d-1696-46a8-8002-53c7cb6cfc84,C0158644,C1175743,can can worsened by ,Congenital anomaly of lung,SARS coronavirus,1,X,[cgab],[virs],,B04.820.504.540.150.113.937
76291263-aad6-49b5-aa16-a1de4a846b9e,C0206750,C0543467,affects indications ,Coronavirus Infections,Operative Surgical Procedures,1,X,[dsyn],[topp],C02.782.600.550.200,E04
b5cd1995-dc42-4889-98d5-6f219da9d6bc,bullae,C0015252,required ,bullae,removal technique,1,X,????,[topp],????,
47b115c6-47e8-4f29-99e0-e7a04baa5f41,C0002055,C0042720,is in ,Alkalies,Viral Genome,2,X,[inch],[gngm],D01.045,G05.360.340.358.840
d943aa98-2f9f-423d-ae82-4ba239f8aafc,C0086418,C1167395,have co-evolved for millennia resulting in complex ,Homo sapiens,Host (organism),1,X,[humn],[orgm],B01.050.150.900.649.313.988.400.112.400.400,
7b083265-8890-40cd-a7f3-83fe68bf3ee3,C0678933,C0003261,associated with viral ,Genetic Loci,Antibody Formation,1,X,[gngm],[biof],G05.360.340.024.380,G12.070
a5867317-8b98-4d89-a8d3-aab10d43c3fc,C0678933,C1414863,associated with viral ,Genetic Loci,FUT2 gene,1,X,[gngm],[gngm],G05.360.340.024.380,
d3e0fab3-9d44-4a04-b667-4892a93c1a10,C0678933,C0005670,associated with viral ,Genetic Loci,BK Virus,1,X,[gngm],[virs],G05.360.340.024.380,B04.280.210.700.615.100;B04.613.204.670.615.100
864fec74-0203-4847-ae6b-44d00f91752c,C2304881,C0796362,for STING1 is ,Merkel cell polyomavirus,chromosome 5q31,1,X,[virs],[celc],B04.280.210.700.615.550;B04.613.204.670.615.550,
ccdc42af-a42d-4211-9da4-2d8a82f142bf,C0079506,C1520405,for CXCR5 Receptors is,Herpesvirus 7 Human,11q23.3,1,X,[virs],[celc],B04.280.382.150.750.420,
589d12ba-7ef8-4bba-b6fa-e06c38f60464,C0005670,C2825753,for FUT2 gene is,BK Virus,19q13.33,1,X,[virs],[celc],B04.280.210.700.615.100;B04.613.204.670.615.100,
48f12ad8-440b-4bc5-8337-46e02ed2b2b3,C2936489,C0042338,is in ,Pleiotropic Gene,Human herpesvirus 3,1,X,[gngm],[virs],G05.420.556;G05.695.550,B04.280.382.100.900.460
40819022-e07f-4fc0-9c78-bf7b56e69f34,C0017428,EHF,is in EHF,Genome,EHF,1,X,[gngm],????,G05.360.340,????
9912f39a-c39e-43cd-943f-c1d1d9336c68,C0009450,EHF,is in EHF,Communicable Diseases,EHF,1,X,[dsyn],????,C01.539.221,????
babcf78c-fc17-4e35-a55b-5370a0523154,C0012655,EHF,is in EHF,Disease susceptibility,EHF,1,X,[clna],????,C23.550.291.687;G07.100.250,????
6a10870b-97ed-4a58-aa27-68b7c1e01e4a,EHF,C1336789,in signal is epithelial-specific ,EHF,Transcription Repressor/Corepressor,1,X,????,[aapp/bacs],????,
24d8b58b-2485-4a48-a1e5-38eb51aeadfd,C2256362,C1602245,allowed for ,system process,Prompt,4,X,[phsf],[phsu],,
dc2e1381-7800-4a8a-bcdd-099ee83b0e1f,C2256362,C0206750,allowed for ,system process,Coronavirus Infections,4,X,[phsf],[dsyn],,C02.782.600.550.200
c0806050-b8c2-4ac4-adcf-b2d0e40ea61f,C0007634,C0854532,are understood Despite current knowledge of injury in ,Cells,Myopericarditis,1,X,[cell],[dsyn],A11,
1c3a394d-9267-4af4-a6a0-8305baa2dba6,C2948600,C0003015,evaluate Clinical Treatment implications with,Aim,Angiotensin-Converting Enzyme Inhibitors,1,X,[inch/phsu],[phsu],,D27.505.519.389.745.085
46321666-e785-4b9a-bfc8-5653b7e9864a,C2948600,C0597357,evaluate Clinical Treatment implications with,Aim,receptor,1,X,[inch/phsu],[aapp/rcpt],,
2082f303-b748-46fa-b291-97b4ffe0ca7e,C0206750,C0237820,of onset is intensive care unit admission ,Coronavirus Infections,Recovery - action,1,X,[dsyn],[acty],C02.782.600.550.200,
a9bf492e-d097-4869-958a-14ccc0d737fa,C0597404,C3694279, includes ,Respiratory viruses,Middle East Respiratory Syndrome,3,X,[virs],[dsyn],,C02.782.600.550.200
3f38ee31-7343-43b8-a070-51d49d62b849,C1416797,C0597404,are longer than other ,STMN1 gene,Respiratory viruses,1,X,[gngm],[virs],,
5cc6dad0-b844-48e3-9609-0fc7e6d4320a,C1416797,C3694279,are longer than other ,STMN1 gene,Middle East Respiratory Syndrome,1,X,[gngm],[dsyn],,C02.782.600.550.200
be3283ba-c6ba-458d-8d58-6c2d009eb5d3,C0206750,C0679225,is with ,Coronavirus Infections,multiple pathologies,3,X,[dsyn],[dsyn],C02.782.600.550.200,
4b0a2583-beb1-41db-992d-17f092cf67c1,C0012634,C0679225,is multiorgan multiple pathologies with,Disease,multiple pathologies,2,X,[dsyn],[dsyn],C23.550.288,
28c9402a-1b29-4186-b476-8945520e903e,C0003250,C1175743,novel specific Viral Vaccines against,Monoclonal Antibodies,SARS coronavirus,1,X,[aapp/imft],[virs],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,B04.820.504.540.150.113.937
28c9402a-1b29-4186-b476-8945520e903e,C0003250,C1175743,targeting ,Monoclonal Antibodies,SARS coronavirus,1,X,[aapp/imft],[virs],D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224,B04.820.504.540.150.113.937
36dad85f-0aca-40d9-a2d5-3a44f144cfb8,C0036734,C0206750,causing ,Serine Endopeptidases,Coronavirus Infections,2,X,[aapp/enzy],[dsyn],D08.811.277.656.300.760;D08.811.277.656.959.350,C02.782.600.550.200
7a068e5b-be25-4ad3-b354-0cefdb8b6437,C1819995,C0024109,is in ,Host Cell,Lung,2,X,[celc],[bpoc],,A04.411
a1475d6a-c461-43dd-bb3b-f105333d706d,C0017262,C0024109,is in ,Gene Expression,Lung,2,X,[genf],[bpoc],G05.297,A04.411
027d3477-7a12-4241-b60c-4e58de0c091a,C1819995,C0458827,is in ,Host Cell,Airway structure,2,X,[celc],[bpoc],,
93d9208d-4f36-4bb5-a4bf-8603219c65e9,C0017262,C0458827,is in ,Gene Expression,Airway structure,2,X,[genf],[bpoc],G05.297,
49efcaa6-7dc0-4c6f-a6a5-7de07d1a9e52,C0458827,C0017262,used public ,Airway structure,Gene Expression,2,X,[bpoc],[genf],,G05.297
e9e43e7c-0591-4273-a1ed-8588962941bf,C0022709,C0005768,was upregulated in ,Peptidyl-Dipeptidase A,In Blood,2,X,[aapp/enzy/imft],[bdsu],D08.811.277.656.350.350.687,x.x.x.x.x
ed9b49e6-1b77-4f36-8cb7-6cf012ed5536,C0022709,C0004096,was upregulated in ,Peptidyl-Dipeptidase A,Asthma,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
ed9b49e6-1b77-4f36-8cb7-6cf012ed5536,C0022709,C0004096,is in primary ,Peptidyl-Dipeptidase A,Asthma,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
26506924-3d3b-41a1-af42-e356bb958aa2,C3263715,C0008058,described ,Pediatric Dermatology Discipline,Chilblains,2,X,[bmod],[dsyn],,C26.212.500.217;C26.417.217
59fdba86-dc30-43cc-96a2-61996ba7eae4,C0206750,C0003467,have increased rates of ,Coronavirus Infections,Anxiety,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
59fdba86-dc30-43cc-96a2-61996ba7eae4,C0206750,C0003467,major negative psychological outcome of is ,Coronavirus Infections,Anxiety,1,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
59fdba86-dc30-43cc-96a2-61996ba7eae4,C0206750,C0003467, includes ,Coronavirus Infections,Anxiety,2,X,[dsyn],[mobd],C02.782.600.550.200,F01.470.132
09d68ab6-c537-4fd5-88f2-8db5e9d3a5e9,C2948600,C0014507,present ,Aim,Epidemiology,2,X,[inch/phsu],[bmod],,H02.403.720.500
dd41cf4b-e8f9-4f37-8d3e-769a28e44dd1,C0014507,C0599878,include data on sociodemographic ,Epidemiology,disease characteristic,3,X,[bmod],[patf],H02.403.720.500,
a21cc094-4b37-45f4-a33b-3e6c662037f4,C0035920,C0034386,were among ,Rubella,Quarantine,4,X,[dsyn],[topp],C02.782.930.700.700,N06.850.780.200.450.700
b940d334-389f-486f-a526-cbdec7c1594e,C0162522,C0149520,treatment for ,Cholecystectomy Laparoscopic,Acute Cholecystitis,2,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C06.130.564.263.500
c812bb11-7abf-48dc-aeb3-d80f3483449a,C0162522,C0206750,remains treatment of choice for ,Cholecystectomy Laparoscopic,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C02.782.600.550.200
c812bb11-7abf-48dc-aeb3-d80f3483449a,C0162522,C0206750,treatment in even ,Cholecystectomy Laparoscopic,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.120.172.140;E04.502.250.520.160,C02.782.600.550.200
88def600-3924-46e1-8fb3-72cf9299b089,C0162522,C1521863,remains treatment of choice for ,Cholecystectomy Laparoscopic,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.210.120.172.140;E04.502.250.520.160,x.x.x.x
88def600-3924-46e1-8fb3-72cf9299b089,C0162522,C1521863,treatment in even ,Cholecystectomy Laparoscopic,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04.210.120.172.140;E04.502.250.520.160,x.x.x.x
78587a4e-d3b5-4733-ae1e-5217c60783ae,C1175175,C0009566,being most fearsome ,Severe Acute Respiratory Syndrome,Complication,2,X,[dsyn],[patf],C02.782.600.550.200.750;C08.730.730,
49d04790-9b54-46e8-9a7a-14d13c3598c4,C0012634,C0015967,was initially characterized by ,Disease,Fever,3,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
49d04790-9b54-46e8-9a7a-14d13c3598c4,C0012634,C0015967,frequently presents with ,Disease,Fever,2,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
49d04790-9b54-46e8-9a7a-14d13c3598c4,C0012634,C0015967,was After emergence of novel ,Disease,Fever,1,X,[dsyn],[sosy],C23.550.288,C23.888.119.344
05886680-7dc3-4175-a00c-a14383120967,C0005516,C0206419,have have observed in patients with ,Biological Markers,Genus: Coronavirus,1,X,[clna],[virs],D23.101,B04.820.504.540.150
5bfb6923-d426-44e2-9d13-8c58b35e57aa,C0022709,C0032285,causing ,Peptidyl-Dipeptidase A,Pneumonia,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C08.381.677;C08.730.610
6c7e2248-da18-47d6-93e8-b2100de496af,C0014695,RAS,is negative RAS ,Ergocalciferol,RAS,2,X,[orch/phsu/vita],????,D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,????
2adefc6d-b674-45e0-b248-f2c282643550,C0014695,C1175175,is in ,Ergocalciferol,Severe Acute Respiratory Syndrome,2,X,[orch/phsu/vita],[dsyn],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,C02.782.600.550.200.750;C08.730.730
9bd26eac-3444-4d35-abc0-25944d01309b,C0206419,C0007222,is with preexisting ,Genus: Coronavirus,Cardiovascular Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C14
9bd26eac-3444-4d35-abc0-25944d01309b,C0206419,C0007222,is with concurrent ,Genus: Coronavirus,Cardiovascular Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C14
20113f70-6dba-4084-ad0b-0022971cbeeb,C2348077,C0206419,have have postulated for ,Date Fruit,Genus: Coronavirus,2,X,[food],[virs],B01.650.940.800.575.912.250.093.615,B04.820.504.540.150
089b8b05-58c8-41d0-bae5-c830cff37a2d,C2348077,C0007222,have have postulated for ,Date Fruit,Cardiovascular Diseases,2,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C14
4d91d06a-9c84-4e98-b050-99d5bf4be565,C2348077,C0597357,have have postulated for ,Date Fruit,receptor,2,X,[food],[aapp/rcpt],B01.650.940.800.575.912.250.093.615,
9df16fa1-0d1b-48a0-ade6-52f5b1e1eecc,C2348077,C0022709,have have postulated for ,Date Fruit,Peptidyl-Dipeptidase A,2,X,[food],[aapp/enzy/imft],B01.650.940.800.575.912.250.093.615,D08.811.277.656.350.350.687
9e3735bf-ca69-4a81-a45f-53665e851f9b,C0040861,C0012634,is with suspected ,Triage,Disease,2,X,[topp],[dsyn],N02.421.297.900,C23.550.288
bb33b56c-c7e2-4c4d-896b-12f921ab5bc7,IRB,C0451610,allow retrospective ,IRB,Patient review,4,X,????,[topp],????,
db41394d-0842-40d8-85fc-d75170c66be5,C0011849,C0021925,of history is ,Diabetes Mellitus,Intubation,2,X,[dsyn],[topp],C18.452.394.750;C19.246,E02.585;E05.497
c9bde1c2-2e38-4f3a-86b0-9bdb1c611533,MEDLINE,C0206419,Web for literature on use for ,MEDLINE,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
ee2491b3-99bc-4498-9674-0ca496049dc1,C1959569,C0206419,spread of ,Volatility,Genus: Coronavirus,1,X,[npop],[virs],G01.645.750;G02.734.933,B04.820.504.540.150
f206dba0-2787-43ea-a961-6735852d59c0,C0031336,C1959569,significantly increase equity market ,Pharmacy (field),Volatility,1,X,[bmod],[npop],H02.646,G01.645.750;G02.734.933
b5ef32a5-426e-4fde-9937-c3477c097768,C0031740,C0206419,mitigate ,Photochemotherapy,Genus: Coronavirus,1,X,[topp],[virs],E02.186.500;E02.319.685;E02.774.722,B04.820.504.540.150
1e217f20-d32e-41e1-9a00-2d2f9672e489,C0206419,C3714514,either prevent ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
1e217f20-d32e-41e1-9a00-2d2f9672e489,C0206419,C3714514,is widely defined as proportion among ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
1e217f20-d32e-41e1-9a00-2d2f9672e489,C0206419,C3714514,causing cluster ,Genus: Coronavirus,Infection,1,X,[virs],[patf],B04.820.504.540.150,C01.539
0922c396-a9a2-44e1-bc04-3965bf1286fa,C0221423,C0319157,caused by novel ,Illness (finding),AS virus,1,X,[sosy],[virs],,
2a8a33ba-16e0-44f6-801a-7c8d4f876884,C1175743,C1160716,highlighting potential for faecal-oral ,SARS coronavirus,viral transmission,2,X,[virs],[celf],B04.820.504.540.150.113.937,
e0a58ea6-5921-41c1-b384-77e310bfde8e,C1419818,C2806453,has has related to lineage B ,SARS gene,Betacoronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113
d76615c8-f95a-4a8b-8617-4b625f9a21a1,C1419818,C1175743,has has related to lineage B ,SARS gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
c40e46e9-dcb6-4424-9d77-77152db68a8e,C1419818,C0008139,has has related to lineage B ,SARS gene,Chiroptera,2,X,[gngm],[mamm],,B01.050.150.900.649.313.937
3a42f5f1-dfbc-49fd-bdf5-57b084ab1503,C1880022,C0002520,revealed existence of distinct four S1 S1,Characterization,Amino Acids,1,X,[acty],[aapp/bacs/phsu],,D12.125
3a42f5f1-dfbc-49fd-bdf5-57b084ab1503,C1880022,C0002520,revealed existence of four S1 S1,Characterization,Amino Acids,1,X,[acty],[aapp/bacs/phsu],,D12.125
dacf4e8b-c9f8-453a-9b90-951a505df301,C1880022,S1,revealed existence of distinct four  S1 S1,Characterization,S1,2,X,[acty],????,,????
dacf4e8b-c9f8-453a-9b90-951a505df301,C1880022,S1,revealed existence of four S1 S1,Characterization,S1,2,X,[acty],????,,????
d14a80fc-6618-4170-bdb1-4705869a9c29,C1880022,C1419032,revealed existence of distinct four S1 S1,Characterization,PSMD2 gene,1,X,[acty],[gngm],,
d14a80fc-6618-4170-bdb1-4705869a9c29,C1880022,C1419032,revealed existence of four S1 S1,Characterization,PSMD2 gene,1,X,[acty],[gngm],,
f4ba11d8-87f4-4462-aa7a-6f5e3231667e,C1880022,C0597358,revealed existence of distinct four S1 S1,Characterization,receptor binding,1,X,[acty],[moft],,
f4ba11d8-87f4-4462-aa7a-6f5e3231667e,C1880022,C0597358,revealed existence of four S1 S1,Characterization,receptor binding,1,X,[acty],[moft],,
375714af-3609-4a1e-9771-f8bfb9d28a29,C1880022,C0599220,revealed existence of distinct four S1 S1,Characterization,Protein Subunits,1,X,[acty],[aapp],,D12.776.813
375714af-3609-4a1e-9771-f8bfb9d28a29,C1880022,C0599220,revealed existence of four S1 S1,Characterization,Protein Subunits,1,X,[acty],[aapp],,D12.776.813
603ba1fe-76f1-4834-8baa-3a587621a757,C0012634,C4704836,rapidly evaluate ,Disease,Medical Countermeasures,1,X,[dsyn],[topp],C23.550.288,N06.230.100.195;N06.850.780.588
a3d462a9-6de3-4714-ad45-3818bc3179ad,C0012634,C0026809,was more severe in aged ,Disease,Mus,1,X,[dsyn],[mamm],C23.550.288,B01.050.150.900.649.313.992.635.505.500
c703a47f-257e-4c3b-b729-9f975880a425,C0012634,hACE2,showed more clinically relevant phenotypes than those seen in hACE2 ,Disease,hACE2,1,X,[dsyn],????,C23.550.288,????
33553874-925d-4315-b1ff-daff5f1d1480,C0012634,C0025936,showed more clinically relevant phenotypes than those seen in hACE2 ,Disease,Mice Transgenic,1,X,[dsyn],[mamm],C23.550.288,B01.050.050.136.500;B01.050.150.900.649.313.992.635.505.500.800
38b13ac0-553a-41d3-aee1-17ee015a1312,C0042210,C0026809,is in immune competent ,Vaccines,Mus,1,X,[aapp/imft/phsu],[mamm],D20.215.894,B01.050.150.900.649.313.992.635.505.500
27d2dcc2-5387-4162-a2ed-21d5065b538e,C0042210,mACE2,is with native expression of mACE2,Vaccines,mACE2,1,X,[aapp/imft/phsu],????,D20.215.894,????
bb8d5099-e548-4eec-881c-68e847eaec85,C0598312,C0086418,is in primary ,DNA Replication,Homo sapiens,1,X,[genf],[humn],G02.111.225;G05.226,B01.050.150.900.649.313.988.400.112.400.400
99e224f1-9256-4d18-872f-5012b503af0d,C0598312,C0458827,is in primary ,DNA Replication,Airway structure,1,X,[genf],[bpoc],G02.111.225;G05.226,
e95476ef-82ad-496c-8faa-67c1dfbda1f0,C0598312,C0014597,is in primary ,DNA Replication,Epithelial Cells,1,X,[genf],[cell],G02.111.225;G05.226,A11.436
9ea2757d-cf2f-4e5e-8ada-b60e4420962b,C0598312,C0007590,is in primary ,DNA Replication,Cell division,1,X,[genf],[celf],G02.111.225;G05.226,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
2c4d7924-6f67-4ea6-8bae-ddf3aad7ef8b,C3652465,C0598312,Lastly can Cardiac Arrest 2,Interferon,DNA Replication,1,X,[aapp/imft/phsu],[genf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G02.111.225;G05.226
7675e924-a26e-4059-ae3d-9c03f9187a99,C3652465,C0086418,Lastly can Cardiac Arrest 2,Interferon,Homo sapiens,1,X,[aapp/imft/phsu],[humn],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B01.050.150.900.649.313.988.400.112.400.400
b5b807a6-10f6-45e7-8afb-0b4f1d1b6d56,C3652465,C0458827,Lastly can Cardiac Arrest 2,Interferon,Airway structure,1,X,[aapp/imft/phsu],[bpoc],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
3c0b8002-107b-4e74-935d-f642e2de340c,C3652465,C0014597,Lastly can Cardiac Arrest 2,Interferon,Epithelial Cells,1,X,[aapp/imft/phsu],[cell],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,A11.436
93653a20-ce0b-4fc1-8ca6-63d594128802,C3652465,C0007590,Lastly can Cardiac Arrest 2,Interferon,Cell division,1,X,[aapp/imft/phsu],[celf],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500
9f1ae489-79c9-4800-9d27-150f61dcb5a8,C3652465,C0087111,Lastly can potently Cardiac Arrest,Interferon,Therapeutic procedure,1,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,E02
02e298be-1a04-4606-89a7-d5598840b3a7,C3652465,C1533734,Lastly can potently Cardiac Arrest,Interferon,Administration procedure,1,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
c397cc19-9add-40a9-b6e9-8a62589e6dde,C3652465,C1175743,can Cardiac Arrest,Interferon,SARS coronavirus,1,X,[aapp/imft/phsu],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
c397cc19-9add-40a9-b6e9-8a62589e6dde,C3652465,C1175743,was associated For adults with ,Interferon,SARS coronavirus,2,X,[aapp/imft/phsu],[virs],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,B04.820.504.540.150.113.937
5d01d709-c54e-430d-8656-6952c35c1380,C0598312,C0026809,is in ,DNA Replication,Mus,1,X,[genf],[mamm],G02.111.225;G05.226,B01.050.150.900.649.313.992.635.505.500
e4f943f0-7aba-4667-9432-e38ae5d2728e,C0087111,C0598312,diminished ,Therapeutic procedure,DNA Replication,1,X,[topp],[genf],E02,G02.111.225;G05.226
e4f943f0-7aba-4667-9432-e38ae5d2728e,C0087111,C0598312,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,DNA Replication,1,X,[topp],[genf],E02,G02.111.225;G05.226
a1b75695-ed12-4462-82a5-bb067000d7a2,C1533734,C0598312,diminished ,Administration procedure,DNA Replication,1,X,[topp],[genf],,G02.111.225;G05.226
8afb6d44-7c6c-4fa8-99ff-81aead90c569,C0087111,C0026809,diminished In ,Therapeutic procedure,Mus,2,X,[topp],[mamm],E02,B01.050.150.900.649.313.992.635.505.500
49d4966a-0148-423d-ba39-fd5457083488,C1533734,C0026809,diminished In ,Administration procedure,Mus,2,X,[topp],[mamm],,B01.050.150.900.649.313.992.635.505.500
e95b2c0b-5b71-4ff9-87d0-43fc263ef113,C2986594,C1516635,supports IFN ,Mouse Model,Clinical Treatment,2,X,[emod],[topp],,
cd9efc22-36b7-4b70-bcb2-0b173c0a0b8e,C2986594,IFN,supports IFN ,Mouse Model,IFN,1,X,[emod],????,,????
ffab2f65-2a18-44d8-bb10-09c4b3b40bc8,C2986594,C0206422,supports IFN ,Mouse Model,Human coronavirus,1,X,[emod],[virs],,
ffab2f65-2a18-44d8-bb10-09c4b3b40bc8,C2986594,C0206422,study ,Mouse Model,Human coronavirus,2,X,[emod],[virs],,
99f33822-eaca-4445-b199-02e7046b85bb,C2986594,C0012634,supports IFN ,Mouse Model,Disease,1,X,[emod],[dsyn],,C23.550.288
f68b3eca-e238-476d-84bd-95a79119cd4c,C1516635,C0206422,is in ,Clinical Treatment,Human coronavirus,1,X,[topp],[virs],,
f21f0c4e-2b47-4538-8d59-8248be698a47,C1516635,C0012634,is in ,Clinical Treatment,Disease,1,X,[topp],[dsyn],,C23.550.288
bda9857d-2cdc-41d7-bd85-77d7c29e7893,C0206419,C0015607,will probably revolutionize approach to patients in ,Genus: Coronavirus,family medicine (field),1,X,[virs],[bmod],B04.820.504.540.150,H02.403.340.500
26e5e8c5-2a00-4910-951d-5eff55d90613,C0005847,C0022709,also express ,Blood Vessel,Peptidyl-Dipeptidase A,1,X,[bpoc],[aapp/enzy/imft],A07.015,D08.811.277.656.350.350.687
bb1b2958-d9bc-4221-a549-4d58b6bf275c,C0027061,C0003130,is with ,Myocardium,Anoxia,4,X,[tisu],[patf],A02.633.580;A07.541.704;A10.690.552.750,C23.888.852.079
b42593d5-7f56-4e85-ad72-2d4e3799b4d9,C0035243,C0003130,is with ,Respiratory Tract Infections,Anoxia,2,X,[dsyn],[patf],C01.539.739;C08.730,C23.888.852.079
05719fe8-0276-448b-9294-a24d8a29858f,C0009450,C0003130,is with ,Communicable Diseases,Anoxia,2,X,[dsyn],[patf],C01.539.221,C23.888.852.079
1c70838b-4a13-4a67-a3ba-d69365340fd8,C0005847,C0206419,are potential targets in ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
1c70838b-4a13-4a67-a3ba-d69365340fd8,C0005847,C0206419,amount of was In ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
1c70838b-4a13-4a67-a3ba-d69365340fd8,C0005847,C0206419,distinguished ,Blood Vessel,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015,B04.820.504.540.150
de0dab47-05aa-4708-84c8-722260b4bf54,C0551718,C0206419,clarify potentiality of ,Study report:Finding:Point in time:^Patient:Document:Pathology,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
b8ab8763-a875-48a8-9830-17f212b7c2a6,RAAS,COVID-19,be maintained in ,RAAS,COVID-19,2,X,????,[virs],????,C000657245
df126ae3-a929-4c1e-abed-7280fb3e8f5d,C0079380,COVID-19,combat ,Frameshift Mutation function,COVID-19,1,X,[comd],[virs],G05.365.590.265,C000657245
a6c303cd-ba98-472d-a24f-e828a89552b7,C0243077,COVID-19,combat ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
a6c303cd-ba98-472d-a24f-e828a89552b7,C0243077,COVID-19,also have ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
a6c303cd-ba98-472d-a24f-e828a89552b7,C0243077,COVID-19,Furthermore interact with dyad ,inhibitors,COVID-19,1,X,[chvf],[virs],,C000657245
fa823f5e-4523-4f13-bb78-171dede899d5,C0206750,C0370003,were assessed in ,Coronavirus Infections,Specimen,2,X,[dsyn],[sbst],C02.782.600.550.200,
d29a5bec-9708-4255-b544-48342fbd868d,C3687742,C1511790,is suitable alternative to NP swabs for ,Oropharyngeal swab,Detection,14,X,[bdsu],[topp],,
d2726144-f5c0-4cef-b032-6719ec4e170c,nares,C1511790,is suitable alternative to NP swabs for ,nares,Detection,7,X,????,[topp],????,
0c1c3b70-ca83-427d-8ece-2def1a129e55,C3687742,C1175743,is suitable alternative to NP swabs for ,Oropharyngeal swab,SARS coronavirus,10,X,[bdsu],[virs],,B04.820.504.540.150.113.937
0c1c3b70-ca83-427d-8ece-2def1a129e55,C3687742,C1175743,were sufficient for use in tests of ,Oropharyngeal swab,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
0c1c3b70-ca83-427d-8ece-2def1a129e55,C3687742,C1175743,are suitable for testing for ,Oropharyngeal swab,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
4374af25-5f15-4bf8-9262-6e93a72e43c0,nares,C1175743,is suitable alternative to NP swabs for ,nares,SARS coronavirus,5,X,????,[virs],????,B04.820.504.540.150.113.937
ab6a15ae-1a32-4335-8bc5-c21f49d7a9eb,C0012634,C0036974,has produced world-wide ,Disease,Shock,1,X,[dsyn],[patf],C23.550.288,C23.550.835
d9aca0ab-2419-4014-901f-5b60ad609a48,C1515933,C0086418,most distal and vulnerable aspect of ,Alveolus,Homo sapiens,1,X,[bpoc],[humn],,B01.050.150.900.649.313.988.400.112.400.400
db55f135-3147-47ef-b3cc-154699515b8f,C1515933,C0040811,most distal and vulnerable aspect of ,Alveolus,Trees (plant),1,X,[bpoc],[plnt],,B01.650.915
126e7234-861f-4053-ae71-6eead5cc34e9,C1515933,C1708715,are responsible for ,Alveolus,Loading Technique,2,X,[bpoc],[acty],,
0104f520-81d7-4947-9378-26877c90e054,C1515933,C0014792,are responsible for ,Alveolus,Erythrocytes,2,X,[bpoc],[cell],,A11.118.290;A11.443.240;A15.145.229.334
12a5bf4f-f0be-46d2-9f1f-1ac48a85180c,C1515933,C0019046,are responsible for ,Alveolus,Hemoglobin,2,X,[bpoc],[aapp/bacs],,D12.776.124.400;D12.776.422.316.762
abdb0cf9-3e06-4144-8ca3-620f6bbfda7f,C0040811,C0021966,is in Part duology ,Trees (plant),Iodides,2,X,[plnt],[inch],B01.650.915,D01.248.497.158.490;D01.475.410
d906c3e8-63b1-49ce-8db0-78c65415e330,C0040811,duology,is in Part duology ,Trees (plant),duology,2,X,[plnt],????,B01.650.915,????
e666949f-74ef-4954-933e-f113aeafa185,C0040811,C1880022,is in Part duology ,Trees (plant),Characterization,2,X,[plnt],[acty],B01.650.915,
db794aa5-fca5-4fd8-8398-58be231a8a9d,C0683325,C0012634,is in patients with ,clinical aspects,Disease,1,X,[clna],[dsyn],,C23.550.288
db794aa5-fca5-4fd8-8398-58be231a8a9d,C0683325,C0012634,might might helpful in ,clinical aspects,Disease,1,X,[clna],[dsyn],,C23.550.288
c49efa0c-9530-452b-a82f-0ba59c6fe0b2,C0683325,C1184743,is in patients with ,clinical aspects,bony process,1,X,[clna],[bpoc],,
4ca4a013-8a36-4957-8f5b-a12f1eb9e81b,COVID-19,C0232462,presented with ,COVID-19,Decrease in appetite,1,X,[virs],[sosy],C000657245,
68bc846d-0231-4198-8048-aac37587490d,C0027950,C0060323,levels of C-reactive protein ,neutrophil,Fibrin fragment D,1,X,[cell],[aapp/bacs],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,x.x.x.x
ae977072-d279-4c9d-80b3-5b11ee396b64,C0027950,C0022917,levels of C-reactive protein ,neutrophil,Lactate Dehydrogenase,1,X,[cell],[aapp/enzy],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,D08.811.682.047.551.400;D08.811.682.047.820.493
4a211fa8-d13f-4576-9d6c-b0e4087bc072,C0025124,C0426576,was used in patients with ,Traditional Chinese Medicine,Gastrointestinal symptom,2,X,[bmod],[sosy],E02.190.488.585.520;I01.076.201.450.654.558.520,
709646b2-3095-4648-9735-5bf68e192afa,C0206750,C0302148,include ,Coronavirus Infections,Blood Clot,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.830
709646b2-3095-4648-9735-5bf68e192afa,C0206750,C0302148,discuss recommendations from Society of ,Coronavirus Infections,Blood Clot,1,X,[dsyn],[patf],C02.782.600.550.200,C14.907.355.830
7fbbea6b-c817-4d90-be09-33bef4dc47b9,C0012634,C0302148,include ,Disease,Blood Clot,1,X,[dsyn],[patf],C23.550.288,C14.907.355.830
cb015fa5-dc93-4c22-af5a-392f35bc0c45,C0206750,C0005778,include disseminated ,Coronavirus Infections,Blood coagulation,1,X,[dsyn],[ortf],C02.782.600.550.200,G09.188.390.150
6a317f44-9bef-4fcc-a1f6-ede65557f9f0,C0012634,C0005778,include disseminated ,Disease,Blood coagulation,1,X,[dsyn],[ortf],C23.550.288,G09.188.390.150
deb7894d-f6ab-4347-b7fe-4e92b1a3978b,C0151942,C2945695,is in form of acute ,Arterial thrombosis,Limb ischemia,2,X,[patf],[dsyn],,
d0e373d4-7e16-433c-ae64-f0caf6614350,C0151942,COVID-19,can occur in ,Arterial thrombosis,COVID-19,1,X,[patf],[virs],,C000657245
ca60770f-586c-4e83-85d3-1805ee9f06fa,C2945695,C2745965,is vascular ,Limb ischemia,Emergencies [Disease/Finding],2,X,[dsyn],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
f4096c1f-24fd-4ac7-9d56-c1b35665d883,C1175743,C1999230,across technologies is ,SARS coronavirus,Providing (action),1,X,[virs],[acty],B04.820.504.540.150.113.937,
1aca47b1-55d5-4aee-bbde-c355b7d98b72,C0740766,C0206750,are hallmarks of severe ,acute pneumonia,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
51bb0305-8050-46bb-97ef-22fb93785eee,C0340194,C0206750,are hallmarks of severe ,Respiratory failure without hypercapnia,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
590f08a4-54a4-484e-be9b-74279c9a24b6,C1999230,C0013964,is in ,Providing (action),emergency medicine (field),3,X,[acty],[bmod],,H02.403.250
98160e5e-649c-45d4-b871-52bf479af7e4,C0872147,1st,were searched until May 1st ,DNA Library,1st,1,X,[gngm/nnon],????,G05.360.325,????
98160e5e-649c-45d4-b871-52bf479af7e4,C0872147,1st,were searched from December 1st 1st ,DNA Library,1st,3,X,[gngm/nnon],????,G05.360.325,????
6a22d108-2d7d-4815-92ff-dc81fcae6c5b,C0872147,C0206419,using keywords of ,DNA Library,Genus: Coronavirus,1,X,[gngm/nnon],[virs],G05.360.325,B04.820.504.540.150
c4e58fb6-37d4-4321-af8a-eed242c73686,C0333557,C0206419,is in patient with ,Watershed infarct,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
d1102e12-8df8-4f6c-a0fe-127dfe36741f,C1856053,C0206419,is in World Health Organization ,Hydranencephaly with Renal Aplasia-Dysplasia,Genus: Coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150
aeaa0258-7d75-4a98-98c1-c5c87a09f914,C2926735,3days,was varied from 3days 35days ,Duration,3days,1,X,[orch/phsu],????,,????
aaee63a8-ee11-425c-af8e-eee3e230f12a,C2926735,35days,was varied from 3days 35days ,Duration,35days,1,X,[orch/phsu],????,,????
b3df915e-e484-4d6c-a4ea-a36adbb2345d,C0206419,C0022646,is in ,Genus: Coronavirus,Kidney,4,X,[virs],[bpoc],B04.820.504.540.150,A05.810.453
e5693969-a5ba-4622-ad53-b8469439da47,C0206419,C0039597,do effect system from ,Genus: Coronavirus,Testis,1,X,[virs],[bpoc],B04.820.504.540.150,A05.360.444.849;A05.360.576.782;A06.300.312.782
7d8b4d80-02bd-4d80-88be-37b79fc259d9,C0030755,C0012634,is with confirmed ,Pediatrics,Disease,1,X,[bmod],[dsyn],H02.403.670,C23.550.288
d2795e65-9744-4cd6-bd0c-0ee5a29a2165,C0030755,C1856053,is with confirmed ,Pediatrics,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bmod],[dsyn],H02.403.670,x.x.x.x
d07e97ba-b6fe-4bc0-b77b-ce869f332c20,C0030755,C1706374,is with confirmed ,Pediatrics,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[bmod],[aapp/bacs],H02.403.670,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
83cb83e6-6bc9-4196-abfd-19ad474cd864,C1175743,C0009758,may Despite prevalence of viral presence in ,SARS coronavirus,conjunctiva,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A09.371.060.200;A09.371.337.168
312f008d-c643-47eb-b42c-c6904045d03e,C0242781,C0009758,may Despite prevalence of viral presence in ,disease transmission,conjunctiva,1,X,[patf],[bpoc],N06.850.310,A09.371.060.200;A09.371.337.168
5299ef5a-0ae9-4d69-b690-79f2634b1254,CRRT,AKI,should should choice for AKI ,CRRT,AKI,1,X,????,????,????,????
e1eded0c-0fe8-48e0-b8c1-b637ec472fd1,CRRT,C0206419,should should choice for AKI ,CRRT,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
1b8b1fc9-ac78-46d2-8472-483b0ccea47f,C0206419,AKI,is with AKI,Genus: Coronavirus,AKI,2,X,[virs],????,B04.820.504.540.150,????
6b90b765-7c4b-4baa-9f8a-1136b300624c,C1533734,C0206419,is in acute phase of AKI,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
6b90b765-7c4b-4baa-9f8a-1136b300624c,C1533734,C0206419,improves clinical outcome of patients with severe ,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
6b90b765-7c4b-4baa-9f8a-1136b300624c,C1533734,C0206419,are are currently tested in ,Administration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
64e45590-e7c7-43b3-9e08-80e435843fb2,C1533734,AKI,is in acute phase of AKI,Administration procedure,AKI,1,X,[topp],????,,????
813861ae-46e4-4d5e-a60e-0d541da43d78,C1290380,C0476236,are most vulnerable for ,Chronic disease of cardiovascular system,Developmental symptoms,8,X,[dsyn],[sosy],,
ce0c840b-33e5-45b4-afba-197ffd37425e,C0018801,C1290380,is main ,Heart failure,Chronic disease of cardiovascular system,2,X,[dsyn],[dsyn],C14.280.434,
5abe67bf-3b05-4647-8cac-412f2a81502e,C0021081,C0018129,avoid ,Immunosuppressive Agents,Graft Rejection,2,X,[imft/phsu],[ortf],D27.505.696.477.656,G12.875.545.328
c8bdd099-eef6-4164-a805-ebf99f09703b,C0007189,C0021665,of Society is ,Cardiology discipline,Insulin-Like Growth Factor I,2,X,[bmod],[aapp/bacs],H02.403.429.163,D12.644.276.937.400;D12.776.124.862.400;D12.776.467.937.400;D23.529.937.400
b64b31a7-0408-4ee5-bf3e-d7c8b389ca62,C0086418,C0003615,was diagnosed with ,Homo sapiens,Appendicitis,4,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
4a12cb2a-4b03-48b3-b481-a08b739a3bd4,C0022709,C0020885,was reduced in inflamed ,Peptidyl-Dipeptidase A,ileum,6,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A03.556.124.684.249;A03.556.249.124
5f905846-d60e-4a87-b1fa-0c7ce04db312,C0035696,C0020885,is in ,RNA Messenger,ileum,2,X,[bacs/nnon],[bpoc],D13.444.735.544,A03.556.124.684.249;A03.556.249.124
c798cc86-411e-4a54-978c-ee0ce8bc31d0,C0022709,C0010346,was restored In active ,Peptidyl-Dipeptidase A,Crohn Disease,12,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C06.405.205.731.500;C06.405.469.432.500
899ac1f7-7b7e-4ebf-b11e-d74edb281711,C0022709,C1707455,was downregulated in ,Peptidyl-Dipeptidase A,Comparison,4,X,[aapp/enzy/imft],[acty],D08.811.277.656.350.350.687,
7e2b73c5-f318-4607-b15b-cd3c830bb17e,C0021852,C0010346,was restored In active ,Intestines Small,Crohn Disease,4,X,[bpoc],[dsyn],A03.556.124.684,C06.405.205.731.500;C06.405.469.432.500
bf053de1-b12e-4d5b-b2e5-5f8980204693,C0021852,C0281481,was In active ,Intestines Small,anti-tumor necrosis factor therapy,2,X,[bpoc],[topp],A03.556.124.684,
bf053de1-b12e-4d5b-b2e5-5f8980204693,C0021852,C0281481,was restored by ,Intestines Small,anti-tumor necrosis factor therapy,2,X,[bpoc],[topp],A03.556.124.684,
ed74879f-4ded-4f67-8f5d-2a3c1f487d0d,C0022709,C0281481,was In active ,Peptidyl-Dipeptidase A,anti-tumor necrosis factor therapy,2,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,
ed74879f-4ded-4f67-8f5d-2a3c1f487d0d,C0022709,C0281481,was restored by ,Peptidyl-Dipeptidase A,anti-tumor necrosis factor therapy,2,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,
31790198-8eef-48c4-ae1d-9eb35e40f884,C0281481,C1448177,is in particularly anti ,anti-tumor necrosis factor therapy,TNF protein human,2,X,[topp],[aapp/bacs],,x.x.x.x
4c1db5bc-8f40-4deb-a118-fa21c371e324,C0013081,C0021368,is associated with ,Down-Regulation,Inflammation,2,X,[moft],[patf],G02.111.240;G05.308.200;G07.690.773.937,C23.550.470
f31aca4b-82df-42b6-b391-d6477713d890,C0013081,C0010346,is associated with ,Down-Regulation,Crohn Disease,2,X,[moft],[dsyn],G02.111.240;G05.308.200;G07.690.773.937,C06.405.205.731.500;C06.405.469.432.500
7cd88421-924a-4f17-9a03-4fe8880b0a63,C0021368,C0010346,is in ,Inflammation,Crohn Disease,2,X,[patf],[dsyn],C23.550.470,C06.405.205.731.500;C06.405.469.432.500
61cbe1e3-9444-486a-81bc-b913f35a45ce,C0013227,C0319157,are active against ,Pharmaceutical Preparations,AS virus,2,X,[phsu],[virs],D26,
1a185706-aa97-4863-a048-6cdfb54c7edd,C0243077,C3694279,is in ,inhibitors,Middle East Respiratory Syndrome,3,X,[chvf],[dsyn],,C02.782.600.550.200
e80c514c-73d1-4383-b6c7-ed5273024cba,C1510827,C0243077,is in range of known ,Affinity,inhibitors,3,X,[npop],[chvf],,
a8127c9b-5ed8-4d50-910c-def2bf0d2671,C0684336,C0178784,is in multiple ,Impaired health,Organ,3,X,[patf],[bpoc],,
d383e2d2-be1b-41ed-bc08-5afd52863c87,C0206419,C0023884, includes ,Genus: Coronavirus,Liver,2,X,[virs],[bpoc],B04.820.504.540.150,A03.620
32174552-5d51-4080-8ad6-b594bda2e086,C0206419,C0006104, includes ,Genus: Coronavirus,Brain,2,X,[virs],[bpoc],B04.820.504.540.150,A08.186.211
49b9bdf2-0bf3-472f-87a3-caf087c901a4,C0684336,C0206419,have have reported in ,Impaired health,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
ec19578b-a9ce-4c49-ad38-6e23fc0cda94,C0684336,C0024109,have have reported in ,Impaired health,Lung,3,X,[patf],[bpoc],,A04.411
e099f989-6812-48ad-9066-fd3b5654d1e2,C0684336,C0018787,have have reported in ,Impaired health,Heart,3,X,[patf],[bpoc],,A07.541
462b7347-80a2-4477-8a96-1bbca4146f0c,C0684336,C0022646,have have reported in ,Impaired health,Kidney,3,X,[patf],[bpoc],,A05.810.453
c6774842-75fd-4311-a642-09def21c7658,C0684336,C0023884,have have reported in ,Impaired health,Liver,3,X,[patf],[bpoc],,A03.620
72907ea4-1b66-4039-9ddc-a5ad761ce9f8,C0684336,C0006104,have have reported in ,Impaired health,Brain,3,X,[patf],[bpoc],,A08.186.211
5f05ceba-9fed-427e-99de-67794ac57eaf,C0005779,C0206419,is in ,Blood Coagulation Disorders,Genus: Coronavirus,4,X,[dsyn],[virs],C15.378.100,B04.820.504.540.150
7356ae4e-e775-4c2d-9189-1ae9db25c729,C0013806,C1175743,more vulnerable to ,Electroconvulsive Therapy,SARS coronavirus,3,X,[topp],[virs],F04.570.200.583;F04.669.224.300,B04.820.504.540.150.113.937
297f77c0-6535-4be5-b641-b8902771144a,C0242781,C2698650,using Markov Chain Monte Carlo ,disease transmission,Optimization,2,X,[patf],[acty],N06.850.310,
3e5b86d0-f4ff-4f2d-9fa3-da955970b70c,C0032105,C0005532,are preserved for later genetic ,Plasma,biology (field),1,X,[bdsu],[bmod],A12.207.152.693;A12.207.270.695;A15.145.693,H01.158.273
8c009881-0588-4e10-9a89-5d059c8a5003,C0814435,C0034019,of combination is ,early identification,public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
1a21f4fb-45a2-4ebb-b65e-d6c522a4ea59,C2242456,C0206750,is in patients with ,thyroid function,Coronavirus Infections,2,X,[phsf],[dsyn],,C02.782.600.550.200
e3ed40a5-3056-49df-8b4e-4a2dd1c93756,C2948600,C2242456,evaluate ,Aim,thyroid function,1,X,[inch/phsu],[phsf],,
649a2e82-9a28-4580-a751-0a7495cf91a5,C0451610,C0206750,is with laboratory-confirmed ,Patient review,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
744bfe35-b791-401d-a14c-f6a8df6589ff,C0040135,C0206750,Comparison between,Thyroid Hormones,Coronavirus Infections,1,X,[horm],[dsyn],D06.472.931,C02.782.600.550.200
4699bb40-963a-4768-98c1-891e433c2b05,C2948600,C0018801,evaluate results of protocol established in advanced ,Aim,Heart failure,1,X,[inch/phsu],[dsyn],,C14.280.434
bb5c34c0-9945-4d15-b464-d056ef76cdd8,C0242656,C0237820,include in mild cases from onset of symptoms ,Disease Progression,Recovery - action,1,X,[patf],[acty],C23.550.291.656,
42481769-2112-43a1-baf5-1db1a5ad8957,et,C0156149,have treated Coronavirus Infections patients with thromboembolic,et,Gastrointestinal tract vascular insufficiency,1,X,????,[dsyn],????,
18cea847-7e12-4a07-9f43-4413e9034c83,al,C0156149,have treated Coronavirus Infections patients with thromboembolic,al,Gastrointestinal tract vascular insufficiency,1,X,????,[dsyn],????,
99864824-0f5a-414d-9847-ad24c6662ce2,et,C0206750,is in their ,et,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
73eae86c-9b23-4bfe-a15f-9ef6e6371449,al,C0206750,is in their ,al,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
ff79ce68-7800-4152-bee8-61bd4f5dd8db,C0014121,C0663332,is In countries still ,Bacterial Endocarditis,Scourge,1,X,[dsyn],[hops/orch],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,
9bec38ee-ffb7-4cfa-973b-6b8e17dc0dad,C0014121,C0035439,is In countries still ,Bacterial Endocarditis,Rheumatic Heart Disease,1,X,[dsyn],[dsyn],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,C01.252.410.890.731.649;C14.280.874
9bec38ee-ffb7-4cfa-973b-6b8e17dc0dad,C0014121,C0035439,is still Scourge in patients with,Bacterial Endocarditis,Rheumatic Heart Disease,1,X,[dsyn],[dsyn],C01.252.300;C01.539.190.249;C14.260.249;C14.280.282.407,C01.252.410.890.731.649;C14.280.874
a36f76ad-01e3-4dc1-ae42-0d12a7148712,C0663332,C0035439,is in patients with ,Scourge,Rheumatic Heart Disease,1,X,[hops/orch],[dsyn],,C01.252.410.890.731.649;C14.280.874
436caf83-149f-4ad7-aaa2-d91d334e449f,C0597177,C3146294,are ,Particle,Generation (action),1,X,[chvs],[acty],,
49b453e4-15cc-4f24-9e1d-69ea4404a6ec,C0597177,C0010200,are Generation (action) by,Particle,Coughing,1,X,[chvs],[sosy],,C08.618.248;C23.888.852.293
f25c4ef2-cd81-4745-89eb-89298086be42,C0597177,C0242781,facilitate ,Particle,disease transmission,1,X,[chvs],[patf],,N06.850.310
250b77ba-2c4b-47eb-a7b2-125b27f841e1,C0151946,COVID-19,appears ,Pulmonary thrombosis,COVID-19,1,X,[patf],[virs],,C000657245
7e866060-a595-4a15-9fa9-be7862491e0e,C0151946,C0032285,appears ,Pulmonary thrombosis,Pneumonia,1,X,[patf],[dsyn],,C08.381.677;C08.730.610
75bb3116-d713-4534-a006-ac38ee63da9e,C0151946,C0034065,takes proximal ,Pulmonary thrombosis,Pulmonary Embolism,1,X,[patf],[patf],,C08.381.746;C14.907.355.350.700
f791048a-b699-4104-86dc-f0f2a0b0f193,C1519836,COVID-19,had During COVID19,Urologic Surgeon,COVID-19,1,X,[bmod],[virs],,C000657245
09183e18-4890-4dfd-baa6-0ef3e2bd3b90,C1519836,COVID19,had During COVID19,Urologic Surgeon,COVID19,1,X,[bmod],????,,????
4d9252e3-95a5-4696-8f8c-98c945dcdd3e,C1519836,C0543467,reorganize their daily ,Urologic Surgeon,Operative Surgical Procedures,1,X,[bmod],[topp],,E04
216479ba-d696-42fe-aa37-292ec5eb8055,C0242781,C1706214,is with ,disease transmission,Creation,2,X,[patf],[acty],N06.850.310,
1d1e78fc-2004-4d88-a0bd-37fb31a8314d,C0242781,C0032320,is with ,disease transmission,Pneumoperitoneum,2,X,[patf],[dsyn],N06.850.310,C06.844.670
6c5c1796-38fe-4fcf-9986-277f80ce93fa,C0028630,C0079941,is in ,Nucleotides,Open Reading Frames,3,X,[nnon],[gngm],D09.408.620;D13.695,G05.360.335.760.640;G05.360.340.024.340.137.650
b3122ba9-9753-4ddf-b8ad-2a995fb0bde6,C1511760,C0079941,is in ,Deletion Mutation,Open Reading Frames,2,X,[comd],[gngm],G05.365.590.762;G05.558.800,G05.360.335.760.640;G05.360.340.024.340.137.650
4ed22f59-dac4-4c69-8337-1f4b9a18f9a2,C0017428,clade,were classified into new clade ,Genome,clade,2,X,[gngm],????,G05.360.340,????
e41efba9-1e72-4086-b728-3aebb195aecc,C0017428,C0026882,were classified into new clade ,Genome,Mutation,2,X,[gngm],[genf],G05.360.340,G05.365.590
cee5436b-49a6-4306-8a37-ffbeee296caa,clade,C0026882,is with ORF1ab-V378I ,clade,Mutation,2,X,????,[genf],????,G05.365.590
ef8efffd-f77b-4940-886a-d463421be19f,C0017428,clades,were classified in addition to dominant clades L84S,Genome,clades,2,X,[gngm],????,G05.360.340,????
365d698b-96a9-44ca-b620-bfa58e822c34,C0017428,C0079941,were classified in addition to dominant clades L84S,Genome,Open Reading Frames,2,X,[gngm],[gngm],G05.360.340,G05.360.335.760.640;G05.360.340.024.340.137.650
20d1076a-063d-4cd6-abcb-8128d1627b19,C0017428,L84S,were classified in addition to dominant clades L84S,Genome,L84S,2,X,[gngm],????,G05.360.340,????
051ae85c-6497-4c0d-951e-e2700fd01d0b,clade,C3714514,may may associated with ,clade,Infection,2,X,????,[patf],????,C01.539
3132bb75-fa15-4c39-8122-1d117fa95954,C0037114,C0325125,compromising masks ,Silicones,Phocidae,1,X,[bodm/orch],[mamm],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,B01.050.150.900.649.313.750.250.700
92c26f2e-53db-4184-89a4-ecf961269929,C0037114,C0222084,is safe and beneficial option for ,Silicones,Skin structure of face,1,X,[bodm/orch],[bpoc],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,
3a89eed4-c3a0-4054-9489-676b8db09f3a,C0037114,C0150638,is safe and beneficial option for ,Silicones,Preventing injury,1,X,[bodm/orch],[topp],D02.715.650.700;D05.750.900.850;D25.720.900.850;J01.637.051.720.900.850,
b88cfa13-7181-4fc8-9101-26839c42c05d,C3495559,C1819995,is In issue of ,Juvenile arthritis,Host Cell,1,X,[dsyn],[celc],C05.550.114.122;C05.799.056;C17.300.775.049;C20.111.198,
7f055557-65c7-4dd3-a70b-49a1ca40d075,etal,C1819995,is In issue of ,etal,Host Cell,1,X,????,[celc],????,
a2752804-2445-40da-b281-6148972a7607,C0004561,C0369497,expressing broadly neutralizing ,B-Lymphocytes,Human immunodeficiency virus type 1 antibody,1,X,[cell],[aapp/imft],A11.063.438;A11.118.637.555.567.562;A15.145.229.637.555.567.562;A15.382.032.438;A15.382.490.555.567.562,
03314ec8-4a89-4803-9f7f-e8844168581d,C1880022,C1947933,may inform post-hospitalization ,Characterization,care activity,1,X,[acty],[acty],,
cb3eff2b-e22b-48bf-ba93-1857c95e2045,C0275524,C4267729,is with other ,Coinfection,Respiratory pathogens,2,X,[dsyn],[orgm],C01.539.218;C02.219;C03.202,
236038ef-f036-4e37-8bbb-a34dd7f19176,C0021760,C0060323,increased significantly at_time ,Interleukin-6,Fibrin fragment D,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,x.x.x.x
236038ef-f036-4e37-8bbb-a34dd7f19176,C0021760,C0060323,Meanwhile increased at_time ,Interleukin-6,Fibrin fragment D,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,x.x.x.x
35ca2a30-f173-45fe-94f3-c4d17b4b405c,C0021760,C0010287,increased significantly at_time ,Interleukin-6,Creatine Kinase,1,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D08.811.913.696.640.150
35ca2a30-f173-45fe-94f3-c4d17b4b405c,C0021760,C0010287,Meanwhile increased at_time ,Interleukin-6,Creatine Kinase,1,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D08.811.913.696.640.150
382f164d-a43b-4d7c-b43a-a449fee3b38e,C0085295,C0010287,Meanwhile increased significantly at_time ,Interleukin-10,Creatine Kinase,2,X,[aapp/imft],[aapp/enzy],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D08.811.913.696.640.150
6055e6d8-90ee-4ca5-8907-c9c7bf0e8d58,C0085295,C0060323,Meanwhile increased significantly at_time ,Interleukin-10,Fibrin fragment D,2,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,x.x.x.x
22af0dbc-b464-4363-a8e0-e4c9cd620689,C0001899,C0010287,increased significantly at_time ,Alanine Transaminase,Creatine Kinase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.100,D08.811.913.696.640.150
22af0dbc-b464-4363-a8e0-e4c9cd620689,C0001899,C0010287,Meanwhile increased at_time ,Alanine Transaminase,Creatine Kinase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.477.700.100,D08.811.913.696.640.150
ebac0cf3-5da8-486f-8d89-7d21134e7b33,C0001899,C0060323,increased significantly at_time ,Alanine Transaminase,Fibrin fragment D,1,X,[aapp/enzy],[aapp/bacs],D08.811.913.477.700.100,x.x.x.x
ebac0cf3-5da8-486f-8d89-7d21134e7b33,C0001899,C0060323,Meanwhile increased at_time ,Alanine Transaminase,Fibrin fragment D,1,X,[aapp/enzy],[aapp/bacs],D08.811.913.477.700.100,x.x.x.x
3a973b2a-6d17-4902-957a-2ca09b97e080,C0010294,C0060323,increased significantly at_time ,Creatinine,Fibrin fragment D,1,X,[bacs/orch],[aapp/bacs],D03.383.129.308.207,x.x.x.x
3a973b2a-6d17-4902-957a-2ca09b97e080,C0010294,C0060323,Meanwhile increased at_time ,Creatinine,Fibrin fragment D,1,X,[bacs/orch],[aapp/bacs],D03.383.129.308.207,x.x.x.x
5ebff0ad-4ccc-432a-a4b5-da01e2929490,C0006560,C0010287,Meanwhile increased significantly at_time ,C-reactive protein,Creatine Kinase,2,X,[aapp/imft],[aapp/enzy],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,D08.811.913.696.640.150
a756cbb4-d480-42fa-93fd-928cfc7ab0f4,C0010294,C0010287,Meanwhile increased at_time ,Creatinine,Creatine Kinase,1,X,[bacs/orch],[aapp/enzy],D03.383.129.308.207,D08.811.913.696.640.150
a756cbb4-d480-42fa-93fd-928cfc7ab0f4,C0010294,C0010287,increased significantly at_time ,Creatinine,Creatine Kinase,1,X,[bacs/orch],[aapp/enzy],D03.383.129.308.207,D08.811.913.696.640.150
e43e825f-626d-4a98-88ad-a2911585ad9f,C0006560,C0060323,Meanwhile increased significantly at_time ,C-reactive protein,Fibrin fragment D,2,X,[aapp/imft],[aapp/bacs],D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157,x.x.x.x
6b72a9f1-3c1a-4678-aa0c-39866c29b85c,C0277560,C0206750,is with ,Infantile disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
7e5c277d-9499-44d1-a9c3-1b4c5580260f,C0206750,C1510889,utilizes ,Coronavirus Infections,Angiotensin-converting Enzyme 2 Pathway,2,X,[dsyn],[moft],C02.782.600.550.200,
a711fbaf-4bc5-43c7-9845-420e73d40eeb,C0960880,C0009450,may contribute to heterogenous ,angiotensin converting enzyme 2,Communicable Diseases,1,X,[aapp/enzy],[dsyn],x.x.x.x,C01.539.221
0a9af383-4a77-483c-9d53-c48e1124d544,C0684167,C0960880,may alter ,hypertensive medication,angiotensin converting enzyme 2,1,X,[phsu],[aapp/enzy],,x.x.x.x
b44fe2e1-bbbd-4969-b297-2ef3aab2e65f,C0684167,C0103306,may alter ,hypertensive medication,angiotensin I (1-7),1,X,[phsu],[aapp/phsu],,x.x.x.x
79be571e-204e-4b65-9c63-bab9abe194bb,C3826426,C3540027,was modeled via ,Dynamics,Adrenergic and dopaminergic agents combinations,2,X,[npop],[phsu],,
2c91fe57-d330-45ad-b7df-2a9bad763ef3,C1825598,C0333957,monitoring ,IMPACT gene,Growth acceleration,2,X,[gngm],[patf],,
beb7cde9-f64f-4779-a6fb-33f7b86da5c8,C1096155,C1175743,is highly effective measure against dissemination of ,Macrophage Activation Syndrome,SARS coronavirus,2,X,[dsyn],[virs],C20.683.515.800,B04.820.504.540.150.113.937
de129083-700f-439b-b307-6ec152044b11,et,C0442893,is in their ,et,Systemic disease,1,X,????,[dsyn],????,
d4c20644-c0ce-44f0-83ee-ae1893efbede,al,C0442893,is in their ,al,Systemic disease,1,X,????,[dsyn],????,
8b62ad81-d040-4f17-805c-f24d6813e8a8,C1333684,C0023745,use simple ,GNA12 gene,genetic linkage,2,X,[gngm],[moft],,G05.348
95db6ba4-cdcc-40b5-8228-a56688aa4b26,C1333684,C4552744,use simple ,GNA12 gene,Daily Living,2,X,[gngm],[dora],,
251b9188-f323-43da-9c07-6d6aadb41e4b,C1825598,C0281190,is in ,IMPACT gene,colorectal cancer prevention,2,X,[gngm],[topp],,
79c79494-5364-4410-949f-c2de1e4c10c5,C0013404,C3177142,was ,Dyspnea,Main presenting symptom,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,
105dfc35-32fd-4418-a4f5-7ef8da840713,C0206750,C0011438,is new challenge in modern ,Coronavirus Infections,Dentistry,1,X,[dsyn],[bmod],C02.782.600.550.200,E06;H02.163
105dfc35-32fd-4418-a4f5-7ef8da840713,C0206750,C0011438,has brought challenge to world of ,Coronavirus Infections,Dentistry,1,X,[dsyn],[bmod],C02.782.600.550.200,E06;H02.163
40cb0fdb-5c8d-4b2f-b0f7-085814b1c894,C0598197,C0010356,caused by ,contagion,Cross Infection,1,X,[npop],[patf],,C01.539.248;C23.550.291.875.500
c69e69f6-3a63-46c3-b4c0-681fc26fb965,C0012683,C0001962,is with ,Disinfection,Ethanol,1,X,[topp],[orch/phsu],N06.850.780.200.450.850.375,D02.033.375;x.x.x.x
9fd1ceee-5dd0-4a14-abc1-c36993b99a32,C0426576,C0206750,are are increasingly recognized in ,Gastrointestinal symptom,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
9fd1ceee-5dd0-4a14-abc1-c36993b99a32,C0426576,C0206750,could could used for prognostication in patients with ,Gastrointestinal symptom,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
9fd1ceee-5dd0-4a14-abc1-c36993b99a32,C0426576,C0206750,frequently reported in ,Gastrointestinal symptom,Coronavirus Infections,3,X,[sosy],[dsyn],,C02.782.600.550.200
bcfd148f-d443-42ad-9252-674841f2158c,C0206750,C0426576,were compared with ,Coronavirus Infections,Gastrointestinal symptom,4,X,[dsyn],[sosy],C02.782.600.550.200,
b56c7472-6974-43bc-8ceb-6f39bfba5fb4,C4524574,C0040300,thus poses arisk through ,Ocular Tissue,Body tissue,1,X,[tisu],[tisu],,A10
8edd286c-25ae-402e-a0fd-368eb1dc85d4,C4524574,arisk,thus poses arisk ,Ocular Tissue,arisk,1,X,[tisu],????,,????
3467c2f6-94ae-432d-9843-ee48aa6a61ad,C4524574,C0009450,thus poses arisk ,Ocular Tissue,Communicable Diseases,1,X,[tisu],[dsyn],,C01.539.221
9bb2e538-6e99-4044-828a-d63fc8aa59b9,C1175743,C4524574,infect ,SARS coronavirus,Ocular Tissue,1,X,[virs],[tisu],B04.820.504.540.150.113.937,
049dd52d-8ff7-4e01-99f4-ef3d6b45c000,CoV2,C4524574,infect ,CoV2,Ocular Tissue,1,X,????,[tisu],????,
3f53154e-8f77-45ff-a8a8-382d74fc8956,C0022709,C0036734,was identified as ,Peptidyl-Dipeptidase A,Serine Endopeptidases,2,X,[aapp/enzy/imft],[aapp/enzy],D08.811.277.656.350.350.687,D08.811.277.656.300.760;D08.811.277.656.959.350
61d401c7-fc1b-4d05-8561-eb5cf810fa8c,C0022709,C0030946,was identified as ,Peptidyl-Dipeptidase A,Endopeptidases,2,X,[aapp/enzy/imft],[aapp/enzy/phsu],D08.811.277.656.350.350.687,D08.811.277.656.300
214f6b54-9afa-4b71-80a0-cf95bc8de6a8,C0009450,CoV2,is with CoV2,Communicable Diseases,CoV2,2,X,[dsyn],????,C01.539.221,????
d671395e-6de0-4a08-83ea-79f37f1ce0a6,C0022709,C0015392,are In ,Peptidyl-Dipeptidase A,Eye,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A01.456.505.420;A09.371
63223671-9e68-4798-8427-ead7f7dcaa26,C1292533,C0597360,loss of ,Tissue specimen,receptor expression,1,X,[tisu],[genf],,
2d570f81-fbcd-4582-b047-9440447971f6,C0009450,C0010042,must In cases of ,Communicable Diseases,Keratoplasty,1,X,[dsyn],[topp],C01.539.221,E02.095.147.725.225;E04.540.825.374;E04.936.580.225
eab454a5-94d6-4b32-880a-92737ea379c3,C1692321,C0032285,consistent with ,Cellular infiltrate,Pneumonia,1,X,[patf],[dsyn],,C08.381.677;C08.730.610
bec39959-652e-47b4-bbdd-ae02e062d798,GGO,C0278459,predominantly distributed in peripheral ,GGO,Structure of pulmonic area,1,X,????,[bpoc],????,
11924019-df16-449c-a0e9-ccdf1da6fc8d,C1692321,C0278459,predominantly distributed in peripheral ,Cellular infiltrate,Structure of pulmonic area,1,X,[patf],[bpoc],,
0ecc70e0-801e-4151-b5ec-a55a4157fd81,GGO,C1692321,was most common ,GGO,Cellular infiltrate,1,X,????,[patf],????,
8f78c7e4-8b7c-40b2-b8bc-907fe60384cf,C0206750,C0005779,is with ,Coronavirus Infections,Blood Coagulation Disorders,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.100
656acfc5-ecdc-4af2-b782-1c8509799f54,C0567416,C0009450,prevent ,Molecule,Communicable Diseases,1,X,[sbst],[dsyn],,C01.539.221
656acfc5-ecdc-4af2-b782-1c8509799f54,C0567416,C0009450,control ,Molecule,Communicable Diseases,2,X,[sbst],[dsyn],,C01.539.221
8e3a06d1-60b7-4c85-ab5b-5bac589c2309,C0019134,C1175743,may attenuate course of ,heparin,SARS coronavirus,2,X,[bacs/orch/phsu],[virs],D09.698.373.400,B04.820.504.540.150.113.937
e7fb76b7-b84f-4c1d-922c-ac4e914dff25,C0079189,C0024115,appear key drivers ,cytokine,Lung diseases,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C08.381
34b49a9e-2444-4626-b9c1-c24678fd1498,C1879547,C0041904,has has linked to ,Activation action,Up-Regulation (Physiology),2,X,[acty],[moft],,G02.111.905;G05.308.850;G07.690.773.998
dc9d669f-ee5f-4ebc-b585-acc0cdf1b724,C1879547,C0127400,has has linked to ,Activation action,Mediator brand of benfluorex hydrochloride,2,X,[acty],[orch/phsu],,
dc9d669f-ee5f-4ebc-b585-acc0cdf1b724,C1879547,C0127400,protecting system from ,Activation action,Mediator brand of benfluorex hydrochloride,1,X,[acty],[orch/phsu],,
1d2aef62-9355-4f67-be4f-9795832c9907,C1879547,C0087111,suggest rational ,Activation action,Therapeutic procedure,2,X,[acty],[topp],,E02
8d92af04-2b3d-4544-ad8b-368fa739ae5c,C1879547,C0206750,suggest rational ,Activation action,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
6e258dfd-7225-43eb-8954-78be4dd80faf,C3463820,C0243026,prevent mortality in at least types of experimental ,Inhibition,Sepsis,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
6e258dfd-7225-43eb-8954-78be4dd80faf,C3463820,C0243026,prevent inflammatory response in at least types of experimental,Inhibition,Sepsis,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
6e258dfd-7225-43eb-8954-78be4dd80faf,C3463820,C0243026,prevent Disseminated Intravascular Coagulation in at least types of experimental,Inhibition,Sepsis,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C01.539.757;C23.550.470.790.500
9c5d283a-be73-452c-902b-dd6a437a3592,C3463820,C1155266,prevent pathologic systemic ,Inhibition,inflammatory response,2,X,[acty],[patf],F01.145.544;F02.463.425.475;F02.739.794.405,
1dac7181-901b-443b-b778-47e08cc0ede3,C3463820,C0012739,prevent ,Inhibition,Disseminated Intravascular Coagulation,2,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C15.378.100.220;C15.378.463.250;C15.378.925.220
c19f6849-e36b-4857-8bcd-72525ba974bd,C0009835,C0038172,also prevented death from ,Contact Inhibition,Staphylococcus aureus,2,X,[celf],[bact],G04.383,B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100
4735c337-e520-4ec5-af49-86e1b8de130c,C0009835,C0242966,also prevented death from ,Contact Inhibition,Systemic Inflammatory Response Syndrome,2,X,[celf],[dsyn],G04.383,C23.550.470.790;C23.550.835.900
77a7f41a-f856-4833-91f1-6dab945f60ee,C0009835,C0237798,also prevented death from ,Contact Inhibition,Nonhuman primate,2,X,[celf],[mamm],G04.383,
ee111577-6ff8-4352-ad39-2a4f59afd8c8,C0038172,C0237798,is in ,Staphylococcus aureus,Nonhuman primate,2,X,[bact],[mamm],B03.300.390.400.800.750.100;B03.353.500.750.750.100;B03.510.100.750.750.100;B03.510.400.790.750.100,
ed296582-3d07-4dbd-867b-22249f262d01,C0242966,C0237798,is in ,Systemic Inflammatory Response Syndrome,Nonhuman primate,2,X,[dsyn],[mamm],C23.550.470.790;C23.550.835.900,
ea3b17b9-ba29-4c57-8424-40c903282ab6,C0087111,C0597404,immune especially anti-influenza Drugs - dental services due to similarities between,Therapeutic procedure,Respiratory viruses,1,X,[topp],[virs],E02,
a9f216ae-6392-4cd2-addb-c7f3d969c5ae,C0087111,C0178784,could Indeed could ,Therapeutic procedure,Organ,1,X,[topp],[bpoc],E02,
5434ab2b-3153-4516-b06d-461d8a67c220,C0087111,C0031843,could Indeed could ,Therapeutic procedure,physiological aspects,1,X,[topp],[phsf],E02,x.x.x.x
5434ab2b-3153-4516-b06d-461d8a67c220,C0087111,C0031843,can cause severe morbidity ,Therapeutic procedure,physiological aspects,1,X,[topp],[phsf],E02,x.x.x.x
0a20f8f7-5a21-41ff-8cca-44a6438ad1f3,C0013404,C0035222,can rapidly progress to ,Dyspnea,Respiratory Distress Syndrome Adult,1,X,[sosy],[dsyn],C08.618.326;C23.888.852.371,C08.381.840;C08.618.840
e0c55e0b-1aec-4fef-8312-d1b4afacbf79,C2364082,C0206750,occur in in to ,Sense of smell impaired,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
e0c55e0b-1aec-4fef-8312-d1b4afacbf79,C2364082,C0206750,are frequent early symptoms of ,Sense of smell impaired,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
e0c55e0b-1aec-4fef-8312-d1b4afacbf79,C2364082,C0206750,were prevalent among ,Sense of smell impaired,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
e0c55e0b-1aec-4fef-8312-d1b4afacbf79,C2364082,C0206750,were independently highly associated with ,Sense of smell impaired,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
d1caa630-d8cf-4c20-abe3-7a90157e0fb3,C1175743,C0014442,binds angiotensin-converting ,SARS coronavirus,Enzymes,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,D08.811
24ca8e33-b885-4203-afde-d85d704c921b,C0521982,C0032105,analyzing ,Response to treatment,Plasma,1,X,[clna],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
7d810626-eff1-432f-8fa4-17efc31373fd,C0521982,C0304475,is with ,Response to treatment,Potassium supplement,1,X,[clna],[inch/phsu],,
f934f0f2-ccac-4be1-99fd-9d974d3915b4,C0920425,C0005525,is with ,cancer therapy,Biological Response Modifiers,1,X,[topp],[imft/phsu],,D27.505.696.477
68559a4c-f7bd-4fb2-a59c-e50eee48939c,PET/CT,C0016327,is with FDG,PET/CT,Fluorides,1,X,????,[inch/phsu],????,D01.248.497.158.380;D01.303.350.300
93f7e81a-6a2b-41fe-b11d-8394e83de473,PET/CT,FDG,is with FDG,PET/CT,FDG,1,X,????,????,????,????
6f180105-04dd-4f8d-9172-c78346fe2885,C1825598,C1516048,should should ,IMPACT gene,Assessed,2,X,[gngm],[acty],,
37a3addd-fc78-49ee-b0ae-c7ea1f6acd8f,C0242781,C0206750,control ,disease transmission,Coronavirus Infections,2,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
37a3addd-fc78-49ee-b0ae-c7ea1f6acd8f,C0242781,C0206750,was reconstructed from 9 120 ,disease transmission,Coronavirus Infections,1,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
6cc8b7fc-8a65-4165-b37f-eccf86d45818,C2948600,C1880177,examine ,Aim,Contribution,1,X,[inch/phsu],[acty],,
4fa1e854-6c94-4773-955e-d7f002d6047b,C2948600,C0011570,enhancing ,Aim,Mental Depression,1,X,[inch/phsu],[mobd],,F01.145.126.350
2208be61-4960-4b6e-a323-aaac496d6925,C0206750,C2259033,is associated with systemic ,Coronavirus Infections,activation of coagulation,1,X,[dsyn],[phsf],C02.782.600.550.200,
2208be61-4960-4b6e-a323-aaac496d6925,C0206750,C2259033,is associated with high prevalence ,Coronavirus Infections,activation of coagulation,2,X,[dsyn],[phsf],C02.782.600.550.200,
53fdb311-85cb-4a37-804d-6b03b9fd4b40,C1155266,C2259033,is with ,inflammatory response,activation of coagulation,1,X,[patf],[phsf],,
e64ccc12-b663-4416-9da4-d8d05b1fb268,C0023756,C0206750,was Due to ,Panthera leo,Coronavirus Infections,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.377.750.600.500,C02.782.600.550.200
e2c2ffff-325e-4be3-abd4-3e52ea3e9bbe,C0022671,COVID-19,thought ,Kidney Transplantation,COVID-19,2,X,[topp],[virs],E02.870.500;E04.936.450.485;E04.950.774.400,C000657245
488356f0-aa43-45cf-b404-04f4bc98d1a8,C0022671,C0012634,thought ,Kidney Transplantation,Disease,2,X,[topp],[dsyn],E02.870.500;E04.936.450.485;E04.950.774.400,C23.550.288
a451dbea-62ae-41b9-8255-53b4c840deda,C0004096,COVID-19,may at ,Asthma,COVID-19,3,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C000657245
3110c947-2681-4b67-92b8-b81ccb34b681,COVID-19,C0598197,is highly ,COVID-19,contagion,2,X,[virs],[npop],C000657245,
45016c44-363e-481c-973e-ce63ced2bc3f,C1880022,C0014442,using ,Characterization,Enzymes,1,X,[acty],[aapp/enzy],,D08.811
de36fb36-6a74-4167-9949-21145569edcb,C1880022,C0022702,using ,Characterization,Kinetics,1,X,[acty],[npop],,G01.374.661;G02.111.490
db54a236-31ef-4bd3-9444-26635a559851,centre,C1527398,effectively managed urgent dental ,centre,Emergency Care,1,X,????,[topp],????,N02.421.297
35fe5453-6519-4190-8c30-5a152c2e1228,DRC,C0206750,is currently experiencing ,DRC,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
65b60641-961e-443f-814a-5dd981efd64a,DRC,C0012634,is currently experiencing ,DRC,Disease,1,X,????,[dsyn],????,C23.550.288
b6bb07e3-bc0f-4877-a017-0671e98ac438,C0086418,C2926735,should ,Homo sapiens,Duration,1,X,[humn],[orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,
0c00d488-3cae-4a63-bb44-061fa7a6fe10,C3266814,C0270724,establish contingency ,Action,Infantile Neuroaxonal Dystrophy,2,X,[acty],[dsyn],,C10.228.140.744
19866353-cde9-4cd4-a876-d1e9e5d013c6,C0021400,C0206750,is potentially more lethal than ,Influenza,Coronavirus Infections,2,X,[dsyn],[dsyn],C02.782.620.365;C08.730.310,C02.782.600.550.200
07b0695b-dca8-4ddb-bbf8-5c0ed063e955,C1290857,C0206750,is with ,Disorder of face,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
deed7152-9925-4c61-8c18-8ca155d57b1d,C0037285,C0015230,are are reported including ,Skin Manifestations,Exanthema,2,X,[sosy],[sosy],C23.888.885,C17.800.257
e3481ebc-4f90-4224-b5fd-6cba5ad7c92c,C0015230,COVID-19,is in covid19 ,Exanthema,COVID-19,2,X,[sosy],[virs],C17.800.257,C000657245
6a474509-7805-4c71-8b31-a202427e4d76,C0015230,covid19,is in covid19 ,Exanthema,covid19,2,X,[sosy],????,C17.800.257,????
b9b4a651-c2c1-4d17-87a2-42ce3e8c756e,C0032285,CoV2,positive for CoV2,Pneumonia,CoV2,2,X,[dsyn],????,C08.381.677;C08.730.610,????
83d38aca-58ee-4b5e-a170-4baabb1711e9,PCR,CoV2,positive for CoV2,PCR,CoV2,2,X,????,????,????,????
6a92114f-26ef-441e-8a9b-7c5443a29b02,C2350332,C0039194,can inactivate ,Exosomes,T-Lymphocyte,1,X,[celc],[cell],A11.284.295.588.750;A11.284.430.214.190.875.190.880.495,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
ff5112d6-dd96-4fb2-ae7e-ca14a17f091a,C0035435,C0085253, includes ,Rheumatism,Adult-Onset Still Disease,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C05.550.114.154.870;C05.799.114.870;C17.300.775.099.870;C20.111.199.870
0ae21a02-2d84-4904-a226-8ce213c78e48,C0035435,C4054044, includes ,Rheumatism,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[dsyn],[dsyn],C05.799;C17.300.775,
a61e2ade-b9f0-4c3c-98e4-88d31d88b9ce,C0035435,C0085278, includes ,Rheumatism,Antiphospholipid Syndrome,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C20.111.197
1bc295a4-2442-4783-ad45-3dede44f553a,C0035435,C0039082,have have included in hyperferritinemic ,Rheumatism,Syndrome,1,X,[dsyn],[dsyn],C05.799;C17.300.775,C23.550.288.500
5df0674a-9ad5-4c76-acce-40625f731365,C0085253,C0039082,have have included in hyperferritinemic ,Adult-Onset Still Disease,Syndrome,1,X,[dsyn],[dsyn],C05.550.114.154.870;C05.799.114.870;C17.300.775.099.870;C20.111.199.870,C23.550.288.500
23c1fdbc-99af-4794-b925-ddc6bb03ce82,C4054044,C0039082,have have included in hyperferritinemic ,Secondary Hemophagocytic Lymphohistiocytosis,Syndrome,1,X,[dsyn],[dsyn],,C23.550.288.500
437c3a67-a0d3-431c-a507-296f1bbe7805,C0085278,C0039082,have have included in hyperferritinemic ,Antiphospholipid Syndrome,Syndrome,1,X,[dsyn],[dsyn],C20.111.197,C23.550.288.500
ea7ff977-7dd3-491d-9c9f-9d32994f77e4,C0206750,C1963758,may benefit from ,Coronavirus Infections,Immunomodulation,1,X,[dsyn],[topp],C02.782.600.550.200,E02.095.465;G12.535
f2e0e304-ee70-4f8b-b892-8112fd196c6c,C1433062,C0206750,is considered as prime target for anti ,3C-like protease SARS coronavirus,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],x.x.x.x,C02.782.600.550.200
46cf2db2-7be2-4d3e-bb35-a9d64c8f3ad9,C0071649,C1254351,possess favorable ,polyphenols,Pharmacologic Substance,1,X,[orch/phsu],[phsu],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,
0561f0e5-6fb0-4c9b-a737-778de56a7173,C0071649,C0206750,are promising ,polyphenols,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,C02.782.600.550.200
bb8fbeb9-58d6-432b-8db3-8bcc80a69bb9,C0206750,C0870392,has triggered massive ,Coronavirus Infections,debate,1,X,[dsyn],[acty],C02.782.600.550.200,
bb8fbeb9-58d6-432b-8db3-8bcc80a69bb9,C0206750,C0870392,has generated wide-ranging ,Coronavirus Infections,debate,1,X,[dsyn],[acty],C02.782.600.550.200,
6bd10098-dd71-42fb-89c1-895d7c2a9bd7,C0026636,C4505065,are most prevalent ,Mouth Diseases,Noncommunicable Diseases,1,X,[dsyn],[dsyn],C07.465,C23.550.291.500.750
402e2e4a-70c6-412a-b815-3ed7dffcc948,C0026636,C0035920,being recognized ,Mouth Diseases,Rubella,2,X,[dsyn],[dsyn],C07.465,C02.782.930.700.700
73880fdb-ed7e-495c-bed0-3aa1ad400b6b,C0026636,C0087111,being recognized ,Mouth Diseases,Therapeutic procedure,1,X,[dsyn],[topp],C07.465,E02
4a1cfe6e-47f2-4941-a496-d244d949093b,C0035920,C0087111,most expensive Rubella to,Rubella,Therapeutic procedure,1,X,[dsyn],[topp],C02.782.930.700.700,E02
ac2181b7-807c-47d2-8339-19fa89a98b05,C0242781,C0009450,possible route of be Here may ,disease transmission,Communicable Diseases,2,X,[patf],[dsyn],N06.850.310,C01.539.221
68db2eff-8ffd-4fd3-8afc-8a8f3806b829,C0012634,C0079189,associated with ,Disease,cytokine,2,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
68db2eff-8ffd-4fd3-8afc-8a8f3806b829,C0012634,C0079189,manifest ,Disease,cytokine,1,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
68db2eff-8ffd-4fd3-8afc-8a8f3806b829,C0012634,C0079189,known as ,Disease,cytokine,1,X,[dsyn],[aapp/imft],C23.550.288,D12.644.276.374;D12.776.467.374;D23.529.374
abef7dac-071e-4b47-bd8b-4de96971c337,C1609165,C1335676,are ,tocilizumab,Recombinant Antibody,4,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,
b01a1014-0a3f-42ca-8662-b1a505a6141e,C1609165,C0003250,are ,tocilizumab,Monoclonal Antibodies,2,X,[aapp/imft/phsu],[aapp/imft],x.x.x.x,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
f95f8f5f-0f35-47af-9ef2-f6def8b1e9f5,C4087043,C1335676,are ,Lenzilumab,Recombinant Antibody,4,X,[aapp/imft/phsu],[aapp/imft],,
e024753e-b703-4fe4-81f7-42327eea6716,C4087043,C0003250,are ,Lenzilumab,Monoclonal Antibodies,2,X,[aapp/imft/phsu],[aapp/imft],,D12.776.124.486.485.114.224;D12.776.124.790.651.114.224;D12.776.377.715.548.114.224
2baa21bd-5cea-400f-b5e6-53cb84f2ced7,C4087043,C0021760,are ,Lenzilumab,Interleukin-6,2,X,[aapp/imft/phsu],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
a6b73ef8-94d1-41df-bf70-1a468bed25e0,hypoxic,C0206750,associated with ,hypoxic,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
e4a9c08e-c6d8-4363-9125-3a4c78b7d5d8,C1609165,C0264490,have have proposed as potential treatment for ,tocilizumab,Acute respiratory failure,2,X,[aapp/imft/phsu],[dsyn],x.x.x.x,
a94ec5db-615c-4143-93cd-f1b2c9a9d525,C4087043,C0079189,is in management of ,Lenzilumab,cytokine,2,X,[aapp/imft/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
31f402f6-c9e7-460f-b9e9-981a22997107,C4087043,C0039082,is in management of ,Lenzilumab,Syndrome,2,X,[aapp/imft/phsu],[dsyn],,C23.550.288.500
8f08ad61-24cc-44e6-bcca-5f98dd578879,C1739395,C0206750,has has scarcely reported in patients with ,Takotsubo Cardiomyopathy,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.945.900.500,C02.782.600.550.200
5c415f09-b30a-48dc-a241-34d0e2ecc01e,C0079189,C1739395,trigger ,cytokine,Takotsubo Cardiomyopathy,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C14.280.945.900.500
ac9e4800-4281-494c-afa9-339e27721892,C0544688,C0206750,rare neurological complication of disease of,complication of disease,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
483825e0-65db-4cb8-a183-4b7ecc00f394,C1521827,C2349975,is fundamental requirement for ,Preparation,Enhance (action),1,X,[acty],[acty],,
efa11635-e237-4ef4-8f1c-88fd6ad4597c,C1521827,C2917745,is fundamental requirement for ,Preparation,Safe-Guard,1,X,[acty],[orch/phsu],,
4ba6977f-e8b5-483b-9521-e185dcff079d,C4267729,C3698360, includes ,Respiratory pathogens,Middle East Respiratory Syndrome Coronavirus,1,X,[orgm],[virs],,B04.820.504.540.150.113.750
24e1cf15-4a77-4e48-b3f1-e17cddf7a43c,C0599878,C0035222,ranging from asymptomatic to ,disease characteristic,Respiratory Distress Syndrome Adult,4,X,[patf],[dsyn],,C08.381.840;C08.618.840
f82380e5-d882-47ad-9a23-278c90b864ca,C0010357,C0700271,is in antibody binding to ,Cross Reactions,M Protein multiple myeloma,2,X,[moft],[aapp/imft],G12.122.281,x.x.x.x
2e246873-9802-4d99-88a7-67df488108a2,C3265468,C0282682,indicating presence of non ,Virus Neutralization,Antibodies Blocking,2,X,[moft],[aapp/imft/irda],,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
b2dd00ba-b538-4439-94cf-a3d205b46b20,C3265468,C0003316,indicating presence of non ,Virus Neutralization,Epitopes,2,X,[moft],[imft],,D23.050.550
ec11423d-9f7c-41ea-9c64-d6564af8dc49,C0282682,C0282632,will lead to ,Antibodies Blocking,Antibody-Dependent Enhancement,4,X,[aapp/imft/irda],[comd],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,G06.920.095;G12.113
b68c4ec9-168c-4da2-8d84-3633b982a058,C0282682,C0012634,will lead to ,Antibodies Blocking,Disease,2,X,[aapp/imft/irda],[dsyn],D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143,C23.550.288
09d7deb8-d5cf-4f80-ad3a-8a1897c23f63,C1457887,C0683325,is In terms of ,Symptoms,clinical aspects,1,X,[sosy],[clna],,
c5fa5e1a-7f70-4403-84eb-f322484dd1a1,C0683325,C0015219,might might helpful in ,clinical aspects,Biological Evolution,1,X,[clna],[genf],,G05.045;G16.075
9c7f1f2c-3a6f-4f56-ba23-e1dc6d3f5b19,C0086418,C0018801,is with prior ,Homo sapiens,Heart failure,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C14.280.434
7ea2dd7a-fecc-4f36-a08d-ef1ec8b0d1e9,C0061751,C0206750,rapidly evaluated for treatment of patients with ,Glycyrrhizic Acid,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.455.849.919.530.466,C02.782.600.550.200
56f37330-4ea4-4289-a695-44e448245f50,titers,C0206750,Noncommunicable Diseases,titers,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
cd1f52b1-bab2-4098-8e3c-db7ecb9c65ef,titers,C4505065,Noncommunicable Diseases,titers,Noncommunicable Diseases,1,X,????,[dsyn],????,C23.550.291.500.750
d1e9a915-657d-4f54-ba44-75a818168e3a,C4505065,C1167395,may influence ,Noncommunicable Diseases,Host (organism),1,X,[dsyn],[orgm],C23.550.291.500.750,
3212e598-274e-4336-b47f-ede41e61250f,C4505065,C0021053,may influence ,Noncommunicable Diseases,Immune System Diseases,1,X,[dsyn],[dsyn],C23.550.291.500.750,C20
e289fe5c-d93f-4fad-9e48-cb60aad1613e,C2745965,C0948008, includes ,Emergencies [Disease/Finding],Ischemic stroke,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,
ac840b67-c61f-46cd-b816-764c75952f88,C0333165,C0040861,require emergent ,Acute obstruction,Triage,1,X,[patf],[topp],,N02.421.297.900
2d730b9c-cae7-4a6d-aa58-b60c1454563a,C0948008,C0040861,require emergent ,Ischemic stroke,Triage,1,X,[dsyn],[topp],,N02.421.297.900
23f77224-b225-46e9-bb79-7a2e5cccad0a,C0333165,C4534538,require emergent ,Acute obstruction,Mechanical thrombectomy,1,X,[patf],[topp],,
d9f39514-6cd8-41cd-88d8-28b06bab9c1d,C0948008,C4534538,require emergent ,Ischemic stroke,Mechanical thrombectomy,1,X,[dsyn],[topp],,
7d6e8db6-a1f0-4d39-93ee-822380e6b307,C0333165,C0225990,is with ,Acute obstruction,Large blood vessel structure,1,X,[patf],[bpoc],,
2f67a6b6-d63a-4446-bb0d-12cad3e50bf5,C0948008,C0225990,is with ,Ischemic stroke,Large blood vessel structure,1,X,[dsyn],[bpoc],,
765e4191-938e-40b9-8ed0-bbd3095a1e7d,C0948008,C0333165,is with ,Ischemic stroke,Acute obstruction,1,X,[dsyn],[patf],,
357ff41f-d6e2-4bba-963c-d0d11da542e3,C0023175,C1433062,were studied through docking against ,Lead,3C-like protease SARS coronavirus,4,X,[elii/hops],[aapp/enzy],D01.268.556.435;D01.552.544.435;x.x.x.x,x.x.x.x
c2827739-aa40-4592-b009-23fe3e7dde0a,C0567416,C1433062,were studied through docking against ,Molecule,3C-like protease SARS coronavirus,4,X,[sbst],[aapp/enzy],,x.x.x.x
fadb918b-d572-439e-8682-5664bbefc2c5,C0206172,C0206750,been how affected by current ,Diabetic Foot,Coronavirus Infections,2,X,[dsyn],[dsyn],C14.907.320.191;C17.800.893.592.450.200;C19.246.099.500.191;C19.246.099.937.250,C02.782.600.550.200
ff89ef50-ae90-4826-b479-4b832396f207,C0071097,C1175743,can reduce ,pioglitazone,SARS coronavirus,2,X,[orch/phsu],[virs],D02.886.675.933.250;D03.383.129.708.933.250,B04.820.504.540.150.113.937
df7fca32-f186-4aa5-9af6-0a3aecc6a887,C0071097,C0301872,moderating exaggerated ,pioglitazone,Immune response,4,X,[orch/phsu],[ortf],D02.886.675.933.250;D03.383.129.708.933.250,
8d795de8-9249-4c23-930c-b57e266fdd07,C0071097,T2DM,can can continued in people with T2DM,pioglitazone,T2DM,2,X,[orch/phsu],????,D02.886.675.933.250;D03.383.129.708.933.250,????
8f293ce8-5ef4-45e8-abe4-e228cfa60e95,C0008139,C0319157,possess ability on potential go with ,Chiroptera,AS virus,1,X,[mamm],[virs],B01.050.150.900.649.313.937,
deed9cc5-673a-4867-8c11-e268191d526e,C0008139,C0018563,possess ability on other ,Chiroptera,Hand,2,X,[mamm],[bpoc],B01.050.150.900.649.313.937,A01.378.800.667
335c7d9f-8bfa-4eff-9e92-7f39176b1cff,C1175743,C0035222,include ,SARS coronavirus,Respiratory Distress Syndrome Adult,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.840;C08.618.840
53e2ef00-3eff-4837-8d15-3fd6d37ad6a4,C0013227,C0079189,are studied associated with ,Pharmaceutical Preparations,cytokine,1,X,[phsu],[aapp/imft],D26,D12.644.276.374;D12.776.467.374;D23.529.374
26e268e8-83e7-4883-8682-ebcf8898107b,C0032285,C0079189,are associated with ,Pneumonia,cytokine,1,X,[dsyn],[aapp/imft],C08.381.677;C08.730.610,D12.644.276.374;D12.776.467.374;D23.529.374
d83326f4-265b-4cf6-b9ee-48d5dcb47afe,C0013227,C0021760,belonging as anti ,Pharmaceutical Preparations,Interleukin-6,1,X,[phsu],[aapp/imft],D26,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
67232220-ef26-41af-b97d-2f1111fc5ba5,C0206750,C0022646,is in ,Coronavirus Infections,Kidney,2,X,[dsyn],[bpoc],C02.782.600.550.200,A05.810.453
7eda2de4-9134-4b8d-bbe0-ba370a1d0a65,C0012634,C0022646,is in ,Disease,Kidney,2,X,[dsyn],[bpoc],C23.550.288,A05.810.453
407d4b21-99da-4a0e-9e71-05d863c1ff53,C0022646,C0206750,in Disease is,Kidney,Coronavirus Infections,1,X,[bpoc],[dsyn],A05.810.453,C02.782.600.550.200
407d4b21-99da-4a0e-9e71-05d863c1ff53,C0022646,C0206750,had positive ,Kidney,Coronavirus Infections,1,X,[bpoc],[dsyn],A05.810.453,C02.782.600.550.200
92f614a1-87d6-4d50-ae66-632ebecc1f39,C1185740,C0022646,are often initial presentation among ,Tract,Kidney,2,X,[bpoc],[bpoc],,A05.810.453
b3618cf3-f667-4826-a9fe-9c957ca42f69,C0037090,C0022646,are often initial presentation among ,Signs and Symptoms Respiratory,Kidney,1,X,[sosy],[bpoc],C23.888.852,A05.810.453
cacf0840-eef7-4080-a4b3-93f224bb1257,C0020625,C0021368,may reflect underlying ,Hyponatremia,Inflammation,2,X,[dsyn],[patf],C18.452.950.620,C23.550.470
fe7fd471-f40a-4da0-939e-8f99f92e157c,C0020625,C0022671,has has reported in case series ,Hyponatremia,Kidney Transplantation,3,X,[dsyn],[topp],C18.452.950.620,E02.870.500;E04.936.450.485;E04.950.774.400
e59c2f08-a065-4183-8601-331739098660,C0020625,C0206750,is in ,Hyponatremia,Coronavirus Infections,1,X,[dsyn],[dsyn],C18.452.950.620,C02.782.600.550.200
284cc5ef-b7b9-47fb-b702-9cdc8375f14f,C0020625,C0021141,secondary to ,Hyponatremia,Inappropriate ADH Syndrome,2,X,[dsyn],[dsyn],C18.452.950.620,C10.228.140.617.738.320;C18.452.950.626;C19.700.490
be934a4e-6049-40a6-a2a7-d57a8757e8c0,C0020625,C0022646,may occur more frequently in ,Hyponatremia,Kidney,2,X,[dsyn],[bpoc],C18.452.950.620,A05.810.453
90a6be8b-ff19-45fe-8dc7-03bb305a05e8,C1550100,C0034386,were obtained on 14 day of ,Specimen Type - Serum,Quarantine,1,X,[bdsu],[topp],,N06.850.780.200.450.700
af0beb89-70e4-468b-b3d0-e2a23c6154a4,C1707455,C0032042,is with ,Comparison,Placebos,2,X,[acty],[topp],,D26.660;E02.785
4a010a79-d102-4c6d-8cfa-224c704f06d1,C1706778,C0028778,using ,Allocation,Obstruction,1,X,[acty],[patf],,
9a6f5d38-7888-46c5-ae6c-bb53d29cb810,ity118,C0022709,widely expressing ,ity118,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
96f09cbf-269c-4b59-b005-e9557279be75,C0023911,C0206750,is with ,Transplantation of liver,Coronavirus Infections,1,X,[topp],[dsyn],E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490,C02.782.600.550.200
a3a0d171-6051-4b1e-9c18-168f72752320,C1175175,C1457887,as clinical,Severe Acute Respiratory Syndrome,Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
a3a0d171-6051-4b1e-9c18-168f72752320,C1175175,C1457887,COVID-19 as clinical ,Severe Acute Respiratory Syndrome,Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,
7843cc3f-3b52-4415-8194-5e7d11f2ec74,C1175175,C0024115,as clinical,Severe Acute Respiratory Syndrome,Lung diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C08.381
66afa858-628c-4941-89e7-f5c96cda3c55,C0683325,C0275522,were compared among patients with disease ,clinical aspects,Asymptomatic Infections,3,X,[clna],[dsyn],,C23.550.291.187.500
bcf2d8d5-3f4a-49b6-82b4-70313b8ad8ee,C0020284,C0030858,were significantly higher in ,Hydrogenase,Pentaerythritol Tetranitrate,2,X,[aapp/enzy],[orch/phsu],D08.811.682.400,D02.033.455.706.690
525bcf46-77cd-434a-a1bc-637ee594d6b4,C0024312,C0242656,might might risk factors for disease ,Lymphopenia,Disease Progression,2,X,[dsyn],[patf],C15.378.553.546.605;C20.673.627,C23.550.291.656
baf1c71d-fe9f-485c-9558-812fc54b6142,C0024312,C0206750,might might risk factors for disease ,Lymphopenia,Coronavirus Infections,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
baf1c71d-fe9f-485c-9558-812fc54b6142,C0024312,C0206750,was associated with severe ,Lymphopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
baf1c71d-fe9f-485c-9558-812fc54b6142,C0024312,C0206750,was common in early stage after onset of ,Lymphopenia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C02.782.600.550.200
c5bd56e2-a792-49b9-80e0-315993639d4a,C0019392,C1533719,is classical ,Hesperidin,Discipline of Herbal Medicine,1,X,[orch/phsu/vita],[bmod],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,H01.158.273.118.598.500;H01.158.703.060.500;H02.628.190
9cf4aef6-e549-48cf-82e0-5595a23a8e01,C0019392,C1360419,is well-known ,Hesperidin,Herbal Drugs,1,X,[orch/phsu/vita],[phsu],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
a2d20312-0bf6-4beb-bc8a-ea6fa7985b40,C0019392,C0003402,is well-known ,Hesperidin,Antioxidants,1,X,[orch/phsu/vita],[phsu],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
585a90fd-6a11-4516-8d48-c8d7d5905879,C0019392,C0022709,entering Host Cell through,Hesperidin,Peptidyl-Dipeptidase A,1,X,[orch/phsu/vita],[aapp/enzy/imft],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,D08.811.277.656.350.350.687
9c5a07e0-24cf-4994-bb0f-00d0ee75a5ad,C0019392,C0597357,entering Host Cell through,Hesperidin,receptor,1,X,[orch/phsu/vita],[aapp/rcpt],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
e2c5a329-d81a-4ebf-94ae-01ee38e4d4f8,C0019392,C1819995,entering ,Hesperidin,Host Cell,1,X,[orch/phsu/vita],[celc],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
76ad2c07-2354-48c1-8a0f-3658c6c0cddc,C0019392,C0206750,can block ,Hesperidin,Coronavirus Infections,1,X,[orch/phsu/vita],[dsyn],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,C02.782.600.550.200
73b9e8f1-9aa6-41d1-aef0-85ccc6d44769,C0439962,C2929959,is with ,Mixture,Diosmin / Hesperidin,1,X,[sbst],[phsu],,
33db8be1-8bbf-4709-8f7b-57e368c3acc0,C2929959,C1861172,protect against ,Diosmin / Hesperidin,Venous Thromboembolism,1,X,[phsu],[dsyn],,C14.907.355.590.700
d1e61be5-1822-472c-a17e-283055ff3972,C0439962,C1861172,protect against ,Mixture,Venous Thromboembolism,1,X,[sbst],[dsyn],,C14.907.355.590.700
c2adb839-b75f-41a4-ab38-a1d86a13b143,C0019392,C0450442,might might used as prophylactic ,Hesperidin,Agent,1,X,[orch/phsu/vita],[chvf],D03.383.663.283.266.450.252.500;D03.633.100.150.266.450.252.500,
b705583c-b99e-4a86-9104-1261fb844f36,nt,C0009450,have COVID ,nt,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
b083df20-4c3e-457f-ad43-1b9876d01ed0,C0206419,spector,raised spector ,Genus: Coronavirus,spector,1,X,[virs],????,B04.820.504.540.150,????
678e9664-9b17-4f85-8b0e-b1a3caa46084,C1880355,C1175175,is with ,Discover,Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
eb5f9205-7f49-426e-a356-1d56dbdb2b7f,C1412002,C0850149,characterized by dyspnea,Atypical pneumonia,Dry cough,1,X,[dsyn],[sosy],,
5f8e6742-fb03-4350-b58b-703ef504a0c3,C1412002,C0476474,characterized by dyspnea,Atypical pneumonia,persistent fever,1,X,[dsyn],[patf],,
f94514f9-9227-4304-94e7-02ec09653f01,C1412002,dyspnea,characterized by dyspnea,Atypical pneumonia,dyspnea,1,X,[dsyn],????,,????
7b442236-f1a3-45dc-a538-8f16bc96da80,C1412002,C0011991,sometimes accompanied by ,Atypical pneumonia,Diarrhea,1,X,[dsyn],[sosy],,C23.888.821.214
d9d4f05f-a414-4f25-aaab-4bd0e5c3344d,C0012634,C0026766,often followed by ,Disease,Multiple Organ Failure,1,X,[dsyn],[patf],C23.550.288,C23.550.835.525
1b177a1b-2873-46ba-8e86-e7add0d6b268,C2936413,C0035950, includes wild ,Host Range,Ruminants,1,X,[npop],[mamm],G06.462.380;G16.527.200.380,B01.050.150.900.649.313.500.380
0baaaf76-ec1f-4895-a587-9bc71c457ba2,C0318856,C1328821,has ,Porcine Respiratory Coronavirus,tissue tropism,1,X,[virs],[phsf],B04.820.504.540.150.075.500.500.600,
caabe153-fb68-4c05-b326-28e8208deebe,C0318856,C1516375,has ,Porcine Respiratory Coronavirus,Cellular Tropism,2,X,[virs],[celf],B04.820.504.540.150.075.500.500.600,
ba72e5e8-4900-472e-9b0d-777d80ca0c0e,C0318856,C0024109,has ,Porcine Respiratory Coronavirus,Lung,1,X,[virs],[bpoc],B04.820.504.540.150.075.500.500.600,A04.411
c6b230f6-0a30-4a47-af16-e94b3cf8ca56,C1516375,C0024109,is in ,Cellular Tropism,Lung,1,X,[celf],[bpoc],,A04.411
b5a95323-46b3-40db-88ba-30510c06a5ff,C0872315,C1456573,cause major threat to ,Communicable Diseases Emerging,Global Health,1,X,[dsyn],[bmod],C01.539.221.500,H02.403.371;N01.400.337
4fd03b06-3648-4177-8d89-d152e3287ee3,C0004933,C0034019,be included in ,Behavior Therapy,public health medicine (field),1,X,[topp],[bmod],F04.754.137,H02.403.720;N01.400.550;N06.850
9b2b4843-388e-4202-ab50-12958ef3167b,C2728259,C0547605,assess its efficacy regarding ,Program,prevention of infection,4,X,[orch/phsu],[topp],V02.355.750,
ddc673cc-e457-458f-bd3d-2648f724eb15,C2728259,C0678222,assess its efficacy regarding ,Program,Breast Carcinoma,2,X,[orch/phsu],[neop],V02.355.750,C04.588.180;C17.800.090.500
8d6df616-86f1-44a5-9550-5fdf7cc31b48,C2728259,C0006141,can can transferred to high-volume ,Program,Breast,2,X,[orch/phsu],[bpoc],V02.355.750,A01.236
7d478ce0-c80c-4c93-b26c-8724a24ef424,C0006145,C0185027,bettered by,Breast Diseases,Imbrication (procedure),1,X,[dsyn],[topp],C17.800.090,
7d478ce0-c80c-4c93-b26c-8724a24ef424,C0006145,C0185027,bettered by,Breast Diseases,Imbrication (procedure),1,X,[dsyn],[topp],C17.800.090,
912da644-f265-4d5d-bd82-024d9ea10f64,C0599878,C0011945,is in ,disease characteristic,Physical Dialysis,1,X,[patf],[npop],,E05.196.353;G02.186
c6eece3e-1916-4f6c-99ce-b6003064e632,C4281807,C1512488,is Homologous Protein of S,Vitronectin human,Homologous Protein,2,X,[aapp/bacs],[aapp],,
366d861a-bbaf-4c9c-a935-062344f11f9a,C0039336,C0034386,suggesting ,Taste Perception,Quarantine,3,X,[ortf],[topp],F02.830.816.724;G11.561.790.724,N06.850.780.200.450.700
3de3a449-faf6-4a57-9866-aa198e09f44c,C0679381,C0206750,is with ,Pediatric Disorder,Coronavirus Infections,7,X,[dsyn],[dsyn],,C02.782.600.550.200
6986987a-781e-428a-8a01-b029c902b096,C0027882,C1175743,are responsible for ,Neurons,SARS coronavirus,6,X,[cell],[virs],A08.675;A11.671,B04.820.504.540.150.113.937
4dce9ac0-6b7e-40fe-b749-97dc1fdf96ce,C0035380,C1175743,is currently standard for ,Reverse Transcription,SARS coronavirus,3,X,[genf],[virs],G02.111.873.500;G05.297.700.500,B04.820.504.540.150.113.937
53ad557b-4ed0-464a-b28a-68def5e241dd,C0370003,C0229671,spiking ,Specimen,Serum,3,X,[sbst],[bdsu],,A12.207.152.846;A15.145.846
f97b9bf4-6d1d-460c-bb92-588528adfa03,C0370003,C0036087,spiking ,Specimen,saliva,3,X,[sbst],[bdsu],,A12.200.666
f97b9bf4-6d1d-460c-bb92-588528adfa03,C0370003,C0036087, includes nasopharyngeal swab ,Specimen,saliva,2,X,[sbst],[bdsu],,A12.200.666
346433fb-809b-47cb-ab66-097eded58375,C0370003,C3687742,spiking ,Specimen,Oropharyngeal swab,3,X,[sbst],[bdsu],,
346433fb-809b-47cb-ab66-097eded58375,C0370003,C3687742, includes nasopharyngeal swab ,Specimen,Oropharyngeal swab,2,X,[sbst],[bdsu],,
8dfb4ab4-3a0f-4163-ae49-80c49475a71b,C0370003,C0035380,using conventional ,Specimen,Reverse Transcription,4,X,[sbst],[genf],,G02.111.873.500;G05.297.700.500
33d11ec3-252c-40f5-b181-71a1bb8581cc,C0035380,C0370003,is in simulated patient ,Reverse Transcription,Specimen,1,X,[genf],[sbst],G02.111.873.500;G05.297.700.500,
c24aceb3-6269-4681-b590-e1fbea7748f8,C1563373,C0370003,is in simulated patient ,LAMP2 protein human,Specimen,6,X,[aapp/bacs],[sbst],x.x.x.x,
3dd1f319-1c17-4654-9ce3-b832fde42836,C1511790,C0370003,is in simulated patient ,Detection,Specimen,3,X,[topp],[sbst],,
3dd1f319-1c17-4654-9ce3-b832fde42836,C1511790,C0370003,is in low viral load ,Detection,Specimen,1,X,[topp],[sbst],,
3dd1f319-1c17-4654-9ce3-b832fde42836,C1511790,C0370003,is in 10 of ,Detection,Specimen,1,X,[topp],[sbst],,
64d56a36-b334-4a56-b171-d31659cf6fef,C2948600,C1514474,provide insights regarding ,Aim,Prognostic Factors,2,X,[inch/phsu],[clna],,E01.789
f229862c-3a95-4821-86a8-72f6fa84b385,C0024117,C2074898,is chronic Lung Inflammations in,Chronic Obstructive Airway Disease,chronic Lung Inflammations,4,X,[dsyn],[dsyn],C08.381.495.389,
6cdd9489-177d-4225-998d-692948c163d8,C2074898,C0001883,causes Airway Obstruction in,chronic Lung Inflammations,Airway Obstruction,4,X,[dsyn],[dsyn],,C08.618.846.185
846cb588-d074-4960-af8b-93328fc3ac10,C2074898,C0231999,causes Airway Obstruction in,chronic Lung Inflammations,Airflow,2,X,[dsyn],[phsf],,
88539fa8-884b-4ee9-8755-09327680043b,C2074898,C0035245,causes Airway Obstruction in,chronic Lung Inflammations,Respiratory physiology,2,X,[dsyn],[phsf],,G09.772
ed7df7b2-8bdb-4a81-bd42-f639362f1951,C1457887,COPD,using COPD ,Symptoms,COPD,2,X,[sosy],????,,????
2f324e09-141f-4d8e-a8d0-c7f57bbef5ce,C0013404,C1540289,using modified ,Dyspnea,CD200 gene,2,X,[sosy],[gngm],C08.618.326;C23.888.852.371,
e154b8b2-5591-4a9b-9c6e-4b1c5b8a99da,C0013404,C0018026,using modified ,Dyspnea,Gold,2,X,[sosy],[elii/phsu],C08.618.326;C23.888.852.371,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
e620b044-323d-417e-96a8-743993bbd8dc,C1947933,C2960841,includes smoking cessation ,care activity,Lifestyle change therapy,2,X,[acty],[topp],,
4912a673-9d29-4166-b4b7-cc7c2c7820fc,C1947933,C0042196,includes smoking cessation ,care activity,Vaccination,2,X,[acty],[topp],,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
4c469c50-7842-44a6-9226-54546365d7cc,C1947933,C0006280,includes smoking cessation ,care activity,Bronchodilator Agents,2,X,[acty],[phsu],,D27.505.696.663.050.110;D27.505.954.796.050.100
0b4a1f69-63f1-4d7e-a435-0cec0b968607,C0024117,C0206750,worsens risk of ,Chronic Obstructive Airway Disease,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.381.495.389,C02.782.600.550.200
0b4a1f69-63f1-4d7e-a435-0cec0b968607,C0024117,C0206750,were most prevalent comorbidities in ,Chronic Obstructive Airway Disease,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.381.495.389,C02.782.600.550.200
cb30c30c-1c56-4a9e-bc83-caceb1407f32,C0024117,C0242656,worsens risk of ,Chronic Obstructive Airway Disease,Disease Progression,4,X,[dsyn],[patf],C08.381.495.389,C23.550.291.656
07c32d79-cc5b-4449-89a3-bed128e7e17f,C1511790,C1706005,has sensitivity for ,Detection,CD40LG wt Allele,6,X,[topp],[gngm],,
3f08851e-96e9-4017-81c7-238e527223a5,C0009262,C0013227,is well-known ,Colchicine,Pharmaceutical Preparations,3,X,[orch/phsu],[phsu],D03.132.225,D26
8f8cbf01-de35-45cb-9839-1ee775a2fe91,C0162529,C0398623,be associated with ,Colitis Ischemic,Thrombophilia,3,X,[dsyn],[dsyn],C06.405.205.265.115;C06.405.469.158.188.115;C14.907.286,C15.378.925
565fd4a4-5e47-42cb-904b-e0efecc9d553,C0206750,U.S.,pandemic simultaneously with U.S. ,Coronavirus Infections,U.S.,2,X,[dsyn],????,C02.782.600.550.200,????
315fd259-83b5-4d2f-89b4-cd023ec6ceae,C0206750,C0242402,pandemic simultaneously with U.S. ,Coronavirus Infections,Opioids,2,X,[dsyn],[hops/orch/phsu],C02.782.600.550.200,D27.505.696.277.600.500;D27.505.696.663.850.014.760.500;D27.505.954.427.040.550.500;D27.505.954.427.210.600.500
a4a9b8a3-960e-44a4-a83b-2f4cf5c28564,C3825816,C0206750,is with ,Pneumonia in children,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
2bf7d4fd-157d-4c99-b002-dd5769997336,C0021054,COVID-19,participate in ,Immunologic Factors,COVID-19,5,X,[imft],[virs],D27.505.696.477,C000657245
c79e157b-3986-43c4-84d2-3497894f18ab,C0497552,COVID-19,is in ,Congenital neurologic anomalies,COVID-19,1,X,[cgab],[virs],C10.500;C16.131.666,C000657245
ad1deabe-8f28-424d-a940-983a49e80a4d,C0030567,COVID-19,long-term sequalae of ,Parkinson Disease,COVID-19,1,X,[dsyn],[virs],C10.228.140.079.862.500;C10.228.662.600.400;C10.574.812,C000657245
0d39ee6f-49f2-492f-9df3-de5f04db0b45,C0002395,COVID-19,long-term sequalae of ,Alzheimer's Disease,COVID-19,1,X,[dsyn],[virs],C10.228.140.380.100;C10.574.945.249;F03.615.400.100,C000657245
8349b5c6-a7cd-492b-97f3-4fe004fb07db,C1452534,COVID-19,been ,ACE protein human,COVID-19,1,X,[aapp/bacs],[virs],x.x.x.x,C000657245
d4fc78af-0151-4eb2-b209-7b82d107e913,C1452534,C2937289,been ,ACE protein human,Adapt (substance),1,X,[aapp/bacs],[orch],x.x.x.x,
72380167-544a-44b0-96b5-ddbcc8d307f3,C0458827,C0079189,are associated with hyperproduction of ,Airway structure,cytokine,1,X,[bpoc],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
59946ec9-64b6-42d1-adea-0b96b8b98335,C0023516,C0021760,in changes is ,Leukocytes,Interleukin-6,1,X,[cell],[aapp/imft],A11.118.637;A15.145.229.637;A15.382.490,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
b22b445c-458c-4151-8e8d-7bbac78063de,C0243083,COVID-19,is with ,associated disease,COVID-19,1,X,[patf],[virs],,C000657245
fda0036e-5ac6-4482-b996-3b926831afeb,C0023516,C0243083,is with ,Leukocytes,associated disease,1,X,[cell],[patf],A11.118.637;A15.145.229.637;A15.382.490,
b2ff6097-096f-44ca-9432-3acc52e8e22a,C0023516,C0024432,is in ,Leukocytes,macrophage,1,X,[cell],[cell],A11.118.637;A15.145.229.637;A15.382.490,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
7e7977e7-3435-40f5-9e31-89dd791b1ffa,C0079189,C0012634,lead to ,cytokine,Disease,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.288
1d50e65e-765a-49a3-8561-cc15cbd58e07,C3463820,C0005456,serving as ,Inhibition,Binding Sites,1,X,[acty],[rcpt],F01.145.544;F02.463.425.475;F02.739.794.405,G02.111.570.120
12802b13-1db8-47f2-a920-ab2c33084fdf,C3463820,C0960880,supposedly increases expression of ,Inhibition,angiotensin converting enzyme 2,1,X,[acty],[aapp/enzy],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
070df188-4e05-4f21-88a0-dd2a7c229945,RAS,C0007222,remains cornerstone therapy in populations with ,RAS,Cardiovascular Diseases,1,X,????,[dsyn],????,C14
ebce58a3-d2ac-4596-b80e-9bea28303c2c,C3463820,C0007222,remains cornerstone therapy in populations with ,Inhibition,Cardiovascular Diseases,1,X,[acty],[dsyn],F01.145.544;F02.463.425.475;F02.739.794.405,C14
f9ebb238-3746-4dfa-94e7-cffa322e01aa,C0003451,C1335057,with Chemoprevention is,Antiviral Agents,PTPN22 protein human,1,X,[phsu],[aapp/enzy],D27.505.954.122.388,x.x.x.x
93a485e7-8697-43a0-b44a-4ccf974ea62a,C0282515,C0003451,is with ,Chemoprevention,Antiviral Agents,1,X,[topp],[phsu],E02.319.162,D27.505.954.122.388
7aa495b3-5e73-48e9-805c-53a0280398ce,C0003297,COVID-19,are available during ,Antiemetics,COVID-19,1,X,[phsu],[virs],D27.505.696.663.050.030;D27.505.954.427.095;D27.505.954.483.200,C000657245
c2b8cc5d-7bad-4cbb-9753-f2a372367224,C0037090,COVID-19,were suspected for ,Signs and Symptoms Respiratory,COVID-19,1,X,[sosy],[virs],C23.888.852,C000657245
c71bfcb7-ad02-482d-bf9e-d8c6f78ed93e,C0597357,C1175175,associated with ,receptor,Severe Acute Respiratory Syndrome,2,X,[aapp/rcpt],[dsyn],,C02.782.600.550.200.750;C08.730.730
9af68416-b024-486d-9067-ee6b12c89503,C0001617,C0035222,are commonly used as ,Adrenal Cortex Hormones,Respiratory Distress Syndrome Adult,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.381.840;C08.618.840
9af68416-b024-486d-9067-ee6b12c89503,C0001617,C0035222,were associated with higher rate of ,Adrenal Cortex Hormones,Respiratory Distress Syndrome Adult,1,X,[horm/orch/phsu],[dsyn],D06.472.040,C08.381.840;C08.618.840
7c34fa8a-c729-4833-aba1-12627bbe695b,ity62,C0036087,is near ubiquitously present in ,ity62,saliva,1,X,????,[bdsu],????,A12.200.666
2ab04b70-7865-498b-b99e-0d76f92c869e,C0005779,C1514474,currently are considered as ,Blood Coagulation Disorders,Prognostic Factors,1,X,[dsyn],[clna],C15.378.100,E01.789
db7e2893-700b-4e90-8d54-5f18243456c6,C1706202,C0012634,was performed on ,Search - action,Disease,3,X,[acty],[dsyn],,C23.550.288
14ccd70f-e2b0-4030-8b3c-17a6a686b959,C0150457,COV,be associated with better prognosis in patients with severe COV ,Anticoagulant therapy,COV,4,X,[topp],????,,????
23c78271-1276-48a4-bccd-4e814b7b0bfb,C0150457,C0009450,be associated with better prognosis in patients with severe COV ,Anticoagulant therapy,Communicable Diseases,4,X,[topp],[dsyn],,C01.539.221
096b1f43-7f80-4926-896c-e527c979c782,C0005778,C1175743,is in patients with CoV2 ,Blood coagulation,SARS coronavirus,2,X,[ortf],[virs],G09.188.390.150,B04.820.504.540.150.113.937
d7ba06ee-edb4-48b2-bfc4-39cfebfc12d2,C0005778,CoV2,is in patients with CoV2 ,Blood coagulation,CoV2,2,X,[ortf],????,G09.188.390.150,????
2767750b-24b2-4a34-9309-abc4d01618de,C0031843,CoV2,is in patients with CoV2 ,physiological aspects,CoV2,2,X,[phsf],????,x.x.x.x,????
8913cef4-dac5-4acd-9fef-adb8197e69d6,C0005778,C0009450,is in patients with CoV2 ,Blood coagulation,Communicable Diseases,2,X,[ortf],[dsyn],G09.188.390.150,C01.539.221
47049f71-806b-44a6-a192-5226900fe265,C0031843,C0009450,is in patients with CoV2 ,physiological aspects,Communicable Diseases,2,X,[phsf],[dsyn],x.x.x.x,C01.539.221
6453730d-ca6b-420c-880e-14ea35261f12,C0015259,C0441655,were ,Exercise,Activities,1,X,[dora],[acty],G11.427.410.698.277;I03.350,
8c6fa2fe-88b2-482b-aa62-2216b8c8c006,C0015259,C0008067,taking ,Exercise,Child Care,2,X,[dora],[dora],G11.427.410.698.277;I03.350,I01.880.787.293.360;N02.421.088
541f931b-04b0-43a3-811a-8a384fb07440,C0033684,C1257954,could suggest six ,Proteins,Cyclooxygenase 2 Inhibitors,1,X,[aapp/bacs],[orch/phsu],D12.776,D27.505.519.389.310.500;D27.505.696.663.850.014.040.500.500.500;D27.505.954.158.030.500.500;D27.505.954.329.030.500.500
95f885ac-b88a-48d7-b656-ae93f0f021f0,C0033684,C3469597,could suggest six ,Proteins,Administration of medication,2,X,[aapp/bacs],[topp],D12.776,
16e220a0-5934-4a0d-b231-a5e4b3e4c216,C0033684,C0206419,could suggest six ,Proteins,Genus: Coronavirus,1,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150
348a441b-e6f2-49a8-b88f-9ad390fc506b,C0206419,C0301872,has has attributed to ,Genus: Coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150,
348a441b-e6f2-49a8-b88f-9ad390fc506b,C0206419,C0301872,manifest ,Genus: Coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150,
69ef16bc-c0e6-4fd0-9ab1-52c525e87731,C1999230,C0376358,is in ,Providing (action),Malignant neoplasm of prostate,2,X,[acty],[neop],,
b2085049-65de-4a45-a7e2-a1f3b67c10a3,C1825598,C0007134,has affected ,IMPACT gene,Renal Cell Carcinoma,2,X,[gngm],[neop],,C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
22494adb-53e1-443d-ad8b-7d1729c81191,C0740457,C0277565,distinguishing mainly between low priority of ,Malignant neoplasm of kidney,Local disease,2,X,[neop],[dsyn],,
89639770-6103-468a-951f-93b8632dd287,ona,C0007134,adaptation in management of ,ona,Renal Cell Carcinoma,2,X,????,[neop],????,C04.557.470.200.025.390;C04.588.945.947.535.160;C12.758.820.750.160;C12.777.419.473.160;C13.351.937.820.535.160;C13.351.968.419.473.160
e829cfe5-061c-4800-a2aa-0c4b9c4fe4d6,ona,C0042077,adaptation among ,ona,Urology,2,X,????,[bmod],????,H02.403.810.860
0a77a527-d483-4e9c-ac81-d54867aeeaa9,C0700781,C0032594,is high-molecular-weight fraction of ,Panavir,Polysaccharides,2,X,[orch/phsu],[orch/phsu],D02.455.426.559.389.657.746,D09.698
200632a6-283e-4b41-8ab0-9063a64d1b64,C0700781,C3853936,is high-molecular-weight fraction of ,Panavir,Solanum tuberosum extract,4,X,[orch/phsu],[orch/phsu],D02.455.426.559.389.657.746,
bdd66ed6-494e-4137-a77b-3937de8ac125,C0700781,C1175743,be effective in therapy of ,Panavir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.746,B04.820.504.540.150.113.937
ee82f04d-e939-4ad1-8eba-9f4963643077,C0206419,C0206061,may need care unit admission in in to positive cases for massive ,Genus: Coronavirus,Pneumonia Interstitial,1,X,[virs],[dsyn],B04.820.504.540.150,C08.381.483
af08b06f-e012-414f-ad8d-5d51aee6444d,C0012634,C0206061,may need care unit admission in in to positive cases for massive ,Disease,Pneumonia Interstitial,1,X,[dsyn],[dsyn],C23.550.288,C08.381.483
364d4d17-c1de-47f3-8c50-e974003ba64a,C0040578,ty434,is with ty434,Trachea,ty434,1,X,[bpoc],????,A04.889,????
b2f25f92-0157-40a3-be68-306a82a28933,C0027540,ty434,is with ty434,Necrosis,ty434,1,X,[ortf],????,C23.550.717;G04.146.638,????
94246704-2a77-42ad-96d2-78bc54e4a7fe,C0018681,C0040997,was due to ,Headache,Trigeminal Neuralgia,1,X,[sosy],[dsyn],C23.888.592.612.441,C07.465.299.625.500.700;C10.292.319.625.700.700
5d6fe9c1-17ff-4f4d-bbc0-2a38849a9d02,C0206419,anosmia,is with sole symptoms of anosmia ,Genus: Coronavirus,anosmia,1,X,[virs],????,B04.820.504.540.150,????
20c06913-adbf-43e8-9853-5e2b92ab0b9d,C3526617,C0012634,is with ,Outpatient Dialysis,Disease,1,X,[topp],[dsyn],,C23.550.288
d2314bd0-8684-4ff0-8a2a-19c8aed77466,C1285162,C0028754, includes ,Degenerative disorder,Obesity,1,X,[dsyn],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
ad693839-d58f-4d0a-adfb-1122b38a62de,C2948600,C3714509,study ,Aim,Nutrition Disorders,1,X,[inch/phsu],[dsyn],,C18.654
abf44ec0-e9f0-49bb-8792-d96f8380e133,C0040038,C0206419,have Despite severity of ,Thromboembolism,Genus: Coronavirus,1,X,[patf],[virs],C14.907.355.590,B04.820.504.540.150
b3cd4e86-f9fc-419f-bf29-d83fcc38abd8,C0079102,C3274800,may complicate initial ,Cerebral Thrombosis,Disease Presentation,1,X,[dsyn],[clna],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,
6e6d06f6-4172-49f7-b3de-0a9201a5b5d3,C0079102,C0206419,may complicate initial ,Cerebral Thrombosis,Genus: Coronavirus,1,X,[dsyn],[virs],C10.228.140.300.525.425;C14.907.253.566.350;C14.907.355.590.213.350,B04.820.504.540.150
a2543b99-03da-400a-81ec-def703d6d146,C0441655,COVID-19,poses dilemma in ,Activities,COVID-19,2,X,[acty],[virs],,C000657245
a698bad2-ac1c-4553-9a1e-245a90eb5d29,C0206419,C0556656,be IHR ,Genus: Coronavirus,Meetings,1,X,[virs],[acty],B04.820.504.540.150,
6355627f-1249-4921-8672-ac6450882eb5,C0206419,IHR,be IHR ,Genus: Coronavirus,IHR,1,X,[virs],????,B04.820.504.540.150,????
fbb0fa5c-5528-4814-b6b5-5c705417296f,C0206419,C1880022,outbreak of was On ,Genus: Coronavirus,Characterization,1,X,[virs],[acty],B04.820.504.540.150,
920b0675-5d43-453e-bd2d-47152a3de235,C3714584,C1705178,is in ,Transformation function,Order (action),1,X,[phsf],[acty],,
b4417ff6-08ce-4286-81b8-9e1b8c9f2b9b,C1175743,C2926735,environmental surveillance of be should priority part of ,SARS coronavirus,Duration,2,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
04780d6b-5bdd-4a7a-bd0d-2b0042980686,C0021368,C1175175,is in severe ,Inflammation,Severe Acute Respiratory Syndrome,2,X,[patf],[dsyn],C23.550.470,C02.782.600.550.200.750;C08.730.730
0bebfda3-a37f-4082-9323-945d8f9ba4e1,C0206419,CD8,decreased CD8 ,Genus: Coronavirus,CD8,2,X,[virs],????,B04.820.504.540.150,????
d335ff42-e127-4e3c-bb4d-e9f8ed4aadc1,C2718014,C3711103,is with ,Compassionate Use Trials,CCR5 protein human,4,X,[topp],[aapp/rcpt],E02.931.500;E05.290.250.199;E05.337.300.199,x.x.x.x
774d705c-ad19-4f7c-910c-2267216d262d,C1947933,C3711103,is with ,care activity,CCR5 protein human,2,X,[acty],[aapp/rcpt],,x.x.x.x
d84aeab2-0d8c-4292-87de-497538699e58,C2718014,C0282682,is with ,Compassionate Use Trials,Antibodies Blocking,4,X,[topp],[aapp/imft/irda],E02.931.500;E05.290.250.199;E05.337.300.199,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
a768bd96-69de-4b0b-ab82-3c9d393680a0,C1947933,C0282682,is with ,care activity,Antibodies Blocking,2,X,[acty],[aapp/imft/irda],,D12.776.124.486.485.114.143;D12.776.124.790.651.114.143;D12.776.377.715.548.114.143
ddcfef2a-9373-4f3a-9fa3-b4de9eafeec8,C2718014,C0032105,is with ,Compassionate Use Trials,Plasma,4,X,[topp],[bdsu],E02.931.500;E05.290.250.199;E05.337.300.199,A12.207.152.693;A12.207.270.695;A15.145.693
8d50593f-40ee-4891-961d-38c8b5e36451,C1947933,C0032105,is with ,care activity,Plasma,2,X,[acty],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
4832f558-0476-43ff-882c-73e6784ace02,C2718014,C0021760,is with ,Compassionate Use Trials,Interleukin-6,4,X,[topp],[aapp/imft],E02.931.500;E05.290.250.199;E05.337.300.199,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
0a6d4373-88d8-4759-8fcc-e26fb426f722,C1947933,C0021760,is with ,care activity,Interleukin-6,2,X,[acty],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
51757b25-c42a-411a-8251-4ff035894463,C0233514,C0020405,is in ,Abnormal behavior,Hygiene,1,X,[mobd],[bmod],F01.145.126.972;F01.145.179.750,E02.547;N06.850.670
535e4f43-6be7-4339-8770-c2cb7b5bb369,C0041755,C0275518,are considered they occur simultaneously with ,Adverse reaction to drug,Acute infectious disease,1,X,[patf],[dsyn],C25.100,
0c1abcc4-f412-4e03-b3f4-6773286682c1,C0020964,C1175743,making more susceptible to ,Immunity,SARS coronavirus,1,X,[phsf],[virs],G12.450,B04.820.504.540.150.113.937
0c1abcc4-f412-4e03-b3f4-6773286682c1,C0020964,C1175743,may have ,Immunity,SARS coronavirus,3,X,[phsf],[virs],G12.450,B04.820.504.540.150.113.937
cdc04b21-b891-4bf0-812e-f0d4007f6b24,C1521863,C0206750,is in development of novel ,estrogen receptor alpha human,Coronavirus Infections,1,X,[aapp/rcpt],[dsyn],x.x.x.x,C02.782.600.550.200
a49a8f01-e364-4063-a7c5-00c598b9ac90,C1521863,C1175743,is in development of novel ,estrogen receptor alpha human,SARS coronavirus,1,X,[aapp/rcpt],[virs],x.x.x.x,B04.820.504.540.150.113.937
73b65abc-1e24-4481-ad5f-93d4ced1ff7f,CoV2,C0206750,have reviewed dermatologists tools for their utility in patients affected by ,CoV2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
73b65abc-1e24-4481-ad5f-93d4ced1ff7f,CoV2,C0206750,is source of ,CoV2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
dd9c6d1a-3614-457e-b604-5edd02a142c2,C0013227,C0011627,Somewhat widely used in ,Pharmaceutical Preparations,Dermatology field,1,X,[phsu],[bmod],D26,H02.403.225
3a0fd94f-7140-41bc-ab1b-faae8315cfad,C0018563,C2359945,also frequently use ,Hand,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[bpoc],[clna],A01.378.800.667,
e76478ba-5237-47f5-ad25-fef4b48ca111,C0018563,C1979687,also frequently use ,Hand,Dermatologic drugs,1,X,[bpoc],[phsu],A01.378.800.667,
e76478ba-5237-47f5-ad25-fef4b48ca111,C0018563,C1979687,also use in our,Hand,Dermatologic drugs,1,X,[bpoc],[phsu],A01.378.800.667,
303821e2-81b8-476e-a296-2ee02fbedca2,C0026082,C0206750,had level regarding ,Midwifery,Coronavirus Infections,1,X,[bmod],[dsyn],H02.478.676.416,C02.782.600.550.200
0f1bddac-ac7d-43f7-b615-76b5230939dc,C0152179,C0206750,elicited Deglutition Disorders following,Vagus Nerve Disorder,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.292.887,C02.782.600.550.200
05de5bd9-f8dc-4e6e-9b4a-8ea6d34e80dc,C0152179,C0011168,elicited ,Vagus Nerve Disorder,Deglutition Disorders,2,X,[dsyn],[dsyn],C10.292.887,C06.405.117.119;C09.775.174
9327fa11-f867-4d30-b4f4-bd540b3c79ff,C0032290,C0035243,might might overlooked in severe ,Aspiration Pneumonia,Respiratory Tract Infections,2,X,[dsyn],[dsyn],C08.381.677.529;C08.730.610.529,C01.539.739;C08.730
97f26799-aafe-47da-b5bd-cecdf42b82dc,C0032290,C0206750,might might overlooked in severe ,Aspiration Pneumonia,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.381.677.529;C08.730.610.529,C02.782.600.550.200
30aec0e1-c4ec-4e41-978f-0782d047a97e,C2926735,C0087111,be considered for IFN ,Duration,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
c740f4fb-f4d3-4af5-a0ad-24ecf7596871,C2926735,C0029341,be considered for IFN ,Duration,Orthomyxoviridae,2,X,[orch/phsu],[virs],,B04.820.545
f7a7c8b9-5cda-4bda-9e88-3f589eded3b7,C0441516,C0206750,may increase with increase in ,Demand (clinical),Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
d8d7104a-8808-4d4c-af25-0da1bb230350,C0441516,C0005516,may may ,Demand (clinical),Biological Markers,1,X,[topp],[clna],,D23.101
d071a3d8-74e7-478e-ad7a-5036fff86c67,C0441516,C1882509,may may ,Demand (clinical),put - instruction imperative,1,X,[topp],[acty],,
319b213d-b3d1-451b-aca3-c38d0357b30a,C0012634,C0287990,moving at frantic rumours,Disease,paired basic amino acid cleaving enzyme,1,X,[dsyn],[aapp/enzy],C23.550.288,D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353
3f98cb6d-a2e6-43b5-b12b-00d32ba11ca5,C0012634,rumours,moving at frantic rumours,Disease,rumours,1,X,[dsyn],????,C23.550.288,????
923e0c9a-fdde-4fe3-b2bf-adb1eb1dd8a2,C0301872,C0206750,contribute to ,Immune response,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
923e0c9a-fdde-4fe3-b2bf-adb1eb1dd8a2,C0301872,C0206750,embodies in decrease of ,Immune response,Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
b4e66dd9-a287-4325-a24d-61f51bbada83,C0301872,C0221423,contribute at second week of ,Immune response,Illness (finding),1,X,[ortf],[sosy],,
a3ec79ed-4742-4180-8c95-d2722ac7f699,C0032285,C0369768,was defined as ,Pneumonia,Molecular oxygen saturation,1,X,[dsyn],[moft],C08.381.677;C08.730.610,
52ef7909-ba46-413f-9f46-caa6ea1a71c8,C0185117,CD4,is in CD4,Expression procedure,CD4,1,X,[topp],????,,????
c8457bbb-8504-475f-ac51-0054fda9e088,C0206750,C1879547,higher degree of proliferation ,Coronavirus Infections,Activation action,4,X,[dsyn],[acty],C02.782.600.550.200,
6d278319-d19e-4632-b530-a3ff5f92e33b,C0206750,C0039195,higher degree of proliferation ,Coronavirus Infections,Cytotoxic T-Lymphocytes,10,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.283.875;A11.118.637.555.567.550.500.200;A11.118.637.555.567.569.220.200;A11.118.637.555.567.569.500.200;A15.145.229.637.555.283.875;A15.145.229.637.555.567.550.500.200;A15.145.229.637.555.567.569.220.200;A15.145.229.637.555.567.569.500.200;A15.382.490.555.283.875;A15.382.490.555.567.550.500.200;A15.382.490.555.567.569.220.200;A15.382.490.555.567.569.500.200
c887dd5e-9d85-41c7-8c7c-9c0eaa30c1a9,C0206750,C1140999,had degree without ,Coronavirus Infections,Contraction (finding),2,X,[dsyn],[patf],C02.782.600.550.200,
f27758a8-e342-4114-b4d9-0d612e425935,C1140999,C0206750,might contribute to development of severe ,Contraction (finding),Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
56669e86-1ec4-45dc-831c-fdad052d4a55,C0206750,RGP,were related to socioeconomic RGP ,Coronavirus Infections,RGP,1,X,[dsyn],????,C02.782.600.550.200,????
c46b52e7-046d-4d6b-958e-17a498615797,C0025424,C0030054,is with ,Mercury,Oxygen,1,X,[elii/hops],[bacs/elii/phsu],D01.268.556.504;D01.268.956.437;D01.552.544.504;x.x.x.x,D01.268.185.550;D01.362.670;x.x.x.x
bd6a2ae1-a5e7-4ed6-b14f-a9b308421561,C2936405,C0037633,seems ,Drug Repositioning,Solutions,2,X,[topp],[sbst],E05.290.875,D26.776
fade9a8a-4de8-4c59-9de7-3dee199b73d2,C0030576,C0206750,have strong ,Paromomycin,Coronavirus Infections,1,X,[antb/orch],[dsyn],D09.408.051.706,C02.782.600.550.200
9876a5df-589b-44d2-af71-0c1a2a735751,C0178849,C0022709,is in their ,species difference,Peptidyl-Dipeptidase A,2,X,[biof],[aapp/enzy/imft],,D08.811.277.656.350.350.687
f889e91d-f6d4-461a-8c06-f24fe9ee96c0,C0178849,C0597357,is in their ,species difference,receptor,2,X,[biof],[aapp/rcpt],,
0db38275-9c24-4d54-ae11-bb489695dd74,C0001560,C0819757,is in ,Administration Intranasal,Structure of parenchyma of lung,1,X,[topp],[tisu],E02.319.267.120.655.500,
1063baed-0bc4-4167-b50e-0adf13c052dc,C0026809,C1175743,were productively infected with ,Mus,SARS coronavirus,1,X,[mamm],[virs],B01.050.150.900.649.313.992.635.505.500,B04.820.504.540.150.113.937
f3dc9bbd-6daf-4674-ab61-1238958448c5,titers,C0024109,is in ,titers,Lung,1,X,????,[bpoc],????,A04.411
2c251490-d301-4ee4-adcf-2b857c609163,titers,C0748168,is in ,titers,Pulmonary Pathology,1,X,????,[dsyn],????,
1eab2dba-8f08-48a6-97c5-4cabf9887515,C0600250,C0024109,reduced burden in ,Passive Antibody Transfer,Lung,1,X,[topp],[bpoc],E02.095.465.425.400.330;E05.478.550.520,A04.411
37225d4e-af2d-46c8-be29-2aed763222cf,C1704241,C0086418,depend on ,complex (molecular entity),Homo sapiens,1,X,[chvs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
2553b6a7-4178-4e16-b58c-d24239653ce4,C0043528,C1704241,are ,Zoonoses,complex (molecular entity),1,X,[dsyn],[chvs],C01.908;C02.968;C03.908;C22.969,
790cc91a-392b-47a5-8b17-5d37ad7c7d94,C1175743,C3698360, includes ,SARS coronavirus,Middle East Respiratory Syndrome Coronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150.113.750
86bf1d5d-d60d-4ea7-8d60-224176dae439,C1175743,C0021403, includes ,SARS coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,D20.215.894.899.302
86bf1d5d-d60d-4ea7-8d60-224176dae439,C1175743,C0021403,is new ,SARS coronavirus,Influenza virus vaccine,1,X,[virs],[imft/phsu],B04.820.504.540.150.113.937,D20.215.894.899.302
25e4bd11-8b6c-4c7c-b916-b9a7800e65bf,C0270724,C0015357,use ,Infantile Neuroaxonal Dystrophy,Extracorporeal Membrane Oxygenation,3,X,[dsyn],[topp],C10.228.140.744,E02.880.301;E04.292.451
6493a86d-d999-49f5-b967-b08a692c0d3c,C0270724,COVID-19,use Extracorporeal Membrane Oxygenation transport for,Infantile Neuroaxonal Dystrophy,COVID-19,1,X,[dsyn],[virs],C10.228.140.744,C000657245
ac7b6989-643b-430b-91ca-979fc58539ce,C0441655,C0949742,regarding spinal ,Activities,Manipulation Therapy,1,X,[acty],[topp],,E02.190.599;E02.779.867;E02.831.535.867
f7eea532-839e-43b6-bfda-a501b42c2595,C0086586,C0885890,is ,Manipulation of spine,Common interventions,1,X,[topp],[topp],E02.779.867.466;E02.831.535.867.466,
4f4ad79e-37ec-4fdf-8522-ea0e126c5525,C0086586,C0018722,is ,Manipulation of spine,Health Occupations,1,X,[topp],[bmod],E02.779.867.466;E02.831.535.867.466,H02
0f642582-5c07-4730-a96b-cc121493d6e6,C1706202,C0441655,describe Twitter SMT,Search - action,Activities,1,X,[acty],[acty],,
e6372f13-4720-44db-8124-e83ef74e0852,C1706202,SMT,describe Twitter SMT,Search - action,SMT,1,X,[acty],????,,????
34854620-056a-468e-b2d5-3c4ff3df9226,C1947933,neuro,characterized reality for patients presenting with neuro ,care activity,neuro,2,X,[acty],????,,????
9a2ba011-7ba3-4066-aec8-4cf42eb7b13b,C1947933,C2745965,characterized reality for patients presenting with neuro ,care activity,Emergencies [Disease/Finding],2,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
9a2ba011-7ba3-4066-aec8-4cf42eb7b13b,C1947933,C2745965,may become first choice in ,care activity,Emergencies [Disease/Finding],4,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
394eb901-9073-4eed-b713-c1f4e6e3fa0b,C0020336,C0003451,have emerged as potential ,Hydroxychloroquine,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180.350,D27.505.954.122.388
511328d8-4b7d-4b97-9bf6-fe9888209456,C0008269,C0003451,Recently have emerged as potential ,Chloroquine,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D27.505.954.122.388
8826abcb-506a-4866-b791-daf16872e9c2,C0013227,C1412268,of events is ,Pharmaceutical Preparations,AES gene,1,X,[phsu],[gngm],D26,
d6c85b3c-76a3-419e-b444-4b8792e30d50,MEDLINE,C0032042,Comparison Hydroxychloroquine with,MEDLINE,Placebos,1,X,????,[topp],????,D26.660;E02.785
602391b8-8b76-4ad7-9d22-9192e6c161dc,MEDLINE,C0020336,Comparison,MEDLINE,Hydroxychloroquine,1,X,????,[orch/phsu],????,D03.633.100.810.050.180.350
7d16a7a3-0479-47f3-b2fe-1d9fd49ad46b,C1412268,C1707455,were statistically higher ,AES gene,Comparison,1,X,[gngm],[acty],,
3016d4b9-da99-4958-a8df-c1da9e4b58da,C1412268,C0008269,were statistically higher ,AES gene,Chloroquine,1,X,[gngm],[orch/phsu],,D03.633.100.810.050.180
3016d4b9-da99-4958-a8df-c1da9e4b58da,C1412268,C0008269,was affected by dosage for ,AES gene,Chloroquine,1,X,[gngm],[orch/phsu],,D03.633.100.810.050.180
5bc648fb-f85f-47df-a406-6de9857b264a,C1412268,C0032042,were statistically higher ,AES gene,Placebos,1,X,[gngm],[topp],,D26.660;E02.785
98dfea51-0279-4837-96ef-accc036e89e6,C0037285,C0009450,related to ,Skin Manifestations,Communicable Diseases,1,X,[sosy],[dsyn],C23.888.885,C01.539.221
6602eb07-98c6-490e-86cf-03a2b359c050,C0206750,C0034150,is with retiform ,Coronavirus Infections,Purpura,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.100.802;C23.550.414.950;C23.888.885.687
108ced9d-1395-4b2d-8ba5-e609f801ee38,C0086418,C0597357,has has identified as functional ,Homo sapiens,receptor,5,X,[humn],[aapp/rcpt],B01.050.150.900.649.313.988.400.112.400.400,
435d3a06-4632-4b1b-a20b-cc45dbc82a77,C0058362,C0597357,has has identified as functional ,dipeptidyl peptidase II,receptor,2,X,[aapp/enzy],[aapp/rcpt],x.x.x.x,
f7b7901b-456c-4706-85c0-7c27f8c6b0e1,C0058362,C1175743,has has identified as functional ,dipeptidyl peptidase II,SARS coronavirus,2,X,[aapp/enzy],[virs],x.x.x.x,B04.820.504.540.150.113.937
425317de-b2c5-432b-947e-4cf2871e6263,C0026809,C0024109,sustained high loads in ,Mus,Lung,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A04.411
b2a43e49-fc29-4f18-b536-650bf14a299f,C0086418,C0040578,sustained high loads in ,Homo sapiens,Trachea,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A04.889
99553a39-e5ed-46fa-82db-f816e54f64b6,C0026809,C0040578,sustained high loads in ,Mus,Trachea,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A04.889
01dd87e3-114b-49c8-91ee-048c3f48b485,C0086418,C0006104,sustained high loads in ,Homo sapiens,Brain,3,X,[humn],[bpoc],B01.050.150.900.649.313.988.400.112.400.400,A08.186.211
5b95aca1-e54a-4cb4-9eab-3fe281a5af75,C0026809,C0006104,sustained high loads in ,Mus,Brain,3,X,[mamm],[bpoc],B01.050.150.900.649.313.992.635.505.500,A08.186.211
a79d186b-af1c-47c7-ae23-1d29c28711f3,C0026809,C0009450,sustained loads upon intranasal ,Mus,Communicable Diseases,3,X,[mamm],[dsyn],B01.050.150.900.649.313.992.635.505.500,C01.539.221
5a56e0d4-d6b8-493c-a9c0-1d2a2f444174,C0086418,C1707455,sustained loads In ,Homo sapiens,Comparison,3,X,[humn],[acty],B01.050.150.900.649.313.988.400.112.400.400,
91394798-9b1c-49c6-8ff0-42086f76371b,C0026809,C1707455,sustained loads In ,Mus,Comparison,3,X,[mamm],[acty],B01.050.150.900.649.313.992.635.505.500,
008f0ed4-ee38-49fa-9435-2e4fa0525c51,C0086418,C1521751,sustained loads In ,Homo sapiens,C57BL/6 Mouse,3,X,[humn],[mamm],B01.050.150.900.649.313.988.400.112.400.400,
a7f78e6e-0b83-435b-b648-bfcee849d247,C0026809,C1521751,sustained loads In ,Mus,C57BL/6 Mouse,3,X,[mamm],[mamm],B01.050.150.900.649.313.992.635.505.500,
60930020-ced5-4c41-b931-c521edebfb48,C1707455,C1521751,is with wild-type ,Comparison,C57BL/6 Mouse,3,X,[acty],[mamm],,
73e9180c-f608-42b2-98ae-a98b67fdde84,C0206061,C1175743,were seen in ,Pneumonia Interstitial,SARS coronavirus,2,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
2902e2f0-9bcb-4632-9f68-aad5bd1a4e94,C0748168,C0086418,is in ,Pulmonary Pathology,Homo sapiens,2,X,[dsyn],[humn],,B01.050.150.900.649.313.988.400.112.400.400
c7abea7f-9dc0-4875-ac48-7c76004bda9c,C0748168,C0026809,is in ,Pulmonary Pathology,Mus,2,X,[dsyn],[mamm],,B01.050.150.900.649.313.992.635.505.500
a6be9232-4f42-4d48-b003-f2541e9184e4,C0012644,C0087111,evaluating ,Animal Disease Models,Therapeutic procedure,3,X,[emod],[topp],C22.232;E05.598.500;E05.599.395.080,E02
5348b15e-6d06-4e1f-afb8-70daecf8b321,C0012644,COVID-19,evaluating ,Animal Disease Models,COVID-19,1,X,[emod],[virs],C22.232;E05.598.500;E05.599.395.080,C000657245
765a4345-8026-4a4c-b625-3778e072036e,C0012644,C0042210,evaluating ,Animal Disease Models,Vaccines,1,X,[emod],[aapp/imft/phsu],C22.232;E05.598.500;E05.599.395.080,D20.215.894
834950a2-7b58-4f8a-b3e4-e2b901b530a7,C1439284,C1883559,is in ,AGTR1 gene,Wild Type,5,X,[gngm],[gngm],,
7f6b08f3-fcca-4160-a464-ae3251a55187,C1167622,C1883559,is in ,Binding (Molecular Function),Wild Type,5,X,[moft],[gngm],,
6718a080-3bdf-4932-8bf0-1c96606a9f7f,C1439284,C0026809,is in ,AGTR1 gene,Mus,5,X,[gngm],[mamm],,B01.050.150.900.649.313.992.635.505.500
81fdb3a4-4a8c-4c67-8037-1e4010ed285c,C1167622,C0026809,is in ,Binding (Molecular Function),Mus,5,X,[moft],[mamm],,B01.050.150.900.649.313.992.635.505.500
08ad54c4-bad0-4a70-b4a8-fa926ab3b54a,C0242656,C0242781,origin of ,Disease Progression,disease transmission,1,X,[patf],[patf],C23.550.291.656,N06.850.310
ecc60296-d9c7-4de0-bd4b-0d4caf1f993b,C0242656,C0206419,origin of ,Disease Progression,Genus: Coronavirus,2,X,[patf],[virs],C23.550.291.656,B04.820.504.540.150
6d075362-27e0-431e-8f00-d214cc8a1f72,C1515933,C0030054,are responsible for ,Alveolus,Oxygen,1,X,[bpoc],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
25ca2894-3b3e-4abf-b069-a3b1e3d7ad83,C0206419,C0003062,is in ,Genus: Coronavirus,Animals,1,X,[virs],[anim],B04.820.504.540.150,B01.050
e0e9d074-edea-486d-96e0-11575e24c439,C0206419,C1167395,is in ,Genus: Coronavirus,Host (organism),1,X,[virs],[orgm],B04.820.504.540.150,
ceb2f2a7-d09d-4160-99a3-9fdd990663b9,C0370003,C1511790,were tested with positives ,Specimen,Detection,2,X,[sbst],[topp],,
b40111ef-0c0b-4cac-ab94-709f767c8880,C0450254,C0270724,is with ,Pathogenic organism,Infantile Neuroaxonal Dystrophy,2,X,[orgm],[dsyn],,C10.228.140.744
391e0548-8e2c-4a94-a80b-291932f370e0,C0020538,C0012634,is most common comorbidity associated with mortality in current ,Hypertensive disease,Disease,2,X,[dsyn],[dsyn],C14.907.489,C23.550.288
30a179f1-d449-4260-94c1-63b8d40dece8,ACE2,C0206419,point for ,ACE2,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
dd53992a-5d23-48bf-acd7-6e427a1b61f2,C0242821,C0022709,using ,Human body,Peptidyl-Dipeptidase A,2,X,[humn],[aapp/enzy/imft],I01.076.201.450.560;K01.093.378,D08.811.277.656.350.350.687
1dd41816-72bf-4ee0-989a-3f030abfd36a,C0242821,C0597357,using Peptidyl-Dipeptidase A as,Human body,receptor,2,X,[humn],[aapp/rcpt],I01.076.201.450.560;K01.093.378,
6b9b47df-ccc0-4765-8741-f8cf3810dd63,C0242821,C1175175,using Peptidyl-Dipeptidase A as,Human body,Severe Acute Respiratory Syndrome,2,X,[humn],[dsyn],I01.076.201.450.560;K01.093.378,C02.782.600.550.200.750;C08.730.730
6c371426-5b32-4cf7-aaa8-5926d07b33e0,C0086418,C0087111,develop ,Homo sapiens,Therapeutic procedure,2,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,E02
2444f92b-5e72-4bf0-8350-b88cb0fbf3db,C0086418,C0199848,develop ,Homo sapiens,Coronavirus vaccination,2,X,[humn],[topp],B01.050.150.900.649.313.988.400.112.400.400,
5c33c17b-b311-4ffa-985e-ac918344fdbe,C0012634,C0199848,develop ,Disease,Coronavirus vaccination,2,X,[dsyn],[topp],C23.550.288,
b2868d7d-908d-41a4-a8f0-c2cfd31c42e8,C0450254,C0042196,develop Communicable Diseases after intranasal,Pathogenic organism,Vaccination,2,X,[orgm],[topp],,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
617894b5-8dd0-46ee-9d24-8550b9ba91a2,C0450254,C0009450,develop rapidly lethal ,Pathogenic organism,Communicable Diseases,2,X,[orgm],[dsyn],,C01.539.221
31e34868-d318-4454-8bb9-1d43f407ed33,C0042196,C1175743,is with ,Vaccination,SARS coronavirus,3,X,[topp],[virs],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,B04.820.504.540.150.113.937
42e11da2-9fdc-46af-97ab-15beb34f42d2,C1515884,C1293116,has officially entered development With ,Acupuncture and Oriental Medicine,Introduction procedure,2,X,[topp],[topp],,
73e91fd8-632c-4235-9f5d-ec3e0577d66a,C1515884,C0014507,has officially entered development With ,Acupuncture and Oriental Medicine,Epidemiology,1,X,[topp],[bmod],,H02.403.720.500
d6dcb280-ac0e-4da3-a02b-cc13ca0cab45,C1515884,C0025124,has officially entered development With ,Acupuncture and Oriental Medicine,Traditional Chinese Medicine,2,X,[topp],[bmod],,E02.190.488.585.520;I01.076.201.450.654.558.520
c24745ce-2033-430a-b2e2-42360c813279,C1515884,C1457887,significantly alleviate ,Acupuncture and Oriental Medicine,Symptoms,2,X,[topp],[sosy],,
7f49ef5f-5b21-40b7-b8a5-f30f6869e71b,C1515884,C0920467,significantly alleviate ,Acupuncture and Oriental Medicine,disorder control (procedure),2,X,[topp],[topp],,
000547aa-8c3c-4554-85e9-bf3a0052bce9,C1515884,C0010340,reduce occurrence of ,Acupuncture and Oriental Medicine,Critical Illness,2,X,[topp],[dsyn],,C23.550.291.625
d65a75e2-f61f-424c-a34d-3b4ec357db85,C1515884,C0034019,is in new ,Acupuncture and Oriental Medicine,public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
3a34267d-fa20-4b39-8d7b-e950049a171b,C1515884,C2745965,is in new ,Acupuncture and Oriental Medicine,Emergencies [Disease/Finding],2,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
13c1ace6-e703-47fd-bab8-0be0da0a60d7,C0034019,C0025124,is with ,public health medicine (field),Traditional Chinese Medicine,2,X,[bmod],[bmod],H02.403.720;N01.400.550;N06.850,E02.190.488.585.520;I01.076.201.450.654.558.520
7f0641dc-2878-4971-838a-9b78330751c3,C2745965,C0025124,is with ,Emergencies [Disease/Finding],Traditional Chinese Medicine,2,X,[patf],[bmod],C23.550.291.781;N06.230.100.083;N06.850.376,E02.190.488.585.520;I01.076.201.450.654.558.520
cfac4412-dcc3-4872-a805-1e5c5d1665e8,C0079189,C0243026,lead to ,cytokine,Sepsis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C01.539.757;C23.550.470.790.500
e18fd26a-8b6e-4e1b-9af2-2dc6740bba1a,C0026766,C0032113,demonstrated significant improvement after ,Multiple Organ Failure,Plasma Exchange,1,X,[patf],[topp],C23.550.835.525,E02.095.135.750
e18fd26a-8b6e-4e1b-9af2-2dc6740bba1a,C0026766,C0032113,underwent ,Multiple Organ Failure,Plasma Exchange,1,X,[patf],[topp],C23.550.835.525,E02.095.135.750
54f71efb-2637-46a2-b605-445c8acd38e9,C0036974,C0013778,requiring ,Shock,Electric Countershock,1,X,[patf],[topp],C23.550.835,E02.331.350
9c415a9f-076e-4d64-a420-8fdecddfb88d,C0036974,C2349751,requiring ,Shock,Invasive positive pressure ventilation,1,X,[patf],[topp],C23.550.835,
9b55df0f-5c64-4a22-820e-39a8434acee5,C0243026,C0026766,is with ,Sepsis,Multiple Organ Failure,1,X,[dsyn],[patf],C01.539.757;C23.550.470.790.500,C23.550.835.525
1bf5ca3f-1b62-4ec1-bf54-67e1fc08754a,ORF8,C0003451,were potential inhibitors of key component for,ORF8,Antiviral Agents,1,X,????,[phsu],????,D27.505.954.122.388
52e2d701-281f-447b-9454-2fcebec0ebb6,C0524816,C0003451,were potential inhibitors of key component for,Nucleocapsid Proteins,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.776.964.970.600,D27.505.954.122.388
5a336f96-b7f6-4b7b-adee-5ddf357f6b3c,C2610474,C0003451,component for ,type I interferon signaling pathway,Antiviral Agents,1,X,[celf],[phsu],,D27.505.954.122.388
8fe147e6-063c-4c5e-8e12-6fd018a987ed,ORF8,C0015980,inhibit Interferon after treatment with,ORF8,Interferon-beta,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
7862fb94-5045-4df0-950d-41e50d167760,C0033684,C0015980,inhibit Interferon after treatment with,Proteins,Interferon-beta,1,X,[aapp/bacs],[aapp/imft/phsu],D12.776,D12.644.276.374.440.890.275;D12.776.467.374.440.890.275;D23.529.374.440.890.275
fdecdc75-83fb-441b-8734-dc25f099712d,ORF8,C3652465,inhibit ,ORF8,Interferon,1,X,????,[aapp/imft/phsu],????,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
3809200a-8861-4e62-845c-3a50d40a8fcf,C1825598,COVID-19,was found ,IMPACT gene,COVID-19,3,X,[gngm],[virs],,C000657245
559a8f4e-25ca-4db3-86e6-d29ebf924ebb,C0206419,C1254373,emerged as ,Genus: Coronavirus,etiologic agent,1,X,[virs],[sbst],B04.820.504.540.150,
559a8f4e-25ca-4db3-86e6-d29ebf924ebb,C0206419,C1254373,with Severe acute respiratory infection is,Genus: Coronavirus,etiologic agent,1,X,[virs],[sbst],B04.820.504.540.150,
8ea1b547-688b-4850-816e-f68182bcd54e,C0008269,COVID-19,were ,Chloroquine,COVID-19,3,X,[orch/phsu],[virs],D03.633.100.810.050.180,C000657245
f2b02352-a0b7-411a-adef-efc67ca4d3d7,C1521863,C1456573,evoking imminent threat to ,estrogen receptor alpha human,Global Health,1,X,[aapp/rcpt],[bmod],x.x.x.x,H02.403.371;N01.400.337
108ee5eb-832c-4a9f-bc25-f459c22b6641,C1521863,C0086418,evoking imminent threat to ,estrogen receptor alpha human,Homo sapiens,1,X,[aapp/rcpt],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
8b9275ff-4cfe-433b-a43f-cf05a1489393,C0319157,C1521863,led ,AS virus,estrogen receptor alpha human,1,X,[virs],[aapp/rcpt],,x.x.x.x
f055b68e-054a-4e46-b004-af48a80a5d83,C1175743,C0037778,has profoundly impacted ,SARS coronavirus,Medical Specialities,4,X,[virs],[bmod],B04.820.504.540.150.113.937,H02.403
5e118ad7-f61d-413e-ae17-262a66a4ae0c,C0007222,C1175743,evidence for direct myocardial injury in ,Cardiovascular Diseases,SARS coronavirus,1,X,[dsyn],[virs],C14,B04.820.504.540.150.113.937
a239f6c0-601b-4e28-971c-6ea9bc6da8f9,C0021918,COVID-19,relate to ,Intrinsic factor,COVID-19,1,X,[aapp/bacs/phsu],[virs],D12.776.395.560.494,C000657245
82d6e0d8-7bd2-4783-b62e-da90ec4cfcb1,C0014467,C0597360,accompanied by increased ,eosinophil,receptor expression,1,X,[cell],[genf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
c4617335-a07d-44a4-a93e-3bb925c39c5f,C0014467,C1175743,accompanied by increased ,eosinophil,SARS coronavirus,1,X,[cell],[virs],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,B04.820.504.540.150.113.937
242adead-34ee-4455-baa2-dc4f76cf55a2,C0597360,C0599333,is in ,receptor expression,Epithelium of bronchus,1,X,[genf],[bpoc],,
c0cf6cde-fb92-4b88-b1f9-869b3f129075,C1422064,C0599333,is in ,ACE2 gene,Epithelium of bronchus,1,X,[gngm],[bpoc],,
535c9e0e-12eb-4c66-b95b-8ef1b022a5c8,C0017337,C1422064,highly correlated with ,Genes,ACE2 gene,1,X,[gngm],[gngm],G05.360.340.024.340,
e1dfb3e5-7698-4c0b-87ec-d34a7dffad4a,C1422064,C0041904,is Linked gene to,ACE2 gene,Up-Regulation (Physiology),2,X,[gngm],[moft],,G02.111.905;G05.308.850;G07.690.773.998
2711db4e-604e-4584-a5be-15df1af98a01,C1422064,C0314613,is Linked gene to,ACE2 gene,Linked gene,2,X,[gngm],[genf],,
f62883a4-9c7e-4751-bf85-8c4667de2660,C0314613,Type-2,is in subset of Type-2 ,Linked gene,Type-2,1,X,[genf],????,,????
3e0bfe77-d85a-4bc8-aacb-1c8a2c0be4b5,C0314613,C0004096,is in subset of Type-2 ,Linked gene,Asthma,1,X,[genf],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
41b3e3c7-108d-4eea-b027-62d476b163c6,C0087111,C1566664,targeting ,Therapeutic procedure,TCF Transcription Factors,1,X,[topp],[aapp/bacs],E02,D12.776.260.730;D12.776.660.235.400.800;D12.776.664.235.400.800;D12.776.930.875
7b3c28a7-4394-48a0-80e6-3e1b439f2a3b,C0087111,C3652465,targeting ,Therapeutic procedure,Interferon,1,X,[topp],[aapp/imft/phsu],E02,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
8c02cc39-6eae-4b5a-8284-194c14cab254,Type-2,COVID-19,may at ,Type-2,COVID-19,1,X,????,[virs],????,C000657245
22d5b311-2fd8-4ac2-8088-4b37749b4e79,C0004096,C1457887,developing ,Asthma,Symptoms,1,X,[dsyn],[sosy],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,
5ec4310a-a709-43d1-96eb-b954bb39f8e1,C0009450,C0027651,may establish parallelism with challenges faced in road to understanding of ,Communicable Diseases,Neoplasms,1,X,[dsyn],[neop],C01.539.221,C04
1d1f72d5-e53d-4b2f-b424-0a079d4f7a37,C0175754,C1705178,will Creation liaison in,Agenesis of corpus callosum,Order (action),1,X,[cgab],[acty],C10.500.034;C16.131.666.034;C23.300.008,
411a9811-1f5f-4508-8cc0-526a9a13c654,C1516048,C0441655,changes in blood bank ,Assessed,Activities,1,X,[acty],[acty],,
aff99a21-7d6c-4309-b9b3-9a9d1ae03045,C0032113,C1456820,remove ,Plasma Exchange,Tumor Necrosis Factor-alpha,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374.500.800;D12.644.276.374.750.626;D12.776.124.900;D12.776.395.930;D12.776.467.374.500.800;D12.776.467.374.750.626;D23.529.374.500.800;D23.529.374.750.626
f11bb6c5-c614-4f0f-a359-ab7bee296b98,C0032113,C0021745,remove ,Plasma Exchange,Interferon Type II,1,X,[topp],[aapp/imft/phsu],E02.095.135.750,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
04a2b486-7eb5-41e6-a4e1-07a418d64e9c,C0032113,C0021757,remove ,Plasma Exchange,Interleukin-3,1,X,[topp],[aapp/imft],E02.095.135.750,D12.644.276.374.410.240.400;D12.644.276.374.465.032;D12.776.395.240.400;D12.776.467.374.410.240.400;D12.776.467.374.465.032;D23.529.374.410.240.400;D23.529.374.465.169
4515b157-04bc-4b63-bc66-f75c927e38a2,C0032113,RT-PCR,to Allergic Reaction is two consecutive negative RT-PCR,Plasma Exchange,RT-PCR,1,X,[topp],????,E02.095.135.750,????
46d30be7-182d-44e1-ba44-bd52ee6aa9d2,C0032113,C1175743,to Allergic Reaction is two consecutive negative RT-PCR,Plasma Exchange,SARS coronavirus,1,X,[topp],[virs],E02.095.135.750,B04.820.504.540.150.113.937
8adac874-c8a5-4c4d-b976-62aca11548ac,C1527304,C1175743,tests for ,Allergic Reaction,SARS coronavirus,1,X,[patf],[virs],C20.543,B04.820.504.540.150.113.937
e3e5f8f7-7b1a-4b81-af56-5eb6511a8c8c,C0032113,C2744539,using Spectra Optia D2000 ,Plasma Exchange,THBD protein human,1,X,[topp],[aapp/bacs],E02.095.135.750,x.x.x.x
45817cfc-a8a0-4a8e-bdfd-aa7b792ab7c4,C0032113,D2000,using Spectra Optia D2000 ,Plasma Exchange,D2000,1,X,[topp],????,E02.095.135.750,????
5a2d385b-3b60-4e23-aa79-4bfa5ec917aa,C2744539,D2000,equipped with Depuro D2000 ,THBD protein human,D2000,1,X,[aapp/bacs],????,x.x.x.x,????
5cb91a49-3c8f-46b0-863f-394e7f0593d2,C2744539,C0001128,operates with,THBD protein human,Acids,1,X,[aapp/bacs],[chem],x.x.x.x,D01.029
2251c133-3f79-47ec-b40e-7d3e0ba1370e,C2744539,C0022646,operates as per ,THBD protein human,Kidney,1,X,[aapp/bacs],[bpoc],x.x.x.x,A05.810.453
a88bd5fa-5c9c-4cba-ac6a-b62a60845266,C0032105,C0001924,is replaced with ,Plasma,Albumins,1,X,[bdsu],[aapp/bacs],A12.207.152.693;A12.207.270.695;A15.145.693,D12.776.034
6eef751e-dbab-4754-bb90-2477d92ce934,C0032105,C0005779,is replaced with ,Plasma,Blood Coagulation Disorders,1,X,[bdsu],[dsyn],A12.207.152.693;A12.207.270.695;A15.145.693,C15.378.100
8e3c6ef9-5ccc-4e40-8360-31e006dc3a5a,C0001924,C0005779,is in patients with ,Albumins,Blood Coagulation Disorders,1,X,[aapp/bacs],[dsyn],D12.776.034,C15.378.100
80c0db0e-37a5-4c4d-8faf-5c3369477e3a,C4082587,C0005516,is in inflammatory ,HLA Class II Histocompatibility Antigen Gamma Chain human,Biological Markers,1,X,[aapp/imft],[clna],,D23.101
2aa4db60-03b5-4616-b609-762068916c54,C0027627,C0021966,are ,Neoplasm Metastasis,Iodides,1,X,[neop],[inch],C04.697.650;C23.550.727.650,D01.248.497.158.490;D01.475.410
0e414262-01c9-4c38-8fd8-a85a747effe7,C0031336,C0242781,reduce ,Pharmacy (field),disease transmission,2,X,[bmod],[patf],H02.646,N06.850.310
5ce2fca0-ba12-4aa3-acc4-d0bda0a41aa3,C0031336,C1175743,reduce ,Pharmacy (field),SARS coronavirus,2,X,[bmod],[virs],H02.646,B04.820.504.540.150.113.937
ad59bc3b-01db-4730-a1fd-9e17ec0e0e28,COVID-19,C0161816,been has associated with ,COVID-19,Cardiac complication,1,X,[virs],[patf],C000657245,
ad59bc3b-01db-4730-a1fd-9e17ec0e0e28,COVID-19,C0161816,contributes to ,COVID-19,Cardiac complication,1,X,[virs],[patf],C000657245,
de6c7f19-6e29-4deb-aae1-a75f9a148a7d,COVID-19,C0038454,leading to wide spectrum of vascular damage myocardial injury ,COVID-19,Cerebrovascular accident,1,X,[virs],[dsyn],C000657245,C10.228.140.300.775;C14.907.253.855
c42636e4-569a-4eb6-aaec-2b1c625a2dde,COVID-19,C0028778,leading to wide spectrum of vascular damage myocardial injury ,COVID-19,Obstruction,1,X,[virs],[patf],C000657245,
101e42bf-1466-4744-8a23-c9dbd78d9d55,C0039082,C0333200,is with characteristics of aortic ,Syndrome,Intramural hematoma,1,X,[dsyn],[patf],C23.550.288.500,
a0f96f8b-81ee-42b2-a712-83e7df428c91,C0206277,C0013227,is with ,Fatal Outcome,Pharmaceutical Preparations,1,X,[patf],[phsu],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,D26
f782748c-3996-43ad-95bd-3e211377ee9c,C1707455,C0020336,is with association ,Comparison,Hydroxychloroquine,2,X,[acty],[orch/phsu],,D03.633.100.810.050.180.350
2381390c-9c17-417e-8274-5eaf696e8a6a,C0020336,C1707455,was In ,Hydroxychloroquine,Comparison,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
c7a83fb7-8ea7-430b-9940-fc268326c00d,C0020336,C0025598,was In ,Hydroxychloroquine,Metformin,1,X,[orch/phsu],[orch/phsu],D03.633.100.810.050.180.350,D02.078.370.141.450
5dad14a8-34de-414a-9d2b-4b3aca209b5b,C0020336,C3470566,was In ,Hydroxychloroquine,LINC-ROR gene,1,X,[orch/phsu],[gngm],D03.633.100.810.050.180.350,
27cf369c-b608-4552-a7b0-c38caf93b417,C1707455,C0025598,is with ,Comparison,Metformin,1,X,[acty],[orch/phsu],,D02.078.370.141.450
7da332f7-f315-4073-973d-a83f121b93a3,C0206277,C0852733,risk by particularly ,Fatal Outcome,Completed Suicide,1,X,[patf],[mobd],E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325,
2e700720-eb8a-4f89-b01e-48f41acabb0d,C0020336,C0852733,appears particularly ,Hydroxychloroquine,Completed Suicide,1,X,[orch/phsu],[mobd],D03.633.100.810.050.180.350,
611679db-cc2f-4c96-a5fe-21e63faf0d70,C0025598,C0852733,appears particularly ,Metformin,Completed Suicide,1,X,[orch/phsu],[mobd],D02.078.370.141.450,
9ceadb74-b61f-4218-bebd-cd702702299e,C0079941,C0042720,viral 3UTR of ,Open Reading Frames,Viral Genome,1,X,[gngm],[gngm],G05.360.335.760.640;G05.360.340.024.340.137.650,G05.360.340.358.840
f8836746-1f50-4467-9159-92519fd87167,C1819995,3UTR,directly target viral 3UTR ,Host Cell,3UTR,1,X,[celc],????,,????
15d7b822-cb3c-4d80-80c6-e670f498b11c,C1101610,3UTR,directly target viral 3UTR ,MicroRNAs,3UTR,1,X,[bacs/nnon],????,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,????
81a72c21-f363-4f63-9fe9-b39dc26b0de7,C1819995,C0042720,viral 3UTR of ,Host Cell,Viral Genome,2,X,[celc],[gngm],,G05.360.340.358.840
5ae17135-29cb-4125-9b18-f4ccfb840c57,C1101610,C0042720,viral 3UTR of ,MicroRNAs,Viral Genome,2,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340.358.840
064445b0-7745-4851-802b-1eab9570dbb4,C1819995,C0003451,induce ,Host Cell,Antiviral Agents,1,X,[celc],[phsu],,D27.505.954.122.388
8db4f509-6fa8-482b-8424-3f1f4ba47ef8,C1101610,C0003451,induce ,MicroRNAs,Antiviral Agents,1,X,[bacs/nnon],[phsu],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,D27.505.954.122.388
235a38de-724f-4c50-8718-62c8f6922860,C1101610,C1175743,targeting ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
235a38de-724f-4c50-8718-62c8f6922860,C1101610,C1175743,are unique for ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
235a38de-724f-4c50-8718-62c8f6922860,C1101610,C1175743,can strongly bind to certain key ,MicroRNAs,SARS coronavirus,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,B04.820.504.540.150.113.937
1b0f5246-489a-45e2-aa00-c5400c0ccb31,C1101610,C0017428,targeting ,MicroRNAs,Genome,1,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340
257c151a-aed2-4765-8383-e04b09cae230,C1101610,COVID-19,are unique for ,MicroRNAs,COVID-19,1,X,[bacs/nnon],[virs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,C000657245
b32f8777-67eb-44af-b39d-613c60c678ac,C1101610,C1764827,are unique for ,MicroRNAs,Isolate - microorganism,1,X,[bacs/nnon],[bacs],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,
1f739d03-1a3b-4192-a849-029dffafc0c0,C1764827,COVID-19,have MicroRNAs targets out of,Isolate - microorganism,COVID-19,1,X,[bacs],[virs],,C000657245
0c634102-0bdc-4b04-8b81-7b9fd4a29dc7,C1764827,C1101610,have identical ,Isolate - microorganism,MicroRNAs,1,X,[bacs],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
0c634102-0bdc-4b04-8b81-7b9fd4a29dc7,C1764827,C1101610,showed four unique ,Isolate - microorganism,MicroRNAs,1,X,[bacs],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
6b2ebfe3-6cc0-489a-b4a4-9d591de4a36a,COVID-19,C1101610,showed four unique ,COVID-19,MicroRNAs,1,X,[virs],[bacs/nnon],C000657245,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
b0db5dfd-361d-46f4-9352-3768c9ef6837,C0037083,C1101610,be due to low abundance ,Signal Transduction,MicroRNAs,1,X,[celf],[bacs/nnon],G02.111.820;G04.835,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
f5bcdc60-44e4-4680-98be-eab0bd9644ad,C4601203,C3947283,was most recently recognized Bat coronavirus of potential,Porcine enteric Alphacoronavirus,Bat coronavirus,3,X,[virs],[virs],,
a02ff36a-db58-4cce-9395-17423617deab,C4601203,C0206419,was most recently recognized ,Porcine enteric Alphacoronavirus,Genus: Coronavirus,1,X,[virs],[virs],,B04.820.504.540.150
8aa11b26-5a8c-498d-9472-c898715be7ff,C4601203,C0012634,was most recently recognized ,Porcine enteric Alphacoronavirus,Disease,1,X,[virs],[dsyn],,C23.550.288
56353dd7-cc3e-4a29-b9b2-ab8a6529928e,C4601203,C0319157,is recognized as regional epizootic ,Porcine enteric Alphacoronavirus,AS virus,2,X,[virs],[virs],,
67eb41f3-4652-448e-bbe1-d3de241a2507,C0319157,C1516375,possesses most extensive ,AS virus,Cellular Tropism,4,X,[virs],[celf],,
ade870f2-2e53-44ef-9a29-0a27892be2fd,C0022237,C0018563,washing properly ,Isopropyl Alcohol,Hand,4,X,[orch/phsu],[bpoc],D02.033.755.615,A01.378.800.667
765ef8c1-82c8-490c-b714-90d4b5b009dc,C0599638,C0239816,may predispose HCWs to ,Drinking Water,Hand eczema,2,X,[sbst],[dsyn],D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418,
3ed6db55-aff7-4b69-94fc-078df6eb71cc,C0011740,C0239816,may predispose HCWs to ,Detergents,Hand eczema,2,X,[chvf],[dsyn],D27.720.877.265;J01.516.381,
f2cdd0f1-89d5-424b-ba16-7c75d1ab537e,C0012682,C0239816,may predispose HCWs to ,Disinfectants,Hand eczema,2,X,[sbst],[dsyn],D27.505.954.122.425;D27.720.274,
5fec7ced-4a3f-4cd3-9ad8-41bf29fabb91,C0042769,C0206419,is caused by novel ,Virus Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C02,B04.820.504.540.150
ee15a5e3-41db-4e8d-9cea-2cd528b14574,C0040034,COVID-19,were significantly common than ,Thrombocytopenia,COVID-19,4,X,[dsyn],[virs],C15.378.140.855,C000657245
72023b23-4f47-4310-acfc-f1561ae97861,C0370003,C0230425,using ,Specimen,Structure of right thigh,2,X,[sbst],[bpoc],,
53f92850-5a80-40b6-abcd-04c1a7902136,C0230425,C0370003,is in simulated patient ,Structure of right thigh,Specimen,2,X,[bpoc],[sbst],,
06a94a46-f467-4649-b297-faac0d7c5a83,C0039082,C0032285,can manifest as severe ,Syndrome,Pneumonia,2,X,[dsyn],[dsyn],C23.550.288.500,C08.381.677;C08.730.610
3107b7db-5393-4e26-bfe1-4da3611e222c,C0016976,C0178784,appear Among adult ,Gallbladder,Organ,1,X,[bpoc],[bpoc],A03.159.439,
fca91fbb-839a-4e56-8d20-29ab7e46a515,C0596155,C0178784,appear Among adult ,Basal Cell,Organ,1,X,[cell],[bpoc],,
eee98765-ac13-4ea0-85c6-5378c29111eb,C0553257,C1175743,appear permissive to ,Epithelial cell of renal tubule,SARS coronavirus,4,X,[cell],[virs],,B04.820.504.540.150.113.937
d49c0893-26bc-4c90-afde-92441ca15770,C0022677,C1175743,appear permissive to ,Kidney Tubules Proximal,SARS coronavirus,2,X,[bpoc],[virs],A05.810.453.736.560.570,B04.820.504.540.150.113.937
f9b7f330-f21b-4a7b-a24f-83976000e512,C0682610,C1175743,appear permissive to ,Enterocytes,SARS coronavirus,2,X,[cell],[virs],A03.556.124.369.290;A10.615.550.444.290;A11.436.290,B04.820.504.540.150.113.937
27783b55-717b-42ac-9418-29d0b1fcdf98,C1519373,C1175743,appear permissive to ,Goblet cell of small intestine,SARS coronavirus,2,X,[cell],[virs],,B04.820.504.540.150.113.937
a4b3d2e8-3d52-4f94-80ad-249e8a603b41,C0682610,C0178784,appear Among adult ,Enterocytes,Organ,1,X,[cell],[bpoc],A03.556.124.369.290;A10.615.550.444.290;A11.436.290,
00806b0a-60e4-461d-b62b-c10a27c23371,C1519373,C0178784,appear Among adult ,Goblet cell of small intestine,Organ,1,X,[cell],[bpoc],,
5906aa9c-5437-4871-91b8-3fb20c90affc,C0016976,C1175743,appear permissive to ,Gallbladder,SARS coronavirus,3,X,[bpoc],[virs],A03.159.439,B04.820.504.540.150.113.937
8be99e95-239b-43b0-b2b3-937b28a43332,C0596155,C1175743,appear permissive to ,Basal Cell,SARS coronavirus,3,X,[cell],[virs],,B04.820.504.540.150.113.937
d1315a7e-ef43-4b7e-ae0a-4394448c8d59,C0553257,C0178784,appear Among adult ,Epithelial cell of renal tubule,Organ,2,X,[cell],[bpoc],,
aa05a94f-c14c-4166-95ed-36d8bdf6a232,C0022677,C0178784,appear Among adult ,Kidney Tubules Proximal,Organ,1,X,[bpoc],[bpoc],A05.810.453.736.560.570,
2ffb70df-8f83-4333-a086-5590e2b7600e,C0033684,C0597357,may use same ,Proteins,receptor,2,X,[aapp/bacs],[aapp/rcpt],D12.776,
af9a971e-88e4-4baa-895a-77abb08681e4,C0033684,C0022709,may use ,Proteins,Peptidyl-Dipeptidase A,2,X,[aapp/bacs],[aapp/enzy/imft],D12.776,D08.811.277.656.350.350.687
617512a7-a04c-41e3-a02b-63b4298c6390,C1510827,C0022709,is much higher than that of ,Affinity,Peptidyl-Dipeptidase A,2,X,[npop],[aapp/enzy/imft],,D08.811.277.656.350.350.687
2d875cae-91d1-4fba-97c2-1ecbcbad2d3f,C1510827,C1167622,is much higher than that of ,Affinity,Binding (Molecular Function),2,X,[npop],[moft],,
f0c80a86-0833-4ef4-915b-776a948dea3d,C1510827,C3711684,is much higher than that of ,Affinity,S protein severe acute respiratory syndrome coronavirus,2,X,[npop],[aapp/bacs],,x.x.x.x
d7dd5f37-38db-4c51-8ce2-89e34e15783a,C0079189,C0021747, includes ,cytokine,Interferons,2,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
26e40931-85ac-4dea-ba1b-3a174a5c5b98,C1948023,C0079189,is with inflammatory ,Stimulation (motivation),cytokine,2,X,[npop],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
26e40931-85ac-4dea-ba1b-3a174a5c5b98,C1948023,C0079189,limit release of pro-inflammatory ,Stimulation (motivation),cytokine,1,X,[npop],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
6f94b6cd-de84-4f96-ad42-dbe24f29eacb,C1948023,C0021747,is with inflammatory ,Stimulation (motivation),Interferons,2,X,[npop],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
7a354020-5b36-4a4c-a21e-89de8b1e3d23,C0042769,C1175175,may increase risk of ,Virus Diseases,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],C02,C02.782.600.550.200.750;C08.730.730
10ca6764-2321-47ef-87a6-3c3f0d81ef30,C3687832,C0872315,may Therefore may developed for future ,Drugs - dental services,Communicable Diseases Emerging,1,X,[topp],[dsyn],,C01.539.221.500
093363fb-7b11-4dbd-a34d-8f4773f7ce23,C3687832,C0206419,may Therefore may developed for future ,Drugs - dental services,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
59984c76-871f-4eaf-8b1f-ce66eb383c37,C0582263,C1622204,include ,Structural protein,envelope,1,X,[aapp/bacs],[celc],,
d3c2f34b-1fc9-4c0f-af9c-691c8de90a56,C0582263,C0599561,include ,Structural protein,e protein,1,X,[aapp/bacs],[aapp/bacs],,
d1d8b53b-f329-479a-81a6-00bc3daa6aea,C0582263,C0369637,include ,Structural protein,M NOS ANTIBODY,1,X,[aapp/bacs],[aapp/imft],,
d19b3f95-78d5-4215-9aa0-904f6a790ef6,C0582263,C0596901,include ,Structural protein,Membrane,1,X,[aapp/bacs],[celc],,A10.615
6e8ae5b1-e58a-4030-aa36-06737a13d492,C0582263,C0369718,include ,Structural protein,N not otherwise specified Antibody,1,X,[aapp/bacs],[aapp/imft],,
d52ae7f5-53af-4795-be66-884e547a223e,C0582263,C0178774,include ,Structural protein,Nucleocapsid,1,X,[aapp/bacs],[aapp/bacs/nnon],,A21.249.500;B04.950.500
0bd82293-fafd-455e-8ceb-cd78ae556eee,C4281807,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,PSMD2 gene,1,X,[aapp/bacs],[gngm],,
f09f627e-57a9-4881-b342-66ef44f05da0,S1,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,PSMD2 gene,1,X,????,[gngm],????,
a9de7054-625a-49cd-af8f-63efed27422c,C0599220,C1419032,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,PSMD2 gene,1,X,[aapp],[gngm],D12.776.813,
7117783a-c320-4d64-803d-4e0495cedce6,C4281807,C0599220,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Protein Subunits,1,X,[aapp/bacs],[aapp],,D12.776.813
dba45566-df8f-4ce6-870e-7f7c5993dd0a,S1,C0599220,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Protein Subunits,1,X,????,[aapp],????,D12.776.813
717ee243-7658-4b00-8a23-916e2098a612,C4281807,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Promotion (action),1,X,[aapp/bacs],[acty],,
f6e8b9f6-f128-481a-8018-847518646c52,S1,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Promotion (action),1,X,????,[acty],????,
866f3c20-e75e-4725-9c42-3727d3405291,C0599220,C0033414,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,Promotion (action),1,X,[aapp],[acty],D12.776.813,
86dee61a-e520-40e8-b461-e60155bde1e1,C4281807,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,Vitronectin human,Membrane Fusion,1,X,[aapp/bacs],[moft],,G04.575
6c93756a-37d0-41f5-a16d-b2aa01fa8470,S1,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,S1,Membrane Fusion,1,X,????,[moft],????,G04.575
c4d6b6de-8168-4268-be21-145ebb70dd33,C0599220,C0025246,facilitates Peptidyl-Dipeptidase A Virus Attachment,Protein Subunits,Membrane Fusion,1,X,[aapp],[moft],D12.776.813,G04.575
3d3ca835-7e32-4dff-8e79-887acecf6702,S1,C0022709,facilitates ,S1,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
89e6aad0-0803-4964-b372-c2193644500e,C0599220,C0022709,facilitates ,Protein Subunits,Peptidyl-Dipeptidase A,1,X,[aapp],[aapp/enzy/imft],D12.776.813,D08.811.277.656.350.350.687
07f7b0db-a8cb-4d8c-89b6-d6a0ce7148de,C4281807,C1721019,facilitates ,Vitronectin human,Virus Attachment,1,X,[aapp/bacs],[biof],,G06.920.868
c28f6084-5f08-404c-85cf-a7032cd1b8ad,S1,C1721019,facilitates ,S1,Virus Attachment,1,X,????,[biof],????,G06.920.868
cfd8aa66-df9f-431e-b410-d1f8ca19840a,C0599220,C1721019,facilitates ,Protein Subunits,Virus Attachment,1,X,[aapp],[biof],D12.776.813,G06.920.868
a2de7d5f-cec2-4594-88ba-3615fcb601e7,C0065827,C0036720,is composed of ,Measles Virus Nucleoprotein,Serine,1,X,[aapp/bacs],[aapp/bacs/phsu],x.x.x.x,D12.125.154.800
ca404bed-4fa7-4bee-a123-7aab2661d880,C0065827,C4543503,is composed of ,Measles Virus Nucleoprotein,Sandwich,1,X,[aapp/bacs],[food],x.x.x.x,
f2d6648b-e7e2-40b0-b4dd-639884973c35,NTD,C0427896,forms orthorhombic ,NTD,Crystal - human material,1,X,????,[bdsu],????,
0b0d9e5a-7745-464c-8645-4f1690013682,NTD,C1167622,forms ,NTD,Binding (Molecular Function),1,X,????,[moft],????,
1556fc10-988b-43bf-824e-6281c1babded,NTD,C0042720,forms Binding (Molecular Function) to,NTD,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
1556fc10-988b-43bf-824e-6281c1babded,NTD,C0042720,forms Crystal - human material to,NTD,Viral Genome,1,X,????,[gngm],????,G05.360.340.358.840
809a41dc-9e66-44d9-aca8-ecae543f3e8f,C1519063,C4552744,regulate its ,Phosphorylation Site,Daily Living,1,X,[amas],[dora],,
f11e23c7-0a07-4b85-8d6a-f9063767d84a,C0599561,NTD,contains NTD ,e protein,NTD,1,X,[aapp/bacs],????,,????
9840bade-57cd-4e9d-90dd-cce4a7aa0e9e,C1442905,C0282629,form viroporins needed for ,CTD gene,Virus Assembly,1,X,[gngm],[biof],,G06.920.925.950
003717dc-ec85-4b9c-b294-610946d3a557,C0700271,C1707271,possesses hydrophilic ,M Protein multiple myeloma,Carboxy-Terminal Amino Acid,1,X,[aapp/imft],[amas],x.x.x.x,
431c36c7-49cf-453d-a318-f240f1ffe73d,C0033414,C0042760,facilitates ,Promotion (action),Virion,1,X,[acty],[celc],,A21.249;B04.950
4f936222-e6b3-4cd2-804b-70c424c074ec,C0033684,C0243052,is essential in ,Proteins,Virus Physiological Phenomena,1,X,[aapp/bacs],[npop],D12.776,G06.920
bf2c84ff-2c26-4173-9022-ca88f3bc3283,C0582263,C0087111,developing ,Structural protein,Therapeutic procedure,1,X,[aapp/bacs],[topp],,E02
1bd14edb-59b1-4a1e-927c-f618ca405136,C0206419,C1515090,has drastically reduced ,Genus: Coronavirus,Surgical Oncology specialty,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.429.515.750;H02.403.810.796
452ab2d9-0385-41d1-a205-c5976586dc0f,C0030858,C0012634,distinguish Coronavirus Infections from non,Pentaerythritol Tetranitrate,Disease,2,X,[orch/phsu],[dsyn],D02.033.455.706.690,C23.550.288
cddab0b3-d7cf-4f8c-8906-0f24f7dbf3c3,COVID-19,AUC,is with AUC ,COVID-19,AUC,1,X,[virs],????,C000657245,????
9ee9b186-6055-445f-ad25-f51b79f89498,C0032105,C1711371,allows to FFP2,Plasma,Reprocess,1,X,[bdsu],[acty],A12.207.152.693;A12.207.270.695;A15.145.693,
70b57bbc-ded5-4b17-99d4-a6a5a78c0f62,C0038280,C1711371,allows to FFP2,Sterilization for infection control,Reprocess,1,X,[topp],[acty],N06.850.780.200.450.850,
db870da7-9f20-4734-83fe-bff5bf730c5a,C0011121,C0032105,is with ,Decontamination,Plasma,3,X,[topp],[bdsu],N06.850.780.325,A12.207.152.693;A12.207.270.695;A15.145.693
a05f7512-9c17-4fc4-afbc-7fa4ddb77312,C0017428,C1175175,is in ,Genome,Severe Acute Respiratory Syndrome,2,X,[gngm],[dsyn],G05.360.340,C02.782.600.550.200.750;C08.730.730
eb07a3d9-5912-469b-b8b7-a4bb8da7872f,C1856053,C1175743,spread of ,Hydranencephaly with Renal Aplasia-Dysplasia,SARS coronavirus,1,X,[dsyn],[virs],x.x.x.x,B04.820.504.540.150.113.937
1e18785d-79b6-45c7-b453-cc58e0cd511c,C1947933,C1856053,was suspended beginning on ,care activity,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[acty],[dsyn],,x.x.x.x
3b57d894-dee3-415f-a5b5-ae622de07537,C2986575,hotline,is with hotline ,Connect,hotline,2,X,[acty],????,,????
787fe3fa-cae7-49a4-84c8-d8e28e8f95a4,C1825598,C0021822,necessitated use of alternative ,IMPACT gene,Interview,2,X,[gngm],[acty],,E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420
ec101770-1523-4778-a6ad-0f30df1238a8,C0021760,C0309872,provide valuable signals for ,Interleukin-6,PREVENT (product),2,X,[aapp/imft],[phsu],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,
c1a6a5ad-a7c7-4b2b-8294-6dab2a50e9cf,IFN,C0042542,is in ,IFN,Vero Cells,3,X,????,[cell],????,A11.251.210.955;A11.436.955
7b1e3c19-d0b1-4872-a668-10b27cad8202,C1175743,C0318356,is sensitive to many other ,SARS coronavirus,Human virus,6,X,[virs],[virs],B04.820.504.540.150.113.937,
663e6c95-6c41-4e1c-8aa0-672f685b1f27,C0206419,C0940933,can have serious complications from ,Genus: Coronavirus,infection as a complication,1,X,[virs],[dsyn],B04.820.504.540.150,
dd5c799a-8e1e-4018-8ca5-5b19754932e1,C0206419,C0004093,can have serious complications from ,Genus: Coronavirus,Asthenia,1,X,[virs],[sosy],B04.820.504.540.150,C23.888.089
0f532010-c222-43ef-8da4-18a5ab0946a8,C0034991,C1947933, includes interdisciplinary ,Rehabilitation therapy,care activity,4,X,[topp],[acty],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,
fddf3eac-a4b1-4630-b949-8ccf90611aee,C0206419,C0370003,pandemic calls for expanded opportunities for testing strategies such as home-collected ,Genus: Coronavirus,Specimen,2,X,[virs],[sbst],B04.820.504.540.150,
6d788f63-185d-4630-9cc3-35e13fbd620d,C2586227,C1175743,were sufficient for use in tests of ,Dried blood spot specimen,SARS coronavirus,2,X,[bdsu],[virs],,B04.820.504.540.150.113.937
6d788f63-185d-4630-9cc3-35e13fbd620d,C2586227,C1175743,are suitable for testing for ,Dried blood spot specimen,SARS coronavirus,1,X,[bdsu],[virs],,B04.820.504.540.150.113.937
14fed8c9-687c-4087-b046-baf61b769a2f,C0146894,C1149341,is with nsp14 ,triphosphate,protein C-terminus binding,1,X,[inch],[moft],,
e5929d51-3d32-41d1-983e-7353e25b8c36,C0146894,nsp14,is with nsp14 ,triphosphate,nsp14,1,X,[inch],????,,????
7f6e4922-4dfd-4139-93ec-7577165278ae,C1149341,nsp14,is with nsp14 ,protein C-terminus binding,nsp14,1,X,[moft],????,,????
1301dd20-389b-40a2-b289-a050c1a26bbb,C0146894,C1175743,is with nsp14 ,triphosphate,SARS coronavirus,1,X,[inch],[virs],,B04.820.504.540.150.113.937
c89df516-1beb-413c-994c-0ebdce13fbf2,C1149341,C1175743,is with nsp14 ,protein C-terminus binding,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
09e1dd93-1628-4441-afee-95c66140d02f,Asn388,C1175743,is highly conserved in present in N7-MTase from ,Asn388,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
5cc73317-4184-4db8-a065-7e093549e773,C0031843,C1422268,is in ,physiological aspects,APOM gene,1,X,[phsf],[gngm],x.x.x.x,
6b8da5f9-8c79-4ac6-a7c1-d21bf941197e,C0031843,C1167622,is in ,physiological aspects,Binding (Molecular Function),1,X,[phsf],[moft],x.x.x.x,
bfa3d449-7a97-456f-bb06-41e8c5cd38ec,C1450224,C0206750,successfully navigating emerging ,forensic pathology discipline,Coronavirus Infections,1,X,[bmod],[dsyn],H02.403.330.300;H02.403.650.249;I01.198.780.937.460,C02.782.600.550.200
6c8b3c7f-12af-4c35-b063-3c86a3e6804d,C0013227,C0279516,include ,Pharmaceutical Preparations,Anti-Bacterial Agents,2,X,[phsu],[antb],D26,D27.505.954.122.085
cdc41a34-e521-4655-b323-df34a85cb6c3,C0013227,C0020974,include ,Pharmaceutical Preparations,passive immunization procedure,2,X,[phsu],[topp],D26,E02.095.465.425.400.330;E05.478.550.520
68baa81f-6d92-4bcc-bef9-903c69ce817f,C0184633,C0344211, includes ,Oxygen Therapy Care,Supportive care,1,X,[topp],[topp],E02.880.690,
b1176a84-7cde-4097-a521-80654c52ca18,C0184633,C0015357, includes ,Oxygen Therapy Care,Extracorporeal Membrane Oxygenation,1,X,[topp],[topp],E02.880.690,E02.880.301;E04.292.451
35d3f40d-5e7a-4ce4-bb61-4b28e15e851f,C0543467,C1515090, includes ,Operative Surgical Procedures,Surgical Oncology specialty,4,X,[topp],[bmod],E04,H02.403.429.515.750;H02.403.810.796
f28aef6b-f756-42fc-8748-2b9c9a99a905,C0039082,C0032587,is acute immune-mediated ,Syndrome,Polyradiculoneuropathy,1,X,[dsyn],[dsyn],C23.550.288.500,C10.114.750;C10.314.750;C10.668.829.800.750;C20.111.258.750
c4efff1e-3180-44d1-8f5c-23cf54e0730e,C0009450,COVID19,causes COVID19,Communicable Diseases,COVID19,1,X,[dsyn],????,C01.539.221,????
324732b4-cd81-49ec-98fd-00343f2d8059,C0035243,C1457887,characterized by main ,Respiratory Tract Infections,Symptoms,1,X,[dsyn],[sosy],C01.539.739;C08.730,
e79669be-40c0-4439-a4e4-8c5b2b5e592d,C0035243,C0032285,characterized by main ,Respiratory Tract Infections,Pneumonia,1,X,[dsyn],[dsyn],C01.539.739;C08.730,C08.381.677;C08.730.610
8529c02f-8ce7-4307-a707-687ee31d9658,C1550661,C0206750,diagnosed with ,Specimen Type - Stool = Fecal,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
9410173c-2bc3-45f1-98d8-65b4733e38eb,C0282560,C0370003,were inoculated with ,Caco-2 Cells,Specimen,1,X,[cell],[sbst],A11.251.210.190.160;A11.251.860.180.160;A11.436.140,
f029ea93-4ac5-418f-a3be-a30fcf765c81,C0007590,C1550101,is in ,Cell division,Supernatant,1,X,[celf],[bdsu],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,
cd2f7197-534d-4955-b5d8-aa1743f1d640,C1511790,C1550661,is in ,Detection,Specimen Type - Stool = Fecal,2,X,[topp],[bdsu],,
fbabbbf9-368e-4ab0-867c-c13f88650c2e,C1511790,C0319157,was intermittent ,Detection,AS virus,1,X,[topp],[virs],,
19685042-36ac-4360-8d76-046882e64ff5,C1511790,C0444279,was intermittent ,Detection,Respiratory sample,1,X,[topp],[bdsu],,
7a5e6841-1df5-4dbb-8346-897d7c9a869c,C0319157,C0444279,remained in ,AS virus,Respiratory sample,1,X,[virs],[bdsu],,
6f16a4d0-e77b-4e4f-8a19-7f98187ba465,C0392676,C0015967,is Fever of,Hyperpyrexia,Fever,3,X,[patf],[sosy],,C23.888.119.344
f75f5706-eb59-40a6-80fc-fc2e3e8e1663,C0392676,C0206750,is in ,Hyperpyrexia,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
8f551af6-0388-450f-a192-febb544ef024,C0034991,C0206750,was During pandemic converted into isolation for ,Rehabilitation therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
8f551af6-0388-450f-a192-febb544ef024,C0034991,C0206750,was converted into 130-bed ,Rehabilitation therapy,Coronavirus Infections,1,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
8f551af6-0388-450f-a192-febb544ef024,C0034991,C0206750,should consider effect on ,Rehabilitation therapy,Coronavirus Infections,5,X,[topp],[dsyn],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C02.782.600.550.200
0a7b6588-84b0-4053-8943-0d4dbae19470,C0034991,130-bed,was converted into 130-bed ,Rehabilitation therapy,130-bed,1,X,[topp],????,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,????
8a3dd032-42d1-40a4-a4bc-fde6307a1be0,C0370003,C0426576,was divided On basis of presence of ,Specimen,Gastrointestinal symptom,1,X,[sbst],[sosy],,
fb23016a-6432-4c46-8075-e6ecdbf14d6c,C0426576,C0011991,were ,Gastrointestinal symptom,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
a64693b6-7531-46bb-91e5-7f9aade5c29b,C0426576,C0003123,were ,Gastrointestinal symptom,Anorexia,1,X,[sosy],[dsyn],,C23.888.821.108
4ce14302-e21a-48be-b2e6-6e0722f27e30,C0426576,C0027497,were ,Gastrointestinal symptom,Nausea,1,X,[sosy],[sosy],,C23.888.821.712
6fbe79cc-0f95-4971-8873-daa3d7fe15c8,C0016452,C2258685,reduce ,Food,angiotensin converting enzyme activity,1,X,[food],[moft],G07.203.300;J02.500,
8e82fdd9-420c-43a4-b536-f66891280bd1,C0016452,C0003402,are ,Food,Antioxidants,1,X,[food],[phsu],G07.203.300;J02.500,D27.505.519.217;D27.505.696.706.125;D27.720.799.047
2400bd1a-2040-4085-b332-5311eb4b841f,C0012155,C0206750,is in populations with different ,Diet,Coronavirus Infections,1,X,[food],[dsyn],G07.203.650.240,C02.782.600.550.200
0819d55a-618d-4d0c-b944-c6356a3a69c1,C0206750,C0917801, includes ,Coronavirus Infections,Sleeplessness,2,X,[dsyn],[sosy],C02.782.600.550.200,C10.886.425.800.800;F03.870.400.800.800
27b6af55-d443-4e97-b7de-f8afc151ef0f,C1880177,C0441516,adds new dimension to ,Contribution,Demand (clinical),1,X,[acty],[topp],,
706dd6b2-3ce1-41ba-9085-706eff35c1e8,C1880177,C0221102,adds new dimension to ,Contribution,Excretory function,1,X,[acty],[phsf],,
0f3d8427-6777-478e-8399-685ae98c7039,C1880177,C0324547,adds new dimension to ,Contribution,New Zealand Rabbits,1,X,[acty],[mamm],,B01.050.150.900.649.313.968.700
40e18e32-9160-4d02-933e-f20c28715715,C0009443,C0319157,minimize exposure to ,Common Cold,AS virus,1,X,[dsyn],[virs],C02.782.687.207;C08.730.162,
b4b93f8f-28d1-40dd-b655-a84c5482c9ce,C0003280,C0019134, includes ,Anticoagulants,heparin,1,X,[phsu],[bacs/orch/phsu],D27.505.954.502.119,D09.698.373.400
1c1b1d16-6c35-42a9-9406-18876cf23720,C0319157,C0007610,may enter system in nasal cavity in brainstem ,AS virus,Cell Nucleus,1,X,[virs],[celc],,A11.284.430.106;A11.284.430.214.190.875.117
956be418-7981-4c43-81d4-ecdd4eb0ba4c,C0319157,C1656385,may enter system in nasal cavity in brainstem ,AS virus,regulation of cellular respiration,1,X,[virs],[celf],,
5e233ec4-0dc4-4f0d-baee-33a6c009cbe6,C0319157,C0028938,may enter system through ,AS virus,Olfactory Nerve,1,X,[virs],[bpoc],,A08.800.800.120.640
e775bae3-48ca-4247-ad20-e34966a6cd1b,C0022709,C0030664,is in various neoplastic ,Peptidyl-Dipeptidase A,Pathology,1,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.350.687,H02.403.650
e775bae3-48ca-4247-ad20-e34966a6cd1b,C0022709,C0030664,exerts Daily Living in various models of,Peptidyl-Dipeptidase A,Pathology,1,X,[aapp/enzy/imft],[bmod],D08.811.277.656.350.350.687,H02.403.650
94e8d677-a2c7-4c2b-be40-3bf669a5da5e,C0008946,C1704241,respond to ,Climate,complex (molecular entity),4,X,[npop],[chvs],G16.500.275.071;N06.230.300.100.250,
2ba3f0e4-6173-4492-96e9-1cdbf373d7b8,C0206750,C0341439,might negatively affect course of patients with ,Coronavirus Infections,Chronic liver disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,
58e5c7a2-b502-4ef5-989d-b4c3fb638c77,C0060323,C1707455,were higher in ,Fibrin fragment D,Comparison,1,X,[aapp/bacs],[acty],x.x.x.x,
5dcf80f1-3d4e-4d87-b895-00559a415e46,C0060323,C1947906,were higher in ,Fibrin fragment D,Sorting,1,X,[aapp/bacs],[acty],x.x.x.x,
27811378-8694-4877-b325-927ec888f490,C1707455,C1947906,is with those from non ,Comparison,Sorting,1,X,[acty],[acty],,
aa4900e1-7126-43b3-bad3-ff112ed986b8,C0012634,C0024115,might complicate ,Disease,Lung diseases,3,X,[dsyn],[dsyn],C23.550.288,C08.381
242e2c64-c68f-4fca-8db5-032b5cd8c327,C0012634,C0036421,might complicate Lung diseases scenario Lung diseases Lung diseases in,Disease,Systemic Scleroderma,1,X,[dsyn],[dsyn],C23.550.288,C17.300.799;C17.800.784
1219f5ae-644e-4da6-80af-f0bfc8d279e0,C0206750,C0206062,of outbreak is many patients with underlying ,Coronavirus Infections,Lung Diseases Interstitial,441,X,[dsyn],[dsyn],C02.782.600.550.200,C08.381.483
6a340e30-c3ec-4b14-bc7a-c52b6a8d3727,NIOSH,U.S.,recently evaluated quality of FFRs sampled from U.S. ,NIOSH,U.S.,2,X,????,????,????,????
06333ccf-6dd6-4567-b6fc-9b00b962d579,NIOSH,C0030858,quality of FFRs sampled from U.S. ,NIOSH,Pentaerythritol Tetranitrate,1,X,????,[orch/phsu],????,D02.033.455.706.690
4b089c7f-2e6e-4892-9a6a-84aea0939b7f,C1521827,C0206750,is in hospital due to ,Preparation,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
9841911c-9def-4b87-bc31-009e52056dc4,C0319157,C0700271,gains entry via ,AS virus,M Protein multiple myeloma,2,X,[virs],[aapp/imft],,x.x.x.x
16a9191a-a5b1-49dd-a5ec-2c0d5ab13b01,C0319157,C1167395,gains entry on ,AS virus,Host (organism),2,X,[virs],[orgm],,
bed8c938-5358-46b9-ab9d-5fb6291e6efd,C0319157,C0034800,gains entry on ,AS virus,Receptors Cell Surface,2,X,[virs],[aapp/rcpt],,D12.776.543.750
b08ad689-de5f-4d90-9056-dd31aadb4918,C0596957,C1704241,further strengthen stability of ,Molecular Dynamics,complex (molecular entity),2,X,[moft],[chvs],E05.599.595.500;G02.111.570.895;L01.224.160.500,
67e7a0d6-22c4-4a84-92e7-857d4b6986e1,C1175743,C0426576,causes ,SARS coronavirus,Gastrointestinal symptom,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
5aaa04ab-8b2b-43bb-935f-8c9a14a3fa3b,C3272275,C0206419,were performed during ,Urgent Procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
6b828d99-cb41-4ab1-82d5-01725f3985d9,C0021368,C0206419,occur with ,Inflammation,Genus: Coronavirus,1,X,[patf],[virs],C23.550.470,B04.820.504.540.150
19acedf9-1b62-4d60-b101-95a7844edd43,C0003209,C0206419,changes occurs with ,Anti-Inflammatory Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.158,B04.820.504.540.150
9aa72bee-0b80-475c-9e0c-c6f6b55247b6,C0242781,C4289682,can can ,disease transmission,Direct Transmission,1,X,[patf],[patf],N06.850.310,
b1965ec5-cb6f-4ca6-a2af-1b905e19d282,C1175743,C1457887,understanding of ,SARS coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
b1965ec5-cb6f-4ca6-a2af-1b905e19d282,C1175743,C1457887,is dominated by ,SARS coronavirus,Symptoms,1,X,[virs],[sosy],B04.820.504.540.150.113.937,
b1965ec5-cb6f-4ca6-a2af-1b905e19d282,C1175743,C1457887,remains detectable following self-reporting of ,SARS coronavirus,Symptoms,2,X,[virs],[sosy],B04.820.504.540.150.113.937,
6786dd1a-f073-4a07-92f8-01256c4c5e36,C0032310,C1457887,is with clinical ,Pneumonia Viral,Symptoms,1,X,[dsyn],[sosy],C02.705;C08.381.677.807;C08.730.610.763,
d0c2d95e-b39d-468f-86e5-44591db3741c,C0032310,C0206419,is with clinical ,Pneumonia Viral,Genus: Coronavirus,1,X,[dsyn],[virs],C02.705;C08.381.677.807;C08.730.610.763,B04.820.504.540.150
3a31164c-f184-4b9b-84e4-bc5e90bbdc07,C0032310,C0012634,is with clinical ,Pneumonia Viral,Disease,1,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C23.550.288
c6bb682d-c05d-4510-892b-34ce532b238e,C0004096,C0012655,affect ,Asthma,Disease susceptibility,1,X,[dsyn],[clna],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.687;G07.100.250
f6370894-b1aa-4761-b014-a5ce7dc5aaeb,C0004096,C0206419,affect ,Asthma,Genus: Coronavirus,1,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,B04.820.504.540.150
f6370894-b1aa-4761-b014-a5ce7dc5aaeb,C0004096,C0206419,Disease susceptibility of,Asthma,Genus: Coronavirus,2,X,[dsyn],[virs],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,B04.820.504.540.150
283b4416-af51-488e-bb0d-3a15005d407d,C0206419,C0004096,significantly impacted pediatric ,Genus: Coronavirus,Asthma,1,X,[virs],[dsyn],B04.820.504.540.150,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
d5c00b8b-a105-4f11-9df6-257d48e54d97,C0476474,C0206419,is with suspected association to ,persistent fever,Genus: Coronavirus,1,X,[patf],[virs],,B04.820.504.540.150
66bdff31-6cc2-46b7-8804-4c2a78989089,C4048285,C0199470,was strongly associated with HFNC,C-Reactive Protein human,Mechanical ventilation,1,X,[aapp/imft],[topp],,
1fa60081-a7ba-486b-80ff-2aaad6d5ea50,C4048285,HFNC,was strongly associated with HFNC,C-Reactive Protein human,HFNC,1,X,[aapp/imft],????,,????
7b56d30e-df2f-48a8-8cb1-09035ca7a947,C0022322,C0005532,plays role in several ,Ivermectin,biology (field),1,X,[orch/phsu],[bmod],D02.540.576.500.997;x.x.x.x,H01.158.273
bd4359a4-499b-47cb-8ac2-5e3af4180eec,C0206419,C0019682,amplify known ,Genus: Coronavirus,HIV,1,X,[virs],[virs],B04.820.504.540.150,B04.820.650.589.650.350
06067396-c0fa-4c82-aa87-6fb6cd192450,C0042776,C0034019,becomes ,Virus,public health medicine (field),1,X,[virs],[bmod],B04,H02.403.720;N01.400.550;N06.850
06067396-c0fa-4c82-aa87-6fb6cd192450,C0042776,C0034019,resulting in ,Virus,public health medicine (field),1,X,[virs],[bmod],B04,H02.403.720;N01.400.550;N06.850
ece04b5d-37a2-48ed-a490-4a378c621531,C0206419,C1947933,can address important questions about ,Genus: Coronavirus,care activity,1,X,[virs],[acty],B04.820.504.540.150,
4e139e2c-722e-4ac5-9d0d-dfc94b4aea1a,C2700061,C0020517,are very ,Transition (action),Hypersensitivity,1,X,[acty],[patf],,C20.543
403e7d2c-659a-4abf-859a-e6b7c9660f1a,C3714552,C0231452,is with cervical ,Weakness,Flexion function,1,X,[sosy],[ortf],,
528209d4-1bcf-4f84-908b-0562d1ab2b17,C3714552,C1540289,is with cervical ,Weakness,CD200 gene,1,X,[sosy],[gngm],,
017172d8-bee1-4c97-83ce-dbbe311ebb10,C2349975,C0039082,is atypical feature in ,Enhance (action),Syndrome,1,X,[acty],[dsyn],,C23.550.288.500
315ebc85-a917-4d72-9a31-3fd38720dd42,C0683201,C0206419,is in critical patients with ,specific immunity,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
24247bc3-67d3-4650-9823-b591e9d3c159,C1512594,C4521448,was investigated in ,IL2 Signaling Pathway,Derived Peripheral Blood Mononuclear Cell,2,X,[celf],[cell],,
95cb6228-9c4f-42da-8868-837fe5f6b73b,C0169658,C0206419,is in critical patients with ,Janus kinase 1,Genus: Coronavirus,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,B04.820.504.540.150
4c52b0a3-4489-48c1-9e2d-32f3ebda649a,C1366394,C0206419,is in critical patients with ,STAT5A protein human,Genus: Coronavirus,1,X,[aapp/bacs],[virs],x.x.x.x,B04.820.504.540.150
a70f8cf7-d835-4f61-9346-b8740a378826,C0206244,C0034386,be unlikely regardless of ,Lifting,Quarantine,1,X,[acty],[topp],G01.374.669,N06.850.780.200.450.700
50f8fe38-7067-4a6a-9aaf-083bacc37719,C0206244,C2926735,be unlikely regardless of ,Lifting,Duration,1,X,[acty],[orch/phsu],G01.374.669,
a51fdeb7-8366-45d7-88c6-e90402f12d7c,C0034386,C2926735,be unlikely regardless of ,Quarantine,Duration,1,X,[topp],[orch/phsu],N06.850.780.200.450.700,
1ccbea86-8170-4474-ad9a-3358d4e0c7cc,C0005779,C0012739,meets laboratory criteria for ,Blood Coagulation Disorders,Disseminated Intravascular Coagulation,2,X,[dsyn],[dsyn],C15.378.100,C15.378.100.220;C15.378.463.250;C15.378.925.220
aee13f78-155d-4d81-a061-55a78f5bfd12,C0630906,C0206419,is in ,vinyltriethoxysilane,Genus: Coronavirus,2,X,[orch],[virs],x.x.x.x,B04.820.504.540.150
8f7876c8-ff9b-4f5c-b6b4-3655e5dc1410,C1175743,C0719214,led to most recent pandemic of ,SARS coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150.113.937,
8f7876c8-ff9b-4f5c-b6b4-3655e5dc1410,C1175743,C0719214,outbreak of is worst healthcare ,SARS coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150.113.937,
28474273-0e04-4c0b-908a-a0f14e3bb4d3,C1707455,C1536220,is In ,Comparison,ST segment elevation myocardial infarction,1,X,[acty],[dsyn],,C14.280.647.500.875;C14.907.585.500.875
be1c7542-5320-401f-8004-0cf3a340c9ba,C0038441,C0012634,create entirely new form of ,Stress Disorders Traumatic,Disease,1,X,[mobd],[dsyn],F03.950.750,C23.550.288
ce92d50b-6c07-4e13-adaf-3fe89ab3a99a,C0206750,C0450442,is At state cited as problematic ,Coronavirus Infections,Agent,1,X,[dsyn],[chvf],C02.782.600.550.200,
ce92d50b-6c07-4e13-adaf-3fe89ab3a99a,C0206750,C0450442,is cited as most worldwide problematic ,Coronavirus Infections,Agent,1,X,[dsyn],[chvf],C02.782.600.550.200,
658771a9-7e33-4b52-9f14-336aaf0b5879,C0022709,C0011334,is highest within sinonasal ,Peptidyl-Dipeptidase A,Dental caries,1,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,C07.793.720.210
557c327d-e104-4950-9c5a-e83f078df334,C0033684,C0011334,is highest within sinonasal ,Proteins,Dental caries,2,X,[aapp/bacs],[dsyn],D12.776,C07.793.720.210
d0e29076-58e3-41dc-b0f6-dd5e843db081,C0033684,C0819757,was found In ,Proteins,Structure of parenchyma of lung,4,X,[aapp/bacs],[tisu],D12.776,
29a36fcc-88ef-46ce-98ff-2c9e63e5bec5,C0022709,C0699040,was found on apical ,Peptidyl-Dipeptidase A,Cell surface,2,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,
ce846416-d675-4ce7-9fc0-eed31a2d6704,C0033684,C0699040,was found on apical ,Proteins,Cell surface,4,X,[aapp/bacs],[celc],D12.776,
fdeeb17b-ded2-41ca-bf8f-c731b0905c85,C0033684,C1742865,colocalized with ,Proteins,TMPRSS2 protein human,2,X,[aapp/bacs],[aapp/enzy],D12.776,x.x.x.x
c6e533aa-955d-4909-8cf0-02ffb5b504fa,C1742865,CoV2,chemical cofactor for CoV2,TMPRSS2 protein human,CoV2,2,X,[aapp/enzy],????,x.x.x.x,????
c928e675-01b2-4745-ac46-4334f4483949,C0033684,C0178555,colocalized with CoV2 ,Proteins,chemical cofactor,2,X,[aapp/bacs],[bacs],D12.776,
4333c9f1-47e4-4133-9d18-483c6476717d,C0033684,C1175743,colocalized with CoV2 ,Proteins,SARS coronavirus,2,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150.113.937
4333c9f1-47e4-4133-9d18-483c6476717d,C0033684,C1175743,could could direct targets for ,Proteins,SARS coronavirus,1,X,[aapp/bacs],[virs],D12.776,B04.820.504.540.150.113.937
1fc651e1-3943-46a3-b40e-7e763695a992,C0033684,CoV2,colocalized with CoV2 ,Proteins,CoV2,2,X,[aapp/bacs],????,D12.776,????
a62f3ea0-fcfc-4eb0-8cb1-8fdb4f11a6f3,C0033684,C0206750,was increased in demographic with incidence of severe ,Proteins,Coronavirus Infections,2,X,[aapp/bacs],[dsyn],D12.776,C02.782.600.550.200
3563e0d2-eaa0-4a14-8308-b8c718a313a9,C0024264,C1514474,were selected as final ,Lymphocyte,Prognostic Factors,1,X,[cell],[clna],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,E01.789
89d3c1d6-ca9c-4da8-8bf0-43b9aa8dd141,C2745965,C0034991,consider specific ,Emergencies [Disease/Finding],Rehabilitation therapy,2,X,[patf],[topp],C23.550.291.781;N06.230.100.083;N06.850.376,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
b495e86a-021b-4fa2-bca6-5fb22dc829b4,C0025242,C0022709,may decrease ,Memantine,Peptidyl-Dipeptidase A,1,X,[orch/phsu],[aapp/enzy/imft],D02.455.426.100.050.035.500,D08.811.277.656.350.350.687
535d3dfb-8029-4e6f-b2bf-5e5930eeeb47,C0025242,C0021368,reduce ,Memantine,Inflammation,1,X,[orch/phsu],[patf],D02.455.426.100.050.035.500,C23.550.470
59bfe0d2-fb94-4ee7-b18b-662494cd5d43,C0025242,C0242606,reduce ,Memantine,Oxidative Stress,1,X,[orch/phsu],[comd],D02.455.426.100.050.035.500,G03.673;G07.775.750
1cfb7c14-6508-46b7-b4c4-de1f8d9b656a,C1443953,C1175743,caused by ,Acute viral disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
c8c1cc5e-afbf-4a40-a843-a6bd90d0e290,C0024109,C1707455,be significantly upregulated in smokers ,Lung,Comparison,2,X,[bpoc],[acty],A04.411,
d1840d06-950c-4a6e-9f8e-940ad573b696,C0458827,C1707455,be significantly upregulated in smokers ,Airway structure,Comparison,2,X,[bpoc],[acty],,
1b7d3636-e669-4695-a360-d552090775ba,C0276653,C0009566,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Complication,2,X,[dsyn],[patf],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,
c914497d-0431-4df1-bd37-d3e9a78d8b5b,C0276653,C0010340,be increasingly observed Complication in,Invasive Pulmonary Aspergillosis,Critical Illness,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C23.550.291.625
c914497d-0431-4df1-bd37-d3e9a78d8b5b,C0276653,C0010340,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Critical Illness,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C23.550.291.625
789a8947-13ed-49f7-a531-46ba7f033b07,C0276653,C1175175,be increasingly observed Complication in,Invasive Pulmonary Aspergillosis,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C02.782.600.550.200.750;C08.730.730
789a8947-13ed-49f7-a531-46ba7f033b07,C0276653,C1175175,seems increasingly observed ,Invasive Pulmonary Aspergillosis,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C01.703.080.768.750;C01.703.492.688;C08.381.472.850.750,C02.782.600.550.200.750;C08.730.730
55d88fac-f251-4c70-8c7d-2a03ec832e96,C0010340,C1175175,is with ,Critical Illness,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C23.550.291.625,C02.782.600.550.200.750;C08.730.730
a31b9c9f-10d9-400f-96b5-8cfb681ed130,C0009566,C0010340,is in ,Complication,Critical Illness,1,X,[patf],[dsyn],,C23.550.291.625
c7fd83c3-467a-40d5-9e72-35ed25d2cb0e,C0009566,C1175175,is in ,Complication,Severe Acute Respiratory Syndrome,1,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
01a3b71e-331a-452e-9f38-a82e7a470c93,C0206750,C3813209,each with its own ,Coronavirus Infections,PROS1 wt Allele,1,X,[dsyn],[gngm],C02.782.600.550.200,
a2c370da-9f41-4904-97aa-137fbdc370dc,C0206750,C4552744,has enforced dramatic changes to ,Coronavirus Infections,Daily Living,1,X,[dsyn],[dora],C02.782.600.550.200,
6d4a3b97-b705-48a5-8cfa-e6eff1121df9,C0206750,C1704272,is with ,Coronavirus Infections,Benign Prostatic Hyperplasia,1,X,[dsyn],[dsyn],C02.782.600.550.200,C12.294.565.500
2fa4ae41-a39d-4ef2-8d96-d987be838aff,C0206750,C0040034,may may associated with ,Coronavirus Infections,Thrombocytopenia,1,X,[dsyn],[dsyn],C02.782.600.550.200,C15.378.140.855
95d5cb5f-484d-4a5f-a2d7-ffb9cbe0c23e,C0012634,C0040034,may may associated with ,Disease,Thrombocytopenia,1,X,[dsyn],[dsyn],C23.550.288,C15.378.140.855
023639cb-6237-4b51-a4c4-6b3d2796c499,C0079189,C0040034,are leading etiologies of ,cytokine,Thrombocytopenia,2,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C15.378.140.855
1158a598-7d0b-4d3f-960a-efe0f8e8f116,C0009830,C0206750,are leading etiologies of ,Consumption of goods,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
63abf87f-cbb0-44c8-9647-e20c87dcb437,C0009830,C0040034,are leading etiologies of ,Consumption of goods,Thrombocytopenia,2,X,[acty],[dsyn],,C15.378.140.855
3365c978-effb-401f-a4cf-26f5a60b99b1,C1948029,C0040034,are leading etiologies of ,Destruction (action),Thrombocytopenia,1,X,[acty],[dsyn],,C15.378.140.855
44ade683-192a-4af4-b1da-d75addc37ae0,C1948029,C0206750,are leading etiologies in ,Destruction (action),Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
21d8cf54-0082-46e3-a17d-ee6613471e64,C4511035,C1269799,is with other ,Isolated thrombocytopenia,Additional pathologic finding in tumor specimen,1,X,[dsyn],[clna],,
7f0120f8-148c-48bb-b924-30e87341deff,C0020336,C0003811,is known potentially ,Hydroxychloroquine,Cardiac Arrhythmia,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.067;C23.550.073
86cf98f9-9ff2-4940-b46d-61854a1802aa,C0026056,C1956064,was initiated for ,Midazolam,Deep Sedation,2,X,[orch/phsu],[topp],D03.633.100.079.080.575,E03.295
107e17ca-b487-49c4-86ff-e35fccbc2f1e,C1533734,C1956064,was initiated for ,Administration procedure,Deep Sedation,2,X,[topp],[topp],,E03.295
128191ac-2aec-46a9-8f43-d259a22f7b88,C0073393,C0011206,was started for ,Risperidone,Delirium,2,X,[orch/phsu],[mobd],D03.383.742.698.685,C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350
8ae761ac-d1c0-48ee-ad93-e1b1b015d7c0,HCP,C0034019,were notified to Hellenic National ,HCP,public health medicine (field),1,X,????,[bmod],????,H02.403.720;N01.400.550;N06.850
c8ac7ca3-12a5-4238-93e2-8b16b1badf01,HCP,C0206750,is with history of occupational exposure to ,HCP,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
30934cf0-f3b8-4e38-960b-174af043afaa,C3641730,C0005818,demonstrated distinct changes in gene expression profile of ,Cell-Free RNA,Blood Platelet Disorders,1,X,[nnon],[dsyn],D13.444.154,C15.378.140
6c18f9ac-b013-4ee8-9496-12c599ddc70b,C3641730,C0206750,demonstrated distinct changes in gene expression profile of ,Cell-Free RNA,Coronavirus Infections,1,X,[nnon],[dsyn],D13.444.154,C02.782.600.550.200
dc180689-b5c7-4215-88b5-6854bbf40de2,C0005818,C0134835,had increased basally and ,Blood Platelet Disorders,P-Selectin,1,X,[dsyn],[aapp/imft],C15.378.140,D12.776.395.550.200.700.775;D12.776.395.550.625.905;D12.776.503.843.775;D12.776.543.550.200.700.775;D12.776.543.550.625.905;D23.050.301.350.700.775
df29593d-70ab-4565-bc58-4209ec01503d,C0039194,C0206750,were significantly elevated in ,T-Lymphocyte,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,C02.782.600.550.200
21236efa-7435-4019-ac33-33182e2ebd67,C0005778,C0302148,is with higher risk of ,Blood coagulation,Blood Clot,2,X,[ortf],[patf],G09.188.390.150,C14.907.355.830
082f4f30-fb7f-45ab-a6c4-11b9844e69f5,C0730585,C0028754,is proposed In ,Low dose heparin prophylaxis,Obesity,2,X,[topp],[dsyn],,C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500
ecab70c4-6cc8-4fc8-94e6-c4dd47e4783f,C0730585,LMWH,is with intermediate LMWH,Low dose heparin prophylaxis,LMWH,2,X,[topp],????,,????
486c07dc-7b12-4fdc-8d7b-6038b07fcd40,C0028754,C0035222,is with ,Obesity,Respiratory Distress Syndrome Adult,2,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.381.840;C08.618.840
e8d63c34-57f6-4a47-8099-5ef4bd3c75a9,C0035078,C1531698,is with ,Kidney Failure,Active monitoring,4,X,[dsyn],[topp],C12.777.419.780;C13.351.968.419.780,
ed4587bd-ce24-4b75-bbc4-863e1e97e8f7,C0035078,C0019139,is with ,Kidney Failure,Heparin Low-Molecular-Weight,2,X,[dsyn],[orch/phsu],C12.777.419.780;C13.351.968.419.780,D09.698.373.400.300
25860614-7ffa-4868-b8bb-ff015ff92961,C0005847,C0441655,were reduced by fishing ,Blood Vessel,Activities,1,X,[bpoc],[acty],A07.015,
aedc1a64-1687-44c9-ac67-09b08281640d,C1706202,C1004593,focused on ,Search - action,Scopus,1,X,[acty],[bird],,
10e27fc8-8da8-4d49-bd92-36ae87f78260,C0207682,C1175175,blocked 2 ,nafamostat mesilate,Severe Acute Respiratory Syndrome,2,X,[orch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
10e27fc8-8da8-4d49-bd92-36ae87f78260,C0207682,C1175175,also inhibits 2 ,nafamostat mesilate,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],,C02.782.600.550.200.750;C08.730.730
3e084441-e4a9-4ae0-88ee-56d94a289600,C0312860,C1533734,is below its average ,Neutrophil migration function,Administration procedure,3,X,[celf],[topp],,
deb6d1a0-e153-40aa-8c33-c1b61662f813,C1175175,C0007634,is in ,Severe Acute Respiratory Syndrome,Cells,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,A11
3aa6c2aa-78e1-45aa-976f-61c326b23416,C0009450,C3698360,can cause ,Communicable Diseases,Middle East Respiratory Syndrome Coronavirus,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540.150.113.750
823d1296-64eb-4afc-86de-ca829815142b,C0118522,C0038441,making elderly susceptible to ,GA-Binding Protein Transcription Factor,Stress Disorders Traumatic,1,X,[aapp/bacs],[mobd],D12.776.260.615.249;D12.776.930.618.249,F03.950.750
e3da32b8-e779-45cf-b730-7fabb49355ab,C0118522,C0022709,downregulates ,GA-Binding Protein Transcription Factor,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],D12.776.260.615.249;D12.776.930.618.249,D08.811.277.656.350.350.687
1439f55b-b8d5-4384-9e21-553637c1198e,C1879547,C0022709,downregulates ,Activation action,Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],,D08.811.277.656.350.350.687
2d4ca80f-d475-4b02-a3a7-432249e783ea,PB125,C0022709,downregulates ,PB125,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
b6c83bfa-9ba0-4340-b8ed-18a3842082c8,C0162867,C1516048,was ,Tunica Media,Assessed,1,X,[tisu],[acty],A07.015.733,
bf3f37c7-f213-44fd-bb04-4a6a56976369,C0162867,C0003467,was associated with more negative affect ,Tunica Media,Anxiety,1,X,[tisu],[mobd],A07.015.733,F01.470.132
88bb2bd5-ebf6-4f58-a7e0-efeb355a7f56,C0079613,C0012634,knowledge of ,Adoptive Immunotherapy,Disease,1,X,[topp],[dsyn],E02.095.465.425.400.330.050.400;E05.478.550.520.050.400,C23.550.288
058ff75a-94b1-4310-95d2-ef62f7fea3e9,C0162867,C1514593,was associated with positive ,Tunica Media,Psychological Impact,1,X,[tisu],[clna],A07.015.733,
27f9d2dd-2e09-4ca0-bf22-be40358d27fd,C0005768,C0012655,might have role in ,In Blood,Disease susceptibility,1,X,[bdsu],[clna],x.x.x.x.x,C23.550.291.687;G07.100.250
27f9d2dd-2e09-4ca0-bf22-be40358d27fd,C0005768,C0012655,role in increased ,In Blood,Disease susceptibility,1,X,[bdsu],[clna],x.x.x.x.x,C23.550.291.687;G07.100.250
9480d014-b871-4c7f-8681-609103978feb,C0005768,C0012634,role to ,In Blood,Disease,2,X,[bdsu],[dsyn],x.x.x.x.x,C23.550.288
9480d014-b871-4c7f-8681-609103978feb,C0005768,C0012634,supporting ,In Blood,Disease,1,X,[bdsu],[dsyn],x.x.x.x.x,C23.550.288
4d25eba8-6b52-48f5-ad05-194f29cdbab7,C0005516,C0206750,showing correlation to mortality in ,Biological Markers,Coronavirus Infections,1,X,[clna],[dsyn],D23.101,C02.782.600.550.200
4d25eba8-6b52-48f5-ad05-194f29cdbab7,C0005516,C0206750,may occur in ,Biological Markers,Coronavirus Infections,1,X,[clna],[dsyn],D23.101,C02.782.600.550.200
cd66d2d0-a695-41fb-bf83-b77f19af4bad,C0005516,C0012634,may occur correlating with severity of underlying ,Biological Markers,Disease,2,X,[clna],[dsyn],D23.101,C23.550.288
cd66d2d0-a695-41fb-bf83-b77f19af4bad,C0005516,C0012634,related to ,Biological Markers,Disease,1,X,[clna],[dsyn],D23.101,C23.550.288
98f61547-85b8-4e9f-a8bf-4d0054e6e8d9,C0021966,C0013227,Speaking remotely with US graduates of Havanas Latin American School of ,Iodides,Pharmaceutical Preparations,1,X,[inch],[phsu],D01.248.497.158.490;D01.475.410,D26
840d24f1-7724-4bcc-adbc-0c3249d27b30,C0013227,C2742136,of School is ,Pharmaceutical Preparations,SELE protein human,1,X,[phsu],[aapp/imft],D26,x.x.x.x
81ed7238-51a2-4510-b4aa-df497abd2063,C0021966,C1706374,spoke during break at home in mid ,Iodides,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[inch],[aapp/bacs],D01.248.497.158.490;D01.475.410,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
2b3bb8e0-d5b9-4e50-8cea-d35ea4c8ddd9,C3146294,C0037633,collectively find ,Generation (action),Solutions,1,X,[acty],[sbst],,D26.776
010996fe-06dc-4f36-8f19-a7f798c3ec57,C3536826,C1707391,were In addition to,antiviral nucleoside analog,Choose (action),6,X,[phsu],[acty],,
f9d11594-b3fa-4bc7-8a64-7ccd0c731926,C1667052,C0014442,are more effective drug candidates than ,maraviroc,Enzymes,1,X,[orch/phsu],[aapp/enzy],D02.455.426.392.368.367.726;D03.383.129.799.682,D08.811
328382c7-6927-44db-a441-90215451e9cf,C1871526,C0014442,are more effective drug candidates than ,raltegravir,Enzymes,1,X,[nnon/phsu],[aapp/enzy],,D08.811
699d99bb-14d5-4de9-b75c-22809bb3d066,C0520510,C0206750,included patients with diagnosis of ,Materials,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
699d99bb-14d5-4de9-b75c-22809bb3d066,C0520510,C0206750,maximize utility participating in ,Materials,Coronavirus Infections,2,X,[sbst],[dsyn],,C02.782.600.550.200
f1888eda-d7cb-4325-9e9b-cf0ced2e2a34,C1175743,C0230425,for reaction is PCR,SARS coronavirus,Structure of right thigh,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
75e29c31-e515-4702-bac1-e646700b6ba6,C1175743,PCR,for reaction is PCR,SARS coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150.113.937,????
75e29c31-e515-4702-bac1-e646700b6ba6,C1175743,PCR,was determined by PCR,SARS coronavirus,PCR,1,X,[virs],????,B04.820.504.540.150.113.937,????
2da0e9a4-55cf-4e7f-ab9d-69d1cf16d4b1,C0206415,C1175743,is with ,Oligonucleotide Primers,SARS coronavirus,4,X,[nnon],[virs],D13.695.578.424.450.275;D27.720.470.530.600.223.600,B04.820.504.540.150.113.937
7711721a-9533-4f28-adf1-0a5c86856403,C2347609,C1175743,is with ,Chemical Probe,SARS coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150.113.937
dc79206e-3344-4d70-a532-465141c8ca36,C0009758,C0039409,disease transmission through,conjunctiva,Tears body substance,1,X,[bpoc],[bdsu],A09.371.060.200;A09.371.337.168,A12.200.882
e7ab27fe-e331-4ffa-b6bf-b34dc863e91d,C3652465,C1422064,highly upregulates ,Interferon,ACE2 gene,1,X,[aapp/imft/phsu],[gngm],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
d75e6c8e-b862-44e0-87cc-2895fb6ea85b,C1742865,C0026727,is part of T2 ,TMPRSS2 protein human,Mucous body substance,1,X,[aapp/enzy],[bdsu],x.x.x.x,A12.200.503
a3e08d2f-4bd4-41f5-a503-c21545b48c58,C1742865,T2,is part of T2 ,TMPRSS2 protein human,T2,1,X,[aapp/enzy],????,x.x.x.x,????
b59126cc-3092-4b3a-91a5-f2a1c53354ab,C1742865,C0021368,is part of T2 ,TMPRSS2 protein human,Inflammation,1,X,[aapp/enzy],[patf],x.x.x.x,C23.550.470
96ecb2f5-4d68-466f-b46c-6154c654caa9,C1742865,C3266814,is part of T2 ,TMPRSS2 protein human,Action,1,X,[aapp/enzy],[acty],x.x.x.x,
15b63fed-e1c6-4e3f-911e-e5d29e9a7070,C1742865,C0214743,is part of T2 ,TMPRSS2 protein human,Interleukin-13,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
b383df69-3948-467e-b2c5-d1c934bee5e3,C3714514,C0301872,also stimulating more pronounced cytotoxic ,Infection,Immune response,2,X,[patf],[ortf],C01.539,
3896ca61-15a5-4a33-8f86-6e54718dc884,C3714514,C0597404,also stimulating more pronounced cytotoxic ,Infection,Respiratory viruses,2,X,[patf],[virs],C01.539,
902c9ba6-f6a4-43db-b843-4ac266b266d7,C3714514,C0021760,upregulate ,Infection,Interleukin-6,2,X,[patf],[aapp/imft],C01.539,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
fbb22bea-9590-4be0-9a9e-c777d3bf1d7e,C1175743,C0450442,is etiological ,SARS coronavirus,Agent,5,X,[virs],[chvf],B04.820.504.540.150.113.937,
92d7ce20-d438-48d1-8143-85e4e3ed9255,C0206750,C0199470,requiring ,Coronavirus Infections,Mechanical ventilation,1,X,[dsyn],[topp],C02.782.600.550.200,
ff7e68fb-419a-45a6-9817-69406d257a86,C0032105,PCR,was associated with negative conversion rate of PCR ,Plasma,PCR,1,X,[bdsu],????,A12.207.152.693;A12.207.270.695;A15.145.693,????
6d1259c3-d989-4968-bb47-246c8e054020,invivo,C0206750,is in treatment of ,invivo,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
c077ca5d-e8e7-473d-b9cb-f6a033aa31e6,invivo,C0870392,is currently matter of ,invivo,debate,1,X,????,[acty],????,
a05de1d4-c4c6-4e6d-b968-7ba161bea39b,C0008269,C1167024,accumulates in ,Chloroquine,food vacuole,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,
a05de1d4-c4c6-4e6d-b968-7ba161bea39b,C0008269,C1167024,increasing pH of ,Chloroquine,food vacuole,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,
06cb4eb6-f610-43d6-8f72-07a73679c53f,C0008269,C0024369,accumulates in ,Chloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.550
06cb4eb6-f610-43d6-8f72-07a73679c53f,C0008269,C0024369,elevating pH of acidic ,Chloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.550
f02072a0-b7f3-418c-9413-5231aa31b384,C0003451,C0221106,results from ,Antiviral Agents,Alkalemia,2,X,[phsu],[dsyn],D27.505.954.122.388,
0efab17a-aeda-411a-9ff9-afa73177ab1f,C0003451,C0024369,results from ,Antiviral Agents,Lysosomes,1,X,[phsu],[celc],D27.505.954.122.388,A11.284.430.214.190.875.190.550
c34cee90-a122-40af-9756-1e9605b8c7d5,C0085078,C0230825,Characterization by accumulation of,Lysosomal Storage Diseases,Multivesicular body,1,X,[dsyn],[celc],C16.320.565.595;C18.452.648.595,A11.284.430.214.190.875.190.880.337.500
b677116c-bac3-4982-8e7b-f5342c1d1e57,C0085078,C0007634,Characterization by accumulation of,Lysosomal Storage Diseases,Cells,1,X,[dsyn],[cell],C16.320.565.595;C18.452.648.595,A11
e30ec20c-ff9f-4d9d-82f2-8905f17df4e5,C0053738,C1166848,Lipid A of,bis(monoacylglyceryl)phosphate,late endosome,1,X,[bacs/orch],[celc],x.x.x.x,
98f37ae5-af3b-438a-8609-3b78600afc7d,C3687832,C0053932,induce accumulation of ,Drugs - dental services,Bone Morphogenetic Proteins,2,X,[topp],[aapp/bacs],,D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200
66241cb0-a534-4cd9-966b-7a3580f22695,C3687832,C1705396,induce accumulation of ,Drugs - dental services,GLI2 wt Allele,2,X,[topp],[gngm],,
145602f0-9fef-4545-be33-7169b07c0cb0,C0053932,C1537068,favour ,Bone Morphogenetic Proteins,Virus Internalization,1,X,[aapp/bacs],[biof],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,G06.920.881
5bf700e1-2794-4cc3-872f-e28292531c18,C0053932,C1704259,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Biochemical Pathway,1,X,[aapp/bacs],[moft],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,
9f72379a-db48-486f-acfa-73b1b63d3b9a,C0053932,C0003451,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Antiviral Agents,1,X,[aapp/bacs],[phsu],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,D27.505.954.122.388
3809a595-321c-4076-a097-55d139c36c56,C0053932,C3687832,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Drugs - dental services,1,X,[aapp/bacs],[topp],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,
d501d53c-385f-43db-8635-6ceafb8fe1df,C0053932,C0008269,favour Virus Internalization through hijacking of endocytic,Bone Morphogenetic Proteins,Chloroquine,1,X,[aapp/bacs],[orch/phsu],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,D03.633.100.810.050.180
5997907d-94fa-49a5-bed9-4d2d2d52d0c5,C0053932,C0042769,play role in ,Bone Morphogenetic Proteins,Virus Diseases,1,X,[aapp/bacs],[dsyn],D12.644.276.954.200;D12.776.467.942.200;D23.529.942.200,C02
7ea95867-d9f6-4ca0-a241-a64226c2ebf6,C0677908,C0005515,is with ,Maintenance therapy,Biological Factors,1,X,[topp],[bacs],,D23
51d7d9c0-5742-4d27-b3a6-298d8883cace,C0021079,C0042776,have role in treatment of ,Therapeutic immunosuppression,Virus,1,X,[topp],[virs],E02.095.465.425.450;E05.478.610,B04
05245e3b-f7a9-4bd3-89fe-cca31a337bfd,C0520997,C1707391,may seem like good ,Thrombolysis function,Choose (action),1,X,[clna],[acty],,
5dcc1768-e0e6-4d5a-b774-11861a2fc3b5,C2939465,C0206750,is in ,Deficiency of glucose-6-phosphate dehydrogenase,Coronavirus Infections,1,X,[dsyn],[dsyn],C15.378.071.141.150.480;C16.320.070.480;C16.320.565.202.402;C18.452.648.202.402,C02.782.600.550.200
51116ece-6b8d-4e37-ab2d-16018ad666cb,C0011334,C0009450,may may site of ,Dental caries,Communicable Diseases,1,X,[dsyn],[dsyn],C07.793.720.210,C01.539.221
4f7e185f-995d-4b4f-ac17-bf87e3017113,C0011334,C1175743,may may site of ,Dental caries,SARS coronavirus,1,X,[dsyn],[virs],C07.793.720.210,B04.820.504.540.150.113.937
f83d8c62-3daa-4a1b-9075-40509717083e,C0919453,C0009450,required for ,cancer-predisposing genes,Communicable Diseases,1,X,[gngm],[dsyn],,C01.539.221
05f1fa1d-3470-48b2-b8dd-fae3fd9c4b80,C0162633,C0028429,appears highest from ,Viral Shedding,Nose,1,X,[patf],[bpoc],G07.925,A01.456.505.733;A04.531;A09.531
b831be8c-9071-4921-ac14-790a72b3ae6f,C1260880,C0678236,be ,Rhinorrhea,Rare Diseases,2,X,[sosy],[dsyn],,C23.550.291.906
a0ecedcd-00e7-4f22-98c4-a0c2bdca4b84,C1260880,C1457887,be ,Rhinorrhea,Symptoms,2,X,[sosy],[sosy],,
f6affe38-e296-4f8b-b3e6-f78c2c388224,C1260880,C0206750,be ,Rhinorrhea,Coronavirus Infections,4,X,[sosy],[dsyn],,C02.782.600.550.200
c27db49f-2455-4ee8-9900-59a5890f8490,anosmia,C1260880,is reported sinonasal ,anosmia,Rhinorrhea,1,X,????,[sosy],????,
9580cd0c-6dfc-4c10-b91f-821ea8263ac0,C0700148,C0678236,appears ,Congestion,Rare Diseases,1,X,[patf],[dsyn],,C23.550.291.906
de0ba712-0ce4-4386-857d-209d4bfd19cf,C0700148,C1457887,appears ,Congestion,Symptoms,1,X,[patf],[sosy],,
36e0ce7f-6316-4b99-b2ec-6d94cff99fb2,C0700148,C0206750,appears ,Congestion,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
912c378f-4dd3-4927-a6e4-562930eb5b1d,C0162633,C0242781,may may important ,Viral Shedding,disease transmission,1,X,[patf],[patf],G07.925,N06.850.310
01f407ef-ec09-41e2-ad60-68d82e2a3f85,C0162633,C0010356,may may important ,Viral Shedding,Cross Infection,1,X,[patf],[patf],G07.925,C01.539.248;C23.550.291.875.500
e0ce3534-0f45-455e-a189-9668792cc826,C1711241,C0009450,may may site of ,Sinonasal Tract,Communicable Diseases,1,X,[bpoc],[dsyn],,C01.539.221
d4fb14ed-0645-4311-9ac2-a0db4ef5a287,C1704259,C1882509,is in ,Biochemical Pathway,put - instruction imperative,2,X,[moft],[acty],,
8ab16eda-b739-48c3-841b-899c1eca4858,C1706202,C0009450,can Providing (action) additional tool for,Search - action,Communicable Diseases,2,X,[acty],[dsyn],,C01.539.221
e8b363e2-880f-46d8-a23b-dc55c7de88a3,DOH,C0206750,initiated nationwide surveillance program for ,DOH,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
b6c2cb26-0c73-414c-8657-31ff5e144102,C0038280,C0020281,using low temperature process ,Sterilization for infection control,Hydrogen Peroxide,1,X,[topp],[inch/irda/phsu],N06.850.780.200.450.850,D01.248.497.158.685.750.424;D01.339.431.374.424;D01.650.550.750.400;D02.389.338.253
96c78aa7-7091-46d6-807b-fabe2c13014e,C2976467,C0024109,improve Respiration at several,EPO protein human,Lung,1,X,[aapp/bacs],[bpoc],x.x.x.x,A04.411
6d7f5806-4e9f-4b80-a006-4977a4303ab3,C2976467,C0035203,improve ,EPO protein human,Respiration,1,X,[aapp/bacs],[phsf],x.x.x.x,G09.772.705
f90f941d-040c-40c1-86c9-2cb4b49ee0c2,C1516048,C0011849,is in people with ,Assessed,Diabetes Mellitus,1,X,[acty],[dsyn],,C18.452.394.750;C19.246
80d114f6-dcdc-41a7-885b-36a5ed9332ec,C0042487,COVID-19,is in ,Venous Thrombosis,COVID-19,1,X,[patf],[virs],C14.907.355.830.925,C000657245
d9ba4647-aaf2-4cd8-9f4e-86616c95e571,C0042487,C1175743,was markedly higher in patients with CoV2,Venous Thrombosis,SARS coronavirus,1,X,[patf],[virs],C14.907.355.830.925,B04.820.504.540.150.113.937
4fbe6b1b-dfa5-4d5a-8ff3-c3170c2039b9,C0042487,CoV2,was markedly higher in patients with CoV2,Venous Thrombosis,CoV2,1,X,[patf],????,C14.907.355.830.925,????
1e9d5597-18f5-4370-8339-452a00fce36c,C0149871,COVID-19,is in ,Deep Vein Thrombosis,COVID-19,1,X,[dsyn],[virs],C14.907.355.830.925,C000657245
3baef066-ee11-4f71-9ed0-205d1942aade,COVID-19,C0199242,should receive ,COVID-19,Anticoagulant prophylaxis,1,X,[virs],[topp],C000657245,
e688acf7-c70c-4c60-b068-ee3be60f7336,COVID-19,C0019139,should receive Anticoagulant prophylaxis with,COVID-19,Heparin Low-Molecular-Weight,1,X,[virs],[orch/phsu],C000657245,D09.698.373.400.300
6ff8efca-4fb3-4492-8315-0fa8afd304bd,C1511790,CoV2,is in CoV2,Detection,CoV2,1,X,[topp],????,,????
9761285e-a1ba-4ded-badf-df318f53d3f3,C0042776,C0039409,is in ,Virus,Tears body substance,1,X,[virs],[bdsu],B04,A12.200.882
9000b9fe-d516-49c5-ab22-076e009cb4fc,C0206750,C0018681,are classified into Central Nervous System related ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
9000b9fe-d516-49c5-ab22-076e009cb4fc,C0206750,C0018681,followed by ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
9000b9fe-d516-49c5-ab22-076e009cb4fc,C0206750,C0018681,also reported ,Coronavirus Infections,Headache,1,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.592.612.441
1805a2d3-c9d5-4272-85b2-003df4981e9e,C0206750,C0009676,has In regard has associated with neurological anosmia ,Coronavirus Infections,Confusion,1,X,[dsyn],[mobd],C02.782.600.550.200,C10.597.606.337;C23.888.592.604.339;F01.700.250
020d2b76-c5ff-478d-a6a8-b4aeac8b8fd8,C0206750,anosmia,has In regard has associated with neurological anosmia ,Coronavirus Infections,anosmia,1,X,[dsyn],????,C02.782.600.550.200,????
ec5bdf69-6bcd-45cb-8fe8-42039bee0f0c,C0206750,C2364111,has In regard has associated with neurological anosmia ,Coronavirus Infections,Ageusia,1,X,[dsyn],[sosy],C02.782.600.550.200,C10.597.751.861.184;C23.888.592.763.861.184
b987da41-1c23-49aa-9283-7ae962d99063,C0007682,C0206750,is in ,CNS disorder,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228,C02.782.600.550.200
61a998fc-ef4f-443a-af14-991958c4270b,C0035668,C0444279,was absent in six ,RNA,Respiratory sample,1,X,[nnon],[bdsu],D13.444.735,
f4a74cb3-0933-4b4d-9430-958195dfe548,C1175743,sera,was absent in acute sera,SARS coronavirus,sera,1,X,[virs],????,B04.820.504.540.150.113.937,????
ab7f3510-03c9-4a57-b973-c10f00a6f613,C0003261,sera,was absent in acute sera,Antibody Formation,sera,1,X,[biof],????,G12.070,????
126770ae-da65-4ee0-b3cd-016ab0156041,C1175743,C0458578,is in ,SARS coronavirus,Upper respiratory tract,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
caca7341-fa30-42b0-a709-cea4ec1eaae2,C0023895,C0023884,clinical implications on ,Liver diseases,Liver,1,X,[dsyn],[bpoc],C06.552,A03.620
5c2a0ff3-673f-4ff5-b8e8-388f02fd0da9,C0012634,C0027926,is in department of ,Disease,Science of neurosurgery,2,X,[dsyn],[bmod],C23.550.288,H02.403.810.425
baa47e68-6f83-4b86-b0fd-eaefee773276,C4042934,C0026882,is in viral ,Mutation Accumulation,Mutation,2,X,[genf],[genf],G05.365.590.594,G05.365.590
6e2f64b2-a508-428f-803c-9f7fc5972308,C0242781,C0023745,emphasize extent of global epidemiological ,disease transmission,genetic linkage,2,X,[patf],[moft],N06.850.310,G05.348
9ea9de2e-5305-4c23-9acc-8fec00487ad1,C1704259,C0042776,emphasize ,Biochemical Pathway,Virus,1,X,[moft],[virs],,B04
fcf58919-4bc1-4eb2-8b19-8b378bf82f41,C1704259,C1293116,emphasize ,Biochemical Pathway,Introduction procedure,1,X,[moft],[topp],,
6151a39a-0927-4981-9809-da6988d07d13,C1697446,C3698360,causes severe disease similar to those caused by ,Genital Viral Infections,Middle East Respiratory Syndrome Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.750
70a50d29-205e-4508-96b4-0329548f16d9,C0010356,C0019004,resulted from human-to-human transmission in ,Cross Infection,Hemodialysis,1,X,[patf],[topp],C01.539.248;C23.550.291.875.500,E02.870.300;E02.912.800
7559a819-0660-48b0-81e8-f13f5fe6bd86,C0019004,HD,is in HD ,Hemodialysis,HD,1,X,[topp],????,E02.870.300;E02.912.800,????
ff1e83f4-c944-4475-bc51-8c0a2e373fa6,C0242781,C0441655,implementing preemptive ,disease transmission,Activities,1,X,[patf],[acty],N06.850.310,
fe87789a-4e3f-4c35-8647-706d5afd5ace,C0242781,C3841812,can can controlled without closure of ,disease transmission,In center hemodialysis,1,X,[patf],[topp],N06.850.310,
b4afd1aa-2184-4b99-b1a2-70b5670e092c,C0206750,C3841812,can can controlled without closure of ,Coronavirus Infections,In center hemodialysis,1,X,[dsyn],[topp],C02.782.600.550.200,
a01be024-523d-4ce7-a913-af84a29ce875,C0010076,C3272452,is family of ,Coronaviridae,Single-Stranded RNA,4,X,[virs],[nnon],B04.820.504.540,
42c16f0c-df38-4c13-a745-843d340cd1b1,C0010076,C0042776,is family of ,Coronaviridae,Virus,2,X,[virs],[virs],B04.820.504.540,B04
a0317ab1-ad9f-4ff1-adfc-607bbfcf674e,C3698360,C0221423,causing severe respiratory ,Middle East Respiratory Syndrome Coronavirus,Illness (finding),2,X,[virs],[sosy],B04.820.504.540.150.113.750,
77c601e2-f323-4d47-9156-54dc832af66b,C3698360,C4284302,causing epidemics in ,Middle East Respiratory Syndrome Coronavirus,EHD1 wt Allele,2,X,[virs],[gngm],B04.820.504.540.150.113.750,
77c601e2-f323-4d47-9156-54dc832af66b,C3698360,C4284302,causing Illness (finding) in,Middle East Respiratory Syndrome Coronavirus,EHD1 wt Allele,2,X,[virs],[gngm],B04.820.504.540.150.113.750,
41132163-755a-450b-a977-bc207be5ef52,C0206750,C0815353,is in ,Coronavirus Infections,Male external urethral sphincter,1,X,[dsyn],[bpoc],C02.782.600.550.200,
6c906c2f-5fc1-425f-bd26-3e2b8cdf908a,C0011206,C0002395,may increase need for treatment of ,Delirium,Alzheimer's Disease,1,X,[mobd],[dsyn],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
9754dd12-c09e-4c95-8184-5901ed102133,C0003130,COVID-19,clinical aspects of,Anoxia,COVID-19,1,X,[patf],[virs],C23.888.852.079,C000657245
34d608b3-87e9-4ed2-9fc6-e8feb571b6d1,C0011206,C0003130,caused by ,Delirium,Anoxia,1,X,[mobd],[patf],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C23.888.852.079
a1cc5716-60eb-4e71-8990-f04f7a8d4633,C0011206,COVID-19,is in ,Delirium,COVID-19,2,X,[mobd],[virs],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C000657245
712324d7-3dcc-40d6-b262-7934d41bde90,C0011206,C0683325,caused by ,Delirium,clinical aspects,1,X,[mobd],[clna],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,
9d47d63c-542b-45e0-835b-283f6f17622d,C0687133,COVID-19,receiving ,Drug Interactions,COVID-19,2,X,[patf],[virs],G07.690.773.968,C000657245
54c1097c-ae96-45ea-9026-0c104cbb2bd8,C0687133,C0002395,should Therefore should considered in ,Drug Interactions,Alzheimer's Disease,1,X,[patf],[dsyn],G07.690.773.968,C10.228.140.380.100;C10.574.945.249;F03.615.400.100
c2a48ded-d3fe-4263-9e6a-b944e8cdd5f7,C1514559,C1290886,is responsible In ,Protein Overexpression,Chronic inflammatory disorder,2,X,[genf],[dsyn],,
6e381e4f-0c0f-4e1c-9d92-8598d1b44e0b,C1514559,C0023516,is in ,Protein Overexpression,Leukocytes,1,X,[genf],[cell],,A11.118.637;A15.145.229.637;A15.382.490
466a7fae-5aaf-457a-a23e-7d7649c6978b,C0013227,C0008269, includes ,Pharmaceutical Preparations,Chloroquine,4,X,[phsu],[orch/phsu],D26,D03.633.100.810.050.180
e2f5e622-3d3b-476c-9876-57818096179f,C0052796,C1153410,strongly suppressed ,Azithromycin,channel activity,1,X,[antb/orch],[moft],D02.540.576.500.992.050,
a8af531f-af47-45e9-8e1b-5328aa235bff,C0052796,C0024264,strongly suppressed ,Azithromycin,Lymphocyte,1,X,[antb/orch],[cell],D02.540.576.500.992.050,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
e55a8002-614f-4eb7-afcc-ed91c222a886,C0013227,C1153410,strongly suppressed ,Pharmaceutical Preparations,channel activity,1,X,[phsu],[moft],D26,
fab5040b-2f1c-4a9c-9248-d7c319840606,C0013227,C0024264,strongly suppressed ,Pharmaceutical Preparations,Lymphocyte,1,X,[phsu],[cell],D26,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
c29281c5-caa4-45a4-ba39-b375ea984879,C0008269,C1153410,strongly suppressed ,Chloroquine,channel activity,1,X,[orch/phsu],[moft],D03.633.100.810.050.180,
28e5c341-09a7-4154-98e1-fc7498fce4c5,C0008269,C0024264,strongly suppressed ,Chloroquine,Lymphocyte,1,X,[orch/phsu],[cell],D03.633.100.810.050.180,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
7dbbcaee-54c5-4d4d-b9af-eeaf8ff06daf,C0079189,C0699748,are responsible for ,cytokine,Pathogenesis,2,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
7a3e1406-2acf-466f-a2b9-b645d86bbac3,C1175743,C4546913,required ,SARS coronavirus,Oxygen-19,1,X,[virs],[elii],B04.820.504.540.150.113.937,x.x.x.x
1c64d9d8-f904-45ea-9873-22862c48e8a0,C1175743,C0242297,required ,SARS coronavirus,Dietary Supplementation,1,X,[virs],[topp],B04.820.504.540.150.113.937,
0682c8e6-09a8-41ee-a39b-e921994cce85,COVID-19,C0199470,required ,COVID-19,Mechanical ventilation,1,X,[virs],[topp],C000657245,
1eed6158-2749-4583-862c-885142d09980,C1175743,C0199470,required ,SARS coronavirus,Mechanical ventilation,1,X,[virs],[topp],B04.820.504.540.150.113.937,
e0cd6a5d-a08e-4f07-8d20-13b29104cd3a,C0023530,C1175743,were significantly more common in ,Leukopenia,SARS coronavirus,2,X,[dsyn],[virs],C15.378.553.546,B04.820.504.540.150.113.937
c9fd9a71-e725-4e7d-920d-ff9906767b76,C0024312,C1175743,were significantly more common in ,Lymphopenia,SARS coronavirus,2,X,[dsyn],[virs],C15.378.553.546.605;C20.673.627,B04.820.504.540.150.113.937
2a5d2254-c462-45ed-9e87-0cf58355f768,C0023530,COVID-19,were significantly common than ,Leukopenia,COVID-19,2,X,[dsyn],[virs],C15.378.553.546,C000657245
e6afa139-85aa-4b29-ad9b-24f19040c861,C0596448,C0242656,Characteristically is associated with ,dimer,Disease Progression,1,X,[chvs],[patf],,C23.550.291.656
7885b8e2-1b02-4f31-a921-f2e9770982fb,C1175175,C0301872,triggers ,Severe Acute Respiratory Syndrome,Immune response,2,X,[dsyn],[ortf],C02.782.600.550.200.750;C08.730.730,
84150a11-0990-40d0-90e0-30152987bfa5,C0398623,C0003280,necessitate ,Thrombophilia,Anticoagulants,1,X,[dsyn],[phsu],C15.378.925,D27.505.954.502.119
5684d8fa-a696-4697-8e43-2267bdf30322,C0398623,C0040018,reduce excessive ,Thrombophilia,Thrombin,1,X,[dsyn],[aapp/enzy/phsu],C15.378.925,D08.811.277.656.300.760.855;D08.811.277.656.959.350.855;D12.776.124.125.890;D23.119.960
fca6bb0d-d63c-4a08-8d8b-1e021cb51016,C0398623,C0019116,preserving adaptive ,Thrombophilia,Hemostatic function,1,X,[dsyn],[ortf],C15.378.925,G09.188.390
ee3314c5-6e68-4cb5-8872-eaa894a59d40,C0398623,COVID-19,bring benefit via ,Thrombophilia,COVID-19,1,X,[dsyn],[virs],C15.378.925,C000657245
a5a24dee-7bc5-4f37-b2b5-a03a62cf8c0d,C0028754,C0301872,is in ,Obesity,Immune response,1,X,[dsyn],[ortf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
dd432c54-59d7-46b7-988d-626d9131c930,C0034848,C1452534,might might ,Receptors Virus,ACE protein human,1,X,[aapp/rcpt],[aapp/bacs],D12.776.543.750.830,x.x.x.x
25ee7419-8635-4234-a752-f0410cfbdccb,C0103306,C0031843,is with quite balancing barbell ,angiotensin I (1-7),physiological aspects,1,X,[aapp/phsu],[phsf],x.x.x.x,x.x.x.x
f4881068-daf3-44f0-981d-40768adedbb9,C0030956,C0003009,converting ,Peptides,angiotensin II,1,X,[aapp/phsu],[aapp/bacs/phsu],D12.644,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
3024dfa7-fa3d-4410-a305-1a7c792984a0,C0030956,C0103306,converting angiotensin II into,Peptides,angiotensin I (1-7),1,X,[aapp/phsu],[aapp/phsu],D12.644,x.x.x.x
2c510ace-46e2-402c-b611-429584b07409,C0030956,C0031843,converting angiotensin II into,Peptides,physiological aspects,1,X,[aapp/phsu],[phsf],D12.644,x.x.x.x
5b7c0b76-3e93-466c-b5bb-80122ef10156,C0003009,C0030956,is profoundly active ,angiotensin II,Peptides,1,X,[aapp/bacs/phsu],[aapp/phsu],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D12.644
b6f4c9e6-4d76-4ca5-99b6-e516c7372853,C2986569,C1452534,usurp ,Buildup,ACE protein human,1,X,[sbst],[aapp/bacs],,x.x.x.x
a925f9da-070c-4b69-9bdb-f8aa68784832,C0087111,C0914912,blockade of ,Therapeutic procedure,Bradykinin B2 Receptor,1,X,[topp],[aapp/rcpt],E02,D12.776.543.750.695.080.500;D12.776.543.750.720.600.220.500;D12.776.543.750.750.555.220.500
8e965af8-8410-4fee-9028-a1487db349ff,C3463820,C0003641,using ,Inhibition,Aprotinin,1,X,[acty],[aapp/bacs/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,D12.776.083
0b6d564c-9414-45cb-967c-50d4ca2ce6da,C0087111,C0003641,using ,Therapeutic procedure,Aprotinin,1,X,[topp],[aapp/bacs/phsu],E02,D12.776.083
10454336-31e1-4252-8990-117603820a88,C3463820,C1722685,using ,Inhibition,ecallantide,1,X,[acty],[aapp/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
69c66b36-b1a4-4914-bdc5-53181a1a8371,C0087111,C1722685,using ,Therapeutic procedure,ecallantide,1,X,[topp],[aapp/phsu],E02,x.x.x.x
55cfd379-4df7-494d-aba4-f5f35dfb1982,C3463820,C0246269,using ,Inhibition,icatibant,1,X,[acty],[aapp/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
5fa2262c-178a-4b13-a8a0-638476781d42,C0087111,C0246269,using ,Therapeutic procedure,icatibant,1,X,[topp],[aapp/phsu],E02,x.x.x.x
e93eb6c4-94f9-49e1-b618-7920c53b3fb2,C0087111,C3549397,Inhibition of,Therapeutic procedure,bradykinin biosynthetic process,1,X,[topp],[moft],E02,
99aa6e25-0d80-4686-9f9c-0b073cedc32e,C3463820,C0087111,hold ,Inhibition,Therapeutic procedure,1,X,[acty],[topp],F01.145.544;F02.463.425.475;F02.739.794.405,E02
c78febd9-ab6b-4e67-bba8-561a8b7911f7,C1512796,C1175743,carry risk of ,Insertion Mutation,SARS coronavirus,1,X,[genf],[virs],E05.393.420.601.550;G05.365.590.575;G05.558.550,B04.820.504.540.150.113.937
4e6d3244-3bde-4216-acf7-84840c20bb09,C0242821,C0024501,worldwide recognized could achieved by ,Human body,Maintenance,4,X,[humn],[acty],I01.076.201.450.560;K01.093.378,N02.628
e590d9c0-05cc-43e4-a196-b47765f385a1,C3643615,C0024501,could could only achieved by ,Triumph,Maintenance,2,X,[elii/phsu],[acty],,N02.628
e127b233-2972-4c04-8fb0-a15a5715608e,C0042776,C1825598,has had direct ,Virus,IMPACT gene,1,X,[virs],[gngm],B04,
cf562706-f076-4b6a-ba33-6adfc4a95c8c,C0016143,C1947933,is essential ,First Aid,care activity,2,X,[topp],[acty],E02.365.305,
14066e05-6051-437a-9524-c5c434961152,C0010332,C2948600,is needed With ,Crisis Intervention,Aim,2,X,[topp],[inch/phsu],F04.754.252,
56d7bb52-3e2f-4968-af57-8f73d0a2a0c9,C0010332,C0206419,is needed With ,Crisis Intervention,Genus: Coronavirus,1,X,[topp],[virs],F04.754.252,B04.820.504.540.150
a77691f8-82b4-4993-a029-5a46c76c93af,C0087111,C0003204, includes ,Therapeutic procedure,Anti-Infective Agents,3,X,[topp],[phsu],E02,D27.505.954.122
fac53808-ae4c-4276-8f7e-89fd83ce5f0e,C0543467,C0087111,routinely give symptomatic ,Operative Surgical Procedures,Therapeutic procedure,1,X,[topp],[topp],E04,E02
39af8754-a3fd-49eb-a417-11b364bb88f1,C0543467,C0003204,routinely give symptomatic ,Operative Surgical Procedures,Anti-Infective Agents,1,X,[topp],[phsu],E04,D27.505.954.122
239f058f-e441-43d3-babf-c9be438e45f1,C0014695,C0339901,decreases ,Ergocalciferol,Acute respiratory infections,1,X,[orch/phsu/vita],[dsyn],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,
05091f71-8c8f-41e9-abe7-64dca3f51c83,C0042870,C0339901,is easily modifiable factor of ,Vitamin D Deficiency,Acute respiratory infections,1,X,[dsyn],[dsyn],C18.654.521.500.133.770,
0074a248-f875-4a8b-89d9-c7a50dc43bda,C1175743,C1327414,caused hypoxemia of ,SARS coronavirus,cytokine secretion,2,X,[virs],[celf],B04.820.504.540.150.113.937,
e2aaa331-d0f1-42ab-9a06-6dc1d86c415b,C0428692,C0206750,have effect on ,Ambient temperature,Coronavirus Infections,1,X,[npop],[dsyn],,C02.782.600.550.200
589715f0-2efd-4ab3-bdb2-40d1215a757a,C0023175,C1167395,expand ,Lead,Host (organism),1,X,[elii/hops],[orgm],D01.268.556.435;D01.552.544.435;x.x.x.x,
c24d016f-d0f9-4844-aedd-4e8fba8dd52f,studys,C0206750,apply morphoproteomics from forensic autopsy of ,studys,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
86799467-023c-49cd-beb8-c54f1339053c,C3812159,C0242629,relative paucity of ,FAM49B wt Allele,CD8-Positive T-Lymphocytes,2,X,[gngm],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
86799467-023c-49cd-beb8-c54f1339053c,C3812159,C0242629,rare PD-1 as ,FAM49B wt Allele,CD8-Positive T-Lymphocytes,1,X,[gngm],[cell],,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
43367745-7d73-4d8a-b1f5-d9dcec1e592c,C0152060,C4322733,absence of ,Transection (procedure),CD56+ NK cell,2,X,[topp],[cell],,
03ee82a4-bce6-4774-bd5e-d469260979a6,C0024115,C4322733,absence of ,Lung diseases,CD56+ NK cell,4,X,[dsyn],[cell],C08.381,
c196f055-9ad4-4b2a-b66d-a33f70449df6,C0206750,C4322733,absence of ,Coronavirus Infections,CD56+ NK cell,2,X,[dsyn],[cell],C02.782.600.550.200,
98d6eab7-ce7e-4bf4-a6f6-cfa247ea198d,C0152060,C0253050,nuclear expression of p ,Transection (procedure),Stat3 protein,1,X,[topp],[aapp/bacs],,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
98d76f57-773d-4417-9511-641373cec56e,C0024115,C0253050,nuclear expression of p ,Lung diseases,Stat3 protein,2,X,[dsyn],[aapp/bacs],C08.381,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
4e056138-f20e-4293-aa03-9523c0714d6c,C0206750,C0253050,nuclear expression of p ,Coronavirus Infections,Stat3 protein,1,X,[dsyn],[aapp/bacs],C02.782.600.550.200,D12.644.360.024.342.300;D12.776.157.057.186.300;D12.776.476.024.430.300;D12.776.930.840.300
68e39012-e45e-4163-870b-1ef10927768d,C3812159,C4322733,absence of ,FAM49B wt Allele,CD56+ NK cell,2,X,[gngm],[cell],,
4a294a39-ac76-47fd-94ea-897a200bacae,C0024115,C0242629,relative paucity of ,Lung diseases,CD8-Positive T-Lymphocytes,4,X,[dsyn],[cell],C08.381,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
4a294a39-ac76-47fd-94ea-897a200bacae,C0024115,C0242629,rare PD-1 as ,Lung diseases,CD8-Positive T-Lymphocytes,2,X,[dsyn],[cell],C08.381,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
d4f2e38a-5a4f-4932-9db3-56a227d78ff5,C0206750,C0242629,relative paucity of ,Coronavirus Infections,CD8-Positive T-Lymphocytes,2,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
d4f2e38a-5a4f-4932-9db3-56a227d78ff5,C0206750,C0242629,rare PD-1 as ,Coronavirus Infections,CD8-Positive T-Lymphocytes,1,X,[dsyn],[cell],C02.782.600.550.200,A11.118.637.555.567.569.220;A15.145.229.637.555.567.569.220;A15.382.490.555.567.569.220
d465d6fe-e855-4acd-b5e9-85e15dff9968,C0152060,C1570089,abundance of intra-alveolar interstitial ,Transection (procedure),CD163 protein human,1,X,[topp],[aapp/imft],,
8c5ec6f4-c27a-416e-843d-06bb9155fb60,C0024115,C1570089,abundance of intra-alveolar interstitial ,Lung diseases,CD163 protein human,2,X,[dsyn],[aapp/imft],C08.381,
148daa33-d408-41b9-b73b-2e45892465ca,C0206750,C1570089,abundance of intra-alveolar interstitial ,Coronavirus Infections,CD163 protein human,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,
4b815ddb-7bec-4dab-ab05-85d5d56e0172,C3812159,C1570089,abundance of intra-alveolar interstitial ,FAM49B wt Allele,CD163 protein human,1,X,[gngm],[aapp/imft],,
d8b4c318-9420-491f-93b8-76247e9f75fa,C0152060,C0041484,nuclear expression of ,Transection (procedure),MONOPHENOL MONOOXYGENASE,1,X,[topp],[aapp/enzy],,D08.811.682.690.708.125.500
727d7848-d20d-408c-a0ae-388e920a4c70,C0024115,C0041484,nuclear expression of ,Lung diseases,MONOPHENOL MONOOXYGENASE,2,X,[dsyn],[aapp/enzy],C08.381,D08.811.682.690.708.125.500
edf56888-314d-4d33-940c-60372fdd4c6e,C0206750,C0041484,nuclear expression of ,Coronavirus Infections,MONOPHENOL MONOOXYGENASE,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.682.690.708.125.500
0f201104-1adb-40d3-be6e-cbc7f74402f4,C2985566,C0206750,could address ,Targeted Therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
4003849c-2967-4d2e-bb96-4d1154865ebb,C0023779,C0161816,risk of ,Lipids,Cardiac complication,4,X,[orch],[patf],D10,
ef70bf52-e683-40ef-acb0-16d7c2b9b4ba,C2003888,C0161816,risk of ,Lower (action),Cardiac complication,4,X,[acty],[patf],,
6053225e-423e-40a9-843b-faf69dd434c9,C0023779,C0206750,risk of ,Lipids,Coronavirus Infections,4,X,[orch],[dsyn],D10,C02.782.600.550.200
99d34e6c-2748-47ee-bb80-539bea42b4a1,C2003888,C0206750,risk of ,Lower (action),Coronavirus Infections,4,X,[acty],[dsyn],,C02.782.600.550.200
5cf0b5fc-958d-4332-b00e-a47edd72964b,C0023779,C0360714,is in particular ,Lipids,Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[orch],[orch/phsu],D10,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
df8d368f-2a55-4b17-82f3-27ed12c66266,C2003888,C0360714,is in particular ,Lower (action),Hydroxymethylglutaryl-CoA Reductase Inhibitors,2,X,[acty],[orch/phsu],,D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370
f69c592b-f276-4a30-b2cf-ec35961b1fb4,C1167250,C0007603,subdomains of ,lipid raft,Plasma membrane,2,X,[celc],[celc],,A11.284.149
0ff20640-f451-49bc-9deb-7b7f060b5b3a,C0020443,C0007603,are associated with subdomains of ,Hypercholesterolemia,Plasma membrane,2,X,[dsyn],[celc],C18.452.584.500.500.396,A11.284.149
6432137e-c98e-4161-809a-be1eefb294af,C0007603,C0960880,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,angiotensin converting enzyme 2,3,X,[celc],[aapp/enzy],A11.284.149,x.x.x.x
074be657-6999-4c4e-84b7-154dfebcf032,C0007603,C0597357,can harbour ,Plasma membrane,receptor,2,X,[celc],[aapp/rcpt],A11.284.149,
ef4fed9a-7ef7-4497-8795-cecb63804083,C0007603,C4281807,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,Vitronectin human,1,X,[celc],[aapp/bacs],A11.284.149,
6fb2d06d-5438-47d5-9e74-d086604e616d,C0007603,C1175743,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,SARS coronavirus,2,X,[celc],[virs],A11.284.149,B04.820.504.540.150.113.937
30eba2e8-dd0d-4e40-95df-9b744933da09,C0360714,C0023779,possess Activities In addition to their,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lipids,1,X,[orch/phsu],[orch],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D10
30eba2e8-dd0d-4e40-95df-9b744933da09,C0360714,C0023779,possess Xyzinclude1 In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lipids,1,X,[orch/phsu],[orch],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D10
30eba2e8-dd0d-4e40-95df-9b744933da09,C0360714,C0023779,possess effects In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lipids,1,X,[orch/phsu],[orch],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D10
e974e44a-0342-4193-9149-c91dff6850c4,C0360714,C2003888,possess Activities In addition to their,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lower (action),1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
e974e44a-0342-4193-9149-c91dff6850c4,C0360714,C2003888,possess Xyzinclude1 In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lower (action),1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
e974e44a-0342-4193-9149-c91dff6850c4,C0360714,C2003888,possess effects In addition to their ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Lower (action),1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
6cbab50c-b955-45da-8155-1eb1901a63e7,C0360714,C0003209,possess pleiotropic ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Anti-Inflammatory Agents,1,X,[orch/phsu],[phsu],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,D27.505.954.158
62741b87-1cdb-47b9-b545-64813f83d702,C0360714,C0441655,possess antithrombotic ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,Activities,1,X,[orch/phsu],[acty],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
9769b9d7-8416-40f7-ae0c-3bee8df4fe4c,C1278454,C0021403,is in ,Statin prophylaxis,Influenza virus vaccine,2,X,[topp],[imft/phsu],,D20.215.894.899.302
3356dc6a-5e61-4507-a54a-f33a50237988,C1278454,C0009450,is in ,Statin prophylaxis,Communicable Diseases,4,X,[topp],[dsyn],,C01.539.221
ad456027-369c-4dc2-90e0-2578b7de5f7d,C1278454,C0005768,increase viral clearance from ,Statin prophylaxis,In Blood,2,X,[topp],[bdsu],,x.x.x.x.x
50b4e2b7-c532-4932-8da6-7a27844dbe0b,C1278454,C0019196,increase clearance during chronic ,Statin prophylaxis,Hepatitis C,2,X,[topp],[dsyn],,C02.440.440;C02.782.350.350;C06.552.380.705.440
bb5f20d9-c460-41b2-94ff-435baa87105d,C0360714,C1433062,may serve as potential ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,x.x.x.x
ee220279-4fc5-4129-82e2-e7b4e9efc3cc,C0360714,C0243077,may serve as potential ,Hydroxymethylglutaryl-CoA Reductase Inhibitors,inhibitors,1,X,[orch/phsu],[chvf],D27.505.519.186.071.202.370;D27.505.519.389.370;D27.505.954.557.500.202.370,
ed0b5d9c-af50-41e3-aeb6-6127495c16c2,C0450254,C1819995,use Peptidyl-Dipeptidase A as its,Pathogenic organism,Host Cell,1,X,[orgm],[celc],,
e8f48846-06c7-4c5a-a138-e4494addcabd,C0450254,C0597357,use Peptidyl-Dipeptidase A as its,Pathogenic organism,receptor,1,X,[orgm],[aapp/rcpt],,
e8f48846-06c7-4c5a-a138-e4494addcabd,C0450254,C0597357,shares same ,Pathogenic organism,receptor,2,X,[orgm],[aapp/rcpt],,
273a2de6-e464-49e6-a2d2-297cfb80f586,C0450254,C0022709,use ,Pathogenic organism,Peptidyl-Dipeptidase A,3,X,[orgm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
273a2de6-e464-49e6-a2d2-297cfb80f586,C0450254,C0022709,shares ,Pathogenic organism,Peptidyl-Dipeptidase A,2,X,[orgm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
f6fde76f-f14f-4ee2-a29d-a221e22db7b6,C1167622,C0034987,locate at ,Binding (Molecular Function),Regulatory Sequences Nucleic Acid,2,X,[moft],[bacs/nnon],,G02.111.570.080.689;G05.360.080.689
240d2bee-2240-4b1a-807b-09d183b00f8b,C0086418,C0014939,upregulated by ,Homo sapiens,Estrogens,1,X,[humn],[horm/orch/phsu],B01.050.150.900.649.313.988.400.112.400.400,D27.505.696.399.472.277
439c706f-7112-4c0b-a6a9-33279170519d,C0444626,C1175743,is considerably similar to previously reported ,Crystal Structure,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
78ef2859-85be-4256-a599-6fcd03fb0fcc,C0199470,COVID-19,might reduce Malnutrition due to,Mechanical ventilation,COVID-19,3,X,[topp],[virs],,C000657245
01070fb9-36b1-48e7-b2b8-e9842c1d069b,C0199470,C0162429,might reduce ,Mechanical ventilation,Malnutrition,3,X,[topp],[dsyn],,C18.654.521
c7a47a6a-2e68-4a09-8a62-646edfbe3963,C0199470,C0264490,might reduce ,Mechanical ventilation,Acute respiratory failure,3,X,[topp],[dsyn],,
5886c0ef-b0fe-4276-ac81-0fe069640a47,C0009450,C0086418,be of zoonotic origin to ,Communicable Diseases,Homo sapiens,1,X,[dsyn],[humn],C01.539.221,B01.050.150.900.649.313.988.400.112.400.400
7ee99c26-f1c3-42ca-987f-0cc2fc33b5e4,C0035204,C0032285,may progress to ,Respiration Disorders,Pneumonia,1,X,[dsyn],[dsyn],C08.618,C08.381.677;C08.730.610
490afe15-c15b-481b-82a4-1f5ed2ed54e3,C0035204,C0035222,may progress to ,Respiration Disorders,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C08.618,C08.381.840;C08.618.840
543677eb-cc22-4586-9dd9-4d633d09f4f3,C0035204,C0026766,may progress to ,Respiration Disorders,Multiple Organ Failure,1,X,[dsyn],[patf],C08.618,C23.550.835.525
a031c0bb-e79b-40c1-9c02-4d16b3003386,C4298940,C0014507,were collected In course of ,Environmental specimen,Epidemiology,1,X,[sbst],[bmod],,H02.403.720.500
fea0504b-0044-4d0a-999a-7b3faf78da6c,C4298940,C0370003,were collected from 68 ,Environmental specimen,Specimen,1,X,[sbst],[sbst],,
46c11483-434e-45c4-9481-7d4af4b95dbc,C0017343,C0206750,identify presence of novel ,Genes env,Coronavirus Infections,1,X,[gngm],[dsyn],G05.360.340.024.340.364.875.172;G05.360.340.358.024.875.172;G05.360.340.358.840.500.172,C02.782.600.550.200
ecdab98a-bb2f-4cda-b8ff-9502dc6d3b9a,C0206750,C1096155,is in ,Coronavirus Infections,Macrophage Activation Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C20.683.515.800
01e483fd-7487-49e0-8971-7834243cf5bb,C0039336,C0206750,is in ,Taste Perception,Coronavirus Infections,3,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C02.782.600.550.200
992e6eae-6752-4c24-9fdb-d311551771c0,C0039336,C0009450,is in ,Taste Perception,Communicable Diseases,1,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C01.539.221
9510631b-1f8e-41e5-81f2-f926508394f4,C1254373,C0206750,was identified as novel ,etiologic agent,Coronavirus Infections,2,X,[sbst],[dsyn],,C02.782.600.550.200
27b2e645-ddd8-45e3-b332-1faf3dfd18cb,C1254373,C0039082,was identified as novel ,etiologic agent,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
27b2e645-ddd8-45e3-b332-1faf3dfd18cb,C1254373,C0039082,is related to ,etiologic agent,Syndrome,1,X,[sbst],[dsyn],,C23.550.288.500
2b721f46-11fb-4b5a-bb63-8a77848f69ae,C1537068,C0014597,identified on ,Virus Internalization,Epithelial Cells,1,X,[biof],[cell],G06.920.881,A11.436
2b721f46-11fb-4b5a-bb63-8a77848f69ae,C1537068,C0014597,takes ,Virus Internalization,Epithelial Cells,1,X,[biof],[cell],G06.920.881,A11.436
b5500ef3-327a-49dc-9a55-ff9af5257da8,C1537068,C1167395,identified on ,Virus Internalization,Host (organism),1,X,[biof],[orgm],G06.920.881,
b5500ef3-327a-49dc-9a55-ff9af5257da8,C1537068,C1167395,takes ,Virus Internalization,Host (organism),1,X,[biof],[orgm],G06.920.881,
065e19f0-2e9c-41ff-8c39-f0af9ea825c4,C1537068,C0022709,takes ,Virus Internalization,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.881,D08.811.277.656.350.350.687
065e19f0-2e9c-41ff-8c39-f0af9ea825c4,C1537068,C0022709,Specifically decreased ,Virus Internalization,Peptidyl-Dipeptidase A,1,X,[biof],[aapp/enzy/imft],G06.920.881,D08.811.277.656.350.350.687
b5bb070f-0fa0-49bc-af6e-84830d27f23b,C1537068,C0042731,takes place upon union of ,Virus Internalization,Viral Matrix Proteins,2,X,[biof],[aapp/bacs],G06.920.881,D12.776.964.970.880.940
f1c3ef9d-9198-4693-a050-649613df3544,C1537068,metallo,takes place with type I transmembrane metallo ,Virus Internalization,metallo,1,X,[biof],????,G06.920.881,????
acc7eb75-21f7-43ef-9f42-0d0579595249,C1537068,C0007075,takes place with type I transmembrane metallo ,Virus Internalization,Carboxypeptidase,1,X,[biof],[aapp/enzy],G06.920.881,D08.811.277.656.350.245
aa145eaa-9297-41bf-a888-33c5e4459739,C0079189,C0021760, includes IP10 ,cytokine,Interleukin-6,2,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
6b7a16e7-703d-4cc3-af5a-85111671b032,C0319157,C0220781,triggers ,AS virus,Anabolism,2,X,[virs],[biof],,G03
89414601-1408-40a4-8959-42324f11c0da,C0319157,C0079189,triggers ,AS virus,cytokine,1,X,[virs],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
366586a9-5cd4-40da-a674-8bfceecb2e2d,C0319157,C0021760,triggers ,AS virus,Interleukin-6,1,X,[virs],[aapp/imft],,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
46657bd3-4a4a-4609-82f3-8f247b046111,C0319157,C0013081,also promotes ,AS virus,Down-Regulation,1,X,[virs],[moft],,G02.111.240;G05.308.200;G07.690.773.937
c76481c5-10f9-44a9-b3fe-7e4f29c0d6e3,C0003009,C1514559,promoting ,angiotensin II,Protein Overexpression,1,X,[aapp/bacs/phsu],[genf],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,
bed0dcbf-7902-4855-9da5-6a61a397909c,C0003009,C0040048,promoting ,angiotensin II,Thromboplastin,1,X,[aapp/bacs/phsu],[aapp/imft],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,D12.776.124.125.900;D23.119.965
0c8be2b3-4420-472b-9805-10dd036b9052,C0003009,C0005821,promoting ,angiotensin II,Blood Platelets,1,X,[aapp/bacs/phsu],[cell],D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x,A11.118.188;A15.145.229.188
31bdca6f-a29f-4801-9814-6ea53ffc2992,C1514559,C0005821,is in ,Protein Overexpression,Blood Platelets,1,X,[genf],[cell],,A11.118.188;A15.145.229.188
5f91c233-8a4d-4a74-8ad3-2ed4eef1878b,C0040048,C1363844,may may critical ,Thromboplastin,Mediator of activation protein,1,X,[aapp/imft],[aapp/bacs],D12.776.124.125.900;D23.119.965,
adc9f69a-73f6-4c8c-9bcd-982b6e7621b4,C0040048,C0206750,may may critical ,Thromboplastin,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.776.124.125.900;D23.119.965,C02.782.600.550.200
cb00bb1e-b5b6-49fc-bd33-273f9846857f,55-item,C1825598,investigate ,55-item,IMPACT gene,1,X,????,[gngm],????,
b8ab5b1b-b4d8-469d-bd77-fcc24c6c457a,55-item,C0206750,investigate ,55-item,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
332692ed-05e9-4d46-8959-1d3770f0509c,C0206750,C0423866,had global ,Coronavirus Infections,Lanugo,2,X,[dsyn],[bpoc],C02.782.600.550.200,A17.360
ecc8fa96-377a-4053-a983-8a31e3cbabf3,C0042075,C0442867,were affected than those for ,Urologic Diseases,malignant disease,1,X,[dsyn],[dsyn],C12.777;C13.351.968,
94c3a2e5-0ab5-4e97-850f-854ed62250f7,C3272452,C0598312,is with specific roles in ,Single-Stranded RNA,DNA Replication,2,X,[nnon],[genf],,G02.111.225;G05.226
bf247cdd-cb60-476b-a69d-5d580c369d6b,C0319157,C0598312,is with specific roles in ,AS virus,DNA Replication,2,X,[virs],[genf],,G02.111.225;G05.226
0aa49901-ec65-404d-8c5e-96d130b753bd,C3272452,C0206419,is with specific roles in ,Single-Stranded RNA,Genus: Coronavirus,2,X,[nnon],[virs],,B04.820.504.540.150
788f7465-5148-450c-af54-1110df2e5b63,C0442893,C0037284,may may associated with ,Systemic disease,Skin lesion,2,X,[dsyn],[dsyn],,
a36bcb7b-0609-4e45-9715-e89682b19bd6,C0037284,C0683325,similar with ,Skin lesion,clinical aspects,2,X,[dsyn],[clna],,
4c8a6ae5-1247-4549-9d8a-dc69cc00bfc6,C0037284,C0011609,similar with ,Skin lesion,Drug Eruptions,1,X,[dsyn],[dsyn],,C17.800.174.600;C20.543.206.380;C25.100.468.380
66e7aef5-3088-4db8-ab4b-fcba7abce434,C0037284,C0008058,similar to ,Skin lesion,Chilblains,2,X,[dsyn],[dsyn],,C26.212.500.217;C26.417.217
b43d7b5d-d0ca-463e-8b74-bea9a7cb456f,C0037274,C1175743,is with ,Dermatologic disorders,SARS coronavirus,2,X,[dsyn],[virs],C17.800,B04.820.504.540.150.113.937
566e46af-0a0d-4e91-9447-7c123f616c63,C0018939,C0024312,exhibits ,Hematological Disease,Lymphopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.553.546.605;C20.673.627
da06c8c3-c50c-41e4-b43e-f70462dd3557,C0018939,C0023530,exhibits ,Hematological Disease,Leukopenia,2,X,[dsyn],[dsyn],C15.378,C15.378.553.546
8eb85f36-2de6-4272-ad55-826c2b654762,C0004623,C0021403,have In ,Bacterial Infections,Influenza virus vaccine,2,X,[dsyn],[imft/phsu],C01.252,D20.215.894.899.302
41fc8064-6ce4-4f36-9236-b9ae2587edd7,=-RRB-,C0206545,is with ,=-RRB-,Human respiratory syncytial virus,1,X,????,[virs],????,B04.820.455.600.670.600.750.730
90c222fb-7fa2-4430-9945-7ae096ece165,C0004623,C0206750,low proportion of ,Bacterial Infections,Coronavirus Infections,2,X,[dsyn],[dsyn],C01.252,C02.782.600.550.200
f4d574e5-71cf-4c45-b8e6-b9b70adb550e,C0003611,C0003615,is in ,Appendectomy,Appendicitis,2,X,[topp],[dsyn],E04.210.078,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
7c468423-fa64-4fa2-a660-898273cbb56f,C0003611,C0018026,is ,Appendectomy,Gold,1,X,[topp],[elii/phsu],E04.210.078,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
2cb3b3f8-bb84-43e5-a92f-f7bb09c2ccc3,C0459914,C0003237,is with intravenous ,Conservative Treatment,Antibiotics Antitubercular,1,X,[topp],[antb],E02.197,D27.505.954.122.085.255.135
3cba6524-f4b9-4cb3-b62d-c3919f0b75c2,C0003611,C0206750,is in ,Appendectomy,Coronavirus Infections,1,X,[topp],[dsyn],E04.210.078,C02.782.600.550.200
82b425f7-a50d-49dd-941d-74a6a91630c0,C0003611,C0012634,is in ,Appendectomy,Disease,1,X,[topp],[dsyn],E04.210.078,C23.550.288
b32fe15c-e7f9-421a-a7fc-3b2904f8b9b6,C0003615,C0206750,is with 2019 novel ,Appendicitis,Coronavirus Infections,2,X,[dsyn],[dsyn],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C02.782.600.550.200
8f20bc2d-8d8b-4f55-9ae7-8a6f8f58f4f1,C0003615,C0012634,is with 2019 novel ,Appendicitis,Disease,1,X,[dsyn],[dsyn],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C23.550.288
3d794134-8c78-4d53-b77f-8202c6cb7021,C3266262,C0206750,was diagnosed with ,Multiple Chronic Conditions,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.500.500,C02.782.600.550.200
f2364726-c027-4ed6-8b62-3e3b35c7bd67,C0015967,C3854129,was predominant ,Fever,Symptom:Find:Pt:^Patient:Nom,1,X,[sosy],[clna],C23.888.119.344,
cd029abc-3cb2-488c-bc3b-a8a67f287bd3,C3854129,C0206750,is in ,Symptom:Find:Pt:^Patient:Nom,Coronavirus Infections,2,X,[clna],[dsyn],,C02.782.600.550.200
a43feaa4-0dd7-4450-a1d9-306473b01645,C3854129,C0206062,is in ,Symptom:Find:Pt:^Patient:Nom,Lung Diseases Interstitial,2,X,[clna],[dsyn],,C08.381.483
b49833c6-b3bf-41f1-9771-a1a2e97fe741,C0015967,C0206062,was predominant Symptom:Find:Pt:^Patient:Nom in,Fever,Lung Diseases Interstitial,2,X,[sosy],[dsyn],C23.888.119.344,C08.381.483
b49833c6-b3bf-41f1-9771-a1a2e97fe741,C0015967,C0206062,was predominant Symptoms in,Fever,Lung Diseases Interstitial,6,X,[sosy],[dsyn],C23.888.119.344,C08.381.483
a59b1fdf-18be-42e0-a1d3-aec5a18610fd,C0206750,C0038056,have ,Coronavirus Infections,Sputum,4,X,[dsyn],[bdsu],C02.782.600.550.200,A12.200.808
522c8b6a-b2ae-4d7c-a4c6-8cbb59149b2b,C0206750,C0011991,have ,Coronavirus Infections,Diarrhea,4,X,[dsyn],[sosy],C02.782.600.550.200,C23.888.821.214
9d1cc48f-f144-47c8-b4d6-54f93c2da2eb,C0206062,C1175743,could could vulnerable to ,Lung Diseases Interstitial,SARS coronavirus,4,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
9d1cc48f-f144-47c8-b4d6-54f93c2da2eb,C0206062,C1175743,tend infected with ,Lung Diseases Interstitial,SARS coronavirus,12,X,[dsyn],[virs],C08.381.483,B04.820.504.540.150.113.937
70051121-533d-4b28-b691-ad898f6c915e,C0036845,C0206750,have potential protect from ,Sesame Oil,Coronavirus Infections,3,X,[food/orch/phsu],[dsyn],D10.212.302.380.775;D10.212.507.775;D10.627.700.865;D20.215.784.750.865;G07.203.300.375.400.725;J02.500.375.400.725,C02.782.600.550.200
e919c364-670e-464d-8c6d-145dba353d7d,C0015690,C0042776,are active against enveloped ,Fatty Acids Unsaturated,Virus,2,X,[orch],[virs],D10.251.355,B04
e919c364-670e-464d-8c6d-145dba353d7d,C0015690,C0042776,are in general active against ,Fatty Acids Unsaturated,Virus,2,X,[orch],[virs],D10.251.355,B04
41f6d4be-586c-4f52-bceb-ceae69d0d233,C0015690,C0206750,are in general active against viruses like ,Fatty Acids Unsaturated,Coronavirus Infections,6,X,[orch],[dsyn],D10.251.355,C02.782.600.550.200
61527e6c-e5a9-44bc-9f24-e8e5f7ae2e86,C2349999,C0015690,incorporate high content of ,Fava Bean (Dietary),Fatty Acids Unsaturated,3,X,[food],[orch],,D10.251.355
d4a015fa-3834-4387-87e7-28c8dad2cfe3,C0008269,C0199244,has has used for treatment against ,Chloroquine,Antimalarial prophylaxis,1,X,[orch/phsu],[topp],D03.633.100.810.050.180,
3676a1aa-da5c-4667-9fa9-6aab32ca7916,C0008269,C0003374,has has tolerated as ,Chloroquine,Antimalarials,1,X,[orch/phsu],[phsu],D03.633.100.810.050.180,D27.505.954.122.250.100.085
4fe69cdf-20bb-499c-9dc0-ae51ca2be0d2,C0852949,C0206750,is in ,Arteriopathic disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
244b79b8-b86c-4ece-bbdd-ce7eb61101da,C0302148,C0206750,is in ,Blood Clot,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.830,C02.782.600.550.200
1ca274a4-ed1d-42e2-892f-7b943694eaff,C1707455,C0920467,timing of ,Comparison,disorder control (procedure),1,X,[acty],[topp],,
9075c8bf-540b-4123-9cbc-3e058d74e3be,C0021966,C0034754,have ,Iodides,Reading (activity),1,X,[inch],[dora],D01.248.497.158.490;D01.475.410,L01.559.423.557
894b8224-c47c-47e1-b42a-286bc7fdcee1,C0013227,C0035452,have have used in ,Pharmaceutical Preparations,Rheumatology specialty,1,X,[phsu],[bmod],D26,H02.403.429.730
a8371e00-6979-4cef-83f3-a4526c52aee8,C0012634,C0960756,be ,Disease,factor A,2,X,[dsyn],[orch],C23.550.288,x.x.x.x
b2c6c672-0679-40bc-841b-642c784e60fa,C0012634,C0035436,be ,Disease,Rheumatic Fever,1,X,[dsyn],[dsyn],C23.550.288,C01.252.410.890.731;C05.550.114.843;C05.799.825
6d12c6dc-5e24-4651-a406-9a1003c76fc1,C0038454,C0035222,developed more ,Cerebrovascular accident,Respiratory Distress Syndrome Adult,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C08.381.840;C08.618.840
c9ab6183-7749-4285-8375-51f981dc2989,C1707455,C1829939,is with,Comparison,{Non-patient},2,X,[acty],[clna],,
9e53e54c-ef58-40e4-b18e-b1fa0645dfd2,C0012634,C0021400,has emerged Like severe ,Disease,Influenza,1,X,[dsyn],[dsyn],C23.550.288,C02.782.620.365;C08.730.310
dfe56d76-9f29-4c65-a3bc-83b08f2496a1,C0033684,C0042769,be altered in response to ,Proteins,Virus Diseases,4,X,[aapp/bacs],[dsyn],D12.776,C02
5d0e5465-1f91-488a-9da3-4703ca8d70ba,C0033684,C0021368,Upregulation of is line with propagation of ,Proteins,Inflammation,2,X,[aapp/bacs],[patf],D12.776,C23.550.470
bd7a3aba-8368-42fe-b374-b94cf3cd9e86,C0581528,C0442886,can reduce risk of ,Close observation,Secondary Infections,1,X,[topp],[dsyn],,C01.539.218;C02.219;C03.202
85db31b4-ce23-49dd-9b4a-14633de7436e,C0282636,C1293130,led to ,Cell Respiration,Stabilization,2,X,[celf],[topp],G03.197;G04.270,
3c89a165-9fc8-4732-be48-dbb226429448,C0281169,C0233494, includes acute ,pulmonary complications,Tension,2,X,[patf],[mobd],,
a13e5791-5732-434a-8e61-6d2954ad6899,C0206750,C0027627,develop severe ,Coronavirus Infections,Neoplasm Metastasis,2,X,[dsyn],[neop],C02.782.600.550.200,C04.697.650;C23.550.727.650
f530dcf7-7fef-47c0-8018-c1c8f404e4cd,C0206750,C0281169,develop severe ,Coronavirus Infections,pulmonary complications,1,X,[dsyn],[patf],C02.782.600.550.200,
dd91c581-eb60-4070-9bc7-9ddaab5d67a6,C0206750,C0264556,develop severe ,Coronavirus Infections,Acute pneumothorax,2,X,[dsyn],[dsyn],C02.782.600.550.200,
e49249a1-1c98-4485-9f44-9685697dfccf,C0206750,C0233494,develop severe ,Coronavirus Infections,Tension,1,X,[dsyn],[mobd],C02.782.600.550.200,
70f5cb2e-904c-4f53-bcc6-d392be3df9a3,C1537068,C0004170,datasets from healthy individuals generated by Human Cell ,Virus Internalization,Cervical Atlas,1,X,[biof],[bpoc],G06.920.881,A02.835.232.834.151.500
21854a2b-eb3b-4f71-8a15-e9905d2433ef,C2717801,C0040649,assessed ,Viral Tropism,Transcription Genetic,1,X,[phsf],[genf],G06.099.925;G06.920.863,G02.111.873;G05.297.700
d7bb718a-197d-40c8-97d7-b9a1698a5b3c,C2717801,C0174990,assessed ,Viral Tropism,coronavirus receptor,1,X,[phsf],[aapp/rcpt],G06.099.925;G06.920.863,x.x.x.x
594d3330-09b0-4b23-8dc8-8d62285c4b30,C0728888,C0155870,was exposed by national survey of patients with critically ,Enterobacter aerogenes,Pneumonia and influenza,2,X,[bact],[dsyn],B03.440.450.425.275.099;B03.660.250.150.170.049,
2d08d3fa-813b-4ca0-bc8e-ab92836071f2,C0020336,C0035435,are widely used in treatment of ,Hydroxychloroquine,Rheumatism,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C05.799;C17.300.775
d702f322-0ad3-45d6-a492-902a7d1bb9b9,C0014898,C0013227,used other anti ,Esters,Pharmaceutical Preparations,1,X,[orch],[phsu],D02.241.400,D26
9ecde443-daa5-4920-bb2a-ff398b43c56a,C0004482,C0013227,used other anti ,Azathioprine,Pharmaceutical Preparations,1,X,[hops/orch/phsu],[phsu],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26
769ab331-f7d6-4eea-b109-c72c46cc209a,C0010583,C0013227,used other anti ,Cyclophosphamide,Pharmaceutical Preparations,1,X,[orch/phsu],[phsu],D02.455.526.728.650.730.243;D02.705.672.500.243,D26
856f498c-70f0-4baf-802e-eb1fa7fa70cb,C3652465,C0013227,used other anti ,Interferon,Pharmaceutical Preparations,1,X,[aapp/imft/phsu],[phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D26
e8ff6c6d-7fff-439e-8599-b981b4d90d01,C0025124,C0013227,used other anti ,Traditional Chinese Medicine,Pharmaceutical Preparations,1,X,[bmod],[phsu],E02.190.488.585.520;I01.076.201.450.654.558.520,D26
890a4279-a797-4bd9-b2b2-d2f38c173129,C0013227,C0009905,is Anluohuaxian ,Pharmaceutical Preparations,Contraceptives Oral,1,X,[phsu],[phsu],D26,D27.505.696.875.360.276.210;D27.505.954.705.360.276.210
580a986d-a177-4eb0-9617-81cdefdeea4c,C0013227,C1136140,is Anluohuaxian ,Pharmaceutical Preparations,Long-Term Synaptic Depression,1,X,[phsu],[ortf],D26,G11.561.638.355
2703af19-6f6f-4acb-92a1-2bcc643b1cbd,C0009905,C0031336,is provided by Senlong ,Contraceptives Oral,Pharmacy (field),1,X,[phsu],[bmod],D27.505.696.875.360.276.210;D27.505.954.705.360.276.210,H02.646
4477da1c-9451-4544-b52f-6af0e1ab25dd,C0017428,C0038164,However also allows for ,Genome,Staphylococcal Protein A,1,X,[gngm],[aapp/imft/irda],G05.360.340,D12.776.097.820;D23.050.161.821
4f6da7c9-0f2b-4874-b135-17085064aaf3,C0015219,C1880355,opening future ,Biological Evolution,Discover,1,X,[genf],[acty],G05.045;G16.075,
582679d6-e7e5-47ec-b930-487b37befaea,C0042736,C3826426,have developed quantitative ,Viral Proteins,Dynamics,1,X,[aapp/bacs],[npop],D12.776.964,
6089a016-229d-4b4f-b0e3-750fbae51e81,C0042736,C4553629,have developed quantitative ,Viral Proteins,MATRix Regimen,1,X,[aapp/bacs],[topp],D12.776.964,
434436d8-9450-44d2-aed2-8410377e9828,C0042736,C0022709,have developed quantitative ,Viral Proteins,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],D12.776.964,D08.811.277.656.350.350.687
434436d8-9450-44d2-aed2-8410377e9828,C0042736,C0022709,binds ,Viral Proteins,Peptidyl-Dipeptidase A,2,X,[aapp/bacs],[aapp/enzy/imft],D12.776.964,D08.811.277.656.350.350.687
6e03ce59-c97d-468d-8553-c38e45f41d7c,C0042736,C1428660,have developed quantitative ,Viral Proteins,SLC6A19 gene,1,X,[aapp/bacs],[gngm],D12.776.964,
a8a9986c-4767-429b-be50-dc7f17d42c79,C0042736,C0596448,have developed quantitative ,Viral Proteins,dimer,1,X,[aapp/bacs],[chvs],D12.776.964,
b045b8f4-ef9a-4869-b219-a8f18e0c9a6c,C4553629,C0017428,warranting ,MATRix Regimen,Genome,1,X,[topp],[gngm],,G05.360.340
741c66d5-69b9-4749-b9d5-fe5e150ca55d,C4553629,C1175743,warranting ,MATRix Regimen,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
7fab63df-b62b-4ded-a760-3ef87f309547,C4553629,C1428660,elucidated potential missense variants from population databases within ,MATRix Regimen,SLC6A19 gene,1,X,[topp],[gngm],,
76d2f7b5-1c27-4db3-8bd3-676b7606ae91,C4553629,C1742865,elucidated potential missense variants from population databases within ,MATRix Regimen,TMPRSS2 protein human,1,X,[topp],[aapp/enzy],,x.x.x.x
1ac67f3d-0d89-4663-9ac4-2f944f03ce9a,C0022709,C0043292,falls on ,Peptidyl-Dipeptidase A,X Chromosome,1,X,[aapp/enzy/imft],[celc],D08.811.277.656.350.350.687,A11.284.187.865.982;G05.360.162.865.982
68d0f7d0-02a5-457f-8518-cd7ac7301fdf,C1521827,C1705178,serve in ,Preparation,Order (action),2,X,[acty],[acty],,
994d14d2-b327-4863-bd11-ad4e72f7aebc,C0017428,C0086418,is virus core interferes with activities of its counterparts within,Genome,Homo sapiens,1,X,[gngm],[humn],G05.360.340,B01.050.150.900.649.313.988.400.112.400.400
0f22be59-fa64-4ad0-9f8e-0ab0285a0090,C0017428,C0598995,is virus core of,Genome,virus core,2,X,[gngm],[aapp/nnon],G05.360.340,
ad1b42a2-9f42-401f-ae3c-6bc9cf016973,C1519302,C0017428,are composed of short ,Short Tandem Repeat,Genome,1,X,[bacs/nnon],[gngm],G02.111.570.080.708.800.500;G05.360.080.708.800.500;G05.360.340.024.850.500,G05.360.340
849b8284-3959-4882-8209-74f32885e310,C1167395,C0012634,diagnose possible ,Host (organism),Disease,1,X,[orgm],[dsyn],,C23.550.288
26e90626-7ea5-4858-9412-a761989a032e,C0162633,C0920467,may pose threat to ,Viral Shedding,disorder control (procedure),2,X,[patf],[topp],G07.925,
fb5509ee-f7f3-4053-8c99-e4679b19f6ca,C1175743,C1882509,has ,SARS coronavirus,put - instruction imperative,1,X,[virs],[acty],B04.820.504.540.150.113.937,
5a896f6f-744b-4255-aa7c-572eac3391ed,C0035691,C0010076, includes ,RNA Viruses,Coronaviridae,3,X,[virs],[virs],B04.820,B04.820.504.540
fe31fcd7-5422-4879-a97b-e1f8798f55d3,C0035691,C1264606,cause ,RNA Viruses,Persistent infection,1,X,[virs],[dsyn],B04.820,
f55533e2-ed1c-4574-ba9c-4d6c50fe7d69,C0010076,C1264606,cause ,Coronaviridae,Persistent infection,1,X,[virs],[dsyn],B04.820.504.540,
b883ffd2-c1b3-4e26-8f67-e21f27fbcd21,C0035691,C1167395,cause Persistent infection in,RNA Viruses,Host (organism),1,X,[virs],[orgm],B04.820,
d38f1890-c6ed-4d94-bc54-3ce44101f9c2,C0010076,C1167395,cause Persistent infection in,Coronaviridae,Host (organism),1,X,[virs],[orgm],B04.820.504.540,
ed4d3319-cf47-432e-a650-6ebe8fe099fb,C0162633,C1264606,Empirical evidence of be may indirect proof for ,Viral Shedding,Persistent infection,4,X,[patf],[dsyn],G07.925,
b6b2c1fd-e5e1-43e7-8f99-5fef48179fbc,C0017428,C1264606,Empirical evidence of be may indirect proof for ,Genome,Persistent infection,2,X,[gngm],[dsyn],G05.360.340,
7c5cc205-e5a9-4b3b-a765-239426ff347a,C0520510,C1264606,Empirical evidence of be may indirect proof for ,Materials,Persistent infection,2,X,[sbst],[dsyn],,
390823f5-9ab0-4122-97d1-241ac417dc49,C0242732,C0042776,may facilitate evasion by ,Tropism,Virus,1,X,[phsf],[virs],G07.345.249.845;G15.920,B04
38dcd7b1-e639-4813-8b4b-6d3f13175db8,C0079419,C0079427,are key gatekeepers with ,TP53 gene,Tumor Suppressor Genes,1,X,[gngm],[gngm],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,G05.360.340.024.340.375.249;G05.360.340.024.340.415.400
1760324f-0bae-4118-a2b7-99356baefe3a,C0079419,C4552744,are key gatekeepers with ,TP53 gene,Daily Living,1,X,[gngm],[dora],G05.360.340.024.340.375.249.385;G05.360.340.024.340.415.400.385,
b1bec6c7-9f12-4730-b570-29b227c8e074,C1155266,C0242606,is with marked ,inflammatory response,Oxidative Stress,1,X,[patf],[comd],,G03.673;G07.775.750
c00824c3-fcc2-4fbd-a903-1b70210ecc20,C0206750,C0242606,features preeminent ,Coronavirus Infections,Oxidative Stress,2,X,[dsyn],[comd],C02.782.600.550.200,G03.673;G07.775.750
1ea6b3d2-f91b-4324-a529-d0074348bfde,C0242606,C0596263,acts as as initiator of ,Oxidative Stress,Carcinogenesis,1,X,[comd],[neop],G03.673;G07.775.750,C04.697.098;C23.550.727.098
4b49542e-2eea-4f11-829f-7a0a3087fa0a,C0596263,C1175743,associated with ,Carcinogenesis,SARS coronavirus,1,X,[neop],[virs],C04.697.098;C23.550.727.098,B04.820.504.540.150.113.937
7d4e2a43-ad74-4906-9ab9-9c1e59cc14ad,C0266257,C0085845,include elevation of ,Congenital anomaly of liver,Aspartate,1,X,[cgab],[aapp/bacs],,D12.125.067.500;D12.125.119.170;D12.125.427.040
7ef2ae58-3f1a-40c4-864d-159019f7825a,C0266257,C0040676,include elevation of ,Congenital anomaly of liver,Transferase,1,X,[cgab],[aapp/enzy],,D08.811.913
a889b7c5-52c4-4594-8ffe-a2f5155186b2,C0266257,C0376147,include elevation of ,Congenital anomaly of liver,SGPT - Glutamate pyruvate transaminase,1,X,[cgab],[aapp/enzy],,
7a29ed1d-d4bc-425d-a388-0d25c01225c4,C0266257,C0005437,include elevation of ,Congenital anomaly of liver,Bilirubin,1,X,[cgab],[bacs/orch],,D03.383.129.578.840.249.184;D03.633.400.909.249.184;D04.345.783.249.184;D23.767.193.184
89c08dda-854f-4212-979a-e12b4280842c,C0058362,C0682610,is expressed on ,dipeptidyl peptidase II,Enterocytes,1,X,[aapp/enzy],[cell],x.x.x.x,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
a2e4835d-a3d9-4826-9fce-80c98b325c0d,C0058362,C0020885,is expressed on ,dipeptidyl peptidase II,ileum,1,X,[aapp/enzy],[bpoc],x.x.x.x,A03.556.124.684.249;A03.556.249.124
108a4325-bb2a-444a-8cb5-4b9a4630fb75,C1292459,C4287874,raised concern in addition to ,Specimen from patient,Droplet Transmission,1,X,[bdsu],[patf],,
ae03d120-1878-4f77-b630-2119f5024acd,C1947933,C3812666,usually take place in ,care activity,Personal Contact,1,X,[acty],[acty],,
bf5567ce-7032-4cd8-a8e1-cf2a4c9e832e,C1947933,C0087111,usually take place to remote ,care activity,Therapeutic procedure,1,X,[acty],[topp],,E02
486d582d-3474-42fa-93ee-b5b306a9e107,C1145670,C0162434,progressing into ,Respiratory Failure,Olfactory Cortex,2,X,[dsyn],[bpoc],C08.618.846,A08.186.211.200.885.287.500.620;A08.186.211.200.885.287.500.814.695;A08.186.211.200.885.287.750
d9d2536a-d8ed-4f76-9b59-32d2147de19a,C1145670,C2699153,may result from viral ,Respiratory Failure,Cell Invasion,1,X,[dsyn],[patf],C08.618.846,
76f2866a-fd46-4e15-9cd0-c636eec85950,C1145670,C0028938,may result from viral ,Respiratory Failure,Olfactory Nerve,1,X,[dsyn],[bpoc],C08.618.846,A08.800.800.120.640
ae73160f-388e-46cb-82a0-7776544d1c2f,C0007820,C0225990,is in particular ,Cerebrovascular Disorders,Large blood vessel structure,1,X,[dsyn],[bpoc],C10.228.140.300;C14.907.253,
e508d495-89c2-40f2-9988-7d9967c5dd16,C0007820,C0948008,is in particular ,Cerebrovascular Disorders,Ischemic stroke,1,X,[dsyn],[dsyn],C10.228.140.300;C14.907.253,
98d1632f-caba-42c7-9ebc-06220836150a,C1855020,C0079189,is associated to ,Acute necrotizing encephalopathy,cytokine,2,X,[dsyn],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
bf479808-56d6-414b-8757-1deaf8b62116,PNS,C0206750,is in ,PNS,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
267dcdb3-540d-4969-a1d8-a6423e24a427,C0027765,C0035410,include rare instances with ,nervous system disorder,Rhabdomyolysis,1,X,[dsyn],[patf],C10,C05.651.807
7258ab45-1421-4062-9448-a4ac2fd2ef3b,C0027765,C0393799,include ,nervous system disorder,Miller Fisher Syndrome,1,X,[dsyn],[dsyn],C10,C10.114.750.100.500;C10.228.140.252.500;C10.292.562.350;C10.314.750.450.500;C10.668.829.350.500;C10.668.829.800.750.300.500;C11.590.312;C20.111.258.750.400.500
e34d61ba-756e-4ae6-83b8-25f22f3bc317,C0027765,C0032541,include ,nervous system disorder,Polyneuritis,1,X,[dsyn],[dsyn],C10,C10.668.829.650
ebfa7c72-05d6-44fc-b29e-3b01b658ec9b,C0027765,C0039082,include Guillain-Barr ,nervous system disorder,Syndrome,1,X,[dsyn],[dsyn],C10,C23.550.288.500
53b162d9-c6a2-4f49-affd-5cbfc254b3b9,C0035222,C0206419,is in ,Respiratory Distress Syndrome Adult,Genus: Coronavirus,3,X,[dsyn],[virs],C08.381.840;C08.618.840,B04.820.504.540.150
1d9fb3ca-3091-4b86-93a7-fe9b4d9e0294,C0079189,C0042769,is in response to ,cytokine,Virus Diseases,4,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02
0f1d1aac-7971-4e70-bca7-6a6c23db528c,C0242656,C1290884,is in ,Disease Progression,Inflammatory disorder,1,X,[patf],[dsyn],C23.550.291.656,
af1f621d-fb4a-49e9-b4a1-f75d80e38067,C0242656,C0079189,is in ,Disease Progression,cytokine,1,X,[patf],[aapp/imft],C23.550.291.656,D12.644.276.374;D12.776.467.374;D23.529.374
f4e4ff8c-a0e8-4b11-bbdf-049b7a4cca14,C0376520,C0162772,induces ,Dietary Iron,Reactive Oxygen Species,1,X,[inch],[bacs/elii],D01.490.600;D02.691.550.600,D01.339.431;D01.650.775
0d29c8a2-16b5-4c7b-9818-62654a60ec53,C0026237,C2244223,are huperzine B of,Mitochondria,cellular homeostasis,2,X,[celc],[celf],A11.284.430.214.190.875.564;A11.284.835.626,
ead491c4-8b55-4d85-986f-c574351c46ec,C0026237,C0063034,are ,Mitochondria,huperzine B,1,X,[celc],[orch/phsu],A11.284.430.214.190.875.564;A11.284.835.626,x.x.x.x
0deda21e-954b-4a61-aecb-986bc51714f8,C0026237,C0005821,may circulate cell-free in non-nucleated ,Mitochondria,Blood Platelets,1,X,[celc],[cell],A11.284.430.214.190.875.564;A11.284.835.626,A11.118.188;A15.145.229.188
f6463b7a-a772-4fa8-870d-3afc08aafe17,C0026237,C3894683,may circulate in ,Mitochondria,Extracellular Vesicles,1,X,[celc],[celc],A11.284.430.214.190.875.564;A11.284.835.626,A11.284.295.588
a721e79e-ef19-4b00-9017-8a4bf2b40f28,C0025123,C0087111,has In China has widely used to ,chinese medicine,Therapeutic procedure,1,X,[bmod],[topp],,E02
0b59b8ee-6daf-436b-b473-d603427410d1,C0025123,C0012634,has In China has widely used to ,chinese medicine,Disease,1,X,[bmod],[dsyn],,C23.550.288
0b8805e7-51b8-4d2c-bf82-4c660957d67c,C0025123,C0035204,plays role in treatment of ,chinese medicine,Respiration Disorders,1,X,[bmod],[dsyn],,C08.618
796db24d-e645-4bd1-81ab-e67669d1dfe6,C0035691,C0312860,containing ,RNA Viruses,Neutrophil migration function,1,X,[virs],[celf],B04.820,
01311348-02b8-4679-be46-ab1fe842471c,C0319157,C1628327,is ,AS virus,Zoonotic pathogen,1,X,[virs],[orgm],,
3d5aa9f6-8758-4bea-a413-8ffc9d077525,C0319157,C0683325,is ,AS virus,clinical aspects,1,X,[virs],[clna],,
5b2cd904-b1f7-4336-990a-dbbdc86eafb6,C0319157,C2936329,is ,AS virus,Asymptomatic Diseases,1,X,[virs],[dsyn],,C23.550.291.187
802317ff-c3c5-4c73-8551-eecdc37e49a1,C2936329,C0086418,is in ,Asymptomatic Diseases,Homo sapiens,1,X,[dsyn],[humn],C23.550.291.187,B01.050.150.900.649.313.988.400.112.400.400
b13023ab-7a79-4a44-a600-ad555ad36f6d,C1112565,C0949920,has has described in association with ,pneumatosis intestinalis,Norovirus,1,X,[dsyn],[virs],,B04.820.095.550
17714827-bce3-43dd-8ee4-4fe0513768a2,C0015929,C0206419,is in ,Fetal Diseases,Genus: Coronavirus,1,X,[dsyn],[virs],C13.703.277;C16.300,B04.820.504.540.150
2673a00b-2332-4002-890a-772be3d560b0,C0042210,C0319157,curb pandemic spread of zoonotic ,Vaccines,AS virus,1,X,[aapp/imft/phsu],[virs],D20.215.894,
2d555685-538e-4556-b21e-f4c7ff6b1477,C1880355,C0319157,curb pandemic spread of zoonotic ,Discover,AS virus,1,X,[acty],[virs],,
8ee89bcc-7735-4136-94fe-95d363f98f51,C0017968,C0475463,is main target of ,Glycoproteins,Antibodies Neutralizing,1,X,[aapp/bacs],[aapp/imft],D09.400.430;D12.776.395,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
32c49763-a636-4d51-a24d-e3794cd773be,S309,C0032594,recognizes ,S309,Polysaccharides,1,X,????,[orch/phsu],????,D09.698
87e51067-189d-4080-9771-7632af016159,S309,C0003316,recognizes ,S309,Epitopes,1,X,????,[imft],????,D23.050.550
2647745c-cccf-4665-b6c3-95c820dd38d9,C0003316,C0597357,is conserved competing with ,Epitopes,receptor,2,X,[imft],[aapp/rcpt],D23.050.550,
635d4adb-b853-42a7-8535-6d817b168829,C0003316,C1947904,is conserved competing with ,Epitopes,Attachment (action),2,X,[imft],[acty],D23.050.550,
97ae4508-dade-4561-b561-ff60dfda4b4e,C0678420,S309, includes S309,Cocktail,S309,1,X,[food],????,,????
b7eb7b7e-b6f1-4be3-9198-2a11f471009e,C0678420,C0596988,may limit emergence of neutralization-escape ,Cocktail,mutant,1,X,[food],[comd],,
afcbfc21-8293-448f-9dd7-16e03f3c5aaa,S309,C0596988,may limit emergence of neutralization-escape ,S309,mutant,1,X,????,[comd],????,
02202f32-f5a6-41fc-857d-8cf1c39609e2,COPC,C2728259,were applied in CST ,COPC,Program,2,X,????,[orch/phsu],????,V02.355.750
ba2baf77-b71d-4155-a40f-93190ee3bb9b,C2948600,C0423866,slow ,Aim,Lanugo,2,X,[inch/phsu],[bpoc],,A17.360
574638d9-31cf-415a-af04-b9ed68aebcae,C2948600,C0814435,slow Lanugo disease transmission through,Aim,early identification,2,X,[inch/phsu],[topp],,
bc8c1b89-e54a-4615-9623-118abc5d6a01,C0003507,COVID,is in COVID ,Aortic Valve Stenosis,COVID,1,X,[dsyn],????,C14.280.484.150;C14.280.955.249,????
2b861ef6-f11e-4dac-b4ec-fc7de720792c,C0003507,C1521863,is in COVID ,Aortic Valve Stenosis,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C14.280.484.150;C14.280.955.249,x.x.x.x
b68c0339-88c8-4121-969a-78ba51833ed4,C0225706,C0225730,was more extensively involved than ,Right lung,Left lung,1,X,[bpoc],[bpoc],,
19a3ca79-2458-4f1f-a9b4-1c4d3c9bf2ca,C0225758,C0225756,was extensively involved than ,Structure of lower lobe of lung,Structure of upper lobe of lung,1,X,[bpoc],[bpoc],,
c1460e65-f371-4187-8417-45ff8bb085be,C0444279,C0035380,tested by ,Respiratory sample,Reverse Transcription,1,X,[bdsu],[genf],,G02.111.873.500;G05.297.700.500
0df7cf02-f0b7-4f6d-b818-c5d309e4f982,C0012739,C0206419,are life-threatening for patients with ,Disseminated Intravascular Coagulation,Genus: Coronavirus,1,X,[dsyn],[virs],C15.378.100.220;C15.378.463.250;C15.378.925.220,B04.820.504.540.150
def8a9b8-62b1-4873-8ba9-3b1e5dc8640c,C0034848,C0042774,significantly decreasing ,Receptors Virus,Virus Replication,1,X,[aapp/rcpt],[celf],D12.776.543.750.830,G06.920.925
e098d9bc-c01e-4818-91f1-093960db87ce,C0034848,C0015219,significantly decreasing risk of ,Receptors Virus,Biological Evolution,1,X,[aapp/rcpt],[genf],D12.776.543.750.830,G05.045;G16.075
74ccdae9-5354-4158-b5f5-c3fea6784157,C0028429,C0039336,identified patients with reduction of ,Nose,Taste Perception,4,X,[bpoc],[ortf],A01.456.505.733;A04.531;A09.531,F02.830.816.724;G11.561.790.724
0ea074dc-2f22-49e5-a61b-2aa8bb10e38e,C0003018,C0030664,is in various neoplastic ,Angiotensins,Pathology,1,X,[aapp/bacs/phsu],[bmod],D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050,H02.403.650
267440e4-b9cf-41fb-a55c-502c13027e0b,C0206419,C0017181,is with ,Genus: Coronavirus,Gastrointestinal Hemorrhage,1,X,[virs],[patf],B04.820.504.540.150,C06.405.227;C23.550.414.788
3ee25729-da8f-4105-b5d2-b1f921e58698,C0849867,C0035222,is with large number of ,Widespread Disease,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],,C08.381.840;C08.618.840
0d74d7a7-5b73-49fb-8d91-af3583896217,PCR,C0014507,is in symptomatic patient at high ,PCR,Epidemiology,1,X,????,[bmod],????,H02.403.720.500
b2d813a8-a8dd-4e87-b74e-4f43f15de1c1,C0009450,C2348077,missed by limited testing performed to ,Communicable Diseases,Date Fruit,1,X,[dsyn],[food],C01.539.221,B01.650.940.800.575.912.250.093.615
18374c4f-bde0-4a6d-8127-80c666a3b427,C0206419,C0559758,can induce ,Genus: Coronavirus,MULTISYSTEM DISORDER,1,X,[virs],[dsyn],B04.820.504.540.150,
37276fec-788f-406f-95e0-1b0fe1d735dd,C0021368,C0005778,participate in dysfunctional ,Inflammation,Blood coagulation,2,X,[patf],[ortf],C23.550.470,G09.188.390.150
dfbe37ea-fda7-4178-93c4-3add0788c4f0,C3241922,C0042776,was how affected by ,Operation Activity,Virus,4,X,[acty],[virs],,B04
4d96897f-1dea-4287-ab19-c61c55c1fb4c,C0543467,C0019144,were performed including major ,Operative Surgical Procedures,Hepatectomy,2,X,[topp],[topp],E04,E04.210.556
d0a5f38a-bebc-46ed-b708-9e532b8bd743,C2948600,C0846672,introduce our experience based remote patient LTSC,Aim,systems therapy,2,X,[inch/phsu],[topp],,
876e43e0-3272-4c4d-b243-3f5c040281d0,C2948600,LTSC,introduce our experience based remote patient LTSC,Aim,LTSC,2,X,[inch/phsu],????,,????
64d8626e-a80a-4938-9164-1d5470c41e68,C0423866,C1175743,spread of ,Lanugo,SARS coronavirus,2,X,[bpoc],[virs],A17.360,B04.820.504.540.150.113.937
730db4f4-c8f2-4025-9fea-ff915d159f02,C0206422,C1550661,can can variably found in ,Human coronavirus,Specimen Type - Stool = Fecal,2,X,[virs],[bdsu],,
3a10fb08-222d-4145-960d-6a65d6eee7d3,C0206422,C1457887,have have variably associated with ,Human coronavirus,Symptoms,2,X,[virs],[sosy],,
aece4c2e-1f80-42c3-ae34-0bfa94e2e5b2,C0206422,C0017160,have have variably associated with ,Human coronavirus,Gastroenteritis,2,X,[virs],[dsyn],,C06.405.205
ef39ceca-00d7-4785-b07f-a13e76e698b4,C0221102,C0015733,is in ,Excretory function,Feces,2,X,[phsf],[bdsu],,A12.459
d64a4fc4-33cf-4e46-ab05-6672e557459c,C0370003,C0206419,exceed fourteen day period after onset for ,Specimen,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
8628935c-4394-492c-af7a-1c51e2a8718e,C0305052,COVID-19,can ,Gamma globulin serum,COVID-19,1,X,[aapp/imft/phsu],[virs],,C000657245
9a0ccbe0-8369-4e1a-8aa9-5586046756a3,TLR3,COVID-19,be considered as ,TLR3,COVID-19,1,X,????,[virs],????,C000657245
ac777529-fdf3-45ce-ab26-1faa265d1b81,C0243192,COVID-19,be considered as ,agonists,COVID-19,1,X,[phsu],[virs],x.x.x,C000657245
62beb658-93cc-4d52-9f0e-997fa9ace184,C2936405,COVID-19,is in ,Drug Repositioning,COVID-19,1,X,[topp],[virs],E05.290.875,C000657245
602400ad-2d97-47d2-9ae2-a7806c1c9383,C0206419,C0011438,has had significant ,Genus: Coronavirus,Dentistry,1,X,[virs],[bmod],B04.820.504.540.150,E06;H02.163
96d9f3b5-282e-42fe-8d64-9f9f812afcc2,C0012634,C0011438,has had significant ,Disease,Dentistry,1,X,[dsyn],[bmod],C23.550.288,E06;H02.163
f56006ad-a362-4011-8883-fa77235427ff,6LU7,C1175743,identity with ,6LU7,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
b5920f5c-c456-4816-b9a2-720167c16b11,C0023911,COVID-19,is with ,Transplantation of liver,COVID-19,1,X,[topp],[virs],E02.095.147.725.490;E04.210.650;E04.936.450.490;E04.936.580.490,C000657245
918bbafd-9673-495b-b6a1-b32b7127c71e,C0206419,C0011311,is with false-positive ,Genus: Coronavirus,Dengue Fever,1,X,[virs],[dsyn],B04.820.504.540.150,C02.081.270;C02.782.350.250.214;C02.782.417.214
dba276cf-594d-48c1-a6f7-500c08f37281,C0206419,C0036745,is with false-positive ,Genus: Coronavirus,Study of serum,1,X,[virs],[bmod],B04.820.504.540.150,H02.781
68b98bb0-b8b9-4818-ab0a-a20b803ac521,C0013227,C3714514,are approved for other ,Pharmaceutical Preparations,Infection,2,X,[phsu],[patf],D26,C01.539
3c4d1a7d-fa46-4800-98bd-871448c0a04d,C0013227,C0683949,have performed well in ,Pharmaceutical Preparations,animal study,2,X,[phsu],[anim],D26,
8cc626ec-3c11-4b65-84ce-5fdf6dfc0e5c,C0207682,C0312860,Furthermore blocked SARS coronavirus with effective concentration around 10,nafamostat mesilate,Neutrophil migration function,1,X,[orch/phsu],[celf],,
433a7cad-5177-4ce4-9bd1-449f85e5f837,C0207682,C0007634,also inhibits SARS coronavirus in,nafamostat mesilate,Cells,1,X,[orch/phsu],[cell],,A11
36eef2fe-09dc-4c0a-a246-bb374f2da702,C2948600,C0544357,evaluate immunoassays in ,Aim,human plasma,1,X,[inch/phsu],[phsu],,
88f07089-6491-4f83-8019-59545996abfa,C1627946,COVID-19,confirmed ,SARS coronavirus IgM,COVID-19,1,X,[aapp/imft],[virs],,C000657245
35c8997d-60a3-4529-be4d-6dcb5a2759bd,C1718953,COVID-19,confirmed ,Severe acute respiratory syndrome coronavirus Ab,COVID-19,1,X,[aapp/imft],[virs],,C000657245
7e428f67-2e0f-42ce-9088-7da10380f6f7,C1627946,C0178913,confirmed ,SARS coronavirus IgM,Blood specimen,1,X,[aapp/imft],[bdsu],,
1cd13ec8-c395-4a75-af78-b5501403c3b7,C1718953,C0178913,confirmed ,Severe acute respiratory syndrome coronavirus Ab,Blood specimen,1,X,[aapp/imft],[bdsu],,
3b617f2b-1b41-4c8b-b29a-cc2eca200524,C1627946,C1718953,is in RT-PCR,SARS coronavirus IgM,Severe acute respiratory syndrome coronavirus Ab,1,X,[aapp/imft],[aapp/imft],,
b0df7eb4-4839-48c1-90ac-22e2fe755315,C1627946,RT-PCR,is in RT-PCR,SARS coronavirus IgM,RT-PCR,1,X,[aapp/imft],????,,????
71c7f2b0-35fd-4b77-a208-d68d8bea8574,C1718953,RT-PCR,is in RT-PCR,Severe acute respiratory syndrome coronavirus Ab,RT-PCR,1,X,[aapp/imft],????,,????
86125fb3-cd99-46d2-a89d-dd4483a318a9,COVID-19,C0178913,is with serial ,COVID-19,Blood specimen,1,X,[virs],[bdsu],C000657245,
9d2f1bcb-4346-4bdd-9197-e1340fc2bfde,C0206419,C0719214,has emerged as once in a ,Genus: Coronavirus,century,1,X,[virs],[phsu/vita],B04.820.504.540.150,
b3e27d7a-221f-4528-97b7-831f04f4102a,C0206419,C1947951,supporting ,Genus: Coronavirus,Anatomical Apparatus,1,X,[virs],[anst],B04.820.504.540.150,
ca58278f-cf61-4715-baa6-aef88cf71115,C0678591,kcal,was calculated -2.80 0.84 kcal ,free energy,kcal,4,X,[npop],????,,????
b8d9a616-a662-4fb1-901d-6dc33e12dfc9,C0678591,C0324740,was calculated -2.80 0.84 kcal ,free energy,Talpidae,4,X,[npop],[mamm],,B01.050.150.900.649.473.450
10c297b6-bb8e-46e1-a5fd-01641ec08da4,C0035139,C1152412,is in blocking of ,Surgical Replantation,RNA-directed RNA polymerase activity,2,X,[topp],[genf],E04.936.494,
de10015f-0765-4260-a2c2-8c2e4da1590d,D618,remdesivir,be contributors to ,D618,remdesivir,2,X,????,[clnd],????,
de10015f-0765-4260-a2c2-8c2e4da1590d,D618,remdesivir,are found ,D618,remdesivir,2,X,????,[clnd],????,
6cf39544-d94e-4bbb-94f2-a7d0fda85305,S549,remdesivir,be contributors to ,S549,remdesivir,2,X,????,[clnd],????,
6cf39544-d94e-4bbb-94f2-a7d0fda85305,S549,remdesivir,are found ,S549,remdesivir,2,X,????,[clnd],????,
40182ebf-0c5c-4b57-84ba-aed065f2284a,R555,remdesivir,be contributors to ,R555,remdesivir,2,X,????,[clnd],????,
40182ebf-0c5c-4b57-84ba-aed065f2284a,R555,remdesivir,are found ,R555,remdesivir,2,X,????,[clnd],????,
5caa06ec-5854-4497-9099-c97498f9bd48,D618,C1167622,be contributors to ,D618,Binding (Molecular Function),2,X,????,[moft],????,
5caa06ec-5854-4497-9099-c97498f9bd48,D618,C1167622,are found ,D618,Binding (Molecular Function),2,X,????,[moft],????,
a7639563-3b63-4b59-b88d-092b0d47874e,S549,C1167622,be contributors to ,S549,Binding (Molecular Function),2,X,????,[moft],????,
a7639563-3b63-4b59-b88d-092b0d47874e,S549,C1167622,are found ,S549,Binding (Molecular Function),2,X,????,[moft],????,
1814fcbd-07bd-4778-b51d-9a1a434435ff,R555,C1167622,be contributors to ,R555,Binding (Molecular Function),2,X,????,[moft],????,
1814fcbd-07bd-4778-b51d-9a1a434435ff,R555,C1167622,are found ,R555,Binding (Molecular Function),2,X,????,[moft],????,
fadcaf81-f52a-401c-9b1b-63b9e29be68a,D618,C1510827,be contributors to ,D618,Affinity,2,X,????,[npop],????,
fadcaf81-f52a-401c-9b1b-63b9e29be68a,D618,C1510827,are found ,D618,Affinity,2,X,????,[npop],????,
fde25a40-f725-478c-a316-ef9b82598a16,S549,C1510827,be contributors to ,S549,Affinity,2,X,????,[npop],????,
fde25a40-f725-478c-a316-ef9b82598a16,S549,C1510827,are found ,S549,Affinity,2,X,????,[npop],????,
e94b6064-c0ed-468b-8c84-70f02a2b9ee4,R555,C1510827,be contributors to ,R555,Affinity,2,X,????,[npop],????,
e94b6064-c0ed-468b-8c84-70f02a2b9ee4,R555,C1510827,are found ,R555,Affinity,2,X,????,[npop],????,
1f2af996-0d16-4c2e-b8d6-42db9e3d91cc,remdesivir,C1628999,potentially act as ,remdesivir,SARS coronavirus RNA,1,X,[clnd],[nnon],,
0e5fb700-f33e-4f44-9698-e39fddbabb30,remdesivir,C0851166,potentially act as ,remdesivir,TERMINATOR Veterinary Product,1,X,[clnd],[phsu],,
1c455ca7-3ffe-4e52-9a2c-a54593fdd09d,remdesivir,C1328949,effectively stopping its ,remdesivir,RNA replication,1,X,[clnd],[genf],,
b934b8c1-bc20-49c6-9bbb-3a74959bf783,remdesivir,C2698650,potentially act with key residues also identified for future lead ,remdesivir,Optimization,2,X,[clnd],[acty],,
65bad936-ec6e-4bd5-b6ed-eafb3a6d834c,27th,C0077401,between one is 2020 with ,27th,Troponin I,1,X,????,[aapp/bacs],????,D05.500.945.925;D05.750.078.730.825.925;D12.776.210.500.910.925;D12.776.220.525.825.925
c583020e-2a37-438f-b73e-88b7eff391e9,C0007222,C0041199,was more prevalent in patients with ,Cardiovascular Diseases,Troponin,1,X,[dsyn],[aapp/bacs],C14,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
d1f66a91-8247-4183-b04a-6f31ead3f578,C1457887,C0022646,are often initial presentation among ,Symptoms,Kidney,1,X,[sosy],[bpoc],,A05.810.453
3900fec9-6e2f-4c41-8cd0-5b81d0c9e6ad,C0020625,COVID-19,is in ,Hyponatremia,COVID-19,1,X,[dsyn],[virs],C18.452.950.620,C000657245
822c9c42-604d-4bed-8989-db6ab0b5abda,C0281182,C0441655,scaled down significantly their ,Screening for malignant neoplasm of breast,Activities,2,X,[topp],[acty],,
8bd47eb8-a098-4379-aa8d-3601adb363ad,C1175743,C0597404,may enter system Like other ,SARS coronavirus,Respiratory viruses,2,X,[virs],[virs],B04.820.504.540.150.113.937,
483be702-b664-4220-9047-5d5c70e0bd07,C0085584,COVID-19,has ,Encephalopathies,COVID-19,2,X,[dsyn],[virs],C10.228.140,C000657245
45f6660c-d4dd-49da-876b-140aab0e2c8e,C0085584,C1457887,has has described as presenting ,Encephalopathies,Symptoms,2,X,[dsyn],[sosy],C10.228.140,
2a1d7fe2-142e-403c-bdf3-39ad4be7745a,C0872315,C0450254,were characterized by their novel ,Communicable Diseases Emerging,Pathogenic organism,4,X,[dsyn],[orgm],C01.539.221.500,
f98e5e72-eeb8-4f8c-8f61-ca29be6e4027,C1275666,C0003241, includes ,Fusion inhibitor,Antibodies,2,X,[phsu],[aapp/imft/phsu],,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
ff991312-e45f-4982-8ee7-71722c3f53f4,C1275666,C0033607, includes ,Fusion inhibitor,Protease Inhibitors,2,X,[phsu],[phsu],,D27.505.519.389.745
46c99e25-1d6d-4e29-9444-506961e85b47,C1275666,C0030956, includes ,Fusion inhibitor,Peptides,2,X,[phsu],[aapp/phsu],,D12.644
c830c8dc-b9eb-43f1-8476-c8248e87057b,WBE,C0005516,Protein Domain in sewage ,WBE,Biological Markers,1,X,????,[clna],????,D23.101
c830c8dc-b9eb-43f1-8476-c8248e87057b,WBE,C0005516,Protein Domain in fragment,WBE,Biological Markers,1,X,????,[clna],????,D23.101
d0edcbf2-cafe-4acc-a693-a4d368e380ed,C1514562,C0005516,is in sewage ,Protein Domain,Biological Markers,1,X,[amas],[clna],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D23.101
d0edcbf2-cafe-4acc-a693-a4d368e380ed,C1514562,C0005516,is in fragment ,Protein Domain,Biological Markers,1,X,[amas],[clna],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,D23.101
cd0d9ae2-7a69-4286-b849-0da0efd131d7,C0005532,C0206419,is partially known with aspects in common with other ,biology (field),Genus: Coronavirus,3,X,[bmod],[virs],H01.158.273,B04.820.504.540.150
360b444d-6bb0-4ab4-a683-a757feaee729,C0005525,C0441655,restores immunological ,Biological Response Modifiers,Activities,1,X,[imft/phsu],[acty],D27.505.696.477,
4950d107-1860-4d79-b22f-55bd12390b96,C0005525,C0334227,restores immunological activity against ,Biological Response Modifiers,Tumor cells malignant,3,X,[imft/phsu],[cell],D27.505.696.477,
68e58e5f-c3e5-4b89-98c2-4d70bc15be22,C0018563,C0441516,be in hence ,Hand,Demand (clinical),2,X,[bpoc],[topp],A01.378.800.667,
7a717519-4e9f-4070-babf-9539eca914de,1st,C0206750,until Search - action is 2019 novel,1st,Coronavirus Infections,2,X,????,[dsyn],????,C02.782.600.550.200
4f783dfd-8e9d-4300-8f83-444bae361f94,C0013227,C0341439,is with ,Pharmaceutical Preparations,Chronic liver disease,1,X,[phsu],[dsyn],D26,
e87df732-eb0e-4406-90e4-6da459652943,C0243077,C1738934, includes ,inhibitors,boceprevir,1,X,[chvf],[aapp/phsu],,x.x.x.x
f9e56309-678c-4e35-9e6a-28548f968f57,C0444626,C1167622,revealed two ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
f9e56309-678c-4e35-9e6a-28548f968f57,C0444626,C1167622,has revealed molecular determinants responsible for ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
f9e56309-678c-4e35-9e6a-28548f968f57,C0444626,C1167622,has revealed potential inhibitor ,Crystal Structure,Binding (Molecular Function),2,X,[chvs],[moft],,
06164680-c661-4b1d-8e90-90d52512d0df,C0444626,C3537453,is with ,Crystal Structure,GBA wt Allele,1,X,[chvs],[gngm],,
a61f0d03-644c-48e7-97b3-05be7b998d38,C0216231,C0086418,is ,sargramostim,Homo sapiens,2,X,[aapp/imft/phsu],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
883471bc-f525-4a6c-8465-4cf5cd4840cc,C0216231,g/m,will Upon g/m ,sargramostim,g/m,3,X,[aapp/imft/phsu],????,x.x.x.x,????
6062c4bc-49df-48f4-89d0-849dd35d8432,C0683325,C0035222,include ,clinical aspects,Respiratory Distress Syndrome Adult,2,X,[clna],[dsyn],,C08.381.840;C08.618.840
efaeba72-67c2-4c67-8982-d1859d757e42,C0683325,C3665444,include ,clinical aspects,Neutrophilia (disorder),2,X,[clna],[dsyn],,
b9fdfce5-bf6e-4173-ac36-082e9bbeec31,C0683325,C0079189,include ,clinical aspects,cytokine,2,X,[clna],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
4d41dfa5-ed67-4302-9a62-0107ccb7e220,C0746885,COVID-19,contributes to ,neutrophilic,COVID-19,2,X,[celf],[virs],,C000657245
8876d555-d022-42e7-b0f6-8546417c5b7b,C0746885,C0011849,contributes to higher mortality of ,neutrophilic,Diabetes Mellitus,2,X,[celf],[dsyn],,C18.452.394.750;C19.246
2e4efcd7-3475-4f94-8970-a91bcecb65c8,C0021368,C0011849,contributes to higher mortality of ,Inflammation,Diabetes Mellitus,2,X,[patf],[dsyn],C23.550.470,C18.452.394.750;C19.246
ba38de21-4723-48e5-924b-15d9489c0dd3,C0543829,C0683465,is in ,pneumonia clinical,novel AODU treatment method,4,X,[dsyn],[topp],,
9cb223a7-ec50-436d-a33b-0c96eb8ab3de,C0543829,C0206750,is in ,pneumonia clinical,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
ca914bf5-f8ad-46cf-8b5d-3b8e90933f91,C2986594,C0032285,study ,Mouse Model,Pneumonia,2,X,[emod],[dsyn],,C08.381.677;C08.730.610
bea0be33-b7cc-4d2b-b15e-b3ad0db93768,C0025124,C0206750,is in Novel ,Traditional Chinese Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C02.782.600.550.200
bea0be33-b7cc-4d2b-b15e-b3ad0db93768,C0025124,C0206750,have shown ,Traditional Chinese Medicine,Coronavirus Infections,1,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C02.782.600.550.200
db205d10-757f-448f-9083-a3ef16841b83,C0025124,C0032285,is in Novel ,Traditional Chinese Medicine,Pneumonia,2,X,[bmod],[dsyn],E02.190.488.585.520;I01.076.201.450.654.558.520,C08.381.677;C08.730.610
76f81bff-e197-4ffd-8bfd-abe43b7d3bc3,C0025919,C0042776,is infected with HCoV-229 E ,Mice Inbred BALB C,Virus,2,X,[mamm],[virs],B01.050.050.199.520.520.338;B01.050.150.900.649.313.992.635.505.500.400.338,B04
2f2eb0c4-8607-4ac1-9ccb-cc8e41a5fb7f,C0039215,C0032285,reduced ,CD4 Positive T Lymphocytes,Pneumonia,2,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C08.381.677;C08.730.610
2234f4e3-4cd7-4b01-9694-49ae0bfb01d5,C0039215,C0040300,reduced ,CD4 Positive T Lymphocytes,Body tissue,1,X,[cell],[tisu],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,A10
304a9991-3456-4cea-8821-05a6a09fa265,C0039082,C0042776,may attribute to its function of in ,Syndrome,Virus,2,X,[dsyn],[virs],C23.550.288.500,B04
82b6c2d9-d295-43cb-9407-8c6104498e2a,C0039082,C1511692,may attribute to its function of in ,Syndrome,DNA Replication Inhibition,2,X,[dsyn],[genf],C23.550.288.500,
48f50ca0-e568-407e-955e-d2b6ee18bf09,C0039082,C3463820,may attribute to its function of in ,Syndrome,Inhibition,2,X,[dsyn],[acty],C23.550.288.500,F01.145.544;F02.463.425.475;F02.739.794.405
76e390dc-f004-48a2-b01e-ac18ef7817e0,C0042776,C0037088,plays role in ,Virus,Signs and Symptoms,1,X,[virs],[sosy],B04,C23.888
d0bd86e1-7cc8-40f5-b755-a75cd5b8ef23,MT-PCR,C1511790,is reliable assay for ,MT-PCR,Detection,1,X,????,[topp],????,
b624b4fc-bff5-4ae5-8fd3-1c90c2bce345,MT-PCR,C1175743,is reliable assay for ,MT-PCR,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
5e76d4c6-e35b-47b7-98b1-92099a99fb89,C0265267,C0206750,is associated with ,Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
fc37bd57-495c-4913-8fd1-be8966277d93,C3864824,C0263940,help ,paritaprevir,Curb,1,X,[orch/phsu],[dsyn],,
dbaa0cfe-5548-4823-9e34-c56d0dc2fc3b,C3864824,C0206750,help ,paritaprevir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],,C02.782.600.550.200
91af4766-0e01-4fe4-a562-faf78f1f054d,C0030106,C0011334,could of could help in control of ,Ozone,Dental caries,2,X,[chem],[dsyn],D01.362.670.600;x.x.x.x,C07.793.720.210
ab01c727-f4b0-4588-93e9-33cfd799fc9a,C0012634,C0011945,occur among patients on in-center ,Disease,Physical Dialysis,2,X,[dsyn],[npop],C23.550.288,E05.196.353;G02.186
e558d59b-5a0f-497d-99b4-3f85a862ecfc,C0015967,C0015672,42-year-old patient ,Fever,Fatigue,1,X,[sosy],[sosy],C23.888.119.344,C23.888.369
2afbe694-6135-4b8e-b910-07b1f1f73b55,C0206750,C1704532,can can treated with ,Coronavirus Infections,Active Method,1,X,[dsyn],[topp],C02.782.600.550.200,
24c0a71c-cfba-4ea1-9f80-d7578f4f6f03,C0021760,C0948245,plays role in ,Interleukin-6,Cytokine Release Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,
6b33edac-d083-4694-bf44-618b11f8b058,C1706202,C0872147,using Cochrane ,Search - action,DNA Library,2,X,[acty],[gngm/nnon],,G05.360.325
b0b127b2-9484-418f-bbad-97c30d593641,C0069590,C0206750,compared between severe ,ORALIT,Coronavirus Infections,1,X,[inch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
b1e2ca4d-864d-49d8-a15a-27bbb0d7d5c7,C0069590,C1829939,compared between severe ,ORALIT,{Non-patient},1,X,[inch/phsu],[clna],x.x.x.x,
9d9de2de-f28c-4f10-96ad-7e7f742bb22b,C0034019,citys,was key to citys ,public health medicine (field),citys,1,X,[bmod],????,H02.403.720;N01.400.550;N06.850,????
267e27f6-5837-461a-9535-7cc08dbc5a5d,C4534538,C0801658,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Diagnosis.primary:Impression/interpretation of study:Point in time:^Patient:Nominal,2,X,[topp],[clna],,
7518c21f-8a99-4ced-bb92-47d4bfdee0e1,C4534538,C1856053,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Hydranencephaly with Renal Aplasia-Dysplasia,4,X,[topp],[dsyn],,x.x.x.x
0a98c05e-26f3-4759-bb62-b09e366ba7b3,C0206750,COV2,is caused by COV2,Coronavirus Infections,COV2,3,X,[dsyn],????,C02.782.600.550.200,????
ba49a485-74db-4255-98d0-a7f06945993e,C0012634,COV2,is caused by COV2,Disease,COV2,3,X,[dsyn],????,C23.550.288,????
5460f871-9dbc-450e-ba18-e33d1967108e,C0310255,C0745283,must Normally must employed for completion of ,survive,INFECTIOUS PROCESS,1,X,[phsu],[patf],,
34b26020-f53d-4d18-abfb-ccb738079fda,C1157569,C0035696,involves interaction of RPs with ,viral translation,RNA Messenger,2,X,[celf],[bacs/nnon],,D13.444.735.544
34b26020-f53d-4d18-abfb-ccb738079fda,C1157569,C0035696,involves interaction with viral ,viral translation,RNA Messenger,1,X,[celf],[bacs/nnon],,D13.444.735.544
0b6a9bb7-e358-4e15-8347-24b6877392c2,C0020538,C0242656,are Additionally risk factors for ,Hypertensive disease,Disease Progression,1,X,[dsyn],[patf],C14.907.489,C23.550.291.656
6f4f65a8-a014-496a-ac2c-826ef7c1a1e9,C0011849,C0242656,is ,Diabetes Mellitus,Disease Progression,2,X,[dsyn],[patf],C18.452.394.750;C19.246,C23.550.291.656
8f5343ca-94ec-485c-8d62-352fc7c3a706,C3489532,C0220806,extract co-occurrences among ,Cone-Rod Dystrophy 2,Chemicals,1,X,[dsyn],[chem],C11.270.152;C11.768.585.658.250;C16.320.290.152,
31a59ccb-6bdb-4a15-87dd-8fd1fbc92f21,C3489532,C0012634,extract co-occurrences among ,Cone-Rod Dystrophy 2,Disease,1,X,[dsyn],[dsyn],C11.270.152;C11.768.585.658.250;C16.320.290.152,C23.550.288
cee9effb-2385-4912-9353-f236f38b961f,C3489532,C0017337,extract co-occurrences among ,Cone-Rod Dystrophy 2,Genes,1,X,[dsyn],[gngm],C11.270.152;C11.768.585.658.250;C16.320.290.152,G05.360.340.024.340
f535f3ba-4d97-469a-9298-136f9eb7fd3f,C3489532,C0026882,extract co-occurrences among ,Cone-Rod Dystrophy 2,Mutation,1,X,[dsyn],[genf],C11.270.152;C11.768.585.658.250;C16.320.290.152,G05.365.590
5147b38b-147a-4715-8f13-1e1cdf23920b,C3489532,SPARQL,first utilized SPARQL,Cone-Rod Dystrophy 2,SPARQL,1,X,[dsyn],????,C11.270.152;C11.768.585.658.250;C16.320.290.152,????
34bd9127-f9a0-4b69-9e36-de80116b4ce9,C3146294,C3241922,using Average ,Generation (action),Operation Activity,1,X,[acty],[acty],,
1f504e13-6d7e-4e81-be33-482780057e84,C0086312,C3146294,achieved precision For edge embeddings ,Forests,Generation (action),1,X,[npop],[acty],G16.500.275.157.437;N06.230.124.343,
fa82a424-be65-4e50-a82e-30936488a74b,C1511790,C1079230,is in their corresponding ,Detection,Subgroup A Nepoviruses,1,X,[topp],[virs],,
8944a0ab-cc8e-4557-ba80-0b2fed8c87cb,C3146294,C0206750,extract significant associations for ,Generation (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
422242ae-ed9b-45d4-b784-463df74ffe5a,C0042765,C0319157,AS virus as well by lower inocula,Virulence,AS virus,1,X,[biof],[virs],G06.930,
77a55f32-ef55-4054-9834-9a29eb860c82,C0042765,inocula,AS virus as well by lower inocula,Virulence,inocula,1,X,[biof],????,G06.930,????
c9e90a6a-b580-4245-9962-125be53720c0,C0022942,C0206419,may of may value during ,Lactoferrin,Genus: Coronavirus,1,X,[aapp/bacs],[virs],D08.811.277.656.300.760.471;D08.811.277.656.959.350.471;D12.776.157.427.750.249;D12.776.256.626.816.500.507;D12.776.377.457.507;D12.776.395.507;D12.776.556.579.750.249,B04.820.504.540.150
dcce8b59-31ae-48e0-ad37-ab8f4dbb9224,C1566558,C1706202,are of relevant interest in ,Natural Products,Search - action,2,X,[bacs],[acty],D20.215,
ff5c6d4f-7bce-4643-a925-cec3a36d91f7,C1566558,C1718097,are of relevant interest in ,Natural Products,New medications,2,X,[bacs],[phsu],D20.215,
f57ce427-6d05-4df5-aa43-7510fbf51a63,C2933176,C0325969,is common in legal ,buriti oil,Amazona,1,X,[orch/phsu],[bird],x.x.x.x,B01.050.150.900.248.710.672.050
a9c451fa-ba8c-4152-88a2-86ceb2ea5ef3,COVID-19,silico,was investigated using in silico ,COVID-19,silico,4,X,[virs],????,C000657245,????
8b4e9920-cb3c-406a-9709-fef62d69aa3e,C0005532,silico,was investigated using in silico ,biology (field),silico,4,X,[bmod],????,H01.158.273,????
9a2aae32-f173-44ed-80dd-c8a28cee4137,C0441655,silico,was investigated using in silico ,Activities,silico,4,X,[acty],????,,????
47c3a097-c866-490a-99fd-043c8e362272,C0542479,C0220781,is in 2GTB ,Energy Physics,Anabolism,1,X,[npop],[biof],,G03
15cd76c1-1da7-4d43-bc90-fef04041eb12,C0542479,2GTB,is in formation of 2GTB ,Energy Physics,2GTB,2,X,[npop],????,,????
40aa13e0-83de-446c-bdfb-0f97316f0a68,C0542479,C4327142,is in formation of 2GTB ,Energy Physics,peptidase complex,2,X,[npop],[celc],,
3e56d47c-ab2e-4ec2-9b01-f57d674e51c1,C0542479,C1742862,is with 13 ,Energy Physics,CISH protein human,2,X,[npop],[aapp/bacs],,
484cff6b-4542-4f73-9f1b-0e4b905392b2,C0872152,COVID-19,is with ,Drug Development,COVID-19,2,X,[bmod],[virs],E05.290;H01.158.703.007.338;H01.181.466.338,C000657245
f50e6cc5-5da5-433c-8ec2-7a8ad79f4eef,C0949266,remdesivir, includes ,Therapies Investigational,remdesivir,1,X,[topp],[clnd],E02.931,
a556b6ed-5a72-46d4-a841-faacd4caf66f,C0683465,remdesivir, includes ,novel AODU treatment method,remdesivir,1,X,[topp],[clnd],,
8b8a2d17-ba25-4d0c-843c-febcd67e29a1,C0206419,C0020538,is with ,Genus: Coronavirus,Hypertensive disease,1,X,[virs],[dsyn],B04.820.504.540.150,C14.907.489
15f7c063-3760-4537-989d-679ce62008e5,C0024109,C0009450,are main ,Lung,Communicable Diseases,1,X,[bpoc],[dsyn],A04.411,C01.539.221
15f7c063-3760-4537-989d-679ce62008e5,C0024109,C0009450,involved in ,Lung,Communicable Diseases,1,X,[bpoc],[dsyn],A04.411,C01.539.221
d688c4f9-6d1f-4907-bfbd-d5023e5248dd,C0206419,C0178784,triggers mechanisms main ,Genus: Coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150,
d688c4f9-6d1f-4907-bfbd-d5023e5248dd,C0206419,C0178784,affecting most ,Genus: Coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150,
e536b9dd-3d2e-4057-b143-c49448323217,C0939237,C3652465,combined with ,lopinavir / Ritonavir,Interferon,1,X,[phsu],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
545535aa-2e94-41fd-a3ae-2fd153cc035f,C0013227,C3652465,include ,Pharmaceutical Preparations,Interferon,1,X,[phsu],[aapp/imft/phsu],D26,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
476a2df2-186c-43bc-84b2-9e2b806cc7d7,C0199176,C0206419,are critical need With rise of ,Prophylactic treatment,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
476a2df2-186c-43bc-84b2-9e2b806cc7d7,C0199176,C0206419,is in moderate-to-severe onco ,Prophylactic treatment,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
b95ed826-0ce2-46dd-ae41-12c7398f0364,C0206419,C0751956,may may also complicated with ,Genus: Coronavirus,Acute Cerebrovascular Accidents,1,X,[virs],[dsyn],B04.820.504.540.150,C10.228.140.300.775;C14.907.253.855
b9edac62-5eda-4689-b5ae-6135b2b56787,C0005532,C1705178,associated with comorbidities ,biology (field),Order (action),1,X,[bmod],[acty],H01.158.273,
0d6d75ce-d445-4058-9c99-300eff56ea93,C0009450,C0029341, includes ,Communicable Diseases,Orthomyxoviridae,1,X,[dsyn],[virs],C01.539.221,B04.820.545
15a69586-bce6-4673-949b-f54eb78dbf9e,C0024264,C2062441,were higher compared with ,Lymphocyte,Influenza A,2,X,[cell],[dsyn],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
0af2d6aa-dca1-4b74-b3a7-194afc7320c8,C0206419,C0023516,showed significantly lower levels of ,Genus: Coronavirus,Leukocytes,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637;A15.145.229.637;A15.382.490
0af2d6aa-dca1-4b74-b3a7-194afc7320c8,C0206419,C0023516,Show levels of,Genus: Coronavirus,Leukocytes,1,X,[virs],[cell],B04.820.504.540.150,A11.118.637;A15.145.229.637;A15.382.490
2b5c43f6-5408-4ea4-ac11-cc101556a144,C0275522,C0012634,ratio of is In fact useful indicator of burden of ,Asymptomatic Infections,Disease,1,X,[dsyn],[dsyn],C23.550.291.187.500,C23.550.288
0dde216d-2cab-403c-aef0-038c2983a650,C1948023,C0520510,design ,Stimulation (motivation),Materials,1,X,[npop],[sbst],,
d9bd0bf9-345f-4929-8aa7-ed761acf3428,C0301872,C1175743,would find applications in context of vaccine development for ,Immune response,SARS coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150.113.937
d9bd0bf9-345f-4929-8aa7-ed761acf3428,C0301872,C1175743,Pathogenesis against,Immune response,SARS coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150.113.937
f9aa85d3-da59-4317-a29f-639e5049e0ba,C0032285,C0026766,is with ,Pneumonia,Multiple Organ Failure,1,X,[dsyn],[patf],C08.381.677;C08.730.610,C23.550.835.525
5c54f124-d984-4a0b-a19b-06411033da27,C1457887,C4521554,comorbidities on ,Symptoms,Time of intubation:TmStp:Pt:^Patient:Qn,2,X,[sosy],[clna],,
f789d7a6-7b88-4f9d-858f-e890dae569ed,C1265799,C1175743,is in patient with presumed ,Massive embolus,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
f807428d-88c3-4138-8bb9-2daf686e3e06,C0021403,C0719214,have occurred for many ,Influenza virus vaccine,century,1,X,[imft/phsu],[phsu/vita],D20.215.894.899.302,
d68bedce-0490-463b-95e5-3f72812d6205,C0037356,C0719214,have occurred for many ,Smallpox Viruses,century,1,X,[virs],[phsu/vita],B04.280.650.160.650.930,
a4bbb7da-0e7b-4499-a215-bc559dac158a,C0032064,C0719214,have occurred for many ,Plague,century,1,X,[dsyn],[phsu/vita],C01.252.400.310.980.745,
3e0dc3f0-a907-46be-aff4-164f8e4c0f43,C1175175,C0042776,counter ,Severe Acute Respiratory Syndrome,Virus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04
3e0dc3f0-a907-46be-aff4-164f8e4c0f43,C1175175,C0042776,is with authentic patient-derived ,Severe Acute Respiratory Syndrome,Virus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04
ace442dd-6bc4-46df-b81f-201c332d48c5,C0028429,C0013404,is complicated by ,Nose,Dyspnea,1,X,[bpoc],[sosy],A01.456.505.733;A04.531;A09.531,C08.618.326;C23.888.852.371
d1d47cc2-90f6-4cfd-b52f-0ceb6f89e6cf,C0040732,C0206419,is in ,Transplantation,Genus: Coronavirus,1,X,[topp],[virs],E04.936,B04.820.504.540.150
b8b0d575-8bab-468c-ba9a-17645648c9c0,C0020119,C1415647,is in ,Human Development,HNRNPM gene,1,X,[phsf],[gngm],F01.525;G07.345.374,
c70f32cf-bf10-4f82-8bcc-739ef683af60,C1457887,C0037090,are mainly ,Symptoms,Signs and Symptoms Respiratory,1,X,[sosy],[sosy],,C23.888.852
d1392bd1-6d21-44c6-ac65-753041c59ad1,C0231528,C0027765,was most common ,Myalgia,nervous system disorder,2,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C10
83535fa7-b69c-4d2e-8da5-0131c34e3e3f,C0231528,C0018681,was most common ,Myalgia,Headache,1,X,[sosy],[sosy],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C23.888.592.612.441
32491bf2-ac5f-4483-b1fc-96184a744b58,C0027765,C0018681,followed by ,nervous system disorder,Headache,2,X,[dsyn],[sosy],C10,C23.888.592.612.441
8fbdd5fa-3ca3-4c97-8b0b-53a5fd75d68f,C0242781,C0439962,was Besides imported cases ,disease transmission,Mixture,3,X,[patf],[sbst],N06.850.310,
567c80b4-62bc-454d-b59e-e46881de7d51,C0013604,C0302158,Leucocytic infiltrate of,Edema,Leucocytic infiltrate,1,X,[sosy],[patf],C23.888.277,
347ab01f-acf9-44b1-8aed-e656e4d4e51a,C1515933,C0302158,of Edema is,Alveolus,Leucocytic infiltrate,1,X,[bpoc],[patf],,
48ac30b0-25da-4a11-b41f-05c2eb9a9b01,C0302158,C0439861,mainly consisted in interstitial ,Leucocytic infiltrate,Substance,1,X,[patf],[sbst],,
63718a41-3dd6-47d8-b0b0-62761825d727,C0302158,C0024432,mainly consisted of ,Leucocytic infiltrate,macrophage,1,X,[patf],[cell],,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
cfd3d984-fb92-4858-9d1b-943d643b4865,C0042769,C0018787,often affected ,Virus Diseases,Heart,1,X,[dsyn],[bpoc],C02,A07.541
b79d31fe-b966-4a96-86cd-a8eb2a813304,LTCF,C1705178,is in ,LTCF,Order (action),1,X,????,[acty],????,
a2af6a03-b212-43d3-8002-0d123b83369f,C0040300,C0206750,known comorbidities of ,Body tissue,Coronavirus Infections,1,X,[tisu],[dsyn],A10,C02.782.600.550.200
13383242-579b-436b-8995-44d39a65c484,C0567416,C0014609,were expressed in ,Molecule,Epithelium,1,X,[sbst],[tisu],,A10.272
24c0c6ac-5bc1-4f5d-a92c-45642f556a2b,C0567416,C4330475,were expressed in ,Molecule,Immune Cell,1,X,[sbst],[cell],,
f5a1578b-d03f-4e9f-80c2-04e6547d5573,C0004096,C0022709,generally led to higher expression of ,Asthma,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,D08.811.277.656.350.350.687
52af0f7e-540b-44ca-a6ff-88da7bede62b,C0024117,C0022709,generally led to higher expression of ,Chronic Obstructive Airway Disease,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C08.381.495.389,D08.811.277.656.350.350.687
5a7e00eb-7704-4cb2-a647-5b75b2085acb,C0020538,C0022709,generally led to higher expression of ,Hypertensive disease,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C14.907.489,D08.811.277.656.350.350.687
9dbac83c-efad-4ec1-92eb-83c20f5ec8ea,C1175175,C4330475,is in ,Severe Acute Respiratory Syndrome,Immune Cell,1,X,[dsyn],[cell],C02.782.600.550.200.750;C08.730.730,
64be53ba-4815-4646-bd31-ea69437ed987,C3176928,C0206750,might contribute to ,Condition status,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
f9041375-b4e5-49d2-85a4-24905a9cc73c,C0597360,C0206750,might contribute to ,receptor expression,Coronavirus Infections,1,X,[genf],[dsyn],,C02.782.600.550.200
e3dfec4e-34af-4f4d-be8d-9e8284709f04,C0079189,C0014038,contributes to ,cytokine,Encephalitis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C10.228.140.430
db505e39-2d3d-4905-aa66-3d87cc403a23,C0014038,C0679861,may Providing (action) clues to,Encephalitis,Complications of treatment,2,X,[dsyn],[patf],C10.228.140.430,
db505e39-2d3d-4905-aa66-3d87cc403a23,C0014038,C0679861,may provide significant clues to ,Encephalitis,Complications of treatment,2,X,[dsyn],[patf],C10.228.140.430,
21e0c1e2-9784-4a5f-b573-24862b43fe0c,C0014038,C1175743,may Providing (action) clues to,Encephalitis,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.430,B04.820.504.540.150.113.937
21e0c1e2-9784-4a5f-b573-24862b43fe0c,C0014038,C1175743,may provide significant clues to ,Encephalitis,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.430,B04.820.504.540.150.113.937
8736e04b-8e57-4039-b1bc-6c1d922959f4,C0679861,C1175743,caused by ,Complications of treatment,SARS coronavirus,2,X,[patf],[virs],,B04.820.504.540.150.113.937
dd04b88b-281e-41dc-8a4a-67d86a9aefb3,C0078057,C0014038,probably plays role in ,vascular factor,Encephalitis,8,X,[aapp],[dsyn],x.x.x.x,C10.228.140.430
56986e81-f2fb-44b5-bf0e-2f18ead14c3c,C0078057,C2949735,facilitating ,vascular factor,Recruitment,4,X,[aapp],[acty],x.x.x.x,
0d8782a2-d430-48fc-a7c6-ba494bb92846,C0078057,C0440752,facilitating ,vascular factor,Inflammatory cell,4,X,[aapp],[cell],x.x.x.x,
66004912-317f-4d52-99b0-ce8875dd8882,C0078057,C1113649,regulating level of ,vascular factor,Angiopoietins,2,X,[aapp],[aapp/bacs],x.x.x.x,D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100
5bdeb061-1b05-4e74-bf54-ef6e510a4d69,C0078057,C0006104,is distributed in ,vascular factor,Brain,2,X,[aapp],[bpoc],x.x.x.x,A08.186.211
984a9a1f-7355-44b2-9d20-5a4d846d03b2,C1113649,C1175743,Also is considered as products of ,Angiopoietins,SARS coronavirus,2,X,[aapp/bacs],[virs],D12.644.276.100.100;D12.776.467.100.100;D23.529.100.100,B04.820.504.540.150.113.937
e7629b2d-ea32-449d-9d4d-ead4ab770c6c,C1175175,C0235031,is with ,Severe Acute Respiratory Syndrome,Neurologic Symptoms,2,X,[dsyn],[sosy],C02.782.600.550.200.750;C08.730.730,C10.597;C23.888.592
c9bfefb6-0b9f-483f-a0d6-8091e4fc9008,C1705178,C1175743,support Organ Transplantation in even,Order (action),SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
a417cea9-0144-48c3-8403-88af6056d603,C1705178,C0029216,support continued ,Order (action),Organ Transplantation,1,X,[acty],[topp],,E04.936.450
afa93938-0d70-4a6b-80f7-be7765095561,C1704259,C0029216,support continued ,Biochemical Pathway,Organ Transplantation,1,X,[moft],[topp],,E04.936.450
a6513a91-805d-411d-bb91-fd7f39cb62ad,C1290857,C0012634,is with ,Disorder of face,Disease,1,X,[dsyn],[dsyn],,C23.550.288
5a0fcafe-16ec-407d-be3a-0de672ac2409,C0221423,C0012634,is with ,Illness (finding),Disease,1,X,[sosy],[dsyn],,C23.550.288
f8610d62-55cf-4187-87c2-7ec9990dd9e5,C0086982,C0007595,implicated in aberrant ,Signal Transduction Pathways,cell growth,2,X,[moft],[celf],G02.111.820;G04.835,
24c805e5-649a-41f6-97a8-eba028c2e12d,C0079189,C0301872,weakens ,cytokine,Immune response,1,X,[aapp/imft],[ortf],D12.644.276.374;D12.776.467.374;D23.529.374,
e270073f-df58-4fa7-97ad-3ead0662c259,C0079189,C0027651,weakens ,cytokine,Neoplasms,1,X,[aapp/imft],[neop],D12.644.276.374;D12.776.467.374;D23.529.374,C04
bf067daf-ee14-4db9-9097-e19377fed72a,C0206750,C3714514,may need monitored post ,Coronavirus Infections,Infection,2,X,[dsyn],[patf],C02.782.600.550.200,C01.539
bf067daf-ee14-4db9-9097-e19377fed72a,C0206750,C3714514,causing cluster ,Coronavirus Infections,Infection,1,X,[dsyn],[patf],C02.782.600.550.200,C01.539
3e64dac4-e220-41be-9df3-890c9ff1edb7,C0319157,C0032285,was identified in outbreak of ,AS virus,Pneumonia,2,X,[virs],[dsyn],,C08.381.677;C08.730.610
d64ef75e-1d27-442b-b77e-069f5c271c2f,C0011682,wetted,using sessile wetted ,Desiccation,wetted,1,X,[npop],????,E05.196.335;G02.176,????
e8cca9ac-c008-4df6-ac0a-5ee75011fa6a,C0006145,GGO,are areas of GGO,Breast Diseases,GGO,1,X,[dsyn],????,C17.800.090,????
2a485c04-320e-41c4-a340-0f1b02eb50cb,C0206419,C0857828,is in ,Genus: Coronavirus,infection in the elderly,1,X,[virs],[dsyn],B04.820.504.540.150,
60b030aa-2a1e-4dd8-b389-75b1cb84c4c9,C0206419,C0277562,is in ,Genus: Coronavirus,Adult disease,1,X,[virs],[dsyn],B04.820.504.540.150,
9741a610-96f9-4031-88e2-594b881327fc,C4050231,C0206419,is in ,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
64204605-5f17-43c0-9bb6-e831d76d6f11,C0014507,C0012655,is mathematical model based on ,Epidemiology,Disease susceptibility,2,X,[bmod],[clna],H02.403.720.500,C23.550.291.687;G07.100.250
1bd468d0-cb3b-4f02-bb04-703ab0eb85e8,C3826426,C0012655,is mathematical model based on ,Dynamics,Disease susceptibility,2,X,[npop],[clna],,C23.550.291.687;G07.100.250
e1b26f27-32cd-4f89-bca3-3879b2e1ce01,C0014507,C0009450,is mathematical model based on ,Epidemiology,Communicable Diseases,2,X,[bmod],[dsyn],H02.403.720.500,C01.539.221
954c1eb6-6a30-4e71-b6e1-cf4fc953354d,C3826426,C0009450,is mathematical model based on ,Dynamics,Communicable Diseases,2,X,[npop],[dsyn],,C01.539.221
0401f69f-7654-457c-a18b-48d2b1dff8cf,C0014507,C0237820,is mathematical model based on ,Epidemiology,Recovery - action,2,X,[bmod],[acty],H02.403.720.500,
34f9f822-b129-49db-b43d-a942b414435c,C3826426,C0237820,is mathematical model based on ,Dynamics,Recovery - action,2,X,[npop],[acty],,
bef33bc1-52d4-4f97-9c37-124b43f10aeb,C1515884,C0206419,can cure ,Acupuncture and Oriental Medicine,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
0b13e87a-1e58-4448-8bbb-86dba76dd439,C1175743,C0075804,encode ,SARS coronavirus,TANDEM,2,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
c09ab8fa-f419-4812-958f-cdd2b3a6abdc,C1175743,C0582263,encode TANDEM macrodomains within non,SARS coronavirus,Structural protein,2,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,
dd2b5b5f-5ddd-46bb-989a-cc33611022b5,Mac1,C0960756,implicating domain as ,Mac1,factor A,2,X,????,[orch],????,x.x.x.x
18528bf4-8bfa-4613-b4d8-09f6cf1cb9c8,Mac1,C0042765,implicating domain as ,Mac1,Virulence,1,X,????,[biof],????,G06.930
7d48c154-aec4-411e-9042-ebe840a07d34,Mac1,C0699748,is essential for ,Mac1,Pathogenesis,1,X,????,[patf],????,
35d75faa-b1aa-45d5-bbac-d8e7515f63e4,Mac1,C0599779,is essential for ,Mac1,Animal Model,1,X,????,[anim],????,E05.598
bc820940-0662-4114-9f86-dbff40893bda,Mac1,C0009450,is essential for ,Mac1,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
d3a57216-1c1c-488d-aff4-920cc5c0e448,C0699748,C0599779,is in multiple ,Pathogenesis,Animal Model,1,X,[patf],[anim],,E05.598
fc0fcaf3-4758-47be-a1db-a35f0f249cb0,C0699748,C0009450,is in multiple ,Pathogenesis,Communicable Diseases,1,X,[patf],[dsyn],,C01.539.221
d704331f-6d54-4c1e-b3de-3e3c31ec8a54,C0033666,C0301872,is part of ,Post-Translational Protein Processing,Immune response,1,X,[moft],[ortf],G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600,
d683e6a3-5807-47c7-a579-ea8506ec0dd6,C0033666,C0042769,is part of ,Post-Translational Protein Processing,Virus Diseases,1,X,[moft],[dsyn],G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600,C02
c5b2dfdb-c0be-4952-86bd-6b44f7d73265,C1704241,C0001461,is with ,complex (molecular entity),Adenosine Diphosphate Ribose,2,X,[chvs],[bacs/nnon],,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
05286172-1d0d-4698-b081-02cfbed8bcee,Mac1,C1704241,is in ,Mac1,complex (molecular entity),2,X,????,[chvs],????,
a938179d-85bd-43c2-9c2e-bcdce196f75f,Mac1,C0001461,is in ,Mac1,Adenosine Diphosphate Ribose,2,X,????,[bacs/nnon],????,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
05052688-e984-4943-9417-5d7fc091daa0,C3694279,C1707455,shown by structural ,Middle East Respiratory Syndrome,Comparison,1,X,[dsyn],[acty],C02.782.600.550.200,
82cb554d-d872-47f0-9177-2fb581bfd60d,C0206419,C0033666,removes ,Genus: Coronavirus,Post-Translational Protein Processing,1,X,[virs],[moft],B04.820.504.540.150,G02.111.660.871.790.600;G02.111.691.600;G03.734.871.790.600;G05.308.670.600
a67382b9-16b7-451a-b580-efdb6f066ba5,C0206419,C0001461,removes ,Genus: Coronavirus,Adenosine Diphosphate Ribose,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D03.633.100.759.646.138.124.070.125;D09.408.620.569.070.125;D13.695.667.138.124.070.125;D13.695.827.068.124.070.125;D13.695.827.708.070.125
d7cdcdea-f1de-49c9-aff5-5486112a88d8,C0206419,C0033684,removes Adenosine Diphosphate Ribose from,Genus: Coronavirus,Proteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D12.776
250c791a-4884-4629-9c4b-03290365a2cc,C1514562,C0699748,is essential for CoV ,Protein Domain,Pathogenesis,1,X,[amas],[patf],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
6d593307-b26f-4a0c-a3a7-352369178baa,C1514562,C0087111,may may novel ,Protein Domain,Therapeutic procedure,1,X,[amas],[topp],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,E02
0ae8754f-1daf-40f0-b105-dbee4a734396,C0020964,C0003320,exposure sunlight exposure to various ,Immunity,Antigens,3,X,[phsf],[imft],G12.450,D23.050
9305e2aa-9d4e-43f7-9c9a-d19b4ad64253,C0025594,C1825598,may have ,Meteorological Factors,IMPACT gene,3,X,[npop],[gngm],G16.500.750;N06.230.300,
9f776520-6027-4b31-9890-c6b1c5bf6d24,C0025594,C1175743,may have ,Meteorological Factors,SARS coronavirus,3,X,[npop],[virs],G16.500.750;N06.230.300,B04.820.504.540.150.113.937
55e82332-395b-421b-8bf2-9c18c4ffad50,C0020964,C1825598,may have ,Immunity,IMPACT gene,3,X,[phsf],[gngm],G12.450,
5a0d4aa6-853a-446a-beb8-bc6bd00de62a,C0391001,C0237820,is with satisfactory ,peginterferon alfa-2a,Recovery - action,1,X,[aapp/imft/phsu],[acty],x.x.x.x,
245d1509-3675-4d19-a6b6-3e65919b8f38,C0700271,C0525033,receptor by,M Protein multiple myeloma,Probiotics,1,X,[aapp/imft],[bact],x.x.x.x,G07.203.300.456.500;J02.500.456.500
92d8fdbb-0964-4572-acd0-5352a1079938,C1522002,C0567416,counter effect of ,RNA Recognition Motif,Molecule,1,X,[aapp/bacs],[sbst],G02.111.570.820.709.275.500.869.500,
422ccab9-8d79-408c-9bd4-84057b296d7a,C1522002,C4281807,Vitronectin human of S,RNA Recognition Motif,Vitronectin human,1,X,[aapp/bacs],[aapp/bacs],G02.111.570.820.709.275.500.869.500,
88226bb1-880c-496f-a8f3-60e7793177dc,C1522002,C0022709,Vitronectin human with,RNA Recognition Motif,Peptidyl-Dipeptidase A,1,X,[aapp/bacs],[aapp/enzy/imft],G02.111.570.820.709.275.500.869.500,D08.811.277.656.350.350.687
c32d7146-8992-4965-905c-c4de0369a67b,C1522002,C0597357,Vitronectin human with,RNA Recognition Motif,receptor,1,X,[aapp/bacs],[aapp/rcpt],G02.111.570.820.709.275.500.869.500,
5169fc72-f89a-433b-9d93-4118f7d1fe1e,C4281807,C0597357,is with ,Vitronectin human,receptor,3,X,[aapp/bacs],[aapp/rcpt],,
5a17dc10-4f5e-4161-8736-1ab34436bd59,C0206419,C0815353,is in ,Genus: Coronavirus,Male external urethral sphincter,1,X,[virs],[bpoc],B04.820.504.540.150,
89acbd33-e205-449b-a0cb-9cfa211968ab,C0042769,C0150755,calls for extended ,Virus Diseases,Safety precautions,1,X,[dsyn],[topp],C02,
cccc6bbb-cf53-4d03-9a68-96234f1b4b22,C0083528,C0935989,managed with ,N(6)-carboxymethyllysine,imatinib,1,X,[aapp/bacs],[orch/phsu],x.x.x.x,
2bcb86c3-1f19-4605-a957-323cc371f174,bullous,C0041834,is with ,bullous,Erythema,1,X,????,[dsyn],????,C17.800.229;C23.888.885.328
c9aa9c3a-4842-4273-9179-a2e06b96b4ee,C0041755,C0041834,is with ,Adverse reaction to drug,Erythema,1,X,[patf],[dsyn],C25.100,C17.800.229;C23.888.885.328
54f3e32f-68a2-4a61-a868-758bb9bc5966,C0206419,C0042077,is in also ,Genus: Coronavirus,Urology,1,X,[virs],[bmod],B04.820.504.540.150,H02.403.810.860
1637013b-9792-4d94-bc9d-85096db3a041,C0001443,C0001471,counteracts effects by ,Adenosine,Receptors Purinergic P1,1,X,[bacs/nnon/phsu],[aapp/rcpt],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,D12.776.543.750.695.700.700;D12.776.543.750.720.700.700
d1e3f796-68c8-433b-ab77-78080c5adc0b,C0001443,C1948023,counteracts effects by ,Adenosine,Stimulation (motivation),1,X,[bacs/nnon/phsu],[npop],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,
d7c1445e-5277-48ae-9221-5b4f08654ea1,C0001443,C0004482,counteracts ,Adenosine,Azathioprine,1,X,[bacs/nnon/phsu],[hops/orch/phsu],D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111
b759d71f-d2ef-4f0c-bb85-a00abe7de749,C1325584,C0006826,are critical ,lateral element,Malignant Neoplasms,1,X,[celc],[neop],,C04
33d8a673-8089-4ac0-9e43-6175b3622bb6,C0015967,C0850149,is with ,Fever,Dry cough,1,X,[sosy],[sosy],C23.888.119.344,
a78be016-9826-401c-83a9-1788967804ba,C0242184,C0850149,is with ,Hypoxia,Dry cough,1,X,[patf],[sosy],C23.888.852.079,
8e2a7273-fa36-4dc6-a3dd-db5f8b22c3f6,C3274800,C0206419,prevalence of ,Disease Presentation,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
a4b473fb-9336-425e-8820-9ce15b66b393,C0206419,C0010340,developed ,Genus: Coronavirus,Critical Illness,1,X,[virs],[dsyn],B04.820.504.540.150,C23.550.291.625
4c0de315-31b0-4b43-90b4-5c40fd895459,C1000689,C0206419,M of ,Clerodendrum,Genus: Coronavirus,1,X,[plnt],[virs],B01.650.940.800.575.912.250.583.520.121,B04.820.504.540.150
d59cf891-c924-438b-be7d-7812c39775db,C0075816,C0597400,displaying efficacy with concerned,taraxerol,respiratory protein,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,
4d7ec3bd-b825-4409-a7df-3c26c51ef724,C0075816,C4050231,exhibited better ,taraxerol,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[orch/phsu],[clna],x.x.x.x,
2d77abcf-130c-401b-bd6c-57e1ad6dfefe,C0206419,C0850624,is emergent ,Genus: Coronavirus,cardiovascular risk factor,1,X,[virs],[dsyn],B04.820.504.540.150,
e2328417-ed12-447f-92b7-9df0b5d47021,C0206419,C0314732,is novel ,Genus: Coronavirus,Infectious agent,1,X,[virs],[orgm],B04.820.504.540.150,
0416db7c-b7af-4a84-b56e-b095d4e4c89b,C0206419,C0225336,affecting ,Genus: Coronavirus,Endothelial Cells,1,X,[virs],[cell],B04.820.504.540.150,A11.436.275
ed10fb5e-c148-46df-99c7-99c08bc80994,C0206419,C0598197,is novel pandemic ,Genus: Coronavirus,contagion,1,X,[virs],[npop],B04.820.504.540.150,
ed10fb5e-c148-46df-99c7-99c08bc80994,C0206419,C0598197,is highly ,Genus: Coronavirus,contagion,1,X,[virs],[npop],B04.820.504.540.150,
7b838ee2-39ba-47a1-8bd1-9e3850d86bad,C0012634,C0598197,is novel pandemic ,Disease,contagion,1,X,[dsyn],[npop],C23.550.288,
7b838ee2-39ba-47a1-8bd1-9e3850d86bad,C0012634,C0598197,is highly ,Disease,contagion,1,X,[dsyn],[npop],C23.550.288,
31910a5d-46cb-45d6-b748-6956a978f186,C0598197,C0015967,frequently presents with ,contagion,Fever,1,X,[npop],[sosy],,C23.888.119.344
4911be05-fb16-4569-b615-b7c464194c32,C0035668,C0026809,is in ,RNA,Mus,1,X,[nnon],[mamm],D13.444.735,B01.050.150.900.649.313.992.635.505.500
7728caf4-0a1f-4afd-abfe-bfdf011f98fa,situ,C0026809,is in ,situ,Mus,1,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.500
01862c8f-c193-4f8d-9748-f6ed66b721c7,C0206419,C1742865,colocalized with ,Genus: Coronavirus,TMPRSS2 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150,x.x.x.x
413919ca-b51a-42a6-bdf0-77aa5890a427,C0035668,C1742865,colocalized with ,RNA,TMPRSS2 protein human,1,X,[nnon],[aapp/enzy],D13.444.735,x.x.x.x
5846f141-87e4-43f2-9377-ba2e7bc02c31,C0206419,C0035696,colocalized with ,Genus: Coronavirus,RNA Messenger,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D13.444.735.544
ad768ed7-ab90-4d52-affe-5a908bac8022,C0035668,C0035696,colocalized with ,RNA,RNA Messenger,1,X,[nnon],[bacs/nnon],D13.444.735,D13.444.735.544
a342e8a5-658b-41e5-a7ab-04fc7728b9d9,C0035668,C0024109,colocalized in ,RNA,Lung,1,X,[nnon],[bpoc],D13.444.735,A04.411
89cfdd62-0058-4f95-93db-355c1caa288d,C0206419,C4289682,may involve ,Genus: Coronavirus,Direct Transmission,2,X,[virs],[patf],B04.820.504.540.150,
e7b80243-4da2-4bc1-8466-a6675bc34fbc,C0206419,C0024141,is in patients with ,Genus: Coronavirus,Lupus Erythematosus Systemic,4,X,[virs],[dsyn],B04.820.504.540.150,C17.300.480;C20.111.590
d1712d10-28a1-4e7f-b205-33a40e656b78,C0206419,C0684249,is in patients with ,Genus: Coronavirus,Carcinoma of lung,2,X,[virs],[neop],B04.820.504.540.150,
85413b3e-29fe-4cc3-a368-8699312a946e,C0684249,C0015967,is with ,Carcinoma of lung,Fever,2,X,[neop],[sosy],,C23.888.119.344
f0f1cc44-7fb7-4884-9f4c-4ee420d527c3,C0206419,C0012655,raised many questions about higher ,Genus: Coronavirus,Disease susceptibility,1,X,[virs],[clna],B04.820.504.540.150,C23.550.291.687;G07.100.250
7c50c4c8-304a-4b1a-b774-3aa3b47ad117,C1565489,C0206750,could potentially induce more complications in patients with ,Renal Insufficiency,Coronavirus Infections,4,X,[dsyn],[dsyn],C12.777.419.780;C13.351.968.419.780,C02.782.600.550.200
91afbcde-0ea0-465d-994d-2f7917a90561,C2948600,C0020538,summarize prevalence of ,Aim,Hypertensive disease,1,X,[inch/phsu],[dsyn],,C14.907.489
13add280-8fcd-4237-b38c-f3467b3562aa,C0302106,C0040034,account for delayed-phase ,Platelet destruction,Thrombocytopenia,2,X,[comd],[dsyn],,C15.378.140.855
9ed3832d-aa0d-46fd-9448-3e974a21196d,C0026187,C1254351,offers advantages compared to ,Minocycline,Pharmacologic Substance,2,X,[antb/orch],[phsu],D02.455.426.559.847.562.900.550;D04.615.562.900.550,
4bed17a2-13a6-485b-b2a0-53e4af36c755,C0206061,C0016059, includes ,Pneumonia Interstitial,Fibrosis,1,X,[dsyn],[patf],C08.381.483,C23.550.355
5e0960c1-dc80-4348-821c-3d92cf171e26,C1457887,C0206062,is in ,Symptoms,Lung Diseases Interstitial,6,X,[sosy],[dsyn],,C08.381.483
8fd40ebd-e560-471a-94b8-8c01d5974620,C0012655,C0010076,is in ,Disease susceptibility,Coronaviridae,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540
4589dfb1-4af1-450f-b0d2-dbbe61c8bd5c,C3652465,C0022709,highly upregulates ,Interferon,Peptidyl-Dipeptidase A,1,X,[aapp/imft/phsu],[aapp/enzy/imft],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D08.811.277.656.350.350.687
e76d2ddb-6cc4-43f8-882c-fe8faeb825b5,C0030946,C0026727,is part of T2 ,Endopeptidases,Mucous body substance,1,X,[aapp/enzy/phsu],[bdsu],D08.811.277.656.300,A12.200.503
f5e78045-839a-44fc-ae81-835991b2e145,C0030946,T2,is part of T2 ,Endopeptidases,T2,1,X,[aapp/enzy/phsu],????,D08.811.277.656.300,????
217be0e9-cdaf-40b1-9f4c-0f689b4e0c98,C0030946,C0021368,is part of T2 ,Endopeptidases,Inflammation,1,X,[aapp/enzy/phsu],[patf],D08.811.277.656.300,C23.550.470
f5689277-2af0-4ea4-939d-7bd832dde4b9,C0030946,C3266814,is part of T2 ,Endopeptidases,Action,1,X,[aapp/enzy/phsu],[acty],D08.811.277.656.300,
539cd3d3-854f-4616-9651-f760f1a4caca,C0030946,C0214743,is part of T2 ,Endopeptidases,Interleukin-13,1,X,[aapp/enzy/phsu],[aapp/imft],D08.811.277.656.300,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
d43d81a7-7cfe-4470-8acc-ad4f0e982bd3,C0206750,C0559758,can induce ,Coronavirus Infections,MULTISYSTEM DISORDER,1,X,[dsyn],[dsyn],C02.782.600.550.200,
88aa2d22-fefb-4162-8ce2-07cc934e7548,C0206750,C0005854,cross ,Coronavirus Infections,Blood - brain barrier anatomy,1,X,[dsyn],[bpoc],C02.782.600.550.200,A07.035;A08.186.211.035
b66c8883-7bcf-4f0d-88d5-600ad1921bd9,C1299575,C0206750,recommended for ,Treatment modification,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
17a078a8-dac3-446a-9513-5fe5aebd9b81,C1299575,C0021390,is in ,Treatment modification,Inflammatory Bowel Diseases,5,X,[topp],[dsyn],,C06.405.205.731;C06.405.469.432
bea8cdef-509d-4659-88b6-9ac79b3105c6,C0394664,C0184661,is effective ,Acupuncture procedure,Interventional procedure,1,X,[topp],[topp],E02.190.044,
b84a7f54-c5d8-4271-b735-14e7c882397b,C0394664,C0012634,is effective and safe Interventional procedure for,Acupuncture procedure,Disease,1,X,[topp],[dsyn],E02.190.044,C23.550.288
4ad36ecf-ca5a-4f92-abb9-c46321b70fa6,C0020852,C0206750,is in ,Immunoglobulin G,Coronavirus Infections,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,C02.782.600.550.200
dbae65e5-7f6b-4201-b61a-f92f576eeefa,C0012634,COVID19,significantly increase COVID19,Disease,COVID19,1,X,[dsyn],????,C23.550.288,????
2a55d04b-4ce3-4d46-ae17-13062aa5b3d8,C0006826,COVID-19,significantly increase COVID19,Malignant Neoplasms,COVID-19,1,X,[neop],[virs],C04,C000657245
1c57486f-782e-4857-8133-8f716a037c1a,C0006826,COVID19,significantly increase COVID19,Malignant Neoplasms,COVID19,1,X,[neop],????,C04,????
e31a921c-ab42-4127-8977-26ede8c52319,C0009450,enzyme2,is facilitated by angiotensinconverting enzyme2,Communicable Diseases,enzyme2,1,X,[dsyn],????,C01.539.221,????
36b86bbe-2ee7-4a6c-9485-ac963238df5b,C0009450,C0022709,is facilitated by ,Communicable Diseases,Peptidyl-Dipeptidase A,1,X,[dsyn],[aapp/enzy/imft],C01.539.221,D08.811.277.656.350.350.687
44c2c86e-ed7d-447e-825a-5fd957e26af0,C0009450,C0006826,is in ,Communicable Diseases,Malignant Neoplasms,1,X,[dsyn],[neop],C01.539.221,C04
2282efb0-cb2e-4149-bb0b-f7534d34f64b,C0127400,C0006826,is in ,Mediator brand of benfluorex hydrochloride,Malignant Neoplasms,1,X,[orch/phsu],[neop],,C04
affd438b-0d1f-4167-8af9-30db62ef582a,C0030946,C0279671,was overexpressed in ,Endopeptidases,Cervical Squamous Cell Carcinoma,2,X,[aapp/enzy/phsu],[neop],D08.811.277.656.300,
b8d4e574-e5f8-4140-a285-38cee57d8628,C0030946,C0007112,was overexpressed with ,Endopeptidases,Adenocarcinoma of prostate,2,X,[aapp/enzy/phsu],[neop],D08.811.277.656.300,
1cc71918-6580-4031-8b9d-5350003a86a0,CTSL,C0598798,was upregulated in ,CTSL,Lymphoid neoplasm,1,X,????,[neop],????,
39d4dd7f-8ba2-4791-ae65-2f5b0a3ce8f2,CTSL,C0024299,was upregulated in ,CTSL,Lymphoma,1,X,????,[neop],????,C04.557.386;C15.604.515.569;C20.683.515.761
9fff4a39-e68f-4155-8018-51d87795d35d,C0024880,C4330475,are ,mast cell,Immune Cell,1,X,[cell],[cell],A11.329.427;A15.382.652,
6f3e9fc0-bc6f-4e84-ba47-e98de2e80a04,C0024880,C0920672,are ,mast cell,virus pathogenesis,2,X,[cell],[comd],A11.329.427;A15.382.652,
de6a8970-250c-4ee3-8611-b2d33af26b71,C0037473,C0024109,improve Mus Continuance of life in,Sodium,Lung,1,X,[bacs/elii],[bpoc],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,A04.411
de6a8970-250c-4ee3-8611-b2d33af26b71,C0037473,C0024109,improve Viral respiratory infection changes in,Sodium,Lung,1,X,[bacs/elii],[bpoc],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,A04.411
49d4d720-390e-4738-a930-e2aeadeb687e,C0037473,C0729531,improve Viral respiratory infection changes in,Sodium,Viral respiratory infection,3,X,[bacs/elii],[dsyn],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
9d33cefe-3782-4378-b5ee-c2b3e05f86d4,C0037473,C0220806,PREVENT (product) release of inflammatory,Sodium,Chemicals,1,X,[bacs/elii],[chem],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
d8c49c53-54fd-414a-9784-58e690d47567,C0037473,C0920880,described as MC ,Sodium,Stabilizer - function,1,X,[bacs/elii],[ortf],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
5b6364f2-a2fd-494c-8362-2e963d3e5cff,C0037473,C0026809,improve ,Sodium,Mus,1,X,[bacs/elii],[mamm],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,B01.050.150.900.649.313.992.635.505.500
1c8680b7-a24c-4fee-876c-981ba17055fb,C0037473,C0038952,improve ,Sodium,Continuance of life,1,X,[bacs/elii],[acty],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,I03.784
f39121e0-584b-44dd-8cc1-c8b24a00b739,C0069964,C0019868,is involved also in MCs ,palmidrol,Homeostasis,1,X,[orch],[biof],x.x.x.x,G07.410
ccfe2095-2bd9-4c85-864b-1b6a2d56df65,C0019868,C0042769,is with inhibitory effect on respiratory tract during ,Homeostasis,Virus Diseases,1,X,[biof],[dsyn],G07.410,C02
22aa28e0-961e-4189-b632-82a0203913e5,C0030738,C0024109,playing role in inflamed ,Peas - dietary,Lung,1,X,[food],[bpoc],B01.650.940.800.575.912.250.401.630,A04.411
2923ef84-5cde-42e3-9d4e-27dab693940f,C0030738,C0206750,playing role in inflamed ,Peas - dietary,Coronavirus Infections,1,X,[food],[dsyn],B01.650.940.800.575.912.250.401.630,C02.782.600.550.200
4d29771f-2dba-4c4d-9d1b-2e5c7c682a99,C0037473,C0127400,suppress pro-inflammatory ,Sodium,Mediator brand of benfluorex hydrochloride,1,X,[bacs/elii],[orch/phsu],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
b153ae18-d878-4f25-9f4a-3f1fa7b19f0c,C0037473,C1879547,suppress MC ,Sodium,Activation action,1,X,[bacs/elii],[acty],D01.268.549.750;D01.268.557.650;D01.552.528.850;D01.552.547.725;x.x.x.x,
b242813c-9277-459c-8efc-de75c8475bac,C0030738,C0127400,suppress pro-inflammatory ,Peas - dietary,Mediator brand of benfluorex hydrochloride,1,X,[food],[orch/phsu],B01.650.940.800.575.912.250.401.630,
c0db8259-ff93-4f07-8904-53adafad1300,C0030738,C1879547,suppress MC ,Peas - dietary,Activation action,1,X,[food],[acty],B01.650.940.800.575.912.250.401.630,
2dad1ec7-9e7b-42fb-a86b-3ae1d07e444c,C1175743,C0022742,has brought world to its ,SARS coronavirus,Knee,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,A01.378.610.450
c03018d7-d17f-4747-844a-2dbf63217f84,C0012634,C0022742,has brought world to its ,Disease,Knee,1,X,[dsyn],[bpoc],C23.550.288,A01.378.610.450
f815a06f-c020-4331-b3e0-ddd6127357aa,C0242821,C0206750,indicates sex differences in clinical outcomes of ,Human body,Coronavirus Infections,1,X,[humn],[dsyn],I01.076.201.450.560;K01.093.378,C02.782.600.550.200
4a06d7d9-2d53-4251-854e-b78a10e54803,C2745965,C0206750,caused by ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
4a06d7d9-2d53-4251-854e-b78a10e54803,C2745965,C0206750,is in patients with ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
4a06d7d9-2d53-4251-854e-b78a10e54803,C2745965,C0206750,should During pandemic should acquainted with ,Emergencies [Disease/Finding],Coronavirus Infections,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.600.550.200
d32115bc-e309-4c50-bb62-f2bd483f2cac,C0021966,durante,is in completo isolamento durante da ,Iodides,durante,1,X,[inch],????,D01.248.497.158.490;D01.475.410,????
d0a01d56-102b-4694-9f4a-0073b930223e,C0021966,C0023749,is in completo isolamento durante da ,Iodides,Linoleic Acid,1,X,[inch],[bacs/orch/phsu],D01.248.497.158.490;D01.475.410,D10.251.355.310.515.500;D10.251.355.343.500.500
e6f144f2-15de-4a57-9f6b-d41dd9d999f4,C0021966,da,is in completo isolamento durante da ,Iodides,da,1,X,[inch],????,D01.248.497.158.490;D01.475.410,????
07c4c997-bffc-4c05-8da8-b478dbec3471,TT,C0021966,Come comunicare con durante da ,TT,Iodides,1,X,????,[inch],????,D01.248.497.158.490;D01.475.410
5838a39f-efa9-416b-a1bb-295d8f4a5813,TT,durante,Come comunicare con durante da ,TT,durante,1,X,????,????,????,????
060aedc6-3637-4c9b-a4ab-47c5fbf35f9e,TT,C0023749,Come comunicare con durante da ,TT,Linoleic Acid,1,X,????,[bacs/orch/phsu],????,D10.251.355.310.515.500;D10.251.355.343.500.500
196302e0-13b1-46cd-9765-933f8fc32058,TT,da,Come comunicare con durante da ,TT,da,1,X,????,????,????,????
c91f2074-bab6-4389-a5f8-219d055b2710,TT,C0206750,Come comunicare con durante da ,TT,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
5aca3cc0-6bbe-4306-997c-9c2019d96025,C0039082,C1706374,is in ,Syndrome,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[dsyn],[aapp/bacs],C23.550.288.500,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
495f288d-1a1f-4cfd-9534-cbd0c4b9b56f,C0547605,C0309872,help ,prevention of infection,PREVENT (product),2,X,[topp],[phsu],,
3b3e78da-6a50-4f51-ab20-7b0861cc0ca1,C0547605,C0063034,becoming independent ,prevention of infection,huperzine B,2,X,[topp],[orch/phsu],,x.x.x.x
ea29768b-d3f3-4b30-be7e-43dd74181fe5,C0547605,C0242781,becoming independent ,prevention of infection,disease transmission,2,X,[topp],[patf],,N06.850.310
3a669be5-936f-4d2f-9312-cb02b93195c7,C0199176,LGBTQ,mitigate Psychological Trauma ramifications among LGBTQ,Prophylactic treatment,LGBTQ,2,X,[topp],????,,????
0a9494c5-65c2-4f5c-aa03-52d33d238c26,C0199176,C3203533,mitigate ,Prophylactic treatment,Psychological Trauma,4,X,[topp],[mobd],,F03.950.750.375
99d31a4e-6f72-43b3-9d69-ba83a4f65f81,C0574785,C0009830,is related to high ,Lower Urinary Tract Symptoms,Consumption of goods,1,X,[sosy],[acty],C23.888.942.343,
3847653d-3464-4422-8eb3-40eb681e7bc5,C0206058,C0543467,individualizing ,Elective Surgical Procedures,Operative Surgical Procedures,1,X,[topp],[topp],E04.249,E04
e7bc0175-67f7-41c9-a4ea-366b7a727f66,C0206058,C1707391,individualizing ,Elective Surgical Procedures,Choose (action),1,X,[topp],[acty],E04.249,
8b2d7e48-8673-4d1f-aec4-817f1dd7d735,C0270724,C0005528,use ,Infantile Neuroaxonal Dystrophy,Biological Transport,2,X,[dsyn],[celf],C10.228.140.744,G03.143
7920a02a-0cce-4b48-b85c-004464f8a145,C1880355,C0206750,is in patients with ,Discover,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
7920a02a-0cce-4b48-b85c-004464f8a145,C1880355,C0206750,improving diagnosis in ,Discover,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
ef489eea-3c87-4d0b-88cc-9c2da391765e,physico,C1179907,enable diffuse passively through ,physico,Wall of endosome,1,X,????,[celc],????,
3953335a-f80c-4b60-847f-78c07f0b9f4f,C0243178,C1179907,enable diffuse passively through ,chemical properties,Wall of endosome,1,X,[npop],[celc],,
660e850f-11eb-4f15-b641-ee2834e1730e,physico,C1659610,undergo trapping in ,physico,vesicle lumen,2,X,????,[celc],????,
7eaa9232-1a65-469a-bc53-9e43fb5cc6cd,C0243178,C1659610,undergo trapping in ,chemical properties,vesicle lumen,2,X,[npop],[celc],,
5124c2aa-2c07-4185-aba5-ed8fe3b8a985,C1947930,C0309872,Aim to,Cleaning (activity),PREVENT (product),2,X,[acty],[phsu],,
4cb7841c-fe8f-484f-b8c0-f04b196b7af0,C0184661,C0309872,Aim to,Interventional procedure,PREVENT (product),2,X,[topp],[phsu],,
c48c6d1b-d3d2-4e2a-afd2-1e80dda54690,C1947930,C0445623,Aim regardless of,Cleaning (activity),Microorganism,2,X,[acty],[orgm],,
59e92f67-72da-4cc4-9489-4e819cd09220,C0184661,C0445623,Aim regardless of,Interventional procedure,Microorganism,2,X,[topp],[orgm],,
b197f79f-7d3a-4f8d-bf50-05499b1ed0cf,C1175175,C0719214,is third zoonotic ,Severe Acute Respiratory Syndrome,century,1,X,[dsyn],[phsu/vita],C02.782.600.550.200.750;C08.730.730,
b197f79f-7d3a-4f8d-bf50-05499b1ed0cf,C1175175,C0719214,is third Coronavirus Infections identified during twentyfirst,Severe Acute Respiratory Syndrome,century,3,X,[dsyn],[phsu/vita],C02.782.600.550.200.750;C08.730.730,
95e79ab4-4f8e-4851-8aff-924f7ab4d995,C0041621,C0204727,managing critically ill patients on ,Ultrasonic Shockwave,Isolation procedure,1,X,[npop],[topp],G01.750.770.776.891.500,
db56096d-3667-46e0-bfcd-fff4017ea562,C1175175,C0012634,is major cause of mortality after ,Severe Acute Respiratory Syndrome,Disease,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C23.550.288
1f936bb9-51da-48d3-a72d-6343d5758ccd,C0520817,C1457887,may may ,Physical disability,Symptoms,1,X,[patf],[sosy],,
0b19cc2e-09fd-4977-aa4e-e2961d7108c0,C0520817,C0730321,may may ,Physical disability,Punctate inner choroidopathy,1,X,[patf],[dsyn],,
5b6dbae3-dc08-4af4-93ef-bc45fa906c96,C0338656,C1457887,may may ,Impaired cognition,Symptoms,1,X,[mobd],[sosy],F03.615.250.700,
dc4b1f95-d70b-4b27-926c-8954779e2a03,C0338656,C0730321,may may ,Impaired cognition,Punctate inner choroidopathy,1,X,[mobd],[dsyn],F03.615.250.700,
e9b4d2aa-b4d1-4596-83ec-88a9af389395,C1815399,C0730321,minimize ,Special Care (pharmacologic substance),Punctate inner choroidopathy,1,X,[phsu],[dsyn],,
044d1f51-79ff-4585-aa2f-a5d7e5545f0a,C3536912,C3830624,of darunavir 800 MG is,Human Immunodeficiency Virus Protease Inhibitor [EPC],Cytochrome P450 3A4 Inhibitor,1,X,[phsu],[chvf],,
a2a6c4fe-7062-495c-b887-533b604f8b15,C3505765,C3830624,of darunavir 800 MG is,darunavir 800 MG,Cytochrome P450 3A4 Inhibitor,1,X,[clnd],[chvf],,
c9b4b523-3758-40fa-8260-27439d67b221,C3830624,C0599685,is indicated in combination with ,Cytochrome P450 3A4 Inhibitor,Anti-Retroviral Agents,1,X,[chvf],[phsu],,D27.505.954.122.388.077
870e0952-54ea-4a72-9adb-65870c4c3e2e,C3830624,C0019693,is indicated in combination with ,Cytochrome P450 3A4 Inhibitor,HIV Infections,1,X,[chvf],[dsyn],,C02.782.815.616.400;C02.800.801.400;C20.673.480
c87acd08-b6ac-4c20-bf04-fee1e56da378,C1435444,C1516048,Activities of was,darunavir,Assessed,1,X,[orch/phsu],[acty],D02.065.884.438;D02.241.081.251.222;D02.886.590.700.400;D03.383.312.303,
1ba3ebcd-ba35-4d9d-a8e2-4f000b4764c7,C0003451,C1516048,were To end ,Antiviral Agents,Assessed,2,X,[phsu],[acty],D27.505.954.122.388,
71d0d8d9-9bf6-41b0-afe5-b7bfeb01acbe,C0441655,C1516048,was ,Activities,Assessed,1,X,[acty],[acty],,
01db57d3-51bf-40d3-a935-66246756b1f2,C0013936,C0319157,could could affected by ,Embryonic Development,AS virus,1,X,[ortf],[virs],G07.345.500.325.180;G08.686.784.170.104,
464784b2-b609-4ab2-bef1-e56136d83680,C0543467,C0278996,is in ,Operative Surgical Procedures,Malignant Head and Neck Neoplasm,2,X,[topp],[neop],E04,
6d0f6804-ed31-47ff-9650-93bf29fc4fc6,C1457887,C0007222,were more common in patients with ,Symptoms,Cardiovascular Diseases,1,X,[sosy],[dsyn],,C14
2e5e59f1-193d-4c32-9aec-4e38e65ae9fe,C0019046,C0849867,were ,Hemoglobin,Widespread Disease,1,X,[aapp/bacs],[dsyn],D12.776.124.400;D12.776.422.316.762,
6c8336ce-0242-4afb-845d-fffa4066201e,C0007222,C0012634,was associated with critical ,Cardiovascular Diseases,Disease,1,X,[dsyn],[dsyn],C14,C23.550.288
6c8336ce-0242-4afb-845d-fffa4066201e,C0007222,C0012634,increase chances of fatal ,Cardiovascular Diseases,Disease,1,X,[dsyn],[dsyn],C14,C23.550.288
a75f1667-4f82-4d52-a4a6-903bcdf3344b,CVD,C0206750,are recommended in ,CVD,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
93547053-2603-4c06-935c-673ff0ce2ad2,C1516048,C0206750,are recommended in ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
93547053-2603-4c06-935c-673ff0ce2ad2,C1516048,C0206750,governing medical recommendations regarding UME during ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
93547053-2603-4c06-935c-673ff0ce2ad2,C1516048,C0206750,is in responses to ,Assessed,Coronavirus Infections,2,X,[acty],[dsyn],,C02.782.600.550.200
93547053-2603-4c06-935c-673ff0ce2ad2,C1516048,C0206750,provide answers in patients with ,Assessed,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
3bd0ecbe-6e07-45ab-9a07-7450b630ab25,CVD,C0007222,are recommended in ,CVD,Cardiovascular Diseases,1,X,????,[dsyn],????,C14
5df28727-d151-4f9b-9a13-b2f1a9ffb88b,C1516048,C0007222,are recommended in ,Assessed,Cardiovascular Diseases,1,X,[acty],[dsyn],,C14
4f7e66fe-0c00-4e79-a54c-508f33d3cedc,C0016143,C0206750,Facing shortage during ,First Aid,Coronavirus Infections,1,X,[topp],[dsyn],E02.365.305,C02.782.600.550.200
2f83b2bb-f795-467b-94b6-fb3161bae0e0,C1999230,C0012634,Facing shortage during ,Providing (action),Disease,1,X,[acty],[dsyn],,C23.550.288
978f14fb-ad5e-426c-9612-ebed28b84aef,C0016143,C0012634,Facing shortage during ,First Aid,Disease,1,X,[topp],[dsyn],E02.365.305,C23.550.288
54df401d-eae9-41df-b83c-a47a35af3c40,C1999230,C0034991,is essential for their ,Providing (action),Rehabilitation therapy,1,X,[acty],[topp],,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
33918908-a353-496d-a6c0-9b730d99fcf2,C0016143,C0034991,is essential for their ,First Aid,Rehabilitation therapy,1,X,[topp],[topp],E02.365.305,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
fd5b1cad-7408-4209-81b8-09b3f862763c,C1947933,C2359945,stopping ,care activity,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[acty],[clna],,
0bdeaaf9-5869-41cf-8c1f-edff3a4792cd,C1300200,C0009450,also is challenge ,Anesthesia management,Communicable Diseases,1,X,[topp],[dsyn],,C01.539.221
796ce63d-2522-4783-b290-2463547b22ff,C0035204,COVID-19,caused by ,Respiration Disorders,COVID-19,1,X,[dsyn],[virs],C08.618,C000657245
45eabc56-c07f-41e7-83ef-7f9b72b8a7e2,C0035204,C0206750,is in ,Respiration Disorders,Coronavirus Infections,2,X,[dsyn],[dsyn],C08.618,C02.782.600.550.200
9a89ac3d-ecc5-41df-a542-d6259ab9aa3d,C0042210,COVID-19,getting ,Vaccines,COVID-19,1,X,[aapp/imft/phsu],[virs],D20.215.894,C000657245
193a8277-2dd4-40e1-8c36-03f83e95b48f,C4048299,C0003451,have ,Tissue Factor,Antiviral Agents,1,X,[aapp/imft],[phsu],D12.776.124.125.900;D23.119.965,D27.505.954.122.388
16e5ce53-4ccf-4534-ba0a-43bbfa936218,C4048299,C1175743,shown in case of ,Tissue Factor,SARS coronavirus,2,X,[aapp/imft],[virs],D12.776.124.125.900;D23.119.965,B04.820.504.540.150.113.937
ea6bf702-c817-4a65-9b24-8fe0ae5c42bb,dyad,COVID-19,is in ,dyad,COVID-19,1,X,????,[virs],????,C000657245
b29bffd1-4af9-4a85-bfe0-c4bdab9228a1,C0012634,C1511790,was first ,Disease,Detection,1,X,[dsyn],[topp],C23.550.288,
4c105a10-e276-4605-a999-8ac9bd819c16,C0567416,C0034850,are known regulators of ,Molecule,Endosomes,1,X,[sbst],[celc],,A11.284.430.214.190.875.190.880.337
f9a69eaa-6bd7-4033-8bdb-6c3cae13bc5f,C0567416,C0024369,are known regulators of ,Molecule,Lysosomes,1,X,[sbst],[celc],,A11.284.430.214.190.875.190.550
3a8bc23d-8f5b-4807-bd6a-ec3c4bed9dbb,C0034850,C0029219,are subcellular ,Endosomes,Organelles,1,X,[celc],[celc],A11.284.430.214.190.875.190.880.337,A11.284.430.214.190.875
3c2a36be-cd74-412a-869c-0c1521a8cf74,C0024369,C0029219,are subcellular ,Lysosomes,Organelles,1,X,[celc],[celc],A11.284.430.214.190.875.190.550,A11.284.430.214.190.875
84985c43-2bd2-41ba-806a-31e65d2f28a0,C0034850,C0004391,are subcellular ,Endosomes,Autophagy,1,X,[celc],[celf],A11.284.430.214.190.875.190.880.337,G04.146.399;G04.417.350.091
db10d5cb-b1a7-463b-ae77-01fd37f581ba,C0024369,C0004391,are subcellular ,Lysosomes,Autophagy,1,X,[celc],[celf],A11.284.430.214.190.875.190.550,G04.146.399;G04.417.350.091
e5be337f-8344-4613-9d29-499ebf2942e2,C0008269,C0004391,inhibit ,Chloroquine,Autophagy,1,X,[orch/phsu],[celf],D03.633.100.810.050.180,G04.146.399;G04.417.350.091
f1de4cc3-6e41-416a-95ab-45a594d21e46,C0020336,C0004391,inhibit ,Hydroxychloroquine,Autophagy,1,X,[orch/phsu],[celf],D03.633.100.810.050.180.350,G04.146.399;G04.417.350.091
1d430bb6-1d2e-4463-b6d7-b563ef1003e1,C0008269,C0034850,elevating pH of acidic ,Chloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.880.337
1d430bb6-1d2e-4463-b6d7-b563ef1003e1,C0008269,C0034850,prevent coronavirus receptor recognition by,Chloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180,A11.284.430.214.190.875.190.880.337
69f50044-c7dd-4dd5-8346-8b09ddee16d2,C0020336,C0034850,elevating pH of acidic ,Hydroxychloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.880.337
69f50044-c7dd-4dd5-8346-8b09ddee16d2,C0020336,C0034850,prevent coronavirus receptor recognition by,Hydroxychloroquine,Endosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.880.337
3c8bee41-6407-4127-b211-ccab6f866ee0,C0020336,C0024369,elevating pH of acidic ,Hydroxychloroquine,Lysosomes,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,A11.284.430.214.190.875.190.550
3803b272-af32-4ca3-b9e9-92a9acb1d585,C0060323,ug/ml,was 2.4 ug/ml,Fibrin fragment D,ug/ml,2,X,[aapp/bacs],????,x.x.x.x,????
3803b272-af32-4ca3-b9e9-92a9acb1d585,C0060323,ug/ml,was 0.93 ug/ml,Fibrin fragment D,ug/ml,2,X,[aapp/bacs],????,x.x.x.x,????
ffe5132d-d99e-43a8-ac0c-cdbda887126a,C1706853,C1511790,can can ,Assembly (construction),Detection,1,X,[acty],[topp],,
761fcf85-0775-447a-8b57-d5bdb735d078,C1155266,C1825598,has direct ,inflammatory response,IMPACT gene,1,X,[patf],[gngm],,
cedcd16a-a02f-4644-9f19-e4cbd6f3e2b4,C0021822,SME,is with UK biomedical SME ,Interview,SME,1,X,[acty],????,E05.318.308.420;L01.399.250.520;N05.715.360.300.400;N06.850.520.308.420,????
a889f303-da66-4b53-8c65-f9e6783d8fdd,C0069590,C2699239,are reported for ,ORALIT,SD Rat Strain,1,X,[inch/phsu],[mamm],x.x.x.x,
8e5dfe3b-f323-467d-9129-2583441137f3,C0206750,cueing,contribute toward deleterious partisan cueing,Coronavirus Infections,cueing,1,X,[dsyn],????,C02.782.600.550.200,????
1db2a6cb-550f-4710-af52-fa1d7395177d,4th,C1706374,were transported On ,4th,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
a78229e0-fd2f-407a-a9d0-02fdfaa48d18,4th,C1709694,were transported to Lahore for ,4th,Processing (action),1,X,????,[acty],????,
313b47de-9018-4e05-bfe3-bfe5c111cd3d,C0035668,PCR,using real-time PCR,RNA,PCR,1,X,[nnon],????,D13.444.735,????
9a3b4af7-6a8d-48f6-b5c7-0c94f073a189,C0035668,C1414174,using QIAsymphony ,RNA,DSPP gene,1,X,[nnon],[gngm],D13.444.735,
9af57f67-1ec1-4c9e-b9b7-9483dd7a85a8,C0035668,C0920672,using QIAsymphony ,RNA,virus pathogenesis,1,X,[nnon],[comd],D13.444.735,
f342fac1-5508-4938-981b-deb892b30111,C1175743,C0225828,affects specific ,SARS coronavirus,Myocytes Cardiac,1,X,[virs],[cell],B04.820.504.540.150.113.937,A07.541.704.570;A10.690.552.750.570;A11.620.500
f342fac1-5508-4938-981b-deb892b30111,C1175743,C0225828,might attack ,SARS coronavirus,Myocytes Cardiac,1,X,[virs],[cell],B04.820.504.540.150.113.937,A07.541.704.570;A10.690.552.750.570;A11.620.500
f065db1a-549d-4539-8352-a0998d64ad8e,C1175743,C1707758,affects patients in aspects of ,SARS coronavirus,Direct Contact Transmission Infection,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
444c25c5-fd06-4f89-b4db-9997f37ddf0d,C0087111,C4522152, includes catheter ,Therapeutic procedure,Directed Blood Product Donation,2,X,[topp],[phsu],E02,
0feaebc3-2f64-4683-84f1-8650192a6b38,C0087111,C0520997, includes catheter ,Therapeutic procedure,Thrombolysis function,2,X,[topp],[clna],E02,
a693d9ea-481d-4c87-a991-a8eafdc3a171,SGP,C0017973,Binding (Molecular Function),SGP,Glycosaminoglycans,1,X,????,[bacs/orch/phsu],????,D09.698.373
d4396485-8996-4df3-94bf-493f9b7b463c,SGP,C0019143,Binding (Molecular Function),SGP,Heparitin Sulfate,1,X,????,[bacs/orch],????,D09.698.373.425
873bc941-d309-4f3d-ad8c-aea6e0a1de3a,C0019143,C1512977,is found on surface of virtually all ,Heparitin Sulfate,Mammalian Cell,1,X,[bacs/orch],[cell],D09.698.373.425,
2318a5bc-194d-4c1a-9ea6-85faeaa4b577,C0032594,C2717802,potently neutralized pLV-S Viral Structures with clear SGP,Polysaccharides,Viral Structures,2,X,[orch/phsu],[anst],D09.698,A21
8abefad0-6bea-484a-9428-af229cab3524,C0032594,SGP,potently neutralized pLV-S Viral Structures with clear SGP,Polysaccharides,SGP,1,X,[orch/phsu],????,D09.698,????
066cfdc8-61c0-4b76-b558-e982364f3663,C2717802,C0243052,is in anti ,Viral Structures,Virus Physiological Phenomena,1,X,[anst],[npop],A21,G06.920
f5c62117-14a2-4759-b3d5-81fa5661b104,C0599331,C1112211,is Hepatic Infection for initial,Nasal Epithelium,Hepatic Infection,2,X,[tisu],[dsyn],A04.531.520;A04.760.600;A10.615.550.760.600,
3468a4bf-68a9-4a33-b3ef-1a11cbd2b364,C0019134,C0199176,Administration Intranasal of be effective,heparin,Prophylactic treatment,1,X,[bacs/orch/phsu],[topp],D09.698.373.400,
def4476e-9bc8-40d2-a823-39dfbf94a98e,C0001560,C0199176,be effective ,Administration Intranasal,Prophylactic treatment,1,X,[topp],[topp],E02.319.267.120.655.500,
b62b357f-8902-49f7-bf25-69b06720b8ea,C0013227,C3463820,can have proarrhythmic actions resulting from their ,Pharmaceutical Preparations,Inhibition,2,X,[phsu],[acty],D26,F01.145.544;F02.463.425.475;F02.739.794.405
960e384f-a2cc-4b71-afb3-52dccd4145ba,C0013227,C0022009,can have proarrhythmic actions resulting from their ,Pharmaceutical Preparations,Ion Channel,1,X,[phsu],[aapp/bacs],D26,D12.776.157.530.400;D12.776.543.550.450;D12.776.543.585.400
74cef5e1-597a-4bd0-9853-5c6eb9ea2087,C0206750,C0349410,clinical presentation of is ,Coronavirus Infections,Single organ dysfunction,1,X,[dsyn],[sosy],C02.782.600.550.200,
c0fa7b21-146c-4f8e-b85f-c71aae143dce,C0005779,C0349410,clinical presentation of is ,Blood Coagulation Disorders,Single organ dysfunction,1,X,[dsyn],[sosy],C15.378.100,
02eec7e1-ec76-4027-821d-746a3e41a529,C0028910,C0015982,is massive ,Oils Volatile,Fibrin,1,X,[orch],[aapp/bacs/phsu],D10.627.675,D12.776.124.270
56120d09-5bfb-4169-98a2-eb6c35002969,C0005779,C0015982,Oils Volatile of is massive,Blood Coagulation Disorders,Fibrin,1,X,[dsyn],[aapp/bacs/phsu],C15.378.100,D12.776.124.270
48b53a8f-1639-4d9d-9acb-65dcbc372d5c,C1707455,C0684256,is with ,Comparison,Bacterial sepsis,1,X,[acty],[dsyn],,
3eea5aa4-7d87-4c0e-bc65-101c0c4a6017,C1707455,C0005779,is with ,Comparison,Blood Coagulation Disorders,1,X,[acty],[dsyn],,C15.378.100
ea067fa3-0ab2-4e72-b6c8-4bf99aa5a7d2,C1707455,C0012739,is with ,Comparison,Disseminated Intravascular Coagulation,1,X,[acty],[dsyn],,C15.378.100.220;C15.378.463.250;C15.378.925.220
ad0ca943-6af0-4ee7-8892-f22e96234892,C0301872,C0024264,orchestrated by inflammatory ,Immune response,Lymphocyte,1,X,[ortf],[cell],,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
ad0ca943-6af0-4ee7-8892-f22e96234892,C0301872,C0024264,embodies in decrease of ,Immune response,Lymphocyte,1,X,[ortf],[cell],,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567
ed26d0eb-13b0-4430-9f53-aef74b8ed463,C0301872,C0007587,orchestrated by inflammatory ,Immune response,Cell Death,1,X,[ortf],[celf],,G04.146
21448e8c-cb55-407e-a9d8-6f9b49c623e1,C0301872,C0003130,orchestrated by inflammatory ,Immune response,Anoxia,1,X,[ortf],[patf],,C23.888.852.079
3b41d6ba-fd0e-4b50-8916-010107eb7eb6,C0012634,C3850088,are analogous with various ,Disease,Neutrophil Extracellular Traps,2,X,[dsyn],[celc],C23.550.288,A11.284.295.495
0e71e8ff-667e-458e-a0d4-60877a78de95,C3714552,C0206750,dealing with spread of ,Weakness,Coronavirus Infections,2,X,[sosy],[dsyn],,C02.782.600.550.200
cac6b2e9-a1ae-4d9f-8c46-141d5b9b8322,C0206750,C1947951,supporting ,Coronavirus Infections,Anatomical Apparatus,1,X,[dsyn],[anst],C02.782.600.550.200,
96ecf4e1-ce91-4747-a50d-a0af8b1760bc,remdesivir,C0023175,potentially act as ,remdesivir,Lead,1,X,[clnd],[elii/hops],,D01.268.556.435;D01.552.544.435;x.x.x.x
cf88f1da-1a99-4faf-834d-813ce072fdb6,C1175743,C0023175,is with key residues also identified for future ,SARS coronavirus,Lead,1,X,[virs],[elii/hops],B04.820.504.540.150.113.937,D01.268.556.435;D01.552.544.435;x.x.x.x
cce38550-b278-424f-a110-e813e59459d1,C1175743,C2698650,is with key residues also identified for future ,SARS coronavirus,Optimization,1,X,[virs],[acty],B04.820.504.540.150.113.937,
d2d88294-717c-456a-a92d-cae572f94cf2,C0520510,U.S.,cost of is 50 U.S. ,Materials,U.S.,1,X,[sbst],????,,????
75097b7a-067c-45e1-909c-7ecfa22402a3,C1175743,C0039082,causes multisystem ,SARS coronavirus,Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C23.550.288.500
1e8e8e9c-9387-4bdf-853a-d7657747279c,C0086418,C1145670,was admitted with ,Homo sapiens,Respiratory Failure,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C08.618.846
f2b3cfa7-40f4-4166-8c3f-4543811535ac,C0086418,C0948245,was admitted with ,Homo sapiens,Cytokine Release Syndrome,2,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,
c6cededf-5304-45b8-ac1a-4601b442ebf9,C0086418,C0022116,was admitted with ,Homo sapiens,Ischemia,2,X,[humn],[patf],B01.050.150.900.649.313.988.400.112.400.400,C23.550.513
f45ecd06-e5ad-4eb4-8bcd-ae27b89a018b,C0005778,C0032143,triggered trial of ,Blood coagulation,alteplase,1,X,[ortf],[aapp/enzy/phsu],G09.188.390.150,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
7e8272ed-f9a6-4e7a-872d-2442ae6e3312,C0005516,C0032143,triggered trial of ,Biological Markers,alteplase,1,X,[clna],[aapp/enzy/phsu],D23.101,D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970
744248e5-819f-44ab-8db7-ac2c50f4a269,C0032143,C0087111,combination of be could ,alteplase,Therapeutic procedure,1,X,[aapp/enzy/phsu],[topp],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,E02
b7f2f58b-b0b3-4b6f-99ea-96160124c9a6,C0032143,C0206750,combination of be could ,alteplase,Coronavirus Infections,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,C02.782.600.550.200
8da7bd04-e6ed-4683-b1d1-56347c89d3ac,C0032143,C0035222,combination of be could ,alteplase,Respiratory Distress Syndrome Adult,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,C08.381.840;C08.618.840
130fdb0e-34e7-44b4-a938-74434883f0ec,C0032143,C2917274,combination of be could ,alteplase,Increased Blood Viscosity [PE],1,X,[aapp/enzy/phsu],[ortf],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,
fb4f7a09-9e50-42d5-80bd-8f6f8df90955,C0041621,C0206750,infected with 2019 ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
fb4f7a09-9e50-42d5-80bd-8f6f8df90955,C0041621,C0206750,valid aid in patients with suspect ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
fb4f7a09-9e50-42d5-80bd-8f6f8df90955,C0041621,C0206750,could represent valid diagnostic aid in patients with ,Ultrasonic Shockwave,Coronavirus Infections,1,X,[npop],[dsyn],G01.750.770.776.891.500,C02.782.600.550.200
5cb77f26-1b83-486a-bfd0-fcc90264e72d,C0041621,C0012634,infected with 2019 ,Ultrasonic Shockwave,Disease,1,X,[npop],[dsyn],G01.750.770.776.891.500,C23.550.288
e7187a01-f36e-43f5-8537-7df0ae6a5e18,C0041621,C4554533,use of is emerging ,Ultrasonic Shockwave,Trend:Type:Point in time:^Patient:Nominal,1,X,[npop],[clna],G01.750.770.776.891.500,
37b16d37-b7d8-416e-b23a-ffa4d59da414,C0024109,C0748159,revealed serious ,Lung,pulmonary involvement,1,X,[bpoc],[dsyn],A04.411,
4dfe35ad-f0cd-42fc-8bb1-2a0f5f4598df,RAS,C0682972,is complicated network of ,RAS,G-Protein-Coupled Receptors,1,X,????,[aapp/rcpt],????,D12.776.543.750.695
033905b1-c875-4009-a8a8-1d5bda4e15aa,RAS,C0030946,produced by ,RAS,Endopeptidases,1,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
a5b7f089-e87d-4bfd-a176-48fb4b038233,C3657282,C0030946,produced by ,alamandine,Endopeptidases,1,X,[aapp],[aapp/enzy/phsu],x.x.x.x,D08.811.277.656.300
72a393b4-0f92-43bc-a54d-c0243148bf29,RAS,C0597357,produced by ,RAS,receptor,1,X,????,[aapp/rcpt],????,
08c04aee-638b-4a81-b636-16c35d5cdaf7,C3657282,C0597357,produced by ,alamandine,receptor,1,X,[aapp],[aapp/rcpt],x.x.x.x,
d16d4f2d-d326-4a39-a796-d292be2baec6,C0004457,RAS,have have identified in RAS ,Axis vertebra,RAS,1,X,[bpoc],????,A02.835.232.834.151.383,????
7e203da8-527f-4ba4-843a-0ccc3244db88,C0021966,C0004457,reviewed possible roles of RAS ,Iodides,Axis vertebra,2,X,[inch],[bpoc],D01.248.497.158.490;D01.475.410,A02.835.232.834.151.383
b32f3ff6-582a-4ff6-b3a1-2235aebba6da,C0021966,RAS,reviewed possible roles of RAS ,Iodides,RAS,2,X,[inch],????,D01.248.497.158.490;D01.475.410,????
26884de9-e6a3-40ba-b915-0db3ba802b9f,C3463820,C0678222,could could useful in ,Inhibition,Breast Carcinoma,2,X,[acty],[neop],F01.145.544;F02.463.425.475;F02.739.794.405,C04.588.180;C17.800.090.500
6fb68c51-5fbc-48d2-b51b-4b724e8a537e,RAS,C0678222,offers multifaceted opportunities for development of compounds for ,RAS,Breast Carcinoma,4,X,????,[neop],????,C04.588.180;C17.800.090.500
701c34e5-2c37-45d2-8c63-cac5951335d9,C0018801,C0206750,structured approach to care of patients with ,Heart failure,Coronavirus Infections,5,X,[dsyn],[dsyn],C14.280.434,C02.782.600.550.200
18230387-81e4-4ad9-9b25-9b02b29c24ee,C0018801,C1882932,is with comorbid ,Heart failure,Representation (action),1,X,[dsyn],[acty],C14.280.434,
1e07faea-9d37-4dbc-9f08-4601c1b39a91,C0018801,C1457887,formidable challenge as ,Heart failure,Symptoms,1,X,[dsyn],[sosy],C14.280.434,
1a3f46e6-e92a-435a-bccf-205ec893d740,C0018801,C0012634,formidable challenge as ,Heart failure,Disease,1,X,[dsyn],[dsyn],C14.280.434,C23.550.288
3c066be6-cbf0-4401-9fc9-6a451acf5150,C0018801,C0243087,is with ,Heart failure,concomitant disease,2,X,[dsyn],[patf],C14.280.434,
beb15158-828b-4117-b2f9-a598f460689c,C0018801,C0556656,conducted web-based ,Heart failure,Meetings,2,X,[dsyn],[acty],C14.280.434,
a635bf1c-19f5-4a27-b9e6-28269c758323,C0009450,C0012634,has spread worldwide Since December 2019 ,Communicable Diseases,Disease,1,X,[dsyn],[dsyn],C01.539.221,C23.550.288
6360cdf4-fa69-4f2f-ab57-808eb8a0b6a3,C0206750,C0178784,is with ,Coronavirus Infections,Organ,1,X,[dsyn],[bpoc],C02.782.600.550.200,
e526c3bb-fcc4-417b-9a8a-7b562a21055d,C0751956,C0012634,may have undiagnosed ,Acute Cerebrovascular Accidents,Disease,2,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C23.550.288
8dc31cf3-7d9b-48e5-bf4c-bbb1a041b503,C0040802,C0206750,compared between ,travel,Coronavirus Infections,1,X,[dora],[dsyn],I03.883,C02.782.600.550.200
1a1c6b9c-3ff4-4a5b-87b8-74bfe917c548,C0079380,C0206750,combat current ,Frameshift Mutation function,Coronavirus Infections,1,X,[comd],[dsyn],G05.365.590.265,C02.782.600.550.200
f8469ebe-1fc0-4ab3-a6b9-2c4d8962cc4f,C0596448,C1184743,being consumed in ,dimer,bony process,1,X,[chvs],[bpoc],,
3443ffe9-bffd-4016-93fe-a8ebb53d0902,C0001617,C1861452,is In other very similar ,Adrenal Cortex Hormones,Storm Syndrome,2,X,[horm/orch/phsu],[dsyn],D06.472.040,x.x.x.x
40d06766-5e61-444e-9e1f-f3ffa167c9a1,C0309847,C0042077,is in functional ,premier,Urology,3,X,[aapp/imft/phsu],[bmod],,H02.403.810.860
9bdb60f4-53ac-42ce-a446-228e46b3174e,C0032143,C1856053,decreased In ,alteplase,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[aapp/enzy/phsu],[dsyn],D08.811.277.656.300.760.875;D08.811.277.656.959.350.875;D12.776.124.125.662.768;D23.119.970,x.x.x.x
6ea4de6d-2cba-4a2f-8231-e80e02eab990,C0678812,C0017710,is with ,systemic administration,Glucocorticoids,2,X,[topp],[horm/orch],,D06.472.040.543;D27.505.696.399.472.488
8207595b-a9d0-4793-8299-9da09ae4cd54,C0678812,C0032285,alleviate ,systemic administration,Pneumonia,2,X,[topp],[dsyn],,C08.381.677;C08.730.610
431210f0-b6b3-48f7-98ae-1c46ef47af0a,C0678812,C0013604,alleviate ,systemic administration,Edema,2,X,[topp],[sosy],,C23.888.277
108e1789-9d7f-40a7-818a-cc89b9332713,C0013604,C0035222,may decrease development of ,Edema,Respiratory Distress Syndrome Adult,2,X,[sosy],[dsyn],C23.888.277,C08.381.840;C08.618.840
402ded18-0afd-4c9e-8ea2-5a104b2c5ef2,C0024109,C0225704,is in imaged ,Lung,Basal segment of lung,3,X,[bpoc],[bpoc],A04.411,
99665534-cbe0-44d8-a4af-9525873c338f,C0933845,C0225704,is in imaged ,Parenchyma,Basal segment of lung,1,X,[bpoc],[bpoc],,
fe679975-8797-4644-b874-d983cf6d62c5,C0009450,C0199470,may lead to requirement of ,Communicable Diseases,Mechanical ventilation,1,X,[dsyn],[topp],C01.539.221,
f083d64a-b2ec-4408-9afc-246bbfba8632,C0206750,C0184893,practice of ,Coronavirus Infections,Emergency operation,1,X,[dsyn],[topp],C02.782.600.550.200,
c9ed8768-705e-4599-8678-4232314f5f33,C0020598,C0014695,may may associated with ,Hypocalcemia,Ergocalciferol,1,X,[dsyn],[orch/phsu/vita],C18.452.174.509;C18.452.950.509,D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439
f44a4f0d-1b8d-4630-b72a-3ee9df6c21e2,C0030946,C1537068,required for ,Endopeptidases,Virus Internalization,1,X,[aapp/enzy/phsu],[biof],D08.811.277.656.300,G06.920.881
c1116747-82c5-4ec6-99f9-fdeb4152073b,C1257974,C0007634,offers various ,Regenerative Medicine,Cells,1,X,[bmod],[cell],H02.403.750,A11
4b7f2480-9a4f-45ee-a280-8475406bbe3c,C1257974,C0040300,offers various ,Regenerative Medicine,Body tissue,2,X,[bmod],[tisu],H02.403.750,A10
8cf8a554-f9a2-45a3-b231-686de3b993b5,C1257974,C0087111,offers various ,Regenerative Medicine,Therapeutic procedure,1,X,[bmod],[topp],H02.403.750,E02
01aba2db-cc1c-4232-9a39-2c3e1d31a10e,C1257974,C0872278,offers related ,Regenerative Medicine,stem cell therapy,1,X,[bmod],[topp],H02.403.750,
d570d56f-f87f-40f3-af86-343bc1026d04,C1257974,C4289797,offers ,Regenerative Medicine,Chimeric Antigen Receptor T-Cell Therapy,2,X,[bmod],[topp],H02.403.750,
3e8a50c9-90fa-4d60-87b9-37d338fb4dd3,C1257974,C2350332,offers ,Regenerative Medicine,Exosomes,1,X,[bmod],[celc],H02.403.750,A11.284.295.588.750;A11.284.430.214.190.875.190.880.495
74401728-485c-4ddd-91dc-6f5033f6ea76,C1257974,C1831784,offers ,Regenerative Medicine,natural killer cell therapy,2,X,[bmod],[topp],H02.403.750,
ed92e863-e521-4a91-8735-2d5f932190a4,C1257975,C1457887,can reduce inflammatory ,Mesenchymal Stem Cells,Symptoms,1,X,[cell],[sosy],A11.329.830.500;A11.872.590.500,
2bde41e5-5eba-4b95-8c9f-ede194d41738,C1257975,C0079189,protect against ,Mesenchymal Stem Cells,cytokine,1,X,[cell],[aapp/imft],A11.329.830.500;A11.872.590.500,D12.644.276.374;D12.776.467.374;D23.529.374
26d91b61-bf1f-45e9-bd42-fd0f4fcc0237,C0022688,C0206750,candidate for ,Natural Killer Cells,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537,C02.782.600.550.200
fc6b22a6-2408-4b1c-aecc-a6875e7d366c,C0022688,C0302189,candidate for ,Natural Killer Cells,Cell Therapy,1,X,[cell],[topp],A11.118.637.555.567.537;A15.145.229.637.555.567.537;A15.382.490.555.567.537,E02.095.147
26310cc3-4fbe-48c0-94e1-237586364f8d,C0004936,C0206750,caused by ,Mental disorders,Coronavirus Infections,1,X,[mobd],[dsyn],F03,C02.782.600.550.200
94bda1eb-d2d7-4727-8439-a3c154284cc0,C1707455,C0039215,is with low ,Comparison,CD4 Positive T Lymphocytes,1,X,[acty],[cell],,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200
c8c24e5a-521f-4d90-9a71-681dd70154ef,C0039215,C0319157,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,AS virus,1,X,[cell],[virs],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,
c032cd03-584b-44f2-a1ca-7b1f2ebf09c1,C0039215,2weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,2weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
233e03ac-d3de-4811-9382-9d3d31cf6c1e,C0039215,3weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,3weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
4a325043-2e54-4b2f-8782-6eb2d1e64874,C0039215,4weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,4weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
43737a6c-cd78-4b21-bdc4-e1d506f3414d,C0039215,5weeks,predicting 2weeks 3weeks 4weeks 5weeks,CD4 Positive T Lymphocytes,5weeks,1,X,[cell],????,A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,????
194ce8d1-60d2-4cb0-a1b3-d6b10abd37c8,C0039215,C0042769,predicting ,CD4 Positive T Lymphocytes,Virus Diseases,1,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C02
db538c25-7f60-435e-9962-16527f4c9baa,C0039215,C0206750,predicting ,CD4 Positive T Lymphocytes,Coronavirus Infections,1,X,[cell],[dsyn],A11.118.637.555.567.569.200;A15.145.229.637.555.567.569.200;A15.382.490.555.567.569.200,C02.782.600.550.200
93cdbca8-76b6-4de0-84f5-c1b90ec1ea07,C1707455,C0012634,is with volume of data on ,Comparison,Disease,1,X,[acty],[dsyn],,C23.550.288
b8c00d3d-8239-42ca-8edb-e937c2c53852,C1268935,C1856053,arrived In late ,Congenital Thrombotic Thrombocytopenic Purpura,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680,x.x.x.x
5041a07e-a372-48c8-9e3b-8d3e5cf5d84c,C1268935,C0543859,arrived in ,Congenital Thrombotic Thrombocytopenic Purpura,Amyotrophic Lateral Sclerosis Guam Form,1,X,[dsyn],[dsyn],C15.378.100.802.687.680;C15.378.140.855.925.750.680;C15.378.925.850;C23.550.414.950.687.680;C23.888.885.687.687.680,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
83718b5e-92fe-4996-bebb-d867505cb7d6,C0475463,C0020964,presence of is promising indicator of short-term ,Antibodies Neutralizing,Immunity,1,X,[aapp/imft],[phsf],D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244,G12.450
df23c26a-4317-47e8-bd64-f2744204fa55,C0475463,C0003241,represent ,Antibodies Neutralizing,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
a8bb7ff3-f51f-46f0-9151-16976bd4ad58,C0009566,C0630906,as Thromboembolism of vein is,Complication,vinyltriethoxysilane,1,X,[patf],[orch],,x.x.x.x
2c8abf79-1ec0-4162-8ffc-b09f3464f061,C0871208,C0009450,reducing ,Rating (action),Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
e655025a-6ed7-45cd-b2c0-bce0c736ca51,C0232024,C2745965,significantly decreased after declaration of ,Total airway resistance,Emergencies [Disease/Finding],2,X,[clna],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
63830fc6-219f-41a4-8b19-8b4e584896cb,C0232024,2-week,significantly decreased during 2-week ,Total airway resistance,2-week,2,X,[clna],????,,????
62f8f4d7-1519-4a27-b72f-4ab591ed9ee8,C0035668,C1546536,is in ,RNA,Air sample,2,X,[nnon],[sbst],D13.444.735,
da0e0e47-ba11-4f7f-90de-78d89ee5bb80,C1546536,C1175743,were negative for ,Air sample,SARS coronavirus,2,X,[sbst],[virs],,B04.820.504.540.150.113.937
9f24ed75-3988-4c11-87c3-e92626db96f0,C0035668,C0009450,is in patients singly isolated inside airborne ,RNA,Communicable Diseases,2,X,[nnon],[dsyn],D13.444.735,C01.539.221
b9c8593d-020e-41b2-945c-6f16bf555ba5,C0035668,C3536832,is in patients singly isolated inside airborne ,RNA,Air,2,X,[nnon],[inch/phsu],D13.444.735,G16.500.275.063.150;N06.230.300.100.150
b5a3fe83-f383-4459-a886-25bc9f4b54cd,C2948600,C0021932,Comparison effectiveness during,Aim,Intubation Intratracheal,1,X,[inch/phsu],[topp],,E02.041.500;E02.585.578;E05.497.578
2b7e483f-78eb-4903-9e27-cfede4bb3b62,C2948600,C0004764,Comparison effectiveness of different,Aim,Contraception Barrier,2,X,[inch/phsu],[topp],,E02.875.194.285
3ed61482-d8af-43b0-a1bb-ae04b2a190f6,C2948600,C0508431,Providing (action) practical,Aim,answer questions,1,X,[inch/phsu],[topp],,
34a5a419-9472-4483-b1cb-f757354ddf48,C0508431,C0015259,promote participation in ,answer questions,Exercise,1,X,[topp],[dora],,G11.427.410.698.277;I03.350
9b95603d-c986-4efb-9f40-e234ffe1064a,C0015259,C1516048,were ,Exercise,Assessed,1,X,[dora],[acty],G11.427.410.698.277;I03.350,
2f51c0e4-82be-446c-864b-30730b69c54a,C0751956,C0037088,was most common ,Acute Cerebrovascular Accidents,Signs and Symptoms,1,X,[dsyn],[sosy],C10.228.140.300.775;C14.907.253.855,C23.888
1705e257-dae9-4c9f-8989-f4fdca3dc6ff,C0751956,C0027855,was most common Signs and Symptoms on,Acute Cerebrovascular Accidents,Neurology speciality,2,X,[dsyn],[bmod],C10.228.140.300.775;C14.907.253.855,H02.403.600
68736eba-dc9c-4151-bda6-c4bc29bfb9b0,C3266262,C1856053,launched Trainee Pandemic Role Allocation Tool In,Multiple Chronic Conditions,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[dsyn],[dsyn],C23.550.291.500.500,x.x.x.x
6df1288d-27e8-4ce7-902e-9297f1ca64a5,C3266262,C1706778,launched Trainee Pandemic Role ,Multiple Chronic Conditions,Allocation,1,X,[dsyn],[acty],C23.550.291.500.500,
c2c390f7-eef3-4cbb-b232-ff2d21234f95,COVID-19,C0851312,may exacerbate delays in time to ,COVID-19,Breast surgery specialty,2,X,[virs],[bmod],C000657245,
20398e13-5018-40a3-a600-66a467d0d965,COVID-19,C0011311,is with false-positive ,COVID-19,Dengue Fever,1,X,[virs],[dsyn],C000657245,C02.081.270;C02.782.350.250.214;C02.782.417.214
2908cec1-9346-4fac-975b-aed56698da63,COVID-19,C0036745,is with false-positive ,COVID-19,Study of serum,1,X,[virs],[bmod],C000657245,H02.781
0da7bd51-8418-42c7-a840-313dbab08a88,C1512523,C0206419,has great potential for treatment of patients with ,hydrochloride,Genus: Coronavirus,1,X,[inch/phsu],[virs],,B04.820.504.540.150
40dc4828-d67b-4f57-bad4-41c965d13c92,C0035222,C0023516,persistently elevated values for ,Respiratory Distress Syndrome Adult,Leukocytes,2,X,[dsyn],[cell],C08.381.840;C08.618.840,A11.118.637;A15.145.229.637;A15.382.490
ed25a9c6-45e8-4598-850a-a7ea4ba2dbf9,C0035222,C0021760,persistently elevated values for ,Respiratory Distress Syndrome Adult,Interleukin-6,2,X,[dsyn],[aapp/imft],C08.381.840;C08.618.840,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
9da4c1c4-5474-4bd7-9624-36844a6764b0,C0035222,C0022917,persistently elevated values for ,Respiratory Distress Syndrome Adult,Lactate Dehydrogenase,2,X,[dsyn],[aapp/enzy],C08.381.840;C08.618.840,D08.811.682.047.551.400;D08.811.682.047.820.493
9ef127da-b984-4218-b147-52a95a40f13c,C0035222,C0010287,persistently elevated values for ,Respiratory Distress Syndrome Adult,Creatine Kinase,2,X,[dsyn],[aapp/enzy],C08.381.840;C08.618.840,D08.811.913.696.640.150
559785be-661f-4e4b-bfbb-278c2002d78b,C0035222,C0060323,persistently elevated values for ,Respiratory Distress Syndrome Adult,Fibrin fragment D,2,X,[dsyn],[aapp/bacs],C08.381.840;C08.618.840,x.x.x.x
8749c4fe-1640-4cf2-a9ff-fd095d849b59,C3826426,C0242781,importance of route of ,Dynamics,disease transmission,1,X,[npop],[patf],,N06.850.310
8749c4fe-1640-4cf2-a9ff-fd095d849b59,C3826426,C0242781,understanding temporal course of ,Dynamics,disease transmission,1,X,[npop],[patf],,N06.850.310
2e29f499-976e-4267-88e8-0abdf2c87ae6,C2926735,C0242781,importance of asymptomatic ,Duration,disease transmission,1,X,[orch/phsu],[patf],,N06.850.310
a4ad40a1-d49e-4a14-bdb8-e53bc0624fde,C1457887,C2364082, includes ,Symptoms,Sense of smell impaired,2,X,[sosy],[sosy],,
7a7e2fc1-b59e-494a-a8b5-b89aecead02c,C1707391,C1457887,ranging from common ,Choose (action),Symptoms,2,X,[acty],[sosy],,
9bc34566-38eb-468e-b356-71b60b9a3319,C1707391,C2364082,ranging from common ,Choose (action),Sense of smell impaired,2,X,[acty],[sosy],,
f3a6a7c7-87fa-4db8-82f1-acb836fab172,CXR,C1175175,is with ,CXR,Severe Acute Respiratory Syndrome,1,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
45cdfede-34e0-44d6-b320-7acc9bec71bd,C0011945,C0206419,are more vulnerable to severe ,Physical Dialysis,Genus: Coronavirus,1,X,[npop],[virs],E05.196.353;G02.186,B04.820.504.540.150
e53b7b59-d2d2-4a23-bd83-7a9188dd641f,HVA,C0019004,has IMPACT gene As life-line of,HVA,Hemodialysis,1,X,????,[topp],????,E02.870.300;E02.912.800
5039f98e-1e6d-4e8b-98b2-512b74c4a4ce,HVA,C1825598,has profound ,HVA,IMPACT gene,1,X,????,[gngm],????,
fdb6c22b-8828-449c-9a4e-a8d1a9b0966c,HVA,C0011945,has profound ,HVA,Physical Dialysis,1,X,????,[npop],????,E05.196.353;G02.186
9ac50950-0c5d-4bd7-847e-168748f142b2,C0028040,CRS,constitute novel potential CRS ,Nicotine,CRS,1,X,[hops/orch],????,D03.132.760.570;D03.383.725.518,????
f7446372-33ca-4981-9c30-670927437a14,CRS,C1175743,is in severe ,CRS,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
2d3bcb5e-ced3-49b3-9121-bbbd431053d7,C0206750,C0010076,is ,Coronavirus Infections,Coronaviridae,1,X,[dsyn],[virs],C02.782.600.550.200,B04.820.504.540
a182c6cd-7c96-4b73-bdf8-841407f79dfb,C0009450,C0010076,caused by new variable ,Communicable Diseases,Coronaviridae,1,X,[dsyn],[virs],C01.539.221,B04.820.504.540
28e2da13-e0cf-4e41-af2d-8c31fd9dcba9,C1511790,C0034019,informs ,Detection,public health medicine (field),1,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
27c85df9-f444-40f1-8570-96791c9380be,C1511790,C3163724,is in respiratory tract ,Detection,Nucleic acid specimen,1,X,[topp],[celc],,
fc627ae8-17b2-46cd-b4a5-2ec6df930c7d,COVID19,C1175743,is ,COVID19,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
276343b5-6862-4bb3-9ca5-65f0730ca0c0,C0009450,C1456573,is In exceptional situation of ,Communicable Diseases,Global Health,1,X,[dsyn],[bmod],C01.539.221,H02.403.371;N01.400.337
276343b5-6862-4bb3-9ca5-65f0730ca0c0,C0009450,C1456573,has led to ,Communicable Diseases,Global Health,1,X,[dsyn],[bmod],C01.539.221,H02.403.371;N01.400.337
6959b683-58be-4443-8235-74512b681e04,C0011127,C0040300,underlying ,Pressure Ulcer,Body tissue,1,X,[dsyn],[tisu],C17.800.893.665,A10
ddaa95e2-53b2-44f7-a629-5503933753fa,C0041582,C0030193,are ,Ulcer,Pain,1,X,[patf],[sosy],C23.550.891,C23.888.592.612;F02.830.816.444;G11.561.790.444
966478c2-975b-4e9a-a687-dbb5d2252a44,C0035203,C0035222,is indicated for patients with severe ,Respiration,Respiratory Distress Syndrome Adult,2,X,[phsf],[dsyn],G09.772.705,C08.381.840;C08.618.840
3ebb3523-bc63-418d-8768-1b05bce60c60,C0035203,C1175175,is indicated for patients with severe ,Respiration,Severe Acute Respiratory Syndrome,2,X,[phsf],[dsyn],G09.772.705,C02.782.600.550.200.750;C08.730.730
bdea852d-2cd0-4212-a333-bb69f3d539e7,C2948600,C0036576,facilitate ,Aim,Genetic Selection,1,X,[inch/phsu],[genf],,G05.783
491c9ff9-9829-4faf-9b18-95c60298fad1,C2948600,C0199176,facilitate ,Aim,Prophylactic treatment,1,X,[inch/phsu],[topp],,
84ae4e76-1ab3-4147-8737-7941d6b5f091,C1947933,C0009450,are of Up of patients admitted to ICU with confirmed ,care activity,Communicable Diseases,1,X,[acty],[dsyn],,C01.539.221
1af91d55-374e-4b94-9543-edcf4d81e128,C0302908,C0206750,nature of ,Liquid substance,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
36176e1a-495f-49b1-8ae5-153aced28744,C1999230,C1521827,is in ,Providing (action),Preparation,1,X,[acty],[acty],,
fec2ab8f-0797-4531-a55b-977778f9e63e,JID,C0042742,of Bulletin is ,JID,Viral Vaccines,1,X,????,[imft/phsu],????,D20.215.894.899
98c1f807-dd87-4e40-962a-9e6cece74c45,C0557989,C0242781,contribute to interruption ,Restriction of movement,disease transmission,1,X,[topp],[patf],,N06.850.310
4768cddf-a834-4553-857e-b6560f564146,C0557989,C0206750,contribute to interruption ,Restriction of movement,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
fdc36b34-c1a3-4357-ab97-33073745e969,KRT,C3649547,moderating ,KRT,Continuous renal replacement therapy,1,X,????,[topp],????,
fded346b-b5ce-4169-84d2-cf69c3b4f46d,C0031139,C1707391,is in ,Peritoneal Dialysis,Choose (action),1,X,[topp],[acty],E02.870.300.650;E02.912.800.650,
86e356e2-d707-4b8b-a70b-c46423e93876,C3714514,C0010200,may result from patient due to ,Infection,Coughing,1,X,[patf],[sosy],C01.539,C08.618.248;C23.888.852.293
e33ca06a-59dd-4d17-acc2-ec861d735bd9,C1947933,C1999230,are reorganizing resources to ,care activity,Providing (action),1,X,[acty],[acty],,
f8c3792b-cd12-4ea0-a347-9bb25a116dc9,C0087111,C0596756,addressing ,Therapeutic procedure,immunopathology specialty,1,X,[topp],[bmod],E02,
dc41b6f7-b43c-429b-a02f-78b726621862,C0301872,C0042769,represents line of defense against ,Immune response,Virus Diseases,3,X,[ortf],[dsyn],,C02
443e37cc-8d35-461a-a278-d78b942460cb,C0282554,C1167395,clearly reflects widespread dysregulation of ,chemokine,Host (organism),1,X,[aapp/imft],[orgm],D12.644.276.374.200;D12.776.467.374.200;D23.125.300;D23.469.200;D23.529.374.200,
c002a113-18c4-4bf9-9563-ad9d0a603032,C0079189,C1167395,clearly reflects widespread dysregulation of ,cytokine,Host (organism),1,X,[aapp/imft],[orgm],D12.644.276.374;D12.776.467.374;D23.529.374,
75575f9b-ab35-43eb-ab78-76a75609acac,C0040408,C0025124,is important component of ,Tongue,Traditional Chinese Medicine,2,X,[bpoc],[bmod],A03.556.500.885;A14.549.885,E02.190.488.585.520;I01.076.201.450.654.558.520
35166b04-1a02-477d-8f33-b005e2677e5f,C0040408,C2646699,First were analyzed by groups of ,Tongue,Assessor (genus),2,X,[bpoc],[fish],A03.556.500.885;A14.549.885,
f7677d52-d0cc-4691-bf40-b62acca1995f,C2948600,C1285375,evaluate ,Aim,Neoplasm of musculoskeletal system,1,X,[inch/phsu],[neop],,
dbe5a0c7-2bea-4a31-aad0-a811fffef728,C0006826,C1692321,involve ,Malignant Neoplasms,Cellular infiltrate,1,X,[neop],[patf],C04,
1e792de0-fdfd-446b-91a3-6381ff073150,C0006826,C0824497,involve ,Malignant Neoplasms,Neurovascular bundle,1,X,[neop],[bpoc],C04,
7453ad11-10a4-4616-b3e2-913c5de57cf2,C0087111,C0030193,can cause severe morbidity ,Therapeutic procedure,Pain,1,X,[topp],[sosy],E02,C23.888.592.612;F02.830.816.444;G11.561.790.444
9bade7ed-f077-49b7-8b8d-3e5af3a2b501,C0520510,C1167395,maximize utility participating in ,Materials,Host (organism),2,X,[sbst],[orgm],,
a452de01-c402-437e-ae14-66b73e1b9dc6,C0520510,C0017398,maximize utility participating in ,Materials,Science of genetics,2,X,[sbst],[bmod],,H01.158.273.343
77021692-36fb-4048-9ea9-9d4187b118a3,C0242656,C0282632,due to ,Disease Progression,Antibody-Dependent Enhancement,1,X,[patf],[comd],C23.550.291.656,G06.920.095;G12.113
8f40cdc1-2b30-452a-8c77-9812dbb94703,C2948600,C1883254,provide rapid ,Aim,Synthesis,1,X,[inch/phsu],[acty],,
6f201a20-1fa7-441a-8713-bed1b64710d8,C1175743,C0027765,causes ,SARS coronavirus,nervous system disorder,2,X,[virs],[dsyn],B04.820.504.540.150.113.937,C10
25f5deb5-7b61-42d4-b161-05f68f98431f,C0235031,C0018681,can can divided into system ,Neurologic Symptoms,Headache,2,X,[sosy],[sosy],C10.597;C23.888.592,C23.888.592.612.441
53f0e562-c5e6-4aae-b783-529e14c2d07d,C0243072,C1883254,were ,derivatives,Synthesis,1,X,[chvs],[acty],,
b3254fcb-5d4e-4dd4-bd98-8639891addee,C0567416,C0013227,be considered as orally active ,Molecule,Pharmaceutical Preparations,1,X,[sbst],[phsu],,D26
f3ff20d1-5e3d-4c3f-99e6-90ab0713e9da,C0243072,C1510827,exhibit good theoretical ,derivatives,Affinity,1,X,[chvs],[npop],,
3a94ba58-1fd8-45d1-8d42-3cccaf87e119,C1457887,C0007450,using ,Symptoms,Felis catus,1,X,[sosy],[mamm],,B01.050.150.900.649.313.750.377.750.250.125
7ef23191-72ab-4ee8-a353-9c6257884780,C0024117,COVID-19,risk of ,Chronic Obstructive Airway Disease,COVID-19,1,X,[dsyn],[virs],C08.381.495.389,C000657245
7ef23191-72ab-4ee8-a353-9c6257884780,C0024117,COVID-19,worsens ,Chronic Obstructive Airway Disease,COVID-19,1,X,[dsyn],[virs],C08.381.495.389,C000657245
b44fc4ca-32a5-49b0-afe5-2bafaaa445f5,C1299575,COVID-19,recommended for ,Treatment modification,COVID-19,1,X,[topp],[virs],,C000657245
91f1f8ad-cb5d-4b51-acf1-671428109eb7,C0206750,C0053260,disproportionally affects ,Coronavirus Infections,benzoyl L-arginine methyl ester,2,X,[dsyn],[aapp/bacs],C02.782.600.550.200,x.x.x.x
2eeb6d78-bf99-4e3b-ab44-09f0022f84a2,C0034019,C0009450,started following ,public health medicine (field),Communicable Diseases,2,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C01.539.221
aea8c02f-de26-4fcb-8fcb-860506b12eca,C0206750,C1708476,has moved despite ,Coronavirus Infections,Implementation,3,X,[dsyn],[acty],C02.782.600.550.200,
aea8c02f-de26-4fcb-8fcb-860506b12eca,C0206750,C1708476,has required worldwide ,Coronavirus Infections,Implementation,1,X,[dsyn],[acty],C02.782.600.550.200,
aea8c02f-de26-4fcb-8fcb-860506b12eca,C0206750,C1708476,has resulted in widespread ,Coronavirus Infections,Implementation,1,X,[dsyn],[acty],C02.782.600.550.200,
15610465-3b7d-463f-8360-685c56add634,C0206750,C2923471,has moved at different ,Coronavirus Infections,Time to peak,2,X,[dsyn],[clna],C02.782.600.550.200,
15610465-3b7d-463f-8360-685c56add634,C0206750,C2923471,has moved from country ,Coronavirus Infections,Time to peak,4,X,[dsyn],[clna],C02.782.600.550.200,
ffc839ad-9684-4846-bb3c-25b7c4e7926a,C0011382,COVID-19,is in ,Dental Occlusion,COVID-19,1,X,[ortf],[virs],E06.276;G10.549.208,C000657245
e6ba79b8-6a9c-4ca6-b516-5f37874c3ad2,C0520997,COVID-19,resulted in ,Thrombolysis function,COVID-19,1,X,[clna],[virs],,C000657245
f7168ef0-76dc-42a8-b256-9d4e0f72ae5d,C0034771,COVID-19,resulted in ,Recanalization,COVID-19,1,X,[topp],[virs],,C000657245
d1bf5ac0-e5a9-4614-a703-d455717cd030,C0034771,C4534538,achieved with ,Recanalization,Mechanical thrombectomy,1,X,[topp],[topp],,
88317d7d-8be4-4711-a2ed-c1fabf98c5be,C1293116,C0042769,is earlier than first case of ,Introduction procedure,Virus Diseases,1,X,[topp],[dsyn],,C02
bc01fa95-087a-433c-bf59-19e1a91f4da1,C0042769,C0040811,are dispersed among most types in phylogenetic ,Virus Diseases,Trees (plant),1,X,[dsyn],[plnt],C02,B01.650.915
ea562cab-a14c-40e0-9141-ff9b84ffb66a,C0017428,C0040811,are dispersed among most types in phylogenetic ,Genome,Trees (plant),1,X,[gngm],[plnt],G05.360.340,B01.650.915
c301da54-5ec5-41c2-a2b4-0516d13f1515,C0087111,C3463820,aimed at ,Therapeutic procedure,Inhibition,1,X,[topp],[acty],E02,F01.145.544;F02.463.425.475;F02.739.794.405
96561687-96fb-4a2d-bdfb-64e0c5971b79,C0087111,C0751982,aimed at ,Therapeutic procedure,Neutrophil Infiltration,1,X,[topp],[phsf],E02,G12.632
4b287fe5-2f61-48cd-8949-d82cbf2289af,C0087111,C1879547,aimed at ,Therapeutic procedure,Activation action,1,X,[topp],[acty],E02,
bd9a5639-a91f-49ba-9490-078f1115f81e,C0087111,C1622891,aimed at ,Therapeutic procedure,Mast cell degranulation,1,X,[topp],[celf],E02,
f548c77c-cb53-4876-99fe-166c7c416ee1,C0087111,C3850088,aimed at ,Therapeutic procedure,Neutrophil Extracellular Traps,1,X,[topp],[celc],E02,A11.284.295.495
761aa0ee-217d-499d-93cf-daf47c4ef576,C1825598,C1856053,is in mid ,IMPACT gene,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[gngm],[dsyn],,x.x.x.x
3a68f5d4-5df8-47d1-98b7-e05ae2faba85,C0028630,C0220781,encode putative ,Nucleotides,Anabolism,1,X,[nnon],[biof],D09.408.620;D13.695,G03
3349ee1d-6535-442b-b40b-a67b23268214,C0028630,C0033684,encode putative ,Nucleotides,Proteins,1,X,[nnon],[aapp/bacs],D09.408.620;D13.695,D12.776
27131328-d0c1-499d-86c1-eb07e50c3c15,C0079941,C0220781,responsible for ,Open Reading Frames,Anabolism,1,X,[gngm],[biof],G05.360.335.760.640;G05.360.340.024.340.137.650,G03
6ef06894-7353-4871-ad1c-7d25c7f67fcb,C0079941,C0033684,responsible for ,Open Reading Frames,Proteins,1,X,[gngm],[aapp/bacs],G05.360.335.760.640;G05.360.340.024.340.137.650,D12.776
85058edc-2fe7-4f2f-a973-3d6c3a450ccf,C0012634,C0040802,may may contained through hand hygiene physical distancing ,Disease,travel,4,X,[dsyn],[dora],C23.550.288,I03.883
3724bd29-e9f6-47bb-bed9-fa566921cc30,dataset,COVID-19,is with ,dataset,COVID-19,2,X,????,[virs],????,C000657245
8214f685-9b1e-4d35-822d-679cb48df98f,dataset,C0012634,is with ,dataset,Disease,2,X,????,[dsyn],????,C23.550.288
e6b9a110-f09a-437a-861e-bf9a46a1a9c1,C0005516,COVID-19,related to ,Biological Markers,COVID-19,1,X,[clna],[virs],D23.101,C000657245
8fd2f9ca-2877-4753-975f-bc383ca0eea2,2B,C1175743,share genetically distinct from original ,2B,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
70dc72e3-b743-4a62-ac17-380a18851f08,C0017428,C0008139,harbored in ,Genome,Chiroptera,1,X,[gngm],[mamm],G05.360.340,B01.050.150.900.649.313.937
9e33516c-241b-474c-8dc8-d2bd05c8a199,C1175743,C0042774,maintains similar ,SARS coronavirus,Virus Replication,1,X,[virs],[celf],B04.820.504.540.150.113.937,G06.920.925
a0edd495-cccf-40ae-9e4b-b96e6c2a542b,C1175743,C0022702,maintains similar ,SARS coronavirus,Kinetics,1,X,[virs],[npop],B04.820.504.540.150.113.937,G01.374.661;G02.111.490
82f6eda4-041d-4b03-9799-2b00fa86da1c,C1175743,C0042542,maintains Virus Replication Kinetics to,SARS coronavirus,Vero Cells,2,X,[virs],[cell],B04.820.504.540.150.113.937,A11.251.210.955;A11.436.955
218d8f8a-9813-4113-aaa6-298b12b1bf3f,C0206750,C3539076,Interferon,Coronavirus Infections,Pretreatment,1,X,[dsyn],[acty],C02.782.600.550.200,
0aa7360f-6e56-46cb-93e6-9a2fb60497b5,C1175743,C0021966,is in context of type IFN,SARS coronavirus,Iodides,1,X,[virs],[inch],B04.820.504.540.150.113.937,D01.248.497.158.490;D01.475.410
e084b45a-26cf-4732-aad8-3395daaff1aa,C1175743,IFN,is in context of type IFN,SARS coronavirus,IFN,1,X,[virs],????,B04.820.504.540.150.113.937,????
1fd08a2c-f9e0-4774-ad05-840f077762ca,C0031715,C1175743,Examining IFN,Phosphorylation,SARS coronavirus,1,X,[moft],[virs],G02.111.665;G02.607.780;G03.796,B04.820.504.540.150.113.937
48beda70-9a93-4dd5-98fb-cb0a5659b3d5,C0031715,C0021966,Examining IFN,Phosphorylation,Iodides,1,X,[moft],[inch],G02.111.665;G02.607.780;G03.796,D01.248.497.158.490;D01.475.410
e435ea15-f249-4aba-8983-3a5ae440de47,C0031715,IFN,Examining IFN,Phosphorylation,IFN,1,X,[moft],????,G02.111.665;G02.607.780;G03.796,????
0d1a1d0d-4e13-45ff-9edb-6033b3a5c040,C0031715,C3652465,Examining ,Phosphorylation,Interferon,1,X,[moft],[aapp/imft/phsu],G02.111.665;G02.607.780;G03.796,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
953130a4-7c69-4101-beb0-83ff95c902db,C0031715,C1948023,Examining ,Phosphorylation,Stimulation (motivation),1,X,[moft],[npop],G02.111.665;G02.607.780;G03.796,
2e8eb761-24d3-476a-9098-f1a07e4196c6,C0031715,C0920532,Examining ,Phosphorylation,gene induction,2,X,[moft],[genf],G02.111.665;G02.607.780;G03.796,
adf7755a-20ea-4fd3-abab-c9ed553f1db0,C0031715,C0162493,Examining ,Phosphorylation,Transcriptional Activation,2,X,[moft],[genf],G02.111.665;G02.607.780;G03.796,G05.308.800
a44c2389-6ce1-4cdb-81e2-42f3d2026603,IFN,C1175743,finding ,IFN,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
104f6327-8ebd-44cb-a3c0-4a0f74d37dd9,Calu3,C1175743,finding ,Calu3,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
ce79c7e0-f888-4729-87fa-1a613865895a,C1425360,C1175743,finding ,CD244 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
0e006c90-fa78-4fca-8f90-93c7db7e7919,C0042774,C1175743,relative to ,Virus Replication,SARS coronavirus,1,X,[celf],[virs],G06.920.925,B04.820.504.540.150.113.937
0e006c90-fa78-4fca-8f90-93c7db7e7919,C0042774,C1175743,targeting ,Virus Replication,SARS coronavirus,1,X,[celf],[virs],G06.920.925,B04.820.504.540.150.113.937
0d047d56-e697-4789-8adc-e91fb54868ad,C1175743,C0042736,is in ,SARS coronavirus,Viral Proteins,1,X,[virs],[aapp/bacs],B04.820.504.540.150.113.937,D12.776.964
187bd05f-3b09-4532-99af-a54ff1009f85,C0005847,C1422064,also express ,Blood Vessel,ACE2 gene,1,X,[bpoc],[gngm],A07.015,
7b4edc8e-a406-4a54-8b16-3aa3431bddbd,C0005847,COVID-19,are potential targets in ,Blood Vessel,COVID-19,1,X,[bpoc],[virs],A07.015,C000657245
468a3091-63fa-4d5a-84f2-55e66e6c24f0,C0018787,COVID-19,are potential targets in ,Heart,COVID-19,2,X,[bpoc],[virs],A07.541,C000657245
fde22f8b-3014-4f75-bf5b-ab4fed3d978e,C0027061,C0027059,cause ,Myocardium,Myocarditis,1,X,[tisu],[dsyn],A02.633.580;A07.541.704;A10.690.552.750,C14.280.238.625
0b54fd6e-8c62-4199-bc15-b4d892951028,C1515090,C1521827,can However under unique circumstances with ,Surgical Oncology specialty,Preparation,1,X,[bmod],[acty],H02.403.429.515.750;H02.403.810.796,
fdb820e4-9eaa-4392-a219-8918745e8f65,C0206750,C1515090,has reduced ,Coronavirus Infections,Surgical Oncology specialty,2,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.429.515.750;H02.403.810.796
ae2f449d-8223-4ae7-8bdd-4e06cb521038,C1175743,C3542961,affect ,SARS coronavirus,NERVOUS SYSTEM DRUGS,2,X,[virs],[phsu],B04.820.504.540.150.113.937,
314f43b1-4bad-4a91-8472-1744be56c1c4,C0596773,C0015219,is with clinical findings during ,Infectious Encephalitis,Biological Evolution,2,X,[dsyn],[genf],C10.228.140.430.520;C10.228.228.399,G05.045;G16.075
acb5e95b-49fc-468b-9159-3b0e218b03ef,C0596773,C0206750,is with clinical findings during ,Infectious Encephalitis,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.228.140.430.520;C10.228.228.399,C02.782.600.550.200
5b3b018e-b4d2-4d3b-8b04-9babeb31d823,C0015392,C1825598,has more devastating ,Eye,IMPACT gene,2,X,[bpoc],[gngm],A01.456.505.420;A09.371,
fd21b320-0291-442d-8018-649cb08ec267,C4554533,C0206419,is in ,Trend:Type:Point in time:^Patient:Nominal,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
8dcd0c8c-5956-46b0-8ef6-d0c06b6b9f3c,C0521982,C0034538,is with ,Response to treatment,Ionizing radiation,1,X,[clna],[npop],,G01.750.750
616a316f-8915-499c-80f5-665eb2c8d42b,C1280903,C0206419,is in severe ,Exploration procedure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
83685881-3cf4-42c5-859a-49a5214f97e4,C0206419,C1706214,is ,Genus: Coronavirus,Creation,1,X,[virs],[acty],B04.820.504.540.150,
23cd0ec2-f07d-4606-9c1e-2da5f871cb1b,C0877629,C0184661,handling ,infection prophylaxis,Interventional procedure,1,X,[topp],[topp],,
9ea05ab2-d452-4ec2-a7ed-1c1a35000f55,EISS,C0009450,specifically tracking confirmed cases of ,EISS,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
08e09128-80c3-43fc-be03-87910c0a79c6,C1516048,C0012155,using Household ,Assessed,Diet,1,X,[acty],[food],,G07.203.650.240
a5031b7d-713f-49ba-a38b-ea133f3b0152,C0206419,C0003968,included ,Genus: Coronavirus,Ascorbic Acid,1,X,[virs],[orch/phsu/vita],B04.820.504.540.150,D02.241.081.844.107;D02.241.511.902.107;D09.811.100
8834ead3-51c0-4c7b-8cf2-cb84751fa06a,C0206419,C0525033,included ,Genus: Coronavirus,Probiotics,1,X,[virs],[bact],B04.820.504.540.150,G07.203.300.456.500;J02.500.456.500
d2e07a4d-d435-4e59-83ec-dd7989e41464,C0206419,C0242295,included ,Genus: Coronavirus,Dietary Supplements,1,X,[virs],[food],B04.820.504.540.150,G07.203.300.456;J02.500.456
bd2257f0-f537-4ecc-8e5d-d9a791268d98,C0206419,C0001962,included ,Genus: Coronavirus,Ethanol,1,X,[virs],[orch/phsu],B04.820.504.540.150,D02.033.375;x.x.x.x
33ee410c-38ed-4594-a513-d53091cca2fd,C0206419,C0148405,included ,Genus: Coronavirus,Vinegar,1,X,[virs],[irda/orch/phsu],B04.820.504.540.150,D02.241.081.018.165;D10.251.400.045.500
ab5e580a-a4e8-44d7-8f1b-1c9372efb1de,C0008067,C0014544,is with ,Child Care,Epilepsy,2,X,[dora],[dsyn],I01.880.787.293.360;N02.421.088,C10.228.140.490
3cd22c81-c79e-404d-b1cd-a1ea6050f9bc,C1328819,C0042769,effective against other ,Small Molecule,Virus Diseases,1,X,[orch],[dsyn],,C02
0579297f-54c1-460e-9bac-059615445551,C1175743,C1152412,of RNA-Directed RNA Polymerase is,SARS coronavirus,RNA-directed RNA polymerase activity,1,X,[virs],[genf],B04.820.504.540.150.113.937,
0579297f-54c1-460e-9bac-059615445551,C1175743,C1152412,is 10-fold more active than other viral ,SARS coronavirus,RNA-directed RNA polymerase activity,1,X,[virs],[genf],B04.820.504.540.150.113.937,
3df97d17-5e1b-441c-a439-d010009a0626,C0598312,C0033684,depends on three encoded ,DNA Replication,Proteins,1,X,[genf],[aapp/bacs],G02.111.225;G05.226,D12.776
6514a01a-202a-4aa7-bde0-100c7d73bb94,C0920283,C1167622,screened Antiviral Agents for,DNA Helicases,Binding (Molecular Function),1,X,[aapp/enzy],[moft],D08.811.277.040.025.159;D08.811.399.340,
d00feb62-419a-465a-a649-dbf10006b140,C0920283,C0033684,screened Antiviral Agents for,DNA Helicases,Proteins,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.040.025.159;D08.811.399.340,D12.776
2f9ef22e-f614-4a76-a270-2b486579ea97,C0920283,C0003451,screened FDA-approved ,DNA Helicases,Antiviral Agents,1,X,[aapp/enzy],[phsu],D08.811.277.040.025.159;D08.811.399.340,D27.505.954.122.388
89572946-a993-4490-933b-f95d89487b43,C0920283,C0013230,screened ~ 3300 ,DNA Helicases,Investigational New Drugs,1,X,[aapp/enzy],[phsu],D08.811.277.040.025.159;D08.811.399.340,D26.371
0b4fb592-75fd-4960-8a26-ce69a7d04136,C0920283,C0678749,screened ~ 3300 ,DNA Helicases,drug binding,1,X,[aapp/enzy],[phsf],D08.811.277.040.025.159;D08.811.399.340,
57861c67-0823-4ff6-9fe6-b76fbc0deffe,C1167622,C1880157,using ,Binding (Molecular Function),Computation (action),1,X,[moft],[acty],,
f7494e1e-ffb9-446c-aa6e-c96c0fbf0d5f,C4080052,C0687133,has well-characterized ,elbasvir,Drug Interactions,1,X,[orch/phsu],[patf],,G07.690.773.968
9b203eee-318d-47ec-ac5a-43f6b8aa484a,C4080052,C0087111,has toxicity At ,elbasvir,Therapeutic procedure,1,X,[orch/phsu],[topp],,E02
3fd8995a-25cd-4189-90a1-0d5cfbad21b0,C1175743,C4080052,treatment with ,SARS coronavirus,elbasvir,1,X,[virs],[orch/phsu],B04.820.504.540.150.113.937,
bb22a01e-8b77-43ab-903d-a97f5248f09f,C0013227,C4080053, includes ,Pharmaceutical Preparations,grazoprevir,1,X,[phsu],[orch/phsu],D26,
34eb740a-41dc-4d20-b641-19210b5a969d,C3266814,C0013227,renders Mutation to,Action,Pharmaceutical Preparations,1,X,[acty],[phsu],,D26
5ded1dd3-9a3f-403d-8604-b36424834aad,C3266814,C0026882,renders viral ,Action,Mutation,1,X,[acty],[genf],,G05.365.590
df590a56-77b7-41ce-9151-724534748e04,C3178870,C0008073,plays role in ,Endoplasmic Reticulum Stress,Developmental Disabilities,4,X,[comd],[mobd],G04.434,F03.625.421
51b983cc-8f53-46ef-bf5f-2b55e106659e,C3178870,C1175743,is in patients infected with ,Endoplasmic Reticulum Stress,SARS coronavirus,1,X,[comd],[virs],G04.434,B04.820.504.540.150.113.937
f866bc84-b923-4230-92c1-fada26261c86,C0005516,C1175743,is in patients infected with ,Biological Markers,SARS coronavirus,1,X,[clna],[virs],D23.101,B04.820.504.540.150.113.937
61aa58c9-085e-42df-b2d5-2afd70dbd19a,C1415761,C1707455,were found 2 positive cases ,HSPA5 gene,Comparison,1,X,[gngm],[acty],,
5bd77213-ec87-428d-beab-49a0ad22f21b,C1415761,C1175743,was significantly higher in ,HSPA5 gene,SARS coronavirus,1,X,[gngm],[virs],,B04.820.504.540.150.113.937
d0ad6cf2-6638-480b-aa38-5d799d4c5768,C0600388,C1175743,was significantly higher in ,Extracellular Signal Regulated Kinases,SARS coronavirus,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.700.567.249;D12.644.360.450.169;D12.776.476.450.169,B04.820.504.540.150.113.937
fe85addc-a47f-4ae3-afcc-5ef3aafa6c98,C1457887,pyrexia,vary from asymptomatic grade pyrexia,Symptoms,pyrexia,2,X,[sosy],????,,????
76c60496-d340-460c-b460-2f52f2824943,C0007806,C0021760,also showed markedly increased levels of ,Cerebrospinal Fluid,Interleukin-6,1,X,[bdsu],[aapp/imft],A12.207.270.210,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224
d2ee444a-8cc3-489c-a3c3-b8c8cc7cf610,C0206419,C0027765,is with ,Genus: Coronavirus,nervous system disorder,1,X,[virs],[dsyn],B04.820.504.540.150,C10
2b9e63e5-f433-4262-9717-e7d332af6636,C0544688,C0027765,is with ,complication of disease,nervous system disorder,1,X,[patf],[dsyn],,C10
250beae4-b966-46ed-89c9-4969080876f9,C1175743,C0151946,often developing into ,SARS coronavirus,Pulmonary thrombosis,3,X,[virs],[patf],B04.820.504.540.150.113.937,
049d093e-5003-4e75-9d4d-b1b0ffbc7956,C1175743,C0034069,often developing into ,SARS coronavirus,Pulmonary Fibrosis,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.381.765
2732729b-2104-4333-935c-2bc5d11e2abc,C0034069,C0151946,is with ,Pulmonary Fibrosis,Pulmonary thrombosis,1,X,[dsyn],[patf],C08.381.765,
232b9fd6-a03e-4ff0-85d9-3a8668739831,C0206419,M1,manifest prevalence of M1 ,Genus: Coronavirus,M1,1,X,[virs],????,B04.820.504.540.150,????
20874ea2-e799-4cbd-8022-87a24219b1e6,C0012634,M1,manifest prevalence of M1 ,Disease,M1,1,X,[dsyn],????,C23.550.288,????
29e37c2f-2645-422d-a3ce-bc2b72bffe00,C0206419,C0024432,manifest prevalence of M1 ,Genus: Coronavirus,macrophage,1,X,[virs],[cell],B04.820.504.540.150,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
dc8e98ba-f92c-47bd-ab45-02d4458443d3,C0012634,C0024432,manifest prevalence of M1 ,Disease,macrophage,1,X,[dsyn],[cell],C23.550.288,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
fc75fe29-a18b-4c38-9980-4f51fee9f924,C0012634,C0301872,manifest ,Disease,Immune response,1,X,[dsyn],[ortf],C23.550.288,
fc75fe29-a18b-4c38-9980-4f51fee9f924,C0012634,C0301872,impair ,Disease,Immune response,1,X,[dsyn],[ortf],C23.550.288,
86f51f0d-8225-4f7b-8ad5-5d6ccc811562,C1948023,C3178844,enhance immune-modulating properties of ,Stimulation (motivation),Mesenchymal Stromal Cells,1,X,[npop],[cell],,A11.329.830.500;A11.872.590.500
b2de28b8-7b65-4629-8c77-f13726b0a591,C0087111,C2745965,is in ,Therapeutic procedure,Emergencies [Disease/Finding],1,X,[topp],[patf],E02,C23.550.291.781;N06.230.100.083;N06.850.376
075771ef-7378-4de4-b329-56de4958a398,C0208757,C0087111,be ,Receptor Cannabinoid CB2,Therapeutic procedure,1,X,[aapp/rcpt],[topp],D12.776.543.750.695.125.200,E02
7c40f131-d323-4b5e-8bea-c0ca5161899b,C0208757,C0206419,be ,Receptor Cannabinoid CB2,Genus: Coronavirus,1,X,[aapp/rcpt],[virs],D12.776.543.750.695.125.200,B04.820.504.540.150
1109fb5a-3596-4a9d-b99f-6b151dcbf2a2,C0208757,C2745965,be ,Receptor Cannabinoid CB2,Emergencies [Disease/Finding],1,X,[aapp/rcpt],[patf],D12.776.543.750.695.125.200,C23.550.291.781;N06.230.100.083;N06.850.376
79d4ff37-125c-4a85-a460-78ed3d0177f2,C1706214,C1175743,are faced with decisions regarding treatment of ,Creation,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
cf1c4997-daa4-49d5-84f5-ba37fa399df3,C0206419,C1096155,caused worldwide rapid ,Genus: Coronavirus,Macrophage Activation Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,C20.683.515.800
0fbc2311-3489-4660-bf48-0ada6229a8a8,C1704259,C0022709,activated by ,Biochemical Pathway,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
c38d3cdb-3f3f-4d6e-8f2f-c6a8308a6cb6,C0301872,C0024109,severely damages healthy ,Immune response,Lung,1,X,[ortf],[bpoc],,A04.411
61aaef02-8a86-4487-b217-ef6273c29b28,C0741933,C0027059, includes fulminant ,cardiac symptom,Myocarditis,6,X,[sosy],[dsyn],,C14.280.238.625
efb837e5-d35f-437b-90f3-9906ad45fe3e,C0741933,C0221423,are frequent in patients in state of ,cardiac symptom,Illness (finding),4,X,[sosy],[sosy],,
d0b14449-6420-480e-a209-bae7175306c2,C0027059,C0221423,are frequent in patients in state of ,Myocarditis,Illness (finding),4,X,[dsyn],[sosy],C14.280.238.625,
e4309f48-eb81-4b17-ab9d-59e24abdd9bf,C0057678,C0003174,is ,diacetylrhein,Anthraquinones,2,X,[orch/phsu],[orch/phsu],x.x.x.x,D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159
682ae1cf-54d9-4b4e-9216-4517569a22d2,C0057678,C0013227,is ,diacetylrhein,Pharmaceutical Preparations,2,X,[orch/phsu],[phsu],x.x.x.x,D26
0b72ade3-3682-4d0c-90f9-96c263cc483a,C0870883,C0073177,is ,Metabolite,rhein,2,X,[bacs],[orch/phsu],,x.x.x.x
c6772450-2dad-40fb-8624-c41f11b66558,C0073177,C1175175,suggesting rhein as potential therapeutic agent for treatment of,rhein,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
e3859115-7702-45d9-b036-9861ae6b545b,C0073177,C3711684,inhibits ,rhein,S protein severe acute respiratory syndrome coronavirus,6,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
98a08237-6c7d-4465-a3b7-f381e1632468,C0057678,C0206750,is multi-target drug useful for ,diacetylrhein,Coronavirus Infections,2,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
cbcbdfe7-5693-4f05-a483-cab497bd9b77,C0003174,C0079189,may control conditions by multi-faceted ,Anthraquinones,cytokine,2,X,[orch/phsu],[aapp/imft],D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159,D12.644.276.374;D12.776.467.374;D23.529.374
82dc09a9-83c1-412c-8c4e-c6d2405d03a2,C0003174,C3463820,may control conditions by multi-faceted ,Anthraquinones,Inhibition,2,X,[orch/phsu],[acty],D02.455.426.559.847.117.159;D02.806.100;D04.615.117.159,F01.145.544;F02.463.425.475;F02.739.794.405
8f440a5a-5697-4941-95ab-de5ca73056d3,C0042210,C0012634,contain spread of ,Vaccines,Disease,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C23.550.288
8f440a5a-5697-4941-95ab-de5ca73056d3,C0042210,C0012634,Pharmaceutical Preparations against,Vaccines,Disease,1,X,[aapp/imft/phsu],[dsyn],D20.215.894,C23.550.288
55157196-d83e-4402-be7e-9eb53ebd9a11,C0748355,C0206750,pathophysiology of ,Acute respiratory distress,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
eb670b02-82e7-4fd8-a4af-707fc1729a54,C0450254,C0007634,shares same ,Pathogenic organism,Cells,2,X,[orgm],[cell],,A11
b3475a06-6017-43d4-88d7-a830ec755cf8,C0450254,C0058362,shares same ,Pathogenic organism,dipeptidyl peptidase II,2,X,[orgm],[aapp/enzy],,x.x.x.x
8aeb018e-0659-4302-bc5e-fffffadbe9e0,C0024109,C0034069,had characteristics of ,Lung,Pulmonary Fibrosis,4,X,[bpoc],[dsyn],A04.411,C08.381.765
e6aa4280-fb14-4282-92a7-ae452949205a,C0022709,C0003842,mainly locates in ,Peptidyl-Dipeptidase A,Arteries,1,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,A07.015.114
b8e11e9f-838b-4b61-b73b-3d990e32c1aa,C0086418,C0225828,Failed have higher percentage of ,Homo sapiens,Myocytes Cardiac,2,X,[humn],[cell],B01.050.150.900.649.313.988.400.112.400.400,A07.541.704.570;A10.690.552.750.570;A11.620.500
5152bd5c-68ac-483d-ba97-e454ddcc0da3,C0018787,C0225828,Failed have higher percentage of ,Heart,Myocytes Cardiac,2,X,[bpoc],[cell],A07.541,A07.541.704.570;A10.690.552.750.570;A11.620.500
04a6d0b6-8cec-4586-b8d5-a7ff6bad0e4d,C0022709,C0206545,was expressed in ,Peptidyl-Dipeptidase A,Human respiratory syncytial virus,3,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,B04.820.455.600.670.600.750.730
0aa41519-8b68-4583-bf71-fd6ba94c1c6d,C0022709,C0026809,was expressed in ,Peptidyl-Dipeptidase A,Mus,3,X,[aapp/enzy/imft],[mamm],D08.811.277.656.350.350.687,B01.050.150.900.649.313.992.635.505.500
4195b39d-e299-481d-a511-03698130adad,C0022709,C0023810,was expressed in ,Peptidyl-Dipeptidase A,Lipopolysaccharides,3,X,[aapp/enzy/imft],[orch],D08.811.277.656.350.350.687,D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500
3906a074-6670-48a1-9973-6b5274af4497,C0206750,C1524029,is with recent confirmed ,Coronavirus Infections,Mouse MIN NOS,2,X,[dsyn],[neop],C02.782.600.550.200,
93dc3088-7483-4669-a548-dbcadf75e613,C0557061,C0018801,may apply focused on ,Discussion (procedure),Heart failure,2,X,[topp],[dsyn],,C14.280.434
26f20336-b215-4186-b3a8-62860528fba9,C0206750,C0232024,of number is ,Coronavirus Infections,Total airway resistance,2,X,[dsyn],[clna],C02.782.600.550.200,
e8e74d2f-5805-4349-91f5-94b417e6b30b,C1175743,C0450254,is highly ,SARS coronavirus,Pathogenic organism,3,X,[virs],[orgm],B04.820.504.540.150.113.937,
92988002-5675-4ceb-9725-ef48a3a84fca,C0544688,C1175743,have have seen following ,complication of disease,SARS coronavirus,4,X,[patf],[virs],,B04.820.504.540.150.113.937
da2d2fda-0574-4ec8-9bb4-f0184d604068,C0543467,C0206750,provide Hospital beds attachment:Finding:Point in time:^Patient:Document for,Operative Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04,C02.782.600.550.200
da2d2fda-0574-4ec8-9bb4-f0184d604068,C0543467,C0206750,provide resources for ,Operative Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04,C02.782.600.550.200
da2d2fda-0574-4ec8-9bb4-f0184d604068,C0543467,C0206750,is in patients with ,Operative Surgical Procedures,Coronavirus Infections,2,X,[topp],[dsyn],E04,C02.782.600.550.200
3118a804-6eab-4d43-bd31-a7bcec5ed0a4,C0543467,C1705178,have As result have suspended in ,Operative Surgical Procedures,Order (action),1,X,[topp],[acty],E04,
3118a804-6eab-4d43-bd31-a7bcec5ed0a4,C0543467,C1705178,is mandatory in ,Operative Surgical Procedures,Order (action),1,X,[topp],[acty],E04,
ce885cdb-4f6b-4052-bc82-43ee7bb0f00e,C0543467,C2359943,provide ,Operative Surgical Procedures,Hospital beds attachment:Finding:Point in time:^Patient:Document,1,X,[topp],[clna],E04,
a3d5b900-0516-4a46-be0e-561bba2ebfa3,C1175743,C0243083,been associated disease with,SARS coronavirus,associated disease,2,X,[virs],[patf],B04.820.504.540.150.113.937,
8f8a21a9-d763-482a-b392-658238964ff5,C1175743,C0011991,been associated disease with,SARS coronavirus,Diarrhea,1,X,[virs],[sosy],B04.820.504.540.150.113.937,C23.888.821.214
3e0c20d2-b657-413d-84dc-5fb896c6b382,C0012634,C0035204,is viral ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
3e0c20d2-b657-413d-84dc-5fb896c6b382,C0012634,C0035204,can result in severe ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
3e0c20d2-b657-413d-84dc-5fb896c6b382,C0012634,C0035204,causes ,Disease,Respiration Disorders,1,X,[dsyn],[dsyn],C23.550.288,C08.618
d6b2dbb3-a770-4350-9b3a-b7c36a0a137d,C1433062,COVID-19,is considered as ,3C-like protease SARS coronavirus,COVID-19,1,X,[aapp/enzy],[virs],x.x.x.x,C000657245
c808f35c-13e9-44c9-ab05-2c58656ea9b9,COVID-19,C0033727,Communicated by Ramaswamy,COVID-19,Protons,1,X,[virs],[elii],C000657245,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
38295ae4-57ef-47b0-9439-da85f1f53e4c,C0071649,COVID-19,are ,polyphenols,COVID-19,1,X,[orch/phsu],[virs],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,C000657245
bf671e6f-7a15-488c-9e64-e4bedd072673,C0071649,C0033727,are ,polyphenols,Protons,1,X,[orch/phsu],[elii],D02.455.426.559.389.657.715;D03.633.100.150.266.450.260.777,D01.248.497.300.459.700;D01.268.406.750;D01.362.340.750;G01.249.660.500
576a81d6-bdcb-4975-be0b-e7e18966389b,C1175743,C0458827,is in ,SARS coronavirus,Airway structure,2,X,[virs],[bpoc],B04.820.504.540.150.113.937,
741e98e8-6bfb-4858-a8c1-2a333b016791,C2948600,C1456573,SARS coronavirus as,Aim,Global Health,1,X,[inch/phsu],[bmod],,H02.403.371;N01.400.337
4f039269-c228-4e1f-80a3-d5a257185acc,C1175743,C1546536,was present in ,SARS coronavirus,Air sample,1,X,[virs],[sbst],B04.820.504.540.150.113.937,
505b75e0-4203-4d10-8d25-edb6d7455185,C0337000,PCR,showed suitable performance followed by PCR ,Cyclonic Storms,PCR,2,X,[npop],????,G16.500.175.500;N06.230.100.230.100,????
7b504170-8665-474d-8fdc-2db3b00f6b11,C0017237,C1175743,showed suitable performance for trapping PCR ,Gelatin,SARS coronavirus,2,X,[aapp/phsu],[virs],D12.776.860.476,B04.820.504.540.150.113.937
5ee66075-b31d-4db0-af5c-ebe1bdeb3dc1,C0017237,PCR,showed suitable performance for trapping PCR ,Gelatin,PCR,2,X,[aapp/phsu],????,D12.776.860.476,????
a0cca0de-0c51-4137-99c7-7602f0636b82,hypoxic,COVID-19,associated with ,hypoxic,COVID-19,1,X,????,[virs],????,C000657245
1d657132-1010-4c9d-8242-093e048b0720,C0264490,COVID-19,associated with ,Acute respiratory failure,COVID-19,1,X,[dsyn],[virs],,C000657245
64e6ca21-14c7-4dfa-af72-60ed471cca03,COVID-19,C0264490,can lead to ,COVID-19,Acute respiratory failure,1,X,[virs],[dsyn],C000657245,
932fc734-10e8-4b38-b2e8-e343e504bae0,C4284302,C0193062,includes ,EHD1 wt Allele,Rectum excision (procedure),1,X,[gngm],[topp],,E04.210.895
d5cb5993-d5df-4c1e-a289-b77a13295150,C4284302,C2887352,includes ,EHD1 wt Allele,Intraoperative cardiac arrest,1,X,[gngm],[patf],,
53a46f44-0570-4c33-b39f-29a94e506359,C0193062,C2887352,is with ,Rectum excision (procedure),Intraoperative cardiac arrest,1,X,[topp],[patf],E04.210.895,
b2e24478-91b4-406a-93cc-99f6e7553995,C0338106,C0034065,ascending ,Adenocarcinoma of colon,Pulmonary Embolism,1,X,[neop],[patf],,C08.381.746;C14.907.355.350.700
234ee17d-9d91-4d54-88ad-a2c7c0deb832,C0019080,C0192861,necessitated acute ,Hemorrhage,Right colectomy,1,X,[patf],[topp],C23.550.414,
a78e6be3-cce1-4b42-8819-0228d5688d75,C0021081,C0009429,multiply chances of opportunistic in ,Immunosuppressive Agents,Combined Modality Therapy,1,X,[imft/phsu],[topp],D27.505.696.477.656,E02.186
ed99ebd1-dc5f-4ecd-a472-79566a1143b2,C0021081,C0206750,multiply chances of opportunistic in ,Immunosuppressive Agents,Coronavirus Infections,1,X,[imft/phsu],[dsyn],D27.505.696.477.656,C02.782.600.550.200
b6652a52-0fe9-4757-b927-a36dbdd472ed,C1531518,C0206750,multiply chances of opportunistic so due to ,Biological treatment,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
8f9ae784-5aef-4f07-b6c8-2878e46827a1,C1175743,C0035204,primarily causes ,SARS coronavirus,Respiration Disorders,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C08.618
1e43fa05-3fd2-4897-ba2b-9107f0577c1e,C0021390,C0960756,can due to can ,Inflammatory Bowel Diseases,factor A,2,X,[dsyn],[orch],C06.405.205.731;C06.405.469.432,x.x.x.x
bbf73931-122d-4d2e-bf79-f1cac4f8913c,COVID,C0009450,is much more than ,COVID,Communicable Diseases,1,X,????,[dsyn],????,C01.539.221
b96bf89f-5e31-463e-9771-9658fbd8532c,C0060323,C0302148,OR for ,Fibrin fragment D,Blood Clot,1,X,[aapp/bacs],[patf],x.x.x.x,C14.907.355.830
7f2d0208-b70d-4278-94c7-7c59b502476f,C0302148,C0019080,OR for ,Blood Clot,Hemorrhage,1,X,[patf],[patf],C14.907.355.830,C23.550.414
1aadc3b6-f4b5-4ea6-86df-8fcdff7f86ec,C0005516,C0006560,included ,Biological Markers,C-reactive protein,1,X,[clna],[aapp/imft],D23.101,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
92eb0ad7-1f65-42e8-93b2-273096adc22b,C0012739,C0019080,were associated with significant ,Disseminated Intravascular Coagulation,Hemorrhage,1,X,[dsyn],[patf],C15.378.100.220;C15.378.463.250;C15.378.925.220,C23.550.414
879cc28e-4ce1-4987-91ca-178d274a671c,C0040034,C0019080,were associated with significant ,Thrombocytopenia,Hemorrhage,1,X,[dsyn],[patf],C15.378.140.855,C23.550.414
293f4b64-878c-4c5a-be81-b159195a575d,C0020517,EMBASE,is in EMBASE,Hypersensitivity,EMBASE,1,X,[patf],????,C20.543,????
d64df5ae-5b42-464e-9a06-77ba0339c9a0,C1706202,EMBASE,is in EMBASE,Search - action,EMBASE,1,X,[acty],????,,????
b78d44d4-5413-4115-9372-3da09c4e50b4,C0009450,C0242295,can can used as ,Communicable Diseases,Dietary Supplements,2,X,[dsyn],[food],C01.539.221,G07.203.300.456;J02.500.456
38ef8d45-9b80-4208-9d81-6cbfef5e6594,C0009450,C0028606,can can used as ,Communicable Diseases,Nucleic Acids,2,X,[dsyn],[bacs/nnon],C01.539.221,D13.444
3cd1984b-cb6a-4f88-8ae5-c9e46cb7b530,C3540676,COVID-19,be maintained in ,Blockade,COVID-19,1,X,[elii/phsu],[virs],,C000657245
f0555d7c-81c0-4657-b55d-ba725d6cfae2,C1708476,COVID-19,will reduce ,Implementation,COVID-19,1,X,[acty],[virs],,C000657245
e916205b-a330-41bd-8c09-93f31fa06c70,COVID-19,C0795934,has opened new ,COVID-19,Digitorenocerebral Syndrome,1,X,[virs],[dsyn],C000657245,x.x.x.x
f40b4162-a69b-4376-b899-a603fd7a4e46,COVID-19,C0003504,has opened new ,COVID-19,Aortic Valve Insufficiency,1,X,[virs],[dsyn],C000657245,C14.280.484.095
40712127-4b30-43f9-995b-afd863199483,C2948600,C0031336,offer ,Aim,Pharmacy (field),1,X,[inch/phsu],[bmod],,H02.646
dafa310e-def9-404d-b1e9-5aa045bb012a,C0242781,C0887950,is scale-free with few ,disease transmission,Genomics,1,X,[patf],[bmod],N06.850.310,H01.158.273.180.350;H01.158.273.343.350
eb183d83-4c76-487b-b400-327d29296835,C1704259,C0023745,emphasize extent of epidemiological ,Biochemical Pathway,genetic linkage,1,X,[moft],[moft],,G05.348
d443972b-6b86-4a2c-98b3-6acc1eb79293,C1293116,C0023745,emphasize extent of epidemiological ,Introduction procedure,genetic linkage,1,X,[topp],[moft],,G05.348
9e04720a-5c96-44bd-a4e7-29ac8af782fc,COVID-19,C0206061,is new clinical syndrome from upper respiratory ,COVID-19,Pneumonia Interstitial,1,X,[virs],[dsyn],C000657245,C08.381.483
9e04720a-5c96-44bd-a4e7-29ac8af782fc,COVID-19,C0206061,is new syndrome from mild upper respiratory ,COVID-19,Pneumonia Interstitial,1,X,[virs],[dsyn],C000657245,C08.381.483
17916137-0cf6-416c-b6b6-8a89d20644a8,COVID-19,C0025962,is new clinical syndrome from upper respiratory ,COVID-19,Microcirculation,1,X,[virs],[ortf],C000657245,G09.330.100.645
17916137-0cf6-416c-b6b6-8a89d20644a8,COVID-19,C0025962,aggravated in ,COVID-19,Microcirculation,1,X,[virs],[ortf],C000657245,G09.330.100.645
1eb0af1a-6b9f-4730-bbf3-b198cb169b9f,COVID-19,C0302148,aggravated by ,COVID-19,Blood Clot,1,X,[virs],[patf],C000657245,C14.907.355.830
208971af-1235-439c-a4de-7bf07ad035e7,C0221423,C1880022,from syndrome is ,Illness (finding),Characterization,1,X,[sosy],[acty],,
e594de7d-9b56-4f88-959a-897f3fc3f27f,C0013227,C0242656,be evaluated in relation to pathophysiology of ,Pharmaceutical Preparations,Disease Progression,1,X,[phsu],[patf],D26,C23.550.291.656
15835e5a-7926-4ea4-af9a-1cf4828a0574,C0024348,C0206419,was optimized with endemic ,Lysis,Genus: Coronavirus,2,X,[patf],[virs],,B04.820.504.540.150
a2811a6a-16f3-487e-ab30-834cd20d8e8c,C0887950,C0520510,were used as control ,Genomics,Materials,1,X,[bmod],[sbst],H01.158.273.180.350;H01.158.273.343.350,
5ae06142-e940-42d6-9453-eab4625314cc,C0035668,C0520510,were used as control ,RNA,Materials,1,X,[nnon],[sbst],D13.444.735,
6c72f492-5551-45df-ba09-ed5e8f02663b,C0035668,C0038164,is in ,RNA,Staphylococcal Protein A,4,X,[nnon],[aapp/imft/irda],D13.444.735,D12.776.097.820;D23.050.161.821
62ce38f5-a3ad-4e84-8200-f4713fa11b2d,C0035668,C2987482,is in ,RNA,Animal Coat,2,X,[nnon],[bpoc],D13.444.735,
3b32c9c8-9d72-42a0-bfad-d9b73bf69a37,C0185115,C0206750,decreased Recovery - action of endemic,Extraction,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
eb52abed-9817-49cc-96e5-3abcea866f1c,C0028606,C0035668,transcribed ,Nucleic Acids,RNA,1,X,[bacs/nnon],[nnon],D13.444,D13.444.735
d3400663-c3b8-41ad-a3c2-72ac7aed6904,C0185115,C0035668,transcribed ,Extraction,RNA,1,X,[topp],[nnon],,D13.444.735
7cf2ae3e-7ff7-46f6-9bbb-285144a24389,C0028606,C4698072,transcribed ,Nucleic Acids,NL63,1,X,[bacs/nnon],[virs],D13.444,
45d82423-cd97-4ac2-af29-195a73b64b16,C0185115,C4698072,transcribed ,Extraction,NL63,1,X,[topp],[virs],,
695783fd-1755-478c-b7f7-c74b1037956b,C0237820,C4698072,transcribed ,Recovery - action,NL63,1,X,[acty],[virs],,
8fd19740-db3f-4e04-be89-ec348425cdf6,C0237820,C0035668,transcribed ,Recovery - action,RNA,1,X,[acty],[nnon],,D13.444.735
94f5d78f-518a-4cf9-ac3b-e722be08cf10,C0042776,C4698072,compared to RNA is,Virus,NL63,1,X,[virs],[virs],B04,
c5064938-abb9-4ba5-aabb-16854abd7c5c,C1628999,C0035668,had Recovery - action through amplification compared to,SARS coronavirus RNA,RNA,1,X,[nnon],[nnon],,D13.444.735
593d73c5-33a5-40a2-9cd4-d31c7531cf9b,C1628999,C0237820,had more reliable ,SARS coronavirus RNA,Recovery - action,1,X,[nnon],[acty],,
a239a3bc-e364-471c-b473-8345c7cc58b7,C1628999,C0185115,had more reliable ,SARS coronavirus RNA,Extraction,1,X,[nnon],[topp],,
c785367b-6e1a-4975-b4f7-31c72de05866,C0237820,C0024348,combining ,Recovery - action,Lysis,2,X,[acty],[patf],,
15e5e549-b087-4be5-8775-16b66c8d60da,C0237820,C0006353,combining ,Recovery - action,Buffers,2,X,[acty],[irda/phsu],,D27.720.470.280
4ed944b9-d458-48aa-8c55-7ef3f93855da,C0237820,C4553629,combining Lysis Buffers with clinical,Recovery - action,MATRix Regimen,2,X,[acty],[topp],,
dcceec8c-f518-4655-adc4-15496c7e8c59,C0206750,C0185115,optimizing ,Coronavirus Infections,Extraction,1,X,[dsyn],[topp],C02.782.600.550.200,
06c350aa-1d76-447b-bc33-087f5c56fcc6,C0597363,C0042776,is In absence of live attenuated ,recombinant virus,Virus,2,X,[virs],[virs],,B04
f77f285c-4b05-42e5-9f8f-5d39b7cebbeb,C0597363,C0038164,is in ,recombinant virus,Staphylococcal Protein A,2,X,[virs],[aapp/imft/irda],,D12.776.097.820;D23.050.161.821
63695d2e-83cf-407a-b1fa-a9795a63c428,C0597363,C2987482,is in ,recombinant virus,Animal Coat,2,X,[virs],[bpoc],,
b8307197-5926-4d80-a11a-6991052e4df5,COVID-19,C0684249,is in patients with ,COVID-19,Carcinoma of lung,2,X,[virs],[neop],C000657245,
e16389f2-4791-4a7a-a7a0-3ddf34faed59,C0242943,C0015219,is ,Molecular Mimicry,Biological Evolution,1,X,[moft],[genf],G02.111.560;G05.545;G16.012.750.500,G05.045;G16.075
73b70050-e052-45a7-98a3-25e20c1a66aa,C0242943,C0042776,is ,Molecular Mimicry,Virus,1,X,[moft],[virs],G02.111.560;G05.545;G16.012.750.500,B04
3b0470c0-ebf2-435d-8493-66fb106a07b0,C0287990,C1879547,is critical for ,paired basic amino acid cleaving enzyme,Activation action,1,X,[aapp/enzy],[acty],D08.811.277.656.300.760.353;D08.811.277.656.837.249;D08.811.277.656.959.350.353,
7b95230d-f560-47ca-bc9d-c013a1d93e2e,C0026882,C0002006,causes ,Mutation,Aldosterone,1,X,[genf],[horm/orch/phsu],G05.365.590,D04.210.500.745.745.654.062;D06.472.040.585.353.118
56d15bdf-455f-4811-928f-bff1d48a38ba,C0034848,COVID-19,is in ,Receptors Virus,COVID-19,1,X,[aapp/rcpt],[virs],D12.776.543.750.830,C000657245
1bd61659-2be1-4d6a-9a52-6c2edc47a95e,C0022709,COVID-19,is in ,Peptidyl-Dipeptidase A,COVID-19,1,X,[aapp/enzy/imft],[virs],D08.811.277.656.350.350.687,C000657245
df665940-dcbb-4ebb-94ce-8437230668d3,C0034848,C0007634,is in ,Receptors Virus,Cells,1,X,[aapp/rcpt],[cell],D12.776.543.750.830,A11
c2f23aec-2ef4-45f4-bc59-8f2a0d2f0d7f,C0034848,C0024109,is in ,Receptors Virus,Lung,1,X,[aapp/rcpt],[bpoc],D12.776.543.750.830,A04.411
625d36c4-c07f-446a-95e1-4a815cf20623,C0007634,C0185027,shows significant ,Cells,Imbrication (procedure),1,X,[cell],[topp],A11,
16c30a75-ed73-48c3-8999-2efc1c512cda,C0035668,C0185027,shows significant ,RNA,Imbrication (procedure),1,X,[nnon],[topp],D13.444.735,
11810a44-3673-41b7-a01a-a3b40a465d76,C0011164,C1175743,wired into ,Abnormal degeneration,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
2fbeff9c-e6c9-4236-8748-3a6a5c80dab1,C0015219,C0233577,may may driven by its ,Biological Evolution,Mimicry,1,X,[genf],[mobd],G05.045;G16.075,
fb01d7c9-2a25-4dae-9b89-ba565166acb8,C0038164,C0019868,critical for ,Staphylococcal Protein A,Homeostasis,1,X,[aapp/imft/irda],[biof],D12.776.097.820;D23.050.161.821,G07.410
8941a74f-0634-4fe3-a609-f3648816d67e,C0038164,C0458827,critical for ,Staphylococcal Protein A,Airway structure,1,X,[aapp/imft/irda],[bpoc],D12.776.097.820;D23.050.161.821,
bcce253f-c3d6-41f2-a536-6887f52b87ba,C0038164,C0302908,critical for ,Staphylococcal Protein A,Liquid substance,1,X,[aapp/imft/irda],[sbst],D12.776.097.820;D23.050.161.821,
1f328389-4a17-4d27-9236-cdc853219d9a,C0005768,C1856053,were in ,In Blood,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bdsu],[dsyn],x.x.x.x.x,x.x.x.x
f986a2b1-724a-4fea-999f-79b50e29c933,C1273858,C0005768,conserve ,Transfusion Medicine,In Blood,1,X,[bmod],[bdsu],H02.403.429.445.500,x.x.x.x.x
236aa8e9-37f7-4f63-8999-6623fa014291,C3658340,C0005768,conserve ,Hospital Medicine,In Blood,1,X,[bmod],[bdsu],H02.403.377,x.x.x.x.x
07d4cb67-b357-44cb-a028-dd6e0e4209b9,C0013227,C0429028,prolong ,Pharmaceutical Preparations,QT interval feature (observable entity),2,X,[phsu],[clna],D26,
1d2d2f18-e300-48c8-a3a1-ce9e68d43341,C0013227,C0040479,accordingly put - instruction imperative patients at increased risk for,Pharmaceutical Preparations,Torsades de Pointes,1,X,[phsu],[dsyn],D26,C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700
1d2d2f18-e300-48c8-a3a1-ce9e68d43341,C0013227,C0040479,accordingly may put patients at increased risk for ,Pharmaceutical Preparations,Torsades de Pointes,1,X,[phsu],[dsyn],D26,C14.280.067.845.940.700;C14.280.123.875.940.700;C23.550.073.845.940.700
ab629459-a4c2-467c-99b6-475b308d44a3,MEDLINE,C0011071,artesunate for risk of QT prolongation torsades ventricular arrhythmia and,MEDLINE,Sudden death,1,X,????,[patf],????,C23.550.260.322
a894b555-2661-480c-9d5c-bc3e85c68e73,MEDLINE,C0008269,artesunate for risk of QT prolongation torsades ventricular arrhythmia and,MEDLINE,Chloroquine,1,X,????,[orch/phsu],????,D03.633.100.810.050.180
26fa2aa5-f507-417e-b365-938d3233523f,C0008269,C0003811,potentially increase risk of ,Chloroquine,Cardiac Arrhythmia,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C14.280.067;C23.550.073
6d3ab372-b0af-4a65-bee4-4ec9bfe652e5,C4553629,genomic,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,genomic,1,X,[topp],????,,????
685ad918-af73-4f4a-9f2b-6239a4805c13,C4553629,y43,elucidated potential missense variants from genomic xentit y43 ,MATRix Regimen,y43,1,X,[topp],????,,????
a4340b5b-0ab3-45a6-9667-ecbcf8211428,C0013227,C0012854,reduce extracellular ,Pharmaceutical Preparations,DNA,1,X,[phsu],[bacs/nnon],D26,D13.444.308
22809f1e-fca4-43e0-a4d9-10afb92ad442,C0013227,C1515933,reduce extracellular ,Pharmaceutical Preparations,Alveolus,1,X,[phsu],[bpoc],D26,
60095fe5-6471-40e0-85a8-272a7f4ea062,PPE,C0206750,becomes at ,PPE,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
fbad9354-b0a7-44e2-aa80-de6e91f5856e,C0282624,C0206750,reconverted during ,Minimally Invasive Surgical Procedures,Coronavirus Infections,1,X,[topp],[dsyn],E04.502,C02.782.600.550.200
f175eb75-241d-42ec-9e12-01e1919821d5,C1415347,RCT,is pragmatic RCT,GTF2I gene,RCT,1,X,[gngm],????,,????
ead1af26-6618-4775-853c-87feb2406b8c,C4082365,RCT,is pragmatic RCT,Choline O-Acetyltransferase human,RCT,1,X,[aapp/enzy],????,,????
3427400b-3ca7-4696-a2aa-0ee1c326e724,RCT,C1415347,using sub-cohort of ,RCT,GTF2I gene,2,X,????,[gngm],????,
8e7be4fa-039b-477f-87c6-4f455ab4e12d,RCT,C0206750,using ,RCT,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
7499b790-52c7-4c97-85ff-62b41f44166a,C0206750,C1415347,sub-cohort of ,Coronavirus Infections,GTF2I gene,1,X,[dsyn],[gngm],C02.782.600.550.200,
8729dea9-22ca-404b-9a22-8a9ad5afd752,C1415347,C0441655,includes ,GTF2I gene,Activities,1,X,[gngm],[acty],,
4ef5b590-f6bf-41ab-abbe-bbc10f7b2089,C4082365,C0441655,includes ,Choline O-Acetyltransferase human,Activities,1,X,[aapp/enzy],[acty],,
4d003157-c5bf-4111-948c-3c2ba0eb5e0d,C2728259,C0441655,includes ,Program,Activities,1,X,[orch/phsu],[acty],V02.355.750,
164a01ca-1ea3-4dcc-8187-59bb4cc2e52a,C0184661,4-week,will receive 4-week ,Interventional procedure,4-week,1,X,[topp],????,,????
a1190c37-ccb9-4a52-b2b8-f084bc7a3ebe,C0184661,C1415347,will receive 4-week ,Interventional procedure,GTF2I gene,1,X,[topp],[gngm],,
d7fd44cc-8139-4a5f-bba7-1611dbe97a25,C0184661,C4082365,will receive 4-week ,Interventional procedure,Choline O-Acetyltransferase human,1,X,[topp],[aapp/enzy],,
13654681-e075-46ff-869e-d6bd563f2cc0,C0184661,C2728259,will receive 4-week ,Interventional procedure,Program,1,X,[topp],[orch/phsu],,V02.355.750
d5625124-ff24-40a4-bd42-35224fa0bf9b,C0918259,C1167518,is among thus mainstay of ,medical nutritional therapy,viral nucleocapsid location,1,X,[topp],[celc],,
49137296-fe5c-4ad1-a8c8-3d8ba94ab734,C0918259,C0206750,is among thus mainstay of ,medical nutritional therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
08953b38-891f-45ac-b2a5-b2fcee73d8e9,C4534538,C0038454,increased including only hospitalizations with discharge ,Mechanical thrombectomy,Cerebrovascular accident,1,X,[topp],[dsyn],,C10.228.140.300.775;C14.907.253.855
bc7728a8-073a-4d8d-8425-2f2c63ed9272,C0206750,C0037633,has demonstrated strong potential of various health ,Coronavirus Infections,Solutions,2,X,[dsyn],[sbst],C02.782.600.550.200,D26.776
6aa90d90-c622-4b04-a17d-eae3326d2483,C0231528,C0009450,were present mostly in early stages of ,Myalgia,Communicable Diseases,3,X,[sosy],[dsyn],C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500,C01.539.221
84d2c340-9728-42af-86a6-5ddbf2132fdf,C0018681,C0009450,were present in mostly stages of ,Headache,Communicable Diseases,2,X,[sosy],[dsyn],C23.888.592.612.441,C01.539.221
592cf5ff-3a34-417e-b775-2427ce942313,C0012833,C0009450,were present mostly in early stages of ,Dizziness,Communicable Diseases,3,X,[sosy],[dsyn],C23.888.592.763.237,C01.539.221
260c57c5-19e8-4089-83bc-3d023c4cf47c,C0009792,C0206750,occurred commonly in severe ,Consciousness Disorders,Coronavirus Infections,2,X,[mobd],[dsyn],C10.597.606.358;C23.888.592.604.359;F01.700.315;F03.615.300,C02.782.600.550.200
39a621ac-3bb3-4155-8a53-60c28e5c1ebe,C2745965,C0719214,is in ,Emergencies [Disease/Finding],century,1,X,[patf],[phsu/vita],C23.550.291.781;N06.230.100.083;N06.850.376,
48a9069b-6fef-4cb6-b45f-1270ac8e04e4,C1181031,L3606F,is with ORF1a L3606F ,Apical ramus of posterior segmental artery,L3606F,2,X,[bpoc],????,,????
97e7187e-d970-4240-9f37-da843c71aa3f,C1181031,C0026882,is with ORF1a L3606F ,Apical ramus of posterior segmental artery,Mutation,2,X,[bpoc],[genf],,G05.365.590
86fb084a-d339-4a4c-b89e-cb4fc330bc55,C0026882,C1181031,most consistent with Western European Clade L3606F ,Mutation,Apical ramus of posterior segmental artery,1,X,[genf],[bpoc],G05.365.590,
80075e18-98d7-472b-92bd-0b58599e9f79,C0026882,L3606F,most consistent with Western European Clade L3606F ,Mutation,L3606F,1,X,[genf],????,G05.365.590,????
43389c56-de5c-47f1-850e-3762fe431778,C0003062,C0003451,identify potential ,Animals,Antiviral Agents,3,X,[anim],[phsu],B01.050,D27.505.954.122.388
3d16960b-da87-4e74-9684-d353291f42ef,C0003062,C0086418,identify potential ,Animals,Homo sapiens,1,X,[anim],[humn],B01.050,B01.050.150.900.649.313.988.400.112.400.400
3d16960b-da87-4e74-9684-d353291f42ef,C0003062,C0086418,identify Therapeutic procedure Antiviral Agents candidates with strong,Animals,Homo sapiens,1,X,[anim],[humn],B01.050,B01.050.150.900.649.313.988.400.112.400.400
8865a265-a8e5-4bd5-9208-c45c80526057,C1516048,C0015859,is in ,Assessed,Ferrets,1,X,[acty],[mamm],,B01.050.150.900.649.313.750.250.575.350
e5b72acd-51d4-4e49-991f-e31ac731a839,C0003451,C0015859,were Assessed in,Antiviral Agents,Ferrets,1,X,[phsu],[mamm],D27.505.954.122.388,B01.050.150.900.649.313.750.250.575.350
e5b72acd-51d4-4e49-991f-e31ac731a839,C0003451,C0015859,were To end ,Antiviral Agents,Ferrets,1,X,[phsu],[mamm],D27.505.954.122.388,B01.050.150.900.649.313.750.250.575.350
82c7adf8-183a-48b5-bd65-39a79105ba82,C0003451,C0009450,were Assessed in,Antiviral Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.122.388,C01.539.221
82c7adf8-183a-48b5-bd65-39a79105ba82,C0003451,C0009450,were To end ,Antiviral Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.122.388,C01.539.221
e02ddfa9-4445-49e3-93b1-6f984e0d3d58,C0939237,C1516048,efficacies of were To end ,lopinavir / Ritonavir,Assessed,1,X,[phsu],[acty],,
e9ab9380-274e-4fe3-abaf-9cfce08328f6,C0596007,C1516048,efficacies of were To end ,Hydroxychloroquine Sulfate,Assessed,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
93e499f1-5a2a-418d-ab1b-4c3ad7af67fe,C1532298,C1516048,efficacies of were To end ,Emtricitabine and tenofovir product,Assessed,1,X,[orch/phsu],[acty],,
6ea5eb66-05b0-4a3d-94fb-2ab6b1c3f885,C0939237,C0015859,efficacies of were To end ,lopinavir / Ritonavir,Ferrets,1,X,[phsu],[mamm],,B01.050.150.900.649.313.750.250.575.350
2b25f86b-8f33-46de-ad3d-57586e2421b7,C0596007,C0015859,efficacies of were To end ,Hydroxychloroquine Sulfate,Ferrets,1,X,[orch/phsu],[mamm],D03.633.100.810.050.180.350,B01.050.150.900.649.313.750.250.575.350
2e8e5a71-9a2e-4af7-895a-026868809ebd,C1532298,C0015859,efficacies of were To end ,Emtricitabine and tenofovir product,Ferrets,1,X,[orch/phsu],[mamm],,B01.050.150.900.649.313.750.250.575.350
9592ed3a-0ed7-4300-b220-cb02ea2ff2ea,C0939237,C0009450,efficacies of were To end ,lopinavir / Ritonavir,Communicable Diseases,1,X,[phsu],[dsyn],,C01.539.221
12628d9f-6b7f-4c2d-bc9c-db8c943d2276,C0596007,C0009450,efficacies of were To end ,Hydroxychloroquine Sulfate,Communicable Diseases,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.539.221
d5845ce9-7466-4f58-8f87-83095bd60b6b,C1532298,C0009450,efficacies of were To end ,Emtricitabine and tenofovir product,Communicable Diseases,1,X,[orch/phsu],[dsyn],,C01.539.221
17c07a0e-086d-43a9-a5c2-83f94a1baec3,titers,C1550661,is in nasal washes ,titers,Specimen Type - Stool = Fecal,1,X,????,[bdsu],????,
44aeeb28-546b-40e2-9160-5e41dcfe5db2,titers,C0040300,is in nasal washes ,titers,Body tissue,1,X,????,[tisu],????,A10
61dc384b-1095-4385-8b28-a3a477e5688c,C1532298,C0036082,showed virus titers than ,Emtricitabine and tenofovir product,Saline Solution,1,X,[orch/phsu],[sbst],,D26.776.498.500.750
e36ef770-62fb-4a43-a479-019a5c0721af,C1532298,titers,showed lower virus titers ,Emtricitabine and tenofovir product,titers,1,X,[orch/phsu],????,,????
f6bd593d-79c3-46ad-ae50-11beb31e13e0,C1532298,8days,showed virus titers at 8days ,Emtricitabine and tenofovir product,8days,1,X,[orch/phsu],????,,????
3b80cd1d-fc5c-476d-a01b-215a16ccc6fc,C0015859,C0004482,were treated with ,Ferrets,Azathioprine,1,X,[mamm],[hops/orch/phsu],B01.050.150.900.649.313.750.250.575.350,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111
8ffe8697-b53d-4a0d-8307-b8d877544ca5,C0015859,C0042769,further explore effect on ,Ferrets,Virus Diseases,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C02
59514479-044f-42af-a9ab-149292f68be2,C0015859,C2359945,were treated with ,Ferrets,Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[mamm],[clna],B01.050.150.900.649.313.750.250.575.350,
3e95737c-40c0-4ed8-95c2-09f7dabea768,C0004482,C0221423,exhibited longer period of ,Azathioprine,Illness (finding),1,X,[hops/orch/phsu],[sosy],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,
9be9d388-fbff-410f-9f1e-36ae514f2905,C0015859,C0221423,exhibited longer period of ,Ferrets,Illness (finding),1,X,[mamm],[sosy],B01.050.150.900.649.313.750.250.575.350,
846e2963-b1af-475c-a135-b230985f9039,C0004482,C0319157,showed delayed ,Azathioprine,AS virus,3,X,[hops/orch/phsu],[virs],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,
a7b6056b-48eb-487f-8d56-eb9cbf041583,C0015859,C0319157,showed delayed ,Ferrets,AS virus,3,X,[mamm],[virs],B01.050.150.900.649.313.750.250.575.350,
40dc14bc-bd19-43d5-80b3-32db19e708c1,C0004482,titers,exhibited virus titers,Azathioprine,titers,1,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
40dc14bc-bd19-43d5-80b3-32db19e708c1,C0004482,titers,exhibited significantly lower serum neutralization antibody titers,Azathioprine,titers,1,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
40dc14bc-bd19-43d5-80b3-32db19e708c1,C0004482,titers,showed low SN titers,Azathioprine,titers,2,X,[hops/orch/phsu],????,D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,????
373a8ba1-b400-44fa-b1d2-1f1d71e4c457,C0015859,titers,exhibited virus titers,Ferrets,titers,1,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
373a8ba1-b400-44fa-b1d2-1f1d71e4c457,C0015859,titers,exhibited significantly lower serum neutralization antibody titers,Ferrets,titers,1,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
373a8ba1-b400-44fa-b1d2-1f1d71e4c457,C0015859,titers,showed low SN titers,Ferrets,titers,2,X,[mamm],????,B01.050.150.900.649.313.750.250.575.350,????
8ec0c40f-7644-4700-bebe-6b1690c7292b,C0004482,C0036082,exhibited period Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
8ec0c40f-7644-4700-bebe-6b1690c7292b,C0004482,C0036082,exhibited virus titers Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
8ec0c40f-7644-4700-bebe-6b1690c7292b,C0004482,C0036082,exhibited AS virus clearance Compared to,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
8ec0c40f-7644-4700-bebe-6b1690c7292b,C0004482,C0036082,exhibited serum neutralization antibody titers Compared to ,Azathioprine,Saline Solution,1,X,[hops/orch/phsu],[sbst],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,D26.776.498.500.750
71f97bee-86e3-4e06-b424-add798097da5,C0015859,C0036082,exhibited period Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
71f97bee-86e3-4e06-b424-add798097da5,C0015859,C0036082,exhibited virus titers Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
71f97bee-86e3-4e06-b424-add798097da5,C0015859,C0036082,exhibited AS virus clearance Compared to,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
71f97bee-86e3-4e06-b424-add798097da5,C0015859,C0036082,exhibited serum neutralization antibody titers Compared to ,Ferrets,Saline Solution,1,X,[mamm],[sbst],B01.050.150.900.649.313.750.250.575.350,D26.776.498.500.750
944844e8-f3da-42e3-9a84-5e47af152f58,titers,C1266928,is in ,titers,Nasal turbinate bone structure,1,X,????,[bpoc],????,A02.835.232.781.324.948;A04.531.898
f8519cd9-1867-4e31-b6f2-ff1edddf4ab0,C0015859,C0003062,should Despite potential discrepancy between ,Ferrets,Animals,1,X,[mamm],[anim],B01.050.150.900.649.313.750.250.575.350,B01.050
22e11e01-2ce5-420f-8e09-2b5298f7f249,C0015859,C0087111,should Despite potential discrepancy between ,Ferrets,Therapeutic procedure,1,X,[mamm],[topp],B01.050.150.900.649.313.750.250.575.350,E02
d1665fc2-3062-4bce-a764-f499bac61f24,C0015859,C0206750,should Despite potential discrepancy between ,Ferrets,Coronavirus Infections,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C02.782.600.550.200
3c3ac6b3-5c30-48c0-8b4e-ee0d036abcd0,C0004482,C0009450,resulting in prolonged ,Azathioprine,Communicable Diseases,1,X,[hops/orch/phsu],[dsyn],D02.886.759.111;D03.633.100.759.570.090;D13.570.900.111,C01.539.221
9a4c93a3-a174-4dfc-bdd0-b5881f19203b,C0015859,C0009450,resulting in prolonged ,Ferrets,Communicable Diseases,1,X,[mamm],[dsyn],B01.050.150.900.649.313.750.250.575.350,C01.539.221
83c43788-cd02-4124-9cb6-631841fafcdf,C0003062,C0087111,identify ,Animals,Therapeutic procedure,1,X,[anim],[topp],B01.050,E02
86f62273-b36a-4c1b-a8d5-ce4657558fe0,C0027651,C0441655,maintaining ,Neoplasms,Activities,1,X,[neop],[acty],C04,
efc7e7a8-5343-4604-9f0e-fbb6ce4be1e9,C0027651,C1856053,was converted On 13th,Neoplasms,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[neop],[dsyn],C04,x.x.x.x
49e24e8a-61e3-47c4-8a7e-42970fc171b3,C0027651,13th,was converted On 13th,Neoplasms,13th,2,X,[neop],????,C04,????
0545496d-d4a5-4aaf-89e7-50c625712aea,PET/CT,C1175743,hypothesize ,PET/CT,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
c614292c-df8c-4f48-8bde-1df8df0423a7,PET/CT,C0032285,hypothesize ,PET/CT,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
a0867824-081e-4fbf-b4f2-8ea6a90bd830,PET/CT,C0020517,is ,PET/CT,Hypersensitivity,1,X,????,[patf],????,C20.543
d73a1132-96f7-4017-9f6d-b8909d128dd0,C2926735,ona,force ona ,Duration,ona,2,X,[orch/phsu],????,,????
71c40b0c-3b4c-4e87-80b0-d17aae154360,C2926735,C0042077,force adaptation in management among ,Duration,Urology,1,X,[orch/phsu],[bmod],,H02.403.810.860
6f46f31f-39b1-4410-93ee-0d666afb000b,C0032857,C3694279,rapidly inactivates ,Povidone-Iodine,Middle East Respiratory Syndrome,2,X,[orch/phsu],[dsyn],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,C02.782.600.550.200
d46be1c2-ab40-471b-acab-350697e45e20,C0032857,C0206419,rapidly inactivates ,Povidone-Iodine,Genus: Coronavirus,2,X,[orch/phsu],[virs],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,B04.820.504.540.150
f03ed0e8-a5c7-4a26-8db1-7b87547be0b9,C0032857,C1175743,rapidly inactivates ,Povidone-Iodine,SARS coronavirus,3,X,[orch/phsu],[virs],D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745,B04.820.504.540.150.113.937
ba213349-13b2-4941-a505-778985cec557,C0206419,C0679637,has brought ,Genus: Coronavirus,major surgery,2,X,[virs],[topp],B04.820.504.540.150,
140e1582-a6e5-4a88-a1f3-8aef953729d5,C0012634,C0679637,has brought ,Disease,major surgery,2,X,[dsyn],[topp],C23.550.288,
5f3256a9-214e-442f-a748-a317cd3da68e,C1135662,C0012854,digests ,Dornase Alfa,DNA,1,X,[aapp/enzy/phsu],[bacs/nnon],x.x.x.x,D13.444.308
137afe66-4943-43c3-be35-171f55ace54c,C1135662,C0577978,digests DNA in,Dornase Alfa,Mucoid sputum,1,X,[aapp/enzy/phsu],[sosy],x.x.x.x,
8e9294f1-b0f4-4567-b003-d86571c71faa,C3850088,C0042784,contributes to ,Neutrophil Extracellular Traps,Viscosity,1,X,[celc],[npop],A11.284.295.495,G02.930
a36def45-f27b-4ced-894b-815e93bb6f74,C3850088,C0036537,contributes to ,Neutrophil Extracellular Traps,Bodily secretions,1,X,[celc],[bdsu],A11.284.295.495,A12.200
49ddd03f-b685-48fd-b3f8-52788f4244a5,C3850088,COVID-19,are found in ,Neutrophil Extracellular Traps,COVID-19,1,X,[celc],[virs],A11.284.295.495,C000657245
8f44f94a-7d21-455d-9815-05e0146f593c,C3850088,C0229671,are found in ,Neutrophil Extracellular Traps,Serum,1,X,[celc],[bdsu],A11.284.295.495,A12.207.152.846;A15.145.846
9f25a374-2833-4258-a483-035d59592ed5,C1135662,COVID-19,may ,Dornase Alfa,COVID-19,1,X,[aapp/enzy/phsu],[virs],x.x.x.x,C000657245
352d5864-5c4e-4c3f-b933-c13c6979237a,C1135662,C0042776,minimize risk of ,Dornase Alfa,Virus,1,X,[aapp/enzy/phsu],[virs],x.x.x.x,B04
3489be19-fead-4d96-acd0-f03235b39673,C1135662,in-line,was administered through in-line ,Dornase Alfa,in-line,1,X,[aapp/enzy/phsu],????,x.x.x.x,????
70306c20-0a71-48d1-b54d-f727aabe41da,in-line,C0001927,is with ,in-line,Albuterol,1,X,????,[orch/phsu],????,D02.033.100.291.057;D02.092.063.291.057;D02.092.471.683.061
f574e50d-1bd4-4048-b9ba-e9f40ebb4067,C3853628,C2926735,can effectively shorten ,Granule,Duration,2,X,[sbst],[orch/phsu],,
0b569b34-443d-491d-9ab6-9bb21dfdf23a,C3853628,COVID-19,can effectively shorten Duration In,Granule,COVID-19,1,X,[sbst],[virs],,C000657245
2fdd7c29-82da-462c-8db0-779d68f5ec6c,C3853628,C3852990,promote ,Granule,Pulmonary Absorption,4,X,[sbst],[ortf],,G03.015.500.703;G03.787.024.500.703;G07.690.725.015.500.703;G09.772.813
c7250606-7ad5-46d6-9b04-a16cd3591b4a,C3853628,C0302306,promote ,Granule,Inflammatory exudate,2,X,[sbst],[bdsu],,
52cc1eee-8580-49b9-bbe6-8f9908de7ecd,C3853628,C0559546,promote Pulmonary Absorption without obvious,Granule,Adverse reactions,2,X,[sbst],[patf],,
15abe680-b07f-4fbe-a303-17d0a7cd496c,C1628999,PCR,Currently takes put - instruction imperative by real-time PCR,SARS coronavirus RNA,PCR,1,X,[nnon],????,,????
3f6bf5dd-abaa-4c82-87aa-bf81a76883b0,C1511790,PCR,Currently takes put - instruction imperative by real-time PCR,Detection,PCR,1,X,[topp],????,,????
57fdfa68-e93e-4d40-b7fa-5f79f08258da,C1628999,C1882509,takes ,SARS coronavirus RNA,put - instruction imperative,2,X,[nnon],[acty],,
b21a9bd1-1d6c-4fca-ac29-295f8e33a3bd,C1511790,C1882509,takes ,Detection,put - instruction imperative,2,X,[topp],[acty],,
d0ce86a2-f22e-48c3-8e72-a2f6d9a9a5a9,GGO,C1265876,combined with focal consolidation ,GGO,Abnormally opaque structure (morphologic abnormality),1,X,????,[patf],????,
027cd73b-6603-4d3d-964e-8e0c4b8ea70f,COVID-19,C1516048,possible IMPACT gene of is,COVID-19,Assessed,1,X,[virs],[acty],C000657245,
fce2ad31-4f66-4045-a2cf-f169bfc1491e,C1321164,C0087111,re-design our ,Gynecologic Oncology,Therapeutic procedure,1,X,[bmod],[topp],,E02
4f8fd8a6-f728-46bf-ac67-9a998cf8d44b,C0856169,C0087086,leads to formation of ,endothelial dysfunction,Thrombus,1,X,[dsyn],[patf],,C14.907.355.830
bdc5f70a-a2b3-404d-80dc-f5f93e0e9894,C0856169,C0507816,leads to formation of ,endothelial dysfunction,Pulmonary capillary,1,X,[dsyn],[bpoc],,
9fd5612d-dc11-466d-b56f-e85749123c1f,C0282636,C0206419,is in patients with severe ,Cell Respiration,Genus: Coronavirus,1,X,[celf],[virs],G03.197;G04.270,B04.820.504.540.150
2ceee23c-fd74-4dc9-a368-bccf67e6a31f,C0282636,C0398623,is in patients with severe ,Cell Respiration,Thrombophilia,1,X,[celf],[dsyn],G03.197;G04.270,C15.378.925
ea64b5d7-feaf-4584-9bb6-7f924d4116af,C1145670,C0199451,requiring helmet ,Respiratory Failure,Continuous Positive Airway Pressure,1,X,[dsyn],[topp],C08.618.846,E02.041.625.790.259;E02.880.820.790.259
c284b54c-5267-4cc9-a870-b6c4db685b4f,C1145670,C0087086,requiring pro ,Respiratory Failure,Thrombus,1,X,[dsyn],[patf],C08.618.846,C14.907.355.830
484d15e6-2710-48bf-a2bf-d50df5a61b13,C1096021,C0042495,improving ,antiplatelet therapy,Ventilation-Perfusion Ratio,1,X,[topp],[ortf],,E01.370.386.700.650.900;G09.772.920
1559252a-a562-4793-8d5b-cb74d232e27a,C1096021,C0206419,improving Ventilation-Perfusion Ratio in,antiplatelet therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
12cf276f-0c23-418f-9ed2-4389441a6d00,C1096021,C1145670,improving Ventilation-Perfusion Ratio in,antiplatelet therapy,Respiratory Failure,1,X,[topp],[dsyn],,C08.618.846
76e5dccf-0d08-47a1-a327-6e7bc0f73ea5,C1825598,C0007222,will translate given high prevalence of ,IMPACT gene,Cardiovascular Diseases,1,X,[gngm],[dsyn],,C14
bdb9eb6f-f5bd-412d-bd4d-062e26d9ed68,C0005821,COVID-19,can Assessed,Blood Platelets,COVID-19,1,X,[cell],[virs],A11.118.188;A15.145.229.188,C000657245
9628cb8b-6977-4dcc-bb2d-2befad850cc6,C0231832,C0206750,is with ,Respiratory rate,Coronavirus Infections,1,X,[clna],[dsyn],E01.370.600.875.875;G09.772.705.730,C02.782.600.550.200
24a625d5-4545-42b1-9586-676042520c94,C0004238,C0206750,is common clinical manifestation in hospitalized patients with ,Atrial Fibrillation,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.280.067.198;C23.550.073.198,C02.782.600.550.200
e11b3675-9dbb-4290-8b69-3270bd9e3275,C0004238,C0012634,is common manifestation in hospitalized patients with ,Atrial Fibrillation,Disease,2,X,[dsyn],[dsyn],C14.280.067.198;C23.550.073.198,C23.550.288
c0e234ca-ef7e-409c-8d41-d5fef526816b,C0003280,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Anticoagulants,Hemorrhage,2,X,[phsu],[patf],D27.505.954.502.119,C23.550.414
218f67f9-8023-44f0-b26a-6de409c12785,C0687133,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Drug Interactions,Hemorrhage,2,X,[patf],[patf],G07.690.773.968,C23.550.414
4aeeade5-7456-420f-b4b7-f20dcade539b,C0003195,C0019080,may lead to significant bradycardia ventricular arrhythmias or severe ,Anti-Arrhythmia Agents,Hemorrhage,2,X,[phsu],[patf],D27.505.954.411.097,C23.550.414
bd8a3936-caad-4191-a81a-08caed6bc4e1,C0206750,C0004238,is with ,Coronavirus Infections,Atrial Fibrillation,2,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.067.198;C23.550.073.198
5aa34dc8-cb3e-40b2-b750-c5b68c9c4e60,C0206750,C0243087,is with ,Coronavirus Infections,concomitant disease,1,X,[dsyn],[patf],C02.782.600.550.200,
f1c79cd6-3fc6-4282-b69b-8d4e8036421d,C0086418,C0003241,clarify role of ,Homo sapiens,Antibodies,1,X,[humn],[aapp/imft/phsu],B01.050.150.900.649.313.988.400.112.400.400,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
34fb117e-1cae-4f80-ac2d-3b1dece769f6,C0086418,C0699748,clarify role of ,Homo sapiens,Pathogenesis,1,X,[humn],[patf],B01.050.150.900.649.313.988.400.112.400.400,
f6b9d678-dbe4-4b66-9a6c-6a35faa78f84,C0012634,C0019682, includes ,Disease,HIV,2,X,[dsyn],[virs],C23.550.288,B04.820.650.589.650.350
def1232e-6a8a-4f75-96bf-8ca1e6cc8295,C4086266,C0206750,takes place in ,Escalation,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
1fa978a6-5d89-43d2-bbe6-c3e8502f488b,C4086266,C0042384,takes place in ,Escalation,Vasculitis,1,X,[acty],[dsyn],,C14.907.940
0a46f14f-ce1f-4447-808a-e0fa4fd684b3,C0021760,myokine,is key myokine,Interleukin-6,myokine,1,X,[aapp/imft],????,D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,????
817bf090-9fa6-42c4-8e44-102a7ab5b644,C1707455,C0815172,was performed between clinicopathological ,Comparison,patient characteristics,6,X,[acty],[clna],,
8f6162ba-f01a-4f40-b79f-7a03221c1f7e,C1707455,C0003615,was performed between clinicopathological ,Comparison,Appendicitis,2,X,[acty],[dsyn],,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
e6bf4d3f-97e9-4ab7-b85d-cb5b14155de5,C2949735,20th,began 20th,Recruitment,20th,1,X,[acty],????,,????
4c48b195-2ee3-47d6-b259-2870eee78a82,C2949735,31st,is expected complete 31st ,Recruitment,31st,1,X,[acty],????,,????
b4fb4c0a-9343-4c97-88d7-a30c193c9d18,C0206750,C0254211,was cured With treatment with ,Coronavirus Infections,arbidol,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,x.x.x.x
d77305d9-54d6-47b5-bd76-85fe59ed0f56,C0206750,C1512523,was cured With treatment with ,Coronavirus Infections,hydrochloride,1,X,[dsyn],[inch/phsu],C02.782.600.550.200,
97c047fe-4271-43a9-96f2-0a8178b18da9,C0000936,C0024299,is in ,Visual Accommodation,Lymphoma,1,X,[ortf],[neop],G14.010,C04.557.386;C15.604.515.569;C20.683.515.761
60680b0b-5144-40ce-a941-ed40ff9fc365,C0024299,C0278348,undergoing intensive ,Lymphoma,Immunotherapy for cancer,1,X,[neop],[topp],C04.557.386;C15.604.515.569;C20.683.515.761,
a5a3a024-13e3-4c75-b035-d09d6888c4d4,C1707814,C0278348,should For patients treated with ,Dose Reduced,Immunotherapy for cancer,1,X,[topp],[topp],,
8b3a0fa0-6f9f-411b-a0e0-76371be0acdb,C0012634,C0024117, includes ,Disease,Chronic Obstructive Airway Disease,1,X,[dsyn],[dsyn],C23.550.288,C08.381.495.389
5eff2960-8236-4a98-b4ee-a637db784717,C0206750,6th,will will enrolled in trial from 6th 31st ,Coronavirus Infections,6th,1,X,[dsyn],????,C02.782.600.550.200,????
5f13cec7-326b-4b76-81dc-848acd4526f3,C0206750,31st,will will enrolled in trial from 6th 31st ,Coronavirus Infections,31st,1,X,[dsyn],????,C02.782.600.550.200,????
93bd23d2-b605-49b4-ba6c-3bb0fd0d98d2,C0229664,C0039194,detect phenotype of ,peripheral blood,T-Lymphocyte,1,X,[bdsu],[cell],,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
3c2ab38f-717e-4726-be35-e58cb10cebbe,C0229664,C0806987,detect gene profile of ,peripheral blood,mononuclear cells,1,X,[bdsu],[cell],,
1c8d1a02-f4e0-40ff-8500-48afdd110fb8,C0005768,C0025320,subjects before ,In Blood,Menopause,1,X,[bdsu],[phsf],x.x.x.x.x,G08.686.157.500;G08.686.841.249.500
c46a383c-b8d1-4cf4-93e4-796e989d087a,C4321295,C0025320,subjects before ,CGA wt Allele,Menopause,1,X,[gngm],[phsf],,G08.686.157.500;G08.686.841.249.500
5fb0002d-78d7-4f84-81f8-56a7e2f54c0f,C0681562,C0012682,applying ,food product,Disinfectants,1,X,[food],[sbst],,D27.505.954.122.425;D27.720.274
785396ff-e3ea-45ae-8081-48c2f9b117d5,C0681562,C1947930,applying household ,food product,Cleaning (activity),1,X,[food],[acty],,
37e63607-c162-4fd4-b74d-52b32749a2b4,C0035372,C0206750,should In context of current ,Rett Syndrome,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.597.606.360.455.937;C16.320.322.500.937;C16.320.400.525.937,C02.782.600.550.200
326c0476-69cc-40f1-b253-22e90e95604a,C1882932,C0012634,great challenge for time-sensitive ,Representation (action),Disease,1,X,[acty],[dsyn],,C23.550.288
b7ec9512-82e8-4716-ab04-8d9174a94440,C0206750,C0872079,was constructed by ,Coronavirus Infections,protein protein interaction,2,X,[dsyn],[moft],C02.782.600.550.200,
a0eebc79-8cf7-4b95-8b2d-6bf9af15c68d,C0684309,C0872079,was constructed by ,Disease model,protein protein interaction,2,X,[emod],[moft],,
d6fb29d5-fc84-48ae-8e3a-f536d211778e,C0206750,C0017337,was constructed by ,Coronavirus Infections,Genes,2,X,[dsyn],[gngm],C02.782.600.550.200,G05.360.340.024.340
b6fdc586-9def-4f88-a94f-209c419aaf96,C0684309,C0017337,was constructed by ,Disease model,Genes,2,X,[emod],[gngm],,G05.360.340.024.340
1fd6848a-8d17-45f1-a9d6-eebc93533453,C0206750,C1518039,was constructed in ,Coronavirus Infections,Mouse Lung,2,X,[dsyn],[tisu],C02.782.600.550.200,
f9f8d326-470e-4a7f-942b-2657cff9ebc8,C0684309,C1518039,was constructed in ,Disease model,Mouse Lung,2,X,[emod],[tisu],,
d02fbd70-3b07-4096-8663-6d6d54e9f35a,C0684309,C1175743,was constructed in ,Disease model,SARS coronavirus,2,X,[emod],[virs],,B04.820.504.540.150.113.937
73e63426-b611-4c1a-b6eb-47f14f189791,C1515884,C4050231,is with high disturbance ,Acupuncture and Oriental Medicine,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,2,X,[topp],[clna],,
da54a69c-eb38-485d-9b1e-ac03ff0c18e2,C1515884,C2741673,is with high disturbance ,Acupuncture and Oriental Medicine,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[topp],[clna],,
22aaea90-c72e-42ef-821c-4cec228e712d,C1515884,C0206750,is with high disturbance ,Acupuncture and Oriental Medicine,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
1df4f3ca-999a-4350-b0f1-67a9b241f840,C0682897,C4050231,is with disturbance ,flavor enhancers,ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated,1,X,[sbst],[clna],D26.650.294;D27.720.372.300.353;D27.720.744.294;G07.203.300.514.500.400;J02.500.514.500.400,
17865d92-77d8-4b25-8bbf-1dccc3ef85a5,C1515884,C0024109,main meridian of is ,Acupuncture and Oriental Medicine,Lung,1,X,[topp],[bpoc],,A04.411
bca3b4a8-30b5-4d98-9c09-4197bcad172a,C1515884,C0018787,main meridian of is ,Acupuncture and Oriental Medicine,Heart,1,X,[topp],[bpoc],,A07.541
e33c6b83-59c1-4ec4-ad87-357d62874f63,C1515884,C0037993,main meridian of is ,Acupuncture and Oriental Medicine,Spleen,1,X,[topp],[bpoc],,A10.549.700;A15.382.520.604.700
8a00182a-57ee-44e8-b65c-cf822a5d1b20,C1515884,C0023884,main meridian of is ,Acupuncture and Oriental Medicine,Liver,1,X,[topp],[bpoc],,A03.620
300d06aa-12d1-48a0-a241-1c1a83df3602,C1515884,C0038351,main meridian of is ,Acupuncture and Oriental Medicine,Stomach,1,X,[topp],[bpoc],,A03.556.875.875
2ac8d6d0-58b6-426e-8eab-d72e2b44d197,C3687832,C1511539,form significant number of non ,Drugs - dental services,Covalent Interaction,1,X,[topp],[moft],,
c227468a-30b5-4833-8757-2204161b1325,COVID,C1825598,perceived ,COVID,IMPACT gene,1,X,????,[gngm],????,
1128dc0b-3196-4615-b471-ac43b3b44e4e,C1552133,C1825598,perceived ,19s,IMPACT gene,1,X,[bpoc],[gngm],,
1f60dbf7-338c-4a4b-a2b1-4e38dc57572f,C0243026,COVID-19,are among ,Sepsis,COVID-19,1,X,[dsyn],[virs],C01.539.757;C23.550.470.790.500,C000657245
19d03d08-559f-433d-b93e-85c3af3a6d35,C0302148,COVID-19,is in ,Blood Clot,COVID-19,1,X,[patf],[virs],C14.907.355.830,C000657245
1806522a-f6c4-4354-9401-1de006744652,MSC,COVID-19,is in ,MSC,COVID-19,1,X,????,[virs],????,C000657245
0d178a2f-6736-493a-b744-cfa5477d998e,C2936490,10-fold,peaked at nearly 10-fold ,Out-of-Hospital Cardiac Arrest,10-fold,1,X,[patf],????,C14.280.383.610,????
24bb6781-727c-4f5d-a503-fb18e7ed3715,C2936490,C1706374,peaked On ,Out-of-Hospital Cardiac Arrest,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[patf],[aapp/bacs],C14.280.383.610,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
35690616-9c24-4dbb-a035-3cb636a99bac,C1707455,C1856053,is with ,Comparison,Hydranencephaly with Renal Aplasia-Dysplasia,5,X,[acty],[dsyn],,x.x.x.x
cc8ebb57-4330-49f3-bcc8-0ec1370a2e85,C1707455,C2936490,is with ,Comparison,Out-of-Hospital Cardiac Arrest,2,X,[acty],[patf],,C14.280.383.610
4dc9bb5c-ba46-4e08-8792-0402d7b92659,C1707455,C1706374,is with ,Comparison,Tumor Necrosis Factor Ligand Superfamily Member 13,2,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
cf39e4e7-716c-44eb-895e-7b30b9a5f46c,C1707455,C0018790,odds of ,Comparison,Cardiac Arrest,1,X,[acty],[dsyn],,C14.280.383
075df73e-b5d5-4080-9c44-e38d9635defa,COVID-19,C0301630,had substantial ,COVID-19,Reduction (chemical),1,X,[virs],[npop],C000657245,
0653db3c-c025-43b2-969e-8cb9b8d81f27,C0001617,COVID-19,mortality of ,Adrenal Cortex Hormones,COVID-19,1,X,[horm/orch/phsu],[virs],D06.472.040,C000657245
0653db3c-c025-43b2-969e-8cb9b8d81f27,C0001617,COVID-19,reduce only ,Adrenal Cortex Hormones,COVID-19,1,X,[horm/orch/phsu],[virs],D06.472.040,C000657245
4ed4931a-55e3-49bf-88ad-e7ed629a17e1,C0011777,COVID-19,mortality of ,Dexamethasone,COVID-19,1,X,[orch/phsu],[virs],D04.210.500.745.432.769.344;D04.210.500.908.238,C000657245
4ed4931a-55e3-49bf-88ad-e7ed629a17e1,C0011777,COVID-19,reduce only ,Dexamethasone,COVID-19,1,X,[orch/phsu],[virs],D04.210.500.745.432.769.344;D04.210.500.908.238,C000657245
c377e519-a211-4933-91d1-ee7ea32bab96,C0079189,C0543419,Instead are responsible for ,cytokine,Sequela of disorder,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,
270c49d7-f207-42b7-b7b4-2ef17d6ac0c8,C0011777,C0001617,is synthetic ,Dexamethasone,Adrenal Cortex Hormones,1,X,[orch/phsu],[horm/orch/phsu],D04.210.500.745.432.769.344;D04.210.500.908.238,D06.472.040
d6375d03-cea3-4385-b766-d767733b25f3,C0011777,C0079189,would limit production of effect of ,Dexamethasone,cytokine,1,X,[orch/phsu],[aapp/imft],D04.210.500.745.432.769.344;D04.210.500.908.238,D12.644.276.374;D12.776.467.374;D23.529.374
f2d84352-0569-474e-a85c-b5902b52c6e9,C0011777,C0024432,Moreover would block ,Dexamethasone,macrophage,1,X,[orch/phsu],[cell],D04.210.500.745.432.769.344;D04.210.500.908.238,A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397
2e1b479a-23ba-4bf1-a46f-5364c5671fab,C0242821,C0003241,generating protective ,Human body,Antibodies,1,X,[humn],[aapp/imft/phsu],I01.076.201.450.560;K01.093.378,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
e8bcbd3a-fc70-4c4e-a5b6-179c794569bb,C0232117,C1533734,may Instead may followed by ,Pulse Rate,Administration procedure,1,X,[clna],[topp],E01.370.600.875.500;G09.330.380.500,
f0940df0-c142-48e1-aaf5-1ae5cd2d8e8c,C0232117,C0040864,may Instead may followed by ,Pulse Rate,Triamcinolone,1,X,[clna],[orch/phsu],E01.370.600.875.500;G09.330.380.500,D04.210.500.745.432.915;D04.210.500.908.891
f4549d76-bf7e-45b6-8dbe-681c4fe4ddaf,C0232117,C0024109,concentrate in ,Pulse Rate,Lung,1,X,[clna],[bpoc],E01.370.600.875.500;G09.330.380.500,A04.411
ec21c9e6-3131-4ee1-82a6-227b7c06f9fd,C0003451,C0018790,ability to ,Antiviral Agents,Cardiac Arrest,1,X,[phsu],[dsyn],D27.505.954.122.388,C14.280.383
214f88c5-960e-42d3-b93e-d242def7408d,C0003451,C0024880,ability to ,Antiviral Agents,mast cell,1,X,[phsu],[cell],D27.505.954.122.388,A11.329.427;A15.382.652
3bfd4ff6-f6d0-4f1d-9d5a-5694efefcb3e,C0024880,C0079189,are main source of ,mast cell,cytokine,2,X,[cell],[aapp/imft],A11.329.427;A15.382.652,D12.644.276.374;D12.776.467.374;D23.529.374
23029c10-3a22-4780-9f90-52982bb7c5f8,C0024880,C0024109,are main source of ,mast cell,Lung,2,X,[cell],[bpoc],A11.329.427;A15.382.652,A04.411
7acf7b1f-4189-472f-b48b-05ab80698c0e,C0451610,COVID-19,is with ,Patient review,COVID-19,1,X,[topp],[virs],,C000657245
b62c0304-6d4d-46cc-aec3-42ac1dd24a4f,C0037088,C1533734,will help local ,Signs and Symptoms,Administration procedure,1,X,[sosy],[topp],C23.888,
04580bb2-d134-44c9-9f9e-d642a186bf1b,C0006863,C1175743,downregulate receptor expression for CoV2,Cannabidiol,SARS coronavirus,1,X,[orch/phsu],[virs],D02.455.849.090.100,B04.820.504.540.150.113.937
ee973b44-b238-4a32-b253-510425a3e79c,C0700268,C1175743,downregulate receptor expression for CoV2,Cannabis sativa plant,SARS coronavirus,1,X,[orch/phsu],[virs],,B04.820.504.540.150.113.937
d90bb918-6399-4831-bbfb-f8057fd9ab5a,C2828366,C1175743,downregulate receptor expression for CoV2,Extract (substance),SARS coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150.113.937
f4dc3495-fb8a-4971-86f2-d5bca2d97abd,C0006863,CoV2,downregulate receptor expression for CoV2,Cannabidiol,CoV2,1,X,[orch/phsu],????,D02.455.849.090.100,????
916a1b83-b88e-403d-acfe-4855602d0539,C0700268,CoV2,downregulate receptor expression for CoV2,Cannabis sativa plant,CoV2,1,X,[orch/phsu],????,,????
702d9125-01e0-4680-b2f6-9cd55ee808af,C2828366,CoV2,downregulate receptor expression for CoV2,Extract (substance),CoV2,1,X,[sbst],????,,????
00c4aef7-5794-4d81-a7b5-41d19f291e85,C0006863,C0086418,downregulate receptor expression for CoV2,Cannabidiol,Homo sapiens,1,X,[orch/phsu],[humn],D02.455.849.090.100,B01.050.150.900.649.313.988.400.112.400.400
b206ee63-e547-474f-880e-ba275dea1941,C0700268,C0086418,downregulate receptor expression for CoV2,Cannabis sativa plant,Homo sapiens,1,X,[orch/phsu],[humn],,B01.050.150.900.649.313.988.400.112.400.400
fe50890a-ee3e-4f92-8fb0-fc7ea538e91c,C2828366,C0086418,downregulate receptor expression for CoV2,Extract (substance),Homo sapiens,1,X,[sbst],[humn],,B01.050.150.900.649.313.988.400.112.400.400
e9021a22-4802-4e4a-a71e-5406292f0e5a,C0006863,C0014609,downregulate receptor expression for CoV2,Cannabidiol,Epithelium,1,X,[orch/phsu],[tisu],D02.455.849.090.100,A10.272
caf7276f-5fd7-4656-a656-42c744a549e5,C0700268,C0014609,downregulate receptor expression for CoV2,Cannabis sativa plant,Epithelium,1,X,[orch/phsu],[tisu],,A10.272
dbd81aa8-f302-4645-aed0-60c02a233a9d,C2828366,C0014609,downregulate receptor expression for CoV2,Extract (substance),Epithelium,1,X,[sbst],[tisu],,A10.272
4d70311c-b4b7-45bd-90b5-88823d7677a8,C0006863,C0597360,downregulate ,Cannabidiol,receptor expression,2,X,[orch/phsu],[genf],D02.455.849.090.100,
5f3fce7e-00dc-42e1-b4f7-c360b88a8959,C0700268,C0597360,downregulate ,Cannabis sativa plant,receptor expression,2,X,[orch/phsu],[genf],,
08cf7e21-92c6-4dd8-ae71-e0393b6c8523,C2828366,C0597360,downregulate ,Extract (substance),receptor expression,2,X,[sbst],[genf],,
afb0d5ab-5feb-4d8f-a6e3-fd546bccc34c,CoV2,C0086418,is in several models of ,CoV2,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
83a8cd83-c356-4e27-b933-2101d1b48179,C1175743,C0014609,is in several models of ,SARS coronavirus,Epithelium,1,X,[virs],[tisu],B04.820.504.540.150.113.937,A10.272
b433d044-4236-43c3-b087-660873576f73,CoV2,C0014609,is in several models of ,CoV2,Epithelium,1,X,????,[tisu],????,A10.272
589a7e0c-7e9d-42ab-8c6e-03f0d4f73452,C2987634,C0003451,can display direct ,Agonist,Antiviral Agents,1,X,[phsu],[phsu],,D27.505.954.122.388
d8884120-0892-4ee8-83fe-8d7170080fad,C0166418,C3156591,are regulators of ,Peroxisome Proliferator-Activated Receptors,fibroblast activation,2,X,[aapp/rcpt],[celf],D12.776.826.239;D12.776.930.705,
0d5b1266-45a6-4280-9026-2e7272228644,C0243192,C3156591,are regulators of ,agonists,fibroblast activation,2,X,[phsu],[celf],x.x.x,
d1751930-0c76-441e-86fc-c8b4ddfe7ffb,C0166418,C0225360,are regulators of ,Peroxisome Proliferator-Activated Receptors,Myofibroblasts,1,X,[aapp/rcpt],[cell],D12.776.826.239;D12.776.930.705,A11.329.228.975;A11.620.520.500
257d6efc-f95a-43cf-bb43-fd0d228c2bf1,C0243192,C0225360,are regulators of ,agonists,Myofibroblasts,1,X,[phsu],[cell],x.x.x,A11.329.228.975;A11.620.520.500
43a1c38a-8a31-49b2-8d9e-9e576b7396f7,C0243192,C0034069,can Cardiac Arrest development of,agonists,Pulmonary Fibrosis,1,X,[phsu],[dsyn],x.x.x,C08.381.765
86b3d677-30e0-480d-84ae-7d5ecbf79c42,C0683201,COVID-19,is in ,specific immunity,COVID-19,1,X,[ortf],[virs],,C000657245
06c1554f-9f44-42d6-8706-1c7daac7ca11,C0169658,COVID-19,is in ,Janus kinase 1,COVID-19,1,X,[aapp/enzy],[virs],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,C000657245
8a50cc95-5147-4d69-b63e-20f9d2b15f8d,C1366394,COVID-19,is in ,STAT5A protein human,COVID-19,1,X,[aapp/bacs],[virs],x.x.x.x,C000657245
87c20d82-66a2-48fe-8593-03256da0ed93,C0169658,C0032285,is in ,Janus kinase 1,Pneumonia,1,X,[aapp/enzy],[dsyn],D08.811.913.696.620.682.725.124.100;D12.776.476.393.100,C08.381.677;C08.730.610
653f57f3-a93a-4a41-9b2f-429451a2f732,C1366394,C0032285,is in ,STAT5A protein human,Pneumonia,1,X,[aapp/bacs],[dsyn],x.x.x.x,C08.381.677;C08.730.610
e73634c9-4a7b-413a-8261-a463e65868a6,C0035685,C1335439,is promising target with ,RNA-Directed RNA Polymerase,Polymerase,1,X,[aapp/enzy],[aapp/enzy],D08.811.913.696.445.735.780,
a713e61f-e4ce-468a-8c2d-13cfe1deeeab,C0035685,C0243077,is promising target with ,RNA-Directed RNA Polymerase,inhibitors,1,X,[aapp/enzy],[chvf],D08.811.913.696.445.735.780,
f7505fcd-2d62-4705-bc25-c208b653757b,C0035685,C0042769,is promising target with ,RNA-Directed RNA Polymerase,Virus Diseases,1,X,[aapp/enzy],[dsyn],D08.811.913.696.445.735.780,C02
c4f48d93-47b5-4678-bef0-27ee4b75c55d,C1152412,COVID-19,supporting Nucleoside Analogs as,RNA-directed RNA polymerase activity,COVID-19,1,X,[genf],[virs],,C000657245
8ecd19ea-74a5-43af-9c9b-9e97d4964f8f,C0206419,C0001074,represents ,Genus: Coronavirus,Structure of achilles tendon,1,X,[virs],[bpoc],B04.820.504.540.150,A02.880.176
0667501e-56aa-46dc-924d-804744a5a6c5,C1152412,C0001074,represents ,RNA-directed RNA polymerase activity,Structure of achilles tendon,1,X,[genf],[bpoc],,A02.880.176
1fa57791-9d2f-4988-86b1-d182de0d7352,C0206419,C0018870,represents ,Genus: Coronavirus,Heel,1,X,[virs],[bpoc],B04.820.504.540.150,A01.378.610.250.510
4c990d19-7aea-4a54-b811-4e16c79a7bcd,C1152412,C0018870,represents ,RNA-directed RNA polymerase activity,Heel,1,X,[genf],[bpoc],,A01.378.610.250.510
5938b4b7-020d-48cb-8394-1e5b972e768e,C1152412,C1175743,represents ,RNA-directed RNA polymerase activity,SARS coronavirus,1,X,[genf],[virs],,B04.820.504.540.150.113.937
bc15e3c8-2d19-4fef-bd59-e7d20bfed191,C0206419,C1579410,supporting ,Genus: Coronavirus,Nucleoside Analogs,1,X,[virs],[nnon/phsu],B04.820.504.540.150,D09.408.595;D13.570
be5de729-993f-470e-b1a4-43f515cd6852,C1152412,C1579410,supporting ,RNA-directed RNA polymerase activity,Nucleoside Analogs,1,X,[genf],[nnon/phsu],,D09.408.595;D13.570
9d6260da-66e7-4bd6-aab4-5ae1792e35f5,C0010357,C0597404,testing clinical samples positive for various ,Cross Reactions,Respiratory viruses,1,X,[moft],[virs],G12.122.281,
79bba107-03fd-4f0b-a57d-3ad7a067b63d,C0206419,C0815107,has daunted world with its ,Genus: Coronavirus,psychological distress,1,X,[virs],[mobd],B04.820.504.540.150,
440675b3-3a7f-4195-b6c6-92047c861e28,C3714634,C1175743,make such individuals more sensitive to environmental stress factors ,Biological Processes,SARS coronavirus,2,X,[biof],[virs],G16,B04.820.504.540.150.113.937
02c40e14-5d31-4593-9e33-0225526fca68,C3714634,C0314732,make such individuals more sensitive to environmental stress ,Biological Processes,Infectious agent,1,X,[biof],[orgm],G16,
38b6ff59-0269-430c-9cb4-2b5198c4b69c,C0030012,C3714634,appear important ,Oxidation-Reduction,Biological Processes,2,X,[moft],[biof],G02.700;G03.295.531,G16
854bfb44-0495-4737-8bb8-271e9a7f31ae,C0019868,C3714634,appear important ,Homeostasis,Biological Processes,2,X,[biof],[biof],G07.410,G16
e6ab7618-9ac6-4ee0-812c-92fbf5e8865d,C3714634,C0012655,may account for increased ,Biological Processes,Disease susceptibility,1,X,[biof],[clna],G16,C23.550.291.687;G07.100.250
f4a93a42-a402-412f-9509-dc08f172bf08,C0162578,C1825598,is highly ,Thrombectomy,IMPACT gene,1,X,[topp],[gngm],E04.100.814.842,
676cc976-f54a-4795-a1b1-84902ab3c7ba,C0024115,C0039082,is related to ,Lung diseases,Syndrome,2,X,[dsyn],[dsyn],C08.381,C23.550.288.500
52e8c821-b31e-4315-99b4-5feb569158fc,C0024115,C0206422,are three ,Lung diseases,Human coronavirus,2,X,[dsyn],[virs],C08.381,
b462c2de-1901-4b58-947f-d6c8da8c96ed,C1254373,C0206422,are three ,etiologic agent,Human coronavirus,1,X,[sbst],[virs],,
dee072bf-b3c3-464c-b53e-f842bcd383c1,C0018787,C1882509,is taking ,Heart,put - instruction imperative,2,X,[bpoc],[acty],A07.541,
f2185bcd-015c-43a9-b460-1e83b294193e,C0184893,C1882509,is taking ,Emergency operation,put - instruction imperative,2,X,[topp],[acty],,
f45c7cb9-4b6b-4e4f-b5d8-a9ba4b0274fe,C2948600,C0038952,model ,Aim,Continuance of life,1,X,[inch/phsu],[acty],,I03.784
a14e9357-19ef-4292-9199-0dafb3edc195,C2948600,C0598934,model ,Aim,tumor growth,1,X,[inch/phsu],[neop],,
20678b7b-ea73-48df-8ca4-7b987a5b6ea9,C2948600,C0007137,model ,Aim,Squamous cell carcinoma,1,X,[inch/phsu],[neop],,C04.557.470.200.400;C04.557.470.700.400
9aa6f615-c0a4-4566-9c88-f5ed9446002a,C0009450,C0062549,measured by levels immunoglobulins M ,Communicable Diseases,gastrin 17,1,X,[dsyn],[aapp/horm],C01.539.221,x.x.x.x
55c8c04a-bcf1-436b-a251-d7acdd4d2970,C1306587,C0036572,is with clinical ,Acute encephalopathy,Seizures,1,X,[dsyn],[sosy],,C10.597.742;C23.888.592.742
6e8188bb-67da-4c80-a0a1-10bd028a403c,C0231217,C0206750,Previously were seen in patients with advanced ,Multiple symptoms,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
6b288dca-b29e-4f07-8c30-aa61bb9f957a,C4023516,C0206750,are possible in patients with ,Symptomatic seizures,Coronavirus Infections,1,X,[sosy],[dsyn],,C02.782.600.550.200
ddf5e201-8727-4142-9067-0ef922f8d406,C0036572,C0079189,precipitated by ,Seizures,cytokine,1,X,[sosy],[aapp/imft],C10.597.742;C23.888.592.742,D12.644.276.374;D12.776.467.374;D23.529.374
106629cd-df98-4f0b-a9a7-3e6801295093,C0036572,C0042769,precipitated as part of ,Seizures,Virus Diseases,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C02
0403cd58-4cfa-424a-97b2-d31f4a311d5d,C0920672,C0301872,involves ,virus pathogenesis,Immune response,1,X,[comd],[ortf],,
466ad3ee-4cc7-43f4-80e5-4793e06e5d69,C0920672,C0079189,involves ,virus pathogenesis,cytokine,1,X,[comd],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
4603105f-65d0-4704-a981-de24cdadfdd0,C0920672,C0040300,causing effect in addition to ,virus pathogenesis,Body tissue,1,X,[comd],[tisu],,A10
f29f6293-bc23-4e5f-89bc-aa4c5b7a85d3,C0920672,C1948029,causing effect in addition to ,virus pathogenesis,Destruction (action),1,X,[comd],[acty],,
9996d27e-5569-4d83-a3fd-b5a4d23c588e,C0920672,C0178784,causing deleterious effect on ,virus pathogenesis,Organ,1,X,[comd],[bpoc],,
7b3e03b2-aaeb-40a4-9a7a-cb9037176bfc,C0920672,C0031843,causing deleterious effect on ,virus pathogenesis,physiological aspects,1,X,[comd],[phsf],,x.x.x.x
4fc232dc-48a0-4c82-897f-3d159c9699d5,C0019185,C0242781,be ,Murine hepatitis virus,disease transmission,1,X,[virs],[patf],B04.450.580;B04.820.504.540.150.113.875,N06.850.310
5ed2c36e-b2b1-4fd3-a974-dc4486ecec91,C0019185,C0006104,be disease transmission into,Murine hepatitis virus,Brain,2,X,[virs],[bpoc],B04.450.580;B04.820.504.540.150.113.875,A08.186.211
f93dacab-6ca3-4ae8-a02c-9e165e583ac7,C1327414,C0281178,indicates rationale for ,cytokine secretion,anti-cytokine therapy,1,X,[celf],[topp],,
e4f0a11c-9dd7-44f2-9dc1-ad6913123155,C1327414,C0206750,indicates rationale for ,cytokine secretion,Coronavirus Infections,1,X,[celf],[dsyn],,C02.782.600.550.200
945a349b-7a52-41ef-9113-b39f4639a9b0,C2985566,C1707391,may become For ,Targeted Therapy,Choose (action),2,X,[topp],[acty],,
eb061c6c-3899-48a4-a60f-6fab19d691f1,C0005525,C1707391,may become For ,Biological Response Modifiers,Choose (action),2,X,[imft/phsu],[acty],D27.505.696.477,
7d17c8e9-4719-49d1-ad54-f72df9995d17,C0746102,C0004096, includes ,Chronic lung disease,Asthma,1,X,[dsyn],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
3581a032-a30f-4ece-8ffd-fa50fec75fe5,C0746102,C0008679,children with data on ,Chronic lung disease,Chronic disease,1,X,[dsyn],[dsyn],,C23.550.291.500
7ac7a4b5-c143-4ed6-85d6-1f66222c3fcd,C0004096,C0008679,children with data on ,Asthma,Chronic disease,1,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.500
7ac7a4b5-c143-4ed6-85d6-1f66222c3fcd,C0004096,C0008679,is common ,Asthma,Chronic disease,2,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C23.550.291.500
f5467bf4-f19f-41e8-8fbc-c2753c8ef8c8,C0011849,C0856169,are linked to ,Diabetes Mellitus,endothelial dysfunction,1,X,[dsyn],[dsyn],C18.452.394.750;C19.246,
c8608e88-2a70-476e-8fd6-7b13af0e9441,C1879547,C0003009,protecting system from ,Activation action,angiotensin II,1,X,[acty],[aapp/bacs/phsu],,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
72ba52ec-41d7-4559-9f21-016d21f4b7d6,C1879547,C0042396,protecting system from ,Activation action,Vascular constriction (function),1,X,[acty],[ortf],,G09.330.380.925
e5cc1504-fadb-4cc9-834d-936261083b6d,C1879547,C0073591,protecting system from ,Activation action,rosoxacin,1,X,[acty],[antb/orch],,x.x.x.x
56bc00ce-b74f-442d-adb9-000bae15d332,C0021966,C0009450,summarize clinical data on risk for ,Iodides,Communicable Diseases,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C01.539.221
c1e8c836-6b62-4dac-8785-9c6dd224f158,C0021966,C0011849,summarize clinical data on risk for ,Iodides,Diabetes Mellitus,2,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C18.452.394.750;C19.246
48b0ae5a-db2a-4236-9788-84fb9965d31e,C0398623,C0011849,may render individuals with ,Thrombophilia,Diabetes Mellitus,1,X,[dsyn],[dsyn],C15.378.925,C18.452.394.750;C19.246
6f0c7256-71f2-4e80-891a-4764735bf55f,C0398623,C0012655,may render individuals with ,Thrombophilia,Disease susceptibility,1,X,[dsyn],[clna],C15.378.925,C23.550.291.687;G07.100.250
26f2569d-b98f-40bc-881b-b972bf11063b,C0398623,C0206750,play role in overall ,Thrombophilia,Coronavirus Infections,4,X,[dsyn],[dsyn],C15.378.925,C02.782.600.550.200
27ad8993-0edc-4c12-b033-5e4ffc0c9197,C0019134,C0206750,may Given complications specific to ,heparin,Coronavirus Infections,1,X,[bacs/orch/phsu],[dsyn],D09.698.373.400,C02.782.600.550.200
182e170f-7641-40a8-b589-722e81ae4ffb,30-day,C0206750,was significantly higher compared with control patients without ,30-day,Coronavirus Infections,6,X,????,[dsyn],????,C02.782.600.550.200
4341a2da-5898-48a0-98dc-2c1a6c8338c2,C0037285,C0206750,are becoming in adults with ,Skin Manifestations,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.885,C02.782.600.550.200
a75e99e0-eaf3-4299-8c3b-67839aaf4d3c,C0011849,C0684336,is with ,Diabetes Mellitus,Impaired health,1,X,[dsyn],[patf],C18.452.394.750;C19.246,
e8a23908-89a1-4d57-b63b-e6105b48fa47,C1175743,C0013969,reduction in non ,SARS coronavirus,Emergency treatment,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.365
db65bbfa-c0e8-4cea-918e-5a565a5c9f6f,C0039984,C0012634,with patients is group of ,Thoracic Outlet Syndrome,Disease,1,X,[dsyn],[dsyn],C10.668.829.550.850;C14.907.863,C23.550.288
dfec5960-39d5-4e00-9e06-122e6db251a1,C0039984,C1880022,with patients is group of ,Thoracic Outlet Syndrome,Characterization,1,X,[dsyn],[acty],C10.668.829.550.850;C14.907.863,
aacdd391-baae-4501-8095-91a689d1d37b,C1956396,C2717899,presenting with acute ,Venous Thoracic Outlet Syndrome,Upper Extremity Deep Vein Thrombosis,1,X,[dsyn],[patf],C10.668.829.550.850;C14.907.863,C14.907.355.830.925.885
73a51087-9f28-490e-852f-79a4b8826661,C1956396,C0919631,presenting with ,Venous Thoracic Outlet Syndrome,Upper Extremity Deep Vein Thrombosis Primary,1,X,[dsyn],[dsyn],C10.668.829.550.850;C14.907.863,C14.907.355.830.925.885
aa6b1773-65e8-4f8b-bca2-e1be5868740f,C0455760,C1707391,may may considered for ,Catheter procedure,Choose (action),2,X,[topp],[acty],,
8a433785-d767-48f1-a4f0-e59c2c07ac1f,C0455760,C0038532,may may considered for ,Catheter procedure,Structure of subclavian vein,2,X,[topp],[bpoc],,A07.015.908.877
a07bf757-2f38-4d81-9a2d-1459135ddd53,C0455760,C1116449,may may considered for ,Catheter procedure,central vein,2,X,[topp],[bpoc],,
30eb0f7a-a34b-47b5-8a0c-ba2e58e853dc,C0455760,C0028778,may may considered for ,Catheter procedure,Obstruction,2,X,[topp],[patf],,
d410345c-8059-4fe6-ae20-49eb03c8f42d,C1707391,C0038532,is with central ,Choose (action),Structure of subclavian vein,1,X,[acty],[bpoc],,A07.015.908.877
9b65380e-45d3-481e-a2f3-dd8ff1f49380,C1707391,C1116449,is with central ,Choose (action),central vein,1,X,[acty],[bpoc],,
c133e1d7-9876-42e4-999a-cc16f47969b9,C1707391,C0028778,is with central ,Choose (action),Obstruction,1,X,[acty],[patf],,
42b1ae48-0cbe-499f-8413-9837c35d227e,C0455760,C0019004,threatened ,Catheter procedure,Hemodialysis,1,X,[topp],[topp],,E02.870.300;E02.912.800
1ba34a37-7796-48f4-8c4d-f3ad51c5463a,C1880177,C0206750,is in ,Contribution,Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
1f917d72-834e-48cd-a779-3004f0832324,C0037274,C0206750,have have reported in patients with ,Dermatologic disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],C17.800,C02.782.600.550.200
90248c02-d063-497c-9816-140bc9051194,C0206750,C2936405,has highlighted important role for ,Coronavirus Infections,Drug Repositioning,1,X,[dsyn],[topp],C02.782.600.550.200,E05.290.875
c1d06696-cce0-4134-8041-bfa72bc543f6,C0567416,C0441655,is with well-known broad-spectrum ,Molecule,Activities,1,X,[sbst],[acty],,
bb3a4a0d-9cc1-4c17-9960-f2ff256cf914,C0007906,C0567416,represent widely accessible ,Cetylpyridinium,Molecule,1,X,[orch/phsu],[sbst],D03.383.725.762.232,
e11aaa94-bfb4-4ce1-a647-c7b0ffb8284d,C0007906,C0003451,represent widely accessible ,Cetylpyridinium,Antiviral Agents,1,X,[orch/phsu],[phsu],D03.383.725.762.232,D27.505.954.122.388
b49040f3-efba-407f-8ed4-62b9c7c7a432,C0007906,C0441655,represent widely accessible ,Cetylpyridinium,Activities,1,X,[orch/phsu],[acty],D03.383.725.762.232,
f03624fc-1959-49df-842f-0acfb7291c0e,C0066586,C0567416,represent widely accessible antiseptic ,miramistin,Molecule,1,X,[orch/phsu],[sbst],x.x.x.x,
13b6b7e2-885d-491a-a0cd-012a237dbeaf,C0066586,C0003451,represent widely accessible antiseptic ,miramistin,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
f14b3f36-ef95-43b3-8f32-96d46b1e6058,C0066586,C0441655,represent widely accessible antiseptic ,miramistin,Activities,1,X,[orch/phsu],[acty],x.x.x.x,
3abc08e5-859e-4c84-b745-499555cb79d4,C0578399,C0567416,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Molecule,1,X,[orch],[sbst],D01.625.062.500;D02.092.877;D02.675.276,
b27f1af6-5d82-4041-b581-558fd165e6f5,C0008203,C0567416,represent widely accessible antiseptic ,Chlorides,Molecule,2,X,[inch],[sbst],D01.210.450.150;D01.248.497.158.215,
43bbb9f8-20d1-4af4-8c4b-a4f4b149639e,C0578399,C0003451,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Antiviral Agents,1,X,[orch],[phsu],D01.625.062.500;D02.092.877;D02.675.276,D27.505.954.122.388
03891e9a-ee3c-44be-b0bc-ca7369becdc6,C0008203,C0003451,represent widely accessible antiseptic ,Chlorides,Antiviral Agents,2,X,[inch],[phsu],D01.210.450.150;D01.248.497.158.215,D27.505.954.122.388
1e165fb6-23e6-4443-ab46-3709b65baacc,C0578399,C0441655,represent widely accessible antiseptic ,Quaternary Ammonium Compounds,Activities,1,X,[orch],[acty],D01.625.062.500;D02.092.877;D02.675.276,
32ee6f8c-4f11-42b6-95cb-e5f2cd390bd0,C0008203,C0441655,represent widely accessible antiseptic ,Chlorides,Activities,2,X,[inch],[acty],D01.210.450.150;D01.248.497.158.215,
bae96c8f-6442-4def-9c01-cbbd30dc49c8,C0008203,C0087111,represent repurposing opportunity as ,Chlorides,Therapeutic procedure,1,X,[inch],[topp],D01.210.450.150;D01.248.497.158.215,E02
3911c309-4323-4f47-89d0-fca29f2d9531,C0008203,C1175743,represent repurposing opportunity as ,Chlorides,SARS coronavirus,1,X,[inch],[virs],D01.210.450.150;D01.248.497.158.215,B04.820.504.540.150.113.937
8bc07a8b-f145-445f-aea7-905268b409e7,C0019004,C0015672,on patients is ,Hemodialysis,Fatigue,1,X,[topp],[sosy],E02.870.300;E02.912.800,C23.888.369
b2ce3f69-a365-4a7e-b398-31acccb3f8a7,C0036974,C0019004,is in patients on ,Shock,Hemodialysis,1,X,[patf],[topp],C23.550.835,E02.870.300;E02.912.800
06510a3c-b950-4563-a21d-8bb4aeafd848,C0024115,C0015967, includes ,Lung diseases,Fever,2,X,[dsyn],[sosy],C08.381,C23.888.119.344
9aff403b-79c9-4026-81b0-1dc5880ccbea,C0024115,C0019004,were less common in patients on ,Lung diseases,Hemodialysis,14,X,[dsyn],[topp],C08.381,E02.870.300;E02.912.800
106162f6-7d56-46b0-b0b3-d3994ead75ad,C0015967,C0019004,were less common in patients on ,Fever,Hemodialysis,2,X,[sosy],[topp],C23.888.119.344,E02.870.300;E02.912.800
f70fbb96-d5b0-4a4c-9792-0370bce3a60c,C0010200,C0019004,were common in patients on ,Coughing,Hemodialysis,1,X,[sosy],[topp],C08.618.248;C23.888.852.293,E02.870.300;E02.912.800
e758d42b-26cd-4341-84fa-49d7c20ea9c7,C0019004,C0206750,is with ,Hemodialysis,Coronavirus Infections,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C02.782.600.550.200
64a37816-5969-4503-888b-4e540976213c,C0019004,C0012634,is with ,Hemodialysis,Disease,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C23.550.288
2b5081ac-fbd4-4b9c-bfce-a63d7b05d50a,C1825598,C1306597,check ,IMPACT gene,Psychiatric problem,1,X,[gngm],[mobd],,
c5fe1158-80c6-4ae0-9c15-32c264ff5c37,C1621287,C1175743,are needed for ,antibody activity,SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
984e36fe-1803-4b1f-84a1-a70191edf048,C1621287,C0042210,are needed for ,antibody activity,Vaccines,1,X,[moft],[aapp/imft/phsu],,D20.215.894
39bcbbbe-cd25-466a-9170-267c5d85f33e,C0302148,C0242656,emerged as possible explanation ,Blood Clot,Disease Progression,2,X,[patf],[patf],C14.907.355.830,C23.550.291.656
be772bd2-1add-4f6d-ba45-7f2b6187461a,C3277428,C0948245,is with ,Severe viral infections,Cytokine Release Syndrome,1,X,[dsyn],[dsyn],,
934b5efd-0cc7-4d29-9056-9fa3ceb7aa0d,C3277428,C0206750,is with ,Severe viral infections,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
3108a47e-5088-4d27-8a60-a491a54d51a6,C3277428,C1706202,is with ,Severe viral infections,Search - action,1,X,[dsyn],[acty],,
b785c1e8-41fa-4508-b076-61f3b1e87a4c,C1167395,C0745283,must Normally must employed for completion of ,Host (organism),INFECTIOUS PROCESS,2,X,[orgm],[patf],,
4a4a56ac-84a3-4c4c-8b60-63c3cb70cf41,C0024312,C3277428,was associated with ,Lymphopenia,Severe viral infections,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,
5261ca31-e123-4e30-ac31-1b370d49e8f4,C0034019,C0031843,classify app ,public health medicine (field),physiological aspects,2,X,[bmod],[phsf],H02.403.720;N01.400.550;N06.850,x.x.x.x
8d3489c5-ca2a-47a9-9a2d-042af4ab7b6c,PIBD,ESPGHAN,affiliated with Porto ESPGHAN,PIBD,ESPGHAN,1,X,????,????,????,????
f31b6d5f-2621-4386-8d74-d0bce8088d26,centres,ESPGHAN,affiliated with Porto ESPGHAN,centres,ESPGHAN,1,X,????,????,????,????
040f039a-c14e-44ff-8f33-bd7bb8cd4c47,C0206750,C2828389,created by ,Coronavirus Infections,Exclusion,1,X,[dsyn],[acty],C02.782.600.550.200,
3da61525-64f9-4ad2-a6d4-718c59eae26f,C0319157,U.S.,reduce burden on U.S. ,AS virus,U.S.,1,X,[virs],????,,????
358b7c6b-4068-4adc-913a-c29653ee3fa2,C1882932,C0034019,always necessitate Emergency Care during even,Representation (action),public health medicine (field),1,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
2561635a-2e3d-45fd-a608-0d66854f8573,C1882932,C2745965,always necessitate Emergency Care during even,Representation (action),Emergencies [Disease/Finding],1,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
151da841-e6be-4548-bffe-9f93ed6471c8,C1882932,C1527398,always necessitate immediate ,Representation (action),Emergency Care,1,X,[acty],[topp],,N02.421.297
6bb89c7f-cd85-475d-896c-64d55c4f0cae,C1457887,C0221423,signs of serious ,Symptoms,Illness (finding),1,X,[sosy],[sosy],,
2498e093-a57c-47ae-8352-8c36630e7d95,C1175175,C0441516,resulting in higher ,Severe Acute Respiratory Syndrome,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,
4993f8f0-d9ba-42f9-b0ad-37840f4f68ff,C1175175,C0040590,resulting in higher ,Severe Acute Respiratory Syndrome,Tracheostomy procedure,1,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E02.041.750;E04.579.935;E04.580.900;E04.928.780
27e94ba8-614b-4907-ab4c-2593a0cef0d9,C0027485,C0012634,like incident is only ,Natural Disasters,Disease,1,X,[npop],[dsyn],N06.230.100.230,C23.550.288
6aebce90-75dc-47b4-ba87-68fc56e77f1e,C0872152,C0206750,combat ,Drug Development,Coronavirus Infections,1,X,[bmod],[dsyn],E05.290;H01.158.703.007.338;H01.181.466.338,C02.782.600.550.200
abb04b03-bbfa-4667-9318-d9f9b9bf31e1,C1175743,C0010827,was characterized by severe lung injury due to ,SARS coronavirus,Cytopathogenic Effect Viral,1,X,[virs],[comd],B04.820.504.540.150.113.937,E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190
eb490eeb-04bb-4444-8733-622b994df030,C0441636,C0018810,is with increasing ,Surgical shortening - action,heart rate,1,X,[topp],[clna],,E01.370.600.875.500;G09.330.380.500
2dd58829-7ec8-48e4-85f5-305e89d1d745,C2347784,C0021932,need for ,Clinical Endpoint,Intubation Intratracheal,1,X,[clna],[topp],,E02.041.500;E02.585.578;E05.497.578
97016ea9-841b-466a-9902-11bef3814e39,C0021932,C0441636,compared to patients with PR interval ,Intubation Intratracheal,Surgical shortening - action,1,X,[topp],[topp],E02.041.500;E02.585.578;E05.497.578,
f1801121-680a-44a0-a267-c8d1365a209f,C0037088,C0021932,need for ,Signs and Symptoms,Intubation Intratracheal,1,X,[sosy],[topp],C23.888,E02.041.500;E02.585.578;E05.497.578
8fcd5b45-8c38-484a-a914-6f9ae41f5257,C2948600,C0678222,advocating delay ,Aim,Breast Carcinoma,2,X,[inch/phsu],[neop],,C04.588.180;C17.800.090.500
ac151d71-51ed-4c28-99c0-a91755916e6f,C0010408,C0678222,also reducing ,Cryosurgery,Breast Carcinoma,2,X,[topp],[neop],E04.014.180,C04.588.180;C17.800.090.500
69d94aff-f4bc-47c2-86bc-0ad2b4227a5e,C0010408,C1825598,also reducing ,Cryosurgery,IMPACT gene,1,X,[topp],[gngm],E04.014.180,
182338e3-04aa-4cff-8a63-b3fd82b7b47a,C0034754,C0450030,were Ease Gunning ,Reading (activity),Fog,1,X,[dora],[npop],L01.559.423.557,G16.500.275.063.725;G16.500.750.775;N06.230.300.100.725
fd788b3f-4d13-4906-af5b-d28c2d7a43f5,C0034754,C0037365,were Ease Simple Measure of Gobbledygook ,Reading (activity),Smog,1,X,[dora],[npop],L01.559.423.557,D20.633.875
71558a56-8679-48a8-916f-b38866c38ad2,C2949735,C1882932,yielded ,Recruitment,Representation (action),1,X,[acty],[acty],,
422c747d-8316-46f8-b319-83d965f6ebe6,C2949735,C0037778,yielded ,Recruitment,Medical Specialities,1,X,[acty],[bmod],,H02.403
6e8c4137-4b59-42a1-8b5f-5b140b97180b,C4083212,NEI,are supported by NEI ,Alopecia Male Pattern,NEI,1,X,[dsyn],????,C17.800.329.937.122;C23.300.035,????
d0c08804-c968-47aa-a0e8-89ec46d61a85,C0050451,RPB,unrestricted grant from RPB,acetohydroxamic acid,RPB,1,X,[orch/phsu],????,x.x.x.x,????
a94101ec-e574-4101-800f-f507c293edd9,ACP,C0150232,are Family support by Parker,ACP,Family support,3,X,????,[topp],????,
6248b606-549b-4305-a6c9-dc2d3477011f,C1552154,C0150232,are Family support by Parker,Js,Family support,2,X,[bpoc],[topp],,
6db88446-31d1-4c31-b2e7-aa8e55ddcfd4,C1148382,C3714514,key Immune Cell in,Monocytes+Macrophages,Infection,2,X,[cell],[patf],,C01.539
6db88446-31d1-4c31-b2e7-aa8e55ddcfd4,C1148382,C3714514,are considered key ,Monocytes+Macrophages,Infection,2,X,[cell],[patf],,C01.539
24fb8530-9f37-4dc8-af58-187f0a9efc53,C1148382,C0019630,key Immune Cell in,Monocytes+Macrophages,Histocompatibility Antigens Class II,2,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
24fb8530-9f37-4dc8-af58-187f0a9efc53,C1148382,C0019630,are considered key ,Monocytes+Macrophages,Histocompatibility Antigens Class II,2,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
7c5d9543-eb9b-43a8-9805-b08bed7283d4,C1148382,C4330475,are considered key ,Monocytes+Macrophages,Immune Cell,2,X,[cell],[cell],,
7de1f917-9fb2-46a5-ad83-0722c68c574a,C4330475,C3714514,is in ,Immune Cell,Infection,1,X,[cell],[patf],,C01.539
e8b37335-21ed-47ae-874d-1e2d83513037,C4330475,C0026473,is in ,Immune Cell,Monocytes,1,X,[cell],[cell],,A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
2bccc050-22ef-4640-b4d6-113a0946672d,C4330475,C0019764,is in ,Immune Cell,HLA-DR Antigens,1,X,[cell],[aapp/imft],,D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440
29018ccf-38ad-4039-a841-b570a6d9e9b9,C4330475,C0019630,is in ,Immune Cell,Histocompatibility Antigens Class II,1,X,[cell],[aapp/imft],,D12.776.395.550.509;D12.776.543.550.440;D23.050.301.500.400;D23.050.705.552.410
81f318b5-75c3-46c6-9b41-95c451569b9e,C0010340,COVID-19,is with ,Critical Illness,COVID-19,1,X,[dsyn],[virs],C23.550.291.625,C000657245
9c2ce162-4737-4001-ad64-94190b42e234,C0026473,C0010340,was significantly lower in ,Monocytes,Critical Illness,4,X,[cell],[dsyn],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,C23.550.291.625
74c97168-0c90-4883-ba00-050fbe4ded01,C0019764,C0010340,was significantly lower in ,HLA-DR Antigens,Critical Illness,4,X,[aapp/imft],[dsyn],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,C23.550.291.625
112973c5-3b88-4e0d-9cfe-dd46649c0fd8,C0026473,C0003241,was significantly lower in ,Monocytes,Antibodies,1,X,[cell],[aapp/imft/phsu],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
112973c5-3b88-4e0d-9cfe-dd46649c0fd8,C0026473,C0003241,was lower with median difference of 21508 ,Monocytes,Antibodies,1,X,[cell],[aapp/imft/phsu],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
29029b22-dc6e-4924-8b06-1eccec53401a,C0019764,C0003241,was significantly lower in ,HLA-DR Antigens,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
29029b22-dc6e-4924-8b06-1eccec53401a,C0019764,C0003241,was lower with median difference of 21508 ,HLA-DR Antigens,Antibodies,1,X,[aapp/imft],[aapp/imft/phsu],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
c44e051d-e7e7-46ab-abb4-56a9eccb96b1,C0026473,C0007634,was significantly lower in ,Monocytes,Cells,1,X,[cell],[cell],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,A11
c44e051d-e7e7-46ab-abb4-56a9eccb96b1,C0026473,C0007634,was lower with median difference of 21508 ,Monocytes,Cells,1,X,[cell],[cell],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,A11
82c6bf05-0050-47e9-9f95-1652ac3c99d2,C0019764,C0007634,was significantly lower in ,HLA-DR Antigens,Cells,1,X,[aapp/imft],[cell],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,A11
82c6bf05-0050-47e9-9f95-1652ac3c99d2,C0019764,C0007634,was lower with median difference of 21508 ,HLA-DR Antigens,Cells,1,X,[aapp/imft],[cell],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,A11
ee9422e9-323e-49f3-9853-99a9cc98c437,C0026473,C1829939,was lower compared to,Monocytes,{Non-patient},4,X,[cell],[clna],A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547,
55c49697-f72e-4baf-a2d6-a41e50ce9e80,C0019764,C1829939,was lower compared to,HLA-DR Antigens,{Non-patient},4,X,[aapp/imft],[clna],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,
5b5fdf5a-73dc-44a2-abe6-00d9801dca95,C0019764,C0301872,indicating dysfunctional ,HLA-DR Antigens,Immune response,1,X,[aapp/imft],[ortf],D12.776.395.550.509.400.440;D12.776.543.550.440.400.440;D23.050.301.500.400.400.440;D23.050.301.500.450.400.440;D23.050.705.552.410.400.440;D23.050.705.552.450.400.440,
560decc0-9a00-4abf-8669-90c74f63bdfb,C2948600,C0010340,is in population of ,Aim,Critical Illness,1,X,[inch/phsu],[dsyn],,C23.550.291.625
c67d3c49-1f86-4440-bd74-0d83f3fd9af4,C1293132,C1705178,is in ,Anchoring procedure,Order (action),1,X,[topp],[acty],,
d35b5068-9215-439d-baea-412be329ddca,C0206750,COVID-19,causes ,Coronavirus Infections,COVID-19,1,X,[dsyn],[virs],C02.782.600.550.200,C000657245
32747b0d-33d2-43e7-adab-d881b1811b2c,C4601203,C0086418,was most recently recognized CoV prior to ,Porcine enteric Alphacoronavirus,Homo sapiens,1,X,[virs],[humn],,B01.050.150.900.649.313.988.400.112.400.400
fbebed21-4345-4969-b200-138898d9a6b6,C4601203,C1175175,was most recently recognized CoV prior to ,Porcine enteric Alphacoronavirus,Severe Acute Respiratory Syndrome,1,X,[virs],[dsyn],,C02.782.600.550.200.750;C08.730.730
73b95a5b-584e-4577-b881-54c67379c27c,C0008139,C0243083,of CoV is ,Chiroptera,associated disease,2,X,[mamm],[patf],B01.050.150.900.649.313.937,
015fb859-2f50-48ab-873e-00e8d60a864b,C4601203,C0008139,was most recently recognized CoV of potential ,Porcine enteric Alphacoronavirus,Chiroptera,1,X,[virs],[mamm],,B01.050.150.900.649.313.937
05a8ce7d-f265-4c24-bcd5-eed36e96b965,C2921039,C0747973,is largely ,Transcatheter mitral valve repair,Elective procedure,1,X,[topp],[topp],,
2c339bc8-2fed-41df-a162-183bc42f9ad3,C0036980,COVID-19,were treated with amidst ,Shock Cardiogenic,COVID-19,1,X,[patf],[virs],C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550,C000657245
e3693503-6738-4915-8246-b6f8a8cb9d80,C0036980,amidst,were treated with amidst ,Shock Cardiogenic,amidst,1,X,[patf],????,C14.280.647.500.750;C14.907.585.500.750;C23.550.835.550,????
ae23a843-815c-4f38-aa25-9b967ece6330,C4048329,C0393022,is with ,Immunosuppression,rituximab,1,X,[dsyn],[aapp/imft/phsu],E02.095.465.425.450;E05.478.610,D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785
d63b768b-4634-4e07-954f-627b537df87e,C0199470,C0206750,treat Respiratory Failure in,Mechanical ventilation,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
007d4a89-a177-4609-b14d-44651f8f5e25,C0199470,C0012634,treat Respiratory Failure in,Mechanical ventilation,Disease,1,X,[topp],[dsyn],,C23.550.288
0ed1d246-bcbe-4f86-bd39-781567d1825d,C0199470,C1145670,treat ,Mechanical ventilation,Respiratory Failure,1,X,[topp],[dsyn],,C08.618.846
1e338c76-2e51-4f13-b3c5-34dab95c4e8b,C0027059,C0018801,is with ,Myocarditis,Heart failure,1,X,[dsyn],[dsyn],C14.280.238.625,C14.280.434
f7da2b39-1467-4c13-85b6-3d58ef2360dc,C3655548,C1707455,is in ,Height Kidney,Comparison,1,X,[clna],[acty],,
f70600b3-03ea-4d0b-963e-e9a200a29377,C3655548,C0026809,is with female ,Height Kidney,Mus,1,X,[clna],[mamm],,B01.050.150.900.649.313.992.635.505.500
e89565b0-d9fc-42cb-b7a9-6621aa4e2337,C0020538,C0960756,is ,Hypertensive disease,factor A,2,X,[dsyn],[orch],C14.907.489,x.x.x.x
43eabdfa-eb73-4e1a-b614-bf815854320e,C0206750,C0700431,is having significant ,Coronavirus Infections,Cardiac rehabilitation,2,X,[dsyn],[topp],C02.782.600.550.200,E02.760.169.063.500.185;E02.831.185;H02.403.680.600.250;N02.421.784.244
c3bb15fc-629b-4b63-80e9-b45658e6455b,C0021852,C1448177,was In active ,Intestines Small,TNF protein human,1,X,[bpoc],[aapp/bacs],A03.556.124.684,x.x.x.x
c3bb15fc-629b-4b63-80e9-b45658e6455b,C0021852,C1448177,was restored by ,Intestines Small,TNF protein human,1,X,[bpoc],[aapp/bacs],A03.556.124.684,x.x.x.x
db545462-a663-4ff2-8c8c-b1f44f76d111,C0022709,C1448177,was In active ,Peptidyl-Dipeptidase A,TNF protein human,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
db545462-a663-4ff2-8c8c-b1f44f76d111,C0022709,C1448177,was restored by ,Peptidyl-Dipeptidase A,TNF protein human,1,X,[aapp/enzy/imft],[aapp/bacs],D08.811.277.656.350.350.687,x.x.x.x
da957136-5ea6-4b57-8091-cfb6348d7267,C2348077,C0206750,Biological Evolution of,Date Fruit,Coronavirus Infections,1,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C02.782.600.550.200
eeac6f8b-c6cd-47be-a66f-e6fc74e58984,C3241922,C0087111,routinely give symptomatic ,Operation Activity,Therapeutic procedure,2,X,[acty],[topp],,E02
fc7f8c03-cfd4-416f-b865-eb1c96447b4b,C3241922,C0003204,routinely give symptomatic ,Operation Activity,Anti-Infective Agents,2,X,[acty],[phsu],,D27.505.954.122
7ad62fc3-66e5-48b7-8e61-c811f73cdbc0,C0206750,GIE,is in GIE ,Coronavirus Infections,GIE,2,X,[dsyn],????,C02.782.600.550.200,????
c5399f38-0414-4eab-8ab9-803a53bf0b42,C0009326,C0206750,is with ,Collagen Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C17.300.200,C02.782.600.550.200
71df6890-6d02-40b5-bdff-f09f5532e154,C0000983,C1457887,improvement in individual ,Acetic Acid,Symptoms,2,X,[irda/orch],[sosy],D02.241.081.018.165;D10.251.400.045.500,
abc592b0-47ed-44ad-a48b-efcf40c572db,C0000983,C0206750,be promising adjuvant therapy in cases of,Acetic Acid,Coronavirus Infections,2,X,[irda/orch],[dsyn],D02.241.081.018.165;D10.251.400.045.500,C02.782.600.550.200
249130f0-9f7f-406e-9881-36652642e2e5,C0012683,C0206750,be promising adjuvant therapy in cases of,Disinfection,Coronavirus Infections,2,X,[topp],[dsyn],N06.850.780.200.450.850.375,C02.782.600.550.200
8e3fc15b-9ca1-4cc7-b78d-dfdd31e2c543,C0677850,C0206750,is in cases of non-severe ,adjuvant therapy,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
990051ff-1327-4307-836b-5968e10a134f,C0000983,C0677850,be promising ,Acetic Acid,adjuvant therapy,2,X,[irda/orch],[topp],D02.241.081.018.165;D10.251.400.045.500,
2e28e4ad-efb1-43a2-97de-0e83e2d5ef14,C0012683,C0677850,be promising ,Disinfection,adjuvant therapy,2,X,[topp],[topp],N06.850.780.200.450.850.375,
6e0ed9e7-df0d-4bda-bc61-34f353fbb612,C0013227,C1707391,could could then ,Pharmaceutical Preparations,Choose (action),1,X,[phsu],[acty],D26,
2d732ef6-516b-4a43-aef3-7f053c73293b,C0014695,C0035100,inhibits ,Ergocalciferol,Chymosin,1,X,[orch/phsu/vita],[aapp/enzy],D04.210.500.247.222.474;D04.210.500.247.808.412;D04.210.500.812.768.462;D10.570.938.439,D08.811.277.656.074.500.200;D08.811.277.656.300.048.200
10a4709b-fea0-4bdc-bbff-dd7576f2f313,C3146294,C2359945,is in certain ,Generation (action),Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc,1,X,[acty],[clna],,
513031da-2697-4384-848c-7a80704558b0,C0026769,C0007634,for treatment is CD20 ,Multiple Sclerosis,Cells,1,X,[dsyn],[cell],C10.114.375.500;C10.314.350.500;C20.111.258.250.500,A11
ed4b3b82-378e-4b3b-81a7-e6c02f41a71e,C0393022,C0007634,with treatment is CD20 ,rituximab,Cells,1,X,[aapp/imft/phsu],[cell],D12.776.124.486.485.114.224.075.785;D12.776.124.790.651.114.224.075.785;D12.776.377.715.548.114.224.284.785,A11
234d0b5e-bd39-4a75-86bf-082ab5bbac41,C0432618,C0450442,depleting ,Blood group antibody B,Agent,2,X,[aapp/imft],[chvf],,
b9ed6048-abd1-4c81-9b15-fce286fe5aa9,CD20,C0450442,depleting ,CD20,Agent,1,X,????,[chvf],????,
1dbb48b3-1957-4386-9059-5b87d6a24fcd,C0007634,C0450442,depleting ,Cells,Agent,1,X,[cell],[chvf],A11,
4c8a6927-fb15-4adc-8107-109005d11a73,C1999230,CoV2,example for control of CoV2,Providing (action),CoV2,1,X,[acty],????,,????
0ea19551-26b0-4b94-b463-8b4fb37d8760,C0683465,C1825598,adapt for ,novel AODU treatment method,IMPACT gene,1,X,[topp],[gngm],,
8f7a82e6-8f1a-43c0-92e1-b6e565eb84b0,C0027059,C0369718,is in ,Myocarditis,N not otherwise specified Antibody,1,X,[dsyn],[aapp/imft],C14.280.238.625,
2f0ed13b-1187-471c-aa54-542db8cf7b0f,C2003888,C0027059,rate of ,Lower (action),Myocarditis,1,X,[acty],[dsyn],,C14.280.238.625
d5d5f129-05b4-4589-b75b-a1d2073d9177,C0521083,C0026691,differed from comparator group of classical ,Kava,Mucocutaneous Lymph Node Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C14.907.940.560;C15.604.560;C17.800.862.560
5f0e5fae-6dab-494e-865d-395bd8f1b388,C0206750,C0026691,differed from comparator group of classical ,Coronavirus Infections,Mucocutaneous Lymph Node Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.907.940.560;C15.604.560;C17.800.862.560
e83cc856-fcf3-48d7-aadb-be66329544fa,C0521083,C0039082,likely represents new inflammatory ,Kava,Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C23.550.288.500
62383d40-a972-41ec-8636-685633afab56,C0521083,C1175175,likely represents new inflammatory ,Kava,Severe Acute Respiratory Syndrome,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.812.666.249,C02.782.600.550.200.750;C08.730.730
e17e8933-a2d2-499d-803b-d17aed1235d6,C0042720,C0012634,were sampled from patients diagnosed with 3rd 15th,Viral Genome,Disease,1,X,[gngm],[dsyn],G05.360.340.358.840,C23.550.288
6f9f0535-2a6c-478b-97e5-660c94966def,C0042720,3rd,were sampled from patients diagnosed with 3rd 15th,Viral Genome,3rd,1,X,[gngm],????,G05.360.340.358.840,????
9c16839a-5de7-42e2-b56e-865238ff4350,C0042720,15th,were sampled from patients diagnosed with 3rd 15th,Viral Genome,15th,1,X,[gngm],????,G05.360.340.358.840,????
4a9ea048-0b4d-4daf-80ea-e49d991f7ab2,C0032105,C3714514,has has used with degrees of success to ,Plasma,Infection,1,X,[bdsu],[patf],A12.207.152.693;A12.207.270.695;A15.145.693,C01.539
a5d3b4ac-635d-4fe9-a650-69d24a77ba36,C0278347,C0032105,is with convalescent ,Transfusion of plasma,Plasma,1,X,[topp],[bdsu],,A12.207.152.693;A12.207.270.695;A15.145.693
ba6f2f7c-6645-4f6e-991a-e4a4a6296864,C2364111,C0206750,were more prevalent among ,Ageusia,Coronavirus Infections,1,X,[sosy],[dsyn],C10.597.751.861.184;C23.888.592.763.861.184,C02.782.600.550.200
54ece54e-3740-4ec7-bc0f-97aee21ab8ef,C0519551,C1175743,is in patients with ,Skull Base Operation,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
242fef53-be52-4a4a-ae30-c17fe149bf41,C4075512,C0206750,associated with ,Flap necrosis,Coronavirus Infections,3,X,[dsyn],[dsyn],,C02.782.600.550.200
242fef53-be52-4a4a-ae30-c17fe149bf41,C4075512,C0206750,is in patient with ,Flap necrosis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d8e5df7e-ee4c-4231-a603-6ac4fd5d7ded,C0002055,C0038925,using ,Alkalies,Surgical Flaps,1,X,[inch],[bpoc],D01.045,A10.850.710;E07.862.710
83cbf62c-e52f-4c31-9fe8-64e63a18a80a,C0002055,C2930680,using ,Alkalies,Pedicled Flap,2,X,[inch],[bpoc],D01.045,A10.850.710;E07.862.710
1351d175-b6ab-4856-93f8-2c0ff7acfe5a,C0035222,C0242184,complicated by ,Respiratory Distress Syndrome Adult,Hypoxia,1,X,[dsyn],[patf],C08.381.840;C08.618.840,C23.888.852.079
4c6fb7f4-e77a-48c5-89e9-0ff87e068110,C0035222,C1145670,complicated by ,Respiratory Distress Syndrome Adult,Respiratory Failure,1,X,[dsyn],[dsyn],C08.381.840;C08.618.840,C08.618.846
63ac07dd-06c2-444c-bbdc-2e4b45080118,C0544688,C2586211,contributed to ,complication of disease,Thrombosis of blood vessel,2,X,[patf],[patf],,
bbbaeaa5-cc45-4b66-94c1-3bcccdb3d393,C0206750,C2586211,contributed to ,Coronavirus Infections,Thrombosis of blood vessel,2,X,[dsyn],[patf],C02.782.600.550.200,
55f74d6a-f3bc-4ebf-993d-9bd19e85d4dd,C0544688,C0456605,contributed to ,complication of disease,Pedicle,1,X,[patf],[bpoc],,
44206841-8107-4a6d-9992-344a33a45540,C0206750,C0456605,contributed to ,Coronavirus Infections,Pedicle,1,X,[dsyn],[bpoc],C02.782.600.550.200,
ab6f22e6-81d9-4263-9331-020788a2d9fc,C0034386,C0815107,experienced greater ,Quarantine,psychological distress,1,X,[topp],[mobd],N06.850.780.200.450.700,
19353805-f5e5-4c22-8b37-4b16b315b5d8,C3273807,C0206750,may increase likelihood of ,Sodium-Glucose Transporter 2 Inhibitors,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D27.505.519.936;D27.505.696.422.750,C02.782.600.550.200
1a1faa8e-4a76-4ce5-bc72-52ed95a7e882,C3273807,C0220982,may increase likelihood of ,Sodium-Glucose Transporter 2 Inhibitors,Ketoacidosis,1,X,[orch/phsu],[patf],D27.505.519.936;D27.505.696.422.750,C18.452.076.176.652
be001d9c-4c4c-4e72-99af-89414ab9b9fa,C3273807,C0311276,may increase likelihood among patients with ,Sodium-Glucose Transporter 2 Inhibitors,Severe malnutrition,2,X,[orch/phsu],[dsyn],D27.505.519.936;D27.505.696.422.750,
490d5838-e376-493e-abe2-cca3ff627154,C3273807,C0021641,may increase likelihood among patients with ,Sodium-Glucose Transporter 2 Inhibitors,Insulin,1,X,[orch/phsu],[aapp/horm/phsu],D27.505.519.936;D27.505.696.422.750,D06.472.699.587.200.500.625;D12.644.548.586.200.500.625
aee25b0a-3a4e-48f7-b962-d4850587b48b,C0206415,C0370003,is with same clinical ,Oligonucleotide Primers,Specimen,1,X,[nnon],[sbst],D13.695.578.424.450.275;D27.720.470.530.600.223.600,
72e2b647-82ae-4181-a9b7-9bfcd9a40e4c,C0206750,C0027855,is in ,Coronavirus Infections,Neurology speciality,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.600
1f3b2f0c-f66b-488f-bc4b-6d36dd502b36,C0020964,C0022661,is in patients with ,Immunity,Kidney Failure Chronic,1,X,[phsf],[dsyn],G12.450,C12.777.419.780.750.500;C13.351.968.419.780.750.500
9423dd02-7306-4ab5-826d-a35aa21f2240,G1P0,C0015915,had conceived twins via ,G1P0,Fertilization in Vitro,1,X,????,[topp],????,E02.875.800.750;E05.820.800.750
a1b8d020-8577-43ed-a01d-0271784464dc,COVID-19,C0035243,poses threat to its high rate of spread of ,COVID-19,Respiratory Tract Infections,1,X,[virs],[dsyn],C000657245,C01.539.739;C08.730
a1b8d020-8577-43ed-a01d-0271784464dc,COVID-19,C0035243,is highly ,COVID-19,Respiratory Tract Infections,1,X,[virs],[dsyn],C000657245,C01.539.739;C08.730
179f4eba-34f3-4bb1-a91b-0ba4f79889e3,C1706202,C2745965,is urgent at time of ,Search - action,Emergencies [Disease/Finding],1,X,[acty],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
4894242f-78e4-4021-88d9-e0484e6bc9c2,C0072027,C0237820,decreased during ,procalcitonin,Recovery - action,1,X,[aapp/bacs],[acty],D06.472.699.666;D12.644.548.744;D12.776.811.555,
f1012323-df86-4340-82ce-860dab190f88,C1999230,C0034072,detects ,Providing (action),Cor pulmonale,1,X,[acty],[dsyn],,C14.280.832
69f04174-fd21-4479-a669-457ea059cd00,C0027442,C1175743,in SARS coronavirus is,Nasopharynx,SARS coronavirus,1,X,[bpoc],[virs],A04.623.557;A14.724.557,B04.820.504.540.150.113.937
0c3885ac-577b-426d-8252-6bb4e4626e8e,C0040053,C0206750,is in ,Thrombosis,Coronavirus Infections,1,X,[patf],[dsyn],C14.907.355.830,C02.782.600.550.200
880f4443-f82a-4d5d-81fa-e6400afdeae8,COVID-19,C0029166,is with ,COVID-19,Oral Manifestations,1,X,[virs],[sosy],C000657245,C07.465.634;C23.888.619
5cd983f5-3e6e-4396-a1a3-1bf345529ee1,intra,C0041582,vary from ,intra,Ulcer,1,X,????,[patf],????,C23.550.891
2512418f-0e5c-4428-8965-c59199d7e900,C0029166,C0041582,vary from ,Oral Manifestations,Ulcer,1,X,[sosy],[patf],C07.465.634;C23.888.619,C23.550.891
3c88cab2-2699-4285-9533-8bd6970e8e27,intra,C0026724,vary in palatal ,intra,Mucous Membrane,1,X,????,[tisu],????,A10.615.550
3a6bc092-14c4-4e4b-8bc2-3e7367593ee3,C0029166,C0026724,vary in palatal ,Oral Manifestations,Mucous Membrane,1,X,[sosy],[tisu],C07.465.634;C23.888.619,A10.615.550
a1f8f4df-992e-453e-9e6f-132072989782,C0042196,C0199810,is with ,Vaccination,Measles-mumps-rubella vaccination,1,X,[topp],[topp],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,
1b86f0bd-2734-41aa-bba0-b03405062608,C0042196,C0042210,is with ,Vaccination,Vaccines,1,X,[topp],[aapp/imft/phsu],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,D20.215.894
95f1f771-65be-468e-be73-bcd2e4b1c243,C0178575,C0199810,offered by ,cross immunity,Measles-mumps-rubella vaccination,1,X,[moft],[topp],,
194ce5ca-1ccc-4a43-b09f-433fc33d9f1e,COVID-19,C0080078,further disease transmission of was,COVID-19,Range of Motion Articular,1,X,[virs],[clna],C000657245,E01.370.600.700;G11.427.760
e4c1dfb2-9b38-494a-a651-556554f6c85a,C0242781,C0086418,was because of ,disease transmission,Homo sapiens,1,X,[patf],[humn],N06.850.310,B01.050.150.900.649.313.988.400.112.400.400
f0152e87-5c2b-4319-acff-8ce378002a90,C0242781,C0080078,was because of ,disease transmission,Range of Motion Articular,1,X,[patf],[clna],N06.850.310,E01.370.600.700;G11.427.760
758e3505-2170-4335-b3e7-47c56e90d5e1,C0034386,C0038436,give rise to ,Quarantine,Post-Traumatic Stress Disorder,1,X,[topp],[mobd],N06.850.780.200.450.700,F03.950.750.500
a067a1ec-14d5-405d-91d9-2421d7eea27f,COVID-19,C0033909,has influenced ,COVID-19,Psychology,1,X,[virs],[bmod],C000657245,F04.096.628
8758f4d4-4041-4c62-8432-f71a62d5fcde,C0034386,C0033909,has influenced ,Quarantine,Psychology,1,X,[topp],[bmod],N06.850.780.200.450.700,F04.096.628
dd2ed3b3-3f51-4b17-82bd-394696c359b2,C1522455,C0011127,cure ,Recombinant Fibroblast Growth Factor 1,Pressure Ulcer,2,X,[aapp/phsu],[dsyn],,C17.800.893.665
b3334acb-efa8-4ac5-8f3e-6274fec1816e,C0086418,C0011127,cure ,Homo sapiens,Pressure Ulcer,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C17.800.893.665
b3334acb-efa8-4ac5-8f3e-6274fec1816e,C0086418,C0011127,is effective agent for facemask wearing-induced ,Homo sapiens,Pressure Ulcer,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C17.800.893.665
06b2ab0f-df29-4085-a7ce-3dd0335a97bf,C0242656,C0001566,Administration Topical with,Disease Progression,Administration Topical,1,X,[patf],[topp],C23.550.291.656,E02.319.267.120
9fc7aba3-5c3c-4795-a59a-e7973187726c,C0242656,C0086418,Administration Topical with,Disease Progression,Homo sapiens,1,X,[patf],[humn],C23.550.291.656,B01.050.150.900.649.313.988.400.112.400.400
78045cf0-4702-49b9-a9f2-e6941f1a76d2,C0001566,C0242656,significantly inhibit ,Administration Topical,Disease Progression,1,X,[topp],[patf],E02.319.267.120,C23.550.291.656
a6c5acf6-a5ec-49b5-a2a1-7db2a3b388de,C0001566,C0011127,significantly inhibit ,Administration Topical,Pressure Ulcer,1,X,[topp],[dsyn],E02.319.267.120,C17.800.893.665
3971b24e-6107-457e-8add-7785768dfbb6,C0001566,C0086418,is with ,Administration Topical,Homo sapiens,1,X,[topp],[humn],E02.319.267.120,B01.050.150.900.649.313.988.400.112.400.400
5f64c348-811d-4d43-89ca-e09a49955cce,C0450254,C1705178,is in ,Pathogenic organism,Order (action),1,X,[orgm],[acty],,
1771473e-8c96-4708-bf0e-76da6aba7856,C1175175,C1510837,positively correlates with ,Severe Acute Respiratory Syndrome,Airborne Particulate Matter,1,X,[dsyn],[hops],C02.782.600.550.200.750;C08.730.730,D20.633
ed972950-dbfe-4223-a5fb-12be5d5958a4,C0001869,C0086589,thus serve as ,Air Pollutants,Surrogate Markers,1,X,[hops],[clna],D27.888.284.101,D23.101
29153318-d0e5-44ca-8733-7aa70b25cb19,C0001869,C0009450,complement ,Air Pollutants,Communicable Diseases,1,X,[hops],[dsyn],D27.888.284.101,C01.539.221
3d646752-6208-4cbd-add0-ffd5589991f6,C0206750,C0004096,is causing shortage of critical inhalers needed by patients with ,Coronavirus Infections,Asthma,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
f62a3cf3-98aa-43c0-81b5-f9dcd9547a28,C1967692,defence,line of defence,Albuterol Metered Dose Inhaler,defence,3,X,[clnd],????,,????
76223f81-40d7-4f5f-8223-5eb8df4c2fc3,C1967692,C0476273,have ,Albuterol Metered Dose Inhaler,Respiratory distress,2,X,[clnd],[sosy],,
e5864ab9-b6d1-4b6f-bcb6-98e831b6bf03,C1967692,C1999230,is on now ,Albuterol Metered Dose Inhaler,Providing (action),1,X,[clnd],[acty],,
bdfa9302-9f7b-47b6-90ac-d2f466c04f2a,C3534575,COVID-19,likely be impacted by ,Animal Health,COVID-19,2,X,[dsyn],[virs],,C000657245
1dd2f384-910a-4bae-8a44-9f017d497590,C0206750,C0003062,is in ,Coronavirus Infections,Animals,1,X,[dsyn],[anim],C02.782.600.550.200,B01.050
116e1a9b-be1d-486f-8b13-95aa52e63a9e,C3266814,C3534575,adapting ,Action,Animal Health,1,X,[acty],[dsyn],,
192e6734-3268-4410-baba-eafb57a22d07,C0079189,C1184743,may complicate ,cytokine,bony process,1,X,[aapp/imft],[bpoc],D12.644.276.374;D12.776.467.374;D23.529.374,
33bdd162-60b9-4443-b794-deae00a620b5,C1861452,C1184743,may complicate ,Storm Syndrome,bony process,1,X,[dsyn],[bpoc],x.x.x.x,
eb5027a3-21df-4faf-82ee-d169b71dde76,C0243026,AKI,is with AKI,Sepsis,AKI,1,X,[dsyn],????,C01.539.757;C23.550.470.790.500,????
a5c64f3e-e7c8-4a7d-a677-1a3c868b62d8,C3649547,C0243026,has has practiced in AKI,Continuous renal replacement therapy,Sepsis,1,X,[topp],[dsyn],,C01.539.757;C23.550.470.790.500
5b6f67d9-1e5e-4dbc-b266-0dc1803e4ab5,C3649547,AKI,has has practiced in AKI,Continuous renal replacement therapy,AKI,1,X,[topp],????,,????
c6e928aa-af77-4f00-a04c-c6224a8f4ef6,C0682568,C1882932,are two ,membrane by function,Representation (action),1,X,[bpoc],[acty],,
09d8591f-5d75-45d2-a4fe-6421ebc575f4,C0682568,C0596901,are two ,membrane by function,Membrane,1,X,[bpoc],[celc],,A10.615
0883222d-cb75-4c20-9043-a77549a2580f,C0441516,C1999230,has rapidly exceeded its ,Demand (clinical),Providing (action),2,X,[topp],[acty],,
28fafc50-39fa-41c2-b2f7-bdba628ca55b,C0206058,C1548354,allocating ,Elective Surgical Procedures,Specialty Type - Intensive care,1,X,[topp],[bmod],E04.249,
0e03d19c-864b-4a7c-a060-35c9654d6d53,C0206058,C2745965,allocating Specialty Type - Intensive care beds to,Elective Surgical Procedures,Emergencies [Disease/Finding],1,X,[topp],[patf],E04.249,C23.550.291.781;N06.230.100.083;N06.850.376
927ec80b-6765-4a9d-a042-187938f092fd,C0184893,C4283938,underwent awake ,Emergency operation,Open Surgical Procedure,2,X,[topp],[topp],,
8c1fe5ee-c9b2-48a1-88ca-8c6a7f8b3a57,C0026764,C0206750,diagnosed with ,Multiple Myeloma,Coronavirus Infections,1,X,[neop],[dsyn],C04.557.595.500;C14.907.454.460;C15.378.147.780.650;C15.378.463.515.460;C20.683.515.845;C20.683.780.650,C02.782.600.550.200
c47affc9-6d0f-41cb-ac81-cce90e4c7b20,C0206750,C3463820,screened compounds for their ,Coronavirus Infections,Inhibition,1,X,[dsyn],[acty],C02.782.600.550.200,F01.145.544;F02.463.425.475;F02.739.794.405
36d66152-15de-425c-bb30-5ee8c3285d83,C0006145,C0206750,thin-section CT of ,Breast Diseases,Coronavirus Infections,2,X,[dsyn],[dsyn],C17.800.090,C02.782.600.550.200
d458d34c-94c8-44d9-ba12-977e80c82057,C1422064,C0206750,point for ,ACE2 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
d458d34c-94c8-44d9-ba12-977e80c82057,C1422064,C0206750,was increased in demographic with incidence of ,ACE2 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
2c775851-6d2d-461f-be21-a38b401069a3,C1155266,C0079189,are counteracted by anti-inflammatory ,inflammatory response,cytokine,1,X,[patf],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
367dc580-cf18-4eed-a8b4-65357ad7a6c0,C0004096,C0027430,Chronic sinusitis with,Asthma,Nasal Polyps,1,X,[dsyn],[dsyn],C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095,C08.460.572;C09.603.557;C23.300.825.557
2dbcadb3-6e0d-4d55-9cd4-9a5a32911b3e,C0149516,C0027430,is with ,Chronic sinusitis,Nasal Polyps,1,X,[dsyn],[dsyn],,C08.460.572;C09.603.557;C23.300.825.557
e0f52cdd-9ef9-41f0-8b15-97e6b8758faa,C1531518,C0237820,be stopped until clinical ,Biological treatment,Recovery - action,1,X,[topp],[acty],,
c1125eef-944b-4c2b-a34d-6e413bc5b2c3,C0206750,C0020115,has changed worldwide ,Coronavirus Infections,Human Activities,1,X,[dsyn],[acty],C02.782.600.550.200,I03
0f72bba6-b043-4ee6-ac1f-14efd3b96a24,C0012634,C0020115,has changed worldwide ,Disease,Human Activities,1,X,[dsyn],[acty],C23.550.288,I03
29ee344c-9f64-4f82-9ac4-6040b0acdcde,C0237798,C1457887,develop ,Nonhuman primate,Symptoms,1,X,[mamm],[sosy],,
14bc7323-3a8d-4c1a-8e69-3e65f288f6ec,C0237798,C0086418,develop ,Nonhuman primate,Homo sapiens,1,X,[mamm],[humn],,B01.050.150.900.649.313.988.400.112.400.400
78c5e401-f11d-4110-9ae9-a9ba969219d3,C1457887,C0086418,similar to those in ,Symptoms,Homo sapiens,1,X,[sosy],[humn],,B01.050.150.900.649.313.988.400.112.400.400
8edd0a38-54bd-4d9e-aa57-eb3479bf46a0,C1175743,C0598312,is ,SARS coronavirus,DNA Replication,1,X,[virs],[genf],B04.820.504.540.150.113.937,G02.111.225;G05.226
412ad34a-8b02-424b-b28d-6a5543280edd,C0037274,C1175175,associated with ,Dermatologic disorders,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C17.800,C02.782.600.550.200.750;C08.730.730
6e6c4a14-4a09-41e3-a141-641625bdfcf1,C0206750,CoV2,is caused by CoV2,Coronavirus Infections,CoV2,1,X,[dsyn],????,C02.782.600.550.200,????
7a09c574-0a72-4ec8-92d6-4dd24b99ccf4,C0008269,C0206750,are are now used for treatment of ,Chloroquine,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C02.782.600.550.200
7a09c574-0a72-4ec8-92d6-4dd24b99ccf4,C0008269,C0206750,clinical symptoms of ,Chloroquine,Coronavirus Infections,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C02.782.600.550.200
4f369d42-3477-4881-817d-2abb9024cbeb,C0079189,C4054044, includes ,cytokine,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
41ed44df-6ad9-49b8-a1b6-f21466b56a80,C0079189,C1334815, includes ,cytokine,Multi-centric Castleman's Disease,1,X,[aapp/imft],[neop],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
78d4be7b-0341-41bf-b971-552aba0b20a9,C0079189,C4289797, includes ,cytokine,Chimeric Antigen Receptor T-Cell Therapy,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
a30f8682-2650-490f-86ac-0c04b9bf3d7b,C0079189,C0948245, includes ,cytokine,Cytokine Release Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,
551f485f-22bd-4d70-a920-3dded729ec0d,C0087111,C0079189,mainstay of treatment in ,Therapeutic procedure,cytokine,2,X,[topp],[aapp/imft],E02,D12.644.276.374;D12.776.467.374;D23.529.374
551f485f-22bd-4d70-a920-3dded729ec0d,C0087111,C0079189,targeting ,Therapeutic procedure,cytokine,1,X,[topp],[aapp/imft],E02,D12.644.276.374;D12.776.467.374;D23.529.374
64ca5fe2-c07e-4c94-99ef-2430897bc1e4,C0087111,C0086982,targeting ,Therapeutic procedure,Signal Transduction Pathways,1,X,[topp],[moft],E02,G02.111.820;G04.835
90dc0c19-5c03-448b-ab71-05c80e2f8b6c,C3540676,C0079189,is in known ,Blockade,cytokine,1,X,[elii/phsu],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
936f8901-c053-41cd-9b42-3441d0e1f91a,C0005516,COVID,establish foundation for future diagnostic criteria of COVID ,Biological Markers,COVID,1,X,[clna],????,D23.101,????
30aa1988-a1ec-4a67-83b1-e993feb6cc75,C0005516,C0079189,establish foundation for future diagnostic criteria of COVID ,Biological Markers,cytokine,1,X,[clna],[aapp/imft],D23.101,D12.644.276.374;D12.776.467.374;D23.529.374
497d6117-ba8e-4f59-be06-29a2b3753658,C0005516,C1705178,contrasted in ,Biological Markers,Order (action),1,X,[clna],[acty],D23.101,
115d44d4-3855-4239-a99c-ccb89f66f3f7,C0026809,COVID-19,exhibit ,Mus,COVID-19,1,X,[mamm],[virs],B01.050.150.900.649.313.992.635.505.500,C000657245
9c3b6b56-4d41-48c5-8cb3-3fbfef881cc7,C0004238,C0206419,is common manifestation in hospitalized patients with ,Atrial Fibrillation,Genus: Coronavirus,1,X,[dsyn],[virs],C14.280.067.198;C23.550.073.198,B04.820.504.540.150
627e6085-fae5-4298-9dff-ebf314460e6f,C0004238,C0003195, includes ,Atrial Fibrillation,Anti-Arrhythmia Agents,1,X,[dsyn],[phsu],C14.280.067.198;C23.550.073.198,D27.505.954.411.097
08ce14bd-1cf8-439d-8751-5438cd4408fa,C0013227,C0004238,used to ,Pharmaceutical Preparations,Atrial Fibrillation,1,X,[phsu],[dsyn],D26,C14.280.067.198;C23.550.073.198
0e59d6f0-482c-49f4-87c2-64834e74dc05,C0013227,C0003195,used to ,Pharmaceutical Preparations,Anti-Arrhythmia Agents,1,X,[phsu],[phsu],D26,D27.505.954.411.097
5464c403-5e98-4725-b8dc-4faf7421b3b5,COVID-19,C0004238,is with concomitant ,COVID-19,Atrial Fibrillation,2,X,[virs],[dsyn],C000657245,C14.280.067.198;C23.550.073.198
07125ecf-3758-4890-a33c-2bf6a324f9a5,C0034386,C0242781,significantly reduced ,Quarantine,disease transmission,1,X,[topp],[patf],N06.850.780.200.450.700,N06.850.310
0320a8ec-1229-4683-868c-cb9272c0d6e8,C0849867,C0038443,has led to unprecedented ,Widespread Disease,Stress Psychological,2,X,[dsyn],[mobd],,F01.145.126.990;F02.830.900
5f452a41-146e-490d-b7af-bf9180a70e67,C0042776,U.S,is in U.S ,Virus,U.S,1,X,[virs],????,B04,????
a4976e46-8c5c-4d65-b752-d0597449075a,COVID-19,C0032285,leading to ,COVID-19,Pneumonia,2,X,[virs],[dsyn],C000657245,C08.381.677;C08.730.610
02f426e6-909c-4ca9-8415-0bac2bbd5672,COVID-19,C1457887,leading to ,COVID-19,Symptoms,1,X,[virs],[sosy],C000657245,
ae234412-c558-4ca1-8567-48eebc491d6d,C0042776,C1457887,leading to ,Virus,Symptoms,3,X,[virs],[sosy],B04,
cf2c9628-b6d9-45ea-b05a-fbef7a46842a,C0042776,C0024109,directly targets ,Virus,Lung,3,X,[virs],[bpoc],B04,A04.411
1f544c66-4df9-493f-9631-f1e055147623,CoV2,COVID-19,agent of ,CoV2,COVID-19,1,X,????,[virs],????,C000657245
99b39100-a36e-4831-b2cf-2fb386e08ffb,CoV2,C0012634,agent of ,CoV2,Disease,1,X,????,[dsyn],????,C23.550.288
95d34479-2e9b-4e84-bb80-cf5e7fb58f31,C2605770,C0005854,was predicted poor ,quinadoline B,Blood - brain barrier anatomy,1,X,[orch],[bpoc],x.x.x.x,A07.035;A08.186.211.035
954be583-f1c1-4974-a037-5df31a1e953d,C2605770,C0870883,was predicted Blood - brain barrier anatomy capacities Of five,quinadoline B,Metabolite,1,X,[orch],[bacs],x.x.x.x,
954be583-f1c1-4974-a037-5df31a1e953d,C2605770,C0870883,was predicted probability Of five ,quinadoline B,Metabolite,1,X,[orch],[bacs],x.x.x.x,
a38598d9-4940-4e9c-9cbe-e084a8fb3e8f,C0005854,ADMET,confer favorable ADMET ,Blood - brain barrier anatomy,ADMET,1,X,[bpoc],????,A07.035;A08.186.211.035,????
5e944fbf-db1f-4615-a381-93ba36d784d9,C0010827,C0024109,mediate ,Cytopathogenic Effect Viral,Lung,1,X,[comd],[bpoc],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,A04.411
c4e53a2d-ac19-4930-adbe-93949ed4a3f7,C1366480,C0229671,is in ,KITLG gene,Serum,1,X,[gngm],[bdsu],,A12.207.152.846;A15.145.846
b8683d82-1ab3-4ccc-8495-126c83989299,C0547605,C0018581,were suboptimal with facilities for ,prevention of infection,Handwashing,1,X,[topp],[acty],,N06.850.670.150.500
8aa4dbf9-b663-4f10-974d-ba5a1660e49f,C0547605,C0369718,were suboptimal with facilities for ,prevention of infection,N not otherwise specified Antibody,1,X,[topp],[aapp/imft],,
8698f607-622f-48c0-8cd8-16362982348c,C4050366,COVID-19,are constrained during ,Petroleum Hydrocarbon Compound,COVID-19,2,X,[hops],[virs],,C000657245
af0ea909-9923-4794-935c-71cc005ffa01,C4050366,C4552744,are constrained in their ,Petroleum Hydrocarbon Compound,Daily Living,2,X,[hops],[dora],,
b0e62148-1544-4ac0-aeaa-b654b2e95547,C4050366,C1999230,is in India ,Petroleum Hydrocarbon Compound,Providing (action),1,X,[hops],[acty],,
956e534c-9e26-4e83-b24d-e480db3241ad,C3537403,C0206419,is in ,Cause of death.primary:Finding:Point in time:^Patient:Nominal,Genus: Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150
80a8b184-e645-4af3-b0c3-d1dfa6597724,C3537403,C0012634,is in ,Cause of death.primary:Finding:Point in time:^Patient:Nominal,Disease,1,X,[clna],[dsyn],,C23.550.288
381fabf6-53c9-4722-8b47-363c271f30da,C0035229,C0206419,is Cause of death.primary:Finding:Point in time:^Patient:Nominal in,Respiratory Insufficiency,Genus: Coronavirus,1,X,[patf],[virs],C08.618.846,B04.820.504.540.150
585d2762-583a-4720-aee8-d42072911023,C0035229,C0012634,is Cause of death.primary:Finding:Point in time:^Patient:Nominal in,Respiratory Insufficiency,Disease,1,X,[patf],[dsyn],C08.618.846,C23.550.288
6eab890f-4f4f-434f-826f-308b77f1910c,C0035229,C3537403,is ,Respiratory Insufficiency,Cause of death.primary:Finding:Point in time:^Patient:Nominal,1,X,[patf],[clna],C08.618.846,
c3f620c7-72bf-43b4-95bf-fbc9f97e8fe2,C0024109,C1285830,also showed distinctive ,Lung,Blood vessel feature,1,X,[bpoc],[clna],A04.411,
c28e9361-7380-4daa-b063-7411c625b8ee,C0024109,C0007603,disrupted ,Lung,Plasma membrane,1,X,[bpoc],[celc],A04.411,A11.284.149
f8f112df-47ca-4944-9cad-e2e6497da86b,C1508661,C0206419,is in patients with ,Pulmonary vessels,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
c64085bd-f73b-45e8-baff-91b30656e38d,C1440080,C0021403,were times as prevalent in patients as in patients with ,Alveolar,Influenza virus vaccine,2,X,[bpoc],[imft/phsu],,D20.215.894.899.302
193921ef-700b-4990-8810-468ca9904dd1,C0006901,C0021403,were times as prevalent in patients as in patients with ,Blood capillaries,Influenza virus vaccine,2,X,[bpoc],[imft/phsu],A07.015.461.165,D20.215.894.899.302
eed0239e-fb27-47bf-b913-68963bdd52f5,C1440080,C0206419,were times as prevalent in patients with ,Alveolar,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
d17b1275-d528-46d9-a3af-5de8e550aed7,C0006901,C0206419,were times as prevalent in patients with ,Blood capillaries,Genus: Coronavirus,1,X,[bpoc],[virs],A07.015.461.165,B04.820.504.540.150
4b52312f-5312-4dd7-a867-c2dd8f547a26,C0027651,C0024109,amount of was In ,Neoplasms,Lung,4,X,[neop],[bpoc],C04,A04.411
0e3b0823-7c85-4503-8fc1-026e879cf0f6,C0027651,C0021403,amount of was In ,Neoplasms,Influenza virus vaccine,2,X,[neop],[imft/phsu],C04,D20.215.894.899.302
a9b8fbcd-4381-4793-8529-a0f93da63d21,C0005847,C0021403,amount of was In ,Blood Vessel,Influenza virus vaccine,1,X,[bpoc],[imft/phsu],A07.015,D20.215.894.899.302
7d42ea2e-7c45-436a-84ed-24e25d1e8cdc,C0005847,C0024115,distinguished ,Blood Vessel,Lung diseases,1,X,[bpoc],[dsyn],A07.015,C08.381
35f6c6e7-b79d-4998-9c34-e85e043c22d3,C0302600,C0024115,distinguished ,Angiogenic Process,Lung diseases,1,X,[ortf],[dsyn],,C08.381
4eb02de0-253d-4d79-b891-ad3e1a57eb3c,C0302600,C0206419,distinguished ,Angiogenic Process,Genus: Coronavirus,1,X,[ortf],[virs],,B04.820.504.540.150
44087f07-2935-401a-99bd-ddc448ee77a1,C0087111,C0003467,increased ,Therapeutic procedure,Anxiety,1,X,[topp],[mobd],E02,F01.470.132
8e845eba-3f5a-46ee-b48d-0dbf76662318,COVID-19,C0282686,causes most damage to ,COVID-19,Respiratory System Agents,1,X,[virs],[phsu],C000657245,D27.505.954.796
f9864d7d-9ea0-4d00-be4e-3a0b2b55cbe4,COVID-19,C0815107,also induces ,COVID-19,psychological distress,1,X,[virs],[mobd],C000657245,
3de5a08f-4efa-44fe-807b-e8f6fd793b19,C0011570,C0034386,affecting ,Mental Depression,Quarantine,1,X,[mobd],[topp],F01.145.126.350,N06.850.780.200.450.700
e436177d-c626-40bc-b074-1168e512b237,C0003467,C0034386,affecting ,Anxiety,Quarantine,1,X,[mobd],[topp],F01.470.132,N06.850.780.200.450.700
ceff5f19-f48f-4f19-b24f-92c7e8ac9007,COVID-19,C0030193,also induces psychological distress Besides physical,COVID-19,Pain,1,X,[virs],[sosy],C000657245,C23.888.592.612;F02.830.816.444;G11.561.790.444
d8c1d5e6-5da8-48a1-8fcc-7de827ce7df3,C0007603,C3711684,can harbour angiotensin converting enzyme 2 receptor for S,Plasma membrane,S protein severe acute respiratory syndrome coronavirus,2,X,[celc],[aapp/bacs],A11.284.149,x.x.x.x
b1e03084-1cc9-4526-98c2-97c9cdc39c88,C0599946,C0007634,is in ,Attenuation,Cells,1,X,[acty],[cell],,A11
523400c3-c00f-4a58-b0f4-a761f1fa9e85,C0206750,C1947932,has quickly ,Coronavirus Infections,Smear - instruction imperative,1,X,[dsyn],[acty],C02.782.600.550.200,
c837cea6-742f-489b-84ee-393698988c38,C0206750,C0040590,may require ,Coronavirus Infections,Tracheostomy procedure,1,X,[dsyn],[topp],C02.782.600.550.200,E02.041.750;E04.579.935;E04.580.900;E04.928.780
a1501087-63cd-4fd7-8d69-a350b87c079d,C2945733,C0206750,is in ,change of tube,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
7dc66e58-6959-4f22-ad14-7753509c5bac,C2945733,C0220781,cause significant droplet ,change of tube,Anabolism,1,X,[topp],[biof],,G03
e984a2c5-73b8-4fbb-9cc0-ffe700003ea1,C2945733,C0883304,is in particular ,change of tube,placement of tube,2,X,[topp],[topp],,
cfdb93ba-facc-40e8-ac7c-c02cceb62597,C0161816,C0018801, includes ,Cardiac complication,Heart failure,1,X,[patf],[dsyn],,C14.280.434
f5cc504f-7bb5-4d55-8134-b9cd2127c077,C1175743,C0010834,localizing at perinuclear locations within ,SARS coronavirus,Cytoplasm,1,X,[virs],[celc],B04.820.504.540.150.113.937,A11.284.430.214
0f7315f5-6558-4248-bda0-59b43a83c36c,C0010827,C3658289,induced ,Cytopathogenic Effect Viral,Human Induced Pluripotent Stem Cells,1,X,[comd],[cell],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,A11.872.040.500;A11.872.700.500
2e7b69d9-c95e-4084-8ca2-f5a826105dd8,C0010827,C0162638,induced ,Cytopathogenic Effect Viral,Apoptosis,1,X,[comd],[celf],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,G04.146.160
10c134ab-b2cc-45dc-b894-b2ae78b01344,C0010827,C0009450,induced ,Cytopathogenic Effect Viral,Communicable Diseases,1,X,[comd],[dsyn],E01.370.225.500.384.235;E05.200.500.384.235;E05.242.384.235;G06.920.190,C01.539.221
4bff4c97-571c-43f6-a994-2cc04e63e188,C0028938,C0348165,is important route of entry to ,Olfactory Nerve,Central Nervous System Viral Diseases,3,X,[bpoc],[dsyn],A08.800.800.120.640,C02.182;C10.228.228.245
d16efda0-9c4d-4fd8-89cd-c62eb91b2e3f,C0597357,C0458827,are found throughout ,receptor,Airway structure,2,X,[aapp/rcpt],[bpoc],,
e45684a0-139e-4800-8845-8b484e68637f,C0007447,C0458827,are found throughout ,Cations,Airway structure,2,X,[chvs],[bpoc],D01.248.497.300,
da943ded-9772-404c-98d7-c94d6822289b,C0369637,C0458827,are found throughout ,M NOS ANTIBODY,Airway structure,2,X,[aapp/imft],[bpoc],,
abdc6f9d-c97b-4f8c-94c8-fdccffabe09a,C1519442,C0042769,are involved in responses to ,Specialized epithelial cell,Virus Diseases,2,X,[cell],[dsyn],,C02
1923aa77-b294-44b0-92fb-6ba17b8f0570,C0021368,C1334521,is in ,Inflammation,TRPM5 protein human,2,X,[patf],[aapp/bacs],C23.550.470,x.x.x.x
5d1da1c4-a826-4475-9709-f3b2990e4ab0,C1519595,C0036734,encodes for ,Transcript,Serine Endopeptidases,2,X,[nnon],[aapp/enzy],,D08.811.277.656.300.760;D08.811.277.656.959.350
541cab50-d490-4c54-8867-7d1eb215de87,C0036734,C1175743,primes ,Serine Endopeptidases,SARS coronavirus,2,X,[aapp/enzy],[virs],D08.811.277.656.300.760;D08.811.277.656.959.350,B04.820.504.540.150.113.937
81266eac-51a5-444d-b0b5-8f1ba58917d6,C1452534,C0597357,is essential ,ACE protein human,receptor,1,X,[aapp/bacs],[aapp/rcpt],x.x.x.x,
e05592cb-438e-4d6d-8222-1fdbcc62182f,C0022709,C1514760,is essential receptor for,Peptidyl-Dipeptidase A,Receptor Cell,2,X,[aapp/enzy/imft],[cell],D08.811.277.656.350.350.687,
8059f485-6597-4763-b26c-4ba808a59876,C1452534,C1514760,is essential receptor for,ACE protein human,Receptor Cell,1,X,[aapp/bacs],[cell],x.x.x.x,
d274d667-e9a5-4ce6-98e7-52ebf9bb857c,C0022709,C4552744,exerts protective ,Peptidyl-Dipeptidase A,Daily Living,2,X,[aapp/enzy/imft],[dora],D08.811.277.656.350.350.687,
91376dbc-9354-4630-a700-0fe859795c9f,C0960880,C0003009,leads to overactivation of ,angiotensin converting enzyme 2,angiotensin II,2,X,[aapp/enzy],[aapp/bacs/phsu],x.x.x.x,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
d61c971f-d136-4cef-b7e1-e2acb3f6cf9d,C0013081,C0003009,leads to overactivation of ,Down-Regulation,angiotensin II,2,X,[moft],[aapp/bacs/phsu],G02.111.240;G05.308.200;G07.690.773.937,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
4fc13f1e-63a3-4b56-9458-eacb71c10f9f,C0960880,C1439284,leads to overactivation of ,angiotensin converting enzyme 2,AGTR1 gene,1,X,[aapp/enzy],[gngm],x.x.x.x,
8f6b643d-8b56-4851-a5ad-1d885fffba9b,C0013081,C1439284,leads to overactivation of ,Down-Regulation,AGTR1 gene,1,X,[moft],[gngm],G02.111.240;G05.308.200;G07.690.773.937,
a3903966-b61c-44c2-b59a-8622ab0de93e,C0960880,C0004457,leads to overactivation of ,angiotensin converting enzyme 2,Axis vertebra,1,X,[aapp/enzy],[bpoc],x.x.x.x,A02.835.232.834.151.383
bdd9d310-b1b2-4f6a-aacf-5edd154cc3e4,C0013081,C0004457,leads to overactivation of ,Down-Regulation,Axis vertebra,1,X,[moft],[bpoc],G02.111.240;G05.308.200;G07.690.773.937,A02.835.232.834.151.383
734a5358-613c-4ba9-a01e-2e36902eb908,C0087111,C0003009,reducing ,Therapeutic procedure,angiotensin II,1,X,[topp],[aapp/bacs/phsu],E02,D06.472.699.094.078;D12.644.400.070.078;D12.644.456.073.041;D12.644.548.058.078;D12.776.631.650.070.078;D23.469.050.050.050;x.x.x.x
a922f9dd-14a9-4325-a36a-0e47d37fb13c,C0087111,C0599946,reducing effects rather than ,Therapeutic procedure,Attenuation,1,X,[topp],[acty],E02,
80987601-f340-4f73-97d2-2b6c2df709b8,C0026639,C0206750,has Furthermore has accepted as high-risk route for ,Oral mucous membrane structure,Coronavirus Infections,1,X,[bpoc],[dsyn],A10.615.550.599;A14.549.512,C02.782.600.550.200
de06f9fa-52b6-4d8b-b2d5-2a7496dd2b3f,C1825598,C0424166,have produced ,IMPACT gene,Social Anxiety,1,X,[gngm],[mobd],,F01.470.132
f6f3f431-2c1f-4166-aabf-22dafa46db92,C1825598,C0011570,have produced ,IMPACT gene,Mental Depression,1,X,[gngm],[mobd],,F01.145.126.350
a711023c-5b0c-454c-86b8-fa8cb66cc779,C0441516,C0033174,were observed in ,Demand (clinical),Private Practice,1,X,[topp],[bmod],,N04.452.758.745
26ff00c6-6e3d-421b-83e0-74eb1e119e20,C0870196,C0003467,suffer including ,Behavioral health,Anxiety,1,X,[bmod],[mobd],,F01.470.132
2bb08845-d643-434f-b93c-82ee891c3443,C0870196,C0011570,suffer including ,Behavioral health,Mental Depression,1,X,[bmod],[mobd],,F01.145.126.350
b5e4a7f6-d3fb-4f93-911d-c273a9937aac,C0870196,C0521991,suffer including ,Behavioral health,Symptoms of stress,1,X,[bmod],[sosy],,
3a683a80-2dfb-4c1f-b1e8-f8379eab6922,C1457887,C0001962,exacerbate ,Symptoms,Ethanol,1,X,[sosy],[orch/phsu],,D02.033.375;x.x.x.x
2a9f6c88-e78c-4e88-94c0-7bb4ab27c5fa,C1457887,C2961731,remit ,Symptoms,Overtime,1,X,[sosy],[orch/phsu],,
2a305e7c-f9fe-4363-89fb-7713a6d24fe3,C1829939,C0035222,those with ,{Non-patient},Respiratory Distress Syndrome Adult,1,X,[clna],[dsyn],,C08.381.840;C08.618.840
59ed4144-e607-482a-ac4c-5eab5e154ea4,C0553741,C0035222,those with ,Fluid Management,Respiratory Distress Syndrome Adult,1,X,[topp],[dsyn],,C08.381.840;C08.618.840
60d3fb0a-fbe1-40d3-bf83-a027ab106e73,C0553741,C1829939,is in critically ill ,Fluid Management,{Non-patient},2,X,[topp],[clna],,
759f1d56-8fe9-403e-a21a-644d14424a41,C0009450,C0041621,contamination of ,Communicable Diseases,Ultrasonic Shockwave,2,X,[dsyn],[npop],C01.539.221,G01.750.770.776.891.500
45163554-35b6-481f-8553-e20d88164b6c,C1140621,C0005889,is better than mini ,Leg,Body Fluids,2,X,[bpoc],[bdsu],A01.378.610.500,A12.207
44498502-15f9-420c-99af-c6d060774ca8,C0008971,C0206750,have During ,Clinical Protocols,Coronavirus Infections,2,X,[topp],[dsyn],E02.183;N05.715.360.330.125,C02.782.600.550.200
20bef3a1-5702-41ed-9d50-9538b29609cd,C0008971,C2745965,have During ,Clinical Protocols,Emergencies [Disease/Finding],2,X,[topp],[patf],E02.183;N05.715.360.330.125,C23.550.291.781;N06.230.100.083;N06.850.376
9b47281a-a312-4a73-bc78-bfc0069e6049,C0027059,C1536220,masquerading as ,Myocarditis,ST segment elevation myocardial infarction,1,X,[dsyn],[dsyn],C14.280.238.625,C14.280.647.500.875;C14.907.585.500.875
ce805cf3-53ce-48a3-9d29-bef8b209af8f,C0206419,C0022658,poses significant challenges in area ,Genus: Coronavirus,Kidney Diseases,1,X,[virs],[dsyn],B04.820.504.540.150,C12.777.419;C13.351.968.419
234858cc-a28e-4ce0-9afc-6059aea1600e,C0543467,C0206419,should should based on recommendations in ,Operative Surgical Procedures,Genus: Coronavirus,1,X,[topp],[virs],E04,B04.820.504.540.150
f81afa86-a1ad-4cc2-a66f-1f06f2935bb8,C0543467,C1521863,should should based on recommendations in ,Operative Surgical Procedures,estrogen receptor alpha human,1,X,[topp],[aapp/rcpt],E04,x.x.x.x
b22eda7c-d8dc-4a21-96da-5f96bd555e9d,C0598294,silico,were subjected to to silico ,Fish Proteins,silico,2,X,[aapp/bacs],????,D12.776.325,????
973c0380-0ec5-47be-8623-3c01a4d03614,C0598294,C0020291,were subjected to to silico ,Fish Proteins,Hydrolysis,2,X,[aapp/bacs],[npop],D12.776.325,G02.380
b29fc47e-af39-476d-a283-41e30ffdebb5,C0027293,C0010744,followed by ,Cytochrome c Reductase,Cytochromes b,1,X,[aapp/enzy],[aapp/enzy],D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500,D08.244.187.249;D12.776.422.220.187.249
c9f766d2-c448-4a67-a48d-b8b55c9c69e8,C0027293,C0038164,be ,Cytochrome c Reductase,Staphylococcal Protein A,2,X,[aapp/enzy],[aapp/imft/irda],D08.811.682.608.504.500;D12.776.157.427.374.375.863.500;D12.776.331.887;D12.776.556.579.374.375.140.500,D12.776.097.820;D23.050.161.821
f8a14a08-7122-4145-8525-b7581239caaf,C0028954,C0303231,can can used as ,Oligopeptides,Lead compound,1,X,[aapp],[chvs],D12.644.456,
1359f1fc-91d0-49ec-bbfa-6bd7ddaab2f7,C0028954,C0243077,design potential ,Oligopeptides,inhibitors,1,X,[aapp],[chvf],D12.644.456,
2d590c4b-5810-4efa-a0f9-cd8baf82849c,C0028954,C0206419,design potential ,Oligopeptides,Genus: Coronavirus,1,X,[aapp],[virs],D12.644.456,B04.820.504.540.150
1f0b1d39-f950-4cb9-8d29-af6f07046197,C0242297,C0206419,can In summary can helpful for ,Dietary Supplementation,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
fd6f3371-c3f8-49d7-9c22-8cb0c47a822d,C0079189,C0026473,may may produced by subset of ,cytokine,Monocytes,1,X,[aapp/imft],[cell],D12.644.276.374;D12.776.467.374;D23.529.374,A11.118.637.555.652;A11.148.580;A11.627.624;A11.733.547;A15.145.229.637.555.652;A15.378.316.580;A15.382.490.555.652;A15.382.670.547;A15.382.680.547
0be7ba5f-c9b9-4923-ad79-dd7fb26a179c,C1704259,C4330475,is in peripheral ,Biochemical Pathway,Immune Cell,1,X,[moft],[cell],,
d1f606bf-e005-4135-b30f-ed2dde779a20,C0596756,C0206419,is in severe ,immunopathology specialty,Genus: Coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150
84336767-2aaf-4777-8157-9c2c62ab36be,C4330475,C0596756,might lead to ,Immune Cell,immunopathology specialty,1,X,[cell],[bmod],,
9382b7c0-3bf1-43bc-ba11-2a4fe6e55590,C4330475,C0206419,might lead to ,Immune Cell,Genus: Coronavirus,1,X,[cell],[virs],,B04.820.504.540.150
f8fb6099-8fd9-479f-83de-fcf7b6497bb4,C0206419,C1413336,applied single ,Genus: Coronavirus,CEL gene,1,X,[virs],[gngm],B04.820.504.540.150,
35278bd5-0ff9-4d4d-bc20-c0934a9e57a1,C0206419,C1321301,profile ,Genus: Coronavirus,Peripheral blood mononuclear cell (cell),1,X,[virs],[cell],B04.820.504.540.150,
80b3da1b-0eb5-4626-aba2-8a667e0bb823,C0206419,C0284778,applied ,Genus: Coronavirus,RNA Small Cytoplasmic,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D13.444.735.790.552.750
04d98d3e-f730-4de1-b3c9-82befb351651,C1828381,C1160716,enforcing best practices for ,Advising (action),viral transmission,3,X,[acty],[celf],,
d24409d2-7a4d-41a3-a32a-eb52d8a0dc18,C0021966,C0012682,offers safe alternative to ,Iodides,Disinfectants,1,X,[inch],[sbst],D01.248.497.158.490;D01.475.410,D27.505.954.122.425;D27.720.274
21519b55-c7aa-4a99-97fc-ecdc5983bd83,C1175743,C0700271,occurs through ,SARS coronavirus,M Protein multiple myeloma,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,x.x.x.x
21519b55-c7aa-4a99-97fc-ecdc5983bd83,C1175743,C0700271,binding ,SARS coronavirus,M Protein multiple myeloma,1,X,[virs],[aapp/imft],B04.820.504.540.150.113.937,x.x.x.x
30222cd8-607f-430c-b259-4985f7cf424c,C1175743,C2247081,occurs to ,SARS coronavirus,host cell membrane,1,X,[virs],[celc],B04.820.504.540.150.113.937,
61e6c3c5-bb45-41c8-ae98-013973269c0d,ACE2,C1171346,is in ,ACE2,Human Embryonic Stem Cells,1,X,????,[cell],????,A11.872.700.250.750
dc0148f8-23bc-4b6e-a739-072af5c1b20c,ACE2,C0920751,is in ,ACE2,Heart cell,1,X,????,[cell],????,
d3263955-f3ad-465a-92be-74fe11480d3c,C0012655,C0206419,is in male ,Disease susceptibility,Genus: Coronavirus,1,X,[clna],[virs],C23.550.291.687;G07.100.250,B04.820.504.540.150
7c3de99e-1158-4238-81f6-6a3a308668a5,C0018581,C0599638,is with ,Handwashing,Drinking Water,1,X,[acty],[sbst],N06.850.670.150.500,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
bd66cd08-02d2-4607-ace0-b7fd93c75398,C0599685,C0206419,has has experimentally used for ,Anti-Retroviral Agents,Genus: Coronavirus,1,X,[phsu],[virs],D27.505.954.122.388.077,B04.820.504.540.150
1539227d-cf64-4c29-9b15-7d600a9d09e2,C0599685,C1856053,has has experimentally used for ,Anti-Retroviral Agents,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[phsu],[dsyn],D27.505.954.122.388.077,x.x.x.x
62f41dc9-4e3c-42b8-836b-df253548af86,C0013227,C1856053,has has experimentally used for ,Pharmaceutical Preparations,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[phsu],[dsyn],D26,x.x.x.x
0c1f9083-7879-451f-a782-a599cb8e38cb,C1138226,C1856053,has has experimentally used for ,favipiravir,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[orch/phsu],[dsyn],x.x.x.x,x.x.x.x
8b1c3752-6fd4-4a17-8e2e-8cc892caf660,C0206419,C0020336, includes ,Genus: Coronavirus,Hydroxychloroquine,1,X,[virs],[orch/phsu],B04.820.504.540.150,D03.633.100.810.050.180.350
de307c5a-3c0a-44a3-92e9-851964f23851,ICTRP,C1706202,were ,ICTRP,Search - action,1,X,????,[acty],????,
38fb0ae9-e3c7-44f7-8cae-84b1a4877828,C1145670,C0221423,is associated with high mortality ,Respiratory Failure,Illness (finding),1,X,[dsyn],[sosy],C08.618.846,
b968e53c-4b86-4a0f-ab41-1812ad225d26,C1145670,C0021925,requiring ,Respiratory Failure,Intubation,1,X,[dsyn],[topp],C08.618.846,E02.585;E05.497
474e9eeb-4f92-4e87-a106-24fae95e1ae2,C0013227,C0700271,measured ,Pharmaceutical Preparations,M Protein multiple myeloma,1,X,[phsu],[aapp/imft],D26,x.x.x.x
42b68b9b-af4e-4098-9043-6bfba2a44826,C0013227,C0042720,measured ,Pharmaceutical Preparations,Viral Genome,1,X,[phsu],[gngm],D26,G05.360.340.358.840
3e5a3977-71d6-4ebd-8aea-98735bb2870b,C0231239,C0596957,is in ,Fluctuation,Molecular Dynamics,1,X,[sosy],[moft],,E05.599.595.500;G02.111.570.895;L01.224.160.500
3cc41638-9b52-44b7-b8a7-1bccac1a99e5,C0596973,C0026597,is in constant ,monomer,Motion,1,X,[chvs],[npop],,G01.482
abe1008e-a211-4859-ad4f-14e70540abc6,C0596973,C1547282,is in constant ,monomer,Show,1,X,[chvs],[anim],,
50940d91-6db2-4e3d-a191-39d248843864,C0700271,C0026597,form of is constant ,M Protein multiple myeloma,Motion,1,X,[aapp/imft],[npop],x.x.x.x,G01.482
670df7c0-3d3c-4b09-9e53-1acafb429c2d,C0700271,C1547282,form of is constant ,M Protein multiple myeloma,Show,1,X,[aapp/imft],[anim],x.x.x.x,
93c6f6e6-c89c-40c9-890f-ebd09165f5d7,C1175743,C1413336,is in published ,SARS coronavirus,CEL gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
67b23d02-28ed-4ea1-b6fb-9c98e15dbed7,C0567416,C0162969, includes ,Molecule,Chitosan,1,X,[sbst],[orch/phsu],,D05.750.078.139.500;D09.698.211.500
ed62ead0-5cd3-4d86-914c-d95b05d8ddf8,C0278996,C1882509,is in ,Malignant Head and Neck Neoplasm,put - instruction imperative,1,X,[neop],[acty],,
fb69f688-0cc0-48a1-a902-a059fe5e8087,C1947933,C1882509,is in ,care activity,put - instruction imperative,1,X,[acty],[acty],,
0825e537-a8cc-45fa-bdeb-549927c925d6,C1552133,C0206419,screening for fear of ,19s,Genus: Coronavirus,2,X,[bpoc],[virs],,B04.820.504.540.150
92cd827e-a41a-46b5-a240-bba5c2d23144,C1257792,C1422064,express ,Vascular Endothelial Cells,ACE2 gene,1,X,[cell],[gngm],A11.436.275,
925f8faa-a609-4c27-9d90-17f3154a80b6,C1257792,C0033684,express ,Vascular Endothelial Cells,Proteins,1,X,[cell],[aapp/bacs],A11.436.275,D12.776
db894345-25c8-4f61-b090-cf1d2dfcae3e,C0040048,C1879547,entails ,Thromboplastin,Activation action,1,X,[aapp/imft],[acty],D12.776.124.125.900;D23.119.965,
818d7f1a-1fdf-4fcd-8390-4a22dbb0231e,C0040048,C0068355,entails ,Thromboplastin,NADPH Oxidase,1,X,[aapp/imft],[aapp/enzy],D12.776.124.125.900;D23.119.965,D08.811.682.608.575;D12.776.331.894;D12.776.543.653
1b9eedff-0783-4e7d-b098-ecb9fce8acea,C1523116,C0040649,drives induced ,positive regulation of NF-kappaB transcription factor activity,Transcription Genetic,1,X,[celf],[genf],,G02.111.873;G05.297.700
0004b1db-df78-4431-959a-b239ccbf9bd6,C1523116,C0812327,drives induced ,positive regulation of NF-kappaB transcription factor activity,Transcription factor genes,1,X,[celf],[gngm],,
6cf0635c-362f-41a1-abd2-78fbc1eb0498,C3272452,C0007634,are taken up into ,Single-Stranded RNA,Cells,1,X,[nnon],[cell],,A11
e3e6c186-fddb-40e0-9032-06324cd8a580,C3272452,C0034850,are taken up into ,Single-Stranded RNA,Endosomes,1,X,[nnon],[celc],,A11.284.430.214.190.875.190.880.337
aa522d49-f2e6-40d4-a9cb-3961b29964b8,C0042776,C0034850,are taken up into ,Virus,Endosomes,1,X,[virs],[celc],B04,A11.284.430.214.190.875.190.880.337
2f4cfc84-ee49-49cb-91fa-a6ce4e6abf44,C0034850,C0035668,stimulate Endosomes Anabolism via,Endosomes,RNA,1,X,[celc],[nnon],A11.284.430.214.190.875.190.880.337,D13.444.735
21657f7a-b674-414b-9cbd-f5580e048ead,C0034850,C1579758,stimulate Endosomes Anabolism via,Endosomes,Toll-Like Receptor 7,1,X,[celc],[aapp/imft/rcpt],A11.284.430.214.190.875.190.880.337,D12.776.543.750.705.910.500.700
973866b4-5a6b-4f7c-830d-079c8d863f7c,C0034850,C0220781,stimulate ,Endosomes,Anabolism,1,X,[celc],[biof],A11.284.430.214.190.875.190.880.337,G03
a3be659d-8b2f-428e-934d-16a91b35b804,C0034850,C1325739,stimulate ,Endosomes,NADPH oxidase complex location,1,X,[celc],[celc],A11.284.430.214.190.875.190.880.337,
97fbf7f2-56fc-444e-a0ef-9639cfa0ddb8,C1175175,C0230425,using real-time PCR,Severe Acute Respiratory Syndrome,Structure of right thigh,1,X,[dsyn],[bpoc],C02.782.600.550.200.750;C08.730.730,
a7b701fb-5b0e-4806-9fc7-0b64f7c6f17b,C1175175,PCR,using real-time PCR,Severe Acute Respiratory Syndrome,PCR,1,X,[dsyn],????,C02.782.600.550.200.750;C08.730.730,????
4e31044f-2cdf-460f-966f-1c739eb8269a,C0184661,C0003451,is In absence of specific ,Interventional procedure,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
f7cdd5c1-4259-455a-a543-e1373aec72d9,C0960756,C0206419,contributing factor A to,factor A,Genus: Coronavirus,2,X,[orch],[virs],x.x.x.x,B04.820.504.540.150
32035765-709c-48db-b7a1-7884463bfa91,C1697446,C3694279,causes severe disease similar to those caused by ,Genital Viral Infections,Middle East Respiratory Syndrome,1,X,[dsyn],[dsyn],,C02.782.600.550.200
6276d1fb-a247-4f24-a0f0-3bf76004b2c0,C0275522,C0206419,substantial component of ,Asymptomatic Infections,Genus: Coronavirus,2,X,[dsyn],[virs],C23.550.291.187.500,B04.820.504.540.150
386ac533-5552-428c-b344-f56f47306336,C0035668,C0206419,decreased Recovery - action of endemic,RNA,Genus: Coronavirus,1,X,[nnon],[virs],D13.444.735,B04.820.504.540.150
b5ef4763-f4ee-49bd-99f5-76588b968741,C0185115,C0206419,decreased Recovery - action of endemic,Extraction,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
fbf22648-e722-40ad-86d4-5c6a8dc6515e,C0206419,C0185115,optimizing ,Genus: Coronavirus,Extraction,1,X,[virs],[topp],B04.820.504.540.150,
fb586b67-77fc-4b9a-8c9b-ef5786fa2645,C1095830,C1706202,were ,Apple,Search - action,1,X,[food],[acty],B01.650.940.800.575.912.250.859.937.500.444,
a2d8c050-c8a6-4650-95b6-21a3eea61c2e,C0001617,bodys,delayed bodys ,Adrenal Cortex Hormones,bodys,1,X,[horm/orch/phsu],????,D06.472.040,????
c02cf50d-6845-4f5e-899b-0b69eaab79d9,C0001617,C0042776,delayed bodys ,Adrenal Cortex Hormones,Virus,1,X,[horm/orch/phsu],[virs],D06.472.040,B04
44015175-e152-473a-96e8-e86d296b40a5,C3714514,C0241144,include ,Infection,Petechiae of skin,1,X,[patf],[sosy],C01.539,
db42b88f-917f-4b2a-98ca-9c032a32faf6,C1416797,C0206750,feel In ,STMN1 gene,Coronavirus Infections,2,X,[gngm],[dsyn],,C02.782.600.550.200
d538815b-599d-4976-a50b-cc423f7bb5f3,C1416797,C0012634,feel In ,STMN1 gene,Disease,1,X,[gngm],[dsyn],,C23.550.288
57905300-7b7b-41b2-a005-e4009ced7a56,C0037090,C0242656,are typically found during ,Signs and Symptoms Respiratory,Disease Progression,2,X,[sosy],[patf],C23.888.852,C23.550.291.656
c91a9d90-71cc-43a6-8a64-717b1b967094,C4554533,C0597404,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Respiratory viruses,1,X,[clna],[virs],,
cf9e9b34-d1fa-4649-ba2a-873fc0ea01a9,C4554533,C0035243,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Respiratory Tract Infections,1,X,[clna],[dsyn],,C01.539.739;C08.730
46168e00-154b-40de-b278-be0bb45249e4,C4554533,C0022882,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Laboratory Infection,1,X,[clna],[dsyn],,C01.539.503;C24.506
5e2aa8a2-d862-4467-90bd-9f99922e51c3,C4554533,C0521839,preventing laboratory-confirmed ,Trend:Type:Point in time:^Patient:Nominal,Influenza-like illness,1,X,[clna],[dsyn],,
38279c58-2a03-4aa5-be9f-3d5533b291ab,C4554533,favour,is in favour N95 ,Trend:Type:Point in time:^Patient:Nominal,favour,1,X,[clna],????,,????
1f1682d0-840e-4034-ba13-8f7e4af17fab,C4554533,N95,is in favour N95 ,Trend:Type:Point in time:^Patient:Nominal,N95,1,X,[clna],????,,????
010f1704-e025-427d-a43a-f3cb1c7784a9,N95,C0035243,protect HCWs from clinical ,N95,Respiratory Tract Infections,1,X,????,[dsyn],????,C01.539.739;C08.730
8e2f9967-1fdd-4e6f-b19e-7340005e7d65,N95,C0275521,protect HCWs from clinical ,N95,Clinical infection,1,X,????,[dsyn],????,
33bdd7f8-53e1-4b10-8442-c4f36011adbe,C2948600,C0038454,describe specific ,Aim,Cerebrovascular accident,1,X,[inch/phsu],[dsyn],,C10.228.140.300.775;C14.907.253.855
43684876-63b6-4fdc-84df-2b5d625219b5,C2948600,C0000983,evaluate effect of ,Aim,Acetic Acid,1,X,[inch/phsu],[irda/orch],,D02.241.081.018.165;D10.251.400.045.500
a6c29b9e-d236-4edb-b5e8-366dee9ee0e2,C0206750,21st,is in 21st ,Coronavirus Infections,21st,3,X,[dsyn],????,C02.782.600.550.200,????
6bbada63-7073-4a9b-9172-acf4518ac8da,C1456573,21st,is in 21st ,Global Health,21st,2,X,[bmod],????,H02.403.371;N01.400.337,????
659afdf3-4133-40af-857c-1589c409acef,C0012634,C0878751,is in ,Disease,late pregnancy,1,X,[dsyn],[patf],C23.550.288,
a6f73e9b-fc3f-4c76-a4ac-9f78ed9a3573,C0025011,C0048243,of Glycoproteins is 6VSB,Measles virus,4-dichlorobenzene,1,X,[virs],[hops/orch],B04.820.455.600.650.500.500,x.x.x.x
9b5c10a7-2d14-4871-a78d-9c2cee9850b3,C0017968,C0048243,of Glycoproteins is 6VSB,Glycoproteins,4-dichlorobenzene,1,X,[aapp/bacs],[hops/orch],D09.400.430;D12.776.395,x.x.x.x
d34cfa4a-34fe-4e67-a602-367d82fb463b,C0025011,6VSB,of Glycoproteins is 6VSB,Measles virus,6VSB,1,X,[virs],????,B04.820.455.600.650.500.500,????
09cf89c3-35c8-4ccd-8e95-e30794bbfa6f,C0017968,6VSB,of Glycoproteins is 6VSB,Glycoproteins,6VSB,1,X,[aapp/bacs],????,D09.400.430;D12.776.395,????
a516322d-c6cc-47f5-af8f-e014be10f0a7,C0849867,C1175743,has has associated with high rates of ,Widespread Disease,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
8c1faa4a-ffd5-4579-9938-ddf28074bbf6,C0026652,C0206750,improve Symptoms with,Moxibustion,Coronavirus Infections,1,X,[topp],[dsyn],E02.190.044.588,C02.782.600.550.200
12fa8a77-8d28-4e25-b64e-7d7252643cfa,C0030755,C0010200,is with ,Pediatrics,Coughing,1,X,[bmod],[sosy],H02.403.670,C08.618.248;C23.888.852.293
c9460979-d500-4958-b4ab-7e565fad1735,C0598197,C3714514,had on growth rate of ,contagion,Infection,1,X,[npop],[patf],,C01.539
ada1fad3-8223-4652-bd94-4ef75ab7ccd7,C1175743,C0005775,might attack Myocytes Cardiac through,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
ada1fad3-8223-4652-bd94-4ef75ab7ccd7,C1175743,C0005775,might attack Organ into,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
ada1fad3-8223-4652-bd94-4ef75ab7ccd7,C1175743,C0005775,can reach system from ,SARS coronavirus,Blood Circulation,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G09.330.100
9ee01d29-3d71-433c-9d9a-58fd98aa6e4d,C0026809,C0023810,treated by ,Mus,Lipopolysaccharides,1,X,[mamm],[orch],B01.050.150.900.649.313.992.635.505.500,D09.400.500;D09.698.718.450;D10.494;D23.050.161.616.525;D23.946.123.329.500
f5432439-86c3-44f6-99d9-fbb7a838e4e1,C1175743,C0178784,might attack other ,SARS coronavirus,Organ,1,X,[virs],[bpoc],B04.820.504.540.150.113.937,
036308a5-200d-4836-a719-418c7fa54ed0,C1175743,C1824356,might attack Organ by,SARS coronavirus,KIAA1551 gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
b856bdf2-18d9-4b30-8609-95fcb4522880,C0206750,C0796085,has placed strain on many aspects of ,Coronavirus Infections,Nance-Horan syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
5b8addde-9c29-4f5b-8f04-d79293d97787,C0029892,C0206750,are needed for preoperative ,Otolaryngology specialty,Coronavirus Infections,2,X,[bmod],[dsyn],H02.403.810.526,C02.782.600.550.200
c1a963b1-6f64-45f6-91dd-1e4d6e5583ed,C0007634,C0022709,targeting ,Cells,Peptidyl-Dipeptidase A,2,X,[cell],[aapp/enzy/imft],A11,D08.811.277.656.350.350.687
7917cb3f-e586-440f-bffa-a30eeacdc37c,C1167622,C0309872,seems to ,Binding (Molecular Function),PREVENT (product),2,X,[moft],[phsu],,
42151626-e63b-4df6-a4ca-40215083f60d,C0022709,C0390423,enter Cells by only,Peptidyl-Dipeptidase A,Angiotensin II Receptor Type 2,2,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,D12.776.543.750.695.047.687;D12.776.543.750.750.130.875
37ad412a-6b1e-460e-ab67-3bc776fabc79,C0022709,C0014139,enter induced ,Peptidyl-Dipeptidase A,Endocytosis,2,X,[aapp/enzy/imft],[celf],D08.811.277.656.350.350.687,G04.417
1172bf65-bfca-48d1-882b-9b7a2707e0e5,C0022709,C1439284,enter Cells by,Peptidyl-Dipeptidase A,AGTR1 gene,2,X,[aapp/enzy/imft],[gngm],D08.811.277.656.350.350.687,
1d0ed0d8-cc14-42bf-ab21-c77e6ac97324,C1439284,C1175743,be ideal candidate for treatment of ,AGTR1 gene,SARS coronavirus,2,X,[gngm],[virs],,B04.820.504.540.150.113.937
4ed82bbc-39bb-40e7-8493-dc01f0430c4a,C0243076,C1175743,be ideal candidate for treatment of ,antagonists,SARS coronavirus,2,X,[chvf],[virs],,B04.820.504.540.150.113.937
2db805c1-473e-494d-a1e0-426751023af9,C4281807,C2700061,being observed ,Vitronectin human,Transition (action),2,X,[aapp/bacs],[acty],,
c94b531c-dedc-4845-8888-12ac7fae18ba,C4281807,C1514535,being observed ,Vitronectin human,Protein Binding Motif,2,X,[aapp/bacs],[amas],,
907561f2-0042-40b9-9627-7bdc523841f5,C4281807,C0597358,being observed ,Vitronectin human,receptor binding,2,X,[aapp/bacs],[moft],,
b66afe75-d9d9-4dcd-b473-ef8a585dbff6,C4281807,C0599638,is in ,Vitronectin human,Drinking Water,2,X,[aapp/bacs],[sbst],,D01.045.250.875.300;D01.248.497.158.459.650.300;D01.650.550.925.199;G07.203.100.418;J02.200.418
4bb2c5f3-c109-402f-b053-34e41b296d91,C0597358,C0013227,was more exposed to solvent to possible ,receptor binding,Pharmaceutical Preparations,2,X,[moft],[phsu],,D26
aad6e615-617f-4160-b925-171a6670b38b,C0023688,C1167622,is with kcal ,Ligands,Binding (Molecular Function),1,X,[chem],[moft],D27.720.470.480,
aad6e615-617f-4160-b925-171a6670b38b,C0023688,C1167622,has revealed molecular determinants responsible for ,Ligands,Binding (Molecular Function),2,X,[chem],[moft],D27.720.470.480,
aad6e615-617f-4160-b925-171a6670b38b,C0023688,C1167622,has revealed potential inhibitor ,Ligands,Binding (Molecular Function),2,X,[chem],[moft],D27.720.470.480,
766e39e5-cf02-482a-b4bd-21787e1123c7,C0023688,C0542479,is with kcal ,Ligands,Energy Physics,1,X,[chem],[npop],D27.720.470.480,
3cbc4e8e-10c8-4f10-8d97-4b113ff69ee0,C0023688,kcal,is with kcal ,Ligands,kcal,1,X,[chem],????,D27.720.470.480,????
142f4b98-b87b-4360-8c70-da03885992da,C0023688,C0324740,is with kcal ,Ligands,Talpidae,1,X,[chem],[mamm],D27.720.470.480,B01.050.150.900.649.473.450
539b6a68-6386-40da-9302-d602c09fff31,C1441506,C1098032,using MM ,Calculation,poly(tetramethylene succinate-co-tetramethylene adipate),1,X,[acty],[orch],,x.x.x.x
cfef9120-bc35-4f01-9867-368921bb4e8f,C1321919,C0751408,indeed may rival ,TLR4 protein human,Suffering Physical,1,X,[aapp/rcpt],[sosy],x.x.x.x,C23.888.592.612;F02.830.816.444;G11.561.790.444
5fc5951c-f09e-4e9b-9de3-b0a402df0a79,C1321919,C0221423,indeed may rival ,TLR4 protein human,Illness (finding),1,X,[aapp/rcpt],[sosy],x.x.x.x,
a10302d7-7a92-4edd-b518-246b640630ab,C4300185,C1947933,incorporate practices into routine ,Palliative care.team,care activity,1,X,[bmod],[acty],,
365eb827-5d29-45fe-874a-8513129b4680,C4300185,C0185027,are well poised Given significant ,Palliative care.team,Imbrication (procedure),1,X,[bmod],[topp],,
3ed004bb-1a11-4483-8ccd-799fb89e6052,C4300185,C0886052,are well poised Given significant ,Palliative care.team,wound care,1,X,[bmod],[topp],,
6741b64b-8c0d-44f5-895c-62d1db2b88be,PHQ-9,C0206750,visited more ,PHQ-9,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
cb591736-fc13-414d-b848-b94b361afc53,C0032227,C0225756,lesions in ,Pleural effusion disorder,Structure of upper lobe of lung,1,X,[dsyn],[bpoc],C08.528.652,
bcbef2f4-ec62-4364-a4dc-48f65fba089e,C2948600,C2700061,compare appointment data in weeks after ,Aim,Transition (action),1,X,[inch/phsu],[acty],,
bcbef2f4-ec62-4364-a4dc-48f65fba089e,C2948600,C2700061,compare patient demographics in weeks after ,Aim,Transition (action),1,X,[inch/phsu],[acty],,
e3e0d089-a79a-4313-9b3a-d83dddbbe4f4,C0206750,C1882509,has ,Coronavirus Infections,put - instruction imperative,1,X,[dsyn],[acty],C02.782.600.550.200,
f0e9eaee-7d61-4d76-9a88-dfe118832ecd,C0012634,C1882509,has ,Disease,put - instruction imperative,1,X,[dsyn],[acty],C23.550.288,
2b6866bb-cde8-4269-ac32-1a22ad1a3836,C2348077,COVID-19,Biological Evolution of,Date Fruit,COVID-19,1,X,[food],[virs],B01.650.940.800.575.912.250.093.615,C000657245
2bddd829-58cd-47b3-a0f1-2faf4266f537,C1457887,C0079189,suggest ,Symptoms,cytokine,3,X,[sosy],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
aa0a3cb7-02b3-4e6c-9a2a-f70bda41f5f2,C1457887,C1861452,suggest ,Symptoms,Storm Syndrome,3,X,[sosy],[dsyn],,x.x.x.x
3b2dbe7a-2dea-476e-b7fa-705c6009acfc,C1457887,C0042769,suggest ,Symptoms,Virus Diseases,3,X,[sosy],[dsyn],,C02
01dddff5-88d0-4f75-ac40-505747f9e1ba,C1861452,C0042769,is in response to ,Storm Syndrome,Virus Diseases,3,X,[dsyn],[dsyn],x.x.x.x,C02
55cdda70-7891-430c-9bb3-87b603e2dcaf,C0003280,C3687832,are among ,Anticoagulants,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.502.119,
e440889a-5e07-42e3-908d-5290d92e993b,C0032105,C3687832,are among ,Plasma,Drugs - dental services,1,X,[bdsu],[topp],A12.207.152.693;A12.207.270.695;A15.145.693,
c4e8738f-3aea-4c2f-aaba-fb1462d3a71c,C0003451,C3687832,are among ,Antiviral Agents,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.122.388,
1025becc-5641-4a4f-a9c7-dcb0208891fb,C0001617,C3687832,are among ,Adrenal Cortex Hormones,Drugs - dental services,1,X,[horm/orch/phsu],[topp],D06.472.040,
74b2a8f8-3ee1-430a-8520-e5ea6e75b0d3,C0003374,C3687832,are among ,Antimalarials,Drugs - dental services,1,X,[phsu],[topp],D27.505.954.122.250.100.085,
1ae1bb5d-3d64-487e-98db-9bbf6bf20d24,C1328819,C3687832,are among ,Small Molecule,Drugs - dental services,1,X,[orch],[topp],,
aa983513-0c5b-4377-abb1-87c679ef5471,C0008679,C0221423,associated with development of ,Chronic disease,Illness (finding),1,X,[dsyn],[sosy],C23.550.291.500,
6ff61252-bee4-48af-a1ce-6c9e65f29772,C0009450,C0450254,is with suspected ,Communicable Diseases,Pathogenic organism,1,X,[dsyn],[orgm],C01.539.221,
8e0cb8f7-797b-4573-bd36-5e33f6b511cf,COVID-19,C0003811,contributes to ,COVID-19,Cardiac Arrhythmia,1,X,[virs],[dsyn],C000657245,C14.280.067;C23.550.073
81653687-e39a-40c5-8d70-6d9176a7285a,C3260929,COVID-19,is in ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,COVID-19,2,X,[clna],[virs],,C000657245
b648f1ec-ff3c-4c67-9641-1de657b02026,C0221423,C1456573,pandemic of is ,Illness (finding),Global Health,1,X,[sosy],[bmod],,H02.403.371;N01.400.337
aee0f426-0bda-460e-8fcb-3abf2f5f94bc,C0023870,C3463820,has shown at ,Lithium,Inhibition,1,X,[elii/phsu],[acty],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,F01.145.544;F02.463.425.475;F02.739.794.405
7fb56a5a-ab07-488f-8c61-9eb988befb07,C0023870,C0598312,has shown at ,Lithium,DNA Replication,1,X,[elii/phsu],[genf],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,G02.111.225;G05.226
1810f1e4-738e-4aa2-91d3-123cd586e8ac,C0023870,C0206419,has shown at ,Lithium,Genus: Coronavirus,1,X,[elii/phsu],[virs],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,B04.820.504.540.150
70453a49-0dc4-4164-815e-39774ece4faf,C0023870,C0003062,has shown at ,Lithium,Animals,1,X,[elii/phsu],[anim],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,B01.050
ae29aeb8-8fbd-4e57-ba18-ab4f8a6f0ac5,C0023870,C3266814,exert protective ,Lithium,Action,1,X,[elii/phsu],[acty],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,
7d078b04-7600-4268-9fc4-8ac477496501,C0023870,C0041912,exert Action against,Lithium,Upper Respiratory Infections,1,X,[elii/phsu],[dsyn],D01.268.549.450;D01.268.557.290;D01.552.528.480;D01.552.547.290,C01.539.739;C08.730
c1012114-7f38-4696-bd39-50031c9729bb,C2948600,C0030106,explore associations among ,Aim,Ozone,1,X,[inch/phsu],[chem],,D01.362.670.600;x.x.x.x
7221c809-687f-4393-8ed4-5e1526a090af,C0034602,C0012634,play role in diagnosis of various ,Interventional radiology,Disease,1,X,[bmod],[dsyn],H02.403.740.675,C23.550.288
86ae780d-3443-4a48-9a86-65df37491330,C0032285,C1861172,increased risk of ,Pneumonia,Venous Thromboembolism,1,X,[dsyn],[dsyn],C08.381.677;C08.730.610,C14.907.355.590.700
8cb6b908-d6cf-4ea5-81ed-56b36d6d3b8e,C0520997,C0940931,death from ,Thrombolysis function,hemorrhage as a complication,1,X,[clna],[dsyn],,
252c600d-f131-4c04-93ba-dde8e6be6580,C0184661,COVID-19,is with ,Interventional procedure,COVID-19,1,X,[topp],[virs],,C000657245
8e4b2e36-5927-4c7e-8b79-f1d96c732799,C0087111,C0025124,is with ,Therapeutic procedure,Traditional Chinese Medicine,1,X,[topp],[bmod],E02,E02.190.488.585.520;I01.076.201.450.654.558.520
6b11f64c-f95f-4d3d-8923-04c3696168f8,C0178784,COVID-19,is in ,Organ,COVID-19,1,X,[bpoc],[virs],,C000657245
a1e6d260-19be-4890-a690-5f2fc773238b,AEC2,C3463820,could could direct targets for ,AEC2,Inhibition,1,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
0bb69987-685c-4574-a59c-f28ed9c9488a,AEC2,C1175743,could could direct targets for ,AEC2,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
cb54d23e-2860-4834-abbf-f8e2db4037db,C0034392,COVID-19,could ,Quercetin,COVID-19,1,X,[orch/phsu/vita],[virs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,C000657245
85b5ce17-da36-4557-a6c3-02c6ff6eb6b6,C0064280,COVID-19,could ,kaempferol,COVID-19,1,X,[orch],[virs],x.x.x.x,C000657245
657f54d6-9b7b-4930-b049-40a7e21029c8,C0065264,COVID-19,could ,Luteolin,COVID-19,1,X,[orch/phsu],[virs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,C000657245
8d61d34c-167f-4441-be1b-58103b681aa9,C0047611,COVID-19,could ,3-methylquercetin,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
62925b3e-2ed2-4fb5-aca1-21025f4a7ad6,C0052927,COVID-19,could ,baicalein,COVID-19,1,X,[orch/phsu],[virs],x.x.x.x,C000657245
0f3a8d26-e805-4d18-a1b8-1c3ff1d0437e,C0251223,COVID-19,could ,wogonin,COVID-19,1,X,[orch],[virs],x.x.x.x,C000657245
df5c64bc-271f-451d-b5aa-d77c26667242,C0034392,AEC2,targeting on AEC2,Quercetin,AEC2,1,X,[orch/phsu/vita],????,D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,????
c5cc0f48-eed4-4488-be24-e9284ccb0460,C0064280,AEC2,targeting on AEC2,kaempferol,AEC2,1,X,[orch],????,x.x.x.x,????
8b2e20ec-250e-41a4-a92b-453f8ea01409,C0065264,AEC2,targeting on AEC2,Luteolin,AEC2,1,X,[orch/phsu],????,D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,????
14f18b7c-af4b-47a1-9851-cbb6061277fe,C0047611,AEC2,targeting on AEC2,3-methylquercetin,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
06f8948a-4ae4-450c-98b1-d6a9f88f842b,C0052927,AEC2,targeting on AEC2,baicalein,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
caf8bf9b-6b10-476e-9c6e-0943fbdde380,C0068450,AEC2,targeting on AEC2,naringenin,AEC2,1,X,[orch/phsu],????,x.x.x.x,????
9f3fb030-3089-49ae-b270-eeb2c7269cc0,C0251223,AEC2,targeting on AEC2,wogonin,AEC2,1,X,[orch],????,x.x.x.x,????
be56a37a-c0d0-45c0-ada7-107cfdc34ef7,C0034392,C0016693,eliminating ,Quercetin,Free Radicals,1,X,[orch/phsu/vita],[bacs/chvs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D01.339;D02.389
c6c90f04-c2af-4228-9120-183711de489a,C0064280,C0016693,eliminating ,kaempferol,Free Radicals,1,X,[orch],[bacs/chvs],x.x.x.x,D01.339;D02.389
cdffbf93-2ad7-4f77-ac60-fa2d448d89a3,C0065264,C0016693,eliminating ,Luteolin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D01.339;D02.389
99149399-e362-4799-9c71-484c7014f75f,C0047611,C0016693,eliminating ,3-methylquercetin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
1431eb32-a3ce-46e0-8bb8-81111b9d4a90,C0052927,C0016693,eliminating ,baicalein,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
069e920f-dfe8-4e05-9674-02ff733eb575,C0068450,C0016693,eliminating ,naringenin,Free Radicals,1,X,[orch/phsu],[bacs/chvs],x.x.x.x,D01.339;D02.389
eb19f9e3-f43e-428c-8458-30bc6ae8fe8a,C0251223,C0016693,eliminating ,wogonin,Free Radicals,1,X,[orch],[bacs/chvs],x.x.x.x,D01.339;D02.389
4fb1102f-32f5-4e67-8197-759a6c8e3e38,C1565860,C1512589,is in NF-B ,PTGS2 protein human,IL17 Signaling Pathway,2,X,[aapp/enzy],[celf],x.x.x.x,
f37bd54f-6e88-4a10-8763-8d5ddd578567,C1565860,C0003695,is in NF-B ,PTGS2 protein human,Arachidonic Acid,1,X,[aapp/enzy],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
db08772f-0f26-40ef-a314-c8cbd21c61c7,C1565860,C0215848,is in NF-B ,PTGS2 protein human,Hypoxia-Inducible Factor 1,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
47651f6b-268e-451d-ad2b-e51161455a85,C1565860,NF-B,is in NF-B ,PTGS2 protein human,NF-B,1,X,[aapp/enzy],????,x.x.x.x,????
5316c52b-d3de-4711-a149-2839fd3deb0e,C1565860,C0034678,is in NF-B ,PTGS2 protein human,ras Oncogene,1,X,[aapp/enzy],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
ce303728-490d-45b7-8a33-547cb78adead,C1565860,C1448177,is in NF-B ,PTGS2 protein human,TNF protein human,1,X,[aapp/enzy],[aapp/bacs],x.x.x.x,x.x.x.x
459bb871-8814-4f52-8e3d-7cd7a4a2d998,C0034392,C1565860,eliminating Free Radicals through NF-B,Quercetin,PTGS2 protein human,1,X,[orch/phsu/vita],[aapp/enzy],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,x.x.x.x
b82de527-3394-4a43-951a-bb3967bf061c,C0064280,C1565860,eliminating Free Radicals through NF-B,kaempferol,PTGS2 protein human,1,X,[orch],[aapp/enzy],x.x.x.x,x.x.x.x
f82aba15-3446-4ae6-8c1e-1fcd4d6cb298,C0065264,C1565860,eliminating Free Radicals through NF-B,Luteolin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,x.x.x.x
fd98e4c8-4eb0-4a5d-802a-91416d1896eb,C0047611,C1565860,eliminating Free Radicals through NF-B,3-methylquercetin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
035f4215-000e-4387-be41-5bcfda129b12,C0052927,C1565860,eliminating Free Radicals through NF-B,baicalein,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
dc587eb6-3593-4e88-bcef-e41340e65b3c,C0068450,C1565860,eliminating Free Radicals through NF-B,naringenin,PTGS2 protein human,1,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
3cc19c10-b519-46c2-b356-e8a94d1c20bf,C0251223,C1565860,eliminating Free Radicals through NF-B,wogonin,PTGS2 protein human,1,X,[orch],[aapp/enzy],x.x.x.x,x.x.x.x
0aadbec1-243a-473c-8e73-0b59399e5857,C0034392,C1512589,eliminating Free Radicals through NF-B,Quercetin,IL17 Signaling Pathway,2,X,[orch/phsu/vita],[celf],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,
bad78ee3-8ada-494a-89ac-e368188eb1ce,C0064280,C1512589,eliminating Free Radicals through NF-B,kaempferol,IL17 Signaling Pathway,2,X,[orch],[celf],x.x.x.x,
6729bc84-e639-42cc-844f-f55898554126,C0065264,C1512589,eliminating Free Radicals through NF-B,Luteolin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,
87c84f9b-1595-4314-8880-644601fc5e9e,C0047611,C1512589,eliminating Free Radicals through NF-B,3-methylquercetin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
71b3aea9-9f26-4d62-8529-eefc08f4bd1a,C0052927,C1512589,eliminating Free Radicals through NF-B,baicalein,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
b5e7cda0-fec5-439b-befe-fe5bffd8f88c,C0068450,C1512589,eliminating Free Radicals through NF-B,naringenin,IL17 Signaling Pathway,2,X,[orch/phsu],[celf],x.x.x.x,
5df6bfd5-807f-4d74-bc09-9b6fd7489f6e,C0251223,C1512589,eliminating Free Radicals through NF-B,wogonin,IL17 Signaling Pathway,2,X,[orch],[celf],x.x.x.x,
3aff3ebb-39d6-4ca6-b662-5602d48e9947,C0034392,C0003695,eliminating Free Radicals through NF-B,Quercetin,Arachidonic Acid,1,X,[orch/phsu/vita],[orch],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D10.251.355.255.100.100;D10.251.355.310.166.100
621b06e1-2ad5-4fb9-b0c0-ba15a42d8a0e,C0064280,C0003695,eliminating Free Radicals through NF-B,kaempferol,Arachidonic Acid,1,X,[orch],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
936674c1-3deb-414e-94ce-0010d5eb9499,C0065264,C0003695,eliminating Free Radicals through NF-B,Luteolin,Arachidonic Acid,1,X,[orch/phsu],[orch],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D10.251.355.255.100.100;D10.251.355.310.166.100
ca03509f-cabb-411b-b952-3b3ff3665ddd,C0047611,C0003695,eliminating Free Radicals through NF-B,3-methylquercetin,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
386855c6-095d-40df-8111-9b4031194eaa,C0052927,C0003695,eliminating Free Radicals through NF-B,baicalein,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
30b1ef7d-4b90-4bca-b667-fe78653e2b08,C0068450,C0003695,eliminating Free Radicals through NF-B,naringenin,Arachidonic Acid,1,X,[orch/phsu],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
318ae7d7-be4e-483c-980a-7d15605cb125,C0251223,C0003695,eliminating Free Radicals through NF-B,wogonin,Arachidonic Acid,1,X,[orch],[orch],x.x.x.x,D10.251.355.255.100.100;D10.251.355.310.166.100
5b8efec4-1cdb-474e-9cbd-10bcc05b060e,C0034392,C0215848,eliminating Free Radicals through NF-B,Quercetin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu/vita],[aapp/bacs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,D12.776.260.103.625;D12.776.930.125.625
1f468284-0745-4b1d-9336-5a545c1426d3,C0064280,C0215848,eliminating Free Radicals through NF-B,kaempferol,Hypoxia-Inducible Factor 1,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
488c62a7-5450-414f-9001-6c2da9ffa038,C0065264,C0215848,eliminating Free Radicals through NF-B,Luteolin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,D12.776.260.103.625;D12.776.930.125.625
bd3c2db2-480e-43e0-9be1-a6f25b165c59,C0047611,C0215848,eliminating Free Radicals through NF-B,3-methylquercetin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
2fd6d395-bfb6-4a0b-a5e1-271d12137fc3,C0052927,C0215848,eliminating Free Radicals through NF-B,baicalein,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
136f566d-d60c-49b7-b5ed-291d0858731e,C0068450,C0215848,eliminating Free Radicals through NF-B,naringenin,Hypoxia-Inducible Factor 1,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
cff5aa2b-5d76-4dab-91c3-e780ea0b344e,C0251223,C0215848,eliminating Free Radicals through NF-B,wogonin,Hypoxia-Inducible Factor 1,1,X,[orch],[aapp/bacs],x.x.x.x,D12.776.260.103.625;D12.776.930.125.625
43ad9e2e-0ef9-4bf1-b91e-497348b7a2cf,C0034392,NF-B,eliminating Free Radicals through NF-B,Quercetin,NF-B,1,X,[orch/phsu/vita],????,D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,????
5527c08d-92b8-4e28-bda9-c98059435096,C0064280,NF-B,eliminating Free Radicals through NF-B,kaempferol,NF-B,1,X,[orch],????,x.x.x.x,????
acce08dd-bfb2-4030-bcbf-16e53e7573a9,C0065264,NF-B,eliminating Free Radicals through NF-B,Luteolin,NF-B,1,X,[orch/phsu],????,D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,????
26fd7f7a-bd5d-4850-814d-1e291571f1b0,C0047611,NF-B,eliminating Free Radicals through NF-B,3-methylquercetin,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
43c0ddbc-dfd7-4495-b168-8205922a4d39,C0052927,NF-B,eliminating Free Radicals through NF-B,baicalein,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
25ae7aac-b363-41db-be0e-c25f4564af41,C0068450,NF-B,eliminating Free Radicals through NF-B,naringenin,NF-B,1,X,[orch/phsu],????,x.x.x.x,????
15e4fb5c-4eac-42c9-ade1-bd9d5b955123,C0251223,NF-B,eliminating Free Radicals through NF-B,wogonin,NF-B,1,X,[orch],????,x.x.x.x,????
79754419-e56e-437b-9676-be29c72c14d4,C0034392,C0034678,eliminating Free Radicals through NF-B,Quercetin,ras Oncogene,1,X,[orch/phsu/vita],[gngm],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,G05.360.340.024.340.375.500.791.550
a6e2e8d4-752a-4e0d-b254-af654f354e00,C0064280,C0034678,eliminating Free Radicals through NF-B,kaempferol,ras Oncogene,1,X,[orch],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
be374e73-5cbf-4697-9dc5-0acca6f72c8d,C0065264,C0034678,eliminating Free Radicals through NF-B,Luteolin,ras Oncogene,1,X,[orch/phsu],[gngm],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,G05.360.340.024.340.375.500.791.550
540a686a-28c9-484f-8206-3fe20abb2906,C0047611,C0034678,eliminating Free Radicals through NF-B,3-methylquercetin,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
09a0e5cb-64fc-4590-a026-1b0421b44d1c,C0052927,C0034678,eliminating Free Radicals through NF-B,baicalein,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
6f1b4b13-f5a2-4e7d-bb06-c4ab035aef75,C0068450,C0034678,eliminating Free Radicals through NF-B,naringenin,ras Oncogene,1,X,[orch/phsu],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
2f78e6e2-502c-444d-813d-c9b97f125e48,C0251223,C0034678,eliminating Free Radicals through NF-B,wogonin,ras Oncogene,1,X,[orch],[gngm],x.x.x.x,G05.360.340.024.340.375.500.791.550
6bf7ff80-059c-40ae-abc2-d4b03a233f36,C0034392,C1448177,eliminating Free Radicals through NF-B,Quercetin,TNF protein human,1,X,[orch/phsu/vita],[aapp/bacs],D03.383.663.283.266.450.284.777;D03.633.100.150.266.450.284.777,x.x.x.x
135ac6d5-9756-4466-b401-c0bcf1c87047,C0064280,C1448177,eliminating Free Radicals through NF-B,kaempferol,TNF protein human,1,X,[orch],[aapp/bacs],x.x.x.x,x.x.x.x
4958990e-bc32-4f03-97f6-2c0a05ca7ec1,C0065264,C1448177,eliminating Free Radicals through NF-B,Luteolin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],D03.383.663.283.266.450.260.555;D03.633.100.150.266.450.260.555,x.x.x.x
52a820a6-aef7-4f87-9673-aad676c4891e,C0047611,C1448177,eliminating Free Radicals through NF-B,3-methylquercetin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
21a53124-b6ad-4e93-b651-d36213823a2c,C0052927,C1448177,eliminating Free Radicals through NF-B,baicalein,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
dd846edf-97da-4845-bf9c-123d6729408a,C0068450,C1448177,eliminating Free Radicals through NF-B,naringenin,TNF protein human,1,X,[orch/phsu],[aapp/bacs],x.x.x.x,x.x.x.x
27b0154f-4cc0-4709-8c5f-7c15460b0929,C0251223,C1448177,eliminating Free Radicals through NF-B,wogonin,TNF protein human,1,X,[orch],[aapp/bacs],x.x.x.x,x.x.x.x
548f9ea3-7111-4037-a043-13a1b85f19d0,C1527398,C0872315,is diagnosed with ,Emergency Care,Communicable Diseases Emerging,2,X,[topp],[dsyn],N02.421.297,C01.539.221.500
ce280b84-23d8-45c5-a319-a9a496ccb634,C0185003,C0206419,have occurred due to ,Reparative closure,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
50fa4237-8f40-414d-afea-4025a529a844,C0185003,C0012634,have occurred due to ,Reparative closure,Disease,1,X,[topp],[dsyn],,C23.550.288
b3ea0d37-8d78-4305-90c0-76e6e1237f00,C0185003,C2745965,are in However contravention of laws for provision of ,Reparative closure,Emergencies [Disease/Finding],1,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
7d244c22-9e5d-4f6a-ac40-4b8887e1ce18,C0185003,C1947933,are in However contravention of laws for provision of ,Reparative closure,care activity,1,X,[topp],[acty],,
d9f98ca0-5fa3-436f-99ca-23e14517b3c7,C1947933,C1602245,enable to avail ,care activity,Prompt,1,X,[acty],[phsu],,
57836165-db31-4c59-86f2-92ba5a531d01,C0185003,C1856053,occurred to ,Reparative closure,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[topp],[dsyn],,x.x.x.x
f9f96ff3-56a5-4f88-8fee-e7f591eaea6a,C0185003,C1516048,present status of were ,Reparative closure,Assessed,1,X,[topp],[acty],,
c812c816-ab31-47e2-9cbb-eb8176a0ed65,C0040861,COVID-19,were effective in ,Triage,COVID-19,1,X,[topp],[virs],N02.421.297.900,C000657245
f4ffd19e-6d91-48bd-a205-82ee647cb9d4,C0040861,C0030693,were effective in ,Triage,Patient Isolation,2,X,[topp],[topp],N02.421.297.900,E02.770;N06.850.780.200.450.650
92e667c7-43e8-4846-b597-0269173b8ba0,C1707455,C1628999,is with PCR ,Comparison,SARS coronavirus RNA,1,X,[acty],[nnon],,
9dd5b498-2dd3-4dd8-a115-fa2c25b6eeb5,C1707455,PCR,is with PCR ,Comparison,PCR,1,X,[acty],????,,????
0652b400-a80b-4e34-84c6-eed13ca235d6,C0036745,C1175743,be useful test for diagnosis of active ,Study of serum,SARS coronavirus,1,X,[bmod],[virs],H02.781,B04.820.504.540.150.113.937
09076ae7-63bf-4d1e-8ecf-bda7490bb026,C0042776,C0003451,propose several possible targets for ,Virus,Antiviral Agents,1,X,[virs],[phsu],B04,D27.505.954.122.388
cd9a2445-444a-4776-972b-7460a1ecf3f2,C0017337,C0543467,could With advantage of CoV2 ,Genes,Operative Surgical Procedures,1,X,[gngm],[topp],G05.360.340.024.340,E04
f691e899-77b2-4ea1-8b96-79fa3a5137f6,C0748355,COVID-19,pathophysiology of ,Acute respiratory distress,COVID-19,1,X,[dsyn],[virs],,C000657245
4be77038-1220-46a1-88d4-4913e3608eea,C0009450,C3714514,evaluated patients with suspected ,Communicable Diseases,Infection,1,X,[dsyn],[patf],C01.539.221,C01.539
e6998e6e-86cf-4894-a493-698b3d9ba68b,C1158478,COVID-19,have role In ,DNA Integration,COVID-19,1,X,[genf],[virs],,C000657245
deb38d7a-958f-4b9c-8fca-e9f7f3fa96b4,C1158478,C2745965,have role In ,DNA Integration,Emergencies [Disease/Finding],1,X,[genf],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
4186a6cf-a6b4-4df9-a676-3c79b798287c,C0174990,C1397014,hypothesized immune-hematological mechanism based on renin-angiotensin system ,coronavirus receptor,Imbalance,1,X,[aapp/rcpt],[sosy],x.x.x.x,
e56a34b4-ae27-49b3-87ec-731af6a44718,C0597357,C1397014,hypothesized immune-hematological mechanism based on renin-angiotensin system ,receptor,Imbalance,1,X,[aapp/rcpt],[sosy],,
3fab282a-4181-45f6-b9bb-124b3ea0fc33,C0597357,C1413811,is with reduction of ,receptor,CTSC gene,1,X,[aapp/rcpt],[gngm],,
c6968114-c8cf-4ab9-8fed-5494a4186f9f,RAS,C1413811,is with reduction of ,RAS,CTSC gene,1,X,????,[gngm],????,
b05cbc00-0108-4be2-8a50-2e005db5dbe8,C0004457,C1413811,is with reduction of ,Axis vertebra,CTSC gene,1,X,[bpoc],[gngm],A02.835.232.834.151.383,
fd00bc3b-9b12-4687-96ff-a60ec5f3a333,C0301630,C0038941,is in perioperative ,Reduction (chemical),Surgical Wound Infection,1,X,[npop],[patf],,C01.539.947.692;C23.550.767.925
98d1a07a-0f7b-4aa1-8fe9-c0378eb23d28,C0301630,C4520447,are obtained by multifaceted approach ,Reduction (chemical),Decolonization,1,X,[npop],[topp],,
98d1a07a-0f7b-4aa1-8fe9-c0378eb23d28,C0301630,C4520447,are obtained by multifaceted patient ,Reduction (chemical),Decolonization,1,X,[npop],[topp],,
9de0a710-370b-4371-b27c-ac07e6ceaae9,C3540027,C3714514,had expected incidence 0.20 ,Adrenergic and dopaminergic agents combinations,Infection,1,X,[phsu],[patf],,C01.539
8da1dc31-d611-45a2-987a-88c6844d7dc2,C0009324,C1705178,is in ,Ulcerative Colitis,Order (action),2,X,[dsyn],[acty],C06.405.205.265.231;C06.405.205.731.249;C06.405.469.158.188.231;C06.405.469.432.249,
717d7e65-b721-4607-aa16-b360a232cba9,C0042776,C0422879,causes ,Virus,CNS symptom,2,X,[virs],[sosy],B04,
765d7997-6f6f-4134-9a7d-17ee4aeed542,C0011206,C3714514,be should recognized as potential feature of ,Delirium,Infection,1,X,[mobd],[patf],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C01.539
743154e7-1cb8-4f76-8490-aef96356a3dc,C0011206,C1175743,be should recognized as potential feature of ,Delirium,SARS coronavirus,1,X,[mobd],[virs],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,B04.820.504.540.150.113.937
4840c4f1-085f-4463-a048-96c9f437fdec,C0011206,C1457887,may may presenting ,Delirium,Symptoms,1,X,[mobd],[sosy],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,
2b6b53ed-89a2-40cf-9ca8-78897fa32e0c,C0011206,C0085584,represents ,Delirium,Encephalopathies,1,X,[mobd],[dsyn],C10.597.606.337.500;C23.888.592.604.339.500;F01.700.250.500;F03.615.350,C10.228.140
de33417c-cfb3-48fb-b77a-03862c725a3e,C0206750,C0002736,has created unprecedented challenges for ,Coronavirus Infections,Amyotrophic Lateral Sclerosis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
b07600ca-d1d1-4509-a518-9a266303aea4,C0012634,C0002736,has created unprecedented challenges for ,Disease,Amyotrophic Lateral Sclerosis,1,X,[dsyn],[dsyn],C23.550.288,C10.228.854.139;C10.574.562.250;C10.574.950.050;C10.668.467.250;C18.452.845.800.050
57f4d327-4dad-4fac-b6a0-6788fec91112,C0012634,C1947933,has created unprecedented challenges for ,Disease,care activity,1,X,[dsyn],[acty],C23.550.288,
7b8ae6ae-6cb9-4d80-aaf2-940b5761c447,C0042776,C1511790,was also ,Virus,Detection,1,X,[virs],[topp],B04,
995c2275-1053-436f-ab0b-4448a5e75164,C1707455,C0021189,may reduce spread in assisted ,Comparison,Independent Living,1,X,[acty],[dora],,I03.050.500;N01.224.791.550;N06.850.505.400.800.550
2faa0f31-ff3c-4272-b268-ca2ff08a6fa9,C1096155,3-D,Fortunately distributed manufacturing with recent development of manufacturing technologies like 3-D ,Macrophage Activation Syndrome,3-D,1,X,[dsyn],????,C20.683.515.800,????
08b10cd8-4f85-4e64-8763-11ee43e0ab5a,C1825598,C0849867,be felt by ,IMPACT gene,Widespread Disease,1,X,[gngm],[dsyn],,
ad4d5c53-8747-456f-9931-f7a1c75ae74e,C1520005,C0221423,ultimately named with clinical ,Viral Pathogenesis,Illness (finding),2,X,[patf],[sosy],,
3bcb0f69-4d2b-41a9-b356-5669d9c9a3d0,C0017181,C1145670,Nevertheless poses challenges to patients due to high-risk of concomitant ,Gastrointestinal Hemorrhage,Respiratory Failure,1,X,[patf],[dsyn],C06.405.227;C23.550.414.788,C08.618.846
263a773b-0f90-41f6-adde-34a0696f18a9,C0017181,C0206750,is in ,Gastrointestinal Hemorrhage,Coronavirus Infections,1,X,[patf],[dsyn],C06.405.227;C23.550.414.788,C02.782.600.550.200
31fcabab-fd08-4a02-8151-d0b5f62f2420,C0035668,C3687742,is in ,RNA,Oropharyngeal swab,1,X,[nnon],[bdsu],D13.444.735,
8b39ec92-c568-44e3-ab68-be4f61fbf90c,C0597404,C0206750, includes ,Respiratory viruses,Coronavirus Infections,1,X,[virs],[dsyn],,C02.782.600.550.200
3da42304-2c9c-458d-804a-0c5d29c3eddd,C1441506,C0034700,introduced novel Au-decorated ,Calculation,Rats Inbred BN,1,X,[acty],[mamm],,B01.050.050.199.520.760.110;B01.050.150.900.649.313.992.635.505.700.400.110
c1043a2a-b8ff-47ac-b9bc-4cc1d04d7ff4,C0005775,C0302908,is with ,Blood Circulation,Liquid substance,1,X,[phsf],[sbst],G09.330.100,
fdcfba3d-71c9-449f-b144-fd392a5697a0,C0012634,C0028429,Cyanosis of,Disease,Nose,2,X,[dsyn],[bpoc],C23.550.288,A01.456.505.733;A04.531;A09.531
26f06f75-3f6c-4a8a-88e4-8c982347749a,C0012634,C0016129,Cyanosis of,Disease,Fingers,2,X,[dsyn],[bpoc],C23.550.288,A01.378.800.667.430
61d7cc3e-81c2-4a36-818c-bb2e77f47a31,C0010520,C0017086,became dried ,Cyanosis,Gangrene,2,X,[sosy],[dsyn],C23.888.248,C23.550.717.427
6650888c-e56c-4c32-87cb-7ad3b651cc69,C0206750,C0036983,could In cases could complicated by ,Coronavirus Infections,Septic Shock,2,X,[dsyn],[patf],C02.782.600.550.200,C01.539.757.800;C23.550.470.790.500.800;C23.550.835.900.712
24533d93-b301-4219-aa55-ac3d16e37b8a,C0206750,C0026766,could In cases could complicated by ,Coronavirus Infections,Multiple Organ Failure,2,X,[dsyn],[patf],C02.782.600.550.200,C23.550.835.525
ac66dc9e-26bb-4b91-8fa9-43675c9d065a,C2745965,C1707455,is in ,Emergencies [Disease/Finding],Comparison,1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
b167712d-77ea-4729-a0da-86d06f778d6c,C2745965,C0018563,is in ,Emergencies [Disease/Finding],Hand,1,X,[patf],[bpoc],C23.550.291.781;N06.230.100.083;N06.850.376,A01.378.800.667
47f3d8a1-f968-4775-bdc6-ccc13df03f1b,C0021760,C0079189,plays role in ,Interleukin-6,cytokine,3,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D12.644.276.374;D12.776.467.374;D23.529.374
383f98bb-51ed-473e-a8ff-43e556a92d71,C1609165,C0087111,has has proposed to ,tocilizumab,Therapeutic procedure,1,X,[aapp/imft/phsu],[topp],x.x.x.x,E02
70143dd5-d40a-4a1f-b768-e0869e52ed59,C0023884,TCZ,caused by TCZ,Liver,TCZ,1,X,[bpoc],????,A03.620,????
562deb03-f74b-46a4-ab2a-b7326b75d6ed,C0860207,TCZ,associated with use of TCZ,Drug-Induced Liver Disease,TCZ,1,X,[dsyn],????,C06.552.100;C25.100.562;C25.723.260,????
41e6d5ea-31e5-4d71-9d2d-14d21a001574,TCZ,C0002594,had effect ,TCZ,Transaminases,2,X,????,[aapp/enzy],????,D08.811.913.477.700
04fb6b28-b8bf-4ff7-9df5-9468f4411f5f,TCZ,C0079189,Nevertheless had effect on clinical parameters in ,TCZ,cytokine,1,X,????,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374
98c374f8-e446-4c15-b388-19f015354daf,C0232741,C2922974,is imperative because of frequent ,Liver function,Polypharmacy,1,X,[ortf],[topp],,E02.319.698
b6e40b02-d392-4297-84f6-4ad9df3f6a3f,C4547399,C0275522,with 3.15 is ,CI-2,Asymptomatic Infections,1,X,[aapp/phsu],[dsyn],,C23.550.291.187.500
2b3e4f53-2e08-4814-9aaa-bd585b4995be,C1963724,C0206750,on female is causative agent for ,Antiretroviral therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
46909ff1-0aa2-4327-a669-fb8d59e3e72d,C1963724,C0012634,on female is causative agent for ,Antiretroviral therapy,Disease,1,X,[topp],[dsyn],,C23.550.288
0d783331-c570-4623-b634-d24d054bf2cd,C0319157,C0086022,acting as inanimate ,AS virus,Cloning Vectors,1,X,[virs],[nnon],,G05.360.337
9523e923-09e3-4647-b919-caf5c15aea72,C0319157,C1533724,acting as ,AS virus,Fomes,1,X,[virs],[fngs],,B01.300.179.120.174
007a3faa-3917-4b69-bd14-9fd96aeb2b4c,C0042760,C0036087,are present in ,Virion,saliva,2,X,[celc],[bdsu],A21.249;B04.950,A12.200.666
c5a39c75-9b56-4ee6-8f25-f9a20d30a3b4,C3826466,C0206750,may how may impacted by ,Dentistry--Practice,Coronavirus Infections,1,X,[bmod],[dsyn],,C02.782.600.550.200
487d2de0-78e6-4fd1-9e09-611f0821498a,C0042769,C3272275,has stimulated ,Virus Diseases,Urgent Procedure,1,X,[dsyn],[topp],C02,
2961dabe-ea41-4b7b-bd94-3d4ad50da936,C0042769,C0015392,has stimulated ,Virus Diseases,Eye,1,X,[dsyn],[bpoc],C02,A01.456.505.420;A09.371
89204e9b-807d-4621-b95e-ea82568ccd52,C0042210,C0057256,is adjuvanted with -3 ,Vaccines,Defensins,1,X,[aapp/imft/phsu],[aapp/imft/phsu],D20.215.894,D12.644.050.200;D12.776.543.695.054.200
59a39831-bd96-4721-b89a-474c927167d4,C0042210,C0301872,elicit strong ,Vaccines,Immune response,1,X,[aapp/imft/phsu],[ortf],D20.215.894,
c1fbd922-b152-4b83-8caf-725626fa4632,C1457887,C0042776,probably linked to ,Symptoms,Virus,1,X,[sosy],[virs],,B04
2b875084-d1a5-4625-b0de-685528818787,C1257753,C0006625,been focus on rising rates of childhood ,Child Malnutrition,Cachexia,1,X,[dsyn],[sosy],C18.654.180,C23.888.144.243.963.500.500
5d8f0307-6b0a-4128-9c97-cb8c25eb9aaa,C1456573,C0162429,is in ,Global Health,Malnutrition,1,X,[bmod],[dsyn],H02.403.371;N01.400.337,C18.654.521
7f903806-fef7-4d84-b33d-58ee185a4107,C0879626,C0206750,Acute disease of cardiovascular system effects of,Adverse effects,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
1991bf5a-400a-4b64-b7c2-f3ad06b7284a,C0007222,C1175175,evidence for direct myocardial injury in ,Cardiovascular Diseases,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],C14,C02.782.600.550.200.750;C08.730.730
89ff0b17-ee9e-4955-9118-b116cc3f163c,C0567416,C0036658,have In ,Molecule,Esthesia,1,X,[sbst],[ortf],,F02.830.816;G11.561.790
dfc03aa9-330e-432c-a745-692d627918bd,C0032100,C0003451,exhibit significant inhibitory ,Plants Medicinal,Antiviral Agents,1,X,[plnt],[phsu],B01.650.560,D27.505.954.122.388
7daad779-74a8-472d-8a2d-cc319920d23b,C0032100,C1175743,exhibit significant inhibitory ,Plants Medicinal,SARS coronavirus,1,X,[plnt],[virs],B01.650.560,B04.820.504.540.150.113.937
bb39d808-cfda-4e30-844c-4c6e4562e83d,C0032081,C1705178,are In review discussed in ,Plant Extracts,Order (action),1,X,[bacs/phsu],[acty],D20.215.784.500;D26.667,
6131ae6d-1388-4d6f-a8c2-e5c8b8bf3823,C0036572,C0009450,determinants for number of ,Seizures,Communicable Diseases,1,X,[sosy],[dsyn],C10.597.742;C23.888.592.742,C01.539.221
ac2458c5-8eb9-4747-b350-f814e235863a,C0206750,C0005717,is in ,Coronavirus Infections,Gilchrist Disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C01.539.800.200.055;C01.703.295.055;C01.703.534.395;C08.381.472.350;C08.730.435.395;C17.800.838.208.055
477a5ad5-fae9-42f7-886f-d7997bdefe72,C0028606,4days,was 4days,Nucleic Acids,4days,1,X,[bacs/nnon],????,D13.444,????
e54c96e2-395a-42d0-83ce-5cd57ad5f740,C0042769,C1457887,may reveal light ,Virus Diseases,Symptoms,2,X,[dsyn],[sosy],C02,
1e3f39e6-9851-4e63-b0cd-34921eb4a7e2,C0206750,C0282632,could promote ,Coronavirus Infections,Antibody-Dependent Enhancement,1,X,[dsyn],[comd],C02.782.600.550.200,G06.920.095;G12.113
d3da24b9-3b20-4189-b472-ec69547ffd15,C1175175,C0003241,experimentally shown for ,Severe Acute Respiratory Syndrome,Antibodies,2,X,[dsyn],[aapp/imft/phsu],C02.782.600.550.200.750;C08.730.730,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
95725a36-4b27-46a8-8da9-b1a78c0b11ac,C1175175,C3694279,experimentally shown for ,Severe Acute Respiratory Syndrome,Middle East Respiratory Syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200.750;C08.730.730,C02.782.600.550.200
42c1ecfa-4978-4b01-8f58-9d824d0900fe,C0206750,C0003241,could promote Antibody-Dependent Enhancement experimentally shown for,Coronavirus Infections,Antibodies,1,X,[dsyn],[aapp/imft/phsu],C02.782.600.550.200,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
727668a7-52b6-445f-9f4c-2f57ab094bc4,C0206750,C3694279,could promote Antibody-Dependent Enhancement experimentally shown for,Coronavirus Infections,Middle East Respiratory Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.600.550.200
69f2a6e5-044d-455d-a982-d059bc898673,C1175175,C0282632,could promote ,Severe Acute Respiratory Syndrome,Antibody-Dependent Enhancement,1,X,[dsyn],[comd],C02.782.600.550.200.750;C08.730.730,G06.920.095;G12.113
6f09c557-ee66-4d56-aab8-793461a7d967,C0206750,C0521839,can manifest with ,Coronavirus Infections,Influenza-like illness,1,X,[dsyn],[dsyn],C02.782.600.550.200,
e544625c-a8c4-446a-bb91-1debbea0a5f5,C1705178,C0015219,postpone opening in response to ,Order (action),Biological Evolution,1,X,[acty],[genf],,G05.045;G16.075
35b2bc08-e793-4951-a189-7ae8a2a112e2,C1705178,C0206750,postpone opening in response to ,Order (action),Coronavirus Infections,1,X,[acty],[dsyn],,C02.782.600.550.200
d807570c-4918-4c58-b81d-872f53bad38d,C0011139,C0086418,is difficult ,Defective Viruses,Homo sapiens,1,X,[virs],[humn],B04.265,B01.050.150.900.649.313.988.400.112.400.400
1a725eba-8a58-43ad-a3ee-aa27dbaa19cf,C0011139,C0042776,is difficult ,Defective Viruses,Virus,1,X,[virs],[virs],B04.265,B04
618f4ad9-3ed4-4184-bf59-90081bbf21e7,C0086418,C0042776,fight against ,Homo sapiens,Virus,1,X,[humn],[virs],B01.050.150.900.649.313.988.400.112.400.400,B04
2575ca4d-6f19-46aa-b979-5be8c8f76062,C0009443,C0042776,minimize exposure of cells to ,Common Cold,Virus,1,X,[dsyn],[virs],C02.782.687.207;C08.730.162,B04
a313da58-9a38-4b67-9ee0-57d31e4ddf90,C0333514,C0006104,is in ,Zonal necrosis,Brain,1,X,[patf],[bpoc],,A08.186.211
5e66283e-0103-4b5f-aabb-9540a6e34f5b,C0264490,C1175743,could due to could effects of ,Acute respiratory failure,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
986f581e-74f1-4489-8f56-218aa0b6b7df,C0264490,C0035216,could due to could effects of ,Acute respiratory failure,Respiratory Center,2,X,[dsyn],[bpoc],,A08.186.211.132.772.646
578cdbb6-a9cc-402a-b4e7-784e9b51f592,C0264490,C0006121,could due to could effects of ,Acute respiratory failure,Brain Stem,1,X,[dsyn],[bpoc],,A08.186.211.132
85a11dae-e994-46d3-a98a-8360ce95aa23,C0035216,C0006121,is in ,Respiratory Center,Brain Stem,2,X,[bpoc],[bpoc],A08.186.211.132.772.646,A08.186.211.132
0fa49178-2e6c-41c8-8eb8-72e3bad9d885,C0035204,C0598197,caused by highly ,Respiration Disorders,contagion,1,X,[dsyn],[npop],C08.618,
739229a1-0575-4326-87ec-b12a44910eb0,C0024264,CD4, includes CD4,Lymphocyte,CD4,1,X,[cell],????,A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,????
5c9be1ca-33e2-4af8-b590-b532225e93f2,C0085295,C0206750,were remarkably up-regulated in patients with severe ,Interleukin-10,Coronavirus Infections,3,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C02.782.600.550.200
ace061f8-7186-48b6-a4dc-5bea3aecdeef,C1704259,C0003451,involved in such ,Biochemical Pathway,Antiviral Agents,1,X,[moft],[phsu],,D27.505.954.122.388
c69252a2-21c3-4948-9c82-9d201abd422f,C2948600,C0032285,discuss emergent repair in patients affected by ,Aim,Pneumonia,1,X,[inch/phsu],[dsyn],,C08.381.677;C08.730.610
c69252a2-21c3-4948-9c82-9d201abd422f,C2948600,C0032285,investigate ,Aim,Pneumonia,1,X,[inch/phsu],[dsyn],,C08.381.677;C08.730.610
233e8d40-ad7b-446f-9bdc-61a5b41fd94b,C0086418,C0741160,was admitted for ,Homo sapiens,Aortic Aneurysm Ruptured,1,X,[humn],[dsyn],B01.050.150.900.649.313.988.400.112.400.400,C14.907.055.185.125;C14.907.055.239.175;C14.907.109.139.175;C26.761.125
1a639574-c78d-48e3-8209-2b21658f23b2,C0034065,C0206750,may play role in severe ,Pulmonary Embolism,Coronavirus Infections,1,X,[patf],[dsyn],C08.381.746;C14.907.355.350.700,C02.782.600.550.200
1b9365cb-2c83-4f56-b3be-18f6edd2805c,C0772257,C0325969,is common in legal ,fruit extracts,Amazona,1,X,[orch/phsu],[bird],,B01.050.150.900.248.710.672.050
092f5914-e4f3-43ac-9449-d6be5e040476,C0872152,C3266814,is with ,Drug Development,Action,1,X,[bmod],[acty],E05.290;H01.158.703.007.338;H01.181.466.338,
8c159fae-6c43-4abd-804f-cc27e0c922c3,on-site,C1706005,rapid diagnosis of ,on-site,CD40LG wt Allele,1,X,????,[gngm],????,
f610e637-7f2c-477a-a1d0-871c6d360fd4,on-site,C1175743,rapid diagnosis of ,on-site,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
87fc6383-f742-48f1-85d7-4f1b43a9df1d,on-site,C0206419,rapid diagnosis of ,on-site,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
9a1086eb-48c8-4fd8-9e2e-61cbe264b1eb,C0009359,C1706005,achieve rapid diagnosis of ,Gold Colloid,CD40LG wt Allele,1,X,[inch/phsu],[gngm],D01.379.400,
35148e2c-bb53-4d83-b4f7-e0e0a1c29766,C0806140,C1706005,achieve rapid diagnosis of ,Flow,CD40LG wt Allele,1,X,[npop],[gngm],,
59e5d174-e064-4b43-b145-5377c81c82e8,C0009359,C1175743,achieve rapid diagnosis of ,Gold Colloid,SARS coronavirus,1,X,[inch/phsu],[virs],D01.379.400,B04.820.504.540.150.113.937
11f73466-0351-4dac-8fd5-39b88cc4e12d,C0806140,C1175743,achieve rapid diagnosis of ,Flow,SARS coronavirus,1,X,[npop],[virs],,B04.820.504.540.150.113.937
f4ea8dd2-a249-42c0-a3f0-842f4604754d,C0009359,C0206419,achieve rapid diagnosis of ,Gold Colloid,Genus: Coronavirus,1,X,[inch/phsu],[virs],D01.379.400,B04.820.504.540.150
35dfb6c8-3cf9-44e4-8d68-9ec7f00c8d86,C0806140,C0206419,achieve rapid diagnosis of ,Flow,Genus: Coronavirus,1,X,[npop],[virs],,B04.820.504.540.150
1f99a2ef-e760-4af1-b00e-7e576938ff60,C2698650,C1706005,altering amount of ,Optimization,CD40LG wt Allele,1,X,[acty],[gngm],,
f4cd0142-dab3-469f-b9a9-5e5135770afd,C1707391,C1511790,is in ,Choose (action),Detection,1,X,[acty],[topp],,
6179bedb-24f6-48ca-9842-301fe5892fec,C1707391,C1706005,is in ,Choose (action),CD40LG wt Allele,1,X,[acty],[gngm],,
824d9706-151b-42cf-aa0a-fe6ac747692f,C0042730,C4284413,is with ,Viral Interference,Severe Fever with Thrombocytopenia Syndrome,1,X,[npop],[dsyn],G06.920.800,
cb6aacfe-7a74-49a8-9391-41fac8c059ba,C3241922,C0023693,is in ,Operation Activity,Light,2,X,[acty],[npop],,G01.358.500.505.650;G01.590.540;G01.750.250.650;G01.750.770.578
ab684dfe-82fe-4dda-8acb-403af7796483,C1175743,C1547282,has ,SARS coronavirus,Show,1,X,[virs],[anim],B04.820.504.540.150.113.937,
061a6108-91c2-4730-98e8-640fe9e956f9,C0009450,C1547282,has ,Communicable Diseases,Show,1,X,[dsyn],[anim],C01.539.221,
b29bdc79-4ee1-4c89-9b31-943c0d284857,C1547282,C0878544,is with acute myocardial injury ,Show,Cardiomyopathies,1,X,[anim],[dsyn],,C14.280.238
297e9f4a-90fd-4278-b4d0-e1f419711c7a,C1547282,C0027059,is with acute myocardial injury ,Show,Myocarditis,1,X,[anim],[dsyn],,C14.280.238.625
f77e35bc-9679-48ad-9b40-41491ab90eaa,C0242781,C0034991,is in ,disease transmission,Rehabilitation therapy,1,X,[patf],[topp],N06.850.310,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
1e23af14-6f9b-4409-bfd9-b3556731d7ce,C0237820,C1175743,assessed risk of ,Recovery - action,SARS coronavirus,1,X,[acty],[virs],,B04.820.504.540.150.113.937
755db069-b63c-484f-8742-60b72d8048df,C0206419,C0011535,were reported in our ,Genus: Coronavirus,Deoxyuridine,1,X,[virs],[bacs/nnon],B04.820.504.540.150,D03.383.742.680.852.300;D13.570.230.430;D13.570.685.852.300
fef75935-a395-4b85-88a8-819ee8e9028a,C0184661,C1175743,spread of ,Interventional procedure,SARS coronavirus,2,X,[topp],[virs],,B04.820.504.540.150.113.937
89c0db09-06d5-428e-8ca5-59dd3e3a1094,C0184661,C0206419,spread of ,Interventional procedure,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
b9125672-cd06-47d7-a14f-a292bc142dc3,C0206419,C0948245,is associated with development with worst outcome resulting in ,Genus: Coronavirus,Cytokine Release Syndrome,1,X,[virs],[dsyn],B04.820.504.540.150,
afbbcfd4-77de-488f-a28d-df8e658d0e37,COV,C2745965,was declared pandemic health ,COV,Emergencies [Disease/Finding],1,X,????,[patf],????,C23.550.291.781;N06.230.100.083;N06.850.376
bbeba587-5e83-4173-91d1-7c81693899e7,COV,C0206419,causing ,COV,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
51278e4d-34d5-4db8-94ab-5b8493f980ec,C1175743,C0301872,inducing disrupted ,SARS coronavirus,Immune response,1,X,[virs],[ortf],B04.820.504.540.150.113.937,
51278e4d-34d5-4db8-94ab-5b8493f980ec,C1175743,C0301872,can stimulate pronounced ,SARS coronavirus,Immune response,2,X,[virs],[ortf],B04.820.504.540.150.113.937,
9ea3091f-c79d-4b8f-b7a9-8066894ec548,C1175743,C0024312,inducing ,SARS coronavirus,Lymphopenia,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C15.378.553.546.605;C20.673.627
828fb687-9543-4f5d-85ec-07936cb4c60c,C0028754,C0021376,is associated with ,Obesity,Chronic inflammation,2,X,[dsyn],[patf],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,
039703a6-ccb0-41f1-b623-72189977ab4e,C0599949,C0009450,could favor ,Arterial Stiffness,Communicable Diseases,1,X,[phsf],[dsyn],G09.330.940,C01.539.221
62f71a12-6402-435d-a02b-631b915e4ac2,C0856169,C0009450,could favor ,endothelial dysfunction,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
b5b08c4d-446d-49f7-82f2-75765e437894,C0856169,C1175743,could favor Communicable Diseases by,endothelial dysfunction,SARS coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150.113.937
dffcc1ab-3839-4e10-9ea2-02d6980a7fb3,C0599949,C1175743,could favor Communicable Diseases by,Arterial Stiffness,SARS coronavirus,1,X,[phsf],[virs],G09.330.940,B04.820.504.540.150.113.937
f64187e8-994b-4121-a9ba-70a8bd0d2e46,C0450442,C1707391,could could administrated in ,Agent,Choose (action),1,X,[chvf],[acty],,
163bc0ab-4c97-48bb-a21b-a23b798ddc7c,C0450442,C0206419,could could administrated in ,Agent,Genus: Coronavirus,1,X,[chvf],[virs],,B04.820.504.540.150
55938d2b-fb65-4683-8b79-bc51e03861b8,C1707391,C0206419,is with ,Choose (action),Genus: Coronavirus,1,X,[acty],[virs],,B04.820.504.540.150
b0630628-2602-4bd7-b707-0ab4e9ba15a0,C0003467,C0206419,caused by ,Anxiety,Genus: Coronavirus,2,X,[mobd],[virs],F01.470.132,B04.820.504.540.150
f4d4ca0c-9f5c-4ee9-9bb1-cb59b2602ba8,C2699153,C0006121,alter ,Cell Invasion,Brain Stem,1,X,[patf],[bpoc],,A08.186.211.132
8668bc37-6dc9-4c2a-82a7-237004a72bf3,C1175743,C0034386,is in rooms of ,SARS coronavirus,Quarantine,1,X,[virs],[topp],B04.820.504.540.150.113.937,N06.850.780.200.450.700
7593946b-d9fc-40af-9734-a763aaa186b6,C0042776,C0598197,is highly ,Virus,contagion,2,X,[virs],[npop],B04,
2b6c6cb1-3de3-46ec-9184-2eb474db2957,C0199176,C0242781,reducing ,Prophylactic treatment,disease transmission,1,X,[topp],[patf],,N06.850.310
756b1e22-aceb-4414-b0a0-9fb9694fac88,C0030975,C0001546,perspective as ,Perceptual Disorders,Adjustment Disorders,1,X,[mobd],[mobd],C10.597.606.762;C23.888.592.604.764;F01.700.750,F03.950.500
926b950f-2345-4837-bb04-b73e7396f201,C0030975,C0206750,perspective as ,Perceptual Disorders,Coronavirus Infections,1,X,[mobd],[dsyn],C10.597.606.762;C23.888.592.604.764;F01.700.750,C02.782.600.550.200
e01cda3a-3b07-402c-8a6b-ff7e640cb22e,C1514593,C1707455,is in ,Psychological Impact,Comparison,1,X,[clna],[acty],,
add98b6c-f11e-4dd8-821c-a296a9f9d387,C1514593,C3698360,is in ,Psychological Impact,Middle East Respiratory Syndrome Coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.750
fb274a05-3a12-4e7f-960b-0bb10b8da020,C2948600,C2922974,reduce ,Aim,Polypharmacy,1,X,[inch/phsu],[topp],,E02.319.698
0413446c-88b8-4add-ac28-f430887ef27a,C0003615,C2745965,is most common abdominal surgical ,Appendicitis,Emergencies [Disease/Finding],2,X,[dsyn],[patf],C01.539.463.099;C06.405.205.099;C06.405.469.110.207,C23.550.291.781;N06.230.100.083;N06.850.376
286963ad-af23-4fcc-ac0b-63e4fb707142,C0012644,C0012634,evaluating ,Animal Disease Models,Disease,2,X,[emod],[dsyn],C22.232;E05.598.500;E05.599.395.080,C23.550.288
0092071c-e847-41b8-af7b-434268ebe398,C0087111,C0242781,can suppress ,Therapeutic procedure,disease transmission,1,X,[topp],[patf],E02,N06.850.310
197b923d-4afb-4ba2-8bc8-4e9dc9373a1e,C0087111,C0012634,ameliorate ,Therapeutic procedure,Disease,1,X,[topp],[dsyn],E02,C23.550.288
91847603-08ee-4b86-b1ee-69ad5386b92a,C0016452,C2741673,taking equity principles into ,Food,Account number:Identifier:Point in time:^Patient:Nominal,1,X,[food],[clna],G07.203.300;J02.500,
4da5834d-beb1-4fad-82a9-421058079a62,C0428719,C0038638,using hospital wall ,Airway pressure,Suction drainage,1,X,[clna],[topp],,E04.237.890
771bcd49-f772-4766-8646-bc14efe57719,C0030693,C0038638,using hospital wall ,Patient Isolation,Suction drainage,1,X,[topp],[topp],E02.770;N06.850.780.200.450.650,E04.237.890
6d222432-8fe6-4d60-a8c6-af0d1002bbc5,C0035691,C0028630,containing ,RNA Viruses,Nucleotides,2,X,[virs],[nnon],B04.820,D09.408.620;D13.695
f8ae8dbe-f03e-4dce-b3f3-9b4a11a70d15,C0028630,C0002520,encoding ,Nucleotides,Amino Acids,2,X,[nnon],[aapp/bacs/phsu],D09.408.620;D13.695,D12.125
f6531962-e411-4b91-b2cf-4859b744cada,C0017428,C1427622,is arranged as ,Genome,AHI1 gene,2,X,[gngm],[gngm],G05.360.340,
1042dcfd-6824-4753-a738-f7500a413f6d,C0017428,5p,is arranged as 5p ,Genome,5p,2,X,[gngm],????,G05.360.340,????
67391407-9150-4ac3-8445-e2352c2310cb,C0017428,C0178827,is arranged as 5p ,Genome,replicase,2,X,[gngm],[aapp/enzy],G05.360.340,
65e04aa9-dcd6-4d8b-8c7d-feff53967663,C0042776,C0314732,are obligate intracellular ,Virus,Infectious agent,2,X,[virs],[orgm],B04,
2b9e7b09-555f-4087-9dff-86eadaeb9cf4,C0042776,C1456706,ensure their ,Virus,Fitness,2,X,[virs],[dora],B04,
caf6c12f-98ef-4a4f-a1fd-8c3f5463a729,C0042776,C0038952,ensure ,Virus,Continuance of life,2,X,[virs],[acty],B04,I03.784
fa1de1eb-54d5-40ff-909f-6696a84f138b,C1101610,C0017262,are potent ,MicroRNAs,Gene Expression,2,X,[bacs/nnon],[genf],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.297
d27061bf-70b1-44eb-841f-78eb1b806f22,C0017262,C0042769,are modulators of ,Gene Expression,Virus Diseases,2,X,[genf],[dsyn],G05.297,C02
d27061bf-70b1-44eb-841f-78eb1b806f22,C0017262,C0042769,could play role in treatment of ,Gene Expression,Virus Diseases,2,X,[genf],[dsyn],G05.297,C02
c8a7ba7f-6b04-4081-97b0-361d1214ed3b,C1171366,C1101610,effects of ,Structural Genomics,MicroRNAs,2,X,[bmod],[bacs/nnon],,D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500
5209107d-fc13-4437-b252-3d78613c6649,C1171366,C0042774,effects on ,Structural Genomics,Virus Replication,2,X,[bmod],[celf],,G06.920.925
f5f27a84-8393-4fc1-bcb5-18fc8d5a79d2,C0206419,C0042774,of Structural Genomics is effects on,Genus: Coronavirus,Virus Replication,2,X,[virs],[celf],B04.820.504.540.150,G06.920.925
b61762e6-4d31-43e0-b5ff-888d3eed3842,C0547605,C0886052,providing practical algorithm for ,prevention of infection,wound care,2,X,[topp],[topp],,
a606e84b-d8eb-415e-b46f-1e1b9c544a19,C0021966,C1880177,deepen ,Iodides,Contribution,1,X,[inch],[acty],D01.248.497.158.490;D01.475.410,
20281ec3-d5dd-4524-8752-01ec1a718578,et,C0026837,criticize lack of ,et,Muscle Rigidity,1,X,????,[sosy],????,C05.651.504;C10.597.613.550.500;C23.888.592.608.550.500
2b1b87d0-5ccb-4e11-9ba3-c0791ba8dede,al,C0026837,criticize lack of ,al,Muscle Rigidity,1,X,????,[sosy],????,C05.651.504;C10.597.613.550.500;C23.888.592.608.550.500
77ef22e7-f5ad-4b82-88ea-548ad1ad92e3,et,C0752252,criticize lack in reports on ,et,Neuromuscular Manifestations,1,X,????,[sosy],????,C10.597.613;C23.888.592.608
cccd1222-bbcf-4f45-98f5-4b9dbadd17ee,al,C0752252,criticize lack in reports on ,al,Neuromuscular Manifestations,1,X,????,[sosy],????,C10.597.613;C23.888.592.608
f083192b-4a61-408d-bc74-3b98d011d898,C3853628,C0206750,treating ,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
f083192b-4a61-408d-bc74-3b98d011d898,C3853628,C0206750,is effective treatment for ,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
f083192b-4a61-408d-bc74-3b98d011d898,C3853628,C0206750,can effectively shorten Duration In patients with,Granule,Coronavirus Infections,1,X,[sbst],[dsyn],,C02.782.600.550.200
364e29c8-54e5-49e6-99de-82d2d1240707,C0042776,C0042736,produce ,Virus,Viral Proteins,1,X,[virs],[aapp/bacs],B04,D12.776.964
6cfc1603-db0c-4435-8523-260ed7b6bc2c,C0030012,C0012634,is maintained In physiological ,Oxidation-Reduction,Disease,2,X,[moft],[dsyn],G02.700;G03.295.531,C23.550.288
c90b201d-6b00-4a3e-9955-38b544fce8da,C0030012,C0014442,is In physiological ,Oxidation-Reduction,Enzymes,1,X,[moft],[aapp/enzy],G02.700;G03.295.531,D08.811
c90b201d-6b00-4a3e-9955-38b544fce8da,C0030012,C0014442,is maintained by ,Oxidation-Reduction,Enzymes,1,X,[moft],[aapp/enzy],G02.700;G03.295.531,D08.811
091f0d32-7a3a-4f74-b4a7-1bc60dfdca00,C0042776,C0242606,induce ,Virus,Oxidative Stress,1,X,[virs],[comd],B04,G03.673;G07.775.750
f2d63e14-d4ae-42f4-abd5-14b3c259777a,C0242606,C0343537,facilitates specific steps of ,Oxidative Stress,Specific viral infections,1,X,[comd],[dsyn],G03.673;G07.775.750,
bd844dcd-d8fb-439b-9c35-471194291a3c,C0242606,C1155266,activates ,Oxidative Stress,inflammatory response,1,X,[comd],[patf],G03.673;G07.775.750,
4af71925-1531-4d1c-9649-b00d0ab5a07f,C0206750,C2963164,has spread like ,Coronavirus Infections,Wildfires,1,X,[dsyn],[npop],C02.782.600.550.200,G01.311.988;N06.230.100.230.925;N06.230.216.875
f3fcb71f-6fc2-4971-953b-c6dc2aff9f3c,C0012634,C2963164,has spread like ,Disease,Wildfires,1,X,[dsyn],[npop],C23.550.288,G01.311.988;N06.230.100.230.925;N06.230.216.875
5382d589-f499-472b-8a0a-e43fb7d63ab5,C0021755,C1175743,have have associated with ,Interleukin-1,SARS coronavirus,1,X,[aapp/imft],[virs],D12.644.276.374.465.010;D12.644.276.374.500.400;D12.776.467.374.465.010;D12.776.467.374.500.400;D23.529.374.465.131;D23.529.374.500.400,B04.820.504.540.150.113.937
ab7ddd82-a130-4859-a277-b545b33b5e2b,C0079189,humoral,are responsible for poor humoral ,cytokine,humoral,1,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
b03c5fca-4222-45ad-9c09-ebdd024cecf7,vitro,C0242606,have demonstrated Acetylcysteine under especially when,vitro,Oxidative Stress,1,X,????,[comd],????,G03.673;G07.775.750
5fd5b64e-70d6-4647-9b5e-704f4864aa62,vitro,C0001047,have demonstrated ,vitro,Acetylcysteine,1,X,????,[aapp/phsu],????,D02.886.030.230.259;D12.125.166.230.259
73d22e70-5967-4f96-aaa7-2f11b7fe383a,C0001047,C0017817,replenish ,Acetylcysteine,Glutathione,1,X,[aapp/phsu],[aapp/bacs],D02.886.030.230.259;D12.125.166.230.259,D12.644.456.448
d41ea5c1-264e-4606-b8d3-60aa46d415be,C0001047,C0086418,is in ,Acetylcysteine,Homo sapiens,2,X,[aapp/phsu],[humn],D02.886.030.230.259;D12.125.166.230.259,B01.050.150.900.649.313.988.400.112.400.400
b729ff97-e899-49c5-abf0-02e3789f0bb9,C0001047,C1155046,increase ,Acetylcysteine,T-Cell Proliferation,2,X,[aapp/phsu],[celf],D02.886.030.230.259;D12.125.166.230.259,
e3682237-168b-4f39-a034-736ba733cfd9,C0001047,C1424250,Cardiac Arrest,Acetylcysteine,NLRP3 gene,1,X,[aapp/phsu],[gngm],D02.886.030.230.259;D12.125.166.230.259,
abc5950a-82bb-415e-abb6-6eb943099998,C0001047,C2936529,Cardiac Arrest,Acetylcysteine,Inflammasomes,1,X,[aapp/phsu],[aapp/bacs],D02.886.030.230.259;D12.125.166.230.259,D05.500.224
1f6fb0d7-df19-4f7d-baff-1f41cd863d86,C0001047,C1704259,Cardiac Arrest,Acetylcysteine,Biochemical Pathway,1,X,[aapp/phsu],[moft],D02.886.030.230.259;D12.125.166.230.259,
60aab712-5966-46f3-a9c1-f451114a2f7a,C0032105,C0086418,is in ,Plasma,Homo sapiens,1,X,[bdsu],[humn],A12.207.152.693;A12.207.270.695;A15.145.693,B01.050.150.900.649.313.988.400.112.400.400
f135dc85-a1b1-4d95-a301-1267f51034f5,C1448177,C0086418,is in ,TNF protein human,Homo sapiens,1,X,[aapp/bacs],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
e916ad66-24e5-406c-9268-3c1d90bf7316,C0001047,C0206750,act as potential agent in treatment of ,Acetylcysteine,Coronavirus Infections,1,X,[aapp/phsu],[dsyn],D02.886.030.230.259;D12.125.166.230.259,C02.782.600.550.200
0bbf8e83-7d4c-486f-b81b-67de66410818,C0001047,C0039194,improving ,Acetylcysteine,T-Lymphocyte,1,X,[aapp/phsu],[cell],D02.886.030.230.259;D12.125.166.230.259,A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569
0e0c6ee3-e245-4863-b89b-b557a9581210,C0001047,C0021368,modulating ,Acetylcysteine,Inflammation,1,X,[aapp/phsu],[patf],D02.886.030.230.259;D12.125.166.230.259,C23.550.470
122ffc7e-4b30-4cb8-a5fb-6673cce815f4,C0304229,C0003451,is with ,Experimental drug,Antiviral Agents,1,X,[phsu],[phsu],,D27.505.954.122.388
29aa5d30-019b-40ee-9e88-bd3ab3d6e0df,C0723285,C0013604,appear depending ,Septa,Edema,1,X,[antb/orch],[sosy],,C23.888.277
758c1327-1d42-4359-bfea-c5b321fdec09,C0723285,C0333563,appear depending ,Septa,Hyaline membrane,1,X,[antb/orch],[patf],,
dfe56a8e-0e8a-48cc-abd1-98db928b89e5,C0723285,C0014609,appear depending ,Septa,Epithelium,1,X,[antb/orch],[tisu],,A10.272
cc43f955-4893-41f4-b8ff-8d0e7536c7ad,C0723285,C0021368,appear depending ,Septa,Inflammation,1,X,[antb/orch],[patf],,C23.550.470
a91001f8-7a8d-4e23-b8cd-627617a83471,C0723285,C0016059,appear depending ,Septa,Fibrosis,1,X,[antb/orch],[patf],,C23.550.355
112d23d0-02fa-4ac4-b29e-b8cbbe5e654b,C1457887,C0282686,are primarily generated from ,Symptoms,Respiratory System Agents,1,X,[sosy],[phsu],,D27.505.954.796
c399d573-aa01-437d-9e44-ea8f6b961dd5,C0235031,C2699153,raising concerns of its potential for ,Neurologic Symptoms,Cell Invasion,1,X,[sosy],[patf],C10.597;C23.888.592,
647c6ba5-d3e1-4614-8860-33bbe71d1685,C2948600,C0003615,Comparison incidence of,Aim,Appendicitis,1,X,[inch/phsu],[dsyn],,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
c8f51919-77ed-4ff6-be75-e438f9819559,C0065827,C0009450,were tested by ,Measles Virus Nucleoprotein,Communicable Diseases,1,X,[aapp/bacs],[dsyn],x.x.x.x,C01.539.221
2124d8ae-9c4b-462e-9b00-f73104c53f67,C1175743,C0442886,can ,SARS coronavirus,Secondary Infections,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C01.539.218;C02.219;C03.202
fcc62e12-1ef6-4229-b77b-f80b050b51ee,CoV2,C0442886,can ,CoV2,Secondary Infections,1,X,????,[dsyn],????,C01.539.218;C02.219;C03.202
fbcf8c9f-61eb-46d2-97cf-377554356ab2,C1175743,C1290379,can ,SARS coronavirus,Acute disease of cardiovascular system,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,
cc640e86-8311-4644-a970-62cf3218cf75,CoV2,C1290379,can ,CoV2,Acute disease of cardiovascular system,1,X,????,[dsyn],????,
2f5ed06f-ce6f-4410-ae5b-7917b0a2089e,C0442886,C1290379,can ,Secondary Infections,Acute disease of cardiovascular system,1,X,[dsyn],[dsyn],C01.539.218;C02.219;C03.202,
90193faf-d11b-4a0b-8579-66619f21d8c1,C0278347,C0003451,repurposing of ,Transfusion of plasma,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
8b2c505a-c385-438b-a01e-122589a8dc01,C0002520,C0319157,is with adaptive value for ,Amino Acids,AS virus,1,X,[aapp/bacs/phsu],[virs],D12.125,
8188ca29-6112-4b8e-bb27-8a7953f4e0b4,C1175743,C0042769,emerged as ,SARS coronavirus,Virus Diseases,1,X,[virs],[dsyn],B04.820.504.540.150.113.937,C02
d9d0776b-0939-4494-a42e-24d853d6f7e1,C0007590,C0086418,is in ,Cell division,Homo sapiens,1,X,[celf],[humn],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,B01.050.150.900.649.313.988.400.112.400.400
f059104c-47fc-4041-924a-20d3b4bd8aa1,C0007590,C0024109,is in ,Cell division,Lung,1,X,[celf],[bpoc],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,A04.411
ea91bc3d-6214-48fd-8699-8793b54b9387,remdesivir,C0001443,Prodrugs of,remdesivir,Adenosine,1,X,[clnd],[bacs/nnon/phsu],,D03.633.100.759.590.138;D13.570.583.138;D13.570.800.096;x.x.x.x
ac49a976-e900-4b28-8902-d2e50dee6741,remdesivir,C0243071,Prodrugs of,remdesivir,Analog,1,X,[clnd],[chvs],,
8f061027-f4f4-4071-b857-a9782afbbcbc,C0030016,C0369637,= ,Oxidoreductase,M NOS ANTIBODY,1,X,[aapp/enzy],[aapp/imft],D08.811.682,
936c7a67-83cf-4766-8bc9-164284b800e1,RDV,C0026809,diminished In ,RDV,Mus,1,X,????,[mamm],????,B01.050.150.900.649.313.992.635.505.500
7db5cf31-aeb2-4578-823a-548babf947c2,C0087111,C0319157,diminished In ,Therapeutic procedure,AS virus,1,X,[topp],[virs],E02,
83640a65-4161-4cac-9586-4f12754befc8,RDV,C0319157,diminished In ,RDV,AS virus,1,X,????,[virs],????,
8ae8ecc9-3408-4424-89ba-ab0147162cde,C1533734,C0319157,diminished In ,Administration procedure,AS virus,1,X,[topp],[virs],,
1a673a09-96a5-4fb2-b698-3d3cea7f47a3,RDV,C0024109,diminished ,RDV,Lung,1,X,????,[bpoc],????,A04.411
d9a813fb-1d3d-4692-896b-dff63f74b2d4,C1533734,C0024109,diminished ,Administration procedure,Lung,1,X,[topp],[bpoc],,A04.411
42de2ad4-2e68-489a-a5a9-fe0d2d15df4b,C0087111,C1707455,improved function as ,Therapeutic procedure,Comparison,1,X,[topp],[acty],E02,
298b8c1a-6352-47f4-9264-9b6747838205,RDV,C1707455,improved function as ,RDV,Comparison,1,X,????,[acty],????,
d8e42605-1137-40e5-9962-b36beb1cf06d,C1533734,C1707455,improved function as ,Administration procedure,Comparison,1,X,[topp],[acty],,
a6710bbf-8df5-4f6d-8d19-6d3496186ed7,C0087111,C0003062,improved function as ,Therapeutic procedure,Animals,1,X,[topp],[anim],E02,B01.050
70218686-1979-4e91-a971-7620a7f0de59,RDV,C0003062,improved function as ,RDV,Animals,1,X,????,[anim],????,B01.050
d3816d09-e454-45ce-bd2c-5efddc7052f7,C1533734,C0003062,improved function as ,Administration procedure,Animals,1,X,[topp],[anim],,B01.050
cd36e78b-1e61-491c-b31c-16ccd7d0b1b3,RDV,C1175743,is potently active against ,RDV,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
14be39d9-36fe-4117-b06c-9cc8e45952be,C1511790,COVID-19,understanding ,Detection,COVID-19,1,X,[topp],[virs],,C000657245
1f1eb88d-4410-4475-b635-784878de83ef,C1175175,C0062549,measured by levels immunoglobulins M ,Severe Acute Respiratory Syndrome,gastrin 17,1,X,[dsyn],[aapp/horm],C02.782.600.550.200.750;C08.730.730,x.x.x.x
2b1ec5aa-2b6b-4a90-a6d6-c28421a85059,C0596957,C0872079,elucidate structural origin of differential ,Molecular Dynamics,protein protein interaction,1,X,[moft],[moft],E05.599.595.500;G02.111.570.895;L01.224.160.500,
ccfb0645-a3e4-41dd-9385-7e2837447df8,C0596957,C0597357,elucidate structural origin of differential ,Molecular Dynamics,receptor,1,X,[moft],[aapp/rcpt],E05.599.595.500;G02.111.570.895;L01.224.160.500,
c288f39b-16a1-4b16-a2f7-88b36d170060,C0596957,C0022709,elucidate structural origin of differential ,Molecular Dynamics,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],E05.599.595.500;G02.111.570.895;L01.224.160.500,D08.811.277.656.350.350.687
8b02a63d-6de6-4261-a0ed-48c2e961ccc5,C0020276,C0206419,is in 2019 novel ,Hydrogen Bonding,Genus: Coronavirus,1,X,[npop],[virs],G02.282,B04.820.504.540.150
9222e7dc-c1c6-4dae-af50-512e3869d736,C0033382,C1175743,is in short 12-residue loop lead to conformation shift toward more tilted binding groove with ,Proline,SARS coronavirus,1,X,[aapp/bacs],[virs],D12.125.072.401.623,B04.820.504.540.150.113.937
8d0d5cc5-e992-4d7a-9833-ffba795be06a,COVID-19,C0309872,could increase public concern to ,COVID-19,PREVENT (product),1,X,[virs],[phsu],C000657245,
3ed45bb2-6865-4328-bd00-7bdafbef68b3,C0065827,C0678815,overcome challenges associated with ,Measles Virus Nucleoprotein,Administration Mucosal,1,X,[aapp/bacs],[topp],x.x.x.x,E02.319.267.120.655
20fc0167-bfdc-4221-a173-e7ed87fd84bf,C0065827,C0024109,offer benefits proposed as administration route for agents against viral ,Measles Virus Nucleoprotein,Lung,1,X,[aapp/bacs],[bpoc],x.x.x.x,A04.411
b3d880a9-aa02-4d20-88ee-fa5062a4dbb4,C0065827,C0042769,offer benefits proposed as administration route for agents against viral ,Measles Virus Nucleoprotein,Virus Diseases,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02
e5f9e434-97b7-4d4b-8f0a-8522bb31274b,COVID-19,C0008073,present greater risk to people with ,COVID-19,Developmental Disabilities,1,X,[virs],[mobd],C000657245,F03.625.421
a309f853-67a7-4442-a8a4-e6bc351f61b2,COVID-19,C0162574,present risk at especially younger ,COVID-19,Glycation End Products Advanced,1,X,[virs],[bacs/orch],C000657245,D12.776.643.500
303d91ee-2b53-4d03-9ef9-801b5649c5b0,C0162358,C2745965,respond to future ,Ecosystem,Emergencies [Disease/Finding],1,X,[npop],[patf],G16.500.275.157;N06.230.124,C23.550.291.781;N06.230.100.083;N06.850.376
0d446df4-2967-4328-af54-7664b17c707b,C3534339,C0243005,avoid disruption in context of small ,alternate pathway,Radiation Oncology specialty,1,X,[moft],[bmod],,H02.403.429.515.500;H02.403.740.650
533f3d2e-a49f-4ca0-aea7-cb88a553ef7b,C0020517,C0087111,dose per fraction ,Hypersensitivity,Therapeutic procedure,1,X,[patf],[topp],C20.543,E02
d8ad14a7-f118-4d96-90ae-50614436f944,C0034519,C0087111,dose per fraction ,Electromagnetic Radiation,Therapeutic procedure,1,X,[npop],[topp],G01.358.500.505;G01.750.250,E02
aa0907ae-c10b-4e31-8edd-efdd5290b366,C0034991,C1825598,merits particular consideration given potential ,Rehabilitation therapy,IMPACT gene,1,X,[topp],[gngm],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,
32f10144-458f-40f1-989f-9eb2c49f0885,C0005778,C1514474,currently are considered as ,Blood coagulation,Prognostic Factors,1,X,[ortf],[clna],G09.188.390.150,E01.789
4564702c-2b3e-4418-852c-0b4107237be7,DIC,C0243026,is known associated with DIC,DIC,Sepsis,2,X,????,[dsyn],????,C01.539.757;C23.550.470.790.500
abcc2ef6-82a6-439d-aedb-3814baab3c90,C0221423,C0009443,ranging from ,Illness (finding),Common Cold,1,X,[sosy],[dsyn],,C02.782.687.207;C08.730.162
27453856-45a9-4250-a6e6-17e915ffd9e4,C0221423,C1442786,ranging from ,Illness (finding),Acute respiratory tract infection,1,X,[sosy],[dsyn],,
62f530e1-ead0-4d6b-8b46-520f3f4fe004,C3463820,C1257954,could suggest ,Inhibition,Cyclooxygenase 2 Inhibitors,1,X,[acty],[orch/phsu],F01.145.544;F02.463.425.475;F02.739.794.405,D27.505.519.389.310.500;D27.505.696.663.850.014.040.500.500.500;D27.505.954.158.030.500.500;D27.505.954.329.030.500.500
e009141e-29a2-44cb-b0fc-4a9d0ebe453b,C3463820,C3469597,could suggest ,Inhibition,Administration of medication,2,X,[acty],[topp],F01.145.544;F02.463.425.475;F02.739.794.405,
d8adbb41-b274-4739-8639-8f41fbf1f86d,C0277554,C0206750,is in ,primary disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
3fffaf43-ab5c-4fc1-8634-c39b1663ef55,C0029235,C0277554,is in ,Organism,primary disorders,1,X,[orgm],[dsyn],,
58c2ca82-ef03-4f16-b463-48f3acf66871,C1704259,C0009450,is in ,Biochemical Pathway,Communicable Diseases,1,X,[moft],[dsyn],,C01.539.221
6b301559-dda7-4e25-b4c3-f2c2cc3a4197,C1704259,C0019879,importance of ,Biochemical Pathway,Homocystine,1,X,[moft],[aapp/bacs],,D02.886.030.554;D12.125.095.533;D12.125.119.658;D12.125.166.554
77d6e621-9055-463d-9844-6f0cb50170b9,C0087162,C1175743,should Hence should incorporated in ,Vitamin B6,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.383.725.676.925,B04.820.504.540.150.113.937
ba2ac913-afa8-4f98-90bd-055688e02fc7,C0016410,C1175743,should Hence should incorporated in ,Folic Acid,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.633.100.733.631.400,B04.820.504.540.150.113.937
0006d8b7-979b-4633-8bf1-9f485b819fad,C0042845,C1175743,should Hence should incorporated in ,Vitamin B 12,SARS coronavirus,1,X,[orch/phsu/vita],[virs],D03.383.129.578.840.437.777;D03.633.400.909.437.777;D04.345.783.437.777,B04.820.504.540.150.113.937
b0a1a646-87b8-447d-bf75-0736cd5c1e99,C0014467,C4330475,have Classically have considered as ,eosinophil,Immune Cell,1,X,[cell],[cell],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
e945bfb5-4d29-4778-8110-81a7fc91b06e,C0014467,C0699748,have Classically have considered as ,eosinophil,Pathogenesis,1,X,[cell],[patf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
491c3d7a-6543-49ca-8f3d-e6aff3483b57,C0014467,C0301872,being always associated to type ,eosinophil,Immune response,1,X,[cell],[ortf],A11.118.637.415.345;A11.627.340.345;A15.145.229.637.415.345;A15.382.490.315.251,
8bd8fcac-d294-46cc-b123-751f2a77fe90,C0567416,C0670896, includes ,Molecule,Toll-like receptors,1,X,[sbst],[aapp/rcpt],,D12.776.543.750.705.910.500
7a31f8ae-b19a-4b6c-aa3c-fa7bf0684ba3,C0597357,C0567416,is in last years recognizing through several ,receptor,Molecule,1,X,[aapp/rcpt],[sbst],,
e1971ca5-8f9f-43d3-a3b3-be7da05bdde5,C0597357,C0670896,is in last years recognizing through several ,receptor,Toll-like receptors,1,X,[aapp/rcpt],[aapp/rcpt],,D12.776.543.750.705.910.500
9a0e138f-da19-44ec-873c-3f53f752838e,C4330475,C0699748,is in ,Immune Cell,Pathogenesis,1,X,[cell],[patf],,
59037a54-f5cc-4902-bdaa-5237372c7dfd,C0596448,C1175743,very similar to that of ,dimer,SARS coronavirus,1,X,[chvs],[virs],,B04.820.504.540.150.113.937
73ed228a-6ac4-4033-b824-f1a93de0e8cb,C0065827,C0003241,is common target of patient ,Measles Virus Nucleoprotein,Antibodies,1,X,[aapp/bacs],[aapp/imft/phsu],x.x.x.x,D12.776.124.486.485.114;D12.776.124.790.651.114;D12.776.377.715.548.114
5491e4f5-2847-4392-b85f-47ec5656161d,C0243071,COVID-19,might ,Analog,COVID-19,1,X,[chvs],[virs],,C000657245
4ed4ec0e-6f02-4c62-a2b8-6eef0eb03195,C0042776,C0231528,causes ,Virus,Myalgia,1,X,[virs],[sosy],B04,C05.651.542;C10.668.491.525;C23.888.592.612.547.249;F02.830.816.353.500;G11.561.790.353.500
b3593a34-f970-4b85-a547-4877c9c8b73f,C0042776,C0009566,causes Coughing most fearsome,Virus,Complication,1,X,[virs],[patf],B04,
5c2911b6-bdfc-4d6f-a2a4-ad7d5b367253,C0015392,C0009450,related to ,Eye,Communicable Diseases,1,X,[bpoc],[dsyn],A01.456.505.420;A09.371,C01.539.221
3f85fe16-e273-448f-a0d8-dce06567e30d,COVID-19,C0277562,is with underlying chronic ,COVID-19,Adult disease,1,X,[virs],[dsyn],C000657245,
d4a1e329-784e-4bfb-afaa-37e0ad06fa80,C0011570,C0012634,has has observed in ,Mental Depression,Disease,1,X,[mobd],[dsyn],F01.145.126.350,C23.550.288
a26ecaaa-e66b-40e5-ac0d-4b4beb0807d2,C0301872,C0011570,patients with self-reported ,Immune response,Mental Depression,1,X,[ortf],[mobd],,F01.145.126.350
a89cb77a-5d5e-4f18-9d0f-81a3fecaa237,C0011570,COVID-19,occurred at ,Mental Depression,COVID-19,1,X,[mobd],[virs],F01.145.126.350,C000657245
4a5b7fe5-85e6-4986-a392-985b817a5416,C0026727,C0006255,is in ,Mucous body substance,Bronchi,1,X,[bdsu],[bpoc],A12.200.503,A04.411.125
79d7b7ef-2f2f-4fea-a407-bd8d39d035e6,C0027540,C0013608,disease with ,Necrosis,Edema Cardiac,1,X,[ortf],[dsyn],C23.550.717;G04.146.638,C14.280.434.482;C23.888.277.197
9c8eb043-0e28-4d4d-a25a-a5c715ef8ccd,C0021368,C0242656,are suggestive of irreversible ,Inflammation,Disease Progression,1,X,[patf],[patf],C23.550.470,C23.550.291.656
fae059ea-c7f7-4ede-b47c-48619c2121e4,C0040156,C1175743,may result in more severe complications from ,Thyrotoxicosis,SARS coronavirus,2,X,[dsyn],[virs],C19.874.397.685,B04.820.504.540.150.113.937
ba687635-da2e-411a-84ea-2ccd4a59468c,C0272178,COVID-19,may favour ,Drug-induced neutropenia,COVID-19,1,X,[dsyn],[virs],,C000657245
cb8f4ed2-99e5-46a3-b6d7-78140e09e91a,C0272178,C0242656,may favour ,Drug-induced neutropenia,Disease Progression,2,X,[dsyn],[patf],,C23.550.291.656
3ff13f2d-8ed7-46bb-84cd-dbb1a3e35c17,C0272178,C0009450,may favour ,Drug-induced neutropenia,Communicable Diseases,2,X,[dsyn],[dsyn],,C01.539.221
7f0067db-629e-4519-b9a5-84aaa568d9f0,C0272178,C1175743,be confused with ,Drug-induced neutropenia,SARS coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150.113.937
48580508-3e9d-4f6c-9bee-ffb1cfbb8b47,C2188405,C0040156,may may undertaken in cases of ,urgent Operation,Thyrotoxicosis,2,X,[topp],[dsyn],,C19.874.397.685
d3e51ff1-60da-43ed-8723-9b4030bfbf1c,C0035139,C0040135,is with ,Surgical Replantation,Thyroid Hormones,2,X,[topp],[horm],E04.936.494,D06.472.931
44ca7346-8b20-4f81-804b-0fc63bf4b609,C1412208,C0035028,is with intervals of ,ADAMTS2 gene,Relaxation,1,X,[gngm],[acty],,I03.450.769
84cb9e6f-43a3-4755-8650-68c55113259d,C0301630,COVID-19,be effective strategy for ,Reduction (chemical),COVID-19,1,X,[npop],[virs],,C000657245
79283f84-667c-4b03-b971-3ef53eb05228,COVID-19,RT-PCR,is with twice negative RT-PCR,COVID-19,RT-PCR,1,X,[virs],????,C000657245,????
2e21c78f-19c5-472c-aeb4-5b7636668b65,C0042210,C0920467,importance in ,Vaccines,disorder control (procedure),2,X,[aapp/imft/phsu],[topp],D20.215.894,
a62f18c2-5ce1-47e4-9b1f-3cd1692e2763,C0206750,C1706202,is current threat is urgent need ,Coronavirus Infections,Search - action,2,X,[dsyn],[acty],C02.782.600.550.200,
a62f18c2-5ce1-47e4-9b1f-3cd1692e2763,C0206750,C1706202,induced cardiac muscle cell apoptotic process In our literature,Coronavirus Infections,Search - action,1,X,[dsyn],[acty],C02.782.600.550.200,
9a9c97f5-4b04-49a7-90f0-e523f36a21cf,C1415188,C1167395,directly Binding (Molecular Function) to,GP2 gene,Host (organism),2,X,[gngm],[orgm],,
07e9212f-dd85-4616-b422-50b543abc453,C1415188,C0022709,directly Binding (Molecular Function) to,GP2 gene,Peptidyl-Dipeptidase A,2,X,[gngm],[aapp/enzy/imft],,D08.811.277.656.350.350.687
6e5f6128-da64-4b67-b286-5f8993b1d106,C2936405,C0009450,may facilitate rapid drug ,Drug Repositioning,Communicable Diseases,2,X,[topp],[dsyn],E05.290.875,C01.539.221
333f3295-544b-4f17-a1e6-4cba3a9757eb,C1831905,C1167622,was verified Through in ,eltrombopag,Binding (Molecular Function),2,X,[aapp/phsu],[moft],x.x.x.x,
333f3295-544b-4f17-a1e6-4cba3a9757eb,C1831905,C1167622,possess ,eltrombopag,Binding (Molecular Function),2,X,[aapp/phsu],[moft],x.x.x.x,
96abb9df-784e-4dff-9cbd-dbe53ab166e3,C1831905,C4281807,possess ,eltrombopag,Vitronectin human,2,X,[aapp/phsu],[aapp/bacs],x.x.x.x,
96abb9df-784e-4dff-9cbd-dbe53ab166e3,C1831905,C4281807,could potentially affect ,eltrombopag,Vitronectin human,4,X,[aapp/phsu],[aapp/bacs],x.x.x.x,
38e3a42e-b1dd-4e41-91d7-cc38d83571dc,C1831905,C1510827,possess ,eltrombopag,Affinity,2,X,[aapp/phsu],[npop],x.x.x.x,
c3f3e319-2a1f-4827-9e2e-1db2e96fa87e,C1831905,C0022709,could potentially affect ,eltrombopag,Peptidyl-Dipeptidase A,2,X,[aapp/phsu],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
7dae43ce-71f7-4c29-877b-72e1dd447eb1,C0032105,C0013227,are among ,Plasma,Pharmaceutical Preparations,2,X,[bdsu],[phsu],A12.207.152.693;A12.207.270.695;A15.145.693,D26
b737e722-82e7-48a8-964b-9afe10914dc1,C0003280,C0013227,are among ,Anticoagulants,Pharmaceutical Preparations,2,X,[phsu],[phsu],D27.505.954.502.119,D26
2ba01b48-4414-4658-9941-2968d7961c25,C0003374,C0013227,are among ,Antimalarials,Pharmaceutical Preparations,2,X,[phsu],[phsu],D27.505.954.122.250.100.085,D26
a857f7bb-c3ef-447b-83bb-3e37235b3fef,C1328819,C0013227,are among ,Small Molecule,Pharmaceutical Preparations,2,X,[orch],[phsu],,D26
ded80c4f-0676-45d6-8e8c-c67faf752c8e,C1514562,C1167395,built ,Protein Domain,Host (organism),2,X,[amas],[orgm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,
30f27bfb-e859-4e93-b8eb-7d6660b8c9cf,C1514562,C0017337,built ,Protein Domain,Genes,2,X,[amas],[gngm],G02.111.570.820.709.275.750;G02.111.570.820.709.610.500,G05.360.340.024.340
6e0cc7c8-b6ed-4a1e-80e9-81625ff2ca28,C0458827,C0206750,is in ,Airway structure,Coronavirus Infections,1,X,[bpoc],[dsyn],,C02.782.600.550.200
60468ad0-d728-434c-bbd4-34d3ba6ca7f9,C1956108,C0206750,is in ,Microbiome,Coronavirus Infections,2,X,[orgm],[dsyn],G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500,C02.782.600.550.200
de6c8238-10aa-42be-9ba2-1b12a332ef40,C0445623,C0206750,were also Detection in in,Microorganism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
de6c8238-10aa-42be-9ba2-1b12a332ef40,C0445623,C0206750,were also detected in in ,Microorganism,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
5d5d3387-600b-4338-a3cb-e92dabfaeba9,C0445623,C1511790,were also ,Microorganism,Detection,1,X,[orgm],[topp],,
74675071-8ef8-4026-a2e8-42183001f318,C1704259,C1511617, includes ,Biochemical Pathway,Cytokine Signaling,2,X,[moft],[moft],,
3ffa64bf-4d61-4759-b208-889d23361500,C1167395,C1704259,revealed transcriptional signature of genes significantly associated with immune ,Host (organism),Biochemical Pathway,2,X,[orgm],[moft],,
3ffa64bf-4d61-4759-b208-889d23361500,C1167395,C1704259,is in certain ,Host (organism),Biochemical Pathway,2,X,[orgm],[moft],,
c10ab3b9-b6ae-410f-a4a5-9794b8810f32,C1167395,C1511617,revealed transcriptional signature of genes significantly associated with immune ,Host (organism),Cytokine Signaling,2,X,[orgm],[moft],,
ef59c046-29c1-489d-9e58-3a6d1493ca94,C0206750,C1956108,have more disrupted airway ,Coronavirus Infections,Microbiome,2,X,[dsyn],[orgm],C02.782.600.550.200,G06.591;G16.500.275.157.049.100.500;N06.230.124.049.100.500
4b215be9-9f21-4616-af5e-3b708aa92c4f,C1704259,C0021745, includes ,Biochemical Pathway,Interferon Type II,1,X,[moft],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
8a76f2f7-226e-4943-8349-5ff2073217a7,C1704259,C0017011, includes ,Biochemical Pathway,Gamma Rays,1,X,[moft],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
fb791197-1d5f-46af-b2f7-d93bc9c8a38a,C0032930,C1704259,is in certain ,Precipitating Factors,Biochemical Pathway,2,X,[clna],[moft],N05.715.350.200.650;N06.850.490.625.500,
312a46dd-07d1-4d13-bda5-9b2b067cfad0,C0301872,C1704259,is in certain ,Immune response,Biochemical Pathway,2,X,[ortf],[moft],,
280ef41f-af76-4a63-a2f9-1fcef3dace93,C0032930,C0037083,is in certain ,Precipitating Factors,Signal Transduction,3,X,[clna],[celf],N05.715.350.200.650;N06.850.490.625.500,G02.111.820;G04.835
c7a5a92b-0b41-4768-84d3-6078d2a2daf7,C1167395,C0037083,is in certain ,Host (organism),Signal Transduction,3,X,[orgm],[celf],,G02.111.820;G04.835
54f95b4f-9657-4a49-9a85-057a4d948c37,C0301872,C0037083,is in certain ,Immune response,Signal Transduction,3,X,[ortf],[celf],,G02.111.820;G04.835
93a8b339-7609-4aad-9e66-40274e272fb3,C0032930,C0021745,is in certain ,Precipitating Factors,Interferon Type II,2,X,[clna],[aapp/imft/phsu],N05.715.350.200.650;N06.850.490.625.500,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
0135712c-fc37-4468-b3e9-90dc1181408f,C1167395,C0021745,is in certain ,Host (organism),Interferon Type II,2,X,[orgm],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
bf5e1b79-aa04-4c5d-8086-e75de5de5c9d,C0301872,C0021745,is in certain ,Immune response,Interferon Type II,2,X,[ortf],[aapp/imft/phsu],,D12.644.276.374.440.893;D12.644.276.374.480.615.350;D12.776.467.374.440.893;D12.776.467.374.480.615.350;D23.529.374.440.893;D23.529.374.480.615.350
6ba3271b-7375-4d74-add3-faebd7aa50a9,C0032930,C0017011,is in certain ,Precipitating Factors,Gamma Rays,2,X,[clna],[npop],N05.715.350.200.650;N06.850.490.625.500,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
2939612b-58be-4cdd-8988-968f9f367b85,C1167395,C0017011,is in certain ,Host (organism),Gamma Rays,2,X,[orgm],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
48dbb805-0006-491b-bcdc-2c410ca47c59,C0301872,C0017011,is in certain ,Immune response,Gamma Rays,2,X,[ortf],[npop],,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
b67ae6e6-12c7-4df5-986f-4be8f46e906b,C0242184,C0184633,is with ,Hypoxia,Oxygen Therapy Care,1,X,[patf],[topp],C23.888.852.079,E02.880.690
7dc73ed4-a2cb-4993-860d-b9d8d4d6161c,C0242184,C1524029,is with ,Hypoxia,Mouse MIN NOS,1,X,[patf],[neop],C23.888.852.079,
d7801af2-d1ac-4284-8cb6-f0cd70603f47,C0806140,C0206750,regarding ,Flow,Coronavirus Infections,1,X,[npop],[dsyn],,C02.782.600.550.200
73b80ff8-c43e-404c-a122-f0a4d9f9dd6b,C0404844,C0206750,have positive attitude toward ,Non-viable pregnancy,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
e262e6d4-450f-4fbf-9bbc-e8001176488f,C0086418,3-week,was brought with 3-week ,Homo sapiens,3-week,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
3a958eb4-d038-4825-aa80-5c4b62761dea,C0086418,4hours,worsening suddenly in preceding 4hours,Homo sapiens,4hours,2,X,[humn],????,B01.050.150.900.649.313.988.400.112.400.400,????
87f4cd60-fcf1-412e-ad94-faddf84f975d,C0079189,C0020336,were compared between ,cytokine,Hydroxychloroquine,1,X,[aapp/imft],[orch/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,D03.633.100.810.050.180.350
028b0c9e-e0cd-4d9a-8301-3cb4f975bcd4,C0028754,C0010200,have ,Obesity,Coughing,2,X,[dsyn],[sosy],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C08.618.248;C23.888.852.293
7cf32442-70c1-434f-a1aa-8209f0a7bc5c,C0042776,C3272452,is with positive-polarity ,Virus,Single-Stranded RNA,1,X,[virs],[nnon],B04,
3d856a3c-f190-40f5-b0ba-3ff8497a1eef,C0041199,C0206750,were frequently observed in ,Troponin,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825,C02.782.600.550.200
d3731fc4-f9fa-43ef-a7f4-fc0a8f8ec1d2,C0206750,C0683585,resulted ,Coronavirus Infections,free time,1,X,[dsyn],[dora],C02.782.600.550.200,
23e7be08-3c98-4618-898e-059c7d1d2205,C2745965,C0683585,resulted ,Emergencies [Disease/Finding],free time,1,X,[patf],[dora],C23.550.291.781;N06.230.100.083;N06.850.376,
da137710-6a33-46ab-b2b8-8d376b067371,C0233514,C0206750,predating ,Abnormal behavior,Coronavirus Infections,1,X,[mobd],[dsyn],F01.145.126.972;F01.145.179.750,C02.782.600.550.200
d430c021-0dec-47bf-b99e-b1f06c2014cb,C0441516,C0087111,would improve our ability to ,Demand (clinical),Therapeutic procedure,1,X,[topp],[topp],,E02
e6f5d1b2-b107-4fae-a742-4a62cff6ebf7,C0543467,C0218063,is critical in ,Operative Surgical Procedures,Ensure (product),1,X,[topp],[food],E04,
40ff900c-add1-4200-996d-1899721e4829,dataset,C1280903,presents dataset ,dataset,Exploration procedure,1,X,????,[topp],????,
434183e4-49d6-4c49-acfe-3fabb34ebaae,dataset,C0872252,presents dataset ,dataset,Proteomics,1,X,????,[bmod],????,H01.158.201.843;H01.158.273.180.350.700;H01.158.273.343.350.700;H01.181.122.738
25ee3111-7917-4089-b92c-aeab79e69017,C0042736,C0041236,digested with ,Viral Proteins,TRYPSIN,1,X,[aapp/bacs],[aapp/enzy/phsu],D12.776.964,D08.811.277.656.300.760.895;D08.811.277.656.959.350.895
312196a8-8521-4262-a892-85cd6802e812,C2718059,C0005532,requires translation of basic ,Precision Medicine,biology (field),1,X,[topp],[bmod],E02.574;H02.403.200.700,H01.158.273
80d4f309-4b21-46dd-8271-87f22f5d519f,C1158478,C0017398,yielded unexpected insights highlighted by unique case of ,DNA Integration,Science of genetics,1,X,[genf],[bmod],,H01.158.273.343
a59073c3-e561-4279-99d3-1afe9a6e2fbe,C0035668,C2718059,power of be can critical tool moving for sciences applied to ,RNA,Precision Medicine,1,X,[nnon],[topp],D13.444.735,E02.574;H02.403.200.700
b4f15721-667e-4f71-a49e-2c38102881d9,C0337279,C0330093,is with cutting ,Drilling - action,Burr - plant,1,X,[topp],[plnt],,
2da0d170-7666-403d-a468-77b324f2f5cc,C0178774,C0003320,is important ,Nucleocapsid,Antigens,2,X,[aapp/bacs/nnon],[imft],A21.249.500;B04.950.500,D23.050
b8c0e923-9445-40e2-8059-ecae1e6576ff,C0065827,C0003320,is important ,Measles Virus Nucleoprotein,Antigens,2,X,[aapp/bacs],[imft],x.x.x.x,D23.050
ca5544bb-45e7-4c3f-ba28-125e46dd5455,C0178774,C0206750,is important Antigens for,Nucleocapsid,Coronavirus Infections,2,X,[aapp/bacs/nnon],[dsyn],A21.249.500;B04.950.500,C02.782.600.550.200
5cc4ffca-5e3c-410f-b3ef-17678fbb72a4,C0206750,C0035668,participate in ,Coronavirus Infections,RNA,2,X,[dsyn],[nnon],C02.782.600.550.200,D13.444.735
cff3998c-8de2-470a-a52e-8c73515d0813,C0065827,C0596448,is largely ,Measles Virus Nucleoprotein,dimer,2,X,[aapp/bacs],[chvs],x.x.x.x,
d13e0524-47bc-43e6-a423-17ab88de98b5,C0028910,C0003451,have shown as ,Oils Volatile,Antiviral Agents,1,X,[orch],[phsu],D10.627.675,D27.505.954.122.388
d13e0524-47bc-43e6-a423-17ab88de98b5,C0028910,C0003451,may potentiate other ,Oils Volatile,Antiviral Agents,1,X,[orch],[phsu],D10.627.675,D27.505.954.122.388
5a324a8b-054a-48c4-82db-6af48d27974d,C0028910,C0042776,have shown as ,Oils Volatile,Virus,1,X,[orch],[virs],D10.627.675,B04
cccde929-e1fc-41f3-8fd8-3bc2564a7478,C0028910,C0033684,interact with key ,Oils Volatile,Proteins,1,X,[orch],[aapp/bacs],D10.627.675,D12.776
5a2699e6-127e-4922-9f3e-593e786b805b,C0028910,C1175743,interact with key ,Oils Volatile,SARS coronavirus,1,X,[orch],[virs],D10.627.675,B04.820.504.540.150.113.937
f5d5ebef-d133-45e4-910b-e156333e56bf,C0015637,C1175743,showed most exothermic docking to ,Farnesol,SARS coronavirus,2,X,[orch/phsu],[virs],D02.033.415.400;D02.455.849.765.424;D10.289.400,B04.820.504.540.150.113.937
58dc2cb6-a542-4e31-aa95-150cbd1ab81b,C0542479,C0033684,is with other ,Energy Physics,Proteins,2,X,[npop],[aapp/bacs],,D12.776
bc0aa1fb-a27c-4965-b45d-fa7cd50e261c,C0015637,C1817569,is with ,Farnesol,acireductone dioxygenase [iron(II)-requiring] activity,1,X,[orch/phsu],[moft],D02.033.415.400;D02.455.849.765.424;D10.289.400,
4af452a8-cdd0-4e37-a257-b326cb2c1aa6,C0542479,C0042776,interact with ,Energy Physics,Virus,1,X,[npop],[virs],,B04
e062462e-65d5-40d0-926e-33392d3e963b,C1184743,C0040452,are at ,bony process,Tooth root structure,1,X,[bpoc],[bpoc],,A14.549.167.900.750
8ce599d5-e7a8-43aa-be96-9cbf3fd8f5d7,C1184743,C0679225,are at ,bony process,multiple pathologies,1,X,[bpoc],[dsyn],,
5ba53779-ae25-4803-97c7-5e95933bdf4d,C0030054,C0013404,incompatible without ,Oxygen,Dyspnea,1,X,[bacs/elii/phsu],[sosy],D01.268.185.550;D01.362.670;x.x.x.x,C08.618.326;C23.888.852.371
afc70774-dec5-4d8b-98e6-680737b46571,C0206750,C1152633,idiosyncratic receptor activity on,Coronavirus Infections,receptor activity,3,X,[dsyn],[moft],C02.782.600.550.200,
1db4f689-1319-4d7d-9a5c-975ee6faaafb,C0206750,C0030054,idiosyncratic receptor activity on,Coronavirus Infections,Oxygen,2,X,[dsyn],[bacs/elii/phsu],C02.782.600.550.200,D01.268.185.550;D01.362.670;x.x.x.x
0ed60404-40ca-4dc7-aa79-4e8f5d180960,C0013404,C0030054,is in ,Dyspnea,Oxygen,1,X,[sosy],[bacs/elii/phsu],C08.618.326;C23.888.852.371,D01.268.185.550;D01.362.670;x.x.x.x
cf51660b-5e78-4dd7-a9f1-c42cb291309a,C0013404,C0086168,is in ,Dyspnea,Dissociation,1,X,[sosy],[mobd],C08.618.326;C23.888.852.371,F03.300
5fe775e7-131e-46ea-9d63-9b6bf562fef9,C0035452,C0009326,received national ,Rheumatology specialty,Collagen Diseases,1,X,[bmod],[dsyn],H02.403.429.730,C17.300.200
ccc61c07-7a57-4e64-a6a9-57be6ee4b756,C0730400,C0206750,have higher risk for ,Solid organ transplant,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
ec1b4f89-a937-402a-a882-acac125a4bd0,C0039336,C0012634,is in ,Taste Perception,Disease,1,X,[ortf],[dsyn],F02.830.816.724;G11.561.790.724,C23.550.288
73be9300-df90-436e-a5e2-89d58469e33c,C1260880,C0012634,was high in ,Rhinorrhea,Disease,2,X,[sosy],[dsyn],,C23.550.288
8a6698ee-a3b8-468f-83f0-3b78c18221b7,C1260880,C0010076,was high in ,Rhinorrhea,Coronaviridae,2,X,[sosy],[virs],,B04.820.504.540
789f66f2-f495-4843-b11d-cfbacab21205,C0206750,C0039336,are associated with smell ,Coronavirus Infections,Taste Perception,1,X,[dsyn],[ortf],C02.782.600.550.200,F02.830.816.724;G11.561.790.724
b776d65f-1a6a-4797-ba0a-c191695e5a7f,C1327414,C0012634,creates critical ,cytokine secretion,Disease,1,X,[celf],[dsyn],,C23.550.288
fbe5d4f7-0faf-4554-b4eb-9533ff2495c8,C1327414,C0018563,creates Disease On other,cytokine secretion,Hand,1,X,[celf],[bpoc],,A01.378.800.667
fb61656e-0e6f-4447-99c0-c60e5f43923d,C0206422,C1456573,recently appeared as ,Human coronavirus,Global Health,1,X,[virs],[bmod],,H02.403.371;N01.400.337
c434fc13-f250-492d-a32d-cb683b6018c0,C0206750,UME,IMPACT gene UME,Coronavirus Infections,UME,1,X,[dsyn],????,C02.782.600.550.200,????
dfae71a5-f7ca-49ec-ba4c-7788567500a7,C1516048,C0242821,governing medical UME,Assessed,Human body,1,X,[acty],[humn],,I01.076.201.450.560;K01.093.378
6f03c652-43c3-4b71-b9c2-38cb2d939cb7,C1516048,UME,governing medical UME,Assessed,UME,1,X,[acty],????,,????
a46745ef-e4af-4c6f-aae2-9ed1cf1bf97c,C1562764,C0237820,alleviate aid in quicker ,Osteopathic Manipulative Medicine,Recovery - action,1,X,[bmod],[acty],H02.403.640,
a46745ef-e4af-4c6f-aae2-9ed1cf1bf97c,C1562764,C0237820,alleviate Lung Symptoms in quicker,Osteopathic Manipulative Medicine,Recovery - action,1,X,[bmod],[acty],H02.403.640,
27aa728d-d27f-440c-a540-c317b5c6bf40,C1562764,C0221423,alleviate aid in quicker ,Osteopathic Manipulative Medicine,Illness (finding),1,X,[bmod],[sosy],H02.403.640,
27aa728d-d27f-440c-a540-c317b5c6bf40,C1562764,C0221423,alleviate Lung Symptoms in quicker,Osteopathic Manipulative Medicine,Illness (finding),1,X,[bmod],[sosy],H02.403.640,
e9688e14-2a8c-4b3e-9b23-550b665a1978,C1562764,C0024109,alleviate ,Osteopathic Manipulative Medicine,Lung,1,X,[bmod],[bpoc],H02.403.640,A04.411
bae8071a-6997-4bd4-8a86-8d421b617021,C1562764,C1457887,alleviate ,Osteopathic Manipulative Medicine,Symptoms,1,X,[bmod],[sosy],H02.403.640,
321e8aff-6159-4e55-badc-2dccfe1981fb,C0206750,C0161816,has many ,Coronavirus Infections,Cardiac complication,1,X,[dsyn],[patf],C02.782.600.550.200,
e846a103-3021-44de-a6c3-b1b28665e6ee,C0034848,C0206750,underlying risk factors for ,Receptors Virus,Coronavirus Infections,1,X,[aapp/rcpt],[dsyn],D12.776.543.750.830,C02.782.600.550.200
7d0b2365-9514-473f-995d-06ba6009d50e,C0023688,C0206750,underlying risk factors for ,Ligands,Coronavirus Infections,1,X,[chem],[dsyn],D27.720.470.480,C02.782.600.550.200
0a4fb4e1-2dc6-40f1-96f1-a76a58a417d4,C2948600,C1621296,emphasize mechanism of ,Aim,receptor ligand,1,X,[inch/phsu],[moft],,
f5e634a3-22c2-4a79-9a51-78eddd2139a7,C0011849,C0960756,is ,Diabetes Mellitus,factor A,2,X,[dsyn],[orch],C18.452.394.750;C19.246,x.x.x.x
f9da8c21-5490-4ff0-80cb-5bc49db072b9,C1862322,C0206750,is in ,Ovalocytosis Malaysian-Melanesian-Filipino Type,Coronavirus Infections,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200
559416f4-16c2-47ec-83bb-224f415526b0,C0087111,C0008679,optimize therapy delivery to patients with ,Therapeutic procedure,Chronic disease,1,X,[topp],[dsyn],E02,C23.550.291.500
df8a45b1-cade-4787-b7bc-2c6efe9a25e5,COVID-19,C3542961,attack ,COVID-19,NERVOUS SYSTEM DRUGS,1,X,[virs],[phsu],C000657245,
7d2422a9-87c7-4bc3-8686-12e76a2108b9,C0242781,C0040802,is in various person-to-person crowd funerals ,disease transmission,travel,1,X,[patf],[dora],N06.850.310,I03.883
a625a533-80cc-4b5b-9e11-c873303edf90,C1175743,C2806453,is ,SARS coronavirus,Betacoronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,B04.820.504.540.150.113
7b83417a-ecf0-418f-8f5f-60345dda1c8d,C0003451,C0949892,was initially developed for treatment of ,Antiviral Agents,Ebolavirus,1,X,[phsu],[virs],D27.505.954.122.388,B04.820.455.300.200
2a20ec87-8596-4eab-a6e8-289af89dd2ca,N95,C0036082,using aerosolized ,N95,Saline Solution,1,X,????,[sbst],????,D26.776.498.500.750
e99a6a74-7333-4ae9-a815-9faddc4a5897,C0036572,C0036082,using aerosolized ,Seizures,Saline Solution,1,X,[sosy],[sbst],C10.597.742;C23.888.592.742,D26.776.498.500.750
198c2cdf-8f71-49b4-877d-293cb2715b4c,C0020852,C0806140,demonstrate performance of two enzyme-linked assay assays in comparison to one ,Immunoglobulin G,Flow,1,X,[aapp/imft/phsu],[npop],D12.776.124.486.485.114.619.393;D12.776.124.790.651.114.619.393;D12.776.377.715.548.114.619.393,
af8f083f-1a0c-426d-8e56-3ff1ed7ca570,C0024875,C0002346,is used as ,Massage,Alternative Medicine,1,X,[topp],[bmod],E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750,E02.190
24ba7107-b6ae-4486-9ea9-2ca30f7536c6,C0024875,C0184661,is effective ,Massage,Interventional procedure,1,X,[topp],[topp],E02.190.599.750.750;E02.779.867.880.750;E02.831.535.867.880.750,
c898c23c-26e2-4b66-86c2-8bde90a364de,C0330941,COVID-19,treating ,Melia azedarach,COVID-19,1,X,[plnt],[virs],B01.650.940.800.575.912.250.715.500.500,C000657245
812b37f8-0814-4c8f-a033-73e39cb3734f,C1414371,COVID-19,treating ,ELAVL1 gene,COVID-19,1,X,[gngm],[virs],,C000657245
96279089-0537-4a6e-adb0-396f7621c2d5,C0010837,COVID-19,treating ,Cytoplasmic Granules,COVID-19,1,X,[celc],[virs],A11.284.430.214.190.500;A11.284.430.214.190.875.190.190,C000657245
5e43086c-9d83-4d61-914c-0cb5643dec05,C0319157,C1825598,has had direct ,AS virus,IMPACT gene,1,X,[virs],[gngm],,
e8fa59a0-5603-47d3-a1f8-6b053bab347a,C0010332,C0206750,is needed With ,Crisis Intervention,Coronavirus Infections,1,X,[topp],[dsyn],F04.754.252,C02.782.600.550.200
32c1c6ef-9d61-4759-a2af-26c8ac348145,C0009450,C1697446,is with zoonotic ,Communicable Diseases,Genital Viral Infections,2,X,[dsyn],[dsyn],C01.539.221,
870401cd-69eb-42be-9203-ac98e14fda80,COVID-19,C1697446,is caused by ,COVID-19,Genital Viral Infections,2,X,[virs],[dsyn],C000657245,
a05b54cd-a717-41c8-a077-8d32266e9113,C1175743,C1668248,is close to genetically two lated ,SARS coronavirus,Iso,1,X,[virs],[fish],B04.820.504.540.150.113.937,
3bfe0a45-0bf2-4218-811b-3c0c860bd4c9,C1175743,lated,is close to genetically two lated ,SARS coronavirus,lated,1,X,[virs],????,B04.820.504.540.150.113.937,????
8a84d3d7-fc0f-4928-8a82-32dba7fac636,C1175743,C0008139,is close to genetically two lated ,SARS coronavirus,Chiroptera,1,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.937
eaac887b-0580-44cd-a416-81381ef7112f,C0162358,C0009450,facilitating emergence of new ,Ecosystem,Communicable Diseases,1,X,[npop],[dsyn],G16.500.275.157;N06.230.124,C01.539.221
eb324167-05ac-4fdd-8559-8f516e3e8885,C0021368,C0699748,play role in ,Inflammation,Pathogenesis,1,X,[patf],[patf],C23.550.470,
b7f2a6c0-bbf7-44e8-9042-be687f9096b3,C1257975,C0031843,possess comprehensive powerful ,Mesenchymal Stem Cells,physiological aspects,1,X,[cell],[phsf],A11.329.830.500;A11.872.590.500,x.x.x.x
f8347682-f0d9-4755-85db-6b4d262b3aad,C0021440,COVID-19,has shown ,Intravenous infusion procedures,COVID-19,1,X,[topp],[virs],E02.319.267.082.500;E02.319.267.510.590,C000657245
e6894507-c01d-48cf-b2d1-fabe6f0bf079,C0040732,C0032285,was ,Transplantation,Pneumonia,2,X,[topp],[dsyn],E04.936,C08.381.677;C08.730.610
8e61dd78-07df-42fd-8c99-bbd20ca1184a,C0042720,FFPE,was sequenced by next-generation sequencing from FFPE ,Viral Genome,FFPE,1,X,[gngm],????,G05.360.340.358.840,????
d98f44ee-3e04-4dba-a8c4-5c2efaed8778,C0042720,C0819757,was sequenced by next-generation sequencing from FFPE ,Viral Genome,Structure of parenchyma of lung,1,X,[gngm],[tisu],G05.360.340.358.840,
eaa1d781-532f-4a1e-9c28-c7a68a8e111a,C0042720,C1533157,was sequenced by next-generation sequencing from FFPE ,Viral Genome,Block Specimens,1,X,[gngm],[bdsu],G05.360.340.358.840,
16011c92-30c7-436f-a56e-e202926bbd91,C0035736,C1511790,was ,RNA Viral,Detection,1,X,[nnon],[topp],D13.444.735.828,
a24b9195-da96-443a-8d62-09db8ce372b9,C0035736,C0006255,was ,RNA Viral,Bronchi,1,X,[nnon],[bpoc],D13.444.735.828,A04.411.125
21b8f9b1-708c-4e3b-9d42-3e541ab1e2ee,C0035736,C0024204,was ,RNA Viral,lymph nodes,1,X,[nnon],[bpoc],D13.444.735.828,A10.549.400;A15.382.520.604.412
6ebf3353-e1de-4f8a-a070-f48c9fcec825,C0035736,C0037993,was ,RNA Viral,Spleen,1,X,[nnon],[bpoc],D13.444.735.828,A10.549.700;A15.382.520.604.700
25b10882-cb9e-4372-9378-0bcff621a38f,C1511790,C0024109,is in ,Detection,Lung,1,X,[topp],[bpoc],,A04.411
aa8524a1-2587-427a-9b17-bd4dc504175b,C1511790,C0006255,is in ,Detection,Bronchi,1,X,[topp],[bpoc],,A04.411.125
fe99ccf7-c509-4dfb-8a4e-42ff8062189b,C1511790,C0024204,is in ,Detection,lymph nodes,1,X,[topp],[bpoc],,A10.549.400;A15.382.520.604.412
8d4a5522-f751-41ab-b083-b81dd871c15a,C1511790,C0037993,is in ,Detection,Spleen,1,X,[topp],[bpoc],,A10.549.700;A15.382.520.604.700
f5885a23-d7c1-4328-8976-5bda754871b0,manythe,C0012222,could have role in rapid ,manythe,Diffusion,1,X,????,[npop],????,G01.202;G02.196
c82cfe53-b9c4-4be1-9491-1a990186bacd,manythe,C0012634,could have role in rapid ,manythe,Disease,1,X,????,[dsyn],????,C23.550.288
a6fc57cd-e5c4-478b-84a2-a933d79ce912,C0282624,C0184661,be ,Minimally Invasive Surgical Procedures,Interventional procedure,1,X,[topp],[topp],E04.502,
10f10b3e-8534-40b4-9bb5-12f2beeb0648,C0806140,C0030054,is preferred for patients with higher ,Flow,Oxygen,1,X,[npop],[bacs/elii/phsu],,D01.268.185.550;D01.362.670;x.x.x.x
455303d8-96d6-4b7e-875f-7550e7b3efbd,C0206419,C1704532,is ,Genus: Coronavirus,Active Method,1,X,[virs],[topp],B04.820.504.540.150,
1a84cd15-8702-4472-8c78-bbf4f334dad6,C2827774,C0206419,are are evaluated for treatment of ,Current Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
1afb3d76-66b3-43fd-8dcb-d3d19843ed6b,C0206419,C0004936,possesses challenges for individuals with ,Genus: Coronavirus,Mental disorders,1,X,[virs],[mobd],B04.820.504.540.150,F03
be57a8ed-b7c2-4236-87bb-671f4895f22c,C0849867,C0034019,represents emergent threat to ,Widespread Disease,public health medicine (field),1,X,[dsyn],[bmod],,H02.403.720;N01.400.550;N06.850
4d93d44f-727e-453d-8b17-a177fd919847,C0012634,C0026769, includes ,Disease,Multiple Sclerosis,1,X,[dsyn],[dsyn],C23.550.288,C10.114.375.500;C10.314.350.500;C20.111.258.250.500
0c3a38c6-0901-4cd0-84b3-fdd6c30987b5,C0021079,C1825598,have major ,Therapeutic immunosuppression,IMPACT gene,1,X,[topp],[gngm],E02.095.465.425.450;E05.478.610,
dd4f0887-bebb-4056-bcb1-194793d941c2,C0021079,C0009450,have major ,Therapeutic immunosuppression,Communicable Diseases,1,X,[topp],[dsyn],E02.095.465.425.450;E05.478.610,C01.539.221
3101e3a7-7e6c-46be-8181-a96aef5b204a,C0021079,C1175743,have major ,Therapeutic immunosuppression,SARS coronavirus,1,X,[topp],[virs],E02.095.465.425.450;E05.478.610,B04.820.504.540.150.113.937
37c40afd-68a8-47d8-85d4-99765fffeb2a,C0206422,C0021747,is in ,Human coronavirus,Interferons,1,X,[virs],[aapp/imft],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
75c8e6e6-2878-4160-99fe-f60bd34f6e95,C0206422,C0289884,is in ,Human coronavirus,glatiramer acetate,1,X,[virs],[aapp/phsu],,D12.644.219
e07ed0bb-aa9b-48fc-9998-c5d675bf53d3,C0206422,C1718383,is in ,Human coronavirus,teriflunomide,1,X,[virs],[orch/phsu],,x.x.x.x
d51c1664-b040-48ea-a852-951bc882fbfe,C0024312,C0092801, includes ,Lymphopenia,Cladribine,1,X,[dsyn],[nnon/phsu],C15.378.553.546.605;C20.673.627,D03.633.100.759.590.138.300.200;D03.633.100.759.590.138.325.075;D13.570.230.229.075;D13.570.583.138.300.200;D13.570.583.138.325.075;D13.570.800.096.300.200
8e12a637-0548-4686-acc4-3952b1929976,C0024312,C0383429, includes ,Lymphopenia,alemtuzumab,1,X,[dsyn],[aapp/imft/phsu],C15.378.553.546.605;C20.673.627,D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375
26ebab9d-dda3-484f-aab0-df868526ae2c,C0024312,C0058218, includes ,Lymphopenia,dimethyl fumarate,1,X,[dsyn],[imft/orch/phsu],C15.378.553.546.605;C20.673.627,D02.241.081.337.302.500
c3f31943-ac33-4186-901c-338dc8da01e0,C0012634,C0024312,causing ,Disease,Lymphopenia,1,X,[dsyn],[dsyn],C23.550.288,C15.378.553.546.605;C20.673.627
b4f0b059-7945-4ea7-a721-de8fe46e84dc,C0012634,C0092801,causing ,Disease,Cladribine,1,X,[dsyn],[nnon/phsu],C23.550.288,D03.633.100.759.590.138.300.200;D03.633.100.759.590.138.325.075;D13.570.230.229.075;D13.570.583.138.300.200;D13.570.583.138.325.075;D13.570.800.096.300.200
26d28852-2f91-4b5c-bd63-caaf51f7ac7b,C0012634,C0383429,causing ,Disease,alemtuzumab,1,X,[dsyn],[aapp/imft/phsu],C23.550.288,D12.776.124.486.485.114.224.060.313;D12.776.124.790.651.114.224.060.375;D12.776.377.715.548.114.224.200.375
913c8ecc-428b-4429-8a12-42c3f4516c4d,C0012634,C0058218,causing ,Disease,dimethyl fumarate,1,X,[dsyn],[imft/orch/phsu],C23.550.288,D02.241.081.337.302.500
c2396317-5f7a-4374-a543-4ba5eb67c14b,C0206419,C0001288,also demonstrated solid discrimination ,Genus: Coronavirus,Activities of Daily Living (activity),2,X,[virs],[dora],B04.820.504.540.150,E02.760.169.063.500.067;E02.831.067;I03.050;N02.421.784.110
d97c32cb-e71e-42cf-8ca9-801408acb29f,C0206419,C0684336,also demonstrated solid discrimination ,Genus: Coronavirus,Impaired health,1,X,[virs],[patf],B04.820.504.540.150,
f30e768c-7718-410a-8895-1e1c2dd20af0,C1705285,C1825598,may have ,Mutation Abnormality,IMPACT gene,1,X,[comd],[gngm],,
370213a9-008f-450f-b4c7-d395f1abd46f,C2948600,C1624602,examine seroprevalence of ,Aim,Anti-Antibodies,1,X,[inch/phsu],[aapp/imft],,D12.776.124.486.485.114.071;D12.776.124.790.651.114.071;D12.776.377.715.548.114.071
951c6060-29c3-40be-81aa-8c156af249b4,C1510586,C0012634,is ,Autism Spectrum Disorders,Disease,1,X,[mobd],[dsyn],F03.625.164.113,C23.550.288
1c2718ea-7996-404c-aa98-2fdb3970f0c2,C1707455,C0041671,draw Attention Deficit Disorder to,Comparison,Attention Deficit Disorder,2,X,[acty],[mobd],,F03.625.094.150
f95bff22-bcbc-4865-a05d-16c028677416,C0012634,C2741673,is well taken into ,Disease,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[dsyn],[clna],C23.550.288,
d451b741-ae3c-4303-9aaf-778a751b6b91,C0025124,C0034019,better serve ethical review in ,Traditional Chinese Medicine,public health medicine (field),1,X,[bmod],[bmod],E02.190.488.585.520;I01.076.201.450.654.558.520,H02.403.720;N01.400.550;N06.850
60c56b06-0315-4f68-a5ed-1fe30088efbc,C0025124,C2745965,better serve ethical review in ,Traditional Chinese Medicine,Emergencies [Disease/Finding],1,X,[bmod],[patf],E02.190.488.585.520;I01.076.201.450.654.558.520,C23.550.291.781;N06.230.100.083;N06.850.376
d2a7150a-5c67-4ea4-a87e-2c83f8375926,C0206750,C0441516,potentially placing additional ,Coronavirus Infections,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200,
d2a7150a-5c67-4ea4-a87e-2c83f8375926,C0206750,C0441516,situation ,Coronavirus Infections,Demand (clinical),1,X,[dsyn],[topp],C02.782.600.550.200,
e3ac2e6b-0254-4268-ba78-4aca5257c3cb,C0206750,3D,= 3D ,Coronavirus Infections,3D,1,X,[dsyn],????,C02.782.600.550.200,????
427e17d9-f70b-4c65-b73e-eaab0b750bac,C2348077,C0012634,develop practical recommendations on use in ,Date Fruit,Disease,1,X,[food],[dsyn],B01.650.940.800.575.912.250.093.615,C23.550.288
56a78ebc-199a-49bb-8f0f-f1c436af614c,C2745965,C0006405,allow ,Emergencies [Disease/Finding],Buprenorphine,1,X,[patf],[orch/phsu],C23.550.291.781;N06.230.100.083;N06.850.376,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150
7211fbbf-3a1b-43de-9272-aadf75b14be1,C0086418,C4237239,is with ,Homo sapiens,Opioid use disorder severe,2,X,[humn],[mobd],B01.050.150.900.649.313.988.400.112.400.400,
ecb1d0c2-a75a-456d-903f-6df47f36848e,C0679771,C0012634,facilitated videoconference at ,Harm Reduction,Disease,1,X,[topp],[dsyn],F01.145.477,C23.550.288
b8b06243-9d03-4c9e-a4ea-a2205caf73b6,C0679771,C0085281,facilitated videoconference with ,Harm Reduction,Addictive Behavior,1,X,[topp],[mobd],F01.145.477,F01.145.527.100.120
f2a50ea5-0efb-487e-ae57-3dd388261c48,C0206750,C0006405,allow ,Coronavirus Infections,Buprenorphine,1,X,[dsyn],[orch/phsu],C02.782.600.550.200,D03.132.577.249.150;D03.605.497.150;D03.633.400.686.150;D04.615.723.795.150
d8d9b0ae-8cd8-4c8f-b3c8-2c8f74118aa7,AKI,C0319157,could from could synergistic effect of ,AKI,AS virus,1,X,????,[virs],????,
3f6347ec-9c31-4aa3-b9db-b90b827adc6c,C4048329,C0870392,is under In addition ,Immunosuppression,debate,1,X,[dsyn],[acty],E02.095.465.425.450;E05.478.610,
913a96ae-5fa3-44d4-b697-647f2247eecd,C0441516,COVID-19,were balanced during ,Demand (clinical),COVID-19,2,X,[topp],[virs],,C000657245
9b5b068b-94b1-435c-9c90-cc08866ef064,C0441516,C0034019,were balanced during ,Demand (clinical),public health medicine (field),2,X,[topp],[bmod],,H02.403.720;N01.400.550;N06.850
6d178c03-c1ec-463e-9edf-81fffc8f348d,C0441516,C2745965,were balanced during ,Demand (clinical),Emergencies [Disease/Finding],2,X,[topp],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
49278160-3e02-4ca4-ba11-ab13485d0c42,C0032583,C0035736,are translated from ,Polyproteins,RNA Viral,1,X,[aapp/bacs],[nnon],D12.776.775,D13.444.735.828
f280d46c-4a61-4411-b308-8e9d76ebe78f,C1441506,C1513397,estimate thermal parameters dipole moment polarizability and ,Calculation,Molecular Medicine,2,X,[acty],[bmod],,H01.158.201.636.475;H01.158.273.343.595.475;H01.181.122.650.475;H02.403.530
1105ea28-0d14-4cd6-9d03-8956680b9fdc,C1441506,C0376534,estimate thermal parameters dipole moment polarizability and ,Calculation,Electrostatics,1,X,[acty],[npop],,G01.358.500.249.820
995c7159-c2a0-4422-a547-1d976dc09c9d,C0013227,C0678749,evaluate ,Pharmaceutical Preparations,drug binding,2,X,[phsu],[phsf],D26,
0a7f6cb6-7399-4d13-bf75-83cd2406c9fa,C0013227,C1433062,were docked on ,Pharmaceutical Preparations,3C-like protease SARS coronavirus,1,X,[phsu],[aapp/enzy],D26,x.x.x.x
a1bc515e-740c-4c0f-8fd2-918a233cea1d,C0002641,C1175743,might serve as good inhibitor to ,Amodiaquine,SARS coronavirus,1,X,[orch/phsu],[virs],D03.633.100.810.050.060,B04.820.504.540.150.113.937
714aee50-b3c3-4140-8f8d-9b2d23a61c81,C0020336,C0024141,is standard of care in treatment of ,Hydroxychloroquine,Lupus Erythematosus Systemic,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C17.300.480;C20.111.590
daad85bd-83f3-47d1-ab70-ccc35087e76b,C0020336,C0003873,is standard of care in treatment of ,Hydroxychloroquine,Rheumatoid Arthritis,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C05.550.114.154;C05.799.114;C17.300.775.099;C20.111.199
3edd8d8c-a543-4109-be32-d29279c90256,C0020336,C0035436,is standard of care in treatment of ,Hydroxychloroquine,Rheumatic Fever,2,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C01.252.410.890.731;C05.550.114.843;C05.799.825
ff913153-7ef7-4b2c-886e-d3692e85c310,HCQ,C0229671,is in ,HCQ,Serum,1,X,????,[bdsu],????,A12.207.152.846;A15.145.846
a813d2f5-b8a1-4541-beac-b77d806dcbf5,C0229664,C4553629,was found superior sample ,peripheral blood,MATRix Regimen,2,X,[bdsu],[topp],,
9e6a7670-b7ee-471d-a1bd-6222ba5d3fe6,C1608383,C0020336,should Thus should used for ,whole blood specimen,Hydroxychloroquine,1,X,[bdsu],[orch/phsu],,D03.633.100.810.050.180.350
7cd323d3-7f8b-4fb5-b07c-c9bab4134484,C0035668,C1550661,was However since ,RNA,Specimen Type - Stool = Fecal,2,X,[nnon],[bdsu],D13.444.735,
f5883a13-a518-43ee-9933-e9909ba899a5,C0178784,C1175175,also be considered as potential high risk for ,Organ,Severe Acute Respiratory Syndrome,1,X,[bpoc],[dsyn],,C02.782.600.550.200.750;C08.730.730
07788524-bf2c-43ab-9835-ca10d001ec5b,C0597360,C0682610,is in absorptive ,receptor expression,Enterocytes,1,X,[genf],[cell],,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
403d0bc9-170b-4c05-98de-c6614df5f108,C0549622,C0206750,is in current ,Sexual Dysfunction,Coronavirus Infections,1,X,[mobd],[dsyn],,C02.782.600.550.200
fd163fd4-039c-4914-a945-f3098352295c,C0598095,C0206750,is in current ,sexual dimorphism (cellular),Coronavirus Infections,1,X,[ortf],[dsyn],,C02.782.600.550.200
9ec6ed92-fe10-42e5-a682-fb48d4bfc7ef,C0549622,C0012634,is in current ,Sexual Dysfunction,Disease,1,X,[mobd],[dsyn],,C23.550.288
0f961fcc-a2c1-4fa5-ada8-fa3baa23921e,C0598095,C0012634,is in current ,sexual dimorphism (cellular),Disease,1,X,[ortf],[dsyn],,C23.550.288
820c2d18-1220-465b-ad80-79a4c56fbc8c,C0036884,C1175175,regulate ,Gonadal Steroid Hormones,Severe Acute Respiratory Syndrome,1,X,[horm/phsu],[dsyn],D06.472.334.851,C02.782.600.550.200.750;C08.730.730
7f557056-c400-48d1-9721-61a93d2ce354,C0206750,C0029355,has refocussed ,Coronavirus Infections,Orthopedics,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.810.494
9893be98-9229-4307-b6d7-000cc7cc6dd0,C0032930,C0543467,are in Paradoxically ,Precipitating Factors,Operative Surgical Procedures,1,X,[clna],[topp],N05.715.350.200.650;N06.850.490.625.500,E04
af9aca8b-1512-44e8-a455-cd5facea18a7,C0004093,C0013404,followed by ,Asthenia,Dyspnea,1,X,[sosy],[sosy],C23.888.089,C08.618.326;C23.888.852.371
30b9b9b3-a6fd-4fcb-b792-29d3314c23a1,C0004093,C0010200,followed by ,Asthenia,Coughing,1,X,[sosy],[sosy],C23.888.089,C08.618.248;C23.888.852.293
b3b53458-d994-4770-885e-4de849df8d1a,C0004093,C0038056,followed by ,Asthenia,Sputum,1,X,[sosy],[bdsu],C23.888.089,A12.200.808
2ef4e5e3-7a0d-43e1-b67a-2d0036d0c02e,C1457887,C0004093,was ,Symptoms,Asthenia,1,X,[sosy],[sosy],,C23.888.089
32a86fef-4e56-4c68-8d79-caf0ada60bb2,C0771571,17th,was From middle of 17th ,Cinchona bark extract,17th,2,X,[orch/phsu],????,,????
c027fbdc-271d-4124-b033-85192872ded3,C0040811,17th,was From middle of 17th ,Trees (plant),17th,1,X,[plnt],????,B01.650.915,????
34a89e5f-6ec3-4e23-934a-5ab5ab4a64a4,C0771571,C0003374,was From middle of 17th ,Cinchona bark extract,Antimalarials,2,X,[orch/phsu],[phsu],,D27.505.954.122.250.100.085
34a89e5f-6ec3-4e23-934a-5ab5ab4a64a4,C0771571,C0003374,was used as ,Cinchona bark extract,Antimalarials,2,X,[orch/phsu],[phsu],,D27.505.954.122.250.100.085
b0b719cc-8281-4038-84cc-24b9056640e3,C0040811,C0003374,was From middle of 17th ,Trees (plant),Antimalarials,1,X,[plnt],[phsu],B01.650.915,D27.505.954.122.250.100.085
b0b719cc-8281-4038-84cc-24b9056640e3,C0040811,C0003374,was used as ,Trees (plant),Antimalarials,1,X,[plnt],[phsu],B01.650.915,D27.505.954.122.250.100.085
4c3ef501-a84f-44b5-87e3-9d08211692a5,C0771571,C1015216,contains ,Cinchona bark extract,Cinchona pubescens,1,X,[orch/phsu],[plnt],,B01.650.940.800.575.912.250.456.937.250
0ac03c7f-a468-4c21-b985-cd5c8f7e6290,C0008269,C0018966,leading to increase in ,Chloroquine,Heme,1,X,[orch/phsu],[bacs/orch],D03.633.100.810.050.180,D03.383.129.578.840.500.640.587;D03.633.400.909.500.640.587;D04.345.783.500.640.587;D23.767.727.640.587
f4c74080-f530-4bcc-a87b-f96f14c110a5,C0008269,C1335439,inhibits protozoan ,Chloroquine,Polymerase,1,X,[orch/phsu],[aapp/enzy],D03.633.100.810.050.180,
ab1e6f49-b271-4dfb-9330-e4e794f6d294,C0013227,C0221106,inhibits infectivity by ,Pharmaceutical Preparations,Alkalemia,2,X,[phsu],[dsyn],D26,
adf17be2-e04d-4c56-8bd6-c8884b5ea3ec,C0013227,C0034848,blocking ,Pharmaceutical Preparations,Receptors Virus,1,X,[phsu],[aapp/rcpt],D26,D12.776.543.750.830
8ef4a182-61a7-43c5-9fc8-5499e6e4ba91,C0013227,C0034800,blocking ,Pharmaceutical Preparations,Receptors Cell Surface,1,X,[phsu],[aapp/rcpt],D26,D12.776.543.750
3d2c1aae-77d1-4745-bec4-027a6b2d77e8,C0319157,C0017082,is with ,AS virus,Gangliosides,1,X,[virs],[orch/phsu],,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
78c00482-b0fd-4bb0-88f0-47b3802ed56d,C4281807,C0017082,is with ,Vitronectin human,Gangliosides,1,X,[aapp/bacs],[orch/phsu],,D09.400.410.420.025.475;D10.390.470.025.475;D10.570.877.360.025.475
0bac9a44-46a6-43b5-9ae5-b037806a75d4,C0872152,C3272275,is Currently ,Drug Development,Urgent Procedure,1,X,[bmod],[topp],E05.290;H01.158.703.007.338;H01.181.466.338,
25e4b5c3-5f5f-446b-a1d6-dabeefddb936,C0013227,C1947933,adoption of be must ,Pharmaceutical Preparations,care activity,1,X,[phsu],[acty],D26,
f72f9e57-2715-4f13-8972-7e3b5c2eec91,C1175743,C0012655,thus highlighting concerns about gender ,SARS coronavirus,Disease susceptibility,1,X,[virs],[clna],B04.820.504.540.150.113.937,C23.550.291.687;G07.100.250
e0589195-27f5-4cb2-b733-c83d442eef87,C0229671,C0242656,could affect ,Serum,Disease Progression,1,X,[bdsu],[patf],A12.207.152.846;A15.145.846,C23.550.291.656
5a4b3017-86ad-408f-882f-d42ee971195e,C2603360,C0022709,co-regulating expression of ,T prime,Peptidyl-Dipeptidase A,1,X,[clna],[aapp/enzy/imft],,D08.811.277.656.350.350.687
8a89bc42-edcd-4144-8a20-ab9e5e455ecd,C2603360,C1819995,co-regulating expression of ,T prime,Host Cell,1,X,[clna],[celc],,
e138b2f5-a91e-492d-a2cd-bcc9badfc849,C2603360,C1175743,may facilitate ,T prime,SARS coronavirus,1,X,[clna],[virs],,B04.820.504.540.150.113.937
650a2107-cb09-4b00-8a63-9c0a15948f89,C0229671,C0856169,may predispose to ,Serum,endothelial dysfunction,1,X,[bdsu],[dsyn],A12.207.152.846;A15.145.846,
958f31ac-886e-4d21-b311-12303af61ade,C0028754,C0020619,is associated with functional ,Obesity,Hypogonadism,1,X,[dsyn],[dsyn],C18.654.726.500;C23.888.144.699.500;E01.370.600.115.100.160.120.699.500;G07.100.100.160.120.699.500,C19.391.482
a9c3092f-a565-4323-8563-7a25153f74ee,C2603360,C0849867,may predispose men to ,T prime,Widespread Disease,1,X,[clna],[dsyn],,
8afb05e6-debb-40dc-8b74-1453a29a489f,C2603360,C0206750,may predispose men to ,T prime,Coronavirus Infections,1,X,[clna],[dsyn],,C02.782.600.550.200
1fc96730-b41f-4e29-828d-93f1ff7cecb4,C2603360,C0009450,may predispose men to ,T prime,Communicable Diseases,1,X,[clna],[dsyn],,C01.539.221
a1cdc55f-fb2a-4dd6-954a-1db6fe9a3caf,C2603360,C1707455,is in ,T prime,Comparison,1,X,[clna],[acty],,
02cc79d9-3744-425d-b90c-6c5157f59162,C0012634,C0441516,situation ,Disease,Demand (clinical),1,X,[dsyn],[topp],C23.550.288,
b5f1ab19-a2a8-4456-8c80-b23d6d8cb451,onwards,C1706374,offered Coronavirus Infections ENUMX4 tracking diary From,onwards,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
77518962-89a7-4992-9fea-c4e274485a6b,ETZ,C1706374,offered Coronavirus Infections ENUMX4 tracking diary From,ETZ,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,????,[aapp/bacs],????,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
ab26009d-8780-45e2-adfb-0a4f4d9070a7,onwards,C0206750,offered ,onwards,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
9d887af1-4999-4b2c-b554-2698101bde56,ETZ,C0206750,offered ,ETZ,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
92dab223-b670-40f4-8788-6aec427fbb76,onwards,C1457887,offered ,onwards,Symptoms,1,X,????,[sosy],????,
ad2124c7-e0d2-4d25-b2a0-8b54dd45dcef,ETZ,C1457887,offered ,ETZ,Symptoms,1,X,????,[sosy],????,
dca7f3b4-c5a6-4395-b655-8522f68a4a4f,C1533734,C1704259,optimize diagnostic ,Administration procedure,Biochemical Pathway,1,X,[topp],[moft],,
525d2792-59f0-4f6c-822e-297b72727628,C0309872,C0521982,can increase chances of ,PREVENT (product),Response to treatment,1,X,[phsu],[clna],,
f2cc830e-8693-4abf-9bcc-61a7ced4173e,C0309872,C0206750,can increase chances of ,PREVENT (product),Coronavirus Infections,1,X,[phsu],[dsyn],,C02.782.600.550.200
dbf3c545-71c3-4beb-809f-29e60c7bceb7,C0309872,C1701940,treating early ,PREVENT (product),Pneumonia Ventilator-Associated,1,X,[phsu],[dsyn],,C01.539.248.500;C08.381.677.800;C08.730.610.750
6b7848ce-1be0-4cc9-ac01-c96edf420f5e,C3260929,C0021368,still remains Due to lack of clinical studies on ,General mechanism of the forces which caused the injury:Find:Pt:^Patient:Nom,Inflammation,4,X,[clna],[patf],,C23.550.470
2bac13a8-b231-47f2-ae64-ea8691136f95,C0206750,C0034848,Affinity to,Coronavirus Infections,Receptors Virus,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,D12.776.543.750.830
3faf46b6-c4d0-4307-8fd9-eb28d6443c64,C0155686,C0034848,Affinity to,Acute myocarditis,Receptors Virus,1,X,[dsyn],[aapp/rcpt],,D12.776.543.750.830
0b1bd8d8-0f1a-4039-a005-a767b8a9a0a5,C0206750,C0700271,Affinity to,Coronavirus Infections,M Protein multiple myeloma,1,X,[dsyn],[aapp/imft],C02.782.600.550.200,x.x.x.x
53824082-3ba4-4982-bca5-fa6176c0f39e,C0155686,C0700271,Affinity to,Acute myocarditis,M Protein multiple myeloma,1,X,[dsyn],[aapp/imft],,x.x.x.x
8cabbf41-7638-4a96-8c07-df64fd30b9d9,C0206750,C1327414,Affinity to,Coronavirus Infections,cytokine secretion,1,X,[dsyn],[celf],C02.782.600.550.200,
31448cc9-6508-47c3-996b-9fb08acb560e,C0155686,C1327414,Affinity to,Acute myocarditis,cytokine secretion,1,X,[dsyn],[celf],,
52bde59c-0918-4b97-b520-a6f1319b5fed,C0155686,C0003130,Affinity to,Acute myocarditis,Anoxia,1,X,[dsyn],[patf],,C23.888.852.079
731fef5d-30e2-4c1a-8fcf-0a8db4b00bc0,C0155686,C1706202,induced cardiac muscle cell apoptotic process In our literature,Acute myocarditis,Search - action,1,X,[dsyn],[acty],,
d6d58902-27b8-4a22-be68-ce56b868a1a1,C0206750,C2611954,induced ,Coronavirus Infections,cardiac muscle cell apoptotic process,1,X,[dsyn],[celf],C02.782.600.550.200,
934ef122-f830-4164-a880-31d1d4243f4d,C0155686,C2611954,induced ,Acute myocarditis,cardiac muscle cell apoptotic process,1,X,[dsyn],[celf],,
dfd3cd08-180f-493c-b769-afcfa77da1d8,C1706202,C0027061,identified several potential mechanisms of ,Search - action,Myocardium,1,X,[acty],[tisu],,A02.633.580;A07.541.704;A10.690.552.750
42618133-8729-437d-a4eb-f37b6e28f7dc,C0206750,C0034865,may become because of ,Coronavirus Infections,Recombination Genetic,1,X,[dsyn],[genf],C02.782.600.550.200,G05.728
003d581d-aee0-4284-b089-8ce1f002b598,C0199176,C0309872,are mandatory to ,Prophylactic treatment,PREVENT (product),2,X,[topp],[phsu],,
61bcbb75-97f6-4163-b03b-0b8a18bba530,C0199176,C1175175,are mandatory to ,Prophylactic treatment,Severe Acute Respiratory Syndrome,2,X,[topp],[dsyn],,C02.782.600.550.200.750;C08.730.730
5ac52cbd-28f7-4b4c-b95c-db8a55af1ac7,C0039986,C1298802,are frequent Among ,Thoracic Surgery Specialty,Emergency procedure,1,X,[bmod],[topp],H02.403.810.803,
0d2e67ad-9146-4f7d-a131-4e1aa5954ec2,C0543467,C1298802,are frequent Among ,Operative Surgical Procedures,Emergency procedure,1,X,[topp],[topp],E04,
1a611d8d-bc73-43aa-bb7e-f471194dbb15,C1704259,C1705178,is mandatory in ,Biochemical Pathway,Order (action),1,X,[moft],[acty],,
849a7c1e-f3ac-4811-9ef2-57f1ce137e7c,C1707455,C0016059,is with non ,Comparison,Fibrosis,1,X,[acty],[patf],,C23.550.355
b53618d9-8328-4f30-a885-42ba07121ae7,C0016059,C0149783,had longer-term of hospitalization pulsed ,Fibrosis,Steroid therapy,1,X,[patf],[topp],C23.550.355,
eb5de59a-e784-43e7-b0e3-bc987a274ab9,C0016059,C0280274,had longer-term of hospitalization pulsed ,Fibrosis,Antiviral Therapy,1,X,[patf],[topp],C23.550.355,
a2b2dd5f-ce49-4725-8864-db25fdc3edb1,C4553629,y31,elucidated potential missense variants from databases within xentit y31 ,MATRix Regimen,y31,1,X,[topp],????,,????
ecac7e42-c4bd-4233-9be0-f1063f13e174,C0026652,COVID-19,improve Symptoms with,Moxibustion,COVID-19,1,X,[topp],[virs],E02.190.044.588,C000657245
b37c7e38-2d1f-4cca-8c80-d612ff0c1dd5,C1265876,C1707455,increase beyond ,Abnormally opaque structure (morphologic abnormality),Comparison,1,X,[patf],[acty],,
dec58371-9e7d-418d-a1c6-74233ee602d0,C1447020,C0014609,is variously expressed on ,DPP4 protein human,Epithelium,2,X,[aapp/enzy],[tisu],x.x.x.x,A10.272
97855b20-2717-4411-bc1d-aaa40fa21e12,C1447020,C0031845,was implicated in various ,DPP4 protein human,Physiological Processes,1,X,[aapp/enzy],[phsf],x.x.x.x,G07
35c433a3-7935-490d-a4f5-b8b7e9bc1f6a,C1447020,C0086418,is in ,DPP4 protein human,Homo sapiens,1,X,[aapp/enzy],[humn],x.x.x.x,B01.050.150.900.649.313.988.400.112.400.400
0032705d-1660-4ef9-9df4-1be0e31d352e,C2728259,C1856053,was held from ,Program,Hydranencephaly with Renal Aplasia-Dysplasia,6,X,[orch/phsu],[dsyn],V02.355.750,x.x.x.x
cb98dd3c-9c85-4a41-b548-6ba34e91bdcb,C0319157,U.S,is in U.S ,AS virus,U.S,1,X,[virs],????,,????
819c9f5e-7cfa-45d3-96fe-965f693ff329,C2936695,C1511790,were proposed for ,Graphene,Detection,2,X,[elii],[topp],D01.268.150.300;D01.578.300;x.x.x.x,
9a375264-7fc3-48c0-8476-d3ca40cbf6e9,C2936695,C0005516,were proposed for ,Graphene,Biological Markers,2,X,[elii],[clna],D01.268.150.300;D01.578.300;x.x.x.x,D23.101
26ac9dd9-afe2-4954-8487-ec595174d28b,C2936695,C1720804,numerous methods including optical ,Graphene,Raman Scattering,2,X,[elii],[npop],D01.268.150.300;D01.578.300;x.x.x.x,E05.196.822.860;E05.196.867.890
5e011bd8-d51e-4a75-88cb-8fbbb082382c,C0038454,COVID-19,should closely Assessed lung apices during,Cerebrovascular accident,COVID-19,3,X,[dsyn],[virs],C10.228.140.300.775;C14.907.253.855,C000657245
e7227f87-5c4d-417c-a0f4-ebb5fafaffa5,C0038454,apices,should Assessed lung apices,Cerebrovascular accident,apices,1,X,[dsyn],????,C10.228.140.300.775;C14.907.253.855,????
5b703e05-679a-41ab-9749-0bddf6457a53,C4554671,COVID-19,may ,CERNA3 gene,COVID-19,1,X,[gngm],[virs],,C000657245
d26571bb-7df8-49b0-8f12-7ef09de11908,C4554671,C0009450,may ,CERNA3 gene,Communicable Diseases,1,X,[gngm],[dsyn],,C01.539.221
d5f1656a-fedb-4467-9186-df0462eba5ab,C0038952,C0374505,was in ,Continuance of life,Group Therapies,1,X,[acty],[topp],I03.784,
6fda59f9-cc86-4609-91e2-7b2ebaccad9e,C0038952,C1707455,was in ,Continuance of life,Comparison,1,X,[acty],[acty],I03.784,
b1797f85-46c5-4d7c-8486-393f68b51d5b,C0231832,C1947933,were associated with need for ICU ,Respiratory rate,care activity,1,X,[clna],[acty],E01.370.600.875.875;G09.772.705.730,
aab1f852-fac2-4cb3-b908-94f027b5e806,C0960756,C0543467,is in ,factor A,Operative Surgical Procedures,2,X,[orch],[topp],x.x.x.x,E04
682b2f55-e3e0-4f28-b28c-e2edb6b3ddf1,C1706202,C0014507,summarize latest publishedinformation about ,Search - action,Epidemiology,1,X,[acty],[bmod],,H02.403.720.500
dd8f3077-8ce0-4f87-a9c0-9bb7e460ef62,C0013404,C0015967,are ,Dyspnea,Fever,1,X,[sosy],[sosy],C08.618.326;C23.888.852.371,C23.888.119.344
1d61a984-92dc-4cc8-aba8-0a3672c529da,C0015967,C0014507,is based on ,Fever,Epidemiology,1,X,[sosy],[bmod],C23.888.119.344,H02.403.720.500
d3949c5c-2b32-4a55-9c22-dc71e685b7cb,C2933547,C1707391,is in 2016 ,Nominee,Choose (action),1,X,[hops/orch],[acty],,
7a53a49a-a4d2-4a13-b420-7498f831c0be,C0679699,C0004153,is in patients with established ,Secondary Prevention,Atherosclerosis,1,X,[topp],[dsyn],E02.897;N02.421.726.825;N06.850.780.750,C14.907.137.126.307
41959918-b604-46f7-b901-ead81df80b88,C0034019,C1707455,were Choose (action) for systematic,public health medicine (field),Comparison,1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
b288f7ba-3893-418e-b28e-f3d67f416679,C0034019,C0270724,were Choose (action) for systematic,public health medicine (field),Infantile Neuroaxonal Dystrophy,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,C10.228.140.744
f141d580-715c-40b4-a9c1-ebab4aee965c,C1707455,C0270724,is with COVID19 ,Comparison,Infantile Neuroaxonal Dystrophy,1,X,[acty],[dsyn],,C10.228.140.744
16f38e69-f7d8-4601-9f88-6d492d7a3b7c,C1707455,COVID19,is with COVID19 ,Comparison,COVID19,1,X,[acty],????,,????
7dcb4495-5252-45fd-9070-b108908cd354,C0034019,C1707391,were ,public health medicine (field),Choose (action),1,X,[bmod],[acty],H02.403.720;N01.400.550;N06.850,
642a74de-abf2-4aff-b88b-6a7b60c97a29,C0013879,COVID-19,basically meet ,Elements,COVID-19,1,X,[elii],[virs],D01.268,C000657245
d3e1a280-c284-43c3-8e7c-0036a555d248,C0034019,C1527075,need ,public health medicine (field),Revision procedure,2,X,[bmod],[topp],H02.403.720;N01.400.550;N06.850,
707bb2aa-8e8e-4cc2-a6c7-a838e59d985d,C3463820,C0319157,blocks ,Inhibition,AS virus,1,X,[acty],[virs],F01.145.544;F02.463.425.475;F02.739.794.405,
c6788f7b-7aaf-4abc-806a-ee2f88081652,C3463820,C0022709,blocks AS virus fusion with,Inhibition,Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],F01.145.544;F02.463.425.475;F02.739.794.405,D08.811.277.656.350.350.687
d39111db-d1a4-48ec-9280-48f38c4acb0f,C0014442,C1656555,facilitates ,Enzymes,viral entry into host cell,2,X,[aapp/enzy],[celf],D08.811,
cc3cfa5e-9b2d-4aba-aa1f-7d3badb4b08c,C0014442,C4085054,facilitates ,Enzymes,PARTICL gene,1,X,[aapp/enzy],[gngm],D08.811,
5dfc42e2-c745-42ed-8ecb-c78df60ceebd,C0702166,C0012634,were most common ,Acne,Disease,1,X,[dsyn],[dsyn],C17.800.030.150;C17.800.794.111,C23.550.288
09b66b69-4591-4fc0-be58-11cb9dbafc72,C3665596,C0012634,were most common ,Warts,Disease,1,X,[neop],[dsyn],C02.256.650.810;C02.825.810;C02.928.914;C17.800.838.790.810,C23.550.288
67065841-79c3-4dee-89ae-241e97a25282,C0036508,C0012634,were most common ,Seborrheic dermatitis,Disease,1,X,[dsyn],[dsyn],C17.800.174.580;C17.800.794.230;C17.800.815.580;C17.800.859.350,C23.550.288
464725b5-bf8d-4759-b792-f60e4e82dbd5,C0042109,C0012634,were most common ,Urticaria,Disease,1,X,[dsyn],[dsyn],C17.800.862.945;C20.543.480.904,C23.550.288
4dd30f3c-e439-4b7d-97d8-e72ffeb73db5,C0033860,C0012634,were most common ,Psoriasis,Disease,1,X,[dsyn],[dsyn],C17.800.859.675,C23.550.288
8cb17c95-5ade-4bf4-acfa-a81c1469dee6,C1825598,C0037274,trends of ,IMPACT gene,Dermatologic disorders,1,X,[gngm],[dsyn],,C17.800
2a61b527-986a-4bd7-9e0c-78ca52504a21,C0206750,DMHS,has resulted in significant increase in contact with DMHS,Coronavirus Infections,DMHS,1,X,[dsyn],????,C02.782.600.550.200,????
32b4b9e8-4ee1-4152-ae39-4a5c6fe8a5d4,DMHS,C1999230,could play role in ,DMHS,Providing (action),2,X,????,[acty],????,
616ca277-e06b-4823-9720-613060a3e8bd,C0018801,C0010340,is in especially ,Heart failure,Critical Illness,1,X,[dsyn],[dsyn],C14.280.434,C23.550.291.625
1a8e81ed-9322-4d99-a3a4-056c9e1aae56,C0597404,C1999230,have ,Respiratory viruses,Providing (action),8,X,[virs],[acty],,
b367ef59-acd1-4697-91de-0556e01db1d5,C0597404,C1521827,have ,Respiratory viruses,Preparation,8,X,[virs],[acty],,
0c103a69-e729-49f2-8df3-daed7a319bec,C0597404,C0015357,have ,Respiratory viruses,Extracorporeal Membrane Oxygenation,4,X,[virs],[topp],,E02.880.301;E04.292.451
8af7e2cc-5552-49c9-a964-1217d5040f56,C1175175,C1999230,have ,Severe Acute Respiratory Syndrome,Providing (action),4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
5c3e54e3-453e-4f69-abe1-34b9453b8dc0,C1175175,C1521827,have ,Severe Acute Respiratory Syndrome,Preparation,4,X,[dsyn],[acty],C02.782.600.550.200.750;C08.730.730,
fcc62ee0-7566-4fa2-b103-38ef240f4f5f,C1175175,C0015357,have ,Severe Acute Respiratory Syndrome,Extracorporeal Membrane Oxygenation,2,X,[dsyn],[topp],C02.782.600.550.200.750;C08.730.730,E02.880.301;E04.292.451
3d3a4dc5-34d7-4f0a-8199-ec06956d3d08,C0746885,C0206750,contributes to higher mortality of ,neutrophilic,Coronavirus Infections,2,X,[celf],[dsyn],,C02.782.600.550.200
2af7d9cd-1fcf-4128-a9e3-c3f42f334472,C0007430,C0547605,are usually built Per ,Catheterization,prevention of infection,2,X,[topp],[topp],E02.148;E05.157,
0e4dbb3f-ecbf-481c-81a8-f7b07098fab3,C0007430,C0021778,are usually built as ,Catheterization,Intermittent Positive-Pressure Ventilation,2,X,[topp],[topp],E02.148;E05.157,E02.041.625.790.550;E02.880.820.790.550
4d9dbf83-1c33-47bf-968f-9b81f04c7a99,C0042776,C0014139,use ,Virus,Endocytosis,1,X,[virs],[celf],B04,G04.417
058136d9-797d-496a-abd3-931161de4c7f,C0085155,C1175743,Furthermore are identified as potential candidates repurposing as blockers of potential routes for ,Generic Drugs,SARS coronavirus,1,X,[phsu],[virs],D26.360,B04.820.504.540.150.113.937
e52998cc-9288-4159-8649-b06d5b0605d6,C1334043,C0206422,is with other ,Homologous Gene,Human coronavirus,1,X,[gngm],[virs],,
98342f30-aed1-452c-b7e6-a7fe8c5ea734,C0206422,C3542961,have had ,Human coronavirus,NERVOUS SYSTEM DRUGS,1,X,[virs],[phsu],,
62f24888-f137-470f-aff8-fc957cdcdb60,C0014038,C0206750,have have associated with ,Encephalitis,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.430,C02.782.600.550.200
7f9b416e-ad2d-4ef3-b101-03746d4deb6a,C0011304,C0206750,have have associated with ,Demyelination,Coronavirus Infections,1,X,[patf],[dsyn],C10.314,C02.782.600.550.200
51a66c21-9468-4c61-9e01-daab998e5a5e,C0442874,C0206750,have have associated with ,Neuropathy,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
8f9a84c0-a901-4c71-aae3-d770abef7bff,C0038454,C0206750,have have associated with ,Cerebrovascular accident,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.300.775;C14.907.253.855,C02.782.600.550.200
aafa0359-75c8-438b-8ce5-f759bd72ba87,C0206750,C0027765,is with ,Coronavirus Infections,nervous system disorder,1,X,[dsyn],[dsyn],C02.782.600.550.200,C10
4ea9c126-ce79-4a8f-9cdc-2df4fecf1779,C0042776,C2806453,are related ,Virus,Betacoronavirus,1,X,[virs],[virs],B04,B04.820.504.540.150.113
1fe65202-ea61-4141-b90b-e6b28ab4d633,ageing,C0243107,Developmental delay (disorder) on,ageing,development aspects,1,X,????,[phsf],????,
b7ab3afb-1a66-46ee-81e3-f369db01cd88,C0035204,C0319157,is in ,Respiration Disorders,AS virus,1,X,[dsyn],[virs],C08.618,
799d29ec-fbe2-4f8c-afae-df1bf9441f6e,C0035204,C0032310,is in ,Respiration Disorders,Pneumonia Viral,1,X,[dsyn],[dsyn],C08.618,C02.705;C08.381.677.807;C08.730.610.763
d935de47-dd7a-4976-844c-3e094754c9ad,C0012634,C0032310,is in ,Disease,Pneumonia Viral,1,X,[dsyn],[dsyn],C23.550.288,C02.705;C08.381.677.807;C08.730.610.763
740e5ce5-5e10-45b6-8484-1b59c0e9b34e,C0035204,C1265876,is in ,Respiration Disorders,Abnormally opaque structure (morphologic abnormality),1,X,[dsyn],[patf],C08.618,
5cb2c020-b2f1-4b25-80b7-37154127bdbf,C0012634,C1265876,is in ,Disease,Abnormally opaque structure (morphologic abnormality),1,X,[dsyn],[patf],C23.550.288,
481cc828-e241-4949-98d4-c333cbca3e85,C1293122,C0206750,is with ,Augmentation procedure,Coronavirus Infections,2,X,[topp],[dsyn],,C02.782.600.550.200
f2eada3c-efcb-4701-88c9-82702fba7d2a,C1997614,C1175743,is in patients hospitalised for ,Thromboembolism of vein,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
fb40cec2-16a0-4781-803e-0cedd46bd134,C0024109,C0398623,may contribute to transient ,Lung,Thrombophilia,1,X,[bpoc],[dsyn],A04.411,C15.378.925
421a753e-b2ca-4a01-b7ae-661a893d3a26,C1155266,C0398623,may contribute to transient ,inflammatory response,Thrombophilia,1,X,[patf],[dsyn],,C15.378.925
d67dde4c-007a-4887-bb8a-61360642139f,C0034065,C0476273,may cause further ,Pulmonary Embolism,Respiratory distress,1,X,[patf],[sosy],C08.381.746;C14.907.355.350.700,
774a4227-a369-46b2-9f6c-f662875fce96,C0034065,C0242656,was in one case diagnosed during phase ,Pulmonary Embolism,Disease Progression,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C23.550.291.656
774a4227-a369-46b2-9f6c-f662875fce96,C0034065,C0242656,was diagnosed during convalescent phase ,Pulmonary Embolism,Disease Progression,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C23.550.291.656
05c59f88-eb28-4341-8cc8-f2161526b0aa,C3272452,RT-PCR,can can detected by RT-PCR ,Single-Stranded RNA,RT-PCR,2,X,[nnon],????,,????
a5fe0182-5cc6-4745-9da1-27e48368aa7f,C1262020,C0013604, includes ,diffuse alveolar damage,Edema,1,X,[dsyn],[sosy],,C23.888.277
ecb3397e-c0f6-4003-a2e3-b698f6284de4,C1262020,C0333563, includes ,diffuse alveolar damage,Hyaline membrane,1,X,[dsyn],[patf],,
832a2b55-1585-4e46-b2cc-0f3a224611c9,C0024109,C1262020,showed various stages of ,Lung,diffuse alveolar damage,1,X,[bpoc],[dsyn],A04.411,
d8748b94-f149-4f73-aa1e-6e39eac2a927,C0024109,C0225698,showed various stages of ,Lung,Alveolar Epithelial Cells,2,X,[bpoc],[cell],A04.411,A04.411.715.100;A11.436.081
f7a95f38-afee-434e-b6a1-0f33ead33f1f,C0024109,C0013604,showed various stages of ,Lung,Edema,1,X,[bpoc],[sosy],A04.411,C23.888.277
a78c6b42-8deb-4c03-b214-449a1ff8c8a5,C0024109,C0333563,showed various stages of ,Lung,Hyaline membrane,1,X,[bpoc],[patf],A04.411,
c65985d6-87a9-4449-a53b-91ede845a49b,C0302148,C0021308,was associated with ,Blood Clot,Infarction,1,X,[patf],[patf],C14.907.355.830,C23.550.513.355;C23.550.717.489
97c75f2f-9d36-4b2e-b367-19adff98b87d,C0206750,C0865850,leading to ,Coronavirus Infections,Acute respiratory insufficiency,1,X,[dsyn],[dsyn],C02.782.600.550.200,
62bf6681-0c11-47d1-b165-992e28830a0b,C0206750,C0376545,poses unique challenge to care of patients with ,Coronavirus Infections,Hematologic Neoplasms,1,X,[dsyn],[neop],C02.782.600.550.200,C04.588.448;C15.378.400
dbde0c0e-7dd9-4132-85a2-0ed58d1e4f93,C0032310,C0006826,cause disproportionately severe disease in patients with ,Pneumonia Viral,Malignant Neoplasms,1,X,[dsyn],[neop],C02.705;C08.381.677.807;C08.730.610.763,C04
c2b089c9-03c3-406f-be71-f231cf19863d,C0678236,C0206750,is in current pandemic ,Rare Diseases,Coronavirus Infections,1,X,[dsyn],[dsyn],C23.550.291.906,C02.782.600.550.200
5bf2a880-d368-4cc6-b509-34ac08596d06,COVID-19,C1155266,triggering ,COVID-19,inflammatory response,1,X,[virs],[patf],C000657245,
813b2b8a-b16c-42b8-8f87-f2322911bc64,COVID-19,C0024291,simulate ,COVID-19,Lymphohistiocytosis Hemophagocytic,1,X,[virs],[dsyn],C000657245,C15.604.250.410.575
8c88a428-32eb-4e26-be29-6d799b64109e,C0020517,C0072027,suggesting ,Hypersensitivity,procalcitonin,1,X,[patf],[aapp/bacs],C20.543,D06.472.699.666;D12.644.548.744;D12.776.811.555
a629d586-e952-47f6-a501-65b27092a233,COVID-19,C0857828,is in ,COVID-19,infection in the elderly,1,X,[virs],[dsyn],C000657245,
bd684131-b728-47fc-80e1-ea1d4859942f,C0857828,COVID-19,is with ,infection in the elderly,COVID-19,1,X,[dsyn],[virs],,C000657245
5b1483bf-3dc9-4aff-afa3-2d9c17e8e9df,C0857828,C0009450,is with ,infection in the elderly,Communicable Diseases,1,X,[dsyn],[dsyn],,C01.539.221
bc76ed7e-a849-4c2a-8540-fe7bae2bb43c,C0242781,COVID-19,was fitted to ,disease transmission,COVID-19,1,X,[patf],[virs],N06.850.310,C000657245
e7aae876-88be-4df8-85bf-111bc15ab369,C0031640,C1448177,of role is particularly ,phosphoric diester hydrolase,TNF protein human,1,X,[aapp/enzy],[aapp/bacs],D08.811.277.352.640,x.x.x.x
c5194022-66cf-4a41-bfed-4e9cd9ea8178,C3463820,C1448177,through role is particularly ,Inhibition,TNF protein human,1,X,[acty],[aapp/bacs],F01.145.544;F02.463.425.475;F02.739.794.405,x.x.x.x
c3762c8f-0d54-48f1-9856-1b56d511c698,C1155266,C1448177,in role is particularly ,inflammatory response,TNF protein human,1,X,[patf],[aapp/bacs],,x.x.x.x
5c284711-91d6-4cee-adec-4ee535e8c74d,C2936609,COVID-19,attenuate cytokine storm in,Phosphodiesterase 4 Inhibitors,COVID-19,1,X,[phsu],[virs],D27.505.519.389.735.374,C000657245
d45e2b8a-9f16-4e38-8bd6-34db490b71f0,C2936609,C0079189,attenuate ,Phosphodiesterase 4 Inhibitors,cytokine,1,X,[phsu],[aapp/imft],D27.505.519.389.735.374,D12.644.276.374;D12.776.467.374;D23.529.374
83a3639b-77fa-4749-a108-5ed4b87cbec9,C3463820,C0079189,attenuate ,Inhibition,cytokine,1,X,[acty],[aapp/imft],F01.145.544;F02.463.425.475;F02.739.794.405,D12.644.276.374;D12.776.467.374;D23.529.374
ef222e8c-3f87-41eb-84b0-cc1b561ff688,C0678236,C0023884,affecting ,Rare Diseases,Liver,2,X,[dsyn],[bpoc],C23.550.291.906,A03.620
6b2c68b8-ba85-4867-b4d9-630107836982,C0678236,C3542961,affecting ,Rare Diseases,NERVOUS SYSTEM DRUGS,2,X,[dsyn],[phsu],C23.550.291.906,
3d3ee38a-6d28-4bdb-9f3c-79bd3a362f89,C0678236,C0018787,affecting ,Rare Diseases,Heart,2,X,[dsyn],[bpoc],C23.550.291.906,A07.541
37d0ed37-1dc6-445f-a86b-69b3c3158141,C0678236,C0022646,affecting ,Rare Diseases,Kidney,2,X,[dsyn],[bpoc],C23.550.291.906,A05.810.453
376423c3-c2b8-453c-8ed3-2b91e6e54beb,C0268381,C0018787,often present with ,Primary amyloidosis,Heart,1,X,[dsyn],[bpoc],C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565,A07.541
4389d99c-d6d4-4773-817a-7babceee34bf,C0268381,C0277543,often present with ,Primary amyloidosis,Functional disease present,1,X,[dsyn],[dsyn],C04.557.595.250;C18.452.845.500.550;C20.683.515.507;C20.683.780.565,
12a2d50f-6a10-4e8a-9ae1-70b9f3665b42,C1457887,C0032310,is in groups with ,Symptoms,Pneumonia Viral,1,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
301f2994-661c-4eb7-8eb3-68439a812869,C0015967,C0032310,were main Symptoms in groups with,Fever,Pneumonia Viral,1,X,[sosy],[dsyn],C23.888.119.344,C02.705;C08.381.677.807;C08.730.610.763
6304dcaf-8e49-4af4-b6e6-3cd8dc6792c3,C0010200,C0032310,were main Symptoms in groups with,Coughing,Pneumonia Viral,1,X,[sosy],[dsyn],C08.618.248;C23.888.852.293,C02.705;C08.381.677.807;C08.730.610.763
9b1d6872-f0dd-4ad9-a8ce-8a46461c73d4,C0038056,C0032310,were main Symptoms in groups with,Sputum,Pneumonia Viral,1,X,[bdsu],[dsyn],A12.200.808,C02.705;C08.381.677.807;C08.730.610.763
f6ba9497-4bcc-42ed-bec6-9479c7d51294,C0032227,C2062441,were more common in patients with ,Pleural effusion disorder,Influenza A,1,X,[dsyn],[dsyn],C08.528.652,
8e716d01-cd6c-4b53-8b75-333ea59fb7dc,C0032227,C0032285,were more common in patients with ,Pleural effusion disorder,Pneumonia,2,X,[dsyn],[dsyn],C08.528.652,C08.381.677;C08.730.610
2556cc8d-9b64-415c-9c37-a14d89807dee,C0020564,COVID-19,were common in ,Hypertrophy,COVID-19,1,X,[patf],[virs],C23.300.775,C000657245
a99f6f9f-cc4c-4354-8fa4-122ebdff5910,C0032227,COVID-19,were common in ,Pleural effusion disorder,COVID-19,1,X,[dsyn],[virs],C08.528.652,C000657245
0edb6d98-7e76-487b-9a9c-34257c50a366,C0020564,C0032285,were common in ,Hypertrophy,Pneumonia,1,X,[patf],[dsyn],C23.300.775,C08.381.677;C08.730.610
0518c5dc-a88a-4fdf-999f-4925e031182f,C0264545,C0032285,were common in ,Thickening of pleura,Pneumonia,1,X,[dsyn],[dsyn],,C08.381.677;C08.730.610
7e884d02-b3e8-4ff4-af15-233805ae8e53,C0086312,C1828170,showed mean standard ,Forests,Mean deviation,1,X,[npop],[clna],G16.500.275.157.437;N06.230.124.343,
e437c375-acdc-42dc-864c-2de37eea65d5,C0086312,C0020517,showed mean standard ,Forests,Hypersensitivity,1,X,[npop],[patf],G16.500.275.157.437;N06.230.124.343,C20.543
e45995e3-5e83-49a5-9bd5-3137a0190e9b,COVID-19,C0878751,is in ,COVID-19,late pregnancy,1,X,[virs],[patf],C000657245,
8c20f85c-317d-4fd3-b8eb-f63d126a21e0,C0009450,C0878751,is in ,Communicable Diseases,late pregnancy,1,X,[dsyn],[patf],C01.539.221,
ae48eb06-227c-4a9e-857f-56a991b5aa54,C0162633,19days,was 19days,Viral Shedding,19days,2,X,[patf],????,G07.925,????
7a69ff5a-e35e-4e8b-a819-eaab31680d26,C0035668,19days,was 19days,RNA,19days,1,X,[nnon],????,D13.444.735,????
85b97dc6-2d22-4ed6-9477-1205264fb8be,C0018581,C0206750,have have advocated as proactive measures against spread of ,Handwashing,Coronavirus Infections,1,X,[acty],[dsyn],N06.850.670.150.500,C02.782.600.550.200
85b97dc6-2d22-4ed6-9477-1205264fb8be,C0018581,C0206750,was most common practice in response to ,Handwashing,Coronavirus Infections,1,X,[acty],[dsyn],N06.850.670.150.500,C02.782.600.550.200
3e3debd3-fc79-4d59-8687-076386853176,C0019247,C0018799,represent heterogenous group of ,Hereditary Diseases,Heart Diseases,2,X,[dsyn],[dsyn],C16.320,C14.280
8fc2f9c6-52b3-421e-a83f-2539ca0d6313,C0018787,C0018799,represent heterogenous group of ,Heart,Heart Diseases,1,X,[bpoc],[dsyn],A07.541,C14.280
9f3e587c-75f1-4ddb-9b4f-3b87dc34b11f,C2316160,C0206750,is in critically ill patients with ,Infection of bloodstream,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
8c35c2ab-0bed-42be-9089-b461e00a6aff,C0018799,C0009450,seems result of inflammatory storm in response to ,Heart Diseases,Communicable Diseases,2,X,[dsyn],[dsyn],C14.280,C01.539.221
d9c8993e-7fd8-48bb-9f42-996f23035ae1,C2948600,C0042776,suppress spread of ,Aim,Virus,1,X,[inch/phsu],[virs],,B04
d9c8993e-7fd8-48bb-9f42-996f23035ae1,C2948600,C0042776,investigate ,Aim,Virus,1,X,[inch/phsu],[virs],,B04
2b6eaee1-a2fb-4bf8-835d-56df039dd65e,C1825598,C3825997,at look is changes to ,IMPACT gene,Medicine--Practice,2,X,[gngm],[bmod],,
14cac370-d8b8-480b-855b-084a3646ccd1,C0021966,C3825997,changes to ,Iodides,Medicine--Practice,2,X,[inch],[bmod],D01.248.497.158.490;D01.475.410,
41b2f277-fed5-4e1b-b11a-202026f2c343,COVID-19,C0032064,comparable to past epidemics like ,COVID-19,Plague,1,X,[virs],[dsyn],C000657245,C01.252.400.310.980.745
13e9feeb-9e77-4a05-a0f8-60abb2e4f908,COVID-19,C0021400,comparable to past epidemics like ,COVID-19,Influenza,1,X,[virs],[dsyn],C000657245,C02.782.620.365;C08.730.310
f647c951-3017-45f8-aebb-04d75d3822b3,C0599779,C0699748,study ,Animal Model,Pathogenesis,1,X,[anim],[patf],E05.598,
345c3e5e-6e63-4f6a-8a7b-9678575c592b,C0599779,C0206750,study ,Animal Model,Coronavirus Infections,1,X,[anim],[dsyn],E05.598,C02.782.600.550.200
f8961688-ab34-42cb-b7c9-b1dee3ef08f0,C0237798,C0009450,are considered gold model for many ,Nonhuman primate,Communicable Diseases,1,X,[mamm],[dsyn],,C01.539.221
f8961688-ab34-42cb-b7c9-b1dee3ef08f0,C0237798,C0009450,gold standard model for many ,Nonhuman primate,Communicable Diseases,1,X,[mamm],[dsyn],,C01.539.221
f5d4cfa2-271d-42e3-9f4a-75b95ec1fe77,C0237798,C0450254,are considered gold model for many ,Nonhuman primate,Pathogenic organism,1,X,[mamm],[orgm],,
f5d4cfa2-271d-42e3-9f4a-75b95ec1fe77,C0237798,C0450254,gold standard model for many ,Nonhuman primate,Pathogenic organism,1,X,[mamm],[orgm],,
6c1dbf3a-d64a-4327-8da6-8cb74d712937,C0026438,C1175743,support high level of ,Cercopithecus aethiops,SARS coronavirus,2,X,[mamm],[virs],B01.050.150.900.649.313.988.400.112.199.120.126.110,B04.820.504.540.150.113.937
e3d15e04-92fc-4988-bd75-d4c7bb85b106,C0026438,C0035204,develop pronounced ,Cercopithecus aethiops,Respiration Disorders,1,X,[mamm],[dsyn],B01.050.150.900.649.313.988.400.112.199.120.126.110,C08.618
e113fc07-f3ce-4995-9d7a-d22cfe919044,C0035204,C0237798,reported for other ,Respiration Disorders,Nonhuman primate,1,X,[dsyn],[mamm],C08.618,
92cbe412-7596-4559-b146-6526ea69db1b,C0042774,C0026438,can Importantly can produced in ,Virus Replication,Cercopithecus aethiops,1,X,[celf],[mamm],G06.920.925,B01.050.150.900.649.313.988.400.112.199.120.126.110
71b40f14-dafa-4090-9d8b-2f17477a16a1,COVID-19,C0010332,is world-wide Crisis Intervention without effective,COVID-19,Crisis Intervention,2,X,[virs],[topp],C000657245,F04.754.252
c096a47b-08b7-478c-b657-46252dc20b8e,C3687832,C0012634,were developed for other ,Drugs - dental services,Disease,1,X,[topp],[dsyn],,C23.550.288
6ceaa926-8744-4bc2-ac17-097cac7c5145,C0206750,C0025831,is methylated by two ,Coronavirus Infections,Methyltransferase,1,X,[dsyn],[aapp/enzy],C02.782.600.550.200,D08.811.913.555.500
7483240f-26a1-4a3b-a273-5eb1e09e0b23,C0035670,C0025831,is methylated by two ,RNA Caps,Methyltransferase,1,X,[bacs/nnon],[aapp/enzy],D03.633.100.759.646.454.700;D13.444.735.544.500;D13.695.667.454.700;D13.695.827.426.700,D08.811.913.555.500
eebd48d7-616f-4b7c-a793-07077964c80a,C0025723,C0036002,form ,Methylation,S-Adenosylmethionine,1,X,[moft],[aapp/bacs/phsu],G02.111.035.538;G02.607.094.538;G03.059.538,D02.886.030.676.180;D03.633.100.759.590.138.264;D12.125.166.676.180;D13.570.583.138.264;D13.570.800.096.264
8c6119cd-a689-46a6-8322-5990fb9eb10c,C0025723,C1167395,depends on level in ,Methylation,Host (organism),1,X,[moft],[orgm],G02.111.035.538;G02.607.094.538;G03.059.538,
5a5c2a66-7b15-413f-894b-cd8fa2feb21d,C1514798,COVID-19,Aim to,Recombinants,COVID-19,1,X,[orgm],[virs],,C000657245
0c60222d-ca04-4460-9df6-25d8462b547c,C0064548,COVID-19,Aim to,Methionine gamma-lyase,COVID-19,1,X,[aapp/enzy],[virs],x.x.x.x,C000657245
32e9fb80-1a0d-4ec5-a887-7a549c32462c,C1514798,C0087111,Aim to,Recombinants,Therapeutic procedure,1,X,[orgm],[topp],,E02
ee181cb8-ac33-47bf-ab26-2116075c6d0e,C0064548,C0087111,Aim to,Methionine gamma-lyase,Therapeutic procedure,1,X,[aapp/enzy],[topp],x.x.x.x,E02
5d75e2d4-2663-4f97-866e-559cb61cad57,C0596290,C0520917,have ,Cell Proliferation,Increased metabolic requirement,1,X,[celf],[patf],G04.161.750;G07.345.249.410.750,
c97c4022-5a56-4a14-bc7f-fda89fff449a,C0596290,C0025646,have ,Cell Proliferation,Methionine,1,X,[celf],[aapp/bacs/phsu],G04.161.750;G07.345.249.410.750,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
9374a1fc-77f7-4967-ad24-115a4a04932f,C0039194,C0025646,greatly increases ,T-Lymphocyte,Methionine,1,X,[cell],[aapp/bacs/phsu],A11.118.637.555.567.569;A15.145.229.637.555.567.569;A15.382.490.555.567.569,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
86c99ce3-6140-421b-a667-646bd7ba16a2,C1879547,C0025646,greatly increases ,Activation action,Methionine,1,X,[acty],[aapp/bacs/phsu],,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
1507cead-5414-459a-8b5f-3fa0eef7e26c,C0024432,C0025646,restricting ,macrophage,Methionine,1,X,[cell],[aapp/bacs/phsu],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
7a48eeaa-6c7e-4fcb-81cb-a8af8074ce73,C0079189,C0025646,restricting ,cytokine,Methionine,1,X,[aapp/imft],[aapp/bacs/phsu],D12.644.276.374;D12.776.467.374;D23.529.374,D02.886.030.676;D12.125.142.557;D12.125.154.549;D12.125.166.676;x.x.x.x
40868e9e-3415-46af-a3cb-f73c8a1deda6,C1514798,C0206750,be promising treatment for ,Recombinants,Coronavirus Infections,1,X,[orgm],[dsyn],,C02.782.600.550.200
40868e9e-3415-46af-a3cb-f73c8a1deda6,C1514798,C0206750,spread of ,Recombinants,Coronavirus Infections,2,X,[orgm],[dsyn],,C02.782.600.550.200
04287364-1ed4-4354-bf43-4372f1e93a82,C0064548,C0206750,be promising treatment for ,Methionine gamma-lyase,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],x.x.x.x,C02.782.600.550.200
ce4c1c78-1b22-43f9-ab26-18f8f619431a,C1708476,C1856053,of weeks is ,Implementation,Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[acty],[dsyn],,x.x.x.x
a1eeb672-f2b6-4391-90e9-2f20697b17ac,C0242781,C0034386,using strategies of ,disease transmission,Quarantine,1,X,[patf],[topp],N06.850.310,N06.850.780.200.450.700
599b47b0-c899-459e-a6e0-fe9bd031fab2,C0079189,C1175175,associated to ,cytokine,Severe Acute Respiratory Syndrome,1,X,[aapp/imft],[dsyn],D12.644.276.374;D12.776.467.374;D23.529.374,C02.782.600.550.200.750;C08.730.730
c0142b88-4e08-4a60-aba0-ccb923729f6e,C1861452,C1175175,associated to ,Storm Syndrome,Severe Acute Respiratory Syndrome,1,X,[dsyn],[dsyn],x.x.x.x,C02.782.600.550.200.750;C08.730.730
785647b8-252c-4161-b4f6-a34bb533251d,C0079189,C0021368,associated with ,cytokine,Inflammation,1,X,[aapp/imft],[patf],D12.644.276.374;D12.776.467.374;D23.529.374,C23.550.470
33ee4e39-1908-4927-8dd2-9a728d637a3b,C1861452,C0021368,associated with ,Storm Syndrome,Inflammation,1,X,[dsyn],[patf],x.x.x.x,C23.550.470
9e905499-4a1c-4153-9c94-ecd811383511,C1720208,C0184893,encompass ,Ophthalmic plastic surgery,Emergency operation,1,X,[bmod],[topp],,
2cc96386-5af9-4199-baaa-344095547208,C0206750,C2364082,lead to ,Coronavirus Infections,Sense of smell impaired,2,X,[dsyn],[sosy],C02.782.600.550.200,
bce2edc8-ee4d-461b-8f96-5d68e935342f,C0018681,C0206750,related to ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
bce2edc8-ee4d-461b-8f96-5d68e935342f,C0018681,C0206750,was reported in in ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
bce2edc8-ee4d-461b-8f96-5d68e935342f,C0018681,C0206750,is in symptomatic ,Headache,Coronavirus Infections,1,X,[sosy],[dsyn],C23.888.592.612.441,C02.782.600.550.200
e57f3266-0522-48bf-87ed-59c8759f93de,C0021966,C0393735,discuss my ,Iodides,Headache Disorders,1,X,[inch],[dsyn],D01.248.497.158.490;D01.475.410,C10.228.140.546
24d38c9c-3c36-48b9-a9b9-d83a95cf1274,C0021966,MEDLINE,review MEDLINE ,Iodides,MEDLINE,2,X,[inch],????,D01.248.497.158.490;D01.475.410,????
be28e0ab-e332-4fe9-8add-7e78f2b5cab7,C0021966,C0018681,review MEDLINE ,Iodides,Headache,2,X,[inch],[sosy],D01.248.497.158.490;D01.475.410,C23.888.592.612.441
7b28f687-aa52-4301-84c0-0b1a02600001,C0018681,C0003130,attributed to ,Headache,Anoxia,1,X,[sosy],[patf],C23.888.592.612.441,C23.888.852.079
b66f9133-a800-4767-a7f1-c5bb94b1dbec,C0744633,C0042749,attributed to ,Acute headache,Viremia,1,X,[sosy],[dsyn],,C02.937;C23.550.470.790.500.900
8d26aad3-1b90-44e7-9781-1b503cd4ca19,C0018681,C0079189,is probably related to ,Headache,cytokine,1,X,[sosy],[aapp/imft],C23.888.592.612.441,D12.644.276.374;D12.776.467.374;D23.529.374
ec1e5690-d9ca-4f27-a905-ad5ae5f91110,C1175743,C0242732,has wide ,SARS coronavirus,Tropism,1,X,[virs],[phsf],B04.820.504.540.150.113.937,G07.345.249.845;G15.920
b828c684-6c25-427b-bd6d-764c5036d37a,N2,C0020517,was found most ,N2,Hypersensitivity,1,X,????,[patf],????,C20.543
82df9a91-303c-49ee-bf0e-5dbe71ff6d0e,N2,C0007806,was found most ,N2,Cerebrospinal Fluid,1,X,????,[bdsu],????,A12.207.270.210
febf3e72-82aa-44fd-b75a-d9e6b6da3d73,C0017337,C0007806,was found most ,Genes,Cerebrospinal Fluid,1,X,[gngm],[bdsu],G05.360.340.024.340,A12.207.270.210
97b04161-fc8d-4b1e-8d13-570b96d7c47e,C0220853,C1175743,were found in PCR-positive for ,Hydroxide Ion,SARS coronavirus,2,X,[elii],[virs],x.x.x.x,B04.820.504.540.150.113.937
6dd09c1c-3bda-42ab-930d-4b68155b48cf,C0849867,C3272275,requires ,Widespread Disease,Urgent Procedure,1,X,[dsyn],[topp],,
45bca7c7-2530-4484-87a9-a2fbfdb774cf,C0849867,C2825812,requires ,Widespread Disease,Deploy,1,X,[dsyn],[acty],,
e35b3d2b-b8a5-4124-af27-d8b088148ba8,C0849867,C0087111,requires ,Widespread Disease,Therapeutic procedure,1,X,[dsyn],[topp],,E02
3d3d0dd6-3c5d-469a-9733-9f65d4604529,C0003451,COVID-19,are main class of ,Antiviral Agents,COVID-19,1,X,[phsu],[virs],D27.505.954.122.388,C000657245
40905eb5-148d-461c-a531-48359cb0108f,COVID-19,C0004093,can have serious complications respiratory with severe ,COVID-19,Asthenia,1,X,[virs],[sosy],C000657245,C23.888.089
729a1167-3294-4efb-8345-ebaa4209ca66,C0035222,C1879547,sustained by uncontrolled inflammatory ,Respiratory Distress Syndrome Adult,Activation action,1,X,[dsyn],[acty],C08.381.840;C08.618.840,
9cda28dd-5ca4-4eb6-b17d-77f2b0a2bc50,C0024432,C0039082,plays role in ,macrophage,Syndrome,1,X,[cell],[dsyn],A11.329.372;A11.627.482;A11.733.397;A15.382.670.522;A15.382.680.397,C23.550.288.500
9675b26b-b9e5-4c71-911e-2dc9dd4f361a,C0597357,C0032285,target in ,receptor,Pneumonia,2,X,[aapp/rcpt],[dsyn],,C08.381.677;C08.730.610
ebc572be-872f-4c7a-aead-ffc5fdd91573,C0370003,and2019,Comparison volumes in 2020 and2019,Specimen,and2019,1,X,[sbst],????,,????
da618f4c-9945-46bf-b856-51f65e149576,C1262020,C0206750,is ubiquitous finding in inpatient ,diffuse alveolar damage,Coronavirus Infections,2,X,[dsyn],[dsyn],,C02.782.600.550.200
2240e1f1-cd33-4120-b165-df8b4925a3e7,C1262020,C0012634,is ubiquitous finding in inpatient ,diffuse alveolar damage,Disease,1,X,[dsyn],[dsyn],,C23.550.288
8f459cec-fc84-4ff8-8bbc-1d81caeac0c6,C0020336,C1706202,conduct literature ,Hydroxychloroquine,Search - action,1,X,[orch/phsu],[acty],D03.633.100.810.050.180.350,
9cbb5472-dc55-4554-a3bf-0199788f89aa,C0206750,C0520679,is with ,Coronavirus Infections,Sleep Apnea Obstructive,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08.618.085.852.850;C10.886.425.800.750.850
468d6385-1f9d-4acf-9c7f-9a69a3777fe3,C0206750,C3714552,has illuminated ,Coronavirus Infections,Weakness,1,X,[dsyn],[sosy],C02.782.600.550.200,
a86600a7-13d0-45f4-b8cc-c820e6de9104,C0206750,C0014507,has generated wide-ranging ,Coronavirus Infections,Epidemiology,1,X,[dsyn],[bmod],C02.782.600.550.200,H02.403.720.500
a33acb1a-35bb-4c3a-b47a-07483328ce6b,C0040038,C0940933,are recognised complications of viral ,Thromboembolism,infection as a complication,1,X,[patf],[dsyn],C14.907.355.590,
f43025a0-5cac-4c32-b45a-3a52728982d1,C0281169,C0206750,is in context of ,pulmonary complications,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
d79d678d-4648-486f-807a-ae6d4528ee64,C0281169,C0012634,is in context of ,pulmonary complications,Disease,2,X,[patf],[dsyn],,C23.550.288
f5aa7dcd-191e-418b-8145-46b5a34dbf61,C0042971,C0206750,of levels is point towards relevant involvement in patients with severe ,von Willebrand factor,Coronavirus Infections,1,X,[aapp/bacs/phsu],[dsyn],D12.776.124.125.920;D23.119.985,C02.782.600.550.200
b285bb74-03c5-49c7-93b4-ed80563f19ab,C0026941,C0450254,is atypical bacterial ,Mycoplasma pneumoniae,Pathogenic organism,1,X,[bact],[orgm],B03.440.860.580.553.553.650,
5fc6a681-763b-4310-b5bd-be676cfaf721,C1457887,C0278061,were ,Symptoms,Abnormal mental state,1,X,[sosy],[mobd],,
4dbad04e-f5f4-4de1-b929-464106e724c1,C0003316,silico,using in silico ,Epitopes,silico,2,X,[imft],????,D23.050.550,????
79c2572b-da67-470a-97d2-1a6c073462d8,C0042210,silico,using in silico ,Vaccines,silico,2,X,[aapp/imft/phsu],????,D20.215.894,????
a5a8ac01-51bf-4919-8997-53ce9dfb9699,C0042210,C0282580,using ,Vaccines,Epitopes T-Lymphocyte,1,X,[aapp/imft/phsu],[imft],D20.215.894,D23.050.550.402
8a6d3c25-1318-47e6-b9a0-57b867ed2ba8,C0282580,C0003320,can act as ,Epitopes T-Lymphocyte,Antigens,1,X,[imft],[imft],D23.050.550.402,D23.050
a56e92d3-bf0f-47f1-b3c0-e066399b98b8,C0282580,C0301872,elicits immune ,Epitopes T-Lymphocyte,Immune response,2,X,[imft],[ortf],D23.050.550.402,
0127d465-e491-489f-83ff-cce87d9ad125,NCBI,C3658243,was used for retrieval of surface ,NCBI,Spike Glycoprotein Coronavirus,2,X,????,[aapp/bacs],????,D12.776.543.512.500.665;D12.776.964.970.880.910.665
e396f85d-fc9f-41e3-beba-8bdf7fa726d3,silico,C0002520,composed of 50S ,silico,Amino Acids,1,X,????,[aapp/bacs/phsu],????,D12.125
506dc585-edfe-41f1-b0b6-1792421af811,silico,50S,composed of 50S ,silico,50S,1,X,????,????,????,????
a3bab432-53b9-4124-b650-1497f16b82c7,silico,C0035552,composed of 50S ,silico,Ribosomal Proteins,1,X,????,[aapp/bacs],????,D12.776.835
28ebd8f1-0296-49c1-a8a2-e28362d9299b,silico,C0001551,composed of 50S ,silico,Immunologic Adjuvants,1,X,????,[imft/phsu],????,D27.505.696.477.067
acbf95b2-9b7e-4329-8ea3-bf835f6ad7e3,C0599934,C0301872,enhance nCoV-19,Vaccines Peptide,Immune response,1,X,[imft/phsu],[ortf],D20.215.894.860,
85836406-8ae3-46aa-9ebe-01fdcc171edf,C0599934,nCoV-19,enhance nCoV-19,Vaccines Peptide,nCoV-19,1,X,[imft/phsu],????,D20.215.894.860,????
9c563fd8-7b01-416a-8c56-a3472290a4a3,C0871208,C1175175,is in patients with ,Rating (action),Severe Acute Respiratory Syndrome,1,X,[acty],[dsyn],,C02.782.600.550.200.750;C08.730.730
44f9159b-bdcc-4b69-913f-c477f07490c8,TOCI,C4048285,had higher baseline ,TOCI,C-Reactive Protein human,1,X,????,[aapp/imft],????,
f0194e2f-d75f-4eee-9710-b8711c58030f,C0023688,C3891814,has revealed molecular determinants responsible for ,Ligands,Substrate,1,X,[chem],[sbst],D27.720.470.480,
50da74bf-eb29-42eb-8565-ed7071d0156f,C1167622,C3891814,has revealed molecular determinants responsible for ,Binding (Molecular Function),Substrate,1,X,[moft],[sbst],,
d6a35d1e-08f7-46f7-8a1a-aa5f790e4bb8,C0043309,C3891814,has revealed molecular determinants responsible for ,Roentgen Rays,Substrate,1,X,[npop],[sbst],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
c0f38b85-f264-4c56-a671-1dcda823a9bf,C0444626,C3891814,has revealed molecular determinants responsible for ,Crystal Structure,Substrate,1,X,[chvs],[sbst],,
f85322af-b9a7-4a98-9e90-627e7bfdd035,C0043309,C1167622,has revealed molecular determinants responsible for ,Roentgen Rays,Binding (Molecular Function),2,X,[npop],[moft],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
f85322af-b9a7-4a98-9e90-627e7bfdd035,C0043309,C1167622,has revealed potential inhibitor ,Roentgen Rays,Binding (Molecular Function),2,X,[npop],[moft],G01.358.500.505.970;G01.750.250.970;G01.750.750.918,
38b88cc3-4d49-4217-9f16-362741c69b37,C0042776,C3947283,is closely related to ,Virus,Bat coronavirus,2,X,[virs],[virs],B04,
578d15e6-008a-461d-befe-82e17162aa30,C0939237,C1167622,show best ,lopinavir / Ritonavir,Binding (Molecular Function),1,X,[phsu],[moft],,
dde8c0d3-412c-4d6b-b664-ece67acbc82a,C0663733,C1167622,show best ,tipranavir,Binding (Molecular Function),1,X,[orch/phsu],[moft],x.x.x.x,
87a948ef-01ab-4ed5-9665-c3571f28dfa7,C1871526,C1167622,show best ,raltegravir,Binding (Molecular Function),1,X,[nnon/phsu],[moft],,
8f265af1-4a49-4fdb-97e1-dd6a70cdc65e,C0939237,C1433062,show best ,lopinavir / Ritonavir,3C-like protease SARS coronavirus,2,X,[phsu],[aapp/enzy],,x.x.x.x
8f265af1-4a49-4fdb-97e1-dd6a70cdc65e,C0939237,C1433062,best Binding (Molecular Function) with,lopinavir / Ritonavir,3C-like protease SARS coronavirus,2,X,[phsu],[aapp/enzy],,x.x.x.x
6fa39c35-6c30-4b7e-94f7-213463230f35,C0663733,C1433062,show best ,tipranavir,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
6fa39c35-6c30-4b7e-94f7-213463230f35,C0663733,C1433062,best Binding (Molecular Function) with,tipranavir,3C-like protease SARS coronavirus,2,X,[orch/phsu],[aapp/enzy],x.x.x.x,x.x.x.x
f49b9b51-af2c-4b54-957a-25a2f4dc4408,C1871526,C1433062,show best ,raltegravir,3C-like protease SARS coronavirus,2,X,[nnon/phsu],[aapp/enzy],,x.x.x.x
f49b9b51-af2c-4b54-957a-25a2f4dc4408,C1871526,C1433062,best Binding (Molecular Function) with,raltegravir,3C-like protease SARS coronavirus,2,X,[nnon/phsu],[aapp/enzy],,x.x.x.x
89ce3f72-e8e8-4706-9141-ddbeb8c3e572,C0184661,at-risk,reaches highly at-risk ,Interventional procedure,at-risk,1,X,[topp],????,,????
33058273-a73a-4a03-acd1-8ac108ca48df,C0033414,C0022709,is ,Promotion (action),Peptidyl-Dipeptidase A,1,X,[acty],[aapp/enzy/imft],,D08.811.277.656.350.350.687
43ac7571-06a3-4a5d-bd55-6439046f628b,C3888108,C0022709,is ,Import into cell,Peptidyl-Dipeptidase A,1,X,[celf],[aapp/enzy/imft],,D08.811.277.656.350.350.687
8a9dd0da-db85-4181-9798-0a8bda54a8b6,C0301626,C3894683,using ,Competitive inhibition,Extracellular Vesicles,1,X,[moft],[celc],,A11.284.295.588
78db364e-fec7-4f65-a948-a191265942bc,C0301626,C3178844,using ,Competitive inhibition,Mesenchymal Stromal Cells,2,X,[moft],[cell],,A11.329.830.500;A11.872.590.500
401b86cd-bcde-4849-94da-2b404b64f17d,C0301626,C1184743,using ,Competitive inhibition,bony process,1,X,[moft],[bpoc],,
a19948e8-a9a5-4116-974a-932100924c2b,C0301626,C0022709,overexpressing ,Competitive inhibition,Peptidyl-Dipeptidase A,1,X,[moft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
65fd5f76-02f5-4635-92fa-087898196851,C0009450,C1515119,is associated with higher mortality in those on ,Communicable Diseases,systemic therapy,1,X,[dsyn],[topp],C01.539.221,
65fd5f76-02f5-4635-92fa-087898196851,C0009450,C1515119,is associated in particularly those on ,Communicable Diseases,systemic therapy,1,X,[dsyn],[topp],C01.539.221,
e8a7fa0c-b183-4343-bd03-e33849c9cf31,C0919976,C1367202,treated with ,renal cancer metastatic,ipilimumab,1,X,[neop],[aapp/imft/phsu],,D12.776.124.486.485.114.224.060.798;D12.776.124.790.651.114.224.060.798;D12.776.377.715.548.114.224.200.798
53b9daf7-5e9c-46e6-9a1e-3ba03716cac3,C4288754,C4055433,treated with ,Metastatic urothelial carcinoma,atezolizumab,1,X,[neop],[orch/phsu],,x.x.x.x
81a41a14-8056-441e-bba4-f6ef6dfd5301,C0005522,C1879547,were originally investigated by rheumatologists for treatment of numerous ,Biological Products,Activation action,2,X,[bacs/phsu],[acty],D20.215,
74feb0e0-8c56-44ba-ad1c-d9670a5a4e7a,C0043528,C0034019,cause grave ,Zoonoses,public health medicine (field),1,X,[dsyn],[bmod],C01.908;C02.968;C03.908;C22.969,H02.403.720;N01.400.550;N06.850
85da30f6-dbb2-4f7c-b2da-69a39103883c,C0206750,C0230770,is with modified ,Coronavirus Infections,Endoplasmic reticulum membrane,1,X,[dsyn],[celc],C02.782.600.550.200,
8e070651-31de-4239-ab4f-18fff314a101,C0035668,C0230770,is with modified ,RNA,Endoplasmic reticulum membrane,1,X,[nnon],[celc],D13.444.735,
9dc98855-000d-4c82-bea8-13eb04af5682,C0230770,C0598312,are transformed into viral ,Endoplasmic reticulum membrane,DNA Replication,1,X,[celc],[genf],,G02.111.225;G05.226
dd2ea7a7-00c5-468a-bbb0-e80ed124cacd,C0230770,C0029219,are transformed into viral ,Endoplasmic reticulum membrane,Organelles,1,X,[celc],[celc],,A11.284.430.214.190.875
9db43ed6-6c4d-4d07-8c04-643aafffc799,C0596901,C3887654,be ,Membrane,POLYARTERITIS NODOSA CHILDHOOD-ONSET,2,X,[celc],[dsyn],A10.615,
0980355d-f3bc-4620-8f00-de99538c59a2,C0596901,C0206750,be ,Membrane,Coronavirus Infections,2,X,[celc],[dsyn],A10.615,C02.782.600.550.200
6546777a-7053-4650-b11a-6f1c3246a91b,C0596901,C0029219,be ,Membrane,Organelles,2,X,[celc],[celc],A10.615,A11.284.430.214.190.875
1602c2c3-d70a-4ec0-a633-dd07fd875cc5,C0596901,C0013879,be ,Membrane,Elements,2,X,[celc],[elii],A10.615,D01.268
f1cd6b11-3e3d-4693-afb2-1707df4ffd50,C0596901,C0017011,previously thought restricted to ,Membrane,Gamma Rays,1,X,[celc],[npop],A10.615,G01.358.500.505.300;G01.750.250.300;G01.750.750.400
e9bff90e-9ff3-4cf6-b963-705bcd73a5f8,C0020336,C0012634,has has proposed as possible treatment for ,Hydroxychloroquine,Disease,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C23.550.288
a9beabc2-b406-4968-b3b4-efa5215b6420,C0060369,C0086982,regulating ,Fibroblast Growth Factor Receptors,Signal Transduction Pathways,1,X,[aapp/rcpt],[moft],D12.776.543.750.750.400.370,G02.111.820;G04.835
27dcd374-d482-45da-95b6-c0ef07e65338,C0060369,C1184743,regulating ,Fibroblast Growth Factor Receptors,bony process,1,X,[aapp/rcpt],[bpoc],D12.776.543.750.750.400.370,
e87c2097-4b41-4754-b50f-e9b50477934b,C0060369,C0034069,regulating ,Fibroblast Growth Factor Receptors,Pulmonary Fibrosis,1,X,[aapp/rcpt],[dsyn],D12.776.543.750.750.400.370,C08.381.765
d91b7c00-f788-4070-88fe-7e766def12b4,C1568520,C2612061,can inhibit proliferation of ,FLT1 protein human,fibroblast migration,1,X,[aapp/enzy/rcpt],[celf],x.x.x.x,
5e10cc27-2967-4a74-b52b-284d9e307fbe,C0060369,C2612061,can inhibit proliferation of ,Fibroblast Growth Factor Receptors,fibroblast migration,1,X,[aapp/rcpt],[celf],D12.776.543.750.750.400.370,
344ec0b3-3b0f-4bc9-ad59-ac6941b60c02,C0206750,C0025124,is in ,Coronavirus Infections,Traditional Chinese Medicine,1,X,[dsyn],[bmod],C02.782.600.550.200,E02.190.488.585.520;I01.076.201.450.654.558.520
b40926a4-f40e-427c-a4c1-1f90099f09fb,C0012634,C0025124,is in ,Disease,Traditional Chinese Medicine,1,X,[dsyn],[bmod],C23.550.288,E02.190.488.585.520;I01.076.201.450.654.558.520
810a6624-5535-425d-921e-fff39852ea16,2019and,C0025124,is in ,2019and,Traditional Chinese Medicine,1,X,????,[bmod],????,E02.190.488.585.520;I01.076.201.450.654.558.520
b6860aee-47bf-4206-b4ef-bff8ff08763b,C0019240,C0272285,were then filtered with ,Herb,Heparin-induced thrombocytopenia,2,X,[plnt],[dsyn],,
265c0146-6d26-43c8-86f0-5ec8dbdd77b9,C0019240,C0871208,were then filtered with ,Herb,Rating (action),2,X,[plnt],[acty],,
2d7c0c55-6027-4a4c-81d5-b74457093df4,C0034069,C0024109,mostly belong to ,Pulmonary Fibrosis,Lung,1,X,[dsyn],[bpoc],C08.381.765,A04.411
6bb7df94-1d81-4689-96a2-ec72ee08cbf0,C1457887,C3891560,is ,Symptoms,Alarmins,1,X,[sosy],[aapp/bacs],,D23.035
398f1aa0-536d-4ddd-8434-fd26a85fcd88,C1457887,C0018837,is ,Symptoms,Heat (physical force),1,X,[sosy],[npop],,
5b74037f-ea45-4021-b06b-e25a6752bced,C0024109,C0005889,always causes impairment of ,Lung,Body Fluids,1,X,[bpoc],[bdsu],A04.411,A12.207
97ca4668-3b19-4abc-8699-c791bdf35dc8,C0034069,C0206750,caused by ,Pulmonary Fibrosis,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.381.765,C02.782.600.550.200
2ea52528-50c1-40db-b04c-71e8972f969a,C0033308,C0021079,give ,Progesterone,Therapeutic immunosuppression,1,X,[horm/orch/phsu],[topp],D04.210.500.745.745.654.829;D06.472.334.734.623;D06.472.334.851.687.750,E02.095.465.425.450;E05.478.610
d59dbc55-098b-492e-a85d-d56d80c8c405,C0014939,C3714514,humoral response to viral ,Estrogens,Infection,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,C01.539
d59dbc55-098b-492e-a85d-d56d80c8c405,C0014939,C3714514,stimulate humoral ,Estrogens,Infection,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,C01.539
7a82f0e9-129d-4a18-b12e-ae2468146d89,C0014939,humoral,stimulate humoral ,Estrogens,humoral,1,X,[horm/orch/phsu],????,D27.505.696.399.472.277,????
b9b1e6e7-67c6-446f-a8be-8e5f42f3904f,C0039601,C0021079,give ,Testosterone,Therapeutic immunosuppression,1,X,[horm/orch/phsu],[topp],D04.210.500.054.079.429.824;D06.472.334.851.968.984,E02.095.465.425.450;E05.478.610
11d260fd-6a35-4541-8a3f-38d0e67ff604,C0014939,C0014912,is in particular ,Estrogens,Estradiol,1,X,[horm/orch/phsu],[horm/orch/phsu],D27.505.696.399.472.277,D04.210.500.365.415.248;D06.472.334.851.437.500
384d0530-a33d-44c3-aea2-bddc2e17865c,C0014939,C0544688,protect women from most serious ,Estrogens,complication of disease,1,X,[horm/orch/phsu],[patf],D27.505.696.399.472.277,
2854ce8b-ec15-432d-ac0a-219300ff5a7b,C0014939,C0206750,protect women from most serious ,Estrogens,Coronavirus Infections,1,X,[horm/orch/phsu],[dsyn],D27.505.696.399.472.277,C02.782.600.550.200
ec3489c5-b132-4e67-aad0-5a456506dc72,C0013227,C0009871,keep such as combined ,Pharmaceutical Preparations,Contraceptive Agents,1,X,[phsu],[phsu],D26,D27.505.696.875.360;D27.505.954.705.360
0f88589c-0dfa-4482-96b3-ed80ef3943d1,C0630906,C0221423,of incidence is particularly those with severe ,vinyltriethoxysilane,Illness (finding),1,X,[orch],[sosy],x.x.x.x,
0ad46bac-c3a2-40de-8fc4-86493a7ff713,C0032310,C1175175, includes ,Pneumonia Viral,Severe Acute Respiratory Syndrome,2,X,[dsyn],[dsyn],C02.705;C08.381.677.807;C08.730.610.763,C02.782.600.550.200.750;C08.730.730
552282c4-6134-4e1c-b1bb-8ec066de7958,C0221423,C0630906,is similar to high ,Illness (finding),vinyltriethoxysilane,2,X,[sosy],[orch],,x.x.x.x
e4ab9a9d-411f-43ea-bf8d-0ba0b264297c,C0221423,C0871208,is similar to high ,Illness (finding),Rating (action),2,X,[sosy],[acty],,
23f4f261-1aa7-487e-8c41-aadd446b8360,C0221423,C0032310,is similar to high ,Illness (finding),Pneumonia Viral,1,X,[sosy],[dsyn],,C02.705;C08.381.677.807;C08.730.610.763
8940b669-bf1e-45d5-b5de-ec26018c0bd9,C0473485,C1825598,has negative ,Maternal distress,IMPACT gene,1,X,[patf],[gngm],,
456d43ca-da6a-4a9f-bb16-4f3fd7d6834d,C0206750,pre,reported less positive affectivity than pre ,Coronavirus Infections,pre,1,X,[dsyn],????,C02.782.600.550.200,????
242df6af-b94c-4377-bf3a-2100e3c591ad,C0040861,C0309872,will assist in ,Triage,PREVENT (product),1,X,[topp],[phsu],N02.421.297.900,
e9c597e6-fc47-43cf-a3de-cfcd0216d6ba,C0013227,C0009450,are used in patients with risk factors caused by ,Pharmaceutical Preparations,Communicable Diseases,1,X,[phsu],[dsyn],D26,C01.539.221
1f6c9fbb-a477-4dab-8559-b03253107b8c,C0022709,C0031843,has central ,Peptidyl-Dipeptidase A,physiological aspects,1,X,[aapp/enzy/imft],[phsf],D08.811.277.656.350.350.687,x.x.x.x
d58c0aab-d63f-4251-b76f-4d1f8d77ef5b,C0597357,C0031843,has central ,receptor,physiological aspects,1,X,[aapp/rcpt],[phsf],,x.x.x.x
0f2a6ddd-bf27-4ce1-890c-ce6e2d79c4a8,C0022709,C0876973,has physiological aspects During,Peptidyl-Dipeptidase A,Infectious Lung Disorder,2,X,[aapp/enzy/imft],[dsyn],D08.811.277.656.350.350.687,
6c7e6024-428f-4155-b799-967b2e3c7bf3,C0597357,C0876973,has physiological aspects During,receptor,Infectious Lung Disorder,2,X,[aapp/rcpt],[dsyn],,
ea8fd999-a96f-42fa-bd3d-dc6248d3ca47,C0597357,C0225698,has physiological aspects During,receptor,Alveolar Epithelial Cells,1,X,[aapp/rcpt],[cell],,A04.411.715.100;A11.436.081
bc5eba8d-ff19-474f-a114-92fd3d9e4bbf,C0003374,C3158557,impair ,Antimalarials,terminal glycosylation,1,X,[phsu],[moft],D27.505.954.122.250.100.085,
66621499-7dad-4954-b4e3-7ab3ba3c077b,C0055447,C3158557,impair ,chloroquine phosphate,terminal glycosylation,1,X,[orch/phsu],[moft],x.x.x.x,
f53f2589-4146-4d9d-9904-9ad8bef0b14c,C0003374,C0022709,impair terminal glycosylation without significant change,Antimalarials,Peptidyl-Dipeptidase A,2,X,[phsu],[aapp/enzy/imft],D27.505.954.122.250.100.085,D08.811.277.656.350.350.687
001995ed-a6b7-42aa-a29c-64aeabe73c5e,C0055447,C0022709,impair terminal glycosylation without significant change,chloroquine phosphate,Peptidyl-Dipeptidase A,2,X,[orch/phsu],[aapp/enzy/imft],x.x.x.x,D08.811.277.656.350.350.687
0fbd6abd-e015-4cdc-8fd9-57b9c8772ce5,C0003374,C0699040,impair terminal glycosylation without significant change,Antimalarials,Cell surface,1,X,[phsu],[celc],D27.505.954.122.250.100.085,
62b02ce3-77bb-4205-98ee-4581112673e2,C0055447,C0699040,impair terminal glycosylation without significant change,chloroquine phosphate,Cell surface,1,X,[orch/phsu],[celc],x.x.x.x,
6b07a3f4-4057-4973-9eec-35e9431c1fff,C0020336,C3158557,impair ,Hydroxychloroquine,terminal glycosylation,1,X,[orch/phsu],[moft],D03.633.100.810.050.180.350,
b749eb65-a0b6-45dd-9b6a-503b1e37baa2,C0020336,C0022709,impair terminal glycosylation without significant change,Hydroxychloroquine,Peptidyl-Dipeptidase A,2,X,[orch/phsu],[aapp/enzy/imft],D03.633.100.810.050.180.350,D08.811.277.656.350.350.687
7703680c-a779-4f4e-83e6-af28c5d0f013,C0020336,C0699040,impair terminal glycosylation without significant change,Hydroxychloroquine,Cell surface,1,X,[orch/phsu],[celc],D03.633.100.810.050.180.350,
b2d2c9f4-0367-4809-bd38-64a2a4f9dbef,C0003374,C0243077,might therefore might potent ,Antimalarials,inhibitors,1,X,[phsu],[chvf],D27.505.954.122.250.100.085,
7e3220f9-a0f3-4da1-8a6e-a2f89dd010f2,C0003374,C1175743,might therefore might potent ,Antimalarials,SARS coronavirus,1,X,[phsu],[virs],D27.505.954.122.250.100.085,B04.820.504.540.150.113.937
555569e8-4c14-47ea-91b7-ddd176007fe7,CQ,C3714514,completely PREVENT (product) in,CQ,Infection,1,X,????,[patf],????,C01.539
f64ed761-4173-4209-bf6c-4ab4b1e12fd2,CQ,C3463820,Starting ,CQ,Inhibition,1,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
f64ed761-4173-4209-bf6c-4ab4b1e12fd2,CQ,C3463820,was effective in ,CQ,Inhibition,2,X,????,[acty],????,F01.145.544;F02.463.425.475;F02.739.794.405
d9100445-73da-42ea-9f8a-7eff852188ab,CQ,C0032285,was effective in ,CQ,Pneumonia,2,X,????,[dsyn],????,C08.381.677;C08.730.610
d9100445-73da-42ea-9f8a-7eff852188ab,CQ,C0032285,could Theoretically could thus effectively used in treatment of ,CQ,Pneumonia,1,X,????,[dsyn],????,C08.381.677;C08.730.610
5e2de76e-0be6-40a5-b18e-c310f129be7b,CQ,C1175743,is in ,CQ,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
0251586e-2f93-4ed2-9bd2-15df822f00d2,C0020336,CQ,is more potent than CQ ,Hydroxychloroquine,CQ,1,X,[orch/phsu],????,D03.633.100.810.050.180.350,????
7d9c6d08-5044-4af9-a245-419f67e799d0,C0087111,C0042776,are based on previous experience with ,Therapeutic procedure,Virus,1,X,[topp],[virs],E02,B04
9e65f943-c93d-4b6d-a5fe-febff1cee315,C0310367,C0042776,are based on previous experience with ,Today,Virus,1,X,[antb/orch],[virs],,B04
3afccd60-865a-45b6-aa4e-c676daeacb45,C0310367,C1175743,are based on previous experience with ,Today,SARS coronavirus,2,X,[antb/orch],[virs],,B04.820.504.540.150.113.937
d05652d5-6680-4f2c-ae4b-cffd1f15e87d,C0054871,C1537068,is required for ,Cathepsin L,Virus Internalization,1,X,[aapp/enzy],[biof],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,G06.920.881
a7496d12-d11b-4db3-a471-d96b73e0f054,C0054871,C0221284,is required for ,Cathepsin L,Leptocyte,1,X,[aapp/enzy],[cell],D08.811.277.656.224.407;D08.811.277.656.262.500.157;D08.811.277.656.300.200.157,
dacfbe6c-92d0-4511-b389-faaa6c07428d,C0221284,C0042774,inhibits ,Leptocyte,Virus Replication,1,X,[cell],[celf],,G06.920.925
458a5216-a9ec-475f-b6ce-fe01988ee0a5,C0145106,C0042774,inhibits ,Teicoplanin,Virus Replication,1,X,[aapp/antb],[celf],D09.400.420.405.500;D12.644.233.352.500;x.x.x.x,G06.920.925
70caba2e-ec4a-4980-9c5b-b0aaac913c98,C0038164,C1167622,restricting ,Staphylococcal Protein A,Binding (Molecular Function),2,X,[aapp/imft/irda],[moft],D12.776.097.820;D23.050.161.821,
57dc27ab-0b99-46cd-9959-c560eb61e596,C1514798,C1167622,restricting ,Recombinants,Binding (Molecular Function),1,X,[orgm],[moft],,
ba64c004-fe7a-40f4-88cb-a49d574e6684,C0038164,C0206750,spread of ,Staphylococcal Protein A,Coronavirus Infections,4,X,[aapp/imft/irda],[dsyn],D12.776.097.820;D23.050.161.821,C02.782.600.550.200
762eb4e9-2979-473a-aaaf-19d8b143fb9b,C0020336,C1155266,decreases ,Hydroxychloroquine,inflammatory response,1,X,[orch/phsu],[patf],D03.633.100.810.050.180.350,
f0df2a0d-9391-40b2-a21b-09a99e6bae50,C2266933,C0874161, includes ,Neuraminidase Inhibitors [MoA],Oseltamivir,6,X,[moft],[orch/phsu],,D02.065.064.525;D02.455.426.392.368.367.379.500
3a0389ec-38d8-4d06-9caf-395014f10e88,C2266933,C1675326, includes ,Neuraminidase Inhibitors [MoA],peramivir,6,X,[moft],[orch/phsu],,x.x.x.x
33ef7a34-9cf8-4343-be5c-550b5df19133,C2266933,C0216660, includes ,Neuraminidase Inhibitors [MoA],Zanamivir,6,X,[moft],[orch/phsu],,D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775
102b8b1e-07ef-4522-af38-2eb2768a7a2d,C2266933,C0254211,has Antiviral Agents effect in combination with,Neuraminidase Inhibitors [MoA],arbidol,1,X,[moft],[orch/phsu],,x.x.x.x
fd87cd5c-b3b8-49e2-936f-08e539911e3b,C0874161,C0254211,has Antiviral Agents effect in combination with,Oseltamivir,arbidol,1,X,[orch/phsu],[orch/phsu],D02.065.064.525;D02.455.426.392.368.367.379.500,x.x.x.x
7ca2b085-8aa5-417c-b8a3-3ece34ff098f,C1675326,C0254211,has Antiviral Agents effect in combination with,peramivir,arbidol,1,X,[orch/phsu],[orch/phsu],x.x.x.x,x.x.x.x
a6e53a17-9235-46e2-b0d0-ff8e51fd457d,C0216660,C0254211,has Antiviral Agents effect in combination with,Zanamivir,arbidol,1,X,[orch/phsu],[orch/phsu],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,x.x.x.x
4c41a397-377b-4660-a16d-262e4f9e9385,C2266933,C0003451,has direct ,Neuraminidase Inhibitors [MoA],Antiviral Agents,1,X,[moft],[phsu],,D27.505.954.122.388
2333a5a0-d2fd-47a2-9de3-eba3f999b4e4,C0874161,C0003451,has direct ,Oseltamivir,Antiviral Agents,1,X,[orch/phsu],[phsu],D02.065.064.525;D02.455.426.392.368.367.379.500,D27.505.954.122.388
f028ff6e-26d0-4dc1-b590-461c0367b093,C1675326,C0003451,has direct ,peramivir,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
b7bd5501-2820-4bcf-8b57-25824643f10e,C0216660,C0003451,has direct ,Zanamivir,Antiviral Agents,1,X,[orch/phsu],[phsu],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,D27.505.954.122.388
166c1451-b25c-4547-9773-5767fb2254f8,C2266933,C0206750,be can useful for patients of ,Neuraminidase Inhibitors [MoA],Coronavirus Infections,1,X,[moft],[dsyn],,C02.782.600.550.200
f8d48782-0974-4e96-8301-f055d58d9e63,C0874161,C0206750,be can useful for patients of ,Oseltamivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.065.064.525;D02.455.426.392.368.367.379.500,C02.782.600.550.200
c9a195a1-965d-4178-9c01-95f3d9b0a233,C1675326,C0206750,be can useful for patients of ,peramivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],x.x.x.x,C02.782.600.550.200
fcff3c55-e0cd-469e-a129-2e021e34f966,C0216660,C0206750,be can useful for patients of ,Zanamivir,Coronavirus Infections,1,X,[orch/phsu],[dsyn],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,C02.782.600.550.200
e67512ba-0d36-49c3-b4b1-7369c6cfac37,C2266933,C0598312,has Antiviral Agents effect on early,Neuraminidase Inhibitors [MoA],DNA Replication,1,X,[moft],[genf],,G02.111.225;G05.226
96f7fa6d-40ee-4197-9c2a-62be7c545159,C2266933,C1175743,has Antiviral Agents effect on early,Neuraminidase Inhibitors [MoA],SARS coronavirus,1,X,[moft],[virs],,B04.820.504.540.150.113.937
d83211ea-a18b-4f42-a92a-0e160887e8c4,C0874161,C0598312,has Antiviral Agents effect on early,Oseltamivir,DNA Replication,1,X,[orch/phsu],[genf],D02.065.064.525;D02.455.426.392.368.367.379.500,G02.111.225;G05.226
56bc7481-1093-4686-bc37-eaef46a3a151,C1675326,C0598312,has Antiviral Agents effect on early,peramivir,DNA Replication,1,X,[orch/phsu],[genf],x.x.x.x,G02.111.225;G05.226
3058cdc8-4d91-4d9c-ae44-4864cabed660,C0216660,C0598312,has Antiviral Agents effect on early,Zanamivir,DNA Replication,1,X,[orch/phsu],[genf],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,G02.111.225;G05.226
97831fc0-7641-4f41-bd65-a6f6fed68020,C0874161,C1175743,has Antiviral Agents effect on early,Oseltamivir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.065.064.525;D02.455.426.392.368.367.379.500,B04.820.504.540.150.113.937
24d319ef-9cfb-47d8-b27c-81b0939f1392,C1675326,C1175743,has Antiviral Agents effect on early,peramivir,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
e1c9525f-2b9f-4b36-97db-982a4da87ee8,C0216660,C1175743,has Antiviral Agents effect on early,Zanamivir,SARS coronavirus,1,X,[orch/phsu],[virs],D02.078.370.926;D02.241.081.844.562.668.775;D02.241.511.902.562.668.775;D03.383.663.859;D09.067.687.668.775;D09.811.589.668.775,B04.820.504.540.150.113.937
9106a04a-71a4-4054-bb4c-98f531956ed4,remdesivir,C0037090,improves ,remdesivir,Signs and Symptoms Respiratory,1,X,[clnd],[sosy],,C23.888.852
98187e1a-167a-40d5-aee0-71067ad587b4,C0939237,C1175743,is in patients with ,lopinavir / Ritonavir,SARS coronavirus,1,X,[phsu],[virs],,B04.820.504.540.150.113.937
28824fd7-ecf4-40bf-88c3-fbceb006da28,C1138226,C0237820,increases clinical ,favipiravir,Recovery - action,1,X,[orch/phsu],[acty],x.x.x.x,
3cb64c54-6078-4926-9dc7-ca56af29e164,C1138226,C0003451,has stronger ,favipiravir,Antiviral Agents,1,X,[orch/phsu],[phsu],x.x.x.x,D27.505.954.122.388
e9795c43-2089-4c75-89c8-6153219a7fbe,C1138226,C0939237,has stronger ,favipiravir,lopinavir / Ritonavir,1,X,[orch/phsu],[phsu],x.x.x.x,
0d434d37-f9b4-48a5-801e-43c423f45b56,C3640049,C0020336,reducing Xyzinclude10 in ,Appropriate Treatment,Hydroxychloroquine,1,X,[clna],[orch/phsu],,D03.633.100.810.050.180.350
801c879b-facb-41d8-9422-d7113c67e4e0,C3640049,C1138226,reducing ,Appropriate Treatment,favipiravir,1,X,[clna],[orch/phsu],,x.x.x.x
72a40a06-6859-475a-b6ab-0407bec56a08,C3640049,C0003015,is currently ,Appropriate Treatment,Angiotensin-Converting Enzyme Inhibitors,1,X,[clna],[phsu],,D27.505.519.389.745.085
d7061df9-865c-4ec9-bb1e-58b7f6cdf95f,C1422064,C1167395,is ,ACE2 gene,Host (organism),1,X,[gngm],[orgm],,
cc777fcb-f988-40c5-a708-22ff3dc35d1f,C1422064,C0011334,is highest within sinonasal ,ACE2 gene,Dental caries,1,X,[gngm],[dsyn],,C07.793.720.210
0bae8d80-c9c5-41fe-949b-eecff65d8431,C1422064,C0819757,was found In ,ACE2 gene,Structure of parenchyma of lung,2,X,[gngm],[tisu],,
afc53813-b040-4686-ab76-35e1e79869c1,C1422064,C0699040,was found on apical ,ACE2 gene,Cell surface,2,X,[gngm],[celc],,
33f2347a-e50e-48bd-b0a5-20723318d322,C0270724,C0034991,consider specific ,Infantile Neuroaxonal Dystrophy,Rehabilitation therapy,1,X,[dsyn],[topp],C10.228.140.744,E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784
2a712838-7cbe-4245-a96c-0a9e4a4875b7,RT-PCR,C0439056,is in ,RT-PCR,Throat swab sample,1,X,????,[bdsu],????,
ecdf3632-db61-48b4-b2db-157aa1c60897,C1511790,C0439056,is in ,Detection,Throat swab sample,1,X,[topp],[bdsu],,
99217ec6-4bf8-4d95-86f6-b378cfe988d5,LDH,C0277562,are potential predictors of fatality in ,LDH,Adult disease,2,X,????,[dsyn],????,
6e64bbcd-3991-49df-9bb7-8ffd6ff4de3c,C0024264,C1707455,was significantly lower ,Lymphocyte,Comparison,1,X,[cell],[acty],A11.118.637.555.567;A15.145.229.637.555.567;A15.382.490.555.567,
b1ed2c92-c5e2-459f-9bc7-e2e0b9f4721d,C0474166,C0237820,are critical to ,Medical counseling,Recovery - action,2,X,[topp],[acty],,
39d5c061-a78d-420e-94aa-82bf10c23db5,C1704532,C0237820,are critical to ,Active Method,Recovery - action,1,X,[topp],[acty],,
fe604c4c-05bc-4ea7-9741-5f29ca2bddf9,C0330941,C0206750,treating ,Melia azedarach,Coronavirus Infections,1,X,[plnt],[dsyn],B01.650.940.800.575.912.250.715.500.500,C02.782.600.550.200
6a004329-7ff5-43c9-9a07-2bcab29a236a,C1414371,C0206750,treating ,ELAVL1 gene,Coronavirus Infections,1,X,[gngm],[dsyn],,C02.782.600.550.200
24293369-94e3-4b22-830c-aea06a8365ca,C0010837,C0206750,treating ,Cytoplasmic Granules,Coronavirus Infections,1,X,[celc],[dsyn],A11.284.430.214.190.500;A11.284.430.214.190.875.190.190,C02.782.600.550.200
59f15dd3-cd1b-40e3-b8a4-a034529fb37e,C5,C0039082,is with unrecognized respiratory ,C5,Syndrome,1,X,????,[dsyn],????,C23.550.288.500
790926e9-933c-4c7e-bea7-9a7710127787,C5,C0206750,is with unrecognized respiratory ,C5,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
67e23d1b-abae-443f-bf71-1682f9f7a52d,C0034991,C0242656,should consider effect on ,Rehabilitation therapy,Disease Progression,3,X,[topp],[patf],E02.760.169.063.500;E02.831;H02.403.680.600;N02.421.784,C23.550.291.656
acf7232f-0758-4768-b083-5e3450fef209,C0369768,C0019134,treatment with ,Molecular oxygen saturation,heparin,1,X,[moft],[bacs/orch/phsu],,D09.698.373.400
ce06d5bf-35cc-4f82-b729-33376494f9b7,C0184633,C0019134,of ENUMX2 is treatment with ,Oxygen Therapy Care,heparin,1,X,[topp],[bacs/orch/phsu],E02.880.690,D09.698.373.400
02896041-7765-48e2-b247-cd4eeb04a71b,C0674432,C0292818,is with ,lopinavir,Ritonavir,1,X,[orch/phsu],[orch/phsu],D03.383.742.698.553,D02.886.675.653;D03.383.129.708.653
0df2ec15-58a5-4c67-a86b-e79607227074,C2745965,C0027765,should During pandemic should acquainted with ,Emergencies [Disease/Finding],nervous system disorder,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C10
fda0b3c8-9480-407f-a056-16571c2a0eda,C0039082,CoV2,following CoV2 ,Syndrome,CoV2,1,X,[dsyn],????,C23.550.288.500,????
9626e00e-642c-49f9-8ef3-26900eba9a71,C0039082,C0009450,following CoV2 ,Syndrome,Communicable Diseases,1,X,[dsyn],[dsyn],C23.550.288.500,C01.539.221
1ad86522-610f-4d2e-827c-bbda2fdaa0ee,C1704259,C0087111,be targeted as ,Biochemical Pathway,Therapeutic procedure,1,X,[moft],[topp],,E02
efed437b-3157-44ab-b41c-850cc9d06ac0,C1175175,C0030755,is in ,Severe Acute Respiratory Syndrome,Pediatrics,1,X,[dsyn],[bmod],C02.782.600.550.200.750;C08.730.730,H02.403.670
b5655a49-81cc-438b-aa13-4a166c1746a0,C1706202,4th,were conducted in PubMed 4th,Search - action,4th,1,X,[acty],????,,????
4cd5d4c5-0706-4427-89f8-fc1f367b6d4a,C0220781,C0281169,suggested severe ,Anabolism,pulmonary complications,1,X,[biof],[patf],G03,
8bd0c34c-8657-49dd-b88a-37241f11df4a,PPE,COVID-19,could ,PPE,COVID-19,1,X,????,[virs],????,C000657245
5f829fd9-a9e0-40a1-a0af-a2d2fb49f590,PPE,C0184661,could ,PPE,Interventional procedure,1,X,????,[topp],????,
28ad4ffb-a31c-4951-adfb-c54ea66a2c62,TRPV4,C0034063,is protective in various preclinical models of ,TRPV4,Pulmonary Edema,1,X,????,[dsyn],????,C08.381.742
59c7db6f-234c-4af1-9331-4ef55bfa2ebf,C0029892,C0034019,are recommending higher level for aerosol-generating procedures than ,Otolaryngology specialty,public health medicine (field),1,X,[bmod],[bmod],H02.403.810.526,H02.403.720;N01.400.550;N06.850
8a4cae83-682b-4db3-9960-1867d7836b67,C0013804,C0038638,advanced energy devices open ,Electrocoagulation,Suction drainage,1,X,[topp],[topp],E02.154.402;E04.014.170.402,E04.237.890
13c0a0ad-3d32-49d3-a47e-c8b9f8331e14,C0013804,C0337279,advanced energy devices open ,Electrocoagulation,Drilling - action,1,X,[topp],[topp],E02.154.402;E04.014.170.402,
6b487bfb-8a75-49af-9e3d-1856dc25731a,hACE2,C1175743,enables Deploy for in-depth analysis following,hACE2,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
c159a3a6-8078-4cd2-a747-51e7a480bd1b,C1564874,C1175743,enables Deploy for in-depth analysis following,Adeno-Associated Virus,SARS coronavirus,1,X,[virs],[virs],B04.280.580.650.170,B04.820.504.540.150.113.937
98e5329f-266b-4463-a569-094df91c0ba8,C2986594,C1175743,enables Deploy for in-depth analysis following,Mouse Model,SARS coronavirus,1,X,[emod],[virs],,B04.820.504.540.150.113.937
e7cd233c-8049-40e8-8b0a-deebc2529ec4,hACE2,C0206750,enables Deploy for in-depth analysis following,hACE2,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
1b089f0e-131a-4bc0-b4a6-3cc7ec276129,C1564874,C0206750,enables Deploy for in-depth analysis following,Adeno-Associated Virus,Coronavirus Infections,1,X,[virs],[dsyn],B04.280.580.650.170,C02.782.600.550.200
9997c55a-28f6-4656-8aa8-c0638148dc6f,C2986594,C0206750,enables Deploy for in-depth analysis following,Mouse Model,Coronavirus Infections,1,X,[emod],[dsyn],,C02.782.600.550.200
2a27fa07-84db-48e4-aa0a-860aa5a75fbd,C1175743,C0026809,is in ,SARS coronavirus,Mus,2,X,[virs],[mamm],B04.820.504.540.150.113.937,B01.050.150.900.649.313.992.635.505.500
07a1db7c-832e-435d-9bb6-e17200364788,C0007590,C0225336,is in ,Cell division,Endothelial Cells,2,X,[celf],[cell],G04.144.220;G04.161.750.500;G05.113;G07.345.249.410.750.500,A11.436.275
7e58a7a5-dce3-4218-8e20-b098826157a3,C0870883,C0019169,prevents ,Metabolite,Hepatitis B Virus,1,X,[bacs],[virs],,B04.280.375.650.425;B04.450.390.650.425
dc17ea06-6811-4da9-a55b-62871e7048f8,C0870883,C0598312,prevents ,Metabolite,DNA Replication,2,X,[bacs],[genf],,G02.111.225;G05.226
589f2fd4-8c42-4a84-b191-40d29ba30995,C0870883,C0029347,prevents ,Metabolite,Influenza A virus,1,X,[bacs],[virs],,B04.820.545.405.400
170a08e9-7d46-4bc6-80a1-436adead5b01,C0073177,C1175743,suggesting rhein as potential therapeutic agent for treatment of,rhein,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
170a08e9-7d46-4bc6-80a1-436adead5b01,C0073177,C1175743,inhibits ,rhein,SARS coronavirus,2,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
bdf3d846-5345-47e3-92f1-22aa93659178,C0073177,C4281807,inhibits ,rhein,Vitronectin human,4,X,[orch/phsu],[aapp/bacs],x.x.x.x,
32c838e4-dc07-4cc7-b243-6ec8bbeeb7c7,C0206750,C0018787, includes ,Coronavirus Infections,Heart,1,X,[dsyn],[bpoc],C02.782.600.550.200,A07.541
6ee6c2c7-06ab-40a3-a471-11f9e67b896c,C0206750,C0023884, includes ,Coronavirus Infections,Liver,1,X,[dsyn],[bpoc],C02.782.600.550.200,A03.620
d971bac3-eded-4279-8f71-4ed5d23d4ae8,C0206750,C0006104, includes ,Coronavirus Infections,Brain,1,X,[dsyn],[bpoc],C02.782.600.550.200,A08.186.211
73cb8f61-d766-43aa-a99a-346a357a4397,C0684336,C0206750,have have reported in ,Impaired health,Coronavirus Infections,1,X,[patf],[dsyn],,C02.782.600.550.200
f0233694-eddd-4479-acf7-a8c10668de46,COVID-19,C0015733,is with positive long-term ,COVID-19,Feces,1,X,[virs],[bdsu],C000657245,A12.459
09f9d4ef-1cbf-4353-afa4-9350e87d87ed,COVID-19,C0028606,is with positive long-term ,COVID-19,Nucleic Acids,1,X,[virs],[bacs/nnon],C000657245,D13.444
cbe0a48d-ec50-4d9e-96c9-3927636d6f7d,C1856053,C0035242,patients with negative ,Hydranencephaly with Renal Aplasia-Dysplasia,Respiratory Tract Diseases,1,X,[dsyn],[dsyn],x.x.x.x,C08
397be9f3-6f59-41d4-9483-6b9a17f97ecc,C1856053,C0028606,patients with negative ,Hydranencephaly with Renal Aplasia-Dysplasia,Nucleic Acids,1,X,[dsyn],[bacs/nnon],x.x.x.x,D13.444
7ee1dedb-3669-4e9e-87f9-eebdd2105a79,C0206750,C0035242,is with negative ,Coronavirus Infections,Respiratory Tract Diseases,1,X,[dsyn],[dsyn],C02.782.600.550.200,C08
0776e371-91f4-4d6f-a199-1caff60db0cd,RT-PCR,C0015733,continuously detect ,RT-PCR,Feces,1,X,????,[bdsu],????,A12.459
0776e371-91f4-4d6f-a199-1caff60db0cd,RT-PCR,C0015733,had results in their ,RT-PCR,Feces,1,X,????,[bdsu],????,A12.459
44371d78-2feb-49f2-baf4-344b0af33bbf,RT-PCR,C0028606,detect ,RT-PCR,Nucleic Acids,2,X,????,[bacs/nnon],????,D13.444
e5384fc6-467e-455b-882a-c20a520c2164,C2754997,7th,was detected on 7th ,IgM immunoglobulin complex circulating,7th,1,X,[celc],????,,????
f98a0a03-3bef-4e73-a261-3103e7b6f026,C0206750,C0229671,have higher ,Coronavirus Infections,Serum,1,X,[dsyn],[bdsu],C02.782.600.550.200,A12.207.152.846;A15.145.846
f98a0a03-3bef-4e73-a261-3103e7b6f026,C0206750,C0229671,are characterized by ,Coronavirus Infections,Serum,1,X,[dsyn],[bdsu],C02.782.600.550.200,A12.207.152.846;A15.145.846
b8e7ff02-cc18-4015-a226-1dbb3924c295,C0085295,C0012634,can Among them can used as predictors for fast diagnosis of patients with higher risk of ,Interleukin-10,Disease,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C23.550.288
d6c36834-3910-4e09-a794-fb775ecc25ec,C0940933,C0206750,is with ,infection as a complication,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
a7a063f0-648d-4f4d-bbe0-8726f5b14237,C0032326,C0206750,is in patient with ,Pneumothorax,Coronavirus Infections,1,X,[dsyn],[dsyn],C08.528.778,C02.782.600.550.200
62c6763e-d580-4f6e-a31f-aed92dc2fb53,C0206750,C0184661,reassessed infection risks involved in ,Coronavirus Infections,Interventional procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
62c6763e-d580-4f6e-a31f-aed92dc2fb53,C0206750,C0184661,affect operations of ,Coronavirus Infections,Interventional procedure,1,X,[dsyn],[topp],C02.782.600.550.200,
d839bea3-4634-48fb-9acc-d158e6189263,C0060520,C0233929,demonstrate reduction in aerosol ,Fluorescein,Emission - Male genitalia finding,1,X,[irda/orch/phsu],[bdsu],D02.455.426.779.347.390;D03.633.300.953.275.390;D04.711.347.390,
b3978792-80fe-4f5b-9bc7-21860fe04192,C1175175,C4284302,were In ,Severe Acute Respiratory Syndrome,EHD1 wt Allele,1,X,[dsyn],[gngm],C02.782.600.550.200.750;C08.730.730,
29f3f42b-adc1-42f7-8e16-62b0d878a0be,C1175175,C0206419,were In ,Severe Acute Respiratory Syndrome,Genus: Coronavirus,1,X,[dsyn],[virs],C02.782.600.550.200.750;C08.730.730,B04.820.504.540.150
d1051fa6-361a-481f-bb73-2b2c0a6a832c,C0272178,C0206750,may favour ,Drug-induced neutropenia,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
74b62d05-4400-4893-bb87-23397952eea8,C1334043,C0020538,have have mostly associated with ,Homologous Gene,Hypertensive disease,1,X,[gngm],[dsyn],,C14.907.489
356266e8-3abc-47f5-bc68-3948c8b369ea,C0042776,C0033684,exploit ,Virus,Proteins,1,X,[virs],[aapp/bacs],B04,D12.776
1f493797-7724-4ffd-8262-aaabd4c593ea,C1175743,C0683278,has caused tremendous ,SARS coronavirus,Mental Suffering,1,X,[virs],[mobd],B04.820.504.540.150.113.937,F01.145.126.990;F02.830.900
ed22886d-69e8-4860-ace2-4d32a1abf868,C0012634,C0683278,has caused tremendous ,Disease,Mental Suffering,1,X,[dsyn],[mobd],C23.550.288,F01.145.126.990;F02.830.900
15d409f5-9321-45c5-904f-227416892ad8,C0042798,C0206750,is in major hotspots of ,Low Vision,Coronavirus Infections,2,X,[dsyn],[dsyn],C10.597.751.941.905;C11.966.905;C23.888.592.763.941.848,C02.782.600.550.200
cdd34e10-8a60-4207-9e17-564294bc26ab,C1856053,C1096155,may may attributed to ,Hydranencephaly with Renal Aplasia-Dysplasia,Macrophage Activation Syndrome,1,X,[dsyn],[dsyn],x.x.x.x,C20.683.515.800
806a03e3-a34f-4a5f-946d-667fc478c978,C0035685,C1268456,Viral Components in,RNA-Directed RNA Polymerase,Viral Components,1,X,[aapp/enzy],[celc],D08.811.913.696.445.735.780,A21
57fb9ffd-7eae-4607-9c7e-c9e827410943,C0035685,C0598312,Viral Components in,RNA-Directed RNA Polymerase,DNA Replication,1,X,[aapp/enzy],[genf],D08.811.913.696.445.735.780,G02.111.225;G05.226
bbc3a852-b005-4edb-9b35-68c6c835b3bc,C1268456,C0598312,is in ,Viral Components,DNA Replication,1,X,[celc],[genf],A21,G02.111.225;G05.226
044d674a-343d-47d8-9b38-f61497f646e2,C1167622,C1152412,poses of three viral ,Binding (Molecular Function),RNA-directed RNA polymerase activity,1,X,[moft],[genf],,
b1111c72-4122-408c-ace0-892a0dcea346,C1167622,C0243077,poses of three viral ,Binding (Molecular Function),inhibitors,1,X,[moft],[chvf],,
633b2d0d-2716-41a8-9ca3-9659c3c6feb1,C1167622,C4519187,poses of ,Binding (Molecular Function),Galidesivir,1,X,[moft],[orch/phsu],,
8c390eae-0c25-4caf-afbc-21210f1e1c93,C1167622,C1138226,poses of ,Binding (Molecular Function),favipiravir,1,X,[moft],[orch/phsu],,x.x.x.x
6d9b379e-c5a0-445c-99c7-caefdb3e01e7,C1167622,C0164815,poses of ,Binding (Molecular Function),penciclovir,1,X,[moft],[nnon/phsu],,x.x.x.x
658a8628-6c6a-4d38-8ef7-bc3d277eb293,C1405301,C0032374,can can caused by ,Poliomyelitis paralytic,Poliovirus Vaccines,2,X,[dsyn],[imft/orch/phsu],,D20.215.894.899.623
109cb840-a6eb-461e-b5c4-4f73f03e3dff,C0032375,C0005775,reverts following prolonged ,Oral Poliovirus Vaccine,Blood Circulation,1,X,[imft/orch/phsu],[phsf],D20.215.894.899.623.750,G09.330.100
2b09554d-121c-4d39-9629-c6b737e8910d,C0042776,C0005775,reverts following prolonged ,Virus,Blood Circulation,1,X,[virs],[phsf],B04,G09.330.100
7fe08541-68f9-4376-bead-6117c08bf165,C2349954,C1706374,is in ,Withdraw (activity),Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
d57ed26f-80fe-4982-a696-388c180ed268,C0206750,C0032371,resume ,Coronavirus Infections,Poliomyelitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
f64c1624-4c43-4b84-8378-e01af45de8f7,C2745965,C0032371,resume ,Emergencies [Disease/Finding],Poliomyelitis,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C02.782.687.359.764;C10.228.228.618.750;C10.228.854.525.850;C10.668.864
9166bfd2-3c5a-448a-b264-eab0d7a76b32,C2745965,C0441655,resume ,Emergencies [Disease/Finding],Activities,1,X,[patf],[acty],C23.550.291.781;N06.230.100.083;N06.850.376,
0e414880-b9e5-41e9-a47b-63aceacafffd,C0026882,C2806453,improved expression of ,Mutation,Betacoronavirus,1,X,[genf],[virs],G05.365.590,B04.820.504.540.150.113
4d0c2a71-76f1-4791-a093-2cf88cf36f3f,C0026882,C0700271,improved expression of ,Mutation,M Protein multiple myeloma,1,X,[genf],[aapp/imft],G05.365.590,x.x.x.x
99a50c9f-7c7c-4d38-9d87-72e4107f4f68,C1175175,C1518420,is in ,Severe Acute Respiratory Syndrome,Mouse Nose,1,X,[dsyn],[tisu],C02.782.600.550.200.750;C08.730.730,
554a0311-9ae5-41b1-8383-219d33b5003a,C0035696,C1175175,protects against ,RNA Messenger,Severe Acute Respiratory Syndrome,1,X,[bacs/nnon],[dsyn],D13.444.735.544,C02.782.600.550.200.750;C08.730.730
ea64108f-f59e-416d-811e-78c66cd0577f,C1516048,C1510711,provide answers about safety of ,Assessed,Abdominal Surgical Procedure,1,X,[acty],[topp],,
834c2d09-de86-4ab3-a569-aacf4da31898,C0459914,C0206750,dedicate reusable laparoscopic instrumentation to ,Conservative Treatment,Coronavirus Infections,1,X,[topp],[dsyn],E02.197,C02.782.600.550.200
685afcb4-ce62-43e3-bbcf-960171bcf145,C0459914,C1185738,dedicate ,Conservative Treatment,Column (anatomic),1,X,[topp],[bpoc],E02.197,
616f60a4-cf7b-4c2c-9b57-c4fe316a374b,C1185738,C0206750,reusable instrumentation to ,Column (anatomic),Coronavirus Infections,1,X,[bpoc],[dsyn],,C02.782.600.550.200
fe62884f-b281-49b7-a33d-812902f3eca6,C2349954,C0010076,is feasible In certain ,Withdraw (activity),Coronaviridae,2,X,[acty],[virs],,B04.820.504.540
29338407-70bb-45c8-9d95-c8747de7abec,C2349954,C0012634,is feasible In certain ,Withdraw (activity),Disease,2,X,[acty],[dsyn],,C23.550.288
760075c8-8fe2-43a4-b29d-30b0bc354711,C0700781,C1175175,be effective in therapy of ,Panavir,Severe Acute Respiratory Syndrome,1,X,[orch/phsu],[dsyn],D02.455.426.559.389.657.746,C02.782.600.550.200.750;C08.730.730
8a1ef8a1-bf17-42da-a93f-df4eb177371d,C1101610,C3272452,are evolutionally conserved ,MicroRNAs,Single-Stranded RNA,1,X,[bacs/nnon],[nnon],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,
bb9e4300-9aa8-46e2-93a5-2d5be61c474c,C1101610,C0017337,regulate ,MicroRNAs,Genes,1,X,[bacs/nnon],[gngm],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G05.360.340.024.340
b7459999-6361-4a9c-9533-ced848e14d2a,C1101610,C3714634,are key players in variety of ,MicroRNAs,Biological Processes,1,X,[bacs/nnon],[biof],D13.150.650.319;D13.444.735.150.319;D13.444.735.790.552.500,G16
b714e6f8-3b19-496b-a2f9-7b2bc359c185,C3714634,C0007589,regulate ,Biological Processes,Cell Differentiation process,1,X,[biof],[celf],G16,G04.152
c566ebc8-66ab-472e-8c04-b5f31c5808fb,C3714634,C1155000,regulate ,Biological Processes,Immune Cell Activation Process,1,X,[biof],[celf],G16,
301963ab-347b-4f54-9e22-6d4864b5d170,C0206750,C0022661,significant threat to immunocompromised patients with ,Coronavirus Infections,Kidney Failure Chronic,2,X,[dsyn],[dsyn],C02.782.600.550.200,C12.777.419.780.750.500;C13.351.968.419.780.750.500
56374667-32e2-4e98-bd84-13559ea416d5,C0015967,C0159028,are most prevalent ,Fever,General symptom,1,X,[sosy],[sosy],C23.888.119.344,
e85c2f50-695d-40a4-9abf-c534190dc256,C0017102,C1175743,is suggested as beneficial preventive measure infected with ,Allium sativum,SARS coronavirus,2,X,[plnt],[virs],B01.650.940.800.575.912.250.618.100.050.060.300,B04.820.504.540.150.113.937
5d5d6629-0963-4a06-a2b5-0f442494f3fd,C0017102,C2717755,is ,Allium sativum,Functional Food,1,X,[plnt],[food],B01.650.940.800.575.912.250.618.100.050.060.300,G07.203.300.572;J02.500.572
04f62d14-a571-426c-8015-33ecabd42764,C0206750,C0598197,is including highly ,Coronavirus Infections,contagion,1,X,[dsyn],[npop],C02.782.600.550.200,
0fde5e1e-ad50-408e-98fd-56f56b6a03e5,C0030858,C0598197,were summarized including highly ,Pentaerythritol Tetranitrate,contagion,2,X,[orch/phsu],[npop],D02.033.455.706.690,
3e214f93-ac74-4e50-b3a5-83ff022bcc2c,C0206750,C0679247,is in ,Coronavirus Infections,Terminal illness,1,X,[dsyn],[dsyn],C02.782.600.550.200,
eb2fd5f5-bde6-420d-8c39-85d04e7b643b,livedo,C0027540,urticarial lesions ,livedo,Necrosis,1,X,????,[ortf],????,C23.550.717;G04.146.638
eb2fd5f5-bde6-420d-8c39-85d04e7b643b,livedo,C0027540,maculopapular eruptions ,livedo,Necrosis,1,X,????,[ortf],????,C23.550.717;G04.146.638
e14af4a2-c29a-4e83-bbff-b0ddcbd77a5b,C2948600,C2366913,is ,Aim,condition assessments,1,X,[inch/phsu],[topp],,
68c45340-a546-4a64-aea7-d697edcc271c,C0012634,C0242656,has heterogenous ,Disease,Disease Progression,1,X,[dsyn],[patf],C23.550.288,C23.550.291.656
1cdce443-5662-4177-8381-1c0e5e793ff2,C1096155,C4054044,also known as ,Macrophage Activation Syndrome,Secondary Hemophagocytic Lymphohistiocytosis,1,X,[dsyn],[dsyn],C20.683.515.800,
b6ec983e-431f-44e6-a85a-10293f202db0,C1096155,C0079189,resulting in ,Macrophage Activation Syndrome,cytokine,2,X,[dsyn],[aapp/imft],C20.683.515.800,D12.644.276.374;D12.776.467.374;D23.529.374
5e0d2b7d-cf45-4997-b02a-713afb965363,C1096155,C1861452,resulting in ,Macrophage Activation Syndrome,Storm Syndrome,2,X,[dsyn],[dsyn],C20.683.515.800,x.x.x.x
4710071b-2915-4aa9-887a-bd53d79a5a2a,C0026882,C0960756,may also constitute ,Mutation,factor A,2,X,[genf],[orch],G05.365.590,x.x.x.x
925642e3-58b5-4b8b-93b6-898fcd3f82ad,C0026882,C0206750,may constitute factor A risk factor A in,Mutation,Coronavirus Infections,1,X,[genf],[dsyn],G05.365.590,C02.782.600.550.200
81e0086c-525a-491a-9725-689dedfe0837,C0003191,C0008269,will will also discussed including ,Antirheumatic Agents,Chloroquine,1,X,[phsu],[orch/phsu],D27.505.954.329,D03.633.100.810.050.180
a9e6e1a9-92a3-4e38-b633-fdc842550161,C0003191,C0544688,managing immunologic ,Antirheumatic Agents,complication of disease,1,X,[phsu],[patf],D27.505.954.329,
148db2cc-ff65-4533-b563-4198f66d169b,C0003191,C0206750,managing immunologic ,Antirheumatic Agents,Coronavirus Infections,1,X,[phsu],[dsyn],D27.505.954.329,C02.782.600.550.200
46cf3248-de95-479c-aa4e-255e3f6a7c81,C0003191,C0009450,managing immunologic ,Antirheumatic Agents,Communicable Diseases,1,X,[phsu],[dsyn],D27.505.954.329,C01.539.221
21e9e2d8-185a-4427-bc94-4b1d5da68c55,C0679861,C0206750,will decrease morbidity in ,Complications of treatment,Coronavirus Infections,2,X,[patf],[dsyn],,C02.782.600.550.200
412feff0-2b95-404d-b476-093bc71e179a,C0679861,C0009450,will decrease morbidity in ,Complications of treatment,Communicable Diseases,2,X,[patf],[dsyn],,C01.539.221
9b278087-1eb5-419e-8006-e26323ca7b13,CHAS,C2728259,implement telehospice ,CHAS,Program,1,X,????,[orch/phsu],????,V02.355.750
0cc270bf-7b89-4244-a714-332f5af43cd5,C0034019,C1856053,began investigation on ,public health medicine (field),Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[bmod],[dsyn],H02.403.720;N01.400.550;N06.850,x.x.x.x
d38903b5-f422-4386-843b-accf6693e482,C0939237,abidol,combined with abidol,lopinavir / Ritonavir,abidol,1,X,[phsu],????,,????
ca5f0526-1195-4888-ab8a-cc9412f89467,C0036974,C0079189,were usually caused by ,Shock,cytokine,1,X,[patf],[aapp/imft],C23.550.835,D12.644.276.374;D12.776.467.374;D23.529.374
3d7c20ce-e0fa-47f7-a389-2d38ce864cdf,C0525033,C0022938, includes ,Probiotics,Lactobacillus,2,X,[bact],[bact],G07.203.300.456.500;J02.500.456.500,B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475
b9a79c5e-7379-47ca-9342-cb9c6ba2ffd2,C4287543,C0525033,is with decreased ,Intestinal dysbiosis,Probiotics,2,X,[sosy],[bact],,G07.203.300.456.500;J02.500.456.500
6096776d-e7ed-46e1-8e40-f6ba5ad409be,C4287543,C0022938,is with decreased ,Intestinal dysbiosis,Lactobacillus,2,X,[sosy],[bact],,B03.353.750.450.475;B03.510.460.400.410.475.475;B03.510.550.450.475
94695d89-820c-47f0-a647-0ad412201ff6,C0027950,C0024109,patients with severe critical ,neutrophil,Lung,2,X,[cell],[bpoc],A11.118.637.415.583;A11.627.340.583;A11.733.689;A15.145.229.637.415.583;A15.382.490.315.583;A15.382.680.689,A04.411
2f357a54-d43a-4bbe-947f-b55aa804beea,C3665444,C0221423,emerged ,Neutrophilia (disorder),Illness (finding),1,X,[dsyn],[sosy],,
5052e5e1-e705-4e72-bdb6-ddf5b8924851,C0009830,C0024109,is in damaged ,Consumption of goods,Lung,2,X,[acty],[bpoc],,A04.411
70a92908-37f3-4560-a295-6dcf2a564d67,C0040034,C0009830,was resulting from ,Thrombocytopenia,Consumption of goods,2,X,[dsyn],[acty],C15.378.140.855,
23f910ef-02d7-49c3-bc05-9920372f95b3,C0040034,C0024109,was resulting from ,Thrombocytopenia,Lung,2,X,[dsyn],[bpoc],C15.378.140.855,A04.411
b33fa1af-234b-4ee2-9b2a-cd5cecdfc109,C1155075,C0024109,aggravates immune damage of ,monocyte activation,Lung,2,X,[celf],[bpoc],,A04.411
28f8f287-90c7-42ce-a6ab-33e154a8e1cf,C0040300,C0596448,leads to increase of D ,Body tissue,dimer,2,X,[tisu],[chvs],A10,
da7fb103-0170-4457-b527-5132d17c4fb0,C0024312,C0035222,followed by ,Lymphopenia,Respiratory Distress Syndrome Adult,1,X,[dsyn],[dsyn],C15.378.553.546.605;C20.673.627,C08.381.840;C08.618.840
408f63af-0bad-4abf-b888-e876f87e9264,C0021368,C0035222,followed by ,Inflammation,Respiratory Distress Syndrome Adult,1,X,[patf],[dsyn],C23.550.470,C08.381.840;C08.618.840
1503c0ba-3a88-4844-b7a4-3eca112557c3,C0155765,C0206750,been has reported in patients with severe ,Disease of capillaries,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
bc644d0c-182d-4c9e-9435-8b1fbfd681f1,C0206750,C0751571,is impacting ,Coronavirus Infections,Cancer of Urinary Tract,2,X,[dsyn],[neop],C02.782.600.550.200,C04.588.945.947;C12.758.820;C13.351.937.820
0f03097d-8399-4beb-950e-31410e742e55,C1880022,C0034019,further understand ,Characterization,public health medicine (field),1,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
0f399bdc-9bb3-42a5-b6b6-e6abf8088217,C1880022,C0699748,further understand its ,Characterization,Pathogenesis,1,X,[acty],[patf],,
8b2d68fe-a49b-4674-9085-258d49b30e96,C1880022,C0242781,further understand ,Characterization,disease transmission,1,X,[acty],[patf],,N06.850.310
a8e49492-2b92-4001-b5ba-96dbca194107,C0458827,C1262020,is with ,Airway structure,diffuse alveolar damage,1,X,[bpoc],[dsyn],,
86588946-8b50-4812-8a83-79f91d724859,C0458827,C0214743,are modulated by ,Airway structure,Interleukin-13,1,X,[bpoc],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
6e0b9e36-bf08-44c9-98ac-81f1f7032e81,C0014597,C0214743,are modulated by ,Epithelial Cells,Interleukin-13,1,X,[cell],[aapp/imft],A11.436,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
e996ed3e-7ac9-44bc-98a0-7aaeb5abbd39,C0185117,C0214743,are modulated by ,Expression procedure,Interleukin-13,1,X,[topp],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
56a3b641-5f3f-40a7-af8b-802c8dd09d23,C2948600,C0214743,extend our work in ,Aim,Interleukin-13,1,X,[inch/phsu],[aapp/imft],,D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513
9abaf496-2de8-414e-8ff4-05cf85211c6d,C2948600,C0005532,extend our work in ,Aim,biology (field),1,X,[inch/phsu],[bmod],,H01.158.273
828ddda4-863d-4d3e-8a4f-8faf2611bfc5,C0022709,C0458827,is in primary ,Peptidyl-Dipeptidase A,Airway structure,2,X,[aapp/enzy/imft],[bpoc],D08.811.277.656.350.350.687,
61168722-aa9a-42b7-83f5-8b137b935b96,C1742865,C0458827,is in ,TMPRSS2 protein human,Airway structure,1,X,[aapp/enzy],[bpoc],x.x.x.x,
19acda24-51f8-4c92-aa36-9fc29463e26b,C0185117,C0458827,is in ,Expression procedure,Airway structure,1,X,[topp],[bpoc],,
8696c324-3441-40ff-a36b-759c3920960e,exvivo,C0458827,is in ,exvivo,Airway structure,1,X,????,[bpoc],????,
1332b460-16bf-4839-8e95-25944e9cfee5,C1742865,C0014597,was increased in nasal ,TMPRSS2 protein human,Epithelial Cells,3,X,[aapp/enzy],[cell],x.x.x.x,A11.436
0ce3c505-1d2e-4d03-ae64-41352331c87c,C0185117,C0014597,was increased in nasal ,Expression procedure,Epithelial Cells,3,X,[topp],[cell],,A11.436
f48fe311-6be7-42af-815a-080a98886e08,exvivo,C0014597,is in ,exvivo,Epithelial Cells,1,X,????,[cell],????,A11.436
b7a33706-260a-4c5f-bab1-6037c6409b96,C1742865,C0004096,was increased in nasal ,TMPRSS2 protein human,Asthma,1,X,[aapp/enzy],[dsyn],x.x.x.x,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
c071c65d-3b44-4dab-b024-18aaa6d71440,C0185117,C0004096,was increased in nasal ,Expression procedure,Asthma,1,X,[topp],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
ba3b4712-41c4-4115-aa99-19e013e3c6b7,C0014597,C0004096,is in ,Epithelial Cells,Asthma,2,X,[cell],[dsyn],A11.436,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
db89d714-8580-477e-a0e8-641f4cf562cd,C1742865,C0079189,was positively associated with type ,TMPRSS2 protein human,cytokine,1,X,[aapp/enzy],[aapp/imft],x.x.x.x,D12.644.276.374;D12.776.467.374;D23.529.374
e9a41d10-8022-40c4-a727-45c440e0bc40,C0185117,C0079189,was positively associated with type ,Expression procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
e9a41d10-8022-40c4-a727-45c440e0bc40,C0185117,C0079189,was significantly negatively associated with type ,Expression procedure,cytokine,1,X,[topp],[aapp/imft],,D12.644.276.374;D12.776.467.374;D23.529.374
5357967d-2398-48ee-aa70-9cfc9ef152f7,C0214743,C0458827,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Airway structure,1,X,[aapp/imft],[bpoc],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,
72989925-ba44-4627-90a9-f124a54f7585,C0214743,C0014597,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Epithelial Cells,1,X,[aapp/imft],[cell],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,A11.436
10f00e99-8f4e-4c14-b057-466ac5e56eda,C0214743,C0004096,modulates Peptidyl-Dipeptidase A Expression procedure in,Interleukin-13,Asthma,1,X,[aapp/imft],[dsyn],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
056ea80a-ca11-4b5e-99fc-25819db628c2,C0214743,C0022709,modulates ,Interleukin-13,Peptidyl-Dipeptidase A,1,X,[aapp/imft],[aapp/enzy/imft],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,D08.811.277.656.350.350.687
f7874c5d-3d7a-47be-a8b3-d7827aebd186,C0214743,C0185117,modulates ,Interleukin-13,Expression procedure,1,X,[aapp/imft],[topp],D12.644.276.374.465.513;D12.776.467.374.465.513;D23.529.374.465.513,
ee5653c4-d80c-418d-8d77-997089a4792d,C0458827,C0004096,is in ,Airway structure,Asthma,1,X,[bpoc],[dsyn],,C08.127.108;C08.381.495.108;C08.674.095;C20.543.480.680.095
9da0de95-fae9-4477-ac9f-102003e394ba,C0016452,C0206750,is in ,Food,Coronavirus Infections,1,X,[food],[dsyn],G07.203.300;J02.500,C02.782.600.550.200
d124213b-0b40-47c1-8e2a-7a9460df823a,C0016452,C0242781,is in ,Food,disease transmission,1,X,[food],[patf],G07.203.300;J02.500,N06.850.310
05592097-5514-406b-b96c-e69260b098df,C0015967,C1948029,can facilitate ,Fever,Destruction (action),1,X,[sosy],[acty],C23.888.119.344,
b0588679-f876-4d1b-a7a8-e3dbd7e0a4ba,C0038817,C1948029,can facilitate ,Sunlight,Destruction (action),1,X,[npop],[acty],G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525,
18cb7780-3c9c-45ab-b2b0-ef358b5a974c,C0038817,C1175743,can facilitate ,Sunlight,SARS coronavirus,1,X,[npop],[virs],G01.358.500.505.650.836;G01.750.250.650.836;G01.750.770.578.836;G16.500.275.063.725.525;G16.500.750.775.525;N06.230.300.100.725.525,B04.820.504.540.150.113.937
f7b7f377-0fe2-4368-aee5-3b80c6d7e5de,C0185117,C0040300,is in ,Expression procedure,Body tissue,1,X,[topp],[tisu],,A10
a8f0308a-ece9-4974-8970-142f6b9a9739,COVID-19,C0030755,presented to tertiary ,COVID-19,Pediatrics,2,X,[virs],[bmod],C000657245,H02.403.670
fa2ddb4b-5b53-4687-b0bc-e20cb2721340,C0011071,C0014544,is in ,Sudden death,Epilepsy,1,X,[patf],[dsyn],C23.550.260.322,C10.228.140.490
0b35ba61-2b03-47fc-9f65-0d4d8ec8638b,C1515884,COVID-19,can cure ,Acupuncture and Oriental Medicine,COVID-19,1,X,[topp],[virs],,C000657245
d87e903a-5ae4-4945-9e46-acc98f8808ee,C1515884,C0032285,can cure ,Acupuncture and Oriental Medicine,Pneumonia,1,X,[topp],[dsyn],,C08.381.677;C08.730.610
4fc76570-6618-407f-96f2-f76c1b637f24,C1145670,C1175743,is with ,Respiratory Failure,SARS coronavirus,1,X,[dsyn],[virs],C08.618.846,B04.820.504.540.150.113.937
202d2d64-4d81-4be6-bc32-f45886a22dab,C0003451,C0012634,are are given empirically to patients with ,Antiviral Agents,Disease,1,X,[phsu],[dsyn],D27.505.954.122.388,C23.550.288
741b5a4b-ed6d-42aa-9ebf-fecd68b13dcc,C0278996,COVID-19,is in ,Malignant Head and Neck Neoplasm,COVID-19,1,X,[neop],[virs],,C000657245
8d1df9a0-7b36-4475-a555-46a5791ce49f,C0020336,C0598312,have shown in activity on ,Hydroxychloroquine,DNA Replication,1,X,[orch/phsu],[genf],D03.633.100.810.050.180.350,G02.111.225;G05.226
19ad83b8-81b5-43b7-a538-7c911094f9c8,C0008269,C1708476,has yielded to ,Chloroquine,Implementation,1,X,[orch/phsu],[acty],D03.633.100.810.050.180,
fca2c7ea-2509-4f5d-8cfb-942acf868730,C2239453,C1708476,has yielded to ,FICD gene,Implementation,1,X,[gngm],[acty],,
56344086-5a19-47f2-b806-c784d5982877,C2699153,C1175743,is in context of high ,Cell Invasion,SARS coronavirus,1,X,[patf],[virs],,B04.820.504.540.150.113.937
b4a5679b-d1c6-4c9e-b0a8-34e05b7f4286,C4283742,C0030755,representing ,Ceramide Glucosyltransferase human,Pediatrics,1,X,[aapp/enzy],[bmod],,H02.403.670
af4105ed-f6a7-467f-9d22-5b25ba96db89,C0005802,C0020205,using ,Blood Glucose,Hybrids,1,X,[orch],[orgm],D09.947.875.359.448.500,B05.200
6ce45f55-de54-4994-b228-60e2fc4c2337,C1135927,COVID-19,is in ,Immunity Herd,COVID-19,1,X,[phsf],[virs],G12.450.400,C000657245
7b914eeb-0139-4782-bde6-32d5a88c55c0,C0037633,C0032857, includes dilute ,Solutions,Povidone-Iodine,1,X,[sbst],[orch/phsu],D26.776,D01.475.557.500;D02.455.326.271.884.533.710;D03.383.773.812.615.630;D05.750.716.721.838.745;D25.720.716.721.838.745;J01.637.051.720.716.721.838.745
fff25c16-18a9-4e24-ae2f-c4a3eaf7522e,C2926735,C1533734,was d in Jinhua Qinggan ,Duration,Administration procedure,1,X,[orch/phsu],[topp],,
d349babd-7890-483a-b76a-821aad8d3b5e,C0028606,C1533734,average Duration of was d in Jinhua Qinggan,Nucleic Acids,Administration procedure,1,X,[bacs/nnon],[topp],D13.444,
2e176c87-1f62-4466-8a00-31c27b399349,C0014442,C0075165,acts as ,Enzymes,Staph protein A receptor,1,X,[aapp/enzy],[aapp/rcpt],D08.811,x.x.x.x
04948689-7881-49d4-b73d-e04a33cbfc3a,C0022709,C0075165,acts as ,Peptidyl-Dipeptidase A,Staph protein A receptor,1,X,[aapp/enzy/imft],[aapp/rcpt],D08.811.277.656.350.350.687,x.x.x.x
694c23b1-6562-4810-b4cf-32afd4762f12,C0014442,C1537068,acts as ,Enzymes,Virus Internalization,1,X,[aapp/enzy],[biof],D08.811,G06.920.881
605cbdd5-e7f3-419f-80b4-9ca16a1e8574,C0014442,C0042196,acts Upon ,Enzymes,Vaccination,1,X,[aapp/enzy],[topp],D08.811,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
927a82dd-edec-419a-ad7e-77adc199ada5,C0022709,C0042196,acts Upon ,Peptidyl-Dipeptidase A,Vaccination,1,X,[aapp/enzy/imft],[topp],D08.811.277.656.350.350.687,E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890
646b2c7c-8979-40dd-bc33-ecb9ba7a5c41,C0014507,C1175175,related to ,Epidemiology,Severe Acute Respiratory Syndrome,1,X,[bmod],[dsyn],H02.403.720.500,C02.782.600.550.200.750;C08.730.730
bbe43b0d-53c6-4c2d-9309-8e09dc0bdd3f,C1276413,C0206750,is in ,Therapeutic regimen,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
fe55a86c-06e7-4475-8389-82633cca20ae,C2949735,C1706374,date of was 9 ,Recruitment,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[acty],[aapp/bacs],,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
0f81f439-6a18-4d03-9f35-76b5b6f7a740,C0699949,C0206750,is in ,airway disease,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
b57f03b5-4e36-4a74-9ae7-faf520716592,C0023882,C0030664,is in children with underlying chronic renal ,Little's Disease,Pathology,2,X,[dsyn],[bmod],C10.228.140.140.254,H02.403.650
83970cf4-2725-4c82-938c-92d36b96c30e,C1706374,C0030664,children with chronic renal ,Tumor Necrosis Factor Ligand Superfamily Member 13,Pathology,2,X,[aapp/bacs],[bmod],D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656,H02.403.650
a1234e4b-471c-47ca-8a7a-4404f7308729,C0237820,C0034997,was rapidly achieved with ,Recovery - action,Rehydration,2,X,[acty],[topp],,E02.319.360
44df0447-b9e0-47cf-acd7-612dec36873e,C0206750,C0403398,provoked Recurrent disease In patients diagnosed with,Coronavirus Infections,Steroid-dependent nephrotic syndrome,2,X,[dsyn],[dsyn],C02.782.600.550.200,
9ab52f32-01dd-4c87-a2d3-6867c3d04ea4,C0206750,C0277556,provoked ,Coronavirus Infections,Recurrent disease,2,X,[dsyn],[dsyn],C02.782.600.550.200,
04d9006d-6892-407d-b570-86d821d83d19,C0206750,C0006008,is in ,Coronavirus Infections,Border Disease,1,X,[dsyn],[dsyn],C02.782.600.550.200,C02.782.350.675.100;C22.836.160
c2b680c9-708e-408f-a7fb-dab02281ac25,C0020517,C2741673,were conducted to ,Hypersensitivity,Account number:Identifier:Point in time:^Patient:Nominal,2,X,[patf],[clna],C20.543,
0c996706-dc73-4379-84b8-ad5c48beb094,C1705178,C1856053,went at 5:00 pm on ,Order (action),Hydranencephaly with Renal Aplasia-Dysplasia,1,X,[acty],[dsyn],,x.x.x.x
7583e9d9-4f62-4848-82c9-b8c3e24d1ec8,C1457887,C0036238,is with ,Symptoms,Satellite Viruses,1,X,[sosy],[virs],,B04.265.658
567f2c40-29ac-4a0c-80c6-a935bed668b9,C0376565,C0674432, includes ,Anti-HIV Agents,lopinavir,1,X,[phsu],[orch/phsu],D27.505.954.122.388.077.088,D03.383.742.698.553
00729134-6148-45e2-a08b-aa8f1ce4b757,C0243077,C1167622,of G is ,inhibitors,Binding (Molecular Function),1,X,[chvf],[moft],,
caafd70f-4a20-4d3b-80d5-7b3aab7c0b96,C0008058,C0206419,are associated with ,Chilblains,Genus: Coronavirus,1,X,[dsyn],[virs],C26.212.500.217;C26.417.217,B04.820.504.540.150
640c4a4b-16f9-4855-952c-2277ef6de221,titers,C0206419,were negative for ,titers,Genus: Coronavirus,1,X,????,[virs],????,B04.820.504.540.150
c23b3be1-0cd8-48a2-8abd-4bbfe1290d8d,C1325583,C3652465,impede delayed ,central element,Interferon,1,X,[celc],[aapp/imft/phsu],,D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440
ebd4748d-0456-4402-88db-59dc0a73f9c4,C0199176,onco,is in moderate-to-severe onco ,Prophylactic treatment,onco,1,X,[topp],????,,????
77b3ea2b-2776-4faf-ad96-2afca1b6d33a,C0199176,C0018939,is in moderate-to-severe onco ,Prophylactic treatment,Hematological Disease,1,X,[topp],[dsyn],,C15.378
9cb6e21c-7541-47fb-b967-e1e721b443fa,C0199176,C0027651,is in moderate-to-severe onco ,Prophylactic treatment,Neoplasms,1,X,[topp],[neop],,C04
75662e3a-e0eb-4a79-8c38-a4b867aaaf47,C0340194,C0206419,are hallmarks of severe ,Respiratory failure without hypercapnia,Genus: Coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150
1e8eced4-4ad4-4400-9f9b-9a5312c674b1,C0740766,C0206419,are hallmarks of severe ,acute pneumonia,Genus: Coronavirus,3,X,[dsyn],[virs],,B04.820.504.540.150
29d1beae-513e-42db-9f6c-8c4caa659485,C0206419,C1706374,has spread worldwide over 80 000 deaths reported by end of ,Genus: Coronavirus,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
f21abe9b-d454-49df-9cb6-9b9f4c0b1087,C0281178,C0206419,be useful in patients with ,anti-cytokine therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
a1651d03-f2d3-42c6-888b-7f5f65297247,C1566558,C0243042,exhibited exceptional act on ,Natural Products,Inflammation Mediators,1,X,[bacs],[phsu],D20.215,D23.469
0584c15b-3d7e-4c36-b454-6b4e617e0f4d,C3873497,C0206419,is with ,Severe acute respiratory infection,Genus: Coronavirus,2,X,[dsyn],[virs],,B04.820.504.540.150
67e7d9f3-4170-4d97-86db-b5e2e2e5b90d,C3873497,C0162633,is accompanied by ,Severe acute respiratory infection,Viral Shedding,2,X,[dsyn],[patf],,G07.925
fc892581-60a2-4cf0-b05a-094d41b8055f,C3873497,C0015733,is accompanied by ,Severe acute respiratory infection,Feces,1,X,[dsyn],[bdsu],,A12.459
8553775c-f040-48d2-bb6f-d1db32f1ec01,CoV2,C0005775,can reach system from ,CoV2,Blood Circulation,1,X,????,[phsf],????,G09.330.100
0a8e0257-e366-4288-aff4-6edac455ca47,CoV2,C0700271,binding ,CoV2,M Protein multiple myeloma,1,X,????,[aapp/imft],????,x.x.x.x
19da5bbb-79e3-4d9b-88ae-5921ec4cfda0,C1175743,C0030946,binding ,SARS coronavirus,Endopeptidases,1,X,[virs],[aapp/enzy/phsu],B04.820.504.540.150.113.937,D08.811.277.656.300
9b3f4127-9528-4528-a1e3-d75763891fac,CoV2,C0030946,binding ,CoV2,Endopeptidases,1,X,????,[aapp/enzy/phsu],????,D08.811.277.656.300
67fc284e-31c3-450c-a492-78f25593227b,C1175743,C1742865,binding ,SARS coronavirus,TMPRSS2 protein human,1,X,[virs],[aapp/enzy],B04.820.504.540.150.113.937,x.x.x.x
edb6419b-68df-4bfe-8a13-2363219425d9,CoV2,C1742865,binding ,CoV2,TMPRSS2 protein human,1,X,????,[aapp/enzy],????,x.x.x.x
63d3c285-217f-4c39-8e78-d14f232f7be1,CoV2,C1452534,binding ,CoV2,ACE protein human,1,X,????,[aapp/bacs],????,x.x.x.x
a043d751-2d85-4a5d-813a-fe518d24c4ff,C1175743,C1418029,binding ,SARS coronavirus,OR2H2 gene,1,X,[virs],[gngm],B04.820.504.540.150.113.937,
cb4deaa9-922e-487c-9f5f-cf511b1921a4,CoV2,C1418029,binding ,CoV2,OR2H2 gene,1,X,????,[gngm],????,
fc235ed8-9575-4cfe-bc16-54ba8e38648a,C0031117,C1175743,can can observed after uneventful CoV2,Peripheral Neuropathy,SARS coronavirus,1,X,[dsyn],[virs],C10.668.829,B04.820.504.540.150.113.937
67708cce-b616-4751-a085-4d0ab1361819,C0031117,CoV2,can can observed after uneventful CoV2,Peripheral Neuropathy,CoV2,1,X,[dsyn],????,C10.668.829,????
2ec1c64e-f5c2-4f67-9740-c867bdcec023,C0235031,C1175743,can In conclusion can observed during CoV2 ,Neurologic Symptoms,SARS coronavirus,1,X,[sosy],[virs],C10.597;C23.888.592,B04.820.504.540.150.113.937
994f5d5e-76a7-47e1-8027-bba8a26ef7eb,C0235031,CoV2,can In conclusion can observed during CoV2 ,Neurologic Symptoms,CoV2,1,X,[sosy],????,C10.597;C23.888.592,????
175e2da6-552e-4f73-86c6-961a7f407863,C0235031,C0009450,can In conclusion can observed during CoV2 ,Neurologic Symptoms,Communicable Diseases,1,X,[sosy],[dsyn],C10.597;C23.888.592,C01.539.221
f3373265-37e3-43eb-9bf2-52ceec119d8b,C0005889,C0206419,nature of ,Body Fluids,Genus: Coronavirus,1,X,[bdsu],[virs],A12.207,B04.820.504.540.150
8f7034d7-abd0-414f-b00a-febd8b543dbc,C0019240,C0031843,is with traditional ,Herb,physiological aspects,1,X,[plnt],[phsf],,x.x.x.x
433dfb5d-b1eb-4464-b065-58f15baab266,C0019240,C0018837,is with traditional ,Herb,Heat (physical force),1,X,[plnt],[npop],,
0ad4cd8b-9121-4be4-bc04-b943118e32cf,PDL,C0087111,might also have ,PDL,Therapeutic procedure,1,X,????,[topp],????,E02
2616391c-a907-42b6-a43e-3af04c87bfd6,PDL,C0206419,might have ,PDL,Genus: Coronavirus,2,X,????,[virs],????,B04.820.504.540.150
5766d23e-252e-498d-9301-4689783427a9,PDL,C1175743,might prevent entrance of ,PDL,SARS coronavirus,2,X,????,[virs],????,B04.820.504.540.150.113.937
5558aa53-1d15-40c6-964f-949cb2dd3031,PDL,C0242656,shorten ,PDL,Disease Progression,1,X,????,[patf],????,C23.550.291.656
6ba15090-d44e-4446-8e1f-da86e7de647a,PDL,C1527144,might have ,PDL,Therapeutic Effect,1,X,????,[clna],????,
ce779a51-053d-41b4-a5be-2f6bc545ac24,C1457887,C0231918,was ,Symptoms,Nose symptoms,1,X,[sosy],[sosy],,
a2d3e33e-ec79-4120-b6a6-a7f64529008b,C1457887,C0011991,was ,Symptoms,Diarrhea,1,X,[sosy],[sosy],,C23.888.821.214
77d01989-e760-450a-8d92-681520c52e6c,C1457887,C0027498,was ,Symptoms,Nausea and vomiting,1,X,[sosy],[sosy],,
3d83639f-207b-4f32-bdd1-7ba5edf15367,C0015967,C0231918,followed by ,Fever,Nose symptoms,1,X,[sosy],[sosy],C23.888.119.344,
dc51d0e8-5c4b-4fad-b3c0-731ccc8d5047,C0015967,C0011991,followed by ,Fever,Diarrhea,1,X,[sosy],[sosy],C23.888.119.344,C23.888.821.214
d89009e7-eb1e-45e2-8b76-9103ab58ffbd,C0015967,C0027498,followed by ,Fever,Nausea and vomiting,1,X,[sosy],[sosy],C23.888.119.344,
00bc25ab-552f-4c0d-b116-939b4f00f4bb,C0204514,C0920672,understand potential ,Structural analysis,virus pathogenesis,2,X,[topp],[comd],,
e982fb07-7bd0-4c83-89ed-19ce049d7a62,C2362546,C1334164,Further belong to novel ,Alpha protein,Immunoglobulin Family Protein,3,X,[aapp],[aapp/imft],,
3d57874a-f49b-44c8-b4de-7b1208c4e06e,C2806453,C1334164,Further belong to novel ,Betacoronavirus,Immunoglobulin Family Protein,3,X,[virs],[aapp/imft],B04.820.504.540.150.113,
59a93b3c-13fd-4f44-abf4-f9a40629bfac,ORF8,C1334164,Further belong to novel ,ORF8,Immunoglobulin Family Protein,3,X,????,[aapp/imft],????,
ddb4ff1d-fe73-412a-ba22-7b0cab54d704,ORF8,C1175743,having hypervariable position among ,ORF8,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
197bdd07-c3f6-4e37-b70a-af93aa83cd96,C0017428,C1517880,is in its predicted ,Genome,Ligand Binding,1,X,[gngm],[moft],G05.360.340,
22fba275-f9ed-4762-9da2-f0cb8c575fb1,C0042736,C1512665,share architectures to those of CoV ,Viral Proteins,Immunoglobulin Domains,1,X,[aapp/bacs],[amas],D12.776.964,G02.111.570.820.709.275.750.250
df134c69-5fcf-471e-bdf6-738997506a87,C0042736,C0033684,share architectures to those of CoV ,Viral Proteins,Proteins,1,X,[aapp/bacs],[aapp/bacs],D12.776.964,D12.776
19b05cd9-3517-4e01-8dd7-0467b44d01b6,ORF8,C0003060,is in ,ORF8,Animal Viruses,1,X,????,[virs],????,B04
fb39af54-1268-427e-9cdc-cdc7012b3b63,ORF8,C1136170,is in ,ORF8,Virulence Factors,1,X,????,[bacs/hops/orch],????,D23.946.896
f3b3d154-d782-44ad-8038-35e141fbcc94,C0033684,C0017428,encoded by ,Proteins,Genome,1,X,[aapp/bacs],[gngm],D12.776,G05.360.340
1cf1f99e-ec4f-4567-95bc-aaeee027ca0b,C0206419,C1334164,comprise novel ,Genus: Coronavirus,Immunoglobulin Family Protein,3,X,[virs],[aapp/imft],B04.820.504.540.150,
1cf1f99e-ec4f-4567-95bc-aaeee027ca0b,C0206419,C1334164,novel Immunoglobulin Family Protein of,Genus: Coronavirus,Immunoglobulin Family Protein,2,X,[virs],[aapp/imft],B04.820.504.540.150,
1d3771ca-f1e8-48b3-8c98-de1837f24f17,C0204514,C2362546,ORF8 from ,Structural analysis,Alpha protein,1,X,[topp],[aapp],,
ea6364d1-529f-44d1-ba08-625bbb7932d4,C1334164,C0005525,might physiological aspects as potential,Immunoglobulin Family Protein,Biological Response Modifiers,1,X,[aapp/imft],[imft/phsu],,D27.505.696.477
532c7ee2-79f2-4b11-a121-c16ca075095b,C1334164,C0682447,attenuate virus by host Immune response against,Immunoglobulin Family Protein,virus by host,2,X,[aapp/imft],[virs],,
db7cb013-282a-4b8f-a415-f792351f3988,C1334164,C0301872,attenuate ,Immunoglobulin Family Protein,Immune response,1,X,[aapp/imft],[ortf],,
5fa4f51f-7882-4b06-8dcb-4226138ae911,C0206419,C0206277,is challenging at enhanced high risk for ,Genus: Coronavirus,Fatal Outcome,2,X,[virs],[patf],B04.820.504.540.150,E05.318.308.985.550.325;N01.224.935.698.201;N06.850.505.400.975.550.325;N06.850.520.308.985.550.325
1c0a32c0-b439-4bbd-8d27-cf4ea7cc56ec,C0005516,C0041199, includes ,Biological Markers,Troponin,2,X,[clna],[aapp/bacs],D23.101,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
cefb63ab-638c-4c37-9bde-e838e4971537,C0206419,C0005516,is challenging as patients with elevated ,Genus: Coronavirus,Biological Markers,1,X,[virs],[clna],B04.820.504.540.150,D23.101
303f23be-de50-4336-8136-eccbeee3ede1,C0206419,C0041199,is challenging as patients with elevated ,Genus: Coronavirus,Troponin,1,X,[virs],[aapp/bacs],B04.820.504.540.150,D05.500.945;D05.750.078.730.825;D12.776.210.500.910;D12.776.220.525.825
14bec3e1-8265-441a-836d-62a7278a6099,C0206419,C0748355,19 with ,Genus: Coronavirus,Acute respiratory distress,1,X,[virs],[dsyn],B04.820.504.540.150,
78798e45-3223-4bd7-a243-3b945b8d257c,C0206419,C0014442,is downregulating ,Genus: Coronavirus,Enzymes,1,X,[virs],[aapp/enzy],B04.820.504.540.150,D08.811
58c62160-2074-44c5-bb20-c057106889c7,C1829939,C0748355,those with ,{Non-patient},Acute respiratory distress,1,X,[clna],[dsyn],,
4a9383de-4cfc-4b32-b1ae-5059839ed899,C0553741,C0748355,those with ,Fluid Management,Acute respiratory distress,1,X,[topp],[dsyn],,
1d543375-b8b9-4e40-b798-05f57004f16f,C0024109,C0748355,can can used in patients with L phenotype ,Lung,Acute respiratory distress,1,X,[bpoc],[dsyn],A04.411,
557de569-28d3-4be5-b8bf-6d6257bebda3,C0242781,C0036537,route of is ,disease transmission,Bodily secretions,1,X,[patf],[bdsu],N06.850.310,A12.200
c9caafd5-aac4-46d8-9190-de09c3eff089,C1175743,C0009429,would overcome limitations associated with ,SARS coronavirus,Combined Modality Therapy,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.186
77293e00-0444-4442-b0b5-548ff2db97f6,C0443640,C0022709,shows potent S ,Specific antibody,Peptidyl-Dipeptidase A,2,X,[aapp/imft],[aapp/enzy/imft],,D08.811.277.656.350.350.687
7d651196-1f16-4c3b-8f47-c53b8c06429c,C3850079,C0018026,is ,Cytoreductive Surgery,Gold,1,X,[topp],[elii/phsu],E04.166,D01.268.556.322;D01.268.956.186;D01.552.544.322;x.x.x.x
04c7b7ed-cdd7-4a50-b78d-8d6f5c741a1b,C0220781,C1516048,reported on uro ,Anabolism,Assessed,1,X,[biof],[acty],G03,
7033ec70-d352-4742-ab5a-bcbae858a45e,C0220781,C0206058,reported on uro ,Anabolism,Elective Surgical Procedures,1,X,[biof],[topp],G03,E04.249
ec59bd68-0a0a-4791-b8dd-8f9377cef6f3,C0220781,uro,reported on uro ,Anabolism,uro,1,X,[biof],????,G03,????
445ac91f-c661-47ff-8e06-57a0457352f6,C0220781,C0278627,reported on uro ,Anabolism,oncology field,1,X,[biof],[bmod],G03,
0f32f61f-b255-43a3-aa24-f8ed9b31f4c2,C0012634,C1708476,has required worldwide ,Disease,Implementation,1,X,[dsyn],[acty],C23.550.288,
0877cad0-0786-4fb1-b594-efcd3e4f5940,TOS,C0014507,was negatively associated with LOS in patients without ,TOS,Epidemiology,2,X,????,[bmod],????,H02.403.720.500
9bcaed18-a3eb-4664-9e17-178ab7a2902a,C1704259,C0012634,is in experimental ,Biochemical Pathway,Disease,1,X,[moft],[dsyn],,C23.550.288
27db9528-4325-4fa6-9de5-f5d6f4e5633d,C0225385,C0301872,is in ,Structure of respiratory epithelium,Immune response,2,X,[tisu],[ortf],,
91e09e2b-909b-4f15-b292-ba9ab78884d1,C1537068,C1171362,Specifically decreased ,Virus Internalization,protein expression,1,X,[biof],[genf],G06.920.881,
f4506428-e2cf-4eed-93d0-1bf5177e95ff,C1537068,C0458827,Specifically decreased ,Virus Internalization,Airway structure,1,X,[biof],[bpoc],G06.920.881,
7727de68-5382-4b04-9f6d-7e18710ec338,C1537068,C0014609,Specifically decreased ,Virus Internalization,Epithelium,1,X,[biof],[tisu],G06.920.881,A10.272
dbb765dd-8ba3-4de4-ac9f-21ba979b2e29,C0022709,C0014609,is in ,Peptidyl-Dipeptidase A,Epithelium,1,X,[aapp/enzy/imft],[tisu],D08.811.277.656.350.350.687,A10.272
97886745-9e3d-4067-a438-7fc8222c069b,C1371550,C1372273,Increased Cytokine Production of immunomodulatory,Decreased Cytokine Production,Increased Cytokine Production,1,X,[ortf],[moft],,
33834118-5faa-4b9e-9874-a5e97ba63774,C3825816,C0042769,may have greater capacity recover after ,Pneumonia in children,Virus Diseases,1,X,[dsyn],[dsyn],,C02
bd9bfd9a-73f8-49cb-ae30-52d7eac92f69,C0275522,C0158644,may may associated with subclinical ,Asymptomatic Infections,Congenital anomaly of lung,1,X,[dsyn],[cgab],C23.550.291.187.500,
d25db986-895e-407a-b61a-24b0effb61e4,C2348077,C1706374,was ,Date Fruit,Tumor Necrosis Factor Ligand Superfamily Member 13,1,X,[food],[aapp/bacs],B01.650.940.800.575.912.250.093.615,D12.644.276.374.750.656;D12.776.467.374.750.656;D23.529.374.750.656
ec04bc28-2c92-4487-8d28-1a97ea443f8c,C0042333,C0999626,was increased with addition of ,Variation (Genetics),Manidae,1,X,[npop],[mamm],G05.365,
86a52f3f-2433-4f02-8144-43c2932ec6d5,C1706202,COVID,using COVID,Search - action,COVID,1,X,[acty],????,,????
766a069d-b17b-44e8-9b0a-fad2fcb5f365,C0206750,C0012222,has attracted worldwide attention for its ,Coronavirus Infections,Diffusion,1,X,[dsyn],[npop],C02.782.600.550.200,G01.202;G02.196
73aedfa4-4c9c-41e4-8935-280856900ead,C0038436,C0206750,related to ,Post-Traumatic Stress Disorder,Coronavirus Infections,1,X,[mobd],[dsyn],F03.950.750.500,C02.782.600.550.200
fb2d3b9d-97e4-4c6e-9831-97fa72b7dd43,C0038436,C2745965,related to ,Post-Traumatic Stress Disorder,Emergencies [Disease/Finding],1,X,[mobd],[patf],F03.950.750.500,C23.550.291.781;N06.230.100.083;N06.850.376
83d977a2-1080-4442-af82-60a03f4712d5,C2347784,C0021403,tested for only ,Clinical Endpoint,Influenza virus vaccine,1,X,[clna],[imft/phsu],,D20.215.894.899.302
befb5989-eff7-4885-bb46-a9494b8c1361,C0037090,C0035222,especially development of severe ,Signs and Symptoms Respiratory,Respiratory Distress Syndrome Adult,1,X,[sosy],[dsyn],C23.888.852,C08.381.840;C08.618.840
63d87dc2-f477-4fe3-b4e0-159fbda3861a,C0037090,C1175175,especially development of severe ,Signs and Symptoms Respiratory,Severe Acute Respiratory Syndrome,1,X,[sosy],[dsyn],C23.888.852,C02.782.600.550.200.750;C08.730.730
54a0f9b4-930a-4422-80ec-f8999a6ecbba,C0161816,C0012634,associated with ,Cardiac complication,Disease,1,X,[patf],[dsyn],,C23.550.288
a1f81dfd-9b56-4d65-90bc-1b7cc22aa2bc,C0161816,C1175175,are similar to those produced by ,Cardiac complication,Severe Acute Respiratory Syndrome,1,X,[patf],[dsyn],,C02.782.600.550.200.750;C08.730.730
8199cd04-0ac1-4f64-86f8-a2ed659c0451,C0036974,C0012634,decreasing chances of serious ,Shock,Disease,2,X,[patf],[dsyn],C23.550.835,C23.550.288
bdbb2803-513d-4ea4-a1f9-54041aa996e2,C0206750,C0597357,acts through ,Coronavirus Infections,receptor,1,X,[dsyn],[aapp/rcpt],C02.782.600.550.200,
fe45ad64-c988-4fb9-8638-a4d5bf293c79,C0085580,C0206750,is in ,Essential Hypertension,Coronavirus Infections,1,X,[dsyn],[dsyn],C14.907.489.165,C02.782.600.550.200
2a5c556f-6053-4035-9d8e-a76ed76a4cb7,C0815017,C0085580,are Essential Hypertension in,Angiotensin Receptor Antagonists,Essential Hypertension,2,X,[phsu],[dsyn],D27.505.519.162,C14.907.489.165
4e6dd3a5-4552-4cbe-a9d1-8b2d00d9f736,C0030755,C0003615,is with ,Pediatrics,Appendicitis,1,X,[bmod],[dsyn],H02.403.670,C01.539.463.099;C06.405.205.099;C06.405.469.110.207
011e3374-fdf4-4085-bc7c-ef77caf3de04,C1632842,C0206750,is in ,Complicated appendicitis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
c27996d5-a490-47e9-9f33-226fc9f730cc,C1632842,C1521863,is in ,Complicated appendicitis,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],,x.x.x.x
d9863d9c-fc6a-4fc1-9dc9-bee7c1d08497,C0009566,C1521863,were found during ,Complication,estrogen receptor alpha human,2,X,[patf],[aapp/rcpt],,x.x.x.x
9d792b1c-5b4a-453c-8348-cf0411ff81d9,C0009566,C1707455,were found during ,Complication,Comparison,2,X,[patf],[acty],,
05652d0a-148e-4b07-9624-5d2a5302ae5f,C1175743,C3697872,belonging to ,SARS coronavirus,Genus Betacoronavirus,1,X,[virs],[virs],B04.820.504.540.150.113.937,
f5b0cb0f-bbe5-4094-8f91-bc683ab36b45,C0030946,C0010813,recognizes specific ,Endopeptidases,Cytokinesis,1,X,[aapp/enzy/phsu],[celf],D08.811.277.656.300,G04.144.220.250
8ce08da5-438d-4630-8efb-152265044dca,C0042774,C0014442,targeting ,Virus Replication,Enzymes,1,X,[celf],[aapp/enzy],G06.920.925,D08.811
78a129df-dc6a-451c-a18d-7f533185159a,C0042774,C1328819,targeting SARS coronavirus M Enzymes with,Virus Replication,Small Molecule,1,X,[celf],[orch],G06.920.925,
956fe12d-d5d7-481e-83cd-703366f73ffb,C1167622,C0020276,was stabilized through four Glu166,Binding (Molecular Function),Hydrogen Bonding,1,X,[moft],[npop],,G02.282
a164beb7-d8a9-4441-883b-2bfc5fc94426,C1167622,Glu166,was stabilized through four Glu166,Binding (Molecular Function),Glu166,1,X,[moft],????,,????
61aff571-eecd-4d20-8de5-6365036548c4,C0020276,Glu166,is with Glu166,Hydrogen Bonding,Glu166,1,X,[npop],????,G02.282,????
6632417f-5d86-4aff-b76e-0f71c00dde00,C0329155,C1175743,is in ,Leiostomus xanthurus,SARS coronavirus,1,X,[fish],[virs],,B04.820.504.540.150.113.937
a8619c24-6bba-4eeb-a0c2-b3c23584fe83,C0329155,C0206750,is in ,Leiostomus xanthurus,Coronavirus Infections,1,X,[fish],[dsyn],,C02.782.600.550.200
31f6df8c-004d-4f0e-913c-02f52f3e358f,C1253910,C1510464,presenting CoV-2 ,Biological Community,Protein Structure,2,X,[npop],[aapp],G16.500.275.157.049.100;N06.230.124.049.100,
854eba9e-0c21-4ae1-9d97-6925e5d34498,C1253910,CoV-2,presenting CoV-2 ,Biological Community,CoV-2,1,X,[npop],????,G16.500.275.157.049.100;N06.230.124.049.100,????
2941ed06-86a6-4fbc-8ee9-67790deb9bee,C0206419,C0282686,target ,Genus: Coronavirus,Respiratory System Agents,1,X,[virs],[phsu],B04.820.504.540.150,D27.505.954.796
6e5f2c62-89de-4f22-ac81-7bcb41927c81,C0007820,COVID-19,simultaneously develop in ,Cerebrovascular Disorders,COVID-19,1,X,[dsyn],[virs],C10.228.140.300;C14.907.253,C000657245
e07d1ea4-ad70-43f2-980e-cf872a454fd1,C0007820,C0012634,simultaneously develop in ,Cerebrovascular Disorders,Disease,1,X,[dsyn],[dsyn],C10.228.140.300;C14.907.253,C23.550.288
4bcf682a-1b3d-40bd-bfe0-40fc745c8d87,C0021368,C0220781,may play role in ,Inflammation,Anabolism,1,X,[patf],[biof],C23.550.470,G03
2a940a93-134a-4b7d-879c-36336a49d990,C0021368,C0022116,may play role in ,Inflammation,Ischemia,1,X,[patf],[patf],C23.550.470,C23.550.513
add5d16e-5c36-4fd9-b8da-58c7d67c9507,C0021368,C0006560,predicted by ,Inflammation,C-reactive protein,1,X,[patf],[aapp/imft],C23.550.470,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
88aceb34-4408-469b-950d-2bca83597295,C0319157,C0015733,is shed via ,AS virus,Feces,2,X,[virs],[bdsu],,A12.459
dabc0a78-7737-439d-a1e7-5e0a2e9f87eb,C0002085,C0042765,may contribute to ,Alleles,Virulence,1,X,[gngm],[biof],G05.360.340.024.340.030,G06.930
acd9852c-1217-424b-9648-6e40f7cd5ddd,C0002085,C0086418,may contribute to ,Alleles,Homo sapiens,1,X,[gngm],[humn],G05.360.340.024.340.030,B01.050.150.900.649.313.988.400.112.400.400
90f179b5-5723-46e2-a9e3-577b86b51a33,C0042765,C0086418,is in ,Virulence,Homo sapiens,1,X,[biof],[humn],G06.930,B01.050.150.900.649.313.988.400.112.400.400
69d2a728-4df3-4fbf-9b30-a3097af38f93,C1707391,C0011627,available to ,Choose (action),Dermatology field,1,X,[acty],[bmod],,H02.403.225
fed96f50-511c-4e59-9867-1f4cc249b3f6,C0206419,C0450442,is causative ,Genus: Coronavirus,Agent,1,X,[virs],[chvf],B04.820.504.540.150,
52c082e0-edbc-4b1c-b39b-b44d88fd5eb9,C0035668,C2347609,can can used for ,RNA,Chemical Probe,1,X,[nnon],[chvf],D13.444.735,
edea5e16-6164-4fd9-a55c-8cbaa21cbf1d,COVID-19,C1704259,may lead to activated immune-inflammatory ,COVID-19,Biochemical Pathway,1,X,[virs],[moft],C000657245,
c405a100-65e8-454c-bb6d-9e665423a1a1,C0009450,C1704259,may lead to activated immune-inflammatory ,Communicable Diseases,Biochemical Pathway,1,X,[dsyn],[moft],C01.539.221,
1da87aee-7ca4-4c08-9573-c3d322c30969,COVID-19,C0004936,is with prior ,COVID-19,Mental disorders,1,X,[virs],[mobd],C000657245,F03
7f2186ab-db64-4b79-a31a-80651c4e29b8,C0282624,COVID-19,reconverted during ,Minimally Invasive Surgical Procedures,COVID-19,1,X,[topp],[virs],E04.502,C000657245
845f167d-b01d-4b98-bf99-5dc4807526be,C0199242,C1175743,is in patients infected with ,Anticoagulant prophylaxis,SARS coronavirus,1,X,[topp],[virs],,B04.820.504.540.150.113.937
f83a46b1-6a5d-4b94-866d-be3b486fca84,C0032712,C0376520,results in displacement of ,Porphyrins,Dietary Iron,1,X,[bacs/orch],[inch],D03.383.129.578.840.500;D03.633.400.909.500;D04.345.783.500;D23.767.727,D01.490.600;D02.691.550.600
42c5eb08-6573-4ec7-bf69-d9f5697987f0,C0032712,C0022023,results in displacement of ,Porphyrins,Ions,1,X,[bacs/orch],[elii],D03.383.129.578.840.500;D03.633.400.909.500;D04.345.783.500;D23.767.727,D01.248.497
c572ed31-2ca2-4dab-a5d0-97bb480a0694,C0019046,C0597157,loses capability for ,Hemoglobin,oxygen transport,2,X,[aapp/bacs],[ortf],D12.776.124.400;D12.776.422.316.762,
461d2e04-e01e-48aa-a50e-0f251a995655,C0597157,C0003130,aggravates ,oxygen transport,Anoxia,1,X,[ortf],[patf],,C23.888.852.079
1c988371-2f55-4f73-bdd2-0e57a5cc882e,C0020452,C0014583,increased ,Hyperemia,Episcleritis,1,X,[dsyn],[dsyn],C14.907.474,C11.790.500
e45345ff-00be-4f99-b47a-2cd9e2b359dc,C0020452,C0271298,increased ,Hyperemia,Chemosis of conjunctiva,1,X,[dsyn],[patf],C14.907.474,
38c2c91e-b04a-4d32-aee1-fdc301073e7e,C0020452,C0036537,increased ,Hyperemia,Bodily secretions,1,X,[dsyn],[bdsu],C14.907.474,A12.200
ae9a814b-a8b1-455b-8094-baa743091952,C1457887,C0085636,was ,Symptoms,Photophobia,1,X,[sosy],[sosy],,C10.597.751.941.661;C11.966.741;C23.888.592.763.941.661
6c055583-2d2e-4277-b28e-f7d5872d7281,C0013227,C0872315,be Therefore may developed for future ,Pharmaceutical Preparations,Communicable Diseases Emerging,1,X,[phsu],[dsyn],D26,C01.539.221.500
51168c8a-9794-44a7-ac0d-cc77ad35b77f,C0013227,C0022709,targeting ,Pharmaceutical Preparations,Peptidyl-Dipeptidase A,1,X,[phsu],[aapp/enzy/imft],D26,D08.811.277.656.350.350.687
17873a6d-1058-4228-992c-3d100271d4c6,C0040408,C1707455,results of were ,Tongue,Comparison,1,X,[bpoc],[acty],A03.556.500.885;A14.549.885,
3d071cd5-eed2-4cdf-98f5-aa4e37231f03,C1292527,C3687742, includes nasopharyngeal swab ,Body fluid sample,Oropharyngeal swab,2,X,[bdsu],[bdsu],,
f7d80199-abb2-467d-9273-7665f94a90a2,C1292527,C0036087, includes nasopharyngeal swab ,Body fluid sample,saliva,2,X,[bdsu],[bdsu],,A12.200.666
f9270020-97b6-4a9b-abcd-c74ae9b79877,C1292527,C0038056, includes nasopharyngeal swab ,Body fluid sample,Sputum,2,X,[bdsu],[bdsu],,A12.200.808
5ff27d66-bfb8-41a6-843b-d79410eced23,C0370003,C0038056, includes nasopharyngeal swab ,Specimen,Sputum,2,X,[sbst],[bdsu],,A12.200.808
6f1092ed-06a7-4ca6-99b3-eff2b64d033e,C1292527,C1610733, includes nasopharyngeal swab ,Body fluid sample,Urine - SpecimenType,2,X,[bdsu],[bdsu],,
a6415ce4-1254-4a15-a59a-5bfcf650ad39,C0370003,C1610733, includes nasopharyngeal swab ,Specimen,Urine - SpecimenType,2,X,[sbst],[bdsu],,
ad048427-272d-4ec9-a4b8-1f2236a0164f,C2936194,C1292527,is in various ,Hydrodynamics,Body fluid sample,1,X,[npop],[bdsu],G01.342,
767698f0-2997-4319-b3f1-f113dccc0dfd,C2936194,C0370003,is in various ,Hydrodynamics,Specimen,1,X,[npop],[sbst],G01.342,
7e7bc26e-ff60-45f1-9cc0-87b554730511,C2936194,C3687742,is in various nasopharyngeal swab ,Hydrodynamics,Oropharyngeal swab,1,X,[npop],[bdsu],G01.342,
ecd04ece-20c8-4c2b-ba87-733db77f8fa0,C2936194,C0036087,is in various nasopharyngeal swab ,Hydrodynamics,saliva,1,X,[npop],[bdsu],G01.342,A12.200.666
dc8eeea0-a600-457a-9964-4d90210c77e8,C2936194,C0038056,is in various nasopharyngeal swab ,Hydrodynamics,Sputum,1,X,[npop],[bdsu],G01.342,A12.200.808
d66ddd47-a3c2-4655-a54c-6cde13ff4128,C2936194,C1610733,is in various nasopharyngeal swab ,Hydrodynamics,Urine - SpecimenType,1,X,[npop],[bdsu],G01.342,
3ea23c62-6df9-46d6-880a-9809419d431a,C0370003,C0352155,using ,Specimen,Chlorhexidine Mouthwash,1,X,[sbst],[clnd],,
5eb4c195-36aa-4073-b2f1-229dfb659a3e,C1175743,C0206074,was determined by PCR,SARS coronavirus,Renal Replacement Therapy,1,X,[virs],[topp],B04.820.504.540.150.113.937,E02.870
8206b017-5919-4edf-8065-b88b9de48ec1,C0352155,C1175743,reducing ,Chlorhexidine Mouthwash,SARS coronavirus,1,X,[clnd],[virs],,B04.820.504.540.150.113.937
9fd838df-48cd-462e-a77e-61238b18299e,C2349975,C0029341,similar to ,Enhance (action),Orthomyxoviridae,1,X,[acty],[virs],,B04.820.545
5c937279-5d18-4bad-8d3a-f4147c27a990,C0012634,C0029341,similar to ,Disease,Orthomyxoviridae,1,X,[dsyn],[virs],C23.550.288,B04.820.545
8038ccca-350d-4714-bbac-020c06d0f677,C0009450,C0018801,can result in myocardial injury ,Communicable Diseases,Heart failure,1,X,[dsyn],[dsyn],C01.539.221,C14.280.434
3dfc9357-59c8-4dd5-abd2-15bbc5b5e016,C0009450,C0003811,can result in myocardial injury ,Communicable Diseases,Cardiac Arrhythmia,1,X,[dsyn],[dsyn],C01.539.221,C14.280.067;C23.550.073
072e8073-6d75-4957-93f4-0375f6750eba,C0949266,C0042769,can interact In addition to ,Therapies Investigational,Virus Diseases,1,X,[topp],[dsyn],E02.931,C02
62aaa682-3e15-41ff-9a06-a6be80a243f0,C0206419,C1516295,affects ,Genus: Coronavirus,Cardiopulmonary Physiology,1,X,[virs],[bmod],B04.820.504.540.150,
0561d7d3-0e6d-4099-b08f-8a82f77a8557,C0012634,C1516295,affects ,Disease,Cardiopulmonary Physiology,1,X,[dsyn],[bmod],C23.550.288,
3539af0e-5729-4149-9861-56f06b6853be,COVID-19,C0013227,was performed in First Affiliated Hospital of Zhejiang University School of ,COVID-19,Pharmaceutical Preparations,1,X,[virs],[phsu],C000657245,D26
c8b4bd2f-3994-4f41-b089-2dad7d4f7bd5,C0002930,C0007876,is preferred in ,Anesthesiology,Cesarean section,2,X,[bmod],[topp],H02.403.066,E04.520.252.500
132336bf-3794-4325-a3e3-e7ae8239a2df,C0002915,C0021932,is with ,General Anesthesia,Intubation Intratracheal,1,X,[topp],[topp],E03.155.197,E02.041.500;E02.585.578;E05.497.578
b31fd13d-c187-4abe-bcde-688bf027e42b,C0002930,C0035203,reduce its influence in ,Anesthesiology,Respiration,1,X,[bmod],[phsf],H02.403.066,G09.772.705
87cdb201-b12d-4d41-898d-1b4403c55b67,C0319157,C0035243,is mainly responsible for ,AS virus,Respiratory Tract Infections,1,X,[virs],[dsyn],,C01.539.739;C08.730
aa8b9a33-14ad-48b4-9681-758b22819f1c,C0206750,C1861452,are characterized with ,Coronavirus Infections,Storm Syndrome,1,X,[dsyn],[dsyn],C02.782.600.550.200,x.x.x.x
e29ec06c-4731-4d78-9184-636054da7a6e,C1285338,C0206750,is in ,Inflammatory disorder of immune system,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
d627d2e7-01a5-47d2-bcb0-850ccb7212d9,C2827774,C0003451,is with ,Current Therapy,Antiviral Agents,1,X,[topp],[phsu],,D27.505.954.122.388
7e2b8325-11e3-4af2-a9db-dc747a41af5f,C0280274,C0441636,were ineffective for ,Antiviral Therapy,Surgical shortening - action,1,X,[topp],[topp],,
c1499177-de0a-437d-bb4f-c58c3c3aa391,C2827774,C0441636,were ineffective for ,Current Therapy,Surgical shortening - action,1,X,[topp],[topp],,
b3e0a34c-922a-4697-8582-ea55f40e46ec,C0678222,C1511300,are concerned with ,Breast Carcinoma,Breast Cancer Therapeutic Procedure,1,X,[neop],[topp],C04.588.180;C17.800.090.500,
beaedfe3-cd15-48f4-ad9f-5e2eb6d1e3e1,C0678222,PRE,were divided into PRE ,Breast Carcinoma,PRE,1,X,[neop],????,C04.588.180;C17.800.090.500,????
e9afa85a-2a47-44e3-b68e-a94a74db5d97,C0678222,C0206750,were divided into PRE ,Breast Carcinoma,Coronavirus Infections,1,X,[neop],[dsyn],C04.588.180;C17.800.090.500,C02.782.600.550.200
12c97506-aee3-4fef-8135-22306edd99bc,C0280274,C0206750,is most important treatment for ,Antiviral Therapy,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
248add9e-7e44-4717-b0b1-e54d096d4a3a,C0008269,C0174990,prevent coronavirus receptor recognition by,Chloroquine,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D03.633.100.810.050.180,x.x.x.x
f0e70adf-bf29-4cca-b533-757ae7605f7a,C0020336,C0174990,prevent coronavirus receptor recognition by,Hydroxychloroquine,coronavirus receptor,2,X,[orch/phsu],[aapp/rcpt],D03.633.100.810.050.180.350,x.x.x.x
910b88a4-9c7c-4188-bd21-71971fd72448,C0008269,C0018790,prevent coronavirus receptor recognition by,Chloroquine,Cardiac Arrest,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180,C14.280.383
13eab412-7ce1-4f29-82d0-eef0e45543f1,C0020336,C0018790,prevent coronavirus receptor recognition by,Hydroxychloroquine,Cardiac Arrest,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,C14.280.383
187189bf-dcf4-4f9e-be1b-57cbcaee8afe,C0806140,C0035203,six with invasive ,Flow,Respiration,1,X,[npop],[phsf],,G09.772.705
c8a769bb-2b35-4656-b45b-7ecca3a01969,C0030054,C0035203,six with invasive ,Oxygen,Respiration,1,X,[bacs/elii/phsu],[phsf],D01.268.185.550;D01.362.670;x.x.x.x,G09.772.705
d371310c-91e1-4774-9298-00bd43158097,C0242297,C0035203,six with invasive ,Dietary Supplementation,Respiration,1,X,[topp],[phsf],,G09.772.705
161aa502-97cb-41b1-9995-63e069fbaae8,C1609165,C0015967,rapidly beneficial effect on ,tocilizumab,Fever,1,X,[aapp/imft/phsu],[sosy],x.x.x.x,C23.888.119.344
760ee523-3206-497c-a20c-caa53df85539,C0042776,C0520510,track disease transmission through,Virus,Materials,1,X,[virs],[sbst],B04,
a39ca512-9eb4-46df-8aa8-09d0cae41a52,C0520510,C0016248,thus avoiding artifacts ,Materials,Floods,2,X,[sbst],[npop],,G16.500.175.812;N06.230.100.230.250
f26703b9-b3f3-44fb-abb6-24c720323ac2,C0520510,C1325742,thus avoiding ,Materials,Pore,1,X,[sbst],[celc],,
ffb8746d-494b-455f-8d9b-90d7906b780c,C0520510,C1511790,greatly assist accuracy of ,Materials,Detection,1,X,[sbst],[topp],,
d49189a3-ffc9-4f0a-8408-ad3337ae7797,C0520510,C0596539,thus avoiding Xyzinclude3 Floods due to,Materials,evaporation,1,X,[sbst],[npop],,
d49189a3-ffc9-4f0a-8408-ad3337ae7797,C0520510,C0596539,avoiding loss due to ,Materials,evaporation,1,X,[sbst],[npop],,
f10dd4a7-3a17-45c0-9d49-fb535149fd18,C0520510,C0934502,comprise absorbent hydrophilic ,Materials,anatomical layer,1,X,[sbst],[bpoc],,
f10dd4a7-3a17-45c0-9d49-fb535149fd18,C0520510,C0934502,comprise hydrophobic ,Materials,anatomical layer,1,X,[sbst],[bpoc],,
209fd9ea-2b51-433d-8cfd-8e7d6f1f9d41,C0934502,C0042776,can adhere ,anatomical layer,Virus,1,X,[bpoc],[virs],,B04
11585c96-ed55-4403-9420-758db9420600,C0934502,C0032582,comprising nonwoven ,anatomical layer,Polypropylenes,1,X,[bpoc],[bodm/orch],,D02.455.326.271.665.590;D05.750.716.550;D25.720.716.550;J01.637.051.720.716.550
b4470a26-04fc-4165-b5fe-821cd953f800,C0934502,C0032474,comprising nonwoven ,anatomical layer,Polyesters,1,X,[bpoc],[bodm/orch],,D05.750.728;D25.720.728;J01.637.051.720.728
8a0064d4-f11f-49e1-a702-59f14cb25fbc,C0087111,C0597039,prevent such dangerous ,Therapeutic procedure,Infectious disease of nervous system,1,X,[topp],[dsyn],E02,
9b16653f-7d18-46b2-8e00-477fd703dcbc,C3652465,C1707814,was For adults with ,Interferon,Dose Reduced,2,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
9b16653f-7d18-46b2-8e00-477fd703dcbc,C3652465,C1707814,was associated with ,Interferon,Dose Reduced,2,X,[aapp/imft/phsu],[topp],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,
292952df-49ea-4492-892b-304d70fac7f2,C3652465,C0001617,was For adults with ,Interferon,Adrenal Cortex Hormones,1,X,[aapp/imft/phsu],[horm/orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D06.472.040
292952df-49ea-4492-892b-304d70fac7f2,C3652465,C0001617,was associated with ,Interferon,Adrenal Cortex Hormones,1,X,[aapp/imft/phsu],[horm/orch/phsu],D12.644.276.374.440;D12.776.467.374.440;D23.529.374.440,D06.472.040
f8b7a6d0-c8c3-412f-a36f-0819dfacb397,C0035525,C0559546,was associated with high risk of severe ,Ribavirin,Adverse reactions,2,X,[nnon/phsu],[patf],D13.570.800.790,
e760e9ea-61ee-4e1d-a00e-aca906c2abf6,COVID-19,C0281169,develop severe ,COVID-19,pulmonary complications,1,X,[virs],[patf],C000657245,
72db6917-2e48-48e0-8de8-d73d1c6e654e,COVID-19,C0264556,develop severe acute ,COVID-19,Acute pneumothorax,2,X,[virs],[dsyn],C000657245,
a6c780de-5f02-4eeb-a5d9-9f0273d8b169,COVID-19,C0233494,develop severe acute ,COVID-19,Tension,1,X,[virs],[mobd],C000657245,
0ba4f151-2355-43e5-a9c6-d7c18e49ce50,C0319157,C1704259,entered Cells through different,AS virus,Biochemical Pathway,1,X,[virs],[moft],,
bb726797-e20d-4dc3-a955-c7ee8504124e,C3687832,C1704259,inhibit ,Drugs - dental services,Biochemical Pathway,1,X,[topp],[moft],,
ce55a6c0-108d-4205-bae9-f62f38661ff4,C3687832,C0597360,significantly increase ,Drugs - dental services,receptor expression,1,X,[topp],[genf],,
ce55a6c0-108d-4205-bae9-f62f38661ff4,C3687832,C0597360,receptor expression of,Drugs - dental services,receptor expression,1,X,[topp],[genf],,
5b609746-33a9-4a5c-aa41-c5f3e73395b9,C3687832,C0024109,significantly increase ,Drugs - dental services,Lung,1,X,[topp],[bpoc],,A04.411
5b609746-33a9-4a5c-aa41-c5f3e73395b9,C3687832,C0024109,receptor expression in,Drugs - dental services,Lung,1,X,[topp],[bpoc],,A04.411
2aa964b0-e316-49d3-8358-1740eacdd663,C0597360,C0024109,is in ,receptor expression,Lung,1,X,[genf],[bpoc],,A04.411
e2fc82ae-f3fd-41f1-aaa9-e49328d50d11,C3687832,C0003018,receptor expression for,Drugs - dental services,Angiotensins,1,X,[topp],[aapp/bacs/phsu],,D06.472.699.094;D12.644.400.070;D12.644.456.073;D12.644.548.058;D12.776.631.650.070;D23.469.050.050
dd10df3e-85d5-4bd0-88aa-3cf41be4c0d0,C3687832,C0014442,receptor expression for,Drugs - dental services,Enzymes,1,X,[topp],[aapp/enzy],,D08.811
35b11d1b-0948-4921-85e2-e17aec24de2d,C0599878,C0012634,ranging from asymptomatic to critical ,disease characteristic,Disease,1,X,[patf],[dsyn],,C23.550.288
f4128442-5500-4eae-9ec5-24f8e215e5e4,C1517281,C0206419,is in patients with ,Focused Ultrasound Therapy,Genus: Coronavirus,1,X,[topp],[virs],,B04.820.504.540.150
af865c74-1aec-4699-ac70-5fb58df3ead9,C0018801,C0302148,is with ,Heart failure,Blood Clot,1,X,[dsyn],[patf],C14.280.434,C14.907.355.830
284dfa7a-163c-406d-ab3b-ab8a930b1923,C0034065,C0302148,is with ,Pulmonary Embolism,Blood Clot,1,X,[patf],[patf],C08.381.746;C14.907.355.350.700,C14.907.355.830
b6243686-2b77-415e-83f2-49c6e8b88173,C0027059,C0302148,is with ,Myocarditis,Blood Clot,1,X,[dsyn],[patf],C14.280.238.625,C14.907.355.830
4eb31fd2-7c6d-4109-9655-5dc92a3d4971,C3526617,COVID-19,is with ,Outpatient Dialysis,COVID-19,1,X,[topp],[virs],,C000657245
1506cb15-6b86-4257-84ea-d83d5cf65592,C3526617,C0009450,is with ,Outpatient Dialysis,Communicable Diseases,1,X,[topp],[dsyn],,C01.539.221
fce59d94-384b-422d-be3a-7ac17ba031ef,C0018563,C0281902,predicted lower psychological ,Hand,maladjustment,1,X,[bpoc],[mobd],A01.378.800.667,
88f5dcbe-b50a-43dd-989c-a4b55ef3aedb,C1947933,C0034019,may become first choice in ,care activity,public health medicine (field),4,X,[acty],[bmod],,H02.403.720;N01.400.550;N06.850
7fdb18df-be0f-49b5-9f6b-252d2c8c396e,C0037633,C0034019,may become first choice in ,Solutions,public health medicine (field),2,X,[sbst],[bmod],D26.776,H02.403.720;N01.400.550;N06.850
500da6ca-3b2e-4e57-9d44-ad9f7835455d,C0037633,C2745965,may become first choice in ,Solutions,Emergencies [Disease/Finding],2,X,[sbst],[patf],D26.776,C23.550.291.781;N06.230.100.083;N06.850.376
f5ec65c6-6bd1-46e2-a8bd-edf37f492fca,C0206419,RTPCR,was In case report found by realtime RTPCR,Genus: Coronavirus,RTPCR,1,X,[virs],????,B04.820.504.540.150,????
f5ec65c6-6bd1-46e2-a8bd-edf37f492fca,C0206419,RTPCR,was found by realtime fluorescent RTPCR,Genus: Coronavirus,RTPCR,1,X,[virs],????,B04.820.504.540.150,????
83485a57-41e4-4652-afab-2f70d2b6cbb6,C0206419,C1608239,was found in COVID19,Genus: Coronavirus,Specimen Type - Bile fluid,1,X,[virs],[bdsu],B04.820.504.540.150,
b844db12-e936-4122-b06e-7256793c4a4b,C0206419,COVID19,was found in COVID19,Genus: Coronavirus,COVID19,1,X,[virs],????,B04.820.504.540.150,????
7ccdf009-142b-4933-8a83-0ca9e5e7b7e2,C1516048,C1707391,were done in standard format from ,Assessed,Choose (action),1,X,[acty],[acty],,
dc7a7626-fa82-4ebc-9aa4-235d07e50236,C2948600,C1527144,investigate ,Aim,Therapeutic Effect,1,X,[inch/phsu],[clna],,
b4a877f7-d4e7-452f-a95c-50992b618b83,C2948600,C0683465,investigate ,Aim,novel AODU treatment method,2,X,[inch/phsu],[topp],,
51523d75-4573-43c8-b016-c91cac13f1eb,C2948600,C0018787,investigate ,Aim,Heart,1,X,[inch/phsu],[bpoc],,A07.541
4fcc7bc6-71c9-42e4-b70f-831c313e35f8,C1999230,C0008964,support for clinical ,Providing (action),Clinical Medicine,1,X,[acty],[bmod],,H02.403.200
7fe51270-b287-4df1-be42-c9441a0e248b,C0543829,C0206419,is in ,pneumonia clinical,Genus: Coronavirus,1,X,[dsyn],[virs],,B04.820.504.540.150
f6b30134-c213-485b-9c55-875c067a025b,C0085295,C0032285,reduced ,Interleukin-10,Pneumonia,2,X,[aapp/imft],[dsyn],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,C08.381.677;C08.730.610
0f087be0-36f9-461f-9d8c-c6f2eaffecb4,C0085295,C0040300,reduced ,Interleukin-10,Body tissue,1,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A10
fcacaa82-6a24-4b9a-9b74-fda08463f6c0,C0085295,C0024109,levels in ,Interleukin-10,Lung,1,X,[aapp/imft],[bpoc],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A04.411
c7268bd1-3fe0-43b8-b936-3344a94a12d0,C2986594,C0439962,evaluate effectiveness of ,Mouse Model,Mixture,1,X,[emod],[sbst],,
056fcca7-0d5f-4810-88ef-9bf7a84ea881,C2986594,C1999230,evaluate effectiveness to ,Mouse Model,Providing (action),1,X,[emod],[acty],,
d0b2dcf0-13e3-4f4a-abc8-702e9f969fdc,C2986594,C0003064,evaluate effectiveness to ,Mouse Model,Animals Laboratory,1,X,[emod],[anim],,B01.050.050.199
e5784888-88a7-4290-b5a6-52d9b6b71c83,C0819757,C0024109,calculate ,Structure of parenchyma of lung,Lung,1,X,[tisu],[bpoc],,A04.411
60e45d61-6f5b-4cdb-a121-e990ac867ee7,RT-PCR,C0819757,detect Nucleic Acids virus load in,RT-PCR,Structure of parenchyma of lung,1,X,????,[tisu],????,
df2682fb-14dc-4534-8b5d-117570a705d7,C0085295,C0819757,is in ,Interleukin-10,Structure of parenchyma of lung,1,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
ad3fcebb-e7b5-4149-aaae-4b5c75e30abf,C0085295,C0033684,is in ,Interleukin-10,Proteins,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D12.776
22b5c4f6-2e27-4776-a6f1-4cc0a03886a3,C0819757,C3463820,calculate ,Structure of parenchyma of lung,Inhibition,1,X,[tisu],[acty],,F01.145.544;F02.463.425.475;F02.739.794.405
6f854580-f70e-4129-ad4b-7234f233b8a7,C0439962,C0024109,could reduce ,Mixture,Lung,1,X,[sbst],[bpoc],,A04.411
e603ea2f-2af9-490d-89d4-80e68402dd32,C0439962,C0206419,could reduce ,Mixture,Genus: Coronavirus,1,X,[sbst],[virs],,B04.820.504.540.150
6b69266c-9577-4f68-9641-fd41ec5d18cc,C0439962,C1518039,could reduce ,Mixture,Mouse Lung,1,X,[sbst],[tisu],,
e3edb7f1-fc18-4d66-901b-6ed0bad449e0,C0085295,C0229671,content in ,Interleukin-10,Serum,1,X,[aapp/imft],[bdsu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,A12.207.152.846;A15.145.846
99fd101c-36ec-4592-84ee-fe993188d3aa,C0085295,C2986594,content in ,Interleukin-10,Mouse Model,1,X,[aapp/imft],[emod],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
7b8b2c84-6207-4477-8ca4-27e68f0dfaca,C0085295,C0026594,content of ,Interleukin-10,motilin,1,X,[aapp/imft],[aapp/horm/phsu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,D06.472.317.525;D06.472.699.500;D12.644.400.470;D12.644.548.500;D12.776.631.650.463
bdff76be-b836-4810-876d-d136ae1ddd02,C0085295,C1518039,is in ,Interleukin-10,Mouse Lung,2,X,[aapp/imft],[tisu],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
85a9fefe-74c1-4576-9bd1-70ac2d34a47c,C0085295,C1519523,is in ,Interleukin-10,Tissue Model,2,X,[aapp/imft],[emod],D12.644.276.374.465.510;D12.776.467.374.465.510;D23.529.374.465.510,
4f87db34-521e-40bc-a8a2-9bb68bc1c0ff,C2936405,C0242656,could Providing (action) pause in,Drug Repositioning,Disease Progression,1,X,[topp],[patf],E05.290.875,C23.550.291.656
167c6fe0-815a-468f-b4b2-4255c5e45e5c,C0023779,C1167395,encounter endosomal/lysosomal ,Lipids,Host (organism),1,X,[orch],[orgm],D10,
47890bb4-69c3-4bd6-b02b-6111930a8255,C0023779,C0009450,encounter Host (organism) compartment in critical step of,Lipids,Communicable Diseases,1,X,[orch],[dsyn],D10,C01.539.221
c7e6d5a0-5029-4db8-b18b-8af5b906ac50,C0220756,C0678236,is ,Niemann-Pick Disease Type C,Rare Diseases,4,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,C23.550.291.906
2258d271-d2b8-4330-aa7e-58fe887d8843,C0220756,C1166848,is ,Niemann-Pick Disease Type C,late endosome,2,X,[dsyn],[celc],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,
042207b0-2681-4a80-87ac-ffbe42c12966,C0220756,C0024369,is ,Niemann-Pick Disease Type C,Lysosomes,2,X,[dsyn],[celc],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,A11.284.430.214.190.875.190.550
00264afa-600f-4169-8d13-a9f8ddf994bb,C0220756,C0042769,been has associated with LE/L ,Niemann-Pick Disease Type C,Virus Diseases,1,X,[dsyn],[dsyn],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,C02
734e30a4-7fbc-413d-b0a6-e75724d06010,C0017337,C0042769,been has associated with LE/L ,Genes,Virus Diseases,1,X,[gngm],[dsyn],G05.360.340.024.340,C02
f701f63e-472d-4dcb-abce-863fa37e6de0,C0220756,LE/L,been has associated with LE/L ,Niemann-Pick Disease Type C,LE/L,1,X,[dsyn],????,C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,????
150a4b2c-110c-4d69-aaa6-87bba15b7751,C0017337,LE/L,been has associated with LE/L ,Genes,LE/L,1,X,[gngm],????,G05.360.340.024.340,????
26a4ffe7-1af4-4287-a628-6a14ed473772,C0220756,C0023779,been has associated with LE/L ,Niemann-Pick Disease Type C,Lipids,1,X,[dsyn],[orch],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D10
c844cce9-f954-4896-ad9d-425b765611e7,C0017337,C0023779,been has associated with LE/L ,Genes,Lipids,1,X,[gngm],[orch],G05.360.340.024.340,D10
f95b0b3a-0443-46d0-bed5-07cabf51bcfe,C0220756,C0040616,could serve as ,Niemann-Pick Disease Type C,Anti-Anxiety Agents,1,X,[dsyn],[phsu],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
155282dd-8e60-4f83-b265-b5fb7edf1ea7,C0920591,C0040616,could serve as ,mimetics,Anti-Anxiety Agents,1,X,[bmod],[phsu],,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
cc083acf-25b5-41ea-be5d-6d0d2ff8be03,C0220756,C1175743,could serve as ,Niemann-Pick Disease Type C,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,B04.820.504.540.150.113.937
1dc8adb6-8461-4b99-9ef7-2178f24bbe06,C0920591,C1175743,could serve as ,mimetics,SARS coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150.113.937
51c0a242-9d37-47de-a8a8-8a8996f178fa,C3179455,C0040616,could serve as ,Niemann-Pick Disease Type C1,Anti-Anxiety Agents,1,X,[dsyn],[phsu],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
ebea899d-a470-4593-9cd3-6253c4dee7ee,C0243077,C0040616,could serve as ,inhibitors,Anti-Anxiety Agents,1,X,[chvf],[phsu],,D27.505.696.277.950.015;D27.505.954.427.210.950.015;D27.505.954.427.700.872.015
37892c0c-03c2-4b03-a6f0-6726adf6525d,C3179455,C1175743,could serve as ,Niemann-Pick Disease Type C1,SARS coronavirus,1,X,[dsyn],[virs],C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875,B04.820.504.540.150.113.937
109ca33c-53fb-4569-9747-d9f3b7857ed5,C0567416,C0220756,causing ,Molecule,Niemann-Pick Disease Type C,1,X,[sbst],[dsyn],,C10.228.140.163.100.435.825.700.875;C15.604.250.410.625.875;C16.320.565.189.435.825.700.875;C16.320.565.398.641.803.730.875;C16.320.565.595.554.825.700.875;C18.452.132.100.435.825.700.875;C18.452.584.687.803.730.875;C18.452.648.189.435.825.700.875;C18.452.648.398.641.803.730.875;C18.452.648.595.554.825.700.875
1edb5371-1316-4bea-984e-c1a8eb04bf3a,C3463820,C0023779,may impair SARS coronavirus via several,Inhibition,Lipids,1,X,[acty],[orch],F01.145.544;F02.463.425.475;F02.739.794.405,D10
a358c655-7d0e-4e7e-8c92-cd6d0940cfeb,C0035668,C1856053,was detected in During ,RNA,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[nnon],[dsyn],D13.444.735,x.x.x.x
bd0168fb-44fc-49a9-bfa3-137645ffb392,C0035668,C0019004,was detected in within overall population of ,RNA,Hemodialysis,1,X,[nnon],[topp],D13.444.735,E02.870.300;E02.912.800
1d0f2761-a359-4b7a-a5aa-fd777ba99d41,C0019004,C1175175,is with ,Hemodialysis,Severe Acute Respiratory Syndrome,1,X,[topp],[dsyn],E02.870.300;E02.912.800,C02.782.600.550.200.750;C08.730.730
038aae43-1564-4378-93c1-03692808154a,C0042776,C0086022,acting as inanimate ,Virus,Cloning Vectors,1,X,[virs],[nnon],B04,G05.360.337
6f2d77b8-da75-4d31-9087-c7b2267d4f19,C0042776,C1533724,acting as ,Virus,Fomes,1,X,[virs],[fngs],B04,B01.300.179.120.174
bbd3801d-3182-4861-941f-46fc3ee94b47,C3826466,C0206419,may how may impacted by ,Dentistry--Practice,Genus: Coronavirus,1,X,[bmod],[virs],,B04.820.504.540.150
62f32afd-5fdd-44b9-b756-85d826220dfc,C0012634,C0206422,caused by novel ,Disease,Human coronavirus,1,X,[dsyn],[virs],C23.550.288,
2d63e970-73e2-4fef-8a66-c7aef554ce3b,C0042736,C1167395,binds ,Viral Proteins,Host (organism),2,X,[aapp/bacs],[orgm],D12.776.964,
8ce89cac-442e-4495-9baa-9e76e3241a4a,C0042736,C0597358,binds ,Viral Proteins,receptor binding,2,X,[aapp/bacs],[moft],D12.776.964,
9ceb48df-c068-4daa-934c-b6a5382bb2a6,RBD,C0086418,may interact with ,RBD,Homo sapiens,1,X,????,[humn],????,B01.050.150.900.649.313.988.400.112.400.400
0993bef4-0d0a-450b-9877-ecc2b82cce98,RBD,C0022709,may interact with ,RBD,Peptidyl-Dipeptidase A,1,X,????,[aapp/enzy/imft],????,D08.811.277.656.350.350.687
1db04ed8-cf36-41ad-a865-5b18cc3b87dc,C0042196,C0475463,induce strong ,Vaccination,Antibodies Neutralizing,1,X,[topp],[aapp/imft],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
1923c539-9ad1-4a65-9ed4-f8548d085bd0,C0042196,C0026809,induce Antibodies Neutralizing in,Vaccination,Mus,1,X,[topp],[mamm],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,B01.050.150.900.649.313.992.635.505.500
8e92cbd4-599a-481a-9870-1b59e279ce67,C0042196,C0597358,is with ,Vaccination,receptor binding,1,X,[topp],[moft],E02.095.465.425.400.530.890;E05.478.550.600.890;N02.421.726.758.310.890;N06.850.780.200.425.900;N06.850.780.680.310.890,
ddac4b80-46f7-42ba-a4b4-a6ff950a7a6b,C0003342,C1522002,are in ,Antigens Viral,RNA Recognition Motif,1,X,[imft],[aapp/bacs],D23.050.327,G02.111.570.820.709.275.500.869.500
0ba98799-4ddb-482d-be21-7ce51c99e3b2,C0037088,C0475463,was confirmed with available ,Signs and Symptoms,Antibodies Neutralizing,2,X,[sosy],[aapp/imft],C23.888,D12.776.124.486.485.114.244;D12.776.124.790.651.114.244;D12.776.377.715.548.114.244
9c707183-2bf0-4b16-bd37-4ef1b28a1be9,C0037088,C1175743,was confirmed with available ,Signs and Symptoms,SARS coronavirus,1,X,[sosy],[virs],C23.888,B04.820.504.540.150.113.937
1e90570b-b28e-412e-93b2-d271f83fbb3c,C0003316,A475,were identified as A475 ,Epitopes,A475,1,X,[imft],????,D23.050.550,????
bf850c56-0347-4296-b42c-83945edc5cc4,C0003316,C1175743,were identified as A475 ,Epitopes,SARS coronavirus,2,X,[imft],[virs],D23.050.550,B04.820.504.540.150.113.937
50dd1bdb-8bc6-4669-b7fc-f1f24214400f,A475,C1175743,is in ,A475,SARS coronavirus,1,X,????,[virs],????,B04.820.504.540.150.113.937
aae44701-7361-4abf-ad4f-d66473fbb7f2,C0206419,C0349410,can cause multiple ,Genus: Coronavirus,Single organ dysfunction,1,X,[virs],[sosy],B04.820.504.540.150,
71fa9642-9e55-498c-9b61-ace826d43793,C0178784,C0206419,is important for patients with ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
71fa9642-9e55-498c-9b61-ace826d43793,C0178784,C0206419,is Given lack of ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
71fa9642-9e55-498c-9b61-ace826d43793,C0178784,C0206419,is in patients with severe ,Organ,Genus: Coronavirus,1,X,[bpoc],[virs],,B04.820.504.540.150
3b965d6f-f706-4c12-a2c6-33aa2410181b,C1562632,C0206419,is important for patients with ,Hoover technique,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
3b965d6f-f706-4c12-a2c6-33aa2410181b,C1562632,C0206419,is Given lack of ,Hoover technique,Genus: Coronavirus,2,X,[topp],[virs],,B04.820.504.540.150
fe31eacb-04aa-4d43-9a71-4865c2919978,C0178784,C0003451,is important Given lack of ,Organ,Antiviral Agents,2,X,[bpoc],[phsu],,D27.505.954.122.388
728175e5-b817-4b9c-a6ec-a5f205ae45f0,C1562632,C0003451,is important Given lack of ,Hoover technique,Antiviral Agents,4,X,[topp],[phsu],,D27.505.954.122.388
0d3cb374-b365-4afd-bc25-cc4afa45d50c,C0042776,C1520005,insights into ,Virus,Viral Pathogenesis,1,X,[virs],[patf],B04,
d780d1d3-7ad7-49c8-8c83-48adcdd0e23f,C0042776,C0014507,insights into ,Virus,Epidemiology,1,X,[virs],[bmod],B04,H02.403.720.500
760dac30-c4b1-4441-b0fd-9c6752ed023c,C2806453,C0450442,is ,Betacoronavirus,Agent,2,X,[virs],[chvf],B04.820.504.540.150.113,
2846ef99-8c44-499d-a086-622115b0674d,C2806453,C0206419,is ,Betacoronavirus,Genus: Coronavirus,2,X,[virs],[virs],B04.820.504.540.150.113,B04.820.504.540.150
9bc954ad-652e-4981-a826-ead66d5deb30,C2806453,C0012634,is ,Betacoronavirus,Disease,2,X,[virs],[dsyn],B04.820.504.540.150.113,C23.550.288
e7ad4cf1-fa42-4223-a374-ce225ec59a33,C2745965,C0563597,has generated unprecedented ,Emergencies [Disease/Finding],Momentum,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,
f6333e25-118e-47d5-9995-fa7f0f291773,C1880019,C1705178,is in ,Cessation,Order (action),1,X,[acty],[acty],,
b5d380be-b70a-42c3-a0a8-97553d6d97f9,C1511790,C0086312,using random ,Detection,Forests,2,X,[topp],[npop],,G16.500.275.157.437;N06.230.124.343
2696847b-6e24-4fc3-b860-a2b7f4212069,C1511790,C1856053,is with random ,Detection,Hydranencephaly with Renal Aplasia-Dysplasia,2,X,[topp],[dsyn],,x.x.x.x
59e8eb41-b725-4964-83fa-04ed0c4c9f6d,C0018563,C0242781,was commonly identified ,Hand,disease transmission,1,X,[bpoc],[patf],A01.378.800.667,N06.850.310
3e3d06d4-a2dc-4413-9f46-9fc184ad5522,C0018581,C0319157,was identified by of respondents as preventive measure against ,Handwashing,AS virus,2,X,[acty],[virs],N06.850.670.150.500,
6708ba85-5647-476d-87ec-c81fd0ab02ce,C0450254,C0221423,spectrum of ,Pathogenic organism,Illness (finding),1,X,[orgm],[sosy],,
eab59d91-a2f2-4d94-97ff-2f9f7b15829e,C0012634,C0184661,affect operations of ,Disease,Interventional procedure,1,X,[dsyn],[topp],C23.550.288,
88d5c3ee-4216-43e0-a1d4-66a9e6040e11,C0079600,C0019693,is in ,Immunodominant Epitopes,HIV Infections,1,X,[imft],[dsyn],D23.050.550.500,C02.782.815.616.400;C02.800.801.400;C20.673.480
7f0f8c66-025b-41f7-a38c-6542cba37135,FMW,C0851578,had higher prevalence of ,FMW,Sleep Disorders,1,X,????,[mobd],????,C10.886;C23.888.592.796;F03.870
1de21aff-8bf1-40b3-b50b-aaded1154487,FMW,PSQI,had significantly higher scores of PSQI,FMW,PSQI,1,X,????,????,????,????
fa86bb05-1dd7-4874-ae78-1f359b58071f,C0015392,C0206750,is reeling under ,Eye,Coronavirus Infections,1,X,[bpoc],[dsyn],A01.456.505.420;A09.371,C02.782.600.550.200
531ff799-ca04-4ca4-8114-3ca07976bcca,C1947933,E/M,be adjunct to to face-to-face E/M ,care activity,E/M,1,X,[acty],????,,????
e3da03e0-4e1f-4ec4-b270-134b4effc119,C0025124,C1527144,have shown ,Traditional Chinese Medicine,Therapeutic Effect,1,X,[bmod],[clna],E02.190.488.585.520;I01.076.201.450.654.558.520,
a9e36335-db58-4d7a-98a6-3b1c38e13ffc,C0032594,C1550600,are important ,Polysaccharides,Ingredient,1,X,[orch/phsu],[chvf],D09.698,
88d49fdc-dea3-4b1b-a1c7-1e397086dd3d,C0022646,C0243077,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,inhibitors,1,X,[bpoc],[chvf],A05.810.453,
7d851aa7-052d-44f3-8e78-ea0bb5f128ec,C0022646,C0020538,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Hypertensive disease,1,X,[bpoc],[dsyn],A05.810.453,C14.907.489
e171c5a5-916b-4044-9a8e-fde8da18715e,C0022646,C0011849,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Diabetes Mellitus,1,X,[bpoc],[dsyn],A05.810.453,C18.452.394.750;C19.246
bac3a121-dfad-4341-a14d-9e440c1f5764,C0022646,C0007222,are commonly prescribed renin-angiotensin-aldosterone system ,Kidney,Cardiovascular Diseases,1,X,[bpoc],[dsyn],A05.810.453,C14
b1325974-bc69-43b4-b672-1455b38fb8bf,C0079189,C0079633, includes IP10 ,cytokine,Interleukin-8,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312
31f7a4ca-7a85-47a6-9269-66a9112b3375,C0079189,C1448177, includes IP10 ,cytokine,TNF protein human,1,X,[aapp/imft],[aapp/bacs],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
d62a3e26-cee4-4e96-80d1-d531cfe9e5fc,C0079189,IP10, includes IP10 ,cytokine,IP10,1,X,[aapp/imft],????,D12.644.276.374;D12.776.467.374;D23.529.374,????
94293633-05ea-4af6-96ee-108b84507771,C0079189,C1449159, includes IP10 ,cytokine,CCL2 protein human,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,x.x.x.x
bedbc9e0-bd2b-4e09-8e12-094cd66c4db2,C0079189,C0072978, includes IP10 ,cytokine,RANTES,1,X,[aapp/imft],[aapp/imft],D12.644.276.374;D12.776.467.374;D23.529.374,D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250
2a075fe3-a190-47d7-b3fe-79f1ae812e84,C0079633,C0206750,were elevated in patients with ,Interleukin-8,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.644.276.374.200.120.800;D12.644.276.374.465.312;D12.776.467.374.200.120.800;D12.776.467.374.465.246;D23.125.300.120.800;D23.469.200.120.800;D23.529.374.200.120.800;D23.529.374.465.312,C02.782.600.550.200
e5bce239-4dfc-450b-93e5-0a81449df8fa,C1448177,C0206750,were elevated in patients with ,TNF protein human,Coronavirus Infections,1,X,[aapp/bacs],[dsyn],x.x.x.x,C02.782.600.550.200
e95c2fc4-15f9-4bcd-a692-91482f98b2c2,IP10,C0206750,were elevated in patients with ,IP10,Coronavirus Infections,1,X,????,[dsyn],????,C02.782.600.550.200
3b38bbd0-daca-4718-ad46-f4882d20c73c,C1449159,C0206750,were elevated in patients with ,CCL2 protein human,Coronavirus Infections,1,X,[aapp/imft],[dsyn],x.x.x.x,C02.782.600.550.200
04f9f048-e8c1-42ef-b847-cea9a605f439,C0072978,C0206750,were elevated in patients with ,RANTES,Coronavirus Infections,1,X,[aapp/imft],[dsyn],D12.644.276.374.200.110.250;D12.776.467.374.200.110.250;D23.125.300.110.250;D23.469.200.110.250;D23.529.374.200.110.250,C02.782.600.550.200
6edb99ed-22f9-40d5-9e1d-29df1e5c6e6c,C1175743,C0225699,infect ,SARS coronavirus,Type-I Pneumocytes,1,X,[virs],[cell],B04.820.504.540.150.113.937,A04.411.715.100;A11.436.081
82770874-0c71-4fcf-a673-468e3e564b3d,C0270942,C0544688,is potentially severe ,Myasthenic crisis,complication of disease,1,X,[dsyn],[patf],,
ef3183f3-109f-4cab-ae31-af64317084e1,C0270942,C0206750,is potentially severe ,Myasthenic crisis,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
ba484697-c708-4c61-bc44-8c4453f7435f,C0020336,C0270942,can aggravate ,Hydroxychloroquine,Myasthenic crisis,1,X,[orch/phsu],[dsyn],D03.633.100.810.050.180.350,
72ed6f8f-862a-4fc1-a9af-306c0d2f135d,C0085297,C0270942,is potential treatment for ,Immunoglobulins Intravenous,Myasthenic crisis,1,X,[aapp/imft/phsu],[dsyn],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,
c3426f17-7e44-4850-b97e-6079b4f70b37,C0085297,C0302148,may cause ,Immunoglobulins Intravenous,Blood Clot,1,X,[aapp/imft/phsu],[patf],D12.776.124.486.485.114.619.393.536;D12.776.124.486.485.114.632;D12.776.124.790.651.114.632;D12.776.377.715.548.114.632,C14.907.355.830
80c75526-0554-47d2-8121-49197e7b3b41,C1817756,C0012634,in improvements is particularly those specific for ,Immune System Processes,Disease,1,X,[ortf],[dsyn],G12,C23.550.288
383f9d40-44bb-4f64-a0eb-5aedb2a4283a,C0015259,C0003451,promote ,Exercise,Antiviral Agents,1,X,[dora],[phsu],G11.427.410.698.277;I03.350,D27.505.954.122.388
c07263ea-7e48-4aef-8a9b-6b0f91ea3d41,C0015259,C0020964,promote ,Exercise,Immunity,1,X,[dora],[phsf],G11.427.410.698.277;I03.350,G12.450
33da3e8b-9897-4650-bf73-e49efc789109,C2745965,C3826426,understand preliminary data behind ,Emergencies [Disease/Finding],Dynamics,1,X,[patf],[npop],C23.550.291.781;N06.230.100.083;N06.850.376,
b28d0aab-d55a-4baa-a120-22069c5f6bee,C2745965,C0012634,understand preliminary data behind ,Emergencies [Disease/Finding],Disease,1,X,[patf],[dsyn],C23.550.291.781;N06.230.100.083;N06.850.376,C23.550.288
7522ec60-a087-43bf-94d7-0f37b346510f,C1710276,C0229671,are characterized by ,Systemic Reaction,Serum,2,X,[biof],[bdsu],,A12.207.152.846;A15.145.846
dca8ed07-dfd6-418b-ad92-11db89f578ab,C0021368,C0229671,are characterized by ,Inflammation,Serum,1,X,[patf],[bdsu],C23.550.470,A12.207.152.846;A15.145.846
5066408a-626a-4162-8991-9ddd03a9e350,C0852312,C0206750,is in ,gender disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
5d59957b-33de-4bbb-88a6-77f9e26530b9,C1552133,C0206750,screening for fear of ,19s,Coronavirus Infections,2,X,[bpoc],[dsyn],,C02.782.600.550.200
5e70e0e1-8a0b-4e54-9df9-1bc116d5599e,C0206750,C0018801,consisting of ,Coronavirus Infections,Heart failure,1,X,[dsyn],[dsyn],C02.782.600.550.200,C14.280.434
6ef8bbe7-b963-4000-a8ad-a35c63933706,C1301700,C0206750,observed mild ,Cardiovascular morbidity,Coronavirus Infections,1,X,[dsyn],[dsyn],,C02.782.600.550.200
c2663622-64d4-46fa-bbbe-bef1e7ff781d,C1301700,C0152021,observed mild ,Cardiovascular morbidity,Congenital heart disease,1,X,[dsyn],[cgab],,
591131e9-512e-46f5-a548-37e352347194,C0206750,C0152021,is in our cohort of ,Coronavirus Infections,Congenital heart disease,1,X,[dsyn],[cgab],C02.782.600.550.200,
dc846c44-3acb-4831-8800-4f1a243aa773,C0008679,C0035435, includes ,Chronic disease,Rheumatism,1,X,[dsyn],[dsyn],C23.550.291.500,C05.799;C17.300.775
956d976f-6b30-462a-a07f-a3212a285538,C1439284,C1175175,be ideal candidate for treatment of ,AGTR1 gene,Severe Acute Respiratory Syndrome,2,X,[gngm],[dsyn],,C02.782.600.550.200.750;C08.730.730
cd2696d1-e37c-413c-a382-8995684f5dcf,C0243076,C1175175,be ideal candidate for treatment of ,antagonists,Severe Acute Respiratory Syndrome,2,X,[chvf],[dsyn],,C02.782.600.550.200.750;C08.730.730
fff27c1c-6899-4134-b3bc-02c2c14e52e9,C0013227,C0441655,is with anti ,Pharmaceutical Preparations,Activities,1,X,[phsu],[acty],D26,
fff27c1c-6899-4134-b3bc-02c2c14e52e9,C0013227,C0441655,were then tested for invitro ,Pharmaceutical Preparations,Activities,2,X,[phsu],[acty],D26,
fff27c1c-6899-4134-b3bc-02c2c14e52e9,C0013227,C0441655,showed invitro ,Pharmaceutical Preparations,Activities,1,X,[phsu],[acty],D26,
2319aba8-b2d4-4bc5-9bb8-6cd23ecea0d3,C0013227,C0936087,were then tested for invitro ,Pharmaceutical Preparations,Coronavirus Feline,2,X,[phsu],[virs],D26,B04.820.504.540.150.075.500.375
0c273811-0e56-4aa5-b77c-5da73529b43b,C0013227,invitro,were then tested for invitro ,Pharmaceutical Preparations,invitro,2,X,[phsu],????,D26,????
0c273811-0e56-4aa5-b77c-5da73529b43b,C0013227,invitro,showed invitro ,Pharmaceutical Preparations,invitro,1,X,[phsu],????,D26,????
542c0881-cc1f-483c-a987-c31ae31d9a5c,C0013227,C0007634,were then tested for invitro ,Pharmaceutical Preparations,Cells,2,X,[phsu],[cell],D26,A11
2678fe95-2a8a-491a-835b-e6ee83dfc2da,C0936087,invitro,is in invitro ,Coronavirus Feline,invitro,1,X,[virs],????,B04.820.504.540.150.075.500.375,????
5b30816c-996e-4a8f-b32e-d4c3410237dd,C0936087,C0007634,is in invitro ,Coronavirus Feline,Cells,1,X,[virs],[cell],B04.820.504.540.150.075.500.375,A11
8fc54e3b-c4b4-4323-a59b-4a29b99c4d29,C0013227,C0085305,showed invitro ,Pharmaceutical Preparations,Feline infectious peritonitis virus,2,X,[phsu],[virs],D26,B04.820.504.540.150.075.500.375
96bd3f6c-3357-48e0-98b3-f7773ac2865c,C0013227,C0336917,were found Active physical exercise during,Pharmaceutical Preparations,Active physical exercise,2,X,[phsu],[dora],D26,
920ad870-4f1e-4d1b-809a-cd5c663fda3b,C0015967,C0282686,manifestations of ,Fever,Respiratory System Agents,1,X,[sosy],[phsu],C23.888.119.344,D27.505.954.796
30cce111-8031-4728-9308-ab511da519e2,C0031350,C0282686,manifestations of ,Pharyngitis,Respiratory System Agents,1,X,[dsyn],[phsu],C07.550.781;C08.730.561;C09.775.649,D27.505.954.796
c8293a18-22c4-4084-99f6-23d913ee51ad,C0010200,C0282686,manifestations of ,Coughing,Respiratory System Agents,1,X,[sosy],[phsu],C08.618.248;C23.888.852.293,D27.505.954.796
50e31044-cd4e-4e0c-be9b-49563d12ffd0,C0013404,C0282686,manifestations of ,Dyspnea,Respiratory System Agents,1,X,[sosy],[phsu],C08.618.326;C23.888.852.371,D27.505.954.796
d95bdcfe-d504-4c85-9fb6-0eb73a873e70,C0206750,C0031350,was After emergence of novel ,Coronavirus Infections,Pharyngitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07.550.781;C08.730.561;C09.775.649
d95bdcfe-d504-4c85-9fb6-0eb73a873e70,C0206750,C0031350,was initially characterized by ,Coronavirus Infections,Pharyngitis,1,X,[dsyn],[dsyn],C02.782.600.550.200,C07.550.781;C08.730.561;C09.775.649
c27a031f-d156-4df2-9296-967cea4fa339,C0012634,C0031350,was After emergence of novel ,Disease,Pharyngitis,1,X,[dsyn],[dsyn],C23.550.288,C07.550.781;C08.730.561;C09.775.649
c27a031f-d156-4df2-9296-967cea4fa339,C0012634,C0031350,was initially characterized by ,Disease,Pharyngitis,1,X,[dsyn],[dsyn],C23.550.288,C07.550.781;C08.730.561;C09.775.649
331c4555-0741-425d-bec0-2ed8e07fbb5f,C0012634,C0010200,was After emergence of novel ,Disease,Coughing,1,X,[dsyn],[sosy],C23.550.288,C08.618.248;C23.888.852.293
331c4555-0741-425d-bec0-2ed8e07fbb5f,C0012634,C0010200,was initially characterized by ,Disease,Coughing,1,X,[dsyn],[sosy],C23.550.288,C08.618.248;C23.888.852.293
8ff44fb5-56e8-4d2c-91e0-632afc7e25fd,C0012634,C0013404,was After emergence of novel ,Disease,Dyspnea,1,X,[dsyn],[sosy],C23.550.288,C08.618.326;C23.888.852.371
8ff44fb5-56e8-4d2c-91e0-632afc7e25fd,C0012634,C0013404,was initially characterized by ,Disease,Dyspnea,1,X,[dsyn],[sosy],C23.550.288,C08.618.326;C23.888.852.371
c89ac0ad-c6dc-4306-824d-83451b87e987,C0029237,C0206750,have have proactive in fight against ,Physiologic Organization,Coronavirus Infections,1,X,[phsf],[dsyn],,C02.782.600.550.200
3e1187c2-cbf0-4a9b-bf6c-eb4369045f9b,C0005802,C1707455,improved as ,Blood Glucose,Comparison,1,X,[orch],[acty],D09.947.875.359.448.500,
0182d73f-2ee5-4db0-ab36-dfc57190d693,C0005802,C1175743,improved before spread ,Blood Glucose,SARS coronavirus,1,X,[orch],[virs],D09.947.875.359.448.500,B04.820.504.540.150.113.937
b2bfac8e-f3f1-49a7-9a29-14cf3911718c,C0005802,7days,improved during first 7days ,Blood Glucose,7days,1,X,[orch],????,D09.947.875.359.448.500,????
3791a24b-fe8d-4ec3-a0a2-510be22ecfdf,C0037090,C0034386,ultimately led to ,Signs and Symptoms Respiratory,Quarantine,1,X,[sosy],[topp],C23.888.852,N06.850.780.200.450.700
44e73a3a-7242-4f0c-a35d-71dba178449a,C0242781,C3694279, includes ,disease transmission,Middle East Respiratory Syndrome,1,X,[patf],[dsyn],N06.850.310,C02.782.600.550.200
590bd207-20db-4299-9535-b5ce1434ab23,C0009450,C0043085,be influenced by ,Communicable Diseases,Weather,1,X,[dsyn],[npop],C01.539.221,G16.500.275.063.725;G16.500.750.775;N06.230.300.100.725
7fe49f1d-2080-49c5-8a13-12934f09b103,C0018681,COVID-19,is in ,Headache,COVID-19,2,X,[sosy],[virs],C23.888.592.612.441,C000657245
ffa5c4c1-acdf-40e9-a6c2-62efffeb31fe,C0018681,C1521863,is in ,Headache,estrogen receptor alpha human,1,X,[sosy],[aapp/rcpt],C23.888.592.612.441,x.x.x.x
28d43728-ebf4-434d-a522-ba4834f23e69,C1947933,C1521863,is in ,care activity,estrogen receptor alpha human,1,X,[acty],[aapp/rcpt],,x.x.x.x
3af41f8f-bd67-4f1f-b01b-6695c01033f4,C0042776,C0026882,is with ,Virus,Mutation,1,X,[virs],[genf],B04,G05.365.590
98ae4b7f-03c0-4143-8a78-01a9f80219b0,C0314620,COVID-19,was expressed in ,Non structural gene,COVID-19,2,X,[gngm],[virs],,C000657245
1a817e42-9537-4b83-a5e3-4c4d662d80af,C0314620,C0206415,Using sequence-independent single ,Non structural gene,Oligonucleotide Primers,2,X,[gngm],[nnon],,D13.695.578.424.450.275;D27.720.470.530.600.223.600
01598395-addb-4297-955f-660025a85a27,C0033684,C0020517,has ,Proteins,Hypersensitivity,1,X,[aapp/bacs],[patf],D12.776,C20.543
d8b7bbf8-433f-4c4e-bc48-94e197ceed4d,RT-PCR,C0020517,has ,RT-PCR,Hypersensitivity,1,X,????,[patf],????,C20.543
f4326240-f50a-404c-b25c-73618fd4f940,C1690518,C0230425,using real-time PCR ,Environmental swab,Structure of right thigh,1,X,[sbst],[bpoc],,
8297c404-d656-4ab1-b893-ca2445db2750,C1690518,PCR,using real-time PCR ,Environmental swab,PCR,1,X,[sbst],????,,????
c2cf8b22-0a73-41c4-9335-e2bbf8a5312d,C1690518,C1511790,using real-time PCR ,Environmental swab,Detection,1,X,[sbst],[topp],,
be585e6e-9b29-4407-a44c-b663dde9bc42,C0012634,C0162574,causes Respiration Disorders in,Disease,Glycation End Products Advanced,1,X,[dsyn],[bacs/orch],C23.550.288,D12.776.643.500
7722230a-50c5-47d4-8db3-f7a1eb853f56,L.,C0016452,may provide promising ,L.,Food,1,X,????,[food],????,G07.203.300;J02.500
3493ac2a-b883-467b-b105-9ebe3c532760,L.,C0042210,may provide promising ,L.,Vaccines,1,X,????,[aapp/imft/phsu],????,D20.215.894
3c3d5ff6-03bc-4a21-bc4a-193a929aecd7,L.,C1175175,may provide promising ,L.,Severe Acute Respiratory Syndrome,1,X,????,[dsyn],????,C02.782.600.550.200.750;C08.730.730
bb48ada6-2826-4a6d-b404-54f6ba43ae5f,C1707455,C1947933,is with standard ,Comparison,care activity,1,X,[acty],[acty],,
3826d4e5-2d6e-4850-a02e-c96a88a535c0,C0939237,C1947933,is with standard ,lopinavir / Ritonavir,care activity,1,X,[phsu],[acty],,
0008cd04-8f8e-456a-bc41-7ef9102bdc8e,C0012634,C0872315,is ,Disease,Communicable Diseases Emerging,1,X,[dsyn],[dsyn],C23.550.288,C01.539.221.500
0d4b2020-d679-4df6-b214-a386ab575294,C0301872,C0035222,can lead to ,Immune response,Respiratory Distress Syndrome Adult,2,X,[ortf],[dsyn],,C08.381.840;C08.618.840
5be088a9-6f29-406b-a06e-92be4a3d463f,C0242129,C0003281,occurred during ongoing ,Thrombotic stroke,Anticoagulation Therapy,1,X,[dsyn],[topp],,
f6b063a9-0245-42c4-9458-b3b9dab29438,C0242129,C0004238,occurred during ongoing ,Thrombotic stroke,Atrial Fibrillation,1,X,[dsyn],[dsyn],,C14.280.067.198;C23.550.073.198
98ff8208-1e0c-403e-8844-2d225398db27,C0242129,C1277289,occurred during ongoing ,Thrombotic stroke,Stroke prevention,1,X,[dsyn],[topp],,
3bb9b173-0521-4b8c-a2a2-d130c4e516a0,C4552744,C0034019,provide reference deal with ,Daily Living,public health medicine (field),1,X,[dora],[bmod],,H02.403.720;N01.400.550;N06.850
b9e86a68-102c-4739-88d4-a347f798a885,C4552744,C2745965,provide reference deal with ,Daily Living,Emergencies [Disease/Finding],1,X,[dora],[patf],,C23.550.291.781;N06.230.100.083;N06.850.376
240511d2-c2b4-47cb-81b7-4214873137f5,C0026691,C1621271,Macrophage Activation Syndrome by,Mucocutaneous Lymph Node Syndrome,Pediatric rheumatology,1,X,[dsyn],[bmod],C14.907.940.560;C15.604.560;C17.800.862.560,
5f5d1316-58d3-4140-9ffb-5540e2b0bcd7,C0036974,C1621271,Macrophage Activation Syndrome by,Shock,Pediatric rheumatology,1,X,[patf],[bmod],C23.550.835,
fd3483f7-c072-4815-b428-80796ef7ace8,C0009450,PCR,was sought by reverse-transcriptase PCR,Communicable Diseases,PCR,2,X,[dsyn],????,C01.539.221,????
9ff1a0cf-8200-40ac-a6a5-cc06d1bd602c,C0009450,C1706005,detecting ,Communicable Diseases,CD40LG wt Allele,1,X,[dsyn],[gngm],C01.539.221,
3f6746ff-d9a3-4963-9903-ccb0c6495330,C0597404,C0020268,sampled by ,Respiratory viruses,Hydrocortisone,1,X,[virs],[horm/orch/phsu],,D04.210.500.745.745.654.600;D06.472.040.585.353.476;D06.472.040.585.478.392
0cbe3c5c-db0c-4d66-89af-753a8a58e067,C0597404,C1175743,had ,Respiratory viruses,SARS coronavirus,1,X,[virs],[virs],,B04.820.504.540.150.113.937
820e74f4-2029-465a-84fe-d087d7597b6c,C0149931,C1521863,is in current ,Migraine Disorders,estrogen receptor alpha human,1,X,[dsyn],[aapp/rcpt],C10.228.140.546.399.750,x.x.x.x
7fffdd1c-93eb-440a-8113-eae7e0d3e4ca,C0149931,C0206750,is in current ,Migraine Disorders,Coronavirus Infections,1,X,[dsyn],[dsyn],C10.228.140.546.399.750,C02.782.600.550.200
b70e9fb6-d596-478f-9d91-6be28cc7f4fb,C0037083,C1175175,are different in case of ,Signal Transduction,Severe Acute Respiratory Syndrome,1,X,[celf],[dsyn],G02.111.820;G04.835,C02.782.600.550.200.750;C08.730.730
1d33c8bd-e727-4f3f-8204-73d320fde589,C0112081,C0206750,is in severe ,D-D mixture,Coronavirus Infections,1,X,[hops/orch],[dsyn],,C02.782.600.550.200
1d33c8bd-e727-4f3f-8204-73d320fde589,C0112081,C0206750,may serve as useful ,D-D mixture,Coronavirus Infections,1,X,[hops/orch],[dsyn],,C02.782.600.550.200
5de2fee3-dcc2-4e65-b698-a581f4152a4b,NLR,C1514474,may serve as useful ,NLR,Prognostic Factors,1,X,????,[clna],????,E01.789
9cab0c7e-9980-45fa-8848-1d748b532a11,C0112081,C1514474,may serve as useful ,D-D mixture,Prognostic Factors,1,X,[hops/orch],[clna],,E01.789
95423348-2cab-4437-9b68-4ef82dec29f9,C0079189,C1514474,may serve as useful ,cytokine,Prognostic Factors,1,X,[aapp/imft],[clna],D12.644.276.374;D12.776.467.374;D23.529.374,E01.789
b390251d-29d0-41b4-911e-ecc2de9aa1d4,NLR,C0814435,may serve as useful ,NLR,early identification,1,X,????,[topp],????,
80bd8294-fa6d-4e19-afb1-015044b02ee6,C0112081,C0814435,may serve as useful ,D-D mixture,early identification,1,X,[hops/orch],[topp],,
14337ca5-e232-4774-8702-da19a203c45a,C0079189,C0814435,may serve as useful ,cytokine,early identification,1,X,[aapp/imft],[topp],D12.644.276.374;D12.776.467.374;D23.529.374,
22967a86-a1c1-4a98-81ac-4952b7d6a917,C0178913,C0206750,were collected from confirmed ,Blood specimen,Coronavirus Infections,1,X,[bdsu],[dsyn],,C02.782.600.550.200
293e0fd9-817c-4e18-8a4b-93f4370e2487,C0013227,remdesivir, includes ,Pharmaceutical Preparations,remdesivir,1,X,[phsu],[clnd],D26,
59b253df-226e-4843-83de-b0ee14c4e282,C0013227,C0207683, includes ,Pharmaceutical Preparations,nafamostat,1,X,[phsu],[orch/phsu],D26,x.x.x.x
534cbd49-c59f-4fd1-ba94-c179ed8ba000,C0013227,C0129975, includes ,Pharmaceutical Preparations,camostat,1,X,[phsu],[orch/phsu],D26,x.x.x.x
d3cf5bbd-70fa-449c-bafa-6a861a55dda0,C0013227,C0022322, includes ,Pharmaceutical Preparations,Ivermectin,1,X,[phsu],[orch/phsu],D26,D02.540.576.500.997;x.x.x.x
127bfe61-0718-4327-8fa8-a7c44c266105,C0207683,C1175743,exhibited anti ,nafamostat,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
a0145f64-1808-4d65-929f-84e499240e33,C0129975,C1175743,exhibited anti ,camostat,SARS coronavirus,1,X,[orch/phsu],[virs],x.x.x.x,B04.820.504.540.150.113.937
ea99646b-8cfc-4187-a3d0-03a759d87e2e,C0022322,C1175743,exhibited anti ,Ivermectin,SARS coronavirus,1,X,[orch/phsu],[virs],D02.540.576.500.997;x.x.x.x,B04.820.504.540.150.113.937
48916a18-40d8-457d-b82c-eff21708aef1,C1948030,C0229671,exceeded their achievable peak ,EC Regimen (Etoposide-Carboplatin),Serum,1,X,[topp],[bdsu],,A12.207.152.846;A15.145.846
241b3437-2bc4-4a47-a67f-81522d552e49,C0021853,C0021852,is shared in ,Intestines,Intestines Small,1,X,[bpoc],[bpoc],A03.556.124,A03.556.124.684
9a5279a9-80d5-47d4-8ff8-e30a92cefe2c,C0021853,C0682610,is shared in ,Intestines,Enterocytes,1,X,[bpoc],[cell],A03.556.124,A03.556.124.369.290;A10.615.550.444.290;A11.436.290
55d98e55-3922-4ba3-9654-87160c43b0e9,C0021853,C0174990,is shared in ,Intestines,coronavirus receptor,1,X,[bpoc],[aapp/rcpt],A03.556.124,x.x.x.x
5f8ecb9a-a39a-44f9-a95f-72c0f43ab72c,C1825598,C0003467,Moreover was associated with health ,IMPACT gene,Anxiety,1,X,[gngm],[mobd],,F01.470.132
e6baf303-4245-4231-a952-c0db5907593a,C2926735,C0206750,is in patients with ,Duration,Coronavirus Infections,2,X,[orch/phsu],[dsyn],,C02.782.600.550.200
a34f0b27-82c6-4219-bece-923be02adf79,C0015967,C2926735,were risk factors for prolonged ,Fever,Duration,1,X,[sosy],[orch/phsu],C23.888.119.344,
a4aed4d7-15a0-45db-8cc1-b03b7be0f99a,C0015967,C0162633,were risk factors for prolonged ,Fever,Viral Shedding,1,X,[sosy],[patf],C23.888.119.344,G07.925
aa06ae4e-b064-4cff-987b-80a61bc82f73,C0012634,C0018581,amplify pro ,Disease,Handwashing,1,X,[dsyn],[acty],C23.550.288,N06.850.670.150.500
909fc230-9cc1-4e34-b439-f9273cde7b6d,C0021376,C0004153,is associated with development of ,Chronic inflammation,Atherosclerosis,2,X,[patf],[dsyn],,C14.907.137.126.307
aad6ef24-6a45-423e-bb7c-687211850f58,C0021760,C0006560,showed positive correlation with ,Interleukin-6,C-reactive protein,1,X,[aapp/imft],[aapp/imft],D12.644.276.374.465.224;D12.776.467.374.465.202;D23.529.374.465.224,D12.776.034.145;D12.776.124.050.120;D12.776.124.486.157
73154719-71fc-47bb-84c4-dde639b15b5c,C0042769,C0301872,preventing aberrant ,Virus Diseases,Immune response,1,X,[dsyn],[ortf],C02,
13eeecfb-a6bd-4219-822c-f877ed1bf7cb,C0003015,C0042776,reduce ,Angiotensin-Converting Enzyme Inhibitors,Virus,1,X,[phsu],[virs],D27.505.519.389.745.085,B04
4cf06524-dea8-4530-b3d9-9a3364633c6d,C0003015,C0024109,reduce ,Angiotensin-Converting Enzyme Inhibitors,Lung,1,X,[phsu],[bpoc],D27.505.519.389.745.085,A04.411
d37cfcab-8159-4238-b29c-2f30bcc9850c,C0003015,C0018787,reduce ,Angiotensin-Converting Enzyme Inhibitors,Heart,1,X,[phsu],[bpoc],D27.505.519.389.745.085,A07.541
8035672b-cd17-48c9-a4ef-b69c4be845c2,C0009429,C0597721,affect ,Combined Modality Therapy,Janus kinase,1,X,[topp],[aapp/enzy],E02.186,D08.811.913.696.620.682.725.124;D12.776.476.393
61944cde-750b-4a46-8c8d-8c66110c9935,C0683465,C0597721,affect ,novel AODU treatment method,Janus kinase,1,X,[topp],[aapp/enzy],,D08.811.913.696.620.682.725.124;D12.776.476.393
bdff4866-f784-4bb9-affb-7e8b88a6c26e,C0683465,C0206750,affect ,novel AODU treatment method,Coronavirus Infections,1,X,[topp],[dsyn],,C02.782.600.550.200
99b01971-e229-41ac-aa7b-dfe345945d94,C0597721,C0206750,is in patients with ,Janus kinase,Coronavirus Infections,1,X,[aapp/enzy],[dsyn],D08.811.913.696.620.682.725.124;D12.776.476.393,C02.782.600.550.200
967ca216-9dde-4a73-98a4-c50b5a83d3c7,C0206750,C1880019,has seen ,Coronavirus Infections,Cessation,1,X,[dsyn],[acty],C02.782.600.550.200,
